<SEC-DOCUMENT>0001564590-20-012816.txt : 20200325
<SEC-HEADER>0001564590-20-012816.hdr.sgml : 20200325
<ACCEPTANCE-DATETIME>20200325160919
ACCESSION NUMBER:		0001564590-20-012816
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		144
CONFORMED PERIOD OF REPORT:	20191231
FILED AS OF DATE:		20200325
DATE AS OF CHANGE:		20200325

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NantKwest, Inc.
		CENTRAL INDEX KEY:			0001326110
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				431979754
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37507
		FILM NUMBER:		20742268

	BUSINESS ADDRESS:	
		STREET 1:		3530 JOHN HOPKINS COURT
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121
		BUSINESS PHONE:		(858) 633-0300

	MAIL ADDRESS:	
		STREET 1:		3530 JOHN HOPKINS COURT
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Conkwest, Inc.
		DATE OF NAME CHANGE:	20140416

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ZelleRx Corp
		DATE OF NAME CHANGE:	20050504
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>nk-10k_20191231.htm
<DESCRIPTION>10-K
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
nk-10k_20191231.htm
</title>
</head>
<!-- NG Converter v5.0.2.38 -->
<body>

<p style="border-bottom:Double 2.25pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:4pt;">&nbsp;</p>
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:16pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">UNITED STATES</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:16pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SECURITIES AND EXCHANGE COMMISSION</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Washington, D.C. 20549</p>
<p style="text-align:center;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-weight:bold;;font-size:3pt;">&nbsp;</p>
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:15pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">FORM 10-K</p>
<p style="text-align:center;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-weight:bold;;font-size:3pt;">&nbsp;</p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Mark&#160;One)</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Segoe UI Symbol;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#9746;</p></td>
<td valign="top"  style="width:96%;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">ANNUAL REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF&#160;1934</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the fiscal year ended December&#160;31, 2019 </p>
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">OR</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Segoe UI Symbol;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#9744;</p></td>
<td valign="top"  style="width:96%;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF&#160;1934 </p></td>
</tr>
</table></div>
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">FOR THE TRANSITION PERIOD FROM&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; TO &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </p>
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;margin-left:4.54%;text-indent:-4.54%;font-weight:bold;font-size:9.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Commission file number:&#160;001-37507</p>
<p style="text-align:center;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-weight:bold;;font-size:3pt;">&nbsp;</p>
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:22pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">NANTKWEST, INC.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Exact name of Registrant as specified in its Charter)</p>
<p style="text-align:center;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-weight:bold;;font-size:3pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:9pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">Delaware</p></td>
<td valign="bottom"  style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">43-1979754</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(State or other jurisdiction of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">incorporation or organization)</p></td>
<td valign="bottom"  style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(I.R.S. Employer<br />Identification No.)</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">3530 John Hopkins Court</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">San Diego<font style="font-family:Times New Roman Bold;">, California</font></p></td>
<td valign="bottom"  style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">92121</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Address of principal executive offices)</p></td>
<td valign="bottom"  style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Zip Code)</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Registrant&#8217;s telephone number, including area code: (858)&#160;633-0300</p>
<p style="text-align:center;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-weight:bold;;font-size:3pt;">&nbsp;</p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Securities registered pursuant to Section&#160;12(b) of the Act:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:3pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:41.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_table_9_8"></a>Title&#160;of each class </p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:14.64%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Trading Symbol(s)</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:41.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Name of each exchange on which registered</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:41.24%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Common Stock, par&#160;value&#160;$0.0001 per share</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:9pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:14.64%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">NK</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:9pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:41.24%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">The Nasdaq Stock Market LLC</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Nasdaq Global Select Market)</p></td>
</tr>
</table></div>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Securities registered pursuant to Section&#160;12(g) of the Act:&#160;<font style="font-weight:bold;">None</font></p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark if the Registrant is a well-known seasoned issuer, as defined in Rule&#160;405 of the Securities Act.&#160;YES&#160;<font style="font-family:Segoe UI Symbol;">&#9744;</font> NO&#160;<font style="font-family:Segoe UI Symbol;">&#9746;</font></p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark if the Registrant is not required to file reports pursuant to Section&#160;13 or 15(d) of the Act.&#160;YES&#160;<font style="font-family:'Times New Roman';"><font style="font-size:9pt;font-family:'Times New Roman'">&#9744;</font></font>&#160;NO&#160;<font style="font-family:Segoe UI Symbol;">&#9746;</font></p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the Registrant:&#160;(1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of&#160;1934 during the preceding 12&#160;months (or for such shorter period that the Registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days.&#160;YES&#160;<font style="font-family:Segoe UI Symbol;">&#9746;</font>&#160;NO&#160;<font style="font-family:Segoe UI Symbol;">&#9744;</font></p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation&#160;S-T&#160;(&#167;232.405 of this chapter) during the preceding 12&#160;months (or for such shorter period that the Registrant was required to submit such files).&#160;YES&#160;<font style="font-family:Segoe UI Symbol;">&#9746;</font>&#160;NO&#160;<font style="font-family:Segoe UI Symbol;">&#9744;</font></p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-size:9pt;letter-spacing:-0.1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b-2 of the Exchange Act.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:4.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="top"  style="width:25%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Large&#160;accelerated&#160;filer</p></td>
<td valign="top"  style="width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="top"  style="width:3.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9744;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="top"  style="width:25%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accelerated&#160;filer</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="top"  style="width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9744;</p></td>
<td valign="top"  style="width:3.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:4.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&nbsp;</p></td>
<td valign="top"  style="width:25%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&nbsp;</p></td>
<td valign="top"  style="width:3.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&nbsp;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&nbsp;</p></td>
<td valign="top"  style="width:25%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&nbsp;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&nbsp;</p></td>
<td valign="top"  style="width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&nbsp;</p></td>
<td valign="top"  style="width:3.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:4.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="top"  style="width:25%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-accelerated&#160;filer</p></td>
<td valign="top"  style="width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="top"  style="width:3.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9746;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="top"  style="width:25%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Smaller&#160;reporting&#160;company</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="top"  style="width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9746;</p></td>
<td valign="top"  style="width:3.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:4.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&nbsp;</p></td>
<td valign="top"  style="width:25%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&nbsp;</p></td>
<td valign="top"  style="width:3.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&nbsp;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&nbsp;</p></td>
<td valign="top"  style="width:25%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&nbsp;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&nbsp;</p></td>
<td valign="top"  style="width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&nbsp;</p></td>
<td valign="top"  style="width:3.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:4.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="top"  style="width:25%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="top"  style="width:3.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="top"  style="width:25%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Emerging&#160;growth&#160;company</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="top"  style="width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9746;</p></td>
<td valign="top"  style="width:3.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If an emerging growth company, indicate by check mark if the Registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act.&#160;<font style="font-family:Segoe UI Symbol;">&#9746;</font></p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the Registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act).&#160;YES&#160;<font style="font-family:Segoe UI Symbol;">&#9744;</font>&#160;NO&#160;<font style="font-family:Segoe UI Symbol;">&#9746;</font></p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The aggregate market value of the voting and non-voting common stock held by non-affiliates of the Registrant, based on the closing price of the shares of common stock on the Nasdaq Global Select Market on June&#160;30, 2019, was approximately $28.8&#160;million.</p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The number of shares of the Registrant&#8217;s common stock outstanding as of March 23, 2020 was 98,483,161.</p>
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;text-indent:2.5%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">DOCUMENTS INCORPORATED BY REFERENCE</p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As noted herein, the information called for by Part&#160;III is incorporated by reference to specified portions of the Registrant&#8217;s definitive proxy statement to be filed in conjunction with the Registrant&#8217;s 2020 Annual Meeting of Stockholders, which is expected to be filed not later than 120&#160;days after the Registrant&#8217;s fiscal year ended December&#160;31, 2019.</p>
<p style="border-bottom:Double 2.25pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:4pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU2"></a><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Table of Contents</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:8.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:88.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:3.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Page</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a href="#PART_I"><font style="text-decoration:none;">PART&#160;I</font></a></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:88.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:3.18%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;1.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:88.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_1_BUSINESS"><font style="text-decoration:none;">Business</font></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:3.18%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;1A.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:88.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_1A_RISK_FACTORS"><font style="text-decoration:none;">Risk Factors</font></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:3.18%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;1B.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:88.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_1B_UNRESOLVED_STAFF_COMMENTS"><font style="text-decoration:none;">Unresolved Staff Comments</font></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:3.18%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">113</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;2.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:88.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_2_PROPERTIES"><font style="text-decoration:none;">Properties</font></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:3.18%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">114</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;3.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:88.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_3_LEGAL_PROCEEDINGS"><font style="text-decoration:none;">Legal Proceedings</font></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:3.18%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">114</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;4.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:88.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_4_MINE_SAFETY_DISCLOSURES"><font style="text-decoration:none;">Mine Safety Disclosures</font></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:3.18%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">114</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:88.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:3.18%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a href="#PART_II"><font style="text-decoration:none;">PART&#160;II</font></a></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:88.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:3.18%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;5.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:88.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;letter-spacing:-0.1pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_5_MARKET_FOR_REGISTRANTS_COMMON_EQU"><font style="text-decoration:none;">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</font></a><font style="letter-spacing:-0.1pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:3.18%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">115</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;6.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:88.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_6_SELECTED_FINANCIAL_DATA"><font style="text-decoration:none;">Selected Financial Data</font></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:3.18%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">117</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;7.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:88.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_7_MANAGEMENTS_DISCUSSION_ANALYSIS_F"><font style="text-decoration:none;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</font></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:3.18%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">118</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;7A.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:88.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_7A_QUANTITATIVE_QUALITATIVE_DISCLOS"><font style="text-decoration:none;">Quantitative and Qualitative Disclosures About Market Risk</font></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:3.18%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">139</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;8.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:88.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_8_FINANCIAL_STATEMENTS_SUPPLEMENTAR"><font style="text-decoration:none;">Consolidated Financial Statements and Supplementary Data</font></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:3.18%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">140</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;9.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:88.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_9_CHANGES_IN_DISAGREEMENTS_WITH_ACC"><font style="text-decoration:none;">Changes in and Disagreements With Accountants on Accounting and Financial Disclosure</font></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:3.18%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">178</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;9A.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:88.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_9A_CONTROLS_PROCEDURES"><font style="text-decoration:none;">Controls and Procedures</font></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:3.18%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">178</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;9B.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:88.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_9B_OTHER_INFORMATION"><font style="text-decoration:none;">Other Information</font></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:3.18%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">179</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:88.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:3.18%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a href="#PART_III"><font style="text-decoration:none;">PART&#160;III</font></a></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:88.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:3.18%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;10.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:88.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_10_DIRECTORS_EXECUTIVE_FICERS_CORPO"><font style="text-decoration:none;">Directors, Executive Officers and Corporate Governance</font></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:3.18%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">180</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;11.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:88.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_11_EXECUTIVE_COMPENSATION"><font style="text-decoration:none;">Executive Compensation</font></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:3.18%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">180</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;12.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:88.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_12_SECURITY_OWNERSHIP_CERTAIN_BENEF"><font style="text-decoration:none;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</font></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:3.18%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">180</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;13.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:88.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_13_CERTAIN_RELATIONSHIPS_RELATED_TR"><font style="text-decoration:none;">Certain Relationships and Related Transactions, and Director Independence</font></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:3.18%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">180</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;14.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:88.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_14_PRINCIPAL_ACCOUNTING_FEES_SERVIC"><font style="text-decoration:none;">Principal Accounting Fees and Services</font></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:3.18%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">180</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:88.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:3.18%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a href="#PART_IV"><font style="text-decoration:none;">PART&#160;IV</font></a></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:88.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:3.18%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;15.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:88.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_15_EXHIBITS_FINANCIAL_STATEMENT_SCH"><font style="text-decoration:none;">Exhibits, Financial Statement Schedules</font></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:3.18%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">181</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;16.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:88.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_16_FORM_10K_SUMMARY"><font style="text-decoration:none;">Form 10-K Summary</font></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:3.18%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">183</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:88.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#SIGNATURES"><font style="text-decoration:none;">Signatures</font></a><font style="text-decoration:none;"></font></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:3.18%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">184</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman Bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Explanatory Note</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As used in this Annual Report on Form&#160;10&#8209;K, or Annual Report, for the year ended December&#160;31, 2019, the terms &#8220;NantKwest,&#8221; &#8220;the company,&#8221; &#8220;our,&#8221; &#8220;us&#8221; or &#8220;we&#8221; refer to NantKwest, Inc.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">i</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU3"></a><a name="PART_I"></a><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="PART_I"></a>PAR</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">T I</font></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Forward-Looking Statements</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This Annual Report on Form&#160;10-K, or this Annual Report, may contain &#8220;forward-looking statements&#8221; within the meaning of the federal securities laws made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Our actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors, including those set forth under Part&#160;I, Item&#160;1A,&#160;&#8220;<font style="font-style:italic;">Risk Factors</font>&#8221;, in this Annual Report. Except as required by law, we assume no obligation to update these forward-looking statements, whether as a result of new information, future events or otherwise. These statements, which represent our current expectations or beliefs concerning various future events, may contain words such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;expect,&#8221; &#8220;anticipate,&#8221; &#8220;intend,&#8221; &#8220;plan,&#8221; &#8220;believe,&#8221; &#8220;estimate&#8221; or other words indicating future results, though not all forward-looking statements necessarily contain these identifying words. Such statements may include, but are not limited to, statements concerning the following:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">our ability to pioneer immunotherapy, harness the power of the innate immune system, implement precision cancer medicine and change the current paradigm of cancer care;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">our expectations regarding the potential benefits of our strategy and technology;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">our expectations regarding the operation of our product candidates and related benefits;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">our ability to utilize multiple modes to induce cell death;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">our beliefs regarding the benefits and perceived limitations of competing approaches, and the future of competing technologies and our industry;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">details regarding our strategic vision and planned product candidate pipeline, including that we eventually plan to advance therapies for virally induced infectious diseases;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">our beliefs regarding the success, cost and timing of our product candidate development activities and current and future clinical trials and studies, including study design;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">our expectations regarding our ability to utilize the phase&#160;I and II aNK and haNK clinical trials data to support the development of all of our product candidates, including our haNK, taNK and t&#8209;haNK product candidates;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the timing or likelihood of regulatory filings or other actions and related regulatory authority responses, including any planned investigational new drug, or IND, filings or pursuit of accelerated regulatory approval pathways or orphan drug status and breakthrough therapy designations;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">our ability to implement an integrated discovery ecosystem and the operation of that planned ecosystem, including being able to regularly add neoepitopes and subsequently formulate new product candidates;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the ability and willingness of strategic collaborators, including certain affiliates of NantWorks, LLC, or NantWorks, to share our vision and effectively work with us to achieve our goals;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the ability and willingness of various third parties to engage in research and development activities involving our product candidates, and our ability to leverage those activities;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">our ability to attract additional third party collaborators;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">our expectations regarding the ease of administration associated with our product candidates;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">our expectations regarding the patient compatibility associated with our product candidates;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">our beliefs regarding the potential markets for our product candidates and our ability to serve those markets;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">our ability to produce an &#8220;off-the-shelf&#8221; therapy;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">our beliefs regarding the potential manufacturing and distribution benefits associated with our product candidates, and our ability to scale up the production of our product candidates;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">our plans regarding our manufacturing facility and our belief that our manufacturing is capable of being conducted in&#8209;house;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">our belief in the potential of our aNK&#160;cells as a technology platform, and the fact that our business is based upon the success of our aNK&#160;cells as a technology platform;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">our aNK platform and other product candidate families, including genetically modified taNK, haNK and t&#8209;haNK product candidates, will require significant additional clinical testing;</font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</a></p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><a name="_AEIOULastRenderedPageBreakAEIOU4"></a><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-family:Times New Roman;">even if we successfully develop and commercialize our aNK product candidate, we may not be successful in developing and commercializing our other product candidates either alone or in combination with other therapeutic agents; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the ability to obtain and maintain regulatory approval of any of our product candidates, and any related restrictions, limitations and/or warnings in the label of any approved product candidate;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">our ability to commercialize any approved products;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the rate and degree of market acceptance of any approved products;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">our ability to attract and retain key personnel;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the accuracy of our estimates regarding our future revenue, as well as our future operating expenses, capital requirements and needs for additional financing;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">our ability to obtain funding for our operations, including funding necessary to complete further development and any commercialization of our product candidates;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">our ability to obtain and maintain intellectual property protection for our product candidates and not infringe upon the intellectual property of others;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">regulatory developments in the United States, or U.S., and foreign countries; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">our expectations regarding the period during which we qualify as an &#8220;emerging growth company&#8221; under the JOBS Act, and a &#8220;smaller reporting company,&#8221; as defined in Rule&#160;12b&#8209;2 of the Securities Exchange Act of 1934.</font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, you should refer to Part&#160;I, Item&#160;1A, &#8220;<font style="font-style:italic;">Risk Factors</font>&#8221; of this Annual Report for a discussion of other important factors that may cause actual results to differ materially from those expressed or implied by the forward-looking statements. As a result of these factors, we cannot assure you that the forward-looking statements in this Annual Report will prove to be accurate. Furthermore, if the forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame, or at all. We undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This Annual Report also contains estimates, projections and other information concerning our industry, our business, and the markets for certain diseases, including data regarding the estimated size of those markets, and the incidence and prevalence of certain medical conditions. Information that is based on estimates, forecasts, projections, market research or similar methodologies is inherently subject to uncertainties and actual events or circumstances may differ materially from events and circumstances reflected in this information. Unless otherwise expressly stated, we obtained this industry, business, market, and other data from reports, research surveys, studies, and similar data prepared by market research firms and other third parties, industry, medical and general publications, government data, and similar sources.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:9pt;">&nbsp;</p>
<p style="margin-top:9pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_1_BUSINESS"></a><a name="ITEM_1_BUSINESS"></a>Item&#160;1. Business.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Overview</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a pioneering clinical-stage immunotherapy company, we are focused on harnessing the power of the innate immune system by using its natural killer cells, or NK&#160;cells, to treat cancer and viral infectious diseases. NK&#160;cells are the body&#8217;s first line of defense due to their innate ability to rapidly seek and destroy abnormal cells, such as cancer or virally infected cells, without prior exposure or co-activation by other support molecules, typically required to train and activate adaptive immune cells such as T&#8209;cells.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A critical aspect of our strategy is to invest significantly in innovating new therapeutic candidates, based upon our proprietary activated&#160;NK, or aNK, cell platform, and conducting clinical testing and scale manufacturing of our most promising biologic product candidates.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We hold the exclusive right to commercialize aNK&#160;cells, a commercially viable natural killer cell line, and a wide range of genetically modified derivatives capable of killing cancer and virally infected cells. We own corresponding United States, or U.S., and foreign composition and methods-of-use patents and applications covering the cells, improvements, methods of expansion and manufacture and use of aNK&#160;cells and their improvements as therapeutics to treat a spectrum of clinical conditions.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU5"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We also license exclusive commercial rights to a </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">high-affinity </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CD16 receptor expressing </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">enhancement</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> of our aNK&#160;cell </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">platform</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, covered in a portfolio of U.S. and foreign composition and methods</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">use patents and applications covering both </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">clinical use as a therapeutic to treat cancers in combination with antibody products</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, as well as the non-clinical use in laboratory testing of monoclonal antibodies</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe our proprietary NK&#160;cell platform, coupled with our integrated discovery ecosystem, positions us to implement precision cancer medicine by taking advantage of the advances that have evolved during the past decade and addressing newly discovered challenges of cancer. Cancer is only recently understood to be a complex of rare diseases, with hundreds of cancer specific proteins. We believe proteins, selectively expressed on the cancer cells and not on the essential normal tissue, represent large untapped targeting opportunities for immune effector cell products derived from our aNK&#160;cell platform.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Our Approach</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Multiple Modes of aNK Directed Tumor Cell Killing.<font style="font-weight:normal;font-style:normal;">&nbsp;&nbsp;Our NK platform has demonstrated the ability to induce cell death in cancers and virally infected cells through a variety of concurrent mechanisms including:</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">i.</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-style:italic;">Innate Killing</font>, whereby all of our NK platforms, aNK, haNK, taNK and t&#8209;haNK, recognize the abnormal proteins typically found on the surfaces of metabolically stressed cells, which upon binding, release toxic granules to immediately kill their targets;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ii.</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-style:italic;">Antibody-Mediated Killing</font> with our haNK and t&#8209;haNK platforms, which are aNK&#160;cells engineered to express antibody receptors that can bind to therapeutically administered antibody products or to antibodies naturally produced in the body, thereby enhancing the cancer cell killing effects of those antibodies through Antibody Dependent Cellular Cytotoxicity, or ADCC; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">iii.</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-style:italic;">CAR-Directed Killing</font> with our taNK and t&#8209;haNK platforms, which are aNK&#160;cells engineered to express chimeric antigen receptors, or CARs, that target tumor-specific proteins commonly found only on the surfaces of cancer cells and upon binding, induce cell death through the release of toxic granules directly into their targets and by the release of cytokines and chemokines, which recruit additional innate and adaptive immune responses, including the recruitment of cytotoxic T&#8209;cells.</p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All three modes of killing; <font style="font-style:italic;">Innate Killing, Antibody-Mediated Killing, and CAR-Directed Killing</font>, are employed by our proprietary t&#8209;haNK platform, which combines all the enhanced NK killing functions of aNK, haNK and taNK into a single product platform.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our primary target therapeutic area is cancer, with a heavy emphasis on solid tumors. According to the National Cancer Institute, there was an estimated 1.7&#160;million newly diagnosed cases of cancer in the U.S. in 2019, adding to the 16.9&#160;million already living with cancer. In addition, we plan to advance therapies for hematologic malignancies and virally induced infectious diseases.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Innate Killing - the aNK Platform.<font style="font-weight:normal;font-style:normal;">&nbsp;&nbsp;We have developed a unique NK&#160;cell platform, which we believe is capable of being manufactured as a cell-based &#8220;off-the-shelf&#8221; therapy that can be molecularly engineered in a variety of ways to boost its killing capabilities against cancers and virally infected cells. Unlike normal natural killer cells, our NK&#160;cells do not express the key inhibitory receptors that diseased cells often exploit to turn off the killing function of natural killer cells and escape elimination. We have developed a unique aNK&#160;cell, which omits key inhibitory receptors, while preserving critical activation receptors that enable selective innate targeting and killing of distressed and diseased cells. They do so through the recognition and binding of stress-proteins that are overexpressed on the surfaces of</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">i.</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">rapidly growing cancer cells due to oxidative and metabolic stress, nutrient deprivation and waste accumulation typical when cell growth outpaces the capacity of local circulation; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ii.</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">virally infected cells where the cellular machinery is hijacked to produce an abundance of viral proteins and virons.</p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our aNK&#160;cells can also deliver a more lethal blow to their target by delivering a larger payload of lytic enzymes and cytokines responsible for both direct and indirect killing when compared to other natural killer cells isolated from healthy donors. This is due to the higher density of lytic granules and larger cell volume possessed by aNK&#160;cells when compared to that of donor derived natural killer cells. We believe that our aNK&#160;cells can be produced at commercial scale as a &#8216;living drug&#8217; using our proprietary manufacturing and distribution processes to adequately address select global cancer markets.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU6"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Several phase&#160;I safety studies with aNK&#160;cells have been conducted in a variety of bulky hematological </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">cancers and solid tumors</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, enrolling 46&#160;patients in a range of dose levels and schedules with encouraging evidence of single-agent activity and a durable remission, including </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">complete responses</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> in liquid tumors. Based on these </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">earlier </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">clinical trials, we have further modified </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> aNK platform through virus-free molecular engineering designed to leverage additional modes of killing available to aNKs, including antibody</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">mediated killing, the haNK platform, and both antibody</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">mediated and CAR</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-directed</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> antigen targeted killing, the t</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8209;</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">haNK platform.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Antibody-Mediated Killing - the haNK Platform.<font style="font-weight:normal;font-style:normal;">&nbsp;&nbsp;We have genetically engineered our aNK&#160;cell platform to overexpress high-affinity CD16 receptors, which bind to antibodies. These antibody-targeted haNK&#160;cells are designed to directly bind to IgG1-type antibodies, such as avelumab, trastuzumab, cetuximab and rituximab with the intention of enhancing the cancer killing efficacy of these antibodies by boosting the population of competent natural killer cells that can kill cancer cells through ADCC. Antibody products are abundantly utilized to treat cancer and it is estimated that they generate over $100&#160;billion in reported annual sales. A growing number of studies suggest that clinically meaningful responses to these antibody therapies correlate directly with the overall health of a patient&#8217;s natural killer cell population and whether they express the high-affinity variant of the CD16 receptor. Currently available literature estimates that only approximately 10% to 15% of the addressable patient population eligible for antibody therapies carry high-affinity CD16 receptors. This implies that our haNK product candidate may have significant market potential as a combination therapy to potentially address a large number of patients who do not carry high-affinity CD16 receptors and, as a result, exhibit a poorer response to antibody therapies. We therefore intend to develop our haNK product candidate as a combination therapy with widely-used U.S.&#160;Food and Drug Administration, or FDA, approved antibody products such as avelumab, trastuzumab, cetuximab and rituximab. Current Good Manufacturing Practice, or cGMP, master and working cell banks of our haNK product candidate have been successfully established and will serve as our source for product for our clinical trials and commercialization going forward. We have optimized our haNK product manufacturing process partly through the successful development of a product that does not require IL&#8209;2 cytokine supplementation to the growth media every few days, thereby enabling us to overcome a technically challenging and costly limitation that many other natural killer cell-based therapies face. We have also successfully established processes for large-scale production, cryopreservation and long-term storage of final dose forms, thereby optimizing production efficiencies and allowing for on-demand availability with minimal handling at the infusion sites. Our cryopreserved haNK product has been approved for clinical testing in several phase&#160;Ib/II clinical trials, including our phase&#160;II Merkel cell cancer study.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">CAR-Directed Killing - the taNK Platform.<font style="font-weight:normal;font-style:normal;">&nbsp;&nbsp;We have genetically engineered our aNK platform to express CARs that target tumor-specific antigens found on the surfaces of cancers and virally infected cells. Our taNK&#160;cells are designed to bind directly to these surface antigens and induce cell death through the release of toxic granules directly into the tumor cells and release cytokines and chemokines to recruit additional innate and adaptive immune responses, including the recruitment of cytotoxic T&#8209;cells. These tumor antigens encompass four categories of proteins, all of which can be targeted individually by our engineered taNK products:</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">i.</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Checkpoint ligands, such as PD&#8209;L1 and B7&#8209;H4;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ii.</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Well-established tumor proteins such as HER2 and CD19;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">iii.</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Novel surface antigens associated with cancer stem cells, such as CD123 and IGF&#8209;R1; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">iv.</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Newly discovered proteins, or neoepitopes, from individual patient tumor samples.</p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Preclinical evidence has been mounting which demonstrates that taNK&#160;cell activation through the binding of its CAR receptors to these cancer specific proteins is potent enough to override many of the pre-existing inhibitory signals and immunosuppressive factors present in the tumor microenvironment that may be responsible for tumor resistance.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">CAR-Directed and Antibody-Mediated Killing - the t&#8209;haNK Platform.<font style="font-weight:normal;font-style:normal;">&nbsp;&nbsp;Our newest and most promising platform for the development of therapeutic product candidates is an innovative, bioengineered combination of our haNK and taNK platforms that incorporates all the features of our haNK platform together with a CAR. The resulting line of products under this platform avails itself to all three modes of killing:&#160;</font><font style="font-weight:normal;">innate</font><font style="font-weight:normal;font-style:normal;">, </font><font style="font-weight:normal;">antibody-mediated</font><font style="font-weight:normal;font-style:normal;"> and </font><font style="font-weight:normal;">CAR-directed killing</font><font style="font-weight:normal;font-style:normal;">. These products also include one or more additional expression elements such as functional cytokines, chemokines and trafficking factors, making them amongst the most versatile in our portfolio. These products are intended to be combined with commercially available therapeutic antibodies to effectively target either two different epitopes of the same cancer specific protein or two entirely different cancer specific proteins. In addition to our two t&#8209;haNK product candidates, PD&#8209;L1.t&#8209;haNK, recently cleared to commence phase&#160;II testing, and CD19.t&#8209;haNK, authorized to commence phase&#160;I testing, a pipeline of prominent CARs for t&#8209;haNK, including HER2, which is nearing IND submission, and EGFR, which is advancing through human enabling studies, among others will enable us to address an even broader range of cancers as part of a chemotherapy-free combination regimen.</font></p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU7"></a><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">The Nant Cancer Vaccine.</font><font style="font-weight:normal;font-style:normal;">&nbsp;&nbsp;The Nant Cancer Vaccine, or NCV, program is a personalized therapy regimen, which utilizes our &#8220;off-the-shelf&#8221; NK&#160;cell</font><font style="font-weight:normal;font-style:normal;"> platform</font><font style="font-weight:normal;font-style:normal;"> as the backbone of the </font><font style="font-weight:normal;font-style:normal;">regimen</font><font style="font-weight:normal;font-style:normal;">. NCV consists of an initial tumor-conditioning regimen followed by a molecularly-informed immunologic conditioning therapy. More specifically, NCV combines tumor and peripheral blood genomic and transcriptomic data derived from our affiliates NantOmics&#8217; and NantHealth Labs&#8217; sequencing and analytical services with the novel delivery of metronomic, albumin-bound low-dose chemotherapy in conjunction with certain other agents, followed by a sequenced administration of tumor-associated antigen vaccines and </font><font style="font-weight:normal;font-style:normal;">a unique </font><font style="font-weight:normal;font-style:normal;">IL</font><font style="font-weight:normal;font-style:normal;">&#8209;15</font><font style="font-weight:normal;font-style:normal;"> cytokine</font><font style="font-weight:normal;font-style:normal;">, all of which potentiate our NK&#160;cell therapy to potentially drive immunogenic cell death while avoiding the ravages of toxic high-dose chemotherapy. By inducing immunogenic cell death and enhancing a patient&#8217;s innate and adaptive immune system, NCV is designed to attain a long-term, durable response in multiple cancer types with a potential for lower toxicity and improved efficacy </font><font style="font-weight:normal;font-style:normal;">and quality of life </font><font style="font-weight:normal;font-style:normal;">in comparison with current standards of care. We believe ultimately that employing our NK&#160;cell therapy in the context of NCV w</font><font style="font-weight:normal;font-style:normal;">ill</font><font style="font-weight:normal;font-style:normal;"> be a highly effective combination for long term clinical success over available standards of care that employ maximum tolerated dose, tolerogenic cell death and immune system compromise.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our Integrated Discovery Ecosystem for Precision Medicine.<font style="font-weight:normal;font-style:normal;">&nbsp;&nbsp;In order to effectively target newly discovered neoepitopes, we plan to eventually integrate the following ecosystem to help drive the utility of our NK&#160;cell therapies against these unique cancer markers, including the use of our haNK platform in conjunction with cancer vaccines that induce </font><font style="font-weight:normal;">in&#160;vivo</font><font style="font-weight:normal;font-style:normal;"> antibody formation directed against these mutated proteins, as well as the development of t&#8209;haNK&#160;cells that directly target these mutated proteins:</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">i.</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">a high-speed supercomputing infrastructure to help identify both known antigens on the surface of tumor cells and neoepitopes in clinical patients suffering from cancer, in a timely manner and at large scale;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ii.</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">a next-generation genomic and transcriptomic sequencing infrastructure to verify the expression of the neoepitopes in the tumor cell, developed by our affiliate entity NantOmics;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">iii.</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">delivering the neoepitope via an adenoviral or yeast platform developed by an affiliate entity to induce production of IgG1-type antibodies in the body, which would in turn combine with our haNK&#160;cells to accelerate ADCC tumor killing;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">iv.</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">a diverse library of human antibodies from which to interrogate and extract an antibody to construct a CAR for genetic incorporation into our t&#8209;haNK platform; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">v.</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">CAR&#8209;targeted t&#8209;haNK&#160;cells potentially capable of being produced as a scalable cell-based &#8220;off-the-shelf&#8221; therapy, without the need for patient compatibility matching.</p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect to regularly add newly discovered neoepitopes and novel antibody/CAR targets from our discovery engine and we believe the thousands of newly discovered antigens selectively expressed on the cancer cells and not on the essential normal tissue will provide us with the ability to create new libraries of cancer-specific antibodies and their corresponding CARs to be potentially delivered as living drugs for selective targeting of metastatic cancer cells and cancer stem cells.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Potential Advantages of Our aNK Platform Over T&#8209;Cell and Other Current Immunotherapies</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The immune system has two components:&#160;innate immune cells, such as natural killer cells, which are always primed and ready to attack diseased cells, and adaptive immune cells, such as T&#8209;cells, which are recruited and educated through a series of antigen presentation and clonal expansion, eventually mounting a delayed response. Our proprietary aNK platform is specifically designed to potentially address many of the limitations associated with current adaptive autologous cellular immunotherapies. We believe key limitations of adaptive autologous immunotherapy are the need to isolate adequate amounts of naive T&#8209;cells from a cancer patient in a lengthy procedure called leukapheresis and the requirement for a complex individualized genetic transfection and expansion campaign to manufacture each patient&#8217;s therapy. As a consequence, current autologous CAR&#8209;T&#160;cell therapies, in large part, are limited to patients from highly selected hematological cancers and leave many patients ineligible for treatment. Additionally, patients must undergo lympho-depleting chemotherapy prior to receiving CAR&#8209;T therapy and rely on engraftment, thereby exposing themselves to life-threatening serious adverse events for extended periods. For instance, recipients of CD19 CAR&#8209;T therapy develop life-long B&#8209;cell aplasia and hypogammaglobulinemia, requiring immunoglobulin infusion therapy. Acutely, patients may develop cytokine release syndrome or acute or chronic neurotoxicities. Due to these and other events, treatment with CAR&#8209;T requires intensive inpatient and long term monitoring. In contrast, our allogeneic &#8220;off-the-shelf&#8221; NK&#160;cells can be infused in the outpatient setting and do not rely on the patient as the source of suitable immune cells for processing, thereby availing every cancer patient as a potential candidate for on-demand treatment. In addition, our NK&#160;cell therapy is intended to be combined with immune potentiating agents, rather than immuno-depleting agents with the interest of driving a more natural and long-lasting adaptive immune response. This is largely due to the unique versatility of our cell products, which more closely approximates the characteristics of a drug rather than a transplant. Most cell-based immunotherapies are limited to one or a constrained number of doses due to product limitations and cost burdens, thereby driving the need for immune-ablative therapies and reliance on long-term engraftment to achieve clinically meaningful results. In comparison, our NK cell based therapies can be re-dosed regularly throughout the year and at much higher dose levels without the same product limitations, cost burdens, reliance on long-term engraftment and potential exposure to long-term toxicities.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU8"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For these reasons, we believe that our approach includes the following advantages:</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;">Innate immune response.</font><font style="font-family:Times New Roman;">&nbsp;&nbsp;aNK platform products are always activated and can naturally detect and rapidly destroy a wide variety of diseased cells without prior exposure to antigens or activation by stimulatory molecules.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;">Promotion of adaptive immune response.</font><font style="font-family:Times New Roman;">&nbsp;&nbsp;aNK platform products stimulate the adaptive component of the immune system by producing chemokines and other molecules that recruit and activate T&#8209;cells directly and through dendritic cells to attack cancers.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;">Enhancement of ADCC effect with CD16 expressing haNK cells.</font><font style="font-family:Times New Roman;">&nbsp;&nbsp;Our haNK product candidates may have significant market potential as a combination therapy with approved monoclonal antibodies, or mAbs, targeting tumor associated antigens, as well as neoepitope induced antibodies, potentially addressing a large number of patients who have poor responses to antibody products.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;">Wide therapeutic potential across multiple tumor types and even late-stage disease.</font><font style="font-family:Times New Roman;">&nbsp;&nbsp;In preclinical studies and phase&#160;I and II clinical trials to date, aNK, haNK and t&#8209;haNK&#160;cells have demonstrated activity in a spectrum of cancers, including bulky hematological cancers and solid tumors, as well as late-stage cancer patients who have failed multiple rounds of chemotherapy, radiation and stem cell transplantation.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;">Ability to attack cancer stem cells.</font><font style="font-family:Times New Roman;">&nbsp;&nbsp;aNK&#160;cells have been shown in preclinical studies to preferentially attack cancer stem cells, which have demonstrated resistance to conventional chemotherapy.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;">Applications in diseases beyond cancer.</font><font style="font-family:Times New Roman;">&nbsp;&nbsp;We believe aNK platform products have the potential to treat diseases beyond cancer, such as viral infectious diseases because of the inherent ability of natural killer cells to kill virally infected cells. Preclinical studies in HIV, HCV, EBV and Ebola viruses demonstrate this capability.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;">Well tolerated.</font><font style="font-family:Times New Roman;">&nbsp;&nbsp;aNK&#160;platform products are hypo-immunogenic and have shown no dose limiting toxicities in over 900&#160;patient infusions, including in recipients who have received long-term repeat infusions beyond a year.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;">Ease of administration.</font><font style="font-family:Times New Roman;">&nbsp;&nbsp;aNK platform products may be administrable in outpatient facilities, offering physicians the flexibility to re-dose therapy in the ambulatory setting for extended periods and in large practices.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;">Virtually universal patient compatibility.</font><font style="font-family:Times New Roman;">&nbsp;&nbsp;aNK platform products do not require patient-donor matching or a minimum level of patient immuno-competence.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;">Low-cost, efficient and scalable manufacturing.</font><font style="font-family:Times New Roman;">&nbsp;&nbsp;aNK, haNK, taNK and t&#8209;haNK&#160;cells have the potential to be expanded on a large scale and readily supplied on demand from what we believe is the world&#8217;s only cGMP compliant aNK, haNK and t&#8209;haNK&#160;cell banks, proprietary assets of our company.</font></p></td></tr></table></div>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Experienced Management Team</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since the founding of our company in 2002, we have assembled a team of proven, experienced and visionary leaders in biotechnology. Our team is led by Patrick Soon-Shiong, M.D., FRCS (C), FACS, our Chairman and Chief Executive Officer, or CEO. Dr.&#160;Soon-Shiong was first introduced to us in 2007 when our technology was at a very early stage of development and he provided us with advice and scientific development strategies, including demonstration of activity in the clinical setting following irradiation of the cells and demonstration of safety and activity following multiple infusions in patients with both end-stage solid and liquid tumors. Dr.&#160;Soon-Shiong made an equity investment in our company in December&#160;2014, joined as our Chief Medical Officer in January&#160;2015, and became our Chairman and CEO in March&#160;2015. Dr.&#160;Soon-Shiong, a renowned surgeon and scientist, has pioneered novel therapies for both diabetes and cancer, published over 100 scientific papers in the U.S., and has been issued over 230 worldwide patents on groundbreaking advancements spanning a myriad of fields. He performed the first encapsulated islet stem cell transplant in a diabetic patient in the U.S. He invented, developed and launched the first nanoparticle delivery system of human albumin, abraxane. Dr.&#160;Soon-Shiong was founder, Chairman and CEO of American Pharmaceutical Partners (sold to Fresenius SE for approximately $4.6&#160;billion in 2008), Abraxis BioScience (sold to Celgene Corporation for approximately $3.8&#160;billion in 2010), and NantWorks, an ecosystem of companies to create a transformative global health information and next generation pharmaceutical development network.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Barry Simon, M.D., our President and Chief Administrative Officer, who was our CEO from May&#160;2007 until March&#160;2015 and our President and Chief Operating Officer from March&#160;2015 to December&#160;2016, brings decades of drug development and executive leadership experience from Roche Labs, F. Hoffmann-La Roche, Connetics Corp. and Immunomedics, having successfully contributed to Biologics License Applications, or BLAs, and drug launches for Xeloda, Pegasys, Kytril, Fortovase, Valcyte, Fuzeon and Tamiflu.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since 2015, we have recruited seasoned executives to lead manufacturing, clinical development, regulatory affairs, medical affairs, quality and other critical staff as we continue to build our management and manufacturing infrastructure.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU9"></a><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Company Vision</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We aspire to be the premier immunotherapy company, with the ultimate goal of harnessing the power of the innate&#160;immune&#160;system&#8212;with the NK&#160;cell at its core&#8212;to pioneer precision medicine in treatments for cancers and viral infectious diseases.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Our Core Strategies</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our goal of becoming the world leader in immunotherapy for cancers and other diseases can be realized through a major reframing of how we apply the collective knowledge amassed in this field to date. This starts with precisely determining the &#8216;molecular address&#8217; of the target disease and leveraging this knowledge in the selection and staging of both tumor and immune conditioning agents in accordance with our understanding of biological mechanisms of action and the natural order of immune biology. Metronomic, low-doses of certain agents would be utilized to potentiate cellular stress and boost tumor immunogenicity, while an array of other agents would be applied selectively and sequentially to propagate a meaningful and lasting adaptive immune response. We believe that by utilizing the NK&#160;cell as the backbone and central coordinator as we engage and sequentially orchestrate the entire ecosystem of immune cells, we can effectively empower the patient&#8217;s own immune system to regain control by becoming its own &#8216;drug factory&#8217; that can establish and once again maintain a cancer-free environment in the body. The key elements of our strategy include:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;">Pursuit of both accelerated regulatory pathways and large market opportunities.</font><font style="font-family:Times New Roman;">&nbsp;&nbsp;We are pursuing a comprehensive clinical development plan designed to maximize the commercial potential of our haNK and t&#8209;haNK platforms as the backbone in the treatment of cancers in a streamlined combination with a PD&#8209;L1 checkpoint inhibitor and a highly selective and molecularly enhanced IL&#8209;15 cytokine immunotherapy. We intend to pursue accelerated regulatory approval pathways and seek indications that can lead to orphan drug status and breakthrough therapy designation, as well as pursue large market opportunities in select solid tumors in the shortest feasible timeframe.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;">Progress our lead haNK product through phase&#160;II and registration trials.</font><font style="font-family:Times New Roman;">&nbsp;&nbsp;We are leveraging the combined human safety and activity data accumulated to date on haNK therapy to conduct our multi-center phase&#160;II trial in patients with Merkel cell carcinoma who have relapsed on checkpoint therapy.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;">Advance our next-generation t&#8209;haNK products towards phase&#160;II and registration trials.</font><font style="font-family:Times New Roman;">&nbsp;&nbsp;Our broadly applicable t&#8209;haNK product, PD&#8209;L1.t&#8209;haNK, is expected to conclude phase&#160;I clinical testing by June&#160;30, 2020, and the first phase&#160;II trials in pancreatic and PD&#8209;L1 expressing non-small cell lung cancers have recently been filed with the FDA, with an additional phase&#160;II trial submission in lung cancer with concurrent chemotherapy in preparation for submission. Additionally, our CD19.t&#8209;haNK IND application has been approved by the FDA for a dose escalation phase&#160;I study in patients with CD19 expressing diffuse large&#160;B-cell lymphomas and our Her2.t&#8209;haNK IND application is nearing completion and being readied for submission with the FDA during the first half of 2020. Additions to our pipeline of IND-ready t&#8209;haNK product candidates may include EGFR and BCMA t&#8209;haNK products during the second half of 2020.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;">Leverage our exclusive co-development agreement with ImmunityBio for N-803.</font><font style="font-family:Times New Roman;">&nbsp;&nbsp;As with the emergence of dozens of CAR&#8209;T companies following the success of a select few, more and more natural killer cell therapy companies are forging ahead into the cancer immunotherapy space. Due to the lack of market access to suitable companion products for co-development, such as cytokine therapies, many natural killer cell therapy developers are following the path of CAR&#8209;T sponsors in the use of myeloablative therapies that support engraftment, but at the same time suppresses immune recruitment and the recipient&#8217;s ability to mount an adaptive immune response. N&#8209;803 is an experimental IL&#8209;15 superagonist, currently in late stage registration trials by ImmunityBio, Inc., an affiliated entity. Our utilization of N&#8209;803 in combination with our NK therapies across our clinical program affords us an additional distinction and competitive advantage where we combine systemic activation of recipient natural killer and T&#8209;cells with chemotherapy-free treatment regimens for maximal immune response and memory T&#8209;cell formation.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;">Pursue partnering opportunities with pharmaceutical companies for commercially approved antibodies and select late-stage antibodies in development.</font><font style="font-family:Times New Roman;">&nbsp;&nbsp;Numerous biopharmaceutical companies have previously licensed our research-grade haNK&#160;cells through an affiliated entity for non-therapeutic applications that facilitate the discovery, selection and validation of their antibody candidates for development. A growing number of these biopharmaceutical companies have also licensed our cells for use in their antibody manufacturing and testing procedures in order to satisfy requirements by the FDA and comparable foreign regulatory agencies. There may be multiple opportunities to leverage these biopharmaceutical business relationships to forge therapeutic collaborations to conduct clinical studies with our haNK and t&#8209;haNK product candidates in combination with their late-stage and commercial antibody products to demonstrate enhanced activity when used in combination.</font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</a></p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><a name="_AEIOULastRenderedPageBreakAEIOU10"></a><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;">Accelerate clinical development of our t-haNK products by implementing phase&#160;Ib/II basket trials.</font><font style="font-family:Times New Roman;">&nbsp;&nbsp;A growing number of antibody and other anti-cancer products are being marketed for multiple cancer types that share the same molecular abnormality. We plan to accelerate clinical development of our PD</font><font style="font-family:Times New Roman;">&#8209;L1.t</font><font style="font-family:Times New Roman;">&#8209;haNK</font><font style="font-family:Times New Roman;">, </font><font style="font-family:Times New Roman;">CD19.t</font><font style="font-family:Times New Roman;">&#8209;haNK and </font><font style="font-family:Times New Roman;">Her2.t</font><font style="font-family:Times New Roman;">&#8209;haNK </font><font style="font-family:Times New Roman;">product candidates by designing trials that permit the enrollment of patients whose cancers demonstrate high levels of PD</font><font style="font-family:Times New Roman;">&#8209;L1</font><font style="font-family:Times New Roman;">, </font><font style="font-family:Times New Roman;">CD19 and</font><font style="font-family:Times New Roman;"> HER2</font><font style="font-family:Times New Roman;">, respectively, from a number of select cancer types. We believe this approach will enhance the development potential of our t</font><font style="font-family:Times New Roman;">&#8209;haNK product pipeline.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;">Employ an adaptive approach to our clinical trials designs.</font><font style="font-family:Times New Roman;">&nbsp;&nbsp;As we explored complex combinations in our NCV trials that combined tumor conditioning agents, IL-15 cytokine activation, adenoviral and yeast vaccine driven dendritic cell activation and antibody therapy together with our haNK cell therapy across multiple tumor types, we continued to optimize the treatment design over time after accumulating sufficient outcome observations through IND amendments and new IND filings. By doing so, we were able to considerably condense the development time frame while providing patient access to the enhanced protocol designs much sooner than would have otherwise been possible.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;">Establish low-cost, scalable manufacturing capabilities to support late-stage clinical trials and global commercialization.</font><font style="font-family:Times New Roman;">&nbsp;&nbsp;We believe our aNK platform products offer unique advantages of a simplified, on-demand manufacturing process that is relatively easy to scale and requires minimal handling at the site of infusion. We opened our state-of-the-art commercial production facility in El Segundo, California, at the beginning of 2019 and transferred all of our manufacturing operations from our pilot facility in Culver City, California. We believe this new facility is capable of producing clinical product for all our clinical trials for multiple product lines and well into commercialization. We have developed novel manufacturing methods, including the use of proprietary equipment that employs state-of-the-art optics, as well as proprietary media, designed to maximize the attributes of our NK product lines. We have eliminated the need for IL&#8209;2 media supplementation in all of our bioreactors and product lines, thereby simplifying the expansion process and shortening the culturing times while significantly reducing production costs. We have also implemented proprietary cryopreservation methods that enable large-scale production yields that can be easily processed into final frozen dose forms for long-term storage and simple, on-demand shipping. Cryopreservation allows for significant cost efficiencies and the establishment of a substantial commercial pipeline supply, much like shelf-stable pharmaceutical drugs. We have effectively eliminated reliance on third party contract manufacturers, with the associated risks to cost, time and reliability. We plan to continue to improve our costs as we scale up production to larger capacity bioreactors that can support serial harvests, the utilization of consumables that will support fully automated production lines from harvest to cryopreserved product and establish additional efficiencies across products pipelines.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;">Pursue opportunities with vaccine combination partnerships that drive in&#160;vivo production of anti-cancer antibodies for ADCC killing with haNK and t&#8209;haNK cells.</font><font style="font-family:Times New Roman;">&nbsp;&nbsp;Upon achieving initially anticipated BLAs for our haNK and PD&#8209;L1.t&#8209;haNK products in simple combinations with N&#8209;803 and a monoclonal antibody, we plan to initiate a wide range of combination therapy studies that incorporate adenoviral and yeast vaccine platforms to deliver tumor associated antigens which induce the natural production of IgG1-type antibodies in patients, and when combined with our haNK and t&#8209;haNK products, would be expected to potentiate ADCC killing.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;">Extend our NK platform to address diseases beyond cancer.</font><font style="font-family:Times New Roman;">&nbsp;&nbsp;We believe our aNK platform has the potential to address diseases beyond cancer such as viral infectious diseases because of the innate ability of natural killer cells to kill virally infected cells. Preclinical studies in HIV, HCV, EBV and Ebola viruses demonstrate this capability. Preclinical efforts are underway to evaluate the role of haNK in combination with select broadly neutralizing antibody, or bNAb, candidates in clearing HIV reservoirs as part of a novel immunotherapy combination regimen. Additionally, exploratory efforts are proceeding with the evaluation of haNK&#160;cells, as well as other variants, in the treatment of moderate to severe respiratory infections due to Coronaviruses, such as SARS&#8209;CoV&#8209;2.</font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU11"></a><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Our Therapeutic Platforms</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Leveraging Our Assets</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have developed a pre-clinical portfolio of t&#8209;haNK products based on the combined attributes of our existing haNK and taNK platforms. We have also advanced our haNK product into clinical trials across several solid-tumor types, which incorporates a comprehensively orchestrated tumor and immune-conditioning regimen known as the Nant Cancer Vaccine, or NCV, and generated compelling safety and activity data. We now plan to advance our lead clinical candidates from the haNK and t&#8209;haNK platforms into checkpoint inhibitor and IL&#8209;15 combination trials in select cancer indications.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our aNK Platform is the Foundation for Our haNK, taNK and t&#8209;haNK Product Candidates.<font style="font-weight:normal;font-style:normal;">&nbsp;&nbsp;Based on the unique characteristics of our aNK&#160;cells, we continue to expand the potential therapeutic applications of this platform through molecular engineering designed to leverage the multiple modes of killing available to aNK&#160;cells, including&#160;(1)&#160;innate plus antibody-mediated killing, the haNK platform; (2)&#160;innate plus antigen targeted killing, the taNK platform; and (3)&#160;a combination of all three, the t&#8209;haNK platform, as illustrated below.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g4i5nix4zlkt000001.jpg" title="" alt="" style="width:671px;height:513px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU12"></a><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Antibody</font><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">-</font><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Mediated Killing - the haNK Platform.</font><font style="font-weight:normal;font-style:normal;">&nbsp;&nbsp;We have genetically engineered our aNK&#160;cells to both overexpress high-affinity CD16 receptors and the IL</font><font style="font-weight:normal;font-style:normal;">&#8209;2 cytokine. These haNK&#160;cells are well suited to directly bind to concurrently administered therapeutic antibodies such as avelumab, trastuzumab, cetuximab and rituximab to potentially enhance their targeted cancer killing effects through ADCC, as illustrated below.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g4i5nix4zlkt000002.jpg" title="" alt="" style="width:671px;height:496px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU13"></a><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">CAR</font><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">-Directed</font><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"> Killing - the taNK Platform.</font><font style="font-weight:normal;font-style:normal;">&nbsp;&nbsp;</font><font style="font-weight:normal;font-style:normal;">We have genetically modified our aNK&#160;cells to incorporate CARs that target cancer specific proteins typically found on the surface of cancer cells. These taNK&#160;cells are designed to directly bind to these surface proteins in a variety of solid and hematological cancers and induce cell death through the release of toxic granules directly into the tumor cell and the release of cytokines and chemokines, which recruit additional innate and adaptive immune responses, including the recruitment of cytotoxic T</font><font style="font-weight:normal;font-style:normal;">&#8209;cells. CARs are complex molecules that are designed to traverse the cell membrane and are comprised of four elements:&#160;(1)&#160;the antibody-derived </font><font style="font-weight:normal;font-style:normal;">single-chain </font><font style="font-weight:normal;font-style:normal;">Fv fragment</font><font style="font-weight:normal;font-style:normal;">,</font><font style="font-weight:normal;font-style:normal;"> </font><font style="font-weight:normal;font-style:normal;">or scFv, </font><font style="font-weight:normal;font-style:normal;">which appears on the external membrane surface of the taNK&#160;cell, where it is exposed and available to bind to cancer specific antigens; (2)&#160;a transmembrane hinge region; (3)&#160;a CD28 co-stimulatory domain; and (4)&#160;one of several signaling domain segments which resides on the internal surface of the membrane where, upon external </font><font style="font-weight:normal;font-style:normal;">scFv</font><font style="font-weight:normal;font-style:normal;"> binding, it is available to signal the activation cascade to release cytotoxic compounds to destroy the targeted cancer cell. Unlike CAR</font><font style="font-weight:normal;font-style:normal;">&#8209;T and T</font><font style="font-weight:normal;font-style:normal;">&#8209;cell receptor therapies, taNK killing is human leukocyte antigen, or HLA, independent for &#8220;off-the-shelf&#8221; applications and does not depend on additional (second generation) co-stimulatory domains, such as 4</font><font style="font-weight:normal;font-style:normal;">&#8209;1BB or OX40, which are often necessary in CAR</font><font style="font-weight:normal;font-style:normal;">&#8209;T cells for immune cell activation and survival.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g4i5nix4zlkt000003.jpg" title="" alt="" style="width:671px;height:504px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU14"></a><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">CAR</font><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">-Directed</font><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"> and Antibody</font><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">-</font><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Mediated Killing - the t</font><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#8209;haNK Platform.</font><font style="font-weight:normal;font-style:normal;">&nbsp;&nbsp;We have genetically engineered our aNK&#160;cells to exhibit all three mechanisms of killing, thereby imparting CAR targeted killing via cancer specific antigens, ADCC based killing as mediated by antibody products, innate killing inherent to </font><font style="font-weight:normal;font-style:normal;">natural killer </font><font style="font-weight:normal;font-style:normal;">cells, as well as independence from IL</font><font style="font-weight:normal;font-style:normal;">&#8209;2 supplementation for expansion and viability. Based on this unique arrangement, t</font><font style="font-weight:normal;font-style:normal;">&#8209;haNK&#160;cells can target two distinct cancer antigens at once:&#160;one via its CD16 receptor </font><font style="font-weight:normal;font-style:normal;">together with</font><font style="font-weight:normal;font-style:normal;"> an antibody such as rituximab&#160;(CD20), and the other through its CAR receptor&#160;(i.e.&#160;</font><font style="font-weight:normal;font-style:normal;">PD</font><font style="font-weight:normal;font-style:normal;">&#8209;L1</font><font style="font-weight:normal;font-style:normal;">), as illustrated below.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g4i5nix4zlkt000004.jpg" title="" alt="" style="width:671px;height:578px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the taNK and t&#8209;haNK&#160;cell lines, the activation signaling that results from the binding of the CARs to the tumor-specific antigens can be strong enough to overcome both cancer escape mechanisms and suppressive factors present in the tumor microenvironment. These tumor antigens encompass four categories of proteins, all of which can be targeted individually by our engineered taNK products:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">i.</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Checkpoint ligands, such as PD&#8209;L1 and B7&#8209;H4;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ii.</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Well-established tumor proteins such as HER2 and CD19;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">iii.</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Novel surface antigens associated with cancer stem cells such as CD123 and IGF&#8209;R1; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">iv.</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Newly discovered proteins, or neoepitopes, from individual patient tumor samples.</p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU15"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The table below </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">is a partial list</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> of CAR</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> modified aNK</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> products </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in the literature </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and their intended</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> tumor types.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g4i5nix4zlkt000005.jpg" title="" alt="" style="width:671px;height:290px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Non-Clinical Validation of Lenti- and Retroviral Generated taNK Cell Lines; a Compelling Case for Virus-Free t&#8209;haNK-Based Therapies.<font style="font-weight:normal;font-style:normal;">&nbsp;&nbsp;We are preparing a novel lineup of virus-free t&#8209;haNK product candidates that are cryopreserved, CAR expressing cell lines based on our haNK&#160;cell therapeutic, one of which is progressing towards phase&#160;II clinical trials. Our rapid advancement of the virus-free t&#8209;haNK platform has enabled us to discontinue all use of viral vectors as a means to genetically enhance our platforms. These next-generation products avoid the safety concerns associated with the use of retro- and lentivirus sequences, incorporate the high-affinity CD16 receptor for enhanced antibody-mediated killing, as well as IL&#8209;2 for IL&#8209;2 growth independence, which can potentially reduce production costs and enhance clinical efficacy.</font></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Clinical Experience With Our Unmodified aNK&#160;Platform as a Cell Therapy Candidate</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our clinical experience with single and multiple intravenous infusions of aNK monotherapy across a range of relapsed and refractory solid and hematological malignancies has been consistently encouraging from both a safety and activity standpoint. We have demonstrated single-agent safety with dose escalations in both single and repeat dosing schedules to doses as high as 1&#160;x&#160;10<sup style="font-size:85%;line-height:120%;vertical-align:top">10</sup>&#160;cells/m<sup style="font-size:85%;line-height:120%;vertical-align:top">2</sup> and as many as 18&#160;infusions over a six-month period, corresponding to a cumulative dose of as high as 15&#160;x&#160;10<sup style="font-size:85%;line-height:120%;vertical-align:top">10</sup>&#160;cells in an individual patient. Infusion-related toxicities remained generally mild across all studies and dose levels, with the exception of one grade&#160;3 fever and one grade&#160;4 hypoglycemic episode, neither of which resulted in dose reduction or study discontinuation. A minority of subjects that proceeded with additional testing were found to have detectable levels of anti-HLA antibodies, but none were required to withdraw from study and some continued to receive additional infusions without sequelae.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">While many cell-based adaptive immunotherapy trials impose heavy pre-screening protocols to cherry-pick likely responders, our subjects were not pre-selected, but rather we accepted all-comers after meeting simple eligibility criteria, including patients who had very advanced disease, having failed multiple rounds of standard chemotherapy, radiation, surgery and even stem cell transplantation. Additionally, none of these patients received lympho-depleting or pre-conditioning regimens in order to enhance therapeutic effects.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Although aNK is not intended as a monotherapy, clinical activity was recorded in all studies conducted to date:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">i.</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Among the three Merkel cell cancer patients receiving aNK&#160;cell monotherapy, one subject achieved a radiologic complete response.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ii.</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Among the four lung cancer patients treated, three subjects had clinically significant responses including one with a resolved supraclavicular lymph node metastasis, the second with a nearly resolved mediastinal lung metastasis and the third with a 23-month disease stabilization with thoracic pain resolution.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">iii.</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Among 12&#160;patients with advanced melanoma and renal cell carcinoma, one melanoma patient went on to have a mixed response with several lesions resolving, and five renal cell carcinoma patients achieved disease stabilization after having breakthrough progression on their prior therapies.</p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</a></p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">iv.</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><a name="_AEIOULastRenderedPageBreakAEIOU16"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Among 12&#160;subjects with advanced hematological malignancies, two&#160;subjects</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, one</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> with Hodgkin&#8217;s lymphoma and </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the other with </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">multiple myeloma, achieved a </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">complete response.</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A third </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">subject achieved a partial response</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">another </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">subject achieved </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a clinical-transient response, and </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a fifth</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> subject achieved a mixed-transient response.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">v.</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Among six patients with acute myeloid leukemia, one subject achieved a significant reduction in percentage of blasts and two subjects achieved a stable percentage of blasts present in their peripheral blood.</p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additional detail on each of these studies follows:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:italic;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">i.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:italic;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Merkel Cell Carcinoma: QUILT&#160;3.009 (NantKwest Sponsored)</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This completed multi-center, nonrandomized, open-label phase&#160;II study was conducted in patients 18&#160;years and older with histologically confirmed stage&#160;IIIB or stage&#160;IV inoperable Merkel cell carcinoma. The primary endpoint was a four month progression-free survival rate, and the secondary endpoints were overall response rate, time to disease progression, median overall survival, safety, and quality-of-life assessment. The study employed a Simon&#8217;s two-stage design where upon if at least one patient from the first stage of treatment with aNK monotherapy achieved progression-free survival for 16&#160;weeks or more, the second stage would initiate and proceed to full enrollment. Shortly after the first patient reached the 16&#160;week progression-free survival metric, the protocol was amended such that all second stage patients would receive aNK in combination with N&#8209;803. The aNK dose of 2&#160;&#215;&#160;10<sup style="font-size:85%;line-height:120%;vertical-align:top">9</sup>&#160;cells/m<sup style="font-size:85%;line-height:120%;vertical-align:top">2</sup> was administered intravenously on two consecutive days every two&#160;weeks (one cycle). N&#8209;803 was administered subcutaneous at 10&#160;&#181;g/kg on the first day of every aNK infusion (prior to aNK infusion) every two&#160;weeks. Patients were withdrawn from the trial if there was evidence of disease progression at any time after the fourth cycle.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g4i5nix4zlkt000006.jpg" title="" alt="" style="width:671px;height:377px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU17"></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A total of three subjects received treatment with aNK monotherapy and a total of four subjects were treated with aNK plus N</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8209;803, all having previously received and failed treatment with multiple lines of therapy that included checkpoint inhibitors. There were no serious adverse events of grade&#160;3 or higher that were considered to be related to treatment with the study drugs. All adverse events that may have been related to study drug administration were grade&#160;2 or milder and included chest tightness, chills, fatigue, upper respiratory infection, strep throat, redness at the injection site, hypokalemia, hypotension, anorexia, mucosal infection, and hyponatremia.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g4i5nix4zlkt000007.jpg" title="" alt="" style="width:671px;height:464px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As reported at the November&#160;2019 Society for Immunotherapy Conference and subsequently updated, of the seven subjects enrolled, three having received aNK monotherapy and four having received aNK plus N-803, three experienced a clinical benefit. The objective response rate was 29%, with two of seven patients experiencing a complete response or partial response:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">One heavily pretreated patient that progressed on pembrolizumab, received aNK monotherapy and achieved and maintained a radiologic complete response until progressive disease was confirmed by biopsy at eight&#160;months. Re-challenge with pembrolizumab after aNK therapy resulted in an ongoing durable complete response at 44&#160;months.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">A second patient receiving aNK plus N&#8209;803 experienced pseudo-progression at three and a half&#160;months after initially responding and was taken off therapy with no subsequent intervention. This patient subsequently went on to experience a durable partial response with more than 86% tumor regression that is still ongoing at 29&#160;months.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">A third patient experienced an ongoing stable disease, now beyond five and a half&#160;months.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">Intriguing changes were noted clinically in superficial tumors in several patients within hours of aNK infusion.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">Three of the remaining four patients showed progressive disease at the first imaging assessment. The final patient was discontinued from treatment due to clinical disease progression prior to the first imaging assessment.</font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g4i5nix4zlkt000008.jpg" title="" alt="" style="width:671px;height:370px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Results from this study show that treatment with aNK and N&#8209;803 is well-tolerated, as no treatment-related serious adverse events were associated with aNK monotherapy or with aNK plus N&#8209;803 combination therapy. Treatment with both aNK monotherapy and aNK plus N&#8209;803 combination therapy were associated with anticancer activity as evidenced by increased antigen presentation, IFN&#8209;&#947; and other immune response gene expression, as well as CD8+ and CD4+ immune cell infiltration in the tumor microenvironment in addition to measurable tumor responses. Moreover, evidence that aNK&#160;cell treatment may reverse refractoriness to immune checkpoint inhibitors was observed with a patient that previously progressed while on pembrolizumab, only later to experience a durable complete response to pembrolizumab re-challenge after completing aNK&#160;cell therapy. These results suggest treatment with aNK and N&#8209;803 at doses sufficient to elicit tumor regression is associated with manageable and relatively modest adverse events and provides a foundation upon which to investigate the use of our &#8220;off-the-shelf&#8221; haNK product in QUILT&#160;3.067, a phase&#160;II trial investigating a chemotherapy-free combination of haNK, N&#8209;803 and the checkpoint inhibitor avelumab.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:italic;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">ii.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:italic;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Advanced Solid Tumors (Investigator Sponsored)<sup style="font-size:85%;line-height:120%;vertical-align:top">1</sup><sup style="font-size:85%;line-height:120%;vertical-align:top"></sup></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This phase&#160;I, single-arm, open-label, dose-escalation study conducted at the University Hospital in Frankfurt, evaluated the safety and efficacy of aNK&#160;cell monotherapy in 15&#160;pediatric and adult patients with advanced cancer resistant to standard therapies. The objectives of the study were to evaluate safety and clinical outcomes. The three aNK dose levels were 1&#160;&#215;&#160;10<sup style="font-size:85%;line-height:120%;vertical-align:top">9</sup>&#160;cells/m<sup style="font-size:85%;line-height:120%;vertical-align:top">2</sup>, 3&#160;&#215;&#160;10<sup style="font-size:85%;line-height:120%;vertical-align:top">9</sup>&#160;cells/m<sup style="font-size:85%;line-height:120%;vertical-align:top">2</sup>, and 1&#160;&#215;&#160;10<sup style="font-size:85%;line-height:120%;vertical-align:top">10</sup>&#160;cells/m<sup style="font-size:85%;line-height:120%;vertical-align:top">2</sup> (1&#160;&#215;&#160;10<sup style="font-size:85%;line-height:120%;vertical-align:top">10</sup>&#160;cells/m<sup style="font-size:85%;line-height:120%;vertical-align:top">2</sup> was administered in adults only). Two infusions of aNK were administered intravenously on days one and three.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All infusions were well tolerated by all patients, even at the highest dose level, with the exception of one&#160;patient whose second transfusion was discontinued after he reported lower back pain. No effect on bone marrow function was observed in any patient as stable blood cell counts observed were over the first four weeks after aNK treatment. Likewise, no changes in renal and hepatic functions were noted. One of seven tested patients had an antibody response to HLA antigens expressed by aNK at the time of testing, one- and four-weeks after aNK infusions; this patient had received blood transfusions after aNK infusion with potential transmission of antibodies.</p>
<div align="left"><table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:20%;"><tr><td style="width:20%;"></td></tr><tr><td valign="top"  style="border-bottom:Solid 1pt #000000;"><p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;text-indent:0pt;font-size:8pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:0%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">1</sup>&nbsp;</font></p></td>
<td valign="top" style="width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:9pt;"> Tonn et al, Cytotherapy. 2013 Dec;15(12):1563-70</font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU18"></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Three patients with advanced lung cancer had clinically significant re</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">sponses after two doses of aNK:</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">One patient had a diagnosis of non-small cell lung cancer with multiple lung metastases resistant to conventional chemotherapy, radiation and surgery. After treatment with two infusions of 1&#160;&#215;&#160;10<sup style="font-size:85%;line-height:120%;vertical-align:top">10</sup>&#160;cells/m<sup style="font-size:85%;line-height:120%;vertical-align:top">2</sup>, the patient experienced stable disease. Four months after receiving two initial infusions, the patient received four additional infusions of aNK&#160;cells (5&#160;&#215;&#160;10<sup style="font-size:85%;line-height:120%;vertical-align:top">9</sup>&#160;to&#160;1&#160;&#215;&#160;10<sup style="font-size:85%;line-height:120%;vertical-align:top">10</sup>&#160;cells/m<sup style="font-size:85%;line-height:120%;vertical-align:top">2</sup>) over a period of six months, with no adverse events from either the initial or subsequent treatments. The patient had an overall survival of 23 months after receiving the initial two infusions of aNK.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">One patient had a diagnosis of small cell lung cancer with a supraclavicular lymph node metastasis, also resistant to conventional chemotherapy, radiation and surgery. After treatment with two infusions of 3&#160;&#215;&#160;10<sup style="font-size:85%;line-height:120%;vertical-align:top">9</sup>&#160;cells/m<sup style="font-size:85%;line-height:120%;vertical-align:top">2</sup>, the patient&#8217;s lymph node metastasis could no longer be detected. This patient experienced a mixed response and went on to have an overall survival of nearly 18 months.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">Another patient had a diagnosis of small cell lung cancer with multiple metastases in the liver and a one inch single metastasis in the lung just behind the sternum. After two infusions of 3&#160;&#215;&#160;10<sup style="font-size:85%;line-height:120%;vertical-align:top">9</sup>&#160;cells/m<sup style="font-size:85%;line-height:120%;vertical-align:top">2</sup>, there was significant regression in the lung metastasis as verified by lateral imaging before and 14&#160;days after aNK treatment with no regression of the liver metastases. This patient was recorded as having a mixed response and an overall survival of eight&#160;months.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Such beneficial effects of aNK&#160;cell therapy in three of four lung cancer patients may not be surprising as we better understand aNK biodistribution upon intravenous administration. After circulating through the right heart and pulmonary vasculature, murine models of aNK trafficking reveal that the cells demarginate and reside in the lungs within the first hours after infusion before circulating systemically to distant organs, including spleen, kidney, bladder and peripherally implanted tumor.<sup style="font-size:85%;line-height:120%;vertical-align:top">2</sup><sup style="font-size:85%;line-height:120%;vertical-align:top"></sup></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g4i5nix4zlkt000009.jpg" title="" alt="" style="width:671px;height:408px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This could potentially make tumors of the lung the most readily accessible among solid tumors to serial infusions of aNK&#160;cells and provide a foundation upon which to investigate the use of our &#8220;off-the-shelf&#8221; PD&#8209;L1.t&#8209;haNK product in QUILT&#160;59, a late-stage trial investigating a chemotherapy-free combination of PD&#8209;L1.t&#8209;haNK, N&#8209;803 and a checkpoint inhibitor.</p>
<div align="left"><table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:20%;"><tr><td style="width:20%;"></td></tr><tr><td valign="top"  style="border-bottom:Solid 1pt #000000;"><p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;text-indent:0pt;font-size:8pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:0%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">2</sup>&nbsp;</font></p></td>
<td valign="top" style="width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:9pt;"> NantKwest, Klingemann H., et al., data on file</font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17</a></p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:italic;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">iii.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:italic;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><a name="_AEIOULastRenderedPageBreakAEIOU19"></a><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"></font><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"></font><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Advanced Melanoma or Renal Cell Carcinoma (Investigator Sponsored)</font><sup style="font-size:85%;line-height:120%;vertical-align:top">3</sup><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top"></sup></font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This phase&#160;I, open-label, single-arm, single-center, dose-escalation study, conducted at Rush University Medical Center, Chicago, evaluated the feasibility and safety of a single cycle consisting of three infusions of aNK monotherapy administered on days one, three and five in 12&#160;patients 18&#160;years and older with measureable refractory or relapsed advanced renal cell carcinoma and melanoma. The primary endpoints were the feasibility and safety of aNK&#160;cells. The four dose levels were 1&#160;&#215;&#160;10<sup style="font-size:85%;line-height:120%;vertical-align:top">8</sup>&#160;cells/m<sup style="font-size:85%;line-height:120%;vertical-align:top">2</sup>, 3&#160;&#215;&#160;10<sup style="font-size:85%;line-height:120%;vertical-align:top">8</sup>&#160;cells/m<sup style="font-size:85%;line-height:120%;vertical-align:top">2</sup>, 1&#160;&#215;&#160;10<sup style="font-size:85%;line-height:120%;vertical-align:top">9</sup>&#160;cells/m<sup style="font-size:85%;line-height:120%;vertical-align:top">2</sup>, and 3&#160;&#215;&#160;10<sup style="font-size:85%;line-height:120%;vertical-align:top">9</sup>&#160;cells/m<sup style="font-size:85%;line-height:120%;vertical-align:top">2</sup> administered intravenously.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Three&#160;patients developed grade&#160;1 fever and one&#160;patient developed grade&#160;3 fever, all possibly related to aNK infusions. One patient with renal cancer, who had extensive liver metastases, developed a transient grade&#160;4 hypoglycemia possibly related to aNK. The patient responded to a 5% dextrose intravenous infusion, and went on to receive two subsequent infusions of aNK uneventfully. Four adverse events were considered not related to aNK and included three exacerbations of tumor pain (grade&#160;2 neck pain, grade&#160;2 chest pain, and grade&#160;3 back pain) and one grade&#160;2 rheumatoid arthritis pain. There were no serious infections reported for patients at the one-year follow-up. Six&#160;patients had elevations in lactate dehydrogenase enzymes, and four&#160;patients had elevated cytokines, potentially due to tumor lysis reaction.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g4i5nix4zlkt000010.jpg" title="" alt="" style="width:671px;height:368px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Six of the 12 patients, or 50%, experienced a clinical benefit in this single-course dose escalation study in a dose-dependent fashion with:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">Zero of three experiencing a clinical benefit in the lowest dose cohort,</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">One of three at the second dose cohort, </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">Two of three at the third dose cohort, and finally </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">Three of three at the highest dose cohort.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Two patients had a mixed response, four patients had stable disease, and six&#160;patients had progressive disease, all assessed four weeks post-infusion. Of note, the one patient with renal cell carcinoma that had a mixed response was observed to have a significant reduction in lung masses, but progressed in the mediastinum. Also, the one patient with advanced melanoma that had a mixed response had a striking reduction in a target lesion in the upper neck on CT imaging noted at two weeks post-infusion. Overall survival in the patients achieving stable disease ranged from seven to 35&#160;months. These encouraging results became the basis to further investigate repeat course therapy at a recommended phase&#160;II dose.</p>
<div align="left"><table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:20%;"><tr><td style="width:20%;"></td></tr><tr><td valign="top"  style="border-bottom:Solid 1pt #000000;"><p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;text-indent:0pt;font-size:8pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:0%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">3</sup>&nbsp;</font></p></td>
<td valign="top" style="width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:9pt;"> Arai et al, Cytotherapy. 2008;10(6):625-32</font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18</a></p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:italic;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">iv.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:italic;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><a name="_AEIOULastRenderedPageBreakAEIOU20"></a><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"></font><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"></font><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Hematologic Malignancies (Investigator Sponsored)</font><sup style="font-size:85%;line-height:120%;vertical-align:top">4</sup><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top"></sup></font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This phase&#160;I, open-label, single-arm, single-center, dose-escalation study conducted at the Princess Margaret Hospital in Toronto, evaluated the safety of aNK monotherapy in patients 18&#160;years and older with histologically confirmed, refractory hematologic malignancies who relapsed after autologous hematopoietic cell transplantation. The primary endpoint was safety and the secondary endpoints were efficacy, immune responses to aNK, and kinetics of infused aNK. The three aNK dose levels were 1&#160;&#215;&#160;10<sup style="font-size:85%;line-height:120%;vertical-align:top">9</sup>&#160;cells/m<sup style="font-size:85%;line-height:120%;vertical-align:top">2</sup>, 3&#160;&#215;&#160;10<sup style="font-size:85%;line-height:120%;vertical-align:top">9</sup>&#160;cells/m<sup style="font-size:85%;line-height:120%;vertical-align:top">2</sup>, and 5&#160;&#215;&#160;10<sup style="font-size:85%;line-height:120%;vertical-align:top">9</sup>&#160;cells/m<sup style="font-size:85%;line-height:120%;vertical-align:top">2</sup> administered intravenously on days one, three, and five of each cycle of treatment. Patients could receive up to six monthly cycles, for a total of 18 infusions.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A total of 12&#160;patients were enrolled in the study and included Hodgkin&#8217;s, mantle cell and diffuse large B&#8209;cell lymphoma, chronic lymphocytic leukemia with Richter&#8217;s transformation and multiple myeloma. Some patients experienced grade&#160;1 fever, chills, fatigue, blurry vision, and nausea. There was a single grade&#160;2 adverse event of fever and chills that occurred during an aNK infusion. No grade&#160;3 or 4 adverse events were observed. There were no clinically significant alterations in hemoglobin, platelets, white cell counts, creatinine, or liver function tests. Six patients developed either class I or II anti&#8209;HLA antibodies, typically after the second cycle of aNK, however, this did not interfere with repeat dosing, with most receiving 15 or more infusions without incident. Cytokine release was not observed in any of the patients, although there was a transient rise in IL&#8209;10 and IL&#8209;6 in two&#160;patients.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Five of 12 patients had responses to aNK&#160;cell therapy:&#160;two durable complete responses, one partial response, one clinical-transient response, and one mixed-transient response.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">One complete response was observed in a patient with relapsed, refractory Hodgkin&#8217;s lymphoma, which was maintained for more than ten&#160;years with no subsequent therapy.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">The second complete response was observed in a patient with IgA&#160;kappa myeloma who received concomitant lenalidomide-dexamethasone therapy during and after aNK&#160;cell infusions, and this patient remains on maintenance therapy with an ongoing complete response two&#160;years after aNK&#160;cell therapy.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">An additional three patients experienced partial or transient responses. One patient diagnosed with Hodgkin&#8217;s lymphoma had a partial response after one&#160;cycle of aNK&#160;cell infusion. This patient elected to undergo allotransplantation and subsequently died of allotransplant-related complications.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">A patient diagnosed with chronic lymphocytic leukemia showed clinical improvement and subsequently progressed after completing six monthly cycles of aNK infusion.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">A patient with diffuse large B&#8209;cell lymphoma, or DLBCL, also showed a transient clinical improvement that was followed by progressive disease.</font></p></td></tr></table></div>
<div align="left"><table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:20%;"><tr><td style="width:20%;"></td></tr><tr><td valign="top"  style="border-bottom:Solid 1pt #000000;"><p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;text-indent:0pt;font-size:8pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:0%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">4</sup>&nbsp;</font></p></td>
<td valign="top" style="width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:9pt;"> Williams et al, Oncotarget. 2017 Jul 12;8(51):89256-89268</font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g4i5nix4zlkt000011.jpg" title="" alt="" style="width:671px;height:364px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Results from this trial demonstrated that it was feasible to safely administer to patients serial dosing of aNK in excess of 7&#160;x&#160;10<sup style="font-size:85%;line-height:120%;vertical-align:top">10</sup>&#160;cells across 18 infusions administered over a six month timeframe. Interestingly, both of the complete responses occurred in the lowest dose cohort, though these patients received 15 or more doses of aNK, indicating that dose-exposure over time could potentially overcome shortcomings a smaller individual dose may have. These observations helped to lay the foundation for subsequent phase&#160;Ib/IIa trials with modified aNK&#160;cells in combination with an immuno-conditioning regimen that includes N&#8209;803 and a checkpoint inhibitor, with repeat NK&#160;cell dosing out to 12 months or for as long as the patient is responding to treatment.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Acute Myeloid Leukemia: QUILT&#160;3.018 (NantKwest Sponsored)<sup style="font-size:85%;line-height:120%;vertical-align:top">5</sup><sup style="font-size:85%;line-height:120%;vertical-align:top"></sup></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This phase&#160;I, open-label, single-arm, dose-escalation/de-escalation study evaluated the safety in patients 18&#160;years and older with refractory or relapsed acute myeloid leukemia, or AML. The primary endpoints were the maximum tolerated dose and safety of aNK monotherapy and the secondary endpoints were therapeutic efficacy and aNK&#160;cell phenotype, cytotoxic activity, presence in bone marrow, and effects on patient immune systems. Two dose levels of aNK were used:&#160;1&#160;&#215;&#160;10<sup style="font-size:85%;line-height:120%;vertical-align:top">9</sup>&#160;cells/m<sup style="font-size:85%;line-height:120%;vertical-align:top">2</sup> and 3&#160;&#215;&#160;10<sup style="font-size:85%;line-height:120%;vertical-align:top">9</sup>&#160;cells/m<sup style="font-size:85%;line-height:120%;vertical-align:top">2</sup>. One course of aNK treatment comprised a total of two intravenous infusions of the same cell dose with each intravenous infusion administered 24&#160;hours apart (i.e., days one and two). Patients underwent bone marrow biopsy 21&#160;days after each course of therapy. Patients who had stable disease or a reduction of leukemia blasts after the initial course were eligible to receive additional aNK infusions.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Seven&#160;patients were enrolled in the study with three having received the lower dose level and the remaining patients received the higher dose level of aNK&#160;cells. None of the seven&#160;patients experienced a dose-limiting toxicity during administration of the aNK&#160;cell infusions or during the 21-day observation period post-infusion. There were no grade&#160;3 or grade&#160;4 toxicities related to aNK&#160;cell infusions. One patient developed grade&#160;2 fever and chills following each aNK infusion that resulted in inpatient observation. These known aNK-related effects were reversible with supportive care.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Of the six patients that were evaluable for response 21 days after therapy, three experienced clinical benefit. One patient had a reduction of the percentage of blasts from 70% to 48% and went on to receive a second course. The other two patients achieved disease stabilization, one of which went on to receive two additional courses. This trial demonstrates early evidence of single agent activity and safety in heavily pretreated relapsed or refractory AML patients and serves as a basis to study modified aNK&#160;cell therapy in combination with an immuno-conditioning regimen that includes N&#8209;803 and a checkpoint inhibitor, with repeat NK&#160;cell dosing for as long as a clinical response is maintained.</p>
<div align="left"><table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:20%;"><tr><td style="width:20%;"></td></tr><tr><td valign="top"  style="border-bottom:Solid 1pt #000000;"><p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;text-indent:0pt;font-size:8pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:0%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">5</sup>&nbsp;</font></p></td>
<td valign="top" style="width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:9pt;"> Boyiadzis et al, Cytotherapy. 2017 Oct;19(10):1225-1232</font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU21"></a><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Our Clinical Pipeline</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">haNK<font style="Background-color:#FFFFFF;"> Product Candidate</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Overview</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Our haNK&#160;cell therapeutic is a molecularly engineered variant of our aNK&#160;cell platform, which incorporates both the expression&#160;of</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">i.</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#FFFFFF;">A natural, high-affinity antibody engager, Fc&#947;RIIIa/CD16 receptor, which binds to therapeutically administered cancer-targeting antibodies, resulting in destruction of the cancer targets through a mechanism widely referred to as ADCC, and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ii.</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#FFFFFF;">The IL&#8209;2 support cytokine, whose expression is retained within the cell where it can exert its maximum effects of supporting growth and killing function while sparing leakage into the extracellular surroundings, where it could result in cytokine-related symptoms.</font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Our internal research efforts have demonstrated that these high affinity CD16 receptors on our haNK&#160;cells are cleaved during ADCC-mediated killing of target cancer cells, thereby enabling them to engage in serial killing of multiple cancer targets, rather than remaining bound to the first target cell it encounters, a key drawback of non-cleavable CD16 receptors. Additionally, internal research efforts have demonstrated that high affinity CD16 receptor expression rebounds and recovers more rapidly in haNK&#160;cells after attacking its target when compared to other types of natural killer cells. This unique feature distinguishes our haNK&#160;cell product as exceptionally well suited for serial killing.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Our haNK cell product retains all the innate killing receptors present on aNK, such as NKG2D and NKp44, and therefore preserves the innate ability to detect and bind a diverse range of ligands unique to cancers through this diverse array of receptors, thereby making it a highly versatile killer product suitable for clinical testing. In preclinical studies, the combination of haNK&#160;cells with a number of different therapeutic antibody products resulted in significantly enhanced tumor cell killing when compared to the use of the antibody as a single agent, or the antibody in combination with low affinity expressing CD16 receptors, thereby providing strong scientific support for our therapeutic approach of combining haNK plus N&#8209;803 together with a commercially available therapeutic antibody.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">A growing body of published and internal research on our haNK cells consistently support its continued study as a therapeutic product for the treatment of cancers. Select highlights from this research include:</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">i.</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Utilization of haNK over a low-affinity natural killer cell allows for a one-third lower concentration of herceptin to achieve half of its maximal effect.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ii.</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#FFFFFF;">haNK demonstrates impressive CD16 receptor expression stability after innate pathway activation and degranulation when compared to that of healthy donor natural killer cells.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">iii.</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#FFFFFF;">haNK also demonstrates CD16 receptor expression stability after chemically induced activation and degranulation whereas healthy donor natural killer cells undergo CD16 depletion and potential exhaustion.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">iv.</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#FFFFFF;">haNK cells also demonstrate rapid and full recovery of CD16 expression after ADCC activation, which may be promoted by its endogenous IL-2 production.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">v.</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Irradiated haNK&#160;cells have a higher innate killing frequency than healthy donor natural killer cells.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">vi.</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Irradiated haNK&#160;cells are efficient killers of a wide range of cancer types through their innate killing mechanism without reliance on their ADCC killing mechanisms.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">vii.</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Hypoxemic conditions of the tumor microenvironment that abolishes the killing ability of healthy donor natural killer cells can be overcome by haNK&#160;cells.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">viii.</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Addition of commercial antibody products to haNK&#160;cells adds an ADCC mechanism for killing tumors that would otherwise be resistant to innate killing, and does so in a dose dependent manner.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ix.</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Synergy was demonstrated when combining two antibody products together with haNK&#160;cells.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">x.</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">haNK enhances the killing capacity of the PD&#8209;L1 checkpoint inhibitor, avelumab.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">xi.</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">haNK and avelumab in combination exhibits potent killing across a variety of cancer types.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">xii.</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">A compelling rationale for developing our haNK product in combination with approved and late-stage antibody products that utilize the ADCC killing pathway resides in the fact that only a small subgroup of antibody recipients can benefit from the full potential of antibody products due to CD16 gene variations and natural killer cell dysfunction which haNK therapy could potentially abrogate.</p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU22"></a><font style="Background-color:#FFFFFF;">These </font><font style="Background-color:#FFFFFF;">findings </font><font style="Background-color:#FFFFFF;">are further detailed in the ensuing sections.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">haNK as the Current &#8216;Gold-Standard&#8217; in Non-Clinical Characterization of Commercial Antibody Products.<font style="font-weight:normal;font-style:normal;">&nbsp;&nbsp;Our haNK&#160;cells have been widely utilized by numerous biopharmaceutical companies, including many well-known large-pharma companies, under non-exclusive licenses for </font><font style="font-weight:normal;">in&#160;vitro</font><font style="font-weight:normal;font-style:normal;"> ADCC testing of their antibodies in development, as well as to release-test their commercially available antibody products. For example, our haNK&#160;cells have been adapted for use in commercial assays such as BioTek&#8217;s automated Delfia ADCC assay system and Agilent&#8217;s xCELLigence system.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Utilization of haNK Over a Low-Affinity Natural Killer Cell Allows for a One-Third Lower Concentration of Herceptin to Achieve Half of its Maximal Effect.<font style="font-weight:normal;font-style:normal;">&nbsp;&nbsp;In the Delfia ADCC assay system it was determined that the concentration of herceptin which achieves the half-maximum response&#160;(EC50) is 48% higher for the low-affinity natural killer cells than for haNK, thereby demonstrating how haNK potentiates herceptin in achieving its peak killing capacity.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g4i5nix4zlkt000012.jpg" title="" alt="" style="width:671px;height:556px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU23"></a><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Natural Killer Cell </font><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Numbers, Function and CD16 Expression Levels Are Deficient Among Cancer Patients and Correspond with Clinical Outcomes.</font><font style="font-weight:normal;font-style:normal;">&nbsp;&nbsp;Immunologic surveillance studies in human subjects have revealed a series of related trends in </font><font style="font-weight:normal;font-style:normal;">natural killer </font><font style="font-weight:normal;font-style:normal;">cell numbers, function and their CD16 receptor expression levels in cancer patients that undergo antibody</font><font style="font-weight:normal;font-style:normal;">-</font><font style="font-weight:normal;font-style:normal;">based treatment regimens. One observation is that </font><font style="font-weight:normal;font-style:normal;">e</font><font style="font-weight:normal;font-style:normal;">vent </font><font style="font-weight:normal;font-style:normal;">f</font><font style="font-weight:normal;font-style:normal;">ree </font><font style="font-weight:normal;font-style:normal;">s</font><font style="font-weight:normal;font-style:normal;">urvival in </font><font style="font-weight:normal;font-style:normal;">diffuse large B</font><font style="font-weight:normal;font-style:normal;">&#8209;cell lymphoma, or </font><font style="font-weight:normal;font-style:normal;">DLBCL</font><font style="font-weight:normal;font-style:normal;">,</font><font style="font-weight:normal;font-style:normal;"> patients corresponded directly with </font><font style="font-weight:normal;font-style:normal;">natural killer </font><font style="font-weight:normal;font-style:normal;">cell counts at diagnosis, whereas CD4+, CD8+ and B</font><font style="font-weight:normal;font-style:normal;">&#8209;</font><font style="font-weight:normal;font-style:normal;">cell counts did not.</font><sup style="font-size:85%;line-height:120%;vertical-align:top">6</sup><font style="font-weight:normal;font-style:normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top"></sup></font><font style="font-weight:normal;font-style:normal;"> Also, when comparing </font><font style="font-weight:normal;font-style:normal;">natural killer </font><font style="font-weight:normal;font-style:normal;">cells from DLBCL patients with that of healthy donors</font><font style="font-weight:normal;font-style:normal;">, </font><font style="font-weight:normal;font-style:normal;">fewer </font><font style="font-weight:normal;font-style:normal;">natural killer </font><font style="font-weight:normal;font-style:normal;">cells from DLBCL patients express CD16 and of those that do, express CD16 at far lower levels and that these cells demonstrate significantly reduced ADCC</font><font style="font-weight:normal;font-style:normal;">&#8209;</font><font style="font-weight:normal;font-style:normal;">mediated degranulation.</font><sup style="font-size:85%;line-height:120%;vertical-align:top">7</sup><font style="font-weight:normal;font-style:normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top"></sup></font><font style="font-weight:normal;font-style:normal;"> Another </font><font style="font-weight:normal;font-style:normal;">noteworthy</font><font style="font-weight:normal;font-style:normal;"> observation was </font><font style="font-weight:normal;font-style:normal;">seen</font><font style="font-weight:normal;font-style:normal;"> in DLBCL patients receiving antibody-based treatment regimens where during and within a month of completing therapy, there was a marked depletion of CD16+ </font><font style="font-weight:normal;font-style:normal;">natural killer </font><font style="font-weight:normal;font-style:normal;">cells and that these cells exhibited markedly diminished ADCC activity.</font><sup style="font-size:85%;line-height:120%;vertical-align:top">8</sup><font style="font-weight:normal;font-style:normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top"></sup></font><font style="font-weight:normal;font-style:normal;"> The same diminished ADCC activity was noted in </font><font style="font-weight:normal;font-style:normal;">natural killer </font><font style="font-weight:normal;font-style:normal;">cells from ovarian</font><sup style="font-size:85%;line-height:120%;vertical-align:top">9</sup><font style="font-weight:normal;font-style:normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top"></sup></font><font style="font-weight:normal;font-style:normal;"> and esophageal</font><sup style="font-size:85%;line-height:120%;vertical-align:top">10</sup><font style="font-weight:normal;font-style:normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top"></sup></font><font style="font-weight:normal;font-style:normal;"> cancer patients, when compared to that of </font><font style="font-weight:normal;font-style:normal;">healthy donor</font><font style="font-weight:normal;font-style:normal;"> </font><font style="font-weight:normal;font-style:normal;">natural killer </font><font style="font-weight:normal;font-style:normal;">cells. It is therefore reasonable to conclude that efforts to address the diminished and exhausted population of </font><font style="font-weight:normal;font-style:normal;">natural killer </font><font style="font-weight:normal;font-style:normal;">cells in the setting of cancer could have broad therapeutic value and is the underlying driver to forge ahead with clinical research on haNK replacement therapy, particularly in combination with the </font><font style="font-weight:normal;font-style:normal;">natural killer </font><font style="font-weight:normal;font-style:normal;">cell induction agent, N</font><font style="font-weight:normal;font-style:normal;">&#8209;</font><font style="font-weight:normal;font-style:normal;">803, targeted antibody products and checkpoint inhibitors.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">haNK Demonstrates Superior CD16 Receptor Stability After Innate Pathway Activation and Degranulation When Compared to That of Healthy Donor Natural Killer Cells.<font style="font-weight:normal;font-style:normal;">&nbsp;&nbsp;Four hours after co-culture with the feeder cell line, K562, which serves to activate the innate pathway of killing, CD16 expression on natural killer cells from healthy donors dropped precipitously and only partially recovered after resting overnight whereas that of haNK was maintained at peak levels throughout the study duration.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g4i5nix4zlkt000013.jpg" title="" alt="" style="width:671px;height:347px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">haNK Demonstrates CD16 Receptor Expression Stability After Chemically Induced Activation and Degranulation Whereas Healthy Donor Natural Killer Cells Undergo CD16 Depletion and Potential Exhaustion.<font style="font-weight:normal;font-style:normal;">&nbsp;&nbsp;Using flow cytometric analysis of CD16 expression after employing a more robust chemical induction model of degranulation, natural killer cells from healthy donors were observed to have a 94% drop in CD16 expression compared to 18% in haNK. Of note, CD16 expression levels in haNK only dropped to average pre-activation levels in healthy donor natural killer cells.</font></p>
<div align="left"><table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:20%;"><tr><td style="width:20%;"></td></tr><tr><td valign="top"  style="border-bottom:Solid 1pt #000000;"><p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;text-indent:0pt;font-size:8pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:0%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">6</sup>&nbsp;</font></p></td>
<td valign="top" style="width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:9pt;"> </font><font style="color:#000000;font-size:9pt;">Plonquet et al, Ann Oncol. 2007 Jul;18(7):1209-15</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:0%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">7</sup>&nbsp;</font></p></td>
<td valign="top" style="width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:9pt;"> Danielou-Lazareth et al, Eur J Immunol. 2013 May;43(5):1383-8</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:0%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">8</sup>&nbsp;</font></p></td>
<td valign="top" style="width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:9pt;"> Cox et al, Oncoimmunology. 2015 Jan 7;4(3):e990773</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:0%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">9</sup>&nbsp;</font></p></td>
<td valign="top" style="width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:9pt;"> Carlsten et al, J Immunol. 2009 Oct 15;183(8):4921-30</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:0%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">10</sup>&nbsp;</font></p></td>
<td valign="top" style="width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:9pt;"> Watanabe et al, Dis Esophagus. 2010 Nov;23(8):675-81</font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g4i5nix4zlkt000014.jpg" title="" alt="" style="width:671px;height:389px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">haNK Demonstrates Rapid and Full Recovery of CD16 Expression by 24 Hours Post-ADCC Activation.</font><font style="Background-color:#FFFFFF;font-weight:normal;font-style:normal;">&nbsp;&nbsp;The bottom figure on the left shows the percent CD16 expression five hours after ADCC activation in haNK&#160;cells using rituximab and deoxyhypusine hydroxylase, or DoHH, cells. We observed that there is only a modest drop in expression at this time point and that it appears to correspond proportionately with the target burden. haNK CD16 levels dropped slightly more than in the IL&#8209;2 dependent haNK-lite cells, possibly due to the greater degree of target killing. The bottom figure on the right shows the shift in CD16 median fluorescence intensity of expression in haNK versus IL&#8209;2 dependent haNK-lite cells from five to 24 hours after ADCC activation. We observed that haNK recovery at 24 hours is nearly complete, whereas haNK-lite recovery requires more time, possibly due to its lack of endogenous IL&#8209;2 production, possessed by haNK&#160;cells. Collectively, these findings indicate that our selected haNK clone is a promising candidate to advance into clinical testing.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g4i5nix4zlkt000015.jpg" title="" alt="" style="width:671px;height:305px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU24"></a><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Irradiated haNK Cells Have a Higher Innate Killing Frequency than Healthy Donor </font><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Natural Killer</font><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"> Cells.</font><font style="font-weight:normal;font-style:normal;">&nbsp;&nbsp;The following graph compares innate killing of target breast cancer cells by </font><font style="font-weight:normal;font-style:normal;">healthy donor natural killer </font><font style="font-weight:normal;font-style:normal;">cells versus irradiated haNK&#160;cells. Irradiated haNK&#160;cells have a three-fold higher killing frequency (on a per cell basis) than the average killing frequency of </font><font style="font-weight:normal;font-style:normal;">healthy donor</font><font style="font-weight:normal;font-style:normal;"> </font><font style="font-weight:normal;font-style:normal;">natural killer </font><font style="font-weight:normal;font-style:normal;">cells, thereby demonstrating substantially greater levels of lysis from irradiated haNK&#160;cells across a range of effector-to-target cell ratios.</font><font style="font-weight:normal;font-style:normal;">&#160;</font><font style="font-weight:normal;font-style:normal;">Quantitative analysis of the killing frequency demonstrated that, on average, it took three </font><font style="font-weight:normal;font-style:normal;">healthy donor</font><font style="font-weight:normal;font-style:normal;"> </font><font style="font-weight:normal;font-style:normal;">natural killer </font><font style="font-weight:normal;font-style:normal;">cells to kill the same amount of tumor target as one irradiated haNK&#160;cell, thereby implying serial killing activity.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g4i5nix4zlkt000016.jpg" title="" alt="" style="width:671px;height:387px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Irradiated haNK Cells are Efficient Killers of a Wide Range of Cancer Types Through Their Innate Killing Mechanism Without Reliance on Their ADCC Killing Mechanisms.<font style="font-weight:normal;font-style:normal;">&nbsp;&nbsp;In the graphs that follow, irradiated haNK&#160;cells exhibit an ability to efficiently kill 13&#160;human tumor cell lines via innate mechanisms such as NKG2D&#8209;NKG2DL receptors, without the addition of antibodies. This was demonstrated in innate killing assays against lung, colon, breast, cervical, ovarian, pancreatic and chordoma cancer lines. With the exception of ASPC&#8209;1, target killing was consistently observed in an effector-to-target, or E:T, dependent manner.</font></p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g4i5nix4zlkt000017.jpg" title="" alt="" style="width:498px;height:881px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU25"></a><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Hypoxemic Conditions of the Tumor Microenvironment That Abolishes the Killing Ability of Healthy Donor </font><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Natural Killer</font><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"> Cells Can Potentially be Overcome by haNK Cells.</font><sup style="font-size:85%;line-height:120%;vertical-align:top">11</sup><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top"></sup></font><font style="font-weight:normal;font-style:normal;">&nbsp;&nbsp;Current research on </font><font style="font-weight:normal;font-style:normal;">healthy donor</font><font style="font-weight:normal;font-style:normal;"> </font><font style="font-weight:normal;font-style:normal;">natural killer </font><font style="font-weight:normal;font-style:normal;">cell function in the hypoxemic </font><font style="font-weight:normal;font-style:normal;">tumor microenvironment</font><font style="font-weight:normal;font-style:normal;"> supports our understanding of the various mechanisms involved in </font><font style="font-weight:normal;font-style:normal;">natural killer cell</font><font style="font-weight:normal;font-style:normal;"> dysfunction:</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">i.</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Exposure to hypoxemia decreases surface expression of NKG2D, the primary receptor needed for innate killing;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ii.</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Exposure to hypoxemia decreases surface expression of CD16 receptors, necessary for ADCC-mediated killing;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">iii.</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Intracellular perforin and granzyme B&#160;levels are also diminished when exposed to hypoxemic conditions, as well as the total percentage of degranulating natural killer cells in a given population; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">iv.</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Natural killer cell activation by IL&#8209;2 can restore NKG2D levels and restore cytotoxicity against a number of hypoxemic cancer cell types.</p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By contrast, haNK&#160;cells possess several inherent features that impart <font style="font-style:italic;">in-vivo</font> advantages over healthy donor natural killer cells including:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">i.</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">haNK produces its own supply of intracellular IL&#8209;2 thereby maintaining itself in a perpetual state of activation;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ii.</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">haNK&#160;cells are naturally larger in diameter and therefore volume when compared with donor natural killer cells and within that larger volume, pack a greater density of perforin and granzyme containing granules; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">iii.</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">haNK&#160;cells start off with a high density of surface CD16 and NKG2D receptors and since it can be frequently re-dosed with relative ease at a cell number per dose that is equivalent to an average person&#8217;s total natural killer cell population, it is feasible to maintain the equivalent of a fully active population of natural killer cells for extended periods to supplement the recipient&#8217;s dysfunctional and exhausted resident population of natural killer cells.</p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">New research conducted internally and by collaborators confirming that irradiated and cryopreserved haNK&#160;cells maintain optimal performance under hypoxemic conditions, is expected to publish in the near term.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Addition of Commercial Antibody Products to haNK Cells Adds an ADCC Mechanism for Killing Tumors that would Otherwise Be Resistant to Innate Killing, and Does so in a Dose-Dependent Manner.<font style="font-weight:normal;font-style:normal;">&nbsp;&nbsp;The graphs that follow depict the increasing ADCC killing activity of haNK&#160;cells in the presence of increasing concentrations of either herceptin or rituxan observed in </font><font style="font-weight:normal;">in&#160;vitro</font><font style="font-weight:normal;font-style:normal;"> studies. The comparative killing activity of aNK alone, low-affinity CD16 receptor expressing aNK&#160;cells, or laNK, cells, and haNK with a non-relevant antibody as a negative control, are included for direct comparison purposes.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the first graph below, aNK, laNK, and haNK&#160;cells were tested separately in killing assays against SKOV&#8209;3 ovarian cancer cells in the presence of logarithmically increasing concentrations of herceptin. The assay was performed by loading the tumor cells with radioactive chromium&#8209;51 and measuring the release by cytotoxicity in a four&#8209;hour assay. haNK&#160;cells responded to a lower dose of herceptin&#160;(0.001&#160;ug/mL) and exhibited stronger maximal killing response as compared to cells expressing the low affinity 158F variant. Parental aNK cells, which lack CD16 expression, and haNK&#160;cells in combination with non-relevant antibody did not exhibit any ADCC response toward the SKOV&#8209;3 cells.</p>
<div align="left"><table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:20%;"><tr><td style="width:20%;"></td></tr><tr><td valign="top"  style="border-bottom:Solid 1pt #000000;"><p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;text-indent:0pt;font-size:8pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:0%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">11</sup>&nbsp;</font></p></td>
<td valign="top" style="width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:9pt;"> Sarkar et al, PLoS One. 2013 May 28;8(5):e64835</font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU26"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the second graph</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> below</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, haNK cells responded to a lower dose of </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">r</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ituxan&#160;(0.001&#160;ug/mL) and exhibited stronger maximal killing response, as compared to laNK cells. Parental aNK&#160;cells, lacking CD16 expression, did not exhibit any ADCC response toward the 721.221&#160;B</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8209;cell lymphoma cells and haNK&#160;cells together with non-relevant antibody did not trigger any ADCC response.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g4i5nix4zlkt000018.jpg" title="" alt="" style="width:671px;height:414px;"></p>
<p style="text-align:center;margin-top:5pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Source: J Immunol. 2008 May&#160;1;180(9):6392-401.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU27"></a><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Synergy Demonstrated When Combining Two Antibody Products together with haNK Cells.</font><font style="font-weight:normal;font-style:normal;">&nbsp;&nbsp;The graph below depicts the synergistic activity of the combination of </font><font style="font-weight:normal;font-style:normal;">h</font><font style="font-weight:normal;font-style:normal;">erceptin and </font><font style="font-weight:normal;font-style:normal;">p</font><font style="font-weight:normal;font-style:normal;">erjeta&#160;(HER2/HER3) to mediate ADCC killing observed in </font><font style="font-weight:normal;">in&#160;vitro</font><font style="font-weight:normal;font-style:normal;"> studies. Through the application of haNK&#160;cells to kill HER2 positive gastric carcinoma cells, the activity observed in the combination of </font><font style="font-weight:normal;font-style:normal;">h</font><font style="font-weight:normal;font-style:normal;">erceptin and </font><font style="font-weight:normal;font-style:normal;">p</font><font style="font-weight:normal;font-style:normal;">erjeta was significantly greater than </font><font style="font-weight:normal;font-style:normal;">with </font><font style="font-weight:normal;font-style:normal;">either agent alone.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g4i5nix4zlkt000019.jpg" title="" alt="" style="width:402px;height:514px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU28"></a><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">haNK Enhances the Killing Capacity of the PD</font><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#8209;L1 Checkpoint Inhibitor, Avelumab.</font><font style="font-weight:normal;font-style:normal;">&nbsp;&nbsp;I</font><font style="font-weight:normal;font-style:normal;">rradiated haNK&#160;cells and MDA</font><font style="font-weight:normal;font-style:normal;">&#8209;MB</font><font style="font-weight:normal;font-style:normal;">&#8209;231&#160;(human breast carcinoma) cells were used as a target at an E:T ratio of 7.5:1. haNK innate killing&#160;(black bars) and innate&#160;+&#160;ADCC killing mediated by avelumab&#160;(grey bars) are shown in the graphs below. While avelumab alone and control Ab alone show no killing and haNK alone demonstrates some killing via innate mechanisms, the combination of haNK and avelumab yields the highest degree of killing, attributable to targeting the PD</font><font style="font-weight:normal;font-style:normal;">&#8209;L1 checkpoint protein as a target&#160;</font><font style="font-style:normal;">(a)</font><font style="font-weight:normal;font-style:normal;">. </font><font style="font-weight:normal;font-style:normal;">Separately, it was demonstrated that irradiated haNK&#160;cells do not exhibit cytotoxic activity against other haNK&#160;cells (fratricide)&#160;</font><font style="font-style:normal;">(b)</font><font style="font-weight:normal;font-style:normal;">.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g4i5nix4zlkt000020.jpg" title="" alt="" style="width:633px;height:489px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU29"></a><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">haNK and Avelumab Combination Exhibits Potent Killing Across a Variety of Cancer Types.</font><font style="font-weight:normal;font-style:normal;">&nbsp;&nbsp;</font><font style="letter-spacing:-0.1pt;font-weight:normal;font-style:normal;">As illustrated in the graphs below, avelumab-mediated ADCC by haNK cells demonstrated enhanced killing against a variety of cancer types in four</font><font style="letter-spacing:-0.1pt;font-weight:normal;font-style:normal;">&#8209;hour assays, which was even more pronounced in 18</font><font style="letter-spacing:-0.1pt;font-weight:normal;font-style:normal;">&#8209;hour assays. Both haNK with isotype control&#160;(black squares) and haNK with avelumab&#160;(blue circles) mediated lysis of H460 human lung carcinoma cells in an E:T dose dependent manner&#160;(</font><font style="letter-spacing:-0.1pt;font-style:normal;">a</font><font style="letter-spacing:-0.1pt;font-weight:normal;font-style:normal;">). Similar results were also seen with several other human cell lines including cervical cancer CaSki cell&#160;(</font><font style="letter-spacing:-0.1pt;font-style:normal;">b</font><font style="letter-spacing:-0.1pt;font-weight:normal;font-style:normal;">); HCC4006: lung carcinoma&#160;(</font><font style="letter-spacing:-0.1pt;font-style:normal;">c</font><font style="letter-spacing:-0.1pt;font-weight:normal;font-style:normal;">); H441: lung carcinoma&#160;(</font><font style="letter-spacing:-0.1pt;font-style:normal;">d</font><font style="letter-spacing:-0.1pt;font-weight:normal;font-style:normal;">); SKOV3: ovarian carcinoma&#160;(</font><font style="letter-spacing:-0.1pt;font-style:normal;">e</font><font style="letter-spacing:-0.1pt;font-weight:normal;font-style:normal;">); MDA</font><font style="letter-spacing:-0.1pt;font-weight:normal;font-style:normal;">&#8209;MB</font><font style="letter-spacing:-0.1pt;font-weight:normal;font-style:normal;">&#8209;231: breast carcinoma&#160;(</font><font style="letter-spacing:-0.1pt;font-style:normal;">f</font><font style="letter-spacing:-0.1pt;font-weight:normal;font-style:normal;">); and HTB</font><font style="letter-spacing:-0.1pt;font-weight:normal;font-style:normal;">&#8209;4: bladder carcinoma&#160;(</font><font style="letter-spacing:-0.1pt;font-style:normal;">g</font><font style="letter-spacing:-0.1pt;font-weight:normal;font-style:normal;">).</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g4i5nix4zlkt000021.jpg" title="" alt="" style="width:671px;height:438px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU30"></a><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Rationale for Developing </font><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">O</font><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">ur haNK in Combination with Approved and Late-Stage Antibody Products That Utilize the ADCC Killing Pathway.</font><font style="font-weight:normal;font-style:normal;">&nbsp;&nbsp;In multiple clinical trials conducted by third parties, patients who were homozygous for high-affinity CD16&#160;(158V/V) generally experienced better responses to antibody therap</font><font style="font-weight:normal;font-style:normal;">ies</font><font style="font-weight:normal;font-style:normal;"> than patients who were carriers of </font><font style="font-weight:normal;font-style:normal;">at least one </font><font style="font-weight:normal;font-style:normal;">low affinity CD16 allele&#160;(158F/F or V/F). The illustration from one study below shows the difference in </font><font style="font-weight:normal;font-style:normal;">progression-free survival</font><font style="font-weight:normal;font-style:normal;"> between HER2 positive breast cancer patients treated with </font><font style="font-weight:normal;font-style:normal;">h</font><font style="font-weight:normal;font-style:normal;">erceptin who have the homozygous high-affinity form of CD16 and those who are carriers for the low affinity form to be far in excess of 20% at 48&#160;months.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g4i5nix4zlkt000022.jpg" title="" alt="" style="width:671px;height:354px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU31"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Data from </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">two additional</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> clinical trials demonstrating th</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">e same</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> point are shown below. The rationale therefore </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">favors</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> combining haNK with </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">r</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ituxan, </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">h</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">erceptin and </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">e</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">rbitux in patients </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">that carry the</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> low affinity CD16 </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">allele&#160;</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">both homozygous </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">158F/F </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and heterozygous carriers</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> 158</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">V and 158V/F</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">) </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in order to improve</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> the killing effect of these </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">antibody products to approximate</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> the results </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">seen in</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> patients </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">that are homozygous</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">158V/V</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">) for the high affinity</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> alleles.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g4i5nix4zlkt000023.jpg" title="" alt="" style="width:556px;height:760px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU32"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Antibodies are prevalently used and it is estimated that they generate over $100&#160;billion in reported global annual sales. It has been reported that only approximately 10% to 15% of the addressable patient population for antibody therapies carry high-affinity CD16 receptors. This implies that our haNK product candidates may have significant market potential for these and possibly all IgG1-type antibody products that kill via the ADCC pathway as a combination therapy to address a large number of patients who would otherwise have poor responses to their antibody treatments.</font></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">haNK Single Agent Phase&#160;I Trial</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">QUILT&#160;3.028&#160;(NCT03027128) was our open-label, phase&#160;I study of haNK for infusion in subjects with metastatic or locally advanced solid tumors. As a first-in-human trial for haNK&#160;cells, our aim was to evaluate safety and single agent activity, determine the maximum feasible dose or highest dose with acceptable toxicity of haNK infusions in up to 16&#160;subjects. The study was conducted in two parts, the first being a standard dose escalation protocol using a 3&#160;+&#160;3&#160;design and the second, an expansion of the highest dose level with acceptable toxicity to further characterize safety and activity. The final treatment was administered during the first quarter of 2019, the same quarter that the trial concluded, and the clinical study report is being finalized for April&#160;2020. Solid tumor types included a wide range of cancers including colorectal, ovarian, head and neck squamous cell and adenoid cystic carcinomas. Patients were highly treatment experienced, with up to seven prior courses of therapy and had progressed on their most recent regiment. A preliminary look at the first two cohorts that received repeat haNK infusions revealed no grade&#160;3 or higher toxicities related to haNK and no dose limiting toxicities. Grade&#160;1 or&#160;2 fever, fatigue, nausea, infusion-related reactions and pain have been reported for most patients. One patient experienced grade&#160;3/4 hyponatremia and another reported grade&#160;4 hyperbilirubinemia, but neither was considered to be related to the administration of the study drug. Transient disease stabilizations were observed in half of the patients treated, though with the absence of concurrent antibody treatment, significant responses were not anticipated. A recommended phase&#160;II dose level of 2&#160;x&#160;10<sup style="font-size:85%;line-height:120%;vertical-align:top">9</sup> was determined and utilized in our subsequent phase&#160;Ib/II and phase&#160;II combination trials.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Transition to Cryopreserved haNK Product Candidate.<font style="font-weight:normal;font-style:normal;">&nbsp;&nbsp;During the QUILT&#160;3.028 study, our haNK product for infusion was changed from fresh irradiated haNK to frozen irradiated, &#8220;off-the-shelf&#8221; haNK product. The administration of both products was found to be equally safe and tolerable. The early favorable safety profile established from this first-in-human study paved the way for numerous successful IND submissions to the FDA for our phase&#160;Ib/II haNK combination trials, which we designated as NCV trials.</font></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">The Distinction of Exclusively Combining Our NK Therapies with a Systemically Administered IL&#8209;15 Superagonist.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">An expansive scientifically-based rationale has evolved that justifies the pairing of our NK&#160;cell therapeutic platforms with a selective IL&#8209;15 activator of the patient&#8217;s own natural killer and T&#8209;cells, while avoiding bystander activation of deleterious inhibitory immune cells. We anticipate that such a combination in conjunction with a tumor conditioning regimen, which promotes tumor immunogenicity, would be most effective at inducing immunogenic cell death, memory immune cells and cancer remissions. We selected N&#8209;803 for use in our combination trials since it is the only IL&#8209;15 superagonist agent that is in late-stage clinical development, has an evolving dossier of clinical safety and has demonstrated consistent synergism when combined with haNK and PD&#8209;L1.t&#8209;haNK&#160;cells in <font style="font-style:italic;">in&#160;vitro</font> and <font style="font-style:italic;">in&#160;vivo</font> experiments both internally and with various research collaborators.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">It is generally known that natural killer cell counts at the time of cancer diagnosis corresponds directly with event free survival and that existing natural killer cell populations in these patients are both low in number and dysfunctional due to impaired innate and ADCC killing mechanisms. It is also known that cancer patients receiving an antibody therapeutic demonstrate marked depletion of ADCC competent natural killer cells both during and up to one month after completing therapy. The administration of an &#8220;off-the-shelf&#8221; replacement natural killer cell therapy such as haNK or t&#8209;haNK, at numbers that readily approximate a patient&#8217;s normal natural killer cell count over an extended period through repeat dosing, would be expected to make available iterative waves of innate and ADCC competent natural killer cells until the patient&#8217;s own immune system is able to reconstitute and defend itself. N&#8209;803 is a stimulating cytokine that promotes the expansion and activation of the patient&#8217;s own natural killer and CD8+ T&#8209;cell populations, a finding that has been demonstrated in numerous preclinical and clinical studies in cancer patients. Moreover, cross reactivity with CD4+ T&#8209;regulatory and MDSC&#160;cells does not occur with N&#8209;803, thereby sparing patients from the counterproductive immune inhibitory effects of this immunologic compartment. Pairing these features with the finding that N&#8209;803 acts synergistically to enhance the anti-cancer effects of haNK and t&#8209;haNK sets the foundation for our combination approach to innate natural killer therapeutics for cancers, where these agents can form the backbone of any combination cancer regimen.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU33"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">following graphs illustrate how the lymphocyte compartments i</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">n human recipients respond to N</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8209;8</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">03 administration. A recently reported clinical study that investigated the combination of N</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8209;</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">803 and rituximab in indolent non-Hodgkin&#8217;s lymphoma patients who relapsed or were refractory to rituximab therapy demonstrated that N</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8209;</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">803 induced expansion of the patient&#8217;s own </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">natural killer </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">cell compartment while avoiding regulatory T</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8209;</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">cell stimulation.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g4i5nix4zlkt000024.jpg" title="" alt="" style="width:671px;height:440px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Natural killer cells, which typically represents 10% of the overall lymphocyte population, expanded three fold to approximately 30% in these recipients, reaching absolute counts averaging 750&#160;cells/&#956;L.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g4i5nix4zlkt000025.jpg" title="" alt="" style="width:671px;height:396px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">N&#8209;803 administration also markedly increased the proliferation marker, Ki67+ on natural killer cells over the full three weeks of patient monitoring.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g4i5nix4zlkt000026.jpg" title="" alt="" style="width:671px;height:388px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU34"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Another recent study in patients with metastatic </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">non-small cell lung cancer</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">who</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> received a checkpoint inhibitor, also demonstrated increased numbers of </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">natural killer </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">cells when administered N</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8209;</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">803 therapy. The ability of N</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8209;</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">803 to drive potent expansion of</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> natural killer </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">cells was identified to potentially have particular value as </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">major histocompatibility complex, or </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">MHC</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> class</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I is lost on a substantial frequency of </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">non-small cell lung cancer</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> tumors, thereby making these tumors potentially susceptible to</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> natural killer </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">cell</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">mediated killing</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font><sup style="font-size:85%;line-height:120%;vertical-align:top">12</sup><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top"></sup></font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These foundational data suggest that IL&#8209;15-based immunomodulation using N&#8209;803 has broad effect on patient natural killer cells and indicate that combination therapy with our NK&#160;cell therapies can potentially deliver more productive natural killer cell driven responses than would be possible with either alone.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Combining haNK and Avelumab as a Versatile Treatment for a Wide Range of Cancer Types.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Programmed cell death ligand&#8209;1, or PD&#8209;L1, which hinders anti-tumor immunity, has been detected on a wide range of tumor types and contributes to cancer escape. Antibody-mediated PD&#8209;L1 blockade has already demonstrated clinical benefit in metastatic cancers such as non-small cell lung cancer, bladder cancer, melanoma, renal cell and ovarian cancers. The human anti-PD&#8209;L1 antibody, avelumab, is a commercially available IgG1<sub style="font-size:85%; vertical-align:bottom"> </sub>antibody product with a fully functional Fc segment that can engage CD16 receptors on natural killer cells, thereby mediating ADCC killing of PD&#8209;L1 expressing cancer cells. Avelumab combinations with haNK, the high affinity CD16 and IL&#8209;2 expressing aNK&#160;cell line, could therefore be considered an ideal pairing of agents for a number of highly prevalent cancer types.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the graphs below, we see that PD&#8209;L1 is expressed, to the greatest extent, in high-grade meningioma, but also in lung, breast, prostate cancers and chordoma. Additionally, the combination of haNK and avelumab has a synergistic effect at controlling meningioma tumor growth by volume in mouse models, when compared with either agent alone. Not shown, is the finding that the combination of haNK and avelumab extended survival in both orthotopic and subcutaneous meningioma mouse models in conjunction with increased cytotoxic immune in&#64257;ltration and tumor necrosis.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g4i5nix4zlkt000027.jpg" title="" alt="" style="width:719px;height:304px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left"><table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:20%;"><tr><td style="width:20%;"></td></tr><tr><td valign="top"  style="border-bottom:Solid 1pt #000000;"><p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;text-indent:0pt;font-size:8pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:0%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">12</sup>&nbsp;</font></p></td>
<td valign="top" style="width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:9pt;"> Wrangle et al, Lancet Oncol. 2018 May;19(5):694-704</font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU35"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Also</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> the data below</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> demonstrates that </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the haNK and avelumab combination more efficiently lysed meningioma cells when compared with healthy donor </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">natural killer</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">cells </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and avelumab. PD</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8209;</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">L1 expression on meningioma cancer cell lines has been shown to increase under conditions of increasing hypoxemia and in the presence of IFN</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8209;</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#947;</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. This can help explain why the observations below were made of heightened ADCC mediated lysis by haNK</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">cells with avelumab under a hypoxemic condition and in the presence of IFN</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8209;</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#947;.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g4i5nix4zlkt000028.jpg" title="" alt="" style="width:671px;height:336px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Combined with our knowledge about haNK&#8217;s ability to function in the hypoxemic tumor microenvironment and the ability of haNK to express IFN&#8209;&#947;, the potential for clinical applications have become increasingly clear.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Building a Blueprint for the Nant Cancer Vaccine&#160;(NCV) Treatment Program</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">QUantum Immuno-Oncology Lifelong Trial<font style="font-weight:normal;font-style:normal;">, or QUILT, is a master clinical trial protocol designed under cooperative research and development agreements between pharmaceutical/biotechnology companies and the National Cancer Institute, in accordance with published FDA guidance. QUILT studies are designed to harness and orchestrate all of the elements of the immune system, including natural killer cell, T&#8209;cell and dendritic&#160;cell therapies, by testing novel combinations of cell-based immunotherapy (i.e., haNK and t&#8209;haNK), cytokines (i.e., N&#8209;803), immunomodulators, including checkpoint inhibitors, vaccines, metronomic chemotherapy&#160;(i.e.,&#160;abraxane and aldoxorubicin) and low dose radiotherapy as a &#8216;triangle offense&#8217; in patients who have undergone next generation whole genomic and transcriptomic analysis, with the goal of achieving durable, long-lasting remission for patients with cancer.</font></p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g4i5nix4zlkt000029.jpg" title="" alt="" style="width:671px;height:423px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">After demonstrating phase&#160;I safety and activity of single and repeat-dosing of fresh aNK monotherapy in several phase&#160;I trials, including QUILT&#160;3.018, we demonstrated the same for both fresh and frozen haNK monotherapy in our QUILT&#160;3.028 study. We next demonstrated safety and activity of the combination of fresh aNK with NCV agents in pancreatic cancer patients in our QUILT&#160;3.039 study and demonstrated the same for both fresh and frozen haNK with NCV agents in our QUILT&#160;3.060 study for patients with pancreatic cancer who have progressed on or after standard-of-care therapy. Then we introduced our cryopreserved haNK formulation together with the addition of low-dose aldoxorubicin and a design change to extend the length of each treatment cycle to three weeks, in our QUILT&#160;3.070 study. Based on the encouraging safety and activity findings, we proceeded to implement this refined NCV design in a new program to better assess responsiveness across several tumor types, which included triple negative breast, colorectal, pancreatic and head and neck squamous cells cancers in QUILT&#160;3.067, 3.071, 3.080 and 3.090, respectively.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g4i5nix4zlkt000030.jpg" title="" alt="" style="width:671px;height:365px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These phase&#160;Ib studies all investigated haNK in combination with metronomic chemotherapy, N&#8209;803, cytokine therapy, cancer vaccines, and stereotactic body radiation therapy and continue to have patients in active follow-up. The primary endpoint is to determine safety and activity of the combination treatment. By March&#160;15, 2020, approximately 540&#160;doses of haNK&#160;cells have been administered to subjects. No immune-related adverse effects or cytokine release syndrome attributable to haNK have been observed. Transient low-grade fevers have been reported in these haNK recipients when administered in this NCV combination therapy.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">QUILT&#160;3.067 <font style="font-weight:normal;font-style:normal;">study of haNK&#160;cells in combination with NCV agents in subjects with triple negative breast cancer who have progressed on or after standard-of-care therapy continues to follow two long-term complete responders on maintenance therapy at 15 and 18 months.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g4i5nix4zlkt000031.jpg" title="" alt="" style="width:671px;height:337px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g4i5nix4zlkt000032.jpg" title="" alt="" style="width:671px;height:388px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have now concluded enrollment for this phase&#160;Ib first-generation NCV program, and while we have demonstrated the safety of this approach, we will continue treatment of patients still on study, analyze data and prepare clinical study reports in select indications.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">t&#8209;haNK Programs</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Novel, First-in-Class PD&#8209;L1.t&#8209;haNK Product Candidate for Solid Tumors.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Introduction.<font style="font-weight:normal;font-style:normal;">&nbsp;&nbsp;PD&#8209;L1.t&#8209;haNK is a human, allogeneic, stable clonal NK cell line generated from our parental clinical-grade aNK master cell bank. This product combines the potent cell killing mechanism mediated through PD&#8209;L1 CAR targeting with the well-known and potent Fc</font><font style="font-family:'Times New Roman';font-weight:normal;font-style:normal;"><font style="font-size:10pt;font-family:'Times New Roman'">g</font></font><font style="font-weight:normal;font-style:normal;">RIIIa/CD16 mediated ADCC killing mechanism. Internal research has demonstrated that such a dual expression is not only stable, but that each component contributes synergistically when used in conjunction with the appropriate therapeutic IgG1 therapeutic antibody. Our PD&#8209;L1.t&#8209;haNK product is highly potent and selectively active through the stable expression of three primary proteins:&#160;(1)&#160;a human PD&#8209;L1&#8211;targeted CAR; (2)&#160;the high-affinity variant of the human IgG1&#160;Fc receptor, Fc&#947;RIIIa/CD16 for enhanced ADCC; and (3)&#160;a variant of the human IL&#8209;2 cytokine for enhanced function, IL&#8209;2 growth independence and limited extracellular leakage of IL&#8209;2 for improved safety.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">In Vitro Research.<font style="font-weight:normal;font-style:normal;">&nbsp;&nbsp;Our PD&#8209;L1.t&#8209;haNK master cell bank is a uniform cell population that can be easily and stably expanded in continuous culture. It has demonstrated exceptionally potent and specific </font><font style="font-weight:normal;">in&#160;vitro</font><font style="font-weight:normal;font-style:normal;"> activity against PD&#8209;L1&#8211;expressing tumors via CAR-directed cytotoxicity. Likewise, it exhibited potent killing through innate mechanisms, including NKG2D and NKp30 receptors. Moreover, since PD&#8209;L1.t&#8209;haNK retains a high expression of the high-affinity CD16 allele, the engineered enhancement of haNK cells, even after irradiation and thawing, it can also mediate antitumor activity via ADCC when administered in combination with a monoclonal antibody. As such, a tri-targeting approach may be more effective at potentiating antitumor activity in all PD&#8209;L1&#8211;expressing solid malignancies, particularly when the appropriate IgG1-type antibody is added to the therapeutic regimen. The receptor expression profiles and </font><font style="font-weight:normal;">in vitro</font><font style="font-weight:normal;font-style:normal;"> killing plots of our PD&#8209;L1.t&#8209;haNK&#160;cells against cancer cell lines utilizing CAR, innate and ADCC mechanisms are illustrated in the following slides. Several NCI manuscripts on PD&#8209;L1.t&#8209;haNK from our collaboration disclosing new and compelling </font><font style="font-weight:normal;">in vitro</font><font style="font-weight:normal;font-style:normal;"> and </font><font style="font-weight:normal;">in vivo</font><font style="font-weight:normal;font-style:normal;"> data are expected to publish in the very near term.</font></p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g4i5nix4zlkt000033.jpg" title="" alt="" style="width:700px;height:482px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g4i5nix4zlkt000034.jpg" title="" alt="" style="width:700px;height:375px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g4i5nix4zlkt000035.jpg" title="" alt="" style="width:700px;height:546px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">In Vivo Research.<font style="font-weight:normal;font-style:normal;">&nbsp;&nbsp;Nonclinical testing was performed to determine the pharmacologic and toxicologic effects of PD&#8209;L1.t&#8209;haNK, which may be predictive of its clinical safety and efficacy in humans. The nonclinical </font><font style="font-weight:normal;">in&#160;vivo</font><font style="font-weight:normal;font-style:normal;"> studies employed immunocompromised mouse models in order to mitigate rejection of PD&#8209;L1.t&#8209;haNK cells by the xenogenic host species. Nonclinical pharmacology data demonstrated that PD&#8209;L1.t&#8209;haNK cells possess potent </font><font style="font-weight:normal;">in&#160;vivo</font><font style="font-weight:normal;font-style:normal;"> antitumor efficacy as demonstrated in PD&#8209;L1&#8211;positive xenograft models. PD&#8209;L1.t&#8209;haNK administration was able to markedly decrease metastatic disease burden and inhibit tumor growth in these tumor-bearing animals.</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A repeat-dose biodistribution study evaluated the dispersion and persistence of the PD&#8209;L1.t&#8209;haNK&#160;cell line following repeated administration in the presence of PD&#8209;L1&#8209;expressing tumors. PD&#8209;L1.t&#8209;haNK&#160;cells were detected at very low frequency in the liver and lungs of PD&#8209;L1 tumor-bearing mice six-hours after dosing and were completely undetectable 48-hours after dosing. This study also indicated that the presence of the PD&#8209;L1-targeted CAR construct does not affect the biodistribution pattern of the PD&#8209;L1.t&#8209;haNK&#160;cells. Likewise, the presence of a PD&#8209;L1&#8211;targeted CAR does not affect the biodistribution of the cells, which circulate through the blood with accumulation occurring in the liver and lungs, and with limited persistence.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A pivotal toxicity study showed that repeat-dose administration of irradiated PD&#8209;L1.t&#8209;haNK cells in an immunocompromised mouse model was well tolerated and did not result in any significant toxicities, pathological changes, or tumor formation. Additionally, no weight loss, distress, or other treatment-related adverse reactions were observed in any animals. Importantly, the tolerability of repeat-dose administration of PD&#8209;L1.t&#8209;haNK&#160;cells was comparable to treatment with other aNK-derived cell lines. In summary, the nonclinical data demonstrated a favorable risk-benefit ratio for PD&#8209;L1.t&#8209;haNK.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU36"></a><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Development Plan.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">QUILT&#160;3.064<font style="font-weight:normal;font-style:normal;"> is a phase&#160;I, first-in-human, open label study to evaluate safety, preliminary efficacy, determine the maximum feasible dose and designate the recommended phase&#160;II dose of PD&#8209;L1.t&#8209;haNK for infusion in subjects with locally advanced or metastatic solid cancers. This study opened mid-2019 and is being conducted in two parts:&#160;the first being a standard dose escalation protocol using a 3&#160;+&#160;3&#160;design, and the second, an expansion of the highest dose level with acceptable toxicity to further characterize safety and efficacy. As of March&#160;15, 2020, we have completed the first two dose levels of 2&#160;x&#160;10<sup style="font-size:85%;line-height:120%;vertical-align:top">9</sup> and 4&#160;x&#160;10<sup style="font-size:85%;line-height:120%;vertical-align:top">9</sup>&#160;cells and are enrolling the fourth patient for our expansion cohort. Since the observation hold period between each patient only applied to the dose escalation potion of the trial, we anticipate study completion during the second quarter of 2020. Patient tumor types so far included head and neck squamous cell carcinoma, breast and triple negative breast cancers, colon cancers, glioblastoma, urothelial cancer and leiomyosarcoma. One-hundred doses at the 2&#160;x&#160;10<sup style="font-size:85%;line-height:120%;vertical-align:top">9</sup> dose level and fifty-six doses at the 4&#160;x&#160;10<sup style="font-size:85%;line-height:120%;vertical-align:top">9</sup> dose level have been administered as of March 2, 2020. One dose limiting toxicity was reported at the 4&#160;x&#160;10<sup style="font-size:85%;line-height:120%;vertical-align:top">9</sup> dose level that did not require dose-reduction and all but one patient are still alive, two stable diseases were noted, one at an early time point and one at four months and several additional patients are scheduled to undergo imaging studies to assess their tumor responses. We anticipate reporting on this trial at the upcoming American Society of Clinical Oncology conference in June&#160;2020.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">After evaluation of safety and initial activity, we plan to conduct a wide range of additional immunotherapy studies with this agent in simple combinations to address the PD&#8209;L1 molecular marker across select tumor types leading with pancreatic and non-small cell lung cancers. By the conclusion of the study, we believe we will have characterized the pharmacologic profile for PD&#8209;L1.t&#8209;haNK, obtained preliminary estimates of efficacy as a monotherapy in terms of objective response rate, progression-free survival and overall survival, assessed tumor molecular profiles, as well as therapy-induced changes in immune responses and their correlations with subject outcomes.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On a related note, a patient with late stage pancreatic cancer was enrolled to a special IND to receive PD&#8209;L1.t&#8209;haNK cells in combination with N&#8209;803 and aldoxorubicin. This patient has been confirmed to have a complete response by Positron Emission Tomography CT at three months. QUILT&#160;88, a phase&#160;II/III protocol that was recently filed with the FDA and described in further detail later in this section, will investigate this combination of agents further.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Novel, First-in-Class CD19.t&#8209;haNK Product Candidate for Liquid Tumors.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Introduction.<font style="font-weight:normal;font-style:normal;">&nbsp;&nbsp;CD19.t&#8209;haNK is a human, allogeneic, stable clonal NK cell line generated from our parental clinical-grade aNK master cell bank. This product combines the potent cell killing mechanism mediated through CD19 CAR targeting of the B-cell marker CD19 with the well-known and potent Fc&#947;RIIIa/CD16 mediated ADCC killing mechanism. Internal research has demonstrated that such a dual expression is not only stable, but that each component contributes synergistically when used in conjunction with the appropriate therapeutic IgG1-type monoclonal antibody. Our CD19.t&#8209;haNK product is highly potent and selectively active through the stable expression of three primary proteins:&#160;(1)&#160;a CD19&#8211;targeted CAR; (2)&#160;the high-affinity variant of the human IgG1&#160;Fc receptor, Fc&#947;RIIIa/CD16 for enhanced ADCC; and (3)&#160;a variant of the human IL&#8209;2 cytokine for enhanced function, IL&#8209;2 growth independence and limited extracellular leakage of IL&#8209;2 for improved safety.</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">In Vitro Research.<font style="font-weight:normal;font-style:normal;">&nbsp;&nbsp;Our CD19.t&#8209;haNK master cell bank is a uniform cell population that can be easily and stably expanded in continuous culture. It has demonstrated potent and specific </font><font style="font-weight:normal;">in&#160;vitro</font><font style="font-weight:normal;font-style:normal;"> and </font><font style="font-weight:normal;">in&#160;vivo</font><font style="font-weight:normal;font-style:normal;"> activity against CD19-expressing tumors via CAR-directed cytotoxicity. Likewise, it exhibited potent killing through innate mechanisms, including NKG2D and NKp30 receptors. Moreover, since CD19.t&#8209;haNK also expresses the high-affinity CD16 allele, the engineered enhancement of haNK&#160;cells, it can also mediate antitumor activity via ADCC when administered in combination with a monoclonal antibody. As such, a tri-targeting approach may be more effective at potentiating antitumor activity in all CD19 expressing liquid tumors, particularly when the appropriate IgG1-type antibody is added to the therapeutic regimen. The </font><font style="font-weight:normal;">in&#160;vitro</font><font style="font-weight:normal;font-style:normal;"> killing plots of our CD19.t&#8209;haNK&#160;cells against cancer cell lines utilizing CAR, innate and ADCC mechanisms are illustrated in the following slides.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU37"></a><img src="g4i5nix4zlkt000036.jpg" title="" alt="" style="width:671px;height:356px;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g4i5nix4zlkt000037.jpg" title="" alt="" style="width:671px;height:463px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU38"></a><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">In Vivo Research</font><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">.</font><font style="font-weight:normal;font-style:normal;">&nbsp;&nbsp;An array of </font><font style="font-weight:normal;">in&#160;vitro</font><font style="font-weight:normal;font-style:normal;"> and </font><font style="font-weight:normal;">in&#160;vivo</font><font style="font-weight:normal;font-style:normal;"> pharmacology proof-of-concept studies have been performed with CD19.t</font><font style="font-weight:normal;font-style:normal;">&#8209;haNK. The </font><font style="font-weight:normal;">in&#160;vivo</font><font style="font-weight:normal;font-style:normal;"> antitumor activity was investigated using a CD19-positive lymphoma cancer line in immunocompromised mouse models. Irradiated CD19.t</font><font style="font-weight:normal;font-style:normal;">&#8209;haNK cells were administered intravenously twice per week over a period of three&#160;weeks and resulted in statistically significant tumor growth inhibition on and after the first week compared to a control group. In addition, it was observed during necropsy that treatment with CD19.t</font><font style="font-weight:normal;font-style:normal;">&#8209;haNK</font><font style="font-weight:normal;font-style:normal;">&#160;</font><font style="font-weight:normal;font-style:normal;">cell treatments reduced liver metastasis, which was further corroborated by histological evaluation. Furthermore, treatment with CD19.t</font><font style="font-weight:normal;font-style:normal;">&#8209;haNK was able to reduce the number of animal death events, with 100% of the study subjects alive at the end of the study compared to only 50% of the subjects in the control group. Results from this study are indicative of the potential pharmacological effects of CD19.t</font><font style="font-weight:normal;font-style:normal;">&#8209;haNK for infusion in human lymphoma patients.</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To investigate the <font style="font-style:italic;">in&#160;vivo</font> biodistribution and persistence of CD19.t&#8209;haNK cells intravenously administered in CD19&#8209;positive Raji tumor-bearing mice, tissues were analyzed at six- and 48-hours after the final dose. CD19.t&#8209;haNK cells were detected at very low frequency in the liver and lungs at six-hours post-dosing, and none were detected at 48-hours post&#8209;dosing. The results of this study are consistent with previous biodistribution studies performed with haNK cells, indicating that the addition of the CD19 CAR does not affect the biodistribution pattern of the cells and that like haNK cells, CD19.t&#8209;haNK cells do not persist <font style="font-style:italic;">in&#160;vivo</font>, a highly favorable feature that may underlie its excellent safety profile without adversely impacting potency.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In investigating <font style="font-style:italic;">in&#160;vivo</font> toxicity and tumorigenicity of CD19.t&#8209;haNK cells after 28&#160;days of repeat dosing in immunocompromised mice, results showed that all mice receiving product were overall as healthy as the control group throughout the study. There were no mortalities in either of the treatment groups and likewise, no adverse events were observed. Blood and serum samples collected at the end of the study revealed no significant differences between animals receiving drug product and those in the control group. In addition, gross necropsy and macroscopic morphologic examination revealed no tumor masses or organ abnormalities. Subsequent pathological evaluation of harvested tissues confirmed that there was no gross or microscopic evidence of toxicity or tumorigenicity associated with administration of irradiated CD19.t&#8209;haNK cells. We believe the results from this study provide strong support for the safety of cryopreserved, irradiated CD19.t&#8209;haNK cell therapy in human clinical trials.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Diffuse Large B-Cell Lymphoma.<font style="font-weight:normal;font-style:normal;">&nbsp;&nbsp;Diffuse large B-cell lymphoma, or DLBCL, the most common subtype of </font><font style="Background-color:#FFFFFF;font-weight:normal;font-style:normal;">non&#8209;Hodgkin&#8217;s lymphoma</font><font style="font-weight:normal;font-style:normal;">, is a heterogeneous disease. The current standard for first-line therapy is a traditional chemotherapy regimen consisting of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. While approximately 50% to 60% of patients respond well to first-line therapy, approximately 15% to 25% of patients suffer from primary refractory disease, approximately 20% to 30% relapse after achieving a complete response, and 5% achieve only a partial response. Patients that relapse or are refractory to first-line therapy can be treated with one of an array of salvage chemotherapy regimens and if responsive, may subsequently proceed to undertake potentially curative stem cell transplantation. However, patients that are refractory or relapse after two or more lines of therapy, especially those that are not eligible for stem cell transplant or CAR&#8209;T cell therapy, have a very poor prognosis. New therapeutic options are critically needed to address this growing patient population.</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe that the combined potential for our CD19.t&#8209;haNK cells to exhibit a robust CAR-directed and ADCC mediated anti-cancer effect against B&#8209;cell malignancies when combined with rituximab or avelumab, given the strong support from our preclinical programs, merits further evaluation in clinical trials to evaluate the safety and preliminary efficacy of CD19.t&#8209;haNK in subjects with relapsed or refractory DLBCL.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Development Plan.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">QUILT&#160;3.061<font style="font-weight:normal;font-style:normal;"> is an open-label phase&#160;I study that will assess the safety and preliminary efficacy of increasing doses of CD19.t&#8209;haNK monotherapy and determine the maximal feasible dose and designate the recommended phase&#160;II dose in subjects with diffuse large B&#8209;cell lymphoma who have progressed through two or more lines of therapy and are ineligible for transplant or CAR&#8209;T therapy. This first clinical trial for our CD19.t&#8209;haNK product candidate cleared FDA review last year for study initiation. The study will be conducted in two parts:&#160;the first being a standard dose escalation protocol using a 3&#160;+&#160;3&#160;design, and the second, an expansion of the highest dose level with acceptable toxicity, to further characterize safety and efficacy.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Results from the trial will help us characterize the pharmacokinetic and pharmacologic profiles for CD19.t&#8209;haNK, generate preliminary estimates of efficacy in terms of objective response rate, progression-free survival, and overall survival, and help us assess tumor molecular profiles, as well as therapy-induced changes in immune responses and their correlations with subject outcomes. Additional study details have been posted to clinicaltrials.gov.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Additional Potential t&#8209;haNK Product Candidates.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depending on the results obtained from our current clinical trial strategy, additional t&#8209;haNK product candidates currently advancing through pre-clinical development, including our EGFR and BCMA t&#8209;haNK programs, may be rapidly moved into first-in-human trials followed by disease and molecular marker specific studies.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU39"></a><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Registration Trials for haNK and PD</font><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#8209;L1.t</font><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#8209;haNK</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Phase&#160;II Second Line or Greater Merkel Cell Carcinoma</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">QUILT&#160;3.063<font style="font-weight:normal;font-style:normal;"> is a phase&#160;II, open label, single-arm trial evaluating the novel triple combination of &#8220;off-the-shelf&#8221; haNK&#160;cell therapy with N&#8209;803 and the checkpoint inhibitor avelumab, without chemotherapy in subjects that have progressed after treatment with a checkpoint inhibitor for Merkel cell carcinoma. This trial, which has already started enrolling, will be evaluating the objective response rate using Response Evaluation Criteria in Solid Tumors Version&#160;1.1 based on Blinded Independent Central Review. Additional measures of efficacy by progression-free survival, overall survival, disease-specific survival, duration of response, disease control rate, and quality of life by patient-reported outcomes and measures of safety will also be assessed. Exploratory objectives include the assessment of the pharmacokinetic and immunogenicity profiles, assessment of tumor molecular profiles and therapy-induced changes in immune responses, and molecular changes in cell-free circulating DNA and RNA, and their correlations with subject outcomes. Additional study details have been posted to clinicaltrials.gov.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This triple combination of immunotherapies has been safely studied in our NCV trials for other solid cancer indications. The goal of combining these therapies is to synergistically maximize the killing of cancer cells while attempting to spare patients from chemotherapy and its associated adverse side effects. In both <font style="font-style:italic;">in vitro</font> and <font style="font-style:italic;">in vivo</font> studies we conducted, the combination of haNK&#160;cells with a number of different therapeutic antibodies, including avelumab, led to enhanced tumor cell killing when compared to the use of the antibody alone. Avelumab, is a checkpoint inhibitor which targets the programmed death&#8209;ligand&#160;1 protein, or PD&#8209;L1, commonly expressed on a wide range of cancers. N&#8209;803 has been shown to synergistically activate natural killer and T&#8209;cells and enhance cancer cell killing in both single agent and combination therapy. When N&#8209;803 is combined with haNK&#160;cells, a synergistic response is likewise observed in both <font style="font-style:italic;">in vivo</font> and <font style="font-style:italic;">in vitro</font> models.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Merkel Cell Carcinoma.<font style="font-weight:normal;font-style:normal;">&nbsp;&nbsp;Merkel cell carcinoma, or MCC, is a rare and aggressive skin cancer that arises from uncontrolled growth of cells in the skin. Increasing in incidence, approximately 2,500 new cases are reported in the U.S. each year. Patients with metastatic or locally advanced MCC have an extremely poor prognosis, with less than 20% of patients surviving longer than five years. Typically, these patients are treated with a range of drugs, including chemotherapy, which can result in significant side effects. Although new immune therapies have the potential to improve survival, MCC is still fatal for a majority of patients who have progressed on or after treatment with a checkpoint inhibitor and represents an unmet medical need.</font></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Phase&#160;II/III Front-Line Maintenance and Second Line Treatment of Locally Advanced or Metastatic Pancreatic Cancer</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">QUILT&#160;88<font style="font-weight:normal;font-style:normal;"> is a phase&#160;II/III open-label, randomized, two-cohort comparative study of PD&#8209;L1.t&#8209;haNK, N&#8209;803 and aldoxorubicin in combination with standard-of-care therapy versus standard-of-care therapy alone for front-line maintenance and second line treatment of subjects with locally advanced or metastatic pancreatic cancer. The two cohorts include:</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A.</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Front-line maintenance therapy in patients that have achieved either a partial response, complete response, or stable disease after first-line standard-of-care therapy; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">B.</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Second or later-line therapy and within each cohort, enrolled subjects will be randomly assigned to receive PD&#8209;L1.t&#8209;haNK, N&#8209;803 and aldoxorubicin with standard-of-care in an experimental arm or standard-of-care only in the control arm.</p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cohort&#160;A will serve as the phase&#160;II portion of the trial and will have three experimental arms, which allows for separate assessment of successively adding only aldoxorubicin, aldoxorubicin and N&#8209;803 and aldoxorubicin, N&#8209;803 and PD&#8209;L1.t&#8209;haNK. Cohort&#160;B would serve as the phase&#160;III potion of the trial. Safety and progression-free survival will be compared between the group using Response Evaluation Criteria in Solid Tumors Version&#160;1.1 based on Blinded Independent Central Review. The IND has been filed and study details will be posted to clinicaltrials.gov upon FDA clearance.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Pancreatic Cancer.<font style="font-weight:normal;font-style:normal;">  Pancreatic cancer is one of the deadliest cancers for patients in the U.S. Pancreatic cancer is the third leading cause of cancer-related death in the U.S., behind only lung cancer and colorectal cancer, and is expected to become the second-leading cause after lung cancer around 2020. The overall five-year survival rate is just 9%. In&#160;2019, an estimated 56,770&#160;people were diagnosed with pancreatic cancer in the U.S., and approximately 45,750&#160;of those newly diagnosed will die from the disease. Pancreatic cancer is the ninth-most commonly diagnosed cancer in women and the tenth-most commonly diagnosed in men. Only about 20% to 30% of cases are found early enough to treat surgically, before the cancer has spread, and surgery gives the only chance that this cancer can be eradicated. Treatment options for pancreatic cancer patients include surgery, chemotherapy, radiation therapy, targeted therapy, immunotherapy, and clinical trials. Pancreatic cancer is uniformly accepted as an area of serious unmet medical need, with five-year relative survival rates by SEER stage at diagnosis of 37% for localized, 12% for regional, 3% for distant, and 9% for all SEER stages combined.</font></p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU40"></a><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Phase</font><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</font><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">IIb Second-Line or Greater Non-Small Cell Lung Cancer</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">QUILT&#160;3.055<font style="font-weight:normal;font-style:normal;"> is a phase&#160;IIb, open label study of PD&#8209;L1.t&#8209;haNK, N&#8209;803 and a checkpoint inhibitor in subjects with non-small cell lung cancer that have confirmed disease progression by investigator assessment per Immune-related Response Evaluation Criteria in Solid Tumors, or irRECIST, during treatment on-study with N&#8209;803 and a checkpoint inhibitor. This is part of a larger trial that initially utilizes N&#8209;803 and a checkpoint inhibitor for subjects who have progressed after an initial response to checkpoint inhibitor therapy. Safety and objective response rate defined as investigator-assessed complete response&#160;+&#160;partial response per Response Evaluation Criteria in Solid Tumors Version&#160;1.1 based on Blinded Independent Central Review and secondarily per irRECIST will be determined. The IND amendment has been cleared by the FDA and study details will be posted to clinicaltrials.gov in due course.</font></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Phase&#160;III First and Second-Line Non-Small Cell Lung Cancer</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">QUILT&#160;59<font style="font-weight:normal;font-style:normal;"> is a phase&#160;III open-label, randomized, three-cohort study of standard-of-care therapy in combination with PD&#8209;L1.t&#8209;haNK, N&#8209;803 and a checkpoint antibody versus standard-of-care chemotherapy alone for first and second line treatment of subjects with locally advanced or metastatic squamous and non-squamous non-small cell lung cancer. The three-cohorts include:</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A.</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Squamous first-line therapy;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">B.</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Non-squamous first-line therapy; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">C.</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Squamous and non-squamous second-line therapy.</p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Within each cohort, enrolled subjects will be randomly assigned to receive PD&#8209;L1.t&#8209;haNK, N&#8209;803 and a checkpoint antibody with standard-of-care in the experimental arms or standard-of-care only in the control arms. Safety and progression-free survival will be compared between the group using Response Evaluation Criteria in Solid Tumors Version&#160;1.1 based on Blinded Independent Central Review. Preparations are being made to file this IND and study details will be posted to clinicaltrials.gov shortly after FDA clearance.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Non-Small Cell Lung Cancer.<font style="font-weight:normal;font-style:normal;">  Lung cancer is the second most common cancer. About 222,500 new cases will be diagnosed this year. Non-small cell lung cancer, or NSCLC, is often insidious, producing no symptoms until the disease is well advanced. NSCLC makes up about 80% to 85% of all lung cancers. The three main types of NSCLC are squamous cell carcinoma, and non-squamous cell carcinoma, consisting of adenocarcinoma and large cell carcinoma. Adenocarcinoma is the most common form of lung cancer in the U.S, among both men and women. Squamous cell carcinoma, is the second most prevalent, accounting for 25% of all lung cancers. Large cell carcinoma is the smallest, accounting for approximately 10% of NSCLC tumors. Early recognition of symptoms may be beneficial to outcome. At initial diagnosis, 20% of patients have localized disease, 25% of patients have regional metastasis, and 55% of patients have distant spread of disease. Symptoms depend on the location of cancer.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The five-year survival rate for NSCLC is 24%. However, it is important to note that survival rates depend on several factors, including the subtype of lung cancer, and the stage of disease. For people with localized NSCLC, which means the cancer has not spread outside of the lung, the overall five-year survival rate is 61%. For regional NSCLC, which means the cancer has spread outside of the lung to nearby areas, the five-year survival rate is approximately 35%. If the cancer has spread to distant parts of the body, called metastatic lung cancer, the five-year survival rate is 6%. But because of new effective treatments, this number is changing, although better therapies are acutely needed.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Phase&#160;II First and Second Line Locally Advanced or Metastatic Triple Negative Breast Cancer</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">QUILT&#160;3.069<font style="font-weight:normal;font-style:normal;"> is a phase&#160;II randomized, two-cohort study of PD&#8209;L1.t&#8209;haNK, N&#8209;803, aldoxorubicin and a checkpoint inhibitor in combination with standard-of-care therapy versus standard-of-care alone for first and second line treatment of subjects with locally advanced or metastatic triple-negative breast cancer, or TNBC. The two cohorts include:</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A.</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">First-line TNBC therapy; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">B.</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Second-line TNBC therapy.</p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Within each cohort, enrolled subjects will be randomly assigned to receive PD&#8209;L1.t-haNK, N&#8209;803 aldoxorubicin and a checkpoint antibody with standard-of-care in the experimental arms or standard-of-care only in the control arms. Safety and progression-free survival per Response Evaluation Criteria in Solid Tumors, or RECIST, Version&#160;1.1, based on Blinded Independent Central Review, or BICR, will be compared across all treatment groups. Preparations are being made to file this IND and study details will be posted to clinicaltrials.gov shortly after FDA clearance.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU41"></a><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Triple Negative Breast Cancer.</font><font style="font-weight:normal;font-style:normal;"> </font><font style="font-weight:normal;font-style:normal;"> Breast cancer is the most common cancer among women in the U</font><font style="font-weight:normal;font-style:normal;">.</font><font style="font-weight:normal;font-style:normal;">S</font><font style="font-weight:normal;font-style:normal;">.</font><font style="font-weight:normal;font-style:normal;">, the second most common cause of cancer death, and the main cause of death in women ages 45 to 55 years. In 2009, approximately 192,370 women </font><font style="font-weight:normal;font-style:normal;">in the U.S. </font><font style="font-weight:normal;font-style:normal;">were diagnosed with breast cancer, and an estimated 40,170 women died of the disease. T</font><font style="font-weight:normal;font-style:normal;">NBC</font><font style="font-weight:normal;font-style:normal;"> accounts for approximately 15% of all breast cancers. Of these TNBC cases, about 75% are "basal-like." TNBC is a subtype of breast cancer that lacks expression of the estrogen receptor</font><font style="font-weight:normal;font-style:normal;">, or ER,</font><font style="font-weight:normal;font-style:normal;"> and progesterone receptor</font><font style="font-weight:normal;font-style:normal;">, or PR,</font><font style="font-weight:normal;font-style:normal;"> and does not overexpress </font><font style="font-weight:normal;font-style:normal;">the </font><font style="font-weight:normal;font-style:normal;">human epidermal growth factor</font><font style="font-weight:normal;font-style:normal;">&#160;</font><font style="font-weight:normal;font-style:normal;">2 receptor</font><font style="font-weight:normal;font-style:normal;">, or HER2,</font><font style="font-weight:normal;font-style:normal;"> protein. TNBC is an important area of research for both researchers and clinicians alike because</font><font style="font-weight:normal;font-style:normal;">:</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">i.</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">TNBC is a poor prognostic factor for disease-free and overall survival;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ii.</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">No effective specific targeted therapy is readily available for TNBC;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">iii.</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">There is a clustering of TNBC cases in premenopausal women and in women of African descent; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">iv.</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The overlap of BRCA1-associated breast cancers with the TNBC phenotype is significant.</p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The prevalence of TNBC is highest in premenopausal African American women. A recent report notes that 39% of all African American premenopausal women diagnosed with breast cancer are diagnosed with TNBC. The prevalence of TNBC in this same age group in non-African American women is much lower, at approximately 15%. After adjusting for age and stage at diagnosis, African American women were almost three times more likely than white women to have triple-negative tumors. These ethnic or menopausal differences are not seen in either the ER+/HER2+ breast cancer subgroup or the ER+/HER2&#8211; subgroup. Five-year relative survival rates for triple-negative breast cancer by SEER stage at diagnosis are 91% for localized, 65% for regional, and 11% for distant.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Triple-negative breast cancer has fewer treatment options than other types of invasive breast cancer. This is because the cancer cells do not have the estrogen or progesterone receptors or enough of the HER2 protein to make hormone therapy or targeted drugs work. If the cancer has not spread to distant sites, surgery is an option. Chemotherapy might be given first to shrink a large tumor followed by surgery. It might also be given after surgery to reduce the chances of the cancer coming back. Radiation might also be an option depending on certain features of the tumor.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Because hormone therapy and HER2 drugs are not choices for women with TNBC, chemotherapy is often used. In cases where the cancer has spread to other parts of the body (i.e., stage&#160;IV) chemotherapy and other treatments that can be considered include PARP inhibitors, platinum chemotherapy, or immunotherapy.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU42"></a><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">NantKwest&#8217;s Ongoing Clinical Trials Activities:</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g4i5nix4zlkt000038.jpg" title="" alt="" style="width:671px;height:516px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Potential Development Catalysts for Driving Value:</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By virtue of parallel development of a range of products derived from our versatile NK&#160;cell platform in a variety of disease settings, numerous potential catalysts have emerged as value drivers for our business:</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Early indicators of efficacy:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">Merkel cell cancer complete responses to aNK therapy;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">Lung cancer responses to aNK therapy;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">Triple negative breast cancer complete responses to haNK therapy;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">Pancreatic cancer complete response to PD&#8209;L1.t&#8209;haNK therapy.</font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Products:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">PD&#8209;L1.t&#8209;haNK in phase&#160;II and IIb trials for pancreatic cancer, non-small cell lung cancer and triple-negative breast cancer;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">haNK in phase&#160;II for Merkel cell cancer;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">CD19.t&#8209;haNK in phase&#160;I for diffuse large&#160;B-cell lymphoma;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">HER2.t&#8209;haNK IND-ready for HER2 expressing cancers;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">EGFR.t&#8209;haNK and BCMA.t&#8209;haNK in preclinical for EGFR and BCMA expressing cancers, respectively.</font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU43"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exclusive Commercial License:</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">We are an early investor and shareholder in Viracta Therapeutics, Inc., or Viracta, and an exclusive licensee of its novel class&#160;1 histone deacetylase inhibitor, or HDACi, nanatinostat, which holds both Orphan Drug and Fast Track Designations from the FDA and is currently in a phase II&#160;clinical trial in combination with valganciclovir for patients with Epstein-Barr virus associated lymphomas. Being an HDACi, nanatinostat acts as an epigenetic activator, inducing cold tumors to express immunogenic proteins, thereby rendering them as immunologically recognizable by an activated immune system for elimination. As an easy to administer, short-acting oral agent, nanatinostat is potentially an ideal agent to use in combination with our NK therapies. Our worldwide exclusivity includes the conduct of research, development and commercial sale of nanatinostat in combination with NK&#160;cell therapies. We plan to explore therapeutic combinations of nanatinostat for patients with EBV, CMV and HPV associated malignancies, including nasopharyngeal, gastric, breast and cervical cancers and diffuse large&#160;B-cell lymphoma.</font></p></td></tr></table></div>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Potential Regulatory Catalysts for Driving Value*:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g4i5nix4zlkt000039.jpg" title="" alt="" style="width:671px;height:379px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additional information can be found in the corporate slide deck presented at the 38<sup style="font-size:85%;line-height:120%;vertical-align:top">th</sup> annual J.P.&#160;Morgan Healthcare Conference on January&#160;14, 2020 at <font style="text-decoration:none;">https://ir.nantkwest.com/static-files/77614f06-5c1f-4c42-8761-b4d2f382425c</font>.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Coronavirus Related Activities:</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Global events relating to the spread of SARS&#8209;CoV&#8209;2 infections, which initially emerged late in 2019 and evolved rapidly into a widespread pandemic, has captured our attention as a unique opportunity to assist our state and country with developing therapies for patients with moderate to severe respiratory infections. Since February&#160;2020, we have been formulating what we believe to be the best approach to study one or more of our clinical candidates, with the objective of hastening the resolution of symptoms, shortening the duration of viral shedding, lessening the burden of intensive care demand, advancing our understanding of this disease, and bridging the health care system to a time when we will have an adequate vaccine deployed around the world. As early clinical data on COVID&#8209;19 patients are being published, we are coming to a better understanding of the associated immunology for patients with moderate and severe disease as well as for convalescent patients.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU44"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A clearer patient narrative has only recently been forming, with clinical presentations of mild to severe disease associated with elevated neutrophil counts and markedly depressed NK and CD8+&#160;T</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8209;lymphocyte counts that is in direct proportion with the severity of disease. Moreover, analysis of these NK and CD8+&#160;T</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8209;lymphocytes reveal that they are functionally exhausted, meaning that they could no longer carry out target cell killing in a standardized assay. Interestingly, the natural killer cells also exhibited a high level of expression of the inhibitory receptor, NKG2A, and reduced expression of interferon-</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#947;, or </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">IFN</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8209;</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#947;;</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> interleukin</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8209;2, or IL</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8209;2; and granzyme&#160;B, or GzB; all of which are associated with exhaustion of chronic viral infection. Convalescent patients were found to have their NK and CD8+&#160;T</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8209;lymphocyte numbers restored, reduced NKG2A expression and normalized expression of IFN</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8209;</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#947;</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, IL</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8209;2 and GzB. Similar data was reported in patients with SARS</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8209;CoV viral infections during the 2003 outbreak.</font><sup style="font-size:85%;line-height:120%;vertical-align:top">13</sup><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top"></sup></font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> These finding are indicative of a SARS</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8209;CoV</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8209;2 induced impairment of the innate immune antiviral response at an early stage of disease.</font><sup style="font-size:85%;line-height:120%;vertical-align:top">14</sup><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top"></sup></font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Mechanistic research on both SARS&#8209;CoV, and MERS&#8209;CoV from the 2012 outbreak, paint the picture of a molecular arms race between host innate antiviral response and human coronavirus adaptations of evasion. MERS&#8209;CoV, for instance, induces repressive histone modifications to downregulate specific subsets of interferon-stimulated genes, or ISGs, which are responsible for establishing an &#8216;antiviral state&#8217; in the cells that is effected through viral-RNA cleavage enzymes and IFN production. Both SARS and MERS CoVs have been reported to suppress IFN production and signaling pathways through these and other mechanisms, particularly in patients with severe diseases. When this was recreated in the laboratory setting and the deficiency in IFN&#8209;&#945; production in CoV-infected cells was remedied by IFN&#8209;&#945; treatment, CoV replication was inhibited.<sup style="font-size:85%;line-height:120%;vertical-align:top">15</sup><sup style="font-size:85%;line-height:120%;vertical-align:top"></sup> This, together with other accumulated data, leads us to better understand the essential role of interferons in the anti-viral effect against CoV infection.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The administration of haNK&#160;cells following the infusion of IgG&#160;SARS&#8209;CoV&#8209;2-neutralizing antibodies obtained from the serum of convalescent patients could accomplish several things for patients with moderate to severe disease due to SARS&#8209;CoV&#8209;2 infection. Firstly, it could immediately supplement patients with ADCC-competent, &#8216;non-exhausted&#8217; natural killer cells in numbers that approximate the body&#8217;s otherwise normal natural killer cell levels. These natural killer cells are fully capable of expressing and potentially delivering IFN&#8209;&#947;, IL&#8209;2, and GzB to the site of infected organs to facilitate immune recruitment and adaptive responses. The neutralizing antibodies from convalescent serum could supplement the patient&#8217;s humoral response, coat the CoV infected cells and mediate ADCC killing between it and the administered haNK&#160;cells. The overall objective is to shift the balance of the molecular arms race in favor of the patient&#8217;s innate immune responses, thereby enabling more patients to recover. With our clinical supply of cryopreserved haNK dose forms in storage and available for on-demand clinical research use, we are well positioned to initiate trials rapidly.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left"><table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:20%;"><tr><td style="width:20%;"></td></tr><tr><td valign="top"  style="border-bottom:Solid 1pt #000000;"><p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;text-indent:0pt;font-size:8pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:0%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">13</sup>&nbsp;</font></p></td>
<td valign="top" style="width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:9pt;"> Zheng, M., et al. Cellular &amp; Molecular Immunology, 2020</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:0%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">14</sup>&nbsp;</font></p></td>
<td valign="top" style="width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:9pt;"> Am J Clin Pathol, 2004. 121(4): p. 507-11</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:0%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">15</sup>&nbsp;</font></p></td>
<td valign="top" style="width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:9pt;"> Wong, L., et al. Virologica Sinica 2016. 31 (1): 12-23</font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">52</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU45"></a><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Achievements in Process Development, Scale-Up Manufacturing and Clinical Supply</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Manufacturing has continued to be one of our fastest growing functions in 2019. We made significant strides throughout the year in all of our core manufacturing and ancillary operational areas, including process development, scale-up manufacturing, materials sourcing, completion and certification of production facilities, pipeline buildup of cryopreserved and ready to infuse clinical product, all the way through and including clinical trial supply. An extensive patent portfolio of manufacturing methods applications has been filed to protect this body of pioneering work, which will serve as an added layer of protection to our existing patent estate.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g4i5nix4zlkt000040.jpg" title="" alt="" style="width:671px;height:377px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have been qualifying, releasing and storing frozen clinical dose forms of haNK from the fourth quarter of 2017 through the fourth quarter of 2018 and PD&#8209;L1.t&#8209;haNK since the first quarter of 2019. Shelf-life stability for frozen haNK now exceeds two&#160;years, which has enabled us to accumulate an inventory of product large enough to satisfy in its entirety our QUILT&#160;3.063 phase&#160;II Merkel cell carcinoma trial in an immediate, on-demand basis. Upon shipping receipt, clinical sites simply thaw the frozen product in a warming bath prior to infusion. We believe such simple clinical site requirements for product administration would expand patient accessibility well beyond select certified hospital centers into community outpatient practices and potentially into physician&#8217;s offices. Developing the capability to freeze and thaw our cell therapy product while preserving optimal viability and potency was a key goal that we both achieved and continue to refine as we further scale our operations. Our therapeutic platform is flexible and thus our investments in developing manufacturing capabilities have been designed with the ability to introduce new variants of our cellular products quickly. Having developed core capabilities for the successful cryopreservation and recovery of our cellular products, we believe we are now well positioned to implement simpler and more cost effective storage and shipping procedures to supply clinical sites that are located thousands of miles from our production facility.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">53</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g4i5nix4zlkt000041.jpg" title="" alt="" style="width:685px;height:390px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe we have unique processing and production capabilities that will enable us to leverage our investments in in-house operations to produce our cell therapy products at commercial scale. These capabilities will enable us to reduce our cost of goods sold and realize significant economies of scale. Further, the flexibility of these capabilities to apply to a wide range of new variants of our aNK cells will allow for more rapid scaling of our newly emerging t&#8209;haNK products from our pipeline and the initiation of a new series of clinical programs.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU46"></a><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">The Production Process</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our aNK platform production process largely resembles the widely used monoclonal antibody manufacturing process, without the laborious extraction and purification steps at the end, and bears the least resemblance to that of autologous CAR&#8209;T&#160;cell manufacturing. The figure below illustrates the key steps involved with master cell bank establishment, often starting with a Chinese hamster ovary, or CHO, cell line, in the case of antibody products and with an aNK cell line in the case of haNK, taNK and t&#8209;haNK products. Both utilize genetic engineering to achieve the desired clones, which after selection, are expanded to create master cell banks. From this point, a culture can be initiated from a single vial from the bank that will eventually be able to fill a bioreactor. In both cases, such a bioreactor can run for months with multiple harvests over the course of the culture. In the case of antibody products, it is the antibody-rich supernatant that must be separated from the cell culture and then purified before making the bulk product. In the case of haNK, taNK and t&#8209;haNK products, the cell culture is itself the product that simply requires centrifugation and washing before making the final dose forms. A single bioreactor can produce a significant number of doses that can be used to treat many patients.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g4i5nix4zlkt000042.jpg" title="" alt="" style="width:671px;height:409px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU47"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The panel below compares the key steps in the manufacture of autologous CAR</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8209;T therapy with that of haNK, taNK and t</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8209;haNK. CAR</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8209;Ts have a high per-unit manufacturing cost due to a series of complex processes, including harvesting T</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8209;cells from patients in an invasive procedure called leukapheresis. Once the T</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8209;cells have been adequately collected, they are sent to the manufacturing facility for individualized processing that starts with genetic engineering and expansion in a dedicated cGMP clean room. Then, through an elaborate series of procedures, the cells are selected using bead removal before a single dose form is prepared and returned to the hospital for infusion back into the original patient. By contrast, the manufacture of our allogeneic &#8220;off-the-shelf&#8221; haNK, taNK and t</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8209;haNK cells involves a rapid, scalable and cost efficient process where cells from a master cell bank vial are grown in a bioreactor and, once ready to harvest, the cells are centrifuged and washed before placement into final dose forms. One vial from the master cell bank can potentially produce thousands of cryopreserved dose forms that would be available on-demand, without the typical two- to three</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">week delay in orchestrating the logistics and preparation involved when using the CAR</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8209;T method.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g4i5nix4zlkt000043.jpg" title="" alt="" style="width:671px;height:395px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Building Out Our Manufacturing Capabilities</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Over the past year our process and manufacturing teams have worked diligently to further scale our operations to meet the anticipated commercial demand for our therapeutic products ahead of achieving regulatory approvals. The development of this capability has been key to ensure not just sufficient supply for our current and planned clinical trial operations, but also to ensure that we will be able to build an ample inventory of product to meet commercial demand, as well as to realize economies of scale for our pipeline of products being readied for the clinic.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">While we initially relied upon external manufacturers, we found that to create a scalable product with a reliable and cost effective clinical supply capability, we needed to build a state of the art cGMP facility for the manufacture of all our cellular therapeutics. In order to ensure uninterrupted clinical supply, we implemented a dual-stage strategy. In the initial stage, we established a pilot cGMP manufacturing facility at our Culver City, California, site and for the second stage we simultaneously built out an approximately 24,250&#160;square foot commercial cGMP facility in El Segundo, California. We completed the El Segundo facility buildout in May&#160;2018 and subsequently outfitted and prepared the facility for commercial scale manufacturing and initiated clinical production of PD&#8209;L1.t&#8209;haNK at this facility starting in the first quarter of 2019.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">56</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU48"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our initial production capabilities involved limited production of the cells in flasks and gas-permeable chambers. By 2016, our company possessed limited laboratory capabilities, as we were still dependent upon university partners and contract manufacturers for all of our cell production capabilities. While these did not yet involve bioreactors, they were sufficient to meet the limited clinical demands for our studies at the time. This foundational work was in part performed using the early production capabilities at Baylor University&#8217;s Cell and Gene Therapy Center, in addition to Northwestern University, and a global contract manufacturing vendor. We recognized the serious limitations and inherent risks in relying on external manufacturing sources, including competition for timely slots for external production runs, exorbitant rising costs, reliance on untrained operators, the need to establish contract manufacturing redundancy in the event of a vendor failure and serious limitations in our ability to achieve consistent scale production. We therefore committed to a strategy of in-sourcing this core capability and have </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">long </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">since achieved this goal.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We commenced production operations at our pilot facility in Culver City, California in 2017. It was there that we initialized our in-house cGMP small-bioreactor program for our haNK product, as we progressed production from smaller bioreactor batches to larger ones. In tandem with this improvement in manufacturing capacity, we also established and refined a process to cryopreserve our cell product in ready-to-infuse bags and then integrated it with our main process into a single production line.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g4i5nix4zlkt000044.jpg" title="" alt="" style="width:671px;height:249px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">57</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU49"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2018, we further increased the scale of our operations twice more by utilizing intermediate-sized bioreactor technologies and were able to outpace demand for clinical drug product while building an inventory of frozen product for future use. In anticipation of increased clinical trial enrollment for 2019, in the final months of 2018 we transferred clinical production operations from our pilot facility in Culver City to our new commercial facility in El Segundo. At present, we are operating fully independent of external manufacturing contractors and partners and have since realized significant improvements in quality, cost</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> time</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and reliability</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g4i5nix4zlkt000045.jpg" title="" alt="" style="width:671px;height:360px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">58</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU50"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2019, we implemented our next larger-scale bioreactor technology in El Segundo, the procedures for which were developed and optimized at our process development facility in San Diego, California in 2018. This upgrade substantially improved our economies of scale</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> with higher production rates</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> within the same </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">footprint</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> while being less labor intensive, just as demand for clinical drug product increased. We now have the capability to continue to scale up ahead of increasing clinical demands through regulatory approval. We believe that developing even larger capacity bioreactors will allow us to scale well beyond regulatory approval from a central location, while meeting commercial drug product demands nationwide</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> as well as ultimately on a global scale.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g4i5nix4zlkt000046.jpg" title="" alt="" style="width:671px;height:363px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">59</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU51"></a><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Manufacturing of </font><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">O</font><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">ur t-haNK Product Candidates</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2018 and 2019, we developed manufacturing processes for our two lead products from our t&#8209;haNK platform, PD&#8209;L1.t&#8209;haNK and CD19.t&#8209;haNK, as well as for Her2.t&#8209;haNK and EGFR.t&#8209;haNK, at our approximately 44,700 square foot process development facility in San Diego. Adding to our already robust patent portfolio, we filed numerous patents protecting innovative methods and modifications to our bioreactor production procedures, media formulations, additives, special cryopreservation procedures and many other components that address the inherent challenges unique to large scale NK&#160;cell production. We believe this places NantKwest at a unique competitive advantage as a leader in commercial scale manufacturing of NK&#160;cell products.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g4i5nix4zlkt000047.jpg" title="" alt="" style="width:671px;height:322px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">60</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU52"></a><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Present Day Manufacturing of Our NK Products</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This year, we have been in production of our PD-L1.t-haNK product, building a clinical supply of product ahead of anticipated demand from our mid- to late-stage clinical trials and Expanded Access Program. This will ensure that ready-to-infuse clinical dose forms are available on-demand at all our clinical testing centers.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g4i5nix4zlkt000048.jpg" title="" alt="" style="width:671px;height:435px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Competition</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The biopharmaceutical industry is characterized by intense and dynamic competition to develop new technologies and proprietary therapies. Any product candidates that we successfully develop and commercialize will have to compete with existing therapies and new therapies that may become available in the future. We believe that our base proprietary aNK platform, differentiated haNK, taNK and t&#8209;haNK product candidates, strategic collaborations and cell-based immunotherapy expertise may provide us with competitive advantages. However, we face potential competition from various sources, including larger and better-funded pharmaceutical, specialty pharmaceutical and biotechnology companies, as well as from academic institutions, governmental agencies and public and private research institutions. The key competitive factors affecting the success of any approved product will include its efficacy, safety profile, pricing, and method of administration, as well as the level of promotional activity invested in it.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our haNK, taNK and t&#8209;haNK product candidates will compete with other cell and molecule-based immunotherapy approaches using and/or targeting natural killer cells, T&#8209;cells and dendritic cells. Competitors focused on CAR&#8209;T related treatment approaches include AbbVie&#160;Inc., Atara&#160;Biotherapeutics,&#160;Inc., Intrexon&#160;Corporation, Allogene&#160;Therapeutics,&#160;Inc., Bristol&#8209;Myers&#160;Squibb&#160;Company, JW&#160;Therapeutics&#160;Co.,&#160;Ltd., Amgen,&#160;Inc., Leucid&#160;Bio&#160;Ltd., Bellicum&#160;Pharmaceuticals,&#160;Inc., Medisix&#160;Therapeutics&#160;Pte&#160;Ltd., Bluebird&#160;Bio,&#160;Inc., Mesoblast&#160;Ltd., Calibr/Scripps&#160;Research, Mustang&#160;Bio,&#160;Inc., CARsgen&#160;Therapeutics, Nanjing&#160;Legend&#160;Biotechnology&#160;Co.,&#160;Ltd, Cartherics&#160;Pty&#160;Ltd, Novartis&#160;AG, Pfizer,&#160;Inc., Cellectis&#160;SA, Poseida&#160;Therapeutics,&#160;Inc., Celularity,&#160;Inc., Servier&#160;Laboratories, Celyad&#160;SA, Takeda/Shire, Fortress&#160;Biotech,&#160;Inc., TC&#160;BioPharm&#160;Ltd., Gilead&#160;Sciences,&#160;Inc., Transposagen&#160;Biopharmaceuticals,&#160;Inc., Humanigen,&#160;Inc., Unum&#160;Therapeutics,&#160;Inc., Immune&#160;Therapeutics,&#160;Inc., and Xyphos,&#160;Inc.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Competitor companies focused on other T&#8209;cell based approaches include Adaptimmune&#160;Ltd., Adicet&#160;Bio,&#160;Inc., Autolus&#160;Therapeutics,&#160;plc, Cell&#160;Medica&#160;Limited, GlaxoSmithKline&#160;plc., Green&#160;Cross&#160;LabCell&#160;Corp., Immunocore&#160;Limited, Iovance&#160;Biotherapeutics,&#160;Inc., Kiadis&#160;Pharma&#160;Netherlands&#160;B.V., Lion&#160;TCR&#160;Pte&#160;Ltd., MolMed,&#160;S.p.A., Precision&#160;Biosciences,&#160;Inc., Janssen&#160;Pharmaceuticals,&#160;Inc., Noile&#8209;Immune&#160;Biotech,&#160;Inc., Anixa&#160;Biosciences,&#160;Inc., Beam&#160;Therapeutics&#160;Inc., BioNTech&#160;SE, Cartesian&#160;Therapeutics,&#160;Inc., and Takara&#160;Bio,&#160;Inc.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU53"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Competitor companies focused on dendritic cell based approaches include Argos&#160;Therapeutics,&#160;Inc., Biovest&#160;International,&#160;Inc., ImmunoCellular&#160;Therapeutics,&#160;Ltd., Merck&#160;&amp;&#160;Co,&#160;Inc./Immune&#160;Design,&#160;Inc., Inovio&#160;Pharmaceuticals,&#160;Inc., Intrexon&#160;Corporation, Medigene&#160;AG, and Northwest&#160;Biotherapeutics,&#160;Inc.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Competitor companies focused on natural killer cell based approaches include Kiadis&#160;Pharma&#160;Netherlands&#160;B.V./CytoSen Therapeutics,&#160;Inc., Dragonfly&#160;Therapeutics,&#160;Inc., Fate&#160;Therapeutics,&#160;Inc., Gamida&#160;Cell,&#160;Ltd., Nkarta&#160;Therapeutics,&#160;Inc., Onkimmune&#160;Ltd., NKMax&#160;America, Artiva&#160;Biotherapeutics, HebeCell&#160;Corp., Vycellix,&#160;Inc., oNKo&#8209;innate&#160;Pty&#160;Ltd., and Ziopharm&#160;Oncology,&#160;Inc.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Competitor companies focused on large molecule immunotherapy approaches include Cytomx&#160;Therapeutics,&#160;Inc., Innate&#160;Pharma&#160;SA, and Sorrento&#160;Therapeutics,&#160;Inc. Other potential immunotherapy competitors include Affimed&#160;GmbH, Agios&#160;Pharmaceuticals,&#160;Inc., Codiak&#160;Biosciences, Glycostem&#160;Therapeutics&#160;BV, Triumvira&#160;Immunologics, Century&#160;Therapeutics, Incysus&#160;Therapeutics,&#160;Inc., GammaDelta&#160;Therapeutics&#160;Ltd., Lyell&#160;Immunopharma,&#160;Inc., and GT&#160;Biopharma,&#160;Inc.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There are currently two approved T&#8209;cell based treatments which are marketed by Novartis&#160;AG and Gilead&#160;Sciences/Kite&#160;Pharma. There is currently one approved dendritic cell-based cancer vaccine which is marketed by Dendron&#160;Pharmaceuticals,&#160;LLC for the treatment of metastatic castration resistant prostate cancer.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Many of our competitors, either alone or with their strategic partners, have substantially greater financial, technical and human resources than we do, as well as significantly greater experience in the discovery and development of product candidates, obtaining FDA and other regulatory approvals of treatments and commercializing those treatments. Accordingly, our competitors may be more successful than us in obtaining approval for treatments and achieving widespread market acceptance. Our competitors&#8217; treatments may be more effective, or more effectively marketed and sold, than any treatment we may commercialize, and they may render our treatments obsolete or non-competitive before we can recover the expenses of developing and commercializing any of our treatments.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Mergers and acquisitions in the biotechnology and pharmaceutical industries may result in even more resources being concentrated among a smaller number of our competitors. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel, and establishing clinical study sites and subject registration for clinical studies, as well as in acquiring technologies complementary to, or necessary for, our programs. Smaller or clinical-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We anticipate that we will face intense and increasing competition as new therapies enter the market and advanced technologies become available. We expect any treatments that we develop and commercialize to compete on the basis of, among other things, efficacy, safety, convenience of administration and delivery, price, the level of generic competition and the availability of reimbursement from government and other third-party payors.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have a better safety profile, are more convenient or are less expensive than any products that we may develop. Our competitors also may obtain FDA or other regulatory approval for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market. In addition, we expect that our therapeutic products, if approved, will be priced at a significant premium over competitive generic products and our ability to compete may be affected in many cases by insurers or other third-party payors seeking to encourage the use of generic products.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Intellectual Property</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We strive to protect and enhance the proprietary technology, inventions, and improvements that are commercially important to our business, including seeking, maintaining, and defending patent rights, whether developed internally or licensed from third parties. Our policy is to seek to protect our proprietary position by, among other methods, filing patent applications in the U.S. and in jurisdictions outside of the U.S. related to our proprietary technology, inventions, improvements, and product candidates that are important to the development and implementation of our business. We seek to consistently file follow-on patent applications on further improvements and features of our NK&#160;cell-based products, thereby adding additional layers of protection and reducing reliance on our original patents that would be the earliest to expire and may be subject to challenge. We also rely on trade secrets and know-how relating to our proprietary technology and product candidates, continuing innovation, and in-licensing opportunities to develop, strengthen, and maintain our proprietary position in the field of natural killer cell-based immunotherapy. We expect to rely on data exclusivity, market exclusivity, patent term adjustments and patent term extensions when available, as well as on regulatory protection afforded through orphan drug designations. Our commercial success may depend in part on our ability to obtain and maintain patent and other proprietary protection for our technology, inventions, and improvements; to preserve the confidentiality of our trade secrets; to maintain our licenses to use intellectual property owned by third parties; to defend and enforce our proprietary rights, including our patents; and to operate without infringing on the valid and enforceable patents and other proprietary rights of third parties.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">62</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU54"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have developed and in-licensed numerous patents and patent applications and we possess substantial know-how and trade secrets relating to the development and commercialization of </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">natural killer</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> cell-based immunotherapy product candidates, including related manufacturing processes and technology. As of December&#160;31, 2019, our owned and licensed patent portfolio consists of </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39&#160;</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">patents and pending patent applications </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and provisional filings </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in the U.S. disclosing subject matter directed to</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> certain of our proprietary technology, inventions, and improvements and our most advanced product candidates, as well as </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">141&#160;</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">licensed and owned patents </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and pending applications </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24&#160;</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">jurisdictions outside of the U.S., </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">including 24&#160;Patent Cooperation Treaty applications, </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">that, in many cases, are counterparts to the foregoing U.S. patents and patent applications. For example, these patents and patent applications include claims directed to:</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">Natural Killer Cell Line Compositions and Methods-of-Use;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">Treatment of Cancer using Natural Killer Cell Lines;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">Treatment of Specific Diseases using Natural Killer Cell Lines;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">Combination Therapy using Natural Killer Cell Lines;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">CD16 Modified Natural Killer Cell Line Compositions and Methods-of-Use;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">CD16 Modified Natural Killer Cell Line with Monoclonal Antibodies for Treatment of Cancer;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">CAR&#8209;Expressing Natural Killer Cell Line Compositions and Methods-of-Use;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">CD16 Modified and CAR&#8209;Expressing Natural Killer Cell Line Compositions and Methods-of-Use;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">Homing and Cytokine Modified Natural Killer Cell Line Compositions and Methods-of-Use;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">Treatment of Viral and Bacterial Diseases using Natural Killer Cell Lines;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">Methods for Expansion, Cryopreservation and Commercial Manufacture; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">Tumoricidal and Antimicrobial Compositions of Natural Killer Cell Line Derived Exosomes and Methods-of-Use.</font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As for the NK cell-based immunotherapy products and processes we develop and commercialize, in the normal course of business, we intend to pursue, when possible, composition, method of use, dosing and formulation patent protection. We may also pursue patent protection with respect to manufacturing and drug development processes and technology. The patents and patent applications outside of the U.S. in our portfolio are held primarily in Europe, Canada, Australia, China, Japan and Korea.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Individual patents extend for varying periods of time, depending upon the date of filing of the patent application, the date of patent issuance, and the legal term of patents in the countries in which they are obtained. Generally, patents issued for applications filed in the U.S. are effective for 20&#160;years from the earliest effective filing date. The patent term may be adjusted to compensate for delayed patent issuance, when such delays are caused by the patent office or successful appeals against patent office actions. There is no limit on this patent term adjustment. In addition, in certain instances, a patent term can be extended to recapture a portion of the term effectively lost as a result of the FDA regulatory review period. The restoration period cannot be longer than five&#160;years and the total patent term, including the restoration period, must not exceed 14&#160;years following FDA approval. The duration of patents outside of the U.S. varies in accordance with provisions of applicable local law, but typically is also 20&#160;years from the earliest effective filing date. Our issued patents are anticipated to expire at varying intervals through 2036. If patents are issued on our pending patent applications, the resulting patents are projected to expire at various dates through 2039. However, the actual protection afforded by a patent varies on a product-by-product basis, from country-to-country, and depends upon many factors, including the type of patent, the scope of its coverage, the availability of regulatory-related extensions, the availability of legal remedies in a particular country, and the validity and enforceability of the patent.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU55"></a>The patent positions of companies like ours are generally uncertain and involve complex legal and factual questions. No consistent policy regarding the scope of claims allowable in patents in the field of immunotherapy has emerged in the U.S. The patent situation outside of the U.S. is even more uncertain. Changes in either the patent laws or their interpretation in the U.S. and other countries may diminish our ability to protect our inventions and enforce our intellectual property rights, and more generally could affect the value of our intellectual property. In particular, our ability to stop third parties from making, using, selling, offering to sell, or importing products that infringe our intellectual property will depend in part on our success in obtaining and enforcing patent claims that cover our technology, inventions, and improvements. With respect to both licensed and company-owned intellectual property, we cannot be sure that patents will be granted with respect to any of our pending patent applications or with respect to any patent applications filed by us in the future, nor can we be sure that any of our existing patents or any patents that may be granted to us in the future will be commercially useful in protecting our products and the methods used to manufacture those products. Moreover, even our issued patents do not guarantee us the right to practice our technology in relation to the commercialization of our products. However, the area of patent and other intellectual property rights in biotechnology is an evolving one with many risks and uncertainties, and third parties may have blocking patents that could be used to prevent us from commercializing our patented product </p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">63</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">candidates and practicing our proprietary technology. Our issued patents and those that may issue in the future may be challenged, invalidated, or circumvented, which could limit our ability to stop competitors from marketing related products or limit the length of the term of patent protection that we may have for our product candidates. In addition, the rights granted under any issued patents may not provide us with protection or competitive advantages against competitors with similar technology. Furthermore, our competitors may independently develop similar technologies. For these reasons, we may have competition for our product candidates. Moreover, because of the extensive time required for development, testing and regulatory review of a potential product, it is possible that, before any particular product candidate can be commercialized, any related patent may expire or remain in force for only a short period following commercialization, thereby reducing any advantage of the patent.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2019, our worldwide trademark portfolio was comprised of (i)&#160;12&#160;U.S. trademark registrations; (ii)&#160;one pending U.S. trademark application; (iii)&#160;35&#160;foreign trademark registrations (five of which are Madrid Protocol International registrations); and (iv)&#160;five pending foreign trademark applications.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may also rely, in some circumstances, on trade secrets to protect our technology. However, trade secrets are difficult to protect. We seek to protect our technology and product candidates, in part, by entering into confidentiality agreements with those who have access to our confidential information, including our employees, contractors, consultants, collaborators, and advisors. We also seek to preserve the integrity and confidentiality of our proprietary technology and processes by maintaining physical security of our premises and physical and electronic security of our information technology systems. Although we have confidence in these individuals, organizations, and systems, agreements or security measures may be breached and we may not have adequate remedies for any breach. In addition, our trade secrets may otherwise become known or may be independently discovered by competitors. To the extent that our employees, contractors, consultants, collaborators, and advisors use intellectual property owned by others in their work for us, disputes may arise as to the rights in related or resulting know-how and inventions. For risks related to our proprietary technology, inventions, improvements and products, please see Part&#160;I, Item&#160;1A, &#8220;<font style="font-style:italic;">Risk Factors &#8211; Risks Related to Intellectual Property</font>&#8221; and &#8220;<font style="font-style:italic;">Legal Proceedings</font>&#8221; of this Annual Report.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Collaboration Agreements</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">ImmunityBio, Inc.<font style="font-style:normal;">&nbsp;&nbsp;In January&#160;2020, we entered into a Cost Allocation Agreement, or the Agreement, with ImmunityBio, Inc. and its subsidiaries, or ImmunityBio. The Agreement is effective as of October&#160;1, 2019. ImmunityBio is a related party, as it is an affiliate of NantWorks. Simultaneously, we and ImmunityBio entered into Work Order Number One under the Agreement. Under the Agreement and Work Order Number One, the parties agreed to conduct a joint study, the clinical research trial being conducted pursuant to the protocol titled QUILT&#160;3.063:</font>&#160;A phase&#160;2 study of combination therapy with an IL-15 superagonist&#160;(N&#8209;803), off-the-shelf CD16&#8209;targeted natural killer cells&#160;(haNK), and avelumab without cytotoxic chemotherapy in subjects with Merkel Cell Carcinoma&#160;(MCC) that has progressed on or after treatment with a checkpoint inhibitor<font style="font-style:normal;">. The ImmunityBio study drug included in the joint study is ImmunityBio&#8217;s proprietary IL-15 superagonist known as N&#8209;803 and our study drug is our proprietary &#8220;off-the-shelf&#8221; CD16-targeted natural killer cell therapy known as haNK.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We will act as the sponsor of this joint study for purposes of regulatory matters, including submissions, correspondence, and communications. Additionally, we are designated as the contracting party to execute agreements with third and related parties relating to the joint study under Work Order Number One. We and ImmunityBio will split certain joint study costs equally related to Work Order Number One, in accordance with the terms of the Agreement. Shared joint study costs include cost related to conducting the joint study development activities, such as personnel related costs, as well as all costs associated to regulatory matters. Costs and expenses incurred in connection with the development, manufacturing, supply, delivery, and pre-patient administration dosing mechanism of each party&#8217;s study drug, are excluded from the shared joint study costs. As of December&#160;31, 2019, there was minimal joint research activity under the Agreement.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the agreement, each of ImmunityBio and the company will receive exclusive rights to any new intellectual property developed that relates solely to its respective study drug, and the parties will have joint co-equal rights in any other intellectual property. The Agreement expires upon the second anniversary of the effective date with the option to renew for additional successive one-year terms, but work orders for any joint studies still in process at the time of termination will continue until the applicable study is completed.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Altor BioScience, LLC.<font style="font-style:normal;">&nbsp;&nbsp;In August&#160;2016, we entered into an exclusive Co-Development Agreement, or the Co-Development Agreement, with Altor BioScience, LLC, or Altor. Altor is a related party, as it is a wholly owned subsidiary of ImmunityBio. ImmunityBio is an affiliate of NantWorks. Under the Co-Development Agreement, the parties agreed to exclusively collaborate on the development of certain therapeutic applications combining our proprietary NK&#160;cells with Altor's N&#8209;801 and/or N&#8209;803 products with respect to certain technologies and intellectual property rights as may be agreed between the parties for the purpose of jointly developing therapeutic applications of certain effector cell lines.</font></p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">64</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU56"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are the lead developer for each product developed by the parties pursuant to the Co-Development Agreement unless otherwise agreed to under a given project plan. Under the terms of the Co-Development Agreement, both parties granted a co-exclusive, royalty free, fully paid-up, worldwide license, with the right to sublicense (only to a third-party contractor assisting with research and development activities under this Co-Development Agreement and subject to prior consent, not to be unreasonably withheld), under the intellectual property, or IP, including the parties interest in the joint IP, solely to conduct any development activities agreed to by the steering committee as set forth in any development plan. Unless otherwise mutually agreed by the parties in the development plan for a project, we are responsible for all costs and expenses incurred by either party related to conducting clinical trials and other activities under each development program, including costs associated with patient enrollment, materials and supplies, third party staffing, and regulatory filings. </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Altor supplies free of charge, sufficient amounts of Altor products for all pre-clinical requirements and </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">certain</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> clinical requirements for up to 400&#160;patients in phase&#160;I and/or phase&#160;II clinical trials, as required under the development plan for a project per the Co-Development Agreement.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Each company owns an undivided interest in and to all rights, title and interest in and to the joint product rights. The Co-Development Agreement expires upon the fifth anniversary of the effective date. We have dosed patients with N&#8209;803, an IL&#8209;15 superagonist, in several phase&#160;Ib/II trials.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Licenses</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Viracta Therapeutics, Inc.<font style="font-style:normal;">&nbsp;&nbsp;In May&#160;2017, we entered into an agreement with Viracta Therapeutics, Inc., or Viracta, to grant us exclusive worldwide rights to Viracta&#8217;s phase&#160;II drug candidate, VRx&#8209;3996, for use in combination with our platform of NK&#160;cell therapies. In consideration for the license, we are obligated to pay to Viracta&#160;(i)&#160;mid-single digit percentage royalties of net sales of licensed products for therapeutic use, and (ii)&#160;milestone payments ranging from $10.0&#160;million to $25.0&#160;million for various regulatory approvals and cumulative net sales levels. We may terminate the agreement, in our sole discretion, in whole or on a product-by-product and/or country by country basis, at any time upon 90&#160;days&#8217; prior written notice. In addition, either party may terminate the agreement in the event of a material breach or for bankruptcy of the other party.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Hans G. Klingemann, M.D., Ph.D.<font style="font-style:normal;">&nbsp;&nbsp;We hold the worldwide rights, title and interest to the NK&#8209;92 cell line and we believe that we control commercial use of our NK&#8209;92 cells in key territories. We also maintain and exclusively control the only clinical grade master cell bank for NK&#8209;92. The original NK&#8209;92 cell line was isolated by Hans G. Klingemann, M.D., Ph.D., our founder and Vice President of Research and Development, and all patents and patent applications pertaining to this cell line are now in the name of NantKwest, Inc. or ZelleRx Corporation, our former name. In February&#160;2003, we obtained an exclusive, worldwide license from Dr.&#160;Klingemann to the NK&#8209;92 cell line, and related NK&#8209;92 patents and know-how, that had been assigned to him by the British Columbia Cancer Agency, to manufacture, use and sell products covered by the scope of any valid claim in any of the licensed patents. Dr.&#160;Klingemann subsequently assigned the cell line and those patents to us, but we are still obligated to pay a single-digit royalty on sales of licensed products to Dr.&#160;Klingemann, as well as to pay the British Columbia Cancer Agency a small percentage of our profits from the sale of the NK&#8209;92 cell line that Dr.&#160;Klingemann obtained from them.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Fox Chase Cancer Center.<font style="font-style:normal;">&nbsp;&nbsp;In July&#160;2004, we entered into an exclusive license agreement with Fox Chase Cancer Center, or Fox Chase, pursuant to which we were granted an exclusive, worldwide, sublicensable license under certain patents and know-how pertaining to CD16 receptors-bearing NK&#8209;92 cell lines. We agreed to pay Fox Chase low single-digit royalties on sales of licensed products. We are also obligated to pay Fox Chase a percentage of the royalties and other compensation we receive from sublicensees of our rights from Fox Chase. Fox Chase is obligated to assign the licensed patents to us if we commence a phase&#160;III clinical trial of a licensed product and, if this does not occur, our license expires when the last of the licensed patents expires.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Rush University Medical Center.<font style="font-style:normal;">&nbsp;&nbsp;In March&#160;2004, we entered into a license agreement with Rush University Medical Center, or Rush, pursuant to which Rush granted us an exclusive, worldwide, sublicensable license to certain intellectual property related to clinical use of NK&#8209;92 to develop and commercialize products and processes for the treatment of melanoma and renal cancer, or for the diagnosis or treatment of non-melanoma and non-renal cancer. In consideration for the license, we were obligated to pay to Rush single-digit royalties on sales of licensed products with a minimum royalty payment of $25,000&#160;per year. The agreement also provided for payments upon completion of certain clinical, regulatory and commercialization milestones. We also agreed to pay to Rush a portion of certain payments that we receive under sublicensing arrangements. The license had a term of 12&#160;years from 2006, the year in which royalty payments were first made, and included customary termination rights for both parties. Beginning in 2018, this license converted to a perpetual, irrevocable, fully paid royalty-free, exclusive license.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">University Health Network.<font style="font-style:normal;">&nbsp;&nbsp;In May&#160;2005, we entered into a license agreement with University Health Network, or UHN, pursuant to which we obtained from UHN an exclusive, worldwide, sublicensable license to certain intellectual property relating to NK&#8209;92 clinical trials data from UHN to develop and commercialize products and processes for the diagnosis and treatment of certain hematological malignancies. Our license from UHN will automatically expire if we have not filed for regulatory approval or launched a licensed product within specified periods of time, and also includes other customary termination rights for both parties.</font></p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">65</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU57"></a><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Joint Development and License Agreements</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Intrexon Corporation.<font style="font-style:normal;">&nbsp;&nbsp;In February&#160;2010, we entered into a 17&#8209;year agreement with Intrexon Corporation, or Intrexon, pursuant to which we granted to Intrexon a worldwide, sublicensable license which may be exclusive with respect to certain indications designated by Intrexon, under certain patents relating to NK&#8209;92 cells to develop and commercialize modified NK&#8209;92 cells that express Intrexon&#8217;s proprietary gene sequences for use as therapeutic and prophylactic agents in humans in specified therapeutic areas. Intrexon paid us a one-time license fee and is also obligated to pay non-material milestone payments with respect to specific indications, a royalty on net sales of the licensed products and a portion of the revenue Intrexon receives from third party sublicensees of its rights from us. Intrexon has the right to terminate the agreement upon 180&#160;days&#8217; notice and both parties have the right to terminate the agreement for the other&#8217;s uncured breach of the agreement.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have licensed or sub-licensed our cell lines and intellectual property to numerous other pharmaceutical and biotechnology companies for non-clinical uses such as laboratory testing. Such licenses generally require the licensee to pay an upfront fee and annual research and commercial fees for products sold using our intellectual property and cell lines.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Supply Agreements</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2018, we entered into various supply agreements with third parties to provide investigational agents to be used in our clinical trials.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Anticipated Agreements and Considerations</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to the collaboration and license agreements discussed above, we may enter into a commercial agreement relating to an IL&#8209;15 superagonist product developed by an affiliate, and we are also pursuing certain strategic research and/or license agreements with third parties to develop our candidate pipeline. These types of collaboration agreements do not typically specify how sales will be apportioned between the parties upon successful commercialization of the product. As a result, we cannot guarantee that we will receive a percentage of the revenue that is at least proportional to the costs that we will incur in commercializing the product candidate. Furthermore, if Dr. Soon-Shiong was to cease his affiliation with us or with NantWorks, any affiliated entities may be unwilling to continue their relationships with us on commercially reasonable terms, or at all, which in turn may impede our ability to control the supply chain for our combination therapies.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Government Regulation</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA and other regulatory authorities at federal, state, and local levels, as well as in foreign countries, extensively regulate, among other things, the research, development, testing, manufacture, quality control, import, export, safety, effectiveness, labeling, packaging, storage, distribution, record keeping, approval, advertising, promotion, marketing, post-approval monitoring, and post-approval reporting of biologics such as those we are developing. We, along with third-party contractors, will be required to navigate the various preclinical, clinical and commercial approval requirements of the governing regulatory agencies of the countries in which we wish to conduct studies or seek approval or licensure of our product candidates. The process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state, local, and foreign statutes and regulations require the expenditure of substantial time and financial resources.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The process required by the FDA before biologic product candidates may be marketed in the U.S. generally involves the following:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">completion of preclinical laboratory tests and animal studies performed in accordance with the FDA&#8217;s current Good Laboratory Practices, or cGLP, regulation;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">submission to the FDA of an IND, which must become effective before clinical trials may begin and must be updated annually or when significant changes are made;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">approval by an independent Institutional Review Board, or IRB, or ethics committee for each clinical site before the clinical trial is begun;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">performance of adequate and well-controlled human clinical trials to establish the safety, purity and potency of the proposed biologic product candidate for its intended purpose;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">preparation of and submission to the FDA of a Biologics License Application, or BLA, after completion of all required clinical trials;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">a determination by the FDA within 60&#160;days of its receipt of a BLA to file the application for review;</font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">66</a></p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><a name="_AEIOULastRenderedPageBreakAEIOU58"></a><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-family:Times New Roman;">satisfactory completion of an FDA Advisory Committee review, if applicable;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">satisfactory completion of an FDA pre-approval inspection of the manufacturing facility or facilities at which the proposed product is produced to assess compliance with cGMP and to assure that the facilities, methods and controls are adequate to preserve the biological product&#8217;s continued safety, purity and potency, and of selected clinical investigational sites to assess compliance with current Good Clinical Practices, or cGCPs; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">FDA review and approval of the BLA to permit commercial marketing of the product for particular indications for use in the U.S., which must be updated annually and when significant changes are made.</font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The testing and approval process requires substantial time, effort and financial resources, and we cannot be certain that any approvals for our product candidates will be granted on a timely basis, if at all. Prior to beginning the first clinical trial with a product candidate, we must submit an IND to the FDA. An IND is a request for authorization from the FDA to administer an investigational new drug product to humans. The central focus of an IND submission is on the general investigational plan and the protocol(s) for clinical studies. The IND also includes results of animal and <font style="font-style:italic;">in&#160;vitro</font> studies assessing the toxicology, pharmacokinetics, pharmacology, and pharmacodynamic characteristics of the product; chemistry, manufacturing, and controls information; and any available human data or literature to support the use of the investigational product. An IND must become effective before human clinical trials may begin. The IND automatically becomes effective 30&#160;days after receipt by the FDA, unless the FDA, within the 30&#8209;day time period, raises safety concerns or questions about the proposed clinical trial. In such a case, the IND may be placed on clinical hold and the IND sponsor and the FDA must resolve any outstanding concerns or questions before the clinical trial can begin. Submission of an IND therefore may or may not result in FDA authorization to begin a clinical trial.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;letter-spacing:-0.1pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">When a clinical trial using genetically engineered cells is conducted at, or sponsored by, institutions receiving National Institutes of Health, or NIH, funding for recombinant DNA research, prior to the submission of an IND to the FDA, a protocol and related documentation is submitted to and the study is registered with the NIH Office of Biotechnology Activities, or OBA, pursuant to the NIH Guidelines for Research Involving Recombinant DNA Molecules, or NIH Guidelines. Compliance with the NIH Guidelines is mandatory for investigators at institutions receiving NIH funds for research involving recombinant DNA, and many companies and other institutions not otherwise subject to the NIH Guidelines voluntarily follow them. The NIH is responsible for convening the Recombinant DNA Advisory Committee, or RAC, a federal advisory committee that discusses protocols that raise novel or particularly important scientific, safety, or ethical considerations at one of its quarterly public meetings. The OBA will notify the FDA of the RAC&#8217;s decision regarding the necessity for full public review of a protocol. RAC proceedings and reports are posted to the OBA web site and may be accessed by the public. If the FDA allows the IND to proceed, but the RAC decides that full public review of the protocol is warranted, the FDA will request at the completion of its IND review that sponsors delay initiation of the protocol until after completion of the RAC review process.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clinical trials involve the administration of the investigational product to human subjects under the supervision of qualified investigators in accordance with cGCPs, which include the requirement that all research subjects provide their informed consent for their participation in any clinical study. Clinical trials are conducted under protocols detailing, among other things, the objectives of the study, the parameters to be used in monitoring safety and the effectiveness criteria to be evaluated. A separate submission to the existing IND must be made for each successive clinical trial conducted during product development and for any subsequent protocol amendments. Furthermore, an independent IRB, for each site proposing to conduct the clinical trial must review and approve the plan for any clinical trial and its informed consent form before the clinical trial begins at that site, and must monitor the study until completed. Regulatory authorities, the IRB or the sponsor may suspend a clinical trial at any time on various grounds, including a finding that the subjects are being exposed to an unacceptable health risk or that the trial is unlikely to meet its stated objectives. Some studies also include oversight by an independent group of qualified experts organized by the clinical study sponsor, known as a data safety monitoring board, which provides authorization for whether or not a study may move forward at designated check points based on access to certain data from the study and may halt the clinical trial if it determines that there is an unacceptable safety risk for subjects or other grounds, such as no demonstration of efficacy. There are also requirements governing the reporting of ongoing clinical studies and clinical study results to public registries.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For purposes of BLA approval, human clinical trials are typically conducted in three sequential phases that may overlap.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-style:italic;font-family:Times New Roman;">Phase&#160;I.</font><font style="font-family:Times New Roman;">&nbsp;&nbsp;The biological product is initially introduced into healthy human subjects and tested for safety. In the case of some products for severe or life-threatening diseases, the initial human testing is often conducted in patients.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-style:italic;font-family:Times New Roman;">Phase&#160;II.</font><font style="font-family:Times New Roman;">&nbsp;&nbsp;The biological product is evaluated in a limited patient population to identify possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the product for specific targeted diseases and to determine dosage tolerance, optimal dosage and dosing schedule.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-style:italic;font-family:Times New Roman;">Phase&#160;III.</font><font style="font-family:Times New Roman;">&nbsp;&nbsp;Clinical trials are undertaken to further evaluate dosage, clinical efficacy, potency, and safety in an expanded patient population at geographically dispersed clinical trial sites. These clinical trials are intended to establish the overall risk to benefit ratio of the product and provide an adequate basis for product labeling.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-style:italic;font-family:Times New Roman;">Phase&#160;IV.</font><font style="font-family:Times New Roman;">&nbsp;&nbsp;In some cases, the FDA may require, or companies may voluntarily pursue, additional clinical trials after a product is approved to gain more information about the product. These so-called phase&#160;IV studies may be made a condition to approval of the BLA.</font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">67</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU59"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Phase&#160;I, phase&#160;II and phase&#160;III testing may not be completed successfully within a specified period, if at all, and there can be no assurance that the data collected will support FDA approval or licensure of the product. Concurrent with clinical trials, companies may complete additional animal studies and develop additional information about the biological characteristics of the product candidate, and must finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. To help reduce the risk of the introduction of adventitious agents with use of biological products, the Public Health Service Act, or PHSA, emphasizes the importance of manufacturing control for products whose attributes cannot be precisely defined. The manufacturing process must be capable of consistently producing quality batches of the product candidate and, among other things, must develop methods for testing the identity, strength, quality and purity of the final product, or for biologics, the safety, purity and potency. Additionally, appropriate packaging must be selected and tested and stability studies must be conducted to demonstrate that the product candidate does not undergo unacceptable deterioration over its shelf life.</font></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">BLA Submission and Review by the FDA</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Assuming successful completion of all required testing in accordance with all applicable regulatory requirements, the results of product development, nonclinical studies and clinical trials are submitted to the FDA as part of a BLA requesting approval to market the product for one or more indications. The BLA must include all relevant data available from pertinent preclinical and clinical studies, including negative or ambiguous results, as well as positive findings, together with detailed information relating to the product&#8217;s chemistry, manufacturing, controls, and proposed labeling, among other things. Data can come from company-sponsored clinical studies intended to test the safety and effectiveness of a use of the product or from a number of alternative sources, including studies initiated by investigators. The submission of a BLA requires payment of a substantial user fee to the FDA, and the sponsor of an approved BLA is subject to annual product and establishment user fees. These fees typically increase annually. A waiver of user fees may be obtained under certain limited circumstances.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Within 60 days following submission of the application, the FDA reviews a BLA to determine if it is substantially complete before the agency accepts it for filing. The FDA may refuse to file any BLA that it deems incomplete or not properly reviewable at the time of submission and may request additional information. In this event, the BLA must be resubmitted with the additional information. Once a BLA has been filed, the FDA&#8217;s goal is to review the application within ten&#160;months after it accepts the application for filing, or, if the application relates to an unmet medical need in a serious or life-threatening indication, six&#160;months after the FDA accepts the application for filing. The review process is often significantly extended by FDA requests for additional information or clarification. The FDA reviews a BLA to determine, among other things, whether a product is safe, pure and potent and the facility in which it is manufactured, processed, packed, or held meets standards designed to assure the product&#8217;s continued safety, purity and potency. The FDA may convene an advisory committee to provide clinical insight on application review questions. Before approving a BLA, the FDA will typically inspect the facility or facilities where the product is manufactured. The FDA will not approve an application unless it determines that the manufacturing processes and facilities comply with cGMP requirements and are adequate to assure consistent production of the product within required specifications. FDA regulations also require tissue establishments to register and list their HCT/Ps with the FDA and, when applicable, to evaluate donors through screening and testing. Additionally, before approving a BLA, the FDA will typically inspect one or more clinical sites to assure compliance with cGCP. If the FDA determines that the application, manufacturing process or manufacturing facilities are not acceptable, it will outline the deficiencies in the submission and often will request additional testing or information. Notwithstanding the submission of any requested additional information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The testing and approval process requires substantial time, effort and financial resources, and each may take several years to complete. The FDA may not grant approval on a timely basis, or at all, and we may encounter difficulties or unanticipated costs in our efforts to secure necessary governmental approvals, which could delay or preclude us from marketing our products. After the FDA evaluates a BLA and conducts inspections of manufacturing facilities where the investigational product and/or its drug substance will be produced, the FDA may issue an approval letter, a complete response letter, or a not approval letter. An approval letter authorizes commercial marketing of the product with specific prescribing information for specific indications. A complete response letter indicates that the review cycle of the application is complete and the application is not ready for approval. A complete response letter may request additional information or clarification. The FDA may delay or refuse approval of a BLA if applicable regulatory criteria are not satisfied, require additional testing or information and/or require post-marketing testing and surveillance to monitor safety or efficacy of a product.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">68</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU60"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If regulatory approval of a product is granted, such approval may entail limitations on the indicated uses for which such product may be marketed. For example, the FDA may approve the BLA with a Risk Evaluation and Mitigation Strategy, or REMS, plan to mitigate risks, which could include medication guides, physician communication plans, or other restrictions to assure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. The FDA also may condition approval on, among other things, changes to proposed labeling or the development of adequate controls and specifications. Once approved, the FDA may withdraw the product approval if compliance with pre- and post-marketing regulatory standards is not maintained or if problems occur after the product reaches the marketplace. The FDA may require one or more phase&#160;IV post-market studies and surveillance to further assess and monitor the product&#8217;s safety and effectiveness after commercialization, and may limit further marketing of the product based on the results of these post-marketing studies. In addition, new government requirements, including those resulting from new legislation, may be established, or the FDA&#8217;s policies may change, which could delay or prevent regulatory approval of our products under development.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A sponsor may seek approval of its product candidate under programs designed to accelerate the FDA&#8217;s review and approval of new drugs and biological products that meet certain criteria. Specifically, new drugs and biological products are eligible for fast track designation if they are intended to treat a serious or life-threatening condition and demonstrate the potential to address unmet medical needs for the condition. For a fast track product, the FDA may consider sections of the BLA for review on a rolling basis before the complete application is submitted if relevant criteria are met. A fast track designated product candidate may also qualify for priority review, under which the FDA sets the target date for FDA action on the BLA at six&#160;months after the FDA accepts the application for filing. Priority review is granted when there is evidence that the proposed product would be a significant improvement in the safety or effectiveness of the treatment, diagnosis, or prevention of a serious condition. If criteria are not met for priority review, the application is subject to the standard FDA review period of ten&#160;months after the FDA accepts the application for filing. Priority review designation does not change the scientific/medical standard for approval or the quality of evidence necessary to support approval.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the accelerated approval program, the FDA may approve a BLA on the basis of either a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments. Post-marketing studies or completion of ongoing studies after marketing approval are generally required to verify the biologic&#8217;s clinical benefit in relationship to the surrogate endpoint or ultimate outcome in relationship to the clinical benefit. In addition, the Food and Drug Administration Safety and Innovation Act, or FDASIA, which was enacted and signed into law in 2012, established breakthrough therapy designation. A sponsor may seek FDA designation of its product candidate as a breakthrough therapy if the product candidate is intended, alone or in combination with one or more other drugs or biologics, to treat a serious or life-threatening disease or condition and preliminary clinical evidence indicates that the therapy may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. Sponsors may request the FDA to designate a breakthrough therapy at the time of, or any time after, the submission of an IND, but ideally before an end-of-phase&#160;II meeting with the FDA. If the FDA designates a breakthrough therapy, it may take actions appropriate to expedite the development and review of the application, which may include holding meetings with the sponsor and the review team throughout the development of the therapy; providing timely advice to, and interactive communication with, the sponsor regarding the development of the drug to ensure that the development program to gather the nonclinical and clinical data necessary for approval is as efficient as practicable; involving senior managers and experienced review staff, as appropriate, in a collaborative, cross-disciplinary review; assigning a cross-disciplinary project lead for the FDA review team to facilitate an efficient review of the development program and to serve as a scientific liaison between the review team and the sponsor; and considering alternative clinical trial designs when scientifically appropriate, which may result in smaller or more efficient clinical trials that require less time to complete and may minimize the number of patients exposed to a potentially less efficacious treatment. Breakthrough designation also allows the sponsor to file sections of the BLA for review on a rolling basis. We may seek designation as a breakthrough therapy for some or all of our product candidates.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fast track designation, priority review and breakthrough therapy designation do not change the standards for approval but may expedite the development or approval process.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Orphan Drugs</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Orphan Drug Act, the FDA may grant orphan designation to a drug or biologic intended to treat a rare disease or condition, defined as a disease or condition with a patient population of fewer than 200,000 individuals in the U.S., or a patient population greater than 200,000 individuals in the U.S. and when there is no reasonable expectation that the cost of developing and making available the drug or biologic in the U.S. will be recovered from sales in the U.S. for that drug or biologic. Orphan drug designation must be requested before submitting a BLA. After the FDA grants orphan drug designation, the generic identity of the therapeutic agent and its potential orphan use are disclosed publicly by the FDA.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">69</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU61"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If a product that has orphan drug designation subsequently receives the first FDA approval for a particular active ingredient for the disease for which it has such designation, the product is entitled to orphan product exclusivity, which means that the FDA may not approve any other applications, including a full BLA, to market the same biologic for the same indication for seven&#160;years, except in limited circumstances, such as a showing of clinical superiority to the product with orphan drug exclusivity or if the FDA finds that the holder of the orphan drug exclusivity has not shown that it can assure the availability of sufficient quantities of the orphan drug to meet the needs of patients with the disease or condition for which the drug was designated. Orphan drug exclusivity does not prevent the FDA from approving a different drug or biologic for the same disease or condition, or the same drug or biologic for a different disease or condition. Among the other benefits of orphan drug designation are tax credits for certain research and a waiver of the BLA application user fee.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A designated orphan drug may not receive orphan drug exclusivity if it is approved for a use that is broader than the indication for which it received orphan designation. In addition, orphan drug exclusive marketing rights in the U.S. may be lost if the FDA later determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantities of the product to meet the needs of patients with the rare disease or condition.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Post-Approval Requirements</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any products manufactured or distributed by us pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA, including, among other things, requirements relating to record keeping, reporting of adverse experiences, periodic reporting, distribution, and advertising and promotion of the product. After approval, most changes to the approved product, such as adding new indications or other labeling claims, are subject to prior FDA review and approval. There also are continuing, annual user fee requirements for any marketed products and the establishments at which such products are manufactured, as well as new application fees for supplemental applications with clinical data. Biologic manufacturers and their subcontractors are required to register their establishments with the FDA and certain state agencies, and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with cGMP, which impose certain procedural and documentation requirements upon us and any third-party manufacturers that we may decide to use. Changes to the manufacturing process are strictly regulated, and, depending on the significance of the change, may require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMP and impose reporting requirements upon us, and any third party manufacturers, that we may decide to use. Accordingly, manufacturers must continue to expend time, money and effort in the area of production and quality control to maintain compliance with cGMP and other aspects of regulatory compliance. We cannot be certain that we or our present or future suppliers will be able to comply with the cGMP regulations and other FDA regulatory requirements. If our present or future suppliers are not able to comply with these requirements, the FDA may, among other things, halt our clinical trials, require us to recall a product from distribution, or withdraw approval of the BLA.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Future FDA and state inspections may identify compliance issues at our facilities or at the facilities of contract manufacturers that may disrupt production or distribution, or require substantial resources to correct. In addition, discovery of previously unknown problems with a product or the failure to comply with applicable requirements may result in restrictions on a product, manufacturer or holder of an approved BLA, including withdrawal or recall of the product from the market or other voluntary, FDA-initiated or judicial action that could delay or prohibit further marketing.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA may withdraw approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical studies to assess new safety risks; or imposition of distribution restrictions or other restrictions under a REMS program. Other potential consequences include, among other things:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market or product recalls;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">fines, warning letters or holds on post-approval clinical studies;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">refusal of the FDA to approve pending applications or supplements to approved applications, or suspension or revocation of product license approvals;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">product seizure or detention, or refusal to permit the import or export of products; or</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">injunctions or the imposition of civil or criminal penalties.</font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU62"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA closely regulates the marketing, labeling, advertising and promotion of biologics. A company can make only those claims relating to safety and efficacy, purity and potency that are approved by the FDA and in accordance with the provisions of the approved label. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses. Failure to comply with these requirements can result in, among other things, adverse publicity, warning letters, corrective advertising and potential civil and criminal penalties, and exclusion from participation in governmental health programs, like Medicare and Medicaid. Physicians may prescribe legally available products for uses that are not described in the product&#8217;s labeling and that differ from those tested by us and approved by the FDA. Such off-label uses are common across medical specialties. Physicians may believe that such off-label uses are the best treatment for many patients in varied circumstances. The FDA does not regulate the behavior of physicians in their choice of treatments. The FDA does, however, restrict manufacturer&#8217;s communications on the subject of off-label use of their products.</font></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Other Healthcare Laws and Compliance Requirements</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our sales, promotion, medical education, clinical research and other activities following product approval will be subject to regulation by numerous regulatory and law enforcement authorities in the U.S. in addition to the FDA, including potentially the Federal Trade Commission, the Department of Justice, the Centers for Medicare and Medicaid Services, or CMS, other divisions of the U.S. Department of Health and Human Services and state and local governments. Our promotional and scientific/educational programs must comply with the federal Anti-Kickback Statute, the False Claims Act, physician payment transparency laws, privacy laws, security laws, and additional federal and state laws similar to the foregoing.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The federal Anti-Kickback Statute prohibits, among other things, the knowing and willing, direct or indirect offer, receipt, solicitation or payment of remuneration in exchange for or to induce the referral of patients, including the purchase, order or lease of any good, facility, item or service that would be paid for in whole or part by Medicare, Medicaid or other federal health care programs. Remuneration has been broadly defined to include anything of value, including cash, improper discounts, and free or reduced price items and services. The federal Anti-Kickback Statute has been interpreted to apply to arrangements between pharmaceutical manufacturers on one hand and prescribers, purchasers, formulary managers, and beneficiaries on the other. Although there are a number of statutory exceptions and regulatory safe harbors protecting some common activities from prosecution, the exceptions and safe harbors are drawn narrowly. Practices that involve remuneration that may be alleged to be intended to induce prescribing, purchases or recommendations may be subject to scrutiny if they do not qualify for an exception or safe harbor. Failure to meet all of the requirements of a particular applicable statutory exception or regulatory safe harbor does not make the conduct per se illegal under the federal Anti-Kickback Statute. Instead, the legality of the arrangement will be evaluated on a case-by-case basis based on a cumulative review of all its facts and circumstances. Several courts have interpreted the statute&#8217;s intent requirement to mean that if any one purpose of an arrangement involving remuneration is to induce referrals of federal healthcare covered business, the federal Anti-Kickback Statute has been violated. The government has enforced the federal Anti-Kickback Statute to reach large settlements with healthcare companies based on sham research or consulting and other financial arrangements with physicians. Further, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it to have committed a violation. In addition, the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the False Claims Act. Many states have similar laws that apply to their state health care programs, as well as private payors.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Federal false claims and false statement laws, including the federal civil False Claims Act, or FCA, imposes liability on persons or entities that, among other things, knowingly present or cause to be presented claims that are false or fraudulent or not provided as claimed for payment or approval by a federal health care program. The FCA has been used to prosecute persons or entities that &#8220;cause&#8221; the submission of claims for payment that are inaccurate or fraudulent, by, for example, providing inaccurate billing or coding information to customers, promoting a product off-label, submitting claims for services not provided as claimed, or submitting claims for services that were provided but not medically necessary. Actions under the FCA may be brought by the Attorney General, or as a qui tam action by a private individual, in the name of the government. Violations of the FCA can result in significant monetary penalties and treble damages. The federal government is using the FCA, and the accompanying threat of significant liability, in its investigation and prosecution of pharmaceutical and biotechnology companies throughout the country, for example, in connection with the promotion of products for unapproved uses and other illegal sales and marketing practices. The government has obtained multi-million and multi-billion dollar settlements under the FCA in addition to individual criminal convictions under applicable criminal statutes. In addition, certain companies that were found to be in violation of the FCA have been forced to implement extensive corrective action plans and have often become subject to consent decrees or corporate integrity agreements, restricting the manner in which they conduct their business.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">71</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU63"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, created additional federal criminal statutes that prohibit, among other things, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, including private third-party payors; knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items or services; and willfully obstructing a criminal investigation of a healthcare offense. Like the federal Anti-Kickback Statute, the Affordable Care Act amended the intent standard for certain healthcare fraud statutes under HIPAA such that a person or entity no longer needs to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Given the significant size of actual and potential settlements, it is expected that the government will continue to devote substantial resources to investigating healthcare providers&#8217; and manufacturers&#8217; compliance with applicable fraud and abuse laws. In addition, many states have similar fraud and abuse statutes or regulations that may be broader in scope and may apply regardless of payor, in addition to items and services reimbursed under Medicaid and other state programs. Additionally, to the extent that our products, once commercialized, are sold in a foreign country, we may be subject to similar foreign laws.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, there has been a recent trend of increased federal and state regulation of payments made to physicians and other healthcare providers. The Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, or collectively, the Affordable Care Act, among other things, imposed new reporting requirements on certain manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program, with specific exceptions, for payments or other transfers of value made by them to physicians and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members. Covered manufacturers are required to collect and report detailed payment data and submit legal attestation to the accuracy of such data to the government each year. Failure to submit required information may result in civil monetary penalties of up to an aggregate of $150,000&#160;per year (or up to an aggregate of $1&#160;million per year for &#8220;knowing failures&#8221;), for all payments, transfers of value or ownership or investment interests that are not timely, accurately and completely reported in an annual submission. Additionally, entities that do not comply with mandatory reporting requirements may be subject to a corporate integrity agreement. Certain states also mandate implementation of commercial compliance programs, impose restrictions on covered manufacturers&#8217; marketing practices and/or require the tracking and reporting of gifts, compensation and other remuneration to physicians and other healthcare professionals.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may also be subject to data privacy and security regulation by both the federal government and the states in which we conduct our business. HIPAA, as amended by the Health Information Technology and Clinical Health Act, or HITECH, and their respective implementing regulations, imposes specified requirements on certain health care providers, plans and clearinghouses (collectively, &#8220;covered entities&#8221;) and their &#8220;business associates,&#8221; relating to the privacy, security and transmission of individually identifiable health information. Among other things, HITECH makes HIPAA&#8217;s security standards directly applicable to &#8220;business associates,&#8221; defined as independent contractors or agents of covered entities that create, receive, maintain or transmit protected health information in connection with providing a service for or on behalf of a covered entity. HITECH also increased the civil and criminal penalties that may be imposed against covered entities, business associates and possibly other persons, and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce HIPAA and seek attorney&#8217;s fees and costs associated with pursuing federal civil actions. In addition, certain states have their own laws that govern the privacy and security of health information in certain circumstances, many of which differ from each other and/or HIPAA in significant ways and may not have the same effect, thus complicating compliance efforts.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If our operations are found to be in violation of any of such laws or any other governmental regulations that apply to us, we may be subject to penalties, including, without limitation, civil and criminal penalties, damages, fines, disgorgement, the curtailment or restructuring of our operations, exclusion from participation in federal and state healthcare programs, imprisonment, contractual damages, reputational harm, and diminished profits and future earnings, any of which could adversely affect our ability to operate our business and our financial results.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to the foregoing health care laws, we are also subject to the U.S. Foreign Corrupt Practices Act, or FCPA, and similar worldwide anti-bribery laws, which generally prohibit companies and their intermediaries from making improper payments to government officials or private-sector recipients for the purpose of obtaining or retaining business. We adopted an anti-corruption policy in connection with the initial public offering of our common stock in July&#160;2015. The anti-corruption policy mandates compliance with the FCPA and similar anti-bribery laws applicable to our business throughout the world. However, we cannot assure you that such a policy or procedures implemented to enforce such a policy will protect us from intentional, reckless or negligent acts committed by our employees, distributors, partners, collaborators or agents. Violations of these laws, or allegations of such violations, could result in fines, penalties or prosecution and have a negative impact on our business, results of operations and reputation.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">72</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU64"></a><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Coverage and Reimbursement</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sales of pharmaceutical products depend significantly on the extent to which coverage and adequate reimbursement are provided by third-party payors. Third-party payors include state and federal government health care programs, managed care providers, private health insurers and other organizations. Although we currently believe that third-party payors will provide coverage and reimbursement for our product candidates, if approved, we cannot be certain of this. Third-party payors are increasingly challenging the price, examining the cost-effectiveness, and reducing reimbursement for medical products and services. In addition, significant uncertainty exists as to the reimbursement status of newly approved healthcare products. The U.S. government, state legislatures and foreign governments have continued implementing cost containment programs, including price controls, restrictions on coverage and reimbursement and requirements for substitution of generic products. Adoption of price controls and cost containment measures and adoption of more restrictive policies in jurisdictions with existing controls and measures could further limit our net revenue and results. We may need to conduct expensive clinical studies to demonstrate the comparative cost-effectiveness of our products. The product candidates that we develop may not be considered cost-effective and thus may not be covered or sufficiently reimbursed. It is time consuming and expensive for us to seek coverage and reimbursement from third-party payors, as each payor will make its own determination as to whether to cover a product and at what level of reimbursement. Thus, one payor&#8217;s decision to provide coverage and adequate reimbursement for a product does not assure that another payor will provide coverage or that the reimbursement levels will be adequate. Moreover, a payor&#8217;s decision to provide coverage for a drug product does not imply that an adequate reimbursement rate will be approved. Reimbursement may not be available or sufficient to allow us to sell our products on a competitive and profitable basis.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Healthcare Reform</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The U.S. and some foreign jurisdictions are considering or have enacted a number of legislative and regulatory proposals to change the healthcare system in ways that could affect our ability to sell our products profitably. Among policy makers and payors in the U.S. and elsewhere, there is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving quality and/or expanding access. In the U.S., the pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by major legislative initiatives.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By way of example, in March&#160;2010, the Affordable Care Act was signed into law, intended to broaden access to health insurance, reduce or constrain the growth of healthcare spending, enhance remedies against fraud and abuse, add new transparency requirements for the healthcare and health insurance industries, impose new taxes and fees on the health industry and impose additional health policy reforms. Among the provisions of the Affordable Care Act of importance to our potential drug candidates are:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">an annual, nondeductible fee on any entity that manufactures or imports specified branded prescription drugs and biologic agents, apportioned among these entities according to their market share in certain government healthcare programs;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">an increase in the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program to 23.1% and 13.0% of the average manufacturer price for branded and generic drugs, respectively;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">a new Medicare Part&#160;D coverage gap discount program, in which manufacturers must agree to offer 50% point-of-sale discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for a manufacturer&#8217;s outpatient drugs to be covered under Medicare Part&#160;D;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">extension of a manufacturer&#8217;s Medicaid rebate liability to covered drugs dispensed to individuals who are enrolled in Medicaid managed care organizations;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">expansion of eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid coverage to additional individuals and by adding new mandatory eligibility categories for certain individuals with income at or below 133% of the federal poverty level, thereby potentially increasing a manufacturer&#8217;s Medicaid rebate liability;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">expansion of the entities eligible for discounts under the Public Health Service pharmaceutical pricing program; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research.</font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">73</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU65"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, other legislative changes have been proposed and adopted since the Affordable Care Act was enacted. These changes include, among others, the Budget Control Act of 2011, which mandates aggregate reductions to Medicare payments to providers of up to 2%&#160;per fiscal year effective April&#160;1, 2013, and, due to subsequent legislative amendments, will remain in effect through 2024 unless additional Congressional action is taken. In January&#160;2013, President Obama signed into law the American Taxpayer Relief Act of 2012, which, among other things, further reduced Medicare payments to several providers, including hospitals and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five&#160;years. These new laws may result in additional reductions in Medicare and other healthcare funding, which could have a material adverse effect on customers for our product candidates, if approved, and, accordingly, our financial operations.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect that the Affordable Care Act, as well as other healthcare reform measures that may be adopted in the future, may result in more rigorous coverage criteria and lower reimbursement and in additional downward pressure on the price that we receive for any approved product. Any reduction in reimbursement from Medicare or other government-funded programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability or commercialize our drugs. Furthermore, the current presidential administration and Congress may continue to attempt broad sweeping changes to the current health care laws. We face uncertainties that might result from modifications or repeal of any of the provisions of the Affordable Care Act, including as a result of current and future executive orders and legislative actions. The impact of those changes on us and potential effect on the pharmaceutical and biotechnology industries as a whole is currently unknown. However, any changes to the Affordable Care Act are likely to have an impact on our results of operations and may have a material adverse effect on our results of operation. We cannot predict what other healthcare programs and regulations will ultimately be implemented at the federal or state level or the effect any future legislation or regulation in the U.S. may have on our business.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Foreign Regulation</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to regulations in the U.S., we will be subject to a variety of foreign regulations governing clinical trials and commercial sales and distribution of our products to the extent we choose to develop or sell any products outside of the U.S. The approval process varies from country to country and the time may be longer or shorter than that required to obtain FDA approval. The requirements governing the conduct of clinical trials, product licensing, pricing and reimbursement vary greatly from country to country.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Employees</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2019, we had 148 employees. Personnel of related companies who provide corporate, general and administrative, manufacturing strategy, research and development, regulatory and clinical trial strategy and other administrative support services under our shared services agreement with NantWorks are not included in this number. For additional information, see Note&#160;9<font style="font-style:italic;">&#160;&#8211;&#160;Related Party Agreements</font> of the &#8220;Notes to Consolidated Financial Statements&#8221; included in Part&#160;II, Item&#160;8 of this Annual Report. Our ability to manage growth effectively will require us to continue to implement and improve our management systems, recruit and train new employees and select qualified independent contractors. None of our employees are represented by a labor union or covered by collective bargaining agreements, and we believe our relationship with our employees is good.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Corporate Information</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We were incorporated on October&#160;7, 2002 in the state of Illinois under the name ZelleRx Corporation. On January&#160;22, 2010, we changed our name to Conkwest, Inc. In March&#160;2014, we formed Conkwest,&#160;Inc., our wholly owned subsidiary in the state of Delaware, or Conkwest Delaware, for the purposes of changing the state of our incorporation to the state of Delaware. In March&#160;2014, we merged with and into Conkwest Delaware, with Conkwest Delaware surviving the merger. On July&#160;10, 2015, we changed our name to NantKwest,&#160;Inc. Our website address is www.nantkwest.com. The contents of our website are not incorporated by reference into this Form&#160;10&#8209;K. We provide free of charge through a link on our website access to our Annual Reports on Form&#160;10&#8209;K, Quarterly Reports on Form&#160;10&#8209;Q and Current Reports on Form&#160;8&#8209;K, as well as amendments to those reports, as soon as reasonably practical after the reports are electronically filed with, or furnished to, the Securities and Exchange Commission.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:9pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">74</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:9pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU66"></a><a name="ITEM_1A_RISK_FACTORS"></a><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_1A_RISK_FACTORS"></a>Item&#160;1A. Ri</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">sk Factors.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Investing in our common stock involves a high degree of risk. You should carefully consider the risks described below, as well as other information included in this Annual Report on Form&#160;10&#8209;K, or Annual Report, including our financial statements and the related notes, and the section titled &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations,&#8221; any of which may be relevant to decisions regarding an investment in or ownership of our stock. The occurrence of any of these risks could have a significant adverse effect on our reputation, business, financial condition, results of operations, growth and ability to accomplish our strategic objectives. We have organized the description of these risks into groupings in an effort to enhance readability, but many of the risks interrelate or could be grouped or ordered in other ways, so no special significance should be attributed to the groupings or order below.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to Our Financial Condition and Capital Requirements</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We are a clinical-stage biopharmaceutical company with a limited operating history and have incurred significant losses since our inception, and we anticipate that we will continue to incur losses for the foreseeable future, which makes it difficult to assess our future viability.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are a clinical-stage biopharmaceutical company with a limited operating history upon which our business can be evaluated. To date, we have generated minimal revenue related to the non-clinical use of our cell lines and intellectual property, and we have no products approved for commercial sale and have not generated any revenue from product sales. We have incurred operating losses on an annual basis since our formation and we may never become profitable. As of December&#160;31, 2019, we had an accumulated deficit of approximately $662.2&#160;million. We incurred net losses of $65.8&#160;million, $96.2&#160;million, and $96.4&#160;million for the years ended December&#160;31, 2019, 2018 and 2017, respectively. Our losses have resulted principally from costs incurred in ongoing preclinical studies, clinical trials and operations, research and development expenses, as well as general and administrative expenses.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A critical aspect of our strategy is to invest significantly in expanding our haNK, taNK and t&#8209;haNK platforms and the development of our product candidates. We expect to incur significant expenses as we continue to expand our business, including in connection with conducting research and development across multiple therapeutic areas, participating in clinical trial activities, continuing to acquire or in-license technologies, maintaining, protecting and expanding our intellectual property, seeking regulatory approvals and, upon successful receipt of U.S.&#160;Food and Drug Administration, or FDA, approval, commercializing our products. We will also incur costs as we hire additional personnel and increase our manufacturing capabilities, including the lease or purchase of a facility for the manufacturing of our product candidates for our ongoing and any future clinical trials and, upon potential receipt of FDA approval, for our initial commercialization activities. Moreover, we do not expect to have any significant product sales or revenue for a number of years. These losses have had and, as our operating losses continue to increase significantly in the future due to these expenditures, will continue to have an adverse effect on our stockholders&#8217; equity and working capital. Because of the numerous risks and uncertainties associated with our product development efforts, we are unable to predict when we may become profitable, if at all. Additionally, our net losses may fluctuate significantly from quarter to quarter, and as a result, a period-to-period comparison of our results of operations may not be meaningful. Even if we do become profitable, we may not be able to sustain or increase our profitability on a quarterly or annual basis.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We do not have any therapeutic products that are approved for commercial sale. Our ability to generate revenue from product sales and achieve and maintain profitability depends significantly on our success in a number of factors.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We currently do not have any therapeutic products that are approved for commercial sale. We have not received, and do not expect to receive for at least the next several years, if at all, any revenues from the commercialization of our product candidates if approved. To obtain revenue from sales of our product candidates that are significant or large enough to achieve profitability, we must succeed, either alone or with third parties, in developing, obtaining regulatory approval for, manufacturing and marketing therapies with commercial potential. Our ability to generate revenue and achieve and maintain profitability depends significantly on our success in many areas, including:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">our research and development efforts, including preclinical studies and clinical trials of our haNK, taNK and t&#8209;haNK platforms and our product candidates;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">continuing to develop sustainable, scalable, reliable and cost-effective manufacturing and distribution processes for our product candidates, including establishing and maintaining commercially viable supply relationships with third parties and establishing our own current Good Manufacturing Practices, or cGMP, manufacturing facilities and processes to support clinical development and meet the market demand for product candidates that we develop, if approved;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">addressing any competing technological and industry developments;</font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75</a></p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><a name="_AEIOULastRenderedPageBreakAEIOU67"></a><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-family:Times New Roman;">identifying, assessing, acquiring and/or developing new technology platforms and product candidates across numerous therapeutic areas;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">establishing and maintaining relationships with contract research organizations, or CROs, and clinical sites for the clinical development, both in the U.S. and internationally, of our product candidates;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">successful and timely completion of preclinical and clinical development of our product candidates and any other future product candidates;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">obtaining regulatory approvals and marketing authorizations for product candidates, including a continued acceptable safety profile both prior to and following any marketing approval of our product candidates;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">making any required post-marketing approval commitments to applicable regulatory authorities;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">launching and commercializing any approved products, either directly or with a collaborator or distributor, including the development of a commercial infrastructure;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">obtaining market acceptance of and acceptable reimbursement for any approved products;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">identifying, assessing and developing new product candidates;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">completing collaborations, licenses and other strategic transactions on favorable terms, if at all;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">maintaining, protecting and expanding our portfolio of intellectual property rights, including patents, trade secrets and know-how; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">defending against third-party interference or infringement claims, if any;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">addressing any competing therapies and technological and market developments; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">attracting, hiring and retaining qualified personnel.</font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even if one or more of our product candidates is eventually approved for commercial sale, we anticipate incurring significant costs associated with commercializing any approved product candidate and we may not generate significant revenue from sales of such products, resulting in limited or no profitability in the future. Our prior losses and expected future losses have had and will continue to have an adverse effect on our stockholders&#8217; equity and working capital for the foreseeable future. Any failure to become and remain profitable may adversely affect the market price of our common stock, our ability to raise additional capital and our future viability.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We will need to obtain substantial additional financing to complete the development and any commercialization of our product candidates, and a failure to obtain this necessary capital when needed on acceptable terms, or at all, could force us to delay, limit, reduce or terminate our commercialization efforts, product development or other operations.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since our inception, we have used substantial amounts of cash to fund our operations and expect our expenses to increase substantially in the foreseeable future. Developing our product candidates and conducting clinical trials for the treatment of cancer, virally infectious diseases, and other diseases requires substantial amounts of capital. We will also require a significant additional amount of capital to commercialize any approved products.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2019, we had cash and cash equivalents of $15.5&#160;million and marketable debt securities of $37.6&#160;million. We are using and expect to continue to use our existing cash and cash equivalents and marketable debt securities to fund expenses in connection with our ongoing and any future clinical trials, our manufacturing facilities and processes and the hiring of additional personnel, and for other research and development activities, working capital and general corporate purposes, including our share repurchase program. We believe that our existing cash, cash equivalents, and investments in marketable debt securities, and our ability to borrow from affiliated entities, will be sufficient to fund our operations for at least the next 12&#160;months following the issuance date of the financial statements based upon our Chairman and CEO&#8217;s intent and ability to support our operations with additional funds, including loans from affiliated entities, as required. Our estimate as to how long we expect our existing cash and cash equivalents to be available to fund our operations is based on assumptions that may be proved inaccurate, and we could deplete our available capital resources sooner than we currently expect. In addition, changing circumstances may cause us to consume capital significantly faster than we currently anticipate, and we may need to spend more money than currently expected because of circumstances beyond our control. We may require additional capital for the further development and any commercialization of our product candidates and may need to raise additional funds sooner than we anticipate if we choose to expand more rapidly than we presently anticipate.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">76</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU68"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our future capital requirements may depend on, and could increase significantly as a result of, many factors, including:</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the timing of, and the costs involved in, preclinical and clinical development and obtaining any regulatory approvals for our product candidates;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the costs of manufacturing, distributing and processing our product candidates and any products for which we receive regulatory approval;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the number and characteristics of any other product candidates we develop or acquire;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">our ability to establish and maintain strategic collaborations, licensing or other commercialization arrangements and the terms and timing of such arrangements, including our arrangements with ImmunityBio and its subsidiaries and Viracta;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the degree and rate of market acceptance of any approved products;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the emergence, approval, availability, perceived advantages, relative cost, relative safety and relative efficacy of other products or treatments;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the expenses needed to attract and retain skilled personnel;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the costs associated with being a public company;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the costs involved in preparing, filing, prosecuting, maintaining, defending and enforcing intellectual property claims, including litigation costs and the outcome of such litigation;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the costs related to commercializing product candidates independently;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the timing, receipt and amount of sales of, or royalties on, any approved products; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">any product liability or other lawsuits related to our product candidates or the company.</font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interest of our stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect our common stockholders&#8217; rights. Debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we raise additional funds through collaborations, strategic alliances or licensing arrangements with pharmaceutical partners, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates, or grant licenses on terms that may not be favorable to us. Additional capital may not be available when we need it, on terms that are acceptable to us or at all. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market any approved products that we would otherwise prefer to develop and market ourselves, or be unable to continue or expand our operations or otherwise capitalize on our business opportunities, as desired, which could materially affect our business, financial condition and results of operations and cause the price of our common stock to decline.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We may use our financial and human resources to pursue a particular type of treatment, or treatment for a particular type of cancer, and fail to capitalize on programs or treatment of other types of cancer that may be more profitable or for which there is a greater likelihood of success.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Because we have limited resources, we must choose to pursue and fund the development of specific types of treatment, or treatment for a specific type of cancer, and may forego or delay pursuit of opportunities with other programs, investigational medicines, or treatment for other types of cancer, which could later prove to have greater commercial potential. Moreover, given the rapidly evolving competitive landscape and the time it takes to advance a product through clinical development, an incorrect decision to pursue a particular type of treatment or cancer may have a material adverse effect on our results of operation and negatively impact our future clinical strategies. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Our spending on current and future research and development programs for investigational medicines or clinical trials may not yield any commercially viable products. If we do not accurately evaluate and anticipate the commercial potential or target market for a particular type of treatment or cancer, we may choose to spend our limited resources on a particular treatment, or treatment for a particular type of cancer, and then later learn that another type of treatment or cancer that we previously decided not to pursue would have been more advantageous.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">77</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU69"></a><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We invest our cash on hand in various financial instruments which are subject to risks that could adversely affect our business, results of operations, liquidity and financial condition.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We invest our cash in a variety of financial instruments, principally commercial paper, corporate debt securities and foreign government bonds. All of these investments are subject to credit, liquidity, market and interest rate risk. Such risks, including the failure or severe financial distress of the financial institutions that hold our cash, cash equivalents and investments, may result in a loss of liquidity, impairment to our investments, realization of substantial future losses, or a complete loss of the investments in the long-term, which may have a material adverse effect on our business, results of operations, liquidity and financial condition. In order to manage the risk to our investments, we maintain an investment policy that, among other things, limits the amount that we may invest in any one issue or any single issuer and requires us to only invest in high credit quality securities.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risks Relating to Our Business and Industry</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">The foundation of our business is based upon the success of our aNK cells as a technology platform. Our aNK platform and product candidates derived thereof, including genetically modified haNK, taNK and t<font style="font-weight:normal;">&#8209;</font>haNK product candidates, will require significant additional clinical testing before we can potentially seek regulatory approval and launch commercial sales.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our business and future success depend on our ability to utilize our aNK cells as a technology platform, and to obtain regulatory approval for one or more product candidates derived from it, and then successfully commercialize our product candidates addressing numerous therapeutic areas. Our aNK platform and our haNK, taNK and t&#8209;haNK product candidates are in varying stages of development and may never become commercialized. All of our product candidates developed from our technology platform will require additional clinical and non-clinical development, regulatory review and approval in multiple jurisdictions, substantial investment, access to sufficient commercial manufacturing capacity and significant marketing efforts before they can be successfully commercialized. Because all of our product candidates are based on the same core aNK technology, if any of our product candidates encounter safety or efficacy problems, developmental delays or regulatory issues or other problems, these could impact the development plans for our other product candidates.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Utilizing haNK, taNK and t<font style="font-weight:normal;">&#8209;</font>haNK cells represents a novel approach to immunotherapy, including cancer treatment, and we must overcome significant challenges in order to successfully develop, commercialize and manufacture our product candidates.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have concentrated our research and development efforts on utilizing aNK cells as an immunotherapy platform and genetically modified aNK cells as product candidates based on this platform. We believe that our product candidates represent a novel approach to immunotherapy, including cancer treatment. Advancing this novel immunotherapy creates significant challenges for us, including:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">educating medical personnel regarding the potential side effect profile of our cells;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">training a sufficient number of medical personnel how to properly administer our cells;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">enrolling sufficient numbers of patients in clinical trials;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">developing a reliable, safe and effective means of genetically modifying our cells;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">manufacturing our cells on a large scale and in a cost-effective manner;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">submitting applications for and obtaining regulatory approval, as the FDA and other regulatory authorities have limited experience with commercial development of immunotherapies for cancer and viral associated infectious diseases; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">establishing sales and marketing capabilities, as well as developing a manufacturing process and distribution network to support the commercialization of any approved products.</font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We must be able to overcome these challenges in order for us to successfully develop, commercialize and manufacture our product candidates utilizing haNK, taNK and t&#8209;haNK cells.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">78</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU70"></a><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Even if we successfully develop and commercialize our haNK product candidate for Merkel cell carcinoma, we may not be successful in developing and commercializing our other product candidates, and our commercial opportunities may be limited.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe that our ability to realize the full value of our aNK platform will depend on our ability to successfully develop and commercialize haNK and our other product candidates in a wider range of indications. We are simultaneously pursuing preclinical and clinical development of a number of product candidates spanning several types of cancers. For example, we are devoting substantial resources toward the development of haNK and t&#8209;haNK product candidates as combination therapies with commercially approved monoclonal antibodies and late-stage product candidates for solid tumors such as breast, gastric, pancreatic, lung, head and neck and colorectal cancers, as well as hematologic malignancies such as indolent B&#8209;cell lymphoma, acute lymphoblastic leukemia, or ALL, and diffuse large&#160;B&#8209;cell lymphoma, or DLBCL.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even if we are successful in continuing to build our pipeline of product candidates based on our technology platform, obtaining regulatory approvals and commercializing any approved product candidates will require substantial additional funding beyond our existing cash and cash equivalents and marketable debt securities, and are prone to numerous risks of failure. Investment in biopharmaceutical product development involves significant risks that any product candidate will fail to demonstrate adequate efficacy or an acceptable safety profile to the satisfaction of regulatory authorities, gain regulatory approval or become commercially viable. We cannot assure you that we will be able to successfully advance any product candidates through the development process. Our research programs may initially show promise in identifying product candidates, but ultimately fail to yield product candidates for clinical development or commercialization for many reasons, including the following:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">our product candidates may not succeed in preclinical or clinical testing due to failing to generate enough data to support the initiation or continuation of clinical trials or due to lack of patient enrollment in clinical trials;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">a product candidate may be shown to have harmful side effects or other characteristics in larger scale clinical studies that indicate it is unlikely to meet applicable regulatory criteria;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">competitors may develop alternatives that render our product candidates obsolete or less attractive;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">we may not be able or willing to assemble sufficient resources to acquire or discover additional product candidates from our technology platform;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">product candidates we develop may nevertheless be covered by third parties&#8217; patents or other exclusive rights;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the market for a product candidate may change during our program so that the continued development of that product candidate is no longer reasonable;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">a product candidate may not be capable of being manufactured in commercial quantities at an acceptable cost, or at all; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">a product candidate may not be accepted as safe and effective by patients, the medical community or third-party payors.</font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If any of these events occur, we may be forced to abandon our development efforts for a product candidate or the entire platform, or we may not be able to identify, discover, develop or commercialize additional product candidates, which would have a material adverse effect on our business and could potentially cause us to cease operations.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We may not be able to file INDs to commence additional clinical trials on the timelines we expect, and even if we are able to, the FDA may not permit us to proceed in a timely manner, or at all.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prior to commencing clinical trials in the U.S. for any of our product candidates, we may be required to have an allowed IND for each product candidate. As of the date of this filing, we have numerous INDs for clinical trials that have been authorized in the U.S. We are required to file additional INDs prior to initiating our planned clinical trials. We believe that the data from previous preclinical studies will support the filing of additional INDs, to enable us to undertake additional clinical studies as we have planned. However, submission of an IND may not result in the FDA allowing further clinical trials to begin and, once begun, issues may arise that will require us to suspend or terminate such clinical trials. Additionally, even if relevant regulatory authorities agree with the design and implementation of the clinical trials set forth in an IND or clinical trial application, these regulatory authorities may change their requirements in the future. The fact that we are pursuing novel technologies may also exacerbate these risks with respect to our product candidates, and as a result, we may not meet our anticipated clinical development timelines.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">79</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU71"></a><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We face significant competition in the biopharmaceutical industry, and many of our competitors have substantially greater experience and resources than we have.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even if our aNK platform products prove successful, we might not be able to remain competitive because of the rapid pace of technological development in the biopharmaceutical field. Our haNK, taNK and t&#8209;haNK product candidates will compete with other cell and molecule-based immunotherapy approaches using and/or targeting natural killer cells, T&#8209;cells and dendritic cells.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Competitors focused on CAR&#8209;T related treatment approaches include AbbVie&#160;Inc., Atara&#160;Biotherapeutics,&#160;Inc., Intrexon&#160;Corporation, Allogene&#160;Therapeutics,&#160;Inc., Bristol&#8209;Myers&#160;Squibb&#160;Company, JW&#160;Therapeutics&#160;Co.,&#160;Ltd., Amgen,&#160;Inc., Leucid&#160;Bio&#160;Ltd., Bellicum&#160;Pharmaceuticals,&#160;Inc., Medisix&#160;Therapeutics&#160;Pte&#160;Ltd., Bluebird&#160;Bio,&#160;Inc., Mesoblast&#160;Ltd., Calibr/Scripps&#160;Research, Mustang&#160;Bio,&#160;Inc., CARsgen&#160;Therapeutics, Nanjing&#160;Legend&#160;Biotechnology&#160;Co.,&#160;Ltd, Cartherics&#160;Pty&#160;Ltd, Novartis&#160;AG, Pfizer,&#160;Inc., Cellectis&#160;SA, Poseida&#160;Therapeutics,&#160;Inc., Celularity,&#160;Inc., Servier&#160;Laboratories, Celyad&#160;SA, Takeda/Shire, Fortress&#160;Biotech,&#160;Inc., TC&#160;BioPharm&#160;Ltd., Gilead&#160;Sciences,&#160;Inc., Transposagen&#160;Biopharmaceuticals,&#160;Inc., Humanigen,&#160;Inc., Unum&#160;Therapeutics,&#160;Inc., Immune&#160;Therapeutics,&#160;Inc., and Xyphos,&#160;Inc.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Competitor companies focused on other T&#8209;cell based approaches include Adaptimmune&#160;Ltd., Adicet&#160;Bio,&#160;Inc., Autolus&#160;Therapeutics,&#160;plc, Cell&#160;Medica&#160;Limited, GlaxoSmithKline&#160;plc., Green&#160;Cross&#160;LabCell&#160;Corp., Immunocore&#160;Limited, Iovance&#160;Biotherapeutics,&#160;Inc., Kiadis&#160;Pharma&#160;Netherlands&#160;B.V., Lion&#160;TCR&#160;Pte&#160;Ltd., MolMed,&#160;S.p.A., Precision&#160;Biosciences,&#160;Inc., Janssen&#160;Pharmaceuticals,&#160;Inc., Noile&#8209;Immune&#160;Biotech,&#160;Inc., Anixa&#160;Biosciences,&#160;Inc., Beam&#160;Therapeutics&#160;Inc., BioNTech&#160;SE, Cartesian&#160;Therapeutics,&#160;Inc., and Takara&#160;Bio,&#160;Inc.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Competitor companies focused on dendritic cell based approaches include Argos&#160;Therapeutics,&#160;Inc., Biovest&#160;International,&#160;Inc., ImmunoCellular&#160;Therapeutics,&#160;Ltd., Merck&#160;&amp;&#160;Co,&#160;Inc./Immune&#160;Design,&#160;Inc., Inovio&#160;Pharmaceuticals,&#160;Inc., Intrexon&#160;Corporation, Medigene&#160;AG, and Northwest&#160;Biotherapeutics,&#160;Inc.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Competitor companies focused on natural killer cell based approaches include Kiadis&#160;Pharma Netherlands&#160;B.V./CytoSen Therapeutics, Inc., Dragonfly&#160;Therapeutics,&#160;Inc., Fate&#160;Therapeutics,&#160;Inc., Gamida&#160;Cell,&#160;Ltd., Nkarta&#160;Therapeutics,&#160;Inc., Onkimmune&#160;Ltd., NKMax&#160;America, Artiva&#160;Biotherapeutics, HebeCell&#160;Corp., Vycellix,&#160;Inc., oNKo&#8209;innate&#160;Pty&#160;Ltd., and Ziopharm&#160;Oncology,&#160;Inc.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Competitor companies focused on large molecule immunotherapy approaches include Cytomx&#160;Therapeutics,&#160;Inc., Innate&#160;Pharma&#160;SA, and Sorrento&#160;Therapeutics,&#160;Inc. Other potential immunotherapy competitors include Affimed&#160;GmbH, Agios&#160;Pharmaceuticals,&#160;Inc., Codiak&#160;Biosciences, Glycostem&#160;Therapeutics&#160;BV, Triumvira&#160;Immunologics, Century&#160;Therapeutics, Incysus&#160;Therapeutics,&#160;Inc., GammaDelta&#160;Therapeutics&#160;Ltd., Lyell&#160;Immunopharma,&#160;Inc., and GT&#160;Biopharma,&#160;Inc.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There are currently two approved T&#8209;cell based treatments which are marketed by Novartis&#160;AG and Gilead&#160;Sciences/Kite&#160;Pharma. There is currently one approved dendritic cell-based cancer vaccine which is marketed by Dendron&#160;Pharmaceuticals,&#160;LLC for the treatment of metastatic castration resistant prostate cancer.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Many of our current or potential competitors have greater financial and other resources, larger research and development staffs, and more experienced capabilities in researching, developing and testing products than we do. Many of these companies also have more experience in conducting clinical trials, obtaining FDA and other regulatory approvals, and manufacturing, marketing and distributing therapeutic products. Smaller or clinical-stage companies like us may successfully compete by establishing collaborative relationships with larger pharmaceutical companies or academic institutions. Mergers and acquisitions in the pharmaceutical and biotechnology industries may result in even more resources being concentrated among a smaller number of our competitors. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects, are more convenient, or are less expensive than any products that we may develop. Furthermore, currently approved products could be discovered to have application for treatment of cancer and other diseases, which could give such products significant regulatory and market timing advantages over any of our product candidates. In addition, large pharmaceutical companies or other companies with greater resources or experience than us may choose to forgo therapy opportunities that would have otherwise been complementary to our product development and collaboration plans. Our competitors may succeed in developing, obtaining patent protection for, or commercializing their products more rapidly than us, which could result in our competitors establishing a strong market position before we are able to enter the market. A competing company developing or acquiring rights to a more effective therapeutic product for the same diseases targeted by us, or one that offers significantly lower costs of treatment could render our products noncompetitive or obsolete. We may not be successful in marketing any product candidates we may develop against competitors.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">80</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU72"></a><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our business plan involves the creation of a complex integrated ecosystem capable of addressing a wide range of indications. As a result, our future success depends on our ability to prioritize among many different opportunities.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We do not have sufficient resources to pursue development of all or even a substantial portion of the potential opportunities that we believe will be afforded to us by our planned integrated ecosystem. Because we have limited resources and access to capital to fund our operations, our management must make significant prioritization decisions as to which product candidates to pursue and how much of our resources to allocate to each. Our management has broad discretion to suspend, scale down, or discontinue any or all of these development efforts, or to initiate new programs to treat other diseases. If we select and commit resources to opportunities that we are unable to successfully develop, or we forego more promising opportunities, our business, financial condition and results of operations will be adversely affected.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our planned integrated ecosystem is to be comprised of multiple novel technologies that have never been tested in combination with our product candidates, and we do not know whether our attempts to use them in combination will be effective.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our business strategy includes using our integrated discovery engine to introduce new product candidates in combination with technologies that were developed by other companies with whom we have entered into strategic collaborations. Each technology and collaboration is unique and has its own risks, and the failure of any individual technology or the combination could materially impair our ability to successfully pursue our own aNK platform and related product candidates.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">While we are free to pursue all antibodies, we are reliant on third parties and affiliates for such antibodies on which to base our taNK, haNK and t&#8209;haNK product candidates. We do not know if we can obtain such antibodies from third parties on commercially reasonable terms and such reliance on third parties may delay our development and increase the associated development costs.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have also entered into collaborations with affiliates of NantWorks, LLC, or NantWorks, to provide us with access to their database of genomic, transcriptomic and proteomic information collected from a broad array of tumor cell and peripheral blood samples. Our rights to use the database are non-exclusive and are governed by agreements cancelable with 90 days&#8217; notice, and we therefore cannot guarantee that we would ultimately have any competitive advantage based on our use of this technology. The database also may not be able to identify novel tumor-associated antigens that are targetable with our technology and the genetic and proteomic analysis capability may not be effective as a companion diagnostic to guide therapeutic treatments.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Although we have agreements with these parties, we cannot control their actions and they may make mistakes, work with our competitors, or not devote sufficient time and attention to us. The arrangements may become cost-prohibitive for us, and their technologies may become obsolete or better options may be available that we are unable to utilize. We cannot assure you that using our technology in combination with theirs will be successful in producing product candidates in connection with these arrangements.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Clinical drug development involves a lengthy and expensive process with an uncertain outcome, results of earlier studies and clinical trials may not be predictive of future clinical trial results, we may not be able to rely on the aNK and haNK phase&#160;I and II clinical trials data for our other product candidates, and our clinical trials may fail to adequately demonstrate substantial evidence of safety and efficacy of our product candidates. The results of our clinical trials may not satisfy the requirements of the FDA or other comparable foreign regulatory authorities, and we may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of such product candidate.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clinical testing is expensive and can take many years to complete, and its outcome is inherently uncertain. A failure of one or more of our clinical trials can occur at any time during the clinical trial process. The results of preclinical studies and early clinical trials of our product candidates may not be predictive of the results of later-stage clinical trials. There is a high failure rate for product candidates proceeding through clinical trials, and product candidates in later stages of clinical trials may fail to show the required safety and efficacy despite having progressed through preclinical studies and initial clinical trials. A number of companies in the pharmaceutical industry have suffered significant setbacks in advanced clinical trials due to lack of efficacy or adverse safety profiles, notwithstanding promising results in earlier clinical trials, and we cannot be certain that we will not face similar setbacks. Even if our clinical trials are completed, the results may not be sufficient to support obtaining regulatory approval for our product candidates. In addition, our strategy and anticipated timelines are predicated upon our ability to utilize the phase&#160;I and II clinical trial data for aNK, haNK, and t&#8209;haNK observed to date to support our planned clinical trials for all of our product candidates, including our haNK, taNK and t&#8209;haNK product candidates. To date, we have several INDs for our haNK product candidates, and we cannot offer assurances that the FDA will allow us to utilize the phase&#160;I and II aNK and haNK data to support other planned clinical trials or allow our anticipated INDs for&#160;(i)&#160;planned phase&#160;I or phase&#160;Ib/IIa clinical trials for our other product candidates, (ii)&#160;planned phase&#160;IIb/III clinical trials for our haNK and t&#8209;haNK product candidates as potential combination therapies, or (iii)&#160;any other planned clinical trials, including registration studies.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">81</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU73"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have in the past experienced delays in our ongoing clinical trials and we may experience additional delays in the future. We do not know whether future clinical trials, if any, will begin on time, need to be redesigned, enroll an adequate number of patients on time or be completed on schedule, if at all. Clinical trials can be delayed, suspended or terminated by us, regulatory authorities, clinical trial investigators, and ethics committees for a variety of reasons, including failure to:</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">generate sufficient preclinical, toxicology, or other </font><font style="font-style:italic;font-family:Times New Roman;">in&#160;vivo</font><font style="font-family:Times New Roman;"> or </font><font style="font-style:italic;font-family:Times New Roman;">in&#160;vitro</font><font style="font-family:Times New Roman;"> data to support the initiation or continuation of clinical trials;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">obtain regulatory authorization, or feedback on clinical trial design, to commence a clinical trial;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">identify, recruit and train suitable clinical investigators;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">reach agreement on acceptable terms with prospective Contract Research Organizations, or CROs, and clinical trial sites;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">obtain and maintain institutional review board, or IRB, approval at each clinical trial site;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">identify, recruit and enroll suitable patients to participate in a clinical trial;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">have a sufficient number of patients complete a clinical trial or return for post-treatment follow-up;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">ensure that our third-party contractors and clinical investigators comply with clinical trial protocols, comply with regulatory requirements, or meet their obligations to us in a timely manner;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">address any patient safety concerns that arise during the course of a clinical trial;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">address any conflicts with new or existing laws or regulations;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">add a sufficient number of clinical trial sites;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">timely manufacture sufficient quantities of product candidate for use in clinical trials; or</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">raise sufficient capital to fund a clinical trial.</font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Patient enrollment is a significant factor in the timing of clinical trials and is affected by many factors, including the size and nature of the patient population, the proximity of patients to clinical sites, the eligibility criteria for the clinical trial, the design of the clinical trial, competing clinical trials and clinicians&#8217; and patients&#8217; or caregivers&#8217; perceptions as to the potential advantages of the drug candidate being studied in relation to other available therapies, including any new drugs or treatments that may be approved for the indications we are investigating.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We could also encounter delays if a clinical trial is suspended or terminated by us, by the data safety monitoring board for such clinical trial or by the FDA or any other regulatory authority, or if the IRBs of the institutions in which such clinical trials are being conducted suspend or terminate the participation of their clinical investigators and sites subject to their review. Such authorities may suspend or terminate a clinical trial due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements, including Good Clinical Practices, or GCPs, or our clinical protocols, inspection of the clinical trial operations or clinical trial site by the FDA or other regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a product candidate, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, even if such clinical trials are successfully completed, we cannot guarantee that the FDA or foreign regulatory authorities will interpret the results as we do, and more trials could be required before we submit our product candidates for approval. To the extent that the results of the trials are not satisfactory to the FDA or foreign regulatory authorities for support of a marketing application, we may be required to expend significant resources, which may not be available to us, to conduct additional trials in support of potential approval of our product candidates. Even if regulatory approval is secured for any of our product candidates, the terms of such approval may limit the scope and use of our product candidate, which may also limit its commercial potential.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we experience delays in the completion of, or termination of, any clinical trial of our product candidates for any reason, the commercial prospects of our product candidates may be harmed, and our ability to generate product revenues from any of these product candidates will be delayed. In addition, any delays in completing our clinical trials will increase our costs, slow down our product candidate development and approval process and jeopardize our ability to commence product sales and generate revenues. Any of these occurrences may significantly harm our business, financial condition and prospects. In addition, many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of our product candidates.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">82</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU74"></a><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We may be unable to obtain regulatory approval for our product candidates. The denial or delay of any such approval would delay commercialization and have a material adverse effect on our potential to generate revenue, our business and our results of operations.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The research, development, testing, manufacturing, labeling, packaging, approval, promotion, advertising, storage, recordkeeping, marketing, distribution, post-approval monitoring and reporting, and export and import of biopharmaceutical products are subject to extensive regulation by the FDA, and by foreign regulatory authorities in other countries. These regulations differ from country to country. To gain approval to market our product candidates, we must provide regulatory authorities with substantial evidence of safety, purity and potency of the product for each indication we seek to commercialize. We have not yet obtained regulatory approval to market any of our product candidates in the U.S. or any other country. Our business depends upon obtaining these regulatory approvals.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA can delay, limit or deny approval of our product candidates for many reasons, including:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">our inability to satisfactorily demonstrate with substantial clinical evidence that the product candidates are safe, pure and potent for the requested indication;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="letter-spacing:-0.1pt;font-family:Times New Roman;">the FDA&#8217;s disagreement with our clinical trial protocol or the interpretation of data from preclinical studies or clinical trials;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the population studied in the clinical trial not being sufficiently broad or representative to assess safety in the full population for which we seek approval;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">our inability to demonstrate that clinical or other benefits of our product candidates outweigh any safety or other perceived risks;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the FDA&#8217;s determination that additional preclinical or clinical trials are required;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the FDA&#8217;s non-approval of the labeling or the specifications of our product candidates;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the FDA&#8217;s failure to accept the manufacturing processes or facilities of third-party manufacturers with which we may contract; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">for clinical trials conducted by the Immuno-Oncology Clinic, Inc., or the Clinic, a related party, the FDA or other regulatory authorities could view our study results as potentially biased even if we achieve such clinical trial endpoints; or</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the potential for approval policies or regulations of the FDA to significantly change in a manner rendering our clinical data insufficient for approval.</font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even if we eventually successfully complete clinical testing and receive approval of any regulatory filing for our product candidates, the FDA may only grant approval contingent on the performance of costly additional post-approval clinical trials. The FDA may also approve our product candidates for a more limited indication or a narrower patient population than we originally requested, and the FDA may not approve the labeling that we believe is necessary or desirable for the successful commercialization of our product candidates. To the extent we seek regulatory approval in foreign countries, we may face challenges similar to those described above with regulatory authorities in applicable jurisdictions. Any delay in obtaining, or our inability to obtain, applicable regulatory approval for any of our product candidates would delay or prevent commercialization of our product candidates and would materially adversely impact our business, results of operations, financial condition and prospects.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Use of our product candidates could be associated with side effects or adverse events.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As with most biopharmaceutical products, use of our product candidates could be associated with side effects or adverse events, which can vary in severity and frequency. Side effects or adverse events associated with the use of our product candidates may be observed at any time, including in clinical trials or once a product is commercialized, and any such side effects or adverse events may negatively affect our ability to obtain regulatory approval or market our product candidates. Side effects such as toxicity or other safety issues associated with the use of our product candidates could require us to perform additional studies or halt development or sale of these product candidates or expose us to product liability lawsuits, which will harm our business. We may be required by regulatory agencies to conduct additional preclinical or clinical trials regarding the safety and efficacy of our product candidates, which we have not planned or anticipated. We cannot provide any assurance that we will resolve any issues related to any product-related adverse events to the satisfaction of the FDA or any regulatory agency in a timely manner or ever, which could harm our business, prospects and financial condition.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">83</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU75"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Adverse events observed in our phase&#160;I clinical trials of aNK conducted at third party centers included several grade&#160;1 and 2 transient fevers and chills and individual occurrences of back pain, a transient grade&#160;4 hypoglycemia and transient hypotension, all responsive to supportive care. </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we are successful in commercializing our product candidates, the FDA and other foreign regulatory agency regulations will require that we report certain information about adverse medical events if those products may have caused or contributed to those adverse events. The timing of our obligation to report would be triggered by the date we become aware of the adverse event</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> as well as the nature of the event. We may inadvertently fail to report adverse events we become aware of within the prescribed timeframe. We may also fail to appreciate that we have become aware of a reportable adverse event, especially if it is not reported to us as an adverse event or if it is an adverse event that is unexpected or removed in time from the use of our products. If we fail to comply with our reporting obligations, the FDA or other foreign regulatory agencies could take action including criminal prosecution, the imposition of civil monetary penalties, seizure of our products, or delay in approval or clearance of future products.</font></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">The clinical and commercial utility of our aNK platform is uncertain and may never be realized.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our aNK platform is in the early stages of development. To date, aNK cells have only been evaluated in early clinical trials including four published phase&#160;I clinical safety trials in approximately 46&#160;patients. These clinical trials were designed to evaluate safety and tolerability, and not designed to produce statistically significant results as to efficacy. Most of the data to date regarding aNK cells were derived from clinical trials not conducted by us, including physician-sponsored clinical trials, and utilizing product not manufactured by us but which we believe is comparable to aNK. The company currently has multiple ongoing clinical trials to evaluate cryopreserved haNK cells in company sponsored clinical trials. Success in early clinical trials does not ensure that large-scale clinical trials will be successful nor does it predict final results. In addition, we will not be able to treat patients if we cannot manufacture a sufficient quantity of NK cells that meet our minimum specifications. In addition, our haNK product candidate has only been tested in a small number of patients. Results from these clinical trials may not necessarily be indicative of the safety and tolerability or efficacy of our products as we expand into larger clinical trials.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may not ultimately be able to provide the FDA with substantial clinical evidence to support a claim of safety, purity and potency sufficient to enable the FDA to approve aNK platform product candidates for any indication. This may be because later clinical trials fail to reproduce favorable data obtained in earlier clinical trials, because the FDA disagrees with how we interpret the data from these clinical trials, or because the FDA does not accept these therapeutic effects as valid endpoints in pivotal clinical trials necessary for market approval. We will also need to demonstrate that aNK platform product candidates are safe. We do not have data on possible harmful long-term effects of aNK platform product candidates and do not expect to have this data in the near future. As a result, our ability to generate clinical safety and effectiveness data sufficient to support submission of a marketing application or commercialization of our aNK platform therapy is uncertain and is subject to significant risk.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We have limited experience as a company conducting clinical trials and have relied and will rely on third parties and related parties to conduct many of our preclinical studies and clinical trials. Any failure by a third party, related party, or by us to conduct the clinical trials according to Good Clinical Practices and in a timely manner may delay or prevent our ability to seek or obtain regulatory approval for or commercialize our product candidates.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Three of our four completed phase&#160;I clinical trials with aNK have been investigator-initiated studies sponsored by the investigator&#8217;s institution. To date, the only company sponsored studies to engage in patient enrollment have been for the following indications:&#160;Merkel cell, pancreatic, squamous head and neck, non-small cell lung, triple negative breast, AML, colorectal and advanced solid tumor. This relative lack of experience may contribute to our planned clinical trials not beginning or completing on time, if at all. In addition, we have entered into an agreement with the Clinic, a related party, to continue to conduct and oversee certain of our clinical trials. Large-scale clinical trials will require significant additional resources and reliance on Contract Research Organizations, or CROs, clinical investigators, or consultants. Consequently, our reliance on outside parties may introduce delays beyond our control. Our CROs, the Clinic, and other third parties must communicate and coordinate with one another in order for our trials to be successful. Additionally, our CROs, the Clinic, and other third parties may also have relationships with other commercial entities, some of which may compete with us. If our CROs, the Clinic, or other third parties conducting our clinical trials do not perform their contractual duties or regulatory obligations, experience work stoppages, do not meet expected deadlines, terminate their agreements with us or need to be replaced, or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical trial protocols, GCPs, or other regulatory requirements or for any other reason, we may need to conduct additional clinical trials or enter into new arrangements with alternative CROs, clinical investigators or other third parties. We may be unable to enter into arrangements with alternative CROs on commercially reasonable terms, or at all.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">84</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU76"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We, the Clinic, and the third parties upon which we rely are required to comply with GCPs. GCPs are regulations and guidelines enforced by regulatory authorities around the world, through periodic inspections, for products in clinical development. If we or these third parties fail to comply with applicable GCP regulations, the clinical data generated in our clinical trials may be deemed unreliable and have to be repeated, and our submission of marketing applications may be delayed or the regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. We are subject to the risk that, upon inspection, a regulatory authority will determine that any of our clinical trials fail to comply or failed to comply with applicable GCP regulations. In addition, our clinical trials must be conducted with material produced under GMP and Good Tissue Practice, or GTP, regulations, which are enforced by regulatory authorities. In addition, our clinical trials must be conducted with material produced under GMP regulations, which are enforced by regulatory authorities. Our failure to comply with these regulations may require us to repeat clinical trials, which would delay the regulatory approval process. Moreover, our business may be significantly impacted if our CROs, the Clinic, clinical investigators or other third parties violate federal or state healthcare fraud and abuse or false claims laws and regulations or healthcare privacy and security laws.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We also anticipate that part of our strategy for pursuing the wide range of indications potentially addressed by our aNK, haNK, taNK and t&#8209;haNK platforms will involve further investigator-initiated clinical trials. While these trials generally provide us with valuable clinical data that can inform our future development strategy in a cost-efficient manner, we generally have less control over not only the conduct but also the design of these clinical trials. Third-party investigators may design clinical trials involving our product candidates with clinical endpoints that are more difficult to achieve or in other ways that increase the risk of negative clinical trial results compared to clinical trials we may design on our own. Negative results in investigator-initiated clinical trials, regardless of how the clinical trial was designed or conducted, could have a material adverse effect on our prospects and the perception of our product candidates.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Moreover, principal investigators for our clinical trials may serve as scientific advisors or consultants to us from time to time and receive compensation in connection with such services. In addition, some of our trials are being run by the Clinic, which is controlled by one of our employees. Under certain circumstances, the company may be required to report some of these relationships to the FDA. The FDA may conclude that a financial relationship between the company, the Clinic and/or a principal investigator has created a conflict of interest or otherwise affected interpretation of the study. The FDA may therefore question the integrity of the data generated at the applicable clinical trial site and the utility of the clinical trial itself may be jeopardized. This could result in a delay in approval, or rejection, of our marketing applications by the FDA and may ultimately lead to the denial of regulatory approval of one or more of our product candidates.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We are heavily dependent on our senior management, particularly Drs.&#160;Patrick Soon-Shiong and Barry Simon, and a loss of a member of our senior management team in the future, even if only temporary, could harm our business.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we lose members of our senior management for a short or an extended time, we may not be able to find appropriate replacements on a timely basis, and our business could be adversely affected. Our existing operations and continued future development depend to a significant extent upon the performance and active participation of certain key individuals, including Drs.&#160;Patrick Soon-Shiong, our Chairman and CEO and our principal stockholder, and Barry Simon, our President and Chief Administrative Officer. Although Dr.&#160;Soon-Shiong focuses heavily on NantKwest matters and is highly active in our management, he does devote a certain amount of his time to a number of different endeavors and companies, including ImmunityBio and NantWorks, which is a collection of multiple companies in the healthcare and technology space. The risks related to our dependence upon Dr.&#160;Soon-Shiong are particularly acute given his ownership percentage, the commercial and other relationships that we have with entities affiliated with him, role in our company and reputation. If we were to lose Drs.&#160;Soon-Shiong or Simon for a short or an extended time, for any reason, including the contraction of COVID&#8209;19, we may not be able to find appropriate replacements on a timely basis and our financial condition and results of operations could be materially adversely affected.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Competition for qualified personnel in the biotechnology and pharmaceuticals industry is intense due to the limited number of individuals who possess the skills and experience required. To induce valuable employees to remain at our company, in addition to salary and cash incentives, we have provided stock options, warrants, and restricted stock units that vest over time. Additionally, we provided warrants that vested upon the achievement of certain performance milestones to Dr.&#160;Soon-Shiong. These performance warrants provided to Dr.&#160;Soon-Shiong were exercised in full in March&#160;2019. The value to employees of stock options, warrants, and restricted stock units that vest over time may be significantly affected by movements in our stock price that are beyond our control, and may at any time be insufficient to counteract more lucrative offers from other companies. Despite our efforts to retain valuable employees, members of our management, scientific and development teams may terminate their employment with us on short notice. We face significant competition for employees, particularly scientific personnel, from other biopharmaceutical companies, which include both publicly traded and privately held companies, and we may not be able to hire new employees quickly enough to meet our needs. Although we have employment agreements with our key employees, these employment agreements provide for at-will employment, which means that any of our employees could leave our employment at any time, with or without notice. Except with respect to Dr.&#160;Simon, we do not maintain &#8220;key man&#8221; insurance policies on the lives of these individuals or the lives of any of our other employees. We may not be able to attract and retain quality personnel on acceptable terms, or at all, which may cause our business and operating results to suffer.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">85</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU77"></a><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Dr.&#160;Soon-Shiong, our Chairman and CEO and our principal stockholder, has significant interests in other companies which may conflict with our interests.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our Chairman and CEO, Dr.&#160;Soon-Shiong, is the founder of NantWorks. The various NantWorks companies are currently exploring opportunities in the immunotherapy, infectious disease and inflammatory disease fields. In particular, we have agreements with a number of related parties that provide services, technology and equipment for use in our efforts to develop our product pipeline. Dr.&#160;Soon-Shiong holds a controlling interest, either directly or indirectly, in these entities. Consequently, Dr.&#160;Soon-Shiong&#8217;s interests may not be aligned with our other stockholders and he may from time to time be incentivized to take certain actions that benefit his other interests and that our other stockholders do not view as being in their interest as investors in our company. In addition, other companies affiliated with Dr.&#160;Soon-Shiong may compete with us for business opportunities or, in the future, develop products that are competitive with ours (including products in other therapeutic fields which we may target in the future). Moreover, even if they do not directly relate to us, actions taken by Dr.&#160;Soon-Shiong and the companies with which he is involved could impact us.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are also pursuing supply arrangements for various investigational agents controlled by affiliates to be used in our clinical trials. If Dr.&#160;Soon-Shiong was to cease his affiliation with us, ImmunityBio, or with NantWorks, these entities may be unwilling to continue these relationships with us on commercially reasonable terms, or at all, and as a result may impede our ability to control the supply chain for our combination therapies. These collaboration agreements do not typically specify how sales will be apportioned between the parties upon successful commercialization of the product. As a result, we cannot guarantee that we will receive a percentage of the revenue that is at least proportional to the costs that we will incur in commercializing the product candidate.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furthermore, in November&#160;2015, we entered into a Shared Services Agreement with NantWorks, pursuant to which NantWorks and/or any of its affiliates provides corporate, general and administrative, manufacturing strategy, research and development, regulatory and clinical trial strategy, and other support services to us and our subsidiaries. If Dr.&#160;Soon-Shiong was to cease his affiliation with us or with NantWorks, we may be unable to establish or maintain this relationship with NantWorks on a commercially reasonable basis, if at all. As a result, we could experience a lack of business continuity due to loss of historical and institutional knowledge and a lack of familiarity of new employees and/or new service providers with business processes, operating requirements, policies and procedures, and we may incur additional costs as new employees and/or service providers gain necessary experience, particularly in connection with issues or concerns we may have as a public company. In addition, the loss of the services of NantWorks might significantly delay or prevent the development of our products or achievement of other business objectives by diverting management&#8217;s attention to transition matters and identification of suitable replacements, if any, and could have a material adverse effect on our business and results of operations.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We will need to grow the size and capabilities of our organization, and we may experience difficulties in managing this growth.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To effect our business plan, we will need to add other management, accounting, regulatory, manufacturing and scientific staff. As of December&#160;31, 2019, we had 148 employees. We will need to attract, retain and motivate a significant number of new additional managerial, operational, sales, marketing, financial, and other personnel, as well as highly skilled scientific and medical personnel, and to expand our capabilities to successfully pursue our research, development, manufacturing and commercialization efforts and secure collaborations to market and distribute our products. This growth may strain our existing managerial, operational, financial and other resources. We also intend to add personnel in our research and development and manufacturing departments as we expand our clinical trial and research capabilities. Moreover, we may need to hire additional accounting and other personnel and augment our infrastructure as a result of operating as a public company. Any inability to attract and retain qualified employees to enable our planned growth and establish additional capabilities or our failure to manage our growth effectively could delay or curtail our product development and commercialization efforts and harm our business.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We have limited manufacturing experience and may not be able to manufacture haNK, taNK or t<font style="font-weight:normal;">&#8209;</font>haNK cells on a large scale or in a cost-effective manner.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU78"></a>haNK, taNK and t&#8209;haNK cells have been grown in various quantities in closed cell culture systems and intermediate to larger-scale bioreactors. With all manufacturing efforts being conducted in-house, we will need to develop the ability to grow haNK, taNK and t&#8209;haNK cells on a large-scale basis in a cost efficient manner. While we have made great strides with our haNK production, including a validated cryopreserved form of the product, we have not demonstrated the ability to manufacture these cells beyond quantities sufficient for our clinical programs. We have not demonstrated the ability to manufacture our taNK and t&#8209;haNK cells beyond quantities sufficient for research and development and limited clinical activities. We have also experienced increases in manufacturing costs and sporadic decreases in manufacturing yield of both haNK, taNK and t&#8209;haNK cells. In addition, we have no experience manufacturing our NK cells specifically at the capacity that will be necessary to support commercial sales. The novel nature of our technology also increases the complexity and risk in the manufacturing process. In 2017, we opened our Culver City, California, site for the manufacture of cryopreserved haNK cells for our planned clinical trials and finished the build-out of our larger El Segundo, California, site in 2018 for the manufacture of our haNK, taNK and t&#8209;haNK cells for our clinical trials and, if we receive </p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">86</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FDA approval, initial commercialization. However, we may encounter difficulties in obtaining the approvals for, and designing, constructing, validating and operating, any new manufacturing facility. We may also be unable to hire the qualified personnel that we will require to accommodate the expansion of our operations and manufacturing capabilities. If we relocate our manufacturing activities to a new facility during or after a pivotal clinical trial, we may be unable to obtain regulatory approval unless and until we demonstrate to the FDA&#8217;s satisfaction the similarity of our haNK, taNK and t</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8209;haNK cells manufactured in the new facility to our cells manufactured in prior facilities. If we cannot adequately demonstrate similarity to the FDA, we could be required to repeat clinical trials, which would be expensive, and would substantially delay regulatory approval.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Because our product candidates are cell-based, their manufacture is complicated. In addition, we rely on certain third party suppliers for manufacturing supplies such as X&#8209;VIVO&#160;10 media to grow and produce our cells. Reliance on such third-party suppliers exposes us to supply interruptions and shortages that could have an adverse effect on our ability to produce product. Moreover, our present production process may not meet our initial expectations as to reproducibility, yield, purity or other measurements of performance. Any supply interruption from third parties and entities that are affiliated with Patrick Soon-Shiong and/or NantWorks could materially harm our ability to manufacture our product candidates until a new source of supply, if any, could be identified and qualified. We may be unable to find a sufficient alternative supply channel in a reasonable time or on commercially reasonable terms. In addition, we may have to customize a bioreactor system to our manufacturing process. Because our manufacturing process is unproven, we may never successfully commercialize our products. In addition, because the clinical trials were conducted using a system that will not be sufficient for commercial quantities, we may have to show comparability of the different versions of systems we have used. For these and other reasons, we may not be able to manufacture haNK, taNK and t&#8209;haNK cells on a large scale or in a cost-effective manner.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">aNK platform cells have been produced at academic institutions associated with our other clinical trial sites. In the past, the lack of production of aNK platform cells has caused delays in the commencement of our clinical trials. We have been establishing NK cell production capacity to meet anticipated demand for our planned clinical trials but may not be able to successfully build out our capacity to meet our current and anticipated future needs. Any damage to or destruction of our facility and equipment, prolonged power outage, contamination or shut down by the FDA or other regulatory authority could significantly impair or curtail our ability to produce haNK, taNK and t&#8209;haNK cells.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We are dependent on third parties to store our aNK, haNK, taNK and t<font style="font-weight:normal;">&#8209;</font>haNK cells, and any damage or loss to our master cell bank would cause delays in replacement, and our business could suffer.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The aNK cells of our master and working cell banks are stored in freezers at a third party biorepository and also stored in our freezers at our production facility. If these cells are damaged at both facilities, including by the loss or malfunction of these freezers or our back-up power systems, as well as by damage from fire, power loss or other natural disasters, we would need to establish replacement master and working cell banks, which would impact clinical supply and delay our patients&#8217; treatments. If we are unable to establish replacement cell banks, we could incur significant additional expenses and liability to patients whose treatment is delayed, and our business could suffer.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If we or any of our third party manufacturers that we may use do not maintain high standards of manufacturing, our ability to develop and commercialize haNK, taNK or t&#8209;haNK cells could be delayed or curtailed.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We and any third parties that we may use in the future to manufacture our products must continuously adhere to cGMP regulations rigorously enforced by the FDA through its facilities inspection program. If our facilities or the facilities of third parties who we may use in the future to produce our products do not pass a pre-approval inspection, the FDA will not grant market approval for haNK, taNK or t&#8209;haNK cells. In complying with cGMP, we and any third-party manufacturers must expend significant time, money and effort in production, record keeping and quality control to assure that each component of our haNK, taNK or t&#8209;haNK cell therapies meets applicable specifications and other requirements. We or any of these third-party manufacturers may also be subject to comparable or more stringent regulations of foreign regulatory authorities. If we or any of our third-party manufacturers fail to comply with these requirements, we may be subject to regulatory action, which could delay or curtail our ability to develop, obtain regulatory approval of, and commercialize haNK, taNK or t&#8209;haNK cells. If our component part manufacturers and suppliers fail to provide components of sufficient quality, that meet our required specifications, our clinical trials or commercialization of haNK, taNK or t&#8209;haNK cells could be delayed or halted, and we could face product liability claims.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">87</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU79"></a><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If we or any of our third-party manufacturers that we may engage use hazardous and biological materials in a manner that causes injury or violates applicable law, we may be liable for damages.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our research and development activities involve the controlled use of potentially hazardous substances, including chemical and biological materials, by us and any third-party manufacturers that we may use in the future. We and any of our third party manufacturers that we may engage are subject to federal, state and local laws and regulations in the U.S. governing the use, manufacture, storage, handling and disposal of medical and hazardous materials. Although we believe that our procedures for using, storing and disposing of these materials comply with legally prescribed standards, we cannot completely eliminate the risk of contamination or injury resulting from medical or hazardous materials. As a result of any such contamination or injury, we may incur liability or local, city, state or federal authorities may curtail the use of these materials and interrupt our business operations. In the event of an accident, we could be held liable for damages or penalized with fines, and the liability could exceed our resources. We do not have any insurance for liabilities arising from medical or hazardous materials. Compliance with applicable environmental laws and regulations is expensive, and current or future environmental regulations may impair our research, development and production efforts, which could harm our business, prospects, financial condition or results of operations.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We have not yet developed a validated methodology for freezing and thawing large quantities of taNK and t<font style="font-weight:normal;">&#8209;</font>haNK cells, which we believe will be required for the storage and distribution of our taNK and t<font style="font-weight:normal;">&#8209;</font>haNK product candidates.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have not demonstrated that taNK and t&#8209;haNK cells can be frozen and thawed in large quantities without damage, in a cost-efficient manner and without degradation over time. We may encounter difficulties not only in developing freezing and thawing methodologies, but also in obtaining the necessary regulatory approvals for using such methodologies in treatment. If we cannot adequately demonstrate similarity of our frozen product to the unfrozen form to the satisfaction of the FDA, we could face substantial delays in our regulatory approvals. If we are unable to freeze taNK and t&#8209;haNK cells for shipping purposes, our ability to promote adoption and standardization of our products, as well as achieve economies of scale by centralizing our production facility, will be limited. Even if we are able to successfully freeze and thaw taNK and t&#8209;haNK cells in large quantities, we will still need to develop a cost-effective and reliable distribution and logistics network, which we may be unable to accomplish. For these and other reasons, we may not be able to commercialize haNK, taNK or t&#8209;haNK cells on a large scale or in a cost-effective manner.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We rely on third party healthcare professionals to administer haNK, taNK or t<font style="font-weight:normal;">&#8209;</font>haNK cells to patients, and our business could be harmed if these third parties administer these cells incorrectly.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We rely on the expertise of physicians, nurses and other associated medical personnel to administer haNK, taNK or t&#8209;haNK cells to clinical trial patients. If these medical personnel are not properly trained to administer, or do not properly administer, haNK, taNK or t&#8209;haNK cells, the therapeutic effect of haNK, taNK or t&#8209;haNK cells may be diminished or the patient may suffer injury.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, if we achieve the ability to freeze and thaw our taNK and t&#8209;haNK cells, third party medical personnel will have to be trained on proper methodology for thawing haNK, taNK or t&#8209;haNK cells received from us. If this thawing is not performed correctly, the cells may become damaged and/or the patient may suffer injury. While we intend to provide training materials and other resources to these third-party medical personnel, the thawing of haNK, taNK or t&#8209;haNK cells will occur outside our supervision and may not be administered properly. If, due to a third-party error, people believe that haNK, taNK or t&#8209;haNK cells are ineffective or harmful, the desire to use haNK, taNK or t&#8209;haNK cells may decline, which would negatively impact our business, reputation and prospects. We may also face significant liability even though we may not be responsible for the actions of these third parties.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Even if any of our product candidates receive regulatory approvals, they may fail to achieve the broad degree of market acceptance and use necessary for commercial success.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any potential future commercial success of any of our product candidates will depend, among other things, on its acceptance by physicians, patients, healthcare payors, and other members of the medical community as a therapeutic and cost-effective alternative to commercially available products. Because only a few cell-based therapy products have been commercialized, we do not know to what extent cell-based immunotherapy products will be accepted as therapeutic alternatives. If we fail to gain market acceptance, we may not be able to earn sufficient revenues to continue our business. Market acceptance of, and demand for, any product that we may develop, if approved for commercial sale, will depend on many factors, including:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">our ability to provide substantial evidence of safety and efficacy;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">convenience and ease of administration;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">prevalence and severity of adverse side effects;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">availability of alternative and competing treatments;</font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">88</a></p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><a name="_AEIOULastRenderedPageBreakAEIOU80"></a><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-family:Times New Roman;">cost effectiveness;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the ability to offer appropriate patient access programs, such as co-pay assistance;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the extent to which physicians recommend our products to their patients;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">effectiveness of our marketing and distribution strategy and pricing of any product that we may develop;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">publicity concerning our products or competitive products; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">our ability to obtain sufficient third-party coverage and adequate reimbursement.</font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If haNK, taNK and t&#8209;haNK cells are approved for use, but fail to achieve the broad degree of market acceptance necessary for commercial success, our operating results and financial condition will be adversely affected. In addition, even if haNK, taNK and t&#8209;haNK cells gain acceptance, the markets for treatment of patients with our target indications may not be as significant as we estimate.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Even if we are able to commercialize any product candidates, such products may become subject to unfavorable pricing regulations, third-party reimbursement practices or healthcare reform initiatives, which would harm our business.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The regulations that govern marketing approvals, pricing and reimbursement for new drugs vary widely from country to country. Some countries require approval of the sale price of a drug before it can be marketed. In many countries, the pricing review period begins after marketing or product licensing approval is granted. In some foreign markets, prescription pharmaceutical pricing remains subject to continuing governmental control even after initial approval is granted. As a result, we might obtain marketing approval for a product in a particular country, but then be subject to price regulations that delay the commercial launch of the product and negatively impact the revenue we are able to generate from the sale of the product in that country. Adverse pricing limitations may hinder our ability to recoup our investment in one or more product candidates, even if any product candidates we may develop obtain marketing approval.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our ability to successfully commercialize any products that we may develop also will depend in part on the extent to which reimbursement for these products and related treatments will be available from government health administration authorities, private health insurers and other organizations. Government authorities and third-party payors, such as private health insurers and health maintenance organizations, decide which medications they will pay for and establish reimbursement levels. A primary trend in the U.S. healthcare industry and elsewhere is cost containment. Government authorities and third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications. Reimbursement may impact the demand for, or the price of, any product candidate for which we obtain marketing approval. Government authorities also impose mandatory discounts for certain patient groups and may seek to increase such discounts at any time. Future regulation may negatively impact the price of our products, if approved. It may be difficult to promptly obtain coverage and profitable payment rates from both the government-funded and private payors for any of our approved product candidates, and this may have a material adverse effect on our operating results, our ability to raise capital and our overall financial condition.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">There are risks inherent in our business that may subject us to potential product liability suits and other claims, which may require us to engage in expensive and time-consuming litigation or pay substantial damages and may harm our reputation and reduce the demand for our product.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our business exposes us to product liability risks, which are inherent in the testing, manufacturing, marketing and sale of biopharmaceutical products. We will face an even greater risk of product liability if we commercialize haNK, taNK and t&#8209;haNK cells. For example, we may be sued if any product we develop allegedly causes or is perceived to cause injury or is found to be otherwise unsuitable during product testing, manufacturing, marketing or sale. Any such product liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the product, negligence, strict liability and a breach of warranties. Claims could also be asserted under state consumer protection acts. If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be required to limit commercialization of our products. Even a successful defense would require significant financial and management resources.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain aspects of how haNK, taNK and t&#8209;haNK cells are processed and administered may increase our exposure to liability. Medical personnel administer haNK, taNK and t&#8209;haNK cells to patients intravenously in an outpatient procedure. This procedure poses risks to the patient similar to those occurring with infusions of other cell products, such as T&#8209;cells and stem cells, including blood clots, infection and mild to severe allergic reactions. Additionally, haNK, taNK and t&#8209;haNK cells or components of our haNK, taNK and t&#8209;haNK cell therapy may cause unforeseen harmful side effects. For example, a patient receiving haNK, taNK and/or t&#8209;haNK cells could have a severe allergic reaction or could develop an autoimmune condition to materials infused with the haNK, taNK and/or t&#8209;haNK cells.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">89</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU81"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, we have not conducted studies on the long-term effects associated with the media that we use to grow our haNK, taNK and t</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8209;haNK cells. Similarly, we expect to use media in freezing our haNK, taNK and t</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8209;haNK cells for shipment. These media could contain substances that have proved harmful if used in certain quantities. As we continue to develop our haNK, taNK and t</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8209;haNK cell therapy, we may encounter harmful side effects that we did not previously observe in our prior studies and clinical trials. Additionally, the discovery of unforeseen side effects of haNK, taNK and t</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8209;haNK cells could also lead to lawsuits against us.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Regardless of merit or eventual outcome, product liability or other claims may, among other things, result in:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">decreased demand for any approved products;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">injury to our reputation and significant negative media attention;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">withdrawal of clinical trial participants or cancellation of clinical trials;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">costs to defend the related litigation;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">a diversion of management&#8217;s time and our resources;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">substantial monetary awards to clinical trial participants or patients;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">regulatory investigations, product recalls, withdrawals or labeling, marketing or promotional restrictions;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">exhaustion of any available insurance and our capital resources;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">loss of revenue;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">a potential decrease in our share price; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the inability to commercialize any products we develop.</font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our inability to obtain and maintain sufficient product liability insurance at an acceptable cost and scope of coverage to protect against potential product liability claims could prevent or inhibit the commercialization of our products. We obtained product liability insurance covering our clinical trials with policy limits that we believe are customary for similarly situated companies and adequate to provide us with coverage for foreseeable risks. Although we maintain such insurance, any claim that may be brought against us could result in a court judgment or settlement in an amount that is not covered, in whole or in part, by our insurance or that is in excess of the limits of our insurance coverage. If we determine that it is prudent to increase our product liability coverage due to the commercial launch of any approved product, we may be unable to obtain such increased coverage on acceptable terms, or at all. Our insurance policies also have various exclusions and deductibles, and we may be subject to a product liability claim for which we have no coverage. We will have to pay any amounts awarded by a court or negotiated in a settlement that exceed our coverage limitations or that are not covered by our insurance, and we may not have, or be able to obtain, sufficient capital to pay such amounts. Moreover, in the future, we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses. If and when we obtain approval for marketing our product candidates, we intend to expand our insurance coverage to include the sale of the applicable products; however, we may be unable to obtain this liability insurance on commercially reasonable terms. If a successful product liability or other claim or series of claims is brought against us for uninsured liabilities or in excess of insured liabilities, our assets may not be sufficient to cover these claims and our business operations could suffer.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We currently have no marketing and sales organization and have no experience in marketing products. If we are unable to establish marketing and sales capabilities or enter into agreements with third parties to market and sell our product candidates, we may not be able to generate product revenue.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We currently have no sales, marketing or distribution capabilities and have no experience as a company in marketing products. If we develop internal sales, marketing and distribution organization, this would require significant capital expenditures, management resources and time, and we would have to compete with other pharmaceutical and biotechnology companies to recruit, hire, train and retain marketing and sales personnel.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we are unable or decide not to establish internal sales, marketing and distribution capabilities, we expect to pursue collaborative arrangements regarding the sales, marketing and distribution of our products. However, we may not be able to establish or maintain such collaborative arrangements, or if we are able to do so, their sales forces may not be successful in marketing our products. Any revenue we receive would depend upon the efforts of such third parties, which may not be successful. We may have little or no control over the sales, marketing and distribution efforts of such third parties and our revenue from product sales may be lower than if we had commercialized our product candidates ourselves. We also face competition in our search for third parties to assist us with the sales, marketing and distribution efforts of our product candidates. There can be no assurance that we will be able to develop internal sales, marketing and distribution capabilities or establish or maintain relationships with third-party collaborators to commercialize any product in the U.S. or overseas.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">90</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU82"></a><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">A variety of risks associated with marketing our product candidates internationally could materially adversely affect our business.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We plan to seek regulatory approval of our product candidates outside of the U.S. and, accordingly, we expect that we will be subject to additional risks related to operating in foreign countries if we obtain the necessary approvals, including:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">differing regulatory requirements in foreign countries;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">unexpected changes in tariffs, trade barriers, price and exchange controls and other regulatory requirements;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">economic weakness, including inflation, or political instability in particular foreign economies and markets;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">compliance with tax, employment, immigration and labor laws for employees living or traveling abroad;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">foreign taxes, including withholding of payroll taxes;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">foreign currency fluctuations, which could result in increased operating expenses and reduced revenue, and other obligations incident to doing business in another country;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">difficulties staffing and managing foreign operations;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">workforce uncertainty in countries where labor unrest is more common than in the U.S.;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">differing payor reimbursement regimes, governmental payors or patient self-pay systems, and price controls;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">potential liability under the Foreign Corrupt Practices Act of 1977 or comparable foreign regulations;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">challenges enforcing our contractual and intellectual property rights, especially in those foreign countries that do not respect and protect intellectual property rights to the same extent as the U.S.;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the impact of public health epidemics on the global economy, such as the coronavirus currently impacting China and elsewhere; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">business interruptions resulting from geo-political actions, including war and terrorism.</font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These and other risks associated with international operations may materially adversely affect our ability to attain or maintain profitable operations.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We have formed, and may in the future form or seek, strategic alliances or enter into additional licensing arrangements in the future, and we may not realize the benefits of such alliances or licensing arrangements.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have formed, and may in the future form or seek, strategic alliances, create joint ventures or collaborations or enter into additional licensing arrangements with third parties that we believe will complement or augment our development and commercialization efforts with respect to our product candidates and any future product candidates that we may develop. For example, we entered into an agreement whereby Viracta granted to us exclusive world-wide rights to Viracta&#8217;s phase&#160;II drug candidate, VRx&#8209;3996, for use in combination with our platform of NK&#160;cell therapies. However, if Viracta fails to raise sufficient capital to complete their pivotal phase&#160;II trial, if their trial is unsuccessful, or if our future clinical trial of NK&#160;cell therapy in combination with VRx&#8209;3996 fails, the value of the Viracta license would be materially adversely affected.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any of these relationships may require us to incur non-recurring and other charges, increase our near and long-term expenditures, issue securities that dilute our existing stockholders or disrupt our management and business. In addition, we face significant competition in seeking appropriate strategic partners and the negotiation process is time-consuming and complex. Moreover, we may not be successful in our efforts to establish a strategic partnership or other alternative arrangements for our product candidates because they may be deemed to be at too early of a stage of development for collaborative effort and third parties may not view our product candidates as having the requisite potential to demonstrate safety and efficacy. If we license products or businesses, we may not be able to realize the benefit of such transactions if we are unable to successfully integrate them with our existing operations and company culture. We cannot be certain that, following a strategic transaction or license, we will achieve the revenue or specific net income that justifies such transaction. Any delays in entering into new strategic partnership agreements related to our product candidates could delay the development and commercialization of our product candidates in certain geographies for certain indications, which would harm our business prospects, financial condition and results of operations.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">91</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU83"></a><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our internal computer systems, or those used by our contractors or consultants, may fail or suffer security breaches.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our business model involves the storage and transmission of clinical trial and other data on our systems and on the systems of our consultants and contractors, and security breaches expose us to a risk of loss of this information, governmental fines and penalties, litigation and/or potential liability, in addition to negative publicity. Despite the implementation of security measures, our internal computer systems and those of our contractors and consultants are vulnerable to damage from computer viruses and unauthorized access. Our security measures and those of our contractors and consultants may also be breached due to employee error, malfeasance or otherwise. If such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our development programs and our business operations. For example, the loss of clinical trial data from completed, ongoing or future clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. Likewise, we rely on affiliated entities and third parties for research and development of our product candidates and to conduct clinical trials and may rely on third parties for the manufacture of our product candidates and similar events relating to their computer systems could have a material adverse effect on our business.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect that these risks and exposures related to our internal computer systems will remain high for the foreseeable future due to the rapidly evolving nature and sophistication of cyber threats to our internal computer systems. There can be no assurance that our efforts to implement adequate security measures will remain sufficient to protect the company against future cyber-attacks. To the extent that any disruption or security breach were to result in a loss of, or damage to, our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability, suffer damage to our reputation, the further development and commercialization of our product candidates could be delayed and our stock price could decline.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Future acquisitions and investments could disrupt our business and harm our financial condition and operating results.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our success may depend, in part, on our ability to expand our products and services. In some circumstances, we may determine to do so through the acquisition of complementary businesses and technologies rather than through, or in conjunction with, internal development. The identification of suitable acquisition candidates can be difficult, time-consuming and costly, and we may not be able to successfully complete identified acquisitions. The risks we face in connection with acquisitions include:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">diversion of management time and focus from operating our business to addressing acquisition integration challenges;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">retention of key employees from the acquired company;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">coordination of research and development functions;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">integration of the acquired company&#8217;s accounting, management information, human resources and other administrative systems;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">liability for activities of the acquired company before the acquisition, including intellectual property infringement claims, employee disputes, and alleged violations of laws; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">unanticipated write-offs or charges.</font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our failure to address these risks or other problems encountered in connection with our past or future acquisitions and investments could cause us to fail to realize the anticipated benefits of these acquisitions or investments, cause us to incur unanticipated liabilities, and harm our business generally. Future acquisitions could also result in dilutive issuances of our equity securities, the incurrence of debt, contingent liabilities, amortization expenses, incremental operating expenses or the write-off of goodwill, any of which could harm our financial condition or operating results.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Business disruptions could seriously harm our future revenue and financial condition and increase our costs and expenses.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our operations, and those of our contractors and consultants, could be subject to earthquakes, power shortages, telecommunications failures, water shortages, floods, hurricanes, typhoons, fires, extreme weather conditions, medical epidemics, acts of terrorism, acts of war and other natural or man-made disasters or business interruptions, for which we are predominantly self-insured. The occurrence of any of these business disruptions could seriously harm our operations and financial condition and increase our costs and expenses. We may rely on third-party manufacturers to produce and process our product candidates. Our ability to obtain clinical supplies of our product candidates could be disrupted if the operations of these suppliers are affected by a man-made or natural disaster, pandemics, epidemics, or other business interruption, including the recent novel strain of coronavirus&#160;(SARS&#8209;CoV&#8209;2) that originally surfaced in Wuhan, China in December&#160;2019. The extent to which COVID&#8209;19 impacts our business will depend on future developments, which are highly uncertain and cannot be predicted, including new information which may emerge concerning the severity of COVID&#8209;19 and the actions to contain SARS&#8209;CoV&#8209;2 or treat its impact, among others. If any disaster were to occur, our ability to operate our clinical trials could be seriously, or potentially completely, impaired. Our corporate headquarters are in California near major earthquake faults and fire zones. Our operations and financial condition could suffer in the event of a major earthquake, fire or other natural disaster.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">92</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU84"></a><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">A coronavirus pandemic is ongoing in many parts of the world and may result in significant disruptions to our clinical trials and/or supply chain which could have a material adverse effect on our business.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A coronavirus pandemic exists as of the filing of this report. As the pandemic is still evolving as of this time, much of its impact remains unknown, and it is impossible to predict the impact it may have on the development of our business.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The coronavirus pandemic may result in significant delays or disruptions in our clinical trials, which could affect or delay the regulatory approval process of our product candidates. If the patients involved with these clinical trials become infected with the coronavirus disease, we may have more adverse events and deaths in our clinical trials as a result. We may also face difficulties enrolling patients in our clinical trials if the patient populations that are eligible for our clinical trials are impacted by the coronavirus pandemic.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, if our clinical trial patients are unable to travel to our clinical trial sites as a result of quarantines or other restrictions resulting from the coronavirus pandemic, we may experience higher drop-out rates or delays in our clinical trials.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The severity of the coronavirus pandemic could also make access to our existing supply chain difficult or impossible by delaying the delivery of key raw materials used in our product candidates and therefore delay the delivery of such products for use in our clinical trials. Any of these results could materially impact our business and have an adverse effect on our business.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our employees, affiliates, independent contractors, clinical investigators, CROs, data safety and monitoring boards, consultants, commercial partners and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements, and insider trading.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are exposed to the risk of employee fraud, misconduct or other illegal activity by our employees, affiliates, independent contractors, clinical investigators, CROs, data safety and monitoring boards, consultants, commercial partners and vendors. Misconduct by these parties could include intentional, reckless and/or negligent conduct that fails to:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">comply with the laws of the FDA and other similar foreign regulatory bodies;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">provide true, complete and accurate information to the FDA and other similar foreign regulatory bodies;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">comply with manufacturing standards we have established;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">comply with healthcare fraud and abuse, privacy and security and other laws in the U.S. and similar foreign fraudulent misconduct laws;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">comply with federal securities laws regulating insider trading; or</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">report financial information or data accurately or to disclose unauthorized activities to us.</font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we obtain FDA approval of any of our product candidates and begin commercializing those products in the U.S., our potential exposure under such laws will increase significantly, and our costs associated with compliance with such laws are also likely to increase. These laws may impact, among other things, our current activities with principal investigators and research patients, as well as proposed and future sales, marketing and education programs. In particular, the promotion, sales and marketing of healthcare items and services, as well as certain business arrangements in the healthcare industry, are subject to extensive laws designed to prevent fraud, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, structuring and commission(s), certain customer incentive programs and other business arrangements generally. Activities subject to these laws also include the collection and/or use of information obtained in the course of patient recruitment for clinical trials. The healthcare laws that may affect our ability to operate include, but are not limited to:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the federal Anti-Kickback Statute, which prohibits, among other things, knowingly and willfully soliciting, receiving, offering or providing any remuneration (including any kickback, bribe, or rebate), directly or indirectly, overtly or covertly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual, or the purchase, lease, order or recommendation of any good, facility, item or service for which payment may be made, in whole or in part, under a federal healthcare program, such as the Medicare and Medicaid programs;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">federal civil and criminal false claims laws and civil monetary penalty laws, including the civil False Claims Act, which impose criminal and civil penalties against individuals or entities for, among other things, knowingly presenting, or causing to be presented, claims for payment or approval from the federal government including Medicare and Medicaid, that are false or fraudulent or knowingly making a false statement to improperly avoid, decrease or conceal an obligation to pay money to the federal government;</font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">93</a></p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><a name="_AEIOULastRenderedPageBreakAEIOU85"></a><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-family:Times New Roman;">the U.S. federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which created additional U.S. federal criminal statutes that prohibit, among other actions, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program or obtain, by means of false or fraudulent pretenses, representations, or promises, any of the money or property owned by, or under the custody or control of, any healthcare benefit program, regardless of the payor (e.g., public or private), and knowingly and willfully falsifying, concealing or covering up by any trick or device a material fact or making any materially false statements in connection with the delivery of, or payment for, healthcare benefits, items or services relating to healthcare matters;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, or HITECH, and their respective implementing regulations, which impose requirements, including mandatory contractual terms, on certain covered healthcare providers, health plans, and healthcare clearinghouses, as well as their respective business associates that perform services for them that involve the use, or disclosure of, individually identifiable health information, relating to the privacy, security and transmission of individually identifiable health information;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the U.S. federal Physician Payments Sunshine Act, created under the Patient Protection and Affordable Care Act, as amended by the Health Care Education Reconciliation Act, which we refer to collectively as ACA, and its implementing regulations, which require certain manufacturers of drugs, devices, biologicals and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program (with certain exceptions) to report annually to the U.S. Department of Health and Human Services, or HHS, information related to payments or other transfers of value made to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors) and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members by the 90th&#160;day of each subsequent calendar year, and disclosure of such information will be made by HHS on a publicly available website; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">federal consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm consumers.</font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, we are subject to state and foreign laws and regulations that are analogous to the healthcare laws and regulations described above, among others, some of which may be broader in scope and may apply regardless of the payor. Some state laws require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and relevant compliance guidance promulgated by the federal government; some state laws require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures; and some state and foreign laws govern the privacy and security of health information in ways that differ, and in certain cases are more stringent than, HIPAA, thus complicating compliance efforts.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have adopted a code of business conduct and ethics, but it is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent inappropriate conduct may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. Efforts to ensure that our business arrangements will comply with applicable healthcare laws may involve substantial costs. It is possible that governmental and enforcement authorities will conclude that our business practices do not comply with current or future statutes, regulations or case law interpreting applicable fraud and abuse or other healthcare laws and regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of civil, criminal and/or administrative penalties, damages, disgorgement, monetary fines, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, contractual damages, reputational harm, diminished profits and future earnings, and curtailment of our operations, any of which could adversely affect our ability to operate our business and our results of operations. Defending against any such actions can be costly, time-consuming, and may require significant financial and personnel resources. Therefore, even if we are successful in defending against any such actions that may be brought against us, our business may be impaired.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Competing generic medicinal products or biosimilars may be approved.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the European Union, or E.U., there exists a process for approval of generic biological medicinal products once patent protection and other forms of data and market exclusivity have expired. Arrangements for approval of biosimilar products exist in the U.S., as well. Other jurisdictions are considering adopting legislation that would allow the approval of generic biological medicinal products. If generic medicinal products are approved, competition from such products may substantially reduce sales of our products.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">94</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU86"></a><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Public opinion and scrutiny of cell-based immunotherapy approaches may impact public perception of our company and product candidates, or may adversely affect our ability to conduct our business and our business plans.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our platform utilizes a relatively novel technology involving the genetic modification of human cells and utilization of those modified cells in other individuals, and no natural killer cell-based immunotherapy has been approved to date. Public perception may be influenced by claims, such as claims that cell-based immunotherapy is unsafe, unethical, or immoral and, consequently, our approach may not gain the acceptance of the public or the medical community. Negative public reaction to cell-based immunotherapy in general could result in greater government regulation and stricter labeling requirements of cell-based immunotherapy products, including any of our product candidates, and could cause a decrease in the demand for any products we may develop. Adverse public attitudes may adversely impact our ability to enroll clinical trials. Moreover, our success will depend upon physicians specializing in the treatment of those diseases that our product candidates target prescribing, and their patients being willing to receive, treatments that involve the use of our product candidates in lieu of, or in addition to, existing treatments they are already familiar with and for which greater clinical data may be available. More restrictive government regulations or negative public opinion could have an adverse effect on our business or financial condition and may delay or impair the development and commercialization of our product candidates or demand for any products we may develop. Adverse events in our clinical trials, even if not ultimately attributable to our product candidates, and the resulting publicity could result in increased governmental regulation, unfavorable public perception, potential regulatory delays in the testing or approval of our potential product candidates, stricter labeling requirements for those product candidates that are approved and a decrease in demand for any such product candidates.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our business may be materially affected by changes to fiscal and tax policies. Negative or unexpected tax consequences could adversely affect our results of operations.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Tax Cuts and Jobs Act of 2017 was approved by Congress on December&#160;20, 2017. This legislation significantly changed the U.S. Internal Revenue Code. Such changes include a reduction in the corporate tax rate and limitations on certain corporate deductions and credits, among other changes. Certain of these changes could have a negative impact on our business. In addition, adverse changes in financial outlook of our operations or changes in tax law could lead to changes in our valuation allowances against deferred tax assets on our consolidated balance sheets, which could materially affect our results of operations.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risks Relating to Government Regulation</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We may fail to obtain or may experience delays in obtaining regulatory approval to market our aNK platform product candidates, which will significantly harm our business.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We do not have the necessary approval to market or sell aNK platform products in the U.S. or any foreign market. Before marketing aNK platform product candidates, we must successfully complete extensive preclinical studies and clinical trials and rigorous regulatory approval procedures. We cannot offer assurances that we will apply for or obtain the necessary regulatory approval to commercialize aNK platform product candidates in a timely manner, or at all.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Conducting clinical trials is uncertain and expensive and often takes many years to complete. The results from preclinical testing and early clinical trials are often not predictive of results obtained in later clinical trials. In conducting clinical trials, we may fail to establish the effectiveness of haNK, taNK and t&#8209;haNK cells for the targeted indication or we may discover unforeseen side effects. Moreover, clinical trials may require the enrollment of large numbers of patients, and suitable patients may be difficult to identify and recruit. Clinical trials are also often subject to unanticipated delays. In addition, haNK, taNK and t&#8209;haNK cells are produced in small-scale cell culture systems and we may be unable to adapt the production method to large-scale production systems. In addition, patients participating in the trials may die before completion of the clinical trial or suffer adverse medical effects unrelated to treatment with haNK, taNK and t&#8209;haNK cells. This could delay or lead to termination of our clinical trials. A number of companies in the biotechnology industry have suffered significant setbacks in every stage of clinical trials, even in advanced clinical trials after positive results in earlier clinical trials.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To date, the FDA has approved only a few cell-based therapies for commercialization. The processes and requirements imposed by the FDA may cause delays and additional costs in obtaining regulatory approvals for our product candidates. Because our aNK platform product is novel, and cell-based therapies are relatively new, regulatory agencies may lack experience in evaluating product candidates like our aNK platform products. This inexperience may lengthen the regulatory review process, increase our development costs and delay or prevent commercialization of our aNK platform products. In addition, the following factors may impede or delay our ability to obtain timely regulatory approvals, if at all:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">potential delays in or failure to reach agreement on acceptable terms with prospective CROs and clinical sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">our failure to obtain sufficient enrollment in our clinical trials or participants may fail to complete our clinical trials;</font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">95</a></p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><a name="_AEIOULastRenderedPageBreakAEIOU87"></a><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-family:Times New Roman;">clinical trials of our product candidates may produce negative or inconclusive results, and we may decide, or regulators may require us, to conduct additional clinical trials or abandon product development programs;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">regulators may require us to perform additional or unanticipated clinical trials to obtain approval or we may be subject to additional post-marketing testing requirements to maintain regulatory approval;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">regulators may revise the requirements for approving our product candidates, or such requirements may not be as we anticipate;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the cost of clinical trials of our product candidates may be greater than we anticipate, and we may need to delay or suspend one or more trials until we complete additional financing transactions or otherwise receive adequate funding;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the supply or quality of our product candidates or other materials necessary to conduct clinical trials of our product candidates may be insufficient or inadequate or may be delayed;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">our product candidates may have undesirable side effects or other unexpected characteristics, causing us or our investigators, regulators or institutional review boards to suspend or terminate trials;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">regulatory authorities may suspend or withdraw their approval of a product or impose restrictions on its distribution;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">our limited experience in filing and pursuing Biologics License Applications, or BLAs, necessary to gain regulatory approvals related to genetically modified cancer cell line therapies;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">any failure to develop substantial evidence of clinical efficacy and safety, and to develop quality standards and manufacturing processes to demonstrate consistent safety, purity, identity, and potency standards;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">a decision by us, institutional review boards, or regulators to suspend or terminate our clinical trials for various reasons, including noncompliance with regulatory requirements or a finding that the participants are being exposed to unacceptable health risks;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">regulatory inspections of our clinical trials, clinical trial sites or manufacturing facilities, which may, among other things, require us to undertake corrective action or suspend or terminate our clinical trials if regulators find us not to be in compliance with applicable regulatory requirements;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">our ability to produce sufficient quantities of haNK, taNK or t&#8209;haNK cells to complete our clinical trials;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">varying interpretations of the data generated from our clinical trials; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">changes in governmental regulations or administrative action.</font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any delays in, or termination of, our clinical trials could materially and adversely affect our development and collaboration timelines, which may cause our stock price to decline. If we do not complete clinical trials for haNK, taNK and t&#8209;haNK cells and seek and obtain regulatory approvals, we may not be able to recover any of the substantial costs we have invested in the development of haNK, taNK and t&#8209;haNK cells.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Even if we obtain regulatory approvals for aNK related platform products, those approvals and ongoing regulation of our products may limit how we manufacture and market our products, which could prevent us from realizing the full benefit of our efforts.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we obtain regulatory approvals, our aNK platform products, and our manufacturing facilities will be subject to continual regulatory review, including periodic unannounced inspections, by the FDA and other U.S. and foreign regulatory authorities. In addition, regulatory authorities may impose significant restrictions on the indicated uses or impose ongoing requirements for potentially costly post-approval studies. aNK platform product candidates would also be subject to ongoing FDA requirements governing the labeling, packaging, storage, advertising, promotion, recordkeeping and submission of safety and other post-market information. These and other factors may significantly restrict our ability to successfully commercialize haNK, taNK and t&#8209;haNK cell therapies.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Manufacturers of biopharmaceutical products and their facilities, vendors and suppliers are subject to continual review and periodic unannounced inspections by the FDA and other regulatory authorities for compliance with cGMP regulations, which include requirements relating to quality control and quality assurance, as well as to the corresponding maintenance of records and documentation. Furthermore, our manufacturing facilities must be approved by regulatory agencies before these facilities can be used to manufacture aNK platform products, and they will also be subject to additional regulatory inspections. Any material changes we may make to our manufacturing process or to the components used in our products may require additional prior approval by the FDA and state or foreign regulatory authorities. Failure to comply with FDA or other applicable regulatory requirements may result in criminal prosecution, civil penalties, recall or seizure of products, partial or total suspension of production or withdrawal of a product from the market.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">96</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU88"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We must also report adverse events that occur when our products are used. The discovery of previously unknown problems with aNK, haNK, taNK and t</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8209;haNK cells and therapies or our manufacturing facilities may result in restrictions or sanctions on our products or manufacturing facilities, including withdrawal of our products from the market or suspension of manufacturing. Regulatory agencies may also require us to reformulate our products, conduct additional clinical trials, make changes in the labeling of our product or obtain</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> further </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">approvals. This may </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">harm our business and results of operations or </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">cause our reputation in the market place to suffer or subject us to lawsuits, including class action suits.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, if one or more of our product candidates receives marketing approval, and we or others later identify undesirable side effects or adverse events caused by such products, a number of potentially significant negative consequences could result, including but not limited to:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">regulatory authorities may withdraw approvals of such product or require additional warnings on the label;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">we may be required to change the way the product is administered or conduct additional clinical trials or post-approval studies;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">we may be required to create a Risk Evaluation and Mitigation Strategy (REMS) plan, which could include a medication guide outlining the risks of such side effects for distribution to patients, a communication plan for healthcare providers, or other elements to assure safe use;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">we could be sued and held liable for harm caused to patients; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">our reputation may suffer.</font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any of these events could prevent us from achieving or maintaining market acceptance of the particular product candidate, if approved, and could significantly harm our business, results of operations, and prospects.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, if we, our product candidates or the manufacturing facilities for our product candidates fail to comply with applicable regulatory requirements, a regulatory agency may:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">issue warning letters that can produce adverse publicity;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">impose civil or criminal penalties;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">suspend regulatory approval;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">suspend any ongoing clinical trials;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">refuse to approve pending applications or supplements to applications filed by us;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">impose restrictions on operations, including costly new manufacturing requirements;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">seize or detain products or request us to initiate a product recall; or</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">pursue and obtain an injunction.</font></p></td></tr></table></div>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not mean that we will be successful in obtaining regulatory approval of our product candidates in other jurisdictions.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not guarantee that we will be able to obtain or maintain regulatory approval in any other jurisdiction, while a failure or delay in obtaining regulatory approval in one jurisdiction may have a negative effect on the regulatory approval process in others. For example, even if the FDA grants marketing approval of a product candidate, comparable regulatory authorities in foreign jurisdictions must also approve the product, manufacturing, and in many cases reimbursement of the product candidate in those countries. Approval procedures vary among jurisdictions and can involve requirements and administrative review periods different from, and greater than, those in the U.S., including additional preclinical studies or clinical trials as clinical studies conducted in one jurisdiction may not be accepted by regulatory authorities in other jurisdictions. In some cases, the price that we intend to charge for our products is also subject to approval by regulatory authorities.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may also submit marketing applications in other countries. Regulatory authorities in jurisdictions outside of the U.S. have requirements for approval of product candidates with which we must comply prior to marketing in those jurisdictions. Obtaining foreign regulatory approvals and compliance with foreign regulatory requirements could result in significant delays, difficulties and costs for us and could delay or prevent the introduction of our products in certain countries. If we fail to comply with the regulatory requirements in international markets and/or receive applicable marketing approvals, our target market will be reduced and our ability to realize the full market potential of our product candidates will be harmed.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">97</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU89"></a><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We may seek orphan drug status or breakthrough therapy designation for one or more of our product candidates, but even if either is granted, we may be unable to maintain any benefits associated with breakthrough therapy designation or orphan drug status, including market exclusivity.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Orphan Drug Act, the FDA may grant orphan designation to a drug or biologic intended to treat a rare disease or condition or for which there is no reasonable expectation that the cost of developing and making available in the U.S. a drug or biologic for a disease or condition will be recovered from sales in the U.S. for that drug or biologic. If a product that has orphan drug designation subsequently receives the first FDA approval for the disease for which it has such designation, the product is entitled to orphan product exclusivity, which means that the FDA may not approve any other applications, including a full BLA to market the same drug or biologic for the same indication for seven&#160;years, except in limited circumstances, such as a showing of clinical superiority to the product with orphan drug exclusivity. In 2012, the FDA established a Breakthrough Therapy Designation, which is intended to expedite the development and review of products that treat serious or life-threatening conditions.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may seek orphan drug status for one or more of our product candidates, but exclusive marketing rights in the U.S. may be lost if we seek approval for an indication broader than the orphan designated indication and may be lost if the FDA later determines that the request for designation was materially defective or if we are unable to assure sufficient quantities of the product to meet the needs of patients with the rare disease or condition. In addition, we may seek breakthrough therapy designation for one or more of our product candidates, but there can be no assurance that we will receive such designation.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We will need to obtain FDA approval of any proposed product brand names, and any failure or delay associated with such approval may adversely impact our business.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A biopharmaceutical product cannot be marketed in the U.S. or other countries until we have completed rigorous and extensive regulatory review processes, including review and approval of a brand name. Any brand names we intend to use for our product candidates will require approval from the FDA regardless of whether we have secured a formal trademark registration from the U.S. Patent and Trademark Office, or the USPTO. The FDA may object to a product brand name if they believe the name creates potential for confusion or inappropriately implies medical claims. If the FDA objects to any of our proposed product brand names, we may be required to adopt an alternative brand name for our product candidates. If we adopt an alternative brand name, we would lose the benefit of our existing trademark applications for such product candidate and may be required to expend significant additional resources in an effort to identify a suitable product brand name that would qualify under applicable trademark laws, not infringe the existing rights of third parties and be acceptable to the FDA. We may be unable to build a successful brand identity for a new trademark in a timely manner or at all, which would limit our ability to commercialize our product candidates.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Coverage and reimbursement decisions by third-party payors may have an adverse effect on pricing and market acceptance.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There is significant uncertainty related to the third-party coverage and reimbursement of newly approved drugs. Patients who are provided medical treatment for their conditions generally rely on third-party payors to reimburse all or part of the costs associated with their treatment. Therefore, market acceptance and sales of our products, if approved, in both domestic and international markets will depend significantly on the availability of adequate coverage and reimbursement from third party and/or government payors for any of our products and may be affected by existing and future healthcare reform measures. Government authorities and third-party payors, such as private health insurers and health maintenance organizations, decide which drugs they will cover and establish approved lists, known as formularies, and establish payment levels for such drugs. Formularies may not include all FDA-approved drugs for a particular indication. Private payors often follow Medicare coverage policy and payment limitations in setting their own payment rates. Any reduction in payment under Medicare Part&#160;D may result in a similar reduction in payments from non-governmental payors. We cannot be certain that coverage and adequate reimbursement will be available for any of our products, if approved, or that such coverage and reimbursement will be authorized in a timely fashion. In addition, we cannot be certain that reimbursement policies will not reduce the demand for, or the price paid for, any of our products, if approved. If reimbursement is not available or is available on a limited basis for any of our products, if approved, we may not be able to successfully commercialize any such products.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reimbursement by a third party or government payor may depend upon a number of factors, including, without limitation, the third-party or government payor&#8217;s determination that use of a product is:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">a covered benefit under its health plan;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">safe, effective and medically necessary;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">appropriate for the specific patient;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">cost-effective; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">neither experimental nor investigational.</font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">98</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU90"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Obtaining coverage and reimbursement approval for a product from a government or other third-party payor is a time consuming and costly process that could require us to provide supporting scientific, clinical and cost-effectiveness data for the use of our products to the payor. We may not be able to provide data sufficient to gain acceptance with respect to coverage and reimbursement or to have pricing set at a satisfactory level. If reimbursement of our products, if any, is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels such as may result where alternative or generic treatments are available, we may be unable to achieve or sustain profitability.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Assuming we obtain coverage for a given product, the resulting reimbursement payment rates might not be adequate or may require co-payments that patients find unacceptably high. Patients are unlikely to use our products unless coverage is provided and reimbursement is adequate to cover a significant portion of the cost of our products.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the U.S., third-party payors include federal and state healthcare programs, government authorities, private managed care providers, private health insurers, and other organizations. No uniform policy of coverage and reimbursement for products exists among third-party payors, and third-party payors are increasingly challenging the price, examining the medical necessity, and reviewing the cost-effectiveness of medical drug products and medical services, in addition to questioning their safety and efficacy. Therefore, coverage and reimbursement for products can differ significantly from payor to payor. As a result, the coverage determination process is often a time-consuming and costly process that will require us to provide scientific and clinical support for the use of our products to each payor separately, with no assurance that coverage and adequate reimbursement will be obtained. We or our collaborators may need to conduct expensive pharmaco-economic studies in order to demonstrate the medical necessity and cost-effectiveness of our products, in addition to the costs required to obtain the FDA approvals.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In some foreign countries, particularly in Europe, the pricing of prescription pharmaceuticals is subject to governmental control. In these countries, pricing negotiations with governmental authorities can take considerable time after the receipt of marketing approval for a product. To obtain reimbursement or pricing approval in some countries, we may be required to conduct additional clinical trials that compare the cost-effectiveness of our products to other available therapies. If reimbursement of any of our products, if approved, is unavailable or limited in scope or amount in a particular country, or if pricing is set at unsatisfactory levels, we may be unable to achieve or sustain profitability of our products in such country.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Recent legislative and regulatory activity may exert downward pressure on potential pricing and reimbursement for our products, if approved, that could materially affect the opportunity to commercialize.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The U.S. and several other jurisdictions are considering, or have already enacted, a number of legislative and regulatory proposals to change the healthcare system in ways that could affect our ability to sell any of our products profitably, if approved. Among policy-makers and payors in the U.S. and elsewhere, there is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving quality and/or expanding access to healthcare. In the U.S., the pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by major legislative initiatives. There have been, and likely will continue to be, legislative and regulatory proposals at the federal and state levels directed at broadening the availability of healthcare and containing or lowering the cost of healthcare. We cannot predict the initiatives that may be adopted in the future. The continuing efforts of the government, insurance companies, managed care organizations and other payors of healthcare services to contain or reduce costs of healthcare may adversely affect:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the demand for any of our products, if approved;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">our ability to set a price that we believe is fair for any of our products, if approved;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">our ability to generate revenues and achieve or maintain profitability;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the level of taxes that we are required to pay; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the availability of capital.</font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March&#160;2010, ACA became law in the U.S. The goal of ACA is to reduce the cost of healthcare, broaden access to health insurance, constrain healthcare spending, enhance remedies against fraud and abuse, add transparency requirements for the healthcare and health insurance industries, impose taxes and fees on the health industry, impose additional health policy reforms, and substantially change the way healthcare is financed by both governmental and private insurers. While we cannot predict what impact on federal reimbursement policies this legislation will have in general or on our business specifically, ACA may result in downward pressure on pharmaceutical reimbursement, which could negatively affect market acceptance of any of our products, if they are approved. Provisions of ACA relevant to the pharmaceutical industry include the following:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">an annual, nondeductible fee on any entity that manufactures or imports certain branded prescription drugs and biologic agents, apportioned among these entities according to their market share in certain government healthcare programs, not including orphan drug sales;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">an increase in the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program to 23.1% and 13% of the average manufacturer price for most branded and generic drugs, respectively;</font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">99</a></p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><a name="_AEIOULastRenderedPageBreakAEIOU91"></a><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-family:Times New Roman;">a new Medicare Part&#160;D coverage gap discount program, in which manufacturers must agree to offer 50% point-of-sale discounts on negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer&#8217;s outpatient drugs to be covered under Medicare Part&#160;D;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">extension of manufacturers&#8217; Medicaid rebate liability to covered drugs dispensed to individuals who are enrolled in Medicaid managed care organizations;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">expansion of eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid coverage to additional individuals and by adding new mandatory eligibility categories for certain individuals with income at or below 133% of the Federal Poverty Level, thereby potentially increasing manufacturers&#8217; Medicaid rebate liability;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">expansion of the entities eligible for discounts under the Public Health Service pharmaceutical pricing program;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="letter-spacing:-0.1pt;font-family:Times New Roman;">new requirements for certain manufacturers of drugs, devices, biologics, and medical supplies for which payment is available under Medicare, Medicaid, or the Children&#8217;s Health Insurance Program, with specific exceptions to report annually certain financial arrangements with physicians and teaching hospitals, as defined in ACA and its implementing regulations, including reporting any payment or &#8220;transfer of value&#8221; provided to physicians and teaching hospitals and any ownership and investment interests held by physicians and their immediate family members during the preceding calendar year;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">expansion of healthcare fraud and abuse laws, including the U.S. federal False Claims Act and the U.S. federal Anti-Kickback Statute, new government investigative powers and enhanced penalties for noncompliance;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in and conduct comparative clinical effectiveness research, along with funding for such research; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted, or injected.</font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The ACA has been modified and amended recently, including the elimination of the individual mandate that individuals purchase healthcare insurance. Furthermore, the current presidential administration and Congress may continue to attempt broad sweeping changes to the current health care laws. We face uncertainties that might result from modification or repeal of any of the provisions of the ACA, including as a result of current and future executive orders and legislative actions. The impact of those changes on us and potential effect on the pharmaceutical and biotechnology industry as a whole is currently unknown. However, any changes to the ACA are likely to have an impact on our results of operations, and may have a material adverse effect on our results of operations. We cannot predict what other healthcare programs and regulations will ultimately be implemented at the federal or state level or the effect of any future legislation or regulation in the U.S. may have on our business.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We are subject to governmental export and import controls that could impair our ability to compete in international markets due to licensing requirements and subject us to liability if we are not in compliance with applicable laws. Compliance with these legal requirements could limit our ability to compete in foreign markets and subject us to liability if we violate them.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our products and solutions are subject to export control and import laws and regulations, including the U.S. Export Administration Regulations, U.S. Customs regulations, and various economic and trade sanctions regulations administered by the U.S. Treasury Department&#8217;s Office of Foreign Assets Controls. Exports of our products and solutions outside of the U.S. must be made in compliance with these laws and regulations. If we fail to comply with these laws and regulations, we and certain of our employees could be subject to substantial civil or criminal penalties, including the possible loss of export or import privileges; fines, which may be imposed on us and responsible employees or managers; and, in extreme cases, the incarceration of responsible employees or managers.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, changes in our products or solutions or changes in applicable export or import laws and regulations may create delays in the introduction, provision, or sale of our products and solutions in international markets, prevent customers from using our products and solutions or, in some cases, prevent the export or import of our products and solutions to certain countries, governments or persons altogether. Any limitation on our ability to export, provide, or sell our products and solutions could adversely affect our business, financial condition and results of operations.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU92"></a><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We are subject to U.S. and foreign anti-corruption and anti-money laundering laws with respect to our operations and non-compliance with such laws can subject us to criminal and/or civil liability and harm our business.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are subject to the U.S. Foreign Corrupt Practices Act of 1977, as amended, or the FCPA, the U.S. domestic bribery statute contained in 18&#160;U.S.C.&#160;&#167;201, the U.S. Travel Act, the USA PATRIOT Act, and possibly other state and national anti-bribery and anti-money laundering laws in countries in which we conduct activities. Anti-corruption laws are interpreted broadly and prohibit companies and their employees, agents, third-party intermediaries, joint venture partners and collaborators from authorizing, promising, offering, or providing, directly or indirectly, improper payments or benefits to recipients in the public or private sector. We have used contract research organizations abroad for clinical trials. In addition, we may engage third party intermediaries to sell our products and solutions abroad once we enter a commercialization phase for our product candidates and/or to obtain necessary permits, licenses, and other regulatory approvals. We or our third-party intermediaries may have direct or indirect interactions with officials and employees of government agencies or state-owned or affiliated entities. We can be held liable for the corrupt or other illegal activities of these third-party intermediaries, our employees, representatives, contractors, partners, and agents, even if we do not explicitly authorize or have actual knowledge of such activities.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We adopted an anti-corruption policy in connection with the consummation of the IPO of our common stock in July&#160;2015. The anti-corruption policy mandates compliance with the FCPA and other anti-corruption laws applicable to our business throughout the world. However, there can be no assurance that our employees and third party intermediaries will comply with this policy or such anti-corruption laws. Noncompliance with anti-corruption and anti-money laundering laws could subject us to whistleblower complaints, investigations, sanctions, settlements, prosecution, other investigations, or other enforcement actions. If such actions are launched, or governmental or other sanctions are imposed, or if we do not prevail in any possible civil or criminal litigation, our business, results of operations and financial condition could be materially harmed. In addition, responding to any action will likely result in a materially significant diversion of management&#8217;s attention and resources and significant defense and compliance costs and other professional fees. In certain cases, enforcement authorities may even cause us to appoint an independent compliance monitor, which can result in added costs and administrative burdens.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Changes in funding for the FDA, the SEC and other government agencies could hinder their ability to hire and retain key leadership and other personnel, prevent new products and services from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal functions on which the operation of our business may rely, which could negatively impact our business.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept payment of user fees, and statutory, regulatory, and policy changes. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of the FDA, SEC and other government agencies on which our operations may rely is inherently fluid and unpredictable.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Disruptions at the FDA and other agencies may also slow the time necessary for new drugs to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, over the last several years, including beginning on December&#160;22, 2018, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA and the SEC, have had to furlough critical FDA, SEC and other government employees and stop critical activities. If a prolonged government shutdown occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business. Further, future government shutdowns could potentially impact our ability to access the public markets and obtain necessary capital in order to properly capitalize and continue our operations.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We may be, or may become, subject to data protection laws and regulations, and our failure to comply with such laws and regulations could lead to government enforcement actions and significant penalties against us, and adversely impact our operating results.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The E.U. has adopted data protection laws and regulations which may apply to us in certain circumstances, or in the future. These laws, which impose significant compliance obligations, are commonly known as the General Data Protection Regulation, or GDPR. The GDPR, which is wide-ranging in scope and applicability, imposes several requirements relating to the consent of the individuals to whom the personal data relates, the information provided to the individuals, the security and confidentiality of the personal data, data breach notification and the use of third party processors in connection with the processing of personal data, including clinical trials. The GDPR also imposes strict rules on the transfer of personal data out of the E.U. to the U.S., provides an enforcement authority, and imposes large penalties for noncompliance, including the potential for fines of up to &#8364;20&#160;million or 4% of the annual global revenues of the noncompliant company, whichever is greater. Implementation of the GDPR, as applicable to us, will increase our responsibility and liability in relation to personal data that we process, including in clinical trials, and we may in the future be required to put in place additional mechanisms to ensure compliance with the GDPR, which could divert management&#8217;s attention and increase our cost of doing business. In addition, other new regulation or legislative actions regarding data privacy and security (together with applicable industry standards) may increase our costs of doing business. In this regard, we expect that there will continue to be new proposed laws, regulations and industry standards relating to privacy and data protection in the U.S., the E.U. and other jurisdictions, and we cannot determine the impact such future laws, regulations and standards may have on our business.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU93"></a><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risks Relating to Our Intellectual Property</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If our efforts to protect the intellectual property related to our product candidates are not adequate, we may not be able to compete effectively in our market.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We rely upon a combination of patents, trade secret protection and contractual agreements, including confidentiality agreements to protect the intellectual property related to our product candidates and technology. Any disclosure to or misappropriation by third parties of our confidential proprietary information could enable competitors to quickly duplicate or surpass our technological achievements, eroding our competitive position in the market. We believe that we have worldwide commercial rights to the NK&#8209;92 cell line and we believe that we control commercial use of our haNK, taNK and t&#8209;haNK cells in key territories. We have developed and in-licensed numerous patents and patent applications and we possess substantial know-how and trade secrets relating to the development and commercialization of natural killer cell-based immunotherapy product candidates, including related manufacturing processes and technology. Our owned and licensed patent portfolio consists of patents and pending patent applications in the U.S. disclosing subject matter directed to certain of our proprietary technology, inventions, and improvements and our most advanced product candidates, as well as licensed and owned patents and pending applications in jurisdictions outside of the U.S., that, in many cases, are counterparts to the foregoing U.S. patents and patent applications. We believe we have intellectual property rights that are necessary to commercialize haNK, taNK and t&#8209;haNK cells. However, our patent applications may not result in issued patents, and, even if issued, the patents may be challenged and invalidated. Moreover, our patents and patent applications may not be sufficiently broad to prevent others from practicing our technologies or developing competing products. We also face the risk that others may independently develop similar or alternative technologies or may design around our proprietary property.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The patent application process, also known as patent prosecution, is expensive and time-consuming, and we and our current or future licensors and licensees may not be able to prepare, file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. It is also possible that we or our current licensors, or any future licensors or licensees, will fail to identify patentable aspects of inventions made in the course of development and commercialization activities before it is too late to obtain patent protection on them. Therefore, these and any of our patents and applications may not be prosecuted and enforced in a manner consistent with the best interests of our business. Defects of form in the preparation or filing of our patents or patent applications may exist, or may arise in the future, for example with respect to proper priority claims, inventorship, etc. If we or our current licensors, or any future licensors or licensees, fail to establish, maintain or protect such patents and other intellectual property rights, such rights may be reduced or eliminated. If our current licensors, or any future licensors or licensees, are not fully cooperative or disagree with us as to the prosecution, maintenance or enforcement of any patent rights, such patent rights could be compromised. If there are material defects in the form or preparation of our patents or patent applications, such patents or applications may be invalid and unenforceable. Any of these outcomes could impair our ability to prevent competition from third parties, which may have an adverse impact on our business.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The strength of patents in the biopharmaceutical field involves complex legal and scientific questions and can be uncertain. This uncertainty includes changes to the patent laws through either legislative action to change statutory patent law or court action that may reinterpret existing law or rules in ways affecting the scope or validity of issued patents. The patent applications that we own or in-license may fail to result in issued patents in the U.S. or foreign countries with claims that cover our product candidates. Even if patents do successfully issue from the patent applications that we own or in-license, third parties may challenge the validity, enforceability or scope of such patents, which may result in such patents being narrowed, invalidated or held unenforceable.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any successful challenge to our patents could deprive us of exclusive rights necessary for the successful commercialization of our product candidates. Furthermore, even if they are unchallenged, our patents may not adequately protect our product candidates, provide exclusivity for our product candidates, or prevent others from designing around our claims. If the breadth or strength of protection provided by the patents we hold or pursue with respect to our product candidates is challenged, it could dissuade companies from collaborating with us to develop, or threaten our ability to commercialize our product candidates.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Patents have a limited lifespan. In the U.S., the natural expiration of a patent is generally 20&#160;years after its earliest effective non-provisional filing date. Various extensions may be available; however, the life of a patent, and the protection it affords, is limited. Without patent protection for our product candidates, we may be open to competition from generic versions of our product candidates. Further, if we encounter delays in our development efforts, including our clinical trials, the period of time during which we could market our product candidates under patent protection would be reduced.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">102</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU94"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to the protection afforded by patents, we also rely on trade secret protection to protect proprietary know-how that may not be patentable or that we elect not to patent, processes for which patents may be difficult to obtain or enforce, and any other elements of our product candidates, and our product development processes (such as a manufacturing and formulation technologies) that involve proprietary know-how, information or technology that is not covered by patents. However, trade secrets can be difficult to protect. If the steps taken to maintain our trade secrets are deemed inadequate, we may have insufficient recourse against third parties for misappropriating any trade secrets. Misappropriation or unauthorized disclosure of our trade secrets could significantly affect our competitive position and may have a material adverse effect on our business. Furthermore, trade secret protection does not prevent competitors from independently developing substantially equivalent information and techniques and we cannot guarantee that our competitors will not independently develop substantially equivalent information and techniques. The FDA, as part of its Transparency Initiative, is currently considering whether to make additional information publicly available on a routine basis, including information that we may consider to be trade secrets or other proprietary information, and it is not clear at the present time how the FDA&#8217;s disclosure policies may change in the future, if at all.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In an effort to protect our trade secrets and other confidential information, we require our employees, consultants, advisors, and any other third parties that have access to our proprietary know-how, information or technology, for example, third parties involved in the formulation and manufacture of our product candidates, and third parties involved in our clinical trials to execute confidentiality agreements upon the commencement of their relationships with us. These agreements require that all confidential information developed by the individual or made known to the individual by us during the course of the individual&#8217;s relationship with us be kept confidential and not disclosed to third parties. However, we cannot be certain that our trade secrets and other confidential proprietary information will not be disclosed despite having such confidentiality agreements. Adequate remedies may not exist in the event of unauthorized use or disclosure of our trade secrets. In addition, in some situations, these confidentiality agreements may conflict with, or be subject to, the rights of third parties with whom our employees, consultants, or advisors have previous employment or consulting relationships. To the extent that our employees, consultants or contractors use any intellectual property owned by third parties in their work for us, disputes may arise as to the rights in any related or resulting know-how and inventions. If we are unable to prevent unauthorized material disclosure of our trade secrets to third parties, we may not be able to establish or maintain a competitive advantage in our market, which could materially adversely affect our business, operating results and financial condition.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Changes in U.S. patent law could diminish the value of patents in general, thereby impairing our ability to protect our products.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As is the case with other biopharmaceutical companies, our success is heavily dependent on intellectual property, particularly on obtaining and enforcing patents. Obtaining and enforcing patents in the pharmaceutical industry involves both technological and legal complexity, and therefore, is costly, time-consuming and inherently uncertain. In addition, the U.S. had previously enacted and implemented wide-ranging patent reform legislation (e.g., the Leahy-Smith America Invents Act in September 2011) and are currently considering additional legislation that may materially impact our ability to obtain or enforce our patents. Further, recent U.S. Supreme Court rulings and recent decisions from the United States Court of Appeals for the Federal Circuit have either narrowed the scope of patent protection available in certain circumstances or weakened the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, changes to U.S. patent laws provide additional procedures for third parties to challenge the validity of issued patents based on patent applications filed after March&#160;15, 2013. If the breadth or strength of protection provided by the patents and patent applications we hold or pursue with respect to our current or future product candidates is challenged, then it could threaten our ability to commercialize our current or future product candidates and could threaten our ability to prevent competitive products from being marketed. Further, if we encounter delays in our clinical trials, the period of time during which we could market our current or future product candidates under patent protection would be reduced. Since U.S. patent applications are confidential for a period of time after filing, we cannot be certain that we were the first to either&#160;(i)&#160;file any patent application related to our product candidates, or (ii)&#160;invent any of the inventions claimed in our patents or patent applications. Furthermore, for applications filed before March&#160;16, 2013, or patents issuing from such applications, an interference proceeding can be provoked by a third party or instituted by the U.S. Patent and Trademark Office, or USPTO, to determine who was the first to invent any of the subject matter covered by the patent claims of our applications and patents. As of March&#160;16, 2013, the U.S. transitioned to a &#8220;first-to-file&#8221; system for deciding which party should be granted a patent when two or more patent applications are filed by different parties claiming the same invention. A third party that files a patent application with the USPTO before us could, therefore, be awarded a patent covering an invention of ours even if we had made the invention before it was made by the third party. The change to &#8220;first-to-file&#8221; from &#8220;first-to-invent&#8221; is one of the changes to the U.S. patent laws resulting from the Leahy-Smith America Invents Act, or the Leahy-Smith Act, signed into law on September&#160;16, 2011. </p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">103</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU95"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Among some of the other significant changes to the patent laws are changes that limit where a patentee may file a patent infringement suit and provide opportunities for third parties to challenge any issued patent in the USPTO. This applies to all of our U.S. patents, even those issued before March</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16, 2013. Because of a lower evidentiary standard in USPTO proceedings compared to the evidentiary standard in U.S. federal court necessary to invalidate a patent claim, a third party could potentially provide evidence in a USPTO proceeding sufficient for the USPTO to hold a claim invalid even though the same evidence would be insufficient to invalidate the claim if first presented in a district court action. Accordingly, a third party may attempt to use the USPTO procedures to invalidate our patent claims that would not have been invalidated if first challenged by the third party as a defendant in a district court action. It is not yet clear what, if any, impact the Leahy-Smith Act will have on the operation of our business. However, the Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could have a material adverse effect on our b</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">usiness and financial condition.</font></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We may not be able to protect our intellectual property rights throughout the world.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We strive to control cell line distribution, as well as limit commercial use through licenses and material transfer agreements with third parties in addition to its patents and patent applications. However, a company may illicitly obtain our cells or create their own modified variants and attempt to commercialize them in foreign countries where we do not have any patents or patent applications where legal recourse may be limited. For example, we believe that certain companies, including at least one in China, may be using our NK&#8209;92 cell line without our permission. This may have a significant commercial impact on our foreign business operations.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Filing, prosecuting and defending patents on our product candidates in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the U.S. can be less extensive than those in the U.S. The requirements for patentability may differ in certain countries, particularly developing countries. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the U.S. and in some cases, may even force us to grant a compulsory license to competitors or other third parties. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the U.S., or from selling or important products made using our inventions in and into the U.S. or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and further, may export otherwise infringing products to territories where we have patent protection, but enforcement on infringing activities is inadequate or not as strong as that in the U.S. These products may compete with our products, and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Patents granted by the European Patent Office may be opposed by any person within nine months from the publication of their grant and, in addition, may be challenged before national courts at any time. Furthermore, even if they are unchallenged, our patents and patent applications may not adequately protect our intellectual property or prevent others from designing around our claims. If the breadth or strength of protection provided by the patents and patent applications we hold, license or pursue with respect to our product candidates is threatened, it could threaten our ability to commercialize our product candidates.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents and other intellectual property protection, particularly those relating to pharmaceuticals or biopharmaceuticals, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights generally. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing, and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. In addition, certain countries in Europe and certain developing countries, including India and China, have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In those countries, we may have limited remedies if our patents are infringed or if we are compelled to grant a license to our patents to a third party, which could materially diminish the value of those patents. This could limit our potential revenue opportunities. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we own or license.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finally, our ability to protect and enforce our intellectual property rights may be adversely affected by unforeseen changes in foreign intellectual property laws.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">104</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU96"></a><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Obtaining and maintaining our patent protection depends on compliance with various procedural, documentary, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent prosecution process. Periodic maintenance fees and various other governmental fees on any issued patent and/or pending patent applications are due to be paid to the USPTO and foreign patent agencies in several stages over the lifetime of a patent or patent application. We have systems in place to remind us to pay these fees, and we employ an outside firm and rely on our outside counsel to pay these fees. While an inadvertent lapse may sometimes be cured by payment of a late fee or by other means in accordance with the applicable rules, there are many situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. If we fail to maintain the patents and patent applications directed to our product candidates, our competitors might be able to enter the market earlier than should otherwise have been the case, which would have a material adverse effect on our business.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Third-party claims alleging intellectual property infringement may adversely affect our business.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our commercial success depends in part on our avoiding infringement of the patents and proprietary rights of third parties, for example, the intellectual property rights of competitors. Our research, development and commercialization activities may be subject to claims that we infringe or otherwise violate patents owned or controlled by third parties. Numerous U.S. and foreign issued patents and pending patent applications, which are owned by third parties, exist in the fields in which we are developing our product candidates. As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that our activities related to our product candidates may give rise to claims of infringement of the patent rights of others. We cannot assure you that our product candidates will not infringe existing or future patents. We may not be aware of patents that have already issued that a third party, for example a competitor in our market, might assert are infringed by our product candidates. It is also possible that patents of which we are aware, but which we do not believe are relevant to our product candidates, could nevertheless be found to be infringed by our product candidates. Nevertheless, we are not aware of any issued patents that we believe would prevent us from marketing our product candidates, if approved. There may also be patent applications that have been filed but not published that, when issued as patents, could be asserted against us.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Third parties making claims against us for infringement or misappropriation of their intellectual property rights may seek and obtain injunctive or other equitable relief, which could effectively block our ability to further develop and commercialize our product candidates. Further, if a patent infringement suit were brought against us, we could be forced to stop or delay research, development, manufacturing or sales of the product or product candidate that is the subject of the suit. Defense of these claims, regardless of their merit, would cause us to incur substantial expenses, and would be a substantial diversion of employee resources from our business. In the event of a successful claim of infringement against us by a third party, we may have to&#160;(1)&#160;pay substantial damages, including treble damages and attorneys&#8217; fees if we are found to have willfully infringed the third party&#8217;s patents; (2)&#160;obtain one or more licenses from the third party; (3)&#160;pay royalties to the third party; and/or (4)&#160;redesign any infringing products. Redesigning any infringing products may be impossible or require substantial time and monetary expenditure. Further, we cannot predict whether any required license would be available at all or whether it would be available on commercially reasonable terms. In the event that we could not obtain a license, we may be unable to further develop and commercialize our product candidates, which could harm our business significantly. Even if we are able to obtain a license, the license would likely obligate us to pay license fees or royalties or both, and the rights granted to us might be nonexclusive, which could result in our competitors gaining access to the same intellectual property. Ultimately, we could be prevented from commercializing a product, or be forced to cease some aspect of our business operations, if, as a result of actual or threatened patent infringement claims, we are unable to enter into licenses on acceptable terms.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Defending ourselves or our licensors in litigation is very expensive, particularly for a company of our size, and time-consuming. Some of our competitors may be able to sustain the costs of litigation or administrative proceedings more effectively than we can because of greater financial resources. Patent litigation and other proceedings may also absorb significant management time. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could impair our ability to compete in the marketplace. The occurrence of any of the foregoing could have a material adverse effect on our business, financial condition or results of operations.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">105</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU97"></a><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We may become involved in lawsuits to protect or enforce our patents or other intellectual property or the patents of our licensors, which could be expensive and time consuming.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;letter-spacing:-0.1pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Third parties may infringe or misappropriate our intellectual property, including our existing patents, patents that may issue to us in the future, or the patents of our licensors to which we have a license. As a result, we may be required to file infringement claims to stop third-party infringement or unauthorized use. Further, we may not be able to prevent, alone or with our licensors, misappropriation of our intellectual property rights, particularly in countries where the laws may not protect those rights as fully as in the U.S.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Generic drug manufacturers may develop, seek approval for, and launch generic versions of our products. If we file an infringement action against such a generic drug manufacturer, that company may challenge the scope, validity or enforceability of our or our licensors&#8217; patents, requiring us and/or our licensors to engage in complex, lengthy and costly litigation or other proceedings.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For example, if we or one of our licensors initiated legal proceedings against a third party to enforce a patent covering our product candidates, the defendant could counterclaim that the patent covering our product candidates is invalid and/or unenforceable. In patent litigation in the U.S., defendant counterclaims alleging invalidity and/or unenforceability are commonplace, and there are numerous grounds upon which a third party can assert invalidity or unenforceability of a patent.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, within and outside of the U.S., there has been a substantial amount of litigation and administrative proceedings, including interference and reexamination proceedings before the USPTO or oppositions and other comparable proceedings in various foreign jurisdictions, regarding patent and other intellectual property rights in the biopharmaceutical industry. The Leahy-Smith Act introduced procedures including inter partes review and post grant review. The implementation of these procedures brings uncertainty to the possibility of challenges to our patents in the future, including those that patents perceived by our competitors as blocking entry into the market for their products, and the outcome of such challenges.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Such litigation and administrative proceedings could result in revocation of our patents or amendment of our patents such that they do not cover our product candidates. They may also put our pending patent applications at risk of not issuing, or issuing with limited and potentially inadequate scope to cover our product candidates. The outcome following legal assertions of invalidity and unenforceability is unpredictable. With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art, of which we and the patent examiner were unaware during prosecution. Additionally, it is also possible that prior art of which we are aware, but which we do not believe affects the validity or enforceability of a claim, may, nonetheless, ultimately be found by a court of law or an administrative panel to affect the validity or enforceability of a claim, for example if a priority claim is found to be improper. If a defendant were to prevail on a legal assertion of invalidity and/or unenforceability, we would lose at least part, and perhaps all, of the patent protection on our product candidates. Such a loss of patent protection could have a material adverse impact on our business.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Enforcing our or our licensor&#8217;s intellectual property rights through litigation is very expensive, particularly for a company of our size, and time-consuming. Some of our competitors may be able to sustain the costs of litigation more effectively than we can because of greater financial resources. Patent litigation and other proceedings may also absorb significant management time. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could impair our ability to compete in the marketplace. The occurrence of any of the foregoing could have a material adverse effect on our business, financial condition or results of operations.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation or administrative proceedings, there is a risk that some of our confidential information could be compromised by disclosure. In addition, during the course of litigation or administrative proceedings, there could be public announcements of the results of hearings, motions or other interim proceedings or developments or public access to related documents. If investors perceive these results to be negative, the market price for our common stock could be significantly harmed.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If we fail to comply with our obligation in any of the agreements under which we license intellectual property rights from third parties or otherwise experience disruptions to our business relationships with our licensors, we could lose license rights that are important to our business.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Licensing of intellectual property rights is of critical importance to our business and involves complex legal, business and scientific issues. We rely on our exclusive license from Hans Klingemann, M.D., Ph.D., one of our founders and the inventor of our aNK and related platform product cell therapies, and may rely on our exclusive licenses from Rush University Medical Center and other licensors such as Fox Chase Cancer Research Center and the University Health Network. If we fail to comply with the diligence obligations or otherwise materially breach our license agreement, and fail to remedy such failure or cure such breach, the licensor may have the right to terminate the license.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">106</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU98"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our obligation to pay royalties to Dr.&#160;Klingemann under the license agreement, as amended, runs until the expiration of the underlying patents and the license agreement may be terminated earlier by either party for material breach. Under the license agreement, we have the right to enforce the licensed patents. Our license agreement with Rush University Medical Center terminated on the 12th&#160;anniversary of our first payment of royalties, at which point the license was deemed a perpetual, irrevocable, fully paid royalty-free, exclusive license.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Disputes may arise between us and our licensors regarding intellectual property rights subject to a license agreement, including:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the scope of rights granted under the license agreement and other interpretation-related issues;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">our right to sublicense intellectual property rights to third parties under collaborative development relationships; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">our diligence obligations with respect to the use of the licensed technology in relation to our development and commercialization of our product candidates, and what activities satisfy those diligence obligations.</font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">While we would expect to exercise all rights and remedies available to us, including seeking to cure any breach by us, and otherwise seek to preserve our rights under the patents licensed to us, we may not be able to do so in a timely manner, at an acceptable cost or at all. Generally, the loss of any one of our current licenses, or any other license we may acquire in the future, could materially harm our business, prospects, financial condition and results of operations.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Confidentiality agreements with employees and others may not adequately prevent disclosure of our trade secrets and other proprietary information and may not adequately protect our intellectual property, which could limit our ability to compete.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Because we operate in the highly technical field of research and development, we rely in part on trade secret protection and confidentiality agreements, including those with our employees and consultants, in order to protect our proprietary trade secrets and unpatented know-how. However, trade secrets are difficult to protect, and we cannot be certain that others will not develop the same or similar technologies on their own. We have taken steps, including entering into confidentiality agreements with our employees, consultants, outside scientific collaborators, sponsored researchers and other advisors, to protect our trade secrets and unpatented know-how. These agreements generally require that the other party keep confidential and not disclose to third parties all confidential information developed by the party or made known to the party by us during the course of the party&#8217;s relationship with us. We also typically obtain agreements from these parties, which provide that inventions conceived by the party in the course of rendering services to us will be our exclusive property. However, these agreements may not be honored and may not effectively assign intellectual property rights to us. Adequate remedies may not exist in the event of unauthorized use or disclosure of our confidential intellectual property. Enforcing a claim that a party illegally obtained and is using our trade secrets or know-how is difficult, expensive and time consuming, and the outcome is unpredictable. In addition, courts outside the U.S. may be less willing to protect trade secrets or know-how. The failure to obtain or maintain trade secret protection could adversely affect our competitive position. Also, third parties, including our competitors, may independently develop substantially equivalent proprietary information and technologies or otherwise lawfully gain access to our trade secrets and other confidential information. In such a case, we would have no right to prevent such third parties from using such proprietary information or technologies to compete with us, which could harm our competitive position.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of third parties.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have received confidential and proprietary information from third parties. In addition, we employ individuals who were previously employed at other biotechnology or pharmaceutical companies, including our competitors or potential competitors. We may be subject to claims that we or our employees, consultants or independent contractors have inadvertently or otherwise improperly used or disclosed intellectual property, including trade secrets, confidential information, or other proprietary information, of these third parties or our employees&#8217; or consultants&#8217; or independent contractors&#8217; former or other employers. Further, we may be subject to ownership disputes in the future arising, for example, from conflicting obligations of consultants or others who are involved in developing our product candidates. We may also be subject to claims that former employees, consultants, independent contractors, collaborators or other third parties have an ownership interest in our patents or other intellectual property. Litigation may be necessary to defend against these and other claims challenging our right to and use of confidential and proprietary information. If we fail in defending any such claims, in addition to paying monetary damages, we may lose our rights therein. Such an outcome could have a material adverse effect on our business. Even if we are successful in defending against these claims, litigation could result in substantial cost and be a distraction to our management and employees.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">107</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU99"></a><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risks Relating to Our Common Stock</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our Chairman and CEO and entities affiliated with him collectively own a significant majority of our common stock and will exercise significant influence over matters requiring stockholder approval, regardless of the wishes of other stockholders.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_157"></a><a name="_cp_text_1_157"></a>As of December&#160;31, 2019, our Chairman and CEO, Patrick Soon-Shiong, M.D., and entities affiliated with him, collectively own approximately 67.3% of the outstanding shares of our common stock. Additionally, Dr.&#160;Soon-Shiong holds vested options to purchase an aggregate of 900,000 additional shares of our common stock, which would give him and his affiliates ownership of approximately 67.6% of our outstanding shares of common stock if they were exercised in full. In addition, pursuant to the Nominating Agreement between us and Cambridge Equities, LP, or Cambridge, an entity that Dr.&#160;Soon-Shiong controls, Cambridge has the ability to designate one director to be nominated for election to our board of directors for as long as Cambridge continues to hold at least 20% of the issued and outstanding shares of our common stock. Dr.&#160;Soon-Shiong was selected by Cambridge to hold this board seat. Dr.&#160;Soon-Shiong and his affiliates will therefore have significant influence over management and significant control over matters requiring stockholder approval, including the annual election of directors and significant corporate transactions, such as a merger or other sale of our company or its assets, for the foreseeable future. This concentrated control will limit stockholders&#8217; ability to influence corporate matters and, as a result, we may take actions that our stockholders do not view as beneficial. As a result, the market price of our common stock could be adversely affected.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">The market price of our stock may fluctuate significantly, and investors may have difficulty selling their shares.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prior to our IPO in July&#160;2015, there was no public market for our common stock. Although our common stock is listed on The Nasdaq Global Select Market, or Nasdaq, the market for our shares has demonstrated varying levels of trading activity. You may not be able to sell your shares quickly or at the market price if trading in shares of our common stock is not active. Further, an inactive market may also impair our ability to raise capital by selling shares of our common stock and may impair our ability to enter into strategic partnerships or acquire companies or products by using our shares of common stock as consideration.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">The market price of our common stock has been and may continue to be volatile.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The stock market in general and the market for biopharmaceutical companies in particular have experienced extreme volatility that has often been unrelated to the operating performance of particular companies. The market price of our common stock has been and may continue to be highly volatile and could be subject to wide fluctuations in response to various factors, some of which are beyond our control, including:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the commencement, enrollment or results of the planned clinical trials of our product candidates or any future clinical trials we may conduct, or changes in the development status of our product candidates;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">any delay in our regulatory filings for our product candidates and any adverse development or perceived adverse development with respect to the applicable regulatory authority&#8217;s review of such filings, including without limitation the FDA&#8217;s issuance of a &#8220;refusal to file&#8221; letter or a request for additional information;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">adverse results or delays in clinical trials;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">our decision to initiate a clinical trial, not to initiate a clinical trial or to terminate an existing clinical trial;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">adverse regulatory decisions, including failure to receive regulatory approval of our product candidates;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">changes in laws or regulations applicable to our products, including but not limited to clinical trial requirements for approvals;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">our failure to commercialize our product candidates;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">additions or departures of key scientific or management personnel;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">unanticipated serious safety concerns related to the use of our product candidates;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">announcements by us or our competitors of significant contracts, acquisitions, strategic partnerships, joint ventures or capital commitments;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">our ability to effectively manage our growth;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">variations in our quarterly operating results;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">our cash position;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">announcements that our revenue or income are below or that costs or losses are greater than analysts&#8217; expectations;</font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">108</a></p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><a name="_AEIOULastRenderedPageBreakAEIOU100"></a><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-family:Times New Roman;">publication of research reports about us or our industry, or immunotherapy in particular, or positive or negative recommendations or withdrawal of research coverage by securities analysts;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">changes in the market valuations of similar companies;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">general economic slowdowns;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">sales of large blocks of our common stock;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">fluctuations in stock market prices and volumes;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">disputes or other developments relating to proprietary rights, including patents, litigation matters and our ability to obtain patent protection for our technologies;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">significant lawsuits, including patent or stockholder litigation;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the perception of our clinical trial results by retail investors, which investors may be subject to the influence of information provided by third party investor websites and independent authors distributing information on the internet; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the other factors described in this &#8220;</font><font style="font-style:italic;font-family:Times New Roman;">Risk Factors</font><font style="font-family:Times New Roman;">&#8221; section.</font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the past, securities class action litigation has often been instituted against companies following periods of volatility in the market price of a company&#8217;s securities. This type of litigation could result in substantial costs and a diversion of management&#8217;s attention and resources, which would harm our business, operating results or financial condition.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Future sales and issuances of our common stock or rights to purchase common stock, including pursuant to our equity incentive plan, could result in additional dilution of the percentage ownership of our stockholders and could cause our stock price to fall.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sales of a substantial number of shares of our common stock in the public market could occur at any time. If our stockholders sell, or the market perceives that our stockholders intend to sell, substantial amounts of our common stock in the public market the market price of our common stock could decline significantly. In addition, as of December&#160;31, 2019 our chairman and CEO, Dr. Soon-Shiong, and his affiliates beneficially owned approximately 67.6% of our outstanding shares of common stock. Sales of stock by Dr. Soon-Shiong and his affiliates could have a material adverse effect on the trading price of our common stock.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain holders of approximately 46.2&#160;million shares of our common stock are entitled to certain rights with respect to the registration of their shares under the Securities Act. Registration of these shares under the Securities Act would result in the shares becoming freely tradable without restriction under the Securities Act, except for shares held by our affiliates as defined in Rule&#160;144 under the Securities Act. Any sales of securities by these stockholders could have a material adverse effect on the market price of our common stock.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, we expect that additional capital may be needed in the future to continue our planned operations, including conducting clinical trials, commercialization efforts, expanded research and development activities and costs associated with operating a public company. To raise capital, we may sell common stock, convertible securities or other equity securities in one or more transactions at prices and in a manner we determine from time to time. If we sell common stock, convertible securities or other equity securities, investors may be materially diluted by subsequent sales. Such sales may also result in material dilution to our existing stockholders, and new investors could gain rights, preferences and privileges senior to the holders of our common stock.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We have incurred and will continue to incur costs as a result of operating as a public company and our management has been and will be required to devote substantial time to compliance initiatives and corporate governance practices, including maintaining an effective system of internal control over financial reporting.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a public company listed in the U.S., and increasingly after we are no longer an &#8220;emerging growth company,&#8221; we have incurred and will continue to incur significant additional legal, accounting and other expenses that we did not incur as a private company. In addition, changing laws, regulations and standards relating to corporate governance and public disclosure, including Sarbanes-Oxley and regulations implemented by the Securities and Exchange Commission or SEC, and Nasdaq, may increase legal and financial compliance costs and make some activities more time consuming. These laws, regulations and standards are subject to varying interpretations and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies. We intend to invest resources to create a larger finance function with additional personnel to comply with evolving laws, regulations and standards, and this investment may result in increased general and administrative expenses and a diversion of management&#8217;s time and attention from revenue-generating activities to compliance activities. If, notwithstanding our efforts to comply with new laws, regulations and standards, we fail to comply, regulatory authorities may initiate legal proceedings against us and our business may be harmed.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">109</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU101"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a public company in the U.S., we are required, pursuant to Section&#160;404 of Sarbanes-Oxley, or Section&#160;404, to furnish a report by management on, among other things, the effectiveness of our internal control over financial reporting. We must disclose any material weaknesses identified by our management in our internal control over financial reporting, and, when we are no longer an &#8220;emerging growth company,&#8221; and if we are not a smaller reporting company at that time we will need to provide a statement that our independent registered public accounting firm has issued an opinion on our internal control over financial reporting.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The controls and other procedures are designed to ensure that information required to be disclosed by us in the reports that we file with the SEC is disclosed accurately and is recorded, processed, summarized and reported within the time periods specified in SEC rules and forms. Our independent registered public accounting firm was not engaged to perform an audit of our internal control over financial reporting for the year ended December&#160;31, 2019, or for any other period. Accordingly, no such opinion was expressed in 2019. For the year ending December&#160;31, 2020, we may be subject to the auditor attestation requirements of Section&#160;404 of Sarbanes-Oxley. There can be no assurance that we will not discover deficiencies or a material weakness in our internal control over financial reporting or that our auditor will agree with management&#8217;s assessment of our internal control over financial reporting.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even after we develop these new procedures, these new controls may become inadequate because of changes in conditions or the degree of compliance with these policies or procedures may deteriorate and material weaknesses in our internal control over financial reporting may be discovered. We may err in the design or operation of our controls, and all internal control systems, no matter how well designed and operated, can provide only reasonable assurance that the objectives of the control system are met. Because there are inherent limitations in all control systems, there can be no absolute assurance that all control issues have been or will be detected. If we are unable, or are perceived as unable, to produce reliable financial reports due to internal control deficiencies, investors could lose confidence in our reported financial information and operating results, which could result in a negative market reaction.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To fully comply with Section&#160;404, we will need to retain additional employees to supplement our current finance staff, and we may not be able to do so in a timely manner, or at all. In addition, in the process of evaluating our internal control over financial reporting, we expect that certain of our internal control practices will need to be updated to comply with the requirements of Section&#160;404 and the regulations promulgated thereunder, and we may not be able to do so on a timely basis, or at all. In the event that we are not able to demonstrate compliance with Section&#160;404 in a timely manner, or are unable to produce timely or accurate financial statements, we may be subject to sanctions or investigations by regulatory authorities, such as the SEC or Nasdaq, and investors may lose confidence in our operating results and the price of our common stock could decline. Furthermore, if we are unable to certify that our internal control over financial reporting is effective and in compliance with Section&#160;404, we may be subject to sanctions or investigations by regulatory authorities, such as the SEC or stock exchanges, and we could lose investor confidence in the accuracy and completeness of our financial reports, which could hurt our business, the price of our common stock and our ability to access the capital markets.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We also expect that being a public company will make it more expensive for us to obtain director and officer liability insurance, and we may be required to accept reduced coverage or incur substantially higher costs to obtain coverage. These factors could also make it more difficult for us to attract and retain qualified persons to serve on our board of directors, on committees of our board of directors or as members of senior management.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If a restatement of our financial statements were to occur, our shareholders&#8217; confidence in the company&#8217;s financial reporting in the future may be affected, which could in turn have a material adverse effect on our business and stock price.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If any material weaknesses in our internal control over financial reporting are discovered or occur in the future, our consolidated financial statements may contain material misstatements, and we could be required to further restate our financial results. In addition, if we are unable to successfully remediate any future material weaknesses in our internal controls or if we are unable to produce accurate and timely financial statements, our stock price may be adversely affected, and we may be unable to maintain compliance with applicable stock exchange listing requirements.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We have not paid cash dividends in the past and do not expect to pay dividends in the future. Any return on investment may be limited to the value of our common stock.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have never paid cash dividends on our common stock and do not anticipate paying cash dividends in the foreseeable future. The payment of dividends on our common stock will depend on earnings, financial condition and other business and economic factors affecting us at such time as the board of directors may consider relevant. If we do not pay dividends, our common stock may be less valuable because a return on your investment will only occur if our stock price appreciates.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">110</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU102"></a><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Because we are relying on the exemptions from corporate governance requirements as a result of being a &#8220;controlled company&#8221; within the meaning of the Nasdaq listing standards, you do not have the same protections afforded to stockholders of companies that are subject to such requirements.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our Chairman and CEO, Dr.&#160;Patrick Soon-Shiong, and entities affiliated with him, control a majority of our common stock. As a result, we are a &#8220;controlled company&#8221; within the meaning of the Nasdaq listing standards. Under these rules, a company of which more than 50% of the voting power is held by an individual, a group or another company is a &#8220;controlled company&#8221; and may elect not to comply with certain Nasdaq corporate governance requirements, including&#160;(1)&#160;the requirement that a majority of the board of directors consist of independent directors and (2)&#160;the requirement that we have a nominating and corporate governance committee that is composed entirely of independent directors with a written charter addressing the committee&#8217;s purpose and responsibilities. Our board of directors is currently comprised of a majority of independent directors. In addition, although not required by the rules of Nasdaq, in August&#160;2019, our board of directors established a nominating and corporate governance committee comprised of three directors, two of which are independent. Accordingly, you do not have the same protections afforded to stockholders of companies that are subject to all of the Nasdaq corporate governance requirements.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We are an &#8220;emerging growth company&#8221; and a &#8220;smaller reporting company,&#8221; and the reduced disclosure requirements applicable to emerging growth companies and smaller reporting companies could make our common stock less attractive to investors.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are an &#8220;emerging growth company,&#8221; as defined in the JOBS Act enacted in April&#160;2012, or the JOBS Act, and may remain an &#8220;emerging growth company&#8221; for up to five&#160;years following the completion of our IPO, or December&#160;31, 2020, although, if we have more than $1.07&#160;billion in annual revenue, the market value of our common stock that is held by non-affiliates exceeds $700.0&#160;million as of June&#160;30 of any year, or we issue more than $1.0&#160;billion of non-convertible debt over a three-year period before the end of that five-year period, we would cease to be an &#8220;emerging growth company&#8221; as of the following December&#160;31. For as long as we remain an &#8220;emerging growth company,&#8221; we are permitted and intend to continue to rely on exemptions from certain disclosure requirements that are applicable to other public companies that are not &#8220;emerging growth companies.&#8221; These exemptions include:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">being permitted to provide only two years of audited financial statements, in addition to any required unaudited interim financial statements, with correspondingly reduced &#8220;Management&#8217;s discussion and analysis of financial condition and results of operations&#8221; disclosure;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">not being required to comply with the auditor attestation requirements in the assessment of our internal control over financial reporting;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">not being required to comply with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor&#8217;s report providing additional information about the audit and the financial statements;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">reduced disclosure obligations regarding executive compensation; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved.</font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have taken advantage of reduced reporting requirements in our public filings. In particular, we have not included all of the executive compensation related information that would be required if we were not an emerging growth company. In addition, the JOBS Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards, delaying the adoption of these accounting standards until they would apply to private companies. We have irrevocably elected not to avail ourselves of this exemption and, as a result, we will adopt new or revised accounting standards on the relevant dates on which adoption of such standards is required for other public companies. Even after we no longer qualify as an emerging growth company, we may, under certain circumstances, still qualify as a &#8220;smaller reporting company,&#8221; which would allow us to take advantage of many of the same exemptions from disclosure requirements, including reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements. Investors may find our common stock less attractive as a result of our reliance on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and the market price of our common stock may be reduced or more volatile.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our ability to use our net operating loss carryforwards, or NOLs, and certain other tax attributes to offset future taxable income may be subject to certain limitations.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2019 we had U.S. federal, state and foreign NOLs of approximately $291.8&#160;million, $255.7&#160;million and $0.2&#160;million, respectively, which begin to expire in various years starting with 2022, if not utilized. As of December&#160;31, 2019, we also had federal and state research and development tax credit carryforwards of approximately $8.5&#160;million and $5.7&#160;million, respectively. These net operating loss and research and development tax credit carryforwards could expire unused and be unavailable to offset future income tax liabilities.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">111</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU103"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under Sections&#160;382 and 383 of the Internal Revenue Code of 1986, as amended, if a corporation undergoes an &#8220;ownership change,&#8221; the corporation&#8217;s ability to use its pre-change NOLs and other pre-change tax attributes, such as research tax credits, to offset its future post-change income and taxes may be limited. In general, an &#8220;ownership change&#8221; occurs if there is a cumulative change in our ownership by &#8220;5% shareholders&#8221; that exceeds 50&#160;percentage points over a rolling three-year period. Similar rules may apply under state tax laws. We completed an IRC&#160;Section&#160;382/383 analysis through March&#160;2019 regarding the limitation of net operating loss and research and development credit carryforwards. As a result of the analysis, the federal and state carryforwards associated with the NOLs were reduced by the amount of tax attributes estimated to expire during their respective carryforward periods.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are a U.S.-based company subject to tax in the U.S. and in Korea. Significant judgment is required in determining our global provision for income taxes, deferred tax assets or liabilities, and in evaluating our tax positions on a worldwide basis. While we believe our tax positions are consistent with the tax laws in the jurisdictions in which we conduct our business, it is possible that these positions may be overturned by jurisdictional tax authorities, which may have a significant impact on our global provision for income taxes.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since we will need to raise substantial additional funding to finance our operations, we may experience further ownership changes in the future, some of which may be outside of our control. Limits on our ability to use our pre-change NOLs or credits to offset U.S. federal taxable income could potentially result in increased future tax liability to us if we earn net taxable income in the future. In addition, under the Tax Cuts and Jobs Act, as enacted on December&#160;22, 2017, or TCJA, the amount of NOLs generated in taxable periods beginning after December 31, 2017, that we are permitted to deduct in any taxable year is limited to 80% of our taxable income in such year, where taxable income is determined without regard to the NOL deduction itself. The TCJA generally eliminates the ability to carry back any NOL to prior taxable years, while allowing post&#8209;2017 unused NOLs to be carried forward indefinitely. Similar rules may apply under state tax laws.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tax laws are dynamic and subject to change as new laws are passed and new interpretations of the law are issued or applied. The U.S. recently enacted significant tax reform, and certain provisions of the new law may adversely affect us. In addition, governmental tax authorities are increasingly scrutinizing the tax positions of companies. If U.S. or other foreign tax authorities change applicable tax laws, our overall taxes could increase, and our business, financial condition or results of operations may be adversely impacted.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, our share price and trading volume could decline.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The trading market for our common stock will depend on the research and reports that securities or industry analysts publish about us or our business. We do not have any control over these analysts. There can be no assurance that analysts will cover us or provide favorable coverage. If one or more of the analysts who cover us downgrade our stock or change their opinion of our stock, our share price would likely decline. If one or more of these analysts&#8217; cease coverage of our company or fail to regularly publish reports on us, we could lose visibility in the financial markets, which could cause our share price or trading volume to decline.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We are not subject to the provisions of Section&#160;203 of the Delaware General Corporation Law, which could negatively affect your investment.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We elected in our amended and restated certificate of incorporation to not be subject to the provisions of Section&#160;203 of the Delaware General Corporation Law. In general, Section&#160;203 prohibits a publicly held Delaware corporation from engaging in a &#8220;business combination&#8221; with an &#8220;interested stockholder&#8221; for a period of three years after the date of the transaction in which the person became an interested stockholder, unless the business combination is approved in a prescribed manner. A &#8220;business combination&#8221; includes a merger, asset sale or other transaction resulting in a financial benefit to the interested stockholder. An &#8220;interested stockholder&#8221; is a person who, together with affiliates and associates, owns (or, in certain cases, within three years prior, did own) 15% or more of the corporation&#8217;s voting stock. Our decision not to be subject to Section&#160;203 will allow, for example, our Chairman and CEO (who with members of his immediate family and entities affiliated with him owned approximately 67.3% of our common stock as of December&#160;31, 2019) to transfer shares in excess of 15% of our voting stock to a third-party free of the restrictions imposed by Section&#160;203. This may make us more vulnerable to takeovers that are completed without the approval of our board of directors and/or without giving us the ability to prohibit or delay such takeovers as effectively.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">112</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU104"></a><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Some provisions of our charter documents and Delaware law may have anti-takeover effects that could discourage an acquisition of us by others, even if an acquisition would be beneficial to our stockholders, and may prevent attempts by our stockholders to replace or remove our current management.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Provisions in our amended and restated certificate of incorporation and amended and restated bylaws, as well as provisions of Delaware law, could make it more difficult for a third party to acquire us or increase the cost of acquiring us, even if doing so would benefit our stockholders. These provisions include:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">a requirement that special meetings of stockholders be called only by the board of directors, the president or the chief executive officer;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">advance notice requirements for stockholder proposals and nominations for election to our board of directors; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the authority of the board of directors to issue preferred stock on terms determined by the board of directors without stockholder approval and which preferred stock may include rights superior to the rights of the holders of common stock.</font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These anti-takeover provisions and other provisions in our amended and restated certificate of incorporation and amended and restated bylaws could make it more difficult for stockholders or potential acquirers to obtain control of our board of directors or initiate actions that are opposed by the then-current board of directors and could also delay or impede a merger, tender offer or proxy contest involving our company. These provisions could also discourage proxy contests and make it more difficult for you and other stockholders to elect directors of your choosing or cause us to take other corporate actions you desire. Any delay or prevention of a change of control transaction or changes in our board of directors could cause the market price of our common stock to decline.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Claims for indemnification by our directors and officers may reduce our available funds to satisfy successful third-party claims against us and may reduce the amount of money available to us.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our amended and restated certificate of incorporation and amended and restated bylaws provide that we will indemnify our directors and officers, in each case to the fullest extent permitted by Delaware law. In addition, as permitted by Section&#160;145 of the Delaware General Corporation Law, our amended and restated bylaws and our indemnification agreements that we have entered into with our directors and officers provide that:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">We will indemnify our directors and officers for serving us in those capacities or for serving other business enterprises at our request, to the fullest extent permitted by Delaware law. Delaware law provides that a corporation may indemnify such person if such person acted in good faith and in a manner such person reasonably believed to be in or not opposed to the best interests of the registrant and, with respect to any criminal proceeding, had no reasonable cause to believe such person&#8217;s conduct was unlawful.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">We may, in our discretion, indemnify employees and agents in those circumstances where indemnification is permitted by applicable law.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">We are required to advance expenses, as incurred, to our directors and officers in connection with defending a proceeding, except that such directors or officers shall undertake to repay such advances if it is ultimately determined that such person is not entitled to indemnification.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">We are not obligated pursuant to our amended and restated bylaws to indemnify a person with respect to proceedings initiated by that person against us or our other indemnitees except with respect to proceedings authorized by our board of directors or brought to enforce a right to indemnification.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">The rights conferred in our amended and restated bylaws are not exclusive, and we are authorized to enter into indemnification agreements with our directors, officers, employees and agents and to obtain insurance to indemnify such persons.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">We may not retroactively amend our bylaw provisions to reduce our indemnification obligations to directors, officers, employees and agents.</font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To the extent that a claim for indemnification is brought by any of our directors or officers, it would reduce the amount of funds available for use in our business.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_1B_UNRESOLVED_STAFF_COMMENTS"></a><a name="ITEM_1B_UNRESOLVED_STAFF_COMMENTS"></a>Item&#160;1B. Unresolved Staff Comments.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">113</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU105"></a><a name="ITEM_2_PROPERTIES"></a><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_2_PROPERTIES"></a>Item&#160;2. Pr</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">operties.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes our principal properties leased as of December&#160;31, 2019:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.04%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Principal Properties Leased:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.12%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Approximate</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Square Feet</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.68%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Operation</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.92%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Lease Expiration Dates</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.04%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">San Diego, California</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.12%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44,681</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.68%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Laboratory - Research, Office</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.92%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">July 2023</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">El Segundo, California*</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,250</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Laboratory - Research &amp; Manufacturing</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">July 2023</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Culver City, California*</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,500</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Laboratory - Research &amp; Manufacturing</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">December 2020</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Woburn, Massachusetts</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,153</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Laboratory - Research, Office</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">May 2022</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Torrance, California**</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,034</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Laboratory - Research</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">June 2027</p></td>
</tr>
<tr>
<td colspan="4" valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">*&nbsp;&nbsp;&nbsp;&nbsp;Property leased from a related party.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:3pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:3pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:3pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:3pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="7" valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:79.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">** Represents square footage dedicated to us within the facility, however, the lease also permits</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;&nbsp;&nbsp; our non-exclusive use of the third party's vivarium premises.</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes our principal property owned as of December&#160;31, 2019:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.88%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Principal Property Owned:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.02%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Approximate</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Square Feet</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.7%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Operation</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.88%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">El Segundo, California</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36,434</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.7%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Distribution Warehouse</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For additional information, see Note&#160;8&#160;&#8209;<font style="font-style:italic;">&#160;Commitments and Contingencies, Contractual Obligations &#8211; Leases</font> and Note&#160;9&#160;&#8209;<font style="font-style:italic;">&#160;Related Party Agreements</font> of the &#8220;Notes to Consolidated Financial Statements&#8221; included in Part&#160;II, Item&#160;8 of this Annual Report.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_3_LEGAL_PROCEEDINGS"></a><a name="ITEM_3_LEGAL_PROCEEDINGS"></a>Item&#160;3. Legal Proceedings.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_179"></a>From time to time, we may be involved in various claims and legal proceedings relating to claims arising out of our operations. We are not currently a party to any legal proceedings that, in the opinion of our management, are likely to have a material adverse effect on our business. Regardless of outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_4_MINE_SAFETY_DISCLOSURES"></a><a name="ITEM_4_MINE_SAFETY_DISCLOSURES"></a>Item&#160;4. Mine Safety Disclosures.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Not applicable.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">114</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU106"></a><a name="PART_II"></a><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="PART_II"></a>PART</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> II</font></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_5_MARKET_FOR_REGISTRANTS_COMMON_EQU"></a><a name="ITEM_5_MARKET_FOR_REGISTRANTS_COMMON_EQU"></a>Item&#160;5. Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_203"></a>Market Information for Common Stock</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our common stock began trading on the Nasdaq Global Select Market under the symbol &#8220;NK&#8221; on July&#160;28, 2015. Prior to that date, there was no public trading market for our common stock.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Holders of Record</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of March 23, 2020, we had 27 holders of record of our common stock. The actual number of stockholders is greater than the number of record holders and includes stockholders who are beneficial owners but whose shares are held in street name by brokers and other nominees. This number of holders of record also does not include stockholders whose shares may be held in trust or by other entities.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Dividend Policy</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To date, we have not declared or paid any cash dividends. We currently intend to retain all available funds and any future earnings for use in the operation of our business and do not anticipate paying any dividends on our common stock in the foreseeable future. Any future determination to declare dividends will be made at the discretion of our board of directors and will depend on, among other factors, our financial condition, operating results, capital requirements, general business conditions and other factors that our board of directors may deem relevant.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Securities Authorized for Issuance Under Our Equity Compensation Plans</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Information regarding our equity compensation plans is incorporated by reference to Item&#160;12, &#8220;<font style="font-style:italic;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</font>&#8221; of Part&#160;III of this Annual Report.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_206"></a>Recent Sales of Unregistered Securities</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Repurchases of Equity Securities by the Issuer</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We did not repurchase any shares of our common stock during the three months ended December&#160;31, 2019. At December&#160;31, 2019, $18.3&#160;million remained authorized for repurchase under our stock repurchase program. For additional information regarding our stock repurchase program, see Note&#160;10<font style="font-style:italic;">&#160;&#8211;&#160;Stockholders Equity</font> of the &#8220;Notes to Consolidated Financial Statements&#8221; included in Part&#160;II, Item&#160;8 of this Annual Report.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">115</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU107"></a><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Stock Performance Graph</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_224"></a><a name="_cp_text_1_226"></a><a name="_cp_text_4_227"></a><a name="_cp_text_1_228"></a><a name="_cp_text_4_229"></a><a name="_cp_text_1_230"></a><a name="_cp_text_4_231"></a><a name="_cp_text_1_232"></a><a name="_cp_text_4_233"></a>The following graph compares the cumulative total return to stockholders on our common stock relative to the cumulative total returns of the Russell 2000 Index and the Nasdaq Biotechnology Index. An investment of $100 (with reinvestment of all dividends) is assumed to have been made in our common stock and in each index on July&#160;28, 2015, the date our common stock began trading on the Nasdaq Global Select Market, and its relative performance is tracked through December&#160;31, 2019. The returns shown are based on historical results and are not indicative of, or<a name="_cp_text_1_224"></a> intended to forecast, <a name="_cp_text_1_226"></a>future performance of our common stock or the index. This performance graph shall not be deemed &#8220;filed&#8221; for purposes<a name="_cp_text_4_227"></a> <a name="_cp_text_1_228"></a>of Section&#160;18<a name="_cp_text_4_229"></a> <a name="_cp_text_1_230"></a>of the Securities Exchange<a name="_cp_text_4_231"></a> <a name="_cp_text_1_232"></a>Act of <a name="_cp_text_4_233"></a>1934, as amended, or the Exchange Act, or incorporated by reference into any filing of NantKwest, Inc. under the Securities Act of 1933, as amended, or the Securities Act.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g4i5nix4zlkt000049.jpg" title="" alt="" style="width:527px;height:588px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">116</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU108"></a><a name="ITEM_6_SELECTED_FINANCIAL_DATA"></a><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_6_SELECTED_FINANCIAL_DATA"></a>Item&#160;6. Selected</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> Financial Data.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following selected consolidated financial data should be read in conjunction with &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations,&#8221; the consolidated financial statements and related notes, and other financial information included in this Annual Report on Form&#160;10&#8209;K, or Annual Report.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The selected consolidated statements of operations data for the years ended December&#160;31, 2019, 2018 and 2017 and the selected consolidated balance sheet data as of December&#160;31, 2019 and 2018 are derived from our audited consolidated financial statements included elsewhere in this Annual Report. The following selected consolidated statements of operations data for the years ended December&#160;31, 2016 and 2015 and the selected consolidated balance sheet data as of December&#160;31, 2017, 2016 and 2015 are derived from our audited consolidated financial statements not included in this Annual Report.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="18" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the Year Ended December&#160;31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="18" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(In thousands, except per share data)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2015</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Revenue</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">236</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating expenses:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development (including</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; amounts with related parties)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49,785</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55,718</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42,044</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29,153</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,434</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Selling, general and administrative</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; (including amounts with related parties)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,065</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42,718</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">57,121</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">95,391</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">227,678</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total operating expenses</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">67,850</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">98,436</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">99,165</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">124,544</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">239,112</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Loss from operations</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(67,807</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(98,389</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(99,120</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(124,500</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(238,876</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other income (expense):</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Investment income, net</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,642</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,857</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,665</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,097</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,988</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change&#160;in&#160;fair&#160;value&#160;of&#160;warrant&#160;liability</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,366</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest expense (including amounts</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; with related parties)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(19</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(433</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(618</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(66</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other income, net (including amounts</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; with related parties)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">298</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">236</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">157</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">88</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">77</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total other income</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,921</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,660</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,204</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,119</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,699</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Loss before income taxes</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(65,886</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(96,729</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(96,916</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(121,381</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(237,177</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Income tax benefit</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">97</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">503</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">493</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">572</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">301</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(65,789</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(96,226</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(96,423</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(120,809</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(236,876</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per share:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic and diluted</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.70</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1.22</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1.20</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1.47</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3.31</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted average number of shares</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; during the period:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic and diluted</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">94,210,087</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">79,132,220</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">80,583,910</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">81,979,005</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">71,519,609</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:35.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="18" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.14%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:35.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="18" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(In thousands)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:35.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2015</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Balance Sheet Data:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.6%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.6%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.6%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.6%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.6%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,508</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,821</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,872</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,083</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">175,908</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Working capital</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44,198</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61,512</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">111,590</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">192,592</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">291,392</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total assets</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">143,123</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">181,950</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">250,440</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">317,496</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">366,849</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total liabilities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,444</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35,944</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31,596</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,078</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,854</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total stockholders' equity</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">120,679</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">146,006</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">218,844</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">293,418</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">355,995</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">117</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU109"></a><a name="ITEM_7_MANAGEMENTS_DISCUSSION_ANALYSIS_F"></a><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_7_MANAGEMENTS_DISCUSSION_ANALYSIS_F"></a>Item&#160;7. Management&#8217;s Discussion and Analysis of</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> Financial Condition and Results of Operations.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">The following discussion and analysis of our financial condition and results of operations should be read together with Item&#160;6,&#160;&#8220;Selected Financial Data,&#8221; the description of the business appearing in Item&#160;1,&#160;&#8220;Business,&#8221; of this report, and the Consolidated Financial Statements in Item&#160;8 of this Annual Report on Form&#160;10&#8209;K and the related notes included elsewhere in this report. This discussion contains forward-looking statements as a result of many factors, including those set forth under Item&#160;1,&#160;&#8220;Business &#8211; Forward-Looking Statements&#8221; and Item&#160;1A,&#160;"Risk Factors", and elsewhere in this Annual Report on Form&#160;10&#8209;K. These statements are based on current expectations and assumptions that are subject to risks and uncertainties. Actual results could differ materially from those discussed in or implied by forward-looking statements. Factors that could cause or contribute to these differences include those discussed below and elsewhere in this report, particularly in Item&#160;1A,&#160;&#8220;Risk Factors&#8221;.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Overview</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a pioneering clinical-stage immunotherapy company, we are focused on harnessing the power of the innate immune system by using its natural killer cells, or NK&#160;cells, to treat cancer and viral infectious diseases. NK&#160;cells are the body&#8217;s first line of defense due to their innate ability to rapidly seek and destroy abnormal cells, such as cancer or virally infected cells, without prior exposure or co-activation by other support molecules, typically required to train and activate adaptive immune cells such as T&#8209;cells.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A critical aspect of our strategy is to invest significantly in innovating new therapeutic candidates, based upon our proprietary activated&#160;NK, or aNK, cell platform, and conducting clinical testing and scale manufacturing of our most promising biologic product candidates.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We hold the exclusive right to commercialize aNK&#160;cells, a commercially viable NK&#160;cell line, and a wide range of genetically modified derivatives capable of killing cancer and virally infected cells. We own corresponding United States, or U.S., and foreign composition and methods-of-use patents and applications covering the cells, improvements, methods of expansion and manufacture and use of aNK&#160;cells and their improvements as therapeutics to treat a spectrum of clinical conditions.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We also license exclusive commercial rights to a high-affinity CD16 receptor expressing enhancement of our aNK&#160;cell platform, covered in a portfolio of U.S. and foreign composition and methods-of-use patents and applications covering both the clinical use as a therapeutic to treat cancers in combination with antibody products, as well as the non-clinical use in laboratory testing of monoclonal antibodies.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe our proprietary NK&#160;cell platform, coupled with our integrated discovery ecosystem, positions us to implement precision cancer medicine by taking advantage of the advances that have evolved during the past decade and addressing newly discovered challenges of cancer. Cancer is only recently understood to be a complex of rare diseases, with hundreds of cancer specific proteins. We believe proteins, selectively expressed on the cancer cells and not on the essential normal tissue, represent large untapped targeting opportunities for immune effector cell products derived from our aNK&#160;cell platform.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Our Approach</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Multiple Modes of aNK Directed Tumor Cell Killing.<font style="font-weight:normal;font-style:normal;">&nbsp;&nbsp;Our NK platform has demonstrated the ability to induce cell death in cancers and virally infected cells through a variety of concurrent mechanisms including:</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">i.</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-style:italic;">Innate Killing</font>, whereby all of our NK platforms, aNK, haNK, taNK and t&#8209;haNK, recognize the abnormal proteins typically found on the surfaces of metabolically stressed cells, which upon binding, release toxic granules to immediately kill their targets;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ii.</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-style:italic;">Antibody-Mediated Killing</font> with our haNK and t&#8209;haNK platforms, which are aNK&#160;cells engineered to express antibody receptors that can bind to therapeutically administered antibody products or to antibodies naturally produced in the body, thereby enhancing the cancer cell killing effects of those antibodies through Antibody Dependent Cellular Cytotoxicity, or ADCC; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">iii.</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-style:italic;">CAR-Directed Killing</font> with our taNK and t&#8209;haNK platforms, which are aNK&#160;cells engineered to express chimeric antigen receptors, or CARs, that target tumor-specific proteins commonly found only on the surfaces of cancer cells and upon binding, induce cell death through the release of toxic granules directly into their targets and by the release of cytokines and chemokines, which recruit additional innate and adaptive immune responses, including the recruitment of cytotoxic T&#8209;cells.</p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">118</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU110"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All three modes of killing; </font><font style="font-style:italic;">Innate</font><font style="font-style:italic;"> </font><font style="font-style:italic;">Killing, Antibody</font><font style="font-style:italic;">-</font><font style="font-style:italic;">Mediated Killing, and CAR</font><font style="font-style:italic;">-</font><font style="font-style:italic;">Directed Killing</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, are employed by our proprietary t</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8209;</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">haNK platform, which combines all the enhanced NK killing functions of aNK, haNK and taNK into a single product platform.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our primary target therapeutic area is cancer, with a heavy emphasis on solid tumors. According to the National Cancer Institute, there was an estimated 1.7&#160;million newly diagnosed cases of cancer in the U.S. in 2019, adding to the 16.9&#160;million already living with cancer. In addition, we plan to advance therapies for hematologic malignancies and virally induced infectious diseases.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Innate Killing - the aNK Platform.<font style="font-weight:normal;font-style:normal;">&nbsp;&nbsp;We have developed a unique NK&#160;cell platform, which we believe is capable of being manufactured as a cell-based &#8220;off-the-shelf&#8221; therapy that can be molecularly engineered in a variety of ways to boost its killing capabilities against cancers and virally infected cells. Unlike normal natural killer cells, our NK&#160;cells do not express the key inhibitory receptors that diseased cells often exploit to turn off the killing function of natural killer cells and escape elimination. We have developed a unique aNK&#160;cell, which omits key inhibitory receptors, while preserving critical activation receptors that enable selective innate targeting and killing of distressed and diseased cells. They do so through the recognition and binding of stress-proteins that are overexpressed on the surfaces of</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">i.</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">rapidly growing cancer cells due to oxidative and metabolic stress, nutrient deprivation and waste accumulation typical when cell growth outpaces the capacity of local circulation; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ii.</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">virally infected cells where the cellular machinery is hijacked to produce an abundance of viral proteins and virons.</p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our aNK&#160;cells can also deliver a more lethal blow to their target by delivering a larger payload of lytic enzymes and cytokines responsible for both direct and indirect killing when compared to other natural killer cells isolated from healthy donors. This is due to the higher density of lytic granules and larger cell volume possessed by aNK&#160;cells when compared to that of donor derived natural killer cells. We believe that our aNK&#160;cells can be produced at commercial scale as a &#8216;living drug&#8217; using our proprietary manufacturing and distribution processes to adequately address select global cancer markets.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Several phase&#160;I safety studies with aNK&#160;cells have been conducted in a variety of bulky hematological cancers and solid tumors, enrolling 46&#160;patients in a range of dose levels and schedules with encouraging evidence of single-agent activity and a durable remission, including complete responses in liquid tumors. Based on these earlier clinical trials, we have further modified our aNK platform through virus-free molecular engineering designed to leverage additional modes of killing available to aNKs, including antibody-mediated killing, the haNK platform, and both antibody-mediated and CAR-directed antigen targeted killing, the t&#8209;haNK platform.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Antibody-Mediated Killing - the haNK Platform.<font style="font-weight:normal;font-style:normal;">&nbsp;&nbsp;We have genetically engineered our aNK&#160;cell platform to overexpress high-affinity CD16 receptors, which bind to antibodies. These antibody-targeted haNK&#160;cells are designed to directly bind to IgG1-type antibodies, such as avelumab, trastuzumab, cetuximab and rituximab with the intention of enhancing the cancer killing efficacy of these antibodies by boosting the population of competent natural killer cells that can kill cancer cells through ADCC. Antibody products are abundantly utilized to treat cancer and it is estimated that they generate over $100&#160;billion in reported annual sales. A growing number of studies suggest that clinically meaningful responses to these antibody therapies correlate directly with the overall health of a patient&#8217;s natural killer cell population and whether they express the high-affinity variant of the CD16 receptor. Currently available literature estimates that only approximately 10% to 15% of the addressable patient population eligible for antibody therapies carry high-affinity CD16 receptors. This implies that our haNK product candidate may have significant market potential as a combination therapy to potentially address a large number of patients who do not carry high-affinity CD16 receptors and, as a result, exhibit a poorer response to antibody therapies. We therefore intend to develop our haNK product candidate as a combination therapy with widely-used U.S.&#160;Food and Drug Administration, or FDA, approved antibody products such as avelumab, trastuzumab, cetuximab and rituximab. Current Good Manufacturing Practice, or cGMP, master and working cell banks of our haNK product candidate have been successfully established and will serve as our source for product for our clinical trials and commercialization going forward. We have optimized our haNK product manufacturing process partly through the successful development of a product that does not require IL&#8209;2 cytokine supplementation to the growth media every few days, thereby enabling us to overcome a technically challenging and costly limitation that many other natural killer cell-based therapies face. We have also successfully established processes for large-scale production, cryopreservation and long-term storage of final dose forms, thereby optimizing production efficiencies and allowing for on-demand availability with minimal handling at the infusion sites. Our cryopreserved haNK product has been approved for clinical testing in several phase&#160;Ib/II clinical trials, including our phase&#160;II Merkel cell cancer study.</font></p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">119</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU111"></a><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">CAR</font><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">-Directed</font><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"> Killing - the taNK Platform.</font><font style="font-weight:normal;font-style:normal;">&nbsp;&nbsp;We have genetically engineered our aNK platform to express CARs that target tumor-specific antigens found on the surfaces of cancers and virally infected cells. Our taNK&#160;cells are designed to bind directly to these surface antigens </font><font style="font-weight:normal;font-style:normal;">and</font><font style="font-weight:normal;font-style:normal;"> induce cell death through the release of toxic granules directly into the tumor cells and release cytokines and chemokines to recruit additional innate and adaptive immune responses, including the recruitment of cytotoxic T</font><font style="font-weight:normal;font-style:normal;">&#8209;cells. These tumor antigens encompass four categories of proteins, all of which can be targeted individually by our engineered taNK products:</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">i.</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Checkpoint ligands, such as PD&#8209;L1 and B7&#8209;H4;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ii.</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Well-established tumor proteins such as HER2 and CD19;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">iii.</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Novel surface antigens associated with cancer stem cells, such as CD123 and IGF&#8209;R1; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">iv.</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Newly discovered proteins, or neoepitopes, from individual patient tumor samples.</p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Preclinical evidence has been mounting which demonstrates that taNK&#160;cell activation through the binding of its CAR receptors to these cancer specific proteins is potent enough to override many of the pre-existing inhibitory signals and immunosuppressive factors present in the tumor microenvironment that may be responsible for tumor resistance.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">CAR-Directed and Antibody-Mediated Killing - the t&#8209;haNK Platform.<font style="font-weight:normal;font-style:normal;">&nbsp;&nbsp;Our newest and most promising platform for the development of therapeutic product candidates is an innovative, bioengineered combination of our haNK and taNK platforms that incorporates all the features of our haNK platform together with a CAR. The resulting line of products under this platform avails itself to all three modes of killing:&#160;</font><font style="font-weight:normal;">innate</font><font style="font-weight:normal;font-style:normal;">, </font><font style="font-weight:normal;">antibody-mediated</font><font style="font-weight:normal;font-style:normal;"> and </font><font style="font-weight:normal;">CAR-directed killing</font><font style="font-weight:normal;font-style:normal;">. These products also include one or more additional expression elements such as functional cytokines, chemokines and trafficking factors, making them amongst the most versatile in our portfolio. These products are intended to be combined with commercially available therapeutic antibodies to effectively target either two different epitopes of the same cancer specific protein or two entirely different cancer specific proteins. In addition to our two t&#8209;haNK product candidates, PD&#8209;L1.t&#8209;haNK, recently cleared to commence phase&#160;II testing, and CD19.t&#8209;haNK, authorized to commence phase&#160;I testing, a pipeline of prominent CARs for t&#8209;haNK, including HER2, which is nearing IND submission, and EGFR, which is advancing through human enabling studies, among others will enable us to address an even broader range of cancers as part of a chemotherapy-free combination regimen.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">The Nant Cancer Vaccine.<font style="font-weight:normal;font-style:normal;">&nbsp;&nbsp;The Nant Cancer Vaccine, or NCV, program is a personalized therapy regimen, which utilizes our &#8220;off-the-shelf&#8221; NK&#160;cell platform as the backbone of the regimen. NCV consists of an initial tumor-conditioning regimen followed by a molecularly-informed immunologic conditioning therapy. More specifically, NCV combines tumor and peripheral blood genomic and transcriptomic data derived from our affiliates NantOmics&#8217; and NantHealth Labs&#8217; sequencing and analytical services with the novel delivery of metronomic, albumin-bound low-dose chemotherapy in conjunction with certain other agents, followed by a sequenced administration of tumor-associated antigen vaccines and a unique IL&#8209;15 cytokine, all of which potentiate our NK&#160;cell therapy to potentially drive immunogenic cell death while avoiding the ravages of toxic high-dose chemotherapy. By inducing immunogenic cell death and enhancing a patient&#8217;s innate and adaptive immune system, NCV is designed to attain a long-term, durable response in multiple cancer types with a potential for lower toxicity and improved efficacy and quality of life in comparison with current standards of care. We believe ultimately that employing our NK&#160;cell therapy in the context of NCV will be a highly effective combination for long term clinical success over available standards of care that employ maximum tolerated dose, tolerogenic cell death and immune system compromise.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our Integrated Discovery Ecosystem for Precision Medicine.<font style="font-weight:normal;font-style:normal;">&nbsp;&nbsp;In order to effectively target newly discovered neoepitopes, we plan to eventually integrate the following ecosystem to help drive the utility of our NK&#160;cell therapies against these unique cancer markers, including the use of our haNK platform in conjunction with cancer vaccines that induce </font><font style="font-weight:normal;">in&#160;vivo</font><font style="font-weight:normal;font-style:normal;"> antibody formation directed against these mutated proteins, as well as the development of t&#8209;haNK&#160;cells that directly target these mutated proteins:</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">i.</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">a high-speed supercomputing infrastructure to help identify both known antigens on the surface of tumor cells and neoepitopes in clinical patients suffering from cancer, in a timely manner and at large scale;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ii.</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">a next-generation genomic and transcriptomic sequencing infrastructure to verify the expression of the neoepitopes in the tumor cell, developed by our affiliate entity NantOmics;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">iii.</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">delivering the neoepitope via an adenoviral or yeast platform developed by an affiliate entity to induce production of IgG1-type antibodies in the body, which would in turn combine with our haNK&#160;cells to accelerate ADCC tumor killing;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">iv.</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">a diverse library of human antibodies from which to interrogate and extract an antibody to construct a CAR for genetic incorporation into our t&#8209;haNK platform; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">v.</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">CAR&#8209;targeted t&#8209;haNK&#160;cells potentially capable of being produced as a scalable cell-based &#8220;off-the-shelf&#8221; therapy, without the need for patient compatibility matching.</p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">120</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU112"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect to regularly add newly discovered neoepitopes and novel antibody/CAR targets from our discovery engine and we believe the thousands of newly discovered antigens selectively expressed on the cancer cells and not on the essential normal tissue will provide us with the ability to create new libraries of cancer-specific antibodies and their corresponding CARs to be potentially delivered as living drugs for selective targeting of metastatic cancer cells and cancer stem cells.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We retain exclusive worldwide rights to clinical and research data, intellectual property and know-how developed with our aNK&#160;cells, as well as what we believe is the only clinical grade master cell bank of aNK&#160;cells in existence.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To date, we have generated minimal revenue related to the non-clinical use of our cell lines and intellectual property. We have not generated any revenue from product sales. We have incurred net losses in each year since our inception and, as of December&#160;31, 2019, we had an accumulated deficit of approximately $662.2&#160;million. Our net losses were approximately $65.8&#160;million, $96.2&#160;million and $96.4&#160;million for the years ended December&#160;31, 2019, 2018 and 2017, respectively. Substantially all of our net losses resulted principally from stock-based compensation expense and costs incurred in connection with our ongoing clinical trials and operations, our research and development programs and from selling, general and administrative costs associated with our operations.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2019, we had 148 employees. Personnel of related companies who provide corporate, general and administrative, manufacturing strategy, research and development, regulatory and clinical trial strategy and other support services under our shared services agreement with NantWorks are not included in this number. For additional information, see Note&#160;9<font style="font-style:italic;"> &#8211; Related Party Agreements</font> of the &#8220;Notes to Consolidated Financial Statements&#8221; included in Part&#160;II, Item&#160;8 of this Annual Report. We expect to continue to incur significant expenses and increasing operating losses for the foreseeable future, which may fluctuate significantly from quarter-to-quarter and year-to-year. We anticipate that our expenses will increase substantially as we:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">continue research and development, including preclinical and clinical development of our existing product candidates;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">potentially seek regulatory approval for our product candidates;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">seek to discover and develop additional product candidates;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">establish a commercialization infrastructure and scale up our manufacturing and distribution capabilities to commercialize any of our product candidates for which we may obtain regulatory approval;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">seek to comply with regulatory standards and laws;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">maintain, leverage and expand our intellectual property portfolio;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">hire clinical, manufacturing, scientific and other personnel to support our product candidates&#8217; development and future commercialization efforts;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">add operational, financial and management information systems and personnel; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">incur additional legal, accounting and other expenses in operating as a public company.</font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We do not expect to generate any revenue from product sales unless and until we successfully complete development and obtain marketing approval for one or more of our product candidates, which we do not expect to happen for at least the next several years, if ever. Until such time that we can generate substantial revenue from product sales, if ever, we expect to finance our operating activities through a combination of equity offerings, debt financings, government or other third-party funding, marketing and distribution arrangements and other collaborations, strategic alliances and licensing arrangements. However, we may be unable to raise additional funds or enter into such other arrangements when needed on favorable terms or at all, which would have a negative impact on our financial condition and could force us to delay, limit, reduce or terminate our research and development programs or commercialization efforts. Failure to receive additional funding could cause us to cease operations, in part or in full.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">PD&#8209;L1.t&#8209;haNK Program</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our novel GMP&#8209;grade, cryopreserved, &#8220;off-the-shelf&#8221; bi-specific PD&#8209;L1.t&#8209;haNK NK&#160;cell therapy, which received authorization from the FDA in June&#160;2019 to proceed with a first-in-human trial, has completed enrollment in the second dose cohort of a phase&#160;I study in patients with locally advanced or metastatic solid cancers. We anticipate that this will prove to be safe to administer, based on past favorable safety profiles for other aNK&#160;cell products, and subsequently progress towards multiple phase&#160;II studies in patients with PD&#8209;L1 positive cancer indications. PD&#8209;L1.t&#8209;haNK is expected to serve as the backbone of a combination regimen that includes a therapeutic monoclonal antibody in addition to the IL&#8209;15 superagonist, N&#8209;803, through our exclusive co-development agreement with Altor, a related party (see Note&#160;7 &#8211; <font style="font-style:italic;">Collaboration and License Agreements</font>, of the &#8220;Notes to Consolidated Financial Statements&#8221; included in Part&#160;II, Item&#160;8 of this Annual Report). We believe that the addition of this selective IL&#8209;15 cytokine therapy will complement the efficacy of our bispecific NK&#160;cell therapy through its stimulation of the patient&#8217;s own resident population of NK and cytotoxic CD8&#160;T&#8209;cells. A similar approach will be used for our CD19.t&#8209;haNK NK&#160;cell therapy in CD19 positive B&#8209;cell malignancies.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">121</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU113"></a><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Viracta Investment and Convertible Notes</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March&#160;2017, we participated in a Series&#160;B convertible preferred stock financing and invested $8.5&#160;million in Viracta Therapeutics, Inc., or Viracta, a clinical stage drug development company. In May&#160;2017, we executed an exclusive worldwide license with Viracta to develop and commercialize Viracta&#8217;s proprietary histone deacetylase inhibitor drug candidate for use in combination with NK&#160;cell therapy and possibly additional therapies.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June&#160;2018, Viracta executed a 2018 Note and Warrant Purchase Agreement with existing and new investors, including us. The initial closing under the Purchase Agreement occurred in June&#160;2018, at which point we purchased a convertible note, for $0.4&#160;million, which under certain circumstances was convertible into preferred stock of Viracta, and a warrant to purchase Viracta&#8217;s common shares. The convertible note accrued interest at 8% and had a one-year maturity date. In September&#160;2018, a milestone closing under the Purchase Agreement occurred, at which point we purchased an additional convertible note for $0.4&#160;million, which under certain circumstances was convertible into preferred stock of Viracta, and a warrant to purchase Viracta&#8217;s common shares. The convertible note accrued interest at 8% and had a one-year maturity date. We classified these convertible notes as held-to-maturity notes receivable on the consolidated balance sheets. Effective January&#160;31, 2019, the notes, together with accrued interest then outstanding, were converted to Series&#160;B preferred stock resulting in an increase to our investment in Viracta&#8217;s Series&#160;B convertible preferred stock totaling $0.8&#160;million. In May&#160;2019, we exercised warrants to acquire 253,120&#160;shares of Viracta common stock. At December&#160;31, 2019, our investment in Viracta totaled $9.3&#160;million.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For additional information, see Note&#160;4<font style="font-style:italic;"> &#8211; Viracta Investment and Convertible Notes</font> of the &#8220;Notes to Consolidated Financial Statements&#8221; included in Part&#160;II, Item&#160;8 of this Annual Report.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Collaboration Agreements</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We anticipate that strategic collaborations will become an integral part of our operations, providing opportunities to leverage our partners&#8217; expertise and capabilities to further expand the potential of our technologies and product candidates. We believe we are well positioned to become a leader in cell-based immunotherapy due to our broad and vertically integrated platform and through complementary strategic partnerships.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to the collaboration and license agreements discussed below, we may enter into a commercial agreement relating to an IL&#8209;15 superagonist product developed by an affiliate, and we are also pursuing supply arrangements for various investigational agents controlled by affiliates and third parties to be used in our clinical trials. These collaboration and supply agreements do not typically specify how sales will be apportioned between the parties upon successful commercialization of the product. As a result, we cannot guarantee that we will receive a percentage of the revenue that is at least proportional to the costs that we will incur in commercializing the product candidate. Furthermore, if Dr.&#160;Soon-Shiong was to cease his affiliation with us, ImmunityBio, or with NantWorks, these entities may be unwilling to continue these relationships with us on commercially reasonable terms, or at all, and as a result may impede our ability to control the supply chain for our combination therapies.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">ImmunityBio, Inc.<font style="font-style:normal;">&nbsp;&nbsp;In January&#160;2020, we entered into a Cost Allocation Agreement, or the Agreement, with ImmunityBio, Inc. and its subsidiaries, or ImmunityBio. The Agreement is effective as of October&#160;1, 2019. ImmunityBio is a related party, as it is an affiliate of NantWorks. Simultaneously, we and ImmunityBio entered into Work Order Number One under the Agreement. Under the Agreement and Work Order Number One, the parties agreed to conduct a joint study, the clinical research trial being conducted pursuant to the protocol titled QUILT&#160;3.063:</font>&#160;A phase&#160;2 study of combination therapy with an IL-15 superagonist&#160;(N&#8209;803), off-the-shelf CD16&#8209;targeted natural killer cells&#160;(haNK), and avelumab without cytotoxic chemotherapy in subjects with Merkel Cell Carcinoma&#160;(MCC) that has progressed on or after treatment with a checkpoint inhibitor<font style="font-style:normal;">. The ImmunityBio study drug included in the joint study is ImmunityBio&#8217;s proprietary IL-15 superagonist known as N&#8209;803 and our study drug is our proprietary &#8220;off-the-shelf&#8221; CD16-targeted natural killer cell therapy known as haNK.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We will act as the sponsor of this joint study for purposes of regulatory matters, including submissions, correspondence, and communications. Additionally, we are designated as the contracting party to execute agreements with third and related parties relating to the joint study under Work Order Number One. We and ImmunityBio will split certain joint study costs equally related to Work Order Number One, in accordance with the terms of the Agreement. Shared joint study costs include cost related to conducting the joint study development activities, such as personnel related costs, as well as all costs associated to regulatory matters. Costs and expenses incurred in connection with the development, manufacturing, supply, delivery, and pre-patient administration dosing mechanism of each party&#8217;s study drug, are excluded from the shared joint study costs. As of December&#160;31, 2019, there was minimal joint research activity under the Agreement and we incurred approximately $0.1&#160;million in costs related to the joint study that are subject to joint cost sharing under the Agreement.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">122</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU114"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the agreement, each of </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ImmunityBio and the company</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> will receive exclusive rights to any new intellectual property developed that relates solely to its respective study drug, and the parties will have joint co-equal rights in any other intellectual property</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Agreement expires upon the second anniversary of the effective date with the option to renew for additional successiv</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">e one-year terms, but work orders for any joint studies still in process at the time of termination will continue until the applicable study is completed.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Altor BioScience, LLC.<font style="font-style:normal;">&nbsp;&nbsp;In August&#160;2016, we entered into an exclusive Co-Development Agreement, or the Co-Development Agreement, with Altor BioScience, LLC, or Altor. Altor is a related party, as it is a wholly owned subsidiary of ImmunityBio. ImmunityBio is an affiliate of NantWorks. Under the Co-Development Agreement, the parties agreed to exclusively collaborate on the development of certain therapeutic applications combining our proprietary NK&#160;cells with Altor's N&#8209;801 and/or N&#8209;803 products with respect to certain technologies and intellectual property rights as may be agreed between the parties for the purpose of jointly developing therapeutic applications of certain effector cell lines.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are the lead developer for each product developed by the parties pursuant to the Co-Development Agreement unless otherwise agreed to under a given project plan. Under the terms of the Co-Development Agreement, both parties granted a co-exclusive, royalty free, fully paid-up, worldwide license, with the right to sublicense (only to a third-party contractor assisting with research and development activities under this Co-Development Agreement and subject to prior consent, not to be unreasonably withheld), under the intellectual property, or IP, including the parties interest in the joint IP, solely to conduct any development activities agreed to by the steering committee as set forth in any development plan. Unless otherwise mutually agreed by the parties in the development plan for a project, we are responsible for all costs and expenses incurred by either party related to conducting clinical trials and other activities under each development program, including costs associated with patient enrollment, materials and supplies, third party staffing, and regulatory filings. Altor supplies free of charge, sufficient amounts of Altor products for all pre-clinical requirements and certain clinical requirements for up to 400&#160;patients in phase&#160;I and/or phase&#160;II clinical trials, as required under the development plan for a project per the Co-Development Agreement.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Each company owns an undivided interest in and to all rights, title and interest in and to the joint product rights. The Co-Development Agreement expires upon the fifth anniversary of the effective date. We have dosed patients with N&#8209;803, an IL&#8209;15 superagonist, in several phase&#160;Ib/II trials during the years ended December&#160;31, 2019, 2018 and 2017. No charges for supplies by Altor were incurred in association with the above trials during the years ended December&#160;31, 2019, 2018 and 2017.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Licensing Agreements</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Viracta Therapeutics, Inc.<font style="font-style:normal;">&nbsp;&nbsp;In May&#160;2017, we entered into an agreement with Viracta to grant us exclusive world-wide rights to Viracta&#8217;s phase&#160;II drug candidate, VRx&#8209;3996, for use in combination with our platform of NK&#160;cell therapies. In consideration for the license, we are obligated to pay to Viracta&#160;(i)&#160;mid-single digit percentage royalties of net sales of licensed products for therapeutic use; and (ii)&#160;milestone payments ranging from $10.0&#160;million to $25.0&#160;million for various regulatory approvals and cumulative net sales levels. We may terminate the agreement, in our sole discretion, in whole or on a product-by-product and/or country by country basis, at any time upon 90&#160;days&#8217; prior written notice. In addition, either party may terminate the agreement in the event of a material breach or for bankruptcy of the other party.</font></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Agreements with Related Parties</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our Chairman and CEO, Dr.&#160;Soon-Shiong, founded and has a controlling interest in NantWorks, which is a collection of multiple companies in the healthcare and technology space. We have entered into arrangements with NantWorks, and certain affiliates of NantWorks that, taken together, we expect will facilitate the development of new genetically modified NK&#160;cells for our product pipeline.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Share Repurchase</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In November&#160;2018, we entered into a share repurchase agreement with an immediate family member of a director of the company, pursuant to which we repurchased 138,349 of our common shares for a total of $0.2&#160;million under our existing share repurchase program.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">123</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU115"></a><font style="font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">NantHealth Labs, Inc.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March&#160;2018, we entered into an agreement with NantHealth Labs, Inc., or NantHealth Labs, to obtain blood-based tumor profiling services. NantHealth Labs is a related party, as it is a wholly owned subsidiary of NantHealth, Inc., a majority owned subsidiary of NantWorks. We are obligated to pay NantHealth Labs fixed, per-patient fees. The agreement has an initial term of five years and renews automatically for successive one-year periods, unless terminated earlier. During the years ended December&#160;31, 2019 and 2018, $10,000 and $0.3&#160;million, respectively, has been recognized in research and development expense on the consolidated statements of operations.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Immuno-Oncology Clinic, Inc.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Beginning in 2017, we entered into multiple agreements with Immuno-Oncology Clinic, Inc., or the Clinic, to conduct various clinical trials. The Clinic was formerly known as John Lee, M.D. and Leonard Sender, M.D., Inc., a professional medical corporation, dba Chan Soon-Shiong Institutes for Medicine, El Segundo, California. The Clinic is a related party as it is owned by one officer of NantKwest and NantWorks manages the administrative operations of the Clinic. Prior to June&#160;30, 2019, one of the company&#8217;s officers was an investigator or sub-investigator for all of the company&#8217;s trials conducted at the Clinic.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In July&#160;2019, we entered into a new agreement with the Clinic which superseded our existing agreements with the Clinic, effective as of July&#160;1, 2019. The new agreement covers clinical trial and research related activities on a non-exclusive basis relating to our existing clinical trials, commenced prior to July&#160;1, 2019, and prospective clinical trials and research projects. The new agreement also specifies certain services and related costs that are excluded from the new agreement. Prior to commencing any work under the new agreement, the parties have agreed to execute written work orders setting forth the terms and conditions related to specific services to be performed, including financial terms. For existing clinical trials, commenced prior to July&#160;1, 2019, fees incurred for services performed after July&#160;1, 2019 are covered under the new agreement and applied towards the below-mentioned prepayments. The initial term of the new agreement is for one year, but the agreement allows for an automatic renewal and additional extensions beyond the initial term. In July&#160;2019, we executed a clinical trial work order under the new agreement with the Clinic for an open-label, phase&#160;I study of PD&#8209;L1.t&#8209;haNK for infusion in subjects with locally advanced or metastatic solid cancers.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In consideration of the services to be performed under the new agreement, we agreed to make payments of $7.5&#160;million to the Clinic, of which $3.75&#160;million and $1.875&#160;million were paid in July&#160;2019 and October&#160;2019, respectively. The prepayments constitute a prepayment by us for services to be performed by the Clinic. We anticipate that the prepayment amount will be utilized in future periods as the Clinic provides additional services pursuant to the new agreement. Under the term of the new agreement, the outstanding balance of our prepayment shall be increased on a quarterly basis by an interest credit computed in accordance with terms specified in the new agreement.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To the extent any portion of the prepayments remain unearned by the Clinic on the third anniversary of the new agreement, we may elect at our sole discretion either to&#160;(i)&#160;not extend the term of the new agreement and have the Clinic reimburse us for the total amount of any remaining unused portion of the prepayments, or (ii)&#160;extend the term of the new agreement for up to three additional one year periods, at which time the Clinic will reimburse us for the total amount of any remaining unused portion of the prepayments plus interest if reimbursement is not made within 60&#160;days of expiration. The Clinic may terminate this agreement upon each anniversary date upon sixty&#160;(60)&#160;days prior written notice and reimbursement in full to us of any outstanding unearned balance of the prepayments, provided that any such termination by the Clinic will not apply with respect to any work orders still in effect at the time of such termination.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the years ended December&#160;31, 2019, 2018 and 2017, expense of $1.1&#160;million, $2.7&#160;million and $0.8&#160;million, respectively, has been recognized in research and development expense on the consolidated statements of operations for services performed by the Clinic.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">605 Doug St, LLC</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In September&#160;2016, we entered into a lease agreement with 605&#160;Doug&#160;St,&#160;LLC, an entity owned by our Chairman and CEO, for approximately 24,250&#160;square feet in El Segundo, California, which we converted to a research and development laboratory and a current Good Manufacturing Practices, or cGMP, manufacturing facility. The lease runs from July&#160;2016 through July&#160;2023. We have the option to extend the lease for an additional three-year term through July&#160;2026. The monthly rent is $0.1&#160;million with annual increases of 3% beginning in July&#160;2017. For the years ended December&#160;31, 2019, 2018 and 2017, we recorded rent expense of $0.9&#160;million, $0.2&#160;million and $0.2&#160;million, respectively, which is reflected in research and development expense on the consolidated statements of operations.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">124</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU116"></a><font style="font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">NantBio, Inc.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August&#160;2018, NantBio, Inc., or NantBio, assigned an agreement to us for the use of a third-party research facility, which provides us with the exclusive right to use, and access to a portion of, the third party&#8217;s laboratory and vivarium premises. NantBio is a related party as it is an affiliate of NantWorks. In conjunction with the assignment, we reimbursed NantBio for upfront payments which it had made to the third party of $0.9&#160;million and paid $0.5&#160;million directly to the third party for an aggregate value of $1.4&#160;million. The assigned agreement is for a term of ten years and expires in June&#160;2027. The agreement may be terminated by us at any time, with or without cause. In case of termination of the agreement, the third party will reimburse us for a pro-rata amount based upon the passage of time.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In January&#160;2018, we entered into a laboratory services agreement with NantBio. The agreement, effective December&#160;2017, included a sublease of approximately 1,965&#160;square feet of laboratory and office space at our San Diego, California, research facility. This sublease was terminated effective December&#160;31, 2019, pursuant to the terms of the agreement. For the years ended December&#160;31, 2019, 2018 and 2017, we recognized $0.1&#160;million, $0.1&#160;million and $10,000, respectively, in other income on the consolidated statements of operations.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March&#160;2016, NantBio and the National Cancer Institute entered into a cooperative research and development agreement. The initial five year agreement covers NantBio and its affiliates, including us. Under the agreement, the parties are collaborating on the preclinical and clinical development of proprietary recombinant natural killer cells and monoclonal antibodies in monotherapy and in combination immunotherapies. We benefited from the preclinical and clinical research conducted during the first four years under this agreement. In each of April&#160;2016, April&#160;2017, August&#160;2018, and May&#160;2019, we paid $0.6&#160;million to the National Cancer Institute as a prepayment for services under the agreement. We recognize expense associated with this agreement ratably over a 12-month period and recorded $0.6&#160;million of research and development expense in each of the years ended December&#160;31, 2019, 2018 and 2017.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">NantWorks</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In November&#160;2015, we entered into a shared services agreement with NantWorks, which became effective in August&#160;2015, under which NantWorks provides corporate, general and administrative, manufacturing strategy, research and development, regulatory and clinical trial strategy, and other support services to us. We are charged for the services at cost plus reasonable allocations for indirect costs that relate to the employees providing the services. For the years ended December&#160;31, 2019, 2018 and 2017, we recorded $2.1&#160;million, $2.8&#160;million and $3.6&#160;million, respectively, to selling, general and administrative expense, and $1.5&#160;million, $3.3&#160;million and $3.2&#160;million, respectively, in research and development expense under this arrangement on the consolidated statements of operations. These amounts exclude certain general and administrative expenses provided by third party vendors directly for our benefit, which have been reimbursed to NantWorks based on those vendors&#8217; invoiced amounts without markup by NantWorks.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June&#160;2016, we entered into an amended shared services agreement with NantWorks to allow for the provision of such support services by us to NantWorks and/or any of its affiliates. For the years ended December&#160;31, 2019, 2018 and 2017, we recorded expense reimbursements of $1.2&#160;million, $0.6&#160;million and $0.4&#160;million, respectively, to selling, general and administrative expense, and $2.3&#160;million, $2.6&#160;million and $1.0&#160;million, respectively, to research and development expense.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In November&#160;2015, we entered into a facility license agreement with NantWorks, which became effective in May&#160;2015, for approximately 9,500&#160;square feet of office space in Culver City, California, which has been converted to a research and development laboratory and a cGMP laboratory. The term of the license extends through December&#160;2020. The monthly rent is $47,000 with annual increases of 3% beginning in January&#160;2017. For each of the years ended December&#160;31, 2019, 2018 and 2017, we recorded rent expense of $0.6&#160;million, $0.2&#160;million and $0.2&#160;million, respectively, which is included in research and development expense on the consolidated statements of operations.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">NantOmics, LLC</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June&#160;2015, we entered into an agreement, as amended in May&#160;2018, with NantOmics, LLC, or NantOmics, which is a related party, as it is an affiliate of NantWorks. Pursuant to the agreement we obtain genomic sequencing and proteomic analysis services, as well as related data management and bioinformatics services, exclusively from NantOmics. We have rights to use the data and results generated from NantOmics&#8217; services in connection with the performance of the particular oncology trial with respect to which the services were performed, but NantOmics owns the data and results, as well as any other intellectual property it creates in performing these services on our behalf. We are obligated to pay NantOmics a fixed, per sample fee, determined based on the type of services being provided. The agreement has an initial term of five&#160;years and renews automatically for successive one-year periods, unless terminated. We have the right to terminate the agreement for convenience on 90&#160;days prior written notice, and both parties may terminate if there is a material, uncured breach of the agreement by the other party. For the years ended December&#160;31, 2019, 2018 and 2017, under this arrangement we recorded operating expense of $0.1&#160;million, $0.1&#160;million and $0.1&#160;million, respectively, to research and development on the consolidated statements of operations.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">125</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU117"></a><font style="font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">ImmunityBio</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ImmunityBio, Inc., or ImmunityBio, is a related party, as it is an affiliate of NantWorks. ImmunityBio was formerly known as NantCell, Inc.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In January&#160;2020, we entered into a cost sharing agreement with ImmunityBio as further described above and in Note&#160;15&#160;&#8209;&#160;<font style="font-style:italic;">Subsequent Events</font> of the &#8220;Notes to Consolidated Financial Statements&#8221; included in Part&#160;II, Item&#160;8 of this Annual Report.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In November&#160;2018, we entered into an agreement with Etubics Corporation, or Etubics, a subsidiary of ImmunityBio. Pursuant to this agreement we sold used laboratory equipment to Etubics for $0.3&#160;million. In conjunction with this sale, we recognized a loss on disposal of related laboratory equipment of $0.1&#160;million, which was included in other income, net on the consolidated statements of operations.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August&#160;2016, we entered into a Co-Development Agreement with Altor as further described above and under <font style="font-style:italic;">Collaborative Arrangements &#8211; Exclusive Co-Development Agreement</font> in Note&#160;7 of the &#8220;Notes to Consolidated Financial Statements&#8221; included in Part&#160;II, Item&#160;8 of this Annual Report. Altor is a related party, as it is a wholly owned subsidiary of ImmunityBio. No charges for supplies by Altor were incurred in association with the trials during the years ended December&#160;31, 2019, 2018 and 2017.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June&#160;2015, we entered into a supply agreement with ImmunityBio pursuant to which we have the right to purchase ImmunityBio&#8217;s proprietary bioreactors, made according to specifications mutually agreed to with ImmunityBio. We also have the right to purchase reagents and consumables associated with such equipment from ImmunityBio. When an upfront payment is made, it is included in prepaid expenses on the consolidated balance sheets until the product is received. The agreement has an initial term of five years and renews automatically for successive one-year periods unless terminated earlier.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2019 and 2018, we had $1.8&#160;million and $1.1&#160;million, respectively, in capitalized equipment purchased from ImmunityBio, which is included in property, plant and equipment, net, on the consolidated balance sheets. During the years ended December&#160;31, 2019, 2018 and 2017, we recorded research and development expense associated with reagents and consumables purchased from ImmunityBio of $0.1&#160;million, $0.1&#160;million and $0.3&#160;million, respectively, on the consolidated statements of operations.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Components of our Results of Operations</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Revenue</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To date, we have derived substantially all of our revenue from non-exclusive license agreements with numerous pharmaceutical and biotechnology companies granting them the right to use our cell lines and intellectual property for non-clinical use. These agreements generally include upfront fees and annual research license fees for such use, as well as commercial license fees for sales of our licensee&#8217;s products developed or manufactured using our intellectual property and cell lines. Our license agreements may also include milestone payments, although to date, we have not generated any revenue from milestone payments. To date, we have generated minimal revenue related to the non-clinical use of our cell lines and intellectual property. We have no products approved for commercial sale and have not generated any revenue from product sales. If we fail to complete the development of our product candidates in a timely manner or fail to obtain regulatory approval for them, we may never be able to generate substantial future revenue.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Operating Expenses</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We classify our operating expenses into research and development and selling, general and administrative expenses. Personnel costs, including salaries, benefits, bonuses, and stock-based compensation expense comprise a significant component of our research and development and selling, general and administrative expense categories. We allocate expenses associated with our facilities and information technology costs between these two categories based on the nature of each cost.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">126</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU118"></a><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Research and Development</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expense consists of expenses incurred while performing research and development activities to discover and develop our product candidates. This includes conducting preclinical studies and clinical trials, manufacturing development efforts and activities related to regulatory filings for product candidates. We recognize research and development expenses as they are incurred. Our research and development expense primarily consists of:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">clinical trial and regulatory-related costs;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">expenses incurred under agreements with investigative sites and consultants that conduct our clinical trials;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">manufacturing and testing costs and related supplies and materials;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">employee-related expenses, including salaries, benefits, travel and stock-based compensation; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">facility expenses dedicated to research and development.</font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We typically use our employee, consultant and infrastructure resources across our development programs. We track outsourced development costs by product candidate or development program, but we do not allocate personnel costs, other internal costs or external consultant costs to specific product candidates or development programs.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Substantially all of our research and development expenses to date have been incurred in connection with our product candidates. We expect our research and development expenses to increase significantly for the foreseeable future as we advance our product candidates through clinical development, including the conduct of our ongoing and any future clinical trials. The process of conducting clinical trials necessary to obtain regulatory approval is costly and time consuming. The successful development of product candidates is highly uncertain. At this time, we cannot reasonably estimate the nature, timing or costs required to complete the remaining development of any product candidates. This is due to the numerous risks and uncertainties associated with the development of product candidates as discussed in greater detail in Part&#160;I, Item&#160;1A,&#160;&#8220;<font style="font-style:italic;">Risk Factors</font>&#8221;.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The costs of clinical trials may vary significantly over the life of a project owing to, but not limited to, the following:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">per patient trial costs;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the number of sites included in the clinical trials;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the countries in which the clinical trials are conducted;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the length of time required to enroll eligible patients;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the number of patients that participate in the clinical trials;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the number of doses that patients receive;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the cost of comparative agents used in clinical trials;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the drop-out or discontinuation rates of patients;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">potential additional safety monitoring or other studies requested by regulatory agencies;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the duration of patient follow-up; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the efficacy and safety profile of the product candidate.</font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We do not expect any of our product candidates to be commercially available for at least the next several years, if ever.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Selling, General and Administrative</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Selling, general and administrative expense consists primarily of salaries and personnel-related costs, including employee benefits and any stock-based compensation, for employees performing functions other than research and development. This includes personnel in executive, finance, human resources and administrative support functions. Other selling, general and administrative expenses include facility-related costs not otherwise allocated to research and development expense, professional fees for auditing, tax and legal services, advertising costs, expenses associated with obtaining and maintaining patents, consulting costs, royalties and licensing costs, and costs of our information systems.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">127</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU119"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Although our selling, general and administrative costs declined during the year ended December&#160;31, 2019 as compared to the year ended December&#160;31, 2018, we expect that our selling, general and administrative expenses during the year ended December&#160;31, 2020 will increase. We have incurred and expect that we will continue to incur in the future, additional costs associated with operating as a public company, including costs to comply with stock exchange listing and SEC requirements, corporate governance, internal controls, investor relations, disclosure and similar requirements applicable to public companies. Additionally, if and when we believe that a regulatory approval of a product candidate appears likely, we expect to incur significant increases in our selling, general and administrative expenses relating to the sales and marketing of the approved product candidate.</font></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Other Income (Expense)</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other income (expense) consists primarily of income from our investments in marketable debt securities, sublease rental income, interest expense from the accretion of our capital lease and financing obligations, foreign currency income (expense), and gains and losses on disposition of assets.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Income Tax</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Income tax expense consists of U.S. federal and state income taxes. To date, we have not been required to pay U.S. federal income taxes because of our current and accumulated net operating losses. Our income tax expense to date primarily relates to minimum income taxes in the State of California. Our tax benefit relates to the amortization of deferred tax liabilities at our Korean subsidiary.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Results of Operations</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Comparison of the years ended December&#160;31, 2019, 2018 and 2017 (in thousands)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:41.78%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.76%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the Year Ended December&#160;31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.12%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Change</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:41.78%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019 vs. 2018</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018 vs. 2017</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenue</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating expenses:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development (including</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; amounts with related parties)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49,785</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55,718</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42,044</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,933</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,674</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:41.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Selling, general and administrative (including</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; amounts with related parties)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,065</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42,718</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">57,121</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(24,653</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(14,403</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:41.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total operating expenses</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">67,850</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">98,436</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">99,165</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(30,586</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(729</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:41.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss from operations</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(67,807</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(98,389</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(99,120</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30,582</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">731</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other income (expense):</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Investment income, net</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,642</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,857</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,665</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(215</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(808</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest expense (including amounts</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; with related parties)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(19</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(433</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(618</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">414</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">185</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:41.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other income, net (including amounts</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; with related parties)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">298</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">236</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">157</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">62</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">79</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:41.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total other income</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,921</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,660</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,204</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">261</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(544</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss before income taxes</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(65,886</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(96,729</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(96,916</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30,843</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">187</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:41.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Income tax benefit</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">97</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">503</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">493</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(406</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:41.78%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(65,789</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(96,226</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(96,423</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30,437</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">197</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Revenue</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The change in revenue was minimal during the comparative periods and consisted of license fees and royalties.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">128</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU120"></a><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Research and Development</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expense decreased $5.9&#160;million during the year ended December&#160;31, 2019 as compared to the year ended December&#160;31, 2018. The decrease in research and development expense was primarily attributable to decreases of $4.7&#160;million in compensation and related expenses due to decreased staff and to fees for shared services rendered under our shared services agreement with NantWorks as a result of less clinical trial support activities, $2.0&#160;million for pre-clinical and clinical trial costs mainly driven by decreased activity related to investigator sponsored trials and research agreements, and $1.7&#160;million of intangible asset amortization expense due to the underlying asset being fully amortized as of March&#160;2019. These decreases were partially offset by a net increase of $1.6&#160;million for laboratory and manufacturing facility related expenses, including increases related to third-party facility and manufacturing process validation and qualification costs, depreciation expense, and lease expense, mainly driven and associated with our El Segundo cGMP facility, and decreases related to third party testing services and laboratory supplies. In addition, we recorded $0.9&#160;million of expense related to impairment of laboratory equipment. We expect our research and development expenses to increase significantly for the foreseeable future as we advance our product candidates through clinical development and conduct our ongoing and planned clinical trials.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expense increased $13.7&#160;million during the year ended December&#160;31, 2018 as compared to the year ended December&#160;31, 2017. The increase in research and development expense was attributable to increases of $7.8&#160;million primarily due to the ramp-up of laboratory and GMP manufacturing activities driven in part by our El Segundo, California, facility where we completed construction in May&#160;2018, $6.1&#160;million in compensation and related expenses due to increased personnel and fees for services rendered under our shared services agreement with NantWorks, and $0.4&#160;million in stock compensation expense primarily related to increased staff. The increase was partially offset by decreases of $0.7&#160;million for clinical and regulatory consultant costs due to bringing these functions in-house.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Selling, General and Administrative</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Selling, general and administrative expense decreased $24.7&#160;million during the year ended December&#160;31, 2019 as compared to the year ended December&#160;31, 2018. The decrease in selling, general and administrative expense was primarily attributable to a decrease of $20.8&#160;million in stock-based compensation expense, which was primarily driven by a decrease due to vesting completed in July&#160;2018 and March&#160;2019 related to service-based equity awards issued to our Chairman and CEO in 2015. In addition, selling, general and administrative expense decreased by $2.3&#160;million due to lower costs associated with litigation, $1.1&#160;million due to decreased activity in shared services provided by NantWorks, and $0.6&#160;million due to lower headcount related expenses. These decreases in selling, general and administrative expense were partially offset by a $0.2&#160;million increase in other administrative costs. We expect our selling, general and administrative expenses to increase in the foreseeable future to support our ongoing operations, including accounting, audit, legal, and regulatory compliance, director and officer insurance costs, and other expenses associated with operating as a public company.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Selling, general and administrative expense decreased $14.4&#160;million during the year ended December&#160;31, 2018 as compared to the year ended December&#160;31, 2017. The decrease in selling, general and administrative expense was primarily attributable to a decrease of $14.0&#160;million in stock-based compensation expense mainly driven by a decrease of $13.8&#160;million due to the completion of vesting in July&#160;2018 related to service-based equity awards issued to our Chairman and CEO in 2015. In addition, selling, general and administrative expense decreased by $0.6&#160;million due to decreased activity in shared services provided by NantWorks, $0.5&#160;million for professional and consulting fees for accounting and compliance related services, and $0.4&#160;million, primarily due to lower travel related expenses. These decreases in selling, general and administrative expense were partially offset by a $1.0&#160;million increase mainly driven by litigation related expenses and other professional fees.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Other Income (Expense)</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other income increased by $0.3&#160;million during the year ended December&#160;31, 2019 as compared to the year ended December&#160;31, 2018. The increase in other income resulted primarily from lower interest expense of $0.4&#160;million, offset in part by a decrease in investment income related to use of our investments for operations of $0.2&#160;million.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other income decreased by $0.5&#160;million during the year ended December&#160;31, 2018 as compared to the year ended December&#160;31, 2017 due to a $0.8&#160;million decrease in investment income related to use of our investments for operations, partially offset by a $0.2&#160;million increase in interest expense related to our financing obligations.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">129</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU121"></a><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Income Tax Benefit</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The $0.4&#160;million decrease in the income tax benefit during the year ended December&#160;31, 2019 as compared to the year ended December&#160;31, 2018, was due primarily to lower income tax benefits related to losses at our Korean subsidiary.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The change in income tax benefit was minimal during the year ended December&#160;31, 2018 as compared to the year ended December&#160;31, 2017.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Liquidity and Capital Resources</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Sources of Liquidity</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our principal sources of liquidity are our existing cash, cash equivalents, and marketable debt securities. We have historically invested our cash primarily in investment grade short- to intermediate-term corporate debt securities, commercial paper, government sponsored securities, U.S. treasury securities, and foreign government bonds and classify these investments as available-for-sale. Certain of these investments are subject to general credit, liquidity and other market risks. The general condition of the financial markets and the economy may increase those risks and may affect the value and liquidity of investments and restrict our ability to access the capital markets. During the year ended December&#160;31, 2019, our Chairman and CEO exercised warrants and options resulting in proceeds to us of $35.2&#160;million and $4.1&#160;million, respectively.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2019, we had cash and cash equivalents, and restricted cash of $15.7&#160;million compared to $17.0&#160;million as of December&#160;31, 2018. The decrease was attributable to cash used in operating activities of $61.4&#160;million, offset in part by cash flows provided by financing and investing activities of $38.6&#160;million and $21.5&#160;million, respectively.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Investments in marketable debt securities were $37.6&#160;million as of December&#160;31, 2019, of which $36.1&#160;million were short-term investments, as compared to $63.0&#160;million as of December&#160;31, 2018, of which $57.3&#160;million were short-term investments.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Cash Flows</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table sets forth our primary sources and uses of cash for the years ended December&#160;31, 2019, 2018 and 2017 (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the Year Ended December&#160;31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash provided by (used in):</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating activities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(61,362</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(63,381</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(48,780</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Investing activities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,456</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">57,101</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">99,552</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financing activities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38,593</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(771</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(34,983</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net (decrease) increase in cash, cash equivalents and restricted cash</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,313</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(7,051</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,789</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Operating Activities</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the year ended December&#160;31, 2019, our net cash used in operating activities of $61.4&#160;million consisted of a net loss of $65.8&#160;million, and $10.9&#160;million of cash used by net working capital changes, partially offset by $15.4&#160;million in adjustments for non-cash items. Adjustments for non-cash items primarily consisted of $9.0&#160;million in depreciation and amortization, $2.6&#160;million in stock compensation expense, $2.6&#160;million of non-cash lease expense related to operating lease right-of-use assets, $0.9&#160;million of impairment related to laboratory equipment, and $0.2&#160;million in non-cash interest. The decrease in net working capital consisted primarily of decreases related to accrued expenses of $12.0&#160;million, other long-term assets of $4.0&#160;million, operating lease liabilities of $2.3&#160;million, due to related parties of $1.1&#160;million, and operating lease right-of-use assets of $0.8&#160;million, partially offset by an increase related to prepaid expenses and other current assets of $9.3&#160;million. The decrease in cash used in operating activities is primarily due to lower laboratory and manufacturing related costs and lower headcount and compensation costs including shared services, partially offset by higher clinical trial and related operational costs.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">130</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU122"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the year ended December&#160;31, 2018, our net cash used in operating activities of $63.4&#160;million consisted of a net loss of $96.2&#160;million, offset by $33.4&#160;million in adjustments for non-cash items, primarily attributable to $23.4&#160;million in stock-based compensation expense, as well as research and development and selling, general and administrative expenses, and a $0.6&#160;million decrease of cash related to changes in working capital. Adjustments for non-cash items primarily consisted of the $23.4&#160;million in stock-based compensation expense, $9.6&#160;million in depreciation and amortization, $0.5&#160;million in amortization of premiums on marketable debt securities, $0.3&#160;million in non-cash interest related to our marketable debt securities, and $0.2&#160;million related to loss on disposal of assets, reduced by $0.5&#160;million of deferred income tax benefit. Changes in net working capital consisted primarily of increases related to prepaid and other current assets of $9.8&#160;million, other assets of $1.2&#160;million, accounts payable of $1.1&#160;million, due to related parties of $0.7&#160;million, and deferred rent of $0.5&#160;million, partially offset by an increase in accrued expenses of $12.7&#160;million. The increase in cash used in operating activities is primarily due to costs incurred in ongoing preclinical and clinical trials, the ramp-up of manufacturing activities, increased personnel, and research and development activities.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the year ended December&#160;31, 2017, our net cash used in operating activities of $48.8&#160;million consisted of a net loss of $96.4&#160;million, partially offset by $44.4&#160;million in adjustments for non-cash items, primarily attributable to $37.0&#160;million in stock compensation expense, as well as research and development and selling, general and administrative expenses, and $3.2&#160;million of cash provided by net working capital changes. Adjustments for non-cash items primarily consisted of the $37.0&#160;million in stock-based compensation expense, $5.6&#160;million in depreciation and amortization, $1.6&#160;million in amortization of premiums on marketable debt securities, $0.7&#160;million in non-cash interest related to our marketable debt securities, and $0.1&#160;million in loss on asset disposals, reduced by $0.5&#160;million of deferred income tax benefit. Changes in net working capital consisted primarily of increases in due to related parties of $1.6&#160;million, deferred rent of $1.2&#160;million, other assets of $0.5&#160;million, accounts payable of $0.2&#160;million, and prepaid and other current assets of $0.2&#160;million, partially offset by a decrease in accrued expenses of $0.3&#160;million. The increase in cash used in operating activities is primarily due to costs incurred in ongoing preclinical and clinical trials, the ramp-up of manufacturing activities, increased personnel, and research and development activities.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Investing Activities</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the year ended December&#160;31, 2019, net cash provided by investing activities was $21.5&#160;million, which was primarily attributable to $112.3&#160;million in sales and/or maturities of marketable debt securities, partially offset by $86.6&#160;million in purchases of marketable debt securities, and $4.2&#160;million in purchases of property, plant and equipment. During the year ended December&#160;31, 2019 our purchases of marketable debt securities included our investment of $39.2&#160;million of cash proceeds received in March&#160;2019 from the exercise of stock options and warrants, together with reinvestment of excess cash related to maturing securities. Our investments in property, plant and equipment during the year ended December&#160;31, 2019 mainly related to our El Segundo, California, facilities.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the year ended December&#160;31, 2018, net cash provided by investing activities was $57.1&#160;million, which was primarily attributable to $165.3&#160;million in sales and/or maturities of marketable debt securities and $0.4&#160;million in proceeds from sales of laboratory equipment, partially offset by $94.8&#160;million in purchases of marketable debt securities, driven by the reinvestment of excess cash resources, $13.1&#160;million in purchases of property, plant and equipment, mainly related to our laboratory and cGMP build out in El Segundo, California, and $0.7&#160;million in purchases of Viracta convertible notes.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the year ended December&#160;31, 2017, net cash provided by investing activities was $99.6&#160;million, which was primarily attributable to $254.2&#160;million in sales and maturities of marketable debt securities partially offset by $111.4&#160;million in purchases of marketable debt securities driven by the reinvestment of excess cash resources, $34.8&#160;million in purchases of property and equipment mainly related to our laboratory and cGMP build out in El Segundo, California, and equipment purchases for the El Segundo, California, research and cGMP facility, and $8.5&#160;million in the purchase of an investment in equity securities.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Financing Activities</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the year ended December&#160;31, 2019, net cash provided by financing activities was $38.6&#160;million, which primarily consisted of cash proceeds of $35.2&#160;million and $4.1&#160;million resulting from the exercise of warrants and stock options, respectively, by our Chairman and CEO during March&#160;2019, partially offset by $0.5&#160;million used for stock repurchases, including commissions, and $0.1&#160;million related to net share settlement of vested RSUs and option exercises for payment of employee payroll taxes.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the year ended December&#160;31, 2018, net cash used in financing activities was $0.8&#160;million, which primarily related to $0.5&#160;million of principal payments on our financing obligations, $0.2&#160;million used for stock repurchases, and $0.1&#160;million in net share settlement of exercised warrants and vesting of RSUs for payment of employee payroll taxes, partially offset by $0.1&#160;million in proceeds from the exercise of warrants.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">131</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU123"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the year ended December&#160;31, 2017, net cash used in financing activities</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> was </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$35.0&#160;million</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, which</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> consisted of $19.9&#160;million in principal payments primarily related to our capital lease obligation, $15.2&#160;million used for stock repurchases, and $1.0&#160;million in net share settlement of exercised stock options and vesting of RSUs for payment of employee payroll taxes, partially offset by $1.2&#160;million in proceeds from the exercise of stock options and warrants.</font></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Future Funding Requirements</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To date, we have generated minimal revenue related to the non-clinical use of our cell lines and intellectual property, and we have no products approved for commercial sale and have not generated any revenue from product sales. We do not expect to generate significant revenue unless and until we obtain regulatory approval of and commercialize any of our product candidates and we do not know when, or if, this will occur. In addition, we expect our expenses to significantly increase in connection with our ongoing development activities, particularly as we continue the research, development and clinical trials of, and seek regulatory approval for, our product candidates. Moreover, since the completion of our IPO in July&#160;2015, we have incurred and expect that we will continue to incur in the future additional costs associated with operating as a public company. In addition, subject to obtaining regulatory approval of our product candidates, we expect to incur significant commercialization expenses for product sales, marketing, manufacturing and distribution. We anticipate that we will need substantial additional funding in connection with our continuing operations. We expect that our expenses will increase substantially if and as we:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">continue research and development, including preclinical and clinical development of our existing product candidates;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">potentially seek regulatory approval for our product candidates;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">seek to discover and develop additional product candidates;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">establish a commercialization infrastructure and scale up our manufacturing and distribution capabilities to commercialize any of our product candidates for which we may obtain regulatory approval;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">seek to comply with regulatory standards and laws;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">maintain, leverage and expand our intellectual property portfolio;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">hire clinical, manufacturing, scientific and other personnel to support our product candidates&#8217; development and future commercialization efforts;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">add operational, financial and management information systems and personnel; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">incur additional legal, accounting and other expenses in operating as a public company.</font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Based upon our current operating plan, we expect that our existing cash, cash equivalents, and marketable debt securities, and our ability to borrow from affiliated entities, will enable us to fund our operating expenses and capital expenditure requirements for at least the next 12&#160;months following the issuance date of the financial statements based on our Chairman and CEO&#8217;s intent and ability to support our operations with additional funds, including loans from affiliated entities, as required. We have based this estimate on assumptions that may prove to be incorrect, and we may use our available capital resources sooner than we currently expect. The successful development of any product candidate is highly uncertain. Due to the numerous risks and uncertainties associated with the development and commercialization of our product candidates, if approved, we are unable to estimate the amounts of increased capital outlays and operating expenses associated with completing the development of our product candidates.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our future capital requirements will depend on many factors, including:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the timing of, and the costs involved in, preclinical and clinical development and obtaining any regulatory approvals for our product candidates;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the costs of manufacturing, distributing and processing our product candidates;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the number and characteristics of any other product candidates we develop or acquire;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">our ability to establish and maintain strategic collaborations, licensing or other commercialization arrangements and the terms and timing of such arrangements including our arrangements with ImmunityBio and its subsidiaries and Viracta;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the degree and rate of market acceptance of any approved products;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the emergence, approval, availability, perceived advantages, relative cost, relative safety and relative efficacy of other products or treatments;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the expenses needed to attract and retain skilled personnel;</font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">132</a></p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><a name="_AEIOULastRenderedPageBreakAEIOU124"></a><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-family:Times New Roman;">the costs associated with being a public company;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the costs involved in preparing, filing, prosecuting, maintaining, defending and enforcing intellectual property claims, including litigation costs and the outcome of such litigation;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the timing, receipt and amount of sales of, or royalties on, any approved products; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">any product liability or other lawsuits related to our product candidates or the company.</font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Because all of our product candidates are in the early stages of preclinical and clinical development and the outcome of these efforts is uncertain, we cannot estimate the actual amounts necessary to successfully complete the development and commercialization of any of our product candidates or whether, or when, we may achieve profitability. Until such time, if ever, as we can generate substantial product revenues, we expect to finance our cash needs through a combination of equity offerings, debt financings, collaborations, strategic alliances and/or licensing arrangements. We do not have any committed external source of funds. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interest of our stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect your rights as a common stockholder. Debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we raise additional funds through collaborations, strategic alliances or licensing arrangements with pharmaceutical partners, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates, or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market our product candidates that we would otherwise prefer to develop and market ourselves.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Contractual Obligations, Commitments and Contingencies</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Contractual Obligations and Commitments</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our contractual obligations as of December&#160;31, 2019 were as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.82%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="18" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.06%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Payments Due by Period</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.82%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Less than</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1 Year</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1-3</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">3-5</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">More than</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">5 Years</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Contractual Obligations</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.82%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease liabilities (1)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,053</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,271</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,424</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,629</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,729</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.82%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total contractual obligations</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,053</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,271</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,424</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,629</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,729</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:2pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:2pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1)</font></p></td>
<td valign="top">
<p style="margin-top:2pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Represents future minimum lease payments under all our leases as of December&#160;31, 2019. The operating lease liability payments above do not include any related common area maintenance charges or real estate taxes.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For additional information, see Note&#160;8&#160;<font style="font-style:italic;">&#8211;&#160;Commitments and Contingencies, Contractual Obligations &#8211; Leases and </font>Note&#160;9&#160;<font style="font-style:italic;">&#8211;&#160;Related Party Agreements</font> of the &#8220;Notes to Consolidated Financial Statements&#8221; included in Part&#160;II, Item&#160;8 of this Annual Report.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Contingencies</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From time to time, we may be involved in various claims and legal proceedings relating to claims arising out of our operations. We are not currently a party to any legal proceedings that, in the opinion of our management, are likely to have a material adverse effect on our business. Regardless of outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Off-Balance Sheet Arrangements</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the periods presented, we did not have, nor do we currently have, any off-balance sheet arrangements as defined under SEC rules.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">133</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU125"></a><a name="_cp_text_1_269"></a><a name="_cp_text_4_270"></a><a name="_cp_text_1_272"></a><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_269"></a>Critical Accounting Policies</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">, Significant Judgements and</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_4_270"></a> </font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_272"></a>Use of </font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Estimates</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Management&#8217;s discussion and analysis of our financial condition and results of operations are based upon our consolidated financial statements, which are prepared in accordance with U.S.&#160;GAAP. The preparation of these consolidated financial statements requires us to make estimates and judgments that affect the reported amounts of assets and liabilities, related disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. We continually evaluate our estimates and judgments, the most critical of which are those related to valuation of equity-based awards, deferred income taxes and related valuation allowances, preclinical and clinical trial accruals, impairment assessments, useful lives of long-lived assets, loss contingencies, and fair value measurements. We base our estimates and judgments on historical experience and other factors that we believe to be reasonable under the circumstances. Materially different results can occur as circumstances change and additional information becomes known.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following is not intended to be a comprehensive discussion of all of our significant accounting policies. See the notes accompanying our financial statements appearing in this Annual Report for a summary of all of our significant accounting policies and other disclosures required by U.S.&#160;GAAP.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Preclinical and Clinical Trial Accruals</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As part of the process of preparing the financial statements, we are required to estimate expenses resulting from our obligations under contracts with vendors, clinical research organizations and consultants. The financial terms of these contracts vary and may result in payment flows that do not match the periods over which materials or services are provided under such contracts.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We estimate clinical trial and research agreement related expenses based on the services performed, pursuant to contracts with research institutions and clinical research organizations and other vendors that conduct clinical trials and research on our behalf. In accruing clinical and research related fees, we estimate the time period over which services will be performed and activity expended in each period. If the actual timing of the performance of services or the level of effort varies from the estimate, we will adjust the accrual accordingly. Payments made to third parties under these arrangements in advance of the receipt of the related services are recorded as prepaid expenses until the services are rendered.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Research and Development Costs</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Major components of research and development costs include cash compensation and other personnel-related expenses, stock-based compensation, depreciation and amortization expense on research and development property and equipment and intangible assets, costs of preclinical studies, clinical trials and related clinical manufacturing, costs of drug development, costs of materials and supplies, facilities cost, overhead costs, regulatory and compliance costs, and fees paid to consultants and other entities that conduct certain research and development activities on our behalf. Costs incurred in research and development are expensed as incurred.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Included in research and development costs are clinical trial and research expenses based on the services performed pursuant to contracts with research institutions and clinical research organizations and other vendors that conduct clinical trials and research on our behalf. We record accruals for estimated costs under these contracts. When evaluating the adequacy of the accrued liabilities, we analyze the progress of the studies or clinical trials, including the phase or completion of events, invoices received, contracted costs and purchase orders. Significant judgments and estimates are made in determining the accrued balances at the end of any reporting period based on the facts and circumstances known at that time. Although we do not expect the estimates to be materially different from the amounts actually incurred, if the estimates of the status and timing of services performed differs from the actual status and timing of services performed, we may report amounts that are too high or too low in any particular period. Actual results could differ from our estimates.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">134</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU126"></a><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Cash, Cash Equivalents and Marketable Debt Securities</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We invest our excess funds in investment grade short- to intermediate-term corporate debt securities, commercial paper, government sponsored securities, and foreign government bonds and classify these investments as available-for-sale. We consider all highly liquid investments purchased with original maturities of three&#160;months or less to be cash equivalents and all investments purchased with original maturities of greater than three&#160;months as marketable debt securities. Marketable debt securities with remaining maturities of 12&#160;months or less are classified as short-term and marketable debt securities with remaining maturities greater than 12&#160;months are classified as long-term. All marketable debt securities are reported at fair value and any unrealized gains and losses are reported as a component of accumulated other comprehensive income (loss), net of tax, on the consolidated statements of stockholders&#8217; equity, with the exception of unrealized losses believed to be other-than-temporary, which are recorded in investment income, net, on the consolidated statements of operations. Realized gains and losses are included in investment income, net, on the consolidated statements of operations. Realized gains and losses from sale of the securities and the amounts, net of tax, reclassified out of accumulated other comprehensive loss, if any, are determined on a specific identification basis.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We periodically evaluate whether declines in fair values of our investments below their book value are other-than-temporary. This evaluation consists of several qualitative and quantitative factors regarding the severity and duration of the unrealized loss, as well as our ability and intent to hold the investment until a forecasted recovery occurs. Additionally, we assess whether we plan to sell the security or it is more likely than not we will be required to sell any investment before recovery of its amortized cost basis. Factors considered include quoted market prices, recent financial results and operating trends, implied values from any recent transactions or offers of investee securities, credit quality of debt instrument issuers, other publicly available information that may affect the value of our investments, duration and severity of the decline in value, and our strategy and intentions for holding the investment. There were no other-than-temporary impairments recorded in years ended December&#160;31, 2019, 2018 and 2017.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We minimize the credit risk associated with cash and cash equivalents by periodically evaluating the credit quality of our primary financial institutions. While we maintain cash deposits in FDIC insured financial institutions in excess of federally insured limits, management believes we are not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held. We have not experienced any losses on such accounts.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have funded a certificate of deposit, or CD, as a substitute letter of credit for one of the leased properties. This CD is reported as long-term restricted cash and is included in other assets on the consolidated balance sheets as the landlord is the beneficiary of the account and we are not able to access the funds during the term of the lease.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Contingencies</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We record accruals for loss contingencies to the extent that we conclude it is probable that a liability has been incurred and the amount of the related loss can be reasonably estimated. We evaluate, on a quarterly basis, developments in legal proceedings and other matters that could cause a change in the potential amount of the liability recorded or of the range of potential losses disclosed. Additionally, we record our rights to insurance recoveries, limited to the extent of incurred or probable losses, as a receivable when such recoveries have been agreed to with our third-party insurers and when receipt is deemed probable. This includes instances where our third-party insurers have agreed to pay, on our behalf, certain legal defense costs and settlement amounts directly to applicable law firms and a settlement fund.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Investment in Equity Securities</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We own non-marketable equity securities that are measured at cost, less impairment, adjusted for observable price changes in an orderly market for an identical or similar investment of the same issuer, because the preferred stock we hold is not considered in-substance common stock and such preferred stock does not have a readily determinable fair value. This investment is reviewed on a regular basis for possible impairment. If the fair value of the investment is determined to be less than its net carrying value, the investment will be written down to its fair value. Such an evaluation is judgmental and dependent on specific facts and circumstances. Factors considered in determining whether an impairment indicator is present include:&#160;the investees&#8217; earning performance and clinical trial performance, change in the investees&#8217; industry and geographic area in which it operates, offers to purchase or sell the security for a price less than the cost of the investment, issues that raise concerns about the investee's ability to continue as a going concern, and any other information that we may be aware of related to the investment. Factors considered in determining whether an observable price change has occurred include:&#160;the price at which the investee issues equity instruments similar to those of our investment and the rights and preferences of those equity instruments compared ours. To date, we have not recorded any adjustments to the cost basis of this investment.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">135</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU127"></a><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Fair Value of Financial Instruments</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We record our available-for-sale investments at fair value. At December&#160;31, 2019, our cash equivalents and investments in marketable debt securities totaled $37.6&#160;million. Financial Accounting Standards Board, or FASB, Accounting Standards Codification, or ASC, Topic 820,&#160;<font style="font-style:italic;">Fair Value Measurements and Disclosures</font>, or ASC&#160;820, establishes three levels of inputs that may be used to measure fair value. Each level of input represents varying degrees of subjectivity and difficulty involved in determining fair value. Valuations using Level&#160;1 and&#160;2 inputs are generally based on price quotations and other observable inputs in active markets and do not require significant management judgment or estimation. We utilize a third-party pricing service to assist us in obtaining fair value pricing for these investments. While pricing for these securities is based on proprietary models, the inputs used are based on observable market information; therefore, we have classified our inputs as Level&#160;1 and Level&#160;2. For additional information, see Note&#160;6<font style="font-style:italic;">&#160;&#8211; Fair Value Measurements</font> of the &#8220;Notes to Consolidated Financial Statements&#8221; included in Part&#160;II, Item&#160;8 of this Annual Report.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Long-Lived Assets</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Long-lived assets include property, plant and equipment and intangible assets. We review long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability is measured by comparison of the carrying amount to the future net cash flows that the assets are expected to generate. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the projected undiscounted future cash flows arising from the assets using a discount rate determined by management to be commensurate with the risk inherent to our current business model. During the year ended December&#160;31, 2019, we determined that certain bioreactor laboratory equipment could no longer be utilized in the production process. As a result, we recorded an impairment charge totaling approximately $0.9&#160;million, which is included in research and development expense on the condensed consolidated statements of operations of the &#8220;Consolidated Financial Statements&#8221; included in Part&#160;II, Item&#160;8 of this Annual Report.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Lease Obligations</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We adopted FASB ASC Topic&#160;842, <font style="font-style:italic;">Leases</font>, or ASC&#160;842, effective January&#160;1, 2019. For contracts entered into on or after the effective date, we determine if an arrangement is, or contains, a lease at lease inception. Our assessment is based on:&#160;(1)&#160;whether the contract involves the use of a distinct identified asset; (2)&#160;whether we obtain the right to substantially all of the economic benefit from the use of the asset throughout the period; and (3)&#160;whether we have the right to direct the use of the asset. At inception of a lease, we allocate the consideration in the contract to each lease component based on its relative stand-alone price to determine the lease payments. Leases entered into prior to January&#160;1, 2019, which were accounted for under ASC&#160;840, <font style="font-style:italic;">Leases</font>, were not reassessed as we elected the package of practical expedients permitted under the transition guidance within the new standard, which among other things, allowed us to carry forward the historical lease classification. We determine the lease term by assuming the exercise of renewal options that are reasonably assured. The exercise of lease renewal options is at our sole discretion. Several of our leases have renewal options, however, exercise of renewal is only assured for the El&#160;Segundo current Good Manufacturing Practices, or cGMP, facility, where we have made significant improvements.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For all leases at the lease commencement date, a right-of-use asset and a lease liability are recognized. The right-of-use asset represents the right to use the leased asset for the lease term. At lease commencement, leases are classified as either finance leases or operating leases. A lease is classified as a finance lease if any one of the following criteria are met:&#160;(1)&#160;the lease transfers ownership of the underlying asset by the end of the lease term; (2)&#160;the lease contains an option to purchase the underlying asset that is reasonably certain to be exercised; (3)&#160;the lease term is for a major part of the remaining economic life of the underlying asset; (4)&#160;the present value of the sum of the lease payments and any guaranteed residual value that is not already included in the lease payments equals or exceeds substantially all of the fair value of the underlying asset; or (5)&#160;the underlying asset is of such a specialized nature that it is expected to have no alternative use to the lessor at the end of the lease term. A lease is classified as an operating lease if it does not meet any one of these criteria.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We do not currently have any leases classified as finance leases. Our operating leases are included in operating lease right-of-use assets, net, other current liabilities, and operating lease liabilities on the consolidated balance sheets. At the commencement date, operating lease right-of-use assets and operating lease liabilities are determined based on the present value of lease payments to be made over the lease term. Operating lease right-of-use assets also include any rent paid prior to the commencement date, less any lease incentives received, and initial direct costs incurred. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term. We have elected to combine our lease components (e.g., fixed payments including rent, real estate taxes and insurance costs) with non-lease components (e.g., common-area maintenance costs and equipment maintenance costs) and as such, we account for lease and non-lease components as a single component. Lease expense also includes amounts relating to variable lease payments. Variable lease payments include amounts relating to common area maintenance and real estate taxes.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">136</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU128"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We also elected not to recognize right-of-use assets and lease liabilities for qualifying short-term leases with an initial lease term of 12&#160;months or less at lease inception. Such leases are expensed on a straight-line basis over the lease term.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The depreciable life of operating right-of-use-assets and leasehold improvements is limited by the expected lease term.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Stock-based Compensation</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We account for stock-based compensation under the provisions of ASC Topic&#160;718, <font style="font-style:italic;">Compensation&#8212;Stock Compensation</font>, or ASC&#160;718, which applies to share-based payments issued to employees and nonemployees in exchange for goods or services. Under ASC&#160;718, the fair value of an equity-classified award is estimated on the grant date without regard to service or performance conditions. The grant date fair values for options and warrants are estimated using the Black-Scholes-Merton option pricing model, and the grant date fair values for restricted stock units, or RSUs, are based upon the closing market price of our common stock on the date of grant.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We use the straight-line method to recognize stock-based compensation expense for our outstanding share awards that do not contain a performance condition. For awards subject to performance-based vesting conditions, we assess the probability of the individual milestones under the award being achieved and stock-based compensation expense is recognized over the service period commencing once management believes the performance criteria is probable of being met. For awards with service or performance conditions, we recognize the effect of forfeitures in compensation cost in the period that the award was forfeited.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Stock Repurchases</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In November&#160;2015, the board of directors approved a share repurchase program, or the 2015 Share Repurchase Program, allowing the CEO or CFO, on behalf of the company, to repurchase from time to time, in the open market or in privately negotiated transactions, up to $50.0&#160;million of our outstanding shares of common stock, exclusive of any commissions, markups or expenses. The timing and amounts of any purchases were and will continue to be based on market conditions and other factors, including price, regulatory requirements and other corporate considerations. The 2015 Share Repurchase Program does not require the purchase of any minimum number of shares and may be suspended, modified or discontinued at any time without prior notice. We have financed, and expect to continue to finance, the purchases with existing cash balances. As it is the intent for the repurchased shares to be retired, we have elected to account for the shares repurchased under the constructive retirement method. For shares repurchased in excess of par, we allocate the purchase price in excess of par value to accumulated deficit.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Utilization of Net Operating Loss Carryforwards, or NOLs, and Research and Development Credits</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2019, we had federal, state and foreign income tax NOLs of approximately $291.8&#160;million, $255.7&#160;million and $0.2&#160;million, respectively, which will begin to expire at various dates starting with 2022. As of December&#160;31, 2019 we also had federal and state research and development tax credit carryforwards of $8.5&#160;million and $5.7&#160;million, respectively, to offset future income taxes.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under Sections&#160;382 and 383 of the Internal Revenue Code of 1986, as amended, or the Code, if a corporation undergoes an &#8220;ownership change&#8221; (generally defined as a greater than 50% change (by value) in its equity ownership over a three-year period), the corporation&#8217;s ability to use its pre-change net operating loss carry forwards and other pre-change tax attributes to offset its post-change income may be limited. We have completed a study to determine the impact of ownership changes on our NOLs and we have undergone significant ownership changes in previous years. Accordingly, some of our NOLs and research and development credits have been derecognized.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">137</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU129"></a><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Recent Accounting Pronouncements</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Application of New or Revised Accounting Standards &#8211; Not Yet Adopted</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December&#160;2019, the FASB issued ASU&#160;2019-12,&#160;<font style="font-style:italic;">Simplifying the Accounting for Income Taxes</font>. The amendments in this update include removing the exception to the incremental approach for intraperiod tax allocation when there is a loss from continuing operations and income, or a gain, from other items (e.g., discontinued operations or other comprehensive income), and the exception to the general methodology for calculating income taxes in an interim period when a year-to-date loss exceeds the anticipated loss for the year. We are currently evaluating the impact that these amendments will have on our consolidated financial statements and we intend to early adopt these amendments on January&#160;1, 2020. We do not expect that the adoption of these amendments will have a significant impact on our consolidated financial statements.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June&#160;2016, the FASB issued ASU&#160;2016&#8209;13,&#160;<font style="font-style:italic;">Financial Instruments&#8212;Credit Losses (Topic 326):&#160;Measurement of Credit Losses on Financial Instruments</font>. The new guidance supersedes existing U.S. GAAP for measuring and recording of credit losses on financial assets measured at amortized cost by replacing the incurred-loss model with an expected-loss model. Accordingly, these financial assets will be presented at the net amount expected to be collected. This new standard also requires that credit losses related to available-for-sale debt securities be recorded as an allowance through net income rather than reducing the carrying amount under the current, other-than-temporary-impairment model. The new guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December&#160;15, 2019, but may be adopted earlier. With certain exceptions, adjustments are to be applied using a modified-retrospective approach by reflecting adjustments through a cumulative-effect impact on retained earnings as of the beginning of the fiscal year of adoption. In May&#160;2019, the FASB issued ASU&#160;2019-05,&#160;<font style="font-style:italic;">Financial Instruments&#8212;Credit Losses (Topic&#160;326):&#160;Targeted Transition Relief</font>, which provides companies with an option to irrevocably elect the fair value option for certain financial assets previously measured at amortized cost basis upon adoption of Topic&#160;326. We are currently evaluating the impact that this new standard and its related amendments will have on our consolidated financial statements and we intend to adopt the standard on January&#160;1, 2021. However, as the impact is dependent upon the investments held as of the adoption date, it is not possible for us to quantify the impact until the date of adoption.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other recent authoritative guidance issued by the FASB (including technical corrections to the ASC), the American Institute of Certified Public Accountants, and the SEC during the three&#160;months ended December&#160;31, 2019 did not, or are not expected to, have a material effect on our consolidated financial statements.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">JOBS Act</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_278"></a><a name="_cp_text_4_279"></a><a name="_cp_text_1_280"></a><a name="_cp_text_4_281"></a><a name="_cp_text_1_282"></a><a name="_cp_text_4_283"></a><a name="_cp_text_1_284"></a><a name="_cp_text_4_285"></a><a name="_cp_text_1_286"></a><a name="_cp_text_4_287"></a><a name="_cp_text_1_288"></a><a name="_cp_text_4_289"></a><a name="_cp_text_1_290"></a><a name="_cp_text_4_291"></a><a name="_cp_text_1_292"></a><a name="_cp_text_4_293"></a><a name="_cp_text_1_294"></a><a name="_cp_text_4_295"></a><a name="_cp_text_4_296"></a><a name="_cp_text_1_297"></a><a name="_cp_text_4_298"></a><a name="_cp_text_1_299"></a><font style="Background-color:#FFFFFF;">On April&#160;5, 2012, the Jumpstart Our Business Startups Act of 2012, or the JOBS Act, was enacted. Section&#160;107 of<a name="_cp_text_4_279"></a> <a name="_cp_text_1_280"></a>the JOBS Act provides that an <a name="_cp_text_4_281"></a>&#8220;<a name="_cp_text_1_282"></a>emerging growth company&#8221;<a name="_cp_text_4_283"></a> <a name="_cp_text_1_284"></a>can take advantage of the<a name="_cp_text_4_285"></a> <a name="_cp_text_1_286"></a>extended transition period provided in Section&#160;7(a)(2)(B) of the Securities Act<a name="_cp_text_4_287"></a> of 1933 <a name="_cp_text_1_288"></a>for complying with new or revised accounting standards. In other words, an &#8220;emerging growth company&#8221; can delay<a name="_cp_text_4_289"></a> <a name="_cp_text_1_290"></a>the adoption of certain<a name="_cp_text_4_291"></a> <a name="_cp_text_1_292"></a>accounting standards until those standards would otherwise<a name="_cp_text_4_293"></a> <a name="_cp_text_1_294"></a>apply to private companies. We have irrevocably elected not to avail ourselves of this extended transition period<a name="_cp_text_4_295"></a> <a name="_cp_text_4_296"></a>and, as a result, we <a name="_cp_text_1_297"></a>adopt new or revised accounting standards on the relevant dates on which adoption of such standards is required for other public companies. Subject to certain conditions set forth in the JOBS Act, as an &#8220;emerging growth company,&#8221; we intend to rely on certain exemptions and reduced reporting requirements provided by the JOBS Act, including those relating to&#160;(i)&#160;providing an auditor&#8217;s attestation report on our system of internal control over financial reporting pursuant to Section&#160;404(b) of the Sarbanes-Oxley Act and (ii)&#160;complying with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor&#8217;s report providing additional information about the audit and the financial statements, known as the auditor discussion and analysis. We will remain an &#8220;emerging growth company&#8221; until the earliest of&#160;(i)&#160;the last day of our first fiscal year in which we have total annual gross revenues of $1.07&#160;billion or more, (ii)&#160;the date on which we are deemed to be a &#8220;large accelerated filer&#8221; under the rules of the SEC with at least $700&#160;million of outstanding equity securities held by non-affiliates, (iii)&#160;the date on which we have issued more than $1.0&#160;billion in non-convertible debt during the previous three years, or (iv)<a name="_cp_text_4_298"></a>&#160;<a name="_cp_text_1_299"></a>the last day of our fiscal year following the fifth anniversary of the date of the completion of our IPO, or December&#160;31, 2020.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">138</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU130"></a><a name="ITEM_7A_QUANTITATIVE_QUALITATIVE_DISCLOS"></a><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_7A_QUANTITATIVE_QUALITATIVE_DISCLOS"></a>Item&#160;7A. Quantitative and Qualitat</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">ive Disclosures About Market Risk.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_305"></a><a name="_cp_text_4_306"></a><a name="_cp_text_1_307"></a>Our exposure to market risk for changes in interest rates relates primarily to interest earned on our cash equivalents and investments. The primary objective of our investment activities is to preserve our capital to fund operations. A secondary objective is to maximize income from our investments without assuming significant risk. Our investment policy provides for investments in low-risk, investment-grade debt instruments. As of December&#160;31, 2019, we had $15.5&#160;million<a name="_cp_text_1_305"></a> in cash and cash equivalents and<a name="_cp_text_4_306"></a> $37.6&#160;million in our investment portfolio. Our cash equivalents are short-term investments with maturities of 90&#160;days or less at the time of purchase. <a name="_cp_text_1_307"></a>We maintain cash deposits in FDIC insured financial institutions in excess of federally insured limits. However, we believe that we are not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held. As of December&#160;31, 2019, we did not hold or issue financial instruments for trading purposes. To date, we have not realized any significant loss of principal on our investments.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Interest rate risk &#8211; cash</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">With the cash discussed above, our primary exposure to market risk is interest income sensitivity, which is affected by changes in the general level of U.S interest rates. However, we do not believe a sudden change in the interest rates would have a material impact on our financial condition or results of operations due to the short-term maturities on our cash equivalents. A hypothetical 100&#160;basis point change in interest rates during any of the periods presented would not have had a material impact on our consolidated financial statements.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Interest rate risk &#8211; cash equivalents and investment portfolio</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We invest a portion of our cash in a number of diversified fixed and floating rate securities, consisting of marketable debt securities and debt funds that are subject to interest rate risk. Changes in the general level of interest rates can affect the fair value of our investment portfolio. If interest rates in the general economy were to rise, our holdings could lose value. At December&#160;31, 2019, a hypothetical increase in interest rates of 100 basis points across the entire yield curve on our holdings would not have resulted in a material impact on the fair value of our portfolio.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Foreign currency exchange risk</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_319"></a><a name="_cp_text_4_320"></a><a name="_cp_text_1_321"></a><font style="Background-color:#FFFFFF;">We contract with clinical research organizations, investigational sites and suppliers in foreign countries</font> and we have a bank account in Korea<font style="Background-color:#FFFFFF;">.<a name="_cp_text_1_319"></a> We are, therefore,<a name="_cp_text_4_320"></a> <a name="_cp_text_1_321"></a>subject to fluctuations in foreign currency rates in connection with these agreements. We have not entered into any material foreign currency hedging contracts although we may do so in the future. To date we have not incurred any material effects from foreign currency changes on these contracts. The effect of a 10% adverse change in exchange rates on foreign currency denominated cash and payables as of December&#160;31, 2019 would not have been material. However, fluctuations in currency exchange rates could harm our business in the future.</font></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><a name="_cp_text_1_322"></a>Inflation risk</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_323"></a><a name="_cp_text_4_324"></a><a name="_cp_text_1_325"></a><a name="_cp_text_4_326"></a><font style="Background-color:#FFFFFF;">Inflation may affect us by increasing our cost of labor, clinical trial, and other costs. We do not believe that inflation has had a material effect on<a name="_cp_text_4_324"></a> <a name="_cp_text_1_325"></a>our business, financial condition or<a name="_cp_text_4_326"></a> results of operations for any period presented herein.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">139</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_8_FINANCIAL_STATEMENTS_SUPPLEMENTAR"></a><a name="ITEM_8_FINANCIAL_STATEMENTS_SUPPLEMENTAR"></a>Item&#160;8. Financial Statements and Supplementary Data.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">INDEX TO CONSOLIDATED FINANCIAL STATEMENTS</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:95%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#REPORT_INDEPENDENT_REGISTERED_PUBLIC_ACC"><font style="text-decoration:none;">Report of Independent Registered Public Accounting Firm</font></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">141</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:95%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:95%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONSOLIDATED_BALANCE_SHEETS"><font style="text-decoration:none;">Consolidated Balance Sheets as of December&#160;31, 2019 and 2018</font></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">142</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:95%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:95%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONSOLIDATED_STMTS_OPERATIONS"><font style="text-decoration:none;">Consolidated Statements of Operations for the years ended December&#160;31, 2019, 2018 and 2017</font></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">143</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:95%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:95%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONSOLIDATED_STMTS_COMPREHENSIVE_LOSS"><font style="text-decoration:none;">Consolidated Statements of Comprehensive Loss for the years ended December&#160;31, 2019, 2018 and 2017</font></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">144</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:95%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:95%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONSOLIDATED_STMTS_STOCKHODLERS_EQUITY"><font style="text-decoration:none;">Consolidated Statements of Stockholders&#8217; Equity for the years ended December&#160;31, 2019, 2018 and 2017</font></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">145</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:95%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:95%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONSOLIDATED_STMTS_CASH_FLOWS"><font style="text-decoration:none;">Consolidated Statements of Cash Flows for the years ended December&#160;31, 2019, 2018 and 2017</font></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">146</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:95%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:95%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#NOTES_TO_CONSOLIDATED_FINANCIAL_STATEMEN"><font style="text-decoration:none;">Notes to Consolidated Financial Statements</font></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">148</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">140</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU131"></a><a name="REPORT_INDEPENDENT_REGISTERED_PUBLIC_ACC"></a><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="REPORT_INDEPENDENT_REGISTERED_PUBLIC_ACC"></a>Report of Independent Regist</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">ered Public Accounting Firm</font></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To the Stockholders and the Board of Directors of NantKwest, Inc.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Opinion on the Financial Statements</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have audited the accompanying consolidated balance sheets of NantKwest, Inc.&#160;(the Company) as of December&#160;31, 2019 and 2018, the related consolidated statements of operations, comprehensive loss, stockholders' equity and cash flows for each of the three years in the period ended December&#160;31, 2019, and the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December&#160;31, 2019 and 2018, and the results of its operations and its cash flows for each of the three years in the period ended December&#160;31, 2019, in conformity with U.S. generally accepted accounting principles.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Adoption of ASU No.&#160;2016-02</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As discussed in Note&#160;2 to the consolidated financial statements, the Company changed its method of accounting for leases in 2019 due to the adoption of Accounting Standards Update&#160;(ASU) No.&#160;2016-02,&#160;<font style="font-style:italic;">Leases&#160;(Topic 842)</font>, and the related amendments<font style="color:#212529;font-family:Arial;">.</font></p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Basis for Opinion</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board&#160;(United States)&#160;(PCAOB) and are required to be independent with respect to the Company in accordance with the U.S.&#160;federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over financial reporting. Accordingly, we express no such opinion.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</p>
<p style="text-align:right;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Ernst&#160;&amp;&#160;Young&#160;LLP</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have served as the Company&#8217;s auditor since 2016.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Los Angeles, California</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March&#160;25, 2020</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">141</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU132"></a><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">NantKwest, Inc.</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="CONSOLIDATED_BALANCE_SHEETS"></a><a name="CONSOLIDATED_BALANCE_SHEETS"></a>Consolidated Balance Sheets</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(in thousands, except share and per share amounts)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">ASSETS</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current assets:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,508</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,821</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid expenses and other current assets (including</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; related parties)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,105</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,900</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Marketable debt securities, available-for-sale</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36,144</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">57,328</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Notes receivable, held-to-maturity</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">723</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total current assets</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55,757</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">88,772</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Marketable debt securities, noncurrent</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,497</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,701</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property, plant and equipment, net</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">60,501</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">76,885</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease right-of-use assets, net (including</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; related parties)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,729</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Equity investment</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,253</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,500</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intangible assets, net</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">565</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other assets (including related parties)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,386</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,527</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total assets</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">143,123</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">181,950</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current liabilities:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts payable</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,749</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,793</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,343</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,104</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Due to related parties</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">486</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,696</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other current liabilities (including related parties)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,981</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,667</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total current liabilities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,559</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,260</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease liability, less current portion (including</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; related parties)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,885</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financing obligation, less current portion</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,945</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred rent</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,739</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total liabilities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,444</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35,944</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commitments and contingencies (Note 8)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stockholders&#8217; equity:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock, $0.0001 par value; 500,000,000 shares authorized;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; 98,460,404 and 79,087,734 issued and outstanding as of</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; December 31, 2019 and December 31, 2018</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additional paid-in capital</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">782,965</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">741,246</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulated other comprehensive loss</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(105</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(267</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulated deficit</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(662,191</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(594,981</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total stockholders&#8217; equity</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">120,679</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">146,006</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total liabilities and stockholders&#8217; equity</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">143,123</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">181,950</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying notes are an integral part of these consolidated financial statements.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">142</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU133"></a><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">NantKwest, Inc.</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="CONSOLIDATED_STMTS_OPERATIONS"></a>Consolidated Statements of Operations</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(in thousands, except share and per share amounts)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the Year Ended December&#160;31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Revenue</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating expenses:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development (including amounts with</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; related parties)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49,785</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55,718</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42,044</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Selling, general and administrative (including amounts with</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; related parties)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,065</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42,718</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">57,121</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total operating expenses</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">67,850</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">98,436</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">99,165</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Loss from operations</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(67,807</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(98,389</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(99,120</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other income (expense):</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Investment income, net</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,642</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,857</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,665</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest expense (including amounts with related parties)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(19</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(433</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(618</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other income, net (including amounts with related parties)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">298</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">236</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">157</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total other income</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,921</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,660</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,204</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Loss before income taxes</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(65,886</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(96,729</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(96,916</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Income tax benefit</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">97</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">503</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">493</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(65,789</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(96,226</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(96,423</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per share:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic and diluted</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.70</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1.22</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1.20</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average number of shares during the period:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic and diluted</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">94,210,087</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">79,132,220</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">80,583,910</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying notes are an integral part of these consolidated financial statements.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">143</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU134"></a><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">NantKwest, Inc.</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="CONSOLIDATED_STMTS_COMPREHENSIVE_LOSS"></a><a name="CONSOLIDATED_STMTS_COMPREHENSIVE_LOSS"></a>Consolidated Statements of Comprehensive Loss</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the Year Ended December&#160;31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(65,789</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(96,226</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(96,423</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other comprehensive income (loss), net of income taxes:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net unrealized gains (losses) on available-for-sale securities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">158</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">114</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(65</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reclassification of net realized gains (losses) on available-for-sale</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; securities included in net loss</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(32</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total other comprehensive income (loss)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">162</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">114</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(97</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Comprehensive loss</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(65,627</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(96,112</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(96,520</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying notes are an integral part of these consolidated financial statements.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">144</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU135"></a><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">NantKwest, Inc.</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="CONSOLIDATED_STMTS_STOCKHODLERS_EQUITY"></a>Consolidated Statements of Stockholders&#8217; Equity</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(in thousands, except share and per share amounts)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.9%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Common Stock</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.96%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Additional</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Paid-in</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.96%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Accumulated</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Other</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Comprehensive</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.96%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Accumulated</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.96%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amount</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Capital</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Loss</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Deficit</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance at December&#160;31, 2016</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">81,983,937</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">8</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">680,757</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(284</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(387,063</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">293,418</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36,997</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36,997</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercise of warrants</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47,226</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercise of stock options</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">614,136</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,154</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,154</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vesting of restricted stock units (RSUs)</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">244,209</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net share settlement for RSU vesting and</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; option exercises</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(234,020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,039</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,039</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Repurchase of common stock</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,633,610</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(15,227</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(15,227</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other comprehensive loss</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(97</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(97</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(96,423</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(96,423</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance at December 31, 2017</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">79,021,878</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">8</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">717,930</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(381</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(498,713</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">218,844</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,382</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,382</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercise of warrants</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">93,254</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">57</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">57</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vesting of RSUs</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">172,330</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net share settlement for RSU vesting and</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; warrant exercises</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(61,379</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(123</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(123</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Repurchase of common stock</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(138,349</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(228</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(228</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cumulative effect of the adoption of the new</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; revenue standard</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">186</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">186</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other comprehensive income</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">114</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">114</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(96,226</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(96,226</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance at December 31, 2018</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">79,087,734</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">8</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">741,246</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(267</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(594,981</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">146,006</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,627</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,627</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercise of warrants</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,589,250</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35,149</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35,151</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercise of stock options</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,986,300</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,070</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,070</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vesting of RSUs</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">395,051</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net share settlement for RSU vesting and</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; option exercises</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(124,345</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(127</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(127</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Repurchase of common stock</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(473,586</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(501</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(501</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cumulative effect of the adoption of the new</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; lease standard</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(920</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(920</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other comprehensive income</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">162</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">162</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(65,789</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(65,789</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance at December 31, 2019</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">98,460,404</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">10</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">782,965</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(105</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(662,191</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">120,679</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:1pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying notes are an integral part of these consolidated financial statements.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">145</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU136"></a><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">NantKwest, Inc.</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="CONSOLIDATED_STMTS_CASH_FLOWS"></a>Consolidated Statements of Cash Flows</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the Year Ended December&#160;31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Operating activities:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(65,789</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(96,226</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(96,423</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Adjustments to reconcile net loss to net cash used in operating activities:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation and amortization</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,012</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,555</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,566</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,627</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,382</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36,997</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-cash lease expense related to operating lease right-of-use assets</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,604</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amortization of net premiums and discounts on marketable debt securities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">463</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,597</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-cash interest items, net</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">246</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">291</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">720</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss on impairment of assets</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">869</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss on disposal of assets</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">209</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">64</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred income tax benefit</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(498</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(497</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gains (losses) on sales of marketable debt securities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(32</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Changes in operating assets and liabilities:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid expenses and other current assets</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,276</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(9,818</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">156</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease right-of-use assets, net</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(800</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other assets</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,063</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,151</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">458</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts payable</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,100</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">150</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses and other liabilities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(12,020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,708</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(299</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Due to related parties</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,093</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(685</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,562</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease liabilities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,276</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred rent and revenue</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(508</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,201</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash used in operating activities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(61,362</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(63,381</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(48,780</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Investing activities:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Purchases of property, plant and equipment</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,182</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(13,102</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(34,815</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from sales of property, plant and equipment</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">412</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Purchases of debt securities, held-to-maturity</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(723</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Purchases of investments in equity securities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(8,500</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Purchases of marketable debt securities, available-for-sale</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(86,618</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(94,770</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(111,355</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sales/maturities of marketable debt securities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">112,259</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">165,284</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">254,222</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash provided by investing activities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,456</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">57,101</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">99,552</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Financing activities:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Principal payments of financing/capital lease obligations</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(477</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(19,932</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from exercises of stock options and warrants</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39,221</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">57</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,215</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Repurchases of common stock with commissions</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(501</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(228</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(15,227</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net share settlement for restricted stock unit vesting and warrant and option exercises</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(127</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(123</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,039</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash provided by (used in) financing activities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38,593</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(771</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(34,983</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net (decrease) increase in cash, cash equivalents, and restricted cash</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,313</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(7,051</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,789</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash, cash equivalents and restricted cash, beginning of period</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,000</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,051</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,262</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash, cash equivalents and restricted cash, end of period</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,687</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,000</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,051</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying notes are an integral part of these consolidated financial statements.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">146</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU137"></a><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">NantKwest, Inc.</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Consolidated Statements of Cash Flows (Continued)</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the Year Ended December&#160;31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Reconciliation of cash, cash equivalents, and restricted cash at end of period:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,508</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,821</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,872</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted cash included in other assets</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">179</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">179</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">179</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash, cash equivalents, and restricted cash, end of period</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,687</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,000</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,051</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Supplemental disclosure of cash flow information:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash paid during the period for:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">475</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">668</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Income taxes</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Supplemental disclosure of non-cash investing and financing activities:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment purchases acquired under capital lease</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,448</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment purchases included in accounts payable, accrued</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; expenses, and other liabilities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">74</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,664</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,500</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Conversion of Viracta convertible notes and accrued interest into</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; investment in equity securities of Viracta (Note 4)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">751</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unrealized gains (losses) on marketable debt securities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">258</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">123</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(97</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cashless exercises of stock options and warrants</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">94</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying notes are an integral part of these consolidated financial statements.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">147</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU138"></a><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">NantKwest, Inc.</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="NOTES_TO_CONSOLIDATED_FINANCIAL_STATEMEN"></a><a name="NOTES_TO_CONSOLIDATED_FINANCIAL_STATEMEN"></a>Notes to Consolidated Financial Statements</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1. &#160;&#160;&#160;&#160;Description of Business</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Organization</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NantKwest, Inc., or NantKwest, was incorporated in Illinois on October&#160;7, 2002 under the name ZelleRx Corporation. On January&#160;22, 2010, the company changed its name to Conkwest, Inc., and on July&#160;10, 2015, the company changed its name to NantKwest, Inc. In March&#160;2014, the company redomesticated from the State of Illinois to the State of Delaware and the Illinois company ceased to exist. We are a pioneering clinical-stage immunotherapy biotechnology company headquartered in San Diego, California with certain operations in Culver City and El Segundo, California and Woburn, Massachusetts. In these notes, the terms &#8220;we,&#8221; &#8220;our,&#8221; &#8220;the company&#8221; and &#8220;us&#8221; refer to NantKwest.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are focused on harnessing the power of the innate immune system by using its natural killer cells, or NK&#160;cells, to treat cancer and viral infectious diseases. A critical aspect of our strategy is to invest significantly in innovating new therapeutic candidates, based upon our proprietary activated NK, or aNK, cell platform, and conducting clinical testing and scale manufacturing of our most promising biologic product candidates.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We hold the exclusive right to commercialize aNK&#160;cells, a commercially viable NK&#160;cell line, and a wide range of genetically modified derivatives capable of killing cancer and virally infected cells. We own corresponding United States, or U.S., and foreign composition and methods-of-use patents and applications covering the cells, improvements, methods of expansion and manufacture and use of aNK&#160;cells and their improvements as therapeutics to treat a spectrum of clinical conditions.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We also license exclusive commercial rights to a high-affinity CD16 receptor expressing enhancement of our aNK&#160;cell platform, covered in a portfolio of U.S. and foreign composition and methods-of-use patents and applications covering both the clinical use as a therapeutic to treat cancers in combination with antibody products, as well as the non-clinical use in laboratory testing of monoclonal antibodies. We have non-exclusively licensed or sub-licensed our high-affinity CD16 bearing aNK&#160;cell platform and corresponding intellectual property to numerous pharmaceutical and biotechnology companies for such non-clinical uses.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Liquidity</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2019, the company had an accumulated deficit of approximately $662.2&#160;million. We also had negative cash flow from operations of approximately $61.4&#160;million during the year ended December&#160;31, 2019. The company expects that it will likely need additional capital to further fund development of, and seek regulatory approvals for, our product candidates, and to begin to commercialize any approved products.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are currently focused primarily on the development of immunotherapeutic treatments for cancers and debilitating viral infections using targeted cancer and viral killing cell lines, and we believe such activities will result in the company&#8217;s continued incurrence of significant research and development and other expenses related to those programs. If the clinical trials for any of the company&#8217;s product candidates fail or produce unsuccessful results and those product candidates do not gain regulatory approval, or if any of our product candidates, if approved, fail to achieve market acceptance, we may never become profitable. Even if the company achieves profitability in the future, it may not be able to sustain profitability in subsequent periods. We intend to cover our future operating expenses through cash and cash equivalents and marketable debt securities on hand and through a combination of equity offerings, debt financings, government or other third party funding, marketing and distribution arrangements and other collaborations, strategic alliances, and licensing arrangements. Additional financing may not be available to us when needed and, if available, financing may not be obtained on terms favorable to the company or its stockholders.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">While we expect our existing cash, and cash equivalents and marketable debt securities, together with the ability to borrow from affiliated entities, will enable us to fund operations and capital expenditure requirements for at least the next 12&#160;months, we may not have sufficient funds to reach commercialization. Failure to obtain adequate financing when needed may require us to delay, reduce, limit, or terminate some or all of our development programs or future commercialization efforts or grant rights to develop and market product candidates that we might otherwise prefer to develop and market ourselves, which could adversely affect our ability to operate as a going concern. If we raise additional funds from the issuance of equity securities, substantial dilution to existing stockholders may result. If we raise additional funds by incurring debt financing, the terms of the debt may involve significant cash payment obligations, as well as covenants and specific financial ratios that may restrict our ability to operate our business.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">148</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU139"></a><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2. &#160;&#160;&#160;&#160;Summary of Significant Accounting Policies</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Basis of Presentation</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America, or U.S.&#160;GAAP.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The consolidated financial statements have been prepared assuming the company will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business, and do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or amounts and classification of liabilities that may result from the outcome of the uncertainty discussed in the Liquidity section of Note&#160;1. We believe our existing cash, cash equivalents, and investments in marketable debt securities, and our ability to borrow from affiliated entities, will be sufficient to fund operations through at least the next 12&#160;months following the issuance date of the financial statements based upon our Chairman and CEO&#8217;s intent and ability to support the company&#8217;s operations with additional funds, including loans from affiliated entities, as required. We may also seek to sell additional equity, through one or more follow-on public offerings, or in separate financings, or obtain a credit facility. However, we may not be able to secure such financing in a timely manner or on favorable terms. Without additional funds, we may choose to delay or reduce our operating or investment expenditures. Further, because of the risk and uncertainties associated with the commercialization of the company&#8217;s product candidates in development, we may need additional funds to meet our needs sooner than planned. To date, the company&#8217;s primary sources of capital were its initial public offering and the concurrent private placement of common shares. In addition, during the year ended December&#160;31, 2019, our Chairman and CEO exercised warrants and options resulting in aggregate cash proceeds of $39.2&#160;million.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Principles of Consolidation</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The consolidated financial statements include the accounts of NantKwest and its wholly owned subsidiaries. All intercompany amounts have been eliminated.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We apply the variable interest model under Accounting Standards Codification, or ASC Topic&#160;810,&#160;<font style="font-style:italic;">Consolidation</font>, to any entity in which we hold an equity investment or to which we have the power to direct the entity's most significant economic activities and the ability to participate in the entity's economics. If the entity is within the scope of the variable interest model and meets the definition of a variable interest entity, or VIE, we consider whether we must consolidate the VIE or provide additional disclosures regarding our involvement with the VIE. If we determine that we are the primary beneficiary of the VIE, we will consolidate the VIE. This analysis is performed at the initial investment in the entity or upon any reconsideration event.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For entities we hold as an equity investment that are not consolidated under the VIE Model, we consider whether our investment constitutes ownership of a majority of the voting interests in the entity and therefore should be considered for consolidation under the voting interest model.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unconsolidated equity investments in the common stock or in-substance common stock of an entity under which we are able to exercise significant influence, but not control, are accounted for using the equity method. Our ability to exercise significant influence is generally indicated by ownership of 20 to 50 percent interest in the voting securities of the entity.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All other unconsolidated equity investments on which we are not able to exercise significant influence will be subsequently measured at fair value with unrealized holding gains and losses included in other income, net on the consolidated statements of operations. In the instance the equity investment does not have a readily determinable fair value and does not qualify for the practical expedient to estimate fair value in accordance with ASC&#160;820, <font style="font-style:italic;">Fair Value Measurement</font>, or ASC&#160;820, we will apply the measurement alternative under ASC&#160;321, <font style="font-style:italic;">Investments&#8212;Equity Securities</font>, or ASC&#160;321, pursuant to which we will measure the investment at its cost less impairment, adjusted for observable price changes in an orderly market for an identical or similar investment of the same issuer.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We own non-marketable equity securities that are accounted for using the measurement alternative under ASC&#160;321 because the preferred stock held by us is not considered in-substance common stock and such preferred stock does not have a readily determinable fair value. All investments are reviewed on a regular basis for possible impairment. If an investment's fair value is determined to be less than its net carrying value, the investment is written down to its fair value. Such an evaluation is judgmental and dependent on specific facts and circumstances. Factors considered in determining whether an impairment indicator is present include:&#160;the investees&#8217; earnings performance and clinical trial performance, change in the investees&#8217; industry and geographic area in which it operates, offers to purchase or sell the security for a price less than the cost of the investment, issues that raise concerns about the investee's ability to continue as a going concern, and any other information that we may be aware of related to the investment. Factors considered in determining whether an observable price change has occurred include:&#160;the price at which the investee issues equity instruments similar to those of our investment and the rights and preferences of those equity instruments compared to ours.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">149</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU140"></a><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Use of Estimates</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. On an ongoing basis, we evaluate our estimates, including those related to valuation of equity-based awards, deferred income taxes and related valuation allowances, preclinical and clinical trial accruals, impairment assessments, useful lives of long-lived assets, loss contingencies, and fair value measurements. We base our estimates on historical experience and on various other market-specific and relevant assumptions that we believe to be reasonable under the circumstances. Actual results could differ from those estimates.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Risks and Uncertainties</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Contingencies</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We record accruals for loss contingencies to the extent that we conclude it is probable that a liability has been incurred and the amount of the related loss can be reasonably estimated. We evaluate, on a quarterly basis, developments in legal proceedings and other matters that could cause a change in the potential amount of the liability recorded or of the range of potential losses disclosed. Additionally, we record our rights to insurance recoveries, limited to the extent of incurred or probable losses, as a receivable when such recoveries have been agreed to with our third-party insurers and when receipt is deemed probable. This includes instances when our third-party insurers have agreed to pay, on our behalf, certain legal defense costs and settlement amounts directly to applicable law firms and a settlement fund.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Concentration of Credit Risk and Other Risks and Uncertainties</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially subject us to concentrations of risk consist principally of cash and cash equivalents and marketable debt securities.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our cash and cash equivalents are held by one major financial institution in the U.S. and one in Korea.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Product candidates developed by us will require approvals or clearances from the U.S. Food and Drug Administration, or FDA, or international regulatory agencies prior to commercial sales. There can be no assurance that any of our product candidates will receive any of the required approvals or clearances. If we were to be denied approval or clearance or any such approval or clearance was to be delayed, it would have a material adverse impact on us.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Cash, Cash Equivalents and Marketable Debt Securities</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We invest our excess funds in investment grade short- to intermediate-term corporate debt securities, commercial paper, government sponsored securities, and foreign government bonds. We consider all highly liquid investments purchased with original maturities of three&#160;months or less to be cash equivalents and all investments purchased with original maturities of greater than three&#160;months as marketable debt securities, classified as available-for-sale. Marketable debt securities with remaining maturities of 12&#160;months or less are classified as short-term and marketable debt securities with remaining maturities greater than 12&#160;months are classified as long-term. All marketable debt securities are reported at fair value and any unrealized gains and losses are reported as a component of accumulated other comprehensive income (loss), net of tax, on the consolidated statements of stockholders&#8217; equity, with the exception of unrealized losses believed to be other-than-temporary, which are recorded in investment income, net, on the consolidated statements of operations. Realized gains and losses are included in investment income, net, on the consolidated statements of operations. Realized gains and losses from sale of the securities and the amounts, net of tax, reclassified out of accumulated other comprehensive loss, if any, are determined on a specific identification basis.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We periodically evaluate whether declines in fair values of our investments below their book value are other-than-temporary. This evaluation consists of several qualitative and quantitative factors regarding the severity and duration of the unrealized loss, as well as our ability and intent to hold the investment until a forecasted recovery occurs. Additionally, we assess whether or not we have plans to sell the security or whether or not it is more likely than not we will be required to sell any investment before recovery of its amortized cost basis. Factors considered include quoted market prices, recent financial results and operating trends, implied values from any recent transactions or offers of investee securities, credit quality of debt instrument issuers, other publicly available information that may affect the value of our investments, duration and severity of the decline in value, and our strategy and intentions for holding the investment. There were no other-than-temporary impairments recorded in the years ended December&#160;31, 2019, 2018 and 2017.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">150</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU141"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We minimize credit risk associated with our cash and cash equivalents by periodically evaluating the credit quality of our primary financial institutions. While we maintain cash deposits in FDIC insured financial institutions in excess of federally insured limits, we do not believe that we are exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held. We have not experienced any losses on such accounts.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have funded a certificate of deposit (CD) as a substitute letter of credit for one of our leased properties. This CD is reported as long term restricted cash and is included in other assets on the consolidated balance sheets as the landlord is the beneficiary of the account and we are not able to access the funds during the term of the lease.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Property, Plant and Equipment</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property, plant and equipment is stated at historical cost less accumulated depreciation. Historical cost includes expenditures that are directly attributable to the acquisition of the items. All repairs and maintenance are charged to net loss during the financial period in which they are incurred. Depreciation of property, plant and equipment is calculated using the straight-line method over the estimated useful lives of the assets, as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Buildings</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> 39 years</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Software</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> 3 years</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Laboratory equipment</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> 5 years</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furniture &amp; fixtures</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> 5 years</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">IT equipment</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> 3 years</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> The lesser of the lease term or the life of the asset</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Upon disposal or impairment of property, plant and equipment, the cost and related accumulated depreciation is removed from the consolidated financial statements and the net amount, less any proceeds, is included in the consolidated statements of operations.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Intangible Assets</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intangible assets, which consisted of the cost of reacquiring a technology license during 2015, were amortized using the straight-line method over an estimated useful life of 4&#160;years. As of December 31, 2019, our intangible assets were fully amortized.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Patents</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Patent costs, including related legal costs, are expensed as incurred and recorded in selling, general and administrative expenses on the consolidated statements of operations.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Impairments</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Long-lived assets include property, plant and equipment and intangible assets. We review long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability is measured by comparison of the carrying amount to the future net cash flows that the assets are expected to generate. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the projected undiscounted future cash flows arising from the assets using a discount rate determined by management to be commensurate with the risk inherent to our current business model.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the second quarter of 2019, we determined that certain bioreactor laboratory equipment could no longer be utilized in the production process. As a result, we recorded an impairment charge totaling $0.9&#160;million, which is included in research and development expense on the consolidated statements of operations. There were no impairment losses recognized during the years ended December&#160;31, 2018 and 2017.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Fair Value of Financial Instruments</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accounting standard for fair value measurements provides a framework for measuring fair value and requires disclosures regarding fair value measurements. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date, based on our principal or, in absence of a principal, most advantageous market for the specific asset or liability.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">151</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU142"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We use a three-tier fair value hierarchy to classify and disclose all assets and liabilities measured at fair value on a recurring basis, as well as assets and liabilities measured at fair value on a non-recurring basis, in periods subsequent to their initial measurement. The hierarchy requires us to use observable inputs when available, and to minimize the use of unobservable inputs, when determining fair value.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The three tiers are defined as follows:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">Level&#160;1&#8212; Observable inputs that reflect quoted market prices (unadjusted) for identical assets or liabilities in active markets at the measurement date. Since valuations are based on quoted prices that are readily and regularly available in an active market, valuation of these products does not entail a significant degree of judgment. Our Level 1 assets consist of bank deposits and money market funds.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">Level&#160;2&#8212; Observable inputs other than quoted prices in active markets that are observable either directly or indirectly in the marketplace for identical or similar assets and liabilities. Our Level 2 assets consist of corporate debt securities including commercial paper, government sponsored securities and corporate bonds, as well as foreign municipal securities.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">Level&#160;3&#8212; Valuations based on inputs that are unobservable and significant to the overall fair value measurement.</font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the years ended December&#160;31, 2019, 2018 and 2017, no transfers were made into or out of the Level&#160;1,&#160;2 or 3 categories. We will continue to review the fair value inputs on a quarterly basis.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We utilize a third-party pricing service to assist in obtaining fair value pricing for our investments in marketable debt securities. Inputs are documented in accordance with the fair value disclosure hierarchy.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Preclinical and Clinical Trial Accruals</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As part of the process of preparing the financial statements, we are required to estimate expenses resulting from obligations under contracts with vendors, clinical research organizations and consultants. The financial terms of these contracts vary and may result in payment flows that do not match the periods over which materials or services are provided under such contracts.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We estimate clinical trial and research agreement related expenses based on the services performed, pursuant to contracts with research institutions and clinical research organizations and other vendors that conduct clinical trials and research on our behalf. In accruing clinical and research related fees, we estimate the time period over which services will be performed and activity expended in each period. If the actual timing of the performance of services or the level of effort varies from the estimate, we will adjust the accrual accordingly. Payments made under these arrangements in advance of the receipt of the related services are recorded as prepaid expenses until the services are rendered.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Transactions with Related Parties</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As outlined in Note&#160;9<font style="font-style:italic;"> &#8211; Related Party Agreements</font>, we have various agreements with different related parties. Some are billed and settled in cash monthly. Others are billed quarterly and settled in cash the following month. Monthly accruals are made for all quarterly billing arrangements.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Lease Obligations</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We adopted FASB ASC Topic&#160;842, <font style="font-style:italic;">Leases</font>, or ASC&#160;842, effective January&#160;1, 2019. For contracts entered into on or after the effective date, we determine if an arrangement is, or contains, a lease at lease inception. Our assessment is based on:&#160;(1)&#160;whether the contract involves the use of a distinct identified asset; (2)&#160;whether we obtain the right to substantially all of the economic benefit from the use of the asset throughout the period; and (3)&#160;whether we have the right to direct the use of the asset. At inception of a lease, we allocate the consideration in the contract to each lease component based on its relative stand-alone price to determine the lease payments. Leases entered into prior to January&#160;1, 2019, which were accounted for under ASC&#160;840, <font style="font-style:italic;">Leases</font>, were not reassessed as we elected the package of practical expedients permitted under the transition guidance within the new standard, which among other things, allowed us to carry forward the historical lease classification. We determine the lease term by assuming the exercise of renewal options that are reasonably assured. The exercise of lease renewal options is at our sole discretion. Several of our leases have renewal options, however, exercise of renewal is only assured for the El&#160;Segundo current Good Manufacturing Practices, or cGMP, facility, where we have made significant improvements.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">152</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU143"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For all leases at the lease commencement date, a right-of-use asset and a lease liability are recognized. The right-of-use asset represents the right to use the leased asset for the lease term. At lease commencement, leases are classified as either finance leases or operating leases. A lease is classified as a finance lease if any one of the following criteria are met:&#160;(1)&#160;the lease transfers ownership of the underlying asset by the end of the lease term; (2)&#160;the lease contains an option to purchase the underlying asset that is reasonably certain to be exercised; (3)&#160;the lease term is for a major part of the remaining economic life of the underlying asset; (4)&#160;the present value of the sum of the lease payments and any guaranteed residual value that is not already included in the lease payments equals or exceeds substantially all of the fair value of the underlying asset; or (5)&#160;the underlying asset is of such a specialized nature that it is expected to have no alternative use to the lessor at the end of the lease term. A lease is classified as an operating lease if it does not meet any one of these criteria.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We do not currently have any leases classified as finance leases. Our operating leases are included in operating lease right-of-use assets, net, other current liabilities, and operating lease liabilities on the consolidated balance sheets. At the commencement date, operating lease right-of-use assets and operating lease liabilities are determined based on the present value of lease payments to be made over the lease term. Operating lease right-of-use assets also include any rent paid prior to the commencement date, less any lease incentives received, and initial direct costs incurred. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term. We have elected to combine our lease components (e.g., fixed payments including rent, real estate taxes and insurance costs) with non-lease components (e.g., common-area maintenance costs and equipment maintenance costs) and as such, we account for lease and non-lease components as a single component. Lease expense also includes amounts relating to variable lease payments. Variable lease payments include amounts relating to common area maintenance and real estate taxes.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We also elected not to recognize right-of-use assets and lease liabilities for qualifying short-term leases with an initial lease term of 12&#160;months or less at lease inception. Such leases are expensed on a straight-line basis over the lease term.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The depreciable life of operating right-of-use-assets and leasehold improvements is limited by the expected lease term.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Income Taxes</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We recognize deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the financial reporting and tax basis of assets and liabilities, as well as for operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using the tax rates that are expected to apply to taxable income for the years in which those tax assets and liabilities are expected to be realized or settled. We record valuation allowances to reduce deferred tax assets to the amount we believe is more likely than not to be realized.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We recognize uncertain tax positions when the position will be more likely than not upheld on examination by the taxing authorities based solely upon the technical merits of the positions. We recognize interest and penalties, if any, related to unrecognized income tax uncertainties in income tax expense. We did not have any accrued interest or penalties associated with uncertain tax positions as of December&#160;31, 2019 and 2018.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are subject to U.S. federal income tax, as well as income tax in Korea, California and other states. The federal returns for tax years 2016 through 2019 remain open to examination; the California returns remain subject to examination for tax years 2015 through 2019. Carryforward attributes that were generated in years where the statute of limitations is closed may still be adjusted upon examination by the Internal Revenue Service or other respective tax authority. All other state jurisdictions remain open to examination. No income tax returns are currently under examination by taxing authorities.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Stock Repurchases</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In November&#160;2015, the board of directors approved the 2015 Share Repurchase Program (Note&#160;10) allowing the CEO or CFO, on behalf of the company, to repurchase from time to time, in the open market or in privately negotiated transactions, up to $50.0&#160;million of our outstanding shares of common stock, exclusive of any commissions, markups or expenses. The timing and amounts of any purchases were and will continue to be based on market conditions and other factors, including price, regulatory requirements and other corporate considerations. The 2015 Share Repurchase Program does not require the purchase of any minimum number of shares and may be suspended, modified or discontinued at any time without prior notice. We have financed, and expect to continue to finance, the purchases with existing cash balances. As it is the intent for the repurchased shares to be retired, we have elected to account for the shares repurchased under the constructive retirement method. For shares repurchased in excess of par, we allocate the purchase price in excess of par value to accumulated deficit.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">153</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU144"></a><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Revenue Recognition</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Beginning January&#160;1, 2018, we adopted the provisions of FASB ASC Topic&#160;606, <font style="font-style:italic;">Revenue from Contracts with Customers</font>, or ASC&#160;606. This guidance requires that entities recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. We adopted ASC&#160;606 on January&#160;1, 2018 by recording the cumulative effect of the adoption to accumulated deficit. We applied the new guidance to contracts that were not complete as of January&#160;1, 2018. Implementation of ASC&#160;606 did not have a material impact on our consolidated financial statements.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We derive substantially all of our revenue from non-exclusive license agreements with a limited number of pharmaceutical and biotechnology companies granting them the right to use our cell lines and intellectual property for non-clinical use. These agreements generally include upfront fees and annual research license fees for such use, as well as commercial license fees for sales of the licensee products developed or manufactured using our intellectual property and cell lines.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account in ASC&#160;606. A contract&#8217;s transaction price is allocated to each distinct performance obligation based on relative standalone selling price and recognized as revenue when, or as, the performance obligation is satisfied.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the company&#8217;s license agreements with customers, the company typically promises to provide a license to use certain cell lines and related patents, the related know-how, and future research and development data that affect the license. We have concluded that these promises represent one performance obligation due to the highly interrelated nature of the promises. We provide the cell lines and know-how immediately upon entering into the contracts. The research and development data is provided throughout the term of the contract when and if available.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our license agreement with Intrexon (Note&#160;7) included a nonrefundable upfront payment of $0.4&#160;million, received when we entered into the contract in 2010. In this instance, we determined that under ASC&#160;606 it would be appropriate to recognize the initial milestone payment at a point in time, when we transferred the license. In this case, the intellectual property provided under the contract is functional intellectual property under ASC&#160;606 and was determined to be a distinct performance obligation in the context of the arrangement. Prior to adoption, the upfront payment had been initially recorded as deferred revenue and was being recognized into revenue on a straight-line basis. As a result, upon adoption of ASC&#160;606, we adjusted our accumulated deficit for the effects of recognizing revenue upfront for the initial milestone. The adjustment to accumulated deficit upon adoption was not material.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The license agreements may include nonrefundable upfront payments, event-based milestone payments, sales-based royalty payments, or some combination of these. The event-based milestone payments represent variable consideration and we use the most likely amount method to estimate this variable consideration. Given the high degree of uncertainly around achievement of these milestones, we do not recognize revenue from these milestone payments until the uncertainty associated with these payments is resolved. We currently estimate variable consideration related to milestone payments to be zero and, as such, no revenue has been recognized for milestone payments. We recognize revenue from sales-based royalty payments when or as the sales occur. On a quarterly basis, we re-evaluate our estimate of milestone variable consideration to determine whether any amount should be included in the transaction price and recorded in revenue prospectively.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Upon adoption, we changed our accounting policy from accounting for milestones payments under the milestone method to accounting for variable consideration as discussed above. The change in accounting policy did not change any amounts in the financial statements because of the significant uncertainty surrounding the estimate of variable consideration for milestone payments.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To date, we have generated minimal revenue related to the non-clinical use of our cells lines and intellectual property. We have no products approved for commercial sale and we have not generated any revenue from product sales. If we fail to complete the development of our product candidates in a timely manner or fail to obtain regulatory approval for them, we may never be able to generate substantial future revenue.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Research and Development Costs</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Major components of research and development costs include cash compensation and other personnel-related expenses, stock-based compensation, depreciation and amortization expense on research and development property and equipment and intangible assets, costs of preclinical studies, clinical trials and related clinical manufacturing, costs of drug development, costs of materials and supplies, facilities cost, overhead costs, regulatory and compliance costs, and fees paid to consultants and other entities that conduct certain research and development activities on our behalf. Costs incurred in research and development are expensed as incurred.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">154</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU145"></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Included in research and development costs are clinical trial and research expenses based on the services performed pursuant to contracts with research institutions and clinical research organizations and other vendors that conduct clinical trials and research on our behalf. We record accruals for estimated costs under these contracts. When evaluating the adequacy of the accrued liabilities, we analyze the progress of the studies or clinical trials, including the phase or completion of events, invoices received, contracted costs and purchase orders. Significant judgments and estimates are made in determining the accrued balances at the end of any reporting period based on the facts and circumstances known at that time. Although we do not expect the estimates to be materially different from the amounts actually incurred, if the estimates of the status and timing of services performed differs from the actual status and timing of services performed, we may report amounts that are too high or too low in any particular period. Actual results could differ from our estimates.</font></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Stock-Based Compensation</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We account for stock-based compensation under the provisions of ASC Topic&#160;718, <font style="font-style:italic;">Compensation&#8212;Stock Compensation</font>, or ASC&#160;718, which applies to share-based payments issued to employees and nonemployees in exchange for goods or services. Under ASC&#160;718, the fair value of an equity-classified award is estimated on the grant date without regard to service or performance conditions. The grant date fair values for options and warrants are estimated using the Black-Scholes-Merton option pricing model, and the grant date fair values for restricted stock units, or RSUs, are based upon the closing market price of our common stock on the date of grant.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We use the straight-line method to recognize stock-based compensation expense for our outstanding share awards that do not contain a performance condition. For awards subject to performance-based vesting conditions, we assess the probability of the individual milestones under the award being achieved and stock-based compensation expense is recognized over the service period commencing once management believes the performance criteria is probable of being met. For awards with service or performance conditions, we recognize the effect of forfeitures in compensation cost in the period that the award was forfeited.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Litigation Costs</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expense legal fees as they are incurred.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Comprehensive Income (Loss)</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Comprehensive income or loss is defined as the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. Comprehensive income or loss is composed of net income (loss) and other comprehensive income (loss). Our other comprehensive income or loss consists of unrealized gains and losses on marketable debt securities classified as available-for-sale, net of income taxes.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Basic and Diluted Net Loss per Share of Common Stock</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic net loss per share is calculated by dividing the net loss by the weighted-average number of common shares outstanding for the period. Diluted loss per share is computed similarly to basic loss per share except that the denominator is increased to include the number of additional shares that would have been outstanding if the potential common shares had been issued and if the additional common shares were dilutive.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For all periods presented, potentially dilutive securities are excluded from the computation of fully diluted loss per share as their effect is anti-dilutive. The following table details those securities that have been excluded from the computation of potentially dilutive securities:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding options</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,506,950</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,493,250</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,693,250</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding RSUs</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,139,428</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">867,911</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">888,189</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding warrants</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,589,250</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,721,088</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,646,378</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,950,411</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,302,527</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amounts in the table above reflect the common stock equivalents of the noted instruments.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">155</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU146"></a><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Segment and Geographic Information</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating segments are defined as components of an enterprise (business activity from which it earns revenue and incurs expenses) for which discrete financial information is available and regularly reviewed by the chief operating decision maker in deciding how to allocate resources and in assessing performance. Our chief operating decision maker is the company&#8217;s CEO. We view our operations and manage our business as a single operating and reporting segment. As of December&#160;31, 2019 and 2018, the majority of our assets were held in the U.S. For the years ended December&#160;31, 2019, 2018 and 2017, all of our revenue was derived in the U.S.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Recent Accounting Pronouncements</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Application of New or Revised Accounting Standards &#8211; Adopted</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We adopted ASC&#160;842 on January&#160;1, 2019, using the simplified transition approach which allowed us to not recast the comparative periods presented when transitioning to the new lease standard, while including required disclosures under ASC&#160;840 for all periods presented under ASC&#160;840. In addition, we elected the package of practical expedients permitted under the transition guidance, which among other things, allowed us to not reassess&#160;(1)&#160;whether a contract is or contains a lease, and (2)&#160;the classification of existing leases.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The adoption of ASC&#160;842 had a substantial impact on our balance sheet. The most significant impacts were (i)&#160;the recognition of $13.5&#160;million of operating lease right-of-use assets, net, and $16.4&#160;million of operating lease liabilities, and (ii)&#160;the derecognition of assets and liabilities associated with the build-to-suit leases under ASC&#160;840 (resulting in the derecognition of property, plant and equipment, net, of $6.6&#160;million and net adjustments to related liabilities of $5.7&#160;million). The build-to-suit leases were recorded as normal operating leases under ASC&#160;842. The difference between the excess of build-to-suit related liabilities and assets of $0.9&#160;million was recorded as an increase to our accumulated deficit. The cumulative-effect adjustment had no tax impact due to the valuation allowance against the gross deferred tax asset less reversing deferred tax liabilities. Adoption of this standard had no material impact on our results of operations and cash flows.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August&#160;2018, the FASB issued ASU&#160;2018&#8209;15, <font style="font-style:italic;">Intangibles&#8212;Goodwill and Other&#8212;Internal-Use Software (Subtopic 350-40): Customer&#8217;s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract</font> (ASU&#160;2018&#8209;15). This update aligns guidance for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs to develop or obtain internal-use software (and hosting arrangements that include an internal-use software license). Capitalized implementation costs will be amortized over the term of the hosting arrangement and expense related to the capitalized implementation costs will be presented in the same line item in the statements of operations as the fees associated with the service contract. As permitted by the standard, we elected to early adopt ASU&#160;2018&#8209;15 on a prospective basis as of October&#160;1, 2019. The adoption did not have a material effect on our consolidated financial statements.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Application of New or Revised Accounting Standards &#8211; Not Yet Adopted</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December&#160;2019, the FASB issued ASU&#160;2019-12,&#160;<font style="font-style:italic;">Simplifying the Accounting for Income Taxes</font>. The amendments in this update include removing the exception to the incremental approach for intraperiod tax allocation when there is a loss from continuing operations and income, or a gain, from other items (e.g., discontinued operations or other comprehensive income), and the exception to the general methodology for calculating income taxes in an interim period when a year-to-date loss exceeds the anticipated loss for the year. We are currently evaluating the impact that these amendments will have on our consolidated financial statements and we intend to early adopt these amendments on January&#160;1, 2020. We do not expect that the adoption of these amendments will have a significant impact on our consolidated financial statements.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">156</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU147"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June&#160;2016, the FASB issued ASU&#160;2016</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8209;</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,&#160;</font><font style="font-style:italic;">Financial Instruments&#8212;Credit Losses (Topic 326):&#160;Measurement of Credit Losses on Financial Instruments</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. The new guidance supersedes existing U.S. GAAP for measuring and recording of credit losses on financial assets measured at amortized cost by replacing the incurred-loss model with an expected-loss model. Accordingly, these financial assets will be presented at the net amount expected to be collected. This new standard also requires that credit losses related to available-for-sale debt securities be recorded as an allowance through net income rather than reducing the carrying amount under the current, other-than-temporary-impairment model. The new guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December&#160;15, 2019, but may be adopted earlier. With certain exceptions, adjustments are to be applied using a modified-retrospective approach by reflecting adjustments through a cumulative-effect impact on retained earnings as of the beginning of the fiscal year of adoption. In May&#160;2019, the FASB issued ASU&#160;2019-05,&#160;</font><font style="font-style:italic;">Financial Instruments&#8212;Credit Losses (Topic&#160;326):&#160;Targeted Transition Relief</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, which provides companies with an option to irrevocably elect the fair value option for certain financial assets previously measured at amortized cost basis upon adoption of Topic&#160;326. We are currently evaluating the impact that this new standard and its related amendments will have on our consolidated financial statements and we intend to adopt the standard on January&#160;1, 2021. However, as the impact is dependent upon the investments held as of the adoption date, it is not possible for us to quantify the impact until the date of adoption.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other recent authoritative guidance issued by the FASB (including technical corrections to the ASC), the American Institute of Certified Public Accountants, and the Securities and Exchange Commission during the three&#160;months ended December&#160;31, 2019 did not, or are not expected to, have a material effect on our consolidated financial statements.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">3. &#160;&#160;&#160;&#160;Financial Statement Details</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Prepaid expenses and other current assets</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2019 and 2018, prepaid expenses and other current assets were made up of (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid preclinical and clinical trial services - with</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; related party (Note 9)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,021</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Insurance premium financing asset</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">757</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">339</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid supplies - with related party (Note 9)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">467</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">532</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid services</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">440</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">230</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid rent</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">392</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">536</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid insurance</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">372</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">343</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid equipment maintenance</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">251</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">329</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest receivable - marketable debt securities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">222</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">473</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid license fees</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">78</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">104</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Insurance claim receivables</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,882</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Due from related parties</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">90</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,105</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,900</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Property, plant and equipment, net</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2019 and 2018, property, plant and equipment, net, was made up of (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Construction in progress</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,480</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33,406</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,087</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Buildings</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,690</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">59,356</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Equipment</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,434</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,878</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Software</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,195</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,264</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furniture &amp; fixtures</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">383</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">381</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">79,108</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">88,446</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulated depreciation</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(18,607</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(11,561</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">60,501</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">76,885</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">157</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation expense related to property, plant and equipment was $8.4&#160;million, $7.3&#160;million and $3.3&#160;million for the years ended December&#160;31, 2019, 2018 and 2017, respectively.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a result of adoption of ASC&#160;842 (Note&#160;2), we&#160;(i)&#160;reclassified $32.0&#160;million of assets from buildings to leasehold improvements, and (ii)&#160;derecognized $6.6&#160;million of assets associated with build-to-suit leases under ASC&#160;840.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The impact of adoption of ASC&#160;842 on property, plant, and equipment at December&#160;31, 2018 was as follows&#160;(in&#160;thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.24%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2018</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.24%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Adoption of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ASC 842</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Increase&#160;(Decrease)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.24%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">January 1, 2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,087</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32,014</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36,101</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Buildings</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">59,356</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(39,893</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,463</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property, plant and equipment, gross</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">88,446</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(7,879</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">80,567</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulated depreciation</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(11,561</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,293</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(10,268</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property, plant and equipment, net</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">76,885</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,586</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70,299</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Intangible assets, net</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2019 and 2018, intangible assets were made up of (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Technology license</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,042</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,042</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less accumulated amortization</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(9,042</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(8,477</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">565</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our intangible assets were fully amortized as of March&#160;31, 2019. Amortization expense was $0.6&#160;million, $2.3&#160;million and $2.3&#160;million for the years ended December&#160;31, 2019, 2018 and 2017, respectively. Amortization for the company&#8217;s technology license is included in research and development expense on the consolidated statements of operations.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Other assets</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2019 and 2018, other assets were made up of (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid preclinical and clinical trial services - with</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; related party (Note 9)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,075</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted cash</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">179</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">179</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Security deposit</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">113</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">113</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid rent</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,205</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,386</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,527</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted cash is comprised of a certificate of deposit that serves as collateral for a letter of credit required by our landlord as a security deposit related to our facility in San Diego, California.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">158</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU148"></a><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Accrued expenses</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2019 and 2018, accrued expenses were made up of (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued bonus</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,002</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,079</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued compensation</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,064</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">943</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued professional and service fees</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">975</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">912</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued laboratory equipment and supplies</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">640</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">678</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued preclinical and clinical trial costs</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">281</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">704</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued franchise, sales/use and property taxes</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">200</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">250</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Litigation settlement accruals</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,000</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued construction costs</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,341</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">181</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">197</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,343</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,104</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Other current liabilities</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2019 and 2018, other current liabilities were made up of (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease liability - current portion (including</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; amounts with related parties, Note 9)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,206</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financing obligation - current portion</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">757</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">965</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred rent - current portion</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">598</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">104</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,981</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,667</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Investment income, net</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net investment income is as follows for the years ended December&#160;31, 2019, 2018 and 2017 (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the Year Ended December&#160;31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest income</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,643</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,317</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,225</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Investment accretion income (amortization expense), net</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(463</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,597</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net realized (losses) gains on investments</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,642</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,857</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,665</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest income includes interest from marketable debt securities, notes receivable, other assets, and interest from bank deposits. We did not recognize an impairment loss on any investments during the years ended December&#160;31, 2019, 2018 and 2017.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">4. &#160;&#160;&#160;&#160;Viracta Investment and Convertible Notes</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March&#160;2017, we participated in a Series&#160;B convertible preferred stock financing and invested $8.5&#160;million in Viracta Therapeutics, Inc., or Viracta, a clinical stage drug development company. In May&#160;2017, we executed an exclusive worldwide license with Viracta to develop and commercialize Viracta&#8217;s proprietary histone deacetylase inhibitor drug candidate for use in combination with natural killer cell therapy and possibly additional therapies. See Note&#160;7<font style="font-style:italic;"> &#8211; Collaboration and License Agreements &#8211; Royalties and In-licensing Agreements &#8211; Viracta License Agreement</font> for further information.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">159</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU149"></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June&#160;2018, Viracta executed a 2018&#160;Note and Warrant Purchase Agreement with existing and new investors, including us. The initial closing under the Purchase Agreement occurred in June&#160;2018, at which point we purchased a convertible note for $0.4&#160;million, which under certain circumstances was convertible into preferred stock of Viracta, and a warrant to purchase Viracta&#8217;s common shares. The convertible note accrued interest at 8% and had a </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">one-year</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> maturity date. In September&#160;2018, a milestone closing under the Purchase Agreement occurred, at which point we purchased an additional convertible note for $0.4&#160;million, which under certain circumstances was convertible into preferred stock of Viracta, and a warrant to purchase Viracta&#8217;s common shares. The convertible note accrued interest at 8% and had a </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">one-year</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> maturity date. We classified the convertible notes as held-to-maturity notes receivable on the consolidated balance sheets. Effective January&#160;31, 2019, the notes, together with accrued interest then outstanding, were converted to Series&#160;B preferred stock resulting in an increase to our investment in Viracta&#8217;s Series&#160;B convertible preferred stock of $0.8&#160;million. In May&#160;2019, we exercised warrants to acquire 253,120&#160;shares of Viracta common stock. At </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2019</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, our investment in Viracta totaled $9.3&#160;million.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Based on the level of equity investment at risk, Viracta is not a VIE and therefore is not consolidated under the VIE Model. In addition, we do not hold a controlling financial interest in Viracta and therefore we do not consolidate Viracta under the voting interest model. As the preferred stock is not considered in-substance common stock, the investment is not within the scope of accounting for the investment under the equity method. As the preferred stock does not have a readily determinable fair value and does not qualify for the practical expedient to estimate fair value in accordance with ASC&#160;820, we have elected to apply the measurement alternative under ASC&#160;321, pursuant to which we measure our investment in Viracta at cost, less impairment, adjusted for observable price changes in an orderly market for an identical or similar investment of the same issuer.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2019, our qualitative impairment assessment did not indicate there were events or changes in circumstances that may have had a significant adverse effect on the fair value of the investment. We have not recorded any impairments as of December&#160;31, 2019, or on a cumulative basis. Further, we have not identified any downward or upward adjustments due to observable price changes in the investment as of December&#160;31, 2019, or on a cumulative basis. Our investment in Viracta is reflected in equity investment on the consolidated balance sheets.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">5. &#160;&#160;&#160;&#160;Financial Instruments &#8211; Investments in Debt Securities</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At December&#160;31, 2019, our investments in debt securities are detailed below (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="18" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contractual&#160;Life</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in years)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cost</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gains</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Losses</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Available-for-sale:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt securities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.2</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32,382</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32,389</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Foreign government bonds</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.3</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,007</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,007</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Government sponsored securities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.5</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,752</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,748</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current portion</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.2</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36,141</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(7</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36,144</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Noncurrent:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Available-for-sale:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt securities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.7</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,501</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,497</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Noncurrent portion</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.7</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,501</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,497</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.94%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.3</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37,642</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(11</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37,641</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">160</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU150"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At December&#160;31, 2018, our investments in debt securities are detailed below (in thousands):</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="14" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.42%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2018</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized&#160;Cost</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gains</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Losses</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair&#160;Value</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Available-for-sale:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt securities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">57,463</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(136</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">57,328</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total available-for-sale</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">57,463</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(136</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">57,328</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Held-to-maturity, notes receivable (Note 4)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">723</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">723</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current portion</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">58,186</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(136</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">58,051</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Noncurrent:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Available-for-sale:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt securities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,067</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(76</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,991</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Government sponsored securities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,756</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(46</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,710</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Noncurrent portion</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,823</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(122</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,701</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">64,009</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(258</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">63,752</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulated unrealized losses on debt securities classified as available-for-sale that have been in a continuous loss position for less than 12&#160;months and for more than 12&#160;months at December&#160;31, 2019 and 2018 were as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="14" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.42%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Less than 12 months</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">More than 12 months</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Estimated&#160;Fair</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross&#160;Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Losses</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Estimated&#160;Fair</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross&#160;Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Losses</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt securities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,021</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,497</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Government sponsored securities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,748</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,021</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,245</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(8</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="14" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.42%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2018</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Less than 12 months</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">More than 12 months</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Estimated&#160;Fair</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross&#160;Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Losses</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Estimated&#160;Fair</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross&#160;Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Losses</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt securities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32,010</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(26</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26,663</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(186</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Government sponsored securities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,710</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(46</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32,010</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(26</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29,373</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(232</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At December&#160;31, 2019, 14 of the securities were in an unrealized loss position. We evaluated our securities for other-than-temporary impairment and concluded that the decline in value was primarily caused by current economic and market conditions. We do not intend to sell the investments and it is not more likely than not that we will be required to sell the investments before recovery of their amortized cost bases. Therefore, we did not recognize any other-than-temporary impairment loss during the years ended December&#160;31, 2019, 2018 and 2017.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We recorded realized gains and losses on sales of available-for-sale debt securities as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;">
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.92%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Realized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gains</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.92%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Realized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Losses</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.92%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Net</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Realized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gains (Losses)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(8</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">52</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(15</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">6. &#160;&#160;&#160;&#160;Fair Value Measurements</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fair value is defined as an exit price that would be received from the sale of an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Authoritative guidance establishes a three-level hierarchy for disclosure that is based on the extent and level of judgment used to estimate the fair value of assets and liabilities.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">161</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU151"></a><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Recurring Valuations</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial assets and liabilities measured at fair value on a recurring basis are summarized below at December&#160;31, 2019 and 2018 (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="14" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.42%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value Measurements at December&#160;31, 2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Assets:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,508</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,508</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt securities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32,389</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32,389</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Foreign government bonds</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,007</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,007</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Government sponsored securities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,748</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,748</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Noncurrent:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt securities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,497</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,497</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total assets measured at fair value</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">53,149</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,508</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37,641</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;">
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="14" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.42%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value Measurements at December&#160;31, 2018</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Assets:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,821</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,821</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt securities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">57,328</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">57,328</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Noncurrent:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt securities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,991</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,991</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Government sponsored securities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,710</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,710</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total assets measured at fair value</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">79,850</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,821</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">63,029</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Non-recurring Valuations</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-financial assets and liabilities are recognized at fair value subsequent to initial recognition when they are deemed to be other-than-temporarily impaired. There were no material non-financial assets and liabilities deemed to be other-than-temporarily impaired and measured at fair value on a non-recurring basis for the years ended December&#160;31, 2019, 2018 and 2017.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">7. &#160;&#160;&#160;&#160;Collaboration and License Agreements</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Collaborative Arrangements</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A collaborative arrangement is a contractual arrangement that involves a joint operating activity. These arrangements involve two or more parties who are&#160;(i)&#160;active participants in the activity, and (ii)&#160;exposed to significant risks and rewards dependent on the commercial success of the activity.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In January&#160;2020, we entered into a Cost Sharing Agreement with ImmunityBio as further described in Note 15 &#8211; <font style="font-style:italic;">Subsequent Events</font>.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Exclusive Co-Development Agreement</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August&#160;2016, we entered into an exclusive Co-Development Agreement, or the Co-Development Agreement, with Altor BioScience, LLC, or Altor. Altor is a related party, as it is a wholly owned subsidiary of ImmunityBio (Note&#160;9). Under the Co-Development Agreement, the parties agreed to exclusively collaborate on the development of certain therapeutic applications combining our proprietary NK&#160;cells with Altor's N&#8209;801 and/or N&#8209;803 products with respect to certain technologies and intellectual property rights as may be agreed between the parties for the purpose of jointly developing therapeutic applications of certain effector cell lines.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">162</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU152"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are the lead developer for each product developed by the parties pursuant to the Co-Development Agreement unless otherwise agreed to under a given project plan. Under the terms of the Co-Development Agreement, both parties granted a co-exclusive, royalty free, fully paid-up, worldwide license, with the right to sublicense (only to a third-party contractor assisting with research and development activities under this Co-Development Agreement and subject to prior consent, not to be unreasonably withheld), under the intellectual property, or IP, including the parties interest in the joint IP, solely to conduct any development activities agreed to by the steering committee as set forth in any development plan. Unless otherwise mutually agreed by the parties in the development plan for a project, we are responsible for all costs and expenses incurred by either party related to conducting clinical trials and other activities under each development program, including costs associated with patient enrollment, materials and supplies, third-party staffing and regulatory filings. Altor supplies free of charge, sufficient amounts of Altor products for all pre-clinical requirements and certain clinical requirements for up to 400&#160;patients in phase&#160;I and/or phase&#160;II clinical trials, as required under the development plan for a project per the Co-Development Agreement.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Each company owns an undivided interest in and to all rights, title and interest in and to the joint product rights. The Co-Development Agreement expires upon the fifth anniversary of the effective date. We have dosed patients with N&#8209;803, an IL&#8209;15 superagonist, in several phase&#160;Ib/II trials during the years ended December&#160;31, 2019, 2018 and 2017. No charges for supplies by Altor were incurred in association with the above trials during the years ended December&#160;31, 2019, 2018 and 2017.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Royalties and In-licensing Agreements</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Viracta License Agreement</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In May&#160;2017, we entered into an agreement with Viracta under which we were granted exclusive worldwide rights to Viracta&#8217;s phase&#160;II drug candidate, VRx&#8209;3996, for use in combination with our platform of NK&#160;cell therapies. In consideration for the license, we are obligated to pay to Viracta&#160;(i)&#160;mid-single digit percentage royalties of net sales of licensed products for therapeutic use; and (ii)&#160;milestone payments ranging from $10.0&#160;million to $25.0&#160;million for various regulatory approvals and cumulative net sales levels. We may terminate the agreement, in its sole discretion, in whole or on a product by product and/or country by country basis, at any time upon 90&#160;days&#8217;&#160;prior written notice. In addition, either party may terminate the agreement in the event of a material breach or for bankruptcy of the other party.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus, or GSH, and DRK-Blutspendedienst Baden-Wurttenberg-Hessen gGmbH, or BSD, License Agreement</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August&#160;2015, we entered into a license agreement with GSH and BSD under which we were granted an exclusive license to certain GSH&#8209;BSD patents, materials and know-how that specifically targets ErbB2 expressing cancers. In addition, GSH granted us an exclusive license to certain GSH only technology and materials. In consideration for the licenses, we agreed to pay initial and annual licensing fees, regulatory and commercial milestones and low single-digit percentage royalties on net sales of licensed products. We paid $1.1&#160;million for the initial license fees, which was included in research and development expenses on the consolidated statements of operations for the year ended December&#160;31, 2015. Annual license fees under the agreement began in 2018. In October&#160;2018, we terminated this agreement in accordance with the terms of the agreement.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Fox Chase Cancer Center License Agreement</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2004 and amended in 2008, we entered into an exclusive license agreement with Fox Chase Cancer Center, or Fox Chase, for the exclusive, worldwide right to certain patents and know-how pertaining to CD16 receptor bearing NK&#8209;92&#160;cell lines. In consideration for this exclusive license, we agreed to pay Fox Chase&#160;(i)&#160;low single-digit percentage royalties on net sales of licensed products for therapeutic and diagnostic use; and (ii)&#160;mid-twenties percentage royalties on any compensation we receive from sublicensees.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Rush University Medical Center License Agreement</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2004, we entered into a 12-year licensing agreement with Rush University Medical Center for the exclusive rights to license and grant sublicenses of certain intellectual property related to clinical use of NK&#8209;92. We are required to pay low to mid-single digit percentage royalties on net sales depending upon the various fields of studies and other factors. We were required to pay a minimum annual royalty of $25,000. The Rush University Medical Center License Agreement also provides for payments in the aggregate amount of $2.5&#160;million upon the company achieving various milestones, including upon&#160;(i)&#160;the completion of phase&#160;II clinical trial associated with the licensed intellectual property; (ii)&#160;the approval by the FDA of a new drug application for a licensed product; and (iii)&#160;the first year that sales of the licensed product equals or exceeds $0.3&#160;million. The license had a term of 12&#160;years from 2006, the year in which royalty payments were first made, and included customary termination rights for both parties. Beginning in 2018, this license converted to a perpetual, irrevocable, fully paid, royalty-free, exclusive license.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">163</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU153"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the years ended December&#160;31, 2019, 2018 and 2017, we recorded royalty expense of </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$0, $4,200</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and $25,000, respectively, related to the Rush University Medical Center License Agreement. Royalty expense is included in selling, general and administrative on the consolidated statements of operations. No milestones were met during the years ended December&#160;31, 2019, 2018 and 2017.</font></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Out-Licensing Agreement</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Intrexon License Agreement</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February&#160;2010, we entered into a 17-year license agreement with Intrexon Corporation, or Intrexon, pursuant to which we granted to Intrexon a non-exclusive, worldwide, sublicensable license to research and sell products under certain patents relating to modified NK&#8209;92&#160;cells that express Intrexon&#8217;s proprietary gene sequences for use as a therapeutic and prophylactic agent in humans in specified therapeutic areas. In consideration for the license agreement, Intrexon paid us a one-time fee of $0.4&#160;million. Prior to adoption of ASC&#160;606, this upfront payment had initially been recorded as deferred revenue and was being recognized into revenue on a straight-line basis. Upon adoption of ASC&#160;606, we adjusted our accumulated deficit in an amount equal to the then remaining deferred revenue after concluding that under ASC&#160;606 the upfront payment would have been recognized when the license was transferred in 2010. Intrexon will pay the following milestone payments:&#160;$0.1&#160;million upon the first IND filing; $0.1&#160;million upon the commencement of the first phase&#160;II clinical trial; $0.4&#160;million upon the commencement of the first phase&#160;III clinical trial; and $0.5&#160;million upon the first commercial sale relating to the licensed products. Intrexon is obligated to pay us a low single digit percentage royalty based on net sales of the licensed products by Intrexon and a mid-teen percentage royalty based on revenues received by Intrexon in connection with sublicenses of the licensed products. No milestone payments were due or received in the years ended December&#160;31, 2019, 2018 and 2017, and, therefore, we recorded no milestone revenue for any of those years on the consolidated statements of operations.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">8. &#160;&#160;&#160;&#160;Commitments and Contingencies</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Contingencies</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We record accruals for loss contingencies to the extent that we conclude it is probable that a liability has been incurred and the amount of the related loss can be reasonably estimated. We evaluate, on a quarterly basis, developments in legal proceedings and other matters that could cause a change in the potential amount of the liability recorded or of the range of potential losses disclosed. Additionally, we record our rights to insurance recoveries, limited to the extent of incurred or probable losses, as a receivable when such recoveries have been agreed to with our third-party insurers and when receipt is deemed probable. This includes instances where our third-party insurers have agreed to pay, on our behalf, certain legal defense costs and settlement amounts directly to applicable law firms and a settlement fund.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Securities Litigation</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_201"></a>In March&#160;2016, a putative securities class action complaint captioned <font style="font-style:italic;">Sudunagunta v. NantKwest, Inc., et al.</font>, No. 16&#8209;cv&#8209;01947 was filed in federal district court for the Central District of California related to the company&#8217;s restatement of certain interim financial statements for the periods ended June&#160;30, 2015 and September&#160;30, 2015. A number of similar putative class actions were filed in federal and state court in California. The actions originally filed in state court were removed to federal court, and the various related actions were consolidated. Plaintiffs asserted causes of action for alleged violations of Sections&#160;11 and 15 of the Securities Act of 1933 and Sections&#160;10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule&#160;10b&#8209;5 promulgated thereunder. Plaintiffs sought unspecified damages, costs and attorneys&#8217; fees, and equitable/injunctive or other relief on behalf of putative classes of persons who purchased or acquired the company&#8217;s securities during various time periods from July&#160;28, 2015 through March&#160;11, 2016. In September&#160;2017, the court denied defendants' motion to dismiss the third amended consolidated complaint. On August&#160;13, 2018, the district court granted plaintiffs&#8217; motions for class certification and to strike plaintiffs&#8217; claims under the Securities Exchange Act of 1934 and Rule&#160;10b&#8209;5. On August&#160;24, 2018, at the district court&#8217;s direction, plaintiffs filed a fourth amended consolidated complaint. On August&#160;27, 2018, defendants petitioned the U.S. Court of Appeals for the Ninth Circuit to authorize interlocutory appeal of the class certification order. On September&#160;7, 2018, defendants answered the fourth amended consolidated complaint. On September&#160;21, 2018, the parties informed the Ninth Circuit that they had reached a settlement in principle, and the parties moved to stay appellate proceedings. On September&#160;24, 2018, the parties notified the district court that they had reached a settlement in principle. On November&#160;9, 2018, the plaintiffs filed an unopposed motion for preliminary approval of the settlement and notice to class members. On January&#160;9, 2019, the district court granted the motion for preliminary approval. A final approval hearing was held on April&#160;29, 2019, and the district court granted final approval and entered judgment on May&#160;31, 2019.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">164</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU154"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the terms of the settlement, we paid $12.0&#160;million to the plaintiffs as full and complete settlement of the litigation. We were responsible for $1.2&#160;million of the settlement amount, which was recognized in selling, general and administrative expense during the third quarter of 2018, while the remaining $10.8&#160;million was fully funded by our insurance carriers under our directors&#8217; and officers&#8217; insurance policy. We and the insurance carriers paid the settlement amount into a settlement fund in January&#160;2019. Subsequent to receiving final approval of the settlement on May&#160;13, 2019, the aforementioned settlement accrual, associated insurance claim receivable and restricted cash were released and are no longer reflected on our consolidated balance sheets as of December&#160;31, 2019.</font></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Stipulation of Settlement</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In early April&#160;2019, following board approval, which occurred in late March&#160;2019, we entered into a settlement agreement, or the Stipulation of Settlement, with three&#160;stockholders of the company, each of whom had submitted a stockholder demand for the board to take action to remedy purported harm to the company resulting from certain alleged wrongful conduct concerning, among other things, disclosures about Dr.&#160;Soon-Shiong&#8217;s compensation and a related-party lease agreement. The Stipulation of Settlement called for us to adopt certain governance changes, and for the three&#160;stockholders to file a stockholder derivative action in the Superior Court of the State of California, County of San Diego, followed by an application for court approval of the Stipulation of Settlement. On May&#160;31, 2019, the court entered an order preliminarily approving the Stipulation of Settlement and scheduling the final settlement hearing for August&#160;9, 2019. Pursuant to the Stipulation of Settlement, we have provided stockholders with notice of the settlement and the final settlement hearing.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the terms of the Stipulation of Settlement, which received final approval by the court on August&#160;9, 2019, we paid an attorney&#8217;s fee of $0.5&#160;million to the plaintiffs as part of the settlement. Of that amount, we were responsible for half, which was recognized in selling, general and administrative expense on the consolidated statements of operations during the first quarter of 2019, while the other half was funded by our insurance carrier. We and the insurance carrier paid the settlement amount into a settlement fund in June&#160;2019. Subsequent to receiving final approval of the settlement on August&#160;9, 2019, the aforementioned settlement accrual, associated insurance claim receivable and restricted cash were released and are no longer reflected on our consolidated balance sheets as of December&#160;31, 2019.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Insurance Recoveries</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have reflected our right to insurance recoveries, limited to the extent of incurred or probable losses, as a receivable when such recoveries have been agreed to with our third-party insurers and receipt is deemed probable. This includes instances where our third-party insurers have agreed to pay, on our behalf, certain legal defense costs and settlement amounts directly to applicable law firms and a settlement fund. The amount of such receivable recorded at December&#160;31, 2019 and 2018 was $34,000 and $10.9&#160;million, respectively, and is included in prepaid expenses and other current assets on our consolidated balance sheets.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Contractual Obligations - Leases</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We adopted ASC&#160;842, as of January&#160;1, 2019, using the simplified transition approach discussed in further detail in Note&#160;2. As a result, prior periods were not recast. The following disclosures relate to our lease balances as of January&#160;1, 2019 and December&#160;31, 2019, under ASC&#160;842 (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.36%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">January 1, 2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.36%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease right-of-use assets, net</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.36%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,532</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.36%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,729</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other current liabilities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.36%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,960</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.36%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,206</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease liability, less current portion</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.36%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,407</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.36%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,885</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a result of new agreements entered into subsequent to our adoption of ASC&#160;842, we recognized an increase of $0.8&#160;million in both operating lease right-of-use assets and operating lease liabilities during the year ended December&#160;31, 2019.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Substantially all of our operating lease right-of-use assets and operating lease liabilities relate to facilities leases. We lease:&#160;(i)&#160;a&#160;research facility and office space in San Diego, California; (ii)&#160;a research and manufacturing space in Culver City, California, from a related party; (iii)&#160;a research and manufacturing facility in El Segundo, California, also from a related party; (iv)&#160;a research facility in Torrance, California, and (v)&#160;a research facility in Woburn, Massachusetts. See Note&#160;9 &#8211; <font style="font-style:italic;">Related Party Agreements</font> for further information.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">165</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU155"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease expense of $5.1&#160;million, including variable lease costs of $1.2&#160;million, was recorded in operating expenses on the consolidated statements of operations for year ended December&#160;31, 2019. The weighted-average remaining lease term as of January&#160;1, 2019 and December&#160;31, 2019 was 5.4&#160;years and 4.5&#160;years, respectively. The weighted-average discount rate as of January&#160;1, 2019 and December&#160;31, 2019 was 9%. For the year ended December&#160;31, 2019, cash outflows from operating leases, excluding variable lease costs, was $4.4&#160;million.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Future minimum lease payments at December&#160;31, 2019 are presented in the following table (in thousands). Common area maintenance costs and taxes are not included in these payments.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:81.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Years ending December 31:</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Operating</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Leases (a)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:81.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,271</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:81.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,753</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:81.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,671</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:81.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,546</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:81.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2024</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,083</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:81.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thereafter</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,729</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:81.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total future minimum lease payments</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,053</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:81.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: Interest</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,962</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:81.8%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Present value of operating lease liabilities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,091</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;margin-right:75.93%;text-indent:0%;font-size:5pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:2pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:2pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top">
<p style="margin-top:2pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Operating lease payments include $3.3&#160;million related to options to extend lease terms that are reasonably certain of being exercised.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August&#160;2018, NantBio, Inc., or NantBio, a related party (Note&#160;9) assigned an agreement to us for the use of a third-party research facility, which provides us with the exclusive right to use and access to a portion of the third party&#8217;s laboratory and vivarium premises. In conjunction with the assignment, we reimbursed NantBio for upfront payments, which it had made to the third party of $0.9&#160;million, and paid $0.5&#160;million directly to the third party for an aggregate value of $1.4&#160;million. The assigned agreement is for a term of ten&#160;years and expires in June&#160;2027. The agreement may be terminated by us at any time, with or without cause. In case of termination of the agreement, the third party will reimburse us for a pro-rata amount based upon the passage of time.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In September&#160;2016, we entered into a lease agreement with 605&#160;Doug St,&#160;LLC, a related party (Note&#160;9), for approximately 24,250&#160;square feet in El Segundo, California, which has been converted to a research and development laboratory and a cGMP manufacturing facility. The lease runs from July&#160;2016 through July&#160;2023. We have the option to extend the lease for an additional three&#160;year term through July&#160;2026. The monthly rent is $0.1&#160;million with annual increases of 3% beginning in July&#160;2017.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March&#160;2016, we entered into a lease agreement for an approximately 7,893&#160;square foot facility in Woburn, Massachusetts, for a research and development laboratory, related office and other related uses. The initial lease term runs for 48&#160;months from April&#160;29, 2016 through May&#160;31, 2020. In June&#160;2016, the lease was amended to add 260&#160;square feet, for a total of 8,153&#160;square feet. Base rent for the initial term of the lease is $19,000&#160;per&#160;month with a $1&#160;per&#160;square foot annual increase on each anniversary date. In August&#160;2019, we exercised our right pursuant to the lease agreement to extend the term of the lease for an additional two&#160;years through May&#160;31, 2022. Consequently, we recognized an increase of $0.6&#160;million in both operating lease right-of-use assets and operating lease liabilities on the consolidated balance sheets.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In November&#160;2015, we entered into a facility license agreement with NantWorks LLC, or NantWorks, a related party (Note&#160;9), for approximately 9,500&#160;square feet of office space in Culver City, California, which has been converted to a research and development laboratory and a cGMP manufacturing facility. The license was effective in May&#160;2015 and extends through December&#160;2020. The monthly rent is $47,000, with annual increases of 3% beginning in January&#160;2017.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June&#160;2015, we entered into a lease agreement for an approximately 44,700&#160;square foot facility in San Diego, California, for a research and development laboratory, related office and other related uses. The term of the lease extends for seven&#160;years commencing on August&#160;1, 2016. The base rent is $0.2&#160;million per month with 3% annual increases on each anniversary date.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prior to adopting ASC&#160;842 on January&#160;1, 2019, we recognized rent expense under operating leases on a straight-line basis. Fixed rent expense under ASC&#160;840 for the years ended December&#160;31, 2018 and 2017 was $2.8&#160;million and $2.7&#160;million, respectively.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">166</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU156"></a><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">9. &#160;&#160;&#160;&#160;Related Party Agreements</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our Chairman and CEO founded and has a controlling interest in NantWorks, which is a collection of multiple companies in the healthcare and technology space. As described below, we have entered into arrangements with NantWorks, and certain affiliates of NantWorks, to facilitate the development of new genetically modified NK&#160;cells for our product pipeline.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Share Repurchase</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In November&#160;2018, we entered into a share repurchase agreement with an immediate family member of a director of the company, pursuant to which we repurchased 138,349&#160;of our common shares for a total of $0.2&#160;million under our existing share repurchase program.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">NantHealth Labs, Inc.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March&#160;2018, we entered into an agreement with NantHealth Labs, Inc., or NantHealth Labs, to obtain blood-based tumor profiling services. NantHealth Labs is a related party, as it is a wholly owned subsidiary of NantHealth, Inc., a majority owned subsidiary of NantWorks. We are obligated to pay NantHealth Labs fixed, per-patient fees. The agreement has an initial term of five&#160;years and renews automatically for successive one-year periods, unless terminated earlier. During the years ended December&#160;31, 2019 and 2018, $10,000 and $0.3&#160;million, respectively, has been recognized in research and development expense on the consolidated statements of operations. At December&#160;31, 2018, we owed NantHealth Labs $49,300, which is included in due to related parties on the consolidated balance sheets. At December&#160;31, 2019, no balances were due between the parties.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Immuno-Oncology Clinic, Inc.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Beginning in 2017, we entered into multiple agreements with Immuno-Oncology Clinic, Inc., or the Clinic, to conduct various clinical trials. The Clinic was formerly known as John Lee, M.D. and Leonard Sender, M.D., Inc., a professional medical corporation, dba&#160;Chan Soon-Shiong Institutes for Medicine, in El Segundo, California. The Clinic is a related party as it is owned by one officer of NantKwest and NantWorks manages the administrative operations of the Clinic. Prior to June&#160;30, 2019, one of the company&#8217;s officers was an investigator or sub-investigator for all of the company&#8217;s trials conducted at the Clinic.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In July&#160;2019, we entered into a new agreement with the Clinic which superseded our existing agreements with the Clinic, effective as of July&#160;1, 2019. The new agreement covers clinical trial and research related activities on a non-exclusive basis relating to our existing clinical trials, commenced prior to July&#160;1, 2019, and prospective clinical trials and research projects. The new agreement also specifies certain services and related costs that are excluded from the new agreement. Prior to commencing any work under the new agreement, the parties have agreed to execute written work orders setting forth the terms and conditions related to specific services to be performed, including financial terms. For existing clinical trials, commenced prior to July&#160;1, 2019, fees incurred for services performed after July&#160;1, 2019 are covered under the new agreement and applied towards the below-mentioned prepayments. The initial term of the new agreement is for one year, but the agreement allows for an automatic renewal and additional extensions beyond the initial term. In July&#160;2019, we executed a clinical trial work order under the new agreement with the Clinic for an open-label, phase&#160;I study of PD&#8209;L1.t&#8209;haNK for infusion in subjects with locally advanced or metastatic solid cancers.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In consideration of the services to be performed under the new agreement, we agreed to make payments of $7.5&#160;million to the Clinic, of which $3.75&#160;million and $1.875&#160;million were paid in July&#160;2019 and October&#160;2019, respectively. The prepayments constitute a prepayment by us for services to be performed by the Clinic. Under the term of the new agreement, the outstanding balance of our prepayment shall be increased on a quarterly basis by an interest credit computed in accordance with terms specified in the new agreement.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To the extent any portion of the prepayments remain unearned by the Clinic on the third anniversary of the new agreement, we may elect at our sole discretion either to&#160;(i)&#160;not extend the term of the new agreement and have the Clinic reimburse us for the total amount of any remaining unused portion of the prepayments, or (ii)&#160;extend the term of the new agreement for up to three additional one year periods, at which time the Clinic will reimburse us for the total amount of any remaining unused portion of the prepayments plus interest if reimbursement is not made within 60&#160;days of expiration. The Clinic may terminate this agreement upon each anniversary date upon sixty&#160;(60)&#160;days prior written notice and reimbursement in full to us of any outstanding unearned balance of the prepayments, provided that any such termination by the Clinic will not apply with respect to any work orders still in effect at the time of such termination.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">167</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU157"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the years ended December&#160;31, 2019, 2018 and 2017, expense of $1.1&#160;million, $2.7&#160;million and $0.8&#160;million, respectively, has been recognized in research and development expense on the consolidated statements of operations. At December&#160;31, 2019 and 2018, we owed the Clinic $0.1&#160;million and $0.6&#160;million, respectively, for services excluded from the new agreement, which are included in due to related parties on the consolidated balance sheets, and as of December&#160;31, 2019, we had a prepaid balance with the Clinic of $5.1&#160;million, which is included in prepaid expenses and other currents assets, and other assets, on the consolidated balance sheets. We anticipate that the remaining prepayment amount as of December&#160;31, 2019 will be utilized in future periods as the Clinic provides additional services pursuant to the new agreement.</font></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Tensorcom, LLC</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In April&#160;2017, we entered into a sublease agreement with Tensorcom, LLC, or Tensorcom, for a portion of our San Diego, California, research and development laboratory and office space. The lease ran from May&#160;1, 2017 through April&#160;30, 2018. Tensorcom is a related party, as it is an affiliate of NantWorks. The sublease included a portion of the premises consisting of approximately 6,557&#160;rentable square feet of space. The monthly base rent was $25,000&#160;per month. For the years ended December&#160;31, 2018 and 2017, $0.1&#160;million and $0.2&#160;million, respectively, was recognized in other income on the consolidated statements of operations under the sublease agreement. At December&#160;31, 2019 and 2018, there were no balances due between the parties.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">605&#160;Doug&#160;St,&#160;LLC</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In September&#160;2016, we entered into a lease agreement with 605&#160;Doug&#160;St,&#160;LLC, an entity owned by our Chairman and CEO, for approximately 24,250&#160;square feet in El Segundo, California, which has been converted to a research and development laboratory and a cGMP laboratory manufacturing facility. The lease runs from July&#160;2016 through July&#160;2023. We have the option to extend the lease for an additional three-year term through July&#160;2026. The monthly rent is $0.1&#160;million with annual increases of 3% beginning in July&#160;2017. Lease expense for this facility is recorded in research and development expense on the consolidated statements of operations and was $0.9&#160;million, $0.2&#160;million and $0.2&#160;million, respectively, for the years ended December&#160;31, 2019, 2018 and 2017. At December&#160;31, 2019 and 2018, no balances were due between the parties.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">NantBio, Inc.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August&#160;2018, NantBio assigned an agreement to us for the use of a third-party research facility, which provides us with the exclusive right to use and access to a portion of the third party&#8217;s laboratory and vivarium premises. NantBio is a related party as it is an affiliate of NantWorks. In conjunction with the assignment, we reimbursed NantBio for upfront payments which it had made to the third party of $0.9&#160;million and paid $0.5&#160;million directly to the third party for an aggregate value of $1.4&#160;million. The assigned agreement is for a term of ten&#160;years and expires in June&#160;2027. The agreement may be terminated by us at any time, with or without cause. In case of termination of the agreement, the third party will reimburse us for a pro-rata amount based upon the passage of time.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In January&#160;2018, we entered into a laboratory services agreement with NantBio. The agreement, effective December&#160;2017, included a sublease of approximately 1,965&#160;square feet of laboratory and office space at our San Diego, California, research facility. This sublease was terminated effective December&#160;31, 2019, pursuant to the terms of the agreement. We recognized $0.1&#160;million, $0.1&#160;million and $10,000, respectively, in other income on the consolidated statements of operations for the years ended December&#160;31, 2019, 2018 and 2017. At December&#160;31, 2019 and 2018, NantBio owed us $8,400 and $49,000, respectively, which is included in prepaid expenses and other current assets on the consolidated balance sheets.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March&#160;2016, NantBio and the National Cancer Institute entered into a cooperative research and development agreement. The initial five-year agreement covers NantBio and its affiliates, including us. Under the agreement, the parties are collaborating on the preclinical and clinical development of proprietary recombinant natural killer cells and monoclonal antibodies in monotherapy and in combination immunotherapies. We benefited from the preclinical and clinical research conducted during the first four years under this agreement. In each of April&#160;2016, April&#160;2017, August&#160;2018, and May&#160;2019, we paid $0.6&#160;million to the National Cancer Institute as a prepayment for services under the agreement. We recognize research and development expense related to this agreement ratably over a 12-month period for each funding year and recorded $0.6&#160;million, of expense associated with the agreement in each of the years ended December&#160;31, 2019, 2018 and 2017. At December&#160;31, 2019 and 2018, we had balances of $0.1&#160;million and $0.1&#160;million, respectively, included in prepaid expenses and other current assets related to this agreement, on the consolidated balance sheets.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">168</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU158"></a><font style="font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">NantWorks</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In May&#160;2018, we entered into an assignment agreement with NantWorks and a third-party construction firm. In connection with the agreement, we assigned our deposit of $0.4&#160;million with the third-party firm to NantWorks for which NantWorks reimbursed us. This assignment represented unutilized deposits that NantKwest had previously made with the construction company, for which NantWorks can now utilize in applying such funds to future planned construction projects.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the NantWorks shared services agreement executed in November&#160;2015, but effective August&#160;2015, NantWorks provides corporate, general and administrative, manufacturing strategy, research and development, regulatory and clinical trial strategy, and other support services. We are charged for the services at cost plus reasonable allocations for indirect costs that relate to the employees providing the services. For the years ended December&#160;31, 2019, 2018 and 2017, we recorded $2.1&#160;million, $2.8&#160;million and $3.6&#160;million, respectively, to selling, general and administrative expense, and $1.5&#160;million, $3.3&#160;million and $3.2&#160;million, respectively, in research and development expense under this arrangement on the consolidated statements of operations. These amounts exclude certain general and administrative expenses provided by third party vendors directly for our benefit, which have been reimbursed to NantWorks based on those vendors&#8217; invoiced amounts without markup by NantWorks.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June&#160;2016, we amended the existing shared services agreement with NantWorks whereby we can provide support services to NantWorks and/or any of its affiliates. For the years ended December&#160;31, 2019, 2018 and 2017, we recorded expense reimbursements of $1.2&#160;million, $0.6&#160;million and $0.4&#160;million, respectively, to selling, general and administrative expense and $2.3&#160;million, $2.6&#160;million and $1.0&#160;million, respectively, to research and development expense.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At December&#160;31, 2019 and 2018, we owed NantWorks a net amount of $0.4&#160;million and $1.1&#160;million, respectively, for all agreements between the two affiliates, which is included in due to related parties on the consolidated balance sheets.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In November&#160;2015, we entered into a facility license agreement with NantWorks, which became effective May&#160;2015, for approximately 9,500&#160;square feet in Culver City, California, which has been converted to a research and development laboratory and a cGMP manufacturing facility. Lease expense for this facility is recorded in research and development expense on the consolidated statements of operations and was $0.6&#160;million, $0.2&#160;million, and $0.2&#160;million for the years ended December&#160;31, 2019, 2018 and 2017.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">NantOmics, LLC</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June&#160;2015, we entered into an agreement, as amended in May&#160;2018, with NantOmics, LLC, or NantOmics, which is a related party, as it is an affiliate of NantWorks. Pursuant to this agreement we obtain genomic sequencing and proteomic analysis services, as well as related data management and bioinformatics services, exclusively from NantOmics. We will have rights to use the data and results generated from NantOmics&#8217; services in connection with the performance of the particular oncology trial with respect to which the services were performed, but NantOmics owns the data and results, as well as any other intellectual property it creates in performing these services on our behalf. We are obligated to pay NantOmics a fixed, per sample fee, determined based on the type of services being provided. The agreement has an initial term of five&#160;years and renews automatically for successive one-year periods, unless terminated earlier. For the years ended December&#160;31, 2019, 2018 and 2017, we recorded operating expense of $0.1&#160;million, $0.1&#160;million and $0.1&#160;million, respectively, to research and development under this arrangement on the consolidated statements of operations. At December&#160;31, 2018, we owed NantOmics $24,000, which is included in due to related parties on the consolidated balance sheets. At December&#160;31, 2019, no balances were due between the parties.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">ImmunityBio</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ImmunityBio, Inc., or ImmunityBio, is a related party, as it is an affiliate of NantWorks. ImmunityBio was formerly known as NantCell, Inc.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In January&#160;2020, we entered into a cost sharing agreement with ImmunityBio as further described in Note&#160;15&#160;&#8209;&#160;<font style="font-style:italic;">Subsequent Events</font>.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In November&#160;2018, we entered into an agreement with Etubics Corporation, or Etubics, a subsidiary of ImmunityBio. Pursuant to this agreement we sold used laboratory equipment to Etubics for $0.3&#160;million. In conjunction with this sale, we recognized a loss on disposal of related laboratory equipment of $0.1&#160;million, which was included in other income, net on the consolidated statements of operations.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">169</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU159"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February&#160;2017, we entered into a research grant agreement with VivaBioCell S.p.A., or VBC, a subsidiary of ImmunityBio. VBC conducted research and development activities related to our NK&#160;cell lines using VBC&#8217;s proprietary technology. For the years ended December&#160;31, 2018 and 2017, $0.1&#160;million and $0.6&#160;million, respectively, was recognized in research and development expense on the consolidated statements of operations. No expense was incurred for the year ended December&#160;31, 2019.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August&#160;2016, we entered into an exclusive Co-Development Agreement with Altor as described in Note&#160;7&#160;&#8211;&#160;<font style="font-style:italic;">Collaboration and License Agreements</font>. Altor is a related party as it is a wholly owned subsidiary of ImmunityBio. No charges for supplies by Altor were incurred in association with the trials during the years ended December&#160;31, 2019, 2018 and 2017.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June&#160;2015, we also entered into a supply agreement with ImmunityBio pursuant to which we have the right to purchase ImmunityBio&#8217;s proprietary bioreactors, made according to specifications mutually agreed to with ImmunityBio. We also have the right to purchase reagents and consumables associated with such equipment from ImmunityBio. When an upfront payment is made, it is included in prepaid expenses on the consolidated balance sheets until the product is received. The agreement has an initial term of five&#160;years and renews automatically for successive one-year periods unless terminated earlier.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At December&#160;31, 2019 and 2018, we had $1.8&#160;million and $1.1&#160;million, respectively, in capitalized equipment purchased from ImmunityBio, which is included in property, plant and equipment, net, on the consolidated balance sheets. During the years ended December&#160;31, 2019, 2018 and 2017, we recorded research and development expense associated with reagents and consumables purchased from ImmunityBio of $0.1&#160;million, $0.1&#160;million and $0.3&#160;million, respectively, on the consolidated statements of operations.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At December&#160;31, 2019 and 2018, we had $0.5&#160;million and $0.5&#160;million, respectively, included in prepaid expenses and other current assets on the consolidated balance sheets related to consumables purchased from ImmunityBio. At December&#160;31, 2019 and December&#160;31, 2018, no balances were due between the parties.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">10. &#160;&#160;&#160;&#160;Stockholders&#8217; Equity</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Stock Repurchase &#8211; <font style="font-style:normal;">In November&#160;2015, the board of directors approved a share repurchase program, or the 2015 Share Repurchase Program, allowing the CEO or CFO, on behalf of the company, to repurchase from time to time, in the open market or in privately negotiated transactions, up to $50.0&#160;million of our outstanding shares of common stock, exclusive of any commissions, markups or expenses. The timing and amounts of any purchases were and will continue to be based on market conditions and other factors, including price, regulatory requirements and other corporate considerations. The 2015&#160;Share Repurchase Program does not require the purchase of any minimum number of shares and may be suspended, modified, or discontinued at any time without prior notice. We have financed, and expect to continue to finance, the purchases with existing cash balances. The shares are formally retired through board approval upon repurchase.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To date, we have repurchased 6,403,489&#160;shares of our common stock under the 2015&#160;Share Repurchase Program at a total cost of $31.7&#160;million. In addition, we have paid approximately $0.1&#160;million of broker commissions on repurchases. We repurchased 473,586&#160;shares, 138,349&#160;shares (Note&#160;9), and 3,633,610&#160;shares during the years ended December&#160;31, 2019, 2018 and 2017, respectively, for a total of $0.5&#160;million, $0.2&#160;million, and $15.2&#160;million, respectively. At December&#160;31, 2019, $18.3&#160;million remained authorized for repurchase under the 2015 Share Repurchase Program.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Common Stock Reserved for Future Issuance</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are authorized to issue up to 500,000,000&#160;shares of our common stock, par value $0.0001&#160;per share at December&#160;31, 2019. As of December&#160;31, 2019, there were 98,460,404&#160;shares of our common stock issued and outstanding.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes the common shares reserved for issuance on exercise or vesting of various awards at December&#160;31, 2019:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:60%;">
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding stock options</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,506,950</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding RSUs</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,139,428</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:78.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding warrants</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.9%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.64%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:78.44%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total shares reserved for future issuance</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.9%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.64%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,646,378</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">170</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU160"></a><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">11. &#160;&#160;&#160;&#160;Stock-Based Compensation</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">2014 Equity Incentive Plan &#8211; <font style="font-style:normal;">In March&#160;2014, the company&#8217;s board of directors and stockholders approved the 2014 Equity Incentive Plan, or 2014&#160;Plan, under which 11,109,000&#160;shares of Class&#160;A common stock were reserved for the granting of incentive stock options, within the meaning of Section&#160;422 of the Internal Revenue Code, or IRC, non-statutory stock options, stock appreciation rights, restricted stock awards, restricted stock units and performance awards to employees, directors and consultants. Recipients of stock awards are eligible to purchase shares of our common stock at an exercise price equal to no less than the estimated fair market value of such stock on the date of grant. The maximum term of awards granted under the 2014&#160;Plan is ten&#160;years. Stock awards are generally not exercisable prior to the applicable vesting date, unless otherwise accelerated under the terms of the applicable stock plan agreement. Unvested shares of our common stock issued in connection with an early exercise allowed by the company may be repurchased by us upon termination of the optionee&#8217;s service.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">2015 Equity Incentive Plan &#8211; <font style="font-style:normal;">In July&#160;2015, the company&#8217;s board of directors adopted and the company&#8217;s stockholders approved the 2015 Equity Incentive Plan, or 2015&#160;Plan. In April&#160;2019, the company&#8217;s board of directors adopted, and in June&#160;2019 the company&#8217;s stockholders approved, an amendment to the 2015&#160;Plan to reserve a further 3,000,000&#160;shares of common stock for issuance pursuant to the 2015&#160;Plan. The 2015&#160;Plan, as amended, permits the grant of incentive stock options to the company&#8217;s employees, and for the grant of non-statutory stock options, restricted stock, restricted stock units, stock appreciation rights, performance units and performance shares to the company&#8217;s employees, directors and consultants.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2019 there were approximately 4.3&#160;million shares of common stock reserved for future grants pursuant to the 2015&#160;Plan. In addition, the shares reserved for future grants under the 2015&#160;Plan include shares subject to stock options or similar awards granted under the 2014&#160;Plan that expire or terminate without having been exercised in full and shares issued pursuant to awards granted under the 2014&#160;Plan that are forfeited to or repurchased by us (provided that the maximum number of shares that may be added to the 2015&#160;Plan pursuant to this provision is approximately 2.3&#160;million shares as of December&#160;31, 2019).</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Stock-Based Compensation</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table presents all stock-based compensation as included on the consolidated statements of operations (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the Year Ended December&#160;31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrants for common stock to an officer</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,817</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31,584</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Employee stock options</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,309</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,057</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,267</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Employee RSUs</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">938</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,193</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">894</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-employee RSUs</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">380</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">315</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">252</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,627</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,382</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36,997</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense in operating expenses:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">499</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">460</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">102</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Selling, general and administrative</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,128</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,922</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36,895</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,627</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,382</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36,997</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">171</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU161"></a><font style="font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Stock Options</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes stock option activity under all equity incentive plans for the years ended December&#160;31, 2019, 2018 and 2017:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise&#160;Price</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Intrinsic</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contractual&#160;Life</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in years)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at December 31, 2016</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,307,386</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.14</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,100</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.4</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options exercised</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(614,136</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.88</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at December 31, 2017</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,693,250</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.71</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,920</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.3</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options granted</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">800,000</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.07</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at December 31, 2018</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,493,250</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.14</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">563</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.8</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options exercised</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,986,300</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.06</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at December 31, 2019</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,506,950</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.37</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,710</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.8</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested and Exercisable at December 31, 2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,973,614</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.22</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,326</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.5</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The vested and exercisable shares at December&#160;31, 2018 and 2017 were 5,577,531 and 5,114,656, respectively.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table provides a summary of options outstanding and vested as of December&#160;31, 2019:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.56%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise Prices</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Outstanding</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average&#160;Remaining</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contractual Life</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in years)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercisable</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average&#160;Remaining</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contractual Life</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in years)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.56%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$0.42</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">589,660</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.9</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">589,660</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.9</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$1.76</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">699,060</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.0</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">699,060</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.0</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$2.00</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">962,780</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.1</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">962,780</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.1</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$3.07</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">800,000</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.7</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">266,664</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.7</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$25.00</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,455,450</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.22%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.6</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,455,450</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.22%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.6</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.56%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,506,950</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.22%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.8</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,973,614</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.22%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.5</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The aggregate intrinsic value of stock options exercised during the years ended December&#160;31, 2019, 2018 and 2017 was $0.2&#160;million, $0.6&#160;million and $1.7&#160;million, respectively. The cash received from exercised options was $4.1&#160;million, $0 and $1.2&#160;million, respectively, for the years ended December&#160;31, 2019, 2018 and 2017.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the year ended December&#160;31, 2018, the company granted 800,000&#160;stock options to key executives. These options have an exercise price of $3.07&#160;per share, which was equal to the closing price of the company&#8217;s common stock on the date of grant, and 25% vest on the one-year anniversary of the date of grant with the remaining options vesting ratably each month over the following three&#160;years. No stock options were granted to employees during the years ended December&#160;31, 2019 and 2017. No stock options were granted to non-employees during the years ended December&#160;31, 2019, 2018 and 2017.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The total unrecognized compensation cost related to non-vested stock options as of December&#160;31, 2019 is $1.1&#160;million, which is expected to be recognized over a weighted-average period of 2.7&#160;years.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The company uses a Black-Scholes option-pricing model to determine the fair value of stock-based compensation under ASC&#160;Topic&#160;718,&#160;<font style="font-style:italic;">Stock Compensation</font>. The assumptions used for employee stock options granted during the year ended December&#160;31, 2018, are presented in the table below:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:60%;">
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term (years)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.0 - 6.1</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.8%</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75.9%</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dividend yield</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0%</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average measurement date fair value</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$2.09</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">172</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU162"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The assumed dividend yield was based on the company&#8217;s expectation of not paying dividends in the foreseeable future. The estimated volatility was based on a weighted-average calculation of the company&#8217;s common stock together with a peer group of comparable companies whose share prices are publicly available. The risk-free interest rate assumption was based on the U.S.&#160;Treasury&#8217;s rates for U.S.&#160;Treasury zero-coupon bonds with maturities similar to those of the expected term of the award being valued. The weighted-average expected life of options was estimated using the average of the contractual term and the weighted-average vesting term of the options.</font></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Restricted Stock Units</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes the restricted stock units, or RSUs, activity under the 2015&#160;Plan:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">RSUs</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Outstanding</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Grant Date</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested balance at December 31, 2016</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">814,456</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13.98</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">615,983</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.50</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(244,209</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15.82</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited/canceled</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(298,041</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.28</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested balance at December 31, 2017</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">888,189</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.14</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">487,472</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.57</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(172,330</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.16</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited/canceled</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(335,420</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.27</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested balance at December 31, 2018</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">867,911</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.69</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">749,793</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.12</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(395,051</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.83</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited/canceled</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(83,225</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.29</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested balance at December 31, 2019</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,139,428</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.88%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.23</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may grant RSUs to both employees and directors of the company and to employees of related parties that provide shared services to the company under the company&#8217;s shared services agreement with NantWorks (Note&#160;9). During the years ended December&#160;31, 2018 and 2017, we granted 90,906&#160;RSUs and 77,250&#160;RSUs, respectively, to non-employees. All of the RSUs granted to non-employees during these periods were granted to employees of related companies under our shared services agreement with NantWorks (Note&#160;9). There were no new grants made to non-employees during the year ended December&#160;31, 2019.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2019, there was $1.4&#160;million of unrecognized stock-based compensation expense related to RSUs that is expected to be recognized over a weighted-average period of 1.7&#160;years. Of that amount, $1.3&#160;million of unrecognized expense is related to employee grants with a remaining weighted-average period of 1.8&#160;years and $0.1&#160;million of unrecognized expense is related to non-employee grants with a remaining weighted-average period of 0.8&#160;years.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Warrants</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes the company&#8217;s warrant activity:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:60%;">
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at December 31, 2016</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,768,314</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrants exercised</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(47,226</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at December 31, 2017</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,721,088</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrants exercised</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(93,254</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrants expired</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(38,584</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at December 31, 2018</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,589,250</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrants exercised</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(17,589,250</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at December 31, 2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested and exercisable at December 31, 2019</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the years ended December&#160;31, 2019, 2018 and 2017, cash proceeds recognized from exercises of warrants were $35.2&#160;million, $0.1&#160;million and $0.1&#160;million, respectively.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">173</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU163"></a><font style="font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Common Stock Reserved for Future Grants under the 2015 Equity Incentive Plan</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At December&#160;31, 2019, there were approximately 4.3&#160;million shares of common stock reserved for future grants of equity awards.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">12. &#160;&#160;&#160;&#160;Income Taxes</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The amount of loss before taxes is as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the Year Ended December&#160;31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. loss before taxes</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(65,286</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(94,423</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(94,734</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Foreign loss before taxes</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(600</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,306</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,182</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss before income taxes</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(65,886</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(96,729</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(96,916</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Income tax benefit for the years ended December&#160;31, 2019, 2018 and 2017 consists of the following (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.84%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the Year Ended December&#160;31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.8%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.8%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current:</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.48%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Federal</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Foreign</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.48%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total Current</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.48%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred:</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.48%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Federal</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(79</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(21</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(8</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Foreign</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.48%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(498</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(497</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total Deferred</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(100</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(506</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(497</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.78%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Income tax benefit</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.48%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(97</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(503</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(493</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The components that comprise the company&#8217;s net deferred tax assets at December&#160;31, 2019 and 2018 consist of the following (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.94%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax assets:</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net operating loss carryforwards</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">78,377</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61,915</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock compensation</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,536</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">79,281</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease liabilities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,884</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation and amortization</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,042</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tax credits</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">898</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">845</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued compensation</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">775</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">795</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leases and other accrued liabilities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">453</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,909</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued legal expenses</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">308</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred tax assets</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">94,965</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">146,053</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax liabilities:</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Foreign intangibles</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease right-of-use assets</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,233</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation and amortization</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,279</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred tax liabilities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,233</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,280</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net deferred tax assets</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">91,732</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">144,773</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Valuation allowance</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(91,732</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(144,773</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.44%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net deferred tax liability</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.4%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">174</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU164"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A reconciliation of the federal statutory income tax rate to the company&#8217;s effective income tax rate is as follows:</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:55.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="12" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.08%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the Year Ended December&#160;31,</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:55.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.02%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.02%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tax computed at federal statutory rate</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.34%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.0</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.34%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.0</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.34%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34.0</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State income taxes, net of federal tax benefit</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.34%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(19.4</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.34%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.2</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.34%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.3</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tax rate adjustment</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.34%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.1</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.34%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.3</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.34%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.8</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tax Cuts and Jobs Act</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.34%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.34%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.34%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(53.4</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development credits</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.34%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.2</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.34%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.1</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.34%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.6</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.34%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(82.5</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.34%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.1</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.34%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.3</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.34%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.1</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.34%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.3</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.34%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.8</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:55.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Valuation allowance</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.34%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">80.5</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.34%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(26.7</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.34%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.7</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:55.54%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Effective income tax rate</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.34%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.2</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.02%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.34%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.5</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.02%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.34%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.5</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.02%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On December&#160;22, 2017, the Tax Cuts and Jobs Act, or the TCJA, was enacted into law. The TCJA made significant changes to U.S. tax laws, including, but not limited to, the following:&#160;(a)&#160;reducing the federal corporate income tax rate from 35% to a flat 21%, effective January&#160;1, 2018; (b)&#160;eliminating the federal corporate alternative minimum tax, or AMT, and changing how existing AMT credits can be realized; and (c)&#160;eliminating several business deductions and credits, including deductions for certain executive compensation in excess of $1.0&#160;million.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a result of the rate reduction, the company reduced the deferred tax asset balance as of December&#160;31, 2017 by $51.7&#160;million. Due to the company&#8217;s full valuation allowance position, we also reduced the valuation allowance by the same amount.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December&#160;2017, the Securities and Exchange Commission issued Staff Accounting Bulletin&#160;No.&#160;118, or SAB&#160;118, which provides guidance on accounting for the income tax effects of the TCJA. SAB&#160;118 provides a measurement period that should not extend beyond one year from the TCJA enactment date for companies to complete the accounting related to the TCJA under ASC&#160;Topic&#160;740, <font style="font-style:italic;">Income Taxes</font>, or ASC&#160;740. In accordance with SAB&#160;118, a company must reflect the income tax effects of those aspects of the TCJA for which the accounting under ASC&#160;740 is complete. To the extent that a company&#8217;s accounting for TCJA-related income tax effects is incomplete, but the company is able to determine a reasonable estimate, it must record a provisional estimate in its financial statements. If a company cannot determine a provisional estimate to be included in its financial statements, it should continue to apply ASC&#160;740 on the basis of the provisions of the tax laws that were in effect immediately before enactment of the TCJA. We completed our evaluation of the potential impacts of IRC&#160;Section&#160;162(m) as amended by the TJCA on our December&#160;31, 2018 consolidated financial statements, resulting in no adjustment for the years ended December&#160;31, 2019, 2018 and 2017.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to IRC&#160;Sections&#160;382 and 383, annual use of the company's net operating loss and research and development credit carryforwards may be limited in the event a cumulative change in ownership of more than 50% occurs within a three-year period. We completed an IRC&#160;Section&#160;382/383 analysis through March&#160;2019 regarding the limitation of net operating loss and research and development credit carryforwards. As a result, we derecognized a portion of the deferred tax assets for net operating losses and federal and state research and development credits of $0.8&#160;million from our deferred tax asset schedule as of December&#160;31, 2019. There is no impact to tax expense for the derecognition of the net operating losses and federal and state research and development credits due to the valuation allowance recorded against the deferred tax assets. Additionally, we have not recognized the deferred tax asset for research and development credits carryforwards as of December&#160;31, 2019 and 2018 because we are a part of a controlled group of affiliated companies with common ownership and cannot complete our calculation of the credit until the time that all members of the controlled group complete their analysis and calculation of qualified research expenditures. We do not expect that the unrecognized tax benefits will change within 12&#160;months of this reporting date. Due to the existence of the valuation allowance, future changes in our unrecognized tax benefits will not impact the company's effective tax rate.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In assessing the realization of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income and tax planning strategies in making this assessment. Based on the level of historical operating results and the uncertainty of the economic conditions, we have recorded a full valuation allowance of $91.7&#160;million at December&#160;31, 2019. The change in the valuation allowance for the year ended December&#160;31, 2019 was a decrease of $53.0&#160;million which was mainly driven by the reversal of deferred tax assets related to stock compensation that will not be realized. The portion of the valuation allowance for deferred tax assets for which subsequently recognized tax benefits will be credited directly to contributed capital is $0.2&#160;million.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">175</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU165"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have not incurred any material interest or penalties as of the current reporting date with respect to income tax matters. We do not expect that there will be unrecognized tax benefits of a significant nature that will increase or decrease within 12&#160;months of the reporting date. We are subject to U.S. federal income tax, as well as income tax in California and other states. The federal returns for tax years 2016 through 2019 remain open to examination and the California returns remain subject to examination for tax years 2015 through 2019. Carryforward attributes that were generated in years where the statute of limitations is closed may still be adjusted upon examination by the Internal Revenue Service or other respective tax authority. All other state jurisdictions remain open to examination.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At December&#160;31, 2019, the company has federal net operating losses, or NOLs, of approximately $291.8&#160;million, state NOLs of $255.7&#160;million, and foreign NOLs of $0.2&#160;million. The federal NOL carryforwards begin to expire in 2024, the state NOL carryforwards begin to expire in 2030 and the foreign NOL carryforwards begin to expire in 2022. At December&#160;31, 2019, the company also had federal research tax credit carryforwards of approximately $8.5&#160;million and California research tax credits of $5.7&#160;million. The federal research tax credit carryforwards begin to expire in 2034 and the state research tax credit carryforwards begin to expire in 2031.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes the changes to the amount of unrecognized tax benefits (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:60%;">
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unrecognized tax benefits at December 31, 2017</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,577</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Increase for prior year tax positions</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">798</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Increase for current year tax positions</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,608</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unrecognized tax benefits at December 31, 2018</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,983</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Decrease for prior year tax positions</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(7</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Increase for current year tax positions</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,680</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unrecognized tax benefits at December 31, 2019</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,656</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Included in the balance of unrecognized tax benefits at December&#160;31, 2019, is $14.1&#160;million that, if recognized, would not impact our income tax benefit or effective tax rate as long as the deferred tax asset remains subject to a full valuation allowance. We do not expect any significant increases or decreases to our unrecognized tax benefits within the next 12&#160;months.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">13. &#160;&#160;&#160;&#160;Summarized Quarterly Data (Unaudited)</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following financial information reflects all normal recurring adjustments that are, in the opinion of management, necessary for a fair statement of the results of the interim periods.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The table below presents unaudited quarterly data for fiscal 2019 and 2018 (in thousands, except for share and per share amounts):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1st Quarter</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2nd Quarter</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">3rd Quarter</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">4th Quarter</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenue</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating expenses</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,340</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,313</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,077</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,120</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating loss</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(18,335</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(17,296</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(16,065</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(16,111</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(17,885</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(16,682</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(15,581</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(15,641</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per share - basic and diluted</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.22</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.17</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.16</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.16</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shares used in calculating net loss per share - basic and</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; diluted</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">81,261,302</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">98,594,355</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">98,331,695</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">98,419,166</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1st Quarter</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2nd Quarter</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">3rd Quarter</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">4th Quarter</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenue</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating expenses</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28,289</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28,282</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,139</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,726</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating loss</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(28,284</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(28,278</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(24,108</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(17,719</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">) </p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(27,519</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(27,732</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(23,635</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(17,340</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">) </p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per share - basic and diluted</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.35</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.35</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.30</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.22</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">) </p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shares used in calculating net loss per share - basic and</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; diluted</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">79,036,614</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">79,107,208</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">79,204,765</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">79,177,962</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">176</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU166"></a><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">14. &#160;&#160;&#160;&#160;Employee Benefits</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Defined Contribution Benefit Plan &#8211; <font style="font-style:normal;">In December&#160;2015, the company adopted a 401(k) retirement and savings plan, or the 401(k) Plan, covering all employees. The 401(k)&#160;Plan allows employees to make pre- and post-tax contributions up to the maximum allowable amount set by the Internal Revenue Service. The company, at its discretion, may make certain contributions to the 401(k)&#160;Plan. We made contributions of $0.6&#160;million, $0.5&#160;million and $0.4&#160;million during the years ended December&#160;31, 2019, 2018 and 2017, respectively.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Compensated Absences &#8211; <font style="font-style:normal;">Under our vacation policy, salaried employees are provided unlimited vacation leave. Therefore, we do not record an accrual for paid leave related to these employees since we are unable to reasonably estimate the compensated absences that these employees will take.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">15. &#160;&#160;&#160;&#160;Subsequent Events</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Collaborative Arrangement</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A collaborative arrangement is a contractual arrangement that involves a joint operating activity. These arrangements involve two or more parties who are&#160;(i)&#160;active participants in the activity, and (ii)&#160;exposed to significant risks and rewards dependent on the commercial success of the activity.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Cost Allocation Agreement<font style="font-style:normal;">&#8212; On January&#160;29, 2020, we entered into a Cost Allocation Agreement, or the Agreement, with ImmunityBio, Inc. and its subsidiaries, or ImmunityBio. The Agreement is effective as of October&#160;1, 2019. ImmunityBio is a related party, as it is an affiliate of NantWorks (Note&#160;9). Simultaneously, we and ImmunityBio entered into Work Order Number One under the Agreement. Under the Agreement and Work Order Number One, the parties agreed to conduct a joint study, the clinical research trial being conducted pursuant to the protocol titled QUILT&#160;3.063:</font>&#160;A phase&#160;2 study of combination therapy with an IL-15 superagonist&#160;(N&#8209;803), off-the-shelf CD16&#8209;targeted natural killer cells&#160;(haNK), and avelumab without cytotoxic chemotherapy in subjects with Merkel Cell Carcinoma&#160;(MCC) that has progressed on or after treatment with a checkpoint inhibitor<font style="font-style:normal;">. The ImmunityBio study drug included in the joint study is ImmunityBio&#8217;s proprietary IL-15 superagonist known as N&#8209;803 and our study drug is our proprietary &#8220;off-the-shelf&#8221; CD16-targeted natural killer cell therapy known as haNK.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We will act as the sponsor of this joint study for purposes of regulatory matters, including submissions, correspondence, and communications. Additionally, we are designated as the contracting party to execute agreements with third and related parties relating to the joint study under Work Order Number One. We and ImmunityBio will split certain joint study costs equally related to Work Order Number One, in accordance with the terms of the Agreement. Shared joint study costs include cost related to conducting the joint study development activities, such as personnel related costs, as well as all costs associated to regulatory matters. Costs and expenses incurred in connection with the development, manufacturing, supply, delivery, and pre-patient administration dosing mechanism of each party&#8217;s study drug, are excluded from the shared joint study costs. We expect that the joint study cost sharing component under the Agreement related to Work Order Number One will total approximately $2.1&#160;million, subject to change dependent on clinical trial enrollments and progress. At December&#160;31, 2019, there was minimal joint research activity under the Agreement and we incurred approximately $0.1&#160;million in costs related to the joint study that are subject to joint cost sharing under the Agreement and are recorded in research in research and development expense on the consolidated statements of operations.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the agreement, each of ImmunityBio and the company will receive exclusive rights to any new intellectual property developed that relates solely to its respective study drug, and the parties will have joint co-equal rights in any other intellectual property. The Agreement expires upon the second anniversary of the effective date with the option to renew for additional successive one-year terms, but work orders for any joint studies still in process at the time of termination will continue until the applicable study is completed.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Coronavirus Pandemic</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Due to the global viral outbreak caused by Coronavirus Disease&#160;2019&#160;(COVID&#8209;19) in 2020, there have been resulting effects which could negatively impact our financial condition or operations, including significant stock market exchange volatility, including various temporary volatility trading halts which commenced initially on March&#160;9,&#160;2020 due to market declines, various temporary business closures and event cancellations, and other effects including strains on hospitals and health provider resources which could result in clinical trial disruptions as the broader economic impact of COVID&#8209;19 develops. The ultimate impact of these matters to us and our financial condition and operations is presently unknown. The accompanying consolidated financial statements as of and for the year ended December&#160;31,&#160;2019 do not reflect the effects of these subsequent events.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">177</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU167"></a><a name="ITEM_9_CHANGES_IN_DISAGREEMENTS_WITH_ACC"></a><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_9_CHANGES_IN_DISAGREEMENTS_WITH_ACC"></a>Item&#160;9. Changes in and Disagreements with Accou</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">ntants on Accounting and Financial Disclosure.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_9A_CONTROLS_PROCEDURES"></a><a name="ITEM_9A_CONTROLS_PROCEDURES"></a>Item&#160;9A. Controls and Procedures.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Evaluation of Disclosure Controls and Procedures</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Management, with the participation of its Chief Executive Officer, or CEO, and Chief Financial Officer, or CFO, evaluated the effectiveness of our disclosure controls and procedures as of December&#160;31, 2019. The term &#8220;disclosure controls and procedures,&#8221; as defined in Rule&#160;13a-15(e) of the Securities Exchange Act of 1934, or the Exchange Act, means controls and other procedures of a company that are designed to provide reasonable assurance that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission&#8217;s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to provide reasonable assurance that information required to be disclosed is accumulated and communicated to our management, including our CEO and CFO, as appropriate, to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their desired control objectives, and management necessarily is required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on the evaluation of our disclosure controls and procedures as of December&#160;31, 2019, our CEO and CFO have concluded that, as of December&#160;31, 2019, our disclosure controls and procedures were effective at the reasonable assurance level.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Management's Report on Internal Control Over Financial Reporting</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Management is responsible for establishing and maintaining adequate internal control over financial reporting as such term is defined in Rule&#160;13a-15(f) under the Exchange Act. Internal control over financial reporting is a process designed under the supervision and with the participation of our management, including our CEO and CFO, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. Our internal control over financial reporting includes those policies and procedures that&#160;(i)&#160;pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of our assets; (ii)&#160;provide reasonable assurance (a)&#160;transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, (b)&#160;our receipts and expenditures are being made only in accordance with authorizations of our management and directors; and (c)&#160;regarding the prevention or timely detection of the unauthorized acquisition, use or disposition of assets that could have a material effect on our financial statements.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">178</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU168"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2019, our management conducted an evaluation of the effectiveness of our internal control over financial reporting using the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission in Internal Control - Integrated Framework&#160;(</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2013</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">). Based on this evaluation, our management concluded that, as of December&#160;31, 2019, our internal control over financial reporting was effective.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This annual report does not include an attestation report of our registered public accounting firm regarding internal control over financial reporting. Management&#8217;s report was not subject to attestation by our registered public accounting firm pursuant to rules of the Securities and Exchange Commission that permit us to provide only management&#8217;s report in this annual report.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Changes in Internal Control over Financial Reporting</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There have been no changes in our internal control over financial reporting that occurred during the last fiscal quarter ended December&#160;31, 2019, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Inherent Limitations on Effectiveness of Controls</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Management recognizes that a control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud or error, if any, have been detected. These inherent limitations include the realities that judgments in decision making can be faulty, and that breakdowns can occur because of a simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by management override of the controls. The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions; over time, controls may become inadequate because of changes in conditions, or the degree of compliance with policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_9B_OTHER_INFORMATION"></a><a name="ITEM_9B_OTHER_INFORMATION"></a>Item&#160;9B. Other Information.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">2020 Goals and Objectives; Changes in Executive Compensation</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On March&#160;20, 2020, the board of directors of NantKwest, Inc., or the company, reviewed and approved metrics with regard to the chief executive officer&#8217;s, chief administrative officer&#8217;s, and chief financial officer&#8217;s target annual bonus relating to the company&#8217;s goals for 2020 such as clinical trials, manufacturing, process development, research and development, and financial management. The board of directors also adopted and approved an increase to the base salary of Sonja Nelson, the company&#8217;s chief financial officer, to $367,000 per year, with a potential cash bonus of up to 40% of her base salary for the year ending December&#160;31, 2020.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">179</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU169"></a><a name="PART_III"></a><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="PART_III"></a>PART</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> III</font></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_10_DIRECTORS_EXECUTIVE_FICERS_CORPO"></a><a name="ITEM_10_DIRECTORS_EXECUTIVE_FICERS_CORPO"></a>Item&#160;10. Directors, Executive Officers and Corporate Governance.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The information required by this item will be contained in our definitive proxy statement to be filed with the Securities and Exchange Commission on Schedule&#160;14A in connection with our 2020 Annual Meeting of Stockholders, or the Proxy Statement, which is expected to be filed not later than 120&#160;days after the end of our fiscal year ended December&#160;31, 2019, and is incorporated herein by reference.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_11_EXECUTIVE_COMPENSATION"></a><a name="ITEM_11_EXECUTIVE_COMPENSATION"></a>Item&#160;11. Executive Compensation.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The information required by this item will be contained in the Proxy Statement under the headings &#8220;Executive Compensation&#8221; and &#8220;Board of Directors and Corporate Governance &#8211; Director Compensation,&#8221; and is incorporated herein by reference.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_12_SECURITY_OWNERSHIP_CERTAIN_BENEF"></a><a name="ITEM_12_SECURITY_OWNERSHIP_CERTAIN_BENEF"></a>Item&#160;12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The information required by this item will be contained in the Proxy Statement under the headings &#8220;Security Ownership of Certain Beneficial Owners and Management&#8221; and &#8220;Executive Compensation &#8211; Equity Compensation Plan Information,&#8221; and is incorporated herein by reference.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_13_CERTAIN_RELATIONSHIPS_RELATED_TR"></a><a name="ITEM_13_CERTAIN_RELATIONSHIPS_RELATED_TR"></a>Item&#160;13. Certain Relationships and Related Transactions, and Director Independence.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The information required by this item will be contained in the Proxy Statement under the headings &#8220;Certain Relationships and Related Party Transactions&#8221; and &#8220;Board of Directors and Corporate Governance,&#8221; and is incorporated herein by reference.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_14_PRINCIPAL_ACCOUNTING_FEES_SERVIC"></a><a name="ITEM_14_PRINCIPAL_ACCOUNTING_FEES_SERVIC"></a>Item&#160;14. Principal Accounting Fees and Services.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The information required by this item will be contained in the Proxy Statement under the heading &#8220;Ratification of Appointment of Independent Registered Public Accounting Firm &#8211; Fees Paid to the Independent Registered Public Accounting Firm&#8221; and is incorporated herein by reference.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">180</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU170"></a><a name="PART_IV"></a><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="PART_IV"></a>PART</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> IV</font></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_15_EXHIBITS_FINANCIAL_STATEMENT_SCH"></a><a name="ITEM_15_EXHIBITS_FINANCIAL_STATEMENT_SCH"></a>Item&#160;15. Exhibits, Financial Statement Schedules.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The consolidated financial statements schedules and exhibits filed as part of this Annual Report on Form&#160;10&#8209;K, or Annual Report, are as follows:</p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(1)<font style="font-weight:normal;"> </font>Consolidated financial statements</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reference is made to the consolidated financial statements identified in the &#8220;Index to Financial Statements&#8221; under Part&#160;II, Item&#160;8 of this Annual Report.</p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(2)<font style="font-weight:normal;"> </font>Financial Statement Schedules</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All other schedules not listed above have been omitted because the information required to be set forth therein is not applicable or is otherwise on the consolidated financial statements or notes thereto.</p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(3)<font style="font-weight:normal;"> </font>Exhibits</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The documents listed in the Exhibit Index of this Annual Report are incorporated by reference or are filed with this Annual Report, in each case as indicated therein (numbered in accordance with Item&#160;601 of Regulation&#160;S-K).</p>
<p style="text-align:center;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Exhibit Index</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td rowspan="2" valign="bottom"  style="width:7.14%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number</p></td>
<td valign="bottom"  style="width:0.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:48.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:0.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td colspan="7" valign="bottom"  style="width:43.08%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Incorporated by Reference Herein</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:0.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:48.22%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Description</p></td>
<td valign="bottom"  style="width:0.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:7.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Form</p></td>
<td valign="bottom"  style="width:0.84%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:10.8%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">File No.</p></td>
<td valign="bottom"  style="width:0.68%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:7.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit</p></td>
<td valign="bottom"  style="width:0.82%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:15.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Filing Date</p></td>
</tr>
<tr>
<td valign="top"  style="width:7.14%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:48.22%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.3%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:10.8%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.54%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:15.1%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:7.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;3.1</p></td>
<td valign="top"  style="width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:48.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1326110/000119312515275314/d158803dex31.htm"><font style="text-decoration:none;">Amended and Restated Certificate of Incorporation of NantKwest, Inc</font></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font></p></td>
<td valign="top"  style="width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8-K</p></td>
<td valign="top"  style="width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:10.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">001-37507</p></td>
<td valign="top"  style="width:0.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.1</p></td>
<td valign="top"  style="width:0.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:15.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">August 4, 2015</p></td>
</tr>
<tr>
<td valign="top"  style="width:7.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:48.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:10.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:15.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:7.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;3.2</p></td>
<td valign="top"  style="width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:48.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1326110/000119312515275314/d158803dex32.htm"><font style="text-decoration:none;">Amended and Restated Bylaws of NantKwest, Inc., effective as of August 2, 2019</font></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font></p></td>
<td valign="top"  style="width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-Q</p></td>
<td valign="top"  style="width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:10.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">001-37507</p></td>
<td valign="top"  style="width:0.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.1</p></td>
<td valign="top"  style="width:0.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:15.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">November&#160;5, 2019</p></td>
</tr>
<tr>
<td valign="top"  style="width:7.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:48.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:10.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:15.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:7.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;4.1</p></td>
<td valign="top"  style="width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:48.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1326110/000119312515229037/d917371dex41.htm"><font style="text-decoration:none;">Nominating Agreement by and between the Registrant and Cambridge Equities, LP, dated June&#160;18, 2015</font></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font></p></td>
<td valign="top"  style="width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1</p></td>
<td valign="top"  style="width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:10.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-205124</p></td>
<td valign="top"  style="width:0.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.1</p></td>
<td valign="top"  style="width:0.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:15.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">June 19, 2015</p></td>
</tr>
<tr>
<td valign="top"  style="width:7.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:48.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:10.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:15.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:7.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;4.2</p></td>
<td valign="top"  style="width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:48.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;letter-spacing:-0.15pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1326110/000119312515229037/d917371dex42.htm"><font style="text-decoration:none;">Form of Registration Rights Agreement by and between the Company and the Purchasers of Common Stock, dated June 2015</font></a><font style="letter-spacing:-0.15pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font></p></td>
<td valign="top"  style="width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1</p></td>
<td valign="top"  style="width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:10.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-205124</p></td>
<td valign="top"  style="width:0.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.2</p></td>
<td valign="top"  style="width:0.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:15.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">June 19, 2015</p></td>
</tr>
<tr>
<td valign="top"  style="width:7.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:48.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:10.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:15.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:7.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;4.3</p></td>
<td valign="top"  style="width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:48.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1326110/000119312515229037/d917371dex43.htm"><font style="text-decoration:none;">Registration Rights Agreement by and between the Company and Cambridge Equities LP, dated December&#160;23, 2014</font></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font></p></td>
<td valign="top"  style="width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1</p></td>
<td valign="top"  style="width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:10.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-205124</p></td>
<td valign="top"  style="width:0.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.3</p></td>
<td valign="top"  style="width:0.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:15.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">June 19, 2015</p></td>
</tr>
<tr>
<td valign="top"  style="width:7.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:48.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:10.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:15.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:7.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;4.4</p></td>
<td valign="top"  style="width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:48.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1326110/000119312515229037/d917371dex44.htm"><font style="text-decoration:none;">Registration Rights Agreement by and between the Company and Sorrento Therapeutics, Inc., dated December&#160;13, 2014</font></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font></p></td>
<td valign="top"  style="width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1</p></td>
<td valign="top"  style="width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:10.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-205124</p></td>
<td valign="top"  style="width:0.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.4</p></td>
<td valign="top"  style="width:0.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:15.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">June 19, 2015</p></td>
</tr>
<tr>
<td valign="top"  style="width:7.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:48.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:10.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:15.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:7.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;4.5</p></td>
<td valign="top"  style="width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:48.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1326110/000119312515229037/d917371dex45.htm"><font style="text-decoration:none;">Form of Subscription and Securities Purchase Agreement among the Company and the Subscribers of Series C Preferred Stock, dated as of April&#160;1, 2014</font></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font></p></td>
<td valign="top"  style="width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1</p></td>
<td valign="top"  style="width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:10.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-205124</p></td>
<td valign="top"  style="width:0.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.5</p></td>
<td valign="top"  style="width:0.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:15.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">June 19, 2015</p></td>
</tr>
<tr>
<td valign="top"  style="width:7.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:48.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:10.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:15.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:7.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;4.6</p></td>
<td valign="top"  style="width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:48.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;letter-spacing:-0.15pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1326110/000119312515229037/d917371dex46.htm"><font style="text-decoration:none;">Registration Rights Agreement, among the Company and the purchasers of Series B Preferred Stock, dated as of June&#160;20, 2013</font></a><font style="letter-spacing:-0.15pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font></p></td>
<td valign="top"  style="width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1</p></td>
<td valign="top"  style="width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:10.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-205124</p></td>
<td valign="top"  style="width:0.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.6</p></td>
<td valign="top"  style="width:0.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:15.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">June 19, 2015</p></td>
</tr>
<tr>
<td valign="top"  style="width:7.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:48.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:10.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:15.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:7.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;4.7</p></td>
<td valign="top"  style="width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:48.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1326110/000119312515252847/d917371dex47.htm"><font style="text-decoration:none;">Specimen common stock certificate</font></a><font style="text-decoration:none;">.</font></p></td>
<td valign="top"  style="width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1/A</p></td>
<td valign="top"  style="width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:10.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-205124</p></td>
<td valign="top"  style="width:0.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.7</p></td>
<td valign="top"  style="width:0.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:15.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">July 15, 2015</p></td>
</tr>
<tr>
<td valign="top"  style="width:7.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:48.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:10.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:15.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:7.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;4.8*</p></td>
<td valign="top"  style="width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:48.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="nk-ex48_1107.htm"><font style="text-decoration:none;">Description of the Registrant&#8217;s Securities.</font></a></p></td>
<td valign="top"  style="width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:10.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:15.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:7.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:48.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:10.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:15.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:7.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;10.1</p></td>
<td valign="top"  style="width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:48.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1326110/000119312515229037/d917371dex101.htm"><font style="text-decoration:none;">Form of Indemnification Agreement between the Company and each of its directors and executive officers</font></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font></p></td>
<td valign="top"  style="width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1</p></td>
<td valign="top"  style="width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:10.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-205124</p></td>
<td valign="top"  style="width:0.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.1</p></td>
<td valign="top"  style="width:0.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:15.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">June 19, 2015</p></td>
</tr>
<tr>
<td valign="top"  style="width:7.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:48.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:10.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:15.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:7.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;10.2+</p></td>
<td valign="top"  style="width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:48.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;letter-spacing:-0.1pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1326110/000119312515229037/d917371dex102.htm"><font style="text-decoration:none;">2014 Equity Incentive Plan and forms of agreements thereunder</font></a><font style="letter-spacing:-0.1pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font></p></td>
<td valign="top"  style="width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1</p></td>
<td valign="top"  style="width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:10.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-205124</p></td>
<td valign="top"  style="width:0.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.2</p></td>
<td valign="top"  style="width:0.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:15.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">June 19, 2015</p></td>
</tr>
<tr>
<td valign="top"  style="width:7.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:48.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:10.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:15.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:7.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;10.3+</p></td>
<td valign="top"  style="width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:48.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;letter-spacing:-0.1pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1326110/000119312515252847/d917371dex103.htm"><font style="text-decoration:none;">2015 Equity Incentive Plan (As Amended and Restated June&#160;6, 2019) and forms of agreements thereunder</font></a><font style="letter-spacing:-0.1pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font></p></td>
<td valign="top"  style="width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-Q</p></td>
<td valign="top"  style="width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:10.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">001-37507</p></td>
<td valign="top"  style="width:0.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.1</p></td>
<td valign="top"  style="width:0.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:15.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">August 6, 2019</p></td>
</tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">181</p>
<hr style="page-break-after:always;width:100%;">
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td rowspan="2" valign="bottom"  style="width:7.14%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number</p></td>
<td valign="bottom"  style="width:0.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:48.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:0.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td colspan="7" valign="bottom"  style="width:43.08%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Incorporated by Reference Herein</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:0.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:48.22%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Description</p></td>
<td valign="bottom"  style="width:0.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:7.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Form</p></td>
<td valign="bottom"  style="width:0.84%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:10.8%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">File No.</p></td>
<td valign="bottom"  style="width:0.68%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:7.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit</p></td>
<td valign="bottom"  style="width:0.82%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:15.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Filing Date</p></td>
</tr>
<tr>
<td valign="top"  style="width:7.14%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:48.22%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.3%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:10.8%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.54%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:15.1%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:7.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:48.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:10.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:15.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:7.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;10.4+</p></td>
<td valign="top"  style="width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:48.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1326110/000119312515252847/d917371dex104.htm"><font style="text-decoration:none;">Executive Incentive Compensation Plan</font></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font></p></td>
<td valign="top"  style="width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1/A</p></td>
<td valign="top"  style="width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:10.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-205124</p></td>
<td valign="top"  style="width:0.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.4</p></td>
<td valign="top"  style="width:0.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:15.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">July 15, 2015</p></td>
</tr>
<tr>
<td valign="top"  style="width:7.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:48.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:10.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:15.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:7.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;10.5+</p></td>
<td valign="top"  style="width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:48.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1326110/000119312515252847/d917371dex105.htm"><font style="text-decoration:none;">Amended and Restated Executive Employment Agreement between the Company and Patrick Soon-Shiong, effective March&#160;24, 2015</font></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font></p></td>
<td valign="top"  style="width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1/A</p></td>
<td valign="top"  style="width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:10.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-205124</p></td>
<td valign="top"  style="width:0.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.5</p></td>
<td valign="top"  style="width:0.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:15.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">July 15, 2015</p></td>
</tr>
<tr>
<td valign="top"  style="width:7.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:48.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:10.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:15.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:7.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;10.6+</p></td>
<td valign="top"  style="width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:48.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1326110/000119312515229037/d917371dex106.htm"><font style="text-decoration:none;">Executive Employment Agreement between the Company and Barry J. Simon, M.D., dated January&#160;1, 2015</font></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font></p></td>
<td valign="top"  style="width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1</p></td>
<td valign="top"  style="width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:10.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-205124</p></td>
<td valign="top"  style="width:0.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.6</p></td>
<td valign="top"  style="width:0.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:15.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">June 19, 2015</p></td>
</tr>
<tr>
<td valign="top"  style="width:7.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:48.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:10.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:15.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:7.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;10.7</p></td>
<td valign="top"  style="width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:48.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1326110/000119312515229037/d917371dex107.htm"><font style="text-decoration:none;">License Agreement between the Company and Brink Biologics, Inc., dated June&#160;9, 2015</font></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font></p></td>
<td valign="top"  style="width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1</p></td>
<td valign="top"  style="width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:10.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-205124</p></td>
<td valign="top"  style="width:0.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.7</p></td>
<td valign="top"  style="width:0.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:15.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">June 19, 2015</p></td>
</tr>
<tr>
<td valign="top"  style="width:7.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:48.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:10.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:15.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:7.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;10.8</p></td>
<td valign="top"  style="width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:48.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1326110/000119312515229037/d917371dex108.htm"><font style="text-decoration:none;">License Agreement between the Company and Coneksis, Inc., dated June&#160;9, 2015</font></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font></p></td>
<td valign="top"  style="width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1</p></td>
<td valign="top"  style="width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:10.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-205124</p></td>
<td valign="top"  style="width:0.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.8</p></td>
<td valign="top"  style="width:0.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:15.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">June 19, 2015</p></td>
</tr>
<tr>
<td valign="top"  style="width:7.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:48.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:10.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:15.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:7.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;10.9</p></td>
<td valign="top"  style="width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:48.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1326110/000119312515229037/d917371dex1010.htm"><font style="text-decoration:none;">License Agreement between the Company and Intrexon Corporation, dated February&#160;23, 2010</font></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font></p></td>
<td valign="top"  style="width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1</p></td>
<td valign="top"  style="width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:10.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-205124</p></td>
<td valign="top"  style="width:0.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.10</p></td>
<td valign="top"  style="width:0.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:15.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">June 19, 2015</p></td>
</tr>
<tr>
<td valign="top"  style="width:7.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:48.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:10.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:15.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:7.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;10.10</p></td>
<td valign="top"  style="width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:48.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1326110/000119312515229037/d917371dex1011.htm"><font style="text-decoration:none;">UHN-ZelleRx License Agreement between University Health Network and the Company, dated May&#160;9, 2005</font></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font></p></td>
<td valign="top"  style="width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1</p></td>
<td valign="top"  style="width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:10.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-205124</p></td>
<td valign="top"  style="width:0.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.11</p></td>
<td valign="top"  style="width:0.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:15.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">June 19, 2015</p></td>
</tr>
<tr>
<td valign="top"  style="width:7.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:48.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:10.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:15.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:7.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;10.11</p></td>
<td valign="top"  style="width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:48.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1326110/000119312515229037/d917371dex1012.htm"><font style="text-decoration:none;">License Agreement, as amended, between Fox Chase Cancer Center and the Company, dated as of July&#160;10, 2004</font></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font></p></td>
<td valign="top"  style="width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1</p></td>
<td valign="top"  style="width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:10.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-205124</p></td>
<td valign="top"  style="width:0.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.12</p></td>
<td valign="top"  style="width:0.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:15.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">June 19, 2015</p></td>
</tr>
<tr>
<td valign="top"  style="width:7.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:48.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:10.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:15.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:7.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;10.12</p></td>
<td valign="top"  style="width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:48.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1326110/000119312515229037/d917371dex1013.htm"><font style="text-decoration:none;">Rush-ZelleRx License Agreement, between Rush University Medical Center and the Registrant, dated as of March&#160;24, 2004</font></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font></p></td>
<td valign="top"  style="width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1</p></td>
<td valign="top"  style="width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:10.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-205124</p></td>
<td valign="top"  style="width:0.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.13</p></td>
<td valign="top"  style="width:0.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:15.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">June 19, 2015</p></td>
</tr>
<tr>
<td valign="top"  style="width:7.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:48.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:10.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:15.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:7.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;10.13</p></td>
<td valign="top"  style="width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:48.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1326110/000119312515263882/d917371dex1014.htm"><font style="text-decoration:none;">License Agreement, as amended, between Hans G. Klingemann and the Company, dated February&#160;10, 2003</font></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font></p></td>
<td valign="top"  style="width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1/A</p></td>
<td valign="top"  style="width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:10.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-205124</p></td>
<td valign="top"  style="width:0.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.14</p></td>
<td valign="top"  style="width:0.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:15.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">July 27, 2015</p></td>
</tr>
<tr>
<td valign="top"  style="width:7.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:48.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:5pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:10.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:15.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:7.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;10.14</p></td>
<td valign="top"  style="width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:48.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1326110/000119312515229037/d917371dex1018.htm"><font style="text-decoration:none;">Genomic and Proteomic Services Agreement by and between the Company and NantOmics, LLC, dated June&#160;18, 2015</font></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font></p></td>
<td valign="top"  style="width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1</p></td>
<td valign="top"  style="width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:10.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-205124</p></td>
<td valign="top"  style="width:0.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.18</p></td>
<td valign="top"  style="width:0.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:15.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">June 19, 2015</p></td>
</tr>
<tr>
<td valign="top"  style="width:7.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:48.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:10.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:15.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:7.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;10.15</p></td>
<td valign="top"  style="width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:48.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1326110/000095012315007692/d917371dex1019.htm"><font style="text-decoration:none;">Lease Agreement by and between ARE - John Hopkins Court, LLC and the Company, dated June&#160;19, 2015</font></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font></p></td>
<td valign="top"  style="width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1/A</p></td>
<td valign="top"  style="width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:10.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-205124</p></td>
<td valign="top"  style="width:0.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.19</p></td>
<td valign="top"  style="width:0.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:15.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">July 27, 2015</p></td>
</tr>
<tr>
<td valign="top"  style="width:7.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:48.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:10.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:15.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:7.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;10.16</p></td>
<td valign="top"  style="width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:48.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1326110/000156459016015596/nk-ex1022_1730.htm"><font style="text-decoration:none;">Shared Services Agreement by and between the Company and NantWorks, LLC, dated November&#160;10, 2015</font></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. </font></p></td>
<td valign="top"  style="width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-K</p></td>
<td valign="top"  style="width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:10.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:3.4pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">001-37507</p></td>
<td valign="top"  style="width:0.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.22</p></td>
<td valign="top"  style="width:0.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:15.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 30, 2016</p></td>
</tr>
<tr>
<td valign="top"  style="width:7.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:48.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:10.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:15.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:7.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;10.17</p></td>
<td valign="top"  style="width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:48.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1326110/000156459016015596/nk-ex1023_1729.htm"><font style="text-decoration:none;">Facility License Agreement by and between the Company and NantWorks, LLC, dated November&#160;10, 2015</font></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. </font></p></td>
<td valign="top"  style="width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-K</p></td>
<td valign="top"  style="width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:10.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">001-37507</p></td>
<td valign="top"  style="width:0.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.23</p></td>
<td valign="top"  style="width:0.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:15.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 30, 2016</p></td>
</tr>
<tr>
<td valign="top"  style="width:7.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:48.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:10.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:15.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:7.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;10.18+</p></td>
<td valign="top"  style="width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:48.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1326110/000156459016019464/nk-ex101_452.htm"><font style="text-decoration:none;">Offer Letter between Sonja Nelson and the Company, dated April&#160;7, 2016</font></a><font style="text-decoration:none;">.</font></p></td>
<td valign="top"  style="width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-Q</p></td>
<td valign="top"  style="width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:10.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">001-37507</p></td>
<td valign="top"  style="width:0.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.1</p></td>
<td valign="top"  style="width:0.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:15.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">May 16, 2016</p></td>
</tr>
<tr>
<td valign="top"  style="width:7.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:48.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:10.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:15.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:7.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;10.19</p></td>
<td valign="top"  style="width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:48.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1326110/000156459016024275/nk-ex101_112.htm"><font style="text-decoration:none;">Amended and Restated Shared Services Agreement by and between the Company and NantWorks LLC, dated June&#160;28, 2016</font></a><font style="text-decoration:none;">.</font></p></td>
<td valign="top"  style="width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-Q</p></td>
<td valign="top"  style="width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:10.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">001-37507</p></td>
<td valign="top"  style="width:0.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.1</p></td>
<td valign="top"  style="width:0.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:15.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">August 15, 2016</p></td>
</tr>
<tr>
<td valign="top"  style="width:7.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:48.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:10.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:15.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:7.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;10.20</p></td>
<td valign="top"  style="width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:48.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1326110/000156459016028905/nk-ex101_159.htm"><font style="text-decoration:none;">Lease agreement by and between the Company and 605 Doug Street, LLC, dated June&#160;28, 2016</font></a><font style="text-decoration:none;">.</font></p></td>
<td valign="top"  style="width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-Q</p></td>
<td valign="top"  style="width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:10.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">001-37507</p></td>
<td valign="top"  style="width:0.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.1</p></td>
<td valign="top"  style="width:0.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:15.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">November 10, 2016</p></td>
</tr>
<tr>
<td valign="top"  style="width:7.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:48.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:10.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:15.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:7.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;10.21+</p></td>
<td valign="top"  style="width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:48.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1326110/000156459018019420/nk-ex101_64.htm"><font style="text-decoration:none;">Letter Agreement with Barry Simon dated May&#160;3, 2018</font></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font></p></td>
<td valign="top"  style="width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-Q</p></td>
<td valign="top"  style="width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:10.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">001-37507</p></td>
<td valign="top"  style="width:0.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.1</p></td>
<td valign="top"  style="width:0.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:15.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">August 06, 2018</p></td>
</tr>
<tr>
<td valign="top"  style="width:7.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:48.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:10.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:15.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:7.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;10.22+</p></td>
<td valign="top"  style="width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:48.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1326110/000156459018019420/nk-ex102_65.htm"><font style="text-decoration:none;">Offer of Employment Letter with Sonja Nelson dated June&#160;11, 2018</font></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font></p></td>
<td valign="top"  style="width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-Q</p></td>
<td valign="top"  style="width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:10.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">001-37507</p></td>
<td valign="top"  style="width:0.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.2</p></td>
<td valign="top"  style="width:0.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:15.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">August 06, 2018</p></td>
</tr>
<tr>
<td valign="top"  style="width:7.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:48.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:10.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:15.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:7.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;10.23</p></td>
<td valign="top"  style="width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:48.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001326110/000119312519169172/d723718dex991.htm"><font style="text-decoration:none;">Notice of Pendency of Proposed Settlement of Stockholder Derivative Action dated May&#160;31, 2019.</font></a></p></td>
<td valign="top"  style="width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8-K</p></td>
<td valign="top"  style="width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:10.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">001-37507</p></td>
<td valign="top"  style="width:0.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">99.1</p></td>
<td valign="top"  style="width:0.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:15.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">June&#160;10, 2019</p></td>
</tr>
<tr>
<td valign="top"  style="width:7.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:48.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:10.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:15.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:7.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;10.24</p></td>
<td valign="top"  style="width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:48.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001326110/000119312519169172/d723718dex992.htm"><font style="text-decoration:none;">Stipulation and Agreement of Settlement dated April&#160;10, 2019.</font></a></p></td>
<td valign="top"  style="width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8-K</p></td>
<td valign="top"  style="width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:10.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">001-37507</p></td>
<td valign="top"  style="width:0.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">99.2</p></td>
<td valign="top"  style="width:0.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:15.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">June&#160;10, 2019</p></td>
</tr>
<tr>
<td valign="top"  style="width:7.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:48.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:10.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:15.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:7.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;10.25</p></td>
<td valign="top"  style="width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:48.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001326110/000156459019029330/nk-ex104_267.htm"><font style="text-decoration:none;">Letter Agreement between the Company and Immuno-Oncology Clinic, Inc., dated July&#160;5, 2019.</font></a></p></td>
<td valign="top"  style="width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-Q</p></td>
<td valign="top"  style="width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:10.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">001-37507</p></td>
<td valign="top"  style="width:0.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.4</p></td>
<td valign="top"  style="width:0.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:15.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">August&#160;6, 2019</p></td>
</tr>
<tr>
<td valign="top"  style="width:7.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:48.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:10.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:15.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">182</p>
<hr style="page-break-after:always;width:100%;">
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td rowspan="2" valign="bottom"  style="width:7.14%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number</p></td>
<td valign="bottom"  style="width:0.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:48.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:0.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td colspan="7" valign="bottom"  style="width:43.08%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Incorporated by Reference Herein</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:0.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:48.22%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Description</p></td>
<td valign="bottom"  style="width:0.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:7.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Form</p></td>
<td valign="bottom"  style="width:0.84%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:10.8%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">File No.</p></td>
<td valign="bottom"  style="width:0.68%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:7.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit</p></td>
<td valign="bottom"  style="width:0.82%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:15.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Filing Date</p></td>
</tr>
<tr>
<td valign="top"  style="width:7.14%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:48.22%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.3%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:10.8%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.54%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:15.1%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:7.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU171"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;10.</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26*</font></p></td>
<td valign="top"  style="width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:48.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="nk-ex1026_1106.htm"><font style="text-decoration:none;">Cost Allocation Agreement between the Company and ImmunityBio, Inc. and its subsidiaries, dated January&#160;29, 2020.</font></a></p></td>
<td valign="top"  style="width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:10.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:15.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:7.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:48.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:10.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:15.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:7.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;21.1*</p></td>
<td valign="top"  style="width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:48.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="nk-ex211_11.htm"><font style="text-decoration:none;">Subsidiaries.</font></a></p></td>
<td valign="top"  style="width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:10.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:15.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:7.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:48.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:10.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:15.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:7.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;23.1*</p></td>
<td valign="top"  style="width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:48.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="nk-ex231_6.htm"><font style="text-decoration:none;">Consent of Ernst &amp; Young LLP, Independent Registered Public Accounting Firm.</font></a></p></td>
<td valign="top"  style="width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:10.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:15.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:7.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:48.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:10.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:15.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:7.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;24.1*</p></td>
<td valign="top"  style="width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:48.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#POWER_ATTORNEY"><font style="text-decoration:none;">Power of Attorney (Contained on Signature Page to this Annual Report on Form 10-K).</font></a></p></td>
<td valign="top"  style="width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:10.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:15.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:7.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:48.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:10.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:15.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:7.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;31.1*</p></td>
<td valign="top"  style="width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:48.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="nk-ex311_7.htm"><font style="text-decoration:none;">Rule 13a-14(a) / 15d-14(a) Certification of Principal Executive Officer.</font></a></p></td>
<td valign="top"  style="width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:10.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:15.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:7.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:48.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:10.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:15.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:7.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;31.2*</p></td>
<td valign="top"  style="width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:48.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="nk-ex312_8.htm"><font style="text-decoration:none;">Rule 13a-14(a) / 15d-14(a) Certification of Principal Financial Officer.</font></a></p></td>
<td valign="top"  style="width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:10.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:15.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:7.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:48.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:10.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:15.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:7.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;32.1**</p></td>
<td valign="top"  style="width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:48.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="nk-ex321_10.htm"><font style="text-decoration:none;">Section 1350 Certification of Chief Executive Officer.</font></a></p></td>
<td valign="top"  style="width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:10.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:15.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:7.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:48.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:10.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:15.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:7.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;32.2**</p></td>
<td valign="top"  style="width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:48.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="nk-ex322_9.htm"><font style="text-decoration:none;">Section 1350 Certification of Chief Financial Officer.</font></a></p></td>
<td valign="top"  style="width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:10.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:15.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:7.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:48.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:10.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:15.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:7.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101.INS</p></td>
<td valign="top"  style="width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:48.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">XBRL Instance Document</p></td>
<td valign="top"  style="width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:10.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:15.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:7.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:48.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:10.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:15.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:7.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101.SCH</p></td>
<td valign="top"  style="width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:48.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">XBRL Taxonomy Extension Schema Document</p></td>
<td valign="top"  style="width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:10.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:15.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:7.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:48.22%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:10.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:15.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:7.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101.CAL</p></td>
<td valign="top"  style="width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:48.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">XBRL Taxonomy Extension Calculation Linkbase Document</p></td>
<td valign="top"  style="width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:10.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:15.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:7.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:48.22%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:10.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:15.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:7.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101.LAB</p></td>
<td valign="top"  style="width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:48.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">XBRL Taxonomy Extension Label Linkbase Document</p></td>
<td valign="top"  style="width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:10.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:15.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:7.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:48.22%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:10.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:15.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:7.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101.PRE</p></td>
<td valign="top"  style="width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:48.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">XBRL Taxonomy Extension Presentation Linkbase Document</p></td>
<td valign="top"  style="width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:10.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:15.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:7.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:48.22%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:10.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:15.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:7.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101.DEF</p></td>
<td valign="top"  style="width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:48.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">XBRL Taxonomy Extension Definition Linkbase Document</p></td>
<td valign="top"  style="width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:10.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:15.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-right:86.67%;text-indent:0%;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:2pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</font></p></td>
<td valign="top">
<p style="margin-top:2pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Filed herewith.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:2pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">**</font></p></td>
<td valign="top">
<p style="margin-top:2pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><a name="_cp_text_1_639"></a><a name="_cp_text_1_641"></a><a name="_cp_text_4_642"></a><a name="_cp_text_1_643"></a><a name="_cp_text_4_644"></a><a name="_cp_text_1_645"></a><a name="_cp_text_4_646"></a><a name="_cp_text_1_647"></a><a name="_cp_text_1_641"></a>The certifications attached as Exhibits 32.1 and 32.2 that accompany this Annual Report<a name="_cp_text_4_642"></a>, are deemed furnished and not filed with the<a name="_cp_text_1_643"></a> <a name="_cp_text_4_644"></a>Securities and Exchange Commission and are not to be incorporated by reference into any filing of NantKwest, Inc. under the Securities <a name="_cp_text_1_645"></a>Act of <a name="_cp_text_4_646"></a>1933<a name="_cp_text_1_647"></a>, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of this Annual Report, irrespective of any general incorporation language contained in such filing.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:2pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">+</font></p></td>
<td valign="top">
<p style="margin-top:2pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Indicates a management contract or compensatory plan.</p></td></tr></table></div>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_16_FORM_10K_SUMMARY"></a>Item&#160;16. Form 10-K Summary.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">183</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="SIGNATURES"></a><a name="_AEIOULastRenderedPageBreakAEIOU172"></a><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">SIGNATURES</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the requirements of Section&#160;13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Annual Report on Form&#160;10-K to be signed on its behalf by the undersigned, thereunto duly authorized.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:59%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NantKwest, Inc.</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:59%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:37%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:59%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: March 25, 2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:37%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Patrick Soon-Shiong</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:59%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:37%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Patrick Soon-Shiong</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:59%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:37%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Chairman and Chief Executive Officer</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="POWER_ATTORNEY"></a><a name="_cp_text_1_353"></a><a name="POWER_ATTORNEY"></a>POWER OF <a name="_cp_text_1_353"></a>ATTORNEY</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_354"></a><a name="_cp_text_4_355"></a><a name="_cp_text_1_356"></a>Each person whose signature appears below constitutes and appoints Patrick Soon-Shiong and Sonja Nelson, <a name="_cp_text_4_355"></a>and each of them, as his or her true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments to this Annual Report <a name="_cp_text_1_356"></a>on Form 10-K, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, or their or his substitutes, may lawfully do or cause to be done by virtue thereof.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Annual Report on Form&#160;10-K has been signed below by the following persons on behalf of the Registrant in the capacities and on the dates indicated.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:30%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Signature</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:50%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Title</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:17.78%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Date</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:30%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:50%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:17.78%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:30%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Patrick Soon-Shiong</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:50%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chairman of the Board of Directors and Chief Executive Officer</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(Principal Executive Officer)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:17.78%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 25, 2020</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:30%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Patrick Soon-Shiong</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:17.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:30%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:17.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:30%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Barry J. Simon</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:50%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">President, Chief Administrative Officer and Director</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:17.78%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 25, 2020</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:30%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Barry J. Simon</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:17.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:30%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:17.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:30%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Sonja Nelson</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:50%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chief Financial Officer</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(Principal Financial and Accounting Officer)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:17.78%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 25, 2020</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:30%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Sonja Nelson</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:17.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:30%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:17.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:30%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Steve Gorlin</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:50%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:17.78%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 25, 2020</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:30%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Steve Gorlin</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:17.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:30%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:17.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:30%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Michael D. Blaszyk</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:50%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:17.78%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 25, 2020</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:30%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Michael D. Blaszyk</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:17.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:30%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:17.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:30%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Frederick W. Driscoll</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:50%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:17.78%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 25, 2020</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:30%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Frederick W. Driscoll</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:17.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:30%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:17.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:30%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;John C. Thomas, Jr.</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:50%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:17.78%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 25, 2020</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:30%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">John C. Thomas, Jr.</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:17.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:30%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:17.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:30%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Cheryl L. Cohen</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:50%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:17.78%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 25, 2020</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:30%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Cheryl L. Cohen</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:17.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">184</a></p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.8
<SEQUENCE>2
<FILENAME>nk-ex48_1107.htm
<DESCRIPTION>EX-4.8
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
nk-ex48_1107.htm
</title>
</head>
<!-- NG Converter v5.0.2.38 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 4.8</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="C1"></a>DESCRIPTION OF THE REGISTRANT&#8217;S SECURITIES</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">EXCHANGE ACT OF 1934</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NantKwest, Inc. has one class of securities registered under Section&#160;12 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), our Common Stock.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:9pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Description of Common Stock</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="C2"></a>The following description of our Common Stock is a summary and does not purport to be complete. It is subject to and qualified in its entirety by reference to our Amended and Restated Certificate of Incorporation (the &#8220;Certificate of Incorporation&#8221;) and our amended and restated Bylaws (the &#8220;Bylaws&#8221;), each of which are incorporated by reference as an exhibit to the Annual Report on Form 10-K of which this Exhibit 4.8 is a part. We encourage you to <a name="C2"></a>read our Certificate of Incorporation, our Bylaws and the applicable provisions of the Delaware General Corporation Law, for additional information.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Common Stock</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are authorized to issue up to a total of 500,000,000&#160;shares of common stock, par value $0.0001&#160;per&#160;share. Holders of our common stock are entitled to one vote for each share held on all matters submitted to a vote of our stockholders. Holders of our common stock have no cumulative voting rights. Further, holders of our common stock have no preemptive, conversion, redemption or subscription rights and there are no sinking fund provisions applicable to our common stock. Upon our liquidation, dissolution or winding-up, holders of our common stock are entitled to share ratably in all assets remaining after payment of all liabilities and the liquidation preferences of any of our outstanding shares of preferred stock. Subject to preferences that may be applicable to any outstanding shares of preferred stock, holders of our common stock are entitled to receive dividends, if any, as may be declared from time to time by our board of directors out of our assets which are legally available.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:10.46%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2019, there were 98,460,404&#160;shares of common stock issued and outstanding and there were approximately 28&#160;holders of record of our common stock. As of December&#160;31, 2019, there were 4,506,950&#160;shares of common stock underlying outstanding options and 1,139,428&#160;shares of common stock underlying restricted stock units.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Preferred Stock</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our board of directors is authorized, subject to certain limitations prescribed by law, to designate and issue up to a total of 20,000,000 shares of preferred stock, par value $0.0001&#160;per&#160;share, without stockholder approval. The board may issue preferred stock from time to time in one or more series and fix the designations, preferences and rights of the shares of each such series and any qualifications, limitations or restrictions on the shares of each such series, including dividend rights and rates, conversion rights, voting rights, terms of redemption, liquidation preferences and the number of shares constituting any such series.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our board of directors may authorize the issuance of preferred stock with voting or conversion rights that could harm the voting power or other rights of the holders of the common stock. The issuance of preferred stock, while providing flexibility in connection with possible acquisitions and other corporate purposes, could, among other things, have the effect of delaying, deferring or preventing a change in control of our company and might harm the market price of our common stock and the voting and other rights of the holders of common stock. We have no current plans to issue any shares of preferred stock.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Registration Rights</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On December&#160;23, 2014, we entered into a Registration Rights Agreement with certain of our existing investors (the &#8220;Registration Rights Agreement&#8221;) pursuant to which we provided such investors with a right to demand registration of their shares on Form&#160;S-3, if we are eligible to use Form&#160;S-3, otherwise, on Form&#160;S-1, exercisable at any time following the consummation of our initial public offering, provided that such demand is made at the request of the holders of at least 50.1% of such shares to be registered, subject to certain obligations set forth in the Registration Rights Agreement.</p>
<p style="text-align:center;margin-top:12pt; clear:both;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU2"></a><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have also granted certain of our existing investors &#8220;piggyback&#8221; registration rights, subject to certain other limitations that allow certain of our investors to include the shares of our common stock in any public offerings of equity securities initiated by us or any demand registration rights holder.</font></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We will pay the registration expenses (other than underwriting discounts and applicable selling commissions incurred in connection with registration) of the holders of the shares registered pursuant to the registration rights described above. In an underwritten offering, the managing underwriter, if any, has the right, subject to specified conditions, to limit the number of shares such holders may include.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Anti-Takeover Effects of Delaware Law and Our Certificate of Incorporation and Bylaws</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The provisions of Delaware law, our amended and restated Certificate of Incorporation and our Bylaws may have the effect of delaying, deferring or discouraging another person from acquiring control of our company. These provisions, which are summarized below, may have the effect of discouraging takeover bids. They are also designed, in part, to encourage persons seeking to acquire control of us to negotiate first with our board of directors. We believe that the benefits of increased protection of our potential ability to negotiate with an unfriendly or unsolicited acquirer outweigh the disadvantages of discouraging a proposal to acquire us because negotiation of these proposals could result in an improvement of their terms.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Amended and Restated Certificate of Incorporation and Amended and Restated Bylaw Provisions</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our amended and restated certificate of incorporation and our amended and restated bylaws include a number of provisions that could deter hostile takeovers or delay or prevent changes in control of our management team, including the following:</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Board of directors vacancies.&#160;<font style="font-style:normal;">Our amended and restated certificate of incorporation and amended and restated bylaws authorize only our board of directors to fill vacant directorships, including newly created seats. In addition, the number of directors constituting our board of directors is permitted to be set only by a resolution adopted by our board of directors. These provisions would prevent a stockholder from increasing the size of our board of directors and then gaining control of our board of directors by filling the resulting vacancies with its own nominees. This makes it more difficult to change the composition of our board of directors but promotes continuity of management.</font></p></td>
</tr>
</table></div>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Advance notice requirements for stockholder proposals and director nominations<font style="font-style:normal;">. Our amended and restated bylaws provide advance notice procedures for stockholders seeking to bring business before our annual meeting of stockholders or to nominate candidates for election as directors at our annual meeting of stockholders. Our amended and restated bylaws also specify certain requirements regarding the form and content of a stockholder&#8217;s notice. These provisions might preclude our stockholders from bringing matters before our annual meeting of stockholders or from making nominations for directors at our annual meeting of stockholders if the proper procedures are not followed. We expect that these provisions may also discourage or deter a potential acquirer from conducting a solicitation of proxies to elect the acquirer&#8217;s own slate of directors or otherwise attempting to obtain control of our company.</font></p></td>
</tr>
</table></div>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">No cumulative voting<font style="font-style:normal;">. The Delaware General Corporation Law provides that stockholders are not entitled to the right to cumulate votes in the election of directors unless a corporation&#8217;s certificate of incorporation provides otherwise. Our amended and restated certificate of incorporation does not provide for cumulative voting.</font></p></td>
</tr>
<tr>
<td valign="middle"  style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Amendment of charter provisions<font style="font-style:normal;">. Any amendment of the above provisions in our amended and restated certificate of incorporation requires approval by holders of at least&#160;two-thirds&#160;of our then outstanding voting securities.</font></p></td>
</tr>
</table></div>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU3"></a>Issuance of undesignated preferred stock<font style="font-style:normal;">. Our board of directors has the authority, without further action by the stockholders, to issue up to 20,000,000&#160;shares of undesignated preferred stock with rights and preferences, including voting rights, designated from time to time by our board of directors. The existence of authorized but unissued shares of preferred stock would enable our board </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><font style="font-style:normal;">of directors to render more difficult or to discourage an attempt to obtain control of us by means of a merger, tender offer, proxy contest or other means.</font></p></td>
</tr>
</table></div>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU4"></a>&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Exclusive forum<font style="font-style:normal;">. Unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware is the sole and exclusive forum for (i)&#160;any derivative action or proceeding brought on our behalf, (ii)&#160;any action asserting a claim of breach of a fiduciary duty owed by any of our directors, officers or other employees to us or our stockholders, (iii)&#160;any action asserting a claim arising pursuant to any provision of the Delaware General Corporation Law, our amended and restated certificate of incorporation or our amended and restated bylaws, or (iv)&#160;any action asserting a claim against us governed by the internal affairs doctrine. This choice of forum provision may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers or other employees, which may discourage such lawsuits against us and our directors, officers and other employees.</font></p></td>
</tr>
</table></div>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Listing</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our common stock is listed on The Nasdaq Global Select Market under the symbol &#8220;NK.&#8221;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Transfer Agent and Registrar</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The transfer agent and registrar for our common stock is American Stock Transfer&#160;&amp;&#160;Trust&#160;Company,&#160;LLC. The transfer agent and registrar&#8217;s address is 6201 15th Avenue, Brooklyn, New York 11219. The transfer agent&#8217;s telephone number is (800)&#160;937-5449.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.26
<SEQUENCE>3
<FILENAME>nk-ex1026_1106.htm
<DESCRIPTION>EX-10.26
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
nk-ex1026_1106.htm
</title>
</head>
<!-- NG Converter v5.0.2.38 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 10.26</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">COST ALLOCATION AGREEMENT</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This Cost Allocation Agreement (this &#8220;<font style="text-decoration:underline;">Agreement</font>&#8221;), entered into on January 29, 2020, but made effective as of October 1, 2019 (the &#8220;<font style="text-decoration:underline;">Effective Date</font>&#8221;), documents the mutual understanding with respect to certain joint clinical research activities that NantKwest, Inc., a Delaware corporation (&#8220;<font style="text-decoration:underline;">NantKwest</font>&#8221;) and ImmunityBio, Inc., a Delaware corporation, and its subsidiaries (&#8220;<font style="text-decoration:underline;">IB</font>&#8221;) intend to conduct as development partners.&nbsp;&nbsp;In consideration of the mutual promises and covenants set forth herein, and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereby agree as follows:</p>
<p style="text-align:justify;margin-top:11pt;margin-bottom:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Joint Studies</font>.&nbsp;&nbsp;The parties may from time to time agree to co-sponsor and conduct certain combination clinical studies (each a &#8220;<font style="text-decoration:underline;">Joint Study</font>&#8221;) pursuant to clinical trial protocols wherein at least one investigational agent is a proprietary therapeutic drug candidate owned or controlled by NantKwest (each, an &#8220;<font style="text-decoration:underline;">NK Study Drug</font>&#8221;) and at least one other investigational agent is a proprietary therapeutic drug candidate owned or controlled by IB (each, an &#8220;<font style="text-decoration:underline;">IB Study Drug</font>&#8221;).&nbsp;&nbsp; Each NK Study Drug and IB Study Drug may be referred to individually or collectively herein as a &#8220;<font style="text-decoration:underline;">Study Drug</font>&#8221; or &#8220;<font style="text-decoration:underline;">Study Drugs</font>.&#8221; </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Work Orders</font>.&nbsp;&nbsp;Prior to initiating any activities for a Joint Study, the parties shall agree in writing in a separate work order (each, a &#8220;<font style="text-decoration:underline;">Work Order</font>&#8221;) describing, amongst other things: (i) their respective development and management responsibilities (the &#8220;<font style="text-decoration:underline;">Development Activities</font>&#8221;); (ii) the respective allocation of Joint Study costs and expenses in accordance with Section 3 below; (iii) regulatory responsibilities; and (iv) any other matters relating to the Joint Study.&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Joint Study Costs and Payment Terms</font>.&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:15.38%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a.<font style="margin-left:36pt;"></font>The parties agree to allocate the total costs (the &#8220;Total Cost&#8221;) associated with each Joint Study (the &#8220;<font style="text-decoration:underline;">Cost Allocation</font>&#8221;) as set forth in the applicable Work Order.&nbsp;&nbsp;Unless expressly agreed otherwise in a Work Order, the following costs shall be included when calculating the Total Cost to be allocated between the parties in connection with each Joint Study:&nbsp;&nbsp;(i) all costs and expenses incurred by a party in connection with the Development Activities of the specific Joint Study including personnel related costs; (ii) all costs and expenses incurred by a party pursuant to third party and related party contracts relating to the Joint Study; (iii) all costs associated with regulatory matters associated with the Joint Study; and (iv) any other fees, charges and expenses incurred in connection with the Joint Study.&nbsp;&nbsp;Any costs, expenses, and fees incurred by each party in connection with each Joint Study that make up the Total Cost shall be charged at cost, without mark-up or profit, but including reasonable allocations of employee benefits and other direct and fairly allocated indirect costs that relate to the employees or consultants providing the applicable services.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:15.38%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">b.<font style="margin-left:36pt;"></font>Notwithstanding anything else in this Agreement to the contrary, each party shall bear its own costs and expenses incurred in connection with the development, manufacturing, supply,  delivery, and pre-patient administration dosing mechnanics of its respective Study Drugs and such costs shall not be included in the Total Cost.</p>
<p style="text-align:center;margin-top:12pt; clear:both;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:15.38%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU2"></a><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">c.</font><font style="margin-left:36pt;"></font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NantKwest and IB will jointly develop a mutually agreeable budget for each Joint Study (the &#8220;</font><font style="text-decoration:underline;">Budget</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221;), which Budget may be updated from time to time upon mutual consent.&nbsp;&nbsp;Neither party may, without the prior written approval of the other party, incur any expenses in connection with a Joint Study except as expressly contemplated in the applicable Budget.&nbsp;&nbsp;For each Joint Study, the parties will also jointly prepare a quarterly, non-binding forecast (each, a &#8220;</font><font style="text-decoration:underline;">Forecast</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221;) in order to estimate the anticipated Joint Study expenses to be incurred in each calendar quarter.&nbsp;&nbsp;Notwithstanding the foregoing or anything else in this Agreement to the contrary, a variance between the actual amounts incurred and the amounts contemplated in each then-current Budget or Forecast shall neither excuse nor waive a party&#8217;s obligations with respect to the sharing of Joint Study expenses in accordance with the cost allocation set forth in the applicable Work Order.&nbsp;&nbsp; </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:15.38%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">d.<font style="margin-left:36pt;"></font>Within five (5) days of the end of each calendar month, each party shall provide the other with a good faith estimate of its itemized costs (internal and external) in the previous month relating to the applicable Joint Study, and a final, itemized report of the previous month&#8217;s costs will be delivered to the other party within ten (10) days of the end of each month.&nbsp;&nbsp;The reports will be used to calculate the amount to be reimbursed by one party to the other by taking into account the over- or under-payment of each party relative to its share based on the Cost Allocation.&nbsp;&nbsp;When calculating the amount owed, one party may offset the amounts owed by the other party and pay the net amount to the other party.&nbsp;&nbsp;Payments of all undisputed amounts invoiced shall be payable within thirty (30) days of invoice receipt.&nbsp;&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Regulatory Responsibilities</font>.&nbsp;&nbsp;Each Work Order shall set forth the respective roles and responsibilities of the parties with respect to regulatory submissions and related activities for the applicable Joint Study, including without limitation the responsibility for preparing and filing the Investigational New Drug application (the &#8220;<font style="text-decoration:underline;">IND</font>&#8221;) filed with the United States Food and Drug Administration (the &#8220;<font style="text-decoration:underline;">FDA</font>&#8221;).&nbsp;&nbsp;Such designated party shall be responsible for preparing, filing and maintaining all regulatory filings, including submissions and correspondence, and compliance with all requirements for the conduct of the applicable Joint Study.&nbsp;&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:15.38%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a.<font style="margin-left:36pt;"></font><font style="Background-color:#FFFFFF;">Each party shall provide the other with a reasonable opportunity to review and comment upon all regulatory submissions no later than 15 days prior to the anticipated date of such submissions and will in good faith incorporate the comments from the other party.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:15.38%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">b.<font style="margin-left:36pt;"></font>Each party hereby grants to the other party a non-exclusive, non-transferable (except in connection with a permitted assignment, sublicense or subcontract) &#8220;right of reference&#8221; (as defined in US FDA 21 CFR 314.3(b)), or similar &#8220;right of reference&#8221; as defined in applicable regulations in the relevant jurisdiction to its regulatory submissions, solely as necessary for the other party to prepare, submit and maintain regulatory submissions for its respective Study Drug(s).&nbsp;&nbsp;Further, each party shall provide to the other a cross-reference letter or similar communication to the applicable regulatory authority to effectuate such &#8220;right of reference&#8221; on a need-to-know basis with respect to the confidential part of the Drug Master Files of both parties. Where a &#8220;right of reference&#8221; is not possible, the parties will promptly discuss in good faith on how to make the required documentation available for regulatory submissions of Study Drug(s).  Neither Party shall have the right to access the other party&#8217;s Chemistry Manufacturing and Controls (CMC) data with respect to its Study Drug(s) without the express written consent of the other Party, except in the following circumstances: (i) to the extent required by applicable law or regulation; (ii) in the event the Parties elect to file joint regulatory submissions for one or more Joint Studies; or (iii) as expressly authorized in writing by the other Party.&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU3"></a><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.</font><font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Joint Study </font><font style="text-decoration:underline;">Contracts</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&nbsp;&nbsp;</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For each Joint Study</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, the parties will designate either NantKwest or IB as the contracting party</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to enter into </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">agreements with third </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or related </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">parties, including without limitation</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> clinical trial agreements, </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">relating to t</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">he conduct and management of the applica</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ble Joint Study; provided, that </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">contracting party</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> may not enter into any material agreement (including without limitation any clinical trial agreement) </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">relating to a</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Joint Study without the express prior written consent of the </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">other party</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and, provided further, that the other party shall also obtain the express prior written consent of the contracting party prior to entering into any agreements with third </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or related </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">parties in connection with a Joint Study.</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;Concurrently with the execution </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of each clinical trial agre</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ement (CTA) relating to a Joint Study, </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the parties will execute a separate sid</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">e letter to document their respective rights and obligations pursuant to such CTA.&nbsp;&nbsp;Further, to the extent of any other material agreements that may be required in connection with a particular Joint Study, the non-contracting party shall have the right to review and comment on the terms of such material agreement prior to execution.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.<font style="margin-left:36pt;"></font>&nbsp;&nbsp;<font style="text-decoration:underline;">Joint Decision-Making</font>.&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:15.38%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a.<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Steering Committee</font>.&nbsp;&nbsp;Within 30 days after the effective date of each Work Order, the parties shall establish a steering committee (the &#8220;<font style="text-decoration:underline;">Steering Committee</font>&#8221;) to discuss Development Activity objectives for the applicable Joint Study and review the data and to monitor and to make certain decisions regarding such Joint Study. The Steering Committee will have reviewing, monitoring and approving responsibilities for the Joint Study and will attempt to facilitate the resolution of any disputes between the parties, as described in Section 6(c) below.&nbsp;&nbsp;The Steering Committee will also provide a forum for sharing advice, progress and results relating to such activities.&nbsp;&nbsp;Each party, through its representatives on the Steering Committee, will be permitted to provide advice and commentary with respect to the Joint Study.&nbsp;&nbsp;Each party will take such advice and commentary into good faith consideration when performing its duties hereunder.&nbsp;&nbsp;More specifically, the Steering Committee will:&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:0%;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:15.38%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">i.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">Review and approve the Joint Study protocol and changes thereto;</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:19.23%;text-indent:0%;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:15.38%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ii.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">Discuss and oversee regulatory related activities to ensure regulatory compliance and timely management of responses to any regulatory authority queries during regulatory review processes;</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:15.38%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">iii.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">Approve publication strategies for Study Data;</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:15.38%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">iv.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">Facilitate the exchange of information in compliance with this Agreement in order to ensure that significant issues concerning adverse event information and safety issues are addressed consistently and in a timely manner; and</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:15.38%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">v.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">Review and approve all Joint Study reports.</p></td></tr></table></div>
<p style="text-align:justify;margin-top:0pt;margin-bottom:0pt;margin-left:23.08%;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For clarity, the Steering Committee will not have any power to amend, modify or waive the terms of this Agreement or any Work Order unless agreed to by both parties in writing.&nbsp;&nbsp; </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:15.38%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU4"></a><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">b.</font><font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Membership; Meetings</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&nbsp;&nbsp;The Steering Committee will be composed of one</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;(1)</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> representative from each of IB and NantKwest, or such </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">other </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">number as the parties may agree, and will meet at least four</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;(4) </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">times per calendar year, or more or less often as the Steering Committee may determine.&nbsp;&nbsp;The Steering Committee will establish a schedule of times for meetings, taking into account, among other things, the planning needs of the Development Activities and the need of the Steering Committee to consult or render decisions.&nbsp;&nbsp;In addition, either party may schedule an additional meeting (not more than one additional meeting per calendar year) with at least 30 days&#8217; prior written notice to the other members of the Steering Committee.&nbsp;&nbsp;Meetings will take place in-person or by telephone or video conference as agreed to by members of the Steering Committee, except that at least one meeting per year will be in-person.&nbsp;&nbsp;In-person meetings will take place at NantKwest&#8217;s or IB&#8217;s offices whenever possible, unless otherwise agreed by the parties.&nbsp;&nbsp;Any member of the Steering Committee may designate a substitute to attend with prior written notice to the other Party.&nbsp;&nbsp;A quorum of the Steering Committee will exist whenever there is present at a meeting at least one representative from each party.&nbsp;&nbsp;Ad hoc guests may be invited to the Steering Committee meetings.&nbsp;&nbsp;Each </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">p</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">arty may replace its Steering Committee member with other representatives, at any time, upon written notice to the other party.&nbsp;&nbsp;Each party will bear its own costs, including travel costs, for personnel participating in the Steering Committee. </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<p style="text-align:justify;margin-top:0pt;margin-bottom:0pt;text-indent:15.38%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">c.<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Decision-Making</font>.&nbsp;&nbsp;Decisions of the Steering Committee will be made by consensus, with each party&#8217;s representatives on the Steering Committee having collectively one vote in all decisions, unless otherwise specified in the Work Order.&nbsp;&nbsp;If the Steering Committee is unable to reach a consensus decision on a matter that is within its decision-making authority within 15 days after it has met and attempted to reach such decision, then such matter shall be resolved pursuant to Section 13(a) of this Agreement.&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Joint Study Data</font>.&nbsp;&nbsp;Each party agrees to promptly and regularly share with the other party, in such format as may be mutually agreed by the parties, all data, results, and other information generated pursuant to a Joint Study (&#8220;<font style="text-decoration:underline;">Study Data</font>&#8221;).&nbsp;&nbsp;Study Data will be provided to the other party in a mutually agreeable format.&nbsp;&nbsp;Subject to any restrictions set forth in third party or related party contracts, the parties will jointly own the Study Data for each Joint Study and shall have equal rights of use for all lawful purposes.&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:0pt;margin-bottom:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Study Inventions</font>.&nbsp;&nbsp;Any idea, concept, invention or discovery, whether or not patentable relating to a Joint Study or that is first conceived or reduced to practice in connection with the conduct of a Joint Study (any of the foregoing, a &#8220;<font style="text-decoration:underline;">Study Invention</font>&#8221;) as between themselves, and subject to the terms and conditions of any applicable third party or related party agreement, the parties hereby agree as follows: (a) if a Study Invention is solely an NK Platform Invention (defined below) then all rights in such Study Invention will vest in NantKwest; (b) if a Study Invention is solely an IB Platform Invention (defined below), then all rights in such Invention will vest in IB; (c) if a Study Invention is (x) both an NK Platform Invention and an IB Platform Invention or (y) neither an NK Platform Invention nor an IB Platform Invention, then the rights in such Study Invention will vest equally in both parties, and each party shall have an undivided co-equal right in such Study Invention.  </p>
<p style="text-align:justify;margin-top:11pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">NK Platform Invention</font>&#8221; means any Study Invention that relates to the applicable NK Study Drug or to any materials or Confidential Information of NantKwest provided hereunder, including without limitation the following: (i) improvements, modifications, derivatives, optimizations, or other compositions of matter; (ii) methods of use, discovery, processing, or manufacture; and (iii) properties or functionality of the drug discovery platform for any NK Study Drug.&nbsp;&nbsp; </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:11pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU5"></a><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;</font><font style="text-decoration:underline;">IB Platform</font><font style="text-decoration:underline;"> Invention</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221; means </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">any Study Invention that relates to </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the applicable</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> IB Study Drug</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or to any materials or Confidential Information of IB</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> provided hereunder</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, including without limitation the following: </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(i) improvements, modifications, derivatives, optimizations, or other compositions of matter; (ii) methods of use, discovery, processing, or manufacture; and (iii) properties </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or functionality </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of the drug discovery platform for an IB Study Drug.&nbsp;&nbsp; </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:11pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Altor-NK Co-Development Agreement</font>.&nbsp;&nbsp;Both parties agree to negotiate in good faith to amend the Exclusive Co-Development Agreement dated as of August 16, 2016 (the &#8220;<font style="text-decoration:underline;">Co-Development Agreement</font>&#8221;), made by and between NantKwest and IB&#8217;s wholly-owned subsidiary Altor BioScience, LLC (&#8220;Altor&#8221;).&nbsp;&nbsp;The amendment shall amend certain terms of the Co-Development Agreement including, but not limited to, the fact that, from and after the Effective Date, no new clinical research activities shall be designated by the parties as Projects (as such term is defined in the Co-Development Agreement), and the Parties will document the specific Projects covered by the Co-Development Agreement, if any.&nbsp;&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Term and Termination</font>.&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:15.38%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a.<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Term</font>.&nbsp;&nbsp;Unless earlier terminated in accordance with its terms, the term of this Agreement shall continue for a period of two (2) years from the Effective Date, and may thereafter be renewed by the parties upon mutual agreement for additional successive one (1) year terms (the initial term and each renewal thereof, the &#8220;<font style="text-decoration:underline;">Term</font>&#8221;).&nbsp;&nbsp;If any Joint Study has not been completed at the end of the initial or any renewal term, as applicable, or upon termination pursuant to Section 10(b)(i) below, then this Agreement will survive expiration of the Term until the completion or earlier termination of the Work Order for any such ongoing Joint Study.&nbsp;&nbsp;A Work Order may be terminated upon mutual agreement of both parties. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:11.54%;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:15.38%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref339288062"></a>b.<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Termination Rights.</font>&nbsp;&nbsp;Either party may terminate this Agreement or any Work Order (i)&#160;upon thirty days&#8217; written notice to the other party; or (ii) in the event of a material breach by the other party that is not cured within thirty (30) days of written notice provided by the non-breaching party.&nbsp;&nbsp;A party may also terminate this Agreement immediately if, at any time, the other party shall (iii)&#160;file in any court or agency pursuant to any statute or regulation of any state, country or jurisdiction, a petition in bankruptcy or insolvency or for reorganization or for an arrangement or for the appointment of a receiver or trustee of that party or of its assets, (iv)&#160;propose a written agreement of composition or extension of its debts, (v)&#160;be served with an involuntary petition against it, filed in any insolvency proceeding, and such petition has not been dismissed within sixty (60) days after the filing thereof, (vi)&#160;propose or be a party to any dissolution or liquidation, (vii)&#160;make an assignment for the benefit of its creditors or (viii)&#160;admit in writing its inability generally to meet its obligations as they fall due in the general course.&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:11.54%;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:15.38%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">c.<font style="margin-left:36pt;"></font>In the event either party elects to terminate this Agreement or its development of any Study Drug for reasons other than safety, such party shall nevertheless continue to provide sufficient quantities of Study Drug to enable the completion of any ongoing Joint Study. </p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU6"></a><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.</font><font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Confidentiality</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&nbsp;&nbsp;</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Each of the parties agrees that any confidential information of the other party disclosed, received, developed or discovered in the course of performance under this Agreement, (&#8220;</font><font style="text-decoration:underline;">Confidential Information</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221;) shall be kep</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">t strictly confidential by the p</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">arties and may be used by the recipient only as necessary to perform its obligations or exercise or enforce its rights under this Agreement, except that either party may disclose such Confidential Information</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to the extent reasonably necessary in connection with the enforcement of this Agreement or as required by law or legal process, including any tax audit or litigation. The obligations set forth in this section shall not apply to (i) information that is al</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ready in the possession of the p</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">arty receiving confidential information, provided that such information is not known by such party to be subject to another confidentiality agreement with or other obligation of secrecy to the other party or another party; (ii) information that becomes available to the public other than as a result of a disclosure, directly or indirectly, by the party receiving Confidential Information or</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> its Affiliates; </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(iii)&#160;</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">disclosures that are required by any legal requirement including any rule or regulation of the </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. Securities and Exchange Commission (</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SEC</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> or of a stock exchange which may require such disclosure; or (iv)</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">information that becomes available to the Party receiving Confidential Information on a non-confidential basis from a source other than the other party; provided that such source is not known by such party to be bound by a confidentiality agreement with or other obligation of secrecy to the other party.&nbsp;&nbsp;Notwithstanding any other provisions in this</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Agreement</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> to the contrary, either party may disclose this </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Agreement</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and/or the existence thereof to</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">investors, potential investors, acquirors, or potential acquirors for the limited purpose of entering into potential transactions; provided, that such potential or actual investors or acquirors are subject to written obligations to protect Confidential Information</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:3.85%;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Indemnification; Limitation of Liability</font>. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:15.38%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a.<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Indemnification</font>.&nbsp;&nbsp;Each party will indemnify, defend, and hold the other party, its affiliates, and its and their respective employees, officers, directors, members, managers, and agents (any or all of the foregoing, the &#8220;<font style="text-decoration:underline;">Indemnitees</font>&#8221;) harmless from and against all damages, liabilities, losses, costs, and expenses (including, without limitation attorney fees) (&#8220;<font style="text-decoration:underline;">Damages</font>&#8221;) arising out of or relating to any suit, action or other legal proceeding to the extent brought as a result of the other party&#8217;s (i) breach of its representations and warranties set forth in this Agreement, (ii) bad faith, (iii) gross negligence, or (iv)&#160;willful misconduct.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:15.38%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">b.<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Limitation of Liability</font>.&nbsp;&nbsp;EXCEPT WITH RESPECT TO INDEMNIFICATION FOR THIRD PARTY CLAIMS, GROSS NEGLIGENCE, WILFUL MISCONDUCT AND BREACHES OF THE CONFIDENTIALITY OBLIGATIONS SET FORTH HEREUNDER, IN NO EVENT SHALL EITHER PARTY BE LIABLE TO THE OTHER PARTY FOR ANY INDIRECT, CONSEQUENTIAL, INCIDENTAL, SPECIAL OR PUNITIVE DAMAGES ARISING FROM ANY CLAIM OR ACTION HEREUNDER (INCLUDING, WITHOUT LIMITATION, DAMAGES FOR LOSS OF PROFITS, REVENUE, ECONOMIC ADVANTAGE OR DATA) BASED ON CONTRACT, TORT OR OTHER LEGAL THEORY, AND WHETHER ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13.<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Miscellaneous</font>.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:15.38%;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a.<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Dispute Resolution</font>.&nbsp;&nbsp;In the <font style="color:#000000;">event</font> of any dispute or difference arising out of or relating to this Agreement or the breach thereof, the parties hereto shall use their best efforts to settle such disputes or differences in good faith negotiations, keeping in mind their mutual interests, in order to reach a just and equitable resolution of the dispute or difference satisfactory to both parties.&nbsp;&nbsp;Either party may make a written request to the other by sending notice thereof for a meeting of authorized senior managerial representatives to resolve the parties&#8217; differences.&nbsp;&nbsp;Such meeting shall take place within thirty (30) days of receipt of such notice at a time and location acceptable to both parties.&nbsp;&nbsp;If within sixty (60) days after a meeting of the senior representatives, the parties have not succeeded in negotiating a resolution of the dispute or difference, either party may pursue such legal and/or equitable remedies as may be available.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:15.38%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">b.<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Assignment</font>.&nbsp;&nbsp;Neither party will assign its rights or delegate any or all of its obligations under this Agreement without the express prior written consent of the other party; provided, that either party may assign all or any part of its rights to any affiliate or in connection with a merger, consolidation or sale or exclusive licensing of all or substantially all of the assets to which this Agreement relates.&nbsp;&nbsp;Any purported assignment or transfer in violation of this section shall be null and void and of no effect. This Agreement shall be binding upon and inure to the benefit of the parties and their respective successors and permitted assigns.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:15.38%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">c.<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Rights of Affiliates</font>.&nbsp;&nbsp;Either party may in its sole discretion grant to one or more of its Affiliates the right to exercise the rights granted to such party, or undertake the obligations of such party, under this Agreement.&nbsp;&nbsp;For purposes of this Agreement, &#8220;Affiliate&#8221; means any person directly or indirectly controlled by, controlling, or under common control with a party, excluding (i) NantKwest, in the case of IB, and (ii) IB, in the case of NantKwest.&nbsp;&nbsp; </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:15.38%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">d.<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Governing Law</font>.&nbsp;&nbsp;This Agreement is to be construed in accordance with and governed by the internal laws of the State of California without giving effect to any choice of law rule that would cause the application of the laws of any jurisdiction other than the internal laws of the State of California to the rights and duties of the parties. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:15.38%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">e.<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Equitable Remedies</font>.&nbsp;&nbsp;Without limiting any other rights or remedies of a party, each party acknowledges that a breach of this Agreement by the other party may cause immediate and irreparable harm to the non-breaching party, for which an award of damages may not be adequate compensation and agrees that, in the event of such breach or threatened breach, the non-breaching party will be entitled to seek equitable relief, including in the form of orders for preliminary or permanent injunction, specific performance, interim or conservatory relief, and any other relief that may be available from any court, and each party hereby waives any requirement for the securing or posting of any bond in connection with such relief.&#160; Such remedies will not be deemed to be exclusive but will be in addition to all other remedies available to the parties at law or in equity.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:15.38%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">f.<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Independent Contractors</font>.&nbsp;&nbsp;The relationship between the parties is solely that of independent contractors.&nbsp;&nbsp;This Agreement does not create any agency, distributorship, employee-employer, partnership, joint venture or similar business relationship between the parties.&nbsp;&nbsp;Neither party is a legal representative of the other party, and neither party can assume or create any obligation, representation, warranty or guarantee, express or implied, on behalf of the other party for any purpose whatsoever.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:15.38%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">g.<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Third-Party Beneficiaries</font>.&nbsp;&nbsp;This Agreement is for the sole benefit of the parties and their permitted successors and assigns, and nothing in this Agreement expressed or implied shall give or be construed to give to any person, other than the parties and their permitted successors and assigns, any legal or equitable rights hereunder, whether as third-party beneficiaries or otherwise.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:15.38%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">h.<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Entire Agreement</font>.&nbsp;&nbsp;This Agreement, together with all Work Orders, constitutes the entire agreement and understanding between the parties with respect to the subject matter hereof and supersedes all prior agreements and understandings and negotiations, both written and oral, between the parties with respect to the subject matter of this Agreement.&nbsp;&nbsp;No representation, inducement, promise, understanding, condition or warranty not set forth in this Agreement has been made or relied upon by any party hereto.&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:15.38%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU7"></a><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">i.</font><font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Modification; Waivers</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&nbsp;&nbsp;No modification, alteration or amendment to this Agreement shall be effective unless in writing and duly signed by authorized representatives of both parties. The waiver by either party of a breach of or a default under any provision of this Agreement shall not be effective unless in writing and shall not be construed as a waiver of any subsequent breach of or default under the same or any other provision of this Agreement, nor shall any delay or omission on the part of either party to exercise or avail itself of any right or remedy that it has or may have hereunder operate as a waiver of any such right or remedy.</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;If there is a conflict between the terms of this Agreement and the Work Order, unless specifically stated otherwise in the fully executed Work Order, the terms of this Agreement shall prevail.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:15.38%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">j.<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Severability</font>.&nbsp;&nbsp;If any section, provision, or part of this Agreement is held to be illegal, invalid or unenforceable, such section, provision, or part shall be fully severable.&nbsp;&nbsp;The remainder of this Agreement shall remain in full force and effect.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:0pt;margin-bottom:0pt;text-indent:15.38%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">k.<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Counterparts</font>.&nbsp;&nbsp;This Agreement may be executed in two or more counterparts, all of which shall be considered one and the same agreement, and shall become effective when one or more counterparts have been signed by each of the parties and delivered to the other party.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[<font style="font-style:italic;">Signature page follows</font>.]</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU8"></a><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">IN WITNESS WHEREOF</font><font style="font-weight:normal;">, the parties hereto have caused their duly authorized officers to execute this </font><font style="font-weight:normal;">Cost Allocation Agreement</font><font style="font-weight:normal;"> as of the Effective Date.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">NANTKWEST, INC.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:40%;">
<tr>
<td valign="top"  style="width:16%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="top"  style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:83%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Steven Yang</p></td>
</tr>
<tr>
<td valign="top"  style="width:16%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name:</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:83%; border-top:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Steven Yang</p></td>
</tr>
<tr>
<td valign="top"  style="width:16%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title:</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:83%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General Counsel</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">IMMUNITYBIO, INC.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:40%;">
<tr>
<td valign="top"  style="width:16%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="top"  style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:83%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ David Sachs</p></td>
</tr>
<tr>
<td valign="top"  style="width:16%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name:</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:83%; border-top:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">David Sachs</p></td>
</tr>
<tr>
<td valign="top"  style="width:16%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title:</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:83%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Acting CFO</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>4
<FILENAME>nk-ex211_11.htm
<DESCRIPTION>EX-21.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
nk-ex211_11.htm
</title>
</head>
<!-- NG Converter v5.0.2.38 -->
<body>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:10pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;text-indent:0%;">EXHIBIT 21.1</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">SUBSIDIARIES OF <font style="text-transform:uppercase;">NantKwest,</font> INC.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr style="height:14.4pt;">
<td valign="bottom"  style="width:48.98%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name of Subsidiary</p></td>
<td valign="bottom"  style="width:2.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:48.98%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Jurisdiction of Organization</p></td>
</tr>
<tr style="height:14.4pt;">
<td valign="bottom"  style="width:48.98%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inex Bio, Inc.</p></td>
<td valign="bottom"  style="width:2.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:48.98%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Republic of Korea</p></td>
</tr>
<tr style="height:14.4pt;">
<td valign="bottom"  style="width:48.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Infacell Therapeutics, Inc.</p></td>
<td valign="bottom"  style="width:2.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:48.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Delaware</p></td>
</tr>
<tr style="height:14.4pt;">
<td valign="bottom"  style="width:48.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">557 Doug St, LLC</p></td>
<td valign="bottom"  style="width:2.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; </p></td>
<td valign="bottom"  style="width:48.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">California</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>5
<FILENAME>nk-ex231_6.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
nk-ex231_6.htm
</title>
</head>
<!-- NG Converter v5.0.2.38 -->
<body>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">EXHIBIT 23.1</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Consent of Independent Registered Public Accounting Firm</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We consent to the incorporation by reference in the Registration Statement on Form S-8 (No. 333-233082) and the Registration Statement (Form S-8 No. 333-205942), each pertaining to the 2015 Equity Incentive Plan and 2014 Equity Incentive Plan, and in the Registration Statement on Form S-3 (No. 333-233434) for the registration of common stock, preferred stock, warrants, debt securities and units of our report dated March 25, 2020, with respect to the consolidated financial statements of NantKwest, Inc., included in this Annual Report (Form 10-K) for the year ended December 31, 2019.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:2pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Ernst&#160;&amp;&#160;Young&#160;LLP</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:40%;">
<tr>
<td style="width:40%;"></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Los Angeles, California</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 25, 2020</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>6
<FILENAME>nk-ex311_7.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
nk-ex311_7.htm
</title>
</head>
<!-- NG Converter v5.0.2.38 -->
<body>

<p style="text-align:right;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="Exhibit_31.1"></a>EXHIBIT 31.1</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Certification of Principal Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I, Patrick Soon-Shiong, certify that:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.69%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;letter-spacing:-0.4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;letter-spacing:-0.4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;letter-spacing:-0.4pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">I have reviewed this Annual Report on Form 10-K of NantKwest,<font style="letter-spacing:-1.05pt;"> </font>Inc.;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.69%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;letter-spacing:-0.4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;letter-spacing:-0.4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;letter-spacing:-0.4pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.69%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;letter-spacing:-0.4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;letter-spacing:-0.4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;letter-spacing:-0.4pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and <font style="letter-spacing:-0.15pt;">for, </font>the periods presented in this<font style="letter-spacing:-0.1pt;"> </font>report;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.69%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;letter-spacing:-0.4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;letter-spacing:-0.4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;letter-spacing:-0.4pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting<font style="letter-spacing:-0.95pt;"> </font>(as defined in Exchange Act Rules 13a-15(f) and 15d-15(f) for the registrant and<font style="letter-spacing:-0.9pt;"> </font>have:</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.69%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;letter-spacing:-0.05pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.45%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;letter-spacing:-0.05pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;letter-spacing:-0.05pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a)</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;letter-spacing:-0.05pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.69%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;letter-spacing:-0.05pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.45%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;letter-spacing:-0.05pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;letter-spacing:-0.05pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">b)</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;letter-spacing:-0.05pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting<font style="letter-spacing:-0.9pt;"> </font>principles;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.69%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;letter-spacing:-0.05pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.45%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;letter-spacing:-0.05pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;letter-spacing:-0.05pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">c)</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;letter-spacing:-0.05pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered<font style="letter-spacing:-0.75pt;"> </font>by this report based on such evaluation;<font style="letter-spacing:-0.25pt;"> </font>and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.69%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;letter-spacing:-0.05pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.45%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;letter-spacing:-0.05pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;letter-spacing:-0.05pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">d)</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;letter-spacing:-0.05pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial<font style="letter-spacing:-0.85pt;"> </font>reporting; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.69%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;letter-spacing:-0.4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;letter-spacing:-0.4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;letter-spacing:-0.4pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control<font style="letter-spacing:-0.55pt;"> </font>over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent<font style="letter-spacing:-0.1pt;"> </font>functions):</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.69%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;letter-spacing:-0.05pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.45%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;letter-spacing:-0.05pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;letter-spacing:-0.05pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a)</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;letter-spacing:-0.05pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize<font style="letter-spacing:-1.2pt;"> </font>and report financial information; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.69%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;letter-spacing:-0.05pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.45%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;letter-spacing:-0.05pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;letter-spacing:-0.05pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">b)</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;letter-spacing:-0.05pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial<font style="letter-spacing:-0.1pt;"> </font>reporting.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:8.04%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:5.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date:</p></td>
<td valign="top"  style="width:36.24%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 25,<font style="letter-spacing:-0.1pt;"> </font>2020</p></td>
<td valign="top"  style="width:50%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Patrick Soon-Shiong</p></td>
</tr>
<tr>
<td valign="top"  style="width:8.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:41.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:50%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Patrick Soon-Shiong</p></td>
</tr>
<tr>
<td valign="top"  style="width:8.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:41.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chief Executive Officer</p></td>
</tr>
<tr>
<td valign="top"  style="width:8.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:41.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Principal Executive Officer)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>7
<FILENAME>nk-ex312_8.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
nk-ex312_8.htm
</title>
</head>
<!-- NG Converter v5.0.2.38 -->
<body>

<p style="text-align:right;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="Exhibit_31.2"></a>EXHIBIT 31.2</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Certification of Principal Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:4.69%;text-indent:-4.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I, Sonja Nelson, certify that:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.69%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;letter-spacing:-0.4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;letter-spacing:-0.4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;letter-spacing:-0.4pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">I have reviewed this Annual Report on Form 10-K NantKwest,<font style="letter-spacing:-1.05pt;"> </font>Inc.;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.69%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;letter-spacing:-0.4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;letter-spacing:-0.4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;letter-spacing:-0.4pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.69%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;letter-spacing:-0.4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;letter-spacing:-0.4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;letter-spacing:-0.4pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and <font style="letter-spacing:-0.15pt;">for, </font>the periods presented in this<font style="letter-spacing:-0.1pt;"> </font>report;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.69%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;letter-spacing:-0.4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;letter-spacing:-0.4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;letter-spacing:-0.4pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting<font style="letter-spacing:-0.95pt;"> </font>(as defined in Exchange Act Rules 13a-15(f) and 15d-15(f) for the registrant and<font style="letter-spacing:-0.9pt;"> </font>have:</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.69%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;letter-spacing:-0.05pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.45%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;letter-spacing:-0.05pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;letter-spacing:-0.05pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a)</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;letter-spacing:-0.05pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.69%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;letter-spacing:-0.05pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.45%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;letter-spacing:-0.05pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;letter-spacing:-0.05pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">b)</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;letter-spacing:-0.05pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting<font style="letter-spacing:-0.9pt;"> </font>principles;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.69%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;letter-spacing:-0.05pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.45%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;letter-spacing:-0.05pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;letter-spacing:-0.05pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">c)</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;letter-spacing:-0.05pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered<font style="letter-spacing:-0.75pt;"> </font>by this report based on such evaluation;<font style="letter-spacing:-0.25pt;"> </font>and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.69%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;letter-spacing:-0.05pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.45%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;letter-spacing:-0.05pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;letter-spacing:-0.05pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">d)</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;letter-spacing:-0.05pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial<font style="letter-spacing:-0.85pt;"> </font>reporting; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.69%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;letter-spacing:-0.4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;letter-spacing:-0.4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;letter-spacing:-0.4pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control<font style="letter-spacing:-0.55pt;"> </font>over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent<font style="letter-spacing:-0.1pt;"> </font>functions):</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.69%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;letter-spacing:-0.05pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.45%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;letter-spacing:-0.05pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;letter-spacing:-0.05pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a)</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;letter-spacing:-0.05pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize<font style="letter-spacing:-1.2pt;"> </font>and report financial information; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.69%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;letter-spacing:-0.05pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.45%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;letter-spacing:-0.05pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;letter-spacing:-0.05pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">b)</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;letter-spacing:-0.05pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial<font style="letter-spacing:-0.1pt;"> </font>reporting.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:8.04%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:5.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date:</p></td>
<td valign="top"  style="width:36.24%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 25,<font style="letter-spacing:-0.1pt;"> </font>2020</p></td>
<td valign="top"  style="width:50%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Sonja Nelson</p></td>
</tr>
<tr>
<td valign="top"  style="width:8.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:41.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:50%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sonja Nelson</p></td>
</tr>
<tr>
<td valign="top"  style="width:8.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:41.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chief Financial Officer</p></td>
</tr>
<tr>
<td valign="top"  style="width:8.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:41.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Principal Financial and Accounting Officer)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>8
<FILENAME>nk-ex321_10.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
nk-ex321_10.htm
</title>
</head>
<!-- NG Converter v5.0.2.38 -->
<body>

<p style="text-align:right;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">EXHIBIT 32.1</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="Exhibit_32.1"></a>CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">AS<font style="letter-spacing:-1.7pt;"> </font>ADOPTED PURSUANT TO SECTION 906 OF THE<font style="letter-spacing:-0.25pt;"> </font>SARBANES-OXLEY<font style="letter-spacing:-1pt;"> </font>ACT<font style="letter-spacing:-0.4pt;"> </font>OF<font style="letter-spacing:-0.55pt;"> </font>2002</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I, Patrick Soon-Shiong, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Annual Report on Form 10-K of NantKwest, Inc. for the fiscal year ended December 31, 2019 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that information contained in such Annual Report on Form 10-K fairly presents, in all material respects, the financial condition and results of operations of NantKwest, Inc.&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:49%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: March 25, 2020</p></td>
<td valign="bottom"  style="width:2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="bottom"  style="width:49%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Patrick Soon-Shiong</p></td>
</tr>
<tr>
<td valign="top"  style="width:49%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name:</p></td>
<td valign="top"  style="width:49%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;Patrick Soon-Shiong</p></td>
</tr>
<tr>
<td valign="top"  style="width:49%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title:</p></td>
<td valign="top"  style="width:49%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;Chief Executive Officer</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>9
<FILENAME>nk-ex322_9.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
nk-ex322_9.htm
</title>
</head>
<!-- NG Converter v5.0.2.38 -->
<body>

<p style="text-align:right;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">EXHIBIT 32.2</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="Exhibit_32.1"></a>CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">AS<font style="letter-spacing:-1.7pt;"> </font>ADOPTED PURSUANT TO SECTION 906 OF THE<font style="letter-spacing:-0.25pt;"> </font>SARBANES-OXLEY<font style="letter-spacing:-1pt;"> </font>ACT<font style="letter-spacing:-0.4pt;"> </font>OF<font style="letter-spacing:-0.55pt;"> </font>2002</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I, Sonja Nelson, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Annual Report on Form 10-K of NantKwest, Inc. for the fiscal year ended December 31, 2019 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that information contained in such Annual Report on Form 10-K fairly presents, in all material respects, the financial condition and results of operations of NantKwest, Inc.&nbsp;&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse;  margin-left:0%;width:100%;">
<tr>
<td valign="top"  style="width:48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: March 25, 2020</p></td>
<td valign="bottom"  style="width:4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="bottom"  style="width:48%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Sonja Nelson</p></td>
</tr>
<tr>
<td valign="top"  style="width:48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name:</p></td>
<td valign="top"  style="width:48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;Sonja Nelson</p></td>
</tr>
<tr>
<td valign="top"  style="width:48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title:</p></td>
<td valign="top"  style="width:48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;Chief Financial Officer</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>g4i5nix4zlkt000024.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g4i5nix4zlkt000024.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &Y J # 2(  A$! Q$!_\0
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MUZ5HM+U2WN95&2BMAL>N#S7#?%FSN(M2T/7);;[9I-E)BX@)XR6!Y!]0,?\
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MC;?^K$QI^](\?\,ZG;>)?A==>$M/\UM5@LI&9"F%/[S( ;U.15;0?B)INB^
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5F"%[O
M4;Q6NKA%C*!5C? &5!]*TZR['-K=:FUQ<%PC*S2. N!L'IQQ0!-_9O\ T^WG
M_?W_ .M1_9O_ $^WG_?W_P"M6-HWB?4M:^S7L'A^1-&N?FBNY+E1(8\$K(8L
M9"GC'.<$<5GZ;X^NY[#2]4U+06L])U)HTBNX[M9O+:0X3S%V@J"2!D9P2,T
M=3_9O_3[>?\ ?W_ZU']F_P#3[>?]_?\ ZU9&H^,(K+Q?IWA^*SDN&N7\N>X5
MP%MV*.Z*1W9A&QQV&#W%;0U*U;5GTL2?Z8D"W#1[3Q&S%0<].JG\J &?V;_T
M^WG_ ']_^M1_9O\ T^WG_?W_ .M61XN\2:EX9M/ML&C17UFIC1W-YY3*[R!
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M /6H_LW_ *?;S_O[_P#6J]168RC_ &;_ -/MY_W]_P#K4?V;_P!/MY_W]_\
MK5>KE[;Q5?ZG=S-I&@O>:9#<M;/=M=)&796VN8T(^95((R2,X.,T ;7]F_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M5%-]L,6H31_.RH!Y:AOE7*MD#';K70>)[*?4/".LV-HGF7%Q8S0Q(6 W,R$
M9/N>]:U%2!B0P2VNB:';S+MEB,".N<X8)@BMNJ.I=;/_ *^4_K5Z@ HHHH *
M*** "BBB@ HHK-U_6K?P[H-YJ]U'))!:1^8ZQ %B/;.* -*LKQ'JDVBZ!=W]
MM:2W4\:@10Q1LY+$@ D*"=H)R<=@:U <@'UI: /%],EM+G3M1TUY;R>VG\3V
MWV^2\MGB\]9%CR&# 8#2*!L[*5&,$5U^CS2Z&OBB'0-)-]!:ZDJV]C;R)$JE
MHHFD52Q"J S,<>I-=5-HNF7%K>VTUC!)!?/ON8W7(E; &2/7"K^0J33=+L='
ML4LM.M8K:V0DK'&N!DG)/N2>] &7X3\2OXGLKV:73I=/N+*\>SFMY9%<JZ!2
M>5X_B_2M^N*^'G^L\7?]C'=?^@QUVM !1110 4444 %%%% !1110 4444 %%
M%% !1110 44CDJC,JEB!D*#U]JXD^/[G_A'YM3'AO4MT=W]G$.T;V7.=^,YQ
MLYST_#F@#MZ*YZ#Q-/-XK71FT>[CC:W$QNFVE Q&=N0>O(&!SWZ<UT- !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M6Y7!:)IUA8?$JZA\.Z:UCI\%DT>I"*$Q6[SED,048 +A=^2O8@&N]H ****
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M-/O2.3A47W)P*<8N345NP(=;URST&P:YNF)8@B*%>7E;^ZH_SCO7FFJ:G?\
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M?1[BTN0\<FZ*5;%A+,#TR#SCT%:>BV']G0ZE<ZWX:U2X5;?$"&SDX<_Q9 X
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MHBC"JHP *=2A2L^:;N_R] J5KQY(*T?S]7_2"DP/2EHK8P# '04444 %%%%
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M@]B0K']36W6.)_BR??7[SP5L4=2ZV?\ U\I_6KU4=2ZV?_7RG]:O5@,****
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MG!N_5WV_X/\ P_KZU/#0C'VE5MKHKO7[NG?[EY8=KX*O$>2>Y\3ZH;F?!G>
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M06).>H'05'JOB^[\*2V'AV34K"YU!+4SS:AJ1:-'3>54;8PQ+G!R>!\I/?%
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MA<:M=7U^R@Q6VF(L7E@C[TC-NVC/J>>P-3KX6TRPNXX]2AANK@6TCQAY6:&
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M_P#&Z[.BI$<9_:OQ"_Z%?1O_  :M_P#&Z/[5^(7_ $*^C?\ @U;_ .-UV=%
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M?O1.)I R'W# BI?A+>^(O^$+\/VYT6S&D^21]L^W'S-N6Y\O9Z\8W4 =W?\
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MHS$$<9S\U:]% '+Z7X$TK2/%.L:]9M,DVJQ[)H<CRU).69>,@D\GGJ35/0?
M=[X>@LK.S\7:M_9]H1LM7B@*LH.2I/E[L'GOGFNTHH X_P 1>!KCQ%JD%Y)X
MFU.V2UN%N;6WACAV02*NT,"4)/4]2>M=3902VMC#!-=274L:!6GD"AI#ZD*
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M$BZ-HDVI7A%G91<M<'YI')Z+&O<D]R<5X1HXOO&GCR36X[9X+?>-JEMQ50,
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M-ENAC9BRY5@<K]3QFM?X,SF>#6;V89NVU14E8]2A3 'X$_I7)^!K(PVK(^&
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MAO2O%6DOINL6JW%NQW#G#(W9E/4&N=\:_#+3/%^E6-L)Y+.YL(_*MKA1OPF
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ML1%U(#8+9[=.17U53,*U#!5)1C&-G[MFG>YCE[Q5:LUBX6MMI_PYG/X+\8^
M/^)G;3+K>GH,SK"")$7N=IZCZ9K6;XI:"=,%TLF^X*\1!?G+>F*]CDB<1,L#
M!6.>O3FN>3PWI(UE[NWT?3/[0#Y:Z6V7,?H2?[WL/J37RN(J87,;/,*2G*.S
MV^_NCT*F7QYW.C)P;WMU_KN<SX*\.WD\LGB'64)UJ_BQ#$W2QMV_]G8?CV]:
M],50JA5&% P!Z5'!;I;Q[5R23EF;DL?4U+7/B*[K2OT_K1>2Z';2IQI04(JR
M17D_X_[?_<?_ -EJQ5>3_C_M_P#<?_V6K%<YH%5K<YNKK@C#@<_[HJS5>#_C
MZNO]Y?\ T$4 23P)<1['SP<@@X(/J#4 L0W$\\DRCHC8"_B!C/XU;HJE-I60
M'D?Q$^&8\7:K)J.G:C%:ZC"BQ^6Z$1L@S@''(8>O/%<)+X#\=:=9^3+I$6H1
MO\B2PW"GKV()!_,5]$WFGP3R_:9#*I5"&\L\L.HZ<Y';'K6>NI?Z?%<31AH"
MIV%3DPGT8>I'?\![^S@\WQ-""C!WBNC_ $.>MAJ57XT<=\+O#6J>"/"VHQZK
M!#%>W4S2HD;!V "  ,1GOG@9ZUWELH2RMV8L@8;OF'S'(SC!JW);),0Q=MF=
MVT'C/KZTDJ)*$GP,!3]Y>Q^O2O-KXB5>HZD]WN;I65CR7XH_#>\\7W4.LZ+'
M"E^G[JX5V""9!]U@?4=.?Z51\-? >P^SB7Q'J,T\[*?W5JVV.,^A;JQ'X5Z^
MT$9Q-$$*;?X"<_\ ZLT1^8[L"5PV<*!R/<UTQS'$PH^QA*R)Y%>YYU>_ KPI
M-;,;5[ZSE'0Q3[P?J&%8%I\!+*'4%?4M<N)[0-D01P!&<#_:W' _#->YF,')
M'#XQNQS6?(CK<>5!,\DI^9U.-B=.2>H''W>_ZT4\RQ:BX*H[ X1WL5K6VM[*
M*UALX0-D0C@MP-JHHXY[A1@?_7-:]M#]G@6,MN;DLV.I)R3^9I+>V6 ,2Q>5
M^7D;JW^ ]JFKAG.^B*(;G_5#_KHG_H0J:H;G_5#_ *Z)_P"A"IJS&%5[LX6(
M8)S*G0=.15BH+K[D?_75/YB@">JALV5F\BYDB1B2R  \GKC/2K=%-2:V S+N
M.*S2,I*(G=QNED)+,!R1DUY9J7P)T/4M9GGL];N[5)W:7R/)#A>>0&X]>G->
MQ31)/"T3C*L,5D7#BQ#6ENSM,PW.YP"<_P!W@#)YR1TS]*Z\/B*M-WIRLR6D
M]SF?"O@#2/#EK+:K#!<6J$^?+/$KO<..Q)'W1Z# R<<X.?F^XTO6)M9NX;71
M;N.269REM#"Q" DX48'05]@6$T5[8JL*^04 &S )4?0_U[@U9CM_+MWA$I+N
M"2Q]2,9 KLPF;5<+4E-:MDRIJ2L?)WB+PC8^%_"%A-JD\_\ PDE\YD6U1AL@
MA''S\?>/U_E6]X:^&7C?4=)M[FWN[6TM[B,2QI-*=Q4C(X .,CG%>S>)O!.A
M^+S:P:M$)+JT4[720HQ'&0<=C6]#$;*!;>W18Q&!&FXY48& ,?05T?VU6A#W
M'[S=W?5>1$J$)Z35T<#X'^$MIX9U3^U-6N8=4U _*F4^2$GJV#G)/(R:H^/O
M@[8:G)-?^'O*L+\ N\)&(IN_  ^4_I_.O6HHA+$WFH"KXX(QG\.U17L0$+,U
MP(DXRQ7)]A[\UP+,<3[?VW.^8TY(VM8\"T3X9^.640W-W::;;[,F9Y/,(7_@
M/MZD5Z]X)\'6'A>T;[()':3F2XG_ -;.Q_B/]T=@O8$YY-;L%K).%>YSY8.Y
M8B!DGL6Q^@[>YK0J\;FF(Q*Y:C^[1?\ !,Z>'I4VY0C9L*KVGW9?^NK?SJQ5
M>T^[+_UU;^=>6;EBBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@"O/N^TVN -OF'///W6JQ44T32&-D8*R-N&1D'@C^M0S32P;#)<6R
M!FQ\XVY^G/)H MT579Y$95>>!6<X4%2-Q]N:1WG5XT\VW!<X 92">.W/- $L
ML$4XQ+&KXZ9'2JRV+6Y9K2;R]QRRNNX$_7K^M))?11.4DO[-''56(!'_ (]4
MLCSQQB0S6XC'+,P( 'KG-4I-: )]HN(^)K4M_M0L&!_ X(KAM=^%^AZQ>OJ%
MG97NE7[DL9[.98PS>I7)'Y 5WN+C_GI%_P!\'_&D87>5VO"1GYLH>!CZ_2MJ
M.)G1ES4]'Y7)E%25I:H\O_X5UXVDA:TD\9Q+:GC>+8F3'YCG\:[;PUX6C\+:
M-'IFGS(D:DO)(8\O*YZNQ)ZG_"MS%Q_STB_[X/\ C32+K(P\.,\_(?\ &JJ8
MRK4CR.R6]DDM>[LM69TL/2I:TXV$BM0DOG22--+C 9\?*/8#@58J+%Q_STB_
M[X/^-(1=9&'AQGGY#_C7,VWN;$U%18N/^>D7_?!_QIK"[WIM:$KGYB5.1QVY
M]:0#-._Y!\/^[5JHK:'[/;1Q;MVT8SC&:EH 0YP<#)]*K:;DZ?%D8.#D9Z<F
MK55K>*>"!8L1MMSSN([_ $H LT5"K7)7+11J<GC>3_2ES/\ W(_^^S_A0 ]T
M212KJK*>H89%4I-*@+*\1,;(0R_Q $=.#_3%6$>Y9<M%&I]-Y/\ 2G9G_N1_
M]]G_  JE)K8"$O=QC$L"3K_>B.#_ -\G_&FS3V\Z+OMIY-K!@/);(-3HUR5R
MT4:G)XWD_P!*7,_]R/\ [[/^%/F78"O,[W$3)]@D8'C$A4#^9I($NHH%CCM[
M>,*,<R$_R%6%:X(R8XP<]-Y_PI<S_P!R/_OL_P"%'/I:P$)AO)05DN(XU/7R
MD(;'U)_I5B**."-8XE"HO0"F(URRY:*-3Z;R?Z4N9_[D?_?9_P *3DWH!+14
M*M<%<M%&I]-Y/]*7,_\ <C_[[/\ A4@,D_X_[?\ W'_]EJQ59$GDFCFE1(]@
M8;0V[J1[>U6: "JUON^TW6['WQC'IM%6:@\B02R/'*%WD$@KGH,4 3T5 $N=
MQS.FWM^[Y_G2^7/_ ,]U_P"_?_UZ )JAFM8)SF2-2W9AP1^(YI ESN.9TV]O
MW?/\Z7RY_P#GNO\ W[_^O33:V C\BYB_U-SO']R89_4<_GFCS[C&U[)BW^RZ
ME3^>#^E/V7.XYG3;V_=\_P Z7RY_^>Z_]^__ *]5S=T!$#=-'L6TA1,8PTG;
MZ 4D<5XJX\RW09S\L9/]:E"76YLSIMXVX3GW[TOES_\ /=?^_?\ ]>CG[("/
M[-.P^>]D_P" (H_H:FA@CMX]D:X&<DDY)/J3W-,"7.YLSIM[8CY_G2^7/_SW
M7_OW_P#7I.3>@$U%5PEUO;,Z;>-N(^??/-.\N?\ Y[K_ -^__KU(!<_ZH?\
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M5HFR>3@J,YYZU9B\0GQ+XA^'EY-%Y-_#>7MM?0=X;A+=@Z_GR/8BM_3OA_\
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M3_H,:=_X+F_^.UM Y ///K2T 8OV7Q+_ -!?33_W#W_^.T?9?$O_ $%M,_\
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MSM=3@J?<5-0!A;?%?_/71?\ OU+_ /%4;?%?_/71?^_4O_Q5;M% &%M\5_\
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M\)7EK?6]W?7%L\BOJ#R&%2,&YD1QMSTP%(_&J9\':O)X>T[3)9[ '29(3:/
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>g4i5nix4zlkt000006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g4i5nix4zlkt000006.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %Z J # 2(  A$! Q$!_\0
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MHX][!5WL!N)Z 9[TLLL<$32S2)'&HRSNV /J30 ^BHGN;>.))9)XDC<@*[.
M&STP>^:EH **3(SC/)I: "BBB@ HJ.*>&X4M#*DBJQ4E&! (ZCCO1'<0RR21
MQS1N\9PZJP)4^X[4 245674;%U#+>V[*7\L$2J1N_N]>OM2M?6B+*SW4"K$V
MV0F0 (?0^AIV87+%%&0>AHI %%%5H-0LKJ5HK>\MYI$^\L<H8K]0#0!9HHJ!
MKVU03%[F%1#CS<R ;,]-WI^- $]%(K*RAE(*D9!!X-,$\)N# )4\X+O,>X;@
MO3./3WH DHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH *BN7>.UFDC7<ZH65?4@<5+10!Y;X0\/^&]<\(IJ6O+;W.HZE++YMQ</^\#
MY/RJ2>" ,\5DZ3=7%Y9^ WN9&F$&K3013/R60<+S^GX5VM_\,M!OYYFWWMO!
M/)YLEM!/B(O_ '@I!P?I4\?@.P;PU#H=[<W%Q#;3&6UF7$<D'/ !7N,GD]<U
MU^UAO??\-S'DD9FL@'XLVIQG&B39]OF-<UHJC^Q_AOP.+Z;'YM7H.D>#-/TB
MZN+SS[V\O+B+R7N+N8R.$]!Z57E^'^D2:1ING">_BCTUW>WDBGVR MU);%2J
ML4K?UL_\Q\CW+WBK1-,U71[F74+&"YDMK>5H6E3)0[>H_(5R?@S^P?#'@#3?
M$=Q8JEQ+%Y<MQ! 7D?<Y'..2.!^5=5IOA2VTV&\B&H:G=)=Q>4XN[HR[1S]W
M/0\UH:-I-MH6CVVF6AD-O;KM0R-EL9SR?QK/G2CRW*Y7>YQ_B+3]/\6:/_;F
MGZ>NIWKVK1V]M>2&,1IN.9 AZ,"/QXK;\%7$4W@73)+>XEN%2VV>9*N&++D$
M$>Q&*?K?@^PUN^6^>>\M+L1&!YK.;RVDC/\ "WJ*FM?"^GV,FEFT:X@CTU&2
M&&.4B-@PY+C^(]\^M-RBX<H)/FN>7Z5;0Q:'X9\1QK_Q.+K7-DTX/SRJ[L&4
M^HP.E,OH8VT#6/$C+_Q.8?$.R.XS\\:JX 0'TQVKT:T\!:/9ZO'J$9NBL4S7
M$-JTV8(I6ZLJ]C^-$W@+1Y]8;4&-T%>X%U):";]P\PZ.5]:U]M&]_P"O0S]F
M[' >+].DLV\475_I%U-?/,MS8:H@RD$0Q@;\_(1R,=\UZ9I+:O<O8W<T\'V"
M6PC9XMA\WSR 2<],8[52U#P'I.I:I/>3RWHCN722YM$G(AG9>A9?_KULKI,*
MZT-4$MP)!;_9Q")/W07.<[?7W]*SG44HI%QBTSBOB@D;WGAA9; WZ&^;-J "
M9AM^Z,\<UD0:)=6\7BK5(M#?0]*ETF2%;-V&9) "=^T' X_G]:]'U30K35[W
M3;JY,HDT^?SX=C8&[&.?45;U"QBU+3KFQGW>3<1-$^PX.&&#@T1K6BH_UN#A
M=MGG?AW5]<TC_A#[2XGM)=.U2#RD@2$JT(5 0=V>3TSQBFS^-M7M]8MY$U&S
MO;274!:O#;6;^4B%L#$YP"_L/>NR_P"$3T[.B'=/_P 28$6WS]<J%^;CG@>U
M9B?#G2(TBB6ZU+[/!<"YMX/M'[N%PV[Y1CU]<]:?/3;NT+EET,*^\9:W8^)+
MB"_NX=+A2Z\N&*ZL7,,T.?O><IX)'MBEUGQMK']MZM#IDL44>F,$CMC923M=
MOC)!=>$'85T5WX"TR\FG\RZU$6=Q-Y\UB+D^0[Y!S@\@9'0&I-0\$:;J%_<7
M2W%_:?:E5;J*TN#&DX48&X#VXR,4*=+30.69LVLW]J:+#,RRVYNH Q7E7C++
MR.>A&:\YTC1-+;QIIL'A>V86^CL_]H:F3_KV(QY9;^,Y//I7I<MFDFGM9*SQ
MQM$8@4;#*,8X)[^]<UH_P]TS0[FWFLK_ %55@?>L+79\IC[KC!J(344]2I)N
MPGQ"TYM6T.WLH[RUAG:Z1XX+J3:ET1_RR/KGT]JY?1T6P\27%J^B?\([KD]A
M((/L\@>UF"\[MH[CZ]J]"UW0+#Q%IWV+4$<QAQ(CQMM>-AT93V-9^D^"M/TO
M4&U![B]O[PQ&$37LYD*(>H7TJH5$H<K%*+<KG%^'M:UC1O /A^X6ZAD2]U-(
M%#QDLL;,VX$D\L2,YK<UCQG?Z1K'BB/9%+;Z98PSP1E<$N^!\Q[C)J^GP]TE
M-";2/M-^UL)Q<09G^:W<9QL...IJQ;>!])@?4'E:[NVU" 0737,V\R*.^>Q^
MGH*<ITVVV)1DE8Y*[37F\6^#7UB\M)Y)C-)"\$.PQ,8QE2,G<!Q@\=ZN6?C+
M6+VTTG3%\E-=EU*2TO/W>0B1Y+L%SQE<8K;LO 6FV%]8WPNM2N;BPR+;[1<[
M@JXP$QCI5'PSX?O'\::IXGU'3%T]IT$<%N95D8' #N2O )P/UIN4&O0+23-?
MQEK]SX?T:*6RBCDO+JYCM8/-SL5G/WFQV%<[>:MXCL[O4/#FHWMI/<3Z;)=V
MUY% 5VA>&5ESZ9P:[36M%LM?TR33[^,O"Y# JVUE8=&![$5F:?X,TZPDNYFG
MO;RZNH#;O<W<WF2+&1C:I["HA*"CKN5)2;,SX661MO!%G,1;_P"D+O4Q0A&V
M]!O/\1Z\UBZWXWU?3=0FN;;4;.[MH;U8&M8+1V14)Q\TYP _L*]!T;2;?0M(
MMM,M#(;>W38AD;+8SGD_C7/2_#C1YHYX#<ZBMI+/]I%LMQB-),Y+ 8_GFFIP
M<W*0G&7*DCC;BZO=$^(_B#Q#;9>TL[B&*_A4<M#(H^;_ ("0#5*ZGC/P\GNH
M5\Y#XH::,*/]8-V1CZUZQ;^'+"WO]5N]KR/J@47*2-E" I7 ';@UF0^ -&@T
M*/1XVNA:QW@O%S+\PD'09QT]JM5H:7Z6)=-G/>$-VH^.M1G\30E/$$2*]I!(
M04A@8?\ +/W&<$__ %ZW/B [2Z?I>E@XBU+4H;:;WCSN(_'&*UM2\-V.IZS8
M:M(TT5[8D^5+"^W<IZJW'*]>/<U7\8Z3<ZIHT;V*AKZRN([NW7(&YD.2N3TR
M,BHYTYIE<K46CDOB3?Z;>ZSI?AK4+U+2P"M<W3]@=I$:X'OS3-)\<7:?#K3C
M:F*75/M::6'ER45C]UR!R1MP?K7<67AZP@U:]U@QR/=WX3S?/(;8%'"J.PJC
M=> ]%NY-2:1)U74&225$DVJDB?==,#Y6]_>FJD.51:V%RRO='/>+O^$HMO!.
MNQ:CJ-E,D:(RW%NACD="0&4KGY>V#GUXIZ27T7B?PO92_89;Z33)RMY]GPT9
MV_*%YX&,9'?%;D7@/218ZE;W$U[=R:B@CN+FXGW2E5^Z << ?2K5GX2LK.]T
MR\^T7D]QIL+PPO-+N+*_7=QSCH/2CVD;6]>GD'*[W.:TWQGJNJ+H6F1B%-8F
MNY8M1&SB)(C\Y [9XQ56]\::Q:ZS')#J-G=VAU%;5K>WLW,:(6QS.<#?[#BN
MTLO"^F6'B.]UV"-Q>WB[9,ME1TR0.Q.!FLD?#G2 GE+=:DMLMQ]JBMUN?W<4
MF[.5&/YYH4Z5]@<9V.:LM6U30M5\<ZO-<QW4=E(H:$H1O8C]W@Y^50#R._6K
MNC>,]82ZQ?,-1MI+*2Z:2*QDMQ;NB[MA+## @8!KIG\%Z7)JFI7KM<LNI1[+
MJU,O[F3@#=M]>.#GBC2_!UCID_FM=7]YM@-O&EW<&18XSU4#@=..<T.=-K5
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MXU1I6E9-+5#=-&FX*7Z*/4]"1VR*I?#F\GOO FG3W-P\\N'4R.VYB [ 9/T
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 96K^(K#19K>"Y,\MS<[C#;VT#S2N%^\0J@G R,GW%6M+
MU.SUG38=0L)Q-;3#*. 1T.""#R""""#R"*YCQMXJM_#UQ:6T!M(M6O$=(KN[
M7]W;1C&YF(Y/.,(/O$#H!FK&BZ1IMW\/GTK2=1>YM[F&9#?*Q#O*Y8O)D8P=
MY)XZ4 =517B":KXAO=FH/]M235XAX=$?($$X5-TWM\WG_-Z**=;"ZCUUXI]4
MBM=:BU<10HPN'NO)$@"*J [#$T0&3C&"23D4 >VU2TS5+36+5KFRD,D2RR0D
ME2OSHY1ASZ%37D=I)>R>)"UUJD-MKW]M,OEXN'N?*\WY4" [/),6/FQM .<[
MA5[P<;NT\0V[ZMO.E3ZA?QZ8(RRI#<?:)"?.'1F=<[">!@C&3F@#U*?4+6UO
M+2TFF5+B[9E@0]7*J6;'T )JS7#^,8+)?&_@N\O5PB7<T8E)8*KF([ <<9+
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M,CF1(CG;O'W=V[=DXR>] '14444 %%%% !1110 4444 %%%% !1110 4444
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M[5RW_"I-!_Z"&O?^#27_ !H_X5)H/_00U[_P:2_XT =YM&[=@9QC.*"H888
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M)/ ')KGM$\86FMWD$$=I=VZW=NUU9RS*H6XB4@%EP21]Y3A@#A@: .BHHHH
M**** "BBB@ HHHH **** "BBL?6/$NG:+>V%E<N[75].D,,4:[C\S!=S?W5!
M/4_0<T ;%%9&I^(['2M7TO2YB[7>HRF.)$&=H"DEF]!QCW/XUKT %%%% !7G
MGQL_Y)G=_P#7S;_^C5KT.O//C9_R3.[_ .OFW_\ 1JT >A+]Q?I2TB_<7Z4M
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MJ&O?#C3]0U2Z>ZNY'E#ROC) D8#I[ 4 =Q1110 4444 %%%% !1110 4444
M%8OB2PN+^VL5M8P[1ZC:S2<@81)0S'\ #Q6U65XGN9K/PGK-U;R&.>&QGDC<
M=58(2#^!H Y?5O".NMXCMM3M-3@F$FJ)<2>9:#?#$L;JJ[MXW*NXC  Y<MZU
MWM<7\*-6O];^&VE:CJ=T]S>3>;YDKXRV)6 Z>P%;7BGQ!'X8T1]5FA:6&*6-
M9%0_,%9@I(]2,YQ32;=D)NRNS:HJKI^H6NJ6,-]93I/;3+NCD0\$5:I#"O//
MC9_R3.[_ .OFW_\ 1JUZ'7GGQL_Y)G=_]?-O_P"C5H ]"7[B_2EI%^XOTI:
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M$M_\37DM%'U6EV#V]3N>M?\ "]K[_H 6_P#X$G_XFC_A>U]_T +?_P "6_\
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MRG^%'_"B](_Z#%__ -\I_A7JM%'UFK_,'L:?8\J_X47I'_08O_\ OE/\*/\
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MZ1RLA5ESDC&>5)7D&O1:.@Q0!R7BV5M,M-%MOM<]CI!NA#>W4+E&CC$;; 7
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M88BC2I1AR\BM>^_X=[_>:5%%%;'G!1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !7GGQL_Y)G=_]?-O_P"C5KT.O//C
M9_R3.[_Z^;?_ -&K0!Z$OW%^E+2+]Q?I2T %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 >;_"7
M_6^-/^QCNO\ V6O2*\W^$O\ K?&G_8QW7_LM>D4 %,\V/SO)WKY@7<4SSCUQ
MZ4^N6U*VG?Q1+>67-Y:6<3HN<"52[[D/U X]"!2;L95:C@DTKG3)*DBDQNK
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MO_T47Q/_ -_Q7HM% 'G7_"L]7_Z*+XG_ ._XH_X5GJ__ $47Q/\ ]_Q7HM%
M'G7_  K/5_\ HHOB?_O^*/\ A6>K_P#11?$__?\ %>BT4 >=?\*SU?\ Z*+X
MG_[_ (H_X5GJ_P#T47Q/_P!_Q7HM% 'G7_"L]7_Z*+XG_P"_XH_X5GJ__11?
M$_\ W_%>BT4 >=?\*SU?_HHOB?\ [_BC_A6>K_\ 11?$_P#W_%>BT4 >=?\
M"L]7_P"BB^)_^_XH_P"%9ZO_ -%%\3_]_P 5Z+10!YU_PK/5_P#HHOB?_O\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M4M]X@8#9YPIQVKLZ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M'M0KT'8^N#@8&*M6_C;7+S5[7:UM"C&Q'V9WC43+,B,[#<?,)R[!=HQ\G/?
M!Z?17F+^)]:31[&676=MS?O<R($MH4"1Q-M WR$+W!.<L>P S4%MXXUBYMQ>
MMJ5K',EGI]Q'IHA&ZZ><#>H)^;D\#'0]>* /5:*Y'0M;U2_\1S:/.X+Z7YOV
MY_* \S<W^CX],QY8X[BNNH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M18)'0GI@\XQ3[#4=;NXXH(-8NY;>:]M(WFC5V=-P?S1O>)<9 3( .PGJ,@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@"":SM[BXMIY8PTMLY>%B3\A*E2?R)'XU/110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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@H **** "BBB@ HHHH **** "BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>g4i5nix4zlkt000003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g4i5nix4zlkt000003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 'Y J # 2(  A$! Q$!_\0
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M]:;;V<%K:BVA3;$ 0%SZT <EX?B>?0M6BC^^PP!^%0:&BR6D@.L263(Q)C!
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M3[FI-7\$WFK?$"RUZ2[@%E:[-L!!WG;D_3J:UA5A%J*>BO\ -D2A)W;ZD_\
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MVD>M%@+VX4;A5'[2/6C[2/6BP%[<*,BJ/VD>M2+.#WHL!;HJ)'S4M( HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M,S1PJC.<L57!;ZU%_8-G^\_T*#][_K/W8^?Z^M=9]G'I1]F'I1SL+(Y4:':
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M9DX_7'Z5G3A&4[;HN4FHDZ?$+5=/O;4>(_#DFG65W((XYQ)NV$]-PKOI;B&
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M7'4BIX+02W+313,92581LV,$=L]O6INV;**CL;"1:9J"^3_9ITZ1EVQRF9I
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MEJD$"!(U\Y> /QJY]@L_^?2#_OV/\*/L%G_SZ0?]^Q_A0YI[M@DUL4A-HHU
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M.'4,,^]/K0Y@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MZ%FN)Q<7;*(S,,C*#H".F1ZUJMCEFK29TM%%%,@**** "BBB@ HHHH ****
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MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***.G6@
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MX_K5U)4-D$!^SMN)5-O1?<]SWHUOY#?*X^9TUG?Z==09U6R^U;2KAE;K['U
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M/0>YK3U#A>3U.1[5'X<D5-:8,0&=/E)^M54DXTVT1%7EJ;UAX&:>(>=J0Z]
MF157Q-X7&B6<=T+X3>8^P(4VGIU%=A$^V%G;.T?PJ<9-4M<1-5L([6YC< -\
MC+RR-CK[BN2&(ES+F>@K=;&O\-?$E_-X7-F\BB.S<Q1!%RQ!YY/MFNKGU"XA
M"DS,LSC@<G->>_#:.?3;O4[.[1HU!5T<CY6/0XKT;3[I$U)+J5<Q,3$IQG9[
MUC524G8V4I2:C<V="EN)K5GN%=23QN[_ $JQJNJV>BZ;-J%_,(K:$99L9]@
M.YS5M'1QE&##V-<UX_LKF_\ "-Q%:0&>=98I%B!&6VR*2.?85RS;2;1ZF%IQ
ME4A";T;2;*T_Q*T!=(^W6TDUS,TODQVBQD3._IM/3J.:ZV)S)#&[(49E!*GJ
MOM7D\$GB$^+KOQ#%X/MQ<31)'$+F]C'E$#!8>Y&/RKU.QDN)K""2ZC2.X:,&
M1(VW*K8Y /<5G3FY7O\ D=F-P].BH\G7?WD_EIV[]2Q1116IYX4444 %%%%
M!1110 4444 %9-QXCTRSOWL[N8V\BC(:12%;Z&M:N;\865[=V$;6EM;W"QDM
M(DJY)'M6M&,92Y9&&(G.$.:'3RN<]?\ BC3;OQOI5PL@6SMMZM<%>&8C Y]*
MZ#Q39VKV8U(74%L\8QYSGAU]..M<'?>(XH]'6VUS1_/TTMM26V41M ?H*YG4
M;Q;1/L4%U<76FP2%X//;KD>G:N]X7GDEM;YG!1Q-DWO?7MJ0ZC.&EWW*?-*=
MT<1/0>I-95W<2&W\F%?W622XX!_^M45Q(]S.TCL3G@8/3Z59DD"0"-!EL848
MKT*=*-.-D92DYN[*VCZLVDZO#.X=K?.)HUYWKBNSF\4Z1%9L8;A/)((,8SGG
MMBN8L].B W/AG/)R>E6/[+MW?F,9]<5A7H0J2O>QI3J."M8Y-DD+[T5ADDD8
MZ<_X5I6XD:,%\@@=2*ZJ'2;0P$,.6!W$G'%0'2O+8".1I%_A[X'I5Q:0I7EJ
M9/V>[6+A4$9ZMC&:R)8ML\D*\JHSD\8'K78FWN#JALS"/L7E!DE4\DXZ?GQ6
M3<:2(YFW(Q5@1AA_6B-133L:3HNDX\^SUT,_0-*2^U@03D^6B^81_>]!]*]-
M"0!+.%[DVML9 )& R%7MQ]:\YTR*ZFUF,VQ$;0X\PG@!<]*[IOG*C!8+_".M
M85Z3DF]]O^"9_6$JL4WIK_P#UW2;.SL;%8;)P\><E]V2Q]2:O5YAX6\:26?B
M=M U"-(H)B/LY!_U9(X!/?/\ZZC5?'>BZ7.;?S)+F<,%*0+NY/OTKRZM*5.5
MI'ITJL:D>:)T]%<?I-SJ'BC4Y;QYYK*QM)=J6JG#LP_O_P"%=A4SAR.SW'3J
M>T3:6@444C,J*69@JCDDG %0:%#6=4&CZ:]XT$DRJ0"L8R1GN?:JOA?5;K6=
M)^V7,2(&D81[#U7/&:2W\3Z??:B^G6Z32SJY5U\L@!?[Q/I6I:6=O8VZV]K$
ML42YPJ^];22C#EDM3&+<Y\T9:?J3$@ DG '4US>FVNE:[K$FO1?:#<02&!6W
MX7"^@'4'WKH+JW6[M9;=V=5D4JQ0X.#Z&J>BZ1'HEC]C@FD>!6)C5\90>F>_
MXUFFDO,T:;:[&C1114E!1110 4444 %%%% !1110 4444 %<+\1;5;I;*.Z\
M01Z;:.2IA=&83-D=<=A[\5W5<KXTL9Y$M+VWEL(&@\Q)9KX_NQ&XP1CN3Q6-
M=7IM&=57@RKX<M-36^^SQ^(K66VL'"36D%D(P!C@9].^171:VTAT\PV^I1Z?
M<S,%BF=0W/4@ ]3@&N#\*Z[IVEZT8;G5?[2N9X(H$DM+=C&BID $]2>>3TKK
MO%.E76H165U8Q1375E-YJP2MM60$%2,]C@]:SIR3I/E_,S@[P=CD]#U/3K;7
M$U*YGUK4LL;5-3GCQ;J6.,*!T!/&:],KSZS\)^);K28=-O=2@L-/B<-'! GF
M2* <A2YX.#7?)\JJA?<RJ,D]3[U6'4DM451YDM4.VCT%&T>@I:*Z#8Y?QW>Q
M67AFXSU)48'?FO'KO6X!\RJ!P!@5Z9\0D,]J8=K/NQA >6YZ?C7/P:1;/J:0
MWGAR"UN4LII"BVC2Q Y78NW_ ):.H)R1ZUTT*O(CEKTN=G#MK,1&15JPO5E5
MMI)C88('45T\/A;2)/&&Z:&Q16M4\NQ9A#O=D8M(8FY7&/N_C7":,I262,D,
M58J2IR/S]*]"C6YW8\^M04%<V&TV.92QG.X8/S)]ZM#2;F[TS[MT9(P<>5C'
M'L?Z5$J?*QY/I@]*@,@RP/8UK*3>AG&C%6=CK;36I[FVD?<WE@A 2!N_.LZX
MF!=LGG'&14>EOC2CS_RT/XU4O90 QSM/K7-"$5)V1O5G)I)O8PK^4H\HSD#/
M->@Z%9)8^'[)H@@::'S7<#YF8^]><W;!L[E+%>A[FI]-\8ZIHD?V:,_:+/&W
M[/-T7_=/45I7I2G"T3.E)*5V;]W(\MZ0C;F)Y7GBM[P[!M226-B['^(CJ<^G
MI7'+XJTV8K)-!<6TA.&"@. /:IKSQVT=L;31H'C?&&NI@,_@H_K7'["H]+&D
M7%2;9J?$6^@6"PT]5#7!D,I YV#IC\:Q;/0=7:W6<:7=M$1G?Y)QBL[P_+>+
MXCMKH6W]IWOF;DBE);S&[?EUKV2QF\52:W;W&IW=A86KL ; N&9A['KG\:Z6
MW0BHJPXQC6E?4X+PU"ESXBL;:>,-&\NV2-N_!XKH_B'X6@MK6'5;"W54@^69
M%'&.Q_I4NIPQP_%>R\L!?,*.P'&6P>:Z.?58&\276A7^&M[J-5C#=,E>5_&N
M>I-\RDNUSIHP2BXOO8Y#0[&PN_ >J:A);1-/&',;[<%/E&!^%'@32=,U7P]J
M%S>V,<\D4A"%^2,*#_.M>VT6?0?!?B.QDRR*TC0OC[R%1C\>U,^%\$J:!?K=
M0/"'F_C&,KL'-14J<T9-,UI4U!Q31E^'_#EMXF7[9>6JV]E V=Z#9YF.J_[O
MK7->,-1T-[K[%H6GP16T3?/.@YE/M_L_SKTW[9I/BS3-4T#39VB$*>6&3Y0?
M<8ZKG@^M>$ZHL^FW<]I<1F.>!RC*1C!']*,)!I6DW=&N.K0J5'.G%13[&?>3
MJS<#'I6>DSV]U%<( 6C;.#W]JDE+,6SV[U7/4BO0LFK,\Y:.YZ9HGB32+FUV
M/=)#<,OS1RG: ?ZU,;[3(RJ1ZG;-N/"F3."/>O*RBG[PJ10!Q@8KG^JQ;W')
MKH>R:!J%MJ&K+IEJWVEO*:61H^0H'09KK5TK58"WD1?NV'W":X[X'V"F75M1
M.,J$@7_T(_TKV+(]17'6M"?*CHIT5**DS-T>QFM(G:XVB1^JKT%4O&L+3^$[
MQ1I_]H*H5GM@Q4NH8%L$<YQDUT%9FO6>J7VF^3I&I#3[K>&\XQ"08[C!]:YY
MZIG?AK0J1UM9];_IK]QY3=0_#9[2W.EZ1=:E?7"!DLK:23>I]'Y^6O6M%B,&
MAV,36WV4I @,&[=Y?'W<]\5P5AX-\9Z%JMW?Z9J>CN]X0TZ/ R*2.X '!^E>
ME1[_ "U\S&_ W8Z9[UC1BTVVK'HYC5C*,8PGS+S;;^YVM^HZBBBMSR@HHHH
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MBO[)I)7,*4/:7N['"FZ$UFY#8!YXZ\U0L+.34]6@LF;8LK8=@<D*.N/?%+8
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MVE3@DGN372T@ '08JU*T7$AQO)2%HHHJ"PHHHH **** "BBB@ HHHH ****
M"BBB@#BO&NHZAI=_:7*ZD]E8"-@NR+>)9^H1QUVD9Z5%X6UI-,TV]NM4,VGZ
M6TBO:"_DS)R/G"YY*YZ?6NMU2R>^L72!XXKI>8)GC#^4W]X ]^M8^F^"M/M;
MD7NH22ZIJ'4W%V=V#_LKT%<TJ<_:<T3!PGSW1T<<B31)+&P9'4,I'<&N1\2:
M5HNGRS:]J5M/J,S,L=O:NV]0YX"HO09K8T?Q!;ZQ<W4,%O/%' VQ))4V";'4
MJ#S@&K.KZ5#K.GM:3/)'\P>.2,X:-P<AA[@UI)*I#34N24XZ:G,>"M7">5I;
MZ<UG'<+)<6P^T>;@!L.ASRI![5VU>8W#?V7JAETN1DU)KU;"[O[J,,-Q0,&"
MC@;SC)KO="U&35=&M[R: P3.")(R",,"0<9[9%10G]A[HFE+[+,SQ=%))IYV
M9X]*\]\0W,3Z'%(-9N+)8;-[:2RB0DS.?_'<'N3S7L4T*3QE'&0:XKQ#HNFF
M&6 1!V;&<C@?_7KJCN74:4=3SWQ#K5L+;6+BVU@:FM[;P1VVGJCNL$B;27;<
M-HQ@\#KFHM,\;:<^OK<7U[#]HGT:&W>XE5U2*96W,K;,,HP,?+[5LOHEM$K$
MQ@*.@QBN$\3:;9P7*W$  0_+(.X/K71"S=F<CJKH4[^[M[KQ1J5W8O*]I+<,
M\32D[BI/4YYJVDI]?QK'CGAA^48R.XJRMW&4/S8KT864;7.65W*]CK8O%$RP
M1I<6<%Q+&,),^<_CZU=M[^SUQ5%\TD5T@YV#B3Z>GTKA1?QGC.?>MFRN+=2Q
M0JS@8!+X^N*Y)X&A5TM8]"EFN*PUI1D]%9=3?U21;@PQ1HRP0KM52>3ZFLEH
M?F+=CVQS3&UV))=MU&ZC^%]O!]JL07=O<#,4BL#Z5O2Y:<5".R.*O[2K-U)Z
MMZE7R^@Y^M-P>PY^G-3S74"OM9ACU%-@EBG8JF,GH/2M?:HQ]DQ$C<\#\=QJ
MU%"1\N.M#;( &F8)W^8U3N=8X*6P(R,&0_T%3*=]BX4BQJ-\MK&;>)LS,,,5
M_A'^-:%E+);Z+:FP3_6 ^:ZC)+9Z'Z5R#,>23DGJ:6*_N[0,+:XDA#==K8S7
M)B:,JL$HNSO<]/ UX8:IS3CS*S7WF_J($$YW,K2JF]R<!D)Z"N;N;B;4KPR"
M(!FX"1C.:A=V9V=F+,W)8G))K>\/'98W;0#-WN&2/O!,=OQK2OB)4J/,]6C/
M"8.-?$JG%\JD^O0SXO#M_/#YK^7;AONI,VUF_"LJZBN+*X>"4%'0\KFN[EB:
M\D@N)I=@*Y\ICAC@=!63K=O;WMA/>,@CG@  8?Q#T-<>%QLZD[36CV/2Q^5T
MZ%+FIRNU\1R;.SXW,3CI0O6E"FI8HR3TZUZR1X#9+"H/MS5J,<\ 9[4Z"#((
MQM [FK4<!E=8T7+.<+CK0W8@]4\ ^$_/\*K=.WE/<N77UP.!7;6.D7%O*#)<
M#8OW0G4_4UB^&[J;3=*M+)6W+'&!MD_H:ZRTN1=1;PI4@X(KQZDI.39WTE3E
M9K<CU'4[+2;47.H7,=O 7">9(<#)Z<UYOJ$UI<>(+W69_#\WB/2=2A2.TGMX
M_,,6T$,F#]W+9.:Z/QK!,\$ZB_L9$N8!!'IE\ZQI(V[)96Z[L<"N4\.:);W>
MI#3+2XUWP]-%MENM,9V>*15(Y23T)[UQ5&W+E/H\%3ITZ3JMZ]?33MK>_75=
M&=SX&TZ]TKPC96E^&690S"-FW&)2250GV&!6S+J%G!=QVDMS$EQ*C.D;, Q5
M>IQZ#UJR2 ,DX KRB]T^^\7ZAJ>LV:[M)<^1,B$&YE6'.8HST"N>>U7)\D4E
MJ<E*FL54G4J/E6_S?3^NQZK'(DL:R1NKHW(93D'\:=7-^!]'GT7PXL%Q#]G:
M6:2=;;?N%NK'(CS[#]<UTE:1;:NSEJPC"HXQ=TNH4444S,**** "BBB@ HHH
MH CGGCMH'FF<)&@W,Q["N)O/BGI%J65++4)CG"E(>&_&NWFBCGA:*9%>-AAE
M8<$5CZ3+9WDDT2Z<L0M7*QOY7R,OJIQS6U/DLW)7.>K[3F2BTCQ/Q2AFNWE6
M'[[%@I_ASSS7+1%HI'*@CLH(Z_\ UJ],\=:<8]9N1$BYSO  P"#7!K;=6^;S
M <#/:O?HS4H)GER3C)IF[H<]A:WWG:A&7A,>S>HSL;UQ3]7\56ZV\]IHUK(7
MDRGGNN %/<#K6#;3E"T$@P5J/[9%YF/?&>U95*$9SYI%1J2@K(MZ?9&TA7]Y
M\I[CO2S6+7&H OO\E5^3WJ]IDP/RG&.@!%:HAB+;I-_/0#!Q6GM.5ZF$J+>J
M.;FTC>&(P/8]:W=#L9X](,:%2BB3;D>O>KL=M&2'\K.">6]/I6C'"?(.6V!N
M./3TJ)5[JQ/U635KF3IEA+'&N\YXZYKH5C,:#<N..*((?)55&WR^_H/PJ'6]
M6@TNT#R')8?*/7'\JYW)SD=BBJ<+LGDE5%SD XS7-W5U/?3-'9VLMPP.&*#(
M'UJI-KLUQI\LC!>/NA:ZK1[-;.QB=B% 4%MO5B>]54E]72=M684U]9;UT1B2
MV1CA O(=K="I&"*?:2#3M)EG0L-\JH67JJD\XK2\2:K;F%M/:WW7"X99=W*9
M['ZU'IOAV]U>Q>WMG4&+$K!NC'L >QI3J.5!REI<NE1Y:O+%WL=9H=GJTQCO
M;6^VVQX,;DD,*[.N>\.IJ%G;QV;VA$,?#,YP0?;U%=#7CRW/8AL%%%%261SW
M$-M'YD\BQID#<QP,FH[2]MK^'SK6=)H\E=RGN.M1ZII\>JZ=-92L5248W#J/
M>J^CZ!9:+"JVZ$R[=KRDG+^YJDH\OF2W+F\C4HHHJ2@HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH *1F5$+,0%49)/84M5[^T6^T^XM&8JL\;1EAU&1BD
M]@9P::J+[Q#/K^C>'[W4UB4QBZDN-B8'!$2GK7;Z3JEOK.F0W]J28I1D!A@J
M>A!]P:Y_PU+JFDVL>C:IIJ6]I:1%!J"3*(W Z<=02*JZ?XF\*>&+>'2;.^DN
M09B"\:F3#.V?F8<=^U<U.7)K)VOOTU.>$N763W^6I<\6:'IX@FU]K*2XN;55
ME,*2%5FV'@L!UP,UCZ-J.JW7BVZ>"^DNXQ<H9(1(&A%M(N591V93P<5Z$0&7
M! ((Y!K-CL]'\.VMU=Q06UC#_K)I%4*/QJYTO>YD[+J7*G[UUH:=8E]H8GE,
MC712$99LCD5QMQKNH>*=:A2"_DT6T"&;3FD7'VMU/5C_ '?;TK2EUS4/$'A9
M;BW0(PD:"Z2/D%U.#M/]T]:NE74Y61$JD)K5&/=+'<1R>6S"10<*W.X>U<E9
M:/INJVVN#59/)C2W40W!) BD9PJL?;) -=YI/AV^O23<QF( \$C'%<AX[\)7
MEG=,GFN+"X7'R9"MCG#?0\UU17,[(Q@K>^UH1Q^!O#\-W<6NH*MK+!<VL*IY
MAQ/*T&XQ;OX0S_Q5S\?@R&^TUKR5KFPOIFNRMJD&8(#!R59B<C(X'O6-J%CJ
M2G$UW<2 LKY:0GE1A3^ X!I\^LZQ>Z3#I<UU+Y*/(\CB1MT^\@G?S\PXKJ5.
M8.I Z^U\(Z9=VVG7,F@2VDT2S>99M*^;IDB#HI)ZECDY3C''6N?UG2X]*\42
M&WM)(81!%+Y+980RN@8QY/<<D \U,CW;VT=X]U<*+(;(<RG,7'\'/%8<]YJ-
MRLT7GR&.:X%RY=LLT@& 2?H32E1FU8=.O#FO;8[Y_":W'AFS\V:-KFXN@+JZ
M:93'%&8]V!SC(_G7&^-M(30M=QIEO/;V7V6&0'=N(++U8C(!)S_2LZZEO9+,
MVTUPWV<MO,0X4MC&2/6J1U"[-K<6S3LT<_EB3<<DA/NCV S6-.A*EN=-;$1K
M.]CT'2/"<,VA:2]W<>;<76HPBYG2=2L<3JQ$8Y^]P,]\GVJOXDTNWL_$%JUH
MK6=G+;>8R1[U+,&*GY7&Y>G?KUKS])'1!#'.Z1F0/M5L ,.C?4>M=@E\BW@>
M\G>[8@*\D[EG?'N>:SQ$Y4UINS? T%7J6:T6Y:O-/L[FPFN;0S+)"-S)(^\,
M._/8UA;JZA)[&Y2>! 8;485_+;YY>^,]@*R]6TRW@LQ=V;R>6&"NCG.W/0@^
ME/!UY65.J[R9MF&%A)NOA8VIK3Y_Y&0S\]?UK6T>PM[B">\O 7CB8*L8;&]N
MO)]*PV/IBM#2M6^Q>9%+%YUM)RR@X(/J#79B(5)4VJ>YY^$J48UHNNKQZEG6
M=.MH[*.^M%*(7V21[L@'L1WK(MYYH)?,AD>)QT93@UH:EJBWT4=M!#Y,"'<0
M3DL?4UF@8_&C#PFJ257<6-J495Y2PZM'H237=S+.L\EQ(TJ_=8MR*==:G>7\
M:PS2 HO. N,GU-0E >G7O5BWM^<D<8Y.*Z5"*L[;'$ZDGI<A2$D8./PJQ#!^
M\P*N>2N< $X'0U+%!@#*''7BJN9L6*'81Z>];NB:6S2+<%"[$_NQUK<\#^#3
MK5P+V^B*Z?&>%/\ RU;T^@KTI] BMX"-.5(I ,+N'%<5>NE[J-HX><HW,31/
M#D$\.;FZD$P.?+1L8]ZT]9:72=%6U@:Z43;DDOH@I-JN"?,;/88ING65['<-
M++;,LD*$HNX;7;L,US$WBK7_ !!JL6AV;1:#JD,;23PW:!Q,P("HA[J1DYKS
MJT[:=SULLPO,^=))1WO^??\ "Q@27$6^XU7Q99)XBTNX@6&WU.R7<(]N>JY!
MC8YYZ<UZ/X&L+W3O"MK!?L3(-QC#-N9(B<HI/<@8KG_">B/-K4U[)87.B7<#
M%+^TB -I>$CAE!X]^*[ZY!^R2A)1"VPA9#T0XZ_A6%*%O>9ZF88A2M1CY>GE
M9;?-:/31;&)XIUN73(;2QL[..\U#49##!#*VU",98L?0#^=<5X7T6:/Q1<6D
M(F\/:E;%)[BUMI?-M;J$GJH;[IXQ5"\U*]FMF3QO]I2!)0UAJVFA2L+KD9RN
M<%N#@UWO@_18+6U.L&[O;V\U"-&>XO1B38!\J[?X1[4D_:3-)16#P[75]5JF
M_P K);IJZ9T]%%%=)X@4444 %%%% !1110 4444 %(".@(X]*JZE9-J%B]LM
MS+;[^"\7WL=Q7'ZYHA\+:9_:NDW=Q')!_K0[[A(#QR#6M.G&>E[,PK59T]>6
MZ6__  P_XAZ<)K:"[C*><IV;2<%N_'K7E6H1"&7>J_*_8?PMW%>IV'@RYU2[
MM]6U_4'N95&Z.-#A0"*Y;7-#.GZC-9WH(MY/G27''M7J86I&/[N]['!74I+V
MCC:YC^&UM9&E:>+!<A?-*A@W^S[&J&K2V6^:"S6-XR23*> @]AW^M3ZC/;V$
M1CA<AL%057A0>IKEK@38>!4(4?Q9X8>U=JC=W.""YFVS;L6C*QM$X=>Q%='9
MD-\S]!C-<_;6R6]G$!\JA.2.N:W=/E#6TNPJ9=ORY'!../UK*HM#KAH-US5Y
M=+O+1(Q$\)&Z:,CY]OM736+QWUE'/#]R10RY'(!]:X_PWH$[3?VMJ&^6ZE)P
MC#A>:[NTD@A@53A,=.,5A5222CN:0?O7;T(&A*?,>N.?2N<\2Z;+?1I)&P*Q
MC#H?3/6NIFG616:-5"C[Q?T]O>N<O?MMP<PY"%L*& &?7Z"E23O<FJXRCRF)
M'80QQ-:%L2RC)4'H*ZW3M0@BL([>^F2&6-0"[#AAV/UKFXX!9W#RR;5=5W%C
MZ_7^54IKM[DL6P ?N@]O>NBI2596D<U*3HOW32NH[8ZW(UM.;N$?.7*XR?2O
M6_#6F_V;H\2L@6:3]Y(/0GM^%>>>"M+MY]<C2XN$#JOF>23R^.@_K7K=>=CJ
MFU-'I8*GHYA1117GG>%%<_>>(I8->M].CL+AP7*R,(R>,<,#TQZUT%4XM6N2
MI)WL%%%%24%%%% !1110 45$MQ"\\D"RH98\%T!Y7/3-2T!<**** "BBB@ H
MHHH **** "BBB@ HHHH R=9\-Z7KYA_M*!I1%G:HD91SZ@'FO/=.CM[#4[AM
M1N$.A>'9F$+>6%::8_=4_P!YEZ5ZQ6-?^&=.U#5+6_N8V?[,6=8/^6;.?XRO
M=JYZM'F:E'<QJ4[NZW,#2?&.HF6"]U>S2#2-1?;9S(V3$>@$G^]ZUVD]O#=0
M/!<1)+$XPR.,@CZ5Y=H>B0:CI\LUU?7,5NVH32V^F;@J3,AR  >1SV%:N@>+
MM6E;3+C4'MKBUU*=K?9"A1[649^5O48%9TJS2M/J13J-*TNI;\2Z5'/X@@N]
M2M(WT&QT^5G&.-W'  Z'&,53\-^*9(9;*R_LJTL=/GF\B&VC<B>(D;E9E/4$
M=Q7<.MIJEC)$3'<6TJF-]K9##H1Q7#^)-%;P_HZ75O=3331RI!#=S@,UC"W#
M$$#) '<]*=2,H/VD1SBXOGB>@U7O;*WU"U>VNHA)$XY![>X]ZXRSO;/PU*EY
M!K;W^C3(865IC/(UR"/N#W&<CZ5UFE:O9ZS;-/:.Q",4D1U*O&P[,#R#6\*J
M;MLS6,U+1GF?BKP1-91M)!NFM_X7 Y3V->:WEF]O-C'-?4C*KJ58 J1@@]Z\
M_P#$_P /HKA9+C35Y/+0]_\ @/\ A7IX?%6]V9QU\*_B@>,(6'RDD+Z'UIIC
M*\GI6U/IS6DSI)$<J<$-QBE^PQRIN5E'&<$_RKOYD<23.5U'(@/MTKHKOPO<
M23^%K^WTECIDEM:_:YE3]VS-)AMQ]3D9J"]TV%E(.02..<YK)73+@!E%S*(U
M^ZOF$ ?A7/5@Y.Z.FG445J=3<1Z-J?BV4Q0:='IVCI--<AK+[-&2#M1'(9MP
M+8YX^E<=JYBL-8FNVN;:33U=9H[9)2LDT3<XC.,8'(S4<^F2C=B1_F&6Y^]]
M?6ETKPC/K"/,2ZQ1ML7C);Z>U<U6@TKLZ*=>][&]K]]9Z?XNDB@M!;6<MM;S
M+%"<["T:D]>M0:AK$=S:BUM49(B0SLW5CV_"IX_ JPR;I9;F11P3W%-N?"-S
M&NZUN%D[A''/THI>Q34I+4<L14<'3C+1]#(Q29.:5!("R2H5=3M93V(J58MV
M#S^'>O02N<3;6@Q!SZDT_:V.%ZU,L3 \+QVXS6A!822D,V1GO1HB;ME""V9W
M4 <'KBM6*%$ V\\=1VK4T[2)KF416=N]P_<(N<5V^B_#)YLS:Q)Y2$<01'YO
MQ-8U*T8[FE.E*6QYQ&J9"8+.?3L:L+8W-U($$BQ1DX.WK^==5/X=2RNFLU7;
M(A."PZC_ !JQ:>%-1NHO/@B5TW$<,.HKEE7<MM <7%V2N=MX+U/[7HT=I(J+
M/:J$(3@,O9JZ&>7R+>28H[[%+;4&6..P'<UYUX?\_3-?2-P488BD4]ZWM9\?
MZ5H^I1VK"6>-9O*NYXE)2U)Z;CC'7MGBN*HU#5L]7!QJ8C2$;M&1KGCZ*]\*
M1W>E?:88YIA!=W*J"^G\C<67KG&<'I5,>&+W4+BVT^]FDUK2)U,MCK44@%Q9
MD#(RW<'M6SKGA.:34TU_PT]NEU. MW;R<P7D1Z[ATSCG/>NDT71+'0+%K/3X
MC%"TC2;-Y8*6Z@9Z#VKGY)2E[QZ[Q-&C27L-W?U7SWTZ=&MUN7+:$V]K%"97
ME,:!3)(<LV!U/O7#>/M6%];C1]-DL[Z195:^L%N-L[QJ02JCOG!R.OM71:WX
MDCTJ[M]/ALKJ_OKA2ZP6J@LJ#@N2> ,UYI!X?UVWO9]-AL1<W%O)(MGJ-NZ8
MADD;<\DS?>WJI  __73JRTY43@*"YO;5':VJOU\_D_\ -;&MX+.FZAXQGG\.
M6LEGI(MMM_9SX4&;/R[8\GIW/2O4:R(_#6F)J]OK#6R_VG%'Y;7"Y4R9&"6
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MX?L-3O(+N='$\)!5T8J>#D UJ44TVG= TFK,**8DT4GW)$;/]U@:?2&%%%%
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MHH **** "BBB@ HHHH *\.^+'_(UQ?\ 7N/YFO<:\.^+'_(UQ?\ 7N/YFNS
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M8:;?0:S=WUS>[XYE"K @.T8Z-ST/TII)IW8FVFK(UZ**:[I%&SR,J(HRS,<
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M6PN[G*0M,VX.K;,''0@ =>*M>)OBC?Z)X@UNRBCT18=+6-@EY=O'-<[DW8C
M4@GM]<5T ^(%E:W%TVJE+.WBBM&\O:[31O."0K@#'48XS0!%9>$;T?!\>%;H
M0?;O[.:W/.Y ^#@YQZXYKE+SX?Z_<6KJ-$TAVO=)BL-LD_&GNA.9$^7G.=W&
M#D5W ^(GAPV"70N9SONFM%@%L_G>:HRR^7C=P.3QTH\.>,1K'@:3Q+<6^Q(_
M/8QPY8E8V8#'?)"_K0!T.GVSV>FVMK),T[PPI&TK=7( !8^YQFK-<)I_Q5T*
M?P[INJ7WGVTM]&\HMDA>5T13AG.T?<'][I7;6MU!>VL5U;2I+!,@>.1#D,IY
M!% $M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%&1ZT
M8[>'H'\0C6//F$P  0'"\#%;%'2J5[K&G:<ZI>7L,+.,A7?!QZ_3WJFY2T)2
M4=B[134=)8UDC=71AE64Y!%.J2@JCJVE6^LV+6ER9!&QR?+<J?\ ZXJ]133:
M=T*45)697L;8V=E#;-*9?*0+O( ) Z=*L444-W=P2LK(****0PHHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH *\.^+'_(UQ?\ 7N/YFO<:\.^+'_(U
MQ?\ 7N/YFNS _P 8Y<9_".-T[_D*6?\ UW3_ -"%?3\'^I7Z5\P:=_R%+/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ KP[XL?\ (UQ?]>X_F:]QKP[XL?\
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MOZ/_ -!.T_[_ "T?V_H__03M/^_RU>\F+_GFG_?(H\F+_GFG_?(H]T/>*/\
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MV8D@#/7D "N'UGQ)I+? V#PN-,N8]9LI%%RKVI40L)#ER^._3UYQ0![UKOQ
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M1=8O-4NI]+-LTZ:>MM;W+D#&W!Y88(Z<YH W?''QDTC_ (1?4/\ A%=;4:K
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M _\ B:.6/<+R[&L+>$,["&,&3[YVCYOKZU)T&!6+_P (\?\ H-:O_P"! _\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
C!1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>g4i5nix4zlkt000004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g4i5nix4zlkt000004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" )# J # 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MR0*0"@&=N>G)./\ ]5>PT5,*[@K)?U>]QRI\SN<'X2@-SX^\3:CY12&#R[*
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M0O-#^&!G:ZE^WBUCC\\M\_F-@$Y]>36$J5_>CLW9&D9VT?1'6W4ZVMI-</\
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M-9/WM5N"K7MIHSUBBBBN8V"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MKTJ2*.:,QRQK(AZJPR#^%+'&D48CC1411@*HP!^%:QJ<M-Q75D.%Y*78^??
MNCS^*M7M+"=F;2[%C<2I_",D?+]6( ^@-=3XVVZO\5=#TA<%(!'N4=LMO/\
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MAQ=:9X=O;YO$=Y=K;Q^9Y$BG:P'_  (_RHT/6A;_  1U(B0!HGDMEY_OD?\
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M_P"%KWW_ $"(/^_S?X4?\+7OO^@1!_W^;_"N"HH_LRB']H53O?\ A:]]_P!
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M *%JZ_[^'_XBK6X^IHW'U-'L:?8/:U.Y5_X6;<_]"U=?]_#_ /$4?\+-N?\
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M!&3QZ5YYW'2UD^)=6DT/P_=:C#$DDD07:KG@DL!S^=<?_P +S^'_ /T%Y?\
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M_P#\(/XG_P"@4W_?U/\ XJC_ (0?Q/\ ] IO^_J?_%4?7J'</J=;L8%%;_\
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M\C)J?_7R_P#.@#V"+6=+GE6*+4;5Y'.%59E))]AFKU>*>&?^1HTS_KNM>UT
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !7B/B'_D9-2_Z^7_G7L=QJ=A:2^5<WMO#(1G;)(%./QKQK79$E
M\0:A)&ZO&]PY5E.01GJ* )?#/_(T:;_UW%>UUXEX>ECA\1Z?+*ZI&DP+,QP
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M/9V]I:S:C?7J[[>W@(!*#DN2>%7W-5]*\6G4?$!T6?2[FRO$MS-*LS [<$
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M>:6VLIX@ET^359#=RPK:QO\ >^[RW/W<5Z(Z)*A21%=&&"K#(-* %4*H  &
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ME\UPIP?K0!;HJ*"ZM[E=T$\4HQG,;AOY57NM6L+.Y@MKBZC2:>011IG)+$9
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M'R!A1CC!'8^U;],04444 %%%% !1110 4444 %%%% !1136D1" SJN>F3C-
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M"$SZG92FZT*]8W$,ELPVO(Q"LA8 D#//'I]:P;$VEJ=\LLES)$#Y4<D7SQD
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M/^MRY2;AQR.>G-13CS[6:.,JS,C*.>^*YA]%U>VBMY+>Y8R1621%F()5E#9
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M$O 5>2/4"D,[F75[F[B$Q4RM<QK]K$N4,AY!(QWZ$"L.>.%=JB%F4(7CA/\
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M!^ _*NOUZWUC[1#>:=<L(X8V#VX_C)[^^!VKG;+QI>0,KW2)/"W4* ''O_\
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M)4O]W\ZD9LWEU'8V4UU,<1PH7;'H!7A=A?W/BSQJK2A'DOBZQ%D#+ N/1NN
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M[Q,^K7TMO.;8/MWQI;DOM /.YONY]A3Y7:X71TM%%%2,**** "BBB@ HHHH
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M3@'C.1Q]:@URTLK7R[G3WD-C/(5BCE4B6+ !9#GKC/!JI93VZ7<2W<#E7"J
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M,\G\3B@9S=CK2W/F+%:89G(G^S 190'"_4C.*WOM%E8W-D+N+9-N;RQ-MW
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M<D\8K-OIXU2-H\JDB!MA/W?:IHR:]QZLUKPO^]@K19B13RS@07=JK@'.[S"
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M+ZYX[5?O-;U>7PMY^BV5T+4.6!E0!B!U51W 'I5F\&JP)/+IGA^TAA:-3$)
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MD264:@H'.03CG@>_>O)M=T26TNIK2\B(96^88_(@_K12T:DMT.K)M<K6C.#
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M+"MK<\:\:^*X]8,&HVF^*2U8PE"2!P>![]>U83R:MJ&I(^HSO9+A51N2,$=
M.]==-\-=9AOTB@LY'L;8%QTW3.3G/X# ]J34K5+/RUU"RCAGADS;LTNT$GL0
M.^:D9R^L*%NUQ,TH"YW>K]@?PJM#YD=Q=/&2TB%9DC^@Y(^O(IUQ<?;3/*\
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MI;71U!26Y41);AB(%8%)0PR3ZY^AJ1$^PZ&F=BV+$^;+(Q)N2V"'&!N#9[#
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MO5O%W@^?Q'JFFW,%TEL+<.'<+E^<8(]<<\'UK0TKPCIFF:?=VA0W*W;;IVE
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M[@_VCWZUAQ>)-4A@CM!;PF+[NS'3(/.>WTKH/$6DOJ 6>]U.)MB[4C@0[S[
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MCQI/_7G<_P#H45;U8-[_ ,CQI/\ UYW/_H45;U-]"8[L****104444 %%%%
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MDDD<,:22'+LJ@%C[GO4E,5SS"7X01[ L.JGCGYX1U_ U4F^$MZJKY-] VT$
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M10 44A8*"6( '))I(Y$E0/&ZNIZ,IR#0 ZBBB@ HHHH **** "BBB@ HHHH
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M.,C- "T4A('4@4M !1110 444=>E !11GC-("#T(/TH 6BBB@ HHHH ****
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MC2U;9EV_A?6IUA>&PG\MA\I(P,=>]9NI>$_$<0XTZZ ;IY:[B/RKWL    8
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MJ:WT"WM;D20W-XL D:1;438B#-G/'7&23@G&3TIN5.VPDIF5;:SJ5_JFAS-
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M*7/+N/E1@-X2LB JW-[&AMH[21$FP)(D! 5N/<Y(P:O:MIHOM&DLH"L3*%:
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M,%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4453U2YFL]-FG@B:251\J@4F[*XI/E5V7**\];QOJ5NX
M$D,;%?OJR$=ZWM#\96.KW'V5P;>Y)PJL>'^AJ8U(LQAB(3=D=)1115FX4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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ML-K>3N(    , =!2T45J=04444 %%%% !28'I2T4 %)@>E+10 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% #4C2,L415+G<V!C)]3[TZBB@ HHHH *:L:(S,J*K.<L0,;CTR?P%.HH
M*A^RVW_/O%_WP*FHH A^R6X.1!&#ZA #5*[T.QFA<1P+%)M.UXQ@@]CQUK3H
MIIM":3W/*-6$EK;6$UU;31R)C[4L "L[KR1Z -@X[<UW=IH6B7?D:BNGPB1E
M#@8Z=QD=,BIM7T*'51OWF.7:$)ZAU!SM8>F3]:K^&_#K: ;O-TTJ3E2(\DK'
MC.<9]<_I5RES*YC3IN#:MH;JJ%4*HP!T I:**S-PHHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
# __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>g4i5nix4zlkt000001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g4i5nix4zlkt000001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" (" J # 2(  A$! Q$!_\0
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MK:V*WLKD0-C#!2>O3BIK>XCNK>.>(YCD7<IQCBN;:^O[/PPLUQ!;G!18@PW
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M8@/N]\X_"@#I;_4[738TDN7*JYPI"D\_A5M6#HK#H1D5QWB)94\/:6LV?,&
MV>OW:V=0NM2BM[2'3;8N\BC=*1E4H V:@FO+>WEBBEE59)6VHO<FN>AU;5;/
M68+'4&@E$Q S'VS5#5FO_P#A*HB(XO/!'V<9X9<G&>?K0!UE]J5KIL:O=2[
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M>_Z5 7T&4PQVMC<W$LAP8_-8%?\ &N[5%10JJ HX  XIB00QMN2)%8]U4 T
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MB!B8VF8 D8Z U=\3D?\ "-1?[R?RK?-O R!##&5'12HP*5XXY$V.BLOHPR*
M.-UBU=]%TF["&2*.)5D [ @5%G0IYX8;.QN;EY#@KYK+MKN0JA-@4!0,8 XQ
M34ABB),<2(3U*J!0!RFO!4\2Z4@Z ( #_O5I>*KB[M]*#6K,@+@2.O4#^E;+
M0Q.X=XT9EZ,5!(IQ 8$$ @]0: /.[]M,?3D-FEQ)<#!FFE).WV].36GXC8-H
MFDE2"-HP?^ BNN%O"$*"&/8>J[1@UB>)-*N;^WM8[*)"(V)(R% &* ,_5O$$
M%[I!LXXI1=R;5:,K]TY&?K5Z72'?P@EHZ_OXX_, ]&ZX_4BMR.",;',:>8%
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M<0:??27EQJ462DYPP7YB/F=MV6QD#'7FK<(<@N:7,>BT445RFH4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !2,RHC.[!549))P
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M2C3_ .WK[1\3?:+*W^TSOM&Q5ZXSGKS69IWQ&T+4UWP"\$2PO-+*\!V0JO\
M>(/4\8 R>12Y)O6P^:)U:(L:*B*%11A548 %.KF--\>:3J6I6MB(+^VDNU+6
MKW5N8TG _NGO57PUJ^H:OXU\2![EFTVR=+>&' P'_B.<9[>O>CV4E=OH'.NA
MV-%<]<ZT;#7KQ;B8_9HX%9(\#ECCI5G16O[P&_NY\12\Q0)C"CU)ZUF4;%%>
M<WWBJ>+3?%^K6NK3RQVC?9K>%[=46&7[N5;)+\\\TZ/6=:_M[PAI#Z@_F2VA
MN]18JO[P8S@\<<@CC%;>PE;^NUR/:(]$HKDU^(NA-<JB_:S:M-Y OOLY^SE_
M3?4NL>.]&T35I=,NA=-=1PB7;#%OW9Z*,');O]*GV4[VL/GCW.GHK.O]8@TW
M0)M7N$D2&*#SF1AANF0I]^U<1:+X]\0:3_;L.KP:?YB&6UT];=6#+U 9CZ_U
M[41IN2NW8'*VAZ117,+XL_LK0-/G\0VTEOJES\@LH$\R21QUV@$^QZ\9H_X3
M*PO/#FKZA:>=#-I\;B6&XCV21/M.T%3ZFE[.78.9'3T5Y=#KVOMI7@NT;4I/
MM^JW!EN9-BY,(.<8QC&#^E>HTYTW#<(RY@HHHK,H**** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M?9U"X&[/?@?_ *Z]*HK*-2RLU<T<;N]SS7Q=H6K-K^AZO-_:%U';VQAN9-)
M6:.0Y^=%]#G'T%9FH:'?_P#"':O+9Z7K7V[5[B*%Q>2":5HU/WV"@;>.#FO7
M:*M8AI)6V)=-,X*VT:Z;XF6!-I*NG:1I@BAF*$(SD8P#T)P?TKO:**SG-RM<
MN,;!1114#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH P_\ F>_^X9_[5JE\
M1M;OO#G@'5=6TV18[RW1#&SH& RZ@\'V)J[_ ,SW_P!PS_VK63\5K&[U+X9Z
MS9V-M-<W,B($AA0L[?O%/ ')X%7/IZ$0ZC1\1]"TJUTNVUN_,>I76FQ7A1('
M;S-P'W0H.23GY1S5N/XB^&)O"USXCBU OIMJXCG81/OC8D#!3&X'D=JY'2=$
MU%?BIX8OIM-N1;6WAI(7G:([8Y<$%2>@;!Z>]<S>^'-;;P?\2[=-'OC+>ZNL
MEK&(&S,GFYW(,?,,<Y%06>IZ9\1_"NL:U%I-EJ>^ZF!,&Z%T2; R=C$ -WZ'
MM5>]^*?@_3]3EL;C52'AE\F:58)&BC?IM:0#:#^-<[XCT34)/%/PRDM=-N&@
ML"PN&CB)6 ;(P Q'W>AZ^AKB/%UGXX\0:1KMA>Z7KOVD79DCM+*SC2Q:(,,,
M7'S2MQT&3P#VH ]%UOXG1Z7\3M-\,B)_L;QEKF9;=W9G93L"8'*\J2PR.W&#
M6S?_ !+\):9JTFFW6JA9H7$<TBPNT43G^%Y -JGZFN1U*UU/3OB3X.U_^QM2
MN[&/21:2FVMR[12,"/G'&T#<,Y]ZY*'P??Z8=8T+6K'QM<QW5\\B+HSH;.YC
M8@[GW# ;CG)["@#Z#FDQ:22QL#A"RD<CIQ7BFD_&#5;KP1I]O%Y.H>,=4N)(
M+:%%55C&[ =QT ] >OT!KU^SL5L/#D%A")BL%HL*"8AI,!<#<1P3]*\+\-?"
M:6Y^%4UXNGW.G^+HKEKFVDF4I(#&?E0 ] 1^N#VH ]+U#4=7\/:5X>BUSQ1#
M%J-W?I%-(FG>8DY;_EBH&-@_VS_]:L*[\=:]$_Q)"7$6-"6(V'[D?)N#$Y_O
M=!UJEKTVO^+_  ]X'O+C0=1@U"UUJ$W\+6K*4V]9,8X0]<]!T[5#>Z#K#R?%
MK;I=X?MZ0BSQ"W^D85L[./F_"@#K=*\47%U>^#8KO7$AN-4T[[1+8BQW?:6\
MO<6$@.(\'G'>I9?B[X+A\W?J<@\F9H9L6LA\H@XRV%X&>A/7G%<S8Z+JJ>+_
M (:3MIMVL-EI#173F([8'\K&US_"<\8-4=(\.ZI%\*?'MH^D727MY?7+0Q-
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MDOKN&V1].VJTSA03YG09J_\ \)5X?_Z#6G_^!"_XUJ2"/;ND"X'=NU'E1?\
M/-/R%:.46E=$6DGHS+_X2KP__P!!K3__  (7_&C_ (2KP_\ ]!K3_P#P(7_&
MN=\<7[Z)<6]W;(NYQM;/08Z<5G6NO:U>V"WJV!$3?Q!!R,XR!UQGOTH?):]O
MZ^XF,I.3CV.S_P"$J\/_ /0:T_\ \"%_QH_X2KP__P!!K3__  (7_&N5DO\
M7HI(XWL#OD8HH"J>0,D<=./6I['Q7':7[6>KB*"4 $JRC//(Z4EROH_Z^13Y
MEU7]?,Z/_A*O#_\ T&M/_P# A?\ &C_A*O#_ /T&M/\ _ A?\:S;GQGI$/$,
M+S'V0 ?K6)<^.9)>+:VAA&.I3<:VC1<OLO\ KY&,J\8_:1UO_"5>'_\ H-:?
M_P"!"_XT?\)5X?\ ^@UI_P#X$+_C7GDWBC4F()NFY[J%7'Z41^+]8M^CI*,\
MK)&I_I5_5?ZO_P  S^MK^E_P3T/_ (2KP_\ ]!K3_P#P(7_&C_A*O#__ $&M
M/_\  A?\:Y.W\?N-HN-+B8=RAQ_.M^Q\7:)=K^]9;5_[LRX_6LY4N7>+^_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M5$C&Z1FZ*/\ &G[6DXMJ6B!X:LI*,HZO8UX=/TZYU_[/&I>*&(LR _?8=O\
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M&Q7[K[B#@CI6A;SI<P+-'G:PXS6!HNF6]Q&)9X5<!<J#[\UT:(J($10J@8
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MB(:+(D/E\CE1M_QKK?!5ZYL;FU#9*MU[;37&,ZDML//7/M78_"O[/-XM>QN
M2D\#%><?,O/\LUEB5^[;"$.=\IZ/I6O+;+"CJ^Z-=O X85U.EZB^H>8WE,D8
M/RDC&:K_ -DZ3;XWD9SW:M2&2!AY<+(0HZ*>E>1)I['HTH3AI)DM%%%2= 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M62#Y?EYS_P#7K<;P));VQGBG#R*N[RRN"3CI6MKWAXW%]_:$,Z0#'[]I&P%
M_BJEJ'B@P7$%S9ZK!<Z??#[%%.B*T-K<X)#.P.2&.!CM64JO*AT,"ZTFK$6D
MZRGASPO?W]U'(\%N5PB#DL3C [=2*LZ7XEO#KTV@>)K2WM9[L&6R"L'CFB/6
M,GNP[^O\^1T[2[K4H+BXCCDN-8BN&MM=TF67;'-&[<% 3A0!@J1Z'\=O_A7U
MQ_;$$0G:33H)(I4N[JX,MRHC.1%&, (N>IY)%<[J3G+FBM/Z_KR/:I83#T*3
MI597EKK]UK:_/^\GI8Z;0_"MEH,EPML[O:O-YUO;R@,MJ2#N\LGD9R:U;N\B
MM4 ::%)G!$*22!?,;L!FN,UOQK?L=2/AZ.R:WT@$WMU>L50L/^62 <EN,9/&
M>*P]<L+KQ'?6FL_V8-4T^]M81/;P.C3VC %MBDG"AB1N8<\'I0ZBBK00HX2I
M5DIXB5K_ '_/;5K77?U9%#J%IKNG6NG:M+/JNL7]^D=U83DQM88W;FB 'RA1
MWSS^E>EZ/HEEH=L\-H)"9'WRRS2%Y)&Z99CR>,"HM L;JVTJU?5%@;5/*"SR
MQH!WX7([ 8'X5K55.%M7N8XO$\[<(:1OWT^6VG8****U.$**** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH *R]8T4:UY4%S<R+8@YFMD&!.>P9NNWV'6M2BDTFK,32:LQ$18T
M5$4*JC"J!@ 4M%%,8FT;MV!N QG'-4=3TBTU9;<72ONMYEFB='*LCCN"*OT4
MFDU9B:3T9Q]]X1U"9M2L[34((M,U2<S7(>(F92<;@ASC!QWZ54_X1K(\0ZE>
MV$WVDN8[%H0&FCB2,(K1\]>I]:[NBLG0@S-THG ^ %>+4;R%;=C"L"?Z4B2Q
M([9Z-&_ ?U(KO719%*NH93U!&12T5=.')'E*A'EC8\]\;ZIX8T2YBLKW2I7F
MFC,@>U55*C..I(KE]!O-.N+J\OK":>!-/A,\B7$0)=.X&T]:7XP?\C/9?]>G
M_LQKE_#[%;;60#C=9,#7L0IKV"EU?^9Y\YWK./\ 6QT-]XK\-ZG(K7-MJJ8X
M'E^7@<]>O-=S8> M'?R[F.[N';AP<@9%>%=J^A/!TC/8)N)/RC^51C(^Q45!
M[E82U1OF6Q;;PCI,WEFYA,ICZ L0/RK4MM/L[, 6UK#%C@;4 -6:*\YR;5KG
M?&$8[(****11Y^/B4+C3_$7E6'V:^TI&:..9MPEPVTGC'1L9'N*KZ1XQU.X3
M3[JX5Y;R^@N;9;5=J0+=1$D#URPP.N*J:Y\/=3U.]UO[(([?S;U9[>9I,"6.
M11YR$#D?,JGD5TL7@>+S+H2W3+$=6&IVODC#1/@9&3V)S7*O:MZGN3> A#W;
M:_.VBT^]W^31RZ:CJ6OQ?V#X@_M6&34_]03:PQI'+'\[*HW$LO&/F_&K^A>%
M]4U,7UMK1OUT>XMO+>WO&B#&;<"'C6/A ,?B:[.P\.:-I=[+>6.FV\%S*27E
M5?F.>O/;\*U*TC2ZR9S5<P23C1C9>FS[KMT^ZY6L[""QC58ES($5'F?!DD"C
M W-U)JS116VQYK;;NSA/&?@K[;?1:[I=G#<WL;J;FQE.(KQ1TW=MPSP370:3
MX5T/2+QK^PTJ&TNI(]K^63@#J0!T'X"MNBH5.*=['1+%UI4U3;T7Y=F%%%%6
M<P4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MX+IY]5=EC>.(LB;1DEB/P^@Y. *=HWB_0]?O'M=.O/-E5#(H:)T$J!MI>,L
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MA@A\16][.MS;ZQ.TI0)M,8.>^3DC.<^U9=I\-I;7P1J7AW^U$9KR82+/Y'W
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MES)YTUHC+Y4DFS9O/R[N@'&[&0#BJK?#W3AI6C65M?7UK+I$+06UW$R>;Y;
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M5J9()5E)SE X.1\I!W=1[T[5_AG=7-G>6>EZM;65MJ%C;VEVALLC,).UHP&
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M>-=4UG4],AU"&Q\C5]/?4+46I8O;JK*-DF20QPP^88Y!&*[V@ HHHH ****
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M-5H%%%%( HHHH **** (KJX6TM)KEP2D4;2,!UP!FL:#7M1N;>.>+PY>F.5
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M;ZC-Y%I("<329QM'OGBCF7;\_P#,.5]_R%_M?5?^A:O?_ B#_P"+H_M?5?\
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MB?4=7TNTLHX],CB2P-UN$SO&PF+0XX&YL)ENH':@#OU\#^%UU;^U1H-A]O\
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MJ2>FIRQP=1[Z'D?GS?\ />7_ +[-'GS?\]Y?^^S7L'_"M+'_ )]D_,_XT?\
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M:PVUT)WD%WYAP$=< ;1_>KHZ**4I7'&-AK(K=0#2@ # %+14E!1110 4444
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M1HIR%%.HH R?$MI<7N@7$%I%YLQ:-ECW!=VUU8C)XZ U'_;&J?\ 0M7O_?\
M@_\ BZVJ*M2LK-$N.MTS%_MC5/\ H6KW_O\ P?\ Q=']L:I_T+5[_P!_X/\
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MSRZ?D6Z1QI&)I C+&<H'0-M?:>1N!KH* "BBB@ HHHH **** "BBB@ HHHH
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M&3QR<<<UYKHUEKEXEEIUQ-KIL/\ A(6_>$7%NQM6MB>K$N(R_'S-GZ&O:**
M/"[F'Q!/X8M(-8B\130?V1>PVZ6XF,C70E98Q,%Y(,>W&_Y2,UZ#?:/'??"5
M;.[TU+BXBT8>7!+ '9)1!@;5(R&!X]:[.B@#PWQ+I^K:;X:T2TT/3=1L)$T9
M;@/IUO*#)=@)E76/ #X&2TF>,@#-;&JVFM?9/&.JQRZLDPNX(X,32)BU*PF8
MPH2%W$;P"!G.0.:]:JM?Z?9ZK8S6-_;17-K,NV2*5=RL/<4 >(2RZO<RZE#I
MESK*Z)#JX243K=2S11_95,8*JPFV;SG (.2N[O75>&-)O+3XBV=]J@U&XGGT
M"&,7DL4B*\JLVX.H)5&V[?E)ZY(Y)KT#2M&TW0[0VNEV4-I 6+E(EQECU)]3
M5Z@#Q77;;Q3<^-KOQE::%));:7?1Q0,687#6\6Y91'%CYE?S'.>^T8K2^P:R
M_B,WV[62)?$[VY3S9A$+%H.2$S@+N_B[$<$5ZQ10!X-H]AX@TGPW;0:7;ZE:
MWMMH^I))YRR*J7'FH5P7XR5Y4C@G..])--JLU[JMMH-QKHTF.33C.EY]IDFC
MA9)=Q"!A+M+[=VT@GMQ7NMU:V][:2VMU#'-;S(4DBD4,KJ>H(/452T?0-)\/
MP20Z3I\%G'(VYQ$N-QQ@9/?B@#RF\TSQ%<:<BRWFO3M;^&KJ:&6,36[/<"7,
M(90Q)<+C 8DD#GO5RV;Q$GQ"TJYD75+M;C[/YT3K<0I;*81O;()A=-VXD, ^
MXX%>N44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M.:2W1T]%%%9EA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M<HHHJ"PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M&=2&!X((]*Y.P^'O@'3-3BU"UTZT2XB?S(MURSI&W7*HS%0?H*Z/_A'-#_Z
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M!=._\!4_PH]SS#WRY]NM/^?J#_OX*QXYHIO'1,4B.!IG.U@<?O:N?\(YH?\
MT!=._P# 5/\ "K%II>GV#,UG8VULSC#&&%4)'O@4TXI.P-2=KENBBBLRPHHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
DH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>g4i5nix4zlkt000025.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g4i5nix4zlkt000025.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &- J # 2(  A$! Q$!_\0
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M7&@W<OQ$LM>5HOL<.GO;,"QW[R^1@8Z8]Z3J+F?I^@*#LO4S/#W_ "53Q?\
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MY)G'0#(^5?6N]K.L[M._ZETU96"BBBL30**** "BBB@ HHHH **** "BBB@
MHHHH **** "JFJ:99ZSILVGZA")K68 21DD9P0>HYZ@5;HH3:=T&XB(L:*BC
M"J, >@I:** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **@N[.WOK=K>ZB
M66)NJFBVL[>TMEMK>)8X0,!!TIZ6 GHI"JG;D#Y3D>U1K;PIG;$@W')P.II
M2T4QX8I 0\:L"03D=QTIV!C&* %HHHH **** "BBB@ HHHH **\W^*<^GQ:C
MX436+V2UTJ2]E%TZSO$"OE,1ED(/WL5F:!<Z.OC[2(? NJ7U[8.DQU9#<RSV
MZ($_=L3(3A]V ,&@#UNBO.M/^)MY<>&&\27GAYK;2Y$"6I%VK2W$YD\L(%P,
M*3GYB>@SBM72?&5U)K]MHVMZ?:V=Q>1/+:R6MZ+A'V %T8[058 YZ$'G!XH
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M 5UD5_!)!),Q,*Q-M?S1MVGC_$59K"O',>FZI(OWDNE8?4;"*T.(TO[4L/\
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M&2<9"$\Y':NVHH \WO;?Q!XJN+*V\0_V;8Z/;W"7,T%EYT\ERR'<J$LBA5R
M3U)Q69J/AF[NM;UR>;3M*U1[^1FM-2U$2LUE&5 $8A,9!V\D;2,YY->MT4 >
M->(@=&^'7AK38+Z&+Q9IAABL40,3*[#R7"Y )4JQ)X_AKTC0_P"S-!T*QTFV
M:7R;2!85/D/\V!@D\=2>?QJKK.M:59>+]%L9+""YU.<LL<Y5=]NA[@XSR0>!
MCH:KMX[4:MY/]E7']FB\^PF_W#;YO3&WKC/>LW5@G9L[(9?B9Q4HQT:OTVV_
M31;OH<P]MXJ/C"[UZXT_1]1='*:;]HN9U%I#T^5!$0';JS=>W2IO%-MXD\0:
MCIADL],N=*@@62XTZ6XG2.6Z]6(B.]%[ X!/)':NILO&,=QJ-U#<6AM[2-)Y
M(K@R [UA;;(2N/EYY'M6UI-Y-J&DVMY/;_9Y)XQ)Y6[)4'D ^^,4XU(RV,ZV
M%K45>HK?=_737MU,W1-9O'L3_;5M;6MP'PD=GYLJ;,#!R47!SGC'I6E_:UG_
M 'I?^_+_ .%7:*LYR*WN(KJ$2PMN0DC.".0<'@^XJ6J6F_ZB;_KXE_\ 0S5V
M@ HHHH **** "BBB@ HHHH **C:>%8GE:5!&F=[EAA<=<GMBHK+4;'4HFEL+
MVWNHU."\$JN ?3(- %FBBB@"FG_(8N/^O>/_ -">FZ8<K='_ *>7_I3T_P"0
MQ/\ ]>\?_H3U#8,%%VQ4G;=/SZ>] $&O:F^G64DI7:B'YFW#IV['C/';K7!Z
M7X^U"[NRLZ E6)(4E5QQ@9Y_+KCGO73^,]2M;+2K@2,Y6=3&P7D,<9QZC_ZU
M>2V]]Y=]'<7$<L1EE4@2 ,H''0<@=",\'WYKZ3+,'3JT&YQUZ')7K*$TG*US
MW2VO!?:1)<(P='B)#JI"MQVSSBF:+(\?A33G2)I&6QB(4'EOW8X%9NB7JW7A
M]G<*I$.0^ NXX.1CMV_.I+._AL?"&FSO+L1+2$NV3D#:HX_'^M>'5HM57!(Z
MHM6NSF/#BZTVMW5QK?A^Y%UJ.^-[YI 4MXL<(J]AT[\U)X=T;6CJ6@V=]I[V
M\&A"?=<%@5G+<+L_#FN=OO'%\^JM-8E@D;;F4G&>>N?[N!T^GKBNOL_'EH8[
M7?(_F$9D3&< C=UZ'C';OUK6ID->E&+W_J^IZ+SY59348I75NNFCCI=_RR:M
ML3^(K'4M3O=2>R@DC^PV+I:$#;YMQ*/F93W(0;<^K&KW@JWGMM-O ]O<VUJ]
MVS6D%UGS$CVKU!)(^;<<&MRRN5NK2.9 VUUR"V.:LUYSH\L[O<F>.E+#^PLK
M:?U]^OE=]PK O_\ D$ZO_P!? _DE;]8%_P#\@G5_^O@?R2M#A-FS_P"/*W_Z
MYK_*IJAL_P#CRM_^N:_RJ:@ K.U__D6]4_Z])?\ T U=\U5=4+ LQ.*H:X6/
MAO5,_P#/I*.G^P:=@,[6]7L--T:RMM3-Q%:7R>0]S$<"'*]SU&>Q%8'AK3M+
MU3P3(=5AW:787,YM)SF-F@'\1*XSD%@?7O7<V\4<^FP1RQK(AB7*NN0>!VHE
M^R- UM)'&\)3#1E,KM]QTQ6+I.4K[GH4<;&E05.*:=T[I]K[=G9VWM8\V.M:
MGH@BN(C#;2WL:Z@\#Q@F8-*D:0+Z;8]O3G->IU6:VM;DQ32VT,AA.Z%FC!*'
MU&>A^E61R,TZ=-PO=DXS%PQ"BXPLU>_Z+Y?\#8****T.$IS?\A>T_P"N4O\
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M.A4P[I5$W*RLWWOK^%E\BU1116QYA2TW_43?]?$O_H9J[5+3?]1-_P!?$O\
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MO7:^7S'#1P]7EB>K3ES1N%%%%>>:%+3?]1-_U\2_^AFKM4M-_P!1-_U\2_\
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M5T/-IXJC[9Q3U.FU%U%LBQQC?$=LJ%MF)/X<D]01T^G'I7&ZCJ,WVN2)55G
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MY'7U':M>]AMA;SL;:W+,I(#1*21Z^]<-JTT-N=ZPQ-N+%7:)<*HX/;&<#O\
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M.Y>W4J/+ #%B<C<"3G_]9'O7N(Z5\KGJMB%K?0^CPDU.DI(****\0Z2EIO\
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M=-Z2LS8A'R0PH" ?F//I_P#7Q6%K)7#1LA=LE@"."<^GXUIV>I1_9 2> O\
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M/7CJ.M>7PQ&V75WW:/8J5XU\WJ2@]%%6.]HHHKN/2*<W_(7M/^N4O\TI+O\
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MXKV"P0QVD:-C<J@-@<9P,XKZ3"^U65T55WU/:X?2]G4Y=KEJBBBLSZ$IP_\
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M6E3V.QHHHK0]TS/^7C5O]U?_ $"I+4*VG6H=B?W*\*P Z=:C_P"7C5O]U?\
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M&1]GC_\ 0GJV2,8/?BJ<J74>H//##'*CQ*GS2;2""Q]#_>H$^H=[*+_P(_\
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M4H0Q4;OESD[?IQGID5YS/IEUH]U)Y9DW.^$(C8*%XQST)(YY]NE>Z.!A0C8
MXP#Q6;<:7#=DK-$FU6W*P(#,00<Y_/\ .NC#9ARP=.HKQ9AB<)3Q$>6:/&K>
MPO+RYCGO $0OAA(-K@YX!7@Y;'!Z5ZYX4LX+'3(X8T*L%P1QCZ#&>.E3#1+4
MRQOM5'12"0,DY[%NXZ\>]:-M"+= A96P/O!0OX8%+&X^->FH15DN@87"0PZY
M8%FH;O\ X\I_^N;?RJ7</4?G4-VR_8Y_F'^K;O[5Y)UE=O\ D -_UZ_^RU/$
M%-G%NSS&!D=>E0-_R+[?]>O_ +)4MO<P_9(L31YV#^,>E" 8^U@ R*T:NIRI
M _$\]CS^%<QXD\/2ZH TRH&S@E5&Z88;@#MV_,UU<DML8SF>-<]3N&.G\JB<
MVTQ0^?$R@#!#^GX\UU4,1*E+FB3**DK,\JTSP2R1H+I?*VN$B$V[&23P&/?Z
M]_K6[J>CI<0&TB5"K,?);R/,$9[G/3)YY]37;[+,%2?(*YR=\@.T^U121V4M
MRV9HLX  $@&WG/3W]?K7=/-*E2?-+H9QHQC'E2/"YTU'3;A8X@TA,A+ILP0,
M<%NYW<D8'-0K%J6L2D1OY4D:(V-X8N3VQC&!W%>NSZ-8R7DAA8(K%2SAD*I@
M<#!SP 3S^53Z=HUCI[LWFVLI4DH^X%MI/(/KT'Y]J]3^V*2CSJ*YCSWE5%U?
M:VU.8\!Z9+;ZV3-!&6CX\Y@=^X9SQT'4=,CGVKU&LZWBM(45%DB55(*C?G;]
M#FKGVB#_ )[1_P#?0KY_&XGZS5YSTZ<%"-D2T5%]H@_Y[1_]]"C[3!G'GQ_]
M]BN,LKZ;_J)O^OB7_P!#-7:I:6P:VE92"#<38(/^V:NT %%%% !1110 4444
M %%%% !1110 4444 %0WEU#8V5Q>7#;(((VED;T51DG\A4U4M9T]=6T/4--9
MMJW=M) 6]-ZE<_K0!QFGW?CSQ+I,>OZ?>:5IMO<IYUGI\]JTI>,\IYL@88+#
M!^4<9I-4\2>*)Y?"-C:PP:+J&L?:!=1WD/G^2T:;L *PR#@XYZ$5#H/CB+P[
MX;M-$US3-5BUK3X%M3;0V,DHN2@VJT3JI4A@ >2.M4M9U/5;74_ >N^)-.DB
MFB>\>[BL8'F\C?'A%(7)SR ??- &[%KGB3P]XBTS3?$LFGWMCJDA@M[VTB:%
MHYPI8(Z%F!# '!!ZBNWKSF[OW\?>)?#Z:;IVH1:9I=Y_:%S>7=L\"EE4A(T#
M@%B2W/& !7HU !1110 453O]+M=36,72RD(25\N9X^O^Z1G\:I?\(KI/_/.Z
M_P# V;_XN@#9HK&_X172?^>=U_X&S?\ Q='_  BND_\ /.Z_\#9O_BZ -FBL
M;_A%=)_YYW7_ (&S?_%T?\(KI/\ SSNO_ V;_P"+H V:*QO^$5TG_GG=?^!L
MW_Q='_"*Z3_SSNO_  -F_P#BZ -FBL;_ (172?\ GG=?^!LW_P 71_PBND_\
M\[K_ ,#9O_BZ -FBL;_A%=)_YYW7_@;-_P#%T?\ "*Z3_P \[K_P-F_^+H V
M:*QO^$5TG_GG=?\ @;-_\71_PBND_P#/.Z_\#9O_ (N@#9I"H88(!^HK'_X1
M72?^>=U_X&S?_%T?\(KI/_/.Z_\  V;_ .+H UO*C_N+^5+Y<?\ <7\JR/\
MA%=)_P">=U_X&S?_ !='_"*Z3_SSNO\ P-F_^+H UO+C_N+^5'EQ_P!Q?RK)
M_P"$5TG_ )YW7_@;-_\ %T?\(KI/_/.Z_P# V;_XN@#7\N/^XOY4GEQ_W%_*
MLG_A%=)_YYW7_@;-_P#%T?\ "*Z3_P \[K_P-F_^+H UO*C_ +B_E1Y4?]Q?
MRK)_X172?^>=U_X&S?\ Q='_  BND_\ /.Z_\#9O_BZ -;RH_P"XOY4>5'_<
M7\JR?^$5TG_GG=?^!LW_ ,71_P (KI/_ #SNO_ V;_XN@#8"JOW0!]!5>;3[
M.XE\V:UADDQC<R G\ZS_ /A%=)_YYW7_ (&S?_%T?\(KI/\ SSNO_ V;_P"+
MH N_V3IW_/E;_P#?L4?V3IW_ #XV_P#W[%4O^$5TG_GG=?\ @;-_\71_PBND
M_P#/.Z_\#9O_ (N@"Y_9&G8Q]AM^/^F8I?[)T[_GR@_[]BJ7_"*Z3_SSNO\
MP-F_^+H_X172?^>=U_X&S?\ Q= %S^R-._Y\;?GC_5BD&BZ6,8T^U&!@?NAT
MJI_PBND_\\[K_P #9O\ XNC_ (172?\ GG=?^!LW_P 70!<&CZ:.EA;#'3$8
MI?[)T[_GRM_^_8JE_P (KI/_ #SNO_ V;_XNC_A%=)_YYW7_ (&S?_%T 7?[
M)T[_ )\K?_OV*/[)T[_GRM_^_8JE_P (KI/_ #SNO_ V;_XNC_A%=)_YYW7_
M (&S?_%T :<%I;VRLL$$<:N<L$4#/UJ+^R]/ P+*W_[]"J/_  BND_\ /.Z_
M\#9O_BZ/^$5TG_GG=?\ @;-_\70!>_LRP_Y\K?\ []"C^S+#_GRM_P#OT*H_
M\(KI/_/.Z_\  V;_ .+H_P"$5TG_ )YW7_@;-_\ %T 7O[,L/^?*W_[]"C^S
M+#_GRM_^_0JC_P (KI/_ #SNO_ V;_XNC_A%=)_YYW7_ (&S?_%T 7O[,L/^
M?*W_ ._0H_LO3_\ GQM^/^F0JC_PBND_\\[K_P #9O\ XNC_ (172?\ GG=?
M^!LW_P 70!>_LRP_Y\K?_OT*/[,L/^?*W_[]"J/_  BND_\ /.Z_\#9O_BZ/
M^$5TG_GG=?\ @;-_\70!>_LRP_Y\K?\ []"C^R]//6QMO^_2_P"%4?\ A%=)
M_P">=U_X&S?_ !='_"*Z3_SSNO\ P-F_^+H V-HV[<#;C&,<8JO_ &=8_P#/
MG;_]^E_PK/\ ^$5TG_GG=?\ @;-_\71_PBND_P#/.Z_\#9O_ (N@#0_LZQ_Y
M\[?_ +]+_A1_9UC_ ,^=O_WZ7_"LF;P_H-N\23O+$TS;(U?4)5+MZ#+\GV%5
MI+#PG"CO+?HBI(8F+:K( KCJI_>?>]NM &__ &=8_P#/G;_]^E_PI/[-L<Y^
MQ6V?7RE_PK)DT'P_%Y/F2R)Y[!8=VHRCS">0%^?D_2F3Z/X:M8Y)+BY,*1,$
MD:34I5",1D Y?@X(.* -K^SK$C!LK?G_ *9+_A5.P?0=421K 6%R(7,4GE*I
M,; X*D=CD=#55] T&/:7>5=R&0;M0E&5&,M]_H,CGWKF/"/PZ\,^%_$TVI1Z
MJUUJ]V[SQ1FYV@1L2>$#9<8[MGIGB@#O?[.L?^?.W_[]+_A1_9UE_P ^=O\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M\$1LT$;%5$@8Y<DCYL],\=*WA+KOB7QI;Z9<ZK?Z/;OX?@O;JULV576=I&!
M<@XQWQUP* /0KN^M;$0FZN(X?.E6"+>V-\C<*H]2?2K%>*7[:AKGA[P['?ZM
M>M/9^+3IPN(V5'D59'59&XQO 7@^YZUK^(M0N+C6=6@M=;\2W4MDH2*'18%6
M*U8)G]](WRNQ/)&>!QB@#U2BO+M*UG5_&4WAK2IM5N;!)]"&J7D]D1'+.Y94
M"AL': <L<>H%9MWXF\1:)I>NV U2ZU"['B"#2[:Y$2--'$\:M\J\*SXR.< L
M<T >QUF7_B#2M,U;3]+O;Q(;S42RVL; _O"N,C., \CJ><\5QOA.[UV#Q5':
M>1XDDT:>W<ROKBQ[X9E(P493DJPR"#T.,5#\0M"M_$OCOPSI=PS1^;9W[13(
M<-#*HB*2+[J0#0!WUUJUC9:E8:?<3[+J_+K;1[2=Y1=S<@8&!SS4=CKVF:CI
MDVI6UVALX'D269P45#&2'SNQP"#S7FMGK]SJWCCP98:LJQ:[I=S>6]_$.C'[
M.=LJ_P"RXY'XCM7,V?\ :A\._:M5LUE\%V6MW)OH(9"9+@&9_P!XX'6)&VY3
MO@D\"@#W/2-8LM=TV/4=.D>6TESY<C1LF\#N P!(]^]7JBMG@DM89+9D:W9
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MU9Z="\,5[IEVJ7UOG&%Y*AXR.#Z8%.\*> HY/#FM6VMV,UO'JM^;N.![DO/
M %".T@)_>Y7<2"<$XKT6L/4O%FE:1</#>F[0JRJ66SE9"6Q@!@I!)R!P>M73
MI3J/E@FWY";2W(M&\'V>DZHVJ2WVH:E?^5Y"7%_.)&BCSDJH  &2!DXR<=:O
MW6AVEWKVGZS+YGVJPCECAPV%Q(%#9'?[HJ;3M3M]4@::W6=55MI$T#Q'/T8
M_C5RE*+B[25F,P[OPGI-YXLL/$TD++JEE&T22(V ZL",,.^,G'UJ?2/#NGZ-
MI4VF6Z-):SRRRR),0VXR,68'CIR>*U:*D#*\/:!:^&M)32[&2X:UC9C$L\F\
MQJ3G8#_='8&M6BB@ HHHH *.HR*S/$-I?7N@W<&F7#P7Q3,#I($PXY&25;CU
MXZ9K-\#Z%J7AWP^NGZG?->2Q.4C?<-OEKPFU<#;P!D$GG/- '2T444 %%%%
M!1110 5P&K^)9K\/(;;5+;2K>5DFEMKB.+S,/LP3]\/G.(Q@D$'/05W]8OBN
M>2R\*:I=6S^3/% TD<BQARK@<$#U]^W6@"$^$[:(![#4-4LYQTD6\DD!/^TL
MA96_$5;UO7+/PSH4VI:I/^[@3DJOS2MCHJ]R?2L/PY;ZFNI0R74&O)&8R2;S
M4()HLX]$.3[&MCQ; ;CPCJZ)"99?L<WEJJ[FW%"./?G% %?4O%D&G/S87D\,
M4"7%U-$J[;>-LX+9(ST)(7) &:F@\0-<:I=V\>FS_8[21HIKXR1B-6"!CQNW
M$<@9Q7-^(-42>>P\.78N;;3C;QS7TRVLK^<O:!2JG&<?,>PX[\5;W2;:ZUN:
M#2]*O+/5Y[JX-W<.',<D#QL-Q?[I5B4PHY!'08- '7:)XE@UJ9H1:7-JYA6X
MA%P%'G0L2%=<$\<=#@C(XYK;K@M(AOM9N8S:&[TN2UT=+*2XDML-%/N4E5#C
M#8"=>1\PYK>\(3WTVD3QZC>M>W%O>W%N;AHU0N$D*@D* !P.U &_1110 54U
M33X]6TJ[TZ:26.*ZB:%WA;:X5A@X/8X-6Z* *EGIMI8:5!ID$2BS@A6!(SR-
M@&T#\JY:/X9:/;1Z?]DOM6M9M.@>WM)X;K#QHSEB.F".<8(/'TS7:44 <L?
M&BG0TTP->*R77VT7PG/VG[1WE\SNQZ=,8XQBG0> ](%GJ<%^]WJCZG&L=U/?
M3;Y'1?NJ"  H!)(V@<\]:Z>B@#FM*\%66FZI#J4]_J>IW5M&T=L^H7'F_9U;
MAM@P.2."QR<=Z@;X>Z0-%TO3;>XO[4Z4[O9W<$^V>(N3N&[&"#D@@CI7644
M<I#\/-$BTS6;!WO9X]9"_;))[@N[LHP&W'H>_I[8XIUQX$LYS9SIJNKP:C:P
M&W_M&*Y GFCSG;(2I#C/(R.*ZFB@#,T'0;'PYI@L;!9-A=I9))7+R2R,<L[L
M>2Q/>ETS1+32;K4KBV\SS-1N?M,^]LC?M"\>@PHK2HH Y2'X=^';>PURPCMG
M6TUJ7S;F(/A5;J"F/NX/(]Z=IW@2PL-9MM7EU'5;^_MXGACFO;KS"$8 %<8
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M4FEN/"&CS3RO+-)91,\CG+,2@R2>YK4N/^/:7_</\JR/!W_(E:'_ ->,/_H
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M !1110 4444 %%%% !1110 4444 %<[X+_Y 4W_7_=_^CWKHJYWP7_R IO\
MK_N__1[UTP_W>?K'_P!N%U.BHHHKF&%<SXW2XFTFW@M[-+OS;@*T<WF&(_*Q
M D5.64L%7!^7)!/ KIJ\X\<'P\/$"_:8=3;5/(&&A#>1MR<;MWR>O3F@#9^'
MTCOI-T#;+;1K<8CBBCDCB3*J2J+(<KAB00/ER#BNNKEO A4Z/,0+$?OC_P >
M@DQT'WM_\7KCBNIH CN/^/:7_</\JR/!W_(E:'_UXP_^@"M>X_X]I?\ </\
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M<TG=EI6"BBBH **** . \8KX3.L,;^WN&U7RE^=(Y"FWMN."A_4UM>"/L_\
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M'-'\)/,]]H=IMDBDW,X\U/G(ZD-C<<=^: .JHHHH YKXA_\ ).?$?_8.G_\
M0#6UI7_('LO^O>/_ -!%8OQ#_P"2<^(_^P=/_P"@&MK2O^0/9?\ 7O'_ .@B
M@"W1110 4444 %>9?$_X@:1H@BT9UEN+X3P7$B18Q&JR*^"3W(7@>]>FU\Z_
M$[P=>:OXRU/5=%4W=OYL,%RQ8*$N&P@123\W\&?0M@U[>08?#UL7_M#LDK]M
M;JUV9U6U'0]CTSX@^&=3T6+5%U6"WBDR#'.X616'4%>N?IFI/^$OBN>-*TG5
M=1ST>.V,49_X')M'Y9K'^&7@/_A#]!(U!()-3GD\V1E4-Y0P $#8SV_,UW=<
MN*6#I5Y1HIRBGHV]/P5_Q''F:U.<\[Q?>_ZNSTO2T/>>5KB0?\!7:O\ X\:/
M^$9OKOG5/$FI3@]8[4K:I_XX-W_CU='17/\ 6I+X$H^B_5W?XE<O<Q+/PCX?
ML9/-BTJW>;_GM./-?_OI\G]:Y7XF>$- UBWMK^ZA"7J7%O;F2*38QC:55(([
MX#''I7HM9-YX8T+4+I[F\TBSN)WQNDDA5F..G)K;"XVI2KJM.<KKMOZ;["E%
M-6)-"T?3-!TJ+3M)A2*UBZ*IR2>Y)[DUI54T_2[#2H6AT^SAM8V;<R1(%!/K
MQ5NN2K+GFY7;OU>XUL%%%%9C"BBB@ HHHH Y?QOY7V"T,EK>2?OR!-:%A)#E
M&'&T');.P C&6YQ4O@V&:#3+E+FTDAN!<$2RR2-(9V"J-V6 /  3H!\G'&*9
MXT@LIK"T_M"Z,=JDY+P!7?SQL;@*GS$C[P[?+S2^"[*&PTV\BADMB#=NQBME
M<+$=J_+\_P W( ;_ (%QQB@#H6@B=65HD8,0S J#DCH3^0_*L/7/^1E\,?\
M7W-_Z3R5T%<_KG_(R^&/^ON;_P!)Y* .@HHHH **Y7Q1X;T8Z)K&H/8Q?:OL
MTLOG9(;?L.#G/7-6--\*Z!]FM+F/38/,"HX<$GYA@YZ^M=7LJ/L^?F?;9?\
MR1-W<Z*BBBN4H**** "BBB@ K'\50O<>%-4@2XCMVDMG42R.$5<CNQ!P/>MB
ML_7;Q-/T.]O))Q L,18R&+S=O_ >-WTH Y'PG/8'5[>"#[$)EB/RP^()+LX
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M_M,K%58'@V\GZ4 =)67J'B31=*N?LU_JEI;3;0WERRA6P>^*U*0JI.2H/X4
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M"J2<A 1\[  DC([<Y-1V_BB2YUG4+98+1;.P=UFE:[_?85 Q81;?NY.,Y[4
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M34TGD"HGV<W.QB<X \OY2>OO0!)X(\IM.NI4N[2[DDGS+/;S22ESM ^9GYR
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MTV_RI]0DV,4?9IEP=K#J#A.#[5\XI22LF;'9T5Q__"S/#?\ >U/_ ,%5S_\
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M@,G^T8[?3=,U%-&MHV5+IM5>:U)[+&K@;Q[C@=C7H]9-AH*:?=+.NI:G/M!
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MN1N^FW0N$3&Y@K <].H&?PK1KD/"-ZQU&ZTVUU;^U],M[2!X[G"?NW;<#'E
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MR0- \$30M]Z-D!4\YZ=.M%LDT=I"EQ(LLZH!)(J[0S8Y(';)[5+0 @ 4
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M0!4U2SDU#2;NRANGM9)XFC6=!EH\C&X>XKSOX5?#.]\"7FJ7-QJ#,MQ(T2P
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MB@ HIJR(Y8*ZL4.U@#G!ZX/YBG4 %%%% !1110 4444 %%%% !1110 4444
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MK>8#N(/!(SGWK-TV/4;"YT_6K_1IIH(1>1JMO9[) SNK+.T(R59PK!L<C.<
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I** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>g4i5nix4zlkt000029.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g4i5nix4zlkt000029.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &H J # 2(  A$! Q$!_\0
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M+]I&]KG8450UPE= U(J2"+64@@X(^4UY)\(M4FM=/\1WMQ)-<BVMTEV/*3G
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MG<_Q?, <-Z9KU>BE]8]]2:V5@]E[K29X-H6DWUO\4]+NVT?4[2TD<.INMTK
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M6NLWDZIY,)%U(Q^ZR<,3^6?QKB?%/Q4T_5?#=_;Z1_:=K<$JL-T$V*2&!(#
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
MX_6/ <>K>-;'Q(=1>)K3R\0"($-L)/7/&<UV%%%5*<I))]!**6P4445(PHHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#BO%7@&X\47TCOXB
MOK:RD"[K)5W1Y7OC/7\*Z;1='M-!TBWTRR4B"!=HW')8]23[DU?HJW4DXJ+>
MB)4$G=!1114%!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MVI#0*2?D(&!T-:5% &7JWAS1]=*'4]/AN6CX5F&"/;(YQ4UOHVFVFFMIT%C
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M  9H^HZ)H;6NI3*\C7$DL<2S/,MO&QRL8D?YG ]3ZT =#1110 4444 %%%%
M!1110 4444 ,EEC@A>:5PD<:EF8G@ <DUE:-XJT'Q#)+'H^K6E[)$ SI#("5
M![X]/>KFK6\EWHU];0@&6:WDC0$XR2I KS&'P[XKGTW32_A^"VFTC1CIXC:_
M :^+>4K /&044"-B,D<L/<T >M5G:CKVDZ1<VMMJ.HVUK-=ML@260*9#[9^H
M_.O)QH/B/3H](TB2XN8I]1O)[22+[6TKQ6+.LH?<#P5"NN?]O'I73?$/PEJF
MO7UHVDPNIEMFL[B=;E$"1F1&PZ,I++\I.4(;( Z&@#T.BD4;5 SG QFEH **
M** "BBB@ HHHH ***;(ZQ1M(YPJC).,T .HKGI_$PCM[N18X@T,XCC21RIE4
M@8(&."22.?2J-SXZB@M+<K:F2Z<XDBW;0I'7GVZUG*K"+LV.,925XJYU]%86
MD^+=)U0^4MY$MPH7<K956)[*6 W<\5N @YP0<'!]JM--70--.S%HHHIB"BBB
M@ HHHH **** "BBB@ HHHH **SM8!,=H SK_ *7%G:Q&1NZ'':M&@E2NV@HH
MHH*"BBB@ HHHH **** "BBC..M !1534K^/3;)KF0$@$*H'<GH*YU_&7V69#
M<Q)Y3\D+U4>H]:QJ5Z=-VDRXTY25T=;12*P=%93E6&0:6MB HHHH **** "B
MBB@ HHJ&[NX+&TENKF01PQ*6=SV%&PFTE=DU%<&OQ3TAR)5@F%KO"-(X*L,]
M]N.<8R>>*Z%?%NC26C74=TTD2Q^:3'$S'9D_-@#./E//M65*M"K?D=[ I)[&
MW17&7GCV,WT$>E1175LXYG9RHW?W0,>F#GWKH]+U:'5(I#&-LL1VR)G.T]N>
MXJ5B:3J^QO[W8B%6,VTNAH4445N:!1110 4444 %%%% !1165K&OV>BJK7))
M!^\%ZCTXII7$VEN2WVMZ;ILJ0W=W''*_W4)Y-9DOC?1H[>1Q/F50<1[222.G
M3UKS_7[G^TM36_FMA)YARBG^ >GUI3$9(]@MQ$NW(QZUU1P\?M,Y?;R;:1U]
MA\1M,N447"-!,QV^63WS@5V2LK %2"#R"#7SQK C"./(5@@SD=Z3PEXMO?#.
MNVDU]]I.ERG82S'&P]P/:JGA5;F@Q0Q+3Y9(^B:*HZ9JUIJ\!GM)-\8. ?7W
MQ5ZN([ HHHH **** "BBB@ HHHH ***@O+E;.SEN71W6)2Q6-<L<>@II7=D)
MNRNR>BN8M/%!N+A;A%6;392%5T'SPMZ..U=,K*RAE((/0@T--.S!--70M%(2
M%&20 .YKG+[Q*UO=-)A8=/@;$LT@YD/]U!W-"3;L@;25V=)15:PO8]1L8;N)
M)$25=RK(N&_*K-#33LP335T%%%%(84444 %%%% !61K\UW;VD<UE*JR1OED8
M_?7!&/S(/X5KU@>+;.&ZTK,@FW(3L:&'S&4D$9XY _P%3._*[ <'="^W2W,K
M))<O(&4NQ.QE SM)R?NYS^8K&FB,4-K#(TWE@N%_O1J_][W/IUJR^QK=&,JI
M<Q$1Q[X6,CJ#DE,GJ<C\*JR2%XE2TE$XM07<+D+*_&2#V_GG->(V^;SZ^1ZL
M$N2^MNFMFV_ZTU_ @N<VS0W"KLCA4-&6;YAD?> _D>M>@^!->65!974TAN9V
M:2-&3)([L3UY]_:O-IXK62"&0,D8MLL\6XY<_P"]Z9/X5WGPVMFBO+EY?*W^
M7C=C!;.#A?8>U=.%E-26]F3C(4^5[<R?S[]_/<](HHHKU#S HHHH **** "B
MBB@ HHHH K7D5U(J&TN5A=6R0T>X./0^GU%<QXB\1R^&U2_OHI4DQY:QQON@
MF[GW5O?'YUUY(52S$ #J37F_Q3C.M:-:K9!YHX9\S2QJ2B@C'7H>:TI)2DD]
MCCQKY*3E%V?]?U^9P^K^.];\1">;[2EK;Q$-%%$VW:V1@YZDUK>&_B]=S1C3
M=793(2%%Y"F7Q_N]"WO7E.IAH+DPQR[D4]0>OO5K1M&O;V^LVLH7N93*I,<0
MR1@Y_I77.,&MM#RJ=2HFY\WQ'U#!%J4EK'%'(;6-0,23'S9F'OV!/XUK54M-
M1M;PE(I?WJCYHG&UU^JGFK=<![T$DM'<****"PHHHH ***ANY'BLIY(QF1(V
M91ZD#BA@<]JGB(O>-8V,FSRSMEF R<_W5_J:S9;59D<S7!9\=99"23^=8GA^
M= 4>5LLR[LGN2>3]:L74,UQ^[N+E1#D[@@YD^I[5X<\1SZR/05-0T1B>();^
M!3!]H<P[PVTN2!Z'%:_ACPNNML;F[OMRQL \*CYF';GL#6-JDOG0N&'W<J/0
M@=*W_AZ\JZS/&,E!"-WIFL</:591FKFE1M4VXGI( 50 , # %+117T1Y8444
M4 %%%% !1110 54U*QBU+3;BSF1725"NU\XSVSCGKBK=%&XFDU9GCNM>&M2T
M'2_,>PT]8F/EM- I=US_ +WW0>F1ZUZ'X6&GIX4MQ!:"U@2(B6*50".I;=['
M)/XUN3(LD+HXRK*0>:\3L);_ /L#Q!Y5V5@!C\Y6R6?+8X/;W]:Z<)@HU$[.
MUK?BSRZ]58*:LKII_@KFA:Z1?Z[XFOELK9+"!B9")$S&H/3';)Z\5Z-X<T:7
M1K*1+F2&6XE?<[PQ!!C& /\ /K5#X?1)'X/M64'+L[-SWW$?TKJ*PJT8TZK6
M[6ESIPD$X1JO=Z_>%%%%2=@4444 %%%% !1110 5YI\3G:WD@D-U*0^,6YQL
MX[COFO2ZY+Q_:VL^A RZ=)=2&50GDH2RG\.<5I1DHS39E7CS0:1YI!/)<Q1S
MR3- L9W,S' V_P"-6[G4?-C"6ER W&TR _,O<_6N+DNIK?4Y;.:*X01N66!P
M>!Z,*FO-6N9HX9/WBL,F+"92,'J<=Z]=+5'F3LU9,WKJZ%UYFVW,RH?*ED4<
MJ<9  [FN2U&ZG%JMNET\EH1\JR+AA[&I[W4HA%*899/.D8,>P7\!5G1?#4OB
MUX8[.YS>%B)(V4[8TS]XFF[1]Z6Q23M9,]A^% N#X,@>X@6/)Q&^S#2+ZD]Z
M[FL+PIIE]I&BQ65[*&\D>6BJH "CIC']:W:\6;O)L].":BDPHHHJ2PHHHH *
M*** "BBB@ HHHH YS5=%FLDGO= AACNI#F>)EXF7TQT!K,TV[NM(BM;DQ20V
METY5[:<8,3=R,]J[:N=\5*'_ +.4]#<#I5RGS1L]^Y$:?+*ZV[&?J=Y<ZO\
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M&[9C]3GUKSZ/X5ZK>3WUG;ZF$@MGVH9HR-_Y5W;_ !)LE)_XEMXV.N-O'ZU
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MFH6Y*G<ZG<0>3CI67J%DD"9A+Y_VN:\7$+-?:/V+CR]._P SI@\/R^]>YO\
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M6N ?POXADC8Q>*V&#QYML&&/SKLTN'ND;#!3TSC(%4G355'RR6#$#DD, ?\
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M V&F3Z=:VMPUW,T;BX#8  !XP1ZUZ!!(9;>*0@ N@8@>XKY2^)Z_$5;+3?\
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MLZX)]D-4)]-O;5L7%I-'W^9#1)1G&S"$I4Y71]%_!2[N)M:U""9]R16HV?\
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M HHHH ***HZOJ]GH>FR7]](4A0A<*I9G8G"JJCDL20 !ZT 7J*YBV\>Z+/Y
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MB0+ESOE)VMQCMR:]&HH S=!O+B^T6WEO(7ANU!CGC8=)%.UOJ"1D'T-:5%%
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M9X?*C<&1C;-F53)$O&&('$C'.3]WZUO>(+\AM-87LMMI<Q<SW5OU!"Y0;L'
M)SSZ@#O0!S%J/&,*/-*NH_:9_+9PJHP\T1 *,'@1EPV_'L>,UL:8WB5=1TTW
MK7CK*TAN$*H$C&]\<@=-H3 R#WR<G%3_ (2?5[6Z\L@O%S@SV[+))B)6R5R
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M!4.UFW# /H?>@#A],N/%!6W&HKJ(A$\@5HHHS(W,93?D#Y,&3)P#Q]*I6?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MJ_\ /C:?^!;?_&Z/.U7_ )\;3_P+;_XW5^BIYEV'9]RAYVJ_\^-I_P"!;?\
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M2@HHHH *K:A_R#;K_KB_\C5FFR(LL;1N,JP*L/4&@#P)9+O1/ AADW2:;KD
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
C%%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>g4i5nix4zlkt000027.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g4i5nix4zlkt000027.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $Q M # 2(  A$! Q$!_\0
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M2RU6SN+B($R1Q3*S*!U. :\N\,VFE7FN0W:ZIJEY/!831O;)I ML1E,%"R@
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MJFGV$]MI-]+;FSB,)0N58;G5,9 _"NC;2X-/\=^!&LK%;=392K*8HMH_U?\
M$1[D]:3H12W[_E<I5)=OZN=CXHU+4-.333876F6YFO$BE-^Y7>AZJGJQ[58N
MO%.@6+RI=ZQ90-%)Y4BR3*I5\9VD>N*Y?XI122Q>&_+C=\:Q"3M4G Y]*Q;3
M2+>[\0?$B:[T]9G$>(7DAR>8V/RY'J!T]!2C3BX)O^M0<VI61ZO'(DL:R1NK
MQL-RLIR"#W!KAX?&NMZY=7C>&- AO=/M)3"US<W7E><XZA!@_F:O_#M)&^&^
MC1R[U<VNT[@01R1WKE/!FO1> ]-NO#VO6=]%<P7,CPO%:O(MPK'(*E0>:4::
M7,DKM#E)Z=$SOKCQ/I.FPVW]L7UKIMS/&KFWN)U#*2.1UYP>,U9N=;TJS$!N
M=1M81<(SPEY5 =5&20>X .<UY3XQU.ZN]>OX?[/CL$N;!#"\FD&XGO"R?<W=
M$*YQ[8JO96!O+3X807=HTT0,XE22,E0 1@,".G Z^E4J"LFW_5KD^U=VD>OV
M.LZ9J=F]Y8ZA;7%LF=\L4H95QUR>U1V'B'1M4$YL-4L[D0#,OE3*VP>IYX'O
M7E.HZ1>R1_$JPTFTD7?);-'#$A4.O5PH[Y&>E7-3ETWQ!X$U"T\+://'J$5A
M&DQ6R,1*!U+0[B!N;@G S^M+V$>__ VW'[5GI.G>(M&U>26/3M5L[IXAF189
ME8J/4X[4VW\3:%=,%@U>RD8Q&?"SK_JP<%NO0>M>9>$+33KOQ'IUU%JVH3WE
MK:R)]G;2!;HBE""CLJ@'VZ\BF>%?#VD/\(KVYU'3KA)YS*DT]O;[KD)Y@ P.
MI P"1Z TY48+J^GXB523/5=+UW2M:60Z7J-M>"(@2>1('VYZ9Q7/^+/%=_I.
MNZ7HNF06?VF_5W%Q?R%(4"]N.2?_ *WK67\-+RZFN=2M?*BN-/MUC6WU-; V
MK3X!^5E(&=OK_C6-\1+9=0\7_9?$AOX-!6S/V"XM(#(J7!QDOM!)[\?2E&E%
M5>5[#E-N%T=KX%\477BK2+FYN[6*&2WN7M]\#%HI=N/F0GMS745X[X%UC6O^
M$FTF#5DO+73DM'M++R[5XX;M@V0[+T4[>Y%>Q5%>'+/0JE+FB%%%%8F@4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M9H4; C3!R1R2>3TI*#:;!R2=CKZ*R)/%&BQ:=8:@U\GV74)$CM7"L?-9N@
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MT[,::>P4444AA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MZ8KT73=!T[2;R_O+. I<7\OFW$C.6+MVZG@<]!6E6DZ]V]"(TK(\6TW1)HO
ML,>I:1KB3Q:O//#-81?O[8_POL/WE/2O0O <VNS^&P_B"-TNO.<1F6,1R/'_
M  LZC@,>:Z>BHG6<U9HJ-/E=SQZ*WU/0M(\4^'[GPUJ%_>:G<S/;W,,(>*4.
M,*6?^';UYK3B\/:GIVN_#V"2WEF_L^WF2YFC4LD9V#@MT'H/I7IU%-UWV_JU
MA>R7<Y7XDVES??#W5[:TMY;B>2- D42%F;YU/ '6N%\2>%];DUVSM=/MIQ8Z
M_:6T&I.L9Q$8R-Q8_P /RCO[BO9**5.LX*R'.FI.YY1?>&M4O=<\>6UG9RPI
M=6,$5H[*5CDVJ/E5NG08J+PKI$<^K:%]NL_%ZWEARHNU46MNP7!PV/NG& ![
M5ZY13]N[6_K:PO9*]SQF#P_J ^$'B:U;2;C[=/J#O'$8#YCKO3! QDC&<?C6
MN=*U$^.+FX^PW)A;PSY D\L[3)@?)G^][5Z?11[=ZZ;_ / _R#V2/'#H.H+\
M*/"ELFE7 O8=3BEFB$!$B#>V688R.,<GVK+U9I)]:\7JXU/^PI+T?;SIT$<J
M$( 3EW(*MQSC.*]WKEKSX=^%[^_FO)]-/F3OOF5)Y$21NY90V#^5:0Q"N^;^
MM294G;0Y>2QN-;\;F^TN&?\ L^\\--%;7;(0@9L[06['D<=:Q38:KJ/@/2_!
MD?AF_M]2M[A/-N980L$85B3().^1Z5[1##';P1PPQK'%&H5$48"@= !3ZA5V
MNFQ7LK]3S:TT>[/C7QU<2Z?*8KBS2."5XCB7]W@A3WY R!6,-!U!?ASX*@72
MKA;N#4XY9T$!#QC>V688R.,<GVKV*BDJ[[=OP5@]DCQ;QC'XIU"X\1Z>UIJH
MA=R;6WL;%#;SQC!W22=2W'0<YXKTVST^2\\"V^FS;H99M-6!]XP4)BVG(]16
MY14RJ\R22M8<:=FW<\T\*:WJ_A;P]#X>U#PMJT][9EHXGM80\,R[B0=^<#KW
MK#\8Q^*K^Z\0V#6FJK!(?]%@L+)&@N$P/FDDZD\=N>PKV>BJ5=*7-RZB=.ZY
M;GF6GZ1?'QWX/N9M/G\FVT(1RR/$=L4@4\$]FY^M85SX9UF?PSX@C@TN<F/Q
M%]L6V*;?/A'78#U'/Z5[5136(:=[ Z29YAXO%_XR\*ROIGA_4K1K6Y@E9)XA
M%+<JN[(0=3MR,9_"J^G:3#=_VU?0VOBR2_.D3P+)JZ !LCB-<#+-GIVKU>BD
MJ[2Y4@=*[NSE?AWIG]F^!]*CEL?LMWY'[Y6BV/DDGYN^?K75445E*7-)MFD5
M96"BBBI&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%<
M7\0+[6K=M#M-$DO%GO+MXW2S:%9'41.V 9@4'*@\^E ':45XY<^)O$>G:H;7
M4/$8CURVBL1'I,<4;)>R2<2C&W=^*D =>E=0_CF*R\;);ZS,VC6#V+^7#J!C
M3S91* '4@G(*YP,_A0!W=%<KH-_JLFN^*+34;N.<6DL1MQ'%L6)&BW!1U)/J
M2>3Z=*\]\,>/M;B\,WFKW.KV^K7D<4#)8-=12/(6?#(L<4:M&YS@!BW/YT >
MV45YBGQ'U'^U(+<'2;A&CM3L@W^9-YT3.SQY/W$*\Y'3.<4^R\?Z_)J&BVL]
MCIQ^W6<%W(1)Y0990QQ'N?+%-HS@-G/\/&0#TNBO)O\ A:>KKX>-\]MIWG0W
M7EW.T[D5/*W_ +O]YB4Y_NMG'\&>*N7GQ U+3Y;\(ML4CN;IHS=[AYHB6$K;
MQXQB1_,.,YZ'@]@#TVBN*T'Q=JFI>)Q8W=M:I:3/>I"(PPE0V\B)\^3@Y#]L
M8(]ZR(?B.+;PU?!;VUOM=M]0FA:V9U#0Q?:C&KNN5PJJ5.21VR1UH ],HKSN
M#QYK;7.G6\FE6[RWEJ;Q/L[&16CC$GF@,I(+$K%MQG_6CKCG+M_B%KU[9V-^
M([",D7#>4DZ>5+MMO,59&W-LVL><D'ID#H #UBBN$C\<SR_#>]UTQ!M01WMH
M8H8C\\Y;9&JC<P;YF7[K,#S@UCZ=\0-5@T2RMKR2"#4(IYX+N[UB%H ?+4/'
MN1>5>1'4CK]UL ]* /4Z*\VOO'VLVD$T[1Z7#";Z\MX99@X15M]V%8YY>3 "
MXQC!X)P*8_Q'U87NI6_V"RADBLOM-M#+)RIQ&2)7W?(1O/RL%Z##')P >F45
MQL.L7OB3X<3:I;WLNGWBQRN9K>)1AHRV0 ^\$';C()'H>]8&F^--3TBTTVTO
M[U+ZYOK;3KF.2Z"I)(;B4K(JA  0@ (XR,\T >HT5Y?I'Q$UZZGT]KJSTYH+
MG[(62!9 ^+A92H!)QD&+\=V.,9J33OB!K6J2Z=;6\.F&6]GMU,RB1H[<212N
MT+C()E3R@#R/O=!0!Z917$^+$UH^+=!M]-\0W5C#?M+&\"11,F8XF<'YE+<D
M 'GITQ6./B/JL]G:S^7IFG1R7GV"66^#A(ID@=YLX(X#J$'XT >G45Y=:_$O
M7+R6XVZ196_EV'GB*ZN1$X?R%D#'+9\O+;<[1C&=W4#L?!NOR^)/#ZWTZHLP
MFDB<(A5<JV./F8'ZAB/0T =!1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%9OB"*YFT*\%I?S6,ZQEUGA569=O/1@1SC'3O7GVF>-=4TC3M
M,@O[]+^XU"RL+N*6["H[O<3".1%"  A%.X<9YYXH ]3HKS#3/B'KUS<V!N;7
M33;W+VNY8ED#A9WE0 $G&08L^^<>].LOB'K6HFRAMX-,\Z\FMEW@.RVOFB4M
M#(,@F5/+&>1UZ#N >FT5P7BO5]<TWQ1;Z19W,@77(XH;*18U;[+*DF9VY'_/
M([AG/*5FW'CW5KF9[:(00'[6B$1 F:U5;V. I,&R,R*Q88 XSC/6@#T^BO,(
M/B3JM]+9VEK#IHNYFABE#;V$$CW$D1# '.0J XZ\U67XGZ[_ &3'/)8:?YTZ
M6LJ2!BL4*S+*?WA=E'6' .X#YQUQR >L45PNC>-M0O\ QE#H][:VD$<]L)46
M%_.8-Y2.0S*WR@$D<J 1C#'.*S]5^(VIV-WK$<-I9.;3[2L<#%_,B\HH%>7G
M[DF[Y< =N3S@ ]*HKS[5/%.J'P%KMY)<PV-[I^H?8FNK=?E51-&I<!\X^5CU
MSTKGYOB1J&AZ;=&UU"#7;>*Z?[-?W*+&+F)8XV=0R[5+*SE00#G'0X) ![#1
M7*>'_$NH:MXDU'29[6&/^S RW4BAN69\P[<]C%\Q]R*X^[\87%I::T9/%,TT
M"30?8YK:*(/)))Y@\C++B,[E&0P)55R3\W !ZW15'1I+F;0["2\F@FNGMXVF
ME@.8W?:-Q4C^$G.*O4 %%%% !1110 4444 %%%% !2$ D$@$CI[4M% #?+3S
M/,V+O'\6.:1XHY""\:,1T+*#3Z* $V@$D 9/4XZTQ8(5.5BC!ZY"BI** *4&
MDV-K?W-]#;(ES=!1*_/S!1@<=!P>U6_+3*G8N5&%..GTIU% #/)BV[?+3;G=
MC:,9]?K2F-#U13AMW3OZ_6G4A 92",@C!H Y"/XB>'Y?-\B.\EFBNA:^3%;%
MI&=E=Q@#L1&WY<XII\=Z+-?:;;Z?:2W8U&2&-IUB*QQB:,R*&8C[VT [?>K.
MF_#_ $/2Y(GMQ='R9(WC#W#,%V)(B 9[!96&/IWHM?A_H=G<V$UN+I/L7DF.
M,7#;&:)"B.R]V"G&?I0 H\474GB":RLM!EN-.LYQ:75^)T3R7*JQPAY*J&7)
MR/8'%9K?$O0I;19]+A^V*))%9>(R!Y$DP<<'AA&1Z\\^E;5QX,TBYU[^UW%T
MLS2+++#'<NL$TBC:KO&#M9@ !GV&:KQ^ =$BL([("Z:WB9C$K3L?+!B:+:OH
MH5V _/M0!9A\01->Z!9+9;1JMK)=(0PQ#L5&QC'/^LZ\=*SKCQ[HUK/<1WEO
M/NAN)D9HH3(%6)T1I&.!@ NOK5_5/!NG:I%IBM<ZA:OIL;16\MG=M"X4A006
M7D\**B?P'HDB7*NMRWVF.6.5C.V6$K(SG/J3&O/U]: *D_Q(\+1?;T:X+FSD
M"NJQYWL9/+RO;A^,G'KTYKJ+.>WO[.*]BC(2XC##>FUBI' (/\JQ1X)TI(+Z
M")[N*&\<NT<<Y"H2Q=MHZ8+$D@Y';I6OI.EVFB:5;:98QF.UMHQ'&I8D@#W-
M %L*JH$"@*!@ #C%-,49*DHIV\+QT^E/HH :(XQC"+QC''ITH$:#HBCYMW [
M^OUIU% ",BMU'T/<5DP>&-'MX;*&.R&RRF>>#<[,1(X8.Q).6)WMDMGK6O10
M W8A??M7<1C..<>E*JJBA44*HZ # %+10 4444 %%%% !1110 4444 %%%%
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M_B*/^$YTG_GVU?\ \%5Q_P#$4 =+5/5=2ATC3)[Z=7:.(#Y4QEB2  ,D#))
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M," VQ4P/;"BM&N:\+>&_^$=OM=$,,$%C=W:S6L4/1%$2*>.WS UTM !1110
M57N+Z"UFMXIF(>X8I'A202%+')[< ]:L5%-;PW!C,L8?RVW+GL<$?R)'XT 4
M)O$&FQ;-LQFWQ^9'Y*%PXW!?E(X)R>E1-XITFW2-KZ\ALA--Y,'VB0+YIXQM
M]<@@X]ZN3Z/I]Q$L;VJ!%4JH3*;06#<8QCD \>E>>_&>U4Z'X=** L&LV^ !
MT'*_UH ]/HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***YRPU#Q'J-E'
M=Q6FFQQR9*K++(& R1S\OM4RFHNQM3HRJ)R322[NV_\ PQT=%8N_Q/\ \\-(
M_P"_TG_Q-&_Q/_SPTC_O])_\34^T79_<5]6?\R^]&C>7L-C$LDV_#-M 12QS
M^'TJG_PD6GDD!Y"1UQ&>.,G\N]0-_P )(X >VT=L'(S+(?\ V6F>1K^2?L.B
M9/4[Y.?_ !VI<Y7T_(VA0II>^U?_ !(LCQ%8E<YDR.HV'Z9^F>,TO_"0V'&&
ME.1GB,GCL?H:H2V.MS-&TFGZ(QB;<G[V08/_ 'S26[ZO<>;]F@\/R;'*R>7,
MYVMW!PO6I]I+^D:?5Z+5U_Z4C<L[^WOTD:W8L(WV-D8YQG^1%6:P8D\10@B*
MTT6,$Y(2209/_?-2;_$__/#2/^_TG_Q-6JFFJ?W'//#J_NR5O5&U16+O\3_\
M\-(_[_2?_$T;_$__ #PTC_O])_\ $T_:+L_N)^K/^9?>C:HK#AO]9AU>SM+^
MVLO*N1)A[=W8J5&><@=:VR0 2>@JHR4MC.K2E3:OUUT^X6BN2_MRZUK4HX-/
MOI+"VD.(96L2WFMLW8RQ ^[\PP.G?/%=%8+?Q0LFH303,I^66)"FX>I4DX/T
M/Y51F6Z*Q8_%FBR0R2I>$J@4@>4X+AFVJ4&,N"> 5S2OXJT6.&WE:\^2<%E(
MB<[0&VDOQ\@#<'=C!H V:X#PO_R5[QW_ -<['_T4:ZZSUW3;^^DLK:XWSINX
M*, VUMK;6(PV#P<$X-<CX7_Y*]X[_P"N=C_Z*- '?T45D:IXGT;1I_(O[Z.&
M?9O$;9R1S[>U7"G.H^6"N_(3:6YKT5YYH?Q=T?5K]K>YMI=/C$9<33."I((X
MX[\_I7>65[;:C9QW=I*LMO*,HZ]".E;8C!U\,[5HM?UW)A4C-7BQSV\$C.SP
MQLSIY;%E!++_ '3ZCD\>]11Z980Q>5%8VR1[#'L6)0-I.2,8Z$]JS[[Q1ING
M7IM;DW".-P#>0VUF"%RJG')V@GCT]:CO/&.BV$KQS7+90G>50D(H"EG)_NC<
M,GZ^AKF+-1],L)'C=[*V9HW,B$Q*2K'DD<<'WH73;!+B.X2RMEFB79'((E#(
MOH#C('M61:^+K*1=0^TGRS9O(6V L#$)"@;..Y'2F_\ ";Z*)60O<C8V&<VS
M[0-YC+9QC:'&": .CHKF-3\:V5C%<".*=KB$H?+DA=?,0RK&S)Q\V"WX\>M;
M>G:G;:I \MN7'ER&*1)$*/&XZJP/0\@_B* +E%%% !1110 4444 %%%% !11
M10 445S5[X@U>W\1QZ3!HL,PE1I8I3>A<HI4,2-IP<L.*UI4956U'IKNE^8F
MTMSI:***R&%<YXQC,^EF%+:Z>9T<1300F7RGQQE0003R W\)YXKHZ* /,GM-
M6*(&L=1%S$\C:D0&(GC,Z,JJW_+0[ 0,=@1QGD>SU-C/Y5EJ ,[G^RCL?%O_
M *03\P_Y9_+@_-CY1CVKTVB@#C4USQ!;_$^/0KPZ>^EW5I+<VQB1Q,@0J,.2
M<'ECT%=E7$:C_P EHT3_ + ]S_Z,2NWH **** "BBB@ HHHH YKQK=:I;Z?I
MT6DW;6D]WJ,%L\ZPK(41B=QPP(JLGAGQ-$NV/QK,BY)PNF6X&2<D_=ZDDFJ_
MCOP-=^+KK3IK;539BU)#*03U(.Y<'[PQ7:1J4C5"Q8J -S=3[UO4ITXTH2C.
M\G>ZMMVUZW)3;;31R@\->)P"!XVF&>O_ !++?G_QVJR>"=9B@\F/Q4%B(8%%
MTBV"X;[PQM[X&?I7;45@4<2O@K6TFBF3Q7MEB79&XTBV!1?0';P.3^9J;_A%
M?$?EQQ_\)E)Y<1!C7^RK;"8Z8&WC%=A10!YKIEWXMO=8;1[K6+I$BO[J$WJ6
M,:EXTCB9."I7!+MR.N*Z=?#VL(JI'XLOD11A52TM@ /0#RZZ.B@#FW\.ZQ+&
MT<GBR^=&!#*UI;$$'L1Y=0'P=>&W^SGQ#.82@3RS86NW:#D#'E],\XKJZ* .
M9/AG5&4*WBF\*JI4 V=M@ \$#]WT]J8WA34'EBE?Q-=-)",1.;*UW1C_ &3Y
M?'X5U-% '.>"Y]3FT28:M--/<0WMQ"LLT81GC21E0D  <@#D"NCHHH ****
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M4Z-@=0>,DX]:[RS-T;*$WJQ+=;!YHA)*;N^W/./K4]% !1110 4444 %%%%
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MJ-+;:G9A"ZC*L9H^5^JMU'8F@#OZ*K_;K/\ Y^H.3C_6#KTI/[1LMY3[7#N
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MXHE0+N 8J26)(X],GM72^%YXKCPOILL*;(V@7:NQ5 'L%^7'ICC% &O1110
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M73^=>WL@^>XD]3Z*.@4< <5R>L^&[ZZ^($-Q'?W*321O) RW\B".,%-Z;0,
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M4L6( !8]3[UV5X16'I24KMWT[:F<6^9JPZBBBN,T"FNN]&7<5R,97J/I3J*
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M1D%%%% %"TUO3;Z^FLK:[CEN(<[T&>QP<'H<'@XZ&N/\+_\ )7O'?_7.Q_\
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M>M%/AKJ!C4OX^\5AL#<!=KP?^^: /0:*\_\ ^%:7W_0_^*__  +7_P")I?\
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M^C>.-:N;\%?+BF>)$;YANR=O]W)_"M#_ (036O\ HH'B#\H?_B* .YHKAO\
MA!-:_P"B@>(/RA_^(H_X036O^B@>(/RA_P#B* .YHKAO^$$UK_HH'B#\H?\
MXBC_ (036O\ HH'B#\H?_B* .YHKS75?!'B^.73QIGC?6IT>Z5;LRO$OEPX.
M67Y>6SCBM'_A!-:_Z*!X@_*'_P"(H [FBN&_X036O^B@>(/RA_\ B*/^$$UK
M_HH'B#\H?_B* .YHKAO^$$UK_HH'B#\H?_B*/^$$UK_HH'B#\H?_ (B@#<NO
M"6F7?B2'791-]LBVD /A"5Z$BMVO-W\$>+1K\,:>.-;.EFV8R3EHMXEW#:H7
M;TQGG':K_P#P@FM?]% \0?E#_P#$46)C",;N*W.YHKAO^$$UK_HH'B#\H?\
MXBC_ (036O\ HH'B#\H?_B*"CN:CF@AN8C%/$DL;=4=0P/X&N*_X036O^B@>
M(/RA_P#B*/\ A!-:_P"B@>(/RA_^(H&FT[HZO^Q=*QC^S++_ ,!U_P *N@!0
M   !P *\VM/!'B]M<U*.Z\;ZTFFHL7V.97B+R$@[]PV\8.,>M:/_  @FM?\
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M"Y(_#O7!&]O&\,>(O[-UN=UM[83PWN_SV(\LDC) V.2O*X^7(QUX] IH1 "
MB@,<D =: ([1B]G S$EFC4DGZ5-110 4444 %%%% !7$ZKKOB2UN-2M[:T+_
M &/YS,("5:.1E"%?[Q1?,+ 9^Z/6NVHH \^@U/Q(\\5\S%HPD4;1B%BLRM<,
MF[H-K!#DX'8=J@;5M=N-'E@F>XM9Q;QB.UCM)-SKL0F42?PG<6&#Z8Z\UZ11
M0!R?AO6-;O\ 7+R#4(5C@0290QE3$PDP@!QA@5YZGU'%=9110!QNO:YK=MXI
MMK"P1Q;LT*.6MRRD.2&<$9SMX[@#OG-9EUXH\4FWA=+$V_+Q,7MV.Z>,*"N
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M  S["@#DE\9:D-4_LZ2PLC,"K,\5R7788FE./ESG"X [Y!Z4Z+QO,GE27=E
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M('!^G2I[+PW8:?-YMM]H1AM"YF8[$!)$8R>$R3Q_@* ->BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
AHH **** "BBB@ HHHH **** "BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>g4i5nix4zlkt000007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g4i5nix4zlkt000007.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" '1 J # 2(  A$! Q$!_\0
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MZ)=1DW]W:F??#S$-OWL$G/7IQ7&:KX=\8ZA:W&EWEEHNJHY98M3N/DE13T.
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MG2_^@E9_]_U_QJ'_ (1W0_\ H#:?_P" J?X4?\([H?\ T!M/_P# 5/\ "CW
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M_A1_PCNA_P#0&T__ ,!4_P */<#WB;^V=+_Z"5G_ -_U_P :/[9TO_H)6?\
MW_7_ !J'_A'=#_Z VG_^ J?X4?\ ".Z'_P! ;3__  %3_"CW ]XF_MG2_P#H
M)6?_ '_7_&C^V=+_ .@E9_\ ?]?\:A_X1W0_^@-I_P#X"I_A1_PCNA_] ;3_
M /P%3_"CW ]X;<WF@7JHMW<Z;.J-N42O&P4^HSWJ?^V=+_Z"5G_W_7_&HO\
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MS_[_ *_XT?VSI?\ T$K/_O\ K_C4/_".Z'_T!M/_ / 5/\*/^$=T/_H#:?\
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MX'TS5H=+O+?2HKR7;MC-HIQN.%W$+A<G@9(SVHO'S#WC>_MG2_\ H)6?_?\
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MTR:VG0212);)AE(R#TH]P/>+O]LZ7_T$K/\ [_K_ (T?VSI?_02L_P#O^O\
MC4/_  CNA_\ 0&T__P !4_PH_P"$=T/_ * VG_\ @*G^%'N![Q-_;.E_]!*S
M_P"_Z_XU%<:CHEW T%S>:?-"_P!Z.25&4_4$TG_".Z'_ - ;3_\ P%3_  H_
MX1W0_P#H#:?_ . J?X4>Z'O#XM4T>")8H;ZQCC485$F0 #V&:?\ VSI?_02L
M_P#O^O\ C6/K*^#O#T-O+JUII5I'<3+!$SVJ_,YZ#A?;KTJ/5)?!6BS30ZC:
MZ7!)#;?:Y%:S!VQ;PF[A>FX@4>Z'O&Y_;.E_]!*S_P"_Z_XT?VSI?_02L_\
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M"2)XDD6733$4:1ML8.Y!C<>!1[@>\=1_;.E_]!*S_P"_Z_XT?VSI?_02L_\
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MS_G>+_\ GRT7_P "I?\ XBCSO%__ #Y:+_X%2_\ Q%'(^X<QT%%<_P"=XO\
M^?+1?_ J7_XBCSO%_P#SY:+_ .!4O_Q%'(^X<QT%%<_YWB__ )\M%_\  J7_
M .(H\[Q?_P ^6B_^!4O_ ,11R/N',=!17/\ G>+_ /GRT7_P*E_^(H\[Q?\
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MDCVS7)7_ (@\ :K+'+?WND74D:E4>8*Q4'J 2.AP/RJ\OCGPFB*BZY8JJC
MDZ"CV<^P<\>YT=(20I(&2!T]:Y[_ (3SPK_T'K+_ +^4?\)YX5_Z#UE_W\H]
MG/L'/'N<_8:Q<+9:-K5UJ>I/-?SA)8XQ&;:-V.WR"APRD'C(R<J2:>_CZ_M]
M-T^\GL['-Q#!<2P12R.Z1S,%7G9M7J>6(!Q@>M7AX@^'XOS?B\T;[8229]J[
M\GJ<XSGWILNN?#R<PF:YT63R(Q'%N13L0=%'' '8=J/9S[!SQ[F;?>-M1M[J
M'4F@A^P&"Z\FVCF+.[+-'$ID&WY<$D\9QDCDUO6GB*YOO#FHW<JK87-G(8O-
M-O)(A("D,(R%<@[@,8!SFJO]O_#[[1/<?:]&\ZX#+-)L7=(&^\&..0<<^M/A
M\3>!+>P:QAO])2T?.Z!0H1L]<C&#1[.?8.>/<MZ7K-_J/AZ]N-2A&CO$&5;I
MB"NW;_K=K<J!_=?TJ/PE=71NM8T^[GGE-I<)Y/VB19'\MD!#%UX.XACCJ <>
ME0VWBCP+90206NH:3!#+_K(X@JJ_&.0!SQ3K'Q5X'TR P6&I:7:Q%MQ2'" G
MUP!1[.?8.>/<ZNBN=_X3SPK_ -!ZR_[^4?\ ">>%?^@]9?\ ?RCV<^P<\>Y6
MUBXN;OQ-+IIN[RW@@L%N8X;)E26Y<NRMAF[*%7C(^^,]JS[#QE=-82/&T,UO
M;6T;-=7S&.261Y'C4%8U89RG\.<YX'-7K_Q/X%U2-4O]1TJZ5#E1-M?:?;(X
MIK>)/ 3V\ENU]I!ADC6-X]J[61<[5(QT&3@=LT>SGV#GCW,FY\<ZI?Z+J$5E
M;6UO>V]O>-+++*T8 BPN4#+G=E@<,!C'/6M'1/&=QJ&LP6#6+&W>22V$Q5PV
M^-<EFRNW!(/ )(X]>$?6/AS);K;O-H;0HQ=8S&A4,1@G&.I &?7%3Q^)? <5
M^;Z._P!)2[*[3.H4/C&,9QGH /PH]G/L'/'N49M9OH-;DO6N[EA'JYL#8(NY
M3 (=^0@&XO\ Q9';CI5B]O[G4=8L7TN_U%+J5HG%C)#Y200!R)'F5AN^8 A0
M<'.,=S5C_A*O _\ :/\ :']I:5]MV[/M'R^9M]-V,U#-KWP^N-0^WS7FCR7F
M5/GL%+_+]WG&>.U'LY]@YX]SLJ*YW_A//"O_ $'K+_OY1_PGGA7_ *#UE_W\
MH]G/L'/'N7_$=]<:9X;U*^M$#W%O;O)&",C('4CN!UQ[5R5]K;^&&\Z/4-1U
M-Y;)YX_M+QFWN2H4[E9>4QGL,<^U;W_"=^%?^@]9?]_*S8M:^'4'G>5/HB><
MNV3:B#>,YP>.F>U'LY]@YX]QE[XYN=+U);>ZMK2=%9X9OLCR,5D6%I2,E O\
M.-N<\@^U43XQU>SU.9;F*VEENEM5MHK>1YHHMZRN6.U2V<(!@#G / K5/B+P
M"U^;YKW1S=D[C.57?G&,YQG../I42ZQ\.8[:6W2?0UAF(,D:QH Y&2"1CG&3
MCTH]G/L'/'N7+CQ)=R^$;/5[=%M;F9POV>6WDFWGY@4PF&&<9#8X[BK#WMWJ
M7A>&:\\S0[JX<(8A,A?.[ 17Z OC /4;O6J<GB?P)+91V4E_I#VD>-D#!2BX
MZ87&!0?$_@0Z<=/^WZ3]B(P;?"^7US]W&.O-'LY]@YX]R_X/OKF^\/JUX[M=
M0SS02B0AF4I(P"EAPQ P"PX)&:WJYBV\9>#;.VCM[75].A@C&$CC8*JCV J7
M_A//"O\ T'K+_OY1[.?8.>/<Z*N&U.^N9[O7YY=1U&W&ENJ16]B8PR)Y:OYS
M!\!P22,$XPN,9S6O_P )YX5_Z#UE_P!_*HWOB+P#J4R2WU[H]S)&,*\RJY Z
MXY'3-'LY]@YX]R!/&=]+#+)#%9"/[0MO;&5I/,F/DK*6\M$)Z-T'3DDU1D\;
MZAJVG6=W9PPVEN)+%KDF?]Z?-9251<888XYP3D^E:T_B+P#=1M'<7ND2HTOG
M%7"D%\8W=.N !GTJ/^W?A[YMO)]IT7?; "!MB9B .1MXXP>1CI1[.?8.>/<L
M>%/%T_B*Z,<M@8(Y+874+@.,(3C:VY1ENARN1U].<G1O$-W;26-]>7-[?+J%
MK//<VL,)F,#I*BJ$1!N &YE/7[N?6M2T\3^!;":::SU#2;>28YD>(*I?OR0.
M>I_.EM_%7@>TN9[FVU+2H9[@YFDCVJTA]R!S1[.?8.>/<;93W=UXO5K+4KRY
M@4NU]'*@6&!63]W"%QGS <$\Y SNZ@5UU<;!KWP_MK]K^"\TB*[9F=ID"ARS
M?>)..I[UH?\ ">>%?^@]9?\ ?RCV<^P<\>YT587BN^N+'2X/L\YMA<7<-O+=
M #]PCM@MSP#V!/ + U%_PGGA7_H/67_?RF3>-O"%Q"\,^LZ?+$XVNCL"K#T(
M/6CV<^P<\>YDG7+K1M5DTBTDO+NXDG@C1-4D7:BOY@\Q73+$'R_NL ?SIO\
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M?*1YCC(['UJU;^%XK2[L+B&[E!M+BXF"E00RS$EE]L'&#[4 ;]%%% !1110
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M,:V0YM1F&27:7D*Y:/IG !7+?[7M3]+\):9HNIRWNG(\#/;+;K'YC,B ,QR
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M=Q-/!;7/F@EWBSNRN/E!VM@Y/W><9KH: "BBB@ HHHH **** "BBB@ HHHH
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MN7DY &=H&0>O;:+<2W>A:?<SMNFFMHY';&,L5!)Q]: +U%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 <]8>&HK/6%N!
M?/+!;/-);6A51Y#3'+DD<D<MC/0$]:Z&O/\ 0;9T\4VN+:5-2CGO6U.8Q,H>
M-G/E98C# C85 )P >G->@4 %%%% !1110 4444 8NNZ*=2D@N(=0>PN8D>'S
M516W))C<N#WRJD'L1WK3L[2*PL;>S@!$,$:Q("<G:HP/Y5ROC2*W:]L9-3M)
M+G31;7*;$A:0"=@NPX /.-X![$^]=%HB7,6@Z='>EC=+;1B;<<G>%&[/OG-
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M]2T,=O"TAV+C+84'"C(_.J">#K;_ $MYKZZFN+RWG@N)FV@OYH0$X P,!%
MX^M2ZWX6M]<L;6TENI8XH%V_*D;$C &064E6&.&7!&: *H\;646H3VMTD@2)
M)7-Q'&Y3Y)O*"=,ER<# ZG@9K5C\1:8^DW&IM.T5O;,5G\V-E>-AC*E2,[N1
MQCG(QUK(N/ >G74<D;W5R8Y!*'4E6R6F$P/(ZJXX]1US5F+P=IT?AF[T25F>
MWNW,DKA$C.[C! 50HQM7MVYS0 LOC71X8U9S=^83(&@%I(94V!6;<N,K@,IY
M['BJFM^.[+3)/(M8);R4VTLX=%/E+MB\U0S8[C'T!!J?3/"%IHLBW<#M-/&)
MB5V1Q+(75!@A5  P@_,UGV/@*+_A'[:TNKB:&X'V@R^4X<;9D*&/+#D*FQ0<
M#[@H TX/&>E2VHD_TKSRZQ_9A:R>:S,F\;4QDC:"<XQ@4/XXT)9(T6XFE\P1
M[6AMI'4F09C7('WF[#KGBH-3\#:?J4YGEGD$^8S&S(CA2B%/NL"#D'G/?&,5
M):^"K"T$:Q3SA8YK:8#Y0,PC"] !SWQ^&* +"^+](?[*0]SY=R5593;2!$9F
M*JKMC"MN!&#T/6MVN/D^'ME)?17)U"\(CF298V",%99#(-I*Y4$GD#&:["@
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M2",N0&?:N/SP,\5;KRXOX@@O+RYLEU2:\DD$L:WELIVK]C(# 8VJVX$8!Z@
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M;^(X]'HH XKP5J^K:AJEXEZ;UK0VL,L;7<6UA(6<.N1&@& %RHW8]:[6BB@
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M0/L_DL"P*GDY &,=R<XI#1U7G2_\]'_[Z-'G2_\ /1_^^C32<L3ZFDIBN/\
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MY73])U"'5;2.6!5M;&ZN[E;GS ?.$V[:H7J"-YSG^Z,9KIZ0Q_G2_P#/1_\
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MRQ/J:2E(PQ'H:2F(**** "D95=&1@&5@0P/0@]12TC;MC; "V#M!.!GMGVH
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M.R,AQ@D,I!&1QUK-/A/2FU.&Y:V0P06RV\5L,A%PY?)P?FR3T.>1FNT>*VC
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M>Q=7K(TWQ)?6]W#:ZY.("C$RL\0W-N"[5.S(4 EB3_=\O/WJW]$O9;G[?;7
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M0E&FV>8RRN0QQN*C*J<8^7/6KVDZ_<:B\EC=W,,%Z\(AB01;E,P#;V)^[U!
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M+[<_G$F58Q(KI\LBG=GRR<$9&>3D@S/HGBORHIF2X?,,"W W8DDC62X(3Y9
MQ*AXL_/DCN>10!VL/A;0(KN)H[)!);HFV/S&*C:NQ&*9P2%& Q!/'7BJMUX)
MTR2T2SMHDBM7GADN%DW2LZ1-N1%+-\B@]AP 2 .:H^$](U.RUB2[U.*X:YGT
MV&,W$CY&Y7D^1AN/S!63GG.#SG-9D.G:VMO;K<V&LR;'4ZH5U#FZ;YLF(;N%
MW%2<%/EPN.* .PN?#&D7<\T\MLXEFD\UWCGD1MVW:2"K#&5 !QC.!G.*DOM&
MTNYT^WMKJ();VV/)*RM&8^-HPZD$<''7G-<?#:^*+> P26^H2M<+;>4_VE6^
MSJEPS,LC;OO>45!(SNP1DU3O/#.M3Z.8YH=0N6F@=[F)KPMND2ZC>,+EL ^7
MOQC ['M0!V$OAKPY8*U]+9PPPV\99]SL(5"IMW%,[<A.-V,X[U+8>%=$T^2*
M>TM")$9'1VF=R"J,B\LQX"NP ]#6!XWTO4M226*&SO[JUETZ2&"*UN1%Y=P>
MADRPR-O'.1UXYK-DTKQF=3U#[/+.DKBXV2A\1M&5_=*,R84CC!" @@DDYR0#
MNK#0].TR8365OY+^2(.'8@H&+ $$X."S<]>36C7GKZ/K-S)(VFV^J6$,=E<_
M9%N[]GQ<'RMC,-Y[B3 )8=3QFJ4>G>)ETUH7LK^6WDN%Q&UPZM%B,@MCS]S*
M6QU< $9Q0!Z?17F4.G>,!)9R(+XW[6"QO)<3_NHI/)*ELJY!._!*LAR>0V*7
M3]+\1I"GVV#5)-/6:,SVL=P5F<B-@65C,21O*$C< <9 ZT >C6MU!>VR7-K,
MDT,@RDB'(8>U35B>#[*XTWPCIMG=0O#/%#M>-V#,IR>"1P3[UMT %%%% !11
M10 4444 %%%% !1110 4444 %%%% &#I\'AQ?$=V;%X&U5-QFC68L4W$%R$S
MA23MW8 YQFMZN*T?2-1AUNPBFLGCCTZ>]F>[9EVSB9B5"X.<_-DY P5^E=K0
M 4444 %%%% !1110!A^)8O#[VT#:_)#%&&*Q/),8CR,,,@@X(ZCICK6S$L:0
MHD058U4! O0#MCVKG/$MK>?VC:7]OI[Z@B6MQ;-"A4%6DV;6^8@8^4@^F:V-
M%M)=/T+3[*9@TMO;1Q.0>"54 _RH O4444 %%%% !5*$Z>VK71ADB:_6.-+A
M5?+*OS%-P[=6Q5VL33M)6P\3ZI=06B0P74$+%T 'F2AI2Q/<GYEY/M0!DZEI
MWAFSNY9M6U!(O+NWG@'VEX6@DD0%P"K#.0"WL&/8U:6'PG%X@A(EA;4@$D4&
M9FR=F%D(SM+;!PYYQWK%G?48HKVUL]-FFO9=2N5N+R.-'DM8FP590Q&2R; .
MW&3G&#)'H$L6J6\&GZ5?VL+/ )9GN\PO:K"$:-TW?>P-N,'GYMU &ZMMX:U<
M0RHT%QYUP\B%93^\DP"P//(PJ\'C ''2KVBVL$%M<2PW"W#75S)-+*O0L3C'
MMM"A?^ URW]CZOI.H+<:3;RNHF,*>>RR,4 0;F)/"L%QD<@1IQR:WO#0)DUF
M5 ?LTNI2-#Z'"JKD>Q</^M &[1110 4444 %8.HP>'&\0VAOW@75'VF&-IBI
MDVDE"5SAL'.W(/.<5O5Q6LZ1J,VLZA%#:22QZE+9.ETK+M@$+@MNR<]!D8!R
M6[4 =K1110 4444 %%%-=%EC:-QN1@58'N#0!2T]-,FMKH6#0RPRSR>?Y;[@
M9"<.#SUSU%4=/ATNVL=(LI;V&X>WD:.Q8OAF**RX S\Q5,@_0FHM#TJ;2]$U
M.SMK9;3-S<&U1 %55)^0@#H*S],TN&YT_P (ZA;6:-<6JI'+,5&^)1"ZLI/7
M[YP0.] &Y+-HEE?7MQ)+;0W4=O&+E@^&2,LVS('3)+8[FJAL="55NK*2"&:V
ML@T,P<LL4>U@DA7.#@%\$\\MSUK&TOPQJJ:MJ9U<V\D5U;Q2/=VI997G21W4
MC)X*_+@=  H'>G:39ZIHM[&);98M+DA\RZW[6$2!6^0OG.5Q&, 8.YS0!UNE
MV4&G:5:V=L<P0Q*B-G.X =?QZU;K&\)17$/A+2X[D,)5MUX;JJX^4'W P*V:
M "BBB@ HHHH P+*#PVOB:Y:S>W.KJ&:6-9B2A;&\A,X4GY=Q STSUK?KB]+T
MG4(M>LXI;%XX[&\O+E[PLNV99BVT+@YS\XSD#&SZ5VE !1110 4444 %%%%
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M -]4>?+_ ,]7_P"^JCHH"Y)Y\O\ SU?_ +ZH\^7_ )ZO_P!]5'10%R3SY?\
MGJ__ 'U1Y\O_ #U?_OJHZ* N2>?+_P ]7_[ZH\^7_GJ__?51TH."#Z4!<JP:
M]:7.H2V$&H![J+.^,$\8QG!Z'&1G!.,\U=\^7_GJ_P#WU7)Z7I.H0:G8Q36X
M2WT^:[E%SYBGS_.)*@ <@C<<Y_NC&:ZBDALD\^7_ )ZO_P!]4>?+_P ]7_[Z
MJ.BF*Y)Y\O\ SU?_ +ZH\^7_ )ZO_P!]5'10%R3SY?\ GJ__ 'U1Y\O_ #U?
M_OJHZ* N5]0URVTJ-)+^^\A7)"[B23@9/ R< <D]!WJVMQ(RAEF9E89!#9!%
M8&N6M]]OMKZRM/MA2VN+9H?,5"/,"X;YN,97![X/>M'2[1K#2+&R=P[V]O'$
MS#H2J@'^5(9?\^7_ )ZO_P!]4>?+_P ]7_[ZJ.BF*Y)Y\O\ SU?_ +ZH\^7_
M )ZO_P!]5'10%R3SIO\ GJ__ 'U5"T\0V5]>26EKJ(EGCW%D4GG:<-@]&P>#
MC.#5L=>N*YW28]0N-=DO-3TN6U$*R16:*\9BBC+#)^5B2[X!)P ,8]24,U[O
MQ!:63E+B^=7$GE[55W;=MW8PH)SMY^E)_P )'8_;5LSJ06X9 X1BPP"N[DD8
M!V@G!YQVKEY=->X%S'+I#:A-!J%TS*MT870R@&-QR 05P,YR,< XI;30=73R
M=/OXUND>\AO;B_,@(;;$JNA7[Q8LN,XQ@]>U SJK77;6^6(VU_YGG,R1@%@2
M5&3P>1P0>?4>HJQ!??:8O-@N&=-Q7(8]0<$?4$$5R+:+JFGWPGT>(HIE\I5D
MD#GRQM^9BV3AL$$#Y@$0>M;&A*3+J\Z9%O/J$CP^X"JK,/8LK4"-OSY?^>K_
M /?5'GR_\]7_ .^JCHIBN2>?+_SU?_OJCSY?^>K_ /?51T4!<D\^7_GJ_P#W
MU5*?7K2UOXK&?4 EU-C9&2><G R>@R00,XSVJS7+ZKI.H7&I7\4%OOM]1DM'
M-QYB@6_DL"P(/)R!QC/).<4AHZSSY?\ GJ__ 'U1Y\O_ #U?_OJF$Y8GU-)3
M%<D\^7_GJ_\ WU1Y\O\ SU?_ +ZJ.B@+DGGR_P#/5_\ OJF2W;00O-+<&.*-
M2SNSX"@<DD^E)4%XSI8W#16PNI!&Q6W) \TXX7)X&>G- 7$T_6[?5HW>QO3,
M$(# ;E*Y&1D$ \CD>M0-XHTU+B*W;5%$DI 09;'+%1DXP,L"!G&2.,UGZ+;:
M@]EJ-Q?6\T&JWB_.[LFT$*0BQA6.%7/?DY)[UE6B7MY::-9#2ICI,=O;_:7B
M:,/++&0-C[F!"HRY/!)/'3.4,Z5?%&FN+@IJBM]G_P!9@L?XMO''S?-Q\N>>
M*L)K5O)$TL=]O1(1<,RL3B,YPWZ'WXKDM,\,71U",7\=PEC96\L%O']H0X+2
MJZ^4R@, -@(9N<D#MFK&F66IZ+>(\B1Q:88O-NURK*BA6^3)^8E0(P,<$;R>
M30!URW,CHKI.S*P!5@V00>AIWGR_\]7_ .^JQO#4$UMX8TR"X!65+=<JW51U
M /T&!^%:M,"3SY?^>K_]]4>?+_SU?_OJHZ*!7)//E_YZO_WU1Y\O_/5_^^JC
MI1P<T!<JPZ]:7&HR:?%J >[BSOB!/&,9&>A(R,@'C/-7?/E_YZO_ -]5R>GZ
M5J$.JVD4MN%MK*ZN[D77F*?.$N[:H'4'YCG/]T8SFNHI#)//E_YZO_WU1Y\O
M_/5_^^JCHIBN7["1WE<,[-\O<U?K-T[_ %K_ .[6E64]S6.P4445)1#=_P#'
MK)]*QZV+O_CUD^E8]:0V,Y[A1115D&+JCWLVO:9I]K?2VD<\4\DC11HS$ILQ
M]X'^\:PXO'?V1?LMY ;JYMVD6XEC.S>JRM&&10#N8[22N0.#SVKI-2L-*U&]
MM8;Y=UT%D-N%E='V\;\%2./NY_"HHM&T*^MX/(M(7AMMT$8B+*HVMRAP1N 8
M'@YYS2U&46\53FVCNH=(:2WN9Q!9N;I%,S&3R\E2,J,\]^.N#Q4$?CJWDN9X
M?L9 C\Y5;SP 7BX8,2 $!(8!B><=!D"MH>&])6[-T-.C$[2"4-\W#AMV5&<+
M\P!.,9/6H9=#T*XO[BWEM(GN9HC)+"6;[K'!8+G"DD=1@Y%&H:&0?'0%JTW]
MF,?+N&@F<3_NDPJL#YA7N'&-P4<'FE?Q_8I<7*_9)7AB:5$DC<%G>/J",84$
M@@-D].V:TKKP]X>M;;==6B1Q22C<[RR9D=]J88YRV["@@Y!XS5L^'=*\Z20Z
M=&6F5E=3DH0PPV$SM&1U(%&H:%32]4OWFUTZG;K;FQE0)")58*ODJY^?@'))
MY.,50M?&4M]<K96NDB:\:58U1+M?+P8VD!WE?]@@X!YQC-;":/I.E6-S +1(
M[:\8).K[G\UF 0!B<D\8%4KCP5I$DUJZV[1)%+YD@\QRTV(V107+;A@.<8/M
M1J&A6@\:+.GVE=,F6P1H$GN&E7,;2\ ;/XL-P<'W&:J)X[DOXH?[/T]3)-+;
ME/,ERIBDD"')"_*_(..>N<G%;-OX6TR#5I-0^SHQQ"((\$+"(UVK@9P?49'%
M3KX;T=(Y(UL5"R%21O;Y=K;EV\_* W.%P*-0T.;@\;SPF4W%J)(,0I;N\H5F
MDD>4'?A<!0(SR!V[DUU.CZHFL:7'>QQ/%O+*R-V920<'N..#W%1'PYHY!'V!
M!E GRLP( 8L,$'@AF8@CD9/-7K6U@LK9+:VC$<*9VJ"3U.3R>2<]S1J#L344
M44Q!1110 4444 %%%% !1110 4444 %%%% !1110 4H&2!ZTE% '+Z7JVH3Z
MG8RS7 >VU":[B%MY8'D"$D*01R2=ISG^\,8KJ*QK$>'_ .W[O[$;?^U!N\X(
MQR.1OP/N@YV[MO.<9K9H0,**** "BBB@ HHHH P]<NK[[?;6-E=BS+VUQ<M-
MY:OGRPN%^;C&6R>^!VK1TN[:_P!(L;UT"/<6\<K*.@+*"?YU3\0#0C;0_P!N
MF 1;CY9D9@<X^;&WG&.O;'6M5-@C41[=FT;=O3';'M0 ZBBB@ HHHH .]8&G
M7&I/XCFMFOQ>VT:/]JVP!([>0L/+C1AR6VYW DXX/&<5O@X.16/I6G:'8:A<
MPZ9L2ZB^:>)+AWV&0ELE2Q +$$],T 9=W?Z[?%GTLX1;R>,JDD2/Y4*[>-ZG
M)+Y/3@8Z9JO:^(-0ODBU&SNMUJ]W#916TT*@N)(0PD8CD-N8' XP#Q5[4;;P
MU;-<IJT\!C:Y:58W+!HG= 9 "O.&'S$=,'GBK"_\(TNN12(+?^T$C0H8U;:J
M[/D/'R#Y,X)YQ[4AE"QUZ]L[N.VUN8Q^6Q,K&-68[@NU6*<* 26)]#'GJ:W-
M*NYIVO[:X(:6SNV@W@8W+@,IP.^& /TJO''X>U40.@@N/,N'DCP6R\F 6SW/
M 4X/&-OM5O2H8([>:6&<7#7%Q)-+*!C<Y.",=L8"X_V: +U%%%,04444 %<O
MJNK:A;ZE?RP7 2WTY[1#;^6I^T><P#$L>1@$8QW!SFNHK&OAX?.O6GVXV_\
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MWVU]:61O0EK<6S0JZJ09 NUOF(&,K@]\'O6EI5H]AH]C9R.'>WMXXF8="54
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M1_\ /-/^^11SAR&)16WY4?\ SS3_ +Y%'E1_\\T_[Y%'.'(<OJ.E6&K1HE]
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M(R2-R@$9!P1^!!%'.@Y&9%%;?E1_\\T_[Y%'E1_\\T_[Y%'.'(8E%;?E1_\
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M/S9.0,%>]=I7(:5KVI7.L64D\L366HS7<,=N(]K0>2Q .[.6R%.<]R,>_7T
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MG(&-G?BNSKD=-US4Y]:M'FEA:QOKJZMH[<18:'R2V&W9Y)V'(/\ >&.G/74
M%%%% !1110 4444 -DD2&-I)75$7JS' 'XU6_M33_P#G_M?^_P O^-37%M!>
M6[V]S#'-"XP\<BAE8>X/6LW_ (1;P]_T M,_\!$_PJER]1._0N?VII__ #_V
MO_?Y?\:/[4T__G_M?^_R_P"-4_\ A%O#W_0"TS_P$3_"C_A%O#W_ $ M,_\
M 1/\*?N"]XDDGT>6^@O'N[4W$"ND;^>/E#8W<9QSM'Y5DMIFBG6=/NTO;%+>
MQ>:>.+S 6,TN=S;BW3DG&.N/2M+_ (1;P]_T M,_\!$_PH_X1;P]_P! +3/_
M  $3_"CW ]XPM)\,>&=/TB.SN+R"YF5%4SFZ(*E6W Q_-^[^;GY2.:N_V+X3
M,:H7MR%C>,DW9RP9PY+'=DMO ;<>0>0:T/\ A%O#W_0"TS_P$3_"C_A%O#W_
M $ M,_\  1/\*/<#WBI'IOAF.*2/SX'\R&6!VDO"[.DF-X+%LG.T<]L<5%)H
MOA2:5I)9(')Z*UZQ5,D$E5W84G:,XQG'UK0_X1;P]_T M,_\!$_PH_X1;P]_
MT M,_P# 1/\ "CW ]XH#1?"8DD?=;'><A3=DJGSB0A!NP@+*"0N,XK3M9M&L
MFN#;W5JAN)C/+^_!W.0 3R?85'_PBWA[_H!:9_X")_A1_P (MX>_Z 6F?^ B
M?X4>X'O%S^U-/_Y_[7_O\O\ C1_:FG_\_P#:_P#?Y?\ &J?_  BWA[_H!:9_
MX")_A1_PBWA[_H!:9_X")_A1[@>\7/[4T_\ Y_[7_O\ +_C1_:FG_P#/_:_]
M_E_QJG_PBWA[_H!:9_X")_A1_P (MX>_Z 6F?^ B?X4>X'O%S^U-/_Y_[7_O
M\O\ C1_:FG_\_P#:_P#?Y?\ &J?_  BWA[_H!:9_X")_A1_PBWA[_H!:9_X"
M)_A1[@>\7/[4T_\ Y_[7_O\ +_C1_:FG_P#/_:_]_E_QJG_PBWA[_H!:9_X"
M)_A1_P (MX>_Z 6F?^ B?X4>X'O%S^U-/_Y_[7_O\O\ C1_:FG_\_P#:_P#?
MY?\ &J?_  BWA[_H!:9_X")_A1_PBWA[_H!:9_X")_A1[@>\7/[4T_\ Y_[7
M_O\ +_C1_:FG_P#/_:_]_E_QJG_PBWA[_H!:9_X")_A1_P (MX>_Z 6F?^ B
M?X4>X'O%S^U-/_Y_[7_O\O\ C1_:FG_\_P#:_P#?Y?\ &J?_  BWA[_H!:9_
MX")_A1_PBWA[_H!:9_X")_A1[@>\7/[4T_\ Y_[7_O\ +_C1_:FG_P#/_:_]
M_E_QJG_PBWA[_H!:9_X")_A1_P (MX>_Z 6F?^ B?X4>X'O%S^U-/_Y_[7_O
M\O\ C1_:FG_\_P#:_P#?Y?\ &J?_  BWA[_H!:9_X")_A1_PBWA[_H!:9_X"
M)_A1[@>\7/[4T_\ Y_[7_O\ +_C1_:FG_P#/_:_]_E_QJG_PBWA[_H!:9_X"
M)_A1_P (MX>_Z 6F?^ B?X4>X'O%S^U-/_Y_[7_O\O\ C1_:FG_\_P#:_P#?
MY?\ &J?_  BWA[_H!:9_X")_A1_PBWA[_H!:9_X")_A1[@>\0VUKX<L]3DU&
M":V6YD+$DW.54L07*J6PI8@$D 9[UI?VII__ #_VO_?Y?\:I_P#"+>'O^@%I
MG_@(G^%'_"+>'O\ H!:9_P" B?X4>X'O%S^U-/\ ^?\ M?\ O\O^-']J:?\
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M3_\ G_M?^_R_XT?VII__ #_VO_?Y?\:I_P#"+>'O^@%IG_@(G^%'_"+>'O\
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M  H]P/>-"&\M;ARD%S#*P&2$D#''X5/5&RT;2].E:6QTVSM9&7:7A@5"1Z9
MZ5>J7;H-7ZA1112&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
#?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>g4i5nix4zlkt000034.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g4i5nix4zlkt000034.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %X KT# 2(  A$! Q$!_\0
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M1&6>5(HQU=V"@?B:XS0?%6M-XRG\-Z_:6D=P(//BDM&)7'H<_P">*=\5L?\
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MBE-H=@\G]EWEH9Q [%@C $\?D?SJ+P-X>T_QI%J7B'Q##]NN)KEHD25CMC4
M< ?C^E#I):MZ!SMZ=3U2*:*>)989$DC;E70Y!_&JMQK&F6DX@N=1M(9C_P L
MY)E5OR)KD%T-_A[X7\07>GW\TL!1I;>WD'RP'H,'OU'Y5G>$/ &AZSX/@O\
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MA<+(['.-I))'L,]Z;J7Q!1-(DN-.TC4Y+AGA6V2:U*"=9'"JZY/(]N#TXYH
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MX9UR2NU58D G.!CK5N[U;Q%X<L9Y-3%CJ32F.*R:W1H"\[MM",I+?+R#N!Z
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M5DGQ]]CN5N. .!W-:%@9-+\76NFR:[KEQ=S*YD6^M\V]QM7),9  3!(Z<=J
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M!N9?.G\J..,''+8)R3D 8[$FL+2-:U/Q3XPL[F O;:+;Z='=-$D^&:27. X
MPP 4\9[@T =[11VHH **** "BBB@ HHHH ***2@!:Y2Z\(W+WM_]AUVYL;'4
M9#)=VT<:EBQ 5C&YY3< ,]?48K-MUO/$-GJ.N7/B.[TF"*XFAM%@D5(H%C<I
MND!'SDD$D$XP<#UJTWB[48[JX(TZ&33K2_BL)KQIMI=FV!G5<$ !GYR: '_\
M(?J4&I:A-8>(6M+6^V+)&EJK2(J($ 60GC '4@\DFM?3_"VBZ9+:SVFGQ)/:
MPB"*8C+A ,8S^?YUA#QIJ-]++'I&D0S[4>Y5[BY\I3;JQ57SM/+LK[1TP,D\
MU!+\0+J2"2^L='673;:"VFN9)+C8Z^:,[%7!RP!4]0#F@#7?PBC:--9K?2)<
MO?MJ"700$I-OWJ=IX(' P>H%.A\,31:%J5F-5F-_J3%[F_$8#%B IVKT4!1@
M>G6L34?B'=6*22_V5'Y$E[+96;M*Q,K1D[I&"H2J#:W3)SCCO1-\0KQ=$L+^
M/2$0SS2PS2W,KQP1LAP/GV9 ?^$LH'!SB@"])\-O#Z/$=/MEL(Q:S6DRVZX,
ML<BA<$^Q -2)X1OVBM#=^(9[F:VNX9T+0*(PL8("!!P"<Y+=<@>F*SI/B,W_
M  D7]FQ:6SQ1W$=K.0SEQ(V-VS"%2JEN26&<'%6K3QM<R26MY>:?#:Z-<RW$
M4=T9R6Q$'8.5Q@*PC..<T 2KX#MBNDK->RR)8O*\R[ !=[Y!)A_8. <=\57?
MX>1OXD&JOJ.Y5O3>JC6J&7<01M,OWMH)RH[8[UG77Q.N(+A(1HK&1(TEGB+2
M%P)#E$7:A!?9AB"0 3C/>I]7\4:OJ36L&F6PMM/O-4CL8[U9\3-L?,C!,<+A
M'7KGVH ?-\-(I[73XVU&-YK2V-F\LMC'+OBW%@5#9".,_>'7TJU=> ?-FDBM
MM7FMM+GF@FGLEA4AVBV@#=U"D(N0/_K5!XSU*8>)]+TQ'UH6PMI;FX72%)D;
ME53=CD+G=^59VFQ:WJ.JV&BWFHZO:0'[5>X:<+<_9\HD2R,O?<7./3 /2@#K
M=5\*V.NZQ#>:LJW=M!"4@LY$^1')^:3W;  'H,^M8Z> [C3YK%]%UD62V3W/
MDQO:"5469PQ4 D8QC /H:=X<\1PV4MYI6JZJ9C%J+VEC/<<R3J N02!@E68K
MGVK1\'7=YJ.@3:C<2O*;J[GE@#GA8]Y5%'H, '\: ()/!:-9;EU*X75OM8OO
M[2**6,P7:,KTV;3MV^GYT2>#7O+"Z74=8NKC4+B2*5;Q5""!HCF/RX_N@ Y)
MZYR<T>#[C6+R\UV75KR*?RKT6T4<"E8H@B L%SR?F8@D]<=JK:-XH=-4U1M<
MN[:"WGU%K73$#$EA'A&[?WOU)]* -C2-$N[.]EU#4M5EU&^>,0JWEB*.-,YP
MJ#C)/4G)X':L>7X;Z5<64C3$2:Q+<"Y?5#&/-\P.&! Z   *!V%9^C^+]2AO
M#+?VZ-IE_>WA@N)+D!HXX@<';C CPG4G.6S5:7X@WNIZ/K5O';+:W:VT9MI[
M>1FVF:3RE^\B_,"<Y&0<=: .B_X0Z</?PIKETFGW/VAH[5(U&QYL[F9NK@%B
M0#TSWP*AD\"^=I=[;-JDBW5Q%:QI<QPA?),'W2J].N3CWK O/%.I6UE#!+>R
M"\T>TOGU$KQYK1*$C8CT8NKBK?ABZU3Q )4UB2\@&F6D:'3'.)KHM'GSI2.N
MXYPH/!!SS0!KWG@2":/9:WC6RI;06T(\H.%$<OFDD'[VX@9^E&CZ)-<>,=2\
M17MM+;J<16EO*P)R%VO-@9P6 "CO@=LUCPZ1J^DR:3)IUM=;X[4^<"[,IFE!
MR6!/.S:/S'K6Y#>3^&/!NF))#-=ZC,8X(XI),-)-(<X9CG&.23V - #M8\)2
MZEJ-W<6VL3V,%_"D%]#'&K&5%R!M8\H<,02,_G6EHFAPZ+]M\I]WVJX,WW<!
M!M550>P50*Y;5?'VH:.T%A=Z3;IJLAD9@L[R0"-2 &W(A;))P 5&"#FJ=UXF
MO]8U:U^QS75C'<K80_9SP4:1FFES[B- /HU 'I=%<IX7\57FOZA>6USI\5F;
M?.8C,?.CYP!(A4=1R&4E3ZUU8Z4 %%%% !1110 4444 %%%% !1110 4444
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M*55$[9ZG/7)R3GK69HGA*P\/O%]AN-0\N)/+C@EO))(U'LI.*XS_ (5-HO\
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M-@#K[U7M-#2WUR[U>:XDN;J91%&7  @B!SL7 Z$\DGD\>E<1M^+/_05\+_\
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M_P#WXEHV_%G_ *"OA?\ [\2T >F45YGM^+/_ $%?"_\ WXEHV_%G_H*^%_\
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MN=3Z^E #A_K#]!2+TC^AH&_S#]WH/6FKOQ']SH?6@ _@_P" _P!:EJ#Y]O\
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M_P A/Q!_V%Y_YU[32$%4M7_Y E__ ->TG_H)J[5+5_\ D"7_ /U[2?\ H)H
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M4^X* #_EH/I1_P M!]#0?]8/I1_RT'T- "=I/\]J#U_X!1VD_P ]J#U_X!0
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MZ?OGEBDNAM+K''G?L('#'& >V?6O3[&S@T[3K:RL[>.&VA 2.-3T']3W)[T
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MG&,IRL<L89&G&67<>2S)D_G6A8"_MKM)+>18P&VEU'0GH1Z'WJO%:74TLL@
M\L%29&/RIV('O[5:FAGM3]I1X6BR0\<N1EE]*R4I2=I;/8NO3A&*C#XEOJ6]
M7\0:S=7T,&KW+W]O;#:N\X;GOGU]S7=>!KK4O$=Z;K3RO_$NLVLXI;AOG3<<
M@D=R/7O7F<URVIW3W494*$&44\_C4V@^([SPSXA@N;%B,+AU/1P>H(JZE)2C
M9:,YHNSNSZATRUDL=-MK::=[B6- KRN<ESW-7*Q="\2:?KFAKJD-Q$L8'[X,
MV/*;N&STK81PZAE8,K#((/!%><TT[,]!--:'G7Q8_P"/CP9_V'X/Y&NS;[Q^
MM<9\6/\ CX\&_P#8?@_D:[-OO'ZT%'GGB>Q\0ZKXH;3FMIQHLTT9CU""&&9K
M5%B)= &!*EGQS^5=/X0GU&X\*V3ZJ'%V RGS$5'*!B$+JO"MMQD#H:X?QW<:
MM8>))G\/P^(HVO!%'J365KYD<D8'WXF/"R!?EZ5W/A.&R@\,VD6GV5[9VP+8
MAO@1/G<<L^><D\T 6=;L;O4M,-K9W4-N[R*7::,NCH#DH0"#@].O2N*MO#?B
M*UT-+*2SMYY;RP^PS-'(L:VN)F8,03R-K'[O< 5Z-10!Q'B'3;F#QOX6NVUB
M\G@EU-E2TD">7%^Y?E<#/YGO7:[6_OG\A7-^*/\ D8O!O_85;_T2]=-0 W:W
M]\_D*:BML'SG\A4G>FI]P4 -VMYGWST]!1M;S!\YZ'L*=_RT'TH_Y:#Z&@!A
M5OWGSG\AZ4%6S]\_<]!3\9\P#_/%8VH>([2UNC96D<NHZCL_X];7#%?=VZ(/
MJ::3>PFTMS5VM_?/\/85C7/B1)+E[+1(9-5O$.'\HA8(C_MR=!]!DU!_8NI:
MR=WB"["6QVXTVR<K&1Z2/U?Z# KH;:V@L[9+:UAC@@086.-0JC\!5>['?5D^
M]+;0PE\-3ZDRS^)+W[:P.Y;.$;+5/JO5S[M^5;L48CC"(=B*2%55  'L*EIJ
M]#_O&I<FQJ*0TJVY?G/?L*"K;E^<]?04\_>7\:0_>3'K2*(9Y8[6*>YGG\N&
M&,R2.0,*HR2:\HOO'-K\0KFWT+0%FFMPVZ:*90ANFS\BD#I$,;G)Z@ =ZZ#Q
MSXE>:UU#0M)>,NT?D7MVR[UB+ XA0?QRMZ=%&2:XCX36$OAZ\U&2SMDNM0N5
M%O#'N!*8.6=F'W4''U[5E.I%/E*A2J57RP7SZ+U?0]1C6U\)Z5'!ODNKZZ)8
MJBCS;N8]3CL/T4"LV[\!R:_?1ZKK=Z4NR1NMX%!C11T3/4^YK>TO1Q9/)>W4
MQNM2F3][<,,;1G[J#^%1Z=^];-'LU->_MV.NGB7A-,,[/J_\O+\QNT@8#G &
M!P*:%;<WSGKZ"I*:/O-]:U.(:RM\OSG[WH*&4_+\Y^\.PIS?P_[U*_\ #_O"
M@!FUO,'SGIZ"D"MA?G/W_04__EH/I31T7_?H ;M;'WSU;L*E'W1]*C[?BU2#
MH/I0 M%%% !1110 4Z/_ %J?44VG1_ZU/J* /*?@[_R$_$'_ &%Y_P"=>TUX
MM\'?^0GX@_["\_\ .O::0@JEJ_\ R!+_ /Z]I/\ T$U=JEJ__($O_P#KVD_]
M!- '#?"G_DEV@_\ 7)__ $8U=C7'?"G_ ))=H/\ UR?_ -&-78TQA1110 5C
M1>%M(ALOL:13^0'WJIN7RC<\J<Y!.3G'7-;-5[V_M--M_M%Y.L,6[:&;)R?0
M <F@#F_%\,5O%X5AAC6..+7+5$51PJ@-@"NLKE?&,B2IX6EC=7C?7;5E=3D,
M"&P0:ZJ@!K=5^M#_ '?Q%#=5^M#_ '?Q'\Z '$$LA />JUU=6]C;/<WEQ#;0
M*V6DF<(H_$UXQ\3[[6U\?[=.UR\LK:&&$-%#*R@MU8@=.A%=.LFF1ZN(X-!O
MM9U@#S%EUFX7>!C.0C'"C'/"CBLO;0NU?8SC5A*3BGJC&U[XPW<'C$:)H=I9
M75I-)'%%>2K)C<^!G'&0">W7%>D:9H5MI$TNI7UT;O4WRLVH7)"X']V,=(T]
MA^)->5:GK_B'5=5?6H(O+M[4[/,M5WPQ@8S\Q'/7_"NG?3-,.JZ7;:SJ>IZA
M<:EAH2D96, ]"Q;)'TXK..(YF^5&T)49-I2;:[+]>WG^!KW_ ,1]*LM<.G)!
M/=*H ,UOA\N>BJ.]7UE\1ZQ;#[-''HD#?\M)_P![<$>RCY5/UR:\]O+OP]I6
MJ7NH6A,6KZ??B&VM"&>)E4A<L>23U/'.<#%=TMYXAU#3=$N+6.5'FD+7@B18
M0J[N_F_,!CL!D^U33E.;:E^!+<Y;PY4MO/\ KR,'P_X?TC2/&=W>3:XMU):H
M\C)-'AE/\3L>G'/2NT2^O+Z*PFTJ".6UE8M+-.60J@/\*XR2><'I7!Z(?$<^
MH:-IMQI%S:PVMU,SW36>-@8/ABY)#=1VYSS7;-H$5WI$%CJ=]?7X67S&E>4Q
M,Y]#Y>WY1Z5I1I\JLE86O9+T.+\-ZS/-K&CP2V]W_9D9N&TN0V10W)VL<%R<
M9P#CU-=@;6_UW3K?[:USH^Y\RVUO,K/(F.%9P.,]POTS5/2_!HTRXTLG6K^Y
MMM+9_LEK*D81,J5Z@;C@$]372KU7\/Y5I""BM!Z=%8Q-*\(6FDWUE=)J.J7)
ML8FAM8KJX#I$K *0  .P _"MYOOI]33J:?OI^-6 KDX'/<4A_P!8OT-#]!]1
M0?OK]#0 @[?[]-/3\#_.E]/]^D/3\#_.@!Z_=_$_SIP)!R#BFI]W\33J $5B
M47))^M+34^X*=0 4444 .C_UJ?[PKS+X-?=U7_L)W'_H0KTV/_6I_O"O,O@U
M]W5?^PG<?^A"D(]@KEO%E[XAT<#5M-^S7-A;INN;-UPY /+*WT[5U-86L^%-
M.UR\2YNVN0ZIY96*=E5USG# <&@4D[:'#_$7Q[8S^%H+/2+D33:BOSB-LE$[
MJ<="3QCZUY"MH;23[1<12R; "WE\A!Z?6NC\;+;6WC>^ATRWBMH8B(ML:X&0
M/F/UJ@[PR:0\:SJ9"IC6+#%B<=NU>C3BH05^IQ3E-RNN@GA^^O?.,MG''<0H
M"LBMGH1[=Q73V6M2#%F(S%)(=LUP&Y*=U'H/>N-TZ;4_#+-,K1!)CMV.-RGC
MKGM6E;ZK>B&ZM;](]MP49 L 'RGG&?3.*PG^[O33T_K0[)>VKKVL8K7MOZB3
MS7$-ZP6./^S03&9&/RE.S<=SZ59U"UAU+2F6.ZM]Q_C!& <#/7V%5+>WCDS"
MYW1CYB&'0U4&C0)<,Y(#[R5 ^Z!W&*K#R4XS4MX_G^1KB:,:4Z<XNW-U\N_<
MIW6E7T :"SP+5MOSH1N?U/TIOD[]3$.]1#$OS$CK]36U"RV'E074AWS$^6,_
M* !U]OI5*X>*%I(C(L:-\P[EL]<53KR=/X;:Z]_4SGAKU.5U+JVCZ>GW&C;Z
MMI;NNFPK<RQ*0\VYO+68YZ8]/3-?0^B7D5_HUK<PPF&-D&V,D':!QCBOE33+
MI?[46[F@SCY BL5X^OK7U5H5M#:Z):16[,T/EAE+'G!&:RKP48I]SGHZ3:3N
MCB?BQ_Q\>#?^P_!_(UV;?>/UKC/BQ_Q\>#?^P_!_(UV;?>/UKG.HP=;\41:5
M'>6\"-+JD,7F06KJRBXSW0_QXY)"Y/'2I_#>J7>LZ)%>WMJ+:9W==H#!7 .
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M"052WWD[G#'CW8!B>F1F@"G'XZ\+,N5UZ%AD\K&Y'7_=I_\ PG'AC_H.1_\
M?J3_ .)J?2KVPT^[.B6<5RL8GF"S/RCR_P"LD0'.<C<3TQU Z5N[V_O&@"II
M]Y;:AI\%Y9SI/;3+NCE3HPSU%6:C@@AMH%@MXDBA3[J(,*O.>!]:DH ****
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M'FO)!^\O+AM\S_\  CT'L,"M7J<FFI]P4G/2RT!16[#K)^']:/\ EH/H:/\
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MO?/"6DZ:/%>J7-A"TMC"JI;S2$E4?G<J$]17FGQ*T2SLO%LZZ3N@5BKSC&Y
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M=JEJ_P#R!+__ *]I/_030!PWPI_Y)=H/_7)__1C5V-<=\*?^27:#_P!<G_\
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MC)P>2>Y]S7?M]X_6K4DOA%RM_$16]O!:6Z6]M#'! @PL<:A5'X"I***@L*4
MD\#-)7'^-Y+19[--3O)+6Q^RW,D;K,T6ZY4+Y8R#RP&2!W/:@#7UWP[%XANM
M':=89(+"[-S)!-%YBS#85VX/'?//I3_^$5\.XS_PC^E?^ 4?^%<]KUW;7%CH
MB:Y?-;VQMI&NV68Q;;H0JR*Q4@AN68#N:MZ8;YM<\/3WMW<-)<:0YDMWX17
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M?=7Z#^5 &3_PBWAW_H7]*_\  */_  JM;^"/#-M=7EPFAV#-=R"1UDMD95(
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M2U?_ ) E_P#]>TG_ *": .&^%/\ R2[0?^N3_P#HQJ[&N.^%/_)+M!_ZY/\
M^C&KL:8PHHHH **** ,_5=4.F0/(+*ZN-L3R9B3*#:,X8]ORJCINMW,T\\-P
M+:[9+=+A7T[+C#'&P@G[W?KR*WNQ/8=3Z52TR73)HI?[*:T:,.?,^S;<;O?'
M>LVGS;D^SJ-\RV1#XCOYM*\,ZIJ-OM,]K:O+'O&5W <9%<5-XH\46<=FFI75
MCI?V@7$L=Q?6RJ9$CC5@&0.0I+%AP<D#I7H%_=6MCIUS=WK!;6&,R3%EW *.
MO'?Z5@7'C'PO)%&UR7D*NP$4E@[21%5#$E"N5 4@YQTK0H9X<\4SZU'>12_8
MX=2 B:VL99-C?- DA##[Q&XGG'2H(_%EY_PB_A^^863WM]<PQW2;MH1'9E+*
M.3_#@9K>@OM&NFNM0A>T8VH'G76P#:"@<'?CIM(.:C35]"ETZPOQ-:BTOW2*
MTD>, 2DD[5 (]02* .?F\??9O$%Q%+:G^R\0JDDJM%+$S1R.2RD9(_=^V/>L
M;4OBA?I;?;++3XU@B@NC<J3YA1DV".0=,IEUR,=#[5Z"=0TR35[C3Y)8/[0A
M5))(Y  V"#M(SUX!Z=*I7.N^&].*12W%F@DMY9T$<896CC_UF-HP<#J.IQ0!
MAZ'XNU/4?%/]F720VUJ)I4CG\O(N66-&\E>?E8;BQ)ZC@=#6MKWBP:)K-MI[
MV8F$L22LWG!6PTHCPB8^8@G./3-3KJVA:I-_9L4HDFDD<>7$A5E*@;F) RO!
M W<=<"IH=-T:PU**0M']O9/+B-S<%Y"N<X7>2>OI0!@6_P 0/,O--@ETF1?M
MHWJ8Y=Y5"[("!CDY0D@= 1UIJ>-+V3Q)/:Q62R6;RPPVR2!H95+0O*[.",YP
MA 7'I75?:=,5?,\^R @<QAMZ?NV/\.?X3[5!)K6C)::AJ+W5N8=.<K=S@9,3
MJ.<GKD X_'% ')Q_%"&6UMYET:X/G284>8/N[5;KC[_S#Y?;K4MS\1UMA</_
M &8L\4=V]M%+!<Y$NQ2SGID=-HSP2#S@5U4-WI$T,9CEL@K.KJA* AVY&1V<
M_G0\NC6RR&1]-B42 2%C& ''//\ M#WYH @\3:C?Z9X5O=2T^.$W$$'G 7.0
MJJ!DD@=3[5S>K>,-2TS4KZ'-H\?EJ;;;AU@'[L/)/@[E"[RV.A KJ[2RT]+B
M=H)FFD^[*CW32@9YP5)(%5KOQ#H&G7&HK<7,"36<*/>;8\LJ,=JAL#DD_P /
MO0!SEGX]F@@>.X0:E(;UK*&XMXQ$DLV%*(,%@=P+'<#_  \C-:_CG7=0\/Z7
M;2Z>D)N)9RG[U<C"HS''(Z[:?<:GX;%_I]O,C+/ RS01I;/MMV?(5G"C:A/.
M-WKFM"TT[3%=A"_VDNH;;+<&<;23@@,2!W&1[T 8NK^.K73[2.:UM)+G?"\^
M^7-O$RK%YGRNP^8D= *H2?$$W&K0Z?96T:EKJV1I2VX,COL=<8&&![\BM#5-
M:\):Q+)I>I,\OV5Y1Y;12*A:,?.JD8#$#J/2M>SO]#NU>6TFL&\IS&[ *"K*
M0/KP2!]<4 :AZFBJQU&Q4;FOK8 8R3,O&20._L?R-21W5M-*\,5S#)+']]$D
M!9?J!R* ):*** "BBB@!T?\ K4_WA7F7P:^[JO\ V$[C_P!"%>FQ_P"M3_>%
M>9?!K[NJ_P#83N/_ $(4A'L%)F@UYKJ&H>,(]9O1")#IJZJZ1E5?S=GV8D #
M;CR]_?.<T >E9HS7DM]XQ\2-:2:9%^[OC9-LC2%FN RP1N),]"2S,-N,C%>@
M^&;[4;VPN/[4A"7%O=2P!EC*"55/#@'U% &R:RM7OY8O+L;+!OKG(3/(C7NY
M]A_.K>I7\6FV;7$N3CA$7J['HH]S572-/EA\R]O<-?7.#)CI&.R#V'ZFM())
M<S,*DG)^SC\_)%K3M/BTVS2WBR<<L[=78]6/N35JEHJ&VW=FT8J*L@HHHI#"
MBBB@#SCXL?\ 'QX,_P"P_!_(UV;?>/UKC/BQ_P ?'@S_ +#\'\C79M]X_6F,
M2BBB@ IKHD@ DC1P"& =0<$=#SWIU% #&AA<,'AC8,P9@R @D="?4^].(!;<
M0"PX#$<BEHH **** "BBE7[R_6@!=C8SM./7%)M;^Z?7I7CWAVTDN_'M]<26
M+2M'K,Z1WCZUL$9!^4?9OXP#CCOFN?TZ/7[:?2=5N]7-W$USJ&H20!I 9'M\
MY!YZ'' [4 >^B&$#"PQ ;]_" ?-_>^OOUIP4#<0H!)^8@=?K7E=C\0O$<V@3
M37"Z>MQ-/:1VUZT>R&'SR<[UW'(7'!.,YIE_XJUZUUC2=1EU33;J*VTV_EG@
MLB3%=/"<';_M$;?7;AO6@#UBE ). "3[5Y2?'?B2&RN(#>:-=WKQV4\%S:QE
MHHA/+L,;C/)'4'K78:MHT^J:7J-AK.I1W,45NDBK9YMY5E16+,VTY"L<8'MW
MH Z8J5/((^HI*\=BU6;P7\.M'N](U"&.^U&U:^N!?F2X>4HF2$!.%'J<\9XK
M7N/'&O+!KFIQ?8Q9Z;IUI<+;&$EFEGC!R7SPBDDGVH ]+HKRFY\?>(K**]LW
MO-*N[M+ZVLXKVTAWPKYD;.S;<_,>,8SCK5S0-<U_5_'>A27UU!:P3:-+)+9#
ME9&67:67DC)P&'7 R* /2C&70@IN0]01D&BO#O&D=X_C+7YXH;F-4O+:WBU0
M:B\45@S(N"T8SE2>_3FNLU#QEJ\'CN/1;6_TZ:WDE>SV+ Q>*40EM[,>"=W\
M(R,=Z!'HV#C.*2O%M$\5ZKI.CVVI74]OJ-TFA2S+*Q;Y2;E4 D.>=N22<9Q7
M?^$-<U+4;S5]-U2YL+V?3VBQ>Z>,12B1=VW&3\R_R(H&=51110 4444 (0"0
M2 2#D$CI]*141"Q2-%+G<Y50"Q]3ZFG44 %%%% !1110 4Z/_6I]13:='_K4
M^HH \I^#O_(3\0?]A>?^=>TUXM\'?^0GX@_["\_\Z]II""J6K_\ ($O_ /KV
MD_\ 035VJ6K_ /($O_\ KVD_]!- '#?"G_DEV@_]<G_]&-78UQWPI_Y)=H/_
M %R?_P!&-78TQA1110 4444 4-2T6QU8#[9'(Q"% 4E9, _0_P ZPM$^'VE:
M*LNZ2XN6=PP+.4V@=!A2,_C6WJHU<P/_ &6UL&\IO]:#OW8^7;V_.LW1!J/F
MW/D_;1!Y*;?[4))\_/S8[[<?AGI6,HQ<U=:GH4JE>.'E&-2R?0U]7TY=8T:]
MTQY&C6[@:$NHR5!&,@5B77@6%39_V+.VDR6R2J[1P"4RB10K$[CUPHP>:T_$
ML-W<^%M5@L!(;R2U=8!&<,7(XP>QKA;SPGJVG0V,<JZCJD#?:)'@TZ:1!;R&
M-1'@M)NQN!.2< D\5L>>=;HOA=] NW%IJ!.F2! UG+;JQ.R,1@[\Y_A!Z4T>
M$2NF:7IW]H/Y.FRQSPY@7)=2Q))ST(;'M@&J?AU=;MY+W3=8AU'S[D1$:E%M
M,2$0(K$,3P=P/;KS4$5KK\?AKPY9K'J*W=I<PR7KA@3)'N<,K$GYOX2?8T 6
M;GP%;37QO(]1O(Y-T;)(^)9%V)(GWVY.?,SSZ"LZ3X4V-Q836TVHW#LZR[)4
MC"M&\A0EAS_L$8[AC4MPOC*W\1W-_%;%HY?(1[:"0/"RB.3<59P""&\OG Z]
MZPM0LOB!J-JUPJW*74-K=1+$2(_/1R@53C'S@%BI]5]Z .NL_!J:-JLVLZ;*
MYOY9':=6 5;F-E4"-CS@*5W!OKZU#?\ AB\U_7XK_41#9P1P1QF.%A+(Y2;S
M!AR!LZ#D<UGZ59ZYIGB1]0UEIGT<3S>4&D(%J2JXF?GYE.&4?W?3FK>IZWJM
MYXFMK;PY<?:;<01R.(T5HMWG8?S&/(&S/3G.* &/\.+1[1H1J$BR#8L,H@4-
M$J;\'@C+_.<L>O0BKTW@>WN+'4K1]0NL7SR297Y0"ZA6+*.'^[D9Z9K)DN/'
M@L972*8S(Z$QB&/<[?/O2,CI']S#$$]<^S[NT\62:-XEMHDN#+=2R- [S@21
MHT:[5AP,'G<#DC':@"[??#ZQO6!:ZD1OM<MP^V,?,)-N5/TV#![<U7'PXMXX
MI(8M1<Q2W"321S0"02HC,ZQOSR-S9)XS@"H[A/&MHD4>GEWB%V\2J\:'9"H4
M1D]RI^?))SP.E0S7/CTPW220W$<CW2)%);0HXA3<V]P#]]-@7 Z[CUZT ;&E
M^%V\.7M[?:=_ILUVQ!2:3R@BEV<\\[OF;C@8%79] >^NI[]VC@NKFUCMWB,*
MSQJ5<OG###YSCM6?H^IZW:7VH2>)Y8;6QW;;9I J@G<<;2.OR8)SWS]*@U;3
M;S4;_5+BVO-2ETZ^TZ)8WLW4[&$N2(@2!G;R>YR?84 *GPZBBBB@M]6O8K97
MADN$5 6DDCSM8-U3@[2.1BK.AZ)?>'OM\UO:6]Q->73.L9N-JV\ ),<8.WG!
M9CCMFN;.F>*C-9RRZ9<2W2O;_9O)N&C@MX@3YBN XVN>&.=P/2NA\/Z[<9OY
M]=U&".UAN#9VTC (+@H26E''<%1CI\IH$02_#NTEDN[P3M;WE^+D7+B,/N6;
MJHS_ '".&&,C(-)<?#R";>%U.2-'D=F40*<JTB2D9S_>3KZ&HM#A\1P>)=7O
M$MFN;>]+/ ]S<%80!+\FW&?O(>, 8V\]:S(]?\6WEWJ5K:>?/<Q(P988H]D#
M^<P&PD?,-@7@\\DT#-6Z^',5Q;:C!_:TT::C<-<W 6W7#.P93CI\H!&!GJ,\
MY-:FB^$;?1=3%]'<O))MG# Q@;O-96.3[;./K2>$8]8$6HSZU%)'<7$T4@5C
MP/W*!]HSP-X;BNCH **** "BBB@!T?\ K4_WA7F7P:^[JW_83N/_ $(5Z;'_
M *U/]X5YE\&ONZM_V$[C_P!"%(1W/CGQ-+X8T);BT2*2^GE$5O'*K,I/))(7
MYB  >GM7.7'Q$U.XO8#I=I9M8SK9;))7)8&<.3D9'3RR,>M>BO#$\L<SQHTD
M>=CD<KGK@]LUQ#>)["+2;O58_"LITZ+:]M<!8@+DB38,#.5.YR1GL2: ,V#X
MB6QM#?C2(EOI+/>UXJJ 7,#3!2,[MNU3W]*OVOQ&<2R17NF8=[HVMIY,H/G2
M8C.T@_=)$A;Z*?2IH?$6C;;:VF\-O!=/J"Z=-;^2C+;N4P"S#Y=I1@!CJ#BI
M_#]UH7BZ\.H6UB(S83[XCO4;VVE!(R*>& ! W= >/8 U;.*35M1_M.Y0K;0D
MK:1,,>QD(]3V]OK6X*,48JI2YF9TZ?(O,6BBBI- HHHH **** /./BQ_Q\>#
M/^P_!_(UV;?>/UKC/BQ_Q\>#/^P_!_(UV;?>/UIC$HHHH ***J:AJ,6FQ))+
M%<R!VV@00F0CZ@=*3:2NRHQE-\L=RW17 VWQ*6;Q/)I[:;,+0,41E1C-D=RG
M].U=K8WL>H6HN(HYXU+%=LT91N/8U$*L)_"SIQ.!Q&&LZL;7U^\LT5Q'BOQJ
MV@^+-,L$GA2U54EOU="69)'V*%/8CEC["K/C3Q%?Z,UU#I[HDEMI,]^SL@;+
M!U1 /Q)/OQ6AR'745Y_;ZIXKN+JPL9;N>SCO;\PP7=S8(DSQB NV8\D !Q@'
MN*>_C>?_ (0EKDW,"ZVDIC 6,[952X$32 =,$9XS0!T8\'^&QJHU4:'9?V@)
M?.%SY?S^9G.[/KFKD.BZ7;M T.GVZ&W,AA(3[GF?ZS'^]WK.\4ZEJFEW^BI9
M) +.YU&*VNI)#E\,2 JCWP<GMBF7GB*6P\8R6-T;>+1XM-%W)<%B75S)LZ =
M.WZT 78?#&@6^GW-A!HMC'9W1S<0+"-LI_VA_G%2+X?T9%L532K-5L,_9 (A
MB#/7;]>]<K;>.[B"]U**^M8Y+9)[O['<^<L898=A","./OCYCU]*S;[XDZA'
M+97D=CY%@L-VNH1GYVA:-Q&L@. 2H9AD8'!H [BW\,:#:6LEM;:-90P22K.\
M<<0 :13E6/N#TJZ+&T%U=70MH_M%T@2XDQ\TJ@$ -[ $_G7G.F^-];O=8L=,
MG=;>&Y:S\S4/(!2,R0!S$.V]VR 3P!6WXK\9G1_%6B:+;20(T]Q&;PS$#$;[
M@BKGN2.3VX]: -^?PWH=W;6EM<Z19S068VVT<D080C&,+GM3+KPYI\NEW]E:
MQ+8F]MUMY)H%&[:HVIUX( XP>U8/@CQ/JFMW6J6NHA7GMXH9E!@\C8[[]T/^
MT 5X;N":J7'B?Q-#X0OM09+!;RUU9K6X89*0Q"1%P@Q\Y^;&3CUH T/#GP]T
MW1M)OK#4##JJ7KHTJRVRQQ@(,(%1>!CUZYKH4T/28YK*:/3;5);%"EHZQ@&!
M3U"^@KF_&'BIK&^LK32[^9,7$T=]]EM/M$L82(N %;KTY([54TSX@W.[1["]
MTXW5_=6\4T\MN?D42LPC; !&"%!;GY<\9Q0!V4NDZ=.E]'-8P2)?X%VK+D3X
M&!N]>*KIX;T.._6_32;-;Q2K"X$8WY484Y]AQ7%Z!\1;UH]-MM5L7NKR[432
MR6X^6%'=EC  '(&WDDC'O5RW^)/FOI"R:),K:C$EQMBE,ACA>38K<+R<Y)'&
M .N: .HM?#>AV1D^RZ19P^8CQN%B&&1SEE(]">35C3=)T[1;3[+I=C;V5ON+
M&.!-H)/?W-<E#\16D5]^BLLDF!9J+D$3$SF#YCCY!N&>_%66\<.GB&UT*;2)
MH[N58UN&BD$HMVD+!2"HPRC;DG(QGZT =A163X8U*;5_#5E?7(47#JR3;1@%
MT8H2/8D9K6H **** "BBB@ HHHH **** "G1_P"M3ZBFTZ/_ %J?44 >4_!W
M_D)^(/\ L+S_ ,Z]IKQ;X._\A/Q!_P!A>?\ G7M-(052U?\ Y E__P!>TG_H
M)J[5+5_^0)?_ /7M)_Z": .&^%/_ "2[0?\ KD__ *,:NQKCOA3_ ,DNT'_K
MD_\ Z,:NQIC"BBB@ HHHH Q?$?B(>'K":?\ LZ_NV2!Y@;> O&NT='8?=']*
MXKP-\7)?%DMVEQX?ND\@)M-@C3_>)^]TP.*[G7O$&F:#I\TM_-$6$+2+:;U\
MR=1U"J>M4-(URSCO[BTGT%M!=;473/-Y*J\>[:,E#Z^M &GXBOYM)\-:IJ-N
M$,UK:O,@<94L!QFN+E\5^)[9+1+]]/TSSQ<2QW%];;!(D<:L 4W_ "Y8D9SD
M@9Q7<:U?1:7H5_?SP>?%;0-*\7'S@#..>.:Y$>-X-62W1/#*7\VZ4JAFB>,"
M-%=FC<C#'# 8'<8H T_#WBF?6K>]#):0Z@HC:VLI9=C'= DA#=\ L>0.E0IX
MLN_^$;\.7S1VCW>HW$,5TF_:(U<MEE'7^' S5_2=8TS68KS6;73"[6P0K,L"
MM-*&B5QM[YPVW&>WI4::_IK:'HNIOI3*FJS16\42Q*QB))(W'IA2">/PH SI
M/'R6^NW,4ML?[+'E+%/(#$\;-$[G>C#./D//;WK'U/XH7D5M]KL]-46\=O<^
M>&^<QR(56-^,90LZYXSS752>*-%/B*?39XT>0"(QW0C$J3,R.0H8 \@*P&>O
M-9%]X_\ #.G)'Y-BLMO+!<'<L*HH>/&8F!'!;@#MG% $F@^+]0U7Q.VEW4,-
MM LDRQS-'Q=E O[M.>"H;<<]>PX-:>O^*QH%Y- VGM,D-JEP[JX7&^3RU&,>
MO4]A533O$NF>(M7GT*WL&6:W9WN&5PA@ P ZD<EF)Q\O('4\U?NM1T+P_))9
MWDDQ9K?SY#.K3_NBVT L<\%N OJ: *_A[Q)=Z_K<\8MDM[&.QBG5&.Z0N[.I
MR>FWY#BL*]\:ZW:^*=2L_*MQI]O-<11N\. WE0B3 ?=S)DCY<8(SSQ6[9:MI
M7B/5)-/LH+A8(+6.<W4#& '+,HC^7!XVMQT%+9:[I<OB"_\ #S6BHM@I=[FY
M=2'8;02=W)/S@;CS0!D1?$5[>TNYM1LHOW0D:/RI@"X2*-\$'HS>9Q]*L7'Q
M%M[>/5"UDN_3Y5AV_:1^_8AF^3 /&U3R>^1VK2D\0>&FEN(FCCE,*M(Q%GN5
MPC!"5.,-@D+Q4VCZGI'B%[M;.S@DMK<1%)6B7;*LB[P0".,'/7OF@"GHOC2+
M6M7BLET]HHIO,\J9I V2D:.05QQQ(.?45U-1);01L&C@B1AG!5 ",\'] /RJ
M6@ H.#U /U%%% !1FBB@ HHHH **** "BBB@!T?^M3_>%>9?!K[NJ_\ 83N/
M_0A7IL?^M3_>%>9?!K[NJ_\ 83N/_0A2$>P5S#^ M%>WO+?_ $Q;>Z&#"MTX
M2+YPY\M<X3Y@#Q73T4 85KX2TJULXK=5F?9>+?&669GDDF7HS,>3T ^@J;1O
M#.EZ#/<36$+(\^ VYRVU020JYZ*"S''O6O10 4444 %%%% !1110 4444 ><
M?%C_ (^/!G_8?@_D:[-OO'ZUQGQ8_P"/CP9_V'X/Y&NS;[Q^M,8E%%% !0"1
MT)HK/U>VU2ZM4CTG4X]/G#Y:62U$X9<=-I(Q]: )TTRQCU!]12SA6\<8:<(-
MY'UJSDGK7B]OX'^(R?%*35#K86W)+'4BH,;)C 3R-WX;>@ZYKUK2K?4;:R\O
M5-1CO[G>3YT=N(1M[#:"?SI));%2G*7Q.Y5OCX<BN;JUU"73HY]255N(IY55
MKA0-J@@GD8R!BDU72=*GN[>ZU&2%(H[66TDBF("30G#%6SV7:#^=<=XXT#5M
M1U_4I+.QO9X[K388(C!'$T3R*[$K(7^95Y'*\\U?\;65Y?WD5HD DEGT&]@M
MXD/RFX/EY4$_[.<>U,DW=3E\*:SIL4VHW>F7-C#+B.5[D;$DQC 8'@X[>E6Y
MK/1)O#GV26*R.B&)?DR!#L!R.1QC..<UR%UX2FTEM+U%;>XUBX.H0W%[%%!$
MF$2%T 6,87@MR>II'T#Q OP\U+38K*W1;LW,RV&<S1;Y=R1KCY.!U'8GB@#K
MTT?1=.LX81;00VT=RDT0D8X6;^%@6/WO2I8-)TNTOH9X;2"*[C601L/OA6;<
M^.>A8Y/N:Y[7[*7Q/IVFW T>_@NK'4;=XXKDA2%#J7? 8@X4'D\]:=J%GJ5W
MXYLM8M=.FC\FTNK1))Y/W0?>I1W53DHPSC'.<9H V6T30KXW"M8VDY#R"9<;
ML/(!O#>A8!<_04V/0?#]B5LTL+*$SQRQ+"1@R(V#(H!/(. 37(C1?$=IX@U+
M4[>&X,MS=3EXX;@I#*OV50K 'IF08#'D8K)A\+^*K];!I1?07-A<W-S9374H
M<QDQ1F-6.XDJS!U(R>M '?&Q\+?V=<1F/3?L16&2;]X-N$PL3$YXQM !]JTK
MZ#3Y1;SZ@ENWDS))#)-CY9.BD$]^>/K7E=EX.\11+8ZE)8N6T^TLY&TMMI2[
MD1Y"Z'G[R!LKVSBNH\?Z+KVM3:1+I<4,]K:7,-PUO)(4?S!(IWMC@A5SQVR3
MSQ0!T%AI7AZ&62+3K:Q$EM<B:18&!:*;! + '@X)P#Z]*FELM':TOK:6*T^S
M^;Y]XC,-H<D/N?G@\ \UQ_A?1=7T+Q1J-]+I\YL]IM8E54#R;[AG\UB&^<*&
M/S'!P<8I;SP9NTCQM81V4S17L@N+)?.)-Q((>I.<GY^QXH [>X6RDGLKNY\D
MS1O_ *+*Y&0[KCY?4D?F*JQ>&=&@FMIHM*MXY+7/D,J$>7DDG'MDD^V3BL+7
M=-UN[L]&BB@@DAM;BUE"QD^=&4C8,6)^7 )&,<UC6NA>)+:T@E(U2>XBT(LT
M3W[+OOF?Y@3GJ%)QVH [1] T*T$%R^GVL L(RL4K#:(4R2>?3))Y]:2'1-"F
M^R>18VC_ -F'R[<Q\_9\8.WCTX.#7G%YH7BZZ\-O97-KK%Q&R7<<, N55U9F
M4Q&7+'<FW<,$G!J[JVF^,!<R?8+;4-HOVGADM[@* O[K *[AE=HDZY[C'.:
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MAT"#3\OI$@LIFC6)Y&3SMR*6(&">N6)S[TR/PMI7VTWUU;)=7CEGE>3)1V8
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MC?E7F?\ PIL?]!G6O_ YJ/\ A38_Z#.M?^!S4 >F>6_]QORH\M_[C?E7F?\
MPIL?]!G6O_ YJ/\ A38_Z#.M?^!S4 >G1QN)5^1NH[5YA\&NFK?]A.X_]"%+
M_P *;_ZC.M?^!S5UG@GP3'X0A:WMWD:-G:0F1]S%CU)- '9T444 %%%% !11
M10 4444 %%%% !1110!YO\6F5)?!SNRJJZ] 2S'  P>M=4VIZ=N/_$QLNO\
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MW_01LO\ P(3_ !H_M/3O^@C9?^!"?XUPG_"BO#7_ #X_^1G_ ,:/^%%>&O\
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M^/X(>%I0#':JV0&XG?H>G>@#OO[3T[_H(V7_ ($)_C1_:>G?]!&R_P# A/\
M&N$_X45X:_Y\O_(S_P"-8R?#?X>R>3LEB;SHY94 DD^Y$2)&/HH((R<=.* /
M5/[3T[_H(V7_ ($)_C1_:>G?]!&R_P# A/\ &O)/^$!^&_V&"]:39!</LB9Q
M.I<X!)"D9V@$'=C'/6K=G\+_  #J&K3Z7:/%+>P9WQ"63L<-@GAL$C."<9YH
M ]0_M/3O^@C9?^!"?XT?VGIW_01LO_ A/\:\JM_AO\.[K7'T2"XMWU%"081-
M)RPZJ&Z%AW .15G4?A1X&TD1F_$<(D21T)ED.5C&YSP>PYH ],_M/3O^@C9?
M^!"?XT?VGIW_ $$;+_P(3_&N B^"/A:9%:*U5@RAAB=\X/(/6I/^%%>&O^?'
M_P C/_C0!W?]IZ=_T$;+_P "$_QH_M/3O^@C9?\ @0G^-<)_PHKPU_SX_P#D
M9_\ &C_A17AK_GQ_\C/_ (T =W_:>G?]!&R_\"$_QH_M/3O^@C9?^!"?XUPG
M_"BO#7_/C_Y&?_&C_A17AK_GQ_\ (S_XT =W_:>G?]!&R_\  A/\:/[3T[_H
M(V7_ ($)_C7"?\**\-?\^/\ Y&?_ !H_X45X:_Y\?_(S_P"- '=_VGIW_01L
MO_ A/\:/[3T[_H(V7_@0G^-<)_PHKPU_SX_^1G_QH_X45X:_Y\?_ ",_^- '
M=_VGIW_01LO_  (3_&G1ZIIPD4_VC9=1_P O"?XUP7_"BO#7_/C_ .1G_P :
M/^%%>&O^?'_R,_\ C0!G_!Q@VHZ^RD,IU:<@@Y!&:]JKD/"?@:R\)@QV$8BA
M+%BH).3ZDGZ5U] !1110 4444 %%%% !1110 4444 %<CK7AK4[S4-<N[*:U
M5K[3X;:$3@L R.Q;</0AL#^5==10!Y5'\-]2CMI&NIHOW-I?K;>2S/)#),RM
M&R#"C*@,.,=>*Q-.\!ZUK5G>,NG1Z;;BYB*V,Q>*.8"#RRPR"P(8[@2O7/UK
MW"DQ0!Q&C^";K3#XDC2:&(ZI B17J,QG1Q"(R6) SAAN!SR2>E<[<_#/5[G1
MK.T6+2[802-YMO;SR!)LQA/.+%3B0$9&!WZYYKUJB@#S&Z^'&I3R76Z>WFCE
MDNF"M,Z,PD2%5RP'7,9SUZ]^:Z/0O#NKV/A&/2Y-1AL+I)69)-/A4A$+9"X9
M<$^IVCZ"NKHH Y#7O">HZOX7CTF36);F87L,[74N(G"+(&(4H.&P#@XZUS__
M  K75I%737U.#[ MY/=R7<JF>XNF=-B>:K<%E4L,Y[*0,UZ?10!Y*_POUR\N
M;6:\U"T+Q6]M8S2(6W36Z%Q(#QU93'^(-3V_P_\ $FFZ5/I]A<:0T6I6,=G>
MM<*Y,.T,NZ/ ^8;6Z'&"*]3HH \]L/ ^K:=XLM[VTN+:WLXI%,TL4L@>ZC5-
MH62(Y0OP/W@(/'2KMSX;U^W\2:A<:9+I3:=JD\,]R;R)GEA*  A .&R%&,D;
M376W=]::?;FXO;F&VA!P9)I BC\3Q4D,\5Q"DT$B2Q.-R.C!E8>H(ZT >7V7
MPTU>V-WYEY!)(]Y#-YQF;]^J7'FEG7;PX'R@Y/Y5+I'P\U?2]:T>]#:<QM>)
MY79G.W>[81"ORG#CD$>X->D&\MEF\DW$0EW!=A<;LD$@8]2 3]!4V:  4M)G
MVHS0 M%)GVHS0 M%)FC- "T4F:,T +129IC3Q+,D+2()7!*(6 9@.I [XR/S
MH DHIBR(Y8*P8J<-@YP?0TDL\4"AII$C4L%!=L#). /J30!)14<TT=O$TLTB
M1QH,L[L  /<FFBZMS*L0GC,C$A4#C)QUX]LC/UH FHIC2HA4,RJ6.%!.,GT%
M.S0 M%,61'W;&5MIVG:<X/I3LT +14,=U!+)LCFC=]H?:K G:>A^AP?RJ7-
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M>,D>F*[JBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M9Y#9[&NJO="%YJNE7&Z,6^G)(4B9=W[PJ%5N?[HW?G110!RL/@#5)+&*SO\
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7 **** "BBB@ HHHH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>g4i5nix4zlkt000044.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g4i5nix4zlkt000044.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #Z J # 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HKG/&>FZYJVD)9:'>1VCR2#SY6<JWE]PI ZUP_V!O"'Q'T/3-%U2]NOM0_
MTVWFE\P!?[Q';C)]L>];0I*2WU(E.SV/6Z*\BMM/N/'^M>);VYU.]@CT^0PV
M,<$I54(W8)'?[H_.MGPKXHUV^^',=U:V9U/5HIS:X=\;NF'8^P(SZXIRH-+?
M7_,2J7/1**\N^'4FIMX\\21ZM<^=>(BB4JQ*!L]%'8#I^%4O&G@O3/#^EW6K
M2:SJSSS2D06ZRC#R,20HXZ#^0I^Q7/R-A[1\O,D>O45S/@30+GP]X8BMKR9Y
M;J9C/*'8G8S ?*,^@ _'-<C\1H%O?'WANPGN)H;:X4I*8Y2G!;KFHC34IN*8
MW)J-['JE%>,:W:1>"O$VB-X<UJ[N9+B8)-:R7'FY7*CG'8Y/7TXKK["XTMOB
M5KD,*Z@-26U!E:24&#;A/NKU!Z?K52HV5T]!*>MCN**\Q^&.K0Z9X$U34=1N
M'$$%V[.[L6.-JX _'M[U<3XJ1JL-Y>>'M2M=)F?:E\X!4^^/3Z$TG0GS-+6P
M*HK)L]"HKRSQSXPN[;Q;HMM9I?-8Q.D[I O%Z#M90A_BQZ=,D5Z;:7'VJR@N
M#$\7FQJ_ER##)D9P1ZBIG3<8J3ZE*2;:)J*\!T34;G3?B&VHO<2FU757M90S
MDJ!(6 ]O_P!52_$S4+J^\67TL$\JVVGF*T^1R!O(+'I^/Y5O]5?.HW,_;:7L
M>\T5R6M>-%T2ZLM*M-+N]4U&: 2>3 ,87'4G\*;I'Q M-3TG5KN2PN;:XTI2
MUQ:OC<, ]#Z\$<XK#V4[7L:<\;V.OHKSR;XK0C3X]1MO#^I3V(P)[C 58F)^
M[GD$]/;FMS4_'.GZ;:Z+<B&>>'5W58&0 ;<XY;)]Z;HS707/'N=/16#K'BJV
MT;7=*TF:WFDEU)]D;IC:G('.3GOVKRW4M2?Q)\2I(+VWUU;5"L45M;,4>(Y
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MX,C(4XR6/T]/4BN)\ ^(O#MEJ<(EBU.[U_49!'->SQ# 9CT!W<+[]3^E>PD
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MZS;_ 'S2DM"H;EM(N<8J8Q[1263!S(/,W%6P1Z5:D3 %9FI385&15ANM1$4
M0XJ2,?)05J:),QGZT#&8YI=M2A.:79BD!#MII6K.RFE*8B#;1LJ;9FG^6,4
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M"E6=H]*0I2 K!*79[5/L%&VF!7V@4F >PJ8KS32M B#"CJ!3''<"I&'6N?\
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MSD "O&Y8RMS,,#_6-CGWIB.AMM5DU&Y6%;94XR3OSQ7->(A_Q.YO]U/Y5O\
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M:</O0X^DZUV\?A70449T:P!]/(!IS:!I,9'EZ3IP&.OV=?\ "J<GO8$CAO\
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M>W(;G!V] :R_LL[6RRQ6LN8@7+;??K[\UTUUJ<4IM?,FCDB,"L!'%LVY^\I
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M:G_U\-_.O::\3\1?\C-J?_7PU*12*MK,8KJ)P 2&'6MGRO.D\R=Y)#OR SG
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MI?BRYO7TW4[TZ9;.L8\M1" <9P#C<WXXKQ26XO\ 6KPS7$LUW<OU=V)QZ\]
M*]D^&VGW&F>%PFX&2YN6D;;T' '/X"FDEJ*]ST,1Q0:<8HX_W>W 3)/'U-<)
M<V<*SL3'@D\9).!7<R[/+$0DVA1BN4U.(PRAL@[CP*&[@9:HR@I$ &;T%,>2
M1?W8;.."1ZU8!*([YP0,9JM%R7!&=IZTA&Q97)CVKN[=36N9LQ[@,MCH*Y&&
M4+<9<G#'"@=_I6W976X$KDG)'(JP+)N A#R# S4$\NRX9&[\TVZ#NBHX!WGE
MAWJ&^+"[1T[+MVMWH M)(IMSR:KC<H)=V9NIRW I/-(AV%%&1Q5W2]/:XVR7
M!/E ]^-W_P!:@!MK8SW(,A_=0CH[#K]!WJ_NM[",O#'O=>=[]\=:GO;\10/L
M16 3A3VK$F?B.09*2C&?[H-2V-"W^J11,UU]DEN97&%)/RQU@23S7+[W8X.3
MP.!^%7AN5FCZ@<;3T-5W>W*.\&]F'WHSU6D#.?UK^V1'LTI8(QG!FX9A^!JS
MX9T7Q)/<0W>I:K&UM'+\T<2##C'3/:M(V\DV N221QMSFNLTBV^SZ>T$D:H2
M?F11^N#0 OE D$9(]/\ /2L*/1M>36A=-XGDDL/,+&R-JHRO]W<*WR1#.8SD
MJ#P3UJ<?-5"*ODJ>JG\ZD6) >4..^*L;:,4P!8K/ W!_Q45,BV8(Y(P<C*BH
ML4N* ,V'PGX9M=7&J06C+>!S)Y@=OO'J<$XK8E6RE0(\32+V![5%BEQ0!D:E
MIX$;O;9V$8(;JM9_VM(GBC$H4<!$Q@^Y-:VK3,D4=N@^>4Y+=@HKG[B&*5O.
M612\?)7<#T]* *DU]<VVK1O<6L)C<E$C)Y..ASVKL8=1@OK,B&5C(GWXV.<'
MW]17!:OAM0AF"E0"6#YR&&.WO6CH4_V(P^:Q*E )3UZDT = MP4=E3E,97)X
M&.N?>L^)&@U29I)Q%"\A=1L+;R>V:M33/%#(D()N(6R!D<J?0>F*S(KYS=30
M2V@CV#E\CYCV.,9H Z(S%[3)'?:5SSS52<)$8HQ]Y0<X]ZKV<[S:?-YFU9F?
MY57@*?:E"$*.<GN3WH M6^H2PX#'>H[9Y%;MI?)*@.[*],]Q]:YBI8)6AD#K
MT/WAZT =CGWHK"774A0*8V?!XI3X@)^Y;_FU &[5>_XT^X/_ $R;^58QUVX/
MW8HQ]:AGU>ZFADC;8%9&S@>U %70LGP7IBCN6_F:E=&V9]><UG>&)G?PY9QE
MLQHIVCTY-6W2ZMY6DM9 ZDY,3<B@8\2!XB&'S)W]157S?)<D'<C?>!.15R.^
MM[B3RY8Q;W(_A/0_2H+NPVYFMLE3]Z//3Z4 (I1^4*\^E29,OW=I([9Y'TK)
M60QL=K8.>4-6$EW,'( <=&3J* )[K1VE@GN!'"Y="<.^,''4"L3P]IVK'0+5
MK:,/%*A))E"AADUT:ZFILIX94 ;R7(![_*>1[U6\(JI\):83*H;RN?7J:CE1
MG+XDQ- LKRW\2VCW5N\>Z&8 E@0?N5W5<U%<P#Q/I]H)XS<"&>0Q@\[?D&?S
MKI:J*LBEL%?)'C?4[ZV\<>)K2&5%@EOYMP*@DYXZU];U\U^+]/M9/&FM.T2%
MFO'))7WIL9YUIC/%?0NC#<LB=![BO>7/+'U'%>:);6L3 B-<@C'RUZ/G< ?8
M?RJ0,&[_ .0X_P#UTC_E4U\7358I(I&BD" AUZCK4.H8&LL?^N9K8M-"O-<U
MB$0_);Q*/.F(X7V'J:0Q--FUJ^=+:RN+@R,,L%; ^I/:NQTW1/[-7S;V[ENK
M@?PAR(U/L._XUHV=E9Z-8_9[5=J#EVS\SGW-07%XN-J8R>K4#N,N+@SQL&7Y
M>P[#TK(2XFBW+*-LA;DC^+T(JZ[AC]X<U0U(/LCEZJ#R1VH"Y9^TE5^8MC\Z
M2.XBD? <%NP:JD$Z2)M9GC8=&'2K#V_F1%9T1@>%D7K3N(G6::.1?,.]"<?2
MLGQ5;F;07989':VE#*Z X53P<UH1!8E"^8S[> ''(_&K[W)MH'F<A(<<[SP?
M;\:8'D?!/;!]ZIW<0B;>N'63_6(#SQR"/\*W;JVTF>[>06\\>YC\D3@(/IZ4
MT6.E(O\ QYR-_OW'^%"0BSX86/4M?LX@=RJ?,<?09_G7=75QY$UK,6(4R>6W
MN#7-^%(K6#68Y+>T6$E3DAR<UOZG&EQ'-;DE2_*G'1J;&:EC*BJZ%A_K&-7^
M,YQ7"6&L[+\QLDDC>5N.S&,]/Z5T=CK+32M%]D90%)!=LFD-&MD!^F,+TI'8
M8Q^=5UGR3W!7-07,[!_EZ=<'H:07(;N1O-6,#Y.I/?'^-1R6R7,D,LIYCZ@=
M_:H)IG:].$RC 9W'A:LK,I0L1M4<9[4/8J"3EJ.DM+2Y7;- H/\ "RC!%<]J
MUC+9>89(U:W*D+(G3\?0UT08>H^H-/\ ,4J8W D5N&5N0:Q]HSIE135T><%_
M*19$.-A!&*Q9Y?\ 2;IFX)DW'\0*[S6O#$9C5]+ 0D_-;.W!]U/;Z5BP>!+R
M^DF%W?VUF&VY3_6...^.!6T7<Y91<79G)"9;W7[3S>5EGB5_^^@*^@I%/D[0
MH 4E1[UP>G?#O0+"ZAGO=0N[QD=67&(E!!R"<=:]"DOK2S*RB/=N/4'.*F4T
MG8E)L9:V-P2Q\O:"!@M0FBQ0WJ7LI#R(?D1>G/?FI9=5$@RI\LC[K$UFW.J&
M=6@N3\I')C['MS57"Q)XF@MY]'O'6<%TBY7.2:YO3OG2+?,K(T/"8Y4[>,57
MU2[MX89(8[C)D4KSQNINEF3S8#GY?* 'M\M"W!['DVF^?97[PQ.[+,=@^3.2
M3Q]#7T':V46BZ;;V43,%A7DD<LQY)_.O%/!]M;ZGXRLHH;A&\JY,TB9R2J')
MX^M>XZBQ;<3P3D_6KE;H2A]O,9K>:0$D@[2#UZ=36%?7*RN&8?-V'H*L$F'2
MI)^FYRJG/4UD,>[9/%9E#YG*V;D<D_-@^@JM;D"U!)SO.\^PJ:]^2,*.R?SK
M/M59[/RI,,RMCV]10!)O=YU9>7SA1CH*W+-"D"J#G'>LVT54F"_>8@DG/>M&
MU;#D$?2J$:"2)'&\A7<R#Y<GN:QWEEGDRWWTX?GH?2M20*UK+E=W&<>M<_8S
M&::>0_QMFF@-!3OFABZEF&1ZUTYN(8%$4:Y/?'\-<I;1S2WBRQE0492-PR",
M\ULWD<L(>=)6SCMV]A28&;>7<PNG1V+*2?QJ*)FD81Y.",=>*8\K/D2("?4=
M:6U.VX5^H]*EC%VL).>M,.G-(YD565O[R]:T9% VOCJU7K=0I.#G<.*0$FD6
MOEV^Z109,]2.:NR$)*C'^+Y32QRAX5(],$5#<DD?3FF LT1E,@5<NHRN>XJ*
MV?@QN<$'C-2^:-@<D@X[&FW2!U601.2!ACCK3N \SPCJZBD^T0#_ ):?D*S&
M/SGG- S5"-+[7 .C'_OFD^V1#H&-9_- S0!?^VCM&?QI/MQ[(/SJGS1]: $U
M"4S(&V#@8(ZY%8MQI\4HWSGRE?E5B')]_P#ZU:DUP8IE41[EQENU8-SKD$DK
M*EK)'+NQN9]PQ]*5QV,RZEB>.2*W>7:IQLD3'/\ >'I5;3+Z-($5WE+ \.,@
M[O2K-^X2222.+RU9<GYLYJC;@+"/E.Y5S@>M"8C=OM<N;RY@BMH4MYF 5W3[
MS #GFI5O9GN)H)!$8@V4*IAOQ/<UGZ;"MR[3ALLG*'/7')_0UJQVO^EGRTRA
M/7^Z/>BX%X,8Q H&-QPI Z>YJU(&V;F'T([UR_C"_M;+3%^T:BVGAG5%N(R0
MP.<X&/7%<E??%.32A!;V]L-2)&7F!*9';@#K3 ]2^AS[4H/KQ7-:+XTLM3MX
MVN[>?3Y7 (6Y7:.?]K_'%=*"K*7#C;C.3TQZT ,FCD.UEC<@<Y ID;9%(T+7
MB*]I^]3&0T39'Z58CLM@'GR%&QRNS./QH 2C^%S_ +)_E5D1VB_?G.?]Y1_6
MDE-HMO*4)+>6V#N]OI2 P/#TLB>';+RR!D'.?]XUJW%W(B 1P>:Y[G@5DZ$T
M7_"*:<HP)0IW'/49-/26\$["TE8 '#9Y'UH0RO?7.HW *>3M&>,#I]*?I^OW
ME@RQWRO*F=H('S#\.];D$[F+==O$,=\5%]I@:Z$-K'&9/XIBO %,!]Q:6]_$
M;FT.[UQP164LGV>3:RN!GJQKG=;O-:TK7#J6D.5"':\;#Y)5]Q_6NHLM9L-?
MA47"?9+S:"Z-RN3Z'O0QHDN9D;3+O:J9$$A#$9/W37GEQ<7J>$=!EMWN$18S
MODB<KAB> <5V]_:7=E8W3!!)#Y+C?&<C&TUS>EZK$/#^G:<@7>8@[@#)QDXX
M]ZEZ$2U:)OAI>/>>/F,N6D6TD!=LDMRG<U[77F7A$VW_  F-N$QY_P!EEW8&
M.,I7IM..P]@KYW\5)_Q6&L' _P"/M_YU]$5\\^*?^1PUC_K[?^=$@,4Q#'2N
MY4_N(SZH/Y5Q9/!KL83NM83_ + _E4C,R[M9[S7HX+6,O-(J;1]#S7ID9&DZ
M;'#;J!L&/]YNYKFM MV74+B_509#$((B?7.3^E;EQ+&8Q )5>52"X!S0!FW.
MIW+2[6D8 G)%-2:28_,<XI+N'+9SCBF6X,<@).588^E,"Z@Y4#OTI\C!!L"Y
M!'S9Z?2A3Y;\8X&10]PVPXBW-Z*.30!0-G/&X8 F'.5&/N_4UK0"(@&1UY[L
M>!5%(KRY!PS6^#QMY-.DTW4)K66"6X9_,'#[0 1Z&@#0;]VQ1T&.WH16+XNO
MWM_!NHR1 "6.,/&Q&1NW#%:%D;R,BVN;=E1% 5CS^7M7&?%6]=[/3_#=C*@N
MKR82R\XV1KTSZ9)_2F@/.CKNKNV0RMD_\\J7^W=;3CS1'DX'[H5E2Z5K0U!+
M#8YN92VP"3CY>I^@Q5SPEIT6MS7=K<ABT49E60,=W!P15".I\%ZKKS^*[.&2
M5I(F8^:KH.% ))KU:]5955UQ]?2N'\&Z%#HGB NDD\K&!@=TA(537<9^0AA\
MOIBDP,#3=.^SSW=RL>U)ILJ#V%= _#PL. #U%5+&87%JK)$57GY?3FK8*^5A
ME.T'BD,GM9=[JO&>0?>FW>3M/J*9;Q/O61%^ZXZ^E2WPP&P"<'\J ,J14-V&
M)ESMQM09!JU,W^C,6) (X!XJ+(BEBWAF+YVE*?>'%I(VP.Q  +'I0!AR:K)8
M,RK!*<G/&"#5RRUZWE(^T![9CU,G*G\1TI+J)&A8Y'!XQUK"O4E&(U!Y')!J
M'!,N-243L9[9=3MD*SXC[/&V0WXBHTTZXA7$+*>W!Q^>:Y/PUJEMIL\DMR66
M C9M5^A)QG:.M=@-1MKBS>4W(1%!)E P%'HP[4E%HKVE]RW;:&7VR75P&7&2
MD1Z?C6E#90L455+QXY!;D5BZ!K&GWD;2QZE;2Q $_)(. .I.>@K8TS5]*U&U
MDNK.[2>)&*;TX&X'!%#5]R6^Q1OR+3:H&X;L<]JYR]:ZE&QKCRXSP5C&"?QK
M:U:XCECD".&Z$$=L52DMQ+&64CD<9JB68,UE&(&**3L!))Y/2M2V!BT?SR>M
MO@?]\TMU;&*V=5<$[&)Q]*JD2R^'/*AC9GEA$$1 .-[_ "\_G36XNA@?#GPS
M+::S<>([8%=,AB:) H/S2-P0/8=<UZ49WN8RP)/\*]\^]7='T==%\/V.D2W$
MT@M(A$)E0(&^JC^=1K;K:RJBMN4-D-38%'6)$4P642XB@'_?3'J36>R;B@]2
M*FOB7O&)/)/-+''F6/G@9)-(#/U25$:1ST3BL_3"TL!Y.YW);Z4[4=UU<L@(
MV(?F]S5O2;8V[3P$IN4CRU)Y.1DGZ4 6(RD3KUW Y/T-:,0^4,2/;VJFT*1E
MG8X]?:J\DVH&0BWM_+B!SO8XR*8C:#N%/EKO"<L=V *P;/F1^ H+DFK]A.$M
M@\GF29?( &<_A6>DHDN)I%&U6?(5>U-,#4#K"RE,<<_6KUMX@'_+2V62.1<[
MU[BN;U74K?1]'N;JXD""-"1O/4]A6[X4*MX5TV[FFA:XF@W>8A!Z\[5'08Z4
MF D\$#DF(A"><-Q595,<H5@1U%;"VB%QN(?N"Q!Y],5&=(ENI!,\BQ,F053E
M?QJ6,@4$6X&<_-D>U7;-N&0Y.#D?C0-+NHU)**P]C4EO!*KY\MORI-I;@3Q!
MP#MY4&DF? =CG&*="_DQE)R$;<3UJEJU[#:6AF+;U_V.?SIK4!L=QYMUY?!6
M-1D>YK0M[IB?DR?QXKCK'7+6[9KN$.T$C%?,*$*"/KU'O6]:7,<L&X/[<4P-
M6Y@AG0@!!,>1(!U^M9QMIE<IY9)'H,U%OD,DGE/\R#<03T'K46I:HVGZ3+=S
M>9-' -S[%W-CN<>@J8R;8VBY]FG_ .>3#Z\4?9Y!][8/JXK@I/B;IV/W=G=R
M?2)1_,U6;XG MMBTF?\ X$ZC^E7<D]($8[RQ?]]4H1 <^8C$=%&>:\X3X@ZC
M+D1Z6J_[TQ/\JV/#6MZSK<M^EY:1VZ0A3 Z,2),]<YHN!TVJPRSQK)',L+#T
M.#]".AKC[^V,7WE.1TDV]:U-2DFM9%5I2=PR0AQBLY[@BW9S(X1>27Y_2D,Q
MY[XW4\-FJ,%BYD;/7'05*Y9!A3AF&.1TI+<1HTEP?O,<\CUJ40?:4*J=Y'(/
M(P:$(T?#Z&!?+<<YWQ'U(X/YBNA:?:K9A1FZ!P,;3[^M8>F &6%3C;M!(]2:
MUI=L,9+,QP  6[X]*8'(^-K:;4(K*&/#,6+;3%N4_7TQ7,Q^-$T[$6F:;"#%
ME!-/AF8CC.!7=7^^15;@$QDCGO[UY#=:3J5O([-;R0Y)P#"2OYB@#O(]?EU"
MS2YG^R$2#:?,7C=Z5D7RFZLFM)&NK2 DG_1)R8B2.ZGH/H:P 9VLXX+K24NH
M V\>3<E&WCO@C%7]*U;3=.:1)[;4X$E !$L0D0$>Z_X4-@7O#MCJFB+)+8ZJ
MEX&C\LQ,IVH,Y'&<U/-KGBGSBBM"H _@AW9_$U2;4=.>X\S3]1A\T'@+)M;\
MC7H^A6@U+1K>^^3+J=VTC[P/-*['8X)9_&5R,"]NU'I&@7^E7]$L/$(UBWN+
MVYO7AC8EQ-)\K#![5WVVTA_U]W;1#U>91C]:YB'QQIU[XBN=$M4BS&S1QS&3
M=]HP#DICT]Z+@9-EX<OKB]L=9MI3&\05D.\X(Z$$=.:[V;S$*LJJF>#N7.#7
M-P>(]#T[18+"YNKB.Z6'#K%;L^PGIST/6MY'\RTM3O=HY8U:-I%P2<=QZTTQ
MLSIUE\\R"9FDSP","NAMFABMUCC3:S?,Y/7-16T9D 3RE#]SBF7-I=M+L@^5
MB>6/ IB'7=A]HF#R@E#P 1Q6;<>&I$,LUL2@5M\94C@8Y%;UM]K1/L]W&)1V
MD3M4LMED@XV*/5LYI#1P>MI>Q>&YIVNYUDR,[!_">""/0URVD/?J\8TQ+*YG
M6/(4Y5T'<9-=QXTN9++03-$C>69/)D*J,88>]>;#5Q8QQI'$V0,$J0"PJ60_
MB/0?AVUZ?'2?;(-A^RS?-NW G*9P:]EKPWX4W_V_QLI,C$I9R_(QZ9*U[E50
MV*"O#/$F@7]QXIU291$(WN7927[9KW.O,]:'_$ZO?^NS42$<./#5Z1\TL"_\
M"K;2)H84B)RRJ%./7I5P]*; 56]C=DW*AW;3T/I4C-F4?V5I\0*A94' [GU-
M8$6HNU[*R(J(F  O<]ZEU.669S+)(S-W)/2LR."22#<C  GGU- '27$^(TE3
MYD;J/2K&GVAOE9U)2'/+$?R]:S- TN6Y?S@[K;H?G8'AS_='O762$)"JH-J#
MA0.U,!\=M!$H^3./XCU-0W!0[MJ >F*19B5;))/;-1.^]0.^>:0$ML/E JP.
M.G&*AAXJ84#'HY4^M9M_X7\/ZM>B_O-.0WN!_I"$JYQTZ=:T.^.].Z<>E,#B
M=1^%\#ZM%JVEZC(ETDQD,<XR&!'*J>P^M8-KX;L].NKB*'0[BUN)F:.5D+D[
M<YX)XP?:O6H78&JVK6-KJEHUM<QEE()0[B"A[$$4TQ'&^&M-^RK(!:/;DKAW
M=@2>>.YK:G8-"[19+8(+H>!4F@>![S3-[27D(\Q1D)DU++HWB.>_$!@L5L%D
MPTC2DN\>>H4#@TV!FZ1;O;Z;'#+N+ =3W]ZGE8H%!4'O]*Z@^&[?=DW$N,]!
M@5#=>&87.^"8A@.C\@G^E &1:R<>9(.,=*AN7F:]+JC;-N.G%5+N\N;:Z:TD
MBC21.J[L\>M<_=^-)]*U62&[@DDL"?ED489![CO6%:JZ>R.K#T%5O=G3E2_E
MX5UVG(([5'>1// RH@W\<OS^548?&>DRQYMK@2*!DX4\?6IX_$27!Q!97$I_
MV4./UKBEC6=\<N5KM$,EA.%8A"YZX7O7+7NJR))(D6E:K/*AVE$MCD5V_P!K
MU*89CL?+'_31@*3RM7'[T21Y7^#)P?:G#&M;JY,\!![.QY]#X?\ $=S:K,-$
MNDB=LJ9<*3SZ=JC/A3Q?.@M7C*VBDXB>==OX^OXUZZM_NL!/J) FC0ED7) P
M.@KC(M>O]2O'E4F! <)$!D >A]Z[X5(S5XGESI3@VF<<GPWUHD&26SCSG/[P
MDX_ 5OZ#8S>#+J9[R=)[>Z0*RPY^7!ZX/M71QW5Z[8>!" .HR,U#<1O>;3+$
M%4=JK0A7+"F*4B6U=9(GZ'J,5H6LF^R60B-<_P"SV%<NSM!+B+*J.% ''>M*
MTN6?288BF"%(8YSGWI#8^28S&:-6.UCZ#)&.F:32W/\ 9EF!R<?*F>.#QQZT
MU08S&=V$)PQ!S5OPI"EP(_M'RVT&6;ZYX'THZAT.WP%@\U"P+#F%SQGO65<*
M/M)\M2N!N()SBKDTT<.3#,LL;?PGJ/3'M6')>&:ZN(AN7RR P/OS0Q%*Y_X^
M&Z\]*=<2"VLF=N#MYS^E+,Q,V1P>F:LPQ6\JR27$?G)&1A3RN?4T 9VE:0CV
M[7%R=K'[J-^I(J>]M(46,V\<;,JX))Y('3GU%33W<B#)*,IX*]#CZUDSZG"D
MN&)B)Y",<@_C3 KF^E$P34+=O+<X1XV!Q^'>K43@7T423><C L'S]T>E9=Y+
M'=-M2(,SD;AC@U- K00-$&R[D*<?PCVIB+5QJ$VFP+%!(ODRJ0"!\V>YJO;W
M+&(#<.>HQS2ZLH:SB\H#Y3C@<XJBSNEO\FS<1_&P&!0!8O--AUZ(:;(B2J[A
MCYC';N'2KHTEO"ND0P+Y*6X=MHA8D+GD_3-9,FLP>'[1-7GW_8[:0>8$7+/G
M@8_'%6=(^(.G>)M332;?3KT+*K,LMP@"<#/\J&!LV>KQ)'MD?;G[I49)]JT8
M]81%RS8!^['G^=<YJ6G"T='M6*J1T<9%9,EU>+G# ^^.:D9Z-+J3"'SUF!$G
MW #7/S>*9-S(TJIM;G<U<Q%>70;<K!2!@8I+R0.LD3QQ,6 W/MY_"LYPYAHG
M?Q-)\PD=MQ8G)XS_ /6JC8)J>OZREEIUQ-%YI)9LY5%[D^U9DL62HD$DP487
M?(3@5:TVVE2;;;SSVPD'(BD(SCUK5:$W/4%\(63:>+.5KF4$#<S2D9(] .GT
MIS>$[:"W.V29<<X#UYAK>KW>E/ (KF9UE4GYY&)!%84_CR]L%2:>5E0MM#!F
M;!]",U6X'KKV]]:6[16MJTD1'S-+(JG/LQ_E5<ZJEO:*Q>.1>589R/<9Z&O+
M+KQCJ>L^6\.L+'QC$(7#_7/-/T66_DO8;<R0W)D.$MY=ZK(WX&BU@.ZMO#&C
MWD?VF*W(\QB0B?='T-22:%HEB_[]+>)]I?$GWL#N1Z4^&;Q=;P+%&NCV,*#Y
M5$:C'_?3US6K:7KU[JDEW=>,M/MMZ[0(W16 Q@CY>Q':IN5;0[6PT>RN[5;J
MP6"XA;(5XL$$^E6Y;?[!82J,)D9(7O7#^%]*^R%-&M/%4\[,QF,=M*RC Z]!
M[5U][*9DD^:01C !SUQ0A&'+(KOM56.>NZFR*([&:5U^0?+Z@DTXK//<>6@,
MA)P!CC\34&KBX'EV<04PQ?.YS@$^IIB,]908\L"1NQC%:5M<--*MI!LA+*26
M./F/I6;A&9<+TXX[FM.*VE<1BW@7S3RSENOTH UM%M8I(]^ R@X_$?RJ347D
M\[RF& J;VP>O/%.TF.2*"4K=A.3YBA:FD@%Q<#8^6;)&\<B@"!]<L=)MTM;R
MWMW<(&&]\%@?PK#OO&MC&2+>&T5<?=\QCS^ KD/BU?R6GBFRMXU1DGM%3<1R
MFUB,@UPTFK+:W$D3M)PW7&0* .YU+Q5=SR-B6RC3LHASM]^:R5UF?S9)))HI
M'<!3^ZXX]!TS7)RW4-U<1R1R,_.UP1CCM^M5[XRB23RKDJJXR@./UHL!TL]W
M:7C?OHTDY_YY@<^GK38;N+88+6SG*J<83<%!/;@UA(2+*&4G!C);GKNQ@?SK
M0+,@N-F],L'V;L'( Z^]3;4+FK#")70&QVAFQD1>85QW-=#I&FO9ZG:W"*P0
M/MXM_+R"IY]<5R<$DL84))(AZY#$$&G>&;NY/BBQCEGED43LWSN22=I'Y4,#
MJ=7AM_,EEDNGCD5XT:)9 ,)@9('T.:]=A6WATJU##>J0H(SUSQP:^>_$(C?Q
MM<,3\Q*ALCA?D%>Q^#M>CU'PO9EA\T*B"7/8KT/OD4XC.D,@5E)?;&W?W]*M
MI(AZ/P.QK,DFB =9#''@9/O]*S3=02DDDL,9RPQGZ50'4K<1 !/-7/IGFH9[
MB$YB$R>^#FO)+CQ9XAANI3:6MLD)/RJ$.0/=O6I['Q5;WDRPW@N+&5^LA&^,
M'U/0BBP7.B^(ES:Q^$V\V1E#3(L:@<E\\5XZ\ZF1SP?F*XSWKJ-5\4FXCFL\
MK<1GY5<@,,_WAFL+^V+188X9-*MIB@P6V ,WN3ZT6(O[QV'P8F:3Q\X( 'V*
M3C'^TE?0E> ?"&YT^Y\?@V5@;5ELI?,^<L&^9,8STKW^A%L*\PUV:*+6;TR3
M1(/.;[S@5Z?7RMXZF7_A.M=4)DB]DZG/>FT(] DU;3(_OZA:C_MH#4FEWUKJ
M N'M;A95C94;;V)R:\=1\_\ +-:[7P#>,8]2MUP%#QR?S%2T!U>HM^[*]A5>
MSD66!(\%I0VTH.N,_P J??,?+R?6E\/)*]W<>0 3M7>YQE5SSUJ01WEN\8MH
MXD18PJX55Z"HYC_HP;T--3Y0.QQBH7FVP .<KNYH*)HSF'T[_6JZ[C)GHI/I
M4AD BSE>G&31%@K'@Y]<T 68_O5-D 5!'_K-IXXJ1P$4MN&!US0 J'=(?;BI
M,@#+' JNKJB ]\9JA<7'G2R&20Q11+EBJY)STQ0,T&U!(V"(,G/-2+=!UR!N
M8=A69:BWP&=#AN!\W/XUJQI#M&P<>QH +SQOH>E316M_=-#,R!L%#@ \?TK"
ME^*^EI*RQVS.H) ;S.OX 4^^\'V^L:A->;3<3!1M!<!4QT%"> 710Y%G#QSN
MYQ3U%H5'^*BR';#IPVGCY@Q_H*Q?%.NZCKND-96^@;HV&X2&=HF3W7!S76CP
M:\%L(Y4CE&2QGMSM=?;:>#573],L&NS]I%S*R'[[MCCZ=J+L#DO#&A6FF1O-
M;2S/)/CS?,<M@C_>Y%;=[8P7,>R:,,I//'-;6J:=912#[$Y6XZ^83D?0U3B<
M3'RY%$<HZJ>A^E$DI+4J-24'>+,R(26:*MN+=T ^X\6TX^HK0BU9%QY\4L'^
MT!N7\Q27$.1A1@CM4;*8[;K]XX%<TL)%['9''S^UJ;-OJ,+. DD3DKN !R<4
MTZL9)9$VH0O. N#TK'L"@>X=54NJ=0/>N@M7TU[ -=+B=4P'1><5C[)Q?*V$
MZ\9>]%"V*W&H*DGD"* ]&<\G\*+W1[F.02VRQR-_<51G'UJ>VN[:*./R9CY2
M\9;DG_"I)]:A#^68G93T92?YU<:48K4SEB)2>FQCV,<D5Q*EVA5B<KN&#4JP
MQ.) >&-7#?K))AE9X%4E_-.2H] :S=QW@J"%/(^E=":Z'.][LRKVWCA+.@Z#
MO5>)U2' !''8U=U%MT9XZG%9ODSW&Y((BY R<<5HK$V$C(64KD_O3C%:'A99
M6*1A'$!+H\A'RCG]351-+OHY$F>V)16Y(.>:IV_BBST.P6WNKH1/)(Y7(SW_
M $I.TGH&R.]O+2WAL)/)G=I(QNV^H^G:L#3O/G:ZNVAD#2,%;<I!^4 9_G6=
M9>*(KV4M#=?:IP,2E)  #VR._%3/K=T&;G!'' QBB,.5BN=!#ILUQ+YK 1V^
M>7;^E6[F:*ULHX+8 KD[MPY-<B?$=U!,KRSL(R,%0>M96J^+;F*X5+:,-%S@
M-U_"HUYQZ6.@NKNVA=BQV.:PI+I[^9H+1(RO_+2?9POTJA;6=UJ;&:]D*1=?
M+4_>K?MK>WCB6"-_+4<;0*T)(X8$M(B"2QQUSBHIHY+F-OL^8RPPK$D8-:*V
M,>YXRP89')7-5[P"T *\A2%(ST%,#GXO$#6MY]@U&!XS_"V,X]_<?RK1A$+R
M[Y8XW;/RMC-5-4FAE$*S(VYVPK;1E!Z_2M!+$6L"L(I)(R."H'\Z8&7XN%U+
MI,/V1EC\N<-(I0.'!!&"/2N.BM]3MVCDM;J4"*43I S?(KCL!V'M[UV>N,?[
M*FRHCA W-)G. #WKA+F[@!^6]W@= ,UI%71,G9GJ[:I(\$3N \;J#M],]:B!
MM)AY@*^]9/@Z*67P<M_.YDM6N'C4;<LN,<_3.:T)[%Q^\@*G(XXVUDU9E(<R
M6Y/RH,^M0-9K)(&7('IFHE\P$AU(;IBFR.\2_=)8CH3S2L,;<62' 5@/?K38
M'2WEE.0Q5-N/0U+IEO)<2;ILAER=I[''%-M[,P(0P#%VW$^IH YCQ9?1B>QM
M6WATC,CE>>O2N,UV\LY='5(I09O/#E<$8&".M=AXRT]Q,NJK&9$"A'PVT+C)
M%</JMJ]I-&T<C2QNNX^8PXJHB,N%1+!.H'*)YB^O!P>?I6C9:C>17+Q)<NJ1
MKA1N[CN#2V<8$_+J?D(* CGCVJF9E1I)"-PZ 'M[U0CL;A9888IW>0*[%<L<
M@G -7?[$MW$;3239*ABP_H*JZ\RP:+8S L4<@ ?\ %="[AX8LH4?RE)0'<5X
MZ'WJ0,G1Q%H?BJ&\ D<6ZNY9/O%3QTZ9]J[&Z\:V:6KWD]P# HY7&'SZ;>_X
M5R%ZP1L@#Y@,GO7,:I>2)<HB(7VG)!&1[5T>QC[/F8KZV/8?"GB1?$=KJ%_Y
M?V>R286\*N,%@!DD_4FJMS(9[F8)GR@^/KBJWP^&[P,DA"HS7,KL"O0C@5,7
M=F,<<@"+DY![]R:YBR=8DA(>9P#_ '3R:O6NI6\3"/[H/\;-_3M63$^R1<()
ML#HQZU;-LETA>!F5E'*,.!^- &]%=P[G2REBE8_,0QP*1WF6-#T*Y4;3Z^]8
MD%I<V<T<SQD)G[PK0FU2+[9;K YD3=E_EP*8'BOC_5)-1\=R(V0EGMMT!]N2
M?S-<SJ?-Z];'C# \=ZP%!&;L[1CD=,55NM%U*:X+M;^7P,ES@4"*%C_KR<XP
M,TEZ&:ZDZ=0..G2M*'P[=L0#<0@MUVY-7?\ A&7,6%N\RYYS'\OYYH$4/L\T
MUE'#$5,@;YCGIC%7;^\0)B:),[@"P7G.!D&F)H&O6,ZS6\$I8'B2 YQ^'6HY
M;'4+W(F90P;)XYS[^_UH&6_[4TN5/]1/#,!PT4_!/^ZU7/#8A/B:R=3)NWL3
MN(/\)KGIM$U" ;OLY=1SE*N>$-P\8:>.1EFR#_NFE8#7UVY5?$5Z4RK,%WX/
M#?**ZCX<:JZ/=V+1[$F7>H&2%(X/TX_E7&:QK6HVFO7:07&V-"I"LHXXKU3P
M/!?7'A(7]Y(BS7K;T)4!O+' _/%%AG36W^GQB!W3STZ%B,L/ZUQ/B_7)]*UH
MZ:(]\2Q*SY.&)/K[>U= $!<*&!93V[5P_CY)8_%)265I&%M'@L<X'/%,!UOX
MBT]AF?S8,=01D?@16'KFJOJ 'EQ+%;QME8\?,P]6/]*SICB!J!^]MR>VWFF(
MC61GN82Q^\0/:DFQO8^YJ]8V$,^GM?/=1YB;;Y2@[L]CZ8JO<6LNW>A##TI$
M?:.Z^"8_XN S?].,G_H25]%U\Y_ _)\?R$YXLY!S_O)7T90C1A7'7_PN\)ZG
MJ5QJ%UI\CW-Q(9)&%Q(,L>O .!78T4Q'#_\ "HO!G_0-E_\  J3_ .*JUIWP
MS\+:5,\UG8RQNZ[&S<2'(_$UUU% &!)X+T.5-KVKD?\ 79_\:6S\':)8-(;>
MV=3(,-F5CG\S6]118#.&B6"C B/_ 'V:'T/3W7:T)(SG[Y_QK1HI607,W^P=
M.P!Y)P.GSG_&G'1; _\ +$_@YK0HIV SUT6Q4Y$1S_OFG/I%DZX:(D?[QJ]1
M18#..B6!;/E-G_?/^--D\/Z;*DBO"Q$F-WSGG'XUIT4K(+F6GA_34((@;CIE
MV/\ 6ICI%F59?+8 ]<.:O44607*=KIEI9,6@C*DC!.XFFMI%HQ<L)3O?>P,K
M8S^=7J*8#%C545!D!1@<U5FTJSGD,DD1+'N&(J[10!F_V#IW_/$_]]G_ !IL
MGA[390-T!XZ$.P(_6M2B@#,.@:<V,PMD#&=Y_P :CE\,Z5,NUX'P!@8D8?UK
M7HH QH/"^D6Z.L=LP#_>S(Q_K4ZZ#IR*%6%A@\'><_SK2HJ7&+=VAW=K&>NB
M6"YVQ%<G)PYYI#HEDQR5D_[^M_C6C11RQ[!=F:="T]CDQ,?K(W^-2C2;(,"(
ML8_VC5VBCDCV"[,V?0=.N=WFP$[CDX<BH8O#&DP,S1P,"PP?WC?XUL44^56M
M8+O<S?["T\#'DMC_ 'S_ (UE3?#_ ,-7"[9=/W\YYE;/\ZZ>BE&$8[(&V]SC
M(/A7X1MK_P"VP:=)'<=V2YD&?PW8J\W@/0GZQ7(^EU(/ZUTM%4(Y4?#OPX)5
ME-M<,Z]"UU(<?K4L?@+PY&218L23G)F<_P!:Z6BBP&$O@_14^[:L/;S6_P :
M</">C Y%LV?^NC?XUMT4 9 \,Z4O2!NF/]8W^--?POI,B[6MVQC'^L;_ !K9
MHH YI_ 7AY[I;EK20RJ, ^>_3\ZN1>%M)A/[N&11_=$K8_+-;-% &!>>#-"O
M[62VN+,M%(,.!*PS^(-8O_"H?!G_ $#91]+J3_XJNYHIW86,33/">C:1I TN
MSMF2S#%PC2,V">2<DYITGA72)?\ 66[MCUE;_&MFBD!@CP;H@)(M7R?^FK?X
MTT^"M"+;C:OG_KL_^-=!10!AIX1T:-MRVS9SG_6M_C2?\(AHO_/JW_?UO\:W
M:* .<E\"^'YM/FL9+-FMYL>8IF?G'OG-9%W\'_!-\L:SZ4["/(7%S(,?^/5W
M5% ' I\&? \8^72Y1D8_X^Y?_BJ3_A2_@;+_ /$JE^<Y/^ER_P#Q5=_10!QU
MS\+O"5W:1VL^G.T,9!5?M$G&!CUI!\+?"8Y%A-GN?M4F3^.ZNRHH Y"7X9>%
M9D"26,K =/\ 29/\:B'PJ\'A@W]FN<>MQ(1_.NTHI\SM8#G++P+H&GZ:UA;V
MLBV[,6*F=R<GKR3FGGP5H)0)]C8*.PE;_&N@HI <\/!.@CI:/_W^?_&IX_"N
MD1.&2W<8&,>:V/YUM446 PI_!^C7)'FPRM@Y \]\?SIB>"M"C(*VK@CI^^?_
M !KH**+ <5>_"CP=J&H/?7.F.]P[!F?[1(,D=.A]JN/\._#+G+6+G/\ TW?_
M !KJ:* .57X<^%E^[I@!]?-;_&IT\">&TVXTU3MZ9=C_ %KHZ* ,*X\(:+<6
MS0?9GB1A@F"5HV/X@YK#?X1^$9+AKA[6\:=NLAOIMQ^OS5W-% '"/\'O!DGW
M[&Z;ZWTW_P 54EI\(_!EC=Q75OIDBS1'*M]ID/MW:NWHH X6Z^$'@J\N&GFT
MR1I&.21=2#/_ (]70?\ "*:-]GB@6TVQ1($15D8  # [UM44 80\(:*N-MLX
MP>TK?XU0O_AOX8U.Z^TW=E+)+M";OM$@X'3H:ZRB@#B&^$G@UE(.FRX/_3U)
M_P#%4)\)/!J#"Z;)CT^TR?\ Q5=O10!Q,7PF\'0AQ'ITJJYRP^U28/X;J?\
M\*L\(_\ 0.D_\"9/\:[.B@#G='\#^']!U,:AIUD8;D1&$-YK$;3@G@G'8<UT
&5%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>g4i5nix4zlkt000035.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g4i5nix4zlkt000035.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" (C KT# 2(  A$! Q$!_\0
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MR<U4*L6I*6E^PI0:::U/2/M$!.!-'_WT*<WW&^AKS2#X,V-O<PSC6KPF*17
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MUH/@>WT'PU?Z+'>S31WF[=*Z@,NY=O %)X=\"6&A:%?:/+,]]:WC9D$R@<8
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MS>EB?9R2:1O:/>6T/AVP:6YAC5;6/<6< #Y17E?A]QXA^--QJ5F=]K%(\OF
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M^T3_ ,AW0?\ KU?_ -#H ]F\%_\ 'A#_ -<U_P#01775R/@O_CPA_P"N:_\
MH(KKJ0@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH @O?^/"X_ZY-_*OG']GC_ )&'7O\
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M6BHP[G.(QP<?>I<R?W!_WU0 ^BF9D_YYC_OJD#NV<1C@X^]0!)13"SA2?+'
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MWC0 K_ZMOH:5?NCZ4C_ZMOH:5?NK]* &Q]&_WC2#_5/]6IT?\7^\::/]4_\
MP*@ _P">7^>U)_\ '*7_ )Y?Y[4GI_UTH =']T_[QI],C^Z?]XT^@ ID?W3_
M +QI],C^Z?\ >/\ .@!]%%% !1110 4444 %> ?M$_\ (=T'_KU?_P!#KW^O
M /VB?^0[H/\ UZO_ .AT >S>"_\ CPA_ZYK_ .@BNNKD?!?_ !X0_P#7-?\
MT$5UU(04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M"6FQ_P"J3Z4F_P#V'_[YIL;_ +I?D?I_=H <GWI/][^E"?Q_[QIJ/\TGR/\
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MW0?^O5__ $.@#V;P7_QX0_\ 7-?_ $$5UU<CX+_X\(?^N:_^@BNNI""BBB@
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M* '\>E,CQY2<=J?38_\ 5)]* $3&Z3C^+^E"]9/]X]J$^])_O?TI4ZR?[QH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 07O\
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M75K[5IK%0ZETMTCW$DC/S,%7'7DUNZ'JTUQ!?PZI);I=:==FUEE7Y(Y. RL
M3QE6'&>M &;X4_Y&KQQ_V$XO_1"UUE<CX1D27Q/XV>-U=&U.+#(P(/[A>]==
M0 4Q/O/]?Z"GTQ/O2?7^@H ?38_]4GTIW:FQ_P"J3Z4 "?>D_P![^@I$ZR?[
MU*OWI/\ >_H*1/X_]XT -'^JB^HH/1_]\?TH'^JB^HH/1_\ KH/Z4 .3J_\
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M_P#'*7_GE_GM2>G_ %TH =']T_[QI],C^Z?]XT^@ ID?W3_O&GTR/[I_WC0
M^BBB@ HHHH **** "O /VB?^0[H/_7J__H=>_P!> ?M$_P#(=T'_ *]7_P#0
MZ /9O!?_ !X0_P#7-?\ T$5UU<CX+_X\(?\ KFO_ *"*ZZD(**** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** (+W_CPN/^N3?RKYQ_9X_P"1AU[_ *]%_P#0Z^CKW_CPN/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MZ2+A,9)PQZ_6GTR/[I_WC0 ^BBB@ HHHH **** "O /VB?\ D.Z#_P!>K_\
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MRI/7_KH*7^&'ZC^5)Z_]=!0 ].C?[QIU-3HW^\:=0 4R/HW^\:?3(^C?[QH
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MZ.O?^/"X_P"N3?RKYQ_9X_Y&'7O^O1?_ $.@#Z HHHIC"BBB@ HHHH ****
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M(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M4 %%%% !7@'[1/\ R'=!_P"O5_\ T.O?Z\ _:)_Y#N@_]>K_ /H= 'LW@O\
MX\(?^N:_^@BNNKD?!?\ QX0_]<U_]!%==2$%%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M4 %%%% !7@'[1/\ R'=!_P"O5_\ T.O?Z\ _:)_Y#N@_]>K_ /H= 'LW@O\
MX\(?^N:_^@BNNKD?!?\ QX0_]<U_]!%==2$%%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M$%[_ ,>%Q_UR;^5?./[/'_(PZ]_UZ+_Z'7T=>_\ 'A<?]<F_E7SC^SQ_R,.O
M?]>B_P#H= 'T!1113&%%%% !1110 4444 %%%% '/:OJOB:TU%H=+\,Q:A:A
M05G:^6(D]QM([5XI:_$#QT_CU4#3R737/E-I1XCQG&S';'][\:^C*B%K;BZ-
MT+>$7!&TS>6-Y'INZUZ&%QM*C&2E24KJQ$HM]3&T74_$=Y?-%J_AV/3;8(2)
MEO5ERW88 _6N@3[X^M-H!P<BN*<E)W2L4CYWT+P3JWBGP_<)8:'H\:2:A*!K
M,LS"XCVR9.%'IVKMHM#\/ZG\6/$L'B.&SNHX+"S"/>,%YV89@21R0,UZ-INE
M6.CVAM-.MEMX#(TA12<;F.2>?6LK5O OA?7=1?4-4T:"ZNW #2NS9( P.AJ!
MG$>!?$X\/>%)XTT_5-4TT:M<0:>UG'YVV%<8R<_=R>/QK9\$7=K#XL\=F:XA
M@+ZHC!99%4_<]Z[FRM+;3;..TL8([:VB7;'%$NU5'TKG]0^'GA'5;^>^OM"M
MY[J=B\LK,P+-Z\&@#E?B/I;'Q)X5UA]2GGCDUFVA@M=P\F)<$EAC[S,0.:Z+
MXHDR_#SQ!'!>>3+';[W"$%BN1\I'8'UK=GT'2KFVT^VFLHWAT^1)+1"3B)D&
M%(^@]:)M!TFXNKZZGL(I)K^$073/D^;&.BD=,4 <WHVOOI%CH>@W%KJVI2SV
M4;?V@EL/)0,O"LPX&T<?3%<-X*U'6M!\.^$+B'4PVFZAJTEB^G^0NT*SMEM_
MWMV1]*]CTS3++1M-CT[3K<6]G&"%A4D@9Z]:IQ^%M#ALK&SCTV);>PN/M-K&
M"<12Y)W#GKDGK0!Y\GC#7/\ A*]+N;;6)+O2;W638>6UK'' 4!QA.3(6'=CQ
M7+VUS>^&I?%NN@O+HU]J%YIM_$HSY+$'RI1^+$'ZU[ O@?PNE^;Y-$M4NC.+
MCS5!!$@.=PYXY].M75\.Z.EA?V(T^+[+J$C2W<1R1*[?>)]SCM0!XW;KKSS>
M H?#7DKJ<WAV6-)9C@1 DY<>X[>YKO?A.=,_X1 K:6[0ZG%,T>K"4[IC<@_,
M7/4@]JZ>U\.Z193V4]M8QQRV,!MK9@3^ZC/51ST^M4;_ $6YLKR?5/#%GI<6
MJ7K#[;+>&0+*HZ'"_P 6>] &/\81GX7ZH, _O(.#_P!=!6%X?\%ZSI_B1/$,
MFD:3H$%G83+Y.G2ES<,4."W; X/X5U\>EZ[K4<UAXNM=#N-*D4$Q6AEW%P05
MSN[5TKHLD31,,HRE"OJ",8_*@#QV/Q9XJM?A_H>L2ZO/=WFNW*6RB.UC)ME!
M;)0' 9VQ_$<5W'@34M=OK;4(=<@NA]FG"VUQ=1)%++&1_&J$@,".WJ*USX9T
M1M!30GTV!]+082V8$JO.<CN#DGFI=(T/2] M#:Z3916D+-O94S\S>I)Y)H \
MACT*]U;Q[XP>V\*Z-K,::F%>34)BC1Y'1?K76/J.LCQYK6G6NI/;:3HFG0W:
M6,4*GS<)_J]Q&0IQVYKMK/2K'3[F]N;2V6*:]E\ZY=2?WCXQD_\ UJ(M+L8-
M5N=4BMD6^N8UCFFYRZKT!'3B@#R[PMXS\77EQ8:G<07U[I]Y#-+<QO:QQP0[
M5)4PLIW$9&#D4_P?XL\7:Q?Z5=7'VV6PU)9/M)DM8HX+48.UX6#;B%/7<*]
MT_PAX=TK5&U*PT>VM[QL_O4!XSUP,X&?85';>"O#-G>S7EMHMK%<3*RNZ@CA
MAAL#.%R#VH X'2_$'B;S]?UNUUZXU;P[HUM+L>Z@C3[;.JG[NT [%.#GV]ZT
M/ WB+Q5J&LV U!;ZZTZ^M#-+-<VT420R8ROE%"2T9Z<\UU.G> O"NDW<=U8:
M-##-&"%(=R ",'Y2<'()[59TGPCX>T&[DN]*TFWM;B0%2Z9R >H&3P/84 <Q
MXN_Y*1HN?^@+J'_H%>3V.CRS^&O#-M=:'I.EV^I2J(?$(9C*&5R<-C[K'&!G
MBOHRYTC3[R_BOKBU22ZAB>&.0DY5'&&'XU6D\,Z)-X>70)-.B?24 "VK9*K@
MY&#G.<]\T :V"H"DDE0!D]3[T4V.-8HDB0$(BA5!.< <#FG4 %%%% !1110
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MG2Y[.S\3Z1C;>HI$<XR=R/@98$=R,UZ(A<QJ9 HD*C>$.5![X]J=10 4444
M%%%% !1110 4444 %%%% !7@'[1/_(=T'_KU?_T.O?Z\ _:)_P"0[H/_ %ZO
M_P"AT >S>"_^/"'_ *YK_P"@BNNKD?!?_'A#_P!<U_\ 01774A!1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M1KNF6DL.M6NKW+0*R$?;+610'0#^(=2/<4"._P!.\?:=?S:0K02VT>I:?)J
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M !1110 4444 %%%% !1110 4444 07O_ !X7'_7)OY5\X_L\?\C#KW_7HO\
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MKYQ_9X_Y&'7O^O1?_0Z /H"BBBF,**** "BBB@ HHHH **** "BBB@ HHHH
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MYH ]B_X230/^@[IG_@6G^-'_  DF@?\ 0=TS_P "T_QKPK_A14W_ $%7_P#
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M %Z /=?^$DT#_H.Z9_X%I_C1_P ))H'_ $'=,_\  M/\:\*_X45-_P!!5_\
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M@[IG_@6G^-'_  DF@?\ 0=TS_P "T_QKPK_A14W_ $%7_P# ?_Z]'_"BIO\
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M-N<_>[XQTH MT44F: %HI,TN10 445FV.LVVHZIJ5A LGF:?(D<S$?*690V
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MYI'B2^EL]&M[1+J"*>Z=1>S.6\R1FSEW&U0%'3/ KU=+>S18K=((%$.'CB5
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M0.UQ+*NTNYQU Z8P!0!R'AG5_$%A-_:]]/9S6.M:^UN2L; J@#QJP)/"YC7
M]SZUW'AG6+O7DOM1*1IIC3F/3\ [I(UX,A/HS9Q[ >M<GJW@RZ.A6/@BS6_N
M=/:=;A]4FD0?98U?<47&"6[#C^+)->BV]K#:6D5I;QK'!$@C2-1@*H& /RH
M\NU/XGWT'B'R[*73+BS%\EFMM'%+))*"X0MYP'EJ>2=O/3%:FM>+?$=GXR?3
M+>+3K>W5XUM8KU74Z@"!N\N8?(K#D!3R2*M6_P ,K2VFLP-;U9[&QNUNK6P>
M13#$0Q;&-N6&2>I..U3'X<V1U'S3JNIG3?M?VW^S&E!@\[=OSTW8W<XSB@#/
MU+Q9XD@\:OID4.G6]N)42V@O%=&OT(&YHYON!ASA3SQ67K?Q/OK+7I4L9M,N
M+2&[2U%JD4TDDV6"D^:HV(<D_*<]*Z5/AU9IJ4<K:MJ<FG17?VV/3'E!A2;=
MN!'&[ 8YQG%5T^&-G'+"HUO5C86]X+RWL#*ODQN'WD8VY89)ZDXS0 M_XROK
M"X\06/D12W\%W#:Z7" 1YQFC!7=[ [R3Z*:HZCXK\467BI=+V:7"J^4D*7:2
M1C420-YBE^XA!R IR>*OZ'H<^J>.;SQ=J>FRV#)$MK9VTSAF.,AIF"D@$@[1
MWQGUJ0_#BQ.H;VU74VTS[7]M_LMI08!-NWYZ;L;N<9Q0!K^+=?\ ^$<\/37X
M>U6;*QPBYD*H78X&< D]S@#)Q7#6'Q)U5M$\2RR"TO;C38(GMIX;:6!9))25
M6,I)SUQR.N:[SQ)X;A\1VEO&]U<6=Q:SBXM[FV(#Q. 1D9!!X)&"*Q[7X=V<
M"W/GZKJ-X]U=V]W/)<NK-(T/*J3C[I..!TQQ0!S>M^/_ !!HVI+H]W)IEM?R
M1"ZDD6UGGCMD/"QX3EG)#$MP,>M=OX.UZ?Q'X9M]2NK8VT[,Z2)M902K$;@&
M (4XR,\\U!K?@V/5M6_M.UU?4=*NWB$$[V,BKYT8)(#9!Y&3@CD9K9@TV*UT
M==-MY)4C6$Q*[.7<<8R6;))[Y- 'GZ>,_%$WA]M<$.G1VMQ=FST^$HQDG9I]
MB.><!0N3CJ<9XK5\3^,;[1[_ %B*TCAECTW2EN&!4EFN9'VQ)UZ'!X]Q6A>>
M"+.Y\+Z7HD-[=V@TQHI+6YA9?,5T! 8Y!!ZGMWJK!\.=/ACNE?4+^X:[O8+R
MXDGD#O(T6"JDX^[D9Q^5 #=$UOQ/_P );%I&NPZ:!<:>;S99[]UN0P7#%N&R
M2>1CI7/?$(SW7C.RCO7LI="TFQ?5;JVEB9BP!V]B 6/.WT()YKT&#1(8?$=Y
MK?FR/<7,$=OM;&V-$).%^I;)^E5KKPGI]]J&K75[OG&IVB6<L3$;5B7=PN.1
MDL30!SMIXC\56.I:+)KMKID>GZQ+Y,=O;%O.M24+KN8\,,+S@#%:'@K6/$/B
M.UCU>^CLK?3)A)Y$2*QED&\A')SA1M'3OUIMC\/;>VF,]WK.J:C-%;O;6;W<
MJM]D5UVDH  "V.-QR:Z72].ATC2;/3;?/DVL*0H6ZD*,9/OQ0!Y%XH_M#Q!K
M_B35+G1+?5=$T(_9Q%<W;1!0J!Y6B4#F3D?,W3  KT+1?%/AN26S\/VVJK)?
M"! MK*Y:;;L#?,>YV\FJVI_#RPU/5+FY;4=1@L[V19;[3X)0L-TX &6&,C(
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M-S(K+:;EVY7Y<L0.!N)H [*BJUA;26=A!;2W4MW)&@5IYL;Y#ZG  S]!5F@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@!.]'>BB@!:*** "BBB@ HHHH
M2EHHH **** "D-%% "=Z=110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 AI1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
D% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>g4i5nix4zlkt000043.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g4i5nix4zlkt000043.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &, J # 2(  A$! Q$!_\0
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M3*&)SC'RX!/UJ_XK\):IJ^JW<AT?2K^.5 +:Y\UK>:W./XB/OXIJ%)/7S_X
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M[A5"]T/2=2F6:^TVTN95Z/+"K$?B15^BDFUL%KC418T5$4*BC"JHP *=112
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M*<(5(.I35K;K]5Y"3:=F>DT445RE!1110 4444 %%%% !1110 4444 %%%%
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MG#)A]%\O.<^W>K,_CZ)8+>Z@M4EMIY#Y;&7#/$&5/, V]-S'J1T]ZAC\97D
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M1>P&?-H>EW%S)<36$#S2 AW9!ELKM.?J./I1/H6E7))FL+=R6#$E!R0 O/X
M#\*T**?,^XK(H3:)I=PNV:P@<>:9<%!]\]3^.!39= TB:6YDDTZV9[E=LS&,
M9<<=?R'Y"M&BCF?<+(SI="TJ<()=/MWV.9%W1@X8]3^.!^56(]/LX9A+';1)
M(K.P8+R"YRQ_$@9JS11S,+(*9+%'/"\,T:R1NI5T89# ]013Z*0SR#6/AKKG
MA?59-;\ 7ACW<R:>[<$=<#/##V/([&EM?C5<:8_V7Q7X<N[*Y7AGB4@'_@+8
M_0FO76;:C,%+8&<#J:Q-.U6U\1M<P2:5<*ENYCD^UQ(5WC&5ZGGD5UJOSK][
M'FMUV9-K;'(-\<_"'ED[=08X^[]G'_Q58\_Q:U[Q$QL_!GAJ=Y&X%Q,NX)[X
M'RC\37H'V?P;&9Y1;Z(#;L%E81Q?(3V/'!S5F/7M-BU!=-@0@F5(E,:CRR6C
M,@(([8!IJ5%:QIM^K%KW.(\*?"VX.JCQ#XSN_P"TM4)#K S;D0]MQ_BQV X'
MO7H]_IUEJMH]I?VL5S;N/FCE0,*M45A4K3J2YF_^ 59'A_A+0=.L/CUJ%G80
ME+33X7>)&8MM8JH."?\ ?.*]=UG4ETVW2=YXXHE.Z5G[(.IR>!_]>O,[=AHW
M[1MPLN%CU*U^0GN2@/\ .,UVVMZ/<O<11PVT-Q83^9]L\Z3&P'E0H^M;XJ5Y
MP<]FD%.-[I&3?)X;719;JQW?8W=[FY1-S>8K=>.3S[5<\-ZAI5S96^H:3:31
MVJQ%8XP,*H7MSW_'MWK F>W\/R:=$;V"PLV9HS;21DF3(X7GT]3ZUMM.^F:#
M-<B-_LD3HKPPQY8DD= .@&164HPC':W9^1O>I4DH\W-?IY_YFCK%W;:E:QV\
M]LC$/'*I=_E5L$CGL<\5G^#IM=F-PE_;6]JR3\K&<[X_7/./Z^U8UIX<M(/M
MWVRYGNXI+A;@+<N1Y1!SD<]O?BNTT2?3&+R6-XL_VAB5VX(P/0^GXT22@G%*
MZ[F5[I:ZZZ$OBBR34?"FK6<@RLMI*OX[3C]:XSX'W37'P\6-CGR+J1![ X;_
M -F-=?XOU!-*\':Q>N<".TDQ_O$8'ZD5YE\'_%OAS1/"G]F:AJ<5K>/<O(5F
M!5<' 'S=.WK6M.$I8:5E?5&;:4E<]<U34K71],N-1OI1%;6Z%Y&/H/Z]J\9T
M[3=7^,NN-JNJR2V?AJUD*P6Z'!?'8>_JW;H*O?%+5CXIUC0?!^CW<<L5[(LL
M\D+AUQG"\CT 9OP%>GQ6*:%X?BL]*B5([2-5C3;G('7/N>>?QIQ?U>FI?:E^
M"_X(_B=B+3+;3=!9=)T^PALK9$W J0H;W]2?<\UJ3R[+=Y%D1<+D,W(%>?\
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MBV2=DA!WM<;]ID;';MV' KI-.C'SRFXDD;)7:9"0!GT]:]G#T94:$*<NB2_
MYY24I-HOUY#X[(N/C;X.@CYDCV.V.PWL?Y*:]=9E1&=V"JHR23@ 5XYX*=O&
MGQ?U;Q2H)L+!##;,1P<C:OZ;F_&N["Z<TWLD_P =")=CV2BBBN4HR?$&N+H-
ME'<- 9?,E$0)<(B9!.78\*.,9]2*KP^*[(QK)=@VJM'$P#-O;=)NPN%SG[IP
M1G-7]4TQ=3BC7[3<6TD3[TD@8 @X(((((88/0@UG6G@_2[(6XA,X$#1,N7SD
MQER">.Y=L_TK1<G+KN2^:^A9'B?1F>W5;Y&-PJ&+"L0=YPN3C@D@X!QT-1:;
MXJTW4([(-*(+F[0.D#')&<X!/3)VG [XK*D\%R1ZC9FRN1'8Q-"TJLY+.8W+
MC(Q@]<9XQ[U>M/!6EV5]:W<)FWVZJ &*D,5SM).,Y&3T([535*VXKR%?Q28M
M4E@ETZ06<5VMFUV)%($C $97J!E@,U8_X2S0_)>47Z%495X1LL6SC:,98'!Y
M&1Q39/"UG-J$ES+/=/')<"Y>U+CRC(  "1C/8<9QD55_X0C3_LK6YN;MUV)%
M&9&5_+C4DJ@!7!&3WR>G/%+]VP]XU4UW3)+^.Q2[0W,BAE3!YR-P&<8SCG'7
M%:-<_9>#M,L-3@OH3,9(450)&#;BJ[ Q)&[./0XKH*B7+]DI7ZA1114C"BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M?3+?#N!YL\G,DGU/I[#BM^HJU8N/LZ?P_F"75A1117.4%%%% !1110 4444
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MK1#2=]61W-O'=6LUM*"8Y4,;@>A&#7'R>"+^X$<%WK0N+6&T>UMU-L%:($*
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M_P )U\1?^A ;_OX:/^$Z^(O_ $(#?]_#1]4J=U]Z_P PNCU.BO+/^$Z^(O\
MT(#?]_#1_P )U\1?^A ;_OX:/JE3NOO7^871ZG17E2_%G5M'N(U\6>$KO3;:
M1L"XCRRC\".?P.:]-L;ZUU*QAO;*=)[:90\<B'(85G4H3IZR6@)W+%%%%9#"
MBBB@ HHHH **** "BBB@ HHHH **** "BBO/?&7Q8TCPYYEII^W4=2'!1&_=
MQG_:8=_8<_2M*=*=67+!7)E)15V=W>7MKI]K)=7EQ%;P1C+R2L%4?B:\H\4?
M&ZUMM]MX;MOM4G3[7."L8_W5ZM^.*\F\0^*M9\4W7GZK>-*H.4A7Y8X_HO\
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M /BV'4["+3+IU2\MXPJEFQYH'''OTK#^'_\ R5?QW_UV7_T(U=--4ZD7Y/\
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M?+_2NEKB_A/"\'PST<.,%D=Q]"[$5VE:UTE5DEW9YZV"BBBLAA1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !4-Y#]HLIX/^>D;)^8Q4U%
M'F'P.N /"-]IS<36=_(KKW&0/Z@_E7*_&*PE?QY;S!,QO8(2>."'8?UK8N)W
M^&GQ3O+J2-CH>NHTNY1Q'*.3^1)_!O:K6K6E[XOGM)&M;--.D:19;RZ=1.NY
M<*RQYRBCH,G/<@5TXNSJ<ZVEK_7S$CSOPM<RGXQZ>\:DC[',F,@9_=-W^M(E
MVT%K$6,L;R*5C9%R<@9SZ?G5Q?"6K>%HKW4;FZM;>"-/*4FX$KS@Y./E)(Y"
MX/!!-.M[F06RP&4B,K@H2.]<C2ZEK4O>,#.;&SF%R[*T04IP!G&2W'<YKL?@
MN#_96JN3D&X1>O<+S_.N1\2%'M+:/(VJ..?8"NI^'&H6'AOP;K.I7<@BM89R
M[G/).T<#U))X'O3BFW9#:T$UPC4_V@-!MH^?L%FTDF.Q(8\_FOYUZK7RA'XW
MUF'QA>>)K280WERYRK*&7RSC"$'L  /PKUCPU\;=-O=EOK]N;"8\>?'EXC]>
MZ_K]:]7%8.KRQY5>R.55H<S39ZO14%I>6M_;)<V=Q%<0.,K)$X93^(J>O+:L
M;A1110 4444 %%%% !1110 4444 %%%% !1110 51UC5;;1-'N]3NVVP6T9D
M;U..P]R>/QJ]7F'QJNII=%TC0H"0VJ7RQL1_=7''YE?RK6A3]I44&)NR*GP]
MT"?Q=JLOCWQ(GFR3.?[.MVY2) >& ]N@_$]Z]7FE2""261PB(I9F/8"HK&SA
MT[3[>RMU"PV\:Q(!V &!6;JZ27=]!8^<L<+)ODR<9 /Z_3WHKU?:2<MDMO0$
MK&=I'B:$221W3W 4@,K3 =>^,=CQ@>]=%%?V\V,/C.,;AP?QZ5S8T:RO;J^B
MED:!X,)"XE&0"-V[CU/;VI-+1+;3[A)2IERR[A]R0J>J^]90<7IU];AJCK65
M70HZAE88((R"*\:UVUD^$OC"+7],C=O#NI-Y=W:)TC?K\O;W'XCI7J6A7MU?
MZ>DMS&JL!M)SR2.N1VJAX\T>/7/!&K63J"WD-+&3V=!N4_F*Z:$_9SY9;/1@
M]5<\8\3_ !BUW6B\&E_\2NS/&8SF9A[MV_#\Z\\_>3SY.^6:1O=F<_S)KMO
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MRT;2]-<O8Z=:6S'JT,*H3^(%7JFI6CRN%-63WONQI6"BBBN8H**** "BBB@
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M_>+]_,\=NKJ>\G:>[N)9Y3UDF<LQ_$UJZ+X1U_Q"P&F:5<3(3_K679&/^!'
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M5*E1C  V].G)K/N_!9ATI[;2KG9/+-)))-.<G]Y'L?&!CGKC'TQ0!OW^KP6
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
,@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>g4i5nix4zlkt000033.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g4i5nix4zlkt000033.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 'C KT# 2(  A$! Q$!_\0
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M?B*UUZUTWQ%X=-NET<1SVC&15_WL9&/7FN_%1*#CN4I)G,?$+_D0=9_ZX?\
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MK0\*>,-7\7>(=3CM[9%T-481S,A#J<849Z$GDD=J[&^\/:-J4WG7NEVD\O\
M?DB!/YU=MK6WLX%@MH(X8EZ)&H4#\!6LJE-W:6K(49;7T/"?!L M;C5;"\\4
MW7A^Y@E.^-2JB3&<GYNX_D:Z7P=9:3_9'BC4=+U.^O?-MI$F:Y@$8+;6.01U
M/^-=]JGA/0=:N!<:CI5M<3 8\QEPQ^I'6KUOIEC:6'V"WM(HK3:5,*( I!Z\
M>]5.NI+U%&G8\@\*8_X4IXB_WI/_ $%:DT^71X_@U;+K=M=S6CW3@/:J"T3[
MCALD\>GXUZI!H.DVVG2Z?!IUO'9S9\R!4 1\^H_"I(-(TZWTYM.AL8$LFSF
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MK<O:L&FFB.54;@QY]@/UJQ9JK_'^ZW $K"2/8^6*]&TGP_I.AHRZ9I\%KO\
MO&->3]3UIZZ/IR:HVIK8P"^88-P$&\C&.OTI>V27*MK6#D=[LO5X_P#%2"*Z
M\<^'[:89BF18W&<9!DP:]AJA>:+IFH7<-U>6,$]Q!_JI)$!9.<\'ZUG2J>SE
MS%3CS*QSMK\+_"5I.LJZ9YA4Y"R2,RY^F>:Y_P"-*JOA_2T "J+H@ < #8:]
M1JEJ.DZ?J\21ZC9PW2(VY5E0, ?6G"JU-2EK8)035D<[XNT^>^^&MS:V:EI!
M:QLJ+U8+M)'Y"L7P+XRT"Q\!6\5U?0P362,LL+G#L<D\#OG->CJH1%50 JC
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MMJ^G:A;.P:T@G:,2>P7'7L<UT:V>F6_P>UR[TNWU""WNBKXOF!+891E<=O\
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M **** "BBB@ HHHH **** "D) ZTM<M\2&9/AMXB=6*L+&0@@X(XH Z<.I.
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M<AN*Q/"OQ+\4>)+NRN(=)T6XT^ZDVO!;:@/M5NN?O,K$9QUP!0!ZU17E^O\
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M9@G.-W;  )/-9^J_$WQ+;^(1X>@L-$MM3MK6.6Z^WW9B221E!*1$XR!G&2:
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M@])?^_3?X4?VA!Z2_P#?IO\ "@"U157^T(/27_OTW^%']H0>DO\ WZ;_  H
MM455_M"#TE_[]-_A3X;J*=F5"VY0"0RD<'Z_2@">BBB@ HJ":ZB@=5<MN89
M52?Y4S^T(/27_OTW^% %JBJO]H0>DO\ WZ;_  H_M"#TE_[]-_A0!:HJK_:$
M'I+_ -^F_P */[0@])?^_3?X4 6J*J_VA!Z2_P#?IO\ "C^T(/27_OTW^% %
MJBJ\5Y%-+Y:%@^-V&0CC\:L4 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !4%XMP]G,MHZ)<E"(GD&55L<$CTS4](3CK0!S%E8>*
M4OH&O-1A:$8\T)W^7!(&WU[>O/M35@\0,LQM=03R,%8]T:JV?FRYR,#YL<?6
MNIW#.,BN8;PTFH_:[AKN:)KF,P,A4': Y.?TZ?7UH ED7Q,L%W';RP-.<+#)
M,5VKT^; &2?4'\*V[5[@V:/>)''-MRZHV5!^M8VE>%(M*U)+R*]N'VJZ^4^-
MIW8Y^N1G/>M34R5TZ?'=<?G3BKNQ,Y<L7+L7 00"#D&JNJ+>OILZZ<Z)>%<1
M,XR%/K3K%MUC ?\ 8%6:&K.P1?-%,YB6#Q+$)&^V!U&% 0("1NY(R,9QCKQU
MJ<MXG^VLR#3_ +,?+ #N21S\YX'4@\>XK0U@P'3Y(+B3RTG4QY^H-8=MX-MA
MI_DIJ%RT<KPR[B><H.,'WYS^'I4]31IVN=95:Q_U#_\ 75__ $(U9JM8_P"H
M;_KJ_P#Z$:9)-(=L;-Z G%<O:^)-5FN;>-]&<1RN@\Q0^ #G).1P?KZ'/:NJ
M8@ DG ')-48]9TR9T2/4+9V<@*HD&23G _0T <\?^$FG9UTU[6VA,[K*78,R
M,7SD<<@#C\:N./% LYTBDM6NFD 220@( #R5 !."!CGD$U VA6^O132?:7C*
MW$J!XB""-ZG^G%6;+PK'936$@O9G%F\C*"H&[?Z_YYIO<47H:,&H.U\ME<(B
M7!A$K!&R <] :T*Y;S5;QQD'.T>5G_@.374U4XVL13DY7OW%KE7B\8/=3O\
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MZG<2:1=7B6=@TQ:'(!Y9?XL9R!TXJ3P+=>*6UCP[J U&XF@U%"U\M]J\,JW
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MG!'3CM5NL1+V]&H79M],ED3*?-)*J=NP]*L?;M5_Z __ ),K0!8U$[=/N/\
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M[5;_ //>+_OL4 2T5%]IM_\ GO%_WV*/M-O_ ,]XO^^Q0!+147VJW_Y[Q?\
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MO8ZBHOM5O_SWB_[[%'VJW_Y[Q?\ ?8K4X26BHOM-O_SWB_[[%'VFW_Y[Q?\
M?8H EHJ+[5;_ //>+_OL4?:K?_GO%_WV* ):*B^U6_\ SWB_[[% N8"0!-&2
M>@WB@"6BBB@ HHICS11D!Y$4GH&8"@!]%1?:K?\ Y[Q?]]BC[5;_ //>+_OL
M4 2T5%]IM_\ GO%_WV*/M-O_ ,]XO^^Q0!+147VJW_Y[Q?\ ?8H^U6__ #WB
M_P"^Q0!+147VFW_Y[Q?]]BG)+')GRY$;'7:P- #Z*** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "L/69+J*\@:RL8KJ9@$Q(>%4L,D_
M3'ZU!JNN:K97\D%II+W4:[2) K8.021G'7C^G6H[E-7U6.W:$+I]R\*OOWG/
MWAN4C&0.A]^AH 2/4-3W*9M&A1'D  $3$@;0<'CJ22,]..:O:7=RWMU=17.B
MO:QQN?*D=5Q(OK['.>*S+S1?$LUQ=26^MB%9&?RTW$A 1QVZC].O>NHA5X[:
M-97WR*@#-_>..30 @@@/_+&+C_9%+]G@_P">,?\ WR*S=&E,DER2?OMO_/\
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MQU&,U:AM[V=Y)HW:W&9D>!I,C<VW:V1W&#^=6-'L=2LFN!?:A]KC8IY&00R
M* 03WR1G/O0!)IT@N]/CN+K3A:2E?WD4BCY3W_#-7!! 1D0Q_P#?(JOJI TZ
M4?WL+^9IVFMNT^$^BX_*JY?=YC+VG[SV?E<+N-(;.>6&TCEE2-F2,*/F(' _
M&N?%_K2KF71+9=L99P$9OF^7I@<@;CQU.TXKJZ8ZED958J2" 1VJ34YR75;Z
M*4+'X:EN$\C<7157=)GH-W;&3S]*Z 6\) )@C!]-HKF;71O$L-K=1S:R)I)(
ME2)BQ'EL#G/3GC\ZZI-P4!B"P R0.IH K62JIN550!YQX ]A5OM5:T^]<_\
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M^14%NUG=>;Y449\IS&V4'45;[9K#\.2!TO 3R9B_YU#=G8UC"\)2[6(-4O\
M4;?5!::?H"W$;!0+AP FXY+ ^@ QSZG%1G5;]+8./#YEE,X5D2/&Q,_-DD<D
M#N.#73US\VF:X?$/VR'5 +#S%;[(^>1MP>1[]OQJC,TM//VNT$MQIOV20LR^
M5(%)P"0#QZCG\:='&D>JN$15S /NC'\1IFD6]W;6/EWTWFS&1FSO+8!/ R1G
MI4H_Y"S?]<!_Z$: +=%%% !6=KVKQ:!H%_J\\;RQ6<#3.B8W,%&<#-:-<O\
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M6_,VZJR?\A*'_KFW\Q5FJTG_ "$H?^N;?S%:'&6JJZA;O=Z?<6\4BH\B%0S
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M']Z)A_*N6?QI'LX>-\--G4T445H<054'_(6;_K@/_0C5NJ@_Y"S?]<!_Z$:
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M+:T#G+"")4W'WQ0!=[4444 %%%% !1110 4444 %5=0DNH;-GLH5EG!7",<
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ML%J'L8%GFWJ"C'^'O5'0K*7,NJW<30WMXB^?%C"@KP#CKG&.I-;=% !1110
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M%J\CQP@A#,^YN23R>_6LFT@U#5]2AGU:T^RM8,LD#1\!F9<,,G.1^7I72T4
M%%%% "8%&*6B@#GKHZGJ%_)IEU8K_9LPD5IUZA<#:<YX.?;^5:]])<0V,KVJ
M+)<*O[M'/#'TJU65KNAQ:]:Q033S1+')YBF(X.[! S^= %?2K>[O+XZIJ,/V
M>XBWP1Q!1C9D'=GK[=<=\5)K5YJUH5.G6:7"%?F)SE3N'N.,9_G47_"- 3VT
MBZA=J+>X:X2,$;2S$Y![D8)&,]Z-6\-#5HXD>_N8!&7(\DX!W<'.<YXR/QH
MT=,L(M-L_L\4C.N]I,MC^(D]N,5BI!J.M:C#'JMJ]M#9NMS$\#E0\BL0 >>0
M1V[?C4@\)01Q7,,%Y<PQ3Q^6=I!<+C!&\Y./3TK<LK8V=E#;&5Y?*0('?[S
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MWA)-P75O7D\U] T4 ?.6H62:?X/\7>']3\,WMUXCFO9;F*Z2S,@="P*R"3L
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M$DTZY2091HF##&>,&L'P/&K>$8(B@$>YU V;<C)ZCUH VUU.PDD$:7D#.3@
M2#).-V/RYJMH)#::Q!!!GEP0?]LU7@\*:5;WD5U'$XDC(P-_RG"[1D=ZG\/A
M5TQE1551/* % P!O;ICBGT)?Q(U#TS7$:!)GQ"CY_P!89>?KDUV%]*(+"XE/
M\,;']*XC0CMUBS_WL?H:UIKW6S*K+WDCOZ***Q-PHHHH *K67^JD_P"NS_\
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M_OOLEKK4-E=1Q,[QNVW*G&#G!Q_]>NEK.N-#TVZNWNIK56G="C2<Y*XQCZ4
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M+Q(]C09ZJXSEN@Y_SQ6_10 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 F:,UPEI<:]XSO=3GL-:?1M+LKM[. 06Z2
M2SO'P[N7! 7=D  =NM0Z_>^*]/\ #.GVUYJ,-MJ-QK,-D+^TC4^9 [8#[&!"
MMCMR.* /0<TN:X"[F\0^#+_2[B]U]]9TN\O$L[A+FW2.2$OPCJR  C. 01WK
M#OO$]S=>*-:2Y\6ZCHME:7HM(A#IZR0J JY9Y60A<L2.30!ZUFEKS/Q)XMF/
MB:]TF/79],@TZ")B]I9?:99G==V]AM.V-1C/ R3UKN?#MW<7_AVPNKJYM+F>
M6$,\]F28I/\ :7/.#UQVH TZ*** "BBB@ I,U@>,=>GT#1%FLX4FOKJXCM+5
M'^[YDC8!;V')/TK.32/&6G7%M=1>(TU4F51=6ES;I%&4/WC&5&5(Z@'.: .P
MS2YKSR"+Q#XA\5^(X;?Q5=Z;;:?<QPPPPVT3K@QAN2RD]3ZU-IFL>*-1TW6=
M$CDLSX@TR\2V>\*;8VB<!A-L_O;"?EZ9% '>T5PW@G7;G4->U?38]9_MS3K-
M(]M\T:HZS$G=&=H ;  .<<9QS7<T %%%% !1110 4444 %&:Q/%NO?\ ",^&
M;S55@\^6)0L46<!Y&8*H)],D5BMH_CBV@COXO$D-Y? JTNGRVR1VS#/S*K ;
MUP,X8D].E ':YI,UP-RNO:YX]UC3;7Q)=:5:V-M;.D<$$3Y9PV<EU)[54N/%
MNLZ%I'BW3]3N8[G4]'M5GM;R.(+YR2@A"R#C<&&#C@\4 >E49KS[P3J3W.J^
M5<^+]0O[@6^\V-[8K;;AQF1/D4LH/''KS2VGBW4=5^(NFV]HRIX=GAN5A;;\
MUT\6T&0'L@)P/7!/3% 'H%<?\0I=-@TJT?4[62YB-TBHD;;2&YP:["N/^(>F
MKJFE6D3WL%H$ND??,< D=A[UG5OR.QUX#E^LPYVTK]-SK8QB)0.F*?4<61$@
M]!4E:'(%)FEKFO'^KW>A^"M1OK!UCN@J1Q2,,B,NX7=^&[- '2T9KB)?AMH\
M%HLUK>WMGJT6USJWVEVE+#DE]QVL#SD$8YK,?PWI/B7XIZ]%K%J+Q+>PM#$&
MD90I;?D@*1UP* /2J3-<%X:2YT;Q3XB\+6%R[VD%M#=V(NG:7[,TFX%"2<E<
MJ"!GN:J^&IM0T:[\>RWFH2:C=VA24S2*%!80;L*HX50> /2@#T?-+7B^@ 0+
MX:U_4-.U.T>]GBWZS]M#/<22 _++%T6)B<#'3Y>E>SB@!:**#TH \_UN&=OB
MSH4ZPN8DMW#2!>%SGJ:[\=*XG5]5NX/B;HVG1S$6DT#M+%@88C.#^E=LO2LJ
M=KRMW.[&<W)2YOY=/O8M)FEKD/B+J.LZ9X>MGT":.+49[^"WB,@!5MS8VG/8
M]*U.$Z[-+7 7?C2;4=%\-WVGLUI-<:W#87]NR@M$?F$D1STY Y],'O5$?$&Y
ML=0US3#)'>ZQ)K#66DV3,J<;%.6/9 222>3T% 'IF:6N'U*^U_1+#1M$348K
MWQ#JT[(;R:("* !2TC!!C(4<*#UR,FE5/$.AZS9)_P )/!J\4LRI>6EX(89(
MT;^.,K@\<?*<Y% ';9HS7 ^)Y?$VG6.LZ_/K\6F6]D6-C9I"DD<R@#;YA(W%
MG/&%(QD=:BEG\0^(?&":?#K=UHD:Z1!>20P0QN1([$,#O4].E 'HE%<?X;U3
M5K7Q3?\ A?6[M+Z6"V2\M;T1"-I8F)4AU'&X,.HZYKL* "BBB@ HHKE/'VOZ
MIX=T:SN='M8[N\FOHH! X_U@;<2H]"<<4 =5FC-<=>>,Q<6/A6_T=HY+76-0
MCMI?,7YD4JY8>S K@_0U2C\?R6RZXES MS>PZO)I^F65N,27)"*0/PR26Z 4
M =_17+'Q+_PC6F6(\6WD*ZE>%]D=I [*6'/EH!DL1D#WI\WB>35M >[\*PI?
M7GGK;F.<&/[.Q(W&53AAM'..IXH Z;-%<!:>-[S3H?$:ZK)9ZDFC6RW'VRP4
MJDC,#^Z8$D*X('0G@BK-CKOB'3M9T:W\0?8)(-:#+%]EC96MI0F\(22=X*@\
M\<B@#MJ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH X:VT_Q'X3U'4X](TJ#5M+OKE[R)/M0@DMY'Y=3N!#*3R".1FJ>
MJZ#XLN?#MI/<F+4=6368=2:T24)%#&ASY2,1S@=SU)->BT4 <)=6'B7Q=J6F
M1ZMI4&D:59727DJ_:A/)<.F=B#:,*N>23Z4W6;/QE>V&LZ UG97EKJ#2)!J+
M2K&((9."'C RS*"<$=>*[VB@#@H]!UKPIKEW?:)I\.K0WUG;V\BRSB%XY(4V
M*Q)&"I'7'((KH/!^AR^'/"MEID\JR3QAGE9!\NYV+$+[ M@>PK=HH **** "
MBBB@# \7Z!+XBT+[-:SK!>P3QW5I*XRJRQMN7</0]#]:R)I/'&M?9;)]/M]#
MC65'N[V*[$S,JG)6)=O&[IEN@-=M10!P$$7BG0?$_B*YLO#L>H6VHW*30R_;
MDBQB,+@@@GJ*DT_0/$^G:9JFJPS60\1:E>I=SP<F'RU 40!B,CY1C=CK7=T4
M <;HFDZK=>-9O$FH:?#I2"Q^QI:QS"1YCNW%W*\<8P!R>379444 %%%% !11
M10 4444 8WBK05\2^&KW26E,+3H/+E SY;J0RM^! KGKB7Q_J>GKI1T^STNX
M?"3ZM%=AU50?F:*/&=Q&< ],]Z[JB@#@YK;Q)HOC?5=3T_0QJEK>VUO$LAO$
MB8-&&!R".^:6T\/>)FCU[7'FL[+Q%J2Q+;Q#][%;QQ?=C8D?,6RV2!WXZ5W=
M% '!3:#K/B[6[:ZUW3TTBTM+.>WVP70DFE>90K$,H^50!QW)-5T^'EQ8^,-
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M<9%=Y10!R7AO1M6?Q'?^)M>B@MKRY@2TM[2"3S!!"I+?,^!EBQSQP*ZVBB@
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M?:90AN9E@A&,[W;H!^1_*G6MXMVLK*DL8CD:,^:A7)4XR,]1Z&@"S129HS0
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MK8]1D$9JYGKR..M:'&+129]Z <T +1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110!P3:@?#'C77;O4-+U&X74%A:TN;2U:;<B)@Q?+]TALGG .ZN?\
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M[5%"[.KQPQ1?,3DY0228P"0?SKTF.'3M5EL-8C59FCC9K68$X"N!DCZ@"K]
M'CG]C'[?)8PZ3JR>(8M15;.Y42+;V=HKC:5?.W9Y8.1R6).:O6%I+>:S+-)I
M>LGQ5%<W$K7C%HX(E&[RHPQ.UHV&P;5![DXQ7IT%Y#<S7$,3,7MW"290@ D
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MM"G2WD>73[Q]9CT"&W@F,3M^]N'82L#TROF8Q]:]BL=1M=229[.82I#,\#D
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M\""* /,M1CO/$=[=+:V6J6=G(++2;=WB>)_*+^;+*!_"-JJ,GFM_QM:6^B>
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>g4i5nix4zlkt000031.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g4i5nix4zlkt000031.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %2 J # 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ II;G !/TIU-'WV^@H -Q_N-^
ME&X_W&_2G44 -W'^XWZ4;C_<;]*=10 W<?[C?I1N/]QOTIU% #=Q_N-^E&X_
MW&_2G44 -W'^XWZ4;C_<;]*=10 W<?[C?I1N/]QOTIU% #=Q_N-^E&X_W&_2
MG44 -W'^XWZ4;C_<;]*=10 W<?[C?I1N/]QOTIU% #=Q_N-^E&X_W&_2G44
M-W'^XWZ4;C_<;]*=10 W<?[C?I1N/]QOTIU% #=Q_N-^E&X_W&_2G44 -W'^
MXWZ4;C_<;]*=10 W<?[C?I1N/]QOTIU% #=Q_N-^E&X_W&_2G44 -W'^XWZ4
M;C_<;]*=10 W<?[C?I1N/]QOTIU% #=Q_N-^E&X_W&_2G44 -W'^XWZ4;C_<
M;]*=10 W<?[C?I1N/]QOTIU% #=Q_N-^E&X_W&_2G44 -W'^XWZ4;C_<;]*=
M10 W<?[C?I1N/]QOTIU% #=Q_N-^E ;)Q@CZTZF_\M!]#_2@!U%%% !1110
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M,ZW$D\R)&FSE8WVY&6Y/3@9/7 Q5S6-9DTN]LD^SM);RK*\SKC*A$+<9(I6
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M5GM9IXE4A1N1&@,ASSUR.W8'OBM?2-9AUF%IH(94C&"K/M(8'_=)Y]0<$46
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M='S^B_G0 ZBF_/Z+^='S^B_G0 ZBF_/Z+^='S^B_G0 ZBF_/Z+^='S^B_G0
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M44 %%%% !1110 4444 %%%% !1110 4444 -3H?J:=34Z'ZFG4 %8MQX?%S
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M=M=%'.>X8G\/K0!)!8ZNVDWL-Q/*UQ(HV[V !/\ %M()(!Z=L>@ILMGJ&?\
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MR%&T_P!\_D*=10 W:?[Y_(4;3_?/Y"G44 ,4E<@ACSUQ2[_]EORIU% #=_\
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MA5VV\%Q6NIW5RDMLR2M+(GF6H>1&D&"-Q."HR>,=\$UA:H\LBR,;K86@N41
MBA6*W8&< <GH3]*ZZPN[F)]7ANKAK@6;@I(8QNVF,/C"X!P2:>H$'AKPVV@-
M=,;I76?;B"%#'$F,Y(4LV"<\XP.!Q4$/A&*/48[@7I/E79G,83_EGU6+KT#
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MR%8MJ_,BH !DX "CUS5C3=&.GW4<WG^9LL8K3&W&=A/S=>^>E9WA[5)[S4S
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M0Z6\WAZ2%[F1UND-PI^RJ#PQX^;/H*/[8UK[+YG_  CLGF_;OL_E?:5_U/\
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M.A4J,'KCBGT4 4+#2+;3I9)8C,\CJ$+S2%R%&< $]N35T(@8L%4$G).*=10
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M)&P3A0,DX'M61J345QW_  M/P?\ ]!1O_ >3_P")H_X6EX/_ .@HW_@/)_\
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M1?\ H KY?/0U]0>$?^1-T7_KRB_] %<^8?"CIR[XV;-?+WBO_D<=:_Z_IO\
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M\C3J* &[U]_R-&]??\C3J* &[U]_R-&]??\ (TZB@!N]??\ (T;U]_R-.HH
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M@'\* %HINQ?[H_*C8O\ ='Y4 .HINQ?[H_*C8O\ ='Y4 .HINQ?[H_*C8O\
M='Y4 .HINQ?[H_*C8O\ ='Y4 .HINQ?[H_*C8O\ ='Y4 .HINQ?[H_*C8O\
M='Y4 .HINQ?[H_*C8O\ ='Y4 .HINQ?[H_*C8O\ ='Y4 .HINQ?[H_*C8O\
M='Y4 .HINQ?[H_*C8O\ ='Y4 .HINQ?[H_*C8O\ ='Y4 .HINQ?[H_*C8O\
M='Y4 .HINQ?[H_*C8O\ ='Y4 .HINQ?[H_*C8O\ ='Y4 .HINQ?[H_*C8O\
M='Y4 .HINQ?[H_*C8O\ ='Y4 .HINQ?[H_*C8O\ ='Y4 .HINQ?[H_*C8O\
M='Y4 .HINQ?[H_*C8O\ ='Y4 .HINQ?[H_*C8O\ ='Y4 .HINQ?[H_*C8O\
M='Y4 .HINQ?[H_*C8O\ ='Y4 .HINQ?[H_*C8O\ ='Y4 .HINQ?[H_*C8O\
M='Y4 .IO_+0?0_THV+_='Y4H4#H /H* %HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
/ HHHH **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>g4i5nix4zlkt000026.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g4i5nix4zlkt000026.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &% J # 2(  A$! Q$!_\0
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MD?-N7M@UHF1!MRZC=]WGK]*35@3'445RWCC7;O1="@NM-FC$K7T$#DJ&&UG
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M)JXSBI:.RNR7%M:J[L7IR?\ A<]J,G']B/QGC_6TLA/_  N>$9./[#/&>/\
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M91I4%BU[/ CE/M#;MJJQ'.T=<55NM)M?!'CCP\VAJ]M9ZK*]K=68<F-L+E7
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M9+?"Q-Y;B[8;A 95\PCUVYSBBZU&RLGB2[O+>W:4[8UEE5"Y]!D\T 6:***
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M$DC895T8$'Z$4 /HHHH **1F5%+,0J@9))X J"SO[/4(VDLKN"YC4[2T,@<
M^F10!8HHHH **** "BBJ=YJVG:<RK?:A:VK,,J)YE0D>V30!<HJ&VN[:]A$U
MK<13Q'@/$X93^(J:@ HHHH **8)HFF:%94,J*&9 PW*#G!(]#@_E5:35=.BF
M,,FH6J2@X*-,H8'TQF@"Y1110 4444 %%4+K6])L9S!=ZI96\PP3'+<(C<^Q
M-7(I8YXEEAD22-AE71@01[$4 /HHHH **1W6-&=V"JHRS$X %5[/4++48C+8
MW=O<QJ=I:"0. ?3(- %FBJL&IV%U=26MO?6TMQ%_K(HY59T^H!R*M4 %%%%
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M8^7)LE7_ &7'(_$=J[36K"'6+K1YO+O8/[-OA>!5M2?,(1EVGT^]U]JSM?\
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M?=S@_P #5W/EW!L?+,ZK<F+:953@/C[P4]L\XKSJXMK?7OBO:ZK%I^IK:Z7
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M$\CGN37J-><^&O#6M^&H[2UM_$5T^G02!Y+8:(BF;G+;GSNW-W;K7<_VDO\
MSZ7G_?@T 7:*I?VDO_/I>?\ ?@TU]6BBC:1[:[5%&68P-P* +]%%% !1110
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MJX;VE!:I:W\E>3_RZ6\T;MQ_Q_S?]?=O_(5MUB7'_'_-_P!?=O\ R%;==!Y
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M_P!=7_(*/_9JC\#OC4=1C_O11-^1<4SQJV=;LDS]VV<_FR_X4SP8V/$%PO\
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MH9LY_P#KFW\J^@RQ?N=>_P#D93W/7Z*BMI/.M(9?[Z*WYBI:\!JSL:A1112
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M6_"QA?J>O44U'62-74Y5@"#ZBG5\H;A1110 4444 4M7_P"05<?[O]:75/\
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M'\ZN1Z[I,T:R1ZG:,C=")E_QK0HP/2HDX?97X_\  &8^IZII\NG31QWUL[L
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M^)K:HH Q=WB;_GEI'_?V3_XFC=XF_P">6D?]_9/_ (FMJB@#%W>)O^>6D?\
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MN_+ZN$IU6\7!RC9Z+O\ @3-2:]TWHW$D:R+G:P!&1ZTZBBN H**** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M-X-^E]_Z*6@"3XB:#IVO>#;U-1#@6L;7$3H<,KJIQCZ],>]8_P )?!MAX?\
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MY>Y'44 >@445S^KZQ?6'B'3[94$>FR@">X:V9QO9PJIN# (23U(/44 &E_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M5O>OLWY?TBHJ2;N+1117G%A1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% &/XJL+O5/#%_8V.W[1-&%4,^P,,C*D
M]@1D?C6%H=EKFD:Q?20>';.VT^\:'$$-ZH6$J"KL%"8R1CIC.VNUHH ****
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M@$X[#O0!S$NK>*XM0MK0Z%IS&='82+?2%$VXX8^5P3NX^AJS]J\6?] G2?\
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MA,8.2,\XZ#J:CF\*^#[:2&.?2=*BDG;9$KQJID;T4'J?I0!T>Y?[P_.C<O\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%<WXIN-7M)=.?3M1BMDN+J.U='MA)]\GY@<CIZ5TE4=3TR/4Q:"21D^S727*
M[?XBO0'VYH YZ;QK!I;7$%S!?7LEL93-)! H")'L#MC=R,N",<GGCBI9_'=C
M;(1-8WJ7"-)YUNPC#Q)&%+.?FP1AU( ))STJ6;P=;32ZC(;N8&^29'  ^7S"
MA./IL'YU%J?@:TU&]FO!=-'<2RNY9H(Y0%944J X(!_=@ANHY[4 7M6UIH%L
M!8E'^U)).'(R/*2,MD?4E1^-96F:UJ]I'I4^ISQW\.I69G58+;9)'(L8DV@
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MB,@OG'!R<TV]T2WM+N*"ZT:ZDT2V\22RBWAMW=$A-H/F"*.8_,)R ,9SQVH
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M5O96LEU=3QP6\2[I)9&"JH]23TKRS6_",4#^+WT_1Y5,$5I+I@AC;"2XR[1
M=&RJY(Y..:]5G@AN8C%<11RQD@E)%##(.1P?0@&@##_X3/23X<M==B-S-9W<
MHBMUB@9I)6+%0%3KS@GZ5J:9J*ZI9BY6UN[8%BOEW4)B?COM/.*X"#3X4\"Z
M!'K6FZJT%OJ$LLHM=ZR09>7:[*GSE?F_A_O ]*Z#P8+^'0M0,B7KVOVJ5M-C
MO&83_9\#:"6^8?-NV[N=N,T =4&!) (R.HSTHR"2 1D=:\0M+"_::UN+329K
M:633;Z.[C@L)T9)&A)6.::0YF?<.N,9Z=16K=^&KVPTZW30M/N8+BY\-NMV8
M@RO-*&A.UF_YZE3* 3SR: /34U:U?6Y-)4L;I+9;D_+\NQF91SZY4\5F:AXT
MTG3+^>UG%TR6K(MW<QP,T-L7P5$C]N"#WP""<5@^$;33D\;WUUHFD7-CIKZ9
M#'F2U>!&D$CY"A@.0",^_P"=0^)=774]?GT*\LM2M]$A=&NG@TZ:0Z@_!V!E
M4A8Q@;CU;H,#)(!TTGC#2H]8_LYC<'%PMJUR(6,"3L 1$7Z;CD>V2!G/%;Y(
M R3@"O,KBVNS:ZCX9^PW9OKK7Q>1RB!O*\@W"S>;YF-HPH*XSG( Q71>+-)7
M6->\,07%HUS8K=S-<KM)3'D/MW]L;L<'@G% '5;@3@$9QFC()(!&1U]J\LT;
MPY-IZZ#=6FGS07ZZI?0O,R-E+?;<")6STB&(L#ITQUJDFGC_ (17[/IFC:I!
MXB73FCU2Y(>$N^Y/-5G; E=\/L()QG((!H ];N;J&TLYKN9P(88VD=O15&3_
M "JGH^N6FMPW$EJ)5^SRB*194VE6**^/R=?QS7F0M;"X\2ZEINA:5>6%K?V-
MG;R1/:O" K3/YK[& *CRU8$X&2._4WX--U*U\<W>IWMK/<Z*=:94M5A;]S(T
M,02ZP/\ 6*""G3"Y+=C@ ]/R,D9&1U%9.L^([719K>V>WN[N\N0S16MG"9)&
M5<;FQP HR.21U%>:6%M!;:EX5%SIMXGB ZQ)]NOVB;9/E)CGS?NR X!4 G:!
MVQBNN\:1VS:GI\M[9ZK%"D<@CU;26D,ULY*Y1E0$E& SD@C*C(Z4 :8\::-_
M8JZGYD^UK@V@MO(;SS.#@Q>7C=OXZ>G/3FI](\36>KWLMCY%W97\2"5K6]A,
M<AC)QO7J&7/&03@]<5Q=JNN;-)UZ\MK^_M=,U*?9YEJ([J6UDBV+,T0 RRL3
MQ@,5YQFKMGK)\2?$C3)TT^]L;>PM[M(Y[J!HQ>;S'@)D X 7<0<$''6@#KM3
MUZRTF0QW!D9UMI;IEC7<5BC&68_F /4GZU6A\6Z1<:)IFKP3-+9ZE-%!;NBY
M.^1MH!';!X/IBN=UV*637?&,!C:2XN/#JBS51EF4>>&51W.YEX]Q6->>']4T
MJ?PZ+"REETR_O[&YNX40YL[A"N^3 '"N!\WHRY_B- 'J]8%OXOTNZU5;&);H
MB29[>*Z-NWD2RIG<BR="1M;V.T@$XK#M_ ]S%XA343:: $6Z\[<L$_FXW9R"
M9-N[\,9[5A>&-/U+2KG1-/A.LC5K>]E341-YGV0VN7.1G]W@Y0J5^;).>] '
MINFZC;ZK8I=VQ;8S,I5QAD92596'8@@@_2K=<OX/!-UXED3_ (]GUB7R?0D)
M&KD?]M _XYKJ* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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H0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>g4i5nix4zlkt000040.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g4i5nix4zlkt000040.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %Z J # 2(  A$! Q$!_\0
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M,,4N@7Z.JYF 9"5.T[?8G;]*MNE[.RM>R_KU%:?/=[7,74?&6KP> ;'4-/\
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MC<0/3->,^,;72U^)6DW>IS75I9:A;1W%P[R$,C8(P,#CHN0.Y/K7J'CLC_A
M-:(/R_9&YK.5**</,I3;YO(YV+XQ:45@FN-(U2WLYGV+<O&ICR.O(/..^*]%
M5E=%=3E6&01W%>*^#/ )\6^$]/N+[7;K^S4F=EL$0;00Q!PV>_/;N:M7FCQZ
M]\:-2TB>\NH;-;2-FB@G*;@J)@?3.#^%:5*-)R:B[6O<F-2=DWU/8:*^>]6N
MX9-4\2'Q'JNH6>J6C%=+MXW95P"=H ';&W\R:M:MJ.HW,7@Y/%=]>VFF30,U
MQ*K,K,0S89L<YV[/P.:7U1Z:_P!6OIW#VZ['K&A>,+37M<U72H+:>*73GV2/
M)C:WS$<8.>W>NBKYUTP@Z-X\-E/<2JJ1-'*Y(D9!-G<>^<<FK::];:AJ/@"W
MM;V222V,<5R-S ;]Z_*3_$?SZU4\)=^[_6EQ1KZ:_P!:GO\ 6-K?B;3M N+&
MVO'<W%]*(K>)%R6.0"?0 9%>+&^TZZU77I_&>LZM::G!<$6T-LY4@9/"CIQQ
MCIQS5OQ[;6,DWA/4[JZU VUW$([BXN_DD\M2N&( ^5L,3D=>#2CA4I)2?]6&
MZSY6T>O_ -O/_P )1_8O]DW^SR]_V[ROW'3.-WKVK8KQS[3)%\6-FD7$DRKH
MFZS5G)#D0?(2#U)XKC1J*C1H]0BUK5&\9&]VFW\Q_N_3'^>F*%A>:UGT0>VM
MN?2M%>(W5I-K/Q*UVSO+V[M\::)I8[>8KEQ$AQ]-W\JZ[X.WUQ?>!\W$[S&*
MY>-&=MQ"X!QG\364Z'+#FOV_$N-7FE:QZ!17A7C[4[2]\9ZC:O<:@)[>/9&D
MMT8H@P QY:(I9B>O)&:R;C5;V\\$>%C)J$_F+J<T*RB4[@ 4QSWQGC-:1PC:
M3ON0ZZ3:L?1=<]XL\76GA&WM)KNVGG6YF\I1#C@XSDY(KS6U-_H'C;Q;I6DW
MUY,8]-DEB$TID<R;5;=_O?,<5Q=W-ILOA[2)8M4O+G5'NB;Z&9V9(SGY2,\
MD>_/-53PB<E=W0IUVEIN?3DLT<$#SRN$BC4N[,>% &237 /\7]%!>:/3M4ET
M^-PC7RP?NP?SS_6NH\66-QJ?@_5+*T!-Q-:LL8'<XZ?CTKR_POX[T+P]\/#I
ME[;"?4H9F5M/DC.927SDY!''OZ5E1I*46[7=RZDVG:]CT*;QUIJ>(-(TF&.6
MX_M2$307$>/+VG.,Y.?X?2K^@:\^N+=%])O]/\B38!>1;/,]U]17G6J77VOX
MK^#+@VK69FM%<6SX#1Y+\$"N/6\F/P[\2.;J4E=6B )E.0/FXSFM5AHR2MY?
MF1[9IZ_UH?1IX&:R/#^NOKL5Q(^DW^G>3)L"WD6PO[KZBO+;"*;1?B/X46+4
M[R8ZG8QRW(GF+!]RMP!Z<# [8K!L-3U>#X<ZY+87-QSJBI/*CDLD14]^P)P*
ME86ZW[?F-UM=CZ(HKR'PA=^&+3Q';+H6MZ[=S-;%[B+'F0L0I)WY&01[=\#/
M->?ZGJ\5S%<:E97VHB\6?=YES>L9@/7:JA5&?4^U$<(Y2M?\ ==)7/?7\7VB
M>-X_"QMI_M3P^:)N-F-I..N>WI4WBKQ-;>$]&_M.Z@FGC\U8]D6-V3GU(]*\
M[TVY:Z^-&C3RN&EFTF.1CGJ3"236Y\9R!X#R2!_I<?7Z-4^QC[2$>]A^T?))
M]CNM.O4U'3;6]C5D2XB655;J PS@U7UW6K7P]HUSJEYO,$"@D(,L23@ ?B:\
MBO86U#QKX,T[[;<V\5QHT*N;>4HV-KYQ]>F:PEC^T>!O%$$]W<2Q:5J$9M@\
MI(!9F0Y]>!T]>:N.%3:;?;\783K.VQ[AX8\1KXGTPW\=A=V<6[""Y0*9!@'<
MN#R.>M;=>"7B0^'K;P!>FXN([%]MS<2-(Q4$E&8<=L=!4EEJBZAK/CRZMM7F
MM+>6'=%<X<[%,@P=HY (XSC@&E+"WUB]/^#8%6MH]_\ @'NS':I."<#.!63X
M?UQ]=MIIGTJ_TXQ2>6$O8MC/P#N'MS7D7@?4HK3Q5IMM'_I+W4#*TUEJ$DB_
M=/S31MG!]N,5GZ;J6KP_"S5Y=/N;@DZJ$N)4<EDB*#//4#. ?K3^JVNK]@]O
MU]3Z$HKP[PY=6\'C6SMO"VJ7]]ILMDS:@)G9E5MC9//0@X_$XKF88I1\,6UU
M=4OA<6VHB&)1<$(H*@DX]<XY]J2PFMK]NG</;Z;'TO169#<7<GA>.YA_>7C6
M0D3/\4A3(_,U\^_VDO\ 8QU#^VM5_P"$R^V[1;[W^[G^[_GTQ6=*@ZE]=BYU
M>0]JUWQY9:+X@@T1;"^OKV50Y2UC#;0?Q]L\=!6IXE\00>&-#EU6YAEFBC95
M*18W'<<=SCO7E*Z+'=?&>RM[UYTGGMTO9PLN&6;9N('HN1TKM?BV0/AY>DG'
M[R+K_OBK=*"G"*Z[DJ<N63[$UQ\2-)A\&Q>)4@N)K=Y1"T*;?,C<YX.3CMZ]
MQ75V5TM]86]VBLJ3Q+*JMU 8 X/YU\W:_I5[H/ABQDBD9M(UFWAN6W=$G5<D
M>W4X]1]*Z'Q9J=G->Z/IUS<7R^5ID!5&NC#;Y* @C:I9F/\ 3%:2PL7;D\R%
M7:^(]JU?5K/0]+GU&_E\JVA +L%)/)P!@=R2!3M+U"+5M*M=0@5UBN8Q(@<8
M(!Z9KP6U,^K?"363=W%Q,VEWR/ #(3MSA6#9[ $G!Z&EOIK"R\)>$;O3[V=K
M=+TM>OYC$1R_NRR_3 X%3]45K7UO;\+C]N][:6/H2BO"CK,6J^+?&UY97<CV
MKZ3*T1W,HP%0;@#TZ'FK&DVMMI/PK?Q-<7VK/=7<7V;=;S\QIYF %SD+TY;W
M-0\+9:OM^)2K7Z'MM<[X6\7VGBI]06UMIX?L,OE/YN/F//(P3Z5XSX6U$VGC
MK0#IUY,(+J18Y5-T\H?/!#$@#/(X&0*[;X.D&?Q/@@XO1_-ZJIAE3A)OR_,(
MUN:22.MU;QG9Z1XJT[0)K:X>>^"E)4V[%R2.<G/:JNF_$&QUGQ-+HVEV-W=B
M$D27:;?*4#J<DYQG@<<]JX3XJ6<VI?$?1=/MI1%<7-NL2.6QM)=AFK'P_O&\
M&^,-2\':D8U,[[K>;:%WMCC\&7IZ$8[T_80]ES+>W],GVDN>W2YU]U\0X;#P
M[-K-]H>JVL<5PMN(9X@COD9W#)Z5;M_'%E<>*K30%M+@3W-LMRLAV[ I7=@\
MYSBO%A</+\)-4:6=I,:O& 7<MCY?>NHBDF3XJZ>UH UTNAJ85]6\@X_6KEAH
M)/Y_H)59.WR/::*^8(+Z]G/VN779(=:-QCYI9S/N_P!Q5*XS_ABNXO-,F\0?
M%I-)U*]N8A)IL;72VTI0LPC!('H-WM6<L)RO67X%*O?9'L5S<PV=K+<W$BQP
MQ(7=VZ*HY)K@O^%OZ+DS?V=JG]G"3RS?>1^[S^>?ZUO^,=*GO/ >HZ9IZ,TO
MV;9$@.2P7!V_4@8KSSP]X_T#1/AU;:;<6HN]2AD*/ISQ\N=Y.[D$=#]<C%31
MI1E&]KN]BJDVI6O8]AM[B&[MHKFWD62&5 \;KT92,@UD>*_$]MX2T7^T[J":
M>/S%CV0XW9.?4CTKRCX@:C?W7B;3X+^1]+TJ2S26*&>1XHU8C+!C&"=P/'2L
MJ\GOI/A/?_:-0-Y8KJ$0MG;?\O#;E!< D=/UJX85>[)O1_UN3*OND>PQ>-[*
M7Q58Z +6X$]Y;"Y20[=B@H6P><YP*Z>O&HW"_%O0SYA0C10=RC)7]P_('>N7
ML-3CTV]M;QKTZM,+W:)K6_EBNG)/>)A@K^'.<9H>%4OA[?YA[9K?N?1M% Z4
M5Q'0%%%% !1110 4444 0W%G;7847-M#,%.5$B!L?3-)/96MRR-/;0RF/[AD
MC#;?IGI4]%.["Q%<6MO=H$N8(IE!R!(@8#\Z;)9VLUNMO+;0O"O2-HP5'X=*
MGHHNP()K*UN!&)K:&01\H'C!V_3/2B2SM9IO.EMH7E"[=[1@G'IGTJ>BB["Q
M'!;PVT0BMX8XHQT2-0H'X"HCI]D;C[0;.W,^<^88EW9^N,U9HHNPL(P#*58
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M3:&J2.=6LPL3;7/G#Y3SP??@_E5R'4;*XFCBANH9))(O.14<$M'G&X>HSWI
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M:@YYDC'X<4AF@9"!C/7\C3-H.'# GG(/<=Q47VH,/E3\:K-=RM<".,ILQ\S
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M[:32;  .]Q.!N93V1>Y^O2BXS(\'Z=-KNH+I^F:++=7>P^;+'<%0J$X+,,8
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MD+__ )"=Y_UWD_\ 0C5>O>5"E;X4>8ZD^YV__"VO&'_/[;?^ RT?\+:\8?\
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M>$?^>%[_ .!)KM:*/K%7^9A[*'8XK_A4WA'_ )X7O_@2:/\ A4WA'_GA>_\
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M<,3ELGDGK7:\5"E148:MD*DY3=]C2\+'S_$5K))N; 9C^1KT62% <KC!X/\
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M,*83*<QL=V[Y< 9&>O:L_4-?N)M2+B2%O+!:0VEU(89O]#G8@'(PN5[8/?J
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MB:.TD589289FBW'<_"95NJ#)QWK/M/'6M6VE68EMX[V>#3H+RZD6WD)G\PG
M#+\J$!>K<$GH!0!T=MX(M8UNUNKVXNQ>6]Q;S[E5"PFD\QFXZ$'@57L_ $%B
M1/;Z@8KZ)T>"XBM(TV;0PPRC[^0[9R?IBNPZC///K10!@#PNI\+W6B3:A/+]
MIE>:2Y9%#EFD\P\#CKQ4EMX;AMI[*474C&UO+F\4%1\QF+Y4^PWG'TK;HH P
M[[P\\]_<WECJ+V4EVJ"Z0VZ3QRE1A6VMT8#C/? R.*RW^'MA_9WV*&^NHD6&
M"%' 7>HC9V)SQ]X2.I]CQ7844 <_!X1LH=8&H,_F@23R+!)$I0>:(QC\!$,?
M4UT       &  .!110 J_>'UI.]*OWA]:3O0!SGC--9;1R^B:C);7$*22F&W
M$?G7.%.U5:3A0#RW!) P,4V&ZO\ 7O FFW=CJR07=Y!"[74,2J9#@%UC5^%9
MCD#.<>E:&M^'-*\0I NIVQD:W9C%)'*T;IN&& 92#@C@C.#5:?P9X?N(I8GT
M\".1(4"QRN@C$6?+*8/R%<GE<&@"CX1N]2\0>!F2YU*6'55DGM);E44RP2(Y
M49&-K.!C) P:XS2-<\6V%\"=;;69)];GT6*WOE6*)=B[A,2@SG@\>YKU/2]+
MLM%L(['3X!#;QDD+DL2Q.2S$\L2>23R:IQ^%M&AFCF2T(DCOWU%3YC<7#C#/
MU[@].E '!R^+-;_M4P"]DC"7VJP2*"&4^3;ATQE00H;D#KZDTNE>/-3AMU64
M-?7MQ::5%;K-(%C-Q<H<LV%RHR,G&<]L5VY\'Z$UPUP;(^:\T\Y;S6Y>=-DI
MZ]UX]NU1_P#"$^'OLDUM_9^8IH((&!E?(6$8BVG.59>S#F@#GO\ A/-:EU&W
MT:WTK3_[5^U75I<F2X?R%:&-9 RD#<0RL.",@U8U#QI=S?"VS\2V,<5I=W_D
M1J9?G2W:20(7/J%Y//M6_:>$M#L7LWM[+;):-,\3F5V8M*,2,Q)R[,.[9-3P
M>'=)M_#J^'ULD;2EB,(MI"7!3.<$GGK0!RE]JFL> ["_EU'7E\0L3 EK!+"$
MG221MF6$8),?<8!)Y K)U'QMKUPED_DW&E2_9M3$L9A9%F:* -%*HD4,!DY
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MTKO+:?[+$(HBH8# &.@^E>'P7.JZ:H^R7$\8/:)CC\JU[+QCJUMN:ZN6FVC
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MK+^TS_\ /5_SH^TS_P#/5_SH U5^\/K2=ZS8KB8RH#*^"P[TC7,^X_O7Z^M
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M">2!@'OFJG_")Z;_ ,]=1/\ W$9__BZ/^$3TS_GIJ/\ X,9__BZTM3[O[O\
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MVJFP)YC[<;"G3.,[25SUQ3?^$3TS_GIJ/_@QG_\ BZ/^$3TS_GIJ/_@QG_\
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MQ< E3MSN&#@\CITK.T_P'=VMNOG3VKW"O%MD&[*QJTFY >" 1)CC'3Z5WM%
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MD#@?=/X=?10!S-^[IXYMV0D$::__ *-2MR"\63"O\K?H:P[\9\<0_P#8,?\
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M,C*$0%2H!8 ,P4$@ GCCK@4 5IO&UO/;0FPBFCGDFM2BW<6WS8)9EC,BX/\
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MU )9@[!5(SC@\Y&*RSXS:74(YK=U?2WDB((BRYC:WED;_@6Z,?J* .^^WO\
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MBBBF(**** .=>*3S&_=OU/\ ":3RI/\ GF__ 'R:UR3D\GK29/J: ,GRI/\
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M*+-0% M5 52H BZ ]0..A]*C.F6Y@6W.GPF!#N6(P+L4^H&, UO9/J:,GU-
M&)/81W2!+FS2=%.0LL(< ^P(IJZ; J1(MA"%B;=&H@&$/JHQP?I6[D^IHR?4
MT 8_D-O#^2=X& VSD#ZT);F- D<!1!T54P!^%;&3ZFC)]30!D^5)_P \W_[Y
M-'E2?\\W_P"^36MD^IHR?4T 9/E2?\\W_P"^31Y4G_/-_P#ODUK9/J:,GU-
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MK*0&SRPQMQS]ZJ%AX2UTVRV]Q9SJA^S)>)\J+<,LRL[Y$C%SM#Y;Y<AL8[
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M:.%59>0-P[>N:R/%UWYWBF^A/&VZE7]:I7\I723M/H/TI-NY5M#HI==OHIQ
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M%).4QBCEN*YRVJS8CC /0UE*^?,).>:?J4Y(_&JD<G[M\=Z2&RUJKK;Z=8O
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M4.0%[ 1@8[@G)I;;P-;6S,PO7/F3F:14@1%8-%Y3H .@*]^H/K7544 <E:>
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J5V=% &+X3^U#PS9K?27$ETH82M<+A]P8]>!^=;5%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>g4i5nix4zlkt000032.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g4i5nix4zlkt000032.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &% J # 2(  A$! Q$!_\0
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MKV-#PT;VOUM^%P]L^Q[M:7UI?QF2SNH;A <%HI P'Y5-)(D4;22.J(HRS,<
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M7AO[ 8S9*6\_S,A\8[8XZUXY965I)+H,NF:CH=AJ"LC(8))FFE;(X<;2 ?\
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MD@?Z7W/^PU9T(Q=3DDKEU&^3F3-[PMXZGU^YF6^T6?2K=(A(EQ</A),G@ D
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M$-AS[=*CL-#TG2Y&DL--M+9V&"T,2J3^(K0HJ;ON.R$[TM%%(84444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HI')"$@9P
M,XSBL)-?E9E7[(K$G&4ER&R<+MXY&1@GVH WJ*SM-U1-0WJ4$<R8W1DY(]?U
MJE/XNTBV%V999@+2Y6UEQ"QQ(W0#CD>XI-I%1A*6R-ZBL*X\6Z3:_;O-EF'V
M*9()\0,<._W<<<_A1<^+M(M%U S2S :>R+<8@8[2_P!W''/X4N9%>RJ=C=HK
M#NO%FDV9OQ-),/L 1I\0L=H?[N..?PI+GQ;I%H;X2RS#[#$DT^(&.%?[N..>
MO:GS(/93[&[16'/XLTFV-V)9)@;2W6YFQ"QQ&W0CCD^PHD\6Z3$UPK2S9M[1
M;R3]RW$1Z'IR>>G6CF0>RGV-RBL-O%FDHSJ99LI9B^;]RW^J]>G7VZT#Q9I)
M=5$DV6L_MP_<M_JO7IU]NM',@]E/L;E%8<?BS29&A59)LS6AO4S"W,0ZGIU]
MNM$'BS2;AK41R3$W5LUU%F!AF->I/'!]NM',@]E/L;E%85OXLTFZ-B(I9C]N
MA>>#,##*)][/''T-+:^+-)O/[/$,DQ^WJ[P9A8;@GWL\<=.]',@]E/L;E%85
MKXMTB\_L_P F68_V@7%OF!AG9][/''XT6WBW2;L6)ADF/VZ5X8,P,,LGWL\<
M=.]',@]E-=#=HK!@\7:/<K9M'+,1>7#6T.8&&77J#QP/<TL7BW2)EMV268BX
MNVLX_P!PW,J]1TX'OTHYD'LJG8W:*PE\7:0ZQL)9L27IL5_</_K1VZ=/?I0?
M%VD*A8RS8%Y]A/[AO];Z=.GOTI<R#V-3L;M%83^+=(C6=FEFQ#>"R?\ <-Q*
M>@Z=/?I23^+M(MUNFDEF M;E;67$#'$C= ..1[]*?,@]E4[&]16%<>+M(MOM
MOFRS#[%,D$^(&.'?[N..?J*+GQ;I-F-0,TLP^P.B7&(&."_W<<<]>U',@]E/
ML;M%8=SXLTFT_M#SI)A]@"&XQ"QQO^[CCG\*2Y\6Z3:&_$TDP^PQ)-/B!CA7
MQMQQSU[4<R#V4^QNT5AW'BS2;8W@EDF!L[=+F;$+'"-T(XY/M1+XLTF%KA7E
MF!M[1;R3$#<1GH1QR?;K2YD'LI]C<HK#;Q9I*&0-)-^[LQ?-^X;_ %1[].OM
MUH'BS22X4239-G]N_P!2W^J]>G7VZT^9![*?8W**PT\6:3(T*K)-F6S-ZG[E
MN8AU/3K[=:(/%FDW#6JQR3$W5LUU%F%AF->I/'!]J.9![*?8W**PX/%NDW)L
MA%),?ML#W$&86&47J3QQ]#1:^+-)NSI_DR3'[>CO;YA89"9W9XXZ=Z.9![*?
M8W**PK;Q;I%Y_9_DR3'[>7%OF!ANV?>SQQ^-%MXMTF[%B89)B+Z5XH,P,,LF
M=V>..G>CF0>RGV-VBL&#Q=I%R+,Q2S$7EPUM#F!AEUZ@\<#W-+%XMTB=;9DD
MF(N+IK./,##,B]1TX'OTHYD'LJG8W:*P5\7:0ZQD2S8DO#8K^X;_ %H[=.GO
MTI3XNT@(6\V; O/L/^H?_6^G3I[]*.9![&IV-VBL%_%VD(LK-+-B*\%D_P"X
M;_6GH.G3WZ43>+M(MUNC)+,!;72VDN(&.)&Z <<CWZ4<R#V53L;U%85QXNTB
MV%Z999A]BG2WFQ QP[= ..1[BBY\6Z1:#4#-),/L#I'/B%CAGQMQQSU[4N9
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MI,9 2]C4?>3LX]U_E6W%(DT2RQL'1P&5@>"#532^);,F+>SW)****@L****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I#TI::W*D9(R,9% "T5Y_H
MOB"]U;5V\/B^<"SE:22[; EGB!X3'][^\?0>];47B2\FDMX4M8!)>@/:[G.
MN3G?QUP.WK1"\KV-:U)T6DWOK\NAT]%<]8^)TOM0L;:.-!YT;&8F0?NW SL
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M3:?KOAV[@NO,TV_F-I*BD%"7&4<'ZC'T-=36;BTDRT[BT444AA1110 4444
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MO79=$MKR2.TO9@\=U(V7@4Y)C!]6Q\N>@S[5TLVMW-JY5(HFB:5K:').X,I
MRQ]#DU9_X1?3FTVZLW61OM,IFDF+?O-^<A@>Q7 QZ8JT-%L27:2'S'D3:[,3
MENF3Z G R16<8S2U9V8BI"<8J'3?S\R@=9O8_+9XX2BW/V:8A6Y.[&[/11C'
M7OQ6_5 :+I^8C]G_ -7TRQYYSSS\W//-:%:13ZG,A#7)>*='U-M=TGQ%HT,=
MS=:>)(Y+61]GFQN.<-T!'O76USOB'Q7'H%_8V(TZ\OKF]#F*.V )^49/4BM:
M?-S:"E:VIBWFD^*O%>BZ[;ZF(=-@NX5CLK/>)"C#DL[CUQC%5/[$\1:YJ%G=
M:AI4&FKIEA-;QJDZN;B1TVX&.B<=ZZ"Q\:6M_9:DZ6-['?:<NZ>PF0)-STQD
MX(/KFMG^U[&..V-U<PVLEP@9(II55N1TZ\_A6G/..EB.6+ZG#Z-X7U2VF\"F
M>R55TNWF6[^=3Y3,N!]>?2L"\TK5-$LM AELX_MC>(YIX())!MD!R5R1G&17
MKMS?V=H8UN;N"!I#A!)(%+'VSUJMJ3Z0DEJ^IR6:O')OMS<,H*OZKGO1&M*]
MVOZU_P P=-6L>>7_ (6\0ZIIFOWTNG)!>:I>VLD=FLRL42(C+,W3)Y/X4FI^
M"]8;7=8A%A-?:?JET)]\>H^1&H.,B1<$DC'!%>E7.I6-D(S=7EO!YGW#+*%W
M?3)YIUS?V=FB27-U!"CG"M)(%#'VSUH5::_K^NP.G$\_UCPGK%YK/B:U@M5^
MQ:O8PQQ79E&(WC7A67J<D8S5KP=X?U&WUM=1U33;FVDM[7[.DL^H^>6SC(50
M,!>,C/-=[N4+O+#;C.[/&*XUOB3I8S<K8:D^DB7RCJ:P9@SG&>N=N>^*%.<H
MN*0.,8N[(M<\')XA\>?:=2L1-I7]FF$2%\%9=Y(QWS@]:PCX-U__ (1"X\/"
MUBW:=?)<V5PCK']KC!S@D?=?W/M7ID^HV-L8OM%Y;PF7_5^9(%W_ $SUIT]Y
M:VJL;BYAA"KN)D<+@>O/:DJTU9#=.+U/.4\)ZE<Z+K$\VA%[R[>']Q>ZF9))
M50Y#;U&$<=CGZUDZSINOV/@'Q$=5:XBL9# +6VO+D7$J'>-Q+CL>.*].OO$>
MEZ?-I\4]VF[4)/+MRA!#<9SGH![U/='2]0']GW;6EP)21]GD96W%>3\O?'%4
MJTD[M$NG'HSA7\-ZYXFU"ZN=0LX=+C&COIT)CF$GFL_\?'11Z'FGZ?H?B'4-
M0\.IJ6E6^GV^@J<RQSA_M#;-H"@=%/4YKNHM1L9EE6UNH)C #O2&0,5QV('2
MJF@^(;37]'M=2A!@2Y++'',0&)4D'O[4O:SML/DCW.'L/">LP>%O#-H]D%N;
M+6!=7"B1?DCW,=V>_!%,?PUXF@\3-+I5BVG*]]YTEQ#?;K62,MEBT+<[R/3O
M7=>(/$-OX>M[=Y8)[B:YE$-O;VZ[GE<@G _ &J,7C73Y?#=QK"P7*_9YOLTM
MJZ@2K+N"[,9QG)'>FJE1J]MP<(['&R>"-675[VQDL)[O3KO4#=B==1\F)5+!
MLLF"2X(_&O1[.:\?5+Z&;3EAMHMGD7(D!-QD<Y'48/'-88^(&E_VM]D-M>"V
M^T_8_M_E_N//_N;L_AGI6[K6KV^A:3/J-T&,<0'R)RSL3@*/<D@5-24W920X
M**U1Q/C"V\3:KXA2(>'VU#0;7#I;B[6);B3KN?N5'9?QK0_L74[\^(KVZTJV
M\Z\M8;:VL[F3,954RRDKT&YB,^V:LZMX^L-(OIK:6POY5M41[V6&,,EJ'Z;C
MG^5+JWC_ $S2KZ6W-M>W4=M&DMW<6\6Z.V5^5+'/ISQVJE[2R20O=NVV9'@C
MPE=:=XAGUBXTP:7$+46T5LUT;AV;.68MSQP !Z5>;S=/^*%_,(_,>]T@-:IG
M'F-&QR@/KR/SK3D\8Z>NN1::L<TBN\<7VE0/+5Y%+(O7/(&<XQ5BSU"SUE9[
M^&R:7[!-+%;RL!F1E&&,9]"<KGOBE*4V[R0U&-K)G'^&K?Q3#XAEU36_#1FO
MIPRF\-XA$$>"5CC3L,X!/?.32^&[;Q0/%/\ :FN^'/,NKAC']L:\0K:0G^".
M,?J>IKNM&U:VUW2+?4K3=Y,ZY"L,,IZ%3[@@BK^.*3JO5- H>9PVNZ!?WFHW
MC:591V:65LTMHR*J">\<$;^.ZKD GNU9&JP:C;_#76K2]2Z3[;<I!I\%U)OE
M <H "<G^+<>O2O4,5%/:07+1--"DAA?S(RZYV-ZCWYI*JU:X."Z!:Q&"TAB8
MY:.-5)]<#%3445D:'+^,[)I=/^VF\T^TM[:)_/>[T\76Y&QE0"1C..@SGBN8
M\%1P)K]I*PL())5G1(UT%+24LAVNN\,<,.NWN*[;Q:;%?"NHG4EF:U\KYA!_
MK"<C;L_VMV,>^*X?PFL</C+R;R[U*],=Q<);33)$D0NBH>8$)R6 )&X\<,!0
M!ZC12#I2T %%%% !11FB@ HHHH *2EHH \Y^(FDR1:GINN6;>7/O6 R?W9 <
MQ,?8G*GV:NBA>/Q7H-GJ=JWV>]0;HV[Q2#AD;VR""*U-<TN/6M%N].EX6>,J
M&_NMV/X'!KAO!FJRV.K+#=#9'J;-'*O:*^CXD'MO ##WS73&3G3TWC^1HTIP
ML^AK3Z>FO12W$4*P:K 0MU:L<!V'0Y['N&%4XKF.5A]O>:&6%MBWZC;-;MV2
M8=Q_M=#73:MI\QE34]. %_",%3P)T[H?Z'M566VM_$%HNI:>X@O0I0[UZ^L<
MB]Q6-2G&HK_UZ/R.)Q:>F_YCEU62T5;;78HVADX2\1<PR _WA_"?TIYT)K4^
M?HEX;7=\WDGYX6_#M^%8]C<S6/G6ZVK201C_ $G3'^9HA_>BS]Y/:K]I#+;0
M+>^'IUN;)N6LI&X'KL)^Z?8UA&I4I/EE_7^92:DOZN6&\0R:<I&M6<EL0.)H
M@9(G^AZ@^QJY;^(-*N8$F6_@56&<.X5A]0>E)::A8ZU#) R_.!MFM9UPR_4'
M^=3+H^F*H4:?:X P/W2_X5LITY*Z*7/T=T']LZ9_T$;7_OZO^-']LZ9_T$;7
M_OZO^-+_ &3IO_0/M?\ ORO^%']D:;_T#[7_ +\K_A3]PKW_ "$_MG3/^@C:
M_P#?U?\ &C^V=,_Z"-K_ -_5_P :7^R--_Z!]K_WY7_"C^R--_Z!]K_WY7_"
MCW ]_P A/[9TS_H(VO\ W]7_ !H_MG3/^@C:_P#?U?\ &E_LC3?^@?:_]^5_
MPH_LC3?^@?:_]^5_PH]SS#W_ "*MYXFTBR5&>]C?>VT"([R/<XZ"K UG3,?\
MA&U_[^K0^BZ8X .GVW!S_J@*=_9&F_\ 0/M?^_*_X4?N[=1?O+]!/[9TS_H(
MVO\ W]7_ !H_MG3/^@C:_P#?U?\ &E_LC3?^@?:_]^5_PH_LC3?^@?:_]^5_
MPH]SS'[_ )"?VSI?_01M?^_J_P"-07=]HU]:2VT]]:M%(NUAYJ_XU8_LC3?^
M@?:_]^5_PH_LC3O^@?:_]^5_PH7(M=1-3>]C(T77+>(2Z?>WT#26W"3F08E3
ML<^O8UK?VSIG_01M?^_J_P"-4-8\/V]Q:+)96MO'=0-YD0\L!7(ZJP[@U)ID
M6DZG8I<)IULK?=DC,*Y1AU4\=JN2@US(B+FGRL?)XDTI+R"U%VDDD[87R_F
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MHI\T>X71;WR?\\C_ -]"C?)_SR/_ 'T*J?VUI?\ T$;7_OZ*/[:TO_H(VO\
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MR44GW%.HH 9Y4?\ <7\J/*C_ +B_E3Z* &>5'_<7\J/*C_N+^5/HH 9Y4?\
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M5%B7^^O_ 'S_ /7HQ+_?7_OG_P"O0!+146)?[Z_]\_\ UZ,2_P!]?^^?_KT
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MWH =15#^W-)_Z"EC_P"!"?XT?VYI/_04L?\ P(3_ !H OT50_MS2?^@I8_\
M@0G^-']N:3_T%+'_ ,"$_P : +]%4/[<TG_H*6/_ ($)_C1_;FD_]!2Q_P#
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MED3W5AR*YK4O#.M06,EG#/'KNEL.;+43B5?]R4=QVS^=:Q<)+E_KY,I6>AW
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M.2]DAB73TD>/._\ >Y4D9VXP<D8QG-5%.X6;10GU'5=)AW2YD\T[HXY/WC
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MS$D>S;@+G()SE3[BH#XHM6,8CMKF3SCBWVJ/WH!P2,G@ ^M)_P );8 ,?+F
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MR[5 00<G).0VX'/?GFJ#Z-I%C<22RP;A/DA2/E3:O0?7!K=-5[RTCO(ECD)
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M?HK U&.X9K$WB7$ML(V$ZV^<^9@;2=N"1UZ=ZQ[.PUP:K!<3&ZDVG(CDDPA
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M"*6:9E4#)); %354U"V^VV4UL"F6 ^]G'7/;GM0!*BK(@=)F93T*MD&E\O\
MZ:2?G6&-$ODA*)?)RFT9W#;SD@8('X]:M:7I5S9,3=7KW.Y"K[B<$]CR>..*
M -)4#+E97(]0U+Y7_323\ZAT^T6QL8[9=NU,XVC  R3C]:M4 1^5_P!-)/SH
M\K_II)^=244 1^5_TTD_.F2>7$NZ2X*+G&6< 5/6;K&G2:C;QI&Z*R-N!;/'
M!';Z_C0!=\O(_P!9)^=-<)$A>2=D4=69@ *Q9]$U*2(I%J"H2^[S/F!/X9P,
M=, 8Q5C^RKM-,FM4N$EDD*D-."X7@!CSGDD$CT)H U%3< 1(^#WW4OE?]-)/
MSIMK"+>VB@4 "- H /I4U $?E?\ 323\Z/*_Z:2?G4E% $?E?]-)/SIC^6CJ
MC7!5G^Z"X!/TJ>LG4M*EO;Z"XBF2(H,%BN2.<_0_CTH TO*/_/23\Z8^R,J'
MG*ECA<N!D^U8<FA:E)Y*C41&J##;"^6]>2>]6KC2)YK"WMC.A,4FXR."6 W9
M&#^&.>M &H(O^FDGYTOE?]-)/SIXI: (_*_Z:2?G1Y7_ $TD_.I** (_*_Z:
M2?G4?[LRF+SR9 ,E-XSCZ58K"N]%N)M0GN8;A(Q(.@!RW &#Z=,9&#B@"C8>
M!+#3?%UQX@M9YXFF0J;9,+&">IX_/'K6W?:78ZAY:7L:S%23'O/S ]\'K6:V
MA:A+=-(^H[8BFT1QLXYQP>O8_G6@VF2-JMK?-<D^3&4,948Y')![9/\ *J<Y
M-W;'=DL.E6<#0M#"L;0(8XM@ V*<9 ]C@4+I5FL=Q&(0([EB\RXXD8]21ZFK
M@Z4M*[%=F:NA::OD8MD_<',7^R<Y_'GGFI;72[2R,AM8O*,AR^WO5VBB['=D
M?E?]-)/SIB>7(S*EP6*G#!7!P?>IZYZ/0;N*1VCN8U0R;M@# 'DG)(.1USC.
M,TA&[Y1_YZ2?G3!L:1HUG)=?O*'&1^%8UOHE_'=F:;4BP$@=44L .1GC/< C
M\:O6VG/;ZK<W>Y DPY5<Y8\<MDXR,8XH O>5_P!-)/SH\K_II)^=244 1^5_
MTTD_.CRO^FDGYU)10!$8\#)E< =>:;'LE3?'.77U5P13KJ+S[6:'('F(5R1D
M<C%8<.A7T,>$O(QPV!\V$SWX(W'W- &[Y7_323\Z8FR0$I.6 ."5<'!]*R]-
MT>\M)%DN+]YCAE(W-C:1P.3V/>I]%TQ]*MWB>42!FR"!Z#&3[F@#0\K_ *:2
M?G1Y7_323\ZDHH C\K_II)^='E?]-)/SJ2B@"&0+$A=YV51U9F  I50,H997
M(/((;K5?5;)K^R,"%0VX,"V>Q]1R*RFT/4/LS1)?H&95 ?# C'8 $ #OG% &
MXRA$+-,RJ!DDM@"DC"2H'CG9U/1E8$&L^RTRZM;>99+PS221[=SY8!^?FP3[
MCCVK0L[9+.TBMHP D:A1@=?>@!_E?]-)/SI1'@Y\QS]33Z* "J.L6+:GH]W8
MI((VGB**Y&0I['%7J* ,79XG_P">^D?]^9/_ (JC9XG_ .>^D?\ ?F3_ .*K
M:HH Q-GB?_GOI'_?F3_XJC9XF_Y[Z1_WYD_^*K;HH Q-GB;_ )[Z1_WYD_\
MBJ-GB;_GOI'_ 'YD_P#BJVZ* ,3R_$W_ #WTC_OS)_\ %4;/$W_/?2/^_,G_
M ,56W10!A+#XD5F99='!8Y8B"3G_ ,>I^SQ/_P ]](_[\R?_ !5;5% &+L\3
M_P#/?2/^_,G_ ,53M,T_4(]5NM0U">V>26%(52WC90 I8Y.2>?F_2MBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N4LK&<^*]1NSIDMH@1T
MBE#*1<DXR['.>V%7' SZUU=)B@#S.#PWXCM8-,2&*1!IJND16<;BD@#/C/\
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M)3K.H75LUND/E(LD>)-Q93W..!],YKHJB2WAB9VCB1&?[Q50"WUJ6@ HHHH
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MMHPPY/I]: )**A2ZA=BJRH2!G@\8^OX4Y)XI&*I(C$=0K XH DHHHH ****
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F H<*N-A.2H':M#2O#-GH]W]IMV;>5VG( SPHY_[YS^)HHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>g4i5nix4zlkt000045.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g4i5nix4zlkt000045.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %I J # 2(  A$! Q$!_\0
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M=0T;6]273YT32B0Z%US)UZ>G3O4>RG=JVQ7/$[&FHZ2#*,K#U!S7#:1\0_\
MA([Z&VM-!O#92QMY]TS86)@I)7.,'MW[U0\(:_H>B^ -2U?2M+NXK2WN,O!+
M,'=F.P9!_$?E5>QDEKN+VBZ'I5%><W7Q5:.QBU&W\-WTNF':)+IF"*KGJHX.
M<'C/ S6]K?CK3-&\-6FL[))UO0IMH5X9R1GGTQWI.C45E;</:1[G445YW+\4
MFL$@35O#=_97,[@1QLPPR'^($@=.,BO1*F=.4/B&I)[!1114%!1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!Q
M_P 0O&/_  B>C)]GVG4+HE( W1<=6/KC(X]37$>!O$GA/3;^.>ZN+V^\07\B
MI)=2PY"LY PISTR>3_3BO89K2VN2IGMXI=O3S$#8_.HUTVP1@RV5LK Y!$2Y
M!_*MX58*'+8S<).5[GEMAJ]MX!^(/B$:TLL-K?GSK>58RP?DM@8_WB/J*U_A
M/97'V35]:GB:)=2NB\088)4$G/TRQ'X5Z!-;P7  GACE .0'4-C\ZD
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M"Z\5ZU&S;=2OL=/]<_\ C4OVB(]-Q_X":I37 WOA)#SV6BXQK>)/$3KE=4U
M,>WG/@?K6QI6MZU)%^]U2_)_VIV_QK"$[GI;RFM72MSHS,A0^A^M-L#0U/7-
M8BL&:/4KT-N49$[ _P ZY^7Q1XC,;*FI:C]1<'^=7]?B=])81N$;>IR1GUK
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M_OJM"VL;=4^<OSC^(TDICAB,DKA$7DL>@I8;^SF*QQ7".V,X7)H MVUE:F;
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MWP;<D_\ /2/_ -"%>+"09Z4I;@:&FWT=M/\ 9V+!Y_ND#C@<T[5KF0VZJ)6
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M_I7$30174JE\_*.@[UVEA_R#K;'01@4K@BQ1110,**** "FOTIU-D^[^-("
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M($?XMFI/[/.,?*:- /'9],NDN]\MK<Q*3G_5$C\ZM,WRQ^JR+U^M>K&TV'
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MHK,K,H)7E21TK.\*MGPW:@]BX_\ 'C6G,>*0BQ9M^ZQGI6@[9CR!V%9]J1L
MVA3CUR3]:N<^2<'KBK)9#)(?-!4GCBLN_<_:86W?=D7]>*T;MG.UHQ\RCG [
M5F:A&#%O0DC(:A :$4;2R%80 5Z^GXFM*W6.W8;-H8]2*S[:5=J$NS*>@SP,
MUHQ1X8AF)'49P?\ ]5 $DYR$(R/4#N:>H\V)HY,888.*J331R1-L.<..<_YX
MI(KCG"(2G0MG _\ KT#*,D#V4H#MU.1D9'_UC4UR5V1EE*R#N#E2/;WJIJ&I
MQ))<6[,K3(#Y:\>G%-.L0B-;:+?.[IG:H&T?\"^M("_%(AQ^[4D]\<4,^&(
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M"9+BUDU"U1XSL<,V-I]Z0'5(\,ZI=VUS;RIRN0V5;\NX-$ERRKDR[5'_ #S
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MJ*.K[Y0O?><#]:Y"?XA6(!6"YGG]K6 X_/BLJ;QG=7'-OICD'H]U< ?H,T7
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M=> 2/-!KOYX+Z&SGM["%069@3+)&-X(QW/UK"L_!FLW<JPP):&0\!#>1[C^
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M)="T5B6-DP)Z[9FI60%S^RM;+%FD#$G/RRJ:EAT_6UD3B0KGYE.""*Y[[#H
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MML2JBR5T.&1U (_#-0I?39_UZ_B13S:Q7YD69(F,PVLX"YY[Y]:+ 5_[>E7
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M#^;L.WL",&M.0V5S T,EG*$;KBX_^QKFK0M%/)AC@KG&>^:U;(-/(P8L<+G
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M[:/2L5<]BBLX+F\61P#@@$'O6GK7@BSNK9;B"%%;&2 *\0@\2>*D8;;@$_\
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MB*Z&;#0R+UW(1^E ',.P\NUE_N31'^E=(V 2*Y>0YTMCW0!OR:NE:0=<]>:
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MY^8?R%)@/"2.<[-H]S2B$M@$#:O0"K"+[5*O!Z#\J0%;[.HP2,^PJ2* 0Y.
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MM1CKFI)1GZ5&HH&64Z"KB=!51/NU;3H* -FQ.8BM5KX8(J?3^XJ+4!\PH!'
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&2T4 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>g4i5nix4zlkt000018.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g4i5nix4zlkt000018.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &? J # 2(  A$! Q$!_\0
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MI1O/L@U*U-SG'E><N[/IB@#0HI*XGPSX]75M2U^WU(6UE#IMW]GCD>4#?^=
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M-QX67PW-;E]-6$0B,GD*.G/K[UFS_#KP]<^%;3PW)#,=.M9!)$OFG<&'O^-
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M4C75NLOE-/$LA_@+C/Y5XYI.GP^$/CI)I>FS3QZ;-IAGFBDE+@'G+<_2N/\
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MN@;:?;/2B:TMKC!GMXI<=-Z!OYT ><S:]9/JVK^+IK64Z);68M5+1$&[8G/
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MQ?,(RD4I'REO08[UW 50Q8*-QZG')ILD,<T;1RQI)&W574$'\* /.?$_B?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!2,=JD^@S2TA (P>0: .176M3A:2.YE"W%RP%LNP;44MC.1UQ[U,VI:M%R'2
M:.VD*2L% \WT^E:Z:%IJ>=BV!\Y=KY)/'MZ5+#IEG#;QP1P@1QMO"Y[^I]:
M*NG:ND]AYC2?:)E&7$:],GCBI$UF*128[>X8 X.$[U/8Z99Z<7-K"L>_[V._
M^<TS2B3!+G_GJU #?[57_GUN/^^*/[57_GUN/^^*T:* ,[^U5_Y];C_OBC^U
M5_Y];C_OBM&B@#._M5?^?6X_[XH_M5?^?6X_[XK1HH SO[57_GUN/^^*/[57
M_GUN/^^*T:* ,[^U5_Y];C_OBC^U5_Y];C_OBM&B@#._M5?^?6X_[XH_M5?^
M?6X_[XK1HH SO[57_GUN/^^*/[57_GUN/^^*T:* ,[^U5_Y];C_OBC^U5_Y]
M;C_OBM&B@#._M5?^?6X_[XH_M5?^?6X_[XK1HH SO[57_GUN/^^*/[57_GUN
M/^^*T:* ,[^U5_Y];C_OBC^U5_Y];C_OBM&B@#._M5?^?6X_[XH_M5?^?6X_
M[XK1HH SO[57_GUN/^^*/[57_GUN/^^*T:* ,[^U5_Y];C_OBC^U5_Y];C_O
MBM&B@#._M5?^?6X_[XH_M5?^?6X_[XK1HH SO[57_GUN/^^*/[57_GUN/^^*
MT:* ,[^U5_Y];C_OBI[:]%RY40RICNZXJU10 4444 %%%% !6/X@:ZCMK62V
MNC !<H),+DNI/3VK8IKHKC#J&&<X(S0!Q>HZC>0/<7%O<RM=F4Q/;;LA(\CY
MP.V!WJ16NBMPMIJ4LUK:R*RR-)EF)'(SW'M76?98/-:7R8_,8;6;;R10EK;Q
M1>7'#&J9SM"X&: ,33-<0P3)()IIXB6EP/NUHIJ;.BNMG,589'%/NX(H;*Z>
M.-59T)8@8S4UEG[##GKL% %?^T7_ .?*?\J/[1?_ )\YORJ_10!0_M%_^?.;
M\J/[1?\ Y\YORJ_10!0_M%_^?.;\J/[1?_GSF_*K]% %#^T7_P"?.;\J/[1?
M_GSF_*K]% %#^T7_ .?.;\J/[1?_ )\YORJ_10!0_M%_^?.;\J/[1?\ Y\YO
MRJ_10!0_M%_^?.;\J/[1?_GSF_*K]% %#^T7_P"?.;\J/[1?_GSF_*K]% %#
M^T7_ .?.;\J/[1?_ )\YORJ_10!0_M%_^?.;\J/[1?\ Y\YORJ_10!0_M%_^
M?.;\J/[1?_GSF_*K]% %#^T7_P"?.;\J/[1?_GSF_*K]% %#^T7_ .?.;\J/
M[1?_ )\YORJ_10!0_M%_^?.;\J/[1?\ Y\YORJ_10!0_M%_^?.;\J/[1?_GS
MF_*K]% %#^T7_P"?.;\J/[1?_GSF_*K]% %#^T7_ .?.;\JO]J** "BBB@ H
MI** %JAI7^IF_P"NK5?JAI7^HF_ZZM0!?HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHJ*XG6V@>9E=E49(09/Y4
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MMIJ%K)>_8TF5I]GF;0?X?6I/M5OYK1>?'YBC)7<,B@"A_P )!8_]/'_?AO\
M"C_A(+'TN/\ OPW^%3W.KV=JD;/*"LA(4KST&34L-];3QHZS)\Z!P"><&@"G
M_P )!8_]/'_?AO\ "C_A(+'_ *>/^_#?X5J!@P!4Y!Z$4M &5_PD%C_T\?\
M?AO\*/\ A(+'_IX_[\-_A6K10!E?\)!8_P#3Q_WX;_"C_A(+'_IX_P"_#?X5
MJT4 97_"06/_ $\?]^&_PH_X2"Q_Z>/^_#?X5JT4 97_  D%C_T\?]^&_P *
M/^$@L?\ IX_[\-_A6K10!E?\)#8^EQ_WX;_"H[CQ3I5I;O<7,LD,,8RTDD3
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M=7,O^W[+TG_[\M_A1_;]EZ3_ /?EO\*U**0&7_;]EZ3_ /?EO\*/[?LO2?\
M[\M_A6I10!F?V]9>D_\ WY;_  K3!R,T44 %%%% !1110 50TK_43?\ 75JO
MU0TK_43?]=6H OUR-WI&LK8B.WCADW7[S2H7 )C/3!/ -==10!PO_"/7=OID
MTEXJ(T<&U6#;BOS9Q5.UM;S6A?7=C:1HB7"$0)+A9<#GYCQ6[_:VI)JSQW+1
MP1-,R1HR$HZ8X.[U]J@TWQ1-?-L1%C6WB>:;*8\W!( 3UZ<FF!;T;1[K3]3B
MGDMTV-;['?S,M&<YQ[U1?0=58ZA;"" ":=YH[TR?.0?X,=15C^U=6@M;/4)I
M('M[Q@@B5>4+?=^OO4MKX@N)H+%)1$EQN<7O/$03K_2D!1M_#^IF!2T"0OO8
MF-I0W\.,Y'K4EEHNJ6>JI*MK'Y(A E+2@B0A<8 ZBK>M:U=VEJNI6,L$UEE
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MMO\ GWB_[X% $7]J6/\ S]1?]]4?VI8_\_47_?52_9+;_GWB_P"^!1]DMO\
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MO^?>+_O@4?9+;_GWB_[X% $7]IV/_/U%_P!]5;J'[);?\^\7_? J:@ HHHH
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M4G>EHKD.L\/UO_D8]4_Z^6KD?'/_ ""-"_Z[7']*Z[6_^1BU3_KY:N1\=?\
M()T+_KM<?TKZ3$?[M#Y?D?&8'_?ZG_;P_P"$/_)3K+_KWD_E7TW7S)\(?^2G
M67_7O+_*OINO"Q'QGU>&^ ****P.@**** "BBB@ HHHH **** "BBB@ HI,T
M4 5[_P#X\)_]PTZR_P"/*'_<%-O_ /CPG_W#3K+_ (\8?]P4 3T444 %%%%
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M -\"C^S[/_GUA_[X% "_;[/_ )^H?^^Q1]OL_P#GZA_[[%)_9]G_ ,^L/_?
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M\^L/_? H_L^S_P"?6'_O@5SG0+]OL_\ GZA_[[%'V^S_ .?J'_OL4G]GV?\
MSZP_]\"C^S[/_GUA_P"^!0 OV^S_ .?J'_OL4^*Y@F.(ID<C^ZP-1_V?9_\
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M,42(?._A&*TP:4J\4SFS*4HX6;B['(:=JFHF?[.^HW!MW23?&S?*<@YS7B+
M"UD ]_YU[)IJAKY5(!&Q^#W^4UXX_P#QZR?\"_G7K8N$8U+15CQ,JJ3J46YN
M^I]8>"+F"+P/HJO-&K?9$X+"M_[;:_\ /Q%_WV*Y_P $VEM+X'T1I($8_9$&
M2M;W]GV?_/M'_P!\UX,MV?41V0[[;:_\_$7_ 'V*/MMK_P _$7_?8IO]GV?_
M #[1_P#?-']GV?\ S[1_]\TACOMMK_S\1?\ ?8H^VVO_ #\1?]]BF_V?9_\
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M2?\ D#6W_785K@O]XB<N:?[I/T.#TO\ Y""?[K_^@FO&W_X]I/JW\Z]DTO\
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M;^8JQ\<;6&T\5Z-'""%-F^<L3_%[U2^#-O%=?$"6.925^PL1AB.X]*[(_P
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MD^$(_P"+G6?_ %[R?RKZ:KYA^$\$=Q\2;..4$J8)#P2.U?1G]@Z?_P \Y/\
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MXY_Y!.A?]=KC^E==K7_(QZI_U\M7(^.O^03H7_7:X_I7TF(_W:'R_(^,P/\
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M7/\ D3=:^D7_ *%7OTJ5-X-3MJ?+SQ<YYA:,O=9P.E?\AO3/^OF/^=?8D?\
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MGTINNV$U_91"WVF6"=)U5C@-M.<9[50_L.:6T ECC6YEF:21P?\ 5@]AZ^E
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M)1@$^N!73:O<Q76I^'KFS?>7N#AAWCQS_2@#IZ*** "BBB@ HHHH *3O2T4
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M10 4444 %%)1^- "T4E% "T444 %%)10 M%)2T %%%% !1110 4444 %%%%
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ML+GID _<^HI\OB2_35;S31-+'YJVX^U,O[NV#)SSZDUTE_X1TW4M";2;CS#
MTAD# X923G@U/_PCEBRWZ/N=+U$212>FT8&/>@HTK6+R+:.+S&EVK@NYR6]Z
MFJO8VOV&RAM1*\HB7:'<Y)'O5B@ HHHH *0]*6D- 'A]]>7@U6^ O;@ 7#
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M]JZ3PGKFIZI<30Z@L+*+>*=)(R@.7SE=JNW''!.,T =517GVI_;;?4?&$?\
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,% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>g4i5nix4zlkt000005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g4i5nix4zlkt000005.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $C J # 2(  A$! Q$!_\0
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M  3!>7[W\.K:G974T2Q7+VTP43@#&2I! /TQ7E__  O+7O\ H%:;^;_XT?\
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MX7EKW_0*TW\W_P :;P^(>HO;4CU/3?!5E974UU=7U_J4\L!MMUY-NVQ'JH
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M;RS+C:WSK$^QV!Z9X)"]3@U6T7QM<Z=J-U>WHEO);A8E8K,(_P#5XVY&T@\
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M_9'A[_H7--_\!T_^)H_LCP]_T+FF_P#@.G_Q-3T50B#^R/#W_0N:;_X#I_\
M$T?V1X>_Z%S3?_ =/_B:@UC4X]'TN2_E3?'&R*PW!<!G5<Y/0#=G\*R=4\8V
M=C-/':_9[WROLX\Q+M%CS-*8P&;D+C&23V-*_F!N_P!D>'O^A<TW_P !T_\
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M(P<$@G&<9 -:+^(-'CGN(6U&%6MP[2%@0H"'#8)&&P2 0"<47\P+?]D>'O\
MH7--_P# =/\ XFC^R/#W_0N:;_X#I_\ $UFMXJTA;J"'[3\LL<SF5D95B\K&
M\/D#:>>^/U&7-XHT1;=9VU! C.8P"C[MP7<1MQNSMYZ=.:+^8&A_9'A[_H7-
M-_\  =/_ (FC^R/#W_0N:;_X#I_\35&/Q+HLL+S1:C%)&A0$H&.[?G9M &6S
M@XVYS@^E7[2[M[^UCNK6598)!E77H<'!^AR",4?,!/[(\/?]"YIO_@.G_P 3
M1_9'A[_H7--_\!T_^)J>BF!!_9'A[_H7--_\!T_^)H_LCP]_T+FF_P#@.G_Q
M-3T4 0?V1X>_Z%S3?_ =/_B:/[(\/?\ 0N:;_P" Z?\ Q-3T4 0?V1X>_P"A
M<TW_ ,!T_P#B:/[(\/?]"YIO_@.G_P 34]% $']D>'O^A<TW_P !T_\ B:/[
M(\/?]"YIO_@.G_Q-3T4 0?V1X>_Z%S3?_ =/_B:/[(\/?]"YIO\ X#I_\34]
M% #?[+T+[)L_L#3_ "O,W>7Y"8W8ZXQUQQ47]D>'O^A<TW_P'3_XFK?_ "[?
M\#_I4=) 0?V1X>_Z%S3?_ =/_B:/[(\/?]"YIO\ X#I_\34]%,"#^R/#W_0N
M:;_X#I_\31_9'A[_ *%S3?\ P'3_ .)J>B@"#^R/#W_0N:;_ . Z?_$T?V1X
M>_Z%S3?_  '3_P")J>B@"#^R/#W_ $+FF_\ @.G_ ,31_9'A[_H7--_\!T_^
M)J&;45AUJSTTQ$M<PRS"3/"^64&,>^_]*R'\8VR?VTC6L@GTN8)Y98#ST+JF
M]3CH&;!';CU%*_F!N_V1X>_Z%S3?_ =/_B:/[(\/?]"YIO\ X#I_\36=?^*-
M(L([YFNO->SCDD>.-&);9PP4XPQ!P#@\=Z='X@M#IFI:C*KQVM@[!VP26"HK
M9 X.3N P>]%_,"__ &1X>_Z%S3?_  '3_P")H_LCP]_T+FF_^ Z?_$UGQ:Q<
M1;I-5TUM/MQ"9O/:=9$0 CY7P/E?D<#(/.#Q0_BC1(H%FDU!%5G= #&^[<@!
M8%<;@0""<CH<]*+^8&A_9'A[_H7--_\  =/_ (FC^R/#W_0N:;_X#I_\354Z
M]I(NX[4ZA!YLBJZC)VX9=R_-]T949 )R1S47_"3Z)]F^T?VA'Y>]8P=CY+,"
M5 7&3N ."!@XXHOY@7_[(\/?]"YIO_@.G_Q-']D>'O\ H7--_P# =/\ XFJ5
M_KMIINH1V]V1% UK)=/<NV%159%P1[EQ^5-;Q-HJVXG;4(Q&79.4;(*@%LKC
M*@ @DD  $>M%_,"__9'A[_H7--_\!T_^)H_LCP]_T+FF_P#@.G_Q-0:=JUMJ
MDM]';[\V=P;>0LI +  Y![CG_/%5+W79+"_2.?3Y%LFN([;[6T@&7=<Y5.K*
M.YSZ\'!H^8&E_9'A[_H7--_\!T_^)H_LCP]_T+FF_P#@.G_Q-8]EXG^TQF2;
M3+F/?:+>VT<1$SSQ%MH^4=&R5R.P8<\&JL_C2*.STB9;:%'U*V-R%NKL1+$H
M*C!;:03EOIP:+^86.B_LCP]_T+FF_P#@.G_Q-']D>'O^A<TW_P !T_\ B:HZ
MIJMQ8WFG6=K8K=7%Z9 H:?RE0(H8Y.TY_*H8?%&G_93)?M]AG2:2"6"3YV1X
M\;CE0<J 5.[IAAG%%_,#4_LCP]_T+FF_^ Z?_$T?V1X>_P"A<TW_ ,!T_P#B
M:@&LZ:VHC3UO8FNCTC&3D[=V-W3.WG&<XYJB/$D;^(6TJ*W5]DODR/\ :$#A
MMFXD1GYF09 +#N>AP:/F!J_V1X>_Z%S3?_ =/_B:/[(\/?\ 0N:;_P" Z?\
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M'OS7>>7%_P \D_*CRXO^>2?E1=!9G!-X*>6S%O)JC;3YRE1&S*BOY9 CW,2
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M;^7%_P \D_*CRXO^>2?E2N@L<%<>"YKJ\N)Y]69_-CNH@S1$N!,".27Q\O
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M5[NWN%C\SH(550F3DX(7J3GFAMC2N6T\6:')%+*M]\L:JXS"X,BLVU3&",R
MMP"N<DBJL/C;2/LD]S=2M!''-.@_=2.WEQ$!I&4+E "<'(&#Q5(>#[HI:^;?
MO))I\4<6G284?9U1U8;AC]X?D4'IP.Q.:I:AX6UR&*X^PS/-=7Z7,-U< Q*
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M^M([8[44^7L+G.#D-G?@@C&![U7L?#,-EHVI6 E3?J*N)9(8%B5<IL 2,<
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M_P!C_OD5!119!=D_VN7_ &/^^11]KE_V/^^14%%%D%V3_:Y?]C_OD4?:Y?\
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MYL<@^E1KXITZ.-C>R_9G669"NUGVI'(8S(Q4?*I(ZG ]Z+(-3HOM<O\ L?\
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MM-NKBR>U6^>6+:S;FBD0MA3@<DA&Z=QCFKUWK%C8VEO=7,KI'<LJ0CRG+.S
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MS5NV\06-S<?9PMS%.#(K130E&78JN<C_ '74CUS1H&IM_:I_[_Z"C[5/_?\
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MSBG:AXDU+3=*U61].AN;[39ECF\F0K#L95<2?-\V,-C:,G/MS2T#4Z[[5/\
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M0#G/&.,"NNWM_>/YT;V_O'\Z+A8P+#3(M.\\QO<32SN'FFN)"\DA  &3[
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MQ[Y.:Z+>W]X_G1O;^\?SHN%CF;;0+.UN8[I?M$MTD_GF>:0N\C["@W'N I(
M& *K1>$M,@$21"Z6)%57B$[!)@K%E\P?Q8)/X<'(KK][?WC^=&]O[Q_.BX6.
M2@\*Z; T3 74GD^6(?-G9_)2-PZHN>B[@..IP!GBK.H:)!J>C/I=U-=M Y&]
MQ+B1@&W8+8Y';&.G%=)O;^\?SHWM_>/YT7"QR<_AFUNH(X[BYU&5D1XC*;@A
MWB?&Z-B ,H<#CMV-7GTNUDNXKEH<M%;M;*A'R>6Q4D%>A^Z*WM[?WC^=&]O[
MQ_.BX6,"QTFRTRYNI[.UC@>Z=7EV(%!*J%& !P,#IZY-9H\&Z.L>P0SX^RK:
M9\TY\L/O'_ L]_3BNQWM_>/YT;V_O'\Z+A8XQO!FDLTA(N]K^</+\\[5\TYD
MP/<\\Y(J]>:,M]<--/<W2LLB26YB?8UNP4J2A_V@QR#P:Z7>W]X_G1O;^\?S
MHN%CBY/"-HT<EK$\\5C<6?V6Y5)&$CX<N&W]<DM(&SUW59_L$K'8VXNKB6UM
MKE;@BX;<V4'R(N  %!P<>U=7O;^\?SHWM_>/YT7"QR:^&H$U1=26_P!4%TL2
M0EOM&=Z*<@'*]">3C&:<GANQ07 +7;B:"2W DG9O)C<Y98\_=!/U/ ["NJWM
M_>/YT;V_O'\Z+A8PSI]JT$4+VL;I%'Y<>] 2BXQ@'J./2JMCH-K8&5D:ZFDD
MA%OYEQ,9&6(9PBD] ,GW]2:Z;>W]X_G1O;^\?SHY@L<G-X6TV>WMH&6Y6*"V
M6TVI,5\V%<$))_>&1^I]36S@^A_*M/>W]X_G1O;^\?SHY@L9F#Z'\J,'T/Y5
MI[V_O'\Z-[?WC^=',*QF8/H?RHP?0_E6GO;^\?SHWM_>/YT<P6,S!]#^5&#Z
M'\JT][?WC^=&]O[Q_.CF"QF8/H?RJ]I@/FR<?PBI=[?WC^=36[$LV23Q2E+0
M:6HES]]?I4%3W()=< GBH=K?W3^52MAO<2BEVM_=/Y4;6_NG\J8'#:KXNU'2
M]2\1PS+"MI!$4TZ?9]RX6W$OER>N[)*_[I'<4^U\4:C?>(CH:%+9FO2@O9(/
MW>Q8HY/*3LTK;F// 4$\D 5T5_X:TO4[/4K2\LS-!J3*UTI8_,54*I']T@*.
MGI2S>'=.GMIK=[>39-<K=EE=@RS+MVNK=5(V+T]_4T@.?C\1WCV=IK-QJ=K:
M6EU<LD5G):,R^4)=AW2KDJ_?G"Y(&.IJ#6M?U[2UU;9=V<\MM:232K%!E+%]
MZB%2V?G9E))4\\9X&,]')X7TR2:1VAN!%)+Y\EJL[B!Y,[MQC!VYR,GL3R15
M=/!FEI:7EIG4&MKWS//A>\D*L7;<S8SPV>_6C48MG<ZE9>)1H]_>1WR36;74
M4P@$3H4=596 ."#O!!XZ&MVJ&GZ':Z;<2W,7VF:YE01O/=3O-)L!R%!8\+DD
MX'>M#:W]T_E30A**7:W]T_E1M;^Z?RH 7_EG_P "IM/VGR^A^]Z4W:W]T_E0
M E%+M;^Z?RHVM_=/Y4 )12[6_NG\J-K?W3^5 "44NUO[I_*C:W]T_E0!QNL:
MQJR>++G3;2>]CMX;."8"TTU;D[G:0'<3T^X,#ZU;NO%;0/<VXL9P(I9+-;QB
MFQKA83*/DSG! _/BM&\\.6E[J3Z@9=0M[F2)(7:UNWB#JI8J"%/."S?G3G\.
M:?)"8I(974W!N26D8DR&/RRQ/^Z?ZT@,>T\9.-+62^TZ2&Z6WMIRLD\2(ZS
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M_P!]&G?\NO\ VT_I4=) .\R3_GH__?1H\R3_ )Z/_P!]&FT4[ .\R3_GH_\
MWT:/,D_YZ/\ ]]&FT46 =YDG_/1_^^C1YDG_ #T?_OHTVBBP#O,D_P">C_\
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MG="U.D\R3_GH_P#WT:/,D_YZ/_WT:P= \21ZY<7, MQ$\,<<N4F$JLK[@/F
M R"ISC(]":W*- '>9)_ST?\ [Z-'F2?\]'_[Z--HIV =YDG_ #T?_OHT>9)_
MST?_ +Z--HHL [S)/^>C_P#?1H\R3_GH_P#WT:;118!WF2?\]'_[Z-'F2?\
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M]'_[Z-86G^(EO]=N-+-HT#1[RADD =PI W;" =ISD$%N.N*=XCN;JTM$GAU
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M$<DGIDX[8GFO-4@\4,+N2Y@TJ:[6TM3$(60L8^-_5QEMWTP.,&BZ Z;S)/\
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M2R-*L@W?*[ AB!G )!.<#GO6GL?^XWY4Q#:*=L?^XWY4;'_N-^5 #:*=L?\
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*BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>31
<FILENAME>g4i5nix4zlkt000022.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g4i5nix4zlkt000022.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %C J # 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M;YLXDDSD]>,59USX=WFNZA*UUJ5H]O)<"99VL@+N%00=BR*1QQC)&:JU&_\
MPXKU/ZL6M#UW7+SXD:[IMQ;#^S[98PN)5Q",$JV,98O^F*;XGN+[5_&^F>%K
M>_N+"SDMGN[J6V;;)( <! W85J6GAN]L?'%YK<%_']BO8D2>V:++ED7"D-GC
MUZ4>)/"TVJZC9:QI>H'3]7L@R1S&/>CHW5&7N*GFASIKM^-BK2Y;>9#INE:M
MX5BU27^T+O6; ('M+24[IU8=5WDX(/O5#3OB%+/>W]C?:9##=6UB]ZJV]XLZ
MD+U1BH^5J/\ A K^\TO7%U37I9]2U:-8VFC0I'"JG("IGVP?:H;'X?7L%Z]U
M-J%BN_3)=/\ )M;/RD4-T88/)[G-/]V[\SNQ>^K<J)=-^(5U>3Z$]UH,EK8:
MR?+MY_M"N0^,\J!T/8U-:^.;_4;IYM.\.7-WHZ79M&NXY5+D@X+B/KM![YI\
M?@B5--\*6GVY"="F61F\O_78&,#GC]:KVG@?5]-N)+33O$36NBR7ANS#'#^^
M7)R4#Y^Z3[4/V73]0_>?U8BU#XFQ6=]?-'IPETO3[@6]S<FZ19-V0&*1GE@"
M:T1XQO;GQ?/H6G:*;I+<PO-=?: JK$X!W8(Y(ST'7%9L_P .9EU:]EL;ZRBL
M[VY^TR">P2::,DY94=N #[CBNATOPX=.\5:OK'VA6COXX46$)CR_+7'7OFE+
MV26G;S\O^""]I?4OZ5>7M['<M?:<UBT<[QQJT@?S$'1^.F?2M"L_2;74;6.X
M&I7ZWCO.[Q,L03RXS]U..N/6M"L)6OH:K8****0PHHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MVP6X\+>'K:*)1')=V\N9@-N"1\@Y/?GO6':?"V[M_",+1)9V_BBRNY+JVNE
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH *R-0\4Z'I4IBO=4MXI!U3=EA^ R:UZ^<O%5C=6.O7FQ)$
M!D8[2".]<^(K.E&Z5ST,NP4<7-QE*UCV)_B/X87[M[(_^Y Y_I3/^%D^'/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M).-O47(KGE"?#7Q*/#=KX=;5M-_LVQO5N;=A$_F2 .6PYZ#&3T[UM:KX#O\
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M0!6^P6O_ #Q6E^PVW_/$?F:L44 5OL%K_P \5H^P6F<^0E6:* (%L[=&#+$
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M6_\ 09TW_P  F_\ BZU8]7T^6ZM[:.[B:>XB\Z) W+I_>'M5QF"*68X &2:
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MSQSZ>U;5#29$J<)_$KF)_P (EHFTK]C."V[_ %K]?SI3X3T4[\V9^?K^]?\
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MM72WU9#8+ID\SK]G8,)$C!(W;\X+9&<8_&MNTTBUL=2O+ZW\Q)+PJTR;OD+
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M9U7_ 'H__0:U*Q])@BMM4U2.)=J!H\#)/\-;% !1110 4444 %%%% !1110
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M!W95MMG(]P:Z>N9UAIK;Q;IMX+>]F@2WD5OL\6\9/3-61XF0A#_9.K?,<?\
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MAI+@G:NPJ2,\ ] ..M<[%I5VAMG:PD\B%8ENX<@FX==V6QGYN2#SU_"NQHH
MXJVTG4H;ZUDE@<+&R, 2&"H"Q(+9RNU6Q@9!P*Z;1(Y(M'MTD5E."0K=54DE
M1^ Q5^B@ HHHH *YJ7_DI-M_V"G_ /1@KI:YJ7_DI-M_V"G_ /1@H Z6BBB@
M HHHH **** "BBB@ HHHH R9BVF:I+=LC-:7*J)&49,;#@$CT(J_'>6TJ!H[
MB)E/<.*GJL^G64C;GM(&8]28Q0!+Y\/_ #U3_OH4>?#_ ,]4_P"^A4']E:?_
M ,^4'_?L4?V5I_\ SY0?]^Q0!/Y\/_/5/^^A1Y\/_/5/^^A4']E:?_SY0?\
M?L5#<6FD6D7FW$%K$F<;G4 9H N^?#_SU3_OH4>?#_SU3_OH5B:?9:<E]>6\
MT=JTKS&2*/ )V8&.*U/[*T__ )\H/^_8H G\^'_GJG_?0H\^'_GJG_?0J#^R
MM/\ ^?*#_OV*/[*T_P#Y\H/^_8H G\^'_GJG_?0H\^'_ )ZI_P!]"H/[*T__
M )\H/^_8J&YM=(LXQ)<06L2$XW,@ H N^?#_ ,]4_P"^A1Y\/_/5/^^A6-IF
MGV$-O#;74-J;I]SJN Q9<DY'MC%:7]E:?_SY0?\ ?L4 3^?#_P ]4_[Z%'GP
M_P#/5/\ OH5!_96G_P#/E!_W[%']E:?_ ,^4'_?L4 3^?#_SU3_OH4>?#_SU
M3_OH5!_96G_\^4'_ '[%4[^TTJ*)H##:QSS(RQ!E RV.,?C0!I^?#_SU3_OH
M4>?#_P ]4_[Z%9FGV&G?9X[9X+9[F&-1, H)!QWJY_96G_\ /E!_W[% $_GP
M_P#/5/\ OH4>?#_SU3_OH5!_96G_ //E!_W[%']E:?\ \^4'_?L4 3^?#_SU
M3_OH4>?#_P ]4_[Z%0?V5I__ #Y0?]^Q5#5].L!8/#'!;1W$PV0Y 4LWH* -
M;SX?^>J?]]"CSX?^>J?]]"L^TMM(ND*PPVDK( 'VJ#@U9_LK3_\ GR@_[]B@
M"?SX?^>J?]]"J]]!I^IV<EI>K!/;R##1N00:7^RM/_Y\H/\ OV*/[*T__GR@
M_P"_8H:3T8XR<6I1=FBAIGA_P_H\$\-C:6\:3C;+EMY<>A+$\>U,TKPWX=T2
MZ>ZT^TMX9F!&_>6(![#)./PK1_LK3_\ GR@_[]BLEH=)CU1KI_L0L_+\K)*X
M\S/3ZXJ53AIIL;2Q5>7->;][?5Z^O<U-0M=-U6RDL[Y(9[=_O([<?_6-5]-T
M;1-'LI;.QM[>*"7/F+NW;^,?,223^-6AI>GD9%G;D'_8%+_96G_\^4'_ '[%
M/EC>]M2%6J*'LU)\N]KZ7]#/TGP_X?T*>6;3;6WMY91AF#Y./09/ ]A5M;+3
MEU*XU E&N9XEA=F?(V#/R@= .3GUJ7^RM/\ ^?*#_OV*/[*T_P#Y\H/^_8I*
M$4K)#GB*LY.4I-MZ/4HZ3H>BZ)+++8(L;R *2TQ?:H.0JY)PN3T%3:IHND^(
M(%AU"VBNEC.5.>5/L1R*EET_3(8FDDM+=4499C&.!6?87&GV^I7,T4]LEO/L
M2/8P +#.1^HHY(VY;:#>(K.I[5R?-WOK]Y97PUHR:*VCK81+8.<M",@,<@Y)
MSDG@<YK2$,8@$ 4>4%V;?;&,4^BFHI;(F56I/XI-ZWWZ]_4J:;IMGI%BEE80
M""W0DJ@)(&3D]?>JNL>&](U[R_[3L8[AH^$8DA@/3((./:M6BDXQ:Y6M!QKU
M8U/:QDU+O?7[SE/$?A%+_1M-TS3(+:&VM;R.9XF&%*#.X>Y.>_6M;2_#6C:-
MY_\ 9^GQ0^>,2'EMP].<\>W2M6BDJ<5+FL:RQM>5+V3D[:O?>^NO<Y^W\#^&
MK65)8=*B61)1*C;F)5@<C'/ ]NE7)/#FD3)?I)8QNM^P>Y#$GS".AZ\8]L5J
M44*G!;(F6,Q$G>51M^K]?S,6P\)Z%I<ZSV>G1QRA#'OW,25/4')Y_&F6_@[0
M+6%88=.18TN!<JN]L"0<!NO:MVBCV<.R&\9B&VW4EKYLQ=3\(Z#K%X+N_P!-
MBFN  "^2"V.F<$9_&KCZ/ISWEG=FUC\ZR4I;L,CRP1@@ <=*O44^2-[V(>)K
M-*+F[+1:O1/<J6FF6=C<75Q;0".6[?S)V!/SMZU;HHII);&<I2D[R=V%%%%,
MD*YCPS_R'_$__7\O_HM:Z>N8\,_\A_Q/_P!?R_\ HM: .GHHHH **** ,+5[
M::XU[31$%&$DRSQ[U'3]:I:A!+>^5<QJ-TU\BH63<%1<@$CTSD_C7544 ,B4
MI"B,5)50"5&!^ [4VY0R6LJ!G0E" R'##Z&I:* ,!3=G3=!E,MQYI>,3#)^8
M%#G?Z\^M6;F9Y=5TN6WEF\DR21R*,A3A&ZCZCK6M10!S>J:A<66J2E91'ND@
MB4LI8+&V[<P'KD=?:KEO?W\FDB<0^9+YK(I\LCS$!(#[<\9&#6I+;PS,C21J
MS(P921T(Z&I* *"7DXTYYKB/RYL[578>IX7CGO7.17-Y^XW7%[]E*Q?;G.X-
M')\VX ]0,[<XX Q7944 <E:3W?VJQ-S)/,7&PPEG1D3<V)&Q\I^7;G-;NB/)
M)H]NTC,QP0K-U*Y.T_EBM @$8(R#2    # '0"@!:*** "N:E_Y*3;?]@I__
M $8*Z6N:E_Y*3;?]@I__ $8* .EHHHH **** "BBB@ HHHH **** "BBB@ H
MHHH *I:M8G4=,GM5*JTBX5F&0*NT4 9*Z==G6HKN5X'@ACV1*,AER.3[D_RK
M6HHH **** "L_6+2ZOK$VUM)$@D.)2X/*=P,=,UH5FZU>7FGV#W5I##*(@6D
M$C$?*!VQWH JQ:#)%K-MJ N,"-"K18X V@!5/I6Y7/6^NWK6UA-<QVD(O)%"
M#>Q)4CZ=:M'Q/HZR;&O%#;RARIX8=NE &O16<FO:;)9/>+=+Y*/L8D$$-Z8Z
MYJ>UU&UO+9[B"4-&A(?@@J1U!!Z4 6JS-5TZ;4)K78\:1PRK(6.2<@^G0_C6
M3=^*+FUT.'4OLL;?:)BL<>3GR^>3[\5:_P"$DW>(K738HE:&:(.TN>02N0/R
MH ET?1I],NYW:YWQ/G"@GYB6)W'/?MQ6U6=#KNFSW9MHKI6ER0!@X8CJ >AQ
M4<'B32;F>.&*[5GD)"C:>2.W3K0!JT5S$OC"*33M0GM8&\VU. LH.&&0,^W7
MI6C9^(M.N;9Y#<HK11"28$$!0?KU% &M6-JFAR7^HVUY'=F-H74A64$ #.<>
MYHN]>2.UM[VW7?:-,(Y2RE6 /0C-;- &+H6BRZ2TQDE1_,"@!0>V>>>G7H.*
MVJ** "BBB@"*YA-Q:RPARAD0KN'49'6N9'A6\6U2,7<7R HJ,"452NTD9YSW
M]*ZNB@"."(06\4(.1&@7)[X&*DHHH **** &2AS$XCV[R#MW=,]LUAR:%<_8
MK2TCD@>)'\VY\P$&9\YZCMFM^B@ HHHH **** "BBB@ HHHH **** "BBB@
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ML])U^VAVM*'DEV^:_GG@CR\L>.20K"F6TFJRVRRQ7=P3$8F=)0WS3,/G0=.
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M"EI&OMJM\\2V^V H9$DSSCY< CU^:MRJ<>E6$+(T5I$A3A=JXQT_^)'Y5<H
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
4* "BBB@ HHHH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>32
<FILENAME>g4i5nix4zlkt000037.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g4i5nix4zlkt000037.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" '0 J # 2(  A$! Q$!_\0
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MFC"D#\1T_*K]@_9J8O:+FY3T-+NVDA:9+B)HE^\X<%1^-/BFBGC\R&1)$/\
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M]@U3YWN+VGO<IZ?3)IXK>/S)I4C0<;G8 ?F:\\?XK*T$M[;>'=1FTV-BIN^
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M(IHKB/S(94D0\;D8$?F*QO&/_(FZO_UZO_*N+\$Z]%X:^$RZG- \R17#@HA
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M)_ T<B^(_&9:-P&#X)4C/S-TJ_\ !R-X_#FHAT9";H\,I'\(KTG:!T &>O%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M]^;?_P"-ULT4 8W]D:K_ -#5J7_?FW_^-T?V1JO_ $-6I?\ ?FW_ /C=;-%
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M3J7_ 'YM_P#XW1_9FK?]#3J7_?FW_P#C=:U%%D%V9/\ 9FK?]#3J7_?FW_\
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MT-.I?]^;?_XW6M119!=F3_9FK?\ 0TZE_P!^;?\ ^-T?V9JW_0TZE_WYM_\
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M]V,_*:Z;6-!L->T8Z3J"2/:$H2JR%6^0@KSUZ@4 >2Z9K>H2^//!GAS6'?\
MMC1KJ>"=\G%Q$8OW<GOD?RKG-$U"\O-/T[2=:2YM?![ZS-'=7D;_ .OE+$HC
M'JJ @9/^%>[7?A71[WQ)8>()K8_VG8J4AF5R.,$88?Q=3C/K58>!M 'A>X\.
M&T=],N)6E>-Y"6WL=Q(;J#F@#G=5U_Q-'XMU7P]X>_LJWM=,TV.[0W,3-QC[
M@P>AQU[5FZU%%\0_ =GX@2S>YU8V#M#I8OO*1&)(:8#@L5(X]>E:4OPQBOO%
M]Y=WLMS_ &6VG0VD#Q7CK.=O#!R.H(XYZUN:C\/O#NI6UE ;:>U%E";:%K2=
MHF$1ZH2#RI]_6@#S?-OXPO/#VG7U[<7NG0^&9;I79VC+W"_*7.#]Y2/TKJ--
MU&[U']GY[R[E=[EM)E!D8_,VT, <^N .:Z'4_A_X=U2RL;5[66WCL8C! UI,
MT3"(_>0D=5/?-:[Z)IS^'VT(6XCTTV_V;R8SMQ'C& ?ZT >/2:'9>%_ _A#Q
M5HQGM=9EFM5D*SL1<B3AU*DX.:T[CQ9J6A+XBFTFULUNI/%"V6)0Q5]RCEN>
M#TZ?E79:7\-_#6D7MK=PP7<\EGS;+=7;S)"?558X!JS-X&T*X,YD@F/GZBNI
MO^^;F=>A^GM0!Q6L^._%FF:M<Z-']AFO],M5GN6CL99%NW;D1H%_U8V\;CWK
M4E\6^)M<UD:;X?AL-/DM],BU"Y&I(Q)9^D?&-H'=JZ+7/!&B^(=0-]>+=1W#
MQ>3,UK<M#Y\><['V_>%1ZQX \/ZW/#-<0W$,D4 M=UK</$7A_P">;8/S+]:
M.:LK[Q'=_&:&&2]M5LQHZ3RVL9:2,*3\VP]"V[^+'2IO&T*Z[\0_#/AG4)91
MH]Q#-<RP)(4%Q(@^521R0/2NF'@S18]9T[5;>"6VN=/@%M"()61#$.B,HX8#
MWJ?Q!X8TKQ/;PQ:E"Y:!]\$T,ACEB;U5AR* .-N[>'X?:-KTWA&]^T-:2Q7%
MUI4S^:MK%_'L&<J2.>3VK#\=>,-<UC0?$DNAW<%OHMC):P"=5/F2L^"X5P>
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M^*9?%FHVVKW3+<O,\^8 "W^K\LD+C''UHN%CU, GH,TE>:I8S>.O&OB6WO\
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MLL2QB*+.2,#JQ/4F@#K**** "BBB@#E/&_\ K/#/_8;@_P#07KHCUKG?&_\
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M/[&\BYNW_LBXFN+?S&!+-*/F#''(KK**+(+LXYOAMH@E\0/"T\"Z['Y=PD9
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 5C>*/^03#_ -?UK_Z.6MFL;Q1_R"8?^OZU_P#1RTGL"W.OHHHK(U"BBB@
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MHH Y#^R+/3_B-IDMN)]UQ97;2>9.\@SNBZ!B=O4],5UNQ??\ZP;[_DH&B?\
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MB6*&%1''&O1% P *F3J/H?YTT*^5^<?>/\-"!\_?'0_P^]6<Q-13</\ W_\
MQVC#_P!__P =H $^XOTH/^L'T--17\M?G[?W:"'WCY^Q_AH 5O\ 6I^-*/\
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M(OA__P >.N?]AN[_ /0ZZVN+^&]I!:Z/JUM A6&'6+I$7<3A0_ R:[+8OO\
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MBGL/5_4UT"DE%R3T[UY_)SS4WTZ'I_6EA\//"TTGS;R_1/MY]>GFQO\ 4/\
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M9+C#\(H."<]P#QQ5_2-9T[7;07FEWD=U;[]A=#T8=01U!H Y[X?_ /'AK?\
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M_P#$KM/W+GR_W8^7_/O6DWW9.>X[4@^__P #-;*G'JKG'+%UGHI679:+\/\
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M%E'N5!'XUA^$M-U>WT_7)='M$T:&[OEDT^VOX3B*,* ^8P?ER0<"BX%WX?\
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M2.:<DNL9QM0D]<>OO6M113$%8WBC_D$P_P#7]:_^CEK9K&\4?\@F'_K^M?\
MT<M)[ MSKZ***R-0HHHH **** "BBB@ KG?$W_(3\-_]A+_VE)715SOB;_D)
M^&_^PE_[2DH U:*** "BBB@ K"UGPX=6N)B+YX(+J)(;N)8P3(BMD8/\)Y(S
MSP:W:* ,'4_#\^I3-,-0^SR20/:S%(00\#-D*,GAATS[GBM!--2+58[U'(6.
MT%JL>.@#9!S^E7J* "BBB@ HHHH **XOQ3XQN=$\2VVDQ2:=;QRV;7!GO1(1
MD-MV@)^=9NM_$B^T>_:V32OMB0:5_:$T\*/L<G@;<]$SU8_E0!U+>'&.J_:A
M?'[,MT;U+8QCB<J5R6SDKSG'K5R;2VN-4TN_EG_>V*R@JJ8$A=0I/MTS7/:;
M\0=/=;"VU026]_.L0FV0,(H))>8T9C]TD=*DO/B%IL6EZG>V=I?W2V4$LR2"
MW98;CR^&V2=, ]3]<9H ZZBN13XAZ1':6LMY%>Q.]M'<W(6V9EM%?[IE/\(/
M;VYJ['XSTZ>_U"SMK74KB33Y!'.T-J63<2HP&SSPP/TR: .AHKD+O7/$D/CB
M#0(HM),4\#W22L9-PC5@I!_VN?I4K?$'0XY=0CF6^A:QMGNG$ML5\R)3AF3/
M7GZ4 =517(W/Q'T.UM?/E@U0*+<W4BBS;=%%G =QGY0QZ9ZU9'CS0CJJ:>LE
MPTKLL8=824$K+N6(M_?([?AF@#I:HRZ<)=<M=3\T@V]O) (\<-O*G.?;;^M8
M&C^-'UCP%?>)$TY[=[=)V6"7HWEYQSWSCGWS65X;^(=UJVH6D$\=A=03V374
M\FFF1VLRJ@[) 1U.<#'.10!Z%17#:E\3;"WTQKFRT^_GGCO(+6:VEA,;Q^;]
MUB/<9P.YXXJ^/'-A";A)TN)KA;^:SAMK2V9Y7\M59OESV#<GI0!U5%5=,U*T
MU?38-0L9?-MIUW1OC&>W([$'C%6J "BBB@ JE>Z>+V[T^<R%?L<QEVX^_E"N
M/;K5VB@##TGP\^FW<,DE^]Q#:Q/#:1&,+Y:L03D_Q'@#/' K<HHH **** .4
M\;_ZSPS_ -AN#_T%ZZ(]:YWQO_K/#/\ V&X/_07KHCUK2!$@HHHJB0JJFF6$
M<31)8VRQNXD9%B4 L#D,1CKGO5JB@"%+.UCNI+J.VA2XD&'E6,!V^IZFGQPQ
M0[_*C1-[%WVKC<QZD^II]% !1110 4444 %(\:NC(Z!E88*L,@CW%<!\7YV@
M\*:>PE\M6U2!9"9C$I4ALAF'(7U-<=K$Z1?#K6'T._L;63[3;I.;#4I+LE&;
M &YL%.3VZ@4FQV/:8].LX(XDBL[>-(6WQ*D0 1O4>A]ZE2"*.222.)%DE(,C
M*H!<CID]Z\3EGU_PCJ_B>_74/M\NE&UT^+>C>7"DB*?,*[L84=<]3R36PGC_
M %]O#MI+-=:= L^HFT;6?+#PQQA=VYE!V@Y^7KBBX6/5Z*\GD\3:O/XC\(WA
MUF%[:>WNMR0P-'%>2)D  -W;@#TZBET?X@ZW=R1,][87C7-G<3S6EO;E7TMH
MU)42$]1D;>><T7"QZO2X-<3X7U76;_1M!OM7UVP635/WBVRVP0RH4_U:G/WA
M][-8^E>'-*LOB-KJ W7D:9:6]W CW<K*CG<22,\CCI1<+'IM%>.:=\3M9N8]
M<9;ZSNT@TF6^MY4M?+"2*V-F"26&".N#[5I7_BWQ+I8T>&^U?3+<WEB]^;N6
MS/ER-@%;=0#UY)SUHN%CU&F1PQ0AO*B2,.Q=MJXW,>I/O7C=Y\3?$L=KHQC-
MC ]QIR7;23Q@+=2%R"BY(QC'\.374>&=1U.;XI>(;6_U(>7]DMY8;!A]T%02
M4/HI)!/?(HN%CT#!]*2O"O$L&H2ZOXUU".TEGAM+\1?:TOI4>R!1?G6).&5>
MIK9U[XAW^B7MA:Z=K5I?1P06IE!MMQN5? :0R$C P<_*#[T<P6/7,45XW>:S
MJ=OJ?BJ&ZU1+EH=;LTBMI%(,<;.H##GA<''IGFM,>/\ 6V\2>5YMD6.JFQ.A
M^0WVD1;L>=O^GS=,8HN%CU&B@]:*8@J$VEL1,#;0D3\S H/WG;YO7\:FHH C
M@@AMH5AMX8X8D&%2-0JCZ 5)110 4444 %8WBC_D$P_]?UK_ .CEK9K&\4?\
M@F'_ *_K7_T<M)[ MSKZ***R-0HHHH **** "BBB@ KG?$W_ "$_#?\ V$O_
M &E)715SOB;_ )"?AO\ ["7_ +2DH U:*** "BBB@ HHHH **Y_6O&WA[08;
MIKO4H#/;#Y[9'!E)_NA?7FL[0/B=X9UVQ:X:^2PD5MK0W;A6^H]177' XF5/
MVJIOE[V)YHWM<[&B@?-C!X/>N5L/%]WJ,+ZA;Z'*VC_OQ'=^>NX^5NR63J%)
M4@=3[5R%'545QVD^.9[LV8U#19;<WUBU]9BVD\\RJN-RXP"&^8<52N?B=';>
M'].U:329$6[$[.DDP7RUB<J5SC!<XR%^M &]JOARZO/$$.M6&L2Z?=1VIM3M
M@60,A;=_%WR*K7_@M-4EO)[S4II+B[THZ9+((U7(+;B^/7VZ5>O_ !/:V&JZ
M+8-#/(=6W&*1$RL8"[LMZ?TJI?>.-*TWQ#_9=XY6-H8I$N8P9$)D<H 2H(49
M Y)[T 5&^'EC_;\>JI>2*?W)FA:"-Q*T2A5(+ E<@#./2G0> 8X+"[TO^VM0
M.DS6\]O%9 J$A67.3G&6(R=N>E.U;X@:7I]MJOV9)KJ^TZ/S'M3&T9D&\(=A
M(YY..*J?\+.TO[/<WHB/V"":UC:=FY F4DDKC(*D8(]: '2_#F.:!H&UR]6&
MYMHK6_1(T NTCX7/'RG'RDCJ*V;3PX=.@U5-/U":VDU"\%V9%16,7"@J >""
M$QSZTFF^)4O/"LOB.XMC;6(B>XC4.'=H5!(8@<!CC[O:J,GB[4K319]4OO#T
MEO"L,4T)%RKAP[!0K8Y5@&!QR/>@#7GT**?Q3;Z\9G66"TDM!$!P0[ YSZC%
M<G%\*;2-;T/K-Y,;JRFLBTD:;@DC;LENK,#W-;\WCGP]!<W<$EZX-JLA=_)?
M8WE_?"-C#%>X!J%_B%X;CTYKV2\E2-9A"4:W</N*[_ND9QM^;/I0!SOCGPCK
MFH7DXT*)Q'?::MC<2+.BAMI^7>&&0 ">5Y.<5L67P\LK+7H]52Z8'?'/-!Y*
M,'E5 NX,P+*#C.!WJ]XC\8V6A:/8:A$([I=0D5+4F41QME2^XN>@P*V]/NQ?
MZ=;7@39Y\2R;=X;;D9QD<'ZB@#$TWPA%IOA.^\.K?32VMR)E1W4!HEDSD#'7
M!)ZU3D^'UIB'['J-W8L--_LZY:VPAN$ PKMZ.O4'\*["B@#@H?A?;16%Y;_V
MO<&6YFMI_.$*+L>#.TA1P<YYS5Y_ :+=F_M-7NK34A>SW:7*1H<><JJZ%2,$
M?*#]:Z^B@#/T32+;0-&MM+M"[0P*0'D.6<DDEC[DDFM"BB@ HHHH **** "B
MBB@ HHHH Y3QO_K/#/\ V&X/_07KHCUKG?&_^L\,_P#8;@_]!>NB/6M($2"B
MBBJ)"BBB@ HJE=ZQIEC(T=W?VT,BKN*/( V/I6+I?C_0=4N98%N#;E!D-<81
M7'L<_I4.K"+LWJ=-/!8FI!U(4VTNMCIZ*BM[F"\A$UM-'-$20'C8,#CKS63J
M_B![#5;72;*P>_U&XB><1"58U2-3@L6/N< 5=UN<[BT[,VZ*Y>;Q7?B]L;&V
M\.W#WMS:/=O;SSK$T01@I4YR"<GBF_\ "=V;VNA3PV-Y(FKS+$K;,+ 2Q4AV
MZ9#*1@>E%Q6.GEABG39-#'*F<[9$##\C4:V-FB,B6=LJMC<JPJ <=,C'-<W8
M^.[.]\6'03:O%(TLT,3M(NYFB&6RG501D@GKBM*U\36-WXFU#0E65+BQC222
M1T*H=W8$\?X]J- -;RH\R'RDS)]_Y1\_U]?QI/(@\CR/(B\G&/*\L;/RZ5@6
MGC72I]>NM&F=K>[BNS:Q;@2LS;0W# 8&0> 3DXJOJ'Q T:UTK4KRT,MY+IZ*
M\EL(VC=E9MH*[@,C/<4:!9G4&&([,PQGR^4R@^3Z>GX4""%6D988@TG^L(0
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M$P_]?UK_ .CEIFD>+]"UV[^RZ;?>=,4:15,3IN53M8@L #@]<4_Q1_R"8?\
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MAX(F!;<0R \^OU]ZD[T4 (RJZ[7564]F&12>5'YOF^6GFXV[]HW8],]:=10
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MX!Q@]L<UVNP# V@8Z<=*R-/\3:+JUR8+&^2>1=Q)5&VC;PWS$8X^M%@.-O\
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M=V3USGK5[;@9 Q^%%@"L;Q1_R"8?^OZU_P#1RUM8/H:Q?%'_ ""8?^OZU_\
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M<I=!M7!89 P6ZFG^$/!ZZ'I!M[^22>:4RB:+SV> J[EL!#P."/UJQX3\5?\
M"46%U<&Q>U:!@.7W*^5W @X'T/%8_@C5?$VM:<=1NFDE\V.3R!*D20.X<J.5
M)<#CN*- U&2^"=13PY:Z?:FV1K;5+B[6*.0Q9C<OM59 "4(##.![5=C\'2QV
M_A-F%H][I$T9N+A4VEHU1AM7\2/KUK%F\7ZZGAC2Y6N(3J%S>WD$OD1+EA#O
MQL#': -HSDYQTYK8C\0ZS-=^#9%>S_L_5MHN&13OD<Q,YV@_=4$?6EH&IGOX
M!U.ZU74S<7D,=I=I>)YD;$G$^,;8\80C')!^:M2ST/7IK![+4H]&2&+3FL8?
M)1F:4D8R6X*)CJHKGX/'NKH=7N&\NZ6&TO)[>)8P%<PR;1MQ\V #\V[&3TK4
MCUW4K?3+R5?$NEZG<MI?VN*((L1BD/ ;<#M\O)_BYHT#4I_\*_U>[\/W=A-J
M$-E')(KQ6$3-<0#;'M )?G!;YL=!@5I1>#;I=-\(K,UK)?Z/)%Y]QMP3&JD;
M%/U(^N,UBS^/-1TWPE?%W-QK,4S0^>R*\$1$8?=NC&&&#P/4X-:T?B?5YY_!
M4L;VQL-74+<-M/F22>46.!T5011H&II>*/"\WB'6-%G6ZEMH+,7'F203&.52
MZ *5(]".:Q;7P-J/]E66GW)LU2"TOK:5HV;;.TN-DC#^\2,M[U-\0/$FL:+=
MV=OI,L<9:VFNI"T:L6"%1CDCC!)XY..*T]2\<Z=9::;FW2:[<Q121XC:.)Q(
M5"GS"-H'S GTIZ!J<O)X$\1QZ.EA9MIT2S:?;6LX$[CRVAD+%DXYW ^V*UX_
M"FKQ>+K_ %J/[&(+E)DBMFE<B%F4 38'&YB,,!C Z5%/\2UMM-O+B6QM5N+:
M\>U\K[:"LFQ [,C ?-UQ@"M3P]XDGUSQ#.@&RQ;2[:\BB(&Y&D)SD]^@HT#4
MYG3/A[KD5C=VM]-9B*YN[.=H;>5PBK&Q\P#OEACZ]ZVDT6?0?"S64SJ8SK4<
MMNJN6$<33J57GT]*[:L;Q1_R"8?^OZU_]'+0UH%]3KZ***R- HHHH **** "
MBBB@ KG?$W_(3\-_]A+_ -I25T5<[XF_Y"?AO_L)?^TI* -6BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** .4\;_ .L\,_\ 8;@_]!>NB/6N=\;_ .L\,_\
M8;@_]!>NB/6M($2"BBBJ)"BBB@"M?:?9ZG:-:7]K%<V[$%HI5#*2.G%4]/\
M#.A:3<_:=.TBSM9]I7S(8@K8/49K5HH *J7VEZ?J8C%_8VUV(VW)Y\2OM/J,
MCBK=% &?>:#H^H7*7-[I5E<SHH5))H%9E Z $CH*MR6\$SPO)#&[0-OB9E!,
M;8QE?0X)%2T4 4AH^EAKIAIUH&O!BY(A7,P_V^/F_&IHK&TM[N2[AM88[F1
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MC_Z&&U_\%H_^+H U**R_[*\1_P#0PVO_ (+1_P#%T?V5XC_Z&&U_\%H_^+H
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
510 4444 %%%% !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>33
<FILENAME>g4i5nix4zlkt000048.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g4i5nix4zlkt000048.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &T J # 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "JSZA91W MY+NW28](VD
M ;\LYI;]+F73KF.RD2.Z:)EB=^BL1P3]#7D&L_#K3]!\%7VIZY>F7602T<R2
MG:[$_*N",DGO_P#6K6E",OB9$Y-;(]F) !)( '4FH;>]M;O=]FN89MOWO+D#
M8^N*\<\1:KJR?"KP[8W$LJSZB^QW8G<T0/R@_4%/K4FM:%;_  Y\5^'+S2)9
MECN'\JY5FSOY4-^!#=.Q%:+#K9O76WR)=3R/8;BZM[1-]S/%"A.-TCA1^M.B
MFBGC$D,B21MT9&!!_$5P>L?#Z?Q)XPEU'7+Q9=(6/;;VT3LK)@#KQ@?Q$D>U
M<[X%N#HFJ>+O[+F>?1+&%WB9CN4NN2N#TS@'GN *E48N-T]1\[3LT>M/?6D=
MPMO)=0+.W2-I &/X=:GKP;3/"D&N_#[5O%-[-/)JP>25)"_'RX)SZYY^G%>I
M?#[59M8\%:?<W,ADG56B=VZL5)&3[X HJT5!73O9V80FY.S1T%Q>VMH4%S<P
MPESA!)(%W?3/6IZ\J^,0!OO#.0#_ *0_\XZ]5J)0Y81EW*4KR:[!17'^)/&E
MWIFN1:)H^C2ZGJ#Q^8PW;$4?7')_^M1X4\;R:]?WVF7^F/8:E9+ODB+[@1G!
MYQP>1^='LI\O,'.KV.PHKS"#XM7.H&./3O#<\\WG!95$A944D '<%XR<]?2M
M35/B!>#Q'-HGA_0Y-5N+;_CX82;%4CJ!QVZ9/>J>'J)V:%[2)W=%<9X<^($?
MB'Q#<:3_ &7-9M!"9)&FD&Y6! 92N.,$GG/:LR7XF7]U+>7&A^&YK_2[-B)K
MKS-N<=2!@]N?ISQ2]A4O:P>TC:YZ-39)$AC:25U1%&69C@ >YK.\/Z[:>)-&
M@U.RW".7(*-]Y&'53]*XSXQ1WS^'+-H5D:Q2XS>"/^[CY<^V<^V<4H4W*?(]
M!RE:/,CM;7Q!HU[<?9[75;*:8G CCG5F/X UHUX9)IO@+7K&VBT'4/[&U177
M:UXSC=]3G&?0@UZ7KOB=?!OANSDU(F]OW5852+CSY .3ST'?\16DZ-FE&]WT
M9,9Z79U%%<!9_$._M]9LK#Q)X?ETM;X[;>;S-PR> ",<<D?3/2K.M>.-0A\0
MS:+H.@RZG<VZ!YG+^6B^P)'/45'L9WL/VD;':LRHI9F"JHR23@ 5';W5O=Q>
M;;3Q31YQOC<,,_45QND>,5\5>'==BELGL[VS@D2>%FW#E6Z'CN""*Q/AOK-G
MX>^%MQJ5X2(8;ESM4<L3M  ]R:?L9).^Z:#VBOY'J5%>;Q_$[4+9;6^U?PS/
M9Z/=,%BNQ)N(!Z$C'IS_ "S7HZ.LB*Z,&5AD$="*B=.4/B'&2EL5I=3L+>?R
M)KVVCFX_=O*H;GIP34L]Q!:Q&6XFCAC!P7D8*/S->#_$FRDO/B'JAA7]Y!:)
M/D#LB FNB\<:NWB7PSX7L+=@9-4Q/(/38O/_ (\3^5;_ %;X7??\#/VN_D>K
M6]U;W<9DMIXID!P6C<, ?3(J6O*_AAJD&B?#?4M2G1VB@NG<I&N68[4P /4F
MIY/B?K%G:V^J:AX4E@TB=@$G$^6P>G&/3UQFH>'ES-1Z%*HK)L]-HKD/%'CV
MW\-3:5NLI+F#4%+AT?!5?EZ+CYB=W3BLV'XC7]OXCL]-UOP[-IL-ZP6"1Y0S
M#)P"PQCKC//&:E49M72&YQ3L>@T5S,WB]8?'MOX7^PDF:+S?M/F\#Y6.-N/]
MGU[TD_C!8?'L'A?["298O,^T>;P/E8XVX_V?7O4^SEVZ7^0^9&S?:SI>F2)'
M?:C:VSN,JLTRH3^9JZK*ZAE(92,@@Y!%>"SW,NM?$RZFU+PM/>NZ!&TUW^:)
M<* Y..@'/_ J[_4/'&HQZU<Z/X=\-RZA]@ 69R_EJ,=EXY]/?%;3P[5DOT(5
M1.]SO**Y+PWX[L]<T"^U.YA:R_L\D7*,VX+@9R#W^GK6 WQ0U5K)M8B\*SMH
M:O@W+3 -C.,XQZ_AGC-9JA-MJVQ7M(VN>ELRHI9V"J.I)P!2UXS\1O$\^J2Z
M$;&"Y_LR4I<QN'PMTV5.S']Y2,=^378ZQX]GT31]'O;S0YHY]0E,;6SS!6A(
M/<[>?7M5/#RLFMV+VBN_([6BN8\8>,%\)+IY-B;K[9,8N)=FSIST.>M4_%?Q
M B\+:W!ILFFRW)FM_-5XY.=Q+!5VXYR0.?>HC2G*UEN4YQ6YUMQ>6UHJM<W$
M, 8X4RN%R?09J:O)/$WB*VU?PMIE[XE\-3J_]H/%';BY:(J0OWSE<^HQCM76
M>)_'<7AC6K#3I-.FN1=1[P\3_,#G 4+CDDX[CK5.A+1+?7\"?:(Z^BN!T_XA
M7W_"4VVBZYH$FFO>8\AC+O/.<9XQR1CCH:L>(/'D]EXB&@:)I#ZIJ*J&E42;
M53C.,X],>@&12]C.]K#]I&USMJ*XC1/B&=6\4Q:!+HT]G<F-C-YL@S&ZC)7&
M.1TP<]Z[>HG"4':12DI;!1114C"BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH K:A
M?0:9IUQ?73[(+>,R2-[ 9KPO_A,](\0^(CJ?BMKE[.W;_0].@0-&!ZOR,GIG
MU^G%>]2Q1SQ-%-&DD;##(ZY!^HJI_8NE?] RR_\  =?\*WI5(P3NM3.<7+8\
MR^(=[%XD\&Z/XDTN*4V=M<MN#)@JN<9(&<#*@?C5;Q+KEGX^\4^&;'1C)*(Y
M/-G)0CRP2I.<^@4Y/2O7DM;>.V-O';Q) 008E0!<'KQTJ"RTC3=-9VL=/M;9
MG^\88E0GZX%5&O&*VVO;YB=-M[GEWQ'\<K)J[>&X;N2UL8V"ZA<0@-(V1DHH
MR.W7W_77\+ZOX9UK0-0\+^&K:YA/V*0DS(!O)&W).3DY(KNY-)TV61I)-/M'
MD8Y9FA4DGW.*?;Z?96CE[:SMX7(P6CB521Z<"DZL.112V_,.27-=L\2T?Q98
MZ/\ #/5_#UX9(M4W2Q)"R'^/@Y/;'.<UZ9\.=-FTOP-I\-PC)+(&F9&'*[F)
M'Z8K<FT72KB\%Y-IMI)<CD3/"I?\\9J]15K*:LEN[CA!IW9Y1\9I4AN?#DDC
M85)I&/T!C)K=_P"%O>$<?\?=Q_X#M79W-E:7FW[5:PS[?N^;&&Q],U!_8NE?
M] RR_P# =?\ "DJD'!1DGH'+)2;3W/,O%/B>\N?'+Z/<Z_+H.CI"LB3Q)AI,
MJ#RW7G)'H,>M4_ALUJ/B!K*VUU-<PM:,8IK@_O)5W+\QSSSU^E>M7FD:;J#1
MM>:?:W!B^X985;;],BIELK1)_/6UA6;;M\P1@-CIC/7%5[>/)RI=!>S?-=L\
MV^"H0Z3K#K@L;L D>R__ %ZS]$UFT\"^/_$4&O%X([R0RPSE"P8;F8=.Q#?F
M*]:M[2VM%9;:WBA5CEA&@4$_A7!ZSI?C:W\1375@MCK.FNQ>&VO0@\@GL"0#
MQVP>E5&HISE?9B<7&*MT.<\+W']O?$GQ'/;Q20"\LI?*$B[6 .P*2.V>#^-8
M?AN>TTW1KZSU+Q3JFC7-M(X>P@ Q)Q@X!'WCC'/M7H_@OPMK%GX@U/Q%KQ@2
M^O1L$$!R$&1GG\ !UKJ[K1-)OK@7%WIEG/,.DDL"LWYD54J\8RY>FGX"5-M7
M.=^&=E9V?A-7L#?&UN)FE3[8BJ_0#@*<8XX-,^(/B+6/#,%C>65M#-I[2;+S
M>A8@<8&<X (W#)[XKLU4*H50 H&  .E))&DL;1R(KHPPRL,@BN?VB=3G:N:<
MONV1XEXUU?P#JFAM)I-JHU:4KY?DP&,KSSOXP>,^M3>)[/4M/\+>"M4U"*60
M:>5^TJPR4&59=WX+CZUZO;^'M%M;@3V^DV,4P.0Z6Z@@_7%7Y(HYHVCE17C8
M896&01[BM?K"5DEHNY'LF[W.'N_B/I5SJ^EV&BVRZQ/=/@[#M\@''/(^I/IB
MN7UCQ)<ZCXUU;3-8\33Z!IMFQ6)8%VF4#_:'.2.?QXKU6RT;3--D:2QTZUMG
M;[S0PJA/X@4MSH^F7MRES=:?:SSI]V22%68?B14QJ4XO1%.,GNSR/X<M$(O&
M21R.RBV)7S>)"N),%AZ],_6J%C93W_P+F-JID\C4#,ZKSE0 #^6<_A7N*V5H
MDLLJVL(DE&)'$8RX]SWIT%K;VL7E6\$4,><[(T"C\A5O$ZW2ZK\"52TL>%75
MUH=]X>L;>Z\6:[?^=L3^S841FC8#@8.!@'@<\U[AIEO]CTJSM@7(AA2/,@&X
MX '..]0P:%I%M=?:H-+LXKC.?-2!0WY@5H5G5JJ:214(<NYY1=6J7_QPO[-R
M-LVFM&P]FB _K7-_#ZVN;WQ(T-PVY=%LKA$4_P !)88_-F_*O=?LEL+K[5]G
MB^T$8,NP;\>F>M)%96D#R/%:PQO+_K&2, O]?6K^L^[RVZ)"]EK<\<\):S>Z
M'\']4O\ 30#<)?;0^-PC!" MCVKGO$=Y;WWAFWNIO%5[JNI2%7EM6!$5N"#G
M(Z @X />OH2*RM(8'@BM88X7SNC2,!6SUR.E5X-#TFVADA@TRSCBE(,B) H#
M8Z9&.:J.)BI.5NI+I-JUSR_QDR/J/P^.Y2K"/'/!YBJ]\4B!XH\)9(!-S_[/
M'7I+6%F_D[K2!O)_U68P?+_W?3H.E.FL[:Y>-Y[>&5HSE&= Q4^V>E9JNDXN
MVU_Q*=.Z?F>6^)+^#0_C3INI:@WDV9M0/-(X&5=<_@2*@MM8M-;^.%C>6,GF
M6Q@*1R8($F(VR5SU&<C/M7JM[IEAJ:*E]96]TJG*B:,. ?;-.2PLXY(Y$M(%
MDB79&RQ@%%] >PIJO'EVUM8/9N^_6YYMI9'_  OK5!D9^S'C_@$=8]UXDGUC
MQ)K%KK_B>ZT.TM)6CBM;92K2 $C&1R3@ ^^>*]C%I;+<M<K;PBX88,H0;B/K
MUJ";1],N+U;V;3[62Z7&V9X5+C'3G&:%7C>[71('3=MSQCP?93:EX#\96-F'
M>X+(RQG[Y R<$>IP1]:W?#WQ#T+1_AS;V\K)+?VL9B-BP(,C;C[$8[YKU&*T
MMH)9)(;>*.20Y=D0 L?<CK55M"TA[S[8^EV37.<^:8%W9]<XZTY5XS;YEI>X
ME3:V9Y;\1;Y[S3_!^JW-FU@KRL[PL<^6,H1GCT&<8JU\5;ZVU+0M U>QD%Q8
MB[8^<G0_Y*FO4+RPM-1@\B]M8;F+.=DR!AGUP:;_ &;8_8/L/V*W^QXQY'E#
M9C_=Z4HUXKETVO\ B-TV[Z[GD'Q*\4:3X@;1%TNY^T)#<;I)%4A5+8PI)_BX
M/'M6QXL"-\:/#"M@_NE(!]0TA%>B1Z-I<-LMO'IUHD"-O6,0KM#>H&.OO4[V
MEM)<)<26\3SH,)(R LOT/44>WBDDEM?\0]FWJ_(\V^-! TO1LD#_ $T]?]TT
MSQJ5_P"%K^$ 2/X.#_OFO3+BTMKM56YMXI@IRHD0-@^HS1)9VTT\<\MM"\T?
MW)&0%E^A[4H5E%)6VO\ B-PNV_0\T\=D#XI>$,D9+K_Z,JI_:4'@GXMZK=ZT
M'BL]1B)BN-A( .T]O<$''M7JTMI;331S2V\,DL?W'= 67Z'M7$^)=+\8KX@-
MYI1L]3TUP#]@O FV-L8.,C\<@U=.HI+E?:Q,HM:KN<WHNK0ZY\;4U&VCD2WD
MMV$1D0J741XWX/8]O:O8*\_\+^%]=;QC/XH\0I;6\YA\J&VMVR%& /R 'J>M
M>@5GB'%R2CT15--)W"BBBL#0**** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ JM+J%I!(8Y9T5AU!JS7*ZP,ZC-^'\A2;L-*YN'6-.'6[C_.F_VWIG
M_/Y%^=<=(M5G%3S,KE1W1US3!UO8A^-']N:8?^7V+\ZX/&]=IZCI35%+G8<J
M._\ [9TX_P#+Y'^=']M::/\ E\C_ #KAUZ4C#YJ?,PY4=Q_;>F?\_D7YT?VY
MIG_/[%^=<(132M+G8<J.]&N:83@7D6?K3_[7T\?\O4?YUP,*$S*,=ZO,OS4^
M9ARH[#^U]/\ ^?N/\Z/[7T__ )^H_P ZX[8:-E','*CL?[7T_P#Y^X_SH_M?
M3_\ G[C_ #KC]E&RGS!RH[#^U]/_ .?J/\Z/[7T__GZC_.N/V4;*.8.5'8?V
MOI__ #]1_G1_:UA_S]1_G7(;:-M','*=?_:]A_S]1_G1_:^G_P#/U'^=<AMI
M-M+F#E.P_M?3_P#G[C_.C^V-/_Y^X_SKC2N 2> .M9\FLZ?'+Y9GW-_LJ2*.
M8.5'H7]KZ?\ \_4?YT?VOI__ #]1_G7#+=0, 4<.IY!7I5K9FCF#E.O_ +6L
M/^?J/\Z7^UK#_GZC_.N.?;$NYV"CWIB7%N_ E7/H>*.8.4[3^U;#_GZCH_M6
MQ_Y^4KD1M)P&4GTS3]E',PY4=7_:EC_S\I1_:EC_ ,_*5RNRC91S,.5'5?VK
M8_\ /RGYU%<Z_I-I"9;B_@BC'5G;%<SMKC_%EG%)?PR.I),?<\?A50O)V1,N
M6*NST)/B#X2DD5$UZS+,< !CR?RK9_M6P_Y^H_SKP=;6%54B$#!SG%>A6-PE
MW9QRIQD8(]"*TJP<-3.G4C4T.V_M6Q_Y^8Z/[5L/^?J/\ZY'%)BL>9FW*=?_
M &K8?\_4?YTHU2Q) %RF2<"N0Q3XA^^C_P!X?SHY@Y3MZ***L@*K7FH6FGHK
MW<Z0JYPI;N:LUR/CT9LK+Y]O[T_^@TF[(:5V;/\ PDNC?]!&'\S1_P )+HW_
M $$(?S->3RRQPCYIP3V4$9-%I=074>^&X4@'##N#[UGSLOD1ZQ_PDFC?]!"'
M\S2_\))H_P#T$(?S->910F:0(LHR?<<5?,5C:)&[LUR[<A<[5QZ_2GSL.1'?
M?\))H_\ T$(?S-.CU_2I6Q'?1,1SP:X"2\LI.MA&O^XVW^56;0Q?ZRWL0V1@
MGS>GUHYV'(CNFUC3T1G:[C"J,DYZ543Q7H4GW=3@/XFN0N=6AAD%G-8YDE&%
M4/D?B?H*H7L^C07RV\EF4<G$864C=@5<E)6;6XE%'H'_  E&B?\ 02@_,TO_
M  D^B?\ 01A_,UY^ITH_\N4G_?XT[&F?\^<O_?VHYV/D1Z#_ ,)#I'&+^(Y&
M1@TJ^(-*>9(5O8S(_P!U><FN*@U>PTY"J6\< D.XEI -Q^IJQ_;T,GSB!FQQ
MD,#2YI=6BG"-M+G72:]I<.[S+V)=IVG)Z&F)XCT>1U1-0A+,<  ]:X>[O[*^
M'D-%-&4P3L XSTS4%KIQ-U#+;7"31JXW+M*NOU']:?.3R'HL^LZ=;6\EQ/=Q
MI#&NYW)X4>M/74[)XUD6Y0JP!4^N:Y40+-&T%PB21MA61AD,,="*LL@BB&WC
M;]WVI\PN0VYM=TNV?;->Q(Q&<$U-%J5G/'YD5PC*>XKE5;[1JNGPS!9$=WRK
M@$<(35#Q;JDFEZ1&+;<)FD3+IC=LW#=G\Q1S,?*CO3>6XZS*/QJ&XUC3K1 \
M]Y%&I;;DMW]*\)M];U(:;>QO9M+(EQ#(&D9B2 3ZFI-6OM5N(-22.RA -\'
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M$B%6W'W!S^E176AF*T81N%D(P@#D8_\ U5#CK<M2TY3(AT*X9I',<X);IGG
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M4Y4?:D;S6[+[=SGVK3L0&\06I[K#)C]*;XNUJ"VLYHXGDFFMBLDJ1C*Q#/\
M&W;/IUJHJX=3E(K_ %A_#Q:;P_(@BCC\B,RC==#/5<=/QJJ?$6M@<^#[\#VG
M0UI:IJ5UIND:5=RB%C)&HM84+;6! PKG'7G/'H:MVLLUTC^?"L-S&?WL08';
M[C_9]ZB,7>7K^B!O8P&\3:N.OA#4\>TB&HSXHU/OX2U8?BE=5M..E,,;_P!V
MF(Y3_A*+XM\WA;5E^JK5QM7N[RPEC72;V!W!C5I!T/\ >..U;<=O([DA&*@X
MX%/NV:*UD*G8RCKCIS2910C.H7TZ3,'LT3*LBD$OR#WZ5>FSL;([5/%@M(HX
M(.2*BN5.P\T@*MU)A%.">16CUCC^E4+@ !1[UI8&Q/I1$&1XJ6VXE_"FXJ2'
M_6CZ58B2YQ]FDSQ\M9<,#PPI'(FUAU%:ERJO:RHPRK+@UG1J?+7+,?<G-)[@
M7X)\J$.=P_6J6HM)N3 .P]0.]1W-NDRH7W91PZD,1@CO6PEI++:@RNI8\Y_I
M3 P1;/,K1XVEAR5[5)#IY1LR R8& QZG\*U%LS$<J<?0=:E"-M8X.X#/(ZTQ
M$<"B.V9)) 1C'/&!6:R<\59D9F;YA@^E1&DQG4^%1C39?^NQ_D*W:Q/#'_(.
MD_ZZG^0K;K2.QD]PKF=5_P"0E-^'\A735S&J?\A*;\/Y"B6P1W*HJ.4<5*M1
MR]*@LK#K5F,<5 O6K,?2D,BU ?Z$WU%8!_UI^M=!J'_'B_U%<^/OTF")TJU'
M59*LQTD,G%0R\BIA4;CBF(Y?56SJ;#TX_2J_F;%R/6KVLP,EYYNPE),$-GH>
MXJC'"\\JP1Q^9(YP!Z>]>W1:]BGY'GU+^T/0;7[B?[H_E3K\9LW%) GEJJYS
M@ 9I;[_CT;Z5XS.\YW3N+]/J:WM3)^P/SVK!L#_Q,$^M;NI_\@]_I4K8;.:7
M[U,;[_XTY>M(W4TAG4P#]U9K_P!,Q5HI56W^];#TB6KY%620;:3;4V*3% $>
MRG!:?BE H K6HRLP])&%9$1!51V7.?SK9M1N-TO_ $U(_05CVJ\L#ZD'\Z '
ML>/E&30D9!^:GF(J>.E1W-S;6$)FO+B&VB ^]*X44P)'3( ';G%*L32.J*,D
MUS:^.])N-5MM/TU9KR6>0)YBKM0?GR:[73V1XV#1A+B-MD@]#_@:&FMQ*2>Q
M4C1M,G19#F"<XR.B/_\ 7K1*4ZX@2X@>&095A@^WO52QE?Y[6<_OX>"?[R]C
M2 E*4PI5@BF$4#(-E&RIL4F*!# M31+^\7_>%(!4D8_>+]10!T=%%%:$!6'X
ME_X][?\ WS_*MRL/Q+_Q[V_^^?Y4I;#CN<T:>O2F'K4B]*S-1XJ&]_X\IO\
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MMKI5A=G][=31=^@-69[6UA">7.\B#C=@54@D99@ <!@,U7N[VXED:,O&JHQ
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MX?R%=/7,:K_R$YOP_D*4@B5UZ5%-TJ5:BFZ5)977[U68^E5EZU9CZ4@&7_\
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MW@KLAFOX:M_*O[;<!YAMG=CCN2"?YUT6L-C1KT+U\A_Y5D:/_P AT#TM6_\
M0A6U?J)+2=&^ZR,#]"*F]W<9SDB2Q*H. ,<L#U%8UYN>YMUV[E+Y.>G0UL"=
M+BP@ECD$B,@VN/XATS65,OFW=O&&9<DY*G!'&/ZTX?$$MBM$\<-].(5D24H/
M-7E5)[8/?(ZU82!$)86D8).203S5B73X\D?:)^#D,'^8^Q./:K#6@CA9UNK@
MD $;FS6SA-+FN9\T6[6*<OF-92A3^](RK =P>E50DT6C3>?]YW4@>GS"M**Z
MEB_=HP"[B<8J#4SNL7)[LG_H0KS_ &"]ISW_ *V.M5I*E[+H8NM23?VLZ[0(
MPHVMGJ>]6O#C%I;I6_V2/UK1NU@>*83A2@Z^H]Q6;X;(-S..Y09_.MK:F-SI
M0 )HS[53N1B[FP,_,:ONH!A/U%4;L9O9!DCG^E4MQZ=2(, A7!S2'GG&*,T&
M@=EN;NF1>5:J?XG^8U99]K*WH:;!E(4'HH%-<[B/K5$,MMDL34&?F8^]3R?*
M#57)Z>IIB),Y&:4TWM2T *3Q2#D$4T]J<* -?1CFS8_[?]!6C6=HW%K(/20_
MR%:-4B'N%<QJO_(3F_#^0KIZY?5?^0G-^'\A2D$2NM13=*E'2H9NE260+]ZK
M4?2JJ]:M1]*0QE__ ,>3USR]:Z"__P"/)ZY]?O4I BRM3KUJNM3KUI#)A2GI
M2+0W2F(S+[4K;30LMS(%R<*!U;Z4:3XHT^\NA LI1FX7?C!-<AXHB>ZUV3<Y
MVQJ%C7'Y_3DUE?9=GS;BNWD$#//:NZE@^>GS-G/.ORRL>OK(?.-%ZVZ*J=C(
MTMG;R.?F:-23ZG JU<G,%<;-S)L/^/Y/K6UJ1_T"2L6Q_P"/]?K6QJ9_T!ZE
M;#.=0\TK=&^E,!QDTX]1[XJ1G2P'_25^@K4K'MV_T@?A6OFM$2%%<UXL\1SZ
M"MJ($C+3%LL_;&./UKHU;<BMZ@&@0ZEIM% %> XU&['LA_0US7BN![CPWJ<$
M:,[F[3:JC)-=$C!-1N6/3RT/\ZK6US_I=XJL!N<-G\*<79I@U=6/$'TK4-_R
M6<Y.<8,1P?TKU_3-,_M3X=1Z//$T,CVAA9'ZHW.#S[X-:4DL,6W>P&XX%6+6
M95D*^8N"./K6M2LYF<::B?/9MI;6]FMY5VRQ#RW'HPZC]*]4^%5X9-'O;0G/
MDS!U^C#G]17)>-[%(?$%Q?6J,;:Z?<7QP'Z,/S&?QK=^%LZK?:E;[EW/&CX'
ML2/ZUT5&IT;F4%RU+'HM[;FYA&P[9HSOB;T8?T/2EM;D75N),;6'RNAZJPZB
MILUGW'^A78NA_J92%F'H>S?T-<)TEJY@2ZMWAD^ZXZCJ#V(]ZK6%Q(P>VN#_
M *1 =K'^\.S#ZU=JC?Q.I2\@&9H1R!_&G<?UH8R]25'%,D\*2QG*L,@T^@0M
M/3_6+_O"HZ<G^L7_ 'A0!TM%%%:$!7)>/"RV=BPC=\3'(1<G[IKK:PO$W_'O
M;_[Y_E4RV''<XJ!3_8I7:P/EGY2.?RIFD-ND8^6R8C53N4CD5ITX&L[&P\54
MU0_\2R?_ '?ZU;%5-4_Y!EQ_N_UIB.9M3\F/5Q74VI_TN3ZBN5T[YYHQ_P!-
M ?RKI;%]]RS>O-0AFO.?GB^M8.M0RSQ0^7")UCEWO"<?/@' YXZUN3GYX_\
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M/Y&L/4+=I;PLI&-H'-4PB4?.;UI\+EYXT_O,!4ATR?9O&W'?YA3M/MI#J,/
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MMVA?@-T(ZJ>Q%06-R\B-#/Q<0G:X]?0CV- %W-.0_O%_WA4>:<A_>)_O#^=
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M4=]"3<I7.>G6H;=VDO/]E5)I"PW?[+#K5BW14W%>]422MTJN1\U3-TJ'^*D
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M<;3C8Z;?]9Z "H[?1+2Q=@@2-I$92"205/7J:4J$I=M=Q<Z1S-M;65S>6D;
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MT+)QY1.:X2V\2F\D*I"5QZD5LVNJ3HI  QUQBDF%CI)FYSFH99!@5A2ZU/\
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M,<JAU8@=",U;75(G4,$?!'M3N!>HJE_:4?\ <?\ 2C^TH_[C_I1<+%VBJ?\
M:,?]Q_TI/[2C_N/^E%P/--2D2TOM1M[57EFFU+SGT&^L2YGD\P$20S+@@' <
M,2P7H<8P+YU6:WO-0FN;O7FUF*YN_P#0;1"Z"W57\HA&&S&T(0PY+G'/(KO/
M[3C_ .>;_I33JL0_Y9O^E*X6/++6_N[VX>W$MS<69?3)U#W,MT/,%XH<[W1<
M-C&Y5^4>U7;4:KJ!N$EU#584ATV^F002O'F5;N0(>.I"@8'0C&0:]%_M:+_G
MG)^E)_;$/_/.3]*+A8\SU/6[[^SY[J^U35+35&6P:QBA+I')&ZQ>8=H&TY=I
M Q/*X'3C/KM<K=6.C7FI&^GM[IG9TDDB$["*1TQL9H]VUB,#J.P]*V/[9A_Y
MYR?I1<+&E166^N0(&_=2G:I8XQ_C4*^)+=D5A;S889[?XT706-JBL7_A)+?_
M )X3?I_C1_PDEM_SPF_3_&BZ VJ*QO\ A)+;_GA-^G^-'_"26W_/&;]/\:+H
M#9HK&_X2*W_YXS?I_C3O^$AM_P#GC+^G^-%T!KT5D_V_!_SQE_3_ !I#XAM5
M^\CK]2!_6BX&O16(?%&G@X+'/H"#_6EC\364H)192 <9VT[@;5%9BZY;O]U7
M/T(_QIW]KP_\\Y/TI7 T:*S_ .UH?^>;_I2C5(B0/+?DX[4P+]%%% !115+4
MM2CTRW6:5'=6;;A,9Z?_ %J +M%<_P#\)9:?\^\_Z?XTO_"5VG_/O/\ D/\
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M69LT5C?\)';?\\9OT_QH_P"$DMO^>,WZ?XT7069LT5B_\));?\\9OT_QI/\
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M)?NXXP*!BQRJZ/(X:&)!EGE&T 5S]YXLC.Y=(L;C4,<>:%VQ_@>_X5/J4_\
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M].GX5J)"HC&% ^5>@J$1C[/[[S_*KR\Q_0**20R39Q3<5.1Q3,50AK_ZA_\
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M0Y6-C^E,!K.@D:,,"1W'2BO-;2]OSIES<"[=+B4@B0<E<GM7IVGQ,[@N0PC
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M9<\=#2>PUN<\M]>]TA/YT\:A=]X(C]&-1C5[1 #]MM?Q;&:>FLP-]ZYLR/\
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M;7WC&[O+JX1(3"5A=YMJ#!P5P>_?\Z=>>(+IC'I^LVT$UI=YC$EL74H^,KN
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M0I.!NQ@'\,DU6U"Z>71KO>GE20R %<Y].<^_6K5^Q_X22#K_ *EOY55UQO\
MB2W!_P!W^8J+:W&95A-^Z(]Q786UL;BT5M[#V"9K@;"3Y<>XKT;2& L Q.%
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M34OL;J+JUD9<?PCVJK-B+#C]Z?H.E1[6#G.<=L50N-=M1M>"VG=G8 +Z#_\
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MO_0$KTFO-?@I_P BC>?]?S?^@)7I5;QV,9;A7DFK7B7/BC68EX^SS!6)SR2
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M !/.BZ;"]G<^4'N@#*#PI.<GZ5U>EZG<Q7L>G:FB":1=T$\9^28#^1KD;J%
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MKY*_X4O]CZ9D'^S[7CI^Y7_"KM%%D%RI_9>G_P#/C;?]^A1_96G_ //C;?\
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"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>34
<FILENAME>g4i5nix4zlkt000019.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g4i5nix4zlkt000019.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" (# 9,# 2(  A$! Q$!_\0
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MD;^Z&/&:Y]]"\0^(]:UC7[S2?[,9M&DT^VM#,KO,[ G+$< 9..?:E?PGK/\
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M-CN758;=;,^8H\TJ/F[\8]\4 6;CQ[/I?C+3[.ZDEN;"?14N@EM;%Y)9BW4
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M7.R3:5S@D'@@'J#5VO$]/UG7+WPIX$2/6+FWFU&]GAN)T(W,N]AWXR!TKKO
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M_ ?AF^U<ZI<:5$]TSB1CN8*[#H64':3]12ZKX&\.:U?M?7VFJ]PZA7='9/,
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M@=^_.3^.*OT4 8_B&")[*-WB1F\^(;BO.-XXK3BMH("3%#'&3UVJ!FJ&O_\
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M_D6-/_ZY"O&:]F\+?\BQI_\ UR%;YQ_"CZG-PY_'GZ?JC8HHHKYX^P,/7O\
MD(Z'_P!?O_LC4:" =2UQR!O-[MW=\!%P*->_Y".A_P#7[_[(U+H/_'_KG_7\
M?_0%H VZ*** "L./_D>+C_L'I_Z&U;E8<?\ R/%Q_P!@]/\ T-J -RBBN0\7
MMJJW$/V'(7RWW>7N+>7CY\XXSTQWS0!U]%5--,QTZ SA!)M_@SC';KSG&.M6
MZ ,/Q8!_8RO@;DN82I[@^8O2MRL3Q9_R _\ MXA_]&+6WVH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH R+V!QKMC
M<*TS#9(I4$[!\O7'K7.VD2PQ1Q8:>QW1-=S>2R,3\WRL.IYVFNYHH Y%+*X^
MSVUW%)*)"SQP)@Y6/,FT\]/D;//<+6[HEU]JTY?W!B6/"*.<$8'3//?'U!K1
MHH PO$EJTD$<HNIHQYL:[%;Y?O#GZUHV=B]HS%[RXN-PQB5LXJOK_P#R#X_^
MOB+_ -#%:E 'B6O_ /(PZC_U\/\ S-9U:.O_ /(PZC_U\/\ S-9U?9TOX<?1
M'YGB/XLO5GKG@?\ Y%2U_P!Y_P#T(UT5<[X'_P"14M?]Y_\ T(UT5?*8K^//
MU9^@X#_=:?\ A7Y >E>$7G_']<?]=&_G7NYZ5X1>?\?UQ_UT;^=>EDV\_D>'
MQ)\-/Y_H05[-X6_Y%C3_ /KD*\9KV;PM_P BQI__ %R%;YQ_"CZG-PY_'GZ?
MJC8HHHKYX^P,/7O^0CH?_7[_ .R-2Z#_ ,?^N?\ 7\?_ $!:37O^0CH?_7[_
M .R-2Z#_ ,?^N?\ 7\?_ $!: -NBBB@ KGVFBMO&-W/,X2*/3D9F8\ !VKH*
MXCQ3SJ6HCL;& '_O\: -D>++%AE+:_=3T9;5L'W%+_PE=G_SYZC_ . K5N+]
MT8]*6@#"_P"$KL_^?/4?_ 5J/^$KL_\ GSU'_P !6K=HH Y;6M5M-5T"1K9F
MW1W, DC=2KH?,7J#74]JXCQ( -:O,<;H;0G'?]]7;T %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!EZ
M_P#\@^/_ *^(O_0Q6I67K_\ R#X_^OB+_P!#%:E 'B6O_P#(PZC_ -?#_P S
M6=6CK_\ R,.H_P#7P_\ ,UG5]G2_AQ]$?F>(_BR]6>N>!_\ D5+7_>?_ -"-
M=%7.^!_^14M?]Y__ $(UT5?*8K^//U9^@X#_ '6G_A7Y >E>$7G_ !_7'_71
MOYU[N>E>$7G_ !_7'_71OYUZ63;S^1X?$GPT_G^A!7LWA;_D6-/_ .N0KQFO
M9O"W_(L:?_UR%;YQ_"CZG-PY_'GZ?JC8HHHKYX^P,/7O^0CH?_7[_P"R-2Z#
M_P ?^N?]?Q_] 6DU[_D(Z'_U^_\ LC4N@_\ '_KG_7\?_0%H VZ*** "N(\4
M_P#(3U#_ *\H/_1QKMZXCQ3_ ,A/4/\ KR@_]'&@#MA]T?2EI!]T?2EH ***
M* .(\2_\AJZ_ZXVG_H^NW[5Q'B7_ )#5U_UQM/\ T?7;]J "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BLC4);N'
M5[0QSGRFCD_< <,P7()-8L5],6M8AJ4KP7"0O<3>9S$S;L@'^') &.U '8T5
MR:W&I"&"\2[+QAGAC!;/F ,X#$?Q9&UL_P"R?6MW2+V.]L5,9D/EX1C(<DG
M.<_0B@"+7_\ D'Q_]?$7_H8K4K"\21WC01M%/&D/FQC8R9.[<,'-:-E%?QLQ
MO+F.92/E"1[<4 >/:_\ \C#J/_7P_P#,UG5HZ_\ \C#J/_7P_P#,UG5]G2_A
MQ]$?F>(_BR]6>N>!_P#D5+7_ 'G_ /0C715SO@?_ )%2U_WG_P#0C715\IBO
MX\_5GZ#@/]UI_P"%?D!Z5X1>?\?UQ_UT;^=>[GI7A%Y_Q_7'_71OYUZ63;S^
M1X?$GPT_G^A!7LWA;_D6-/\ ^N0KQFO9O"W_ "+&G_\ 7(5OG'\*/J<W#G\>
M?I^J-BBBBOGC[ P]>_Y".A_]?O\ [(U+H/\ Q_ZY_P!?Q_\ 0%I->_Y".A_]
M?O\ [(U&@?\ '_KG_7\?_0%H W**** "N:U6VTF_O+EY=7@B>2)(67S%^78^
M[UZ]JZ6N9\2:;8A].?['!NDU",.?+&6SG.: .@M[JWND+6T\<R@X)C<, ?PJ
M:H;>UM[1"EO!'$I.2$4 $_A4U !1110!Q'B7_D-77_7&T_\ 1]=OVKB/$O\
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M?#_S-9U?9TOX<?1'YGB/XLO5GKG@?_D5+7_>?_T(UT5<[X'_ .14M?\ >?\
M]"-=%7RF*_CS]6?H. _W6G_A7Y >E>$7G_']<?\ 71OYU[N>E>$7G_']<?\
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M]JGTB_\ 036I678_\A[5/I%_Z": -2BBN9O_ !>UKJMQI]IHFHW\EOM\UK=
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH R]?_ .0?'_U\1?\
MH8K4K+U__D'Q_P#7Q%_Z&*U* ,#QEY:>&+RX>R@NGB3*+-'N"DD#/KQUX]*X
MS3+^[M/$5G;S3Z/O-TD?EVUDJ2NC+N#J<?=.<$UV/B,Z[%^_T^_TNUL4C_?&
M]1CSGU'&.E8&E7U]<:Y:/-K?A>X(8)BWC_?%?[JGM0!Z!67J'_(9TG_?D_\
M0#6I67J'_(9TG_?D_P#0#0!J4444 %%%% &4?^1I7_KS/_H8K5K*/_(TK_UY
MG_T,5JT %%%% !678_\ (>U3Z1?^@FM2LNQ_Y#VJ?2+_ -!- &I1110 4444
M 9>B_P#+_P#]?DG]*TR0!DG '4FLS1?^7_\ Z_)/Z5<O[7[;IUS:[RGG1-'N
M'5<C&: .+U.SDNM0O/$6B7VD7%L8_+N#>1F18]G7:1T]ZV_!=C%9:#OBO(+O
M[3,\[26XQ$"QY"CL!BL2PM_%VCZ:FE0:#I=Q;QKL\T3!!)VRRGJ3WK?\*:+/
MHFDR0W+1>?/.\[I",)&6_A7V% &X?NGZ5F>'O^0%;?0_S-:9^Z?I69X>_P"0
M%;?0_P S0!J4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 9>O_ /(/C_Z^(O\ T,5J5EZ__P @^/\ Z^(O_0Q6
MI0!GZXCOHMTL?V3=L_Y>QF+_ (%[5P.F6OVG7]-D-_X7B,,X<"P7$DG&-H^M
M=?XU4-X.U,&(RCRL[0V.XY_#K^%<SH$5Q_:%B[67AD+N&9+9AYGU7WH ]%K+
MU#_D,Z3_ +\G_H!K4K+U#_D,Z3_OR?\ H!H U**** "BBB@#*/\ R-*_]>9_
M]#%:M91_Y&E?^O,_^ABM6@ HHHH *R['_D/:I](O_036I678_P#(>U3Z1?\
MH)H U**** "BBB@#+T7_ )?_ /K\D_I6I67HO_+_ /\ 7Y)_2M2@ HHHH 0_
M=/TK,\/?\@*V^A_F:TS]T_2LSP]_R K;Z'^9H U**** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,O7_ /D'Q_\
M7Q%_Z&*U*R]?_P"0?'_U\1?^ABM2@#!\12W?D7$)T^TN+ V^6:XG$89]P^4^
MV.<US6F:9/9:O92W/A32;%3*%6=;P%E/^R.Y]JW/'&FZ;=Z#+=:C]IV6PR/L
M[X)R0,>AYQUKE; :'!XGLUALKZ>&*X2(7,MT71)R,@!>^.Y[4 >HUEZA_P A
MG2?]^3_T UJ5EZA_R&=)_P!^3_T T :E%%% !1110!E'_D:5_P"O,_\ H8K5
MK*/_ "-*_P#7F?\ T,5JT %%%% !678_\A[5/I%_Z":U*R['_D/:I](O_030
M!J4444 %%%% &7HO_+__ -?DG]*U*R]%_P"7_P#Z_)/Z5J4 %%%% "'[I^E9
MGA[_ ) 5M]#_ #-:9^Z?I69X>_Y 5M]#_,T :E%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &7K_\ R#X_^OB+
M_P!#%:E9>O\ _(/C_P"OB+_T,5J4 9/B:Y2T\-WT\EFMXB1_- QP&'O[=ZY+
M1%F:_P!+3^R-#BMX'+1&"[#,F[J0,\G@5T/B5]8D'V.ST&#4[.6/][YMR(^<
M],?E7-:?!#I.MZ?_ &GX.MM.\^81P7,-SYFV3MD4 >CUEZA_R&=)_P!^3_T
MUJ5EZA_R&=)_WY/_ $ T :E%%% !1110!E'_ )&E?^O,_P#H8K5K*/\ R-*_
M]>9_]#%:M !1110 5EV/_(>U3Z1?^@FM2LNQ_P"0]JGTB_\ 030!J4444 %%
M%% &7HO_ "__ /7Y)_2M2LO1?^7_ /Z_)/Z5J4 %%%% "'[I^E9GA[_D!6WT
M/\S6F?NGZ5F>'O\ D!6WT/\ ,T :E%%% !1110 4444 %%%% !1110 4444
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M4 %%%% !1110 4444 %%%% !1110 4444 9>O_\ (/C_ .OB+_T,5J5EZ_\
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:%%% !1110 4444 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>35
<FILENAME>g4i5nix4zlkt000038.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g4i5nix4zlkt000038.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" (% J # 2(  A$! Q$!_\0
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MDG,4K,S/(P+Y88Z@8Z =JF==2Y[=?R*C3:Y?(X/X;;-0\6>)-:D*K$6*AB<
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M*3IS70:G%]37HHHJ"@HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M)!*DB3+;[;@*H'[O>#RIQW!X)%=/64^73E+C?J%%%%04%%%% !1110 4444
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M;1=--LTB,6E:3;&I$<>3]U 22%%:M92M?0T5[:A1114C"BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KQCXV$_P!L^%O:Y;_T
M*.O9Z\8^-G_(:\+_ /7RW_H25MA_XB_KH9U?@/9(N8Q3Z9%_JQ3ZQ- HHHH
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MLHKD_P#A-Y/^A2\3?^ :?_%T?\)O)_T*7B;_ , T_P#BZ NCK**Y/_A-Y/\
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M?_%T?\)O)_T*7B;_ , T_P#BZ NCK**Y/_A-Y/\ H4O$W_@&G_Q='_";R?\
M0I>)O_ -/_BZ NCK**Y/_A-Y/^A2\3?^ :?_ !='_";R?]"EXF_\ T_^+H"Z
M.LHKD_\ A-Y/^A2\3?\ @&G_ ,71_P )O)_T*7B;_P  T_\ BZ NCK**Y/\
MX3>3_H4O$W_@&G_Q='_";R?]"EXF_P# -/\ XN@+HZRBN3_X3>3_ *%+Q-_X
M!I_\71_PF\G_ $*7B;_P#3_XN@+HZRBN3_X3>3_H4O$W_@&G_P 71_PF\G_0
MI>)O_ -/_BZ NCK**Y/_ (3>3_H4O$W_ (!I_P#%T?\ ";R?]"EXF_\  -/_
M (N@+HZRBN3_ .$WD_Z%+Q-_X!I_\71_PF\G_0I>)O\ P#3_ .+H"Z.LHK)T
M#Q!;^(+>YDAM;NUDM9S;S0W<81T<*K= 2.C ]:UJ "BBB@#E?&'_ "%/"?\
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M2_["$W_I-+3?'O\ R(VJ?[L7_HU*=X@_Y&/PE_V$)O\ TFEIOCW_ )$;5/\
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M$))%;WEW8PS))]Y8F=<JWY &N:OM+UG6?'OC[3])LM$FCG^S0SRZB"6@#0D
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MIW<G/U':BX6/9:*,D\D8)&2/2BJ$%%%% !1110 4444 %%%% !1110 4444
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MUMTCD),B+$H5R>N0!@_C35L;)(WC2SMEC=0CHL*@,HZ C'('I5'_ (0_4_\
MH==<_P"_=K_\:H_X0_4_^AUUS_OW:_\ QJCF0<K-!+.UC1TCM;=$D4*ZK$H#
M # !&.0!QS3X88K>)8H(HX8U^ZD:!5'T XK,_P"$/U/_ *'77/\ OW:__&J/
M^$/U/_H==<_[]VO_ ,:HYD'*S3BBBA79#$D:DEMJ*%&3U/'>F?9+4J5-K!M9
M_,(\I<%_[QX^][]:S_\ A#]3_P"AUUS_ +]VO_QJC_A#]3_Z'77/^_=K_P#&
MJ.9!RLTWBCD='DC1VC.Y&902I]0>Q^E,CM+6($16L$8*E2$B494G)' Z9[5G
M_P#"'ZG_ -#KKG_?NU_^-4?\(?J?_0ZZY_W[M?\ XU1S(.5E_P"Q6>W;]CM]
MH3R\>2N-G]WI]WVZ5, %4*H 4#  & !65_PA^I_]#KKG_?NU_P#C5'_"'ZG_
M -#KKG_?NU_^-4<R#E9K45D_\(?J?_0ZZY_W[M?_ (U1_P (?J?_ $.NN?\
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MF9A?9_&?_0S:9_X*#_\ 'J/L_C/_ *&;3/\ P4'_ ./5NT4<J#F9A?9_&?\
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M]#-IG_@H/_QZJ-AX_P!,U#Q&FD1VEZD<MQ):V]^\8$$\T8^=%.<\<\XYQ3M
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M/_!0?_CU'V?QG_T,VF?^"@__ !ZM"SU2WN]#M]78^1;36RW)\TC]VA7=R>G
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M<6AEAB,:N(W*@[23C/UKH:Y7P)_QXZS_ -AJ]_\ 1IKJJR-$%%%% '*^,/\
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MMW?VE'Y&[/\ K-CXQ[XS3CN)[%BBBBM3,**** "BBB@ HHHH **** "BBB@
MHHHH *X?Q/!J^C^,K;Q5IFE3:K'_ &;)836\&#)&2V]'"Y&X9X.*[BB@#Q=]
M-\2>*+'Q9?76A36.L7#V$T>GNI42)"<G:YX+'GCJ,8-:6LV^M>+;S7M77PYJ
M-A$OAZ6P@ANT FFF=MV%4$Y&.,UZM12L.YY?;RZIX:\76VH/X:UF_@?P]:6A
M^Q6X<I*O+*V2,8K;\5PWVN6?A*[MM,O$*ZQ;W,\$D>)+= &R7 Z8[UVM%%A7
M,[7;W4-/TF:ZTS3CJ-RA'^C+)L9U)^;:?[P'('>N2\%'4-"M+Z630=4BT^^U
M9?L=HZB2YA1Q\\LQ)SMW#.2216]XK\86'@^+3IM1CD,%[="V\Q",1<9W-GL/
M:JVI^/-,TF?7X[N"<+HT=N\CIAO.,WW%0>N>.:!G(:1H&NQZMI&AS:1<10:3
MK%SJ+:@S#R)HVW% IZ[B6P1CBHM!\-W0\16\NG^#)M"6VL[N+45EN28KXN,1
MHLF26&>=V./P%=K8>-H)8]0;5M*U#16L;?[5(+Q 5:+^\K+D$]L=:9I/C9M3
MU"UMIO#FLV$-XC/:W-Q"/+D &>=I.S(Z9I6079SG@/0YK;Q:M_9^%[GPW81:
M=]FNX)I"1<3[L@KR=P S\YJ+Q!8W=WJWQ*L8+>2>\O--LWM8T&6= I4A1_O
MUWGAOQ!!XE\.V^M0PO;0S[R$F8$J%8J<D<=LUS=MXUTZ^UFUU6#PQJ\EK*38
MP:TD.492W]T'=LW#[Q%%E8!(? OV32[C4;C4M5U75!I,MM;)>2!A!OCP510!
MR3Q6!IUOK>NZ%X0\-MX:U/3UTJXMI[V\OHQ'&!".B<Y))XZ5WOBCQ,/#,>GX
MTVYU">^N1:PP6[*K%R"1][CM62GQ'M!&ZW6D7]G>Q:A!83VDY4/$TWW'SG!7
M HT#4RO%ECXLCCT>\O@NN?8]9BNA#I5F4D2-5?=D$\]5%;.I7L_BOP1KX7P[
MJ=G=K9SQV\-_;JLCNT;#]V 3ZX_&NNAEBN%#031RH3@/&X89^HKE;7Q[97=Q
M90K8W"F[U*XTU267Y7A&2Q]CVI@+9QS#PCI/AZYTFZD>ZT@Q2LT0,4#K$!LD
MST)/08ZBL?PAI7B&U\(:/:6"V^CI;1>7J-K=V'[VXD'WF5@>XX#5U'AOQ-;>
M*-!@U.RC$<LZ.Z6DTR[QM9E&[&< E>N.]5_!>JZQJ^DW%QK$%O'(EW-%&89=
MV0KLN#\HQC&,]^O% ' ^&_"FHZ39>!;JWT.6#48?MG]H,4*/\ROL65NH4G;C
M/3-4?#_AW6X;^>9M#O;7SM N[:919B)#.<D)NR6D//#N23VKV^BBP7/&--\&
M:WI&K>!Y;6RG&G2/:W6HP;.;2YCCV,S?W0P(S[K3=%\':SX;L8/%UA97TFM0
M:C,+C3WSF:S=R"J+Z\[OQ->TT4<H7.-T@_:/BMX@N80ZPKIEG'(&7!$AW, 1
MZA:[*J]M8VMG+=2V\"QR74OG3L,YD? &3^  _"K%-""BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@#+\"?\>.L_P#8:O?_ $::ZJN5\"?\>.L_]AJ]_P#1
MIKJJQ9HM@HHHH&<KXP_Y"GA/_L+_ /MO/5*+_DI5U_V!(O\ T?)5WQA_R%/"
M?_87_P#;>>J*,J_$JZW,!_Q)(NIQ_P MY*N.Q$MSHJX3X@:7)J-YI[7/AB36
M]-C1\M8N4O+:7(P5.X90CJ/45W/F1_\ /1/^^A1YD?\ ST3_ +Z%6R3RRRT/
MQ78Z=X=URXL[N_NM(O;EETZ:</<BTE7:HWGAG4<X]ZU=;7Q'XQ\/S.OAZ73I
M-/OK>\L+>\G4277EG+*P'">W/-=]YD?_ #T3_OH4>9'_ ,]$_P"^A2L.YQEU
M=ZYXUTK5]&E\-W>C6=S8O&+F^E4-YQZ (N<KZFG:!KOB4G2](G\(75KY$:PW
MMY-.HA557&Z,C)?..GO78^9'_P ]$_[Z%'F1_P#/1/\ OH46$<1XS\.W^N^,
MO"SVL^H6=M;I=^??6+!7@W*NT;B#C=@CI5._\!6]G>^%;2UM+C4;1-5EN]2G
MNCYK.6CQOD/0Y( Z8KT/S(_^>B?]]"CS(_\ GHG_ 'T*+!<Y+P!I5WI&BZQ:
M7-H]JAU6[>UB9=H\EB-FT=E/.*XC1_#E_8P^#)-7\*WFH6UA97J7=J(%D9&=
MSLRK'!)]/Q[5[)YD?_/1/^^A1YD?_/1/^^A18=SAO!_@KRO#FAMKB7,=[82/
M+#;"Y;9$/,9HU90<$J#^'3I7=TWS(_\ GHG_ 'T*/,C_ .>B?]]"F(Y_QM_R
M+\'_ &$K'_TICH\?_P#(D:K](_\ T:E-\:NAT" !T)_M*QX##_GYCIWC_P#Y
M$C5?I'_Z-2DQH[BD;[C?2EI&^XWTK(T,#P/_ ,B+H?\ UYQ_^@UMM;1.<L@)
MK%\#_P#(BZ'_ -><?_H-;]5/XF3'X40?9(?[@_*@V<!&-@_*IZ*DHBB@CA&$
M4"I:** "BBB@ K!\3+:%]%^TE=PU*,P;B1^\V/C'OC-;U<[XMDT^&/2)]1GA
M@2+48WCDFD"*'V/CD\=">M-;B>Q<HK-_X2+0O^@YI?\ X&Q__%4?\)%H7_0<
MTO\ \#8__BJUN9FE16;_ ,)%H7_0<TO_ ,#8_P#XJC_A(M"_Z#FE_P#@;'_\
M51<#2HK-_P"$BT+_ *#FE_\ @;'_ /%4?\)%H7_0<TO_ ,#8_P#XJBX&E16;
M_P )%H7_ $'-+_\  V/_ .*H_P"$BT+_ *#FE_\ @;'_ /%47 TJ*S?^$BT+
M_H.:7_X&Q_\ Q5'_  D6A?\ 0<TO_P #8_\ XJBX&E16;_PD6A?]!S2__ V/
M_P"*H_X2+0O^@YI?_@;'_P#%47 TJ*S?^$BT+_H.:7_X&Q__ !5'_"1:%_T'
M-+_\#8__ (JBX&E16;_PD6A?]!S2_P#P-C_^*H_X2+0O^@YI?_@;'_\ %47
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MO^@YI?\ X&Q__%47 TJ*S?\ A(M"_P"@YI?_ (&Q_P#Q5'_"1:%_T'-+_P#
MV/\ ^*HN!I45F_\ "1:%_P!!S2__  -C_P#BJ/\ A(M"_P"@YI?_ (&Q_P#Q
M5%P-*BLW_A(M"_Z#FE_^!L?_ ,51_P )%H7_ $'-+_\  V/_ .*HN!I45F_\
M)%H7_0<TO_P-C_\ BJ/^$BT+_H.:7_X&Q_\ Q5%P-*BLW_A(M"_Z#FE_^!L?
M_P 51_PD6A?]!S2__ V/_P"*HN!I45F_\)%H7_0<TO\ \#8__BJ/^$BT+_H.
M:7_X&Q__ !5%P-*BLW_A(M"_Z#FE_P#@;'_\51_PD6A?]!S2_P#P-C_^*HN
MWP)_QXZS_P!AJ]_]&FNJKDOA]-%<:7JTT,B2Q/K-XR.C!E8>:>01U%=;6+-5
ML%%%% '*^,/^0IX3_P"PO_[;STNI^'=$UJ9)M4TFSO9(UV(\\(<JN<X!/;-)
MXP_Y"GA/_L+_ /MO/63.FJ:MXOU6Q@U^\TZVLK:U=([:*%MS2>86)+HQ_A%7
M'8B6Y9_X03PC_P!"SI7_ (#+1_P@GA'_ *%G2O\ P&6D_P"$<U?_ *'36/\
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MK_P&6D_X1S5_^ATUC_OQ:_\ QJC_ (1S5_\ H=-8_P"_%K_\:H 7_A!/"/\
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MA7-?\(!X1_Z%^R_)O\:/^$ \(_\ 0OV7Y-_C1R,.8Z7_ (1K0?\ H":;_P"
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M^$ \(_\ 0OV7Y-_C1R,.8Z7_ (1K0?\ H":;_P" B?X4?\(UH/\ T!--_P#
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M%>D<2!5'X"I:X[P#:6^GOXELK2(0VL&KLL42D[4'D0G STY)/XUV-24%%%%
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MR3_T8M.^(/\ R)6K?]L__1J4WQ__ ,B%K'_7)/\ T8M.^(/_ ")6K?\ ;/\
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M;I;QI _4 ; O!Z]S755B^+])N==\'ZMI5H8Q<7=N8XS(V%SD=3^%6R4<??\
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M_P#&Z/\ A.M#]-4_\%-S_P#&ZZC$WH_ZT8F]'_6@#E_^$ZT/TU3_ ,%-S_\
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M / FU_\ CM']MZY_T).K_P#@3:__ !VNTHHYF'*CB_[;US_H2=7_ / FU_\
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M_P#T"?#_ /X,9O\ XS1_:GC?_H$^'_\ P8S?_&:++L_O_P" %WW,#[-\+_\
MGXF_\#+S_P"*H^S?"_\ Y^)O_ R\_P#BJW_[4\;_ /0)\/\ _@QF_P#C-']J
M>-_^@3X?_P#!C-_\9HLNS^__ ( 7?<P/LWPO_P"?B;_P,O/_ (JC[-\+_P#G
MXF_\#+S_ .*K?_M3QO\ ] GP_P#^#&;_ .,T?VIXW_Z!/A__ ,&,W_QFBR[/
M[_\ @!=]S ^S?"__ )^)O_ R\_\ BJ/LWPO_ .?B;_P,O/\ XJM_^U/&_P#T
M"?#_ /X,9O\ XS1_:GC?_H$^'_\ P8S?_&:++L_O_P" %WW,#[-\+_\ GXF_
M\#+S_P"*H^S?"_\ Y^)O_ R\_P#BJW_[4\;_ /0)\/\ _@QF_P#C-']J>-_^
M@3X?_P#!C-_\9HLNS^__ ( 7?<P/LWPO_P"?B;_P,O/_ (JC[+\+<J6E=P&#
M;9+F[920<C(+8/([UO\ ]J>-_P#H$^'_ /P8S?\ QFJNI^)/&6DZ3>:E/H^A
M-#:0//(L>H2[BJ@D@9BZ\4679_?_ , +ON:W_"?>%_\ H+)_WZ?_ .)I&\?>
M%RI']K)T_P">3_\ Q-=%#)YL$<F,;U#8],BG-]T_2E>/;\?^ /WC@O"'C7P[
M9^#](MKC4T2:*UC5U\MS@@<CI6U_PGWA?_H+)_WZ?_XFI? __(BZ'_UYQ_\
MH-;].;CS/3^ON%'FLCF_^$^\+_\ 063_ +]/_P#$T?\ "?>%_P#H+)_WZ?\
M^)KI**5X]OQ_X _>.;_X3[PO_P!!9/\ OT__ ,31_P )]X7_ .@LG_?I_P#X
MFNDHHO'M^/\ P ]XYO\ X3[PO_T%D_[]/_\ $T?\)]X7_P"@LG_?I_\ XFND
MHHO'M^/_   ]XYO_ (3[PO\ ]!9/^_3_ /Q-12^/?#9,>R^CE ?+'RW'EC!^
M;E?P_&NIJK>7$<#VH>(.99Q&I_ND@G/Z?K0N7M^/_ #WNYB_\)]X7_Z"R?\
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M/_\ $UTE%%X]OQ_X >\<W_PGWA?_ *"R?]^G_P#B:/\ A/O"_P#T%D_[]/\
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M]X7_ .@LG_?I_P#XFC_A/O"__063_OT__P 372447CV_'_@![QS?_"?>%_\
MH+)_WZ?_ .)H_P"$^\+_ /063_OT_P#\372447CV_'_@![QS?_"?>%_^@LG_
M 'Z?_P")H_X3[PO_ -!9/^_3_P#Q-=)11>/;\?\ @![QS?\ PGWA?_H+)_WZ
M?_XFC_A/O"__ $%D_P"_3_\ Q-=)11>/;\?^ 'O'-_\ "?>%_P#H+)_WZ?\
M^)H_X3[PO_T%D_[]/_\ $UTE%%X]OQ_X >\<W_PGWA?_ *"R?]^G_P#B:/\
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M+\0?^">X_P#B*/\ A8&F_P#0+\0?^">X_P#B*ULGUHR?6CD#F,G_ (6!IO\
MT"_$'_@GN/\ XBC_ (6!IO\ T"_$'_@GN/\ XBM;)]:,GUHY YC)_P"%@:;_
M - OQ!_X)[C_ .(H_P"%@:;_ - OQ!_X)[C_ .(K6R?6C)]:.0.8R?\ A8&F
M_P#0+\0?^">X_P#B*/\ A8&F_P#0+\0?^">X_P#B*ULGUHR?6CD#F,G_ (6!
MIO\ T"_$'_@GN/\ XBC_ (6!IO\ T"_$'_@GN/\ XBM;)]:,GUHY YC)_P"%
M@:;_ - OQ!_X)[C_ .(H_P"%@:;_ - OQ!_X)[C_ .(K6R?6C)]:.0.8R?\
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M<?\ Q%:$%W!="0V]Q',(W,;^6X;8XZJ<="/2ILGWI\@<QD_\+ TW_H%^(/\
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MWJV.,U6TJS\,:==WFE:1!I=M<LN;JTM@BN5QU=1SC#=_6FE8&S)^%VGV5IX
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MXX_Z!/A[_P &,W_QFC'CC_H$^'O_  8S?_&:KF1-F0?\(SJ/_0YZ_P#^2_\
M\:H_X1G4?^ASU_\ \E__ (U4^/''_0)\/?\ @QF_^,T8\<?] GP]_P"#&;_X
MS1S(+,@_X1G4?^ASU_\ \E__ (U1_P (SJ/_ $.>O_\ DO\ _&JGQXX_Z!/A
M[_P8S?\ QFC'CC_H$^'O_!C-_P#&:.9!9D'_  C.H_\ 0YZ__P"2_P#\:H_X
M1G4?^ASU_P#\E_\ XU4^/''_ $"?#W_@QF_^,T8\<?\ 0)\/?^#&;_XS1S(+
M,@_X1G4?^ASU_P#\E_\ XU1_PC.H_P#0YZ__ .2__P :J?'CC_H$^'O_  8S
M?_&:,>./^@3X>_\ !C-_\9HYD%F0?\(SJ/\ T.>O_P#DO_\ &J/^$9U'_H<]
M?_\ )?\ ^-5/CQQ_T"?#W_@QF_\ C-&/''_0)\/?^#&;_P",T<R"S(/^$9U'
M_H<]?_\ )?\ ^-5!KFF0Z+\+-5TNV>1X;729XT:0@L1L;DX[U>QXX_Z!/A[_
M ,&,W_QFJ6L:;XVUC1+_ $QM.\/PK>6[P&07\S%-RD9QY7.,T<R"S.WL_P#C
MQM_^N2_RJ9ON-]*9!&8K>*,G)1 I(]A3V^Z?I69H8/@?_D1=#_Z\X_\ T&M^
ML7PC:SV7@_2+6ZB:*>*U1)(VZJ0.0:VJJ?Q,4=D%%%%2,**** "BBB@#D(O
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M^_Z'/Q#^=O\ _&:/^$-OO^AS\0_G;_\ QFNKHHNPLCE/^$-OO^AS\0_G;_\
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M1_PL/P__ -13_P %%U_\;H ZJBN5_P"%A^'_ /J*?^"BZ_\ C='_  L/P_\
M]13_ ,%%U_\ &Z .JHKE?^%A^'_^HI_X*+K_ .-T?\+#\/\ _44_\%%U_P#&
MZ .JHKE?^%A^'_\ J*?^"BZ_^-T?\+#\/_\ 44_\%%U_\;H ZJBN5_X6'X?_
M .HI_P""BZ_^-T?\+#\/_P#44_\ !1=?_&Z .JHKE?\ A8?A_P#ZBG_@HNO_
M (W1_P +#\/_ /44_P#!1=?_ !N@#JJJWB6[O:^>Y4K.#%@_>?!P/RS7/_\
M"P_#_P#U%/\ P477_P ;J&X\<>'+IH"[:JODRB5?^)5<C) (QS'SUZ"FA'84
M5RO_  L/P_\ ]13_ ,%%U_\ &Z/^%A^'_P#J*?\ @HNO_C=(9U5%<K_PL/P_
M_P!13_P477_QNC_A8?A__J*?^"BZ_P#C= '545RO_"P_#_\ U%/_  477_QN
MC_A8?A__ *BG_@HNO_C= '545RO_  L/P_\ ]13_ ,%%U_\ &Z/^%A^'_P#J
M*?\ @HNO_C= '545RO\ PL/P_P#]13_P477_ ,;H_P"%A^'_ /J*?^"BZ_\
MC= '545RO_"P_#__ %%/_!1=?_&Z/^%A^'_^HI_X*+K_ .-T =517*_\+#\/
M_P#44_\ !1=?_&Z/^%A^'_\ J*?^"BZ_^-T =517*_\ "P_#_P#U%/\ P477
M_P ;H_X6'X?_ .HI_P""BZ_^-T =517*_P#"P_#_ /U%/_!1=?\ QNC_ (6'
MX?\ ^HI_X*+K_P"-T =516?HVMV&OV37>G2O)$LC1-OB:-E=>"I5@""/<5H4
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MM_>/YTE% "[V_O'\Z-[?WC^=)10!E>!O]5X@_P"PY=_^A"NKKE/ W^I\0?\
M8<N__0A75UB:A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M+'E>#QCO76?$4#[1X/X_YF*VQ^347'8L^"[GP=+-J</A6TL[=[:;RI_(0 R
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MX@_[#EW_ .A"NKK$U"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M3_P$M?\ XW1_PB6M_P#0[:I_X"6O_P ;HYT'*S7HK(_X1+6_^AVU3_P$M?\
MXW1_PB6M_P#0[:I_X"6O_P ;HYT'*S7HK(_X1+6_^AVU3_P$M?\ XW1_PB6M
M_P#0[:I_X"6O_P ;HYT'*S7HK(_X1+6_^AVU3_P$M?\ XW1_PB6M_P#0[:I_
MX"6O_P ;HYT'*S7HK(_X1+6_^AVU3_P$M?\ XW1_PB6M_P#0[:I_X"6O_P ;
MHYT'*QW@;_4^(/\ L.7?_H0KJZR/#NA+X?L9X/MD]Y+<7,ES-/,%#.[G)X4
M#\!6O6984444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 45PGB;2=/UOX
MA:=::G:1W=NFE7$JQ2YVA_-B&[&>N"1^-._X0'PC_P!"]8_]\G_&J4;DN5CN
M:J7MJ]R]J58+Y,XE;/< $8_6N1_X0'PC_P!"]8_]\G_&FOX#\-J4^S:+9Q*6
M F #?/'W7KZX_*FHL.9'=T5PW_" ^$?^A>L?^^3_ (T?\(#X1_Z%ZQ_[Y/\
MC2Y6',CN:*X;_A ?"/\ T+UC_P!\G_&C_A ?"/\ T+UC_P!\G_&CE8<R.YHK
MAO\ A ?"/_0O6/\ WR?\:/\ A ?"/_0O6/\ WR?\:.5AS([FBN&_X0'PC_T+
MUC_WR?\ &C_A ?"/_0O6/_?)_P :.5AS([FBN&_X0'PC_P!"]8_]\G_&C_A
M?"/_ $+UC_WR?\:.5AS([FBN&_X0'PC_ -"]8_\ ?)_QH_X0'PC_ -"]8_\
M?)_QHY6',CN:*X;_ (0'PC_T+UC_ -\G_&C_ (0'PC_T+UC_ -\G_&CE8<R.
MYHKAO^$!\(_]"]8_]\G_ !H_X0'PC_T+UC_WR?\ &CE8<R.YHKAO^$!\(_\
M0O6/_?)_QH_X0'PC_P!"]8_]\G_&CE8<R.YHKAO^$!\(_P#0O6/_ 'R?\:/^
M$!\(_P#0O6/_ 'R?\:.5AS([FBN&_P"$!\(_]"]8_P#?)_QH_P"$!\(_]"]8
M_P#?)_QHY6',CN:*X;_A ?"/_0O6/_?)_P :/^$!\(_]"]8_]\G_ !HY6',C
MN:*X;_A ?"/_ $+UC_WR?\:/^$!\(_\ 0O6/_?)_QHY6',CN:*X;_A ?"/\
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M;W_T<U=56+-0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M"3JW_@5:_P#QVC^VM=_Z$G5O_ JU_P#CM=I11S,.5'%_VUKO_0DZM_X%6O\
M\=H_MK7?^A)U;_P*M?\ X[7:44<S#E1Q?]M:[_T).K?^!5K_ /':/[:UW_H2
M=6_\"K7_ ..UVE%',PY4<7_;6N_]"3JW_@5:_P#QVC^VM=_Z$G5O_ JU_P#C
MM=I11S,.5'%_VUKO_0DZM_X%6O\ \=H_MK7?^A)U;_P*M?\ X[7:44<S#E1Q
M?]M:[_T).K?^!5K_ /':/[:UW_H2=6_\"K7_ ..UVE%',PY4<7_;6N_]"3JW
M_@5:_P#QVE_MK7?^A)U;_P "K7_X[79T4<S#E1S?@FROK/1[MM0LWLYKG4+F
MY$#NK,BO(67)4D9P>QKI***DH**** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HJ*YN([2UFN9CMBA0R.<9P ,FJ>C:[I7B&P6^TB^@O+=OXHFS@^A
M'4'V- &C1110 4444 %<%\3-)\2ZQ:6*>'-<DTJ2%V:9DD=/,! P/E],'KZU
MWM-:-7^\ : /GO\ X0_XG_\ 0^77_@5/_A1_PA_Q/_Z'RZ_\"I_\*^@?L\7]
MP?E1]GB_N#\J /G[_A#_ (G_ /0^77_@5/\ X4?\(?\ $_\ Z'RZ_P# J?\
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M@$E5 '))H^SQ?W!^5 'S]_PA_P 3_P#H?+K_ ,"I_P#"C_A#_B?_ -#Y=?\
M@5/_ (5] _9XO[@_*C[/%_<'Y4 ?/W_"'_$__H?+K_P*G_PH_P"$/^)__0^7
M7_@5/_A7T#]GB_N#\J/L\7]P?E0!\_?\(?\ $_\ Z'RZ_P# J?\ PH_X0_XG
M_P#0^77_ (%3_P"%?0/V>+^X/RH^SQ?W!^5 'S]_PA_Q/_Z'RZ_\"I_\*/\
MA#_B?_T/EU_X%3_X5] _9XO[@_*C[/%_<'Y4 ?/W_"'_ !/_ .A\NO\ P*G_
M ,*/^$/^)_\ T/EU_P"!4_\ A7T T4" %PBY.!GC)I?L\7]P?E0!\_?\(?\
M$_\ Z'RZ_P# J?\ PH_X0_XG_P#0^77_ (%3_P"%?0/V>+^X/RH^SQ?W!^5
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MK_P*G_PH_P"$/^)__0^77_@5/_A7T#]GB_N#\J/L\7]P?E0!\_?\(?\ $_\
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M5E>9I)63YV>!8"3A1_"@/'?\JYI_ACJ%OKMBNGZFD>A0M9/+"[-YDC6QR"P
MPQ("C.5 ]"0* .G\6[]:^'^KK:V%[-)-:S)';A&BE+ ,H^4D$C(SCN,<'-<_
M>_$:/PN?L-SH\ZP6=Q:VLS-/ODC26)I&<CG.P+R,GCOQ7=Z7;W=K8+%>W1NI
MP[DRD '!8E1P!T! Z=JR+GP5IMUKTFKRR7!FDN8KEH\J4)2)H@,8Z%7.1ZT
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M8-@;F*HB*%.XEL#J,DX&2*EE^'^C/K]IJ\?FPR6T<4?DH$V.(L^7G*EAC/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
&%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>36
<FILENAME>g4i5nix4zlkt000014.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g4i5nix4zlkt000014.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" && J # 2(  A$! Q$!_\0
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M@S+&A<A1DD 9XK*\,>(X/%&D_P!H6]O/ @D:/9, #D8YX[<T[.UPN;-%%%(
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MKVKHZ;36XD[A1112&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M74.H3#Q6^J 6C-]GFBV2PR>N#U';BLG3O&VKV'PL;4I+EKG49;TVT4LV&VY
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M_P!N^Q^=L.[/<[L_CTZ4*E)MKL',K7/4:**\T\/7$FM^-/$?B96+6]C$UM:
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MCR;R&[==A3E<C.,>O>NCMKS4O&_P*CU6^U2\MYK>TN&N/L[!#=&,,%W,.<<
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M9TMO"VKSR01W"164SM#)]V0!"2I]CTK4K+\23I;>%M7N)(([A(K*9VAD^[(
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M)?D]<_2MGQ'_ ,>MC_V$+;_T:M &Q1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %8'B^WAN]'C@FO+6U#3HVZY?:K8.2/KBM^FO&D@PZ*P'J,T#3
ML[G'M_8,7B&*_LM1TBWMUM9(7CCD52S,1@X'%9L"(VA0Z'<Z]HL=BK9EDAN-
MTDB[MV.< 5W_ -F@_P">,?\ WP*/LT'_ #QC_P"^!07SG-Z_>Z1JFBM8VVLZ
M=&VY"I>X& %8'M["L^XCTH^*[?5;?7=-2V#^;-"9QDR;2NY>W(QGZ5VGV:#_
M )XQ_P#? H^S0?\ /&/_ +X% E*QP%K:V5B8;NUU[24U"*ZDD+?:!LDA<Y*-
MWS6UKUUHVLI9H-;LT2&X620"[VY4=0,'KTP>U=+]F@_YXQ_]\"C[-!_SQC_[
MX% ^?6YS?AZ[T;1K!XI-;LY)I)6D=OM88$DG&,GTQGU-8)L[1IBK:[HY!O/M
M/VWS_P#2,9SM]/;KCVKT+[-!_P \8_\ O@4?9H/^>,?_ 'P* Y];F9+*@\86
M<>>6L)B/?YXZV*YO4F,7C;2Y<':MI,&QV!>,5T>Y?[P_.@AK1,6BF&1 0"PR
M>E'F)_>H$/HJ,S1@9+"F_:H<9W'_ +Y- [,FHJL;Z+;D+(?8(<U6;49CNV6Q
M'INS2N-1;-*BL*22YDE\QFDR#E0H( IZ7-XC$AG.>S+D47*]FS:KCOB5JTFB
M^%X;J*VM+AFOK>/9=1"1 &<#.#W'8]JWO[0N<_ZD?]\FN.^(FM7FF^&H[OR8
M)B;Z",1W$(= &;&<'N.QHN+D9Z)TK-O-1&#%;$%^AD[+]/4U3F$SNP?S&'3G
M/2F>6X& C?\ ?-)LN,$MR-4"Y(R2>I)R33J=L?\ N-^5&Q_[C?E2-+EK29O+
MGDMC]U_WB?7^(?UK7KG=DJNKH&5T.5.WI6K!J <!9HWB?Z$J?H::9E..MT-T
MO1=-T5+A-.M([<7$S7$VS^.1NK$^IHT[1=.TF2[DL+2.![R8SW#+G,DAZL2:
MN>:G]ZE$B,,A@1]:HR,34M TE/#FL6@L(3!=K+/<(RY$LA&2S9ZG('TP/2I_
M#.FV6E>&["UL+:.W@$*MLC&!DC)/N23UJSJK+_9%[R/^/>3_ -!-+I/_ "!K
M'_KWC_\ 010!<HHHH **** "BBB@ HHHH **** "BBB@ I#T-+2'[I^E '-^
M S_Q25HOH/Y@&NEKE? #^;X0LIXL&.1. W!!7Y3_ "KI\R?W5_[Z_P#K4D]"
MI6;NA]%0YN,GY8@.W)I&^UD?*81[G)IBL3TUY$B0O(P51U).*KLEZ>DL2\]E
MJJ^FSR',DP<@Y&XGBD-)=6,N]2,P\JV+JO\ %(1CCV^OK5( #I5_^RY?^>B?
MK1_9<O\ ST3]:5F:J45L4::ZAT9&Z,,&M#^RY/\ GHE']ER_\]$_6E9CYT2V
M%_Y@$$Y F X;LX]?K[5'XDG2V\+:O<201W"164SM#)]V0!"2I]CTI#I4A&"Z
M$?C5+7TN+'POJD\ACN(8+*9V@ER5E4(25;O@]*I7,Y*+U3)?!=U'>^"=$NH;
M6*TBFLHG6WBSLC!4?*,]A6[7,>#9KB]\&:+=VT=O:0S64;I;(IV1 J,*.^!7
M09NL?=A)QZD<TR+$]%0_Z3Z1?F:<IFQ\ZIGV8T!8DHIN7_NK^=&7_NK^= CF
MY/ /AZ;5DU&>VGF>.;[0D,MU(\"2YSO$9;:#GVK2/A[3'OM1O);?SI]0A%O<
M&5BV8@"-@!^ZO)) ZDYK2R_]U?SHR_\ =7\Z ,CP_P"%]*\,031:9#(GG%3(
M\LS2NP484;F). . .U+XC_X];'_L(6W_ *-6M;+_ -U?SK'\1;OLMCD#_D(6
MW?\ Z:K0!M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !117+^/I
M'B\.(Z%]PNX>$."?FZ5,Y<L6Q-V5SJ**XF2_GO/'5J9+2ZLPNG3_ +N<K\W(
MY&UB*Q;>TBLOAY!K]O++!J<3;EE$K?O#YFW:P)P016;K;V1/.>H45R_C9W?P
M;(26C:1H@VTD$989K"MKRY36-"TB\E8W>GWKQ.=Q_>QF,E&]\C^5.57EE:P.
M=G8]%HKRW0I7U#4[;2KZ62*P-[<3(=Y_TF16X0GL!UQWKJ?'=ZUMHL5NEPD+
M7,Z1DLC,=NX$XV^GZC-)5;Q<NP*=U<ZFBN4\$W4M['JMS+<QS^9>,04C91P,
M9&X]" ,#MWJAJFD6$_C'3M-L8/+D5C>7DB2-D*#PO7N:?M/=4DMPYM+G2R_\
MC7;?]>,W_H<=:F!Z"L:>XC3QI96[$B22PG*C'7#QYK:K4L3 ]!2T44 %%%%
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M3T1OES71^(_^/6Q_["%M_P"C5H V**** "BBB@ HHHH **** "BBB@ HHHH
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M (];'_L(6W_HU:U/(B_YYK^59'B&*-;:Q*HH/]H6W0?]-5H VZ*** "BBB@
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M<C. #DUZIX4>&3PII9@U#^T$%N@^U;U;S#CDY7CK^5<QXF\"R:SHWB6XU#4
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MQ#+N%^II-I*[$VEN/K,O[CS6:V3&P ;V'?VHN[LS'RXB1'_$W0GV%5@ !@#
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M\P'S.>3Q^)K=\1_\>MC_ -A"V_\ 1JT ;%%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 5#<0-.@59Y8<'.8\9/Y@U-12:35F!1_L^7_H)7?YI_\
M$T?V?+_T$KO\T_\ B:O45'LH_P!-D\J*/]GR_P#02N_S3_XFC^SY?^@E=_FG
M_P 35ZBCV4?Z;#E11_L^7_H)7?YI_P#$T?V?+_T$KO\ -/\ XFKU%'LH_P!-
MARHH_P!GR_\ 02N_S3_XFC^SY?\ H)7?YI_\35ZBCV4?Z;#E1SVH(Y\8Z:ZJ
M6"6DI8@=M\=;WF#) #''M6;)_P C7:_]>,W_ *''6K34+2;3W$HV;:ZC-_\
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MANO#^GSV\R30O;IM>-@RGY1T(JRS0HHJIJ=TUCI5W=HH9H86D"MT) S32N[
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MI716D_Y&NU_Z\9O_ $..M6LJ3_D:[7_KQF_]#CK5KH.<**** "BBB@ HHHH
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M3?\ H'VO_?E?\*/[(TW_ *!]K_WY7_"O2_M!?RGG?4'_ #'C6Y?[P_.C<O\
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M$'))QU-8 \*Z3X7L($TQ9LS:A9AWGG:5MJ2 (H+$X51D =J .THHHH ****
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MJ]R'I^K"BBBJ, HHHH *SM9U$Z=9;XP&GD81Q*?[Q[_0#)_"I=2U&+3;<22
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MJMY+']G=HBT,$$<@=(=N<E6(R_J3["M)O FFNS,TUR"7=@$E8 !F) Z]LX_
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M:V*-:1XM5D)$/RCY<GDXZ5L?\)3H.UF_M6UVKG<?,&!CKFG:5IJ>'/#-GIT
M>Y6PMEA3@!I-JX'MDXHTHV&JZ(9HK4);WV]I8F_B+$A\_7FF9C#XJT$==6M!
M@ G,@Z'H:8WB_P .(NY]:L54+NR9@!CU^E7;C1[&Y1UD@'SQI$2#@[4;<H_
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MUJHM9)+F.REDF0RPA5VQY.#GJ#C;M/US746T"VMK%;JS,L:!0S8R<>N*EHH
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M;0K;5[%)TMK@$HL\>QQ@D'(^HH U**** "BBB@ HHHH **** "BBB@ HHHH
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M&6C)QR><8K(_M+4GAT.0WM^VDR:.9-3DBD?S1;&\^9U]\8!/4)NQ0!]!4A(
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M^<$/V&/IGFM_X>>+M5\1WUQ%=W5I?0"TBN&EM;9XA:S,3NMVW$[F7'7@^HH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
J4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>37
<FILENAME>g4i5nix4zlkt000028.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g4i5nix4zlkt000028.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %1 J # 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M]3W-/HI.3:LQI):E1],L9-4CU-[6)KZ.,Q).5^=4/) /I5L\C%%%*XS'\/\
MAG3?#-M/!IL<BBXE,TK2.79F/N::OA;2T\5-XD1)5U%XO*=A(0K+C'*],X _
M*MJBJYY7;ON+E6QS>D>!-!T/79]9L;9TNYM^2TA*KN.3M':H]<^'_A[7]0.H
M7=M+'>,,/-;S-$S_ %P>:ZBBG[2=[WU%R1M:QS$O@#P_+X9'A\V\PL!-YY F
M;<7]2V<U-KO@K0_$<-I'J%LY:T&V&6.0HZCTR.W KH:*/:3O>X<D=K'-Z5X%
MT#1+Z6[T^T:&26V^S.!(2"I.2>?XCZTZS\%:-8^%[GP[!%,-/N"QD4RDL=V,
M_-U["NBHH=2;W8<D>QSU[X*T:_\ #-KX>GBF.GVI0Q*LI##;G&3U/4U%KG@'
MP_XANXKN]MI1<1H(_-AF:-F4= <'FNFHH52:V8.$7T.7MOA_X>L]+U33;:VD
MBM-2V^?&LK<8Z;?2JJ_"[PFE[#<C3V/DX(B,K>6S ?>*YP3QSZUV5%/VL^X<
MD>P5Q$_PI\,SW5Q<%;^.2>1I)/+NW4$DY/ /O7;T5,9RC\+L-Q3W/,_&_@VY
MU[7_  QI]KISMIUFH6YO6D!Q&"/D.3DG"_K77^(/"&C^)H[==1@??;9\F2&1
MHW0'J 1VX%;M%4ZLK*W0E4XZ^9R__"OO#H\-S:"EHZ64[B24K*V]V!R"6Z]J
M-7^'WA_6A:&ZMYEDM8%MXY(IV1C&.BD@\BNHHI>TG>]Q\D>Q1TC1[#0M-CT_
M3;=8+:/.$'.2>I)/))K)U_P+H'B2\2\O[5UNU7;Y\$K1N1Z$CK7244E.2?,G
MJ-Q35K&-I/A71]$TB;3-/M!#;S@B4AB6?(P26/).*FT#0;'PWI,>F:<KK;1D
MLH=RQR3D\FM.BARD]V"BEL9&K>&].UK4=-OKU)&GTZ3S;<JY4!N.H[]!4-WX
M0T:^\3VWB&>W9M0ME 1@Y"\9P2.A(S6[10IR6S#E3,=?#.F+XI;Q&(Y/[1:'
MR"WF';MX_AZ9XK&O_AAX7O[^6\:TG@DF8M*MO</&KD]20#BNQHIJI-;,3A%[
MHYZY\%:)<KHZM;R*FCL#:*DK +C'7UZ#K5J?PUIMQXFMO$$B2'4+:(Q1L'(7
M:<]5Z=S6O12YY=PY5V.:A\":'!IVKV,<,P@U9]]T#,<DYSP>U2WO@O1K_P +
MV_AV>*4Z?;[?+592&&WI\W6N@HI^TGO<.2/8\D\6>$]2G\:OJ%SX9&OZ3]F2
M"WABN1"T> /O'@DYS^=7O!O@*Z_L76['7K=K33=2D5H=.2Y+F!5.?O>O0?AS
M7IM%:/$2Y>4A4H\USG]1\%:%JNB6>DWEGYEO9H$MVWD/&  .&'/04GA_P3H7
MAF>2YT^U;[3(-K3S2&1\>F3T%=#16?M)VM?0OEC>]C!TKPAI&C66I6EG%*L.
MHLS7 :0DDL"#CTZU&/!.BCPB?# CF_LT\[?-._[V[[W7K7144>TEO<.6/8YG
M5O 6@:U;6,-W;RYL8A#!+',R2*@& -PZU-H'@O1/#-[/=Z5;O#)/&L;@R%@0
M/KW)Y)KH**/:3MRWT#DC>]BKJ.FV6KV$MCJ%M'<6THP\;C@_X'WKF-/^&'A?
M3;^&[AM9W>!Q)"DMP[)&P.00I..*[&BE&<HJR8.,6[M'(7?PQ\+7NISWTMC)
MOG8O+&D[+&S'N5!QG/-6)? &@S:/IFE/#.;739?-MQYQR&R3R>_)KIZ*KVL^
MX<D>QD7_ (:TW4M>T_6;E)#>6&1 RR$*,^H[UEZO\./#6M:G)J%U9R+<2_ZX
MP3-&)?\ > /-=71252:V8.,7NCG-9\#>']<M;2"[L=HLXQ';O"Y1XT'100>E
M,T_P%H.F:9J%A;PSF/4(_+N6DG9G=<$=2>.IZ5TU%'M)VM<.2-[V*.CZ3::%
MI-OIEBK+;6ZE4#MN.,D]?J:O445+;;NRDK!1112 **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M1+33H&O[?3[\1:Y+#-(4EMQ&I0PLN?E#/Y1(SC[WO0!Z;<7,%I 9KF>.&)2
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MLQD83E0&#;@F,HI7(KN_AS%JD'A%(-6^V_:(KF=4-ZI$AB\P[,Y)_AQW/UH
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M]#6_110 45Q%QXA\67GB;5],T+3=)DM]->)&DO+B1&8N@?HJD8YJ3[7\1_\
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M?\CUXT_Z^+7_ -$+77UR'AC_ )'KQI_U\6O_ *(6NOH **** "BBB@ HHHH
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M&.AP<#/2MRB@#!TCPK:Z1=+,MW=W(BA-O;QW#AE@B+9*K@#/0#)R<*!6=X<
M7Q_XR   W6? '_3$UU]<CX=_Y*!XR_WK/_T2: .NHJK?:E8Z9")K^\M[6(G
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MFAGUOQ///-"NU)4L8HVV^A*]1_C0!I_"'Q?J/C+P7]LU15-W;SM;O*J[1+@
MAL=,\X.*[ZN"^%]K)I%EK7A_SEEM])OS;0.(5C)78K$MMZDECDUWM '(7O\
MR572_P#L'2_^A&NOKD+W_DJNE_\ 8.E_]"-=?274PH;S]?\ (****9N<AX5_
MY&[Q9_U\Q?\ H)KKZY#PK_R-WBS_ *^8O_0377TH[&&&_A_-_FPHHHIFX444
M4 %%%% 'FWCB[L3JK&693.+8"Q$44,B22!F!64N#A00!R0/O=Z]%@+&VB+A
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MG/'/_(JS_P#76'_T:M='6:_B/T7ZG7/_ '6'^*7Y1"BBBM#D.9TC_D??$?\
MURM?_06KIJYG2/\ D??$?_7*U_\ 06KIJRI?"_5_FSLQW\2/^&'_ *2@HHHK
M4XSGO&;"/P_,TC9A<K$T91"I+.H#,7!"@>IZ?E6/X*U*WM+R;04C#-O>19HC
M&R-M";N4 S]X#)SR".U:_C65QX=GAAE9)'VL5#,F^,.N]=P4[<@XSC/-0^"/
ML1TN7[':FW1)"@5KAIL# . 6 ('L.* %UO1-5U?4RC&R_LK9@*799!(0078;
M2&VY^49 [GMC,U?0[R+X?:['J<RI-]B.#8RNH(CBP,D@'G'(Z8XKNJQO%_\
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M. 9#VR>,UZS0 445SVHZ_?Z=K,$4NFH--EG6V6<S?O79E+;E3'*#&#D@]3C
MH Z&N1\._P#)0/&7^]9_^B34NC^+)[NXM_[3M;>RM;VT:\M91<;L1@@$/D
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M_7\O_HM:Z2N;\-?\AOQ+_P!?R_\ HM:Z2LZ7P_?^9UX[^-\H_P#I*"N:O?\
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M "%8?ZUT^X>H_.LH?Q)?([*_^[TO^WOS%HI-P]1^=&X>HK4XSG_#'_'WK_\
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M$FG-]C=0DDX8'S(LISQR<XQZT =1I/\ R ['_KVC_P#017+_  G_ .2<Z?\
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M95YW !N_?:OY4KQ^&I2Q=]/8N6+9E7G<P8]^Y4'\*P7^'7PXBD\N31=*1R2
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MTO6+.X-^DT$+QRGEE965-NQ0.-GH"> 2,&NH\3Z3<ZUHK65K+%'(9$<^8.&
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M4 %%%% !1110!SC> /![L6;PSI+,3DDVB9/Z4G_"OO!W_0KZ1_X")_A7244
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MP;X:TR[CN['0=.MKB,Y26*V567Z$"MNB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M4RXSCDGH#ZDD]:LR^'=4U35[RZU&:UEL[F&2W@7:ZR6L+I@A1]W>3]YCSVX
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M 2?F;C/^Z/K71444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
9110 4444 %%%% !1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>38
<FILENAME>g4i5nix4zlkt000030.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g4i5nix4zlkt000030.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %N J # 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JIJ6J6.D69N]0N
M8[: $*7D.!D]!5NO.OBD3?2^']#1L&]O06 [ 87/_CQ_*M*4%.:BR)RY8W1W
MECJ-GJ=DE[97$<]LX)61#P<=:CTS5]/UFW:XTV[CN84<HSQG@,.WZUY9X5U>
M3P_X>\7:+<-B;3A*\0^N4_GM/_ JL:5KC^"_A?I?V6$2ZEJ4C-!&PR,L?O$=
M^-O'J16TL-:Z7?3\S-5MKGK%%>4ZKXC\>>&A9V^HR:?/-J+JL#K'DQ-D!E(&
M,_>'/ZUK^)?%^M6'C2ST+1[>&ZDDM\M&ZXS(V<$G/"@#)J/J\NC7_#%>U74[
M^HA=6[7+6RSQ&=1DQ!QN ]<=:\]\/^(O%)\7:GX>U.6TNKB*V:2)HTVHKX!4
M9 SM^8=>:YOP>GBC4_&6I:M:-8&Y658+Z60?*%SSY8^B52PSLVVM$+VVUD>U
MUC:QXKT+09!'J6HQ02D9$?+-CUP 2*GU_5!HN@7VI$9-O"SJ#W;L/SQ7"?#?
MPS;ZG8S>)-:B6]O;R5BAG7<  <$X/&2<_0 5%.G%Q<Y[%2D[\L=SO=(US3->
MM6N-,O([F-3M8KD%3Z$'D5H5POBC4;3P)9^7H&G0IJ>K3@1QJOR[@ -VW\0
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M]\YKU*BDZ_,FFM[?@"IV:=]C&\5Z5+K?A;4-.MR!--%^[R< L""!^)&*\_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH S=<UJWT'3OMUTDKQ"14(B )&XXSUZ#J:+C6[6WUJQTHAWGO$>1&4
MJJJ,Y)]^<?2F:]I\FI6MM"D:R*MW$\JL<#8&^;]*YEO"VKW$$:3-&LR"6V68
M/]V$0M'&?7)+9./6MH1@UJS.3DGH=BFI6$D3RI>VS1HVUG652%/H3G@T'4[
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M_8$__0QZ_P#^!*?_ !NCE8<R.OHKD/[ G_Z&/7__  )3_P"-T?V!-_T,>O\
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MQI8I(X9YHK5WA@=\;%=P,*3D?G5D#/&'B2;P[9VIM(X)+JZD=8TF#$$(A=B
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M1RPVX5EA/SMM& 1D\D=S6=HFK>&=8DFTB#1'LC<0_:VM;W3! MQ'D#S ",,
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M*W^)12/Q'+>65U!=&:-[D/'#+&RDJ4P!"J#(#?Q=Z[J**VCFN&A2%9I&#3E
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M(?\ H4YO_!A#1]N\0_\ 0IS?^#"&J;1-F<;_ ,*^O9[V62\@LIH"^K.B.VX
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MGFI/MWB'_H4YO_!A#1]N\0_]"G-_X,(:+H5F<M>^$-;F\8G4[5-/MBUZD_\
M:EO<213& $9BDA'R2$@%=Q/0UBCX<Z]+#KBW$6G;[_39;8%)1L:8S>8K[=@(
M&.Y+,#WKT/[=XA_Z%.;_ ,&$-'V[Q#_T*<W_ (,(:5T.S.1M_A_?1>+C>.UO
M_9YG,H*LH*QF#R_(V;,E<YXW;<=LUAP^#[JTO/#GALQ01/<6P@UM+8%DEMX9
M!*DC-@ %CE,'GG%>E?;O$/\ T*<W_@PAI?M_B'&/^$4FQZ?VA#1=!J:Y.3FE
MC_UJ?[PK&^W>(?\ H4YO_!A#3EO_ !"K _\ ")S<'/\ R$(:?,A<K)O :AO
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M@J,YR>:IQ^ [R;7K;5;O^S(U6_@N);*W5C"$BA>,%<J,N2P/(  4<G%=7O\
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M5TTN.R\_29=VB_V7)),KDQ$RLYDC^7J PP#CD=1BN_W^*?\ H!:=_P"#1O\
MXS1O\4_] +3O_!HW_P 9HO$+,S/$?A(>(+GP\DLS?9--D=I\3/'+(#%L&UDP
M0<X)Y'>L#Q/\-YK^*&ST-K&TT^&U$*12EPR/YPD+%@"7W8Z$\'GFNRW^*?\
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M6CC521WP,5$G<J*L2T445)04444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 5SFL>,]/T3Q3HWA^XAN'NM5+"%XPNQ<?WLG/Y UT=
M>0?$'_DMG@'_ 'G_ )T >OT4@Z"EH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BN6M_&T=Y MQ::!K=Q;OGRY4@CVN <9&7!QQZ5+_ ,);+_T+
M.O?]^(__ (Y19BNCI**YO_A+9?\ H6=>_P"_$?\ \<H_X2V7_H6=>_[\1_\
MQRG9A='245S?_"6R_P#0LZ]_WXC_ /CE'_"6R_\ 0LZ]_P!^(_\ XY19A='2
M45S?_"6R_P#0LZ]_WXC_ /CE'_"6R_\ 0LZ]_P!^(_\ XY19A='245S?_"6R
M_P#0LZ]_WXC_ /CE'_"6R_\ 0LZ]_P!^(_\ XY19A='245S?_"6R_P#0LZ]_
MWXC_ /CE'_"6R_\ 0LZ]_P!^(_\ XY19A='245S?_"6R_P#0LZ]_WXC_ /CE
M'_"6R_\ 0LZ]_P!^(_\ XY19A='245S?_"6R_P#0LZ]_WXC_ /CE'_"6R_\
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M4M5M/MH[+3K>UA0)%#&L:(/X5 P!^56: "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@#C?!O_ ")NE?\ 7$_^A-6Y6'X-_P"1-TK_ *XG_P!":MRM
MEL9!1110 4444 5M1O$T[3+N_D1G2V@>9E7JP522![\51L/$^C:AI U)-1M(
MX!&DDV^=/W&\ A7YX/.*MZO9/J6BW]@CB-[JVDA5V'"EE(!/YUQD_P /K_\
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MMW^K?\)%::7IMW;6JO9RW,DDUL9B2KHH &]<??/K47E^*?\ H/:?_P""L_\
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M YJKH'C_ $G7;FRL1NAU&ZA\SR/O*AV;]A;^]L(;ICG&<T<J#F9O?\)5<?\
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MIECXIBMM,&K6^OS;;,");*Y"/%<_:'+&4DX(,>S!;(QD8S7J)Z_X4)B97O\
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M^N)_]":MRN9T1?$.CZ+:Z=)X8GF:V4H98[V *_S$Y&6SW[U?_M#7O^A2N_\
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M"RM$N(KHHRP"0O<, #QP%7ISU%5GT+Q+::G=2V]K<7,43W.Q6U(B.YMV3;!
MH+90J3N9S@_*<$YKK?[0U[_H4KO_ ,#K?_XJC^T->_Z%*[_\#K?_ .*K.Z+L
MSAH/"GBA8='B%UJD404R7.V[0O%<&0$MS(1Y80849;@'(RV:9>Z%X@2U=+IK
MEKG5K6XMFB:Z,B>?-<90!<D*L409L@8ZC/:N\_M#7O\ H4KO_P #K?\ ^*I?
M[0U__H4[O_P.M_\ XJC0-36 V@+G.!C)[T5D?VAKW_0I7?\ X'6__P 51_:&
MO?\ 0I7?_@=;_P#Q5/F0K,UZ*R/[0U[_ *%*[_\  ZW_ /BJ/[0U[_H4KO\
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M%+'/#'-#(LD4BAT=#D,#R"#W%',PLCF_[*\4_P#08TC_ ,%LG_QZC^RO%/\
MT&-(_P#!;)_\>KIZ*.9A9',?V5XI_P"@QI'_ (+9/_CU']E>*?\ H,:1_P""
MV3_X]73T4<S"R,'1=%U"RU>\U+4;ZVN9IX(H%6WMC$JJC.V3EVR3O]NE;U%%
M(84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %>0?$1B/C/X ]I'_]"%>OUX]\1?\ DL_@'_KH_P#Z$* /
M8!T%+2#[HI: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH \\^-Q(^%.K#U,.?\ OZM=+X*);P/H6?\ H'P#_P AK7,_&_\
MY)5JWUB_]&K72^"/^1&T+_KP@_\ 18H WZ*** "BBB@ HHHH **** "BBB@
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M=RK%;P1F261NBJ!DG\J )Z*YS_A._#O_ #]S_P#@%/\ _$4?\)WX=_Y^Y_\
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MBJ>F:I9:Q9"\L)Q- 69-VTJ0RG!!! (((/6KE !1110 4444 %%%% !1110
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MQ-JMA87,JVBQQSS32O; '4"DA79%V"H-NXCDG\32LAW9VV/%?_0:TK_P6/\
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M_P @_4?^PK>?^CFKHZQ9HM@HHHH&%%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% '*S_P#)0KC_ +!$7_HYZU*RY_\ DH5Q_P!@B+_T<]:E:1V,Y;D%
MQ?6EI+;Q7-S%#)<R>5 KM@R/C.U?4^U5;C7]&M+.:[N-5LX;:"8V\LLDH54E
M'5"3_%[5SWC[PY<>)9/#]K$)DCCOGDDN(NMN1$^R0_1]M<QHNE>(;*:RUW6=
M!GNY+?5+Z6ZLK=%9MTJH%GC5B PRK>^&XIW"QZ79ZUI>HRQQ6.HVMS))#YZ+
M#*&+1YV[QCMGCZT^+5=/GTTZE%?6[6 #,;D2#RP%)!.[I@$$5P'B*QUIM-TS
M7?#?AN33]27[3:/8@(&$4ZG$C!. 0X5\=L\ULZ_X9EA\!Z;HVF6XNTTR6UD:
MUR!]JCB8%TYXRV"<'@FBX&Q;R:!XHGL]4LKRWOVT^1_)EMY]PC9T*MD ]U/>
MJ2_#_P .(L"QV<Z+ L2*$N9 #Y;%XRPS\Q4DX)]:R]0GU+4K-KK3?#6I:3"U
M]!]N*(D-Y=VP!W;0AW#!VCKDC.*PI]/\:36UP2^M((]-O'L56=A)Y@G!MUEP
M?FDV9X.>.M%P.UN?#GAJWETU+F)(Y5U-KRRWRL&-TY+MMYYS@G;TX]JL1>$M
M&@M],ABMG1=+G:>S996W1LQ);YLY(.XY!X-<+?Z1KS:A EQ;ZW=V%KK%O<(R
M2,TRQFU(E*-G./,)& >,X%*]MXT_LJ 7*ZV[?89Q8BVEQ+'<F5O)-R0><1[/
MO9'WL\TK@>BZIK6EZ) D^JW]M90R-L1YW"AFQG ]\5CZII_A/QLEG%<S6]ZT
MD4DEJ]M<E7:+(63:R$$KG (Z53\5:3K>IKX36VD6.]M[P275TMN)HX3Y#!F*
M$@$%C@?45@WO@B_TV]C6PFU">1-+U"9KRU/D%KN1U=5 3A02.%Z<4VP.J7X?
M^'4TJVTU;:X6WM)7DMBEU(DD&_[RJZD,%/IFII/!'AY[0VG]G[(#8_V?Y:2,
MH\C?OV]>N[G/6N1C_P"$TE\3Z5/+!JL<:FV2XP28F0V_[PD9V+^]/(*D@C.0
M.*HV=MX^CTG480-4=B;=FEG9UD8"0^:J+N)W%.IC8 C[N#2T [IO#>@Z3H&J
M6UU-=#3+F$K=M>7TD@6/!!PS,2HY[5=N+31_$&F7&DR&.ZMH2D4L:2$-$R@,
MO(.58#:0>O2N8FT_7;OX1ZQ8WD=S<:C/#.MO%(I\TH6^13EB2<>ISC&>:S;?
M2]?M?%EU)9VNJP//K,$IEW8M&M1$BR[QG!/&!QG(&.AIW WKNW\#^'8XM)U"
M^M;-'AE'V:ZO& G64X=G!/SDD?>;D=JTK3P?H5MID=G;VSFV%U'>AFG=VDE3
M!1F<DE@,# )Q@"L#Q#X8U77/'5R;:Y-AI\VBBUFN6M%G$F96S&NX_*V#G/-4
M38^)-/\ %]C:V,.JKI%G)':J=[/$]L("H8X(4?/C(VEL\Y P* .TOO"VCZCK
M4&L7=GYE[ 5*OYC!6*DE"R@X8J22,@XK8YKR>WT_QS;:-"+>75VO)]#!N?/F
M+%;D3KE4W'"2>5N QCMGFMJ&QU.[UO14@7Q';Z.D]TTPO;DAL;$,8<@[]F_.
M Q)Z]C1<+'>TR26.%<RR(@P3\QQP!D_D.:\ILHO'\6GZD]RFI2W#6X29%8C=
M*9AEXB6/2//$84$8'#46NC^(I;G1;W4;;5YI+.XU&)&+.'1'0>02-Q.W.1DD
M^A)Q1<+'JEM<P7EK%=6LJ36\R!XY4.5=3T(/I4M>;:+;^)8I],&K0Z^[K:6(
MM_LLH6-' _T@7&XXSGKN!)'W>:])/6FF(R_$O_(IZU_V#[C_ -%M70Z=_P @
MRT_ZXI_Z"*Y[Q+_R*>M?]@^X_P#1;5T.G?\ (,M/^N*?^@BHF7$LT445!044
M44 %8'C?_D1==_Z\9O\ T UOU@>-_P#D1==_Z\9O_0#0!9[#Z5PWC;PSJ.NZ
MO;W-E"<VUDT4$XGV&*625 SJ,\%8@Y!]P/2NY[#Z5A"^UT^-?L']G1_V/]EW
M_:?-YW[L9^[U[;,].<]JV9DCF+C0/$=GJEY)9VMQ=0QO/Y0?4V"7%NT86*#!
M;*D.2[.<'@X)R *MKX7\4VTVDM'<ZD(K>$2LK72$BX#LSA\N?D8;%4#=A>#@
MY-,O_'FJZAJ6I:9IQ$<;.D%O+''MGB<W"Q$?>/) D/(7H"!@U##X\UJ[U*WN
MQ?6$5BT$*S'RF\FQ>=V_UV3\S(L1'51N?G%3H5J:UA8ZUX6T'6M0OIKJ5H]&
MB"A[@S>9=!7+L!DXPS*HQC(%5M)\*^(WELX;M[RVT_*O/'+J+2.TB6Y7<S!L
M[7D8$J#T3D#.*2#X@ZW/<VL4=K;%FL'NYD$,@;?&KMY*_P"W(@1P#RH)X/%3
M6/C76[^ZM[2&33YA(YD:^AMW,7EK!YDJJN[YF5BJYSSGD @T:"U(+70/%L=O
M%]HBO)+<F!;^U&I_O;N11(9)4?=B-2QC^4%257H.AAT7PMXNT^*WL\/$-T,\
MEP;P,BNJ2R,"H.6+3NNXXP0HZTQ_'VHZC86)74;.P626S$UXL9*1NRO-*IYY
M4((U(R.6/-2)X[UMY8Y9_LVG>;;Q1R2W,4C0Q3>4TQ C!SN?=& .O7J1BC0-
M2_IGAO5S=:#)?6E\D<%UYUX)M4\XLZP@"0C. &DRVT$_=!P,D5Z%7F-UXUU^
M&XU>2T6U*VXED"RH[K\CQ0HB#(QOD,O)],XKT[D<$8/<>AIH3*7@W_D'ZC_V
M%;S_ -'-71USG@W_ )!^H_\ 85O/_1S5T=9,T6P4444#"BBB@ HHHH ****
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MS3VDT4:_V5<#+,A &2GJ:[6Q1H]/MD<%66)00>QP*L44F[C2L%%%%(84444
M%8/C8$^!== !)^PS< 9_@-;U% ''?\)CX:P/^)]8=/\ GL*/^$Q\-?\ 0>L/
M^_PKL:*OG)Y3CO\ A,/#.<_V[I^?7S11_P )CX9P1_;NG\]?WHYKL:*.<.4X
M[_A,?#/_ $';#KG_ %HZT?\ "8^&>VNZ?QT_>BNQHHYV'*<=_P )AX8QC^W-
M/_[^BC_A,?#/_0=T_KG_ %HZUV-%'.'*<=_PF'AG_H.Z?_W]%'_"8^&?^@]8
M?]_A78T4<X<IS/@>:.YT:\N(7$D,NIW;QNO1U,S8(]173445!04444 %%%%
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MYXKFVBG@E26&10R2(<JP/0@]Q7 SWDYUV\O8I#)+'<38BC\WS$1$*C(^YL+
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MK^]5%8GH2REC[=1QU[FBJ]K=W:%R=F<3_P )#JO[QC*%C)VSLUHV+$[\#/\
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MKQF,#/S5TS#:Q'H<46079B_V#<?]#)KW_@1'_P#&Z/[!N/\ H9->_P# B/\
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MLZ"XD9$7Y'<DE03_  8Z=Z.5!=D7]@W'_0R:]_X$1_\ QNC^P;C_ *&37O\
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ML:W8Z?I\FA:1<203)+(XN9Q$<2.F/E7!S@'KBI;CQI>)H^N7T5M;L;'5XK&
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MIVL0 5/0=\BO_P )UJCZHD4!TYP8$WN)'-NN(9)Y)5X#$;1%P?[V/>NN.O\
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MX\#&:ZY=?\,+C;J^BK@@C%S",$=#U[4JZ_X91MR:QHJMN+96YB!W'J>O4^M
M%_4?^07>_P#7O)_Z":L^%O\ D4=%_P"O"#_T6M85_P")= ;3+Q5UW2RQMY
M+R/).T^];OA?_D4=%_Z\(/\ T6M3,J)K4445!04444 %%%% !1110 4444 %
M%%% !1110 4444 ':N,\'R1_\(5HG[Q/^/*/^(>E=G6(?!OAAF)/AW2B2<D_
M8X_\*:=A-7'^:@.1*G_?0IWGC_GLO_?8J'_A#/"__0N:3_X!Q_X4?\(9X7_Z
M%S2?_ ./_"JYR>4F\\?\]E_[[%'GC_GLO_?8J'_A#/"__0N:3_X!Q_X4?\(9
MX7_Z%S2?_ ./_"CG#E)O/'_/9?\ OL4>>/\ GLO_ 'V*A_X0SPO_ -"YI/\
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M$,\+_P#0N:3_ . <?^%'.'*3>>/^>R_]]BCSQ_SV7_OL5#_PAGA?_H7-)_\
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M $+FD_\ @''_ (4?\(9X7_Z%S2?_  #C_P *.<.4F\\?\]E_[[%'GC_GLO\
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-_"K   P!@"BB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>39
<FILENAME>g4i5nix4zlkt000012.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g4i5nix4zlkt000012.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" (M J # 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M-<)9:M"P)D/ <#I^->D44 >8>,OA_K?BO3-'NGNX$UG3Q@@\QR>]9_B+X?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% '/>-?$$_AGPU-JEO%'+)&ZKMD.!@G%&D>,M'U:>&SCO$
M^V/&'\O!&>.<$]:J?$?2[S6?!MQ96,!GG>1"(QW /-9.I>';X^*/"=U:6 $5
MG"5G=5 "';W_ !K6*BXZF4I24M-M#H)O'/AVWOC9R:@HD5]C-M.T-Z%NE8.N
M_$=M!\;VVDW-LATZ5 6N5))3/0^F*Y/6]"\4:OI^H6MSIET;HW7F1K"%6W*9
MZCN373?\(I/J?BUCJ%BQTZ;2U@9V[.!_,57+!:LCGG+8UY/%UR/%U_I,<$+6
M]O8BZCE!.6.,X^E8EO\ %%I?#UNZVD<^N74AC@L86)SSC)]!6?X8\)>(-)\3
M:M]N1Y[<6;06MP3]]<?**KZ5\,9QX/>Z2![/Q)',TT,K-R,'A?H:?+36_D+F
MJ/;S/5-(;4GTV)]62&.\89=(22J^W-7JQO#%[J5]H<$FKV3VE\HVRHW<CN/K
M6S6#W.B.P4444AA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 C?=/TKQ+1?\ D?X_^OEO
MYU[:WW3]*\2T7_D?X_\ KY;^=- >W4444@"BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M&9;==L+[>4'H*3J)]!JDUU/.OAUJNG:?>>(4N[ZW@8WS$+)(%/ZUZ7;W$-U
MLUO*DL3<JZ-D'\:RIO"/AZXF>6;2+1Y'.69H^2:T[2SM["U2VM(4A@085$&
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M_'W!_P!]M6-X:B:#QC:0N<M'*5)'J*8'NM%%%( HHHH **** "BBB@ HHHH
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MFUV2*<ZPKA0?D,@PU:M]KVF:<#]IO(U8?P@Y/Y5YP^L^(_$LS16S2%>Z0_*
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M !1110 C?=/TKQ+1?^1_C_Z^6_G7MK?=/TKQ+1?^1_C_ .OEOYTT![=1112
M**** "BBB@ HHHH **** "BBB@#@/'O@7P]J45UX@U!)A-!"2WE-C?CIQ7S>
MY1W9HEVH3\H)S@5[I\2_B'J.BZG+H<.DQS6TL.'>96(<'TQ7AC*Q9BL3J"<@
M!3Q7?04E'4\[$.+E[I[#\,?!'AOQ!IMOK,L4_P!JMY,/&7^4L.AKVP *  ,
M<"OGGX?_ !!U'17L=#MM&CDMI)<.R(WF,3WKWRZU.RL(/.O;J*W0#),C@8KG
MKJ7-J=5!QY="W2,ZHI=V"J!DDG %>:^(?C/H.EAXM-5M0N!P"O"#\>]>;7?B
M#QO\1KHVUJDWV<G_ %5N"L:_5J4:,GJ]$$J\5HM6=A\7/%_AS4]';1XIVNKR
M.0.K0\HC#U->7>'/"6L^*+D1:;:LR9^>=QA%_&O5O"OP2MK;9<^(9A<2#G[-
M&<(/J>]>L6EE;6%LMO:01PPH,!$7 K3VL::Y8:F?L95)<T]#B?!OPMTGPR$N
MKH"]U <^:X^5#_LBN]HHKGE)R=V=,8J*L@KD?&'BE=-A:QLW!NW'S,/^68_Q
MJYXI\21Z):>7$0UY(/D7^[[FN-\,>'I_$%^U]>EC;AMS,W_+0^E>A@\-%1^L
M5OA7XGCYCC9RG]4PWQO=]D1:)I]K:^5K&N%EMG?]TI&3(WJ?:NXM_&6BSSQV
M\4S;G.U1LJOXPT.ZU33K6WT^)#Y3_=S@ 8KE]-\&:U;:G;3R01A$<%CO'2NF
M3H8J'M*LK/6RN<4(XK 5/8T(7CI=V>O<]1HI!T%+7B'TX4444 %%%% !1110
M 4444 %%%% !1110 5%]GAVNOE)A_O#;U^M2%@HRQ 'J:;YT1.!(G_?0IJ_0
M3MU&):6T6/+@C7;TPHXIZQ1HA144*>H XI7D2,9=U4>I.*4,&&5((]0:&V]Q
M)16B(_LT'EB/R4V Y"[> :=)#%*H62-74= PS3Z*+L?*NP@    P!2T44AA1
M12%@&"DC)Z#- "T4UG12 S*">@)IU !133(@;:74-Z9YIU !1110 44A( R>
M!0"&&5((]10 M%%)N&<9&?2@!:*** "BBB@ HHHH **** "BBB@ HHHH ***
M* /,/B_I]SJ?]@VUL9XV>\ \Z%"QC]Z/^%7:[C_D?]7_ .^17IW&<'&:Q_$/
MB:P\-V\<EYYKR3-MBAA3<[GV% %+PCX8OO#<=PM[KUWJIE.5-P!\GTKIJP?#
MWBW3_$;S16Z3P7,/^L@N(RCJ/7'I6]0 4444 %%%% "-]T_2O$M%_P"1_C_Z
M^6_G7MK?=/TKQ+1?^1_C_P"OEOYTT![=1112 **** "BBB@ KAM:^*_AO1-6
METZ=YY)HCB0QID*?2NYKCM:^&/AG7-0DOKFT9;B0Y=HW(W'UJX<M_>(GSV]P
MS%^,_A0CF2X'UCIQ^,OA/_GM/_W[J)O@KX6/07(_X'31\$_#']ZZ/_ ZT_<^
M9E^_\AS_ !J\++T^U-](ZJR?'3PZOW+._<_[@']:NI\%_"B]8YV^LE6XOA%X
M.C^]IS2?[TIH_<^86K^1R%_\<=,F^YH/GD=//(_PK#N/C%=W.5L/#NGQ-V_=
MAS_*O6[;X=>$[4CRM&@X_O9/\ZV+?0=(M<>1IEI'CNL*YI^TI+9"]G5>\CY]
M'B'Q_KLO^A6<L+'H;:U\K]<5<M?A3XSUZ7SM5N/(R?F-S*6;\A7T,JJJ@*
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M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M1?9:N45QU,35J_')L]&C@\/0_AP2$ "C   '84M%%8G2%%%% !1110 4444
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M -^C7K7DQ?\ /-/^^11Y,7_/-/\ OD4 >2_\)[XG_P"?=?\ OT:/^$]\3_\
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MY+_PGOB?_GW7_OT:/^$]\3_\^Z_]^C7K7DQ?\\T_[Y%'DQ?\\T_[Y% 'DO\
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MWB;QM'\/8?%[:W&/+E"?91",2#.,L:TM3\0^+]!N/#^K76K0W%OJDB))9+$
MB;O0]>] 'J UW3#KAT87:?V@$\PP=]OK6C7DL0_XR0<X_P"89G]*]:H ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M ZFBL;6O$,.C+8,T33+>3K"A0C W=_I3;7Q+;W&M:IISQM"-. :29V&T@C-
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MP"W,=O(;A77:S, 5*X!#'/&?6@#>HKFE\9Z>FLZI971,$5B8U,S(V&+<'/&
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
IBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>40
<FILENAME>g4i5nix4zlkt000046.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g4i5nix4zlkt000046.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %L J # 2(  A$! Q$!_\0
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M?+R3Q_C3A0U5WN*53>W0];HKS/Q;J.NGXEZ;HVEZK+:1W5L 0!N5<[\MM[D
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M(3#)Q]F']*!&-'H^F36T1.EZM)*4&Z2,DJQ]1GM3UT.5,_9-+NAZ?:(H2/\
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M_CM=-7F\%]<I<->><_VCY29#U)YK17Q;J$*Y<PRX_OIC]13L%SKM0XTVZ/\
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M_P#OX*X PDVT*FX"L"7(('(.*ABLQ&&!N-^YBV2!Q[46"YZ,NI:>IYOK<?\
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MER-US,PZ8;:1@\'M2W=C>>'%<6Z/=:.[;C$.7MSZCU%:.T9'(ZULZ@#]GRI
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M6WF;ZSM2^8")<>!H/NVVFC_MAN_F*LIXC\)6_P#JQ:+C^Y:C_"F+X1T)?^7
M'_>E<_UJ5?#&B+TTNW/UW'^M*R"Y(/'GA^+A)F&/[D!%(WQ&T,=9+EO^V?\
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MU'J5U]KU&:53E =J?0?YS^-+ =HS6D59$MZFYINF"_GD496"!#+-(.RC^I/
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M5(5EC:-4\L;AB/ [K_6JB)GH'B7G2)/D+?O5QA0=O/WN>..OX5QA9EQ@MG/
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MX]EK&D_X]YA_LM_(4T#W([T[;I1G^&L:0YN!6OJ'_'VG^[62R_Z0*I"+D/\
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M^M2WJLBB=E;>JL"!ZC(_PIIJXM;&,DTT@^>1'QW4 C]:K7D44C1>;&C,1QA
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MNZTFU;:>@WI@_@QJ1_&2K!([:;%$ZKD.TS,H^JXY_.N2N;R6:Z:5L+P%"@Y
MQ4D%P3DKE6'7(J;!<OSZIJ6I2^;)*\0_A>1?F _V$Z+]3^55EA2-V*!C(_WI
M';<[?5C_ "Z5+&P*Y(I 07^E $UO:S3S(D2,[9& !7N7AG_D%I7C.A2O%JLK
M1R,I\G!(.,Y->S>&?^06E5$EFU7S;<?\?<__ %U?_P!"-?25?-MQ_P ?<_\
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MO;GI]U>N/ZU[=X9_Y!:5426;5?-MQ_Q^7'_75_\ T(U])5\V7!_TRX_ZZO\
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MCCN9@H(R&&X-SP#Z>]-B*RV^G2[1'?R0%2,+<0'^:Y_E4<FA7LWS6LEM>#/
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M/JY_D*ONEOW?;[9R:8NFB;E%)'J1BBX%*:_WNS@8)YR!M_05FFZO&?,> /\
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MQ^05)+]RJELY"^M3R/\ )4C)(#\K#V-7+1O]#@_ZYK_*L^!NOTJ[9G_0;?\
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M202HEY /I6\"#@KR*) B0 ]:JW=A!>?,PV2CI(O7\?6K0-%2,YYK2>SN(_-
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MW4B2P,\;AT).&!R#72JI$:?[H_E0! RG'2HC5IQE:KD4@&9IM.QSQ2[#WXH
MB(XJ$K5HJ![U&P&/2@"L5H I9IHH6"R2 ,>B]6/X#FH1)/(?W=N47LTK8_\
M'1D_RJE%[BNB7;44TL4&!(X5CT7JQ^@')IWV>5_];<OC^[$-@_/D_K3H[>*
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M>2ZA"(S8=2V!G R.?I7TQX:_Y!BU\U63.NI6XC=DWN%;:<;E/4'VKZ5\-?\
M(,6KB2S:KYNU]G?5F9UVYW +Z ,:^D:^=/$XQJBGU#_^A&FQ&15+5GQ9*O\
M><#\JNUEZR_,*>Q:DMP+>F+MT^/C&XD_K5P5%;ILM84]$%2BDQBUD7?_ !^C
MCHY_E6L>E8FH$K=\%0=Q.6Z#BFA%BTD9'=<Y7/2KZ$'!%<ZNI+#OR-[9_AZ&
MMZRD$UJKCH3D4V@+T9Q4A-0*W-.+5(R:(_,*OPE4MB\C*BAFR6.!U-9T1^85
MIVMK;[1,84:0DG<PW8Y[9Z?A0 BW2R?\>\4L_NBX7_OHX%2+%>2'YI(K=?1!
MYC?F>/T-6LFE&<\4 54L(' >6.25O2X??@_3I^E6L\ = .@'057NM0M+' NK
MF.)CT0G+GZ*.3^55Q?WEP/\ 0M-D"GI+>-Y*_P#?/+'\A0!HCG@57N]0L[ @
M75U%$QZ(3ES]%')_*JW]G7=R#]MU*4KWBM%\E/Q;EC^8J&&[T;3I6AL(5EN/
MXDLH_-D/^\W^)H LC4;VXXL=-DV'_EM>-Y*_@O+'\A3SI]S<J6OM3EV#[T=J
M/(0?5N6/YBHMVKW7*1V]A&>\I\Z7_OD84?B345S9:9;*LNL7;7+9ROVV7Y<_
M[,8P/T- %ZW:VMM.W:='YT,9.U+=@Y9L\X)/)SZFH<ZQ=]!;Z>A]?W\O]%'Z
MU/%=>=8>990@<$1),AB4_AC('X5!_9]U<_\ 'YJ4FT]8;0>2GXMRQ_,4 5[B
M#2+.56U.Y:[N/X5NG\UC_NQ#C\EJVM]?W"A;/3_)C'22]/E@#VC7+?GBI;:R
MM;$$6MM'#G[S(OS-]3U/XFIQ1<"K_9KW _XF%]/< ]8HSY,7Y+R?Q)J[;P06
MD7E6T,<$?]V-0H_2D!IP:@"6CO3 :6D!C2?ZFX_Z[2?^A&O0(_\ CWB_W%_E
M7GTO^IN/^NTG_H1KT*(?Z-#_ -<U_D*&""FLM/Q1MI#*["F,O%6'6HB* *K+
MS3"*G<5$PH A-,-2$4PBG<+$=%#%4&6.!4/FO(=L2D>_?_ZU3*:B=%#"U*RN
MM$NKV)F=4'S'\.]1B268XB7:O<__ %Z<EL.LAW'T[58' XJ+2EOHCI4\/A_@
M7/+N]ODB%+9$Y;YF]^E2TM)FJC%1V.6K7G5?--W&.BN/F4'ZU7\A%.5W+]&J
MR:C-'*F[L(XBK!<L9.Q'BEQ3L4AJC$8>M(!2FLW6I9;>S2=,&)) )5W88J1V
M^AK2G#GDHWM<B<N6+9HXHJEIUZ)T2-WWEAF.3^^/\1Z5H8IU:4J4N60J52-2
M/-$CK%TP?\3;4#_M-_Z%6M>7"6-I)<R<I&,D9QWK#T[4=/%[(\<TCO=2852@
M&W)[G//X4HTIR5TANI&+LV;N*3%28K'U?47L]QC8*(D+/QU/8?Y]:NA0E6GR
MQ(K5HT8\TA?$/&BR9Z&2,?\ CPK GVB&W 5<")/_ $$5?\57A/AG>C[6=HF!
M7UZUA66V;10%EW7$<G!)QO0_U!K:C3;CH9U9I,MQOV-.:&)CDH*K@D#FIDD!
M7Z"M'%HR31?T&"&368T,2N$5I%0\#>!P3ZUO:>^(Y6X.Z>;/XN:YW1;ZVL=3
M>[NFVQQ0L>.K'@!0.Y-;&ER[[&.0='9WP>V6)KFK)W.FEL:RK4F*@68[<'G'
M3VH,Q].*YS8BG/[SZ"N.FYO9C_TT;^==9(W/XUR#/FXD/J[?SH&A)AR*E4?*
MOTJ&8Y-6E(#[6ADD' _=D CWYZT  '%!'-.XR0.@.!FBD%QN*::DIA'- !12
M@4X+0,J7B[VM4'5IU'\ZNSV[0 !R03V*E2.O8_2J[)NU+3T];E:]"O;<7]BU
MLSF+G(D #8_.FD2S@3]WKT%53*50L.<*3S6]XGMH-/%H8+?!F+AVCX4  8."
M?4GI7.2<0O\ [IH [>[^7PC"(D$,<<#2R*&),CLN,D_C^@K@VZ5WNL?N_"LR
M^ENJ_P JX!J )=-7=JMK[2 U]*>&O^06M?/.CVN&6Y<=\(/YFOH;PU_R"UJX
MDLVJ\UUWX=+>7BR133X7=CIW.?2O2J*H1Y#_ ,*QD_Y[3?I_A5:Y^$?VJ4.]
MQ<# P -N/Y5[/10!Y%_PK&3_ )ZS?I_A1_PK*3_GK-^G^%>NT46 \B_X5E)_
MSUF_3_"J=U\(1=$E[BX4DYRNWC]*]IHHL!X6?@C$?^7N[_-?\*T;;X5&TMUA
MCFG*KT)Q_A7L=% 'D0^&4@_Y:S?I_A2_\*TE_P">LOZ?X5ZY118#R5?AM*IR
M)9?T_P *M1^!;F- H9B!ZXKU"BE9 >9#P3=>K54N/AY?74G[R_NUA[PPD1@_
M5@-WZUZQ118#RNU^'GV'/V6W2(GJRCYC]6/)_.IV\%7A4@,0Q'#8!Q7IM%%D
M!Y$?AE+.<W]Q<WW.0DS@1C_@"X'YYJ_'X'N(8Q%$HCC'1$4*!^ KTZBG8#RJ
MZ\!:A<E0E]<6\8^\L&T%O^!$$C\*2U^'*V;F2" "8]9G^>0_5FR:]6HHL!YH
M?!EX>K-2?\(7=^IKTRBE9 >:?\(;>>I-'_"&7?J:]+HHL@/-/^$,N_4T?\(;
M=^IKTNBBR \V_P"$/O/4T?\ "'WGO7I-%%D!Y8W@&X99%WO\[LYZ=2<UMII&
MII&J".,A5"CKVKN**+(#B?[*U3_GE'^M)_9.I_\ /./]:[>BBR X8Z/J9_Y9
MQ_K3?[#U+^XE=W119!<X/^PM1_YYI33X>U _P+7?4460[GGW_"-W_P#=6D_X
M1F__ +HKT*BBR"YYV?"UZPPRJ1Z&E'A>^48"J!Z5Z'11RH?/*W+?0\\_X1B_
M]!2_\(S?^@KT*BBR%=GGO_",W_H*3_A&+_T%>AT4607///\ A%[[T%)_PBU]
MZ"O1**+(+GG7_"*WWH*#X5OCVKT6BBR"YYQ_PB=[39?!UW+#)$P&)%V,=H/&
M0?Z5Z31181Y-!\-YK<.J2S;6.X+D?*WJ*TQX4O@H!.X@=3WKT:BM)U)324G>
MQ$:<8.\4>8:AX&NM2L9+21F1),99,9X.>]5#\- %L_*C$+6K J\:@,^,?>/?
MD9_&O6J*(U)Q5HL;A&3NT><?\(E>YS6=<_#F:Z;=+)(<R"1AQAL'.#QTKUBB
MB%25._*[7%.$9VYE>QY!>_"^6_M#;2W$XC+AQMV\$=AQTYJJ/A$P8'[7<Y'L
MO^%>TT41J3BK)A*$9;H\=_X56_>XN#_WS_A2K\+'4Y$\_P#X[_A7L-%-UIOJ
M+V4%T/&V^$^X@F:?@Y'W?\*TK?P%<6T"PHS[5&!G%>I45,I.6Y:BH['F8\%W
M@_B:E_X0V[]37I=%19%7/,&\#W3'[S#\JS?^%6MN+>=-R<]O\*]AHHL@NSQY
MOA8S'F:?]/\ "I3\,Y#_ ,M9?T_PKURBCE079Y&/AI*/^6LOZ?X4O_"M9?\
MGK+^G^%>MT4<J"[/)/\ A6LO_/67]/\ "C_A6LO_ #UE_3_"O6Z*.5!=GDG_
M  K27_GK+^G^%'_"M91_RUE_3_"O6Z*.5!=GD:_#.1;JWN/-E+0/O4'&"??B
MM5_"=^8BL;>4QZ.HR1^!XKT>BBR%<\BN_AQJ=\ZM<ZM=R!<[5\N, 9Z]%J+_
M (56YCVM<3MGO\H_I7L5%%D%SS.]\%W=[8/:.2B, "5QG __ %5C'X3$GFXN
I/_'?\*]EHHLAW/*%^'4R;0KR!5Q@#':O1=%M'L[%8Y.HK2HHM81__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>41
<FILENAME>g4i5nix4zlkt000017.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g4i5nix4zlkt000017.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" -R ?,# 2(  A$! Q$!_\0
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MX?O-4=-_V>/<J9^\Q. /S(KGG%<_+$UBWRW9J45Y99W/Q(OM)A\16MU:3+,
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MII"]HCTNJ=_JMCI:Q->W4</FN(XPQY=CP !U->9:[KWC?1M*L?$T][9K:2E
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MO+/R5F.-KY" @=^Q_*N_HI>UWLK#Y.[/%;/PQJOAR.\TV;P5;:U(7)M+\A6
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M U"P35]%TYM&AU/5)9-UJL\I2.,Y R<=<GM[5S5E%?6WQET];];"*Z:$[X[
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M23Q#X8MK]RNDR3DSY.%ZJ.?P)_6JOQ-L]-TZX\/S:/%#;ZI]H41"U 5B@Z'
M]\ ?4TH48M*^['*;3?D;&J_$>VL?'<.DM<V\6F0JPO)RK%A)@X3IQ@XZ>M17
M'BJXL/BK=6E[J8AT6&S$I23 13L!SG&>IJAJEC92?&ZPAGMK<QRVF^5&0;7?
M#\D=SP*2:PMK_P"/+Q74*2Q1VRR!'7*DB,8X]LYJU&';[)-Y?B=_HWB?1?$!
MD&E:A%<M&,NJY! ]<$#BJ^I^-?#>CWILK_5H(;A<;HSDE?K@'%<;!;1V'QPN
M8[&)8@^GE_+084L5';Z@5SO@F'4;VTUR0:=I%W(\K?;'U&4JZ<'..#@=>:E4
M(;]++\1^T>Q['=ZYIECI/]JW%[$MB0")P=RG/ Z9JMI_BS0M5U'^S['4HI[K
M9YGEH#]W .<XQW%>8SV4VG?!;4+=[ZUO(UNU:)[:7>BJ64[<]N<G'O7H'@G0
M]-T[PYIEU;6<*7,MFADF"#>VX!CD_6IG3A&+=^MBE-MV.ANKJWLK:2YNIDA@
MC&7DD; 4?6L73?&_AK5[Y;*QU:"6X;[L>"I;Z9 R?:N6^,KRKX>T] 2+=[L>
M=CZ'&?U_*M'6K+P-:G1)+Z."$;P+)K?*Y/!!)3G'3KWI1IQY4W?7L#D[V1OZ
MSXLT+P_*D6J:E%;2.-RHV22/7 !Q4UAXBTC5-.FU"QOXI[6$$RR+GY !DY'4
M<5PU_=KJ?Q!O[/0M!T^;5+>(+<7NH2':!QT3G.,@5C>"%:,^/(W,!98&#?9Q
MB+.),[1Z57L8\E^NGXBYWS6/0)/B!X5BMX)WUJW$<^?+X8DX.#QC(_&MN+4K
M*?3EU".ZB:S9/,$^\;-OKFO,/ &BZ=<_##4Y[BSAEFE\X-(R@MA5XP>V.M83
M2SCX"1B-FPU\5?!_AW'CZ9Q5.A%OE3ZV%[1VN^QZI9>._"^H7RV5KK-N]PYV
MJO*[CZ D8J]K/B+2/#\:2:K?Q6PD.$#Y);Z <UR=_8^!8/"VBS:G';QVGR>1
M)#D,S%><E?F(SR?>N?U<75U\8F6"WM+MTM$-I%J#LL>-@/'!R>6/Y^E3&E"3
MTO;4;FTCT_2]=TO6K)KS3KV*Y@0D,R'[OU'45G#QWX89+=UUB$BXD,<0"MEF
M! (QC/4BN2\,:9>VGC+6[DRZ3"LMNPNK&RG+&-\#!VD#'?\ .JOPAT33KW3;
MZ^N[*&:>.[ BDD7)3: 1CTYYH=*"3=]K?B"G)M(]9KFY_'WA6VO6M)=:MEF5
MMK 9(!^H&*M>+GN8O"&K26A83K:N4*]1Q7#>$+'PJ_PK:?4XH&A&YKN0C]X&
M#< $<YQC&/6HIPBX\TN]M"I2:=D>C7^KZ?I>GF_O;N*&T !\UFX.>F,=<^U5
M-&\4Z'X@>1-*U*&Y>,99%R& ]<'!Q7EWC5[627P?!I BET,\VRSNWENV\#:Q
M/..W/0$UK#2M2_X6'H]Y/_8>F74?$EO:7!#SQG(^Z0,]Q5^QCRW;UU)]H[FQ
MX=UK4KSXE>)--N+MY+.U0&"$@83[O3C/>CX9:UJ6M6&JR:E=O<M#>&.,L -J
MX'' JAX4_P"2N^+?^N8_FM+\'O\ D&:W_P!A!O\ T$552*Y):?RDQ;YE\RW\
M3M<U/18]&.FWCVQGN2DFT [AQQR*OZG>W4?Q TFU37H;>WDAR^G,A+SGYOF!
MVX[>HZ5@?&+_ %6@?]?A_D*?X@_Y+3X;_P"O7_XY1"*<(^C&VU)_(Z^[\8>'
M[&XO+>ZU2"&6S ,ZOD%,XQVYZCIFK.C^(-)U^%Y=*OHKE8SA]F05/N#S7 Z/
MI]I?_&KQ ;NWCF\B$21B1<A6(09Q]":I^&U-GXV\=1V2^5Y<$IB6(8VD$XP/
MJ:ET8V=M[)C4W<[R[\=>&+'4&L;G6;:.X5MK+DD ^A(&*U+_ %?3]+T\W][>
M10VN 1*S<'/3'K^%>,>%;*ZN_ 5]LL-$DMI"_P!INKR9EEC/J>#C'45JWNB&
M?X<:+87NOZ9%<P7):RE:7=%,N2 N<=1GT]JJ5""=K];"5235['H6D^,_#NN7
M?V33M5@GN""1&,J3CTR!FMVO'X]0U+0_%&CCQ7X;TYI)91%;7EL K*20,@*<
M$Y(/0=:]@K&K!0:MLRX2ON%%%%9%A1110 4444 %96O>'-,\2V:VVIV_FJIW
M(P)5D/J"*U:*:;3NA-7W.:\/^!-#\-W375E!(]R1M$TTA=E'H/2H];^'OA_7
MKYKVYMY(KE_OR02%"_U'0_6NIHJO:3OS7U%RQM:QDZ9X;TO2-(DTNQMA#;2J
MRR8)W/D8))ZDXIFF>%])TK07T2"W+V#[MT4S;]V[KG-;-07MY#I]C/>7#%8(
M(VDD8#.% R:7-)]1V1R4'PL\+6]ZMP+6:0*VY89)BT8/T[_C6[K7AK3=>-D;
MZ-S]BE$L(C<J PQZ=N!3]-\0Z9JNC?VO;72BQYS+)\@&.N<TS4O$NE:5HL>K
MW-S_ *#(5"2HI;=NZ<5;E4<M;W)M!(35_#6G:W?6%Y>I(TUB^^ HY4 Y!Y'?
MH*S'\.R3?$B+7EMO*C@M3&\[29\XD8"A?X=O.3WR*Z:WGCNK6*XB.8Y4#H<8
MR",BI:E3DM!\J>I%<VZ7=K-;2@F.5"C@'!P1@UQS_"GPL]O%"MO<((R?F6<[
MG&<X;UKMJ*49RC\+&XI[F)>^$M'OO#JZ"]N8]/7;B.)BI&#D<_6M);&V&G+8
M-$'MA$(=C\@J!C!]>*LU6@U"SN;N>U@N8Y9K?'FHC9*9Z9]#Q1S2:"R1RD?P
ML\+QW0F^S3M&K[Q;O.QCS]*U=?\ !VD>)#;O>Q2)+;C$4L#[&4>G':MV21(H
MVDD=411EF8X 'N:SKCQ!IEOH3ZT;D/IZ#<9HP6!&=O'KS5>TJ-IW8N6*1F:=
MX"T+2M4M]2LXITNX 0)#,S%\YR6SU/-5K_X:^';Z^ENQ'<6SS',JVTQ17SUR
M*Z;3[^WU33K>^M7+V\Z!XV(QD'VJS1[2:=[ZARQML9$/AC2(/#\FA16:KI\B
ME7CR<MGJ2>N?>HO#?A/3?"T5Q'IWG[9V#/YLF[ITQ6Y14\\K-7W'RHP_$7A+
M2O$ZP_VA')YD!)CEB<JRYZC/X53L? &@:?J5IJ%O#.+NV)*RM,S%R<Y+Y^\>
M:ZBBFJDDK)Z"Y5>]C(T[PWIVE:OJ&J6J2"ZOVW3EG)!.<\#MUINE^%],TC4[
M[4;2.07%\<SEG+ \YX';K4FN^(=.\.6D=UJ4K1Q22>6I5"WS8SV^E:@(*@CN
M,T.4[7?4+(Y#_A6/A<ZHU]]B?YF+&#S#Y6?7;_3I6YH'A^P\-Z<;'3D=8#(9
M"'<L=QQGD_2DO/$.G6.N6>CSRLM[>*6A0(2&'/?MT--M/$NEWNOW6B03EK^U
M7=+'L( ''?\ $4VZDEK>PDHIZ$VLZ'IVOV!LM2MEGA)R 3@J?4$<@UBZ+\._
M#VA7ZWUM;R2W"?ZMYY"_E_0>OO70V^I6=W/<PVUS'-);$+,J-G83T!]^.E5-
M"\1:;XC@GFTR8RQP2F)R5*X;&<<_6A2FHM+8;46RAXA\#:+XFO(KN_CE%Q&N
MS?#(5++G.#5J+PMID/B+^WD27[?Y0AW&0D;0 .GK@5M45//*UKCY5>YD?\(W
MIP\3'Q#LD_M Q>3NWG;M^E9.J?#?P[JVH2WLL$T,LQS+]GE*+)ZY%=;1352:
M=TQ.*?0Q+CPEH]QX<&@?9O*TX8_=Q,5/!SG/7.:U+.TBL+*"S@!$,$:QH"<G
M:!@<U/14N3:LV.R14U/3+/6-/EL;^!9K>489&_F/0^]<WI7PT\-Z1J$=[#;S
M2RQ-NC$\I=4/L/\ &K%GX]T'4-=&D6D\TUR7*!EA;R]PZC=^!KIZN]2"Y=KB
MM&6IR^K> =#UC56U*=+B*Y<8D:WF,?F#&.<>WI4VG>"=$T@W_P!A@DACOHO)
MFC$AV[<$<#L>3^==%12]I.UKARQO>QD:3X:T[1=$DTBS21;23?N#.6/S#!YI
MFG^%=(TWP^^A16YDT]]VZ*9B^=QR>:VJK+?VCW[6"7$;7:)YC0ALLJYQDCM2
MYI/J.R.5L?A=X8L;Y+M;::4QMO2.:8LBGZ=_QK5\0^#M'\3-%)J$#^?$,)/$
MY1P/3(ZCZU-9>)]+U"_U*RMIV:?3B1<KL(VXR/QZ&I=#U[3_ !%8M>Z;*TD"
MR&,L5*_,,9Z_45;E5OS.^A*4-D5="\(Z1X=@GCL(&#W Q+-(Y9W'ID]JGT#P
MYIWAJTDM=-218I)/,8.Y8YQCO6M14.<G>[W*44A&4,I5@"I&"".#7%S?"KPM
M->-<?9IT5FW&%)B(R?IV'M7:UE:WXBTWP^+8ZC,T8N9/*BVH6RWX4X2FG: I
M*+W&ZKX8TC6=)CTR\LT-K$ (E3Y3'@8&TCIQ5#0? >A^'KTWMI#+)=;=JS7$
MA=E'H/2KTWB;2X/$<.@R3D:C*F](]AP1R>O3L:V*.::5KZ,+1;N9%EX:T[3]
M=OM8MTD%Y>C$S%R0>G0=NE&@^&].\-PW$6G)(JW$OFR;W+?-T[UKT4G.3T;'
MRHQ]>\,:;XD6U&HI(PMI/,CV2%<'WQUZ4MUX:TZ\\06FN3)(;ZT3RXF#D*!S
MU'?[QK7HH4Y+2X<J,BT\.:=9>(+S7(4D%[=H$E8N2I''0=ONBDT_PQINF:W?
M:O;)(+N].9BTA(/.>!VJYJFIVNC:9/J%[(8[:!=TC 9P,XZ?C2Z;J-MJVG6]
M_:.7MYTWQL1C(^E.\[7^0K*]CF+OX8>&;R\DN3;SP^:VZ2*&8JC'Z=OPK9O_
M  KHNI:+%I%Q8Q_8H0/*1/E,>.ZD<@ULT4.I-VUV#ECV.4TKX=Z!I6H17R)<
M7%Q#_JFN9BXC^@Z5U=%%*4I2=Y,:26P4445(PHHHH **** "BBB@ KC/$WB'
M4M!\8:%"'C_LF_?R90R9(?.!@_B*[.N2^(NBW&M>%)!91M)>VTJ7$"I]XD'D
M#WP36E*W.E+8F=[:&';^/KZ7XH/HK&+^RC,;9?DR?,"_WO=ATI]CXKU76+;Q
MA>@P-IEA')':(T08,P!.2>XP!P?[U8,GA#6Q\/(;R.TN!KRZDUZR*,2C=\O
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M9TK45N)0DUE!M+19//*CC'3.36_XI\4Z[IWCFPT72EMY!=P?*DRX <YPQ/7
MQG'M7':IH6H7VCZ<NE^")M.6UG1[AB 9I6QS@?>*]3D]\5UFN:5J-W\5=!U.
M&QG:RBB'F3;/E0_-P?3J*U:A=/39D)R_(31_$'B?3O'L?AS7Y[6[6ZB:6*6%
M-NS@D8Z<?*1@_G6#X6A\1?\ "T]6 N;/[2K(=0;:=KQ97A..#C%=-J>E:A+\
M8-)U*.SF:QBM"DDX7Y%;$G!/XC\ZS[:WUO0OBKJ5ZFB7%U9:DR)]HC^[&ORY
M8GVP>*2:L[6U7ZC:=]>Y;T#6;F_\1^,;*6*V6*UWK&T4(1SRP^9ARW3O7+>
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MN4445(PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M''6D:1%3>SJ%/<GB@!U%-WIN"[EW$9 SR:9+<V\#JDL\<;."55W )QR<?04
M2T4BNKH'1@RL,@@Y!I: "BBB@ HHHH ***C2XADFDA25&ECQO0,"5STR.V:
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M;ZV2T-L $$*EE8MU)R*]0:UMW<.T$3,!@$H"0/2H;W3+/4;&:SN8$>"965U
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M44 %4+O1-,O[G[1=V,$TP0Q[W3)VGM5^B@#C=3M+>R\;^$;>UA2&%%N55$&
M!Y==E7)Z[_R/_A7_ +>O_1==90!@_P#"&Z']O^W?9&^U9_UOFONQG..O3/:M
MZBB@""YL[:]B,5U;Q3QD8*RH&'ZURFL?#S2Y[&Z.BK)I5\\9$;VDS1(3V#*#
M@CUXKLJ@O)9X;5Y+>W-Q*HRL0<+N_$U4).,E)=!-75CQCX?Z1XF\-WE]JD5@
M+RVBD:TNK2*?]XS*>60'AB/UKUK1O$.FZ]$[64^98SB6"0;)8CZ,IY%8_A*'
M6;&>_BO](%O%=7DMTLHN%?:&.0I [U?UGPII^KSB\!EL]208COK5MDJ^Q/\
M$/8Y%=&,Q=3%U75J;OL33IJG'E1NT5R UK7?#;>7X@M3?V Z:G8QDE1_TTB'
M(^JY%:TOBO0H=.CU!M2A-G("1,F648ZY(!Q^-<I9LT52T[5;+5H6FL9O-C!Q
MNV,OOW S5V@ HHHH **** "BBB@ IKH)(V1ONL"#BG44 <+!\,;&(PJVH73P
M1OS%@ %0<JH(Y4YY)')J7X?6<6GS^);2#?Y46JN%WN6;[J]2>37:UR7@S_D*
M>*O^PL__ *"M &QXBMM*O=%GMM9:%;*4;6,KA!GMR>AS7$>%O#-C%I,-[X2U
ME(-45/WX\T313<G E4'\B,$5Z)>V%IJ-N;>]MHKB$G)CE0,N?H:BL=(TW2S(
M;"PMK4R8W^3$$W8]<5HJU14W24GROIT%RJ][:F1IOBL?;8]+UVU_LO5'X17;
M,4__ %S?H?H>:Z2J6J:38:U9-::C:QW$).=KCH>Q!Z@^XKG3!KWA/FT\[6]'
M7K [9NH!_LL?]8!Z'FLQG7T5RC_$/0%C@D6:9UFD$2[8\%9#_ P)!4_45T\$
MOGP)+L=-XSM<8(^M-II787)****0!1110 4444 %%%% !1110 4444 %%%%
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M110 4444 %%%% !1110! ;*U,RS&VA\U"65]@R">IS7,^#/^0IXJ_P"PL_\
MZ"M=;7)>#/\ D*>*O^PL_P#Z"M '6T444 %%%% !1U&#110!QD;CP1KBVS_+
MX?U*7]RV/ELYV_@/HC'IZ'ZUV=5K^PMM4L)[&\B66WG0HZ,.HKG= O9]/O9/
M"FL2F2:.,M97#'FZ@Z<_[:]#^!H ZK>IZ,.?>EKC=$T/3X/&6K&.%Q]G$+1
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MQFEKB_$_AK5-8UP7%H(8H5M619/-979\_=8#^#&1^.>U %C7.?'WA7_MZ_\
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M=.G7VGL&.U(FRQ9B>0>.]0+#J_@G<81<:OH Y\K.ZYM!_L_\]$'IU'O79T4
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M>F>F:W-'\,^$-;TN'4+?0H4CE!PLB%6&#CD9XH ZO[5;_P#/>+_OL4?:K?\
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MV>DQZ;XU\'Z;9JX>SL;BXNU>0NR^8%&6)ZY?->E4P11B8S"-1(PVE\<D>F:
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MB@#E-=_Y'WPK_P!O7_HNNKKE-=_Y'WPK_P!O7_HNNKH **** "BBB@ HHHH
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M\$VMO9:AXFM[6"."%-2(6.-=JC]VO:@#KZ*** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** .4\/?\CQXL_P"NEM_Z*%=77*>'O^1X\6?]
M=+;_ -%"NKH Y'0_^2C^*/\ KC:?^@M76D@#).!7):'_ ,E(\4?]<;3_ -!:
MNCU(69TZX_M )]D"$R[_ +NT<G--)MV0%H.I. P)]C2UP?P]N_#-]+J#Z/L-
MS'/(>=VX1%OEZ]J[RJJ4YTY<E16?F)--70445C>(]3O](TV6^M+:">.%-SK)
M(5)Y[<5 S9HJKI\EW+:*]['%'*W.V)BPQ]35J@ HHHH **** "BBB@ HHHH
M**** "BBB@#E-=_Y'WPK_P!O7_HNNK/ S7*:[_R/OA7ZW7_HNNK- ')I\0M&
MDUO^QA!J'V_.##]F.0,XS]*ZRO"#X(\2)XX>_LX;N.$7!GBNYDR=V> R@YV^
M_I7ID7C%M-F6V\46#Z7(QVK= [[60^SC[OT;%=>+HT*3C[&ISW6NEK/L9TY2
ME?F5CJZ*9')'-&LD3J\;#*LIR"/8T^N0T"BBB@ HHHH **** "BBB@ HHHH
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MF/X7O85@U+3CEPKY6=&)(E3/8],=B*[2LJB@IM0=U?3T*5[:A1114#"BBB@
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M^81B/=\B_P (Z5V5<MX3_P"0SXI_["7_ +36@#J:*** "BBB@ HHHH ****
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M+TJ2T:S$\8M7F>-/-.TF4Y8L._/3/2HM2\&:5J6LC5F-S;W94)*UM.T8G4=
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M:YC;7K&>^NKQ+/47AA>Y?>X3:IQGOUH Z^BBB@ HHHH **** "BBB@ HHHH
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MS>PS0!/16%HGB.76;B2/^Q[ZTCC+*TLX4+N4X*\&MV@ HHHH **** "BBB@
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M%% !1110 4444 %%%% '(?$C_D6K?_L(VO\ Z-6NOKD/B1_R+5O_ -A&U_\
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M+6Y;5',D(</L.U?XAUKM:Y+P9_R%/%7_ &%G_P#05H ZVBBB@ HHHH ****
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MDA=W1>[G!Z>U=CI<[W6F6UQ)-%,TL8?S(00C9[@&N&\?>"I?$^JVUS#8.S1
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MHH *Y+P9_P A3Q5_V%G_ /05KK:Y'P7_ ,A3Q5_V%G_]!6@#KJ*** "BBB@
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M%% !1110 4444 %%%% !1110 4444 %,ED6&)Y7.$12S'V%/I" 000"#P0:
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M^2A>%?\ =NO_ $776UR6N_\ )0O"OTNO_1==;0 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 5R7@O_D*>*O\ L+/_ .@K76UR7@S_ )"G
MBK_L+/\ ^@K0!UM%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% '*>'O^1X\6?\ 72V_]%"L&[\1>-#JE[&NE7%M#'=*ML/(6195QPI8
M=F/);M6]X>_Y'CQ9_P!=+;_T4*ZN@#A?!\]]<^.?$\NHV2V5R4M@85E$@QM;
M!R/7TKNJY'0_^2C^*/\ KC:?^@M774 %%%% !1110 5YK\2-)\/ZM>6@NO/C
MU 2)$\L,;$K$V<DX&"!UKTJBM*5:I1ESTW9^0I14E:2.8\#:S'J.B?8F1(KS
M3C]FGB12HX^ZX!_A9<$?C73UR7B>.30]1@\5VB,4@40ZE$@_UEOG[^.Y0\_3
M-=5%+'/"DT3AXY%#(RG((/0U#=W=C'T444@"BBB@ HHHH **** "N0\4^)]4
MTC6+>SLM-DDMWMY))+EHF90P' !'IR3FNOHH \TL]:OM:\:^%9+W39K8K'=%
M;@@".?Y,909W#(YYKTNN2UW_ )*%X5_W;K_T776T %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4V1BL;,JEF )"CO[4ZB@#S:'Q%XUDNX]^D7$
M3_:G MGA7;(F1@>8/N@+D[NYK3^'DMS/+XDEO;86MR^J.9(!('"':O\ $.M=
MM7)>#/\ D*>*O^PL_P#Z"M '6T5%<7$-K \]Q(L4,:[G=S@**K:7K&G:U;&X
MTV\ANH0=I:)LX/I5<DG'FMH*ZO8O4445(PHHHH **** "BBB@ HHHH ****
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M8<=CGBNM_P"$S\,D_P#(>T[_ ,"%_P : -RBL,^,O#2D@Z]IX(_Z>%_QI/\
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MR('GZK^52DY.RW&W8]$HKC="^)OAS6_.!NOL+1'[MX0F\>H.>:V?^$M\._\
M0<T__P "%_QK2M1J49NG45FB8R4E>)LT4BL'4,I!4C(([BEK(H**** "BBB@
M#E/#W_(\>+/^NEM_Z*%;6J:'IVLF#[?;B;R'WIDD?@?4>U8OA[_D>/%G_72V
M_P#10KJZ *!T/2#UTNR/_;NG^%)_86D?] JQ_P# =/\ "M"B@#R[7+_0+\?V
M9=^'4MU6_P!DC1B-741LN&&!SDD?+Z9KJK(:1>:]<Z8?#]K%Y-O'.LKP1_O
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M+=QNWX*#[V<Y^N:GCL;6%U>.WC5TW;6"\C/7!]Z *_\ 86D?] JQ_P# =/\
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M"P*-@DX'>M:31].FO6O)+.)KE@ 92OS8'3FK,-O#;JRPQK&&8NP48RQZGZT
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M]I# A1[,E1CY@?FSUK4UB67PG\+XI]!"6MP4@VLRF0!G*@D@]>M &GM\>?\
M/30/^^)?\::[^-XRH>?P\I8[5W+*-Q]!S7):WXOU?1?$UGI*:Q)<W<$MM'<J
M]O'''*).I ^\3].!WK)TG4;V-])@NM2_M.Y3Q/)$\,\8WVPQ(1@]06[$],T
M>BX\>?\ /30/^^)?\:-OCS_GIH'_ 'Q+_C7+>$O&.KZGXITZWEU2*\^V+<&^
ML$@VG3]A^0$]>>G/6O4Z .5V^//^>F@?]\2_XT;?'G_/30/^^)?\:ZJB@#E=
MOCS_ )Z:!_WQ+_C1M\>?\]- _P"^)?\ &NJHH Y7;X\_YZ:!_P!\2_XT;?'G
M_/30/^^)?\:ZJB@#E=OCS_GIH'_?$O\ C1M\>?\ /30/^^)?\:ZJB@#E=OCS
M_GIH'_?$O^-&WQY_STT#_OB7_&NJHH Y7;X\_P">F@?]\2_XT;?'G_/30/\
MOB7_ !KJJ* .5V^//^>F@?\ ?$O^-&WQY_STT#_OB7_&NJHH Y7;X\_YZ:!_
MWQ+_ (T;?'G_ #TT#_OB7_&NJHH Y7;X\_YZ:!_WQ+_C1M\>?\]- _[XE_QK
MJJ* .5V^//\ GIH'_?$O^-&WQY_STT#_ +XE_P :ZJB@#E=OCS_GIH'_ 'Q+
M_C1M\>?\]- _[XE_QKJJ* .5V^//^>F@?]\2_P"-&WQY_P ]- _[XE_QKJJ*
M .5"^.\\R:!_W[E_QKB? <'Q/C\17AOG@71?M;[ENP22N>?*_B ],\5[!10
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 5#/9VUT5-Q;PR[>GF(&Q^=344 1?9X,./)CP_#C:
M/F^OK3FCC=-CHK)_=(R*?10!"]I;23":2WB>51@.R L!]:46MN)#(((@Y;<6
MV#)/KGUJ6B@"*.V@BEDEC@C223[[J@!;ZGO4M%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !2444 +1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
9110 4444 %%%% !1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>42
<FILENAME>g4i5nix4zlkt000013.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g4i5nix4zlkt000013.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %< J # 2(  A$! Q$!_\0
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M&L+-[<6[VD#0+TC,8*C\.E+VVB#D.,^&>HI?VFIJEC90^3.%-Q8QE(KDXQN
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MM=6D$Y484RQAL?3-)5%S\P<NECSJ[N_"%O\ #C5[:TU.74[7=C][,7D\YON
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M^W36%MJ4TOF3HVUO+W_*H/;J?S%=#I\=QX9^(B:%::K=WEC<V3RO'<R^8T3
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MX^RW<_VB7]\=V_V/8<5T]%'/*][ARHY?5?A_H.L74=Q<QW D2)8?W<[*&5>
M#CK706-C;:;8PV=G$L5O"NV-%Z 58HH<FU9L+)!1114C"BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M6_N%O?,D57W;6160C(SC!Q6CX?\ &>LZSIFL6K:)"/$FE7 MIK07&V%BWW9
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MAV^OI]* /:J*XKP[8^*X/'6NW&J75N^FR+!Y>V!U#X1O]7F0A<<;N.3Z5VM
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M\.:/I>H>'-/NYK&-I9859V)));N>OK0!U%(RJZE64,K#!!&0167_ ,(WH_\
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M6&Y89/"R'H?8^]-,F5.RT,/QEX3U/Q7;S:;_ &E90Z7<JHD#V6^>/!R?+?<
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M?)9%(!!SP#GIBH/!I_XI>S'H@_D#7'5Y55CR]G^@7?.K^?Z&]1115&P4444
M%(2 ,DX%0SW<<*]=[]E7O69))),<RMGN .@KGJXF,-%JS&I7C#1:LDN+F26Y
M+12%4C.$QT)[D^H[5?MKE;A.FUQ]Y?3_ .M651CZ@]B.HKBIUYQDY/6YRPK2
MC)O>YN5R^IWNI1?$30+.!"=.FM;EKAO)# ,NW9\^,KU/&1FK[32NV6D8_CBL
M&]EUP>.-#>W>=M*CMKD7.'.S>=NS<,\GKBNN.+BW9HZ(XB+>QV]%94EY,XP&
MV^NT=:@!8$,K,&!R#FIEC(IZ(3Q*OHC<HK*%Y<;PQ<'U4+Q4RZCUWQ_3::N.
M*IO?0I8B#,OQG97E[HX%C;7UU,K$B"SU#[&6X/)<8. <<9KS?0-4U#Q/#X8T
MF]U[43 =(NKFXGBE:WEDN(Y-F&8')V?7!QDYKU35-%T?Q-!&E_;^>L1)7$C1
MLA/7E2#S^M5[OP3X:OM/L["?2+?[-9@K;I'F/RP?O %2#@]QW[UT)IJZ-DTU
M='EEN^OW^D^%/%TUTMS=R1P101><Z32RH\F45!\K"5=N]C]U5)YKNOAUK%I?
MVUU#OO)=2DVWMS<7";5N1(64/$,G$?[LJHX("C(YKJ8]$TR&YL[B*RB22RA,
M%KM&!"AQD*.@X &<9QQ4.C^&]'T![E]+L([9KEMTI0DYP20!D\ $G@8')XIC
M#PW_ ,@*#_?D_P#1C5JUE>&_^0%!_OR?^C&K5H **** "JTUM+++O2[EB&,;
M553_ #!-6:*3BFK,35RC]AG(P;^8C_KG'_\ $TOV*X'349_^^$_^)J[14>RC
MY_>Q<J*7V*?&/[0FQZ;(_P#XFC[%<?\ 00GYZ_)'_P#$U=HH]E'S^]CY44OL
M5Q_T$9^.GR)_\31]BN!TU&?_ +X3_P")J[11[*/G][#E15AM)HI S7DKJ.JE
M$ /Y"L_PY;F+2W9'_P!9/,3D=#YK5M5F:!_R"5_Z[3?^C7I^SB+E1H[6_O\
MZ4FU_P#GI^E/HJK(=B(Q2$']\PSZ <5&;/<NUII"/0FK-%0Z<7N2X1>Y3_L^
M,# =J/[/C_OM5RBI^KT^PO8P[%/^SX_[[4?V>G]]JN44>PI]@]C#L<QXQM[6
MT\%:W<W$'VJ&*QF>2!G*B50A)4D<C/3(JUH-I;W'AW2YHHS#'):1,D0;(0%
M0N3R<=,TOC*[:Q\$ZY=K##.T-C-((ITWQOA"<,O<'N*MZ!,;GPYI<[1QQM+:
M1.4C7:JY0' '8>U/V%/:P>RAV)?[/C_OM2-8Q*I9I&"@9)/:KM4M5?;8M'GY
MI2$']?TS45*5*$7*VQ4,/"4E&Q4M3!<R;/WB,1E-V/F'^>U7/[/C_OM64K^5
M<02] L@S]#P?YUT-8X>$)I\RU1K7PM*#7*M&4SIT9'WVJPJ.N 9-WU%<Q??$
M#1]/U::QEBO7CM[B.VN;V.',$$KXVH[9SGD= 0,C.*'^(.C)K?\ 9Q2\\L7O
M]GF^\G_1Q<X_U6[.=W;IC/&:ZHTH1^%&,:<8['58;U'Y5EZ'_JK[_K^F_P#0
MJYNQ^)VGWMC=W/\ 9]W&R)$]I"2C/>"5F6(( >&9D;Y3@@<GBNB\/EFMKQG7
M8QO)2RYSM.[IFM"S7J.>XAM8&FGD6.)?O.QP!VI[[BC!" V."1D UR-[8:T^
MA:Q%<.)C+-F)(H3N/S)\R_,>.#Q6D(*3U9$Y.*T1T5QJ^GVI<3WD2%'$; MT
M8C('UQS2S:MI]O;17$UW$D4O^K9FQN^E<]'9B#3DM;R._AN+.Y+BYM(BYF8@
M_O.ASD$Y]#QZ56G35RUK>70OUN#8O&C6L0+>9ORH<8(7(VYZ#(-:*E%]3-U9
M+H=6=4L%O$M#=PBX?&V,N,G(R/TJW7+W$T]WJ.GVM[:W$8MFBN)Y8[=F66;'
M 4@8"@\D^P'K745E.*C8TA+FN97B0 Z#< C/*?\ H:UJ;%_NC\JR_$?_ " K
MCZI_Z&M:M18L38O]T?E2>6A_@7\J=12LA60W8G]Q?RHV)_=7\J=119!9#=B?
MW5_*C8G]U?RIU%%D%D-V)_=7\J-B?W5_*G446060W8O]T?E7*> ;V74M(U&2
MXMK>%H]5NHE6& 1@JKD D#J3W/>NMKF?!$FLRZ7?G6Q<"<:E<K#YZ;3Y(?Y,
M<?=QT-%D%D=)L3^ZOY56O9TM8@1&K2.<(N._^%6ZQ=0D\W4, Y6%-O\ P(\G
M],5C7ER0TW-J%-3GKL6-/N6FGDAF",VT.I"XXZ$?Y]:T-B?W5_*L&*7[/=0S
M'[JG:W^Z>/YXKH*C#2YHM/=%8BFHRNEN-\M/[B_E1Y:#HH%>.?$K6-:A\3ZC
M'IU[J+6]EI\4KM8SM&NFN7.99E'^M!7)V\\*>.],\5ZIXFTVZNM:$VJR1&YL
MVTJXMIU%D\+% RO'NRS,2W53U&, 5TV1SV1[-L7T%96N* --P/\ E_B_K7E^
MLC6?"OB35I#J)#7T<S230322R1P/,NR4QM\J.H_<Q@?>9L]%-=M8WMA>^'=&
M&FQ7,,%MJ"6IANL^;&\;%65^3E@0<G)S19#L:^OZQ)I3V2I+;PI.[AY;A694
M"J6Z CTJ*+Q3;16%K+J"-%/+#YSHBDA$S@.?0'KZUJ7-@EU>V=RSL#:L[!0.
M&W*5.?SK)_X1.W4PF.X8&-#%^\B23Y-Q90-P.,9P#Z5TQ=)Q2E_6YD^>]T7F
MUVR6693YIB@!\V<1DQJ0NX@MZXID?B&R=U1TN(79T4++"5.')"M]"1C/K39-
M 20W<7VJ5;.[+-);@+C<PP2&QD=CCUIK>'A/#<B[O9IYYHEA68JJF,*=RD #
M&0W.?84K4AWF+<>)]-MMV]I#M9P=J9P$.&;Z \?A3Y?$5C%),O[YDA"-)*L9
M**& (.?H<U7D\+6S+:F.4K)!#Y)9XDDWC.22&! .<G(]35PZ3$D6H##3+=H
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M#TK/U#X<Z-<RV<MK$L#V]W!</D9$B1C!0CT8'GWYK/V5^IVK'J*LHZ%;<O\
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MLT;7-/-]:W:I!]J:T#3_ +O=*#C:,]3Z5MT (!@ 9)QW-+110 4444 %%%%
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M#SNUN=:NO%_CJ_\ [:U)H= D\VSTZ.7$4CF$G:XZE?E^Z,#))K'T?6M1MO\
MA"=9M_&%]JFH:Y>)%?Z=+.KQ!&SOVQ@?)LZ5[5:Z7865W=W5M:0Q7%XP>XD1
M<-*0, L>_%4K#PGX>TO4GU&PT6PMKQ\[IHH%5N>O('&?:@#D?A#_ ,>?BG'_
M $,-W_,5Z-52PTNPTI9UL+2&V6>9IY1$N-\C=6/N:MT %%%% !1110 4444
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M+=2Q(Z$G')^M 'D^M:WJ%^WC?5;GQ??:1>:%<O%I^GPSK'&RJ/E+(1F3>:]
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MC\<^&I;V.S758_M$B!U0HXR"GF#J, E>0.I'2L=/A1X>0Z@FZZ-M?ONG@W(
MPW[RFX+OVEL'!;L*CM/AK$-:NKJ_U.[N;7=";>'>.62W\D/)\O+@$XQ@=,@T
M ;<'CKPS<O9I%JT1-[_Q[Y5@'YP#DC@$\ G )Z9IUOXW\-W;6:P:I'(;V9H+
M<!&_>,N,XXZ?,OS=.1S6=-\-=#FO=&NV>Y\W2K:&UB)*-O2(Y3=N4\Y[K@TV
M#X:Z5 UJPO\ 4F-O>&\&94&Y_EXX4;1\HSMQG)SG- %R^\:6]CXB_L=K.9Y/
MM-K;^8&&,SAR#]!Y9S]:M>*?$3^&M(DU)=.EO8807G\J5$\M!U/S$9/HHY-5
M=8\$6.KZA-?F]OK6[DE@F$MNZ QM"'"%=RD?QG.<]J;J/@/3KY(?)NKJPE2X
M%U+-:"-6N9@.'E#(58@\CCKSZ4 =/&XDB20!E#*&PPP1GUIU,B0QPI&9&D*J
M 7?&6QW..,T^@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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B1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>43
<FILENAME>g4i5nix4zlkt000039.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g4i5nix4zlkt000039.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %\ J # 2(  A$! Q$!_\0
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M#/2J&B:BVK:/;WK6EQ:&4']Q<+AUP2.1^&?QKR#[7'XG^*KMJ6FZLT:O''#
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M<A7'JY[G^(#BK-Y/<>;8:?'?-]ABT@3PR2ZFT \PD[GW@'>4Z!>PHL%SULD
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M_P!TDCD<#BB?3-/NI(I+BQMIGA_U;21*Q3Z$CBN?_P"%E^#O^@Y#_P!^W_\
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MFC?]?T/_ *&*F?PL<=T9LW_'Q+_OM_.F4^;_ (^)?]]OYTRF(****8!1110
M4444 %%%% !6S<?\B5IW_80N/_1<58U;-Q_R)6G?]A"X_P#1<51+=#74QJ**
M*L04444 %%%% !1110 4444 7=(_Y#FG?]?47_H8KZSKY,TC_D.:=_U]1?\
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M5?):JEI,J8#)NS\P.>E="^N:)_PAUQ+)=6<FK3Z.FGYB,@F8@C"M&1M  '+
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M:1B-$GNGN& '^TW/)/08%22_\B/:?]A.;_T5'6NMES;D:7=C&HHHK4@****
M"BNO\$^'=,U=+BXUGSA;&>*RMS$2#Y\A."?8 <_6JVF^";R^,@N;ZTL"M_\
MV=&+G=F6<=5& <?4^M9NK%-I]"N25DSF:*ZT?#[4S87%R+B NAN/)AVONG6$
MD.P.-J]#@$@G%)<>!9;:R-R^LV!\N&"XFB ??%#*0 YXYQGH.>*7M8=Q^SEV
M.3HKO=3^'*1ZGJ8L=4C%C9S+"S/#+*Z.4W$/L4X'?=C'S =JX,C#$9!P<9'0
MU4*D9KW12BX[B44459(5J^&/^1LT;_K^A_\ 0Q656KX8_P"1LT;_ *_H?_0Q
M4S^%CCNC-F_X^)?]]OYTRGS?\?$O^^W\Z93$%%='X0T*RUR^NA?WBP0VUN\I
M0JY+?*0#E0< ,5R.IZ"I-5\,(WCMO#FC.)2&6(,[$!7"9D))'0$,>.W2H]I%
M2Y2N1VN<Q17=Z#X&L)]7MGOM5MKS2)8)Y$FM2Z^8\0^9#QE<?>SCD=*S?"^E
M:-J^IZFLRB4QJ6L+(W@@%Q\V,>:P[+ST!-+VL=?(?LV<M17>?\(;8R:EJ]N8
MKFRBMYK-%-VQ\R#S7VL %!$@[ Y]#3;CX<3W&J7\6F7\#6\=W);6BR*Y:5T&
M60G;@$=-QP">E+V\.H>SD<+1717_ (1N=-\/P:K<W<2^=$DJ0^5(<ACT$F-F
MX=USQ7.UI&2EL2TUN%;-Q_R)6G?]A"X_]%Q5C5LW'_(E:=_V$+C_ -%Q4I;H
M%U,:BBBK$%%':N\F\+:,WA!K^S@NKIDL1.U_;W*R".;^*.2#JJCD;N<5$YJ-
MK]2HQ<MC@Z*[:^\#67]MV^G6.N6_SV<,S>9'(SLS@?=55R0<Y_V1UJ1?A\AT
M^&!]3A35Y-6?3]A#&/Y1G XZX^;/IQUJ/;0L/V<CA:*ZG3_ M]J45G)%=0!;
MDW( V,S*(#AL*!EB<\ <UAZKI_\ 9>HR6?VA)]@'SJC)U&<%6 (([@BK4XMV
M0G%I792HHHJR2[I'_(<T[_KZB_\ 0Q7UG7R9I'_(<T[_ *^HO_0Q7UG7F9AO
M$[,+LPKY3\2_\C7K'_7[-_Z&:^K*^4_$O_(UZQ_U^S?^AFEE_P 4AXK9&711
M17J'$%%%% !1110 5HZ/J\FC7-Q/%$DIGM9;8AB1@.,$_45G44FDU9@G8ZG0
M/&TNA6-G;_V7:7C64LLEM-,[AHO,&' P<<^]5W\77#V)M3:0A3I/]E;MQSLW
M;M_U]NE<]14>RA>]BN>5K'6/XZEN)[C[=I%G=VD_D,;65W"K)$NU7!&#TZCH
M:SM8\3WNN6?D7B1ES>27C2KD$LZA=N.P  Q6)10J<4[I YR9H6&K2:?IVJ6:
M1(ZZA"D3L2<H%8-D?E6_=>(((O NCZ##>BYD%T+BY*Q,ODH#N6(D_>PQ8\<5
MR%%-P3=P4FCO?$'C_;K]Y-H-K:11O>QW+7:A]UUY8^7<K=!R<XQFLJ;QDL^J
MQWCZ+;LB(R^4UU.QW,02ZN6RAXP-N.*Y>BI5&"5ANI)F[>^*[Z\\5P^(A'%'
M=0M&8T&64!!@ DG+<=23FKNJ>-Y-1\/RZ)'I%G:V4DOGA4DD=DDW;BP+'OD\
M=!FN5HI^SCIIL+GEJ=%I_BZYT_3K.R2TA=;6.Z169CEO/&&S].U/M_&4L=M#
M:7&FVUU9+IR:?+;R,P$JHY=6)&""">U<U11[.+Z!SR.MF\?Z@]]<7D-G;033
M7%M.-A)5#"NT #T(ZTD'C=+2]::T\/Z=;0R020RQ1,ZL^]@S'S =PY'&#P"1
M7)T4O90[#]I+N=;<>/)[N6^>?2[5EN_L[%!(X$;PC"LO/Z'-.7X@7)N7N9M*
MLIYDNY+RS>0MFUD?[V,'YAGG![UR%%'L8=@]I+N=%%XONXUMMUO'(\%A<6.]
MF.7$Q)9S[@DTM[XODN?#;:)!IMM:0RF,S-$[D,4Z;48E4R>3MZUSE%/V<;WL
M+GD%%%%:$A1110 4444 %%%% &SXN_Y''6/^OIZT_ NG65^^LO>6]C-]FL?-
MB^WNR0HV\#+$'(&#69XN_P"1QUC_ *^GJG8ZI<Z=;W\$&S9?0?9YMRY.S(/'
MH<BLK.5-)>1=TIW9T4F@Z?>RZAJ5]>V&F:;;2Q6P;2D:XC>1QGY<G. .2<_2
MK+?#U+>)XKO5A'J#ZB=.MH5A+),^%96+9^48;)XXKG=&\17NAQSQ01VL]O.R
MN\%W")4WK]UL'H1ZT^X\4ZO<B(RW(,T5\U^LP7#B8@#/I@8&!BI<:E[)Z#O"
MVJ.BN_AS]GO[=%U)Q9LL[7$LUL4>(0C+,$S\P(^Z<BJ6D>$M+UG59+>SUJXN
M+4)$R2PV+,P+G!$@)"IM[\\]LU2?QCJ)U6'48K;3;>>,.&$%HJK-O^_Y@_BS
M4T?CW6(I)62'31&XB"0&S7RX3'G847L1D\\U/+6MO_7W#O3OL76\!"/3-0N/
MM\MQ/9RSQ/':6XE$9C) \P;@R[L9!"D =:N7NE^"=*:U6Z>\8W.CQS)\I&9'
M!(?/S8)_)<#AL\8B^.=61KJ1(=/6XN&E;[2+4>;'YGWPK=0#D]<XK+U+6KK5
M;2PM[E+?_081!%(D>UV0<*&/?';\::A4;]Y@Y02T1G?ABMF7_D1[3_L)S?\
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M7_\ 0"N/^^T_^*H]K3_F7WAR2[',45T__"N_%_\ T KC_OM/_BJ/^%=^+_\
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MX_[[3_XJC_A7?B__ * 5Q_WVG_Q5'M:?\R^\.278YBBNG_X5WXO_ .@%<?\
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M%_\ T KC_OM/_BJ/:T_YE]X<DNQS%;-Q_P B5IW_ &$+C_T7%5[_ (5WXO\
M^@%<?]]I_P#%5J3>!/%#>%+*U&C3F>.]GD9-R9"LD8!Z]R#^53*K"Z]Y?>4H
M2UT.$HKI_P#A7?B__H!7'_?:?_%4?\*[\7_] *X_[[3_ .*JO:T_YE]Y/)+L
M<Q173_\ "N_%_P#T KC_ +[3_P"*H_X5WXO_ .@%<?\ ?:?_ !5'M:?\R^\.
M278YBBNG_P"%=^+_ /H!7'_?:?\ Q5'_  KOQ?\ ] *X_P"^T_\ BJ/:T_YE
M]X<DNQS%%=/_ ,*[\7_] *X_[[3_ .*H_P"%=^+_ /H!7'_?:?\ Q5'M:?\
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M5!M;.-IS]*-IYX/'7B@"?[;<_P#/9OTH^VW/_/9OTJM(RPQ-+*P2)%+,['
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M^PV_D[_*\I-GF9W;=HQG/.<=<U-110!+<_\ 'U+_ +QJ*I;G_CZE_P!XU%0
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M'&)3*$42%0I?') Y SZ<G\Z=110 4444 %2G_CT3_?;^0J*I3_QZ)_OM_(4
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M_L__ *;#_ODT?V?_ --A_P!\FKE% %/^S_\ IL/^^31_9_\ TV'_ 'R:N44
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M *;#_ODU<HH I_V?_P!-A_WR:/[/_P"FP_[Y-7** *?]G_\ 38?]\FC^S_\
MIL/^^35RB@"G_9__ $V'_?)H_L__ *;#_ODU<HH I_V?_P!-A_WR:/[/_P"F
MP_[Y-7** *?]G_\ 38?]\FGQ6.V9&\X'# XVFK-*OWU^M %(Z?R?WP_[Y-']
MG_\ 38?]\FKE% %/^S_^FP_[Y-']G_\ 38?]\FKE% %/^S_^FP_[Y-']G_\
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MP[IMI=WD%J+NZDO)VCC16)"(-H)+-@^PJI%X)N4\2)JK7L!5=;DU0QA3G:T
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M$KF-\L1N3!( ]!5ZR\(VMAK/VZ"ZF$0FDN$M?+C 5WR6RX7>RY9B%)P"?88
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M -*V74@4HYM]WF  $MT5B"1SBK6@^*K/7[B:VCB>WN8HDG\IY8W)C8D!LHS
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MF'^SS:#5)0/[/L;'=Y(Z6TGF!L9_BZ8[>]5Y/A9I[+J\<=U&D>H+.$8V2&:
MRG+8ESN8#) ''!Y)JKX9\5:KXB\8Z'<7$EM#8WNEW5Q':6TS,5 D15\T'C>.
M>1ZD=J](H Y#4/ B7NHW=_'JDL%Q-=V5W&?)5A$]LI51@GY@V3GIBNOHHH 5
M?O#ZU<JFOWA]:N4 %4V^^WUJY6-->S+-(H"8#$?=H N450^WS>D?_?-'V^;T
MC_[YH OT50^WS>D?_?-'V^;TC_[YH OT50^WS>D?_?-'V^;TC_[YH O]Z<_W
MV^M9POYMPXCZ_P!VGS7LRS2* F Q ^6@"Y15#[?-Z1_]\T?;YO2/_OF@"_WI
M6^^WUK/%_-N Q'U_NT^:]F6:10$P&(^[0!<HJA]OF](_^^:/M\WI'_WS0!?H
MJA]OF](_^^:/M\WI'_WS0!?HJA]OF](_^^:/M\WI'_WS0!?HJA]OF](_^^:/
MM\WI'_WS0!?HJA]OF](_^^:/M\WI'_WS0!?HJA]OF](_^^:/M\WI'_WS0!?H
MJA]OF](_^^:/M\WI'_WS0!?HJA]OF](_^^:/M\WI'_WS0!?HJA]OF](_^^:/
MM\WI'_WS0!?HJA]OF](_^^:/M\WI'_WS0!?HJA]OF](_^^:/M\WI'_WS0!HO
M]]OK3:ISWLJ3R* F V.5IGV^;TC_ .^: +]%4/M\WI'_ -\T?;YO2/\ [YH
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M&\?R/%X,\1R1NR.MI*593@@^QKK*-O:W/!XZ\=*2O#;?4]2FU+POIDEU<_\
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MST%>@:9/>7;&ZFFMOLL]O!+#;QK^\B9ER^X]P21CZ4 :-%%% !1110 4444
M2W/_ !]2_P"\:BJ6Y_X^I?\ >-14 %%%* 3T!.* $HI<' .#@]*-K9QM.?3%
M "4444 %2G_CT7_KH?Y"HJE/_'HO_70_R% $5%%'0X- !12X.,XX%&TCJ#^5
M "44I!!P1@TE !12D$=01FDH **7!SC!SZ4NQLXVG)[8H ;12D$'!!'UH((Z
MC% "5);_ /'S%_OC^=1X(ZBI+?\ X^8O]\?SH 8?O'ZTE*?O'ZT $G !/TH
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M WH&X/7K2-!"^[=#$VXAFR@.XCH3ZD4 >=?VY>2_"VZV:7<*DMA>L;VV91%
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M;\Q0!!14_P!CN/\ GDWYBC['<?\ /)OS% $%%3_8[C_GDWYBC['<?\\F_,4
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M^T/,6V*PQ\H7S&R>^T8Z\1_8/$T6C-!;Z>ZWM[<%]2NS?1B>1=H!,9QM3H$
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M$N+:[@:&:(D97<C<X(Z&O/9?AUK>G7.M#3/(NK-IK*33(99]A2.*<S-$3@X
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0[L<XSSC-244 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>44
<FILENAME>g4i5nix4zlkt000047.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g4i5nix4zlkt000047.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %# J # 2(  A$! Q$!_\0
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MS5!_RPM/^^6_QJ)OB#JP_P"7>S_[Y;_XJCF0N5GI5%>6O\2-87I;67_?#?\
MQ55I/BAK:=+6Q_[X?_XJCF0^5GK=%>.'XKZZ#C[)I_\ WP__ ,51_P +7UW_
M )]-/_[X?_XJCF0<K/8Z*\>'Q6UT_P#+I8?]\/\ _%4O_"U-=_Y];#_OA_\
MXJCF0<K/8**\@_X6IKG_ #ZV'_?#_P#Q5'_"T]<_Y];#_OA__BJ.9!R,]?HK
MR#_A:FN_\^MA_P!\/_\ %4T_%77?^?6P_P"^'_\ BJ.9!RL]AHKQL_%?7O\
MGUT__OA__BJ8?BUKX_Y=-/\ ^^'_ /BJ.9!RL]GHKQ0_%[Q!_P ^FG?]\/\
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M%0K*9@\<GTIEA\C/D?,&P: -BD/W3]* <C-(WW3]*!&,;];#=(ZE@6QQ4O\
M:S.@9(P,^IK)U17DB 52WS]!4L$4OEJ-C=/2HN58NMJ-P>A ^@J,W4S=9&J,
M6TI8 C'UJPMF/XI/R%&H:$.\GJ2?QI<U96VB'4L:! @?.,CT- 716W488]%8
M_A5X8'15'X4NX^M.P7*8AF;HA_&I%MI>Y4?C4^2>YHHL*Y&+<?Q2#\!3A!$.
MI8TZEQ0%Q D0Z1Y^II<@=$4?A1BC% A=Y]?RI-Q]31BDI@(>AJC)N!ZFK]5I
M8Z0RF6JQ%=#'ES<KV/I4$B5 20>:!E^6(J-ZG<A[BI/MYC@*M\PQ5&&Z:$XZ
MH>JFGSP"XC\VW.<=4H TK*9< L0!CO5HWD ./,'X5A[O]%.1C@4Q""RTKA8V
MGU*!.Y/T%1?VLC?=0_C67+D]!FFQH^>$;\J+L+&H=2?L@'XU&;^8]P/PJL(9
M3_ :=]GD[X'U-&H:#FNYF_Y:&HC*[=78_C4GV<]Y%% MU[N3]!0&A!FD)JT+
M>/T8TH@3M'^9HL%RGNI.3T!J^(?15'X4X1GU_2BP7,[8YZ*:##*0?E[5I>5Z
MDT&(8IV"YU,'%M$/]@?RKQ/41B]D^M>VQ?ZF/_=%>+:BO^F/3GL3#<99_P"H
MD_WJNQ]:J6@_<R?[U7$'2I6Q3W.:\3K_ ,3. _\ 3'^IKKO"/S>'60GL:Y3Q
M./\ 3K<_],_ZUUG@L;]*V>I-3U*6PF.*B;'..<=:L,,,1Z&L:[O8],BEEFY8
M\(F>7:J).=\26Z->EV;!92H /(]ZI"UFU "X?,T5JGEQHYVB0@$X'L .:FBB
MEU>\DN+ACY0.9''?T5:Z>&S"6DC,H"B)EB3_ )YKCH*GJ5LC>\-:=!9V4=S$
MFUKFU!;!R,E><?C66EG;1D,EO$K#G(09S75Z'9O_ ,(EIUSCY3;C)_#%<Z13
M0GJ1,*@<<59(J%Q0(SYDQ6=.M:=W&)+>1&SAE*\'!K!L4OHX!#>HQ90</G.1
M]:I1NF^Q+G:25MR-A\QH J1U^:D J"P IP%*!3P#Z4#&XI<4\+2[* (B*:14
M^VFD8H$0$5"XXJP14+CBF!3Q\Z_6NKC@+ ?2N7 S,G^\*[V*# '%#!%>&T'I
M5*TM ?&FM#'W8X!_XZ:Z*.+BLVR4?\)EXA([& ?^.4 :L4008 JPHI%%2 4#
M'**D44T"GB@0O:N?3YO&4 ]$)_2N@[5S]L,^,U]HB: .KI13:6F ZMS0/]3/
M_O#^58=;F@_ZF;_>'\J<=R9;#?$J,^FKM(!$@.<9[&L*1/M%HKH?WJ#MWKHM
M<_X](QZR?T-<_""CLH]<BK8EL58RYCY/)X)I;9WCNUC;CG\ZDN!Y;&11\K?>
M%5F;+0S@'"N ?84BBZC.+IP01GUJTJD3;@/E(Y^M0R@JT<F>",594\?2@1<B
M/%1W#3JI\M P]*5#A@:FR!U(H R(9F:0JT6PCU%3[C5BX*%>,;JK4@%)YI,T
MIIOXT +FC--+*.I%-,T8ZL* )*6JYNXAWJ-M0C'0&D!=I16<=2]%J5K@_9#,
M,;J L7254?,<4P7-L3@3QYSC&X=:P-0O9C:.PR2JEOE%<!IIEFUM'SP#GGZ\
MT[A8]B+(.XIAEC'\8K \]SW/YTGFMZTKA8W3<Q#^*F?;8AV)K$,C>M-WG^]1
M<=C8:\5N,8%.$O'/*^M8PFQU.:D2X*G*FBX6-1E##(YJK)%21W(8\'#>GK5@
M.K\'@T",]E(HC=XFW(2#5N2+TJ,1T#'Q3&=G$B @8XJTJ@?=B456B&V9OH*N
M@\4(& W'^Z/PHVM_>-.%.H$,\OU)/XTOEKZ4ZB@ V+Z48'I2\>M(64=6'YT"
M%HJ,SQ+U<?G4;7UNO604#)Z*HMJUJO\ '4+Z[;CIS1<#4H/2L1O$"?PH:KR>
M(7VG:G:BZ"QZ3%_J4_W17C-_\URS#H>:]DM6WVD+'^*-3^E>,2\NWU/\Z)B@
M.LQ^ZD_WJN1BJMH/W<GUJ[&*2V*>YS7BE?\ 2K<_],S_ #KI_ DJBU0,< L1
M^AKF?%V1<6N#C*,/UJ&UU.YT?P\MY"P+).I5-OWN<$?E4-V92V.IO;V&QMGN
M9VP@Z =6/8"N#FEN-=U!Y96V1KU/:-?04^YN[S7[]%V[$481,\1KW)]ZV+33
MT2-%53]G4YY'^M/J?:ANX)#M/@3=&@3;"H^1/ZGWK;<9MI!_L'^55"/^)CP,
M#''Y5>(_=/\ [I_E5+8ELG\(:[>75BFDR>68(HPJ$ AL=<'G!IDB[78>A(JC
MX# ;5U7/WL"M*Y7;<S#T=A^M*.PV5F%9]S?V\+,F[?*#CRUZYQFI=3OTL(<\
M-*WW$_J?:L:ULIKF5II<F23JS#.T=_Q]/2AOL"0^P%[,\UU=I''O;]VBG)"C
MWJ:84NGH42Z3)*K.P4$_=&!Q3IA0!ERQ_-3 E6)1S3 *!C0M/Q2@4N* &XI<
M4_%&*0$9%-(XXJ;:32^73 J%:AD7 JZR>U03+\M B@@S<QCU<?SKTA(^E>=0
M#-Y"/^FB_P Z], I@@ XK'TX$^+/$A/:>(?^."ML#D5RS7LMGXA\2>6G[R2X
M4ID=<(!P/SH V;G5X+>7RD_>/DAMO1:U-/N;>\CSY;9!PP!Y%>5_:)$E<%S\
MQZ^N>]=;X?NY51&+,Z$D?E4WU*2T.YCT])R/(E_!A55T:-RC@AE."#4NFZA'
M<3C=\DHX5QT/UK7O+9+B)F<8D13AAWQZU:U)>A@GI6!8<^,)/:(UOG[M8&F#
M/BR<^D5(#J:6D%+3 <.M=%I"JD<NT8^89_*N<7[P^M=+IG^KD^HIQW)EL9_B
MN?[/9VLASC[0 <>FTUB><"B31$.AY!!ZBMOQ; DVF1;FVE)=RD] <&N9MP!;
M-!&_S E@/Y_K5,([&AGSXR..1D51*_N9$/ ()%6+=B)%?UPM1L#]I=2/FW'\
MJ5QI%HW&=.1R,J5Y'O4L$FZ,-ZCG-0+$K:<(@>AX^M,@8E) /X&"XHN#1JHW
M-#=>M-0_,*><=30(C8BL_49IX+5GC(![5I9'I5'50TMJ$C3+$\ 4@,%=1U0#
M<TH\L\9VBK*7<[*=[$GVI/[+O&MU SUSLSTJU%IUQC!CP?K0,J&=SZ_G3?,8
MU9FM)(CAU_*JS)Z4@#S&_O4F[U-)L8G@$_05*MI,W2,CZT 1/(D:%V. !DFM
M:PV7FEQECL1QFJL>EI,K1W&"I'*@U)(@6TDMK?@IA5YZ4P&ZJ\-G8F.VNHH9
M7X!E'##TJIH-KN:1[NWM@V/EDB[UF:Q>W"!+1[*.YA09);KFK>FJJV:F"$P*
M_)C#9Q0!9EP)G"_=!XIG-3+!(W1":E6QF/8#ZFD!4Q28K173&/WI%'ZU,NEQ
M_P 4K'Z"@+F1BDY%;HTVV7KN/U:F2V]M%&Q6-"0.F:=@N8V35B.<@8;D4U9(
MIK<N(]F.G/O2PH&XR#2&7(IMW&<CWIWFQ@?>%1F("%\#M6))(ZL1F@1N+,FY
MW!X YI3J<"#K7./>R0(P/W6X)]*A\[S!D/D4KCL=/_;,>/E&:B?7,#A:YWS
M/6C?GM1<5C;.N2'H *B?6)CT:LK=[49-%QV+K:E=-_RT(J(W5PW61JK9-'-
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M7)))/ K>6)8TV@5-% L,851T%(PJDA-F=' T+3EL8DE+C'I@5#**OR"J<HH
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M;+@H .F,'_"M^(?+7G^@ZEJ?]LQV\DLY=ICYT97G&>I&.*3:5K@D>B*H50%
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MN>>AS5>YB:1<H<.IR#4V*19M]1%VBA+6XC XWR1X K+.IW*S.J:7-+AB"V0
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ML;.X2/>?-,?7&,C(_E6Q\-KBYN+"^:Y0IB50H+9XVT+XA2^$ZK4_^/=?]_\
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MUC_$?^FC5IL-L.?:LZP'!'_35JT+UA':2-_=4UU'.<-*_F:A(WJQI9_NXJO
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M69\-6R^N#^[<H/\ QVA?$A/X6==JK[+93C/S_P!#6,2S\L>M;.J@&V3/]_\
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ME+J+A]2EWQ]H%^5/I@=:T))/W(C10J*,*H'% 6/%F,MCXRU:U:XQ#)\T$8/
M3)R/K706OW17/_$>U.D>*HGE!;S4$ZD?+G.05/Z5JZ+=B]TZWN5X5UP0#T8<
M$5M.@U250SC-<W*;T)^3'?-7 '*#'7V-9Z[@ 0.*TK1B0  >1WX%8&@^*5T.
M""/:M6PE\PE3D'K50(."0N?K5N#&<D<8XI@7B1N%,\%#&N>*/>[B/_D,4N>%
M(I?!@QKGB;WN8C_Y"%5'<F6QT.K?\>R?[_\ 0UCBM?5SBU3/]_\ H:QQUJF0
MA<')Q363OTQ4W3)/2J<]T#E4YQU- Q7*Y'O5:^C86Q9@!&>N:--D:X9F;KNP
M/:M1HPPVL 5QCFD/8XK4M1C,D,(7#(?PJ^[[K)SZK67XFTY;&^1UP/-.XJ.Q
M[X]JNQMG2R?]FHZE]">RED:#:!G'&2>E11'-U[YYI^G'_1Y/I5>U/[\?6@1M
MQG]W^-<YXB/^E+_USKH$.(Q7-^(F_P!,'_7.E/8:W.>NC_H3_C46F\W$7^[1
M=-_HCBFZ2<SI["LEN4SO5YTQ?89JN[?Z,1Z9JW:C=8JOJM9TC81U/936S(1S
M:^.)8KE++RAD,$S@UTEJ<S@^U>:9)U=?^NP_G7I5J,2@^U2AG1J?E'TILG*T
MU3\H^E.;I5DE.45/'44H-,5FSP30!H"G=JJ(6/4M4W0<DT -D^^:@;.*E)ZD
M'-1,: ,>\;&E:G[;OY5YFC9<5Z->S*=.UB,9W)DG\17GFF>4VI6XG_U6\;OI
M6<AG?:#HUM<:?#=7$C;FZ+T KHH[&U081]OT%94.L::K"*0DHJY50.!5U=?T
ML 8+CT^456B#4M_V;"QSYY_*F?V<@?=YXVCH,57_ +?TW^\__?-']OZ;C[S_
M /?-.Z#4N/$,?Z[]*A6.!3EV+?05!_;NE_WF_P"^*/[:TGON/_ *+A8D,D"G
M@&G"ZMQ_RS-1?VUH_P#<'_?LTHUO1\?ZL?\ ?LT7"Q8^W(!\JD?A33?KZ-47
M]N:1CF-?^_9I?[;T?O&G_?LT7\PL+]KBZE3^50R7$+GDO4O]MZ-W1/\ OV:3
M^V=&Q_JD_P"_9HOY@5)8;2=<2*YJ!=*TXGY8IC[!S6@=8T@J=L:9[?(:SM0U
M9'M_*M6"EF^<J,'%*XREJU[:Z%9A[. &XD8J"_(3 ZX[FN0-W+<3&>>1GD;[
MQ8\UI>(F/]G0]_WK?RK#N%,-C'-W8<TA'TQIW_(,M/\ KBG_ *"*^;9M8*&9
MWMU?:S'Y"<GFOI#2SG2;,^L"?^@BOC>UM[N#68RZ2I&T[9YX/)K62NC.+LSU
M&T:WGM(;E%<B1-P5AR/:JNKS%;9, */,7%2V!VZ; ?\ 9JCJX'DAEZ-*IX[]
M>:PZFHBN<=:E1F8X7)/M553Q5>YOGMYXH429FEX)C7H.^3VJ@-;S74_>-/6[
ME'1S2(S2694J0=H=<G/&>15;-" O+J$O0D'ZBE^VJWWX8V^JU1S13 N'^SY/
M]991GZ"H6T[1IC@VY3C)P:AS1G%  _AW1I?NR2)^M-@\,6D$I>"\0Y&"'7_"
MI-U*": %_L.X5-MO/:8Z\@\U$VBZD.MM:3#_ &7Q_.IPQ]34BRN.C$?C0%C/
M;2;@?ZS2)/K&5:HC80)]^SNXO^ ,/Y5MI=S+TD/YU82_G'\9HN%CG!;V!&#/
M.GLV?ZTAT;3YO^7Y_P#OO_Z]=8NHR]]I^HJ5;[/WH8C]4%%V%CCAX:L6Z7\@
M_P"VM2)X5M0PQJ$A_P"VO_UJ[1+J(];6#_O@582YA_Y]H?\ OV*+L+')VVA0
MP,K+=DD'C]YC^5;BRW707 _ &MF.Y7M#&/HHJ=;MNRJ/PHU"Q@-#=3C:9;@@
M\87</Y4Z/1)V4*(KAE'0%FP/S-="+N3Z4\3R-U8T#,"/PU@Y-K&#_MG-7H-#
M5,9,:>R)6H"3WJ510!7BTZ!?[S'WK0AB6(87CUQ1'&[=%-6XK<G[QQ3 8H)Z
M"K<<*QKYDO;H*/-A@&$&YO6J-W>+'$\]Q*L<48W,S' 44"/+_BM93ZKJL3VX
M#3QQ@HF<94Y!']:Q?"%CJFGQ3K?,J0LV4AR"0W=N*V=2U/\ M74Y+L B(MB+
M<.=@Z?X_C4L!YJG4ER\E]!<JOS&M!<[<8&?6M*-M\0;C&*QX=H[5I6<ZCC/?
MIBH*+(<=GR?>M2Q82Q#/!'!YJA*@:,21GGO5G2Y"&*_WAFF(U'/RJ1@8I_@[
M_D-^(_>>'_T4*CXVD?G4W@_']L^(,?\ /:'_ -%BJCN3+8VM:_X]8_\ KI_0
MUD[TBCWR,% K6UR01V:,?[_'Y&N.N)6N9<,3L':J9"V)[C4GNG\N %(N['JU
M/5-MN0!U%16=LS-D\*.]:1AR JCB@H@T>/9YOUJ^TH\QL<[!N/\ 2FP0>0>.
M],"^5!,['F1B:!$=Y96U_"(KB%7+ D,1RI]0:YB/<E@R-T7Y6S[&NO7'EJWH
M*Y/4H-2AENMMEOMW<LL@;L3FI941]J76!O+QMQS6-=P*[?:07\R/C )QBJI\
M5?V>7M[BRE#-\H*D$5<TQM0U%LQZ/=F"3Y6=UV#![\TJ=91E=#E"Z.CL9O-M
M5.<D<?6N?\0MF^;V05TND:'=6UN%NYD#\C"<\9XYJIJWA:\NI7F@FA;*X"L2
M#152N[!!]SS^Y;]Q(/:DTDXF7'I4NIVL]E)-!<1M'*HY5JATD9F4CTK!;EGH
MEE_QZQ_2L^]79++_ +I-7K,_Z+']*K:HH"%_]DBMGL0CR\$C4T.!_K1_.O1+
M.X5Y=HZXKA=7M!9ZW;[00DA5A78V" 7>1Z5"&CJX^@^E2GI4"'@?2I">*T$1
MO0J\9Y_*FM]ZN$\1ZU>Q:K+;I<O%''@*J'% CT'=M'&3^%,L;Y+Z-RHVLCE&
M'H17">'_ !+>27T5G<3^;%(<;GZC\:Z+0I-FHW4?.&E8BE?4#6SAY/\ >-,9
ML&GJR!Y-RD_,<<U',R,1M!%,#"OY(SIVK("#( =P[@8XKS.,X(->EWL:#3M6
MD"X=@03ZX'%>:1CD5E(I%EM@V%I#O;E8QR?QK3$&X [=N.>*J^4D=NLZJ RM
M\Q]JZ^V\-W4D".LD;*Z@CFG:^P;;F&L@ QY"&GAU_P">*UJ3>'+V-L#8<=>:
M$\.WKIN 3'^]1RL=T9H*]X5_.I08\?ZE:O?V%?)_ OYT'2;P?\LQ^=%F%RE^
M[/\ RQ'YTA"G_EF!^-6C87*]8Z8;:8<;#2L%R'=&HYB!_&FF2/M$/SJ3[),W
M1&---I,!_JS18"/SXP<>3_X]1]HB/_+$_P#?5'V6<'_5&FM;3?\ /(_E0,4R
MPCK$3_P*F%HP0\0=&![G(-(;:?/^K;\J40SXP8F_*@"KKUR)]*C4*=R2[F/U
M&*H:J<:&GT'\JU+BSDFMI8BC?.IQQW[5C:T2FB(#P< '\J9+/I?2/^0+8_\
M7O'_ .@BODUM-CLKJ2X^US"*.1F9&.1C)KZQTC_D"V'_ %[Q_P#H(KY9",]P
M\8[R,""<]SS6TC.*.HMKB&#2[=Y)512F02>M4+N7[25_=R!-V0S#K5&+)82
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M2FDY)Q3 5/[Q[=*6@^@Z"DH 6BBB@0M.%-%.% QXJ1:C%2"@"1:E3K40J5*
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M-%F%T8(EW7487( .?K72,3@TZ#P/JRRK)+;CCG:KKS^M7V\.:P1Q9G_OM?\
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MXGN)%,6EE@!_SV3_ .*HU6B0:/<X*% K84  = *?.>*ZB/X;^+@Y)TAO^_\
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M5$T[$IHQ$#(XDA; )^8?XBM.QVB96V;3GJO3\JUD^''BU2KC26##K^_CY_\
M'JTK3P#XFCDW/I17W$R?_%5SRA+L:*2[D-T,LIZ_**HNHQSUKKIO!VNL1ML"
M<*!_K$_QJLW@G7R.-//_ ']3_&NJ*M%&3:N<9<VZRH58=:]'^#*-%IFKHW:Y
M7_T&L)_ OB+;\NF$_P#;5/\ &NU^'.B:GHMIJ*ZG:_9VEF5D&]6R N.Q-+E]
MY2-/;M472Z/4[:BBBM#E"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _
"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>45
<FILENAME>g4i5nix4zlkt000021.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g4i5nix4zlkt000021.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &W J # 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M<T6\D:X"3:;:1E_+4G'^L%=%JFO>(I?B#-X<TF>TBC:S699)XMWE'NW'WCV
MZ<U;H20O:([VBO.-,\=:E9^'_$LVLI!<7FBS>4'B78LI)(&1VY'Y5<TB?QZS
MZ9?W+Z=>V5X%>>WC41-;HPR"&)^8@'I2=)K<%-/8[NBO*=2\?:I=:MJPT_6-
M)TRVT]VCBAO%R]VRYSCT&1CCVJUJ?CW5I]#\+W^CQP)/JDS0RPR#<N\$+C/8
M9_2G[">@>T1Z9169H4.L0::$UR[M[F\WL3);IL7;V&*TZR:LRPHHHI %%%%
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MK$#A5C;/S>_!'X"O8%4(H50 H& !V%9>A7>C:K9_VKHZ0F*Y)S,D.PN0><\
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M 3T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M[>XNV5IV+*[(N <,1G';I6K6)X2_Y%NW_P!^3_T-JVZ "BBB@ HHHH ****
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M5/$VLW-HY>,PVP.5((.'XYKIZP=-54\7ZRJJ%406P  ]GK>H **** "BBB@
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M9HQ*#.<N PS@_G5VLVFG9C"BBBD 4444 %%%% !1110 4444 %%%% !1110
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MB@ HHHH **** "BD8D*2!DXX'K7#:-XUUK5=;M8'\/2V]@[FWGED#!UF ).
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M!X-+3(HHX(EBB0)&HPJCH!3Z0%:[U&SL7A2ZN(X6G?9&'.-S>E8WA2\M5T%
M;F$?O9/^6@_OFM74-(L=5,)O8%E\E]Z ],^_K55O#.BK&WEZ5:;@"5&P 9H
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** (+V::VLIIH+9
MKF9$+)"K!2Y] 3P*XGPYXT\0:U?V-I=Z##IY8N;II;R,L ,X"H#NSG'6N\;&
MPY.!CKFO'? $=M::]&B'198DNY84NQ92+<2LVYQB1NO&>>^* ._\+_\ (3\2
M?]A(_P#H"5TE<WX7_P"0GXD_["1_] 2NDH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MW37DTJ2+OGF)SN;C'49P *[:B@".",PV\<32/*R*%+O]YL=S[U)110 4444
M>=7O@+4;[QX-2\]8=)^VQWTT/GEA.Z+@?)C@_B1Q74WGAF'4/#=UHE[?7EQ#
M<LQ::1P9 "V[ ..@Z#VK<HH PI/"EE+J%]>&2827M@+"0 C C&>1QUYK.O/A
M_97-OI446HW]JVFVC6<<D+J&>-@ P;(/4 5UU% '/Q>!_#::1#IC:1:RVT*J
MJ^8@+';T);J34WAGPOIOA.PELM,1DBEG>9MQR<L<X^@Z5M44 %%%% !1110
M4444 %%%<CIJ:]K7VZY7Q ]K&E]<01PQV<3!5CE9!RPR3A: .NHKGO[&U_\
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M#T =315/^R=._P"?"V_[]+_A1_9.G?\ /A;?]^E_PH N453_ +)T[_GPMO\
MOTO^%']DZ=_SX6W_ 'Z7_"@"Y15/^R=._P"?"V_[]+_A1_9.G?\ /A;?]^E_
MPH N5C>&/^09<?\ 7_=_^CWJ[_9.G?\ /A;?]^E_PJAX518])F1%"HM]=A5
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M*PP589!%8/B6&*'3[7RHTCW7UOG:H&?G% '04444 8USX9L7F:YLS)I]T?\
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M].LY+NZD$<$8RS'MSBL/PO\ \A/Q)_V$C_Z E;UU:P7MK);7,8DAD&&1NAH
MYK3=:TMO%>L2C4;4(\%MM)E49X>K6JP^$M<>!M4;2[LP-NB\Z1&V'VYK371M
M,50%T^V ''^J%<S?64TFNVMN_AVT>RCNMZ3HF, #@GZ9/UH U95\*3_ZPZ2W
M_ HZJ_V9X+SE1IB-_>295/Z&M'3-.AGLE>^TJSBGW,"J1#& Q /XC!JT^DZ>
M$8KI]L6 X'E#F@#A;#P/X0TWQ+>:W:Z_-'<70(*)?@!<X]\GIWS6[MBB.;?Q
MFPQT6:2*1?Y _K5;2K.626"ZF\/6L4US,([O,?W4"G:RCIC(Q^-=/_9&F_\
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M/XU_Y_\ 1?\ P'D_^*H Z:BN9^S^-?\ G_T7_P !Y/\ XJC[/XU_Y_\ 1?\
MP'D_^*H Z:BN9^S^-?\ G_T7_P !Y/\ XJC[/XU_Y_\ 1?\ P'D_^*H Z:BN
M9^S^-?\ G_T7_P !Y/\ XJC[/XU_Y_\ 1?\ P'D_^*H Z:BN9^S^-?\ G_T7
M_P !Y/\ XJC[/XU_Y_\ 1?\ P'D_^*H Z:BN9^S^-?\ G_T7_P !Y/\ XJC[
M/XU_Y_\ 1?\ P'D_^*H Z:BN9^S^-?\ G_T7_P !Y/\ XJC[/XU_Y_\ 1?\
MP'D_^*H Z:BN9^S^-?\ G_T7_P !Y/\ XJC[/XU_Y_\ 1?\ P'D_^*H Z:BN
M9^S^-?\ G_T7_P !Y/\ XJC[/XU_Y_\ 1?\ P'D_^*H Z:BN9^S^-?\ G_T7
M_P !Y/\ XJC[/XU_Y_\ 1?\ P'D_^*H Z:BN9^S^-?\ G_T7_P !Y/\ XJC[
M/XU_Y_\ 1?\ P'D_^*H Z:BN9^S^-?\ G_T7_P !Y/\ XJC[/XU_Y_\ 1?\
MP'D_^*H Z:BN9^S^-?\ G_T7_P !Y/\ XJC[/XU_Y_\ 1?\ P'D_^*H Z:BN
M9^S^-?\ G_T7_P !Y/\ XJC[/XU_Y_\ 1?\ P'D_^*H Z:BN9^S^-?\ G_T7
M_P !Y/\ XJN(L-/^*0^(M]-'>6J:09%\PS*?(<8&?+4G<#[YQ0!Z[12#.T;L
M9QSBEH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_P!2U/PE:76J[C<L7 D>/8TB!B%<KV)&#718&,8&*6@ HHHH **** "BBB@
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!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>46
<FILENAME>g4i5nix4zlkt000020.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g4i5nix4zlkt000020.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 'J GH# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MOF([9ZU;7Q'X?7X-'27FB&H>5L^S%<.9"V0_T[YKUW^RM._TC_0;;_2?]?\
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M_ 0!0!;HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M6XUSPMINIW<'D7%S 'DBP1M;N,&MB@ HHHH **** "BBB@ HHHH *\T\<?\
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MI%X^H:-97LL?ER3P)(R$?=) )% %VBBB@ HHHH **** "BBB@ HHHH ****
M/-_C5_R)]C_V%+?^9KT6+_4Q_P"Z*\Z^-7_(GV/_ &%+?^9KT6+_ %,?^Z*
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MSB_U,?\ NB@!]%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 445X9>:I=CQUJNLZB
MDLD.G:O#:1F.[*21(W"A8^C GDYZT >YUYIXX_Y*KX%_ZZR_RKDM-U6\L]1T
MOQ##+=7FK7NJW=O=6@F)\R-,X3;T&W QQ5B\\3:AXB^*G@[[?X=O-'\J639]
MI8'S,CM@4 >X4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MR_RH ]+HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M%?\ D5M-_P"N K8H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_L*6_P#,UZ+%_J8_]T5YU\:O^1/L?^PI;_S->BQ?ZF/_ '10 ^BBB@ HHHH
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M5''%=+0 5YIXX_Y*KX%_ZZR_RKTNO-/''_)5? O_ %UE_E0!Z71110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5P'Q)_P!9I_\ P/\
MI7?UP'Q)_P!9I_\ P/\ I0!PE%%% !2'[I^E+2'[I^E 'M'AW_D7=/\ ^N"U
MIUF>'?\ D7=/_P"N"UIT %%%% !1110 4444 %%%% 'C_P 0=5?6M3O+&[T.
M&XT/2+F"*YN5N6BN5>7',>.V",@UZ3X=\.:9X8TW[#I<3)$6+LSN7=V/=F/)
M-8>M?"[POK^J7.HW]O<M<7)4R^7<NBL5&!P#CC%;GA[PWI_AFQ>ST[S_ "G?
M>?.F:0Y^K&@#7HHHH \W^-7_ ")]C_V%+?\ F:]%B_U,?^Z*\Z^-7_(GV/\
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MY]36E0 5YIXX_P"2J^!?^NLO\J]+KS3QQ_R57P+_ -=9?Y4 >ET444 %%%%
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M+_4Q_P"Z* ,#Q[_R(.O?]>4G_H-?$5?;OCW_ )$'7O\ KRD_]!KXBH ****
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M'_)5? O_ %UE_E0!Z71110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 5P'Q)_P!9I_\ P/\ I7?UP'Q)_P!9I_\ P/\ I0!PE%%% !2'
M[I^E+2'[I^E 'M'AW_D7=/\ ^N"UIUF>'?\ D7=/_P"N"UIT %%%% !1110
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MR=6P$>/=D>N176^%O'_A_P 93W$.C73RR6ZAI%9"N >]?$]>X?LV?\A[6_\
MKV3_ -"- 'T?7 ?$G_6:?_P/^E=_7 ?$G_6:?_P/^E '"4444 %(?NGZ4M(?
MNGZ4 >T>'?\ D7=/_P"N"UIUF>'?^1=T_P#ZX+6G0 4444 %%%% !1110 44
M44 %%%% !1110!YO\:O^1/L?^PI;_P S7HL7^IC_ -T5YU\:O^1/L?\ L*6_
M\S7HL7^IC_W10!@>/?\ D0=>_P"O*3_T&OB*OMWQ[_R(.O?]>4G_ *#7Q%0
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M &SI?_02L_\ O^O^->9?%?4+*XETXPWMM)A6SME4XY'O6]_PIGP+_P! 5?\
MOXW^-'_"F? O_0%7_OXW^- 'C/VB#_GO%_WV*/M$'_/>+_OX*]F_X4SX%_Z
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M1MP,]^*]D_MG2_\ H)6?_?\ 7_&N0_X4UX%_Z J_]_&_QH_X4SX%_P"@*O\
MW\;_ !H ZB\\2Z)86S3W&JV:QKP2)E/]:Q[CXE^$[>WDF.JQ.$7<5C.6/T'>
ML_\ X4SX%_Z J_\ ?QO\:/\ A37@7_H"K_W\;_&@"D?CGX, R7O\#_IU/^-
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M!.!TR:L_\+Y\<_\ /U:?^ XKV?\ X4-X%_Y\[O\ \"6H_P"%#>!?^?.[_P#
MEJ +'PE\:7_BSPI)?:U<6_VE+AHP5 3CZ5WWVNV_Y^8?^^Q7GL?P.\&0C;%%
MJ$:GJ$O7 _2G_P#"D_"/_44_\#Y/\: .2^(\L3^,K@K*C#RTQAQZ5R>Z/^^O
M_?5>JM\#/!3MN>&_9CW:\<FD_P"%%>"/^?>^_P# MJ /*&2W>5)&V%X\[&+<
MC/6G[D_OK_WU7JG_  HKP1_S[WW_ (%M1_PHKP1_S[WW_@6U 'F5B\8U&U/F
M*,3)SN]Q7T>EW;>6N;B+H/XQ7GO_  HKP1_S[WW_ (%O4O\ PI/PA_U$_P#P
M/D_QH Z+QG=6[>"=<"SQ$FQEX#C^Z:^(Z^N6^"/@]U*LNI,IX(-\Y!J'_A0W
M@7_GSN__  ):@#Y,HKZS_P"%#>!?^?.[_P# EJ/^%#>!?^?.[_\  EJ /DRO
M;OV;Y8XM=ULR2(@^S)]Y@/XC7HO_  H;P+_SYW?_ ($M3X_@7X*A),4%_&3U
M*7CC^5 'H?VNV_Y^8?\ OL5P7Q&N('?3]LT1^_T<>U-_X4GX1_ZBG_@?)_C3
M6^!_@V0Y>/46QTW7KF@#B?-C_P">B?\ ?0H\V/\ YZ)_WT*[3_A1?@K_ )X7
M_P#X&/1_PHOP5_SPO_\ P,>@#B_-C_YZ)_WT*#+'M/[Q.G]X5VG_  HOP5_S
MPO\ _P #'H_X47X*_P">%_\ ^!CT =AX>NK=?#U@#<1 ^2O\8]*T_M=M_P _
M$/\ WV*\_'P2\'J,*-3 '0"^>E_X4GX1_P"HI_X'R?XT >AHZR+N1@RGN#D4
MZLW0=#L_#FDQ:98>;]GBSM\V0NW/N:TJ "BBB@ HHHH **** "BBB@ HHHH
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M%@.)$]_]KOF@"IX.\/P^(-3GOUO]2N;#3KE'TG4YR4G92/WD18C+QY]:]9I
M !@  >U+0 4444 %8][XFTVPU;^RI9&_M!K=KB* *<S!>H0]"WM5^^U"UTV
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M&B^&].AO-/MEU*%=TTH =C(>K;SSDUU% !1110 4444 %%%% !1110 4444
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MI','52PP20#U],]*\>T6.+QKXBAN[>"W_P"$JTN0&Y2X@9+?4X1\I=E(^60
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M!Z@XZCV-:=% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M/89[O6=,;5=(:R641L7B;>1G[CJV/QVXH 34M?TW24B:ZN1F6X6V14&\F1B
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M:PLT<++YZAP0T@S]X+E1CU)]AT= !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
+!1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>47
<FILENAME>g4i5nix4zlkt000042.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g4i5nix4zlkt000042.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &: J # 2(  A$! Q$!_\0
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %0"ZMVNFMEN(C<*NYH@XW@>
MI'7%3UY7<S:I#\9-5&C6L$]Y+8HH-PY6.,84EFQR>F,#UJX0YKDRE:QZG17&
M>'/%VJ:MI&L>=I:/JVERF%K>!\+*W;!/3D&LJ/QQX@L-;TNTUFVTDQZA*(S#
M:3EIK<G&-PR1WI^RE=H7.MST)+RUDN7MH[F%IXQEXE<%E^HZB@7=L;HVHN(O
MM 7<8MXW@>N.N*\2UB?4-*^)NN:]IZ;_ .S9(WN8QU>)@%8?3_\ 773Z1>V^
MI_&0W]JP>&XTA'1O8X_6M'0LKWZ7$JFMCT:WN[:[#&VN(9PC;6,;AMI]#CO3
M8;^SN9GA@NX)98_OI'(&9>W('2O -.\5W6A:%K6G::DB75S>-))<JN1!%]TG
MCN3QFO6O#.EZ/X4\'/?6$BSJUN;J6[/6;Y<Y^GH/ZTJE#D6OR"-3F.F@O;6Y
M61H+B*18G,<A1P0K#J#Z&IZ\+U%-8L/"7A81(@CO[O[8^9"IDG=]RJP_NXV\
MUZ+JVL>*[:&QBM].TZ&:2'?=W=S/BWA?^Z.<GZTI4;6LP4[G63316\32S2)'
M&@RSNP  ]R:1;F![;[0D\;0;=WFA@5QZYZ8KS.X\5W'B?X=>*8[V"W2YLD,3
MM;ONCD]"I_ UC^$]7N-)T"_\-ZF<17FFR7>G.>A#(24'Z\>H--4'9WW0>T5S
MUXZE8K;)<M>VPMW.$E,J[6/H#G!J6XNK>TB\VYGBACSC?(X49^IKQ34]J_!+
MPZ6'RK>J3Q[O5VUU&#XC^.8+;5FDM]*@C,UE8N"/M..Y/OR?H,#O5?5]+WT5
M_P !>TUL>M2ZC90VJ74EW"ENY 24R#:Q/3![YJSD;MN1GKBN+\6QI>:]X7T&
M%%$;7)NWC P D*Y QZ9(K \"WVO2>.?$#WD5OY8EQ?,TQ/D8#;1'GJO\JS5*
M\>:Y7/K8]0EEC@B:6:1(XU&6=S@ >YK$O?"OAK7Y5O[K3;.[=P")QSO'U!YJ
MAXNU?3=1\%:W%9W]K<N+-V*Q2JQ ]<"N1TSQ7XA\-^"=%U#^R[,Z(BI =TA\
MYQG&[T X.!S3A3E:Z=F*4E>S/5K2TM[&VCMK6&.&",82.-<!1]*6:>*VA:6>
M5(HE^\[L% ^I-<SXBUKQ!;7-O%H]G9);/%YDE_J$VR)/1< YS_C7*W_BJ?Q3
M\,/$AO+>&.XLV$,A@;=&_P PY7VI1I2EJ-S2T/3Q=6YMOM(GB-OMW^;O&W;Z
MYZ8J-M1L4@CN&O;=893B.0RJ%<^QS@UX]H6JW.E^$]6\+ZH0!-ICW>GN>C(R
M$E1^O'UJ+7=B?"'PDS#Y4N58\=@6K3ZO[UK]2?:Z7/:;B[M[.+S;JXB@CSC?
M*X49],FI(I8YHEDB=7C895E.01Z@UY!87T'Q(\=I'K+/!IUO'YUCI[C N!_>
M;UXY^G'K7KZ(L:*B*%51@ #  K*I#DLGN7&7-J.90RE6&01@BJFG:99:3:_9
M=/MH[>#<6\N,8&3U-<OIGC:4_P#"1Q:Q#!;W.C$L5B)Q)'@[3SZ_U%9EU\0=
M5L_"6D:E<65G#=ZK,5C,C,(84[,YZ].::I3V%SQW/1J*Y;PKK>MZE<3Q:E!I
MTUNBAHK[3YP\;D_PD$Y!_P *ZJLY1<79E)W5RK/J-C:RK%<7EO#(_*I)*JD_
M0$TZYO;2R56N[J&!6.%,L@4$_C7D/Q7L7OO&%JD7^MBTQYUP.<HS-_2J?CS5
M/^$JM-+,;;H[723?S8[.Q"X/X_SKHCAU+E=]S-U+7/;XY$EC62-U=&&593D$
M>H-.K@9/%,OA[PAX9M+"T%WJ=_;PQ6T+-M7[JY)/IR*L:5XLUFV\36^@>)[&
MV@N+M"]M/:N2CXZJ<]^*R]E*URN=';TE><0^-?%&J)K7]EZ5I^-+GD5Y99&
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MOFR!=Q]L]:I^'>/#.D_]><7_ * *\Q\:VLOC;Q9J=E;R8AT2R9EY^].>=O\
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MBPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M,CW)X'XFLBS\+P> =&2_F,%SK5QGS)I&.8B>3Y?T[GJ:Z*5**2E/6^R[_P#
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M+"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MKJ:Z>LD\5E'/-#;30X5RH\U6.TY(Y&SJ2!S^?0)XIT 6\4R7:"!V*(XA;;U
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MD/UR*ZQX3$H!7!SR.PKDO%C7J75KY0C\A%+,-I)D.>@].*<*TX;,R;3>IO\
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MRQJIV[^P.,KGTK)NQ%KZGN%I#%+&)YI1B1N(P<L >YK/\1VNFOI>;2-7G63
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M>A4]F_.AT(S7-2=[=.H<[3M(]7HI*6N8T"BBB@ HHHH **** "BBB@ HHHH
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M*-[G4).9;VY.^5S]3T_"M:^U2PTR(RWUY!;H.\C@5SHL/%FM,3?W\6D6I/\
MJ+/YY2/=ST_"KUCX+T.RD$IL_M,_>:Z8RL?SK&4Y2=V2IS:]R-EY_P"14/CJ
MRN&*:38:AJ;#O;P$)_WTV!5.]AU[7L>?X4TA$/1M0D$C#\%%=JJ*BA44*HZ
M# IU)76MQ^RG+XI?=_3/.5^'-R[[]NA6C9X\G3]^/^^C6[#X9UF")8XO$LD2
M#^"*SC51] !74T53;EN[@L/!=_O9R[Z#XC5<P^*Y=V?^6EHA%!B\:6H)2YTJ
M^ _A>-HB?RR*ZBBIL/V$>C:^;.2/BW4-..-<\/7EO&/O7%L1/&/?CD5NZ7KF
MFZS#YNGWD4Z]PI^9?J.HJ_BL#5?!^EZC+]JB1K&_'*W=J=C@^^.#^-&HK58;
M._KO]YOYI:XZ+7=4\-3QVOB4">S=ML6J1+A?82+_  GWKKTD21%=&#(PRK*<
M@BA,NG44_7L.HHHIF@4444 %%%% !1110!YA\2;VYUS7=+\%6$A3[4PFO''\
M*=@?8 %ORJC8^)-1T"Q:QA6"RL[6=XXD$ 8F(' <\Y8GJ:N>&%74OC%XHO)O
MF-M'Y,>>PX7^2G\ZY_6H8YO$TMLV&17.,G&S-=%=\L8TUVO\V9T]6Y,N:I\3
MM6LHTEM+N&]B(^8Q6GEE3G !W&J&F?%OQ)=7DD,RV4052<O"3DCM\IJCXGT0
MZ-!BSM!?0R+EI)G$>#UX"]:Y;1H3)J;&6T'SEAQ(<<^O/2N?4U/5H_B!J4EH
M)6U*S$[$ 0)9OD$]LDXJ+6;&Y\?>'[[SXH#J&GKOM98QAWZ[HS['''O6+=Z#
M::?I;WC[Q)@%$4@QY^I.>*W?AG,SZG,1(=CH!Y6<JI!_G5TYN$E);HF24E9F
M[\*_$DFO>%A!<N6N[!A"[-U9<?*3[XX_"NZKR#X=J-,^*?B32XN(3YA"^FV0
M8_\ 0C7K]:XJ*C4?+L]?O(I-N.H4445SF@4444 %%%% !1110 4444 %%%%
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MJUS\-=)E7]U<W<3_ -YF#_S%(9Q=E\(FT:QUJ]O;RPN7=#,F(2?NY8J23T(
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MK*<G)W9226B&@+_PEUMW_P!'<BM6>6\>5H;:%4 ',\OW?P4<G]*Q'D:/QC8
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MNUNTBFBD4"1.JD'((KSB;Q7I_P!J9HH;B<MP56V5<GL<YKT/P)<O=Q7,CP-
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MVUTR,AG0;IG'\<AY8_Y["OI''V.'M+>7Y'FWYZEULC;HHHKB-@HHHH ****
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M[F;@F[K0\Y_X67XH<>7'X'NO.Z<[\9_[YJ&6R^)'C0&&]:+0M.?[Z)\K$>F
M2Q_,"O11XBTDZD=.^W1B[$GE>6<CY\9VYQC..V:TZ?MU'6,$G]_YAR7W9SWA
M3P9I?A*S,=DA>XD'[VYD^^_M[#V%=%4"7EO)>2VJ2J9XE5Y(^ZALX/XX-3UA
M*4I.\MRTDE9!1114C"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MO"D+:B+Q)&N790 H&##C:6X/S9R,U7L/!>J"?_33;_9Y+B&6:&*5MK;0X;C
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M **** "BBB@ HHHH **** "JU]="RLY+@HSA!]U>IR<59K.US_D#S_\  ?\
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M6FKZ;+J+Z='J%HU\@RULLRF11[KG-%PMYC/ME_\ ] M_^_Z4?;+_ /Z!;_\
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M]_XO_BJ/[1U'_H!W'_?^+_XJBP71Y;X@\%:Q>)XLAM])+P7NKV,MNBE0'A0
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MY([B>ZN)XV+O&FU515)ZGUK$TGP;K<3Z)I+>'&MM5T_6#?7?B$LFV>+>S'#
M[V+ @;2.,5Z[_:.H_P#0#N/^_P#%_P#%4?VCJ/\ T [C_O\ Q?\ Q5%F%T>3
M>'_"OB#3_%]NEGHUS:6J37)E>^C@E2V63=AX;A<2,22.".*=\/\ P;K.F^(=
M%%_IE]:RZ4LXN+K; D,I?(P'7YY@W7YONFO5_P"T=1_Z =Q_W_B_^*H_M'4?
M^@'<?]_XO_BJ+,+HY'QIX/E\3^/O#<L]O<-I5O!<BYF@G,1C8@;!E2&Y([53
M\3>$Y-+U/PS=6FC7&O:)I:3QRZ>T@FD#/RLF)#\^#D<GCM7=?VCJ/_0#N/\
MO_%_\51_:.H_] .X_P"_\7_Q5%F%T>5:3\/]4>X\*)J>BQG38]3OKN6Q<I(E
ME#(N8HR.AY'09I-<^'U[?6WBIET%))[K6[>2U;";C;+L#;3GY1C=QQ7JW]HZ
MC_T [C_O_%_\51_:.H_] .X_[_Q?_%46871YEK7@B[\[Q@EMH,YL+F\L9[..
MQDCB/[M/G=%/RD@_PD#-=-\,+#6+#3M3&J6(MHY;OS+9Y+:.">92.6E2,E0>
MU=/_ &CJ/_0#N/\ O_%_\51_:.H_] .X_P"_\7_Q5%@NAFH?\C#HW_;?_P!
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MCS<.?L^ Z%\?-\H(('/\/;K6[H4^M+;7!U57FD6&*2/$:H2Q3+H,<<-QSZT
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M"%0V,@'!R,TC(K8W*#M.1D=#ZTZB@ IB11QEBD:KN.YMHQD^II]% !1110 4
MF*6B@ HHHH **** "D"J"2  3U..M+10 4444 %%%% !1110 4FT D@#)ZGU
MI:* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *0J&&" 0>H-+1
H0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>48
<FILENAME>g4i5nix4zlkt000008.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g4i5nix4zlkt000008.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %S J # 2(  A$! Q$!_\0
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M,;YI'(6YL=5@_P!83VC8< YZ9/\ A2^KRLW?8?M5H>MS2I!!)-(<1QJ68XZ
M#)KD!\4_!Y(']JD9]8)!_P"RUTVK?\@:^_Z]Y/\ T$UPGPHTZROO "K=6D$X
M:>56\R,-D<>M3",.1RD.3?,DCO[&^M=2LX[NRN(Y[>0922,Y!JQ7BFA:A>:)
MX2\;Q:;</"MA=J;9P0=F7*G&?8"NB\3>(=6LOAAHFIVU])'?3M )9@%R^Y23
MVQS52P[YK)];?J2JFEV>DUF2>(--C\0Q:$]QC498C,D6P\J,\YQCL:X;Q)J'
MB.\^(</A[2=6:RBN;(,S; 0GWBS#OGC'7O5BUN=4T[XEZ-H=QJ+W4:Z:3,[H
MN99 &RV<9'3IFDJ.EV^EQ\^IZ)17DVE7'B7Q+!XD)\1W5I%IUS+Y/E(H9B-Q
M"EL9V@ <>]1GQSK3_#32Y8[@#5;V[-G]I*C( /WO3.,#/XT_J\KV3#VJ/7:*
M\LUS_A)/"6J^'[4>);J]M;V[5)?.1=^<J",X^Z0>G:O3KES':32"2.(JC$/)
M]U>.I]A6<Z?*D[WN4I7N2T5X5J7BG4-/MUO['Q=J.IWJ3 R[+8K9XST&178:
M]JFN7/Q#TS1=/U1[*WO+'?)M16V?>)89'WL# K1X:2Z]_P "%53/1:JZCJ%M
MI6G3W]Y(8[:!=\CA2<#Z#FO.]#U[5="USQ3I=_J,VIPZ9:FZA>X^^2 #@D>N
M1^59,UKXBU?X;7OB2\\0SR?:8G=[$HOD^4&P0/0\9!'TH5#75Z:?B#J::(];
MT[4+;5=/@OK.0R6\Z[XV*D9'T/-4]=\1Z5X;MXI]5N?(25]B81F).,] #5'P
M#_R(>B_]>RUQ7B?4-*UGXH6]AJUW!#I6EP-YGG.%5Y6'3Z\K_P!\FE"DG4:Z
M*XW-J*?<]/T_4+75=/@OK*42VTZ[XW (R/H:R;;QMX>O-7DTR#44>YCW[L(V
MP;02WSXV\8/>N-^&5Y)=:%K'AF#41'/:2/\ 9KJ+#X1B<.N>" 1G_@5<YX6T
MO4+CP3XFN8-:FMX8FF66!85(F(4$DD\C(X_&K]A%.2;V_4GVCLK'M>GZC::K
M9I>6,ZSV[DA9%Z-@D''X@U9KQ?3M8U/PO\*;:\M=0=Y-0F$-M&\8VV@W/N*_
MWB<9Y[UH:+X@U#3_ !7I=K;:SJ>M6%XWE77VRS=/)<]&4E1@9I2P[UL^_P"
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M;MSZ   < 5D0>!]/A^R0O>ZC/I]G(LMMI\TX:&,J<IVW,%.,!F(&!Z"NGHH
MPSX3TM]$U/2)DDFM-2GFGG#MR'D;<2IQQ@\CN,"M:T@-K9PV[3RSF) AEF(+
MO@8RQ &2>_%344 %%%% !1110 4444 %%%% !1110!Q7Q<_Y)5X@_P"N"_\
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M0P8]AEAG -7/#5M>Z;<7\D>EW5MIUY<H+6S=U)M@(_GD8;CM5F'W02<\XY-
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M!P<,V?0#)%<#?W%UXETR&^NM1F>:WTS61'Y8B;+1.JJV0I&XJ0"RXZ?+C)R
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M5W#VS['4?:K?_GO'_P!]"C[5;_\ />/_ +Z%<O11[%=P]L^QU'VJW_Y[Q_\
M?0H^U6__ #WC_P"^A7+T4>Q7</;/L=1]JM_^>\?_ 'T*/M5O_P ]X_\ OH5R
M]%'L5W#VS['4?:K?_GO'_P!]"C[5;_\ />/_ +Z%<O11[%=P]L^QU'VJW_Y[
MQ_\ ?0H^U6__ #WC_P"^A7+T4>Q7</;/L=1]JM_^>\?_ 'T*/M5O_P ]X_\
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M^$'\+_\ 0"L?^_0H_P"$'\+_ /0"L?\ OT*T-:U:VT+1[G4KLGR8%R0.K$G
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M'MYASLV_MNG?W5_[]_\ UJ/MNG?W5_[]_P#UJQ**/;S#G9M_;=._NK_W[_\
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MYYO_ -\FCRI?^>;_ /?)HL RBG^5+_SS?_ODT>5+_P \W_[Y-%@&44_RI?\
MGF__ 'R:/*E_YYO_ -\FBP#**?Y4O_/-_P#ODT>5+_SS?_ODT6 913_*E_YY
MO_WR:/*E_P">;_\ ?)HL RBG^5+_ ,\W_P"^31Y4O_/-_P#ODT6 V='_ ./(
M_P"^?Z5;N?\ CUF_W#_*JNDJRV9#*0=YX(QZ5:N03:R@#)V'^5=D/@-U\)S'
M:BG^5+_SR?\ [Y-'E2_\\W_[Y-<=F8#*='_K%^HI?*E_YYO_ -\FCRI?^>;_
M /?)HL!X#X=\5Z1H]C<V=[=213"\F8J(G/!;CD"MJ'QQH%Q<1P1WTADE<(@,
M+C))P!R*]A-J>?\ 1O\ R%_]:J?Q$\$S>-=#TO2[:2.U1+Z.>XG PR1JC@[1
MW;) %>K1Q\[<MMB'AH3;9Y=::3>>.O&%I!H#-;?V3,'N=:C_ .6'_3-#T8GT
MZ?AFOHA054 L6(&"3WK.T'0=-\-:/!I6E6ZP6L(P .K'NS'N3W-:514J.I+F
M9TTX*$>5!1114%A1110 4444 %%%% !1110 4444 %%%% !1110 4444 07'
M5:S]2OH]+TJ\U"5'>.UA>9D3&Y@H)(&>_%:%QU6LK7+&34_#^HZ?"ZI+=6TD
M*,_0%E(!..W- &<?&&G"U\/SK'.PUR58K=0!NC)&27YXP?E.,\FN@KC!X-O%
MU5)Q<VYMK?4(;BUCYS%'N,DR].I<\>P%=G0 5BVWB2WNM1EMX[2Z^S1M(AO2
MJ^5NCSOSSN R& 8C!((%;0."#Z5Q^E^#YM-U^&YC%DEO!=W%R+F/=]IG$N[]
MT_&-JEL]3G:O YH W]&UJUUVTENK19A%'.\&94*%BO< \@'/&<&M&L[2-/ET
M\:AYKHWVF^EN4VYX5\8!]^*T: (;NY%G9S7)BFF$2%O+A3>[^RCN3572M575
M!=(;::UN+27R9X)2I*,5##E2000P/!JS>"Z:SF%C)%%=[?W3S*60-VW $''T
MK)\-Z+/I#:C+,EK;K>3B9;.T9FBA(4!B"0,LQY/ [>YH W:CN)X[6VEN)FV1
M0HTCMC.% R3^0J2JVHV[7FEWEJIVM/ \0/IN4C/ZT 16^L:?=O MO<K+Y\*3
MQE 2K(^=K9Z8.T_E5S>F_9O7=C.W<,_E7%-X*E-Y)(K;;<H!'!N&(6V2 E3V
M&^3?CL0?7BS8>%[JSU.UNV\N1HW6660@"620(RMAL\(Q8L5QU[TKE^S?E]Z_
MS.QB_P!8M8NK70M/&>DN5+9L;L8!_P!N"MJ+_6K7.>(_^1MT?_KRN_\ T*"K
M@KRLS*3M&YL?VVG_ #P?\Q1_;:?\\'_,5CT5T>RB<_M9&Q_;:?\ /!_S%']M
MI_SP?\Q6/11[*(>UD;']MI_SP?\ ,4?VVG_/!_S%8]%'LHA[61L?VVG_ #P?
M\Q1_;:?\\'_,5CT4>RB'M9&Q_;:?\\'_ #%']MI_SP?\Q6/11[*(>UD;']MI
M_P \'_,4?VVG_/!_S%8]%'LHA[61L?VVG_/!_P Q1_;:?\\'_,5CT4>RB'M9
M&Q_;:?\ /!_S%']MI_SP?\Q6/11[*(>UD;']MI_SP?\ ,4?VVG_/!_S%8]%'
MLHA[61L?VVG_ #P?\Q5"]DM+NX%X+8K>QJ!%,3G9@Y''ISS[56HIJ"3NA.;:
MLS4@\0)-$&-NZL#M==P^5AU%2?VVG_/!_P Q7/3?Z/+]I'W#Q,/;LWX?R^E6
M:'2@-59&Q_;:?\\'_,4?VVG_ #P?\Q6/12]E$/:R-C^VT_YX/^8H_MM/^>#_
M )BL>BCV40]K(V/[;3_G@_YBKEG>"\1F5"NTXY-<W6SHO^HE_P!_^E14A%1N
MBX3DY69J4445@;A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!#,K,
M5P,U%Y;_ -TU;HH J>6_]TT>6_\ =-6Z* *GEO\ W31Y;_W35NB@"IY;_P!T
MT>6_]TU;HH J>6_]TT>6_P#=-6Z* *GEO_=-'EO_ '35NB@"IY;_ -TT>6_]
MTU;HH KQHPD!*FN:\1_\C;H__7E=_P#H4%=;7+ZY;R7'C#2$B +"QNSR<?QP
M54':2)GK%D5%7/[*O/[B_P#?0H_LJ\_N+_WT*ZN>/<YN278IT5<_LJ\_N+_W
MT*/[*O/[B_\ ?0HYX]PY)=BG15S^RKS^XO\ WT*/[*O/[B_]]"CGCW#DEV*=
M%7/[*O/[B_\ ?0H_LJ\_N+_WT*.>/<.278IT5<_LJ\_N+_WT*/[*O/[B_P#?
M0HYX]PY)=BG15S^RKS^XO_?0H_LJ\_N+_P!]"CGCW#DEV*=%7/[*O/[B_P#?
M0H_LJ\_N+_WT*.>/<.278IT5<_LJ\_N+_P!]"C^RKS^XO_?0HYX]PY)=BG15
MS^RKS^XO_?0H_LJ\_N+_ -]"CGCW#DEV*=%7/[*O/[B_]]"C^RKS^XO_ 'T*
M.>/<.278I_6JT/[B3[,WW<9B)].Z_A_*M7^RKS^XO_?0J.?1;N:/:%56!W(V
MX?*>QIJ<>XG"78KT5-;6=U<1L?+59$;9(F[[K#_.1[$5-_95Y_<7_OH4.45U
M!1;Z%.BKG]E7G]Q?^^A1_95Y_<7_ +Z%+GCW'R2[%.MG1?\ 42_[_P#2J7]E
M7G]Q?^^A6GIEM+;12+* "S9&#GM45))QT9=.+4M2]1117,= 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% 'GWPXT-H["SU673]*7S(6*7,0?
M[0Q+?QD\<C.<5Z#2*H50J@ #H *6@ KQJZNKR*34YT,+ZY+)J,16"607<*J'
M*,PS@Q[%0*N!@E""237LM-$:"0R!%#D8+8Y(^M ')>#SIZZSK$>AR(^BK';&
M+R7+1B8A]^#TSM\LGW//)-=?34C2-=L:*BYSA1@4Z@#+\1RV$/AS4)-4NY+2
MQ6$F>:-RC*G?!'.3TXYYK%\!K;/;:A=V3VT5K<3AXK"WG606JA0/FVDA7;&X
M@<#/<Y)ZQT61"KJ&4]0PR#38H(8 1#$D8/)"*!G\J )*SM?,X\.ZD;4N+C[+
M)Y10X;=M.,8[YK1I&574JP!4]01UH X&YNO$&@^6;0Q7$=R^?*$TEP(BJ@!=
MS?,-Y+$G&!M]ZNV.L>()+Z-KAH!;M*FZ(0$$*TDB$;MW\*JC9Q_%Z$5UOV6W
M_P">$7_? H%M;@Y$$61_L"EJ7[GF2US.M7+VOC'2'15)-C=CG_?@KIJY+Q'_
M ,C;H_\ UY7?_H4%7!7DKF4W:+-+^V9_^><?ZT?VS/\ \\X_UK-HKI]G'L<W
M/+N:7]LS_P#/./\ 6C^V9_\ GG'^M9M%'LX]@YY=S2_MF?\ YYQ_K1_;,_\
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MH **** *#ZUIL<C1M>1!D8JPST(X(I/[=TS_ )_(_P!:=I/_ !Y/_P!?$_\
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M1@U03PI:6]K=):W5XEW=&,RWLEP\DQ"-D+N)R%ZC X^8\<F@#?HHHH ****
M*.D_\>3_ /7Q/_Z->N(UK_A(&\?2:@_AB^O[&Q@$.G-;S0!=SC,LA#N"&/"#
MV!]:[?2?^/)_^OB?_P!&O7/:S\2?#VA:Q<:5=F^>ZM]OFB"SDD5=RA@,@8Z$
M5AB:$,12E2J;/?H'.H>\V9_A%-<MO&.HR/X>O-.TG4(A/-]HFA(2Z7"[E".W
M#KC/NH/<UW]<MX>^(&A>)M4;3; WBW0A:8)<6KQ90$ D%ASRPKJ:JA2C1I1I
MPV6B#F4_>1YYX:\%R7WAJ&'6;[55MC<RR/I;[$B($[,H/R;RIX.-W.?2LB6T
MU.7Q?:7L>CW-M<)KG[YUMIG?R"S+N:X9MAC88.Q5( /.,$UZN9HEE6(R()&&
M50L,D?2GUJ!Y19>%8X-'\,7]WHLTEY'K+R7CM"SRJA,P1F'7:"8_H,'I5.33
M=2DTG3[*]T2YDVV]T5EGM9KG]XT[X41JRJC[=I$CGH>.]>QT4 <-X'M=2COX
M[C4+>Z21]!TZ.22X4@F9?-W@D]6!(S]:Q;_P[J+:3XBO+6SN!>SZV?,;8S22
MV6]"RH RED(!.U2-W(!R:]2W+OV;ANQG&><4M 'DG]C7;:'=KLU!; ZC%)#!
M'I#B!<1L&)MFD,C1$D9 Q\P! QFHH(8/M^AV^OZ%>R6Z6-]MM((YI 1Y\>QS
M&2752#\JMG9D=.WL%0-96S7\=\T*&ZCC:))<?,$8@E?H2H_*@#RV+2KR.WMA
MXJTK5=14:2D=DD(>9H)M\A*L5/RR[3"/,/\ =/S>L<_AG5KC2/$%SJ=G>7&M
M0:79?9IE9B?M*P_.T9'!?>!DBO7:* /,KK3[V+X@B\@L+RZD?4(F8S6TB&*/
M:JL\=RC;/* R3$XR3D8Y!JIX6TC6H/$&FO>)=1ZE'<S-J$XL9 )D.[AYVDV.
MA.TJ%7(P.%P:]8HH **** "BBB@ JCI/_'D__7Q/_P"C7J]5'2?^/)_^OB?_
M -&O0!/<=5K/U*QCU32KO3YF=(KJ%X79/O ,,$CWYK3EC+XP1Q4?D-ZB@#FO
M^$/L!J,M\)K@227D%YMW#:K1 \#C@,26/N:Z"I?(;U%'D-ZB@"*LN30+*<:P
MMQOE35@%N%8XPHC"!5(Z# S]2:V?(;U%'D-ZB@#'TO1AIL]Q<RWMS?7=PJ(\
M]QMW;$SM4!0!QN8YQDDFM.I?(;U%'D-ZB@"AJ6GP:KIMQ8708P3H4;:<,/0@
M]B#@CZ5#I>E+IIN97NI[RZNG#SW$X4,^U0JC"@   =AZGO6KY#>HH\AO44 1
M45+Y#>HH\AO44 5;BVM[N+RKF"*>,D'9*@=<CH<&I:E\AO44>0WJ* &Q?ZQ:
MP->GD@\8:0T3;2;*[!./]N"NC2%E<$D<5S'B/_D;='_Z\KO_ -"@JH?$B9_"
MRU_:5W_SV/Y"C^TKO_GL?R%5:*Z^6/8Y>:7<M?VE=_\ /8_D*/[2N_\ GL?R
M%5:*.6/8.:7<M?VE=_\ /8_D*/[2N_\ GL?R%5:*.6/8.:7<M?VC>?\ /8_D
M*9IVO+?:G)9PW\4TMM(J7$2$%HR>0&]*SM2M[F[TRZMK*[-G=2QE(KA5W&-C
MT.*\!MAJ&A:I<1VMW+I^J6CO;SS6TF[=G[WS?Q9SG)Y!]#7+B:T:"3<='^!Z
MF69?4S"<J=.:4DKI/KW/JJTU2POY[J"SO()Y;23RKA(W#&)\9PP['_Z]6Z^>
MOA)HM_>>,3?:9=_8[33P%O6W9:Y#<B,J>H/7>>AZ<YKZ%K&G/GBI6L5C,-]6
MKRH\RE;JN_5?(****LY0HHHH **** "BBB@ HHHH **** "LSQ&K/X8U0)+)
M"WV24B2,@,ORGI6G00",$9!H \BL-5N]&T);>VU4VLUC9V;:;I_DQ_Z>9$5F
MR-N7RQ9/EQMVY/)S4:7T^F:E<7-K-]F;-W')<; _V>-M3VO)@\':I)YX[G@5
MZM>W=E8"VDNF2/?,L$)*9^=SM &!QGI5GRT'(1>?;UH \QNO$^K6!N&L]5?4
M-/2Z.GVUT41O-EFB4QY90 VR7Y<CCY\'D5 _BKQ$]A&S7?EI#=QZ3>7!9(0L
MT:2&63>RD+O?RU!(P.V"<UZHL4:HJ*BA5Z*!P*4QHR,A12K?>!'!^M 'D]_K
M^H76B75MJWB""TMO[,NI(+F!HW6\8.R!"Y0!BJ[<J@&XMD5M>(61/"/@YI+S
M["@O+/=<8'[H>4PS\V0/3)X&<UWIBC954QH57[H*C ^E*41EVLBE?0CB@#S-
MO%.MV5I]HCNWOK:XGN=+L)S&N)I]P^SR'  ()\Q"1P=@/>MOQK:2O9>&;5H;
M;49AJ<:E+S"QS$02Y+84X]>G6M;74TJTET[4=2GF2.UF"V]O&I97F8;5^102
MS#)QCIU[9%^[U2RM;ZRLYW/VF[+>1&L;,3MQN;@':!N&2<#F@#SS4/#-W8S6
M >TTA&U#6TDCT]49[2';:RJ>,#+-C)PH&0/K6UX$A^S:QXBAN8K:RU$31"6P
MM(]D"(%(26/^]O'4X'*[2/ER>V*@D$@'!R,CI6>-9TMK];9;E#=/.UJ %)/F
M*GF%"<=EYH \ULM6UEM%OY;756LX]/TB6_CB@MX@KRBXN?O97[I$8! QGKG-
M=7XJ;SG\)7,EW):H=4C+E'"J=T,F 20>IP/^!>N*Z[RXP" BX(P>.HH9%==K
M*&7T(XH \BTW5=;\.^#-)DL;R2Z:YT:YF2VDB79"T9CVE !NX5VR"3G%=AX*
MU._OY]0CN-1MKZVC$9B>.Z2>1&;=N#-&BK@X! ZC)SQBNFM+JTO4=[5TD6&1
MX6*C[KJ<,OX$8_"ITC2)=L:*BYSA1B@!U%5[J^MK+R/M,RQ^?*L,6?XG/11[
M\&K% !114<\T=M;R3S.$BB4N['HJ@9)H DHJ.WGBNK:*X@</#*@=&'1E(R#^
M524 %%%% %'2?^/)_P#KXG_]&O7B'C&1$^)/B0-(BGS+;JP'_+!*]OTG_CR?
M_KXG_P#1KU3U'PSX9U.\:ZU+1M+NKI@ TMQ;1NY &!DD9Z5,X\RL<N,PRQ-%
MTF[7/*OALZ/\2X=KJV-*N/NL#_RTBKV^LC2_#WA[2;EI])TG3;2=EVL]K B,
M5STRHSC@5KT1CRJQ6$H+#T8TD[V_S/+])M/#=SX!NM6\2F-=2669M0O"<74$
MZR'Y48?,K# "J.V, YYM:CXHUB&+6]4AU&"&/2;U+5-,DA!:X4A/O-]X.^\[
M<8'3@\UVTFA:1-J*ZC+I=D]ZI!%PT"F0$=#NQG(I\NC:7/J,>HS:=:27L>-E
MP\*F1<=,-C-4=!P<FN>)9+L21:O#'#-X@ETE(3:*P2(;\/GJ7&WCMZ@T6_B#
M7KS4M.T<ZW!;.U[J%K+=FW3?,("NS"GY0V"<\8P#Q7?_ -FV(Q_H=O\ +.;D
M?NQQ*<Y?_>Y//7FLO4?".E:GJ5G=7%K T-OY[/;- K),\NW+,".ORYS[T >>
MW/BS48)!KX%O<7T&CW4"RHN(Y-M]'$)@,_=(^?&0/?'-6-8U7Q!<Z/J-A=7U
MQ!Y$^GRI<R+;K./,N%4JR1LPV]&!XSR#D=?3AIE@-N+*V&V$VZXB7B(XRG3[
MO XZ<57A\/:+;V$UC#I-C':3_P"N@6W4))_O#&#^- '"2>+O$7]L7LD09K:R
MU1=/\EU@2*1=RJ2SLX<2-N+* N/NC!SFNF\37NIIKN@:9IU\+-;^2<32^2LC
M82,L,!N <BM<Z%I)OX[XZ99F[B 6.<P+O4 8&&QD8%6Y+:"6>&>2&-YH"3$[
M*"R9&#@]LCB@#SG3?%_B&[U6WN60BSFU62Q:WD6!(D179,AB_F&4;=Q&W!&0
M!T-55\9:_::7J,M[>H+MM*N;RUQ!%);.T>#OAEC8[D (R'&[ISU%>CC1=+74
MSJ:Z;:"_/6Y$*^8>,?>QGIQ5"_\ ".D76EZI9VMG;6,FHP/#-<6\"J^&')Z<
M^M ')ZAXIUK1'N+8ZM9ZAYMI;W"WAA"I:&6=8BS!3RF&++DY^0Y)%.O]?UZP
MU*71(=8@NI5NK!%O6MEW(L[NK(ZKA20$##&.&&?4]O9Z'I5A:S6UMIUI%%./
MWZ) JK+QCY@!@_C1;:'I-G;I;VVF6<,*2B98XX%51(.C8 ^\/6@#BI]<\211
M76GPWRW-S:ZL;4RQI#'<S0^0LO[M'(C9P6Y']T$@9JE_PF>MZB]A:6-Q,3]A
MEN)KF&SB5WD25HRK)+(%4+M^;:3R1@@5Z'<Z+I5[%-%=:;:3QS2"619(58.X
M  8Y')P ,^@IMQH&C7=I!:W&DV,MO;_ZF)[=2L?^Z,8'X4 -\/:A<:KX=T^_
MNXHHKBXMTDD2*0.@8CG:P)!'IR:TZ1$6-%1%"JHPJ@8 'I2T %4=)_X\G_Z^
M)_\ T:]7JHZ3_P >3_\ 7Q/_ .C7H O5#=W4%C9SW=U*L5O!&TDLC=%51DD_
M0"IJR?%%O/=^$]8MK:-I;B6RF2.->K,4( 'XT 3-KNEI;Z?.U]"(M1=$LVSQ
M,67<H7Z@9K0KS+_A'=574=-MOL$ILM&U*(V3@@@Q.Y=VZ\!%Q'^=>FT %9T6
MOZ5-J[Z5'?PM?)G,(;G( )'H2 02!R*T:\]T71]6M->2UEBOGA%[=R73S%#:
MM!(9&0Q]Q(2Z@]_O@\8H [JSO[34$D>SN(YUBE:%VC;(5UX9?J#5BL#PIIK:
M5;:E;_91;0G49G@C50J^6<;2 .U;] %>\O[33H5EO+B."-Y%B5I&QN=CA5'J
M23C%53X@TD:O_9)OX?MQ.WRL\[L;MN>F['.W.<<XJCXNTH:EID+QV:W%W!=0
M/"=H+(/.C+D9Z?*#SZ9K)E,M_P",DMI]%O;;3;2[$\3Q6PV74^W'G2.#PHS@
M#J2,G@ 4 =M39)$BC:21U1$!9F8X  ZDFG5GZ[;27OA_4;6(9DGMI(UXSRRD
M#^= %FUO+6]C,EI<PW$8."T4@< ^F14]<%J6A:BLD4VEWEZ)I#_I+O&8R2 !
M&P"*!A?FX(.=W.<5/8Z9JL-_%<2W5\["5'8-+*4/[R3?\IXP4:,8Z?+VQFE=
M%^SGV.VKDO$?_(VZ/_UY7?\ Z%!76USFJ6R77C324<L +&[/'^_!5Q=I79E)
M75BK16W_ &-!_P ])/S'^%']C0?\])/S'^%='M8F'LI&)16W_8T'_/23\Q_A
M1_8T'_/23\Q_A1[6(>RD8E%;?]C0?\])/S'^%']C0?\ /23\Q_A1[6(>RD<U
MJ5K->Z7=6MO>26<TT91+B,9:,GN*\CT/X;Z_J&HRZ9<;=+AMR5-WM\P3N>5V
M ]5/!8GGMUKZ!_L:#_GI)^8_PI\6DPQ2I('D)4Y&2*QK1I5;<VMCMP>+Q6#4
ME0E;FT;Z_)[H\>^'W@/Q1:>-1?WR/I46GDQS2(V1>C^XOK&>#DC(/ P<X]PH
MHK"$(PCRQV-,3B:F)JNK5=Y/Y!1115G.%%%% !1110 4444 %%%% !1110 5
M2UG[1_8E^+2 W%R;>010K*8R[;3@!Q]W)[]JNT4 >.IX?U)S,#H%R=/=]/D:
MVAM_LX<QS.9<*TC$MM*Y8D%L5:O] OY+/S(M(O4LS=7#V5B\*SI$C)& KQ;U
M*;F5V5E8;-QZ9X]8HH \M30M=D\11SZA;WD5P\]K+#):Q),MO&J)NC$S."JA
MA(&&#N!S\Q/#!X5UF#1K)],M)[;5IX-0CN)O,VM\^XQ!FSZ[=I_A]J]5HH \
MMU#1;B>*%](\/WNG:5'<(UW;2()3.1&XW?9R^&"L4R<Y8\X.WG=32-67X97&
MG6;WGVUT<Q).5BE"%R?+!5B$^7*KSD C)&*[6B@#R]_#1O\ 4H);7P]-;:0N
MH6;I:W" ;67S/.E"9.T$&,'^\5S[G9\:^')M9U2.:UL%FG&D7]NDY &R5U01
MC=VY+X/;FNWHH \SO=.U'Q!J/F2:-?Q6;R:6CI< *76.24RY ;H PSZ@]Q20
M>#H_^$G^S2:%ML!K4ETY$8$3PFT*IG'4!\@KZGIS7IM% 'D%SX;ULPVT5U:W
M[V:6\]O;1Q0+.\#?:)-I&YQL)C,6U^P7&1W[7PGHDEC?:Q>WMNYO9;H*ES-@
MO)$(8AVX +*Q..^:ZJB@#S33?"C?\)!;1RZ.8[:#4=1G=F0")B[*87P#\W'3
M/0CVK,T[0?$%I8W+/9:A/J:64L=T@184NW8C),RR;I#U92,$#(RN<5Z]10!Y
M';>';]KN2:;0Y#81:I9744*V@B4*%=9&2(NQ7!VYYR>N*M6'@N1K?2OMFE2-
M(]I?_;=[$[Y"ZF'?SR1\VWT[8KU*B@#R2'P_X@DOK-]034?/:&Q,$\4"2O!L
MC3S%,C./+.\.6X.X-WZ5:_X1&\.GVA33'%Y=/J<=Z6;[T<@F,2OD_=SY>!VX
MZ<UZC10!D>%H/LWA32X/LCVABMD1H'3:48#!R/KFM>BB@ HHHH HZ3_QY/\
M]?$__HUZS-4_Y"$GT'\JT])_X\G_ .OB?_T:]/GTZ"XE,K[]QZX-73DHN[(G
M%R5D9NC_ /'XW^X?YBMVJMO80VTA>/=N(QR:M43DI.Z"$7%69Y]IBZMX@\(G
MQ1_;]Y9WT\<EQ;PQE?L\ !.U&0CY@  &).<YP1QB[X2UZ\US7I9YG9()]%L+
MQ;;/RQ/+YI;'Y ?@*FU+X<Z+J:RPO/J$%G+(\K6EO=%(M[@[F ZKG<<@$ Y.
M1S5VZ\(6ES);7"7^H6EY#;+:FZM)1$\L8Z*P VG!)(P!C)QBH+.8TO6M4FO=
M*62^F99=4U>)P3PR1F3RQ]%P,?2M[PU'<>(?AUHK7FH7J7$]I%))<P2[)6;
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MK*X8 J2H*G*ME<>A'%=-5/3M)T_2(6ATZSBMHW;<PC'WCC')ZGCCVJY0!6U
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MBLK>"3?'$%;&,Y-3*JFK#C2:=R>BBBL#<**** "BBB@ HHHH **** "BBB@
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M5245EX) (7[V.#0!Z?17D#>)=5.C10PWDZVHU7R+J[?45:-$,.]52["'Y2^
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MWK[_ *%C6/\ OJV_^.T ;E%8?]O7W_0L:Q_WU;?_ !VC^WK[_H6-8_[ZMO\
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M1V&Q23CCVS6Q7*Z[Y^G^*;75S87=[:_V?/:E+6(R,LC.C %1T#!2,] 0,XH
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MFW^D64D>H[K47"Z@;E!]G YV-"<8R20?EY(+;N<5Z30 4444 %%%% !1110
M4444 8O]JZ!8:_-9_:H8M3NW3S5R?F;;A 3T#%1P.":T[RSM]0M)+6[B$L$@
MPZ$GGG/:O/-5TO4I/%=Y*EKJ!FDU2TG@ACCS931($!DE;LZX;N#E(\ ]_2J
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M\/?V>(;:)I"DH)(1P0-NX,,D_*"IR>E>AZ%9S:?X>TVRN"#/;VL44A!SEE0
M_J* -"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ K(UCQ/H^@.BZI=FWW@%3Y+L#DX'*@C)/&*UZY[QI;7-YX=$-K#)-+]LM'
MV1C)VK<1LQ^@ )_"@#3TW5['5D=K*5I F-VZ-D(SG'# >E7JX#5=(O\ 4?&#
MQS07K::^HV[/M=U1HQ:S!LX/W=Y4$=SC-8PT+Q!::1 VEQ:C%J4MGJ,,CO*Y
M.!(/(4EC@'8,(>/K0!ZQ6.OBG0WU7^S%U*$W9D,07G!D'5 V-I;_ &<YK%\#
MV5Q:SZ@^Z\2U=8@D$UE);HKC=N91)([$G@,> 2 1GFL>"VU*WU.&WLM/U2!_
M[2$DVGW$"SV 4R[GFCF(!0X)<8.0QQMH ]$M+N&]MDN;=]\3YVM@C.#CH>>U
M35Y-'X?U6XT74)KFVU,WMOHRFR!DD#"Y$MPP*@'E\>7^! Z&M&:QU9M0U%DL
MM3;Q!)<3&TO1(R6\<)B/EY)^0J#@%,9W<^] 'I%8">-?#\FI#3EO7-X6"^5]
MFESRVT'[O3/&>E8/@*PO;6^DDF-_&ALT6>&>S>%#-GEBSR.7?J"RC:<CD\5J
M75I=GQO?W202F%M$6))0ORF3S)#M!]<$'\: .IHKR2;P]J5KIFA1O#?"S;2@
MUR@@FN9!>E4W,RK(K!\# 8D@$'IFI+VUUW^U+1C9:E)=VL]B/M;QRL\L8\OS
M6!5O*C'WPR?,2=QZ$$ 'J5M=07<1EMY5EC#LA93D;E8JP_ @C\*EKRFS\+.S
M-9G3+Z&"%=59T4R(CRM.I@8$'YODQM(]#W%)/HNO6^G(EG%J"BXT_3Y=0W>9
M(TL@D;S^-P)?;C<H()''I0!ZO42W4#7<EJLJFXC19'C!Y56)"D_4JWY&O.-+
M\.7%[J.FP7JZC-I.^\;RI(9+:.,%80J[2[-MW!RH8@YS@  5=\$Z;=6VN17F
MI6-TM[/HEK&US,C$ET:0.KMT#8\OKR>OK0!V]K?6MZUPMM,LAMIC!,%_@< $
MJ??!'YTR?4[*VG:">=8Y%$9(8$#]XVQ!GIDMQBN#CT&[N_$1BN[.[^P2Z[=S
M2@%D1XS;*%+8(RI8?3(K+?1-3N-,$>I:?J%S!;)9$1R!W8K'?2[L#.680[?<
MC'M0!ZK;W4-W&TD#[E5VC)P1\RDJ1S[@U"^JV*7)MC<+YRRK"R*"2KLNY0<=
M,CGFO,-9L=:FLIK;^R[^1B;][:5EF?#M.YC"JC+L;;M*NYP <#O4UOI.KQZN
MUS#8WD5]=7-C/)<,C;6 M2K;STXD^\/TH ]5HKR*;2M5ET;RM/L-;M[DZ>(]
M4:1Y TUSYL6&0D_,PQ*=Z\8/7H!W/AS3I=+US7;:.*>+3?,ADM0[,R9,?S[2
M2>XY]\^M &];W<%T9A!*LGDR&*3;_"XQD?49J:O,--T>;5M-\/17,-U)%%;:
M@+U4=E7[3YB_?VD9._>1GOS5=-&UJVM+(K;:J\=QIME)JR"1S),XD'G#).?,
MVDY P2,CTH ]7JE=ZOI]BTBW5U'&T8C9P3RHD?8A/U8$#Z5P-GH,]_KMG%)8
MZE'X>^U7+0V\[2)LC\F,8<9RJF0.55OR' K';P[J-Q8.+K3-1:^N=-L83/M<
MO^[O#O!;LPC\LY/.!D=#0!['4*7<#W<MHLJFXB57>/N%;.#]#@_E7FNKZ'=V
M]S>VD%OJ"Z9%?B2WC$$MS P:W7=N17#E=^[!4G:V<CFMS3#=OXA\,F:U:UO%
MT>;[; TID,:YBV!F/).X-@GG[WO0!VE%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 10
MVT%NTK0Q)&97\R3:,;FP!D^_ J6BB@ HHHH *B6VA2YDN%B432JJO)CE@N<#
M/H,G\S110!+1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
-110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>49
<FILENAME>g4i5nix4zlkt000002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g4i5nix4zlkt000002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 'Q J # 2(  A$! Q$!_\0
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M"QMQ!;ILC!R!G-8?B+3+S4%M;BVCS)']Z,D9'>M?3'OGLPVH1HD^3\J],=J
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MW-TP!/VEEQMJYI3%O!E\I.0NX#VI]K::]_9QTSR(88L$&4GG'IQ3[2QNM/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MV@N[>.>%NJ2*&'Y&JXT72A:I;#3K3R$.5C\E=H/KC'6K]%.[0K(155%"J %
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M3U6@Z"K/:L"@HHHH **** "BD+!1EB /4FL6[\7^'[&9HKG5K:-U."-V?Y4
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M8][)IMN^HQ1Q7C)F:.,Y56] :9);HHHH **** "BBB@ HHHH **** "BBB@
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MM6[XE_U.F_\ 80A_F:NG\2(G\+-NBBBH+"BBB@ HHHH **** "BBB@ HHHH
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M[W7[Z"^>!(DMH9$@C&2I;=D[L\CBDX-*X*:;L=+1114EA1110 4444 %%%%
M!1110 4444 %%%% !17,7WBD:3JTEM?% G5 HYV^M6AXJT]@&64%3R"*;5B8
MS4KV-VBL0>)[ C_6"KMGJMM>_P"J<$TBB]12,ZH,LP4>I.*S[K7M,M ?,NXR
M1_"AW']*:3>PFTMS1HKE+GQU:1,1%:RN,?>8@"JJ_$*(,-]EE?5) :T5&H^A
MFZ]-=3M:*YFT\=:-<MM>5X6_VUX_,5L6VLZ;>'%O>PN?0-S4N$H[HJ-2,MF7
MJ**PM>UK["1;0;C.5W-M&2!4I7'.:A'F9NT5D^'?,;25EE=V>5BQ#GE?:M5F
M5$+,<*!DDT,(NZN+134=9$#HP*GH13J104444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% %74H!<Z9=0%BHDB9<CMD5X!;)%Y81
MUP@;##/0 ]:]-\;>.HM&?[!:I]I=P4D,$@WQ/V4_6O,+9_M6^61W#SIY@7/*
M'/3..*0T=II<=K'9EH69HY<^8IX8>X/H*VA'+]GF@5V>?9E9BOWE]:Y[0KR!
M1!:RE0%Z''!R.171P$J\T,KDPA,QYX)]<>HI@9#ZE'>ZC#;0%A;SL4,A; &!
MS\I'6K]TT=NJZ>TNV8P>9">N1VP!S3OLWV:2%T,3*1O$#IG:A^\4/7-.O]%,
MFJPZE:+;8C92)_-(<1D<_7V% '$:AX-BF*SV]V\<]S)@@Y.UP,G'UJWIWAUO
ML&)+J5KE9"(Y3'M$9(].X/KVKHKI4\Z*T+,)II=\3A>$(Z_3(JM'J%R-)G$F
M!.)VMS.N-L7/!YI!<Y34/#-U NWRS<G<J%D) 7!R2,>O/)Z4)X<>YMXH(=-#
M*6,ADXZY^ZW&.M=UI*M%HL,5VX\^1F#-NW%R2><_2IX/+@O'M0CH6&Y6 ^5C
MWY[&BP^8YG0-(2XNKF6^B4S1L%8*FQEXQAS@!A["M^YEN+=G$<49B$86$$X!
M;W] *NR2IS#N#L!RN[H/>L+59[Z:UG6V00"/"I,Y!&<\X_\ KTQ-W,>X==,N
M8TO;>.>-V:6XNF&%C8#DX] .E6H);1YH"+ZU99D,XSD (1]XGUQVK-U.]TY=
M*DA^V)?WC'8[B3!.XX("C@4Z7PY+9Z9<7&F0B.>8*AD8[]B]^/?IP* .9U5I
M4U0Z<9;A+51F#+;00>P/<=,5+I6I7374>C:C^\0RB19FD_@4<J?6M7Q=#-/X
M6LSJLUNNI6SJ(Y+=<+%&>-K>IKE[E(8TL6M9LJKJ"P/)#<''OB@#L'N)Q;7U
MU%+NLV_U'V:0 JN1@G\>U8(BBNKN\MKA5>6$<7"H5R#W(]35'3YFT6ZB-A+/
M+;VTDB@!<#YNH;/WORK8AFFNRLJB R,I#&5BG?@$X["J@]==B9;:&=HFCWNN
M3-8Z=&9I4#,5SM&SMSVKOO#W@[Q%:I#%>^?&)H'C<%Q(J$_=)]-O6MKPML\-
MR2W%[ICP_;$3_2H5W(V/8=/7/>NXL]2L]0B$EK<)(I]#S^5)Q:'S7,#6/"%Q
MKGABWT>ZUZ^C9$"S3P[09_\ >&.GMFJ'A+X;V'AN.6&Z6UU) ^^"6:W'F1^H
M.<C\L5W%%-3DERDN$6^9C8XXXD"1HJ(.BJ, 4ZBBI*&F.,@@HI!.3QU--:WA
M?&Z&-L'(RH.#TS4E% $7V6W\PR>1%O*[2VP9(],^E-%E:!(T%K#MB.8QY8PG
MT]*GHH"Q6M;""S@DB12PD=GD+G<78]2:?]DMM[/]GBWL<LVP9/UJ:BBX6*7]
ME69O9;MX0\LJ>6V_D%?3'2K$=O!$08X8T(78"J@87T^E2T47"P4444 %%%%
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M8A%Y*<K&J_,0/>MR>]M6M5F>1H#,!(BM+M#?2@"GK-DD\,MO+&)DF<,Z<J6
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MU!5CH_->"%V7R9)G&<J<'/H:S+OS 5/G74^Q@Y+S;8@?85CMJ&%8C*9X(/\
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MSM=2IQZ&L4^$]*\QY"LOSL68>9P24V?R_7FK@X6]XF7-T*,&NVEG+$L5[<M
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M;78&+D?=R#70VDYN+=92NW=TKA::W/4IU(27ND]%%%(T"BBB@ HHHH ****
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MG'.T]Q5BJ6D1/!H]G%);I;.D*AH8SE8SC[H^E7:Z5L>+.W,[!1113)"BBB@
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M346H6%G)I[WMFKQM$1YB,VX$'N">:A8V'.J;W9U1RJM*B\1%>ZB*ZU=Y T<
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M5SY6/N>I[DUIBY 3D!1V-93WT.N#[EX,DB%3A7!R #@9_K5"XTO?!EA\H
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M*Y7&6UOW(./7%7?)7. "<#OTJVD2(/EYXZBI(U0L$5=S$=NU0Y):L+,K1P8
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MUG_NO_*O>G_N_P OT/&C_'^?ZGT$.E% Z45X)[(4444 %%%% !1110 4444
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MVD]1\]U='H\<D<T:R1.KQL,JRG((]C3JPO#&TVUW);JRV,EP6M@1@%<#) [
MMDUNUA)6=BT[H****0PHHHH **** "BBB@ HHHH **** "N=\<>(+GPQX3NM
M5LX89KB)D5$F)VDLP7G'/>NBK$\6^'5\5>'+C2&NFM?.*L)E0,5*L&'!Z]*
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M%+7_ +^"M/:U+6Y?S[W)Y8=SA-3\$7NH_#C2!%;O#KFGV^%3(#,#]Y,U4O\
MPMJ]S\/O#.FG3)7F@N@;F'(RB9.<\^AKT;_A)-%_Z"EK_P!_!1_PDFB_]!2U
M_P"_@H56JNG6X<L.YR?BWPS?:?JNF>(?"]GNNK3$,MM%A1)%Z?EQ7;"&WU*V
M@FN[%-Q4,(YXPS1GT^M5?^$DT7_H*6O_ '\%'_"2:+_T%+7_ +^"LY.<DDUL
M4G!/<U  !@# '04M97_"2:+_ -!2U_[^"C_A)-%_Z"EK_P!_!6?)+L5SQ[FK
M165_PDFB_P#04M?^_@H_X231?^@I:_\ ?P4<DNP<\>YJT5E?\))HO_04M?\
MOX*/^$DT7_H*6O\ W\%')+L'/'N:M%97_"2Z)_T%+7\9!6H"&4,""",@BDXM
M;H::>PM%%%(84444 %%%% !1110 4444 %>1_$/X@W.B>,8+>QU2&WMM)2.X
MOK9B-UT'8#8ONJ_-7KE8D7A+1(SJA-DLC:F[2732DN7)&W@GH,= .E ',ZA\
M2;BTOK_R-'6?3K"YMH);D7(!83!=I5<<XW#/-8]CXRU^[DB_M%C#NUVYLXC;
M2+@JD;$*X*\@8'(.2:["W^'OAVVTNXTY+:<V\\D,D@:X=B3%C9R3GC J1/ >
M@)?O>+;S"1KMKS;Y[[!*RE68+G R": ./\._$F]L- TB3Q'9.T=WI\US%>),
M'>8Q#+;E &W(Z<GWK0?XGSZ=:S2:SH9MI6TX:C:1Q7(D\U"P4*QP-K98>HK;
MTKX=>&-'EWVU@S 0-;JD\SRHB-]\*K$@;N^.M+8_#OPU86MY;I8O+'=P_9W%
MQ,\NV+M&I8G:H]!B@#B+_P 7>(8=6\0IJ+2V/V==.\NWM9U<1F23#$,5[CJ,
M?2M^P^)XU#79;.#2)9+;S)X8I(V)D+Q _>7;@!B"!\Q]ZU(/AOX;@AN(Q;W+
M_:?)\YY;J1V?RFW)R3G@U;A\#Z#!JL^H1VTHDFWEHO/?R07&'81YV@GN<4 9
MO@?QX?%T]S!-:06<T*+)Y'GDRKDX(=&52"/49'O79M]TU@Z%X-T;P[=RW=C#
M,;B2,1>;/.\K)&#D(I8G"^PK>;[IH ^;/%G_ "-NJ?\ 7PU:7PZ_Y':S_P!U
M_P"59OBS_D;=4_Z^&K2^'7_([6?^Z_\ *O>G_N_R_0\:/\?Y_J?00Z44#I17
M@GLA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !6'I,:/K6N%D4_OTZC_IF
M*W*Q='_Y#6N?]=T_]%BKCL_ZZD2W1K^3%_SR3_OD4>3%_P \D_[Y%/KQ#Q=\
M5-=TKXA3+IQ#>&]*GAM]1/E*<LY.?FQD>G'I47+/;/)B_P">2?\ ?(H\F+_G
MDG_?(K(UOQ;HGAVSL[O5+Y;>WO)!'#(5+*Q(R.0.!CN:S=)^)7A/6[^YL;#5
M!)<6\;2LIB==Z*,EER/F&/2BX'4^3%_SR3_OD4>3%_SR3_OD5Y;X2^+,7BVX
M\16OVB*SE@21]/(A=OW2J<R-QUS@[?TK*UKQ_K>F>!/"^J6_B*VO&O-1,-U?
M):B-'C#'(VLHVX'? Z47 ]G\F+_GDG_?(H\F+_GDG_?(KF=!^(GA?Q+JDFFZ
M7J8ENT!81O&R;P.Z[@-P^E0:U\4?!^@:JVFW^KJMTAQ(L<;2"(_[14$"BX'6
M^3%_SR3_ +Y%'DQ?\\D_[Y%8^J^+]!T;08];O=2A33Y0#%,IW"3/3:!R3]*X
M)/B@NK?$K2+31M3$NARV<LMU%]GPZLH8\@C<#@ X'6BX'JODQ?\ /)/^^11Y
M,7_/)/\ OD5A6OC;P_>>%IO$L%^&TF$-YDYC8;<'!&TC.?PK5TO4K76-,M]1
MLG9[6X021,R%2RGH<'D47 L>3%_SR3_OD4>3%_SR3_OD5Y5#\2YM(\:^-(]?
MOU_LG2E3[+"(U#%C_"#U8GWK0\&ZGXQUW3]0\3ZS>1Z=IDT,CZ?8^0I*+CY9
M'.-Q'?'>BX'HODQ?\\D_[Y%'DQ?\\D_[Y%>.ZIXYUVR^&>C:O9>((-0NKG4A
M!)>QV@170L1MV,HQCIG%=,GB;5C\99/#QN5_LP:2+D1>6N?,SUW8S^%%P.\\
MF+_GDG_?(H\F+_GDG_?(K@/#/C>WM/"6H:UX@\20:A;07K0FY@M'C$?0!"NT
M$G)ZX[UJ6'Q-\(:GKL>CVFKI)=R\1?NV"2'T5R,$_C1<#J_)B_YY)_WR*/)B
M_P">2?\ ?(KF=:^(OA;P_K*:3J6J+%>, 618V<1@]"Y (7\:TO#_ (FTGQ39
M2WFCW7VFWCE,3.$91N'7J!GZT7 C\4PQ#PIJA$:?\>S_ ,(]*T[#_D&VO_7%
M/Y"J'BK_ )%35?\ KV?^57[#_D&VO_7%/Y"M'\'S(7Q_(L44V22.&-I)75$4
M9+,< ?C7">(/BII&F!X=-4ZA<#C*'$8/NW?\**=*=1VBKA.I&"O)G>T5G:#J
M,FK:%97\J*DD\0=E7H"?2M&H:L[,I.ZN%%%%(84444 %%%% !1110 4444 %
M%%% !1110 4C?=-+5#5]7L=%L)+N^N$BC1<X)Y8^@'<TTFW9";25V?/7BS_D
M;=4_Z^&K2^'7_([6?^Z_\JY_4[UM2U2ZO67:9Y6?'ID\5TWPSMGF\8Q2*/EA
MC9F/UX%>[57+0:?8\:G[U9-=SWP=**!THKP3V@HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ K%T?\ Y#6N?]=T_P#18K:K%TC_ )#6N?\ 7=/_ $6*N.S_
M *ZDRW0_Q1K<?ASPQJ&K2<_9H6=1_>;HH_/%>%>'_ /CS6O -X8;G1TL]>)N
MYH[E'\]FSD<[>.G'UKZ+95==KJ&'H1F@  8 P!T J"CYEU/6)=<^%WABPO49
MKS3-92RN(W!)P!QG\./PKT7Q);10_'CP>88%0&RF5BB8! #8!Q7J?DQ?\\DY
M.?NCK2E%+!BH+#H<<B@#PCP-?65C<_$31+C$6J32W,L,)C()C"MG!QTZ<5R^
MHJ1\$_!.^W>8#5)"T2H27&YN,>]?3GV>#SFF\F/S6&"^T;B/3-.\J,!1Y:X4
MY V]* /$=0U;3?&GQ:\)OX51I#IR,UY,D)C$*_W6R!R.1CWQ67X9US1/!>F^
M+]%\76SKJ]Q<2L%DMRYNU887:<<\G/XYKZ!C@AB=WCBC1G.7*J 6/OZTDEM!
M,ZO+!'(Z?=9D!*_2@#YN?1]2T'P)X%U+7+*=M,LM1DGN8&0L88G8%2R_0'KZ
MUTD.MZ1XC^/^B:CHJ,]H;-XVN1"469@K9QD#. <5[@Z+(A1U#*PP589!I@MX
MTC"11I'M7";5 V_2@#YQUC3[[3_%&H?#&VB<66L:I%=PN#PD!^9Q]./_ !VO
MHZVMXK2UAMH5"Q0H$11V &!7#^'/A]>V/B^;Q1XAUPZMJ7EF&WQ"(TB3Z#OC
M^9KO: / +7P-IOC;XT^,8M5\[R;8!D5"0"[# )/MUK6\"Z]?:18Z_P##W7BW
MVW3K>;[%*P/[Z+:3@'O@<CV/M7LX1 Q8*H8]2!R:0Q1E]Y12WJ1S0!\U;6_X
M4+X9&ULC6N1C_;:O0T!_X:(E.#C^P1SCCK7J7E1[0OEIM!R!M&*78N_?M&[&
M,XYH ^:$5O\ A0/B0;6R=:/&/]I:[+QE:002_"_R;9$VW,0^1,8&U../>O9/
M*CVE?+3:3DC:,4I1#MRBG;TR.E 'AUAJ]AX)^(_C*+Q+87$DNJOYEDZVQE^T
M(<_(N!WR!^%;GP"Q_P (9J&(C$/[1EQ&1]S@<?A6QK'@CQ,VO7>H^'_&4]C%
M=G,EM<P"=(R>ICR?E_"MSP5X1M_!?A]=,AN)+EVD:::>08,CMU..U %SQ5_R
M*FJ_]>S_ ,JX_6_B;;:'!'I]E9R3WD<2AFE!2-3M'XM^%=?XJ_Y%/5?^O9_Y
M5E:GX5M=<TRW,\:R'R4P2.1\HZ&NBE*"2<U=7,*BFVU!V=CQ?6_%&L>(9"=0
MO'>/.1"GRQK^ _K617;:U\.[RR9GLF,BC_EF_7\#7'7%O/:2F*XB>)Q_"PQ7
ML4:E*:M3/*JTZD7>8JWEVBA4NKA5'0+*P _6G?;[W_G]N?\ O\W^-;-GX,U2
M^M(KF$Q>7(NY<DYQ^53_ /"!:Q_TQ_,_X4GB**=FT-4*K5TCG_M][_S^W/\
MW^;_ !H^WWO_ #^W/_?YO\:Z#_A M8_Z8_F?\*/^$"UC_IC^9_PI?6*'\R'[
M"MV9S_V^]_Y_;G_O\W^-'V^]_P"?VY_[_-_C70?\(%K'_3'\S_A1_P (%K'_
M $Q_,_X4?6*'\R#V%;LSG_M][_S^W/\ W^;_ !H^WWO_ #^W/_?YO\:Z#_A
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MA_&_4?0=J] AB6&,(HP!7GXK%^T7)#8[L-AO9OFEN24445PG8%%%% !1110
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M]P?E1]GB_N#\JDHH C^SQ?W!^5'V>+^X/RJ2B@"/[/%_<'Y4?9XO[@_*I**
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@H **** "BBB@ HHHH **** "BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>50
<FILENAME>g4i5nix4zlkt000009.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g4i5nix4zlkt000009.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &9 J # 2(  A$! Q$!_\0
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MX0S*Y'UP:33"Y;HJ"ZO;6QB\V[N8;>/.-\L@0?F:;!J%E<VQN(+NWE@'61)
MRC\1Q19[CN6:*Y+PCXU3Q7-J82!+=+>0) CR O)P221^':KGA/4M=U*VNFUV
MTM+>1)=L0MI0X9<=3AFP:J5.4;WZ$J2>QT-%4I=8TR"Y^S3:C:1W&<>4\ZAO
MRSFK4DL<,9DED1$'5F; _.ILRKCZ*IS:MIMO+'%/J%K%)( 41YE!8'I@$\U<
MHLP"BBBD 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %>5>+W\.W/C<H^E:EK^JQQ!&LHW_<QC'Y@\Y/;GFO5
M:X'5/ FK)XMGU_P[K,=C+=+B998M_7&<=CG .#WK>@XJ3;=C.HFUH<]\,1+;
M>,_$-I]D:PB\G<UGOW")MPP,]\ GFN3T;0+B_P##&I:WIQ==1TJ\$JE.I0#)
MQ[@\_G7J7ACP-J'A[Q1?:E)J:7L-Y"5D:12)6<D$L>W7/X5:\!^$;KPI9W\%
MW<P7'VF;S!Y:D #&,'-=$J\4Y2B^W_!,U3;LGYG!:1KZ>)?BKH.I*-LC6H29
M>RR!'W8]NX^M5O$,&KWGQ8U:RT5F6ZNE$+..-L91-Q)[#CK78:;\-)-(\>)K
M5G=0+IR2,ZVY4[UW*1@'I@$\>U:EEX/N[;XD7GB9KJ$VT\1180#O!VJ.>W\-
M#K4U*\>P<DFK/N<M\,[M?#?B+4O"FI0117C29BF P9,#[N>X(^9?QKUJN(\;
M>!)O$6HV6J:7=QV6HVY ,K _,!RIX[@_SKL;07(LX1>&-KD(!*8L[2W<C/:N
M>M*,[36[W-()Q]T\<UB+6)OC1>)H5Q#;Z@8QLDF&5 \I<]CV]JS_ (A6OBVW
MM=//B6_M+J)IB(1 H!5L<YPH[5Z/%X.NX_B9)XH-U ;9X]@AP=_W O7IVI?'
M_@^[\76MA%:74$!MI6=C*"<@C'&*WC7BIQVM8S=-M,YOQR7UKQKX;\,W$KQZ
M;,BRRJK8\PG/]%P/K53QYHMCX'OM%UKP]%]BG\\QO'&QVR #/(/KR#ZYKM?%
M?@J/Q''97$-X]EJ=ECR+E!GWP1]1D>E9=OX"U;4]9M+_ ,6:VFHI9G,-O%%L
M0GU;\AGCG'6E"K%):Z+==QR@VWH<]J6EVNM?'![*\1C;2VZM+&"5W@1 [6QV
MR!D>U4]/\,:7-\7+_0S 1I:*93:AR$?"J0#Z@%B:[P>$+O\ X68?%'VJ'[-Y
M7E^3@[\[-O7I267@^[MOB/>>)FNH&MIXRBP@'>/E4?3^&CVR2LG]G\0Y'?;J
M<SX#MXM)^*GB+2[-3'9I&Q6('@89<?EN(JE\/E \*^-\ #(DSQ_L/7::-X0N
M]-\?ZKXADNH7M[U&5(E!W+DKU[?PU5\,^!KW0]'\064UY;R/J881LBMA,JPY
MS]:)58M/7^4%!Z?,Y#P=X2TG5OAM?ZC?P&:Y19A;L7/[D*,C:.@RV2?6JUGK
M%Y:? V<0RNI:]-L&!Y6-L,0/3N/QKT7PQX3NM"\$7.A37,,L\HF D0$*-XP.
MO-8D?A2S\,_#.^TOQ'=AK9YO,:XMHV;RB=H5L8SP15>VC*3N[ZJPN1I?(RM6
M\#:)8_"P:E;P[+]+1)VN0QS)NQN4]MISC'TKL?AH /A[I( Q\C_^AM7FNH1N
MG@66&3QM:WNFPK_HEE$NV21@?E#@_, .N/:O3_AW!);^ =(252K&(O@CLS$C
M]"*FO?V6KOJ.G;GT70POB1+X??4=+M]5AU&_O 2\&G6C?+)DX^8>^,<<\&N5
M\/1M:?%G3TAT1]$CN(6#69DW90HW)^I'3VKN?%W@F[UG6[+7-(U%;+4K50H:
M1-RD D@_7DCWS5*S\!ZU!XQT_P 176MQ7MQ'G[5YD97(((P@'  ![]Z(5(*G
M:_1]_P#A@E&3E>QRFE>%=&E^+=]HSVF;"W4RQ1>8WRL A!SG/4FG:7X8TB;X
MOWVDO:YLH 9HX][?*X"-G.<]2:[JP\'W=I\1KWQ*]U UM<1E5A .\9"CD]/X
M:IZGX&U?_A-I/$6B:O#:-.H6598=Q P P';D ?2G[9-VYNGXB]GY=3B895U[
MQQKMWJGA^^UT0R&&*" C; H8@9!([+Q^)K3\/V6KZ7X=\765SIM[9Z2]K)+:
M)=8)3(;Y?KC&?I71ZEX$U2W\1W.M^&-833YKL'[1%+%O0D]2/QYZ=:LZ3X%F
MTSPSJUE)J3W6H:E&ZR3RD[%)!Z#/3))/K1*M!QT?;O\ \,"@[G*_#'P5IVIZ
M5::]?&:2XM[@_9X]^$0(>.._S9->K7[6JZ?<&^>-+0QD2M(V%"D8.36-X*\/
M7'ACPW%IES/'-(DCN7C! Y.>];5]9P:C83V5RF^">,QR+Z@C!KGK5.>HW?0T
MA'EB>2V_@C7=/1K_ ,#>)$GL)&)1!+C.#C'=6QTR<5H:#XLU76]&\2Z+JENJ
M:M9VDIWQJ%+<%2"!QD'TZYI+3P1XV\.>=:>'M>MOL$C%E6=?F7/?!4@'Z5T/
M@GP2_AIKR]O[L7FIWA_>R ':!G)'/)R>2:Z)SCRMMI]N_P S.,7?16,SX-/"
M?!LR(5\Q;M_, Z\JN/TKL'U;14U]=.DN;9=59 5C8 2%><8/Y\5QMW\-M0T_
M5)[[PGKC:6MP<R0,I*CZ>WH"./6M#PIX _L759-:U74'U+59 0)6!PF>I&>2
M<<9]*RJ>SDW/FWZ%QYDE&QV5Q)'%;2R2R>7&B%F?.-H Y->$30:#>:3JCZ'X
M8U/4U^=WU:\DQY1QDD8ZXZX/)[U[I>6L=]8SVDV?*GC:-\=<$8-><V7PVUZS
MT^YT5/$JIHLQ8F..#]XV1T)/0'C.#1AYQBG=V_KR"I%O9'/SR23? .'SB7"7
M01=W/RB0X%/\0>$]*M?A5::P("VIND$CW+.2S;L#'T . .V!73#X?ZFWPX;P
MR]]:>>+CS4F"MMV[MV".N>M:VL^$KK4_A_;^'8[F%+B*.%#*P.P[,9]^U:^V
MBGH_M?@1R-K5=#A?%E[<ZGX<\$:9-/(L%\D9N'S]\_(HSZXR32_%'PAHWA_1
M+*ZTJW%LS3>3(BN2)!M)#')ZC'7WKL-3^'ZZMX-TO2)KL17VG1J(;F-20& P
M>.N#@?D*Q=8^'/B?Q!81KJOB2&YN("!"IB*QA>Y..2W2G"K%-6E9)L)0=GH>
MDV/_ "#[;_KDO\A7F1_Y."'_ %P_]HUZA;QF&UAB)!*(%)'? KDO^$.N_P#A
M9G_"4?:H/LWE[/)P=_\ J]O7IUKFI22<K]F:33=K=SF-7QX2^,EGJ.1'9ZHN
M)23@ M\K9_X$%;\:F\!1MXC\?ZYXHE!,43F&V)[9X'Y(!_WU73>/?![^+]-M
MHK>>*"ZMY=Z22 D;2,,./P_*KW@[PX/"WAR'3FD22;<TDTB# 9B>WX8'X5JZ
ML?9?WMOD2H/G\MS?KQOX?*!X5\;X &1)GC_8>O9*X7PSX&O=#T?Q!937EO(^
MIAA&R*V$RK#G/UK.E)*$D_(J:;:^9R'@[PEI.K?#:_U&_@,URBS"W8N?W(49
M&T=!ELD^M0V4SS_ 6_21BRQ781 ><#>AP/;)->A>&/"=UH7@BYT*:YAEGE$P
M$B A1O&!UYKBM<TN/P9\+[OP_?ZC;2W]S.)H4CR"Z[DS@'TQ72JBG-J]_>5C
M)QY8W\BIXHO;A/AWX/TN+S1;W:#SDCX,@7;A1_WUT]<47>DWMMJVEZAX9\&Z
MMI<]K(/-+$$2KQU^8]LY]<UUD'A&#Q7\,]#M996MKF&W22"8#)0X[CN"/Z4M
MIX&UZ\UBQO/$?B(WD-CS%% I3?T^\>/09ZDXI*K%*U]K]PY&_P #'NK2'Q;\
M9+G3M7!FL;"#,5NS$*2 O\RQ/X"NCL?AUHMC?ZFD-Q+]AOX_+FTT/A .#_O=
MN.>]+XC\$75]X@B\0Z%J0T[5478[,FY)!C'(^G'?/%+X8\$W.F:[<:_K6I?V
MAJLR[ RIM1!P.!] !VP*SE47*N65M-O/^NI:CKJCC_A'H]C<3ZIJ<L.Z[LI?
M+MY-Q^165@1CH?QJKX*U"?1_ASXLO;/Y)XY1L8#[I("Y_#.:Z_PSX&U?PSKM
MQ);:O VD7$C/);F+YWX(49[8SVZXJQX1\"/HFB:KI>J3074-^Y+"($84KC'/
M>KG5@W)WO>Q,82TT[G/^%_ &A:M\/UO[V$S7]Y$\INF<ED;)QCZ8YSUYK#M]
M4NM2^"6I07;M+]DNHXHW?G*;D(&?;/Y8KIX_A[XEL+*;2-,\4B/1YB<I)#F1
M5/4 ^_L1FM>^\ Q+X ?PSI4RQLS*[3S#.]@P))QZX_E1[6-]97U3] Y';16T
M.*U7PEI47PC@UIH"^IM%#*;AG);#$#;Z;0IQCVKTKP1<277@G1YIG9Y#;*"S
M')../Z51U#PG=7GPYB\-)<PK<I!%$9B#L)0@D^O:MCPUI4NB>&[#3)I$DDMH
M@C.@."?;-95*BE"S>M_P+A&TOD:M%%%<QJ%%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %,FACN(7AFC62)QM9'&0P]"*?10!SB> ?"
MD=P)UT*S\P'(RN1^72NB "J%4  #  [4M%4Y2ENQ));!1114C"BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *R=5\,Z+K=S%
M<:GIT-U+$-J-("<#.<?2M:BFFT[H32>XB(L:*B*%11A5 P /2EHHI#"BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M1&9-W*]ONYQWJW&';^M2;R-A?$&L7<EU=:=I<-QIUM=-;,OFD3R[6VNR#&W
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M/'J,LDM_9Q1"=XGPLK1L73G&["DD#!&1P<]* .^HHHH **** "BBB@ HHHH
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MW<@9Q[=*FT7QO\,/#L4T.DZM:6D,K;VBC678&QU"XP/PH ]'HKC/^%L>!?\
MH8K?_OA__B:7_A:_@;_H8K?_ +X?_P")H [*BN-_X6OX&_Z&&W_[X?\ ^)I?
M^%J^!ST\0V__ 'P__P 30!V-%<>/BGX)/3Q!;_\ ?#__ !-*/BCX*/37[?\
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MXC\QP2-QZ#@'TH TJ*XO_A;7@3_H8[;_ +X?_P")I?\ A;/@7_H8K;_OA_\
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MV<EW=RK%;Q#+NW1120WMO<75Q;12AIK?;YJX/R[AD?F*+/<+EBBBBD 4444
M%%%0R7=O%<PVTDR+/,&,<9/+;>3@>U $U%%% !7E'Q]4/X/TI#]UM4C!^FQZ
M]7KR?X_?\B=I?&?^)I'_ .@/0!\VO@7#JO3<0*=[5#(S"=^/XC2!W]!0!;&5
M*GT(HD&UV'H:J?:)#Q@59E9O,ZC) /3VI=2U\#"E'2K>CZ>=5O# 9UAQ$[[B
MI/W5)Q^-1O;;-/AN?.4M([+Y>.1CN?SID$/-* >OK499MP''-,>=T<@H#@T
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M!%6YE\IS&P((-,<\]>U %9+8E>2*#:GVJPG2G4 51:D.G ^\/YU]S0_ZB/\
MW1_*OB,??7_>'\Z^W(?]1'_NC^5 #Z\U^./_ "(4/_81@_K7I5>:_''_ )$*
M'_L(P?UH ^:YXU6XE7 .'(SCWI@1/[H_*IKG_CZF_P!\_P ZC[4 0Q "9P
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M%#;2%?,98I@S.P!P.">,YP*[^BCVSO>P<B,/['<?\)V+WR6^S?V88O-XQO\
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MUH YY3EU_P!X?SK[<A_U$?\ NC^5?$9C,<P1L!E< @'/>OMR'_41_P"Z/Y4
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M_$O9XI0C;2>M>*2)(EPV1CGM0!LZI)9>5'"EH;2YCD'R#G*_7O7V1#_J(_\
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MZ_A6'JTMEKEI(+:=&8#D Y'_ -:L[6O#\M];_:8V)=>I3KBL33M,U&SE-PI
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M+R=H(?&3G/I]*O71$D31O$)-V1C'0>U85\&Z-1PDN62-5F.*A^[K/G7:6O\
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M4[$ Z@#)W''?-5=1L?$&HV]M>36MMY]MJ,=U%9)+@B-5((,F,%B23TQVJO\
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M,1S5U=-A3'SJ 3^M5X$$,0VC,C=?:K/S>3ES[T 4DM1$DJ1L#ME9<?CD?SI
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH *\R^.8!\#0Y[7:_^@-7IM>;_&P*?!$>[_GZ7'_?+4 ?--LV--D(/*S+
MC\170 B6%)1_$.17.VHWV5RO8,C?K77Z/:17,2P32%-P^4XZ''&:]#+,:\%B
M%5Z=?-?U8[L#B(TY.%3X9?@UL_T?J9<D>XU6!DM;F*>(X,;[ORK<U+1[S2IA
M'=0E01E7'*L/4&L]HPPZ5^F87%TL13YZ4N:+_K4Z,5@HU8N,EN=1IWCGR-%:
M215>X60X!8C(X]!7(WVIW6K74C3R,4#LZ+G(4$]*;]E'H<?6I4@51P**.%PV
M'E*=.-FSY_ \.4L/6=1+<;%"%'0#FK]G!/-*!!!),5^8JB%N/PJ[IGAW5-8@
MFN+&V\V& @2OO50F?7)%=?X0\-WL<37?G26UO/$T,YP 9!NZ1D'H0.6]^/6O
M.S3-Z&$IRU3GTC?7Y]O4^GC&%.+=TDM_Z_)'GGCV,B^CF@0+92%O+(& 2.#7
M*V'_ !^+7H/Q.E@CDM[.)5 4':J]E'2O/K 9O5^G>OS-7ZGD5ZOM)N2VV7HM
M%^!TVF6PEU2>1^VT<]N*[CPIMDU^+:/W< +-]>U<5H<H;5;B(GJW>NYT6WEM
MK@O"=K/UXIF)[18RY@4D[4QCZFK(F&">.N *X2VU+4+9 LB;E'I6C%KNY@ F
M&/'- '9QS(EL=QSC]:KS3?Z.)!R0.,]JPSJ8;9$IR>YJ^]PFQ%SG/2@#,GMC
M=2 R9*+SCUK-N+.-DD& >.!6O<72!RA/4=JR+JZ#%]IQQQ0!F3P+<6S1*N%
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M/_010!;HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M-XT:/3PD+%IV&%&>![T_P;I,.IZ19W,_S.F5/&<8KC/%,*Q^)+J-?NI@#VH
MP)&DFF::=V>0\DDUZ]H"O#X=L8-S!%B'/^T><5Y3&B><AE)*;AOQUQ7I^G>)
M-*2R5V80Q1KMA3&=B^I]6/I0!Q_CBW\K75?',L8)/KCBN<52"5!(4]?>MSQ#
MJ_\ ;>HF=4V0HNR)3UVCN?<UBY(Z4  B.=PY%5YL%F)'2KJMD57GB+9QW[T
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M&TO_ !(%7(.V1QP.E<'XO^7Q3=C/4 UV?PT;&DR\XQ<-7%^+=K^*KS;TX!H
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M[.,!L]N: /1:*Q=#\0'5K[5+">S:TO-.E1)D\P.I#J'4AA['D8XK:H ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KRSX]$
M#P78Y( _M!.O^X]>IU6OM.L=3A6&_L[>ZB5MP2>,. ?7![T ?%^]?[P_.C>N
M<;A^=?8'_"(^&_\ H :7_P" D?\ A1_PB/AO_H :7_X"1_X4 ?).FW8L]4M9
MQ( %D //8UZ!XPA%YH+R9!8*)%(]17NW_")>&_\ H :7_P" B?X5:;0])>/R
MVTRS9,8VF!2,?E0!\:[U*@AAR,]:-Z]=P_.OL#_A$?#>,?V!I?\ X"1_X4?\
M(EX;_P"@!I?_ (")_A0!\?%U_O#\Z-Z_WE_.OL'_ (1'PW_T -+_ / 2/_"L
M[7M-\'^&]$NM7U#0M/6TME#2%+)&."0.!CU(H ^3MZX^\/SI-P_O#\Z^G])N
MO NJZA!8?\(W%975PI>WCOM)$/G@#)*$KAL#G&<UMKH?@U[UK)-,T-KI1EH!
M#$7'U7&: /D;>O\ >'YT;U_O"OKB+1/!=Q,88=.T*64%@42&)F&W[W ';OZ4
M6^B>#+R1X[;3="G>/[ZQPQ,5^H XH ^1MZ?WA^==]X093X=?YEX)S^=>W7UO
MX#L-.O[U].T66.QB::X2"WBD=5 Y^4#-:NEZ5X?NM+M[NQTFR2VNHEF0"V5<
MJP!&1CWH ^1]3=3J]V=P^_ZU4++_ 'A^=?8S>$_#CL6;0=,+'DDVB9/Z4G_"
M(^&O^A?TO_P$C_PH ^.2Z_WA^=&]?[P_.OL;_A$?#7_0OZ7_ . D?^%'_"(^
M&O\ H7]+_P# 2/\ PH ^.-Z_WA^=&]?[P_.OL?\ X1#PU_T+^E_^ D?^%'_"
M(>&O^A?TO_P$C_PH ^.0Z[U^8?>'?WK[<A_U$?\ NC^59/\ PB'AK_H7]+_\
M!(_\*V0 !@=!0 5YM\<2!\/UR<?Z=#_[-7I-5[VPL]2@\B^M8+F'<&\N:,.N
M1T.#WH ^,MZY^\/SHWK_ 'A^=?7O_")>'/\ H :9_P" B?X4?\(GX<_Z .F?
M^ B?X4 ?(>]/[P_.@.O]X?G7UY_PB?AS_H Z9_X")_A1_P (GX<_Z .F?^ B
M?X4 >'?#C:-"E8D<RN:X/7IUE\17[;AQ)MZU]:P:%I%K'Y=OI=G"G]V.!5'Z
M"H&\*^'G=G?0M-9F.2QM4)/Z4 ?(&X9^\/SHWK_>'YU]??\ ")>'/^@#IG_@
M(G^%8\$'@F:?6(3HVFQ2:0?],$MDB[%V[@XXY4C//L: /EG>O]X?G2;ES]Y?
MSKZKLK/P5>:':ZP=(TJUL[I \37=K'$2#TZCO5J71/!MNR+-INAQ,Z&1 \,0
MW*.I&1R/>@#Y*WJ/XA^='F+TW#\Z^J+R+X?6$=I)=0>'HDO'V6[&*+$I]CCI
M[]*N+HO@Q[DVZZ=H33JQ4Q"&+<"!DC&,Y YH ^2MZYSN'YT@=1_$/SKZNFL?
M \-C?7:Z=HL\=E$TTX@@BD9%4$G@#T%3:3HOA+6M(M-3L]!TXVUW$LT1:R0'
M:PR,C'% 'R7O7^\/SK7\,()O$=L-P^7)KZI_X1+PW_T -+_\!$_PJ2'PQH-N
M^^#1=.C?^\EL@/\ *@#YM^(=TK3P0;A][/7TKB]Z]=P_.OL:?PUH-RX>?1=/
ME8="]LA/ZBH_^$1\-_\ 0 TO_P !(_\ "@#X\+K_ 'A^=)O7^\/SK[$_X1'P
MW_T -+_\!(_\*/\ A$?#?_0OZ7_X"1_X4 ?'$CKL;YAT]:^U=+_Y!%E_UP3_
M -!%4?\ A$/#6,?\(_I?_@)'_A6PJJB*BJ%51@ #@"@!:*** "BBB@ IDD,4
MVSS8DDV,'3<H.UAT(]#[T^B@" 65J'#BVA#"0RAA&,AR,%OKCC-(EA9Q;?+M
M($V(47;&!A2<D#V)[58HH K)IUC%#'#'9VZ11/YD:+$H5&_O 8X/O3IK.UN9
M(I)[:&62%MT;2(&*'U!/0U/10!!]BM=^_P"S0[O,\W/EC._&-W^]CC/6F?V9
M88Q]AML8QCREZ;MWI_>Y^O-6J* &)#%'+)*D2+)(09&50"^!@9/?BGT44 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %8'C;P_+XJ\':CHD$Z027:*JRNI(7#!N@^E;]% '$6
MWA'6K_6-&O?$6HV+QZ/N:VAL('3<Y3;N=F8]!V K-M/AE=P6^FZ<]_:?9-/U
M#[<M]' 1>RG>S;6?..=V"W<#I7I-% ''>&O \>C:9KMK=FUN)-4O;F?>L1&(
MY?X">IQ[$50\/^ -1T:[7;J%I#9QVDEM'%';^:1N& P:3+*!_=R0>]>@44 >
M07_PAU:_@MM^KV:W$-M<6LDJQR#SUE0KN89PN#@[5&*]0T2P?2M!T[3I'61[
M6VC@9U& Q50,C\JOT4 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 5PGC+X?S>)=9CO+/4OL,-S"+358PF3=0!PP4'LW49]&KNZ* .*\5^!7UO4
M]+U"RNEA-A"\"6DC,L15L#(*$%2,?B.*IZ9\-%T_5O#-P]S!<6VCVT\3Q21D
M[VD)/R[B< $\ FO0:* /,?\ A5MS'>?:8[RR/E:^^K0P/ ?+$;@ Q>W3/'%;
M>E^!Y-/N?%5P;FW%QK-P\L$X@#M;AEVX(;@_3H:[.B@#RM?A9JC7$%S)J=H)
MTTVYL)71)/W_ )L94.<G P3G: !Z5WWAC29-!\+:7I$LJRR6=LD#2*,!BHQD
M5K44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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##__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>51
<FILENAME>g4i5nix4zlkt000041.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g4i5nix4zlkt000041.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &' JX# 2(  A$! Q$!_\0
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M XT1T62&63[0"<%3G.3^&/RJAXI\56/_  KZ]N_"K"!6NQ;2RPP^5M)/S$'
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 <%XU_P"1T\.?]>=[_P"AVU=K
M9?\ 'JGTKBO&O_(Z>'/^O.]_]#MJ[6R_X]4^E &/9_\ )0]9_P"P58?^C;NN
M@KG[/_DH>L_]@JP_]&W==!0 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 P '3J3GBO0Z\\FAWZWK)_Z?3_Z+CK.H[1*CN8G]D67_/I%_P!\TTZ19?\
M/I%_WS6Z;?VIA@]JY[LTL8ATFR_Y](O^^::=)LO^?6+_ +YK;,%,,%.["QBG
M2K/_ )]8O^^:;_9=G_SZQ?\ ?-;)@]J;Y-%V!D?V79_\^T7_ 'S1_9=G_P ^
MT7_?-:WDT>33NP,G^R[/_GVB_P"^:3^R[3_GVC_*MJ2! ^(R64=R.M,\CVHN
MQ&/_ &7:?\^T?_?-)_9EI_S[1_\ ?-;'D>U'D>U%P,?^S+3_ )]H_P J3^R[
M3_GVC_[YK8\CVI?(]J=V%C'_ ++M/^?:/\J7^R[/_GVC_*KD]Y96YQ+<(&]
M<G]*S)_$-NF1#"SX[L<5O3PU:I\,69SJTX;LL?V79_\ /K'^5']EVG_/K'_W
MS69_PDL_:"+]:!XFF7[]O$?3!(KI_LW$]OQ,OK='N:1TNT_Y]8_RI8[(6T@F
MLWDLYU^[- Q5E/\ (CV.0:S#XHDSQ:Q_]]&HW\6/&1NLTV]_F-+^SL5_+^*#
MZU1[GL'A+79-<T=);A56ZC+13!>F]25)'L<9_&M^O//A;.;G3;B8@#S+B9L#
MMES7H=9--.S-$T]4%%%%( HHHH **** ."\:_P#(Z>'/^O.]_P#0[:NULO\
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M32_^AFO2*\V^$?\ R F_Z[2_^AFO2:^4J_Q)>K/9A\*"BBBLR@HHHH ****
M."\:_P#(Z>'/^O.]_P#0[:NULO\ CU3Z5Q7C7_D=/#G_ %YWO_H=M7:V7_'J
MGTH Q[/_ )*'K/\ V"K#_P!&W==!7/V?_)0]9_[!5A_Z-NZZ"@ HHHH ****
M "J6L_\ (#U#_KVD_P#035VJ6L_\@/4/^O:3_P!!- %#3O\ D%67_7O'_P"@
MBK-5]._Y!5E_U[Q_^@BK-<)L)13L'TJ&6X@@&9IXHP.[N!_.@"6N#\;G['KV
MF7X4G"\X[[6S_(UT-WXP\-6.?M.NV"$=O/4G]*Y[4OB=X"90ES?QW@4Y"I;L
M^#[<5<;IWL)VL+-XVL<;8[>>0GM@"H(/$UW(X2UTF5E8@$G)X_ 5E2_&CPC9
MY%CI%U+CIM@2,?J:R[KX_, 19>'OH9KC^@%:<KZ(BZ[GHDF5F;@E8_T!JPDJ
MLNX&L_1;ZXU>Q2\@0".Z@1WV\XR,X%4YY9;&X:*0E6':LW<LIZY_Q]W#>P)_
M*L'1&">);67CYBP'_?)K8UF4R:=)<*?NX5C]36'I:EM;1D(98(RW'J>!7J)W
MPU_(P^V;^K1JVH/*/NR+S]16)+BVFCDC'W6S6O?2Q^1LW@RCD<_I6)/?P/#M
M! /0Y/-+#R4Z?*^@YZ.YT%[(0L5]:QQRS*OW'Z$?XUD1ZAJ$EVTDX9.XSQS2
M6EWFSC#'V_"JD]T1<@>C8Q7-[22CR="K*]S)U;Q380M+:W>G7MVSR"=BLX1,
MXQ@=P/6L>X\76[6B06^A>5#&Y8;KMN_4' Z<#BE\2^1:W),@49)7)4G/<?SK
MG9-0AVE40D'_ &,4DE838_5M1EU34YKZ:)(I)2"4C)P,#'?Z5[7X?E632;5]
MV-\0;/UKP5Y]YSM/3N:]T\*H/^$=T]"#_P >R?RJ:FQ4-S=9R_+'YAW'>ECG
MPV&J#:4X/:F.W0^E9%&IYN!D&LGQ!)G16&?^6\'_ *-6IQ-F+K6?K;YTK&?^
M6\'_ *-6G'<&>GZ5_P @V'_=J[5+2O\ D&P_[M7:Z#,AN[:.\LY[67/ES1M&
MV/0C!KR[PUXE7P!$WA/Q;')!;P.WV.]\LM%-$23@X^O]#C%>KU%/;074?EW$
M,<J9SMD0,/UK2$TDXR5TR)1;=UN>9>*?&L7C"S?POX022^N+T>7/=!"L4$9Z
MDD_Y_&MKQCI(TSX37&EVJO*+:WBB7:I);:RY./UKL[>UM[52MM!%"I.2(T"@
M_E4M7[5)I16B=Q<C=[O5G-^)/#G]OZ%;B"0VVIVFV:RN1P8I0/Y'H17":7+X
MAF\)>+[J.TN;34I=04SQPJ=Z@!1+Y?J<9QBO7Z*4*SBK6N$J=W<\DUJ/PY)H
MUDOALWDLOVVV,P3S7&/,',N[@']<UU^DQR#XE^(I"CA&M+4!BIP>&Z&NLHHE
M6NK?UT_R!4[.YPXMYY?$OCA4AD)ELH5C^4_.?)88'KS3_"FJ6FH?#V.TMGD:
MXL[%8KB-HF4HX7&.1R>#TKM:*3J75K=OP#D_4P4TU[?3[.\T^,)=11+NCZ"4
M$9*GW]*+^Z9H+/5[:*0LNY&3;\V&&,$>S 5O45//K=A[/2R.>O+>;2[*TE@1
MGE6)H'VC));D'_OK^=.O=/-K;Z:ZB9HK4%)?))#@$<L,>];]%'.P]FC"A&G7
M5S#''/>7)#!P"S%5(Y!.>E1W3:;YTTBR75E=Y.0@8%SZXZ-FNAHHYPY-# GG
MFC31[N^5E*%O.8+]TE>,@5NHZR1JZG*L,@X[4ZBDW<J,;!1114E!7)6S*NHZ
MLI."VH, /7]W'76UR,5Q':S:W-(0%6^8Y/\ USCK*M\)<-RTS@2;.K#DCT%/
M.W'W:J(_E@LC(Q<[F9LY-2"?/WL?AFN>QJ17ES' T:8^:0X S498'O7)ZOJ+
MW%W+("P"$JOL!3&U'4+V[@TO3Y?(9HO-GN2NXQKV"@]S3Y2;G7@@U/:QB2<9
MY YKCI)-8T "XGNGU.P'^NW1A98A_>&.& ]*[+1I8KF 7$3AXW *L#P0:+!<
MVT5$3@ ?2@NH' %-49'M2&,^M2,IWY,D1XZ<UEO'P<$\UN-&3U%5'M.<J<>Q
MZ5<6)E#[JYRQ_&N!\7ZX;F8V$#?NT/[QA_$?2NP\1&ZL-*GF@0EL8RO.W/>O
M([F?9DG+,3T')->OEM",FZL^APXNHTN1=2*63&?N_6JT<F_!SG/>NJT3PJMS
MLN]7E18CADMA(,M_O'^E8VO11Q^(KQ(0@CW J(\8 P.F*]..,A5J^SAT.65"
M4(<S(QRHJM<.2,8.*L!1Y8!.!5">7]YY-MO>3O@\5WWLCF2(K.;$S1@$D'IZ
M5H-*V_'RY%9\6G2HQE,@$W4!3Q]/>I'E$DC%>*%>VHWOH6'F8CHM1-<#?\V.
M1VJL7. <]:A=SYASV&:S<RE$]M^$)SH!/K++_P"AFO2J\S^#AW>&E)[R2?\
MH9KTROF*FLWZGK1^%!1114%!1110 4444 <%XU_Y'3PY_P!>=[_Z';5VME_Q
MZI]*XKQK_P CIX<_Z\[W_P!#MJ[6R_X]4^E &/9_\E#UG_L%6'_HV[KH*Y^S
M_P"2AZS_ -@JP_\ 1MW704 %%%% !1110 52UC_D"7__ %[2?^@FKM4M8_Y
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M5C_W\H_X61X-_P"ABL?^_E'LY]F'-'N=317+?\+(\&_]#%8_]_*/^%D>#?\
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MO6H84@B6.-0% [4L<:1+M10![4^B4G-\T@C%15D%%%%2,*^>O'/_ "/FM?\
M7=?_ $4E?0M?//CK_D?-:_Z[K_Z*2D]@.?-)0:2I ,TN:;10(>#73>"9"OB2
MWYP&!%<P#6YX5?;XAM3G^(_RIJ-] O;4]W@(Q]ZK!KC-6\7PZ7<FU@C$]PO+
MY.%7V^M2:!XT74[\6%W L$SC,;*V5;V^M2\+5Y/:6T*]M#FY;ZG74A-+N&.*
M05S&HPJ2:0I@5+33S0@.2\>6HNO"5\N,E4WC\#FO V45](Z[;_:-(O(/[\3#
M]*^;WX)4]N*Z:>QE/<B*TPBGM43YQ6A(UFKTWP;J<DWAZ$><NZW8Q89,X'4?
MSKRTFNU^'%Z(]2N;,\B:/>HSW'_UC436A4=STF*W35(66YM["?'_ #UMP<U2
MF\%:2S;UTBS4G_GC(\>?R-:T1;Y65>0?7M5TG(YK*YI8J_#:W6TM[VW1-B17
M<RA=Q; $A[GDUWU</X!P)-3 _P"?V?\ ]&&NXK=;&3"BBBF 4444 %%%% '!
M>-?^1T\.?]>=[_Z';5VME_QZI]*XKQK_ ,CIX<_Z\[W_ -#MJ[6R_P"/5/I0
M!CV?_)0]9_[!5A_Z-NZZ"N?L_P#DH>L_]@JP_P#1MW704 %%%% !1110 52U
MC_D"7_\ U[2?^@FKM4M8_P"0)?\ _7M)_P"@F@#XQCF7[/'C/W!_*FF7GI5>
M%OW$?^Z/Y4[-9%$OFMZ"D\QO6F44P) [?WC4JL3WJOFGJ: +&/?'X5>349%0
M+@' QD]ZSP<BGK4E'I7A>0SZ!#D?.\QX'?FO1M(N?LB;DC5I", MVKAO"EK%
M>>$K6WW2130,75QU5F.<CU[5T]BNHVX=KDQS*.08S@M^!Z5/*YNT0T1LSD7+
M%VA16/4IP#^%0^3BH!JPC7_2(VC^H_K4\=_:W( 24!CT!/6AT9PW0*2>PW8!
MUIW%#>A&:C*X[U* F"BHG'S4Y=P&[DK396 !:KCN)D<X)A8>XKF;S$4S^P'\
MJZ1&9T8MR,YKGK\"2^<#IQG\J]3"W2:,9ZE>'E0?6HKZ4(F,U8=UA3WQ7.:G
M?;=QS7?LKF+,_4K@!B,]>M5[70[F\C6[F^2W)XS]YOI[46%G+JMWYL@(MD8;
MV]?:NY>,-:[0H"C& *\O$XC6T3:G#N;7A&..QT)88EVJ)&.*G\1W$DFDE2Y(
M^T0<?]M5JGIK&.T55;;R>U,UN1CIZ@S%\W$'&,?\M5K@WD;]#U;2O^0;#_NU
M=JEI7_(-A_W:NUN9A1110 45@>,9Y+3P])<KK8T:&)U>XNQ$)'\O/*H#D;SP
M <'Z$U@#5/$5I\'-1U34)98=6BLKB:&26-5E51N,3.H&T/MVDC'6@#OJ*\6M
M/%7B#38[X:A>ZTD4GA^>]A&HI LCS(H8M T:D  '.'SU'%:#>*]:_P"$B%NF
MH2BW.M:5;A"JG]U+:[Y%)QW;DG\L4 >LT5Y=I7Q$U%]%LX[+3GU*]%G<:C<M
M=W2Q%8(YGCP"J89CMX&   ,FK-U\4Y1'<7MEHHGTRU@L;F::2YV2".ZQMVIM
M.6&?7'% 'I%%<=XQU#46\0^'?#MC?R::FJO.TUY$JF0+$@8(FX$ MGKCH#61
M>>,[SPE;VFE&]B\2:A-/<JL_^KV)#@E)/+5LR#<!PH'.3CN >D45Y/J'C/5[
MB]NY[6XGLX'&C216\L8#0B>9A*IR.I P?IQ72:%X[EU7Q=<:'=:<EBR&41+-
M*RS.$;&X*4"L".<HS8'6@#M**X34=6U"\UKQ7%%K::/::3;VT0N'C5UC+CS9
M9,'^+9M5<\#G@UCQ>/-9\+>#HM:UFTGU#3Y[V6*UFG9(+DPD9@9TP!\Q!R>"
M 0<'F@#U.BN%UC5O$L'BGP@DDEI::??3>7<V\),CO)Y+N07(QL! QCD]:Y>'
MQ'XFU"\7R]4G/]LG5((K6.),VAMFQ&8SP=Q (.3U88QQ0![%17GOAO4=>T[7
M]$T[69)BNIVEVRP2MN:$Q2AHR6/))CD .3GY1GG->A4 %%%% !7SSXZ_Y'S6
MO^NZ_P#HM*^AJ\.\5-9CQGK0GM3*_P!H7YA)CCRTI2V XJD_"NC5M,/_ ##W
M/_;7_P"M3\Z6!_R#&_[_ !J .7I>.]=+_P 2T_\ ,-/_ '^-.5-./_,+)_[;
M&@+',Y7H,UK^&L_V]:L.-KC.:U1:V17(TA#]9FJQ9"UMKZ*1;)8<'D!R2:VH
MKFFD1/1$?BW;'XGN/+X+*C-]<5CQ75S!.DT;;71LH>X-:OBG=_PDD\CC"R(K
M+GTQ6-NW-G&?K7T.&BG1BGV/-JMJHV>Q>%?$<>M6(+X6YC $J?U'L:Z08ZUX
M3H^M2:+JD=S"25'RR)V9>XKV+3]6@U&RCNH'W1.,@_TKP,=A'1G>/PL]+#UO
M:1UW-(M32:A-PH7)('UJC/JT,9PI\QO0=*X5%G1<L73KY3ANA&#7S7JT7V75
M[R#^Y,P_6OH'[6]P':0[?0"O$O%$=O+XDOF0'E^2#QG'-;4U8SD<]NJ-VP*N
M?9X_]JA88<<JQK0DS&/-:/A^].GZY:7(. KX;Z'@T[[+;>C_ )TAMX%!*AL]
MLFDP/6!J*,0=Q&/0U875]BA0Q('K7A)U/4U=@+Z0 'CFM;PYK%ZNLQ1W-RTD
M<P*88]#U%9.G8T4CWKX<2>;#?2?WKN<_^1#7>UYY\+3G3;@_]/$W_H9KT.M5
ML0PHHHI@%%%% !1110!P7C7_ )'3PY_UYWO_ *';5VME_P >J?2N*\:_\CIX
M<_Z\[W_T.VKM;+_CU3Z4 8]G_P E#UG_ +!5A_Z-NZZ"N?L_^2AZS_V"K#_T
M;=UT% !1110 4444 %4M8_Y E_\ ]>TG_H)J[5+6/^0)?_\ 7M)_Z": /B.$
M_N8_]T?RJ6H(L^2G/\(I]9%$F1ZT9'K3<44 /W"G!O:HP*D IB)0Q(["K%M$
M]Q/'#&"SR,%4#N3591S6WX<AWZQ ?[AR,>O04F4CU[1[8:5I\<+F-6'7+#'I
M6LL^Y<^9&![<TMO9-,541;RHQ]W)J^LD%GS+;R3$?PX*K3H):ML<V4FE13L;
M>Q(Z!"W\JIO96T\GF10M%,O*N(ROYCO6Y;W]]?3?9K*,0*Q^[&NW\S5F>=;%
M)(5<W$[#$DK\JH]!_C76I1CL9N[.:>^>)$,D9! PQ!P":GCO&F084?6J]U:S
M2+$)!S(Q9![5:MH-H QDUG5A'=((MFSILL4-I(DP5S/P0?X1_C65J*-#(8E.
M>X/J*DD1\JJ\9_2EAMWDQ),^%7C+'H*QBE'WF4[O0JR2K:6):3J1@#UKGW8&
M1Y6XW$FK6L7:S79",##%P".A]ZY>_P!75 1NZ5[&&I<L.:74YYRULAVHWZ[C
M\W2L6QB36M6%O(Y$:J78#JV.U9=[?-/,!D_-D"MKP5&C:W(7/2$@#UR17+BL
M5]B)=.G?5G3PVT<49MXXU15'R "K4(_<E2./3TJU+;C!*_>3D>XJ)EXSV->9
M<W$CD7:"00/:H-3F3[+&@W-FXAY/;]XM6XHP47,BK]35/5440Q8D5B+B'H?^
MFBT+<;V/9=*_Y!L/^[5VJ6E?\@V'_=J[709&9>>(]"TZY:VOM:TZUG4 M%/=
M(C 'ID$YK1CD2:))8G5XW4,K*<A@>A!]*XCQIHL-]XI\)3C2X[@?V@WVF3[.
M'^3R7 WG'3..O?%<[=G7K2P\07TD^O%?[:-C;06[M'';VFY2) %1FV=1N0$X
MX&.M 'I&N>'M*\2V*V6KV@NK99!*(R[*-PS@_*1ZFF6_AG2+70)="BLP--E5
MTD@:1FW!_O#))/.?6O,-./BS5+32;2[O]=MU6'4_.EC#QNQ1U\C<S+G.#QGD
M_G3(M4\7_P!K^'+B=]8N'EM;'SK-8Y(/F(_>MD(8W]6#[2,<8H [C2_!_@=)
M]1L]/M+26?R#:7<8N6E>.-QRARQ* XZ#'2M?_A$]"^TBX_LZ/SA/#<AMS?ZR
M)-D;=?X5XKS31K;5/"MU]M U@V4GBB[%[^Z>5I(=KB-RJKN8,Q4YZ$X-9UQJ
M7C--*T2Y>77GN#',6LQ%+%)(_P!I?;\ZHPW;-HVR +CG- 'J-QX!\+75E:V<
MVD1&"U#B)5=UPKMN=20<E2225.1[5-<^'?#4\US93V=KYNH11>;!OVF5("-F
M%!Z*2.GM7#17GC%_B-<1O+>1 7K^5;M'(UNUIY7R]%\L'=_'NW;N,8JKX'35
M+KQOHMYJ!UR:Z33+E+]]0@98X;@O'N2,E0,<< <8 QWH ]/UK0-+\16:VNJV
M:7,2.)$R2K(PZ,K*05/N#6?)X%\,R:7;:;_9,26MJS-"(W=&4MPQWJ0QW#KD
M\]ZXK4-4\1?\++C%J-8BM4U);>6)Q(\+0&(_.JA!&%+8P2Q;.<X%6?AI>^('
MUJ^M=6?4[J,6X8W=R)(T$F\C:8Y%&Q\'.$8I@4 =JWA/0G8DZ;%R+=3@L!B
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M]^3S[U52E&K'ED*$W!W1T<OBS4[ELJL1]=Y)J&;Q)J*H=OEJQZ87I6*LAC8
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M4M;>YGGDB4B*.25=H"@\E0 .O)YH SK;XLZ7=6?AJ:.PNM^NW36RQ97=;E9
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M9 _Y^GK!KH?'(QXXUC_KY)_E7/UNMC/J?17P3_Y%&#_>D_\ 0S7J->7?!/\
MY%&'_>D_]#->HTAA1110 4444 %%%% '!>-?^1T\.?\ 7G>_^AVU=K9?\>J?
M2N*\:_\ (Z>'/^O.]_\ 0[:NULO^/5/I0!CV?_)0]9_[!5A_Z-NZZ"N?L_\
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M_P#0/MO^_*_X5ZD<T:6L?Q.1X-=SP)+E3GYQ^=31W"X^^OYU[O\ \*[\/_\
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ME972-C%]\"3;M.#P<9QZ5B:Q\/+O4M4U">'6D@M=0>SEN(6M=[%[<C;M;<,
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M4D1)W>5O(RV2&P5'IBNR\+^'T\-Z/]A62*1VE>:1XH!$K,QR<*,^PY)/')-
M&S1110 4444 %%%% !1110!P7C7_ )'3PY_UYWO_ *';5VME_P >J?2N*\:_
M\CIX<_Z\[W_T.VKM;+_CU3Z4 8]G_P E#UG_ +!5A_Z-NZZ"N?L_^2AZS_V"
MK#_T;=UT% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 <%XU_Y'3PY_
MUYWO_H=M7:V7_'JGTKBO&O\ R.GAS_KSO?\ T.VKM;+_ (]4^E &/9_\E#UG
M_L%6'_HV[KH*Y^S_ .2AZS_V"K#_ -&W==!0 4444 %%%% !1110 445QNHR
M7_B'QM<Z!#J5SIVGZ?9Q7%PUHP2:>21F"KO(.U0$)..23UXH [*BN,N+_4_
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MED,EO@3Q3ON. &^5A@8/(]JV-=T*]N]7L-:TF[@M]1LXY(<7$1DBEBDVEE8
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M_$NC^'%A.K7JVWG[O*4JS-)MQD*%!)/(XJO)XS\/1:F-.?4XUN"ZQD%&V*[
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M\!:*2*XE\PQL P.00I!!['CFM>\\;^'-/OYK&ZU2..XMW5)UV,1"6P1O8#"
MY')(%2:IXQ\/Z->FSO\ 4HXIE57D&QF$2GHSE00@/JQ% ">%="N= T^ZAO+U
M;RXN;R:[DF6+RP3(V2-N3C'UK'M?!%W;WEN6U&%[6VUN75H5$!#XD67=&QW8
M/S2\''05L:CXR\/Z5>?9;W4HXI $9SL9DC#?=+N 50'MN(J/2O%EMJOBS6=!
MCC99--$9WD-B3<,MVP,$@=>>HH Q]:\!3ZG<ZC<)>V[?:=2AOA;7,!>&01PB
M/RY0&&Y3C=[$#@XJ*/X=W TWQ! VH6L,VJ>1+ ;2T\I+.:+[A1<\@$*?7@^M
M2Z[\0TTV?Q-9VML'NM&LX[E?-#!9"V=P)Q@ <=^<\=#6YI_C+P_J?VD6VIQ$
MVL/VB8R*T86+_GH"P&4X^\,CWH QK#X=P66OZ9?_ &LM;6>G+:/;;,"68*R"
M8G/78[C_ (%4&B?#ZXTBXT^ 7.EG3[!\QR1Z:@NIU (5))#D<9&64 G Z<UL
MP>/?#-Q%<2)JBJMO#]HD,D,D?[K(&\;E&Y<D<C(YK3DU[2X;ZZLI+Z);FUMO
MM<\9/,<7/SGVX- '*6_@;5K>/1]-&LVYT;2+U+FVC^S'SG12=L;ONQA0< @<
MX&:Z36M%;5;_ $6Y6<1C3;W[45*Y\P>4Z8]OOY_"M.VN8KRTANK=]\,R+)&V
M,;E(R#S[5+0!Q&K?#\ZE<:C=?:X/M$VIQZC;+-;"2-66$1%)%)^96 /3!&1C
MI5>X^']Y=Z1+#+=Z9'.][%=?98+ 1V;+&"/*= =SJ<EB2W7'&!BN_HH \^A^
M'5RLE](]]91&[N;&Y\FTL_*BA^SON*JH;H1W/.<GVKM=6L%U71[[3FD,:W=O
M) 7 R5#*5S^M7** .6\/^&+W3-4M=0OKZ">:'2DTXB&$H&V2%@W+''! (]?R
MK#B^&DME!I<MM<:;=7EG:O9R+J%EYL,J&1I%(7=E64L>0>037HM% &7H6E/H
MVAPV,DZ7$J!B\B0+"K,22<(HPHYP!Z#J:X;P5X6UF^\*>&(M:NXUT^PV726A
MM62<R+G8DC$XVJ3GA03@9]_3:* .'L_ ^HPVNFZ-/J\,F@Z;<QW$$8MR+AQ&
MVZ.-WW;=JG'(4$[1TYJSHO@N72K_ $FY:^67[!]ORHCQO^T3"0=^-N,>_M77
MT4 <5%X(O;2XL+JTU* 7%IJUU?\ [V LKQSEMR<,"& ;@^HZ5VM%% !1110
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MB,NZ12!UQU&"R]?6K\NB:BWP9_L(6Q.I?V(+7R-X_P!;Y6W;G..O&<XKM**
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M/I0!CV?_ "4/6?\ L%6'_HV[KH*Y^S_Y*'K/_8*L/_1MW704 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110!P7C7_D=/#G_7G>_^AVU=K9?\>J?2N*\:
M_P#(Z>'/^O.]_P#0[:NULO\ CU3Z4 8]G_R4/6?^P58?^C;NN@KDM0NKW1/%
M]]J2Z)?7]I<Z?:PK):/ -KQR7!8$22(>DJXQGO5=OB*JG!\+:]GZVO\ \?H
M[6BN)_X6.G_0KZ]_Y*__ !^C_A8Z?]"OKW_DK_\ 'Z .VHKB?^%CI_T*^O?^
M2O\ \?H_X6.G_0KZ]_Y*_P#Q^@#MJ*XG_A8Z?]"OKW_DK_\ 'Z/^%CI_T*^O
M?^2O_P ?H [:BN)_X6.G_0KZ]_Y*_P#Q^C_A8Z?]"OKW_DK_ /'Z .VHKB?^
M%CI_T*^O?^2O_P ?H_X6.G_0KZ]_Y*__ !^@#MJ*XG_A8Z?]"OKW_DK_ /'Z
M/^%CI_T*^O?^2O\ \?H [:BN)_X6.G_0KZ]_Y*__ !^C_A8Z?]"OKW_DK_\
M'Z .VHKB?^%CI_T*^O?^2O\ \?H_X6.G_0KZ]_Y*_P#Q^@#MJ*XG_A8Z?]"O
MKW_DK_\ 'Z/^%CI_T*^O?^2O_P ?H [:BN)_X6.G_0KZ]_Y*_P#Q^C_A8Z?]
M"OKW_DK_ /'Z .VHKB?^%CI_T*^O?^2O_P ?H_X6.G_0KZ]_Y*__ !^@#MJ*
MXG_A8Z?]"OKW_DK_ /'Z/^%CI_T*^O?^2O\ \?H [:BN)_X6.G_0KZ]_Y*__
M !^C_A8Z?]"OKW_DK_\ 'Z .VHKB?^%CI_T*^O?^2O\ \?H_X6.G_0KZ]_Y*
M_P#Q^@#MJ*XG_A8Z?]"OKW_DK_\ 'Z/^%CI_T*^O?^2O_P ?H [:BN)_X6.G
M_0KZ]_Y*_P#Q^C_A8Z?]"OKW_DK_ /'Z .VHKB?^%CI_T*^O?^2O_P ?H_X6
M.G_0KZ]_Y*__ !^@#MJ*XG_A8Z?]"OKW_DK_ /'Z/^%CI_T*^O?^2O\ \?H
M[:BN)_X6.G_0KZ]_Y*__ !^C_A8Z?]"OKW_DK_\ 'Z .VHKB?^%CI_T*^O?^
M2O\ \?H_X6.G_0KZ]_Y*_P#Q^@#MJ*XG_A8Z?]"OKW_DK_\ 'Z/^%CI_T*^O
M?^2O_P ?H [:BN)_X6.G_0KZ]_Y*_P#Q^C_A8Z?]"OKW_DK_ /'Z .VHKB?^
M%CI_T*^O?^2O_P ?H_X6.G_0KZ]_Y*__ !^@#MJ*XG_A8Z?]"OKW_DK_ /'Z
M/^%CI_T*^O?^2O\ \?H [:BN)_X6.G_0KZ]_Y*__ !^C_A8Z?]"OKW_DK_\
M'Z .VHKB?^%CI_T*^O?^2O\ \?H_X6.G_0KZ]_Y*_P#Q^@#MJ*XG_A8Z?]"O
MKW_DK_\ 'Z/^%CI_T*^O?^2O_P ?H [:BN)_X6.G_0KZ]_Y*_P#Q^C_A8Z?]
M"OKW_DK_ /'Z .VHKB?^%CI_T*^O?^2O_P ?H_X6.G_0KZ]_Y*__ !^@#MJ*
MXG_A8Z?]"OKW_DK_ /'Z/^%CI_T*^O?^2O\ \?H [:BN)_X6.G_0KZ]_Y*__
M !^C_A8Z?]"OKW_DK_\ 'Z .VHKB?^%CI_T*^O?^2O\ \?H_X6.G_0KZ]_Y*
M_P#Q^@#MJ*XG_A8Z?]"OKW_DK_\ 'Z/^%CI_T*^O?^2O_P ?H [:BN)_X6.G
M_0KZ]_Y*_P#Q^C_A8Z?]"OKW_DK_ /'Z .VHKB?^%CI_T*^O?^2O_P ?H_X6
M.G_0KZ]_Y*__ !^@#MJ*XG_A8Z?]"OKW_DK_ /'Z/^%CI_T*^O?^2O\ \?H
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MIX<_Z\[W_P!#MJ[6R_X]4^E>;:CK$OB7Q5I-U'H]_90V=M<1NUV8?F:1X2H
MCD;M&V<X[5Z39<6J?2@"26%9EVL,BJ9T>T)R8Q^5%% "?V-:?\\Q^5']C6G_
M #S'Y444 ']C6G_/,?E1_8UI_P \Q^5%% !_8UI_SS'Y4?V-:?\ /,?E110
M?V-:?\\Q^5']C6G_ #S'Y444 ']C6G_/,?E1_8UI_P \Q^5%% !_8UI_SS'Y
M4?V-:?\ /,?E110 ?V-:?\\Q^5']C6G_ #S'Y444 ']C6G_/,?E1_8UI_P \
MQ^5%% !_8UI_SS'Y4?V-:?\ /,?E110 ?V-:?\\Q^5']C6G_ #S'Y444 ']C
M6G_/,?E1_8UI_P \Q^5%% !_8UI_SS'Y4?V-:?\ /,?E110 ?V-:?\\Q^5']
MC6G_ #S'Y444 ']C6G_/,?E1_8UI_P \Q^5%% !_8UI_SS'Y4?V-:?\ /,?E
M110 ?V-:?\\Q^5']C6G_ #S'Y444 ']C6G_/,?E1_8UI_P \Q^5%% !_8UI_
MSS'Y4?V-:?\ /,?E110 ?V-:?\\Q^5']C6G_ #S'Y444 ']C6G_/,?E1_8UI
M_P \Q^5%% !_8UI_SS'Y4?V-:?\ /,?E110 ?V-:?\\Q^5']C6G_ #S'Y444
M ']C6G_/,?E1_8UI_P \Q^5%% !_8UI_SS'Y4?V-:?\ /,?E110 ?V-:?\\Q
M^5']C6G_ #S'Y444 ']C6G_/,?E1_8UI_P \Q^5%% !_8UI_SS'Y4?V-:?\
M/,?E110 ?V-:?\\Q^5']C6G_ #S'Y444 ']C6G_/,?E1_8UI_P \Q^5%% !_
M8UI_SS'Y4?V-:?\ /,?E110 ?V-:?\\Q^5']C6G_ #S'Y444 ']C6G_/,?E1
M_8UI_P \Q^5%% !_8UI_SS'Y4?V-:?\ /,?E110 ?V-:?\\Q^5']C6G_ #S'
MY444 ']C6G_/,?E1_8UI_P \Q^5%% !_8UI_SS'Y4?V-:?\ /,?E110 ?V-:
M?\\Q^5']C6G_ #S'Y444 ']C6G_/,?E1_8UI_P \Q^5%% !_8UI_SS'Y4?V-
M:?\ /,?E110 ?V-:?\\Q^5']C6G_ #S'Y444 ']C6G_/,?E1_8UI_P \Q^5%
6% #DTFU1@PC&1[5>50J@#H*** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>52
<FILENAME>g4i5nix4zlkt000011.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g4i5nix4zlkt000011.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %M J # 2(  A$! Q$!_\0
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M%<1_PMKP;_T$Y/\ P&D_^)H_X6UX-_Z"<G_@-)_\31[&I_*P]I#N=O17$?\
M"VO!O_03D_\  :3_ .)H_P"%M>#?^@G)_P" TG_Q-'L:G\K#VD.YV]%<?/\
M$_PG;0VTLNH.J7,9EB/V>0Y7<5STXY4U!_PMKP;_ -!.3_P&D_\ B:7L:G\K
M#VD.YV]%<1_PMKP;_P!!.3_P&D_^)H_X6UX-_P"@G)_X#2?_ !-/V-3^5A[2
M'<[>BN(_X6UX-_Z"<G_@-)_\31_PMKP;_P!!.3_P&D_^)H]C4_E8>TAW.WK.
MU'0['5+[3[RZ1VFT^0RVY5R &..H'7IWKF?^%M>#?^@G)_X#2?\ Q-'_  MK
MP;_T$Y/_  &D_P#B:%2JK5)B=2#ZHW[SPQI5]KUIK<UN?M]J,1R*Y&>N,@<'
MJ>M3:9H=CH]Q?3V<;J]].9YRSELN>XSTKFO^%M>#?^@G)_X#2?\ Q-'_  MK
MP;_T$Y/_  &D_P#B:?LZUK68<]/>Z-_1O#.F:!<WDVFQR0_:WWRQ^82F[GD*
M>!U[4:]X7TGQ*D*ZG;&1H23'(CE'7/7!'.*P/^%M>#?^@G)_X#2?_$T?\+:\
M&_\ 03D_\!I/_B:?)6OS6=PYZ=K71K3^"="G\/QZ']D:+3TD$OEQ2,I9AW)S
MD_C[5!HOP_\ #^@:HFHZ?;RI<HK*K-,S#!&#P35#_A;7@W_H)R?^ TG_ ,30
M?BWX, S_ &G)Q_T[2?\ Q-/EKVM9BYJ6]T=!K_AO3?$MM#;ZG'(\<,GF)LD*
M$-@CJ/K5/1_ OA_1+X7UI9LUTHPDL\K2%/IN/%4[SXG>$["Z:WN=0=)0JL1]
MGD/#*&'0>A%5_P#A;7@W_H)R?^ TG_Q-)1K<MDG8;E3O=M&OJW@O0]:O6O+J
MVD6X==DKP3/$95]&VD;A]:DOO!^A:AIUI8RV")#9_P#'MY+&-H?]U@<BL3_A
M;7@W_H)R?^ TG_Q-'_"VO!O_ $$Y/_ :3_XFCDKZ:/3U%S4^Z->#P5H=MI=]
MI\=M(8[]=MS(\S-)(/=R<U/'X7TN*_TR]2*03:;!]GMCYAPJ8Q@COQW-8/\
MPMKP;_T$Y/\ P&D_^)H_X6UX-_Z"<G_@-)_\31R5^S#FI]T:MUX8MK>UUN;3
MK2&:\U0;IH[MV,4IYX./NC!/2N.T[P-J$FM:/*VB0Z7!83B>65M0:Y9PO(1
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MT[:%$"\ 8.001SG/.:YS_A;G@S./[4?/I]FD_P#B:0_%SP6#@ZHX/_7M)_\
M$TW&N[73T]1<U/NC5T_P-H6F:C:ZA;03?:K8,J2R7#N2",8.2<@#IZ5-;>#]
M$M+N_N(K5O\ 3U9;B%I&,3[CEOD)P":Q?^%M>#?^@G)_X#2?_$T?\+<\%_\
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M6QHO_(-\0?\ 8/\ _:T58];&B_\ (-\0?]@__P!K15,MAQW,>BBBJ$%%%/\
M)E">889-F,[MAQ^= #**4JP 8JP#="1P?I24 %%%% !112LK(VUU96]&&#0
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MN>]/^T:A*_VSS[QW@ 'G[W)C'8;OX?;FO2#X6T/2]<AT)K:VO]1BL[J]0.Y
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M_0N6_P"9_P :/KD>S#ZN^Y\X45]'_P#"%^"_^A<M_P S_C1_PA?@O_H7+?\
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MN?.%%?1__"%^"_\ H7+?\S_C1_PA?@O_ *%RW_,_XT?7(]F'U=]SYPHKZ/\
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M"]"(538B*8HVVJ/0%CU))KH_L<OJG_?0J*+2E@EGDBCB1YW$DK!OOL %R?P
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M6;_6,AZ\YQ[#))P,#-3U&345/]CE]4_[Z%'V.7U3_OH55T*S(**G^QR^J?\
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MD@$HI=K?W3^5&UO[I_*F E%+M;^Z?RHVM_=/Y4 1RLR0R.L9D95)5%(!8@<
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MQZ#O3-[?WC^=+)]_\!_*FT +O;^\?SHWM_>/YTE% "[V_O'\Z-[?WC^=)10
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MO'\Z\YU'Q5JLLFBI;7!MVB26/4PH!W3B*8!3Z8:%F_*I?#.IZM/J^AP2W.K
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ML$;:\*&-7PRD$E"0000<],UI:9X?MM)N5GBEGDE%O]G)DV\C>7S@  ')/3
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MK^1HYD%F12?ZN'_<_J:CJZ]H2D8\U>%QT/J:C^QG_GJOY&DF@LRM15G[&?\
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M2L%S1HI-R?\ /2/_ +Z%&Y/^>D?_ 'T*8"T4FY/^>D?_ 'T*-R?\](_^^A0
MM.7[K_2F;D_YZ1_]]"G*R;7_ 'B=/[WO0 E%)N3_ )Z1_P#?0HW)_P ](_\
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M2\T)M&FBG^QM +<A6PP0  8/KP.:BL/#:V-XUX6O[N[,?E":\F,C(F<E5Z
MD G YP*0R]14OV>?_GD_Y4?9Y_\ GD_Y4[H5B*BI?L\__/)_RH^SS_\ /)_R
MHN@L15)']R;_ '/ZBE^SS_\ /)_RI\<$P27,3<KQQ[BAM!8KT5+]GG_YY/\
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MZEJ<FH74<+00?N%A2)6(+$*,Y8[5Y)Z"EJ,V**,'T-&#Z&F(**,'T-&#Z&@
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M_P#OHU)#-*90#(YX/\7M4%20?ZY?H?Y&AK0$Q//E_P">K_\ ?1H\Z7_GJ_\
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M4-:D>-$AN;M)( A&-@AC3H.G*GB@#6^7^XG_ 'R*/E_N)_WR*** #Y?[B?\
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MHNPL/B\8Z6]Q<K-#);PP-(/,E5LR!1$<H .<^:HQUZ8!SQ-)XOT*&,-)]J#
M2-)']ED+PB/;O+KC*@!U.3V.1FHI? UK+-*[7UR V6C"A08G(A^8'')!@0\^
MI[5*G@Z$F\EN+^XFNKVVG@N)BJC=YHC&0 ,#:(U 'USFB["Q/JNO:?H]]9PW
M,4GD7$,TS7*@E(EC ))QZYXIZZ[I;:3?:B5F2.P5FN8I8F26/"[L%&P>5P1Z
MYINK^&+?6(K2*:XFC2WB>$^7C+*R@=2.""JL"/2GVOAR%+34HK^>2^EU(;;N
M5U";UV; H"X  7]231=A8S+_ ,07^E:/<:E?Z#'%$D*RH1>@@%G5=LAV_*1N
MSD!AP>?6WX?UR/6[J\@\BV9;8(?M%G<F>%RV<KNVK\PV\CMD>M1R^$9+NT>V
MOM<OKJ/RUCB#!%"JKJ^2  &8[ -Q[9QC)K4M='CLM7OKZVF=%O54RP8&SS%X
M\P>C$8!]=HHNPL9FD^(!JFKRZ7_9CQ75GN&H!I/E@/\ RSP<?/O'S#&,#K@\
M4NH>)(-,U#4+:;3K@16EBUV9LC$N"!L09R>HY.!FI--\*6VEW\-_!=3F\*N+
MR5L9O-QSF3CJI^[C&T?*.*M:EX?M=5N)I+EY-LUD]FZ*0/E8@D@^HQ2NP*EK
MKD8MM4?5+06DVF8:Y2*0S*$*!PP( )XSGCJ#3KWQ-HEA))'+)(S1L0PBB=\
M(KLW ^Z%=23VR.]36>C-IUIJ$DDCZG>78W3-*%3S<)M5,  *,#'XDU@VWP_B
M?0M,@NKC;?6R2"24Q1S@^806&'4@D;5 ;&?E]\4[L+&O/XHT.VE=99)5C6)Y
M1/Y#^4X5/,8*^,,0O/%/L_$.DWU^EE"ER)F R'MY%"$KN"L2/E)49 /:LJX^
M'EG<7LD[7]QAA($78A9 \1B*[L9V@'(7H*U)O#$4WB*VU=KN0-;X*(L: \*5
MQO W;#G)4G&>:+L+#K_7M,T^[:UFBN3(,JI6!RCOL+A V,%BH)QFL?2/'%E?
MVK27FF7=I)B'RXA&\AE,B%PJC:"2%!)X[>E7+WP5;WVO_P!K27LV\3K.J%$8
MJ1&4VAB-P3!)V@]234,W@&TE2-?M;DQ+!Y7FPQR*K1QF+)5A@[D/(/0@$8HN
MPL:NG:YI.KW?V>P:2<B%9C(L3; K#*Y8C&3SQUX-:OD1_P!W]:S=%T&#1#,8
M97D\U(T.Y54#8N,@* !GKP,5K4786(_(C_N_K1Y$?]W]:DHHNPL1^1'_ '?U
MH\B/^[^M244786(_(C_N_K3E14SM&,TZBE< KC-?TO49?&,6KZ="YN;'3\PG
MHDW[SYX2>GS+T]"%/:NSK!U;6]4L-8@M;30KB]M7MY)7N(V ".H)5/J<'\2*
M .&L]#UA;2TNWL+A[*UT^P>YTIX<-=;?-W)[LFX-LZ%@ >HKHO$MOJ%U]CN[
MFQAFB@F?R(4MI+M71D(!DCPI5NPQD D@X!S5&[\?:K;&!+FTT_2[DV NGM=0
ME82.^]U\M-H//R>_WAUK:N_&L%I'LETZ\CNVMFECBD"KN=83*8QDYR "-V-N
M01G/% &!HVGLNK:-8WNFW4%U8QP27-^;21VN9Q"%""4 JL:CACGDC [DVK[0
M[BZ\;3-MU..*6^@E,T+NJA!:RH2K=%^8@'&#R/6KY\?V%K:B6_BECF8D^0H4
M,BB*-V))8 X\P=#DY  -2W7CJQC@NWMK2[G\I)?*DV 1S2)%YNP-G/*\YQC@
M]^* .=L7\7OJ&GF[EOHV$=N%!@=E=<'S?,QA QYR6Y'RE?2FWG_"2VFG:4EN
M-;EO!:6\\DCO(X:5G'F*55< @ Y#D#!^4$YKK;_7+]8=+CL+.+[;?0M/LNG*
MK&J*&8';GG+*/QSVK/T_Q?=ZAK%D&M%M-+NTB,,TT4A,S/$'VJX&P$$XYZ[3
MWQ0!B6MYJ\MI=7UK>:H1 MU/</<DB$F*XS&D9/!!174X['YN<5V?ARYGFTV%
M[S[1]INE-X1(IQ&KL2L><8RH(&.O&:S7UK3AJMYX?O-(S8I<QPHZP!H6=T$H
M##U+9Z \XSR:FA\;:?-*UNEI?&\#HBVNQ3(^\,P. V!PCDAB",<CD9 .EHKG
M-/\ %2S^%M-U:YM9?/OF"16L"[G9R3\HSCLI)R1C!JH_C>."YNC=6LL%O "V
MUHF\XJ(%E(*]F&<8YS0!UU%<S)XSLXI6$\%S;^5Y@FAEB_>!E$94#:2#N\U<
M>N<<8-27GC"TT^VCGO=/U&V1F(D\V)5\K#!<D[L-US\FXXH Z*BL*+7V;28K
MR6-(VDU V>T98<3F('ZG&?:JEKXZT^ZDA"V.I1I*(7$DD "A)6V1N?FZ%ACU
M[XQS0!U%%<NGCO3G@$HLM1'F8^SJ8 #<9E$7R<]F9>N."#TYJ23QMIT.]IK:
M]CA4R*LS1#8[1G$BJ<\E,-GM\C8)Q0!TE%<SJ'CO1M-EDCG,W[MI Y 4 +&0
M'?DC*@G'&22K8!Q3)_'FG02S+]BU&1(_//F)""KK"0)64[NBY!]^V3Q0!U-%
M<M/\0-"M[FZA:25A;K(=Z $.8UW.JC.[(&>H .#@FI8_%@GUFQTZ/3;M&GFE
MAG\X*K0%8UD!(R<@AAT_GQ0!TE%<_J?BVUTV]DLGM+IIPDABX55F=(S(57)S
M]U3\V-N1C.:Q],^(.ZS9]7TY[:XWQ)$D;IB5GA$IP68 ;5/<CMW.* .XHK&T
M?Q+9:[</'81W$D*11RFX* 1G>H90#G.<'TXJ#2-9U&YURXTV_M;:-XX!.?L\
MI?R-S86.0XQN(Y&/0^Q(!T%%8$'BVRN'A(M;Y+>>80PW3PXBD)) (.> 2,<@
M'D<8.:KR>-+:2TFFLK*]G$=N9C)Y7[M"4+('.<@, #D X##.,T =/17*+\0-
M'1S%<-(LB1DR% &'F+'YC( #N)"YYQC@C.:TH/$UC-H$^LNLT-K#DMO4,3C'
MW=I(;.1C!//'6@#9HKECXNEN-:TW3+33IHY9IWCNQ<@!K=50/T#')8,,$$CK
MWXJO=>-9;2^UJTDLE5K1A]C<O\MP (_,'LR^8#CN"#V- '8T5RNF>+CJ^N3:
M7:QP"2SFF^VN[D".-)&10O\ >8[03V4'GD@5'K'C,:9K'D*+0VD8@+EY<23^
M;(4_= <,%(R?RXZT ==17/Z3K6HW.O7&F7]K;1LD G/V>4N8,MA4D.,;B.1C
MT/L3T% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !2%U#A"P#$$A<\D#K_,4M86K>$],UG58=2N_M'VB*![=?
M+E*KM8$'CN>>#VP* )I&T>TUL:E-J$$5U<VR0(LDZJ'0,S J#UY8\U1G\$Z5
M-JDVHRRW.Z2229DWJ%#/$8FYQNQM8\$X';%8#^!&35VTS3RD.F)I*VXFN[47
M1.99255F(PP#=\]15;4+/7&U.33+6VU7["L<UFV^61EDA^RL$8'A!EPO(RV<
MY(!Q0!T@\&:7*@,5[=_:(R5:X21#)@QQJ5/RX&1&AZ @\@C-6YO"FF20/'(T
MXC,TL[?O.\D1B;GTVL?QYKBI;?Q''911VHU2WL1N"[8Y6F#^1 (\A6#8R)?O
M';D?-QBKM]IGB"YL[SSI-3FDN9+JWDB$A$9B-JVW:H.%S*!@CN2,X- '67V@
MVMUI]FDE]=0M9H5CNXY%63:5VMDXQR.O'4 C&*CB\+Z=;W]LZ3W(BA99(;(S
M9B#H@0,%// QQG&><9YJAKVDC4_AZELMK<S2QV\3Q0N7#[P!C<"<DCT;N*O3
MZ6!XYL=4CMW+&RGBEFR2%&Z(JO7 SACQUQ0!/=^&K"]EN))C/FXG2X<+)CYE
M0(,8Y P/SK+M? NDZ<\?DWUY'=8C$,PD173RPX&T!0#\LC Y!R#D\\UG:Y+X
MB/BP?V;!?HJ3HBL6=H'C,1RV!A N\@'.6R,\#%4X-+OM2NM)\Q/$""'>US-<
M3,C+*8&#;&^\J[L=/E)QMXS0!UD7AO3UT2TTB"ZN5&G2!H9UE!FC< \DD$$D
M,<Y'(:J[>"-+>.17FO',BD.[S;F;,8C))(ZX&?K^5<I.OBU[2%Y?[0B1\&=H
MHG,GF?98=O$94XW^9_L[NO%7[N'Q@$O+>WDNFEBLS=PSD@"29XPABQG&582N
M%S@%DYXH Z/4/"NEWMQ=7=R\P:8,SD2;0I*QKN'H1Y2$'U%4;KP'IFICS;B_
MU"=Y8RLDS3*QD4MN'.W"]ON;1CKFN;N(-<DTJXCN#K<^GR)<+%'!'*LWF&-
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M[1FN(6NEL6ECE3RG:W&W=YC%BI<'!?@'CIB@#JQX'TM+6R@AFNXC:0&W$JR
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MM(=1]W(3D8!QUJ2T'BJ36].>Z-_;Q[;79'M:5=FW]Z)&!5-Q.[)8;N5V\\4
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MA<Q"X#%(XIU4,^S:74@;LX&>#C/.,U+!X>T>WL;W19+@ROJ!,TRO(JR/P%W
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M@LM9NK34K:YMM6E@F:<6D=J#M9S<,?W@'5?+V8W<8W=\5I:2OBP:Y=,\DC3
MS[HKE)!;$>8/*P^2!\G38OKNYH [3^T;'[;]B^VV_P!J_P">'FKOZ9^[G/2K
M->:W>GSSOKEB^B3G5KO4HYK>[2V/EQX2']X)B. I5N^>,8YI=GB@W6J&:75/
M-(N $@C?:29!]G*.6V  8SM'3=OH ])HKRZ]D\5K8VJ"#5CJ42;II49S&\_G
M?/L5<+LV\KO.-A  )!JS<Z?XBV7,\=QK7FFUO9T59FQYRSCR%"],;"<+T8=<
MT >CLP52S$!0,DD]*1'20$HZM@E3@YP1U%>8ZG8^)+\Z[;W)U"19([L&&-)/
M+=,YA"-NVYQMX09/S!JG^Q:SIL=Q=V$.KN+B>^+VXD8?(<F-@&!VL3SNQN))
MZT >DT5Y8W_"3?8Y6']LXCNI#;0J)AYJF.,J-Y)=?FWX,@*]=P'%6]07Q,YO
MA;?VPE\QN?.(8^2(CGR?)_AWCY.G/W]W:@#TBF/+'$N9'5  3ECC@=:\ZUFU
M\26UU<6]I/JG]FQSR^5(OF32[C%$4Y5@Q7<9<9.W/!XQ5[QAI=_?66F,T-W<
M7*V-W#(8%('FO!@;E4D8+ CG(R<4 =UU&117F^IVGB*SF:UMIM4;3$F#&3,L
MLO, Q@H0Y7?NX!P#C/%3/#K\5C<3W9U:>XDNK>$^7(Z*D?D1EG"1Y.#)N!V'
M.3UP#0!Z%17ENEW'B":XM[>X?6?[4BAM,1Y81)F:02&7G&3&O\6<X&.:Z7PO
M)JMRNIF:XDE-CG3[=I'RLS1ECYI]2=R GU4T =7YB>:8]Z^8!N*YY ]<>G!H
M>1(DWR.J*"!EC@<\"O,;"+6+;58M1-KKC/'#9+?O,K,SL'F\U4'\2@LIPO&,
M8JU96WB&YLIKFZ_M43*MOY,,KG'-U(7RN<$B/9US@8Q0!Z-17FKQZ]8VEM+/
M<ZMY=R@-[NF.\?Z0HVQ_W7*$@!>2!QSBNH\%7,MUH4LDDMU*HO;E(VNF)DV+
M*P4$GT Q^'/- '14444 %%%% !1110 5C:YXEM- :/[9#<&-\%I4"[4!8+_$
MP+')Z*"<=JV:YWQ!X8TG6+M+G4+B6%Y(UM<)*$$@W;E7D9SG/W<9Z'(H 8WC
M;3T,OF6E]&B^:(G:-<7#1RB)E3#9SO90,XSGZU-I?B*6\L-6N[FPGA^PW3PB
M +F4A54\@'&?F/0XQSFDG\-:/<6QBDE?9;>?EA-@Q-(ZREL]B&"L/2EC\+:?
M)H5]IKW-U<PZA(9YII)MSLQV\@@8Q\J\8Q[8XH P]2^(,JQB32M+>X6%+I[H
M2.F4,**VT%7(.=ZG()&/?I?D^(6CP3W$,RSK);I(7 V,2\:;W0 -NR #SC:2
M" 35B+P1I44-Q&9+I_M"SK*S2#)\U$1SP !Q&N,<"D_X1#2Y)+R$WEVPGC;S
MX!. -TB[6D( SEL$^F<D#- $^J^(+C3[+3ITTR<M>3^4T4C(&B&QVRV&Q_#V
M)K.M_']D-*@N+^TN;6YEBMW6%]B^9YJL5*DM@+\C_>((V\]JW-5L++4TM[>X
MN&B>*99(_+D"MNVL,<]<J6X^OI5.;P?IDR0@-<1R00P10RHXW1B+>%(R",XD
M8'(((/2@!Q\3VDNCZ=JELQ:VO)A&,IDCALCKP05(SR/K65=>.9)+>T_LW2[D
M37$UOQ=*JXAE5V$F W/$;#&001R/7=DT"TFTZTL9'N'CM7$B.TA+LV",L3U^
M\:HW>C:#IOV6XO;M;9(%@BC:>X"*?*5P@.>IQ(V?7\* &W7C?3+6&*1H[@^;
M!;SH,*H*S;]@+,P53\C9R0.G))I!XPA-S)"EG=W$S%#%;0Q 2[3$LC%MS <!
MAW') &:I+HOARPA7/B.6+[3#%%!))?IS%&6V(H(PR_.1R#GC//-7H_!&EV\4
M8LYKRU>,*(Y8)L.H$8CP"0>"JC/N 1C H 2/QSIDS@QP7KVI(472Q9C+&'S@
MH&=Q)4^G7BM/0M<M]?L3=VT4J1[L#S"IW< Y!5B#U]<@Y!Q56/PEI4,"P0K-
M%$LZ3HJ2D;66(1#!ZCY0.^<\YJ72O#MOI$LDL%S=/++)YD[R,I,Q"[1NP!T'
MI@D]2: -BF21QS1/%*BR1NI5T89# ]01W%/HH 0    8 Z 4M,DECAC,DKJB
M#JS' 'XT^@ HHJ*.Y@ED,<<\;NN<JK@D8.#Q]01]: '/%'(T;/&C-&VY"RY*
MG!&1Z'!(_&GT44 %%%-DDCAB:25U2-!EF8X 'J30 ZBJ3:QI:6J73ZE9K;R-
MM24SJ$8^@.<$\59@N(;J!)[>:.:%QE9(V#*P]B* )**KM?6B7B6CW4"W+C*P
MF0!V'J%ZFK% !113?,3S1%O7S"NX)GG'KCTH =13=Z[]FX;R,[<\X]:;//#;
M0O-/*D42#+/(P55'N3TH DIDL,4\9CFC21"02KJ",@Y'!]QFHK2_L[]&>RNX
M+E5.&:&0. ?0XJQ0!$UM ]S'</!&T\8*I*4!90>H!Z@' _*I:** "BBB@ HJ
MN+ZT:W6X%U 87?8L@D&UFSMP#TSGC'K4<.K:;<71M8-0M);@$@PI,K.,=> <
M\4 7**CEGA@"&:6./>X1-[ ;F/0#/4GTIK7=LLQA:XB$HVY0N-PW9V\>^#CU
MQ0!-1110 453CU;39KPVD6H6CW()4PK,I<$=1MSGBKE !1110 4444 %%5[F
M^M++R_M=U!!YC;4\V0+N/H,]34JRQN[HKJS(<.H.2IQGGTXH ?15>>^M+::*
M&XNH(I93B-)) K.?8'K3TN())#&DT;.,Y56!(P<'CV/% $M%-\R/S3%O7S N
MXIGG'KCTIW09- !148N(2D3B:,K+CRV###Y&1CUXYJ2@ HHHH **** "BBD+
MJ'"%@&() SR<4 +13$ECE#>6ZOM8JVTYP1U'UI] !1110 44F]=X3<-Y&0N>
M<>M+0 4444 ,6*-97E6-!(X =PHRP&<9/?&3^=-M[:"T@6"V@CAA7.V.- JC
M)R< >]2T4 %%%% $5S;07EN]O=01SPN,-'*@96^H-+!!#:P)!;Q1PPH,)'&H
M55'H .E244 %%%% !1110 4444 %<9XPTC5_$&H16MA' D-G 9XY[C<%^TL<
M1LN/XDVD\\?.*[.B@#S*2WU>^O+^XBTS5[:ZOG622)R1;^4;15=",X+;QM'&
M<@8XS4VB:;JTC:7;A=;M],0P"=+F=E?S%@EW\@Y$>[RN <$CCBO1Z* /---@
M\60VMS=W#:E+>VL:3RVQ5E2>97RR(S.00R;E 4!>5[BII[;Q!;CRYHM1N!,M
ML9I8Y9,*Y69G^X0Q4,47 (Q\N3@&O1:* /+++3O$R^3<K!?)K$]I;^;+*QV>
M8L$Z_-DE00YCS]0><FM*QL-5O=0M8<Z[!I#2+YPN;EUFWB&7?EMVX(6\KH<;
MLXXKT&B@#SK3$\0IJ6FR7JZO+NM46Z#%E$8\DAF!#%&.['RE0^XY!Q6UXATR
M\U.3PV+(LGDSL[S7-OYWEKY#C+J2.22!]375T4 >>#1H_#FNQK<:5=:M:R6$
MJLT-D'5I9)S(R[1\J [N!TQWKHO#%G<Z;H5O9WAG%U!91)(&8F-,!L!3T)'0
MD>@KH:.HP: /+M&BUG4['2FBDUW['.MF;R2>X<,[88NR-G(0C;DK@'*XYS4M
MS_PD-NLLC/J<3HT@U*1Y]L;QF9=@MR3@-Y>X#;CK@_-BO2HXTAB6.)%2- %5
M5& H'8"DFABN(7AFC26)QM9'4%6'H0>M 'FNGIK.I)J,FEW&J;;=;Y;(7-PW
M$P,8C5\GG'SX#9QSGFF2VWB(:0S1RZVZB8F*$Q2H2?+Z%O-,@&[D,<J&SP1B
MO2[>W@M(%@MH8X84&%CC4*J_0"I: /.+F+Q(;_4=D.IR&6,MAV(6([HR%7!*
M./O8*A2.=V:DU"U\4[+Z*)[T06=PD,;J[,UQ \GF.P"L&)5-B<$-P^.M>AT4
M <<(M:'@B%&>^EF%R&F 4QW)MO-R57YBV[9QRVXC_:KG;?3M9AMKGR(=7MK9
MY)9%^1FD8-=2-\X5@YRI4DJ=V,=>:]3HH \V@C\5OJFGR7 U"$".V\N-=TH"
MC/FB1MZID]RZD\C'(-584\32QW)D36;:!XH'9/WLK"4.^]3\X<C!7)BVC@$
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MRADQ_L_O)#_O"M/3O#VI6ESHUW=1336B:E<.]JL**]NS22>7+N W,F&Y!/\
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M*[A8V6%EW$GD$B0 MGH!V%=O10!YY?6'B":?5'C;4X_*BO);00S,@:7S08N
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CKG'<>H]ZEHH **** "BBB@ HHHH **** "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>53
<FILENAME>g4i5nix4zlkt000023.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g4i5nix4zlkt000023.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" +Y BT# 2(  A$! Q$!_\0
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M\GSH_-QG9N&['TKC_$?C.\T;Q[X?T"&VA>WU(_O)'SN3G'':O._&G@VQ\-^
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M>/?;OC'_ ,^-K_WRG^-'V[XQ_P#/C:_]\I_C1[+S0>V\G]Q[#17CWV[XQ_\
M/C:_]\I_C1]N^,?_ #XVO_?*?XT>R\T'MO)_<>PT5X]]N^,?_/C:_P#?*?XT
M?;OC'_SXVO\ WRG^-'LO-![;R?W'L-%>*:CKWQ9TK3YKZ]MK6*VA7=(^Q#@?
MG7HO@#7KOQ+X-LM4OA']HE+J_EC .UBN<?A2E3<5>Y4:JD[6.FHHHK,T"BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH *H:OI4>KVT4$DC((YTF!4=2IR!5^L35?$UKI=V]N;>YN&
MBB\ZX,";A#'G[S?KQUP#0!+JFB?VM%<PW%W*(I AB5  874Y#*?7..M+I&C'
M3I[JZN+IKN]NROFS,@08484!1T J6_UFST[21J4CL\#!?+\M=S2%ONA1W)S3
M--UN#4!<(\<EK<6Q GAG&UDR,@^A!]: *]W_ ,CAIW_7O+_2N3\7A=(\86>H
MJ\@$@#OCM@X('U%=3/+'+XNTYHW5Q]GEY4Y]*V)[6WN<?:+>*7;T\Q V/SKI
MPU=49\S5U:QQX["O$TN2+LTTT_0Q]'\6Z=K5X;6W$JR[2P#KP0.M;U>9Z[%?
M>&/$S:I:Q0QP3';'@#;C R,=J[NRUO3;YTB@O8))F7.Q'!/O6F)PRBHU*7PM
M>MC# XR4I2HUW:<7Z772QHT445Q'IA1110 4444 <O\ $;_DGNM?]</_ &85
MF_"#_DFNF_[\W_HQJTOB-_R3W6O^N'_LPK-^$'_)---_WYO_ $8U:_\ +KYF
M/_+WY'=4445D;!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %<7K"7>GZUK<BZ?=72:I9)% T$>\
M+(JLNUO[H^8')]Z[2FO(D94.ZJ6.%!.,GVH Y*]LG'A&+2);.^EGL(+<B2W7
MG>H'S1D\,5(Z4GA73KF;4]6U*_%S+'=+%$IO(1&TFT<GR_X5R>*[ D 9)P!3
M4D25 \;JZGH5.10!A2P0V_BW3UAB2-3;RDA% ';TK?K$N_\ D<-._P"O>7^E
M;= %#5=&LM:@2&]C+*C;E*G!!KSW4;6+PKXO@FM;69[>)0X')W$@@\UZC2$
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M!X[_ ,*Q\=_]#G_Y%EK$\5^%_&?A+0WU6Y\62SQHZILBFD!R?K7OM>>_&?\
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MBNDGT;3KH7 GM$D%PBQR@YPRKT&.V/:ETW2+#2(Y$L;<1"1MSG<69C[DDDT
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M_P"?2V_[]1_XU[%11[7^Z@]D_P"9GCO]H?&7_GTMO^_4?^-']H?&7_GTMO\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH *8\,4A4R1HY4Y4LH./I3ZX_5[W4[O5]7AL]0>S32K1)E5$4^;(P9OFR
M#\N%Q@>M '6M%&^=\:-GKE0<T1PQ19\N-$SUVJ!FL^SOKJ_\.6U_;11&ZN+9
M)421BJ;F4'D\G'-9WA34KV?P_-<ZK-Y]Q'<RH[11''#8 51DXH LW?\ R.&G
M?]>\O]*VZYYKF.Z\6:>\8D $$H_>1LA[=B!70T %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M&(VT@F;R@.4^3:6QWSZ^] &[_P (S:?\_-[_ -_S1_PC-I_S\WO_ '_-;5%
M&+_PC-I_S\WO_?\ -'_",VG_ #\WO_?\UM44 8O_  C-I_S\WO\ W_-'_",V
MG_/S>_\ ?\UM44 8O_",VG_/S>_]_P U5G\/VQF2&WO;@RJZM*AN3D1]SBMR
M^N)+2PGN(H'N)(T++$GWG(Z 5Y4ES=F\\1.]O?IJ-SI EG>6)E"D$Y4>BA<@
M?0T =Y;:-I5X'-KJ5Q-L;:_EW6[:?0XJ?_A&;3_GYO?^_P":QM)CM(O%^GKI
MBQK"VC@S"(#!&X;"<=^M=G0!B_\ ",VG_/S>_P#?\T?\(S:?\_-[_P!_S6U1
M0!B_\(S:?\_-[_W_ #1_PC-I_P _-[_W_-;5% &+_P (S:?\_-[_ -_S37\.
M64:,[W=XJJ,EC<$ "MRL;Q6JR>%M1B>Z2U26+RVFD4E4#$ Y [<T 5].AL8;
MX7-AJ0G@CC;S]UR'"],'VZ&MNVNK>\A$UK/'-$3@/&P8?F*\TU'=IZ7&BO\
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MXC^+=5GMXX[#4[5HK>42J220O51R.AK)\)>%/%NE^!M6\,7V@:?-&2TL)GN
M4G8D97Y>5X&0?6O8J* /%_"?@;Q/I_BW3+R"QDT.P@YO8O[0\Z.;_951T'UK
MTOQEI-QKO@W5M+M-OVBYMV2/<<#=VR:W:* /$;KP;XRU/X21>&9='@BN[*X0
M0#[4G[V/DLQ.< @FNB\?^ M2\0^$]#BTX1_;M+"$VYDVA_E (#= >.M>F44
M>3>'?!FLMX@DU>[T5=.N(;=EMIY]2:ZD\PJ0/^ Y]:Y>_P#A]X[UGP]=6NI:
M>;K5/.\P7MQJ>X,O]U$SM7ZFOH&B@#R/Q1X2\4'5_"&MZ3IT-U/I%JL<MN\Z
MI\X]_3W%5O$/@/Q"GC>;Q%9:>U]#?0@S6\-^;9X9"!D;AU7->RT4 >*WWPKU
M2Y\ /!:V%M9:L;P71M5N3(KX&,%CQN_2K6G^%O&=_P#$;0O$>KZ9:6T%M%Y<
MJPSJQ0!2!GU)SVZ5[!10!D>*=$C\1>&-0TJ0 _:(2JY[-U7]<5X_:?"WQ0_A
MN^OKV./_ (26*X@:Q/GJ?DBZ#=T'_P!:O=Z* /';OX<:V/A"VC06\<NN75V+
MNZ4RJ!N).?FZ' Q4WBOP;XED/A#4-*LH;JYTB)%FMVF"_,N#U[CMQ7KE% 'F
MEMX6UZ7XPQ>*+JQBBL6LE1R)E8I)L ( ZG!R,U/\)_"NL>%K'5XM7MTA>YN_
M-B"RJ^5QUXZ5Z)10!Y?X\\$ZMXB^(N@:G!90W&EVR(EUYDBC@2$D;3UX-0:%
MX*\0^$/B'>RZ1;)+X9O@0Z^<JF/(R,*3GY3Q]#7J]% 'C6B?#OQ%!\+O$V@W
M-O%%?WUR);=?.5@P!0\D<#.T]:BU7P7XNUWX6:?H\VF06]_I=PHBB%PI\Z(+
MC=GH#D]*]JHH \BTSPSXTF^)-AXIUC3;54BM61X[>X7Y2$90O)Y)..>G-8E]
M\-?&.I7]UXLD@M(M=^W+-!8AT,>P=RW3/3KUP:]XHH \K\4Z1XXUC7=+N_L4
MLFE_9P+G38-0$&V7!SEQ]X9P?I7/V?PV\46WA7QEIQTZW2;4Y(&M$2Y4J0DA
M8C).1@'O7NE% 'D.H^ _$$X\ >39Q?\ $H"_;?WRC9AE)Q_>Z'I7KU%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110!YOJ4U\-0U:X43QHFHK"M_]J8):C:G)C[KD^G?
MFM$^+]2-W=>7;P>4CW$4:2L$P8PV&+9Z,5]. 0<UV36\#1RHT,927/F*5&'S
MQSZU'_9]D)WG%G;^<Z[7D\I=S#I@G'(H Y*W\4:A<F"U^T6D$[3.DDD\178%
MC#@8S@D^H.,?E1!XPOKB%;S9;Q)&\$;6K9\R7S-N70^GS<<<X.<5T4OA[29F
MM]UC ([=F9(1$HC)88)*XP35QK&S:>.=K2 S1C:DAC&Y1Z ]10!R \3ZPMK'
M(ZV;/=6IGA4?+Y>)$0C).&)#Y'3D8J"3QKJ'EQI!'$TD<3R2N\90.5;&W!/R
M\=2,]L9KMWLK22/RWM863:4VM&"-IZC'IP.*C;2].:**)K"U,<)S$IA7"'V&
M./PH S=3U6\AO--AMO)B6X1Y9FE!;:JKNP,?E7,-XLU.\$<<5U%$'DM9EF$6
MT;'E"E<$]"#U.#7H+11NZNR*S+D D<C/6JRZ3IJ1M&NGVBH_WE$*@-SGD8]:
M ./C\8ZK*D\B6]N RRF))&">648J,DGG..^.:U[7Q$S>%KW4II(_-M"Z.7B9
M0&&.JC)[CIFMO^S;#?,_V*VW3C$K>4N9!Z-QS^-/2RM8[4VL=M"MN008EC 0
M@]>.E '&67B'4[[7-/M7N8XT2]:*7]V%\Y3"6 (R<'(]:O:KKNJP:W-:VGV5
M88YK6 >8I))F)&>.F,=.]=$FF6$2JL=C;($8.H6)1AAT(XZCUJ5K>!G+M#&6
M)#%BHR2.A_#M0!QO_"5ZB8I 7LXI+2)Y)#("!<%7VX7GCCZ\XI+CQ+JTL5Q(
MA@AB=YX(EV$O&5BWAB>YSQBNODTZQF,9EL[=S&Q9"T2G:3U(XX-2&VMSG,$7
M+%C\@ZG@GZF@#A-,UO5H)%N)+N&Y@DEM8G# \F2,$L#G P?ZUM^&M>NM3N+F
M"],2S(@D547@*21PP)##WZ^U;L=C:0QK'%:P1HI!54C  (Z''M2V]C:6GF?9
MK6"'S#E_+C"[C[XZT <UX?D%QKDTMEJ$EQ9HC)+)+,&^T2[NJKV"],C /ZU3
MN/&-W#JDT<7D308N @V%<-$N1R3DY/!XQZ9KK;;2M.LYFFM;"U@E88+Q0JK'
M\0*7^S;#SGF^Q6WFOG>_E+N;/7)QS0!RT?B/5/M26$TEHDLK1$7)4A(U:/>0
M1GDYX'/-:'AN2\U#P1:O]MVW4L;?Z2!OP=QY&>OM6W+8V<\;1S6L$B-C<KQ@
M@XZ9^E2Q0Q01+%#&D<:C"HB@ #V H X%KOS?#.DI+J5P^I3V["W3S]F7R?WS
MGCA??CMBM[7M9O="L;)U6.X:9/(WG^*<@"/IV+9S[5K7&CZ9=A!<Z=9S!!M0
M20*VT>@R.*LM!"Z(C1(50@H"HPI'3'IB@#A3XVU"XCA:V@B1)?, D9<C=$HW
MKR1_'D9]/6I9_%VK8DE2"!(_-@MU0 L4:1-Y<G(&!T [Y%=A+IUC/"(9K*WD
MB#;@CQ*5!]<8ZTY[.UDCDCDMH7CDP'5D!#8Z9'?H* ,[1KZ[U;17DD*07(>2
M(2* P^4D!L9_3-<S!<3366E6M_J<X@<7;2W!DV,SH1LRP],DX]O:N[AABMX5
MA@B2*)1A410H'T J*6PLYX1#-:021!MP1XP5!]<'O0!P=IJE].JWMS<RKJ$4
MMI'#!OP'1U7?\O?.6.>V/:I_MEYH-X8[^Y>XBBD\V4Q2$EF"$\ENF0&8J/\
M9QUKMFLK5KE+EK:$SQC:DIC&Y1Z ]122V-I.K+-;0R!F#L'0'+#@'ZXH RM?
MUF2RALUM9426Z)*;HRY( STR .HZD5BV?BS4[RRAU$):I;A;0R18)9C,5!P>
MV"V?>NPN+.UNT5+FVAF5#E1(@8 ^V:%L[5(_+6VA5/E^41@#Y>GY=J .6T76
M+W4]?T^6:YA\JXLI9?LL9^:([D #^I'KQSFL?5-3U6PN[N2VDDENC-=AI$F#
MH(E1V0"/J"I" \=<]<UZ!%8V<$[SPVL$<SYWR)& S9ZY/4TJV5JER]RMM"L\
M@P\HC 9AZ$]30!QAAN)Q?6FGZD6LX(X;AI);AL;BK[AO'(QA'Q_0UI^'-9:Y
MOI;6Z\XW4@W@O@ *JI@8Z@X=2?<GTK?BL+."W>WAM((X7SOC2,*K9ZY ZT];
M6W2Y:X6",3L-K2!!N(],_E^5 '(7OB75H97"+!Y<E^]G$0A)0*I8L<D DXQC
MBF1>+M0:YLC/';Q02!%?;^\R[,5YP<J#@8X(YY-=A+96D\+0S6L,D3MN9'C!
M4GU(/>F'3;%GC<V=OYD2[8W\I<H/13CC\* .,_X3+48=.AN&6UN7NK=95$ .
M+<F1$PW//W\]OND59@\3:E.XMFDLK5XQ*[7,_P!R0)LP, _*3OYY.-M='8:'
MINFV LX+2+RB@C?=&I,@'][CYOQJ8Z7IQ@C@-A:F&-MR1F%=JGU Q@&@#C8M
M;U47]WLFBNY5GG:&(9 "K&C!??.>":?<>-+V<QR6$47V6=99K>9U^_''M7!R
M1C+%N?05VBV=LL[3K;PB9_O2!!N;C')Z]*9+IUC/#'#-96\D49RB/$I5?H,<
M4 <;%XHO+%KVZFB,D,UR8XX]VXI*8(G1 ?0DL/J15[Q3<WUI)HDAER(VDEGA
MCR!,R1,P&0<XR.E;UUI-M=W%O+)N"PRB?RTP%=QC:S<<D8&/I5QHHW96=%9D
MSM)&2,C!Q^% '&_\))JIN[>PBFL9IKAHB+A%)1 X8E<9Y(V\<\^U7M>U&?0=
M16\9W>&ZMF@6,<C[0.4P.V?F'N<5O0Z?96R[8+.WB&[?B.)5^;UX'7WJ:2&.
M8*)8T?:P9=R@X(Z$>] '&7'V^T5;@7<TAT>.(W&UR5G+'=-D>H'3TS6KIE[-
M+I>IZWYADCE+R6JL?E$2 A>/<@G/H16\(8@) (TQ(27&W[Q(QSZ\4R2UADLG
MM H2%HS'M08PN,8'IQ0!QJ>++X011R7%H\UQ'!(DL,98(7ZIC/)'4$D<=:I1
M^)M1O?+NI9D$36H)MTXRXGV%@<YZ#I7:VVAZ9:Z>EC'8VYMU"_*T2G<5& 3Q
MR?>IAIMB-F+*W'EC"?NE^4=<#CB@#B_^$UU3[+=7*VT&-DC1(_'EE7VC/.3G
MZ#%37.N:O%K%O ]U;C[/-<)(,;$GVQ;U!R?EYKKQIUB))9!96X>;_6L(ER_U
M..?QITEE:RL&DMH78-O!:,$AL8S]<<9H Q?#&N2ZI#-'>21BYB905";>JYQU
M(;Z@FNAJM!I]E;*JV]G;Q!&+*(XE7!/!(P.M6: "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** .-BUW4;;6/^)E<>1;F:0!&MOW3QC<5\N4
M'E\ '!]Q5^+Q8#+;1W.G3P-=^4T +JV]'8+DX/&-PR/>K<?AC2XKOSUA<J':
M183(3$KMG+!>F>3^=,7PII2PM%Y<I!"!&,I+1!#N4(>P!YH IW'C**&6=1I\
M[QVZ323R!U 18VVDXSR2>@HOO%YTSRHK[39(+J4L4B:9,%  2=PX[XQZUHV_
MAK2K:*2-;;<LL;Q2!V+;U<Y;/U-1_P#"+Z<%!!N1,#D3^<WF8QC&[TQQB@"[
MIM__ &E;1W*0/'!+&DD;.1EMPR1CJ"/>LZ\N=1O=?DTNQNTLU@MUF>1HA(SE
MB0  3T&TY^HK6MK.&T!$.\+M5 I<D *,#&:K:CHEGJ<J33"5)D4H)89"C%3U
M4D=10!DS^*CI<UI:7R13S/Y:R302 *69MN54\]N:KOXPNS+:S)I3K8N]P&=I
M5+.(@V2!GCE>]:A\):/N&RW:- (P8XW(5MARA([D9-32^'=-EMX(&A81P/(Z
M!6(^_G=^!W&@#-7Q>WE-++I,\<4,<<MRQE0^2C_=.,_-P,D#I5G3/$O]HWT<
M#6$L$<QF$,K.I#F-RK<#D="1FK$WAS39YHY'B;Y41&4.0LBI]T,.^*GM]'LK
M5X&ABVM 9#'STWDLWYDF@##NO&]NE]=V5O;-))"SQ*^X<R*N[&.H7MFKH\02
M0>%K#5;FW'G7$43-'Y@4 L >I[5;_L"P^V27.V0>869XQ(1&6(VEMO3)'%(V
M@6+:=9V.)!'9E3;L'.^/;P,'Z<4 4-#\1MK>HQF)-EK):&4(<%@XD*GD=1Q5
M'Q1K>J66O165B\ZQFQ>X(@LOM#,X< 9Y&!S6S#X:L+18A:"2 QD?,KDDJ'WD
M9/J>M2:CX?L=4NTNI_.698C#NBE*90D$@X[9% &%I_BR[FNO(,"74TT5N8(H
M2%&YHV>3YCQ@8JPGC6"6)YXK"=H+<(;MRR@P%F(QC^+&.U:+>&-*V_NX&A8;
M-CQ.59-@*C!^A(]\TW_A%=(!C"VY1$559%<A9 IR-X_BP>: *EGXCN=1UJQC
MAM&BT^X68K*Y!,NPXX Y7OUJ7Q+J=YI[V:P3K;0RE_-N&A\P*0N57'N>]3?\
M(OIZ2R2P>;%*RNJ%9#B(,<MM';)YJY?:3;ZA%$D[3 Q A7CD*M@C!!(]10!Q
MT7C'47>VN9=L4<AA"6OD$F97X9PW;![=J[743*NGS/%=+:LBEC,T>\(!R3C(
M[55_X1[3A<Q3")P(MNV(.?+RHPIV],@5/'IL8TIM/GD>>-T9'9SRP;.?YXH
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M !1110 4R:&.XA>&9%>-QM96&013ZR_$>JMH?AZ]U)(Q(\$>Y48\$YP,^W-
M&DJK'&$4!448 '0"J@LM-N].^RK!;361)_=J R9SG\\UQGB"]UVQM+S2KS4(
M9GNM-EGCGBAV&)DQN7'=2#P>M=3X9M4T_P +Z?%^[&VW5F*($!R,YP* '_V9
MHGDKIGV:S*(=RVY"\'UQZ^]2-H>EM8+8FPM_LJMN6+8, ^OU]Z\YDTY--TZ2
M_O=.CU"Q\\W URPN,7"#?G<0>N.AP<8'2NDO?$]]#HWB6[C,6[3[@1VY*\;2
M$//K]XT =$=#THP& Z=;>26#%/*&"0,9QZ^]/CTW3K.WBCCM8(HH6W1C: %8
M]_K7-)J/B.]O/$+VMQ;+#I\CPV\'DY:1@BL,G\2/QJAJ?BN74].GN+:&"2QA
M@MFE21=V9I)!\O\ P$9_&@#METNP5-@LX IB,.-@QL)R5^F>U9J^'$&MV=X9
M4%GI\96SM$B $3,,,V>_'0=JRT\2WYODTAC$-0746BE)7 %LHW^9CME<#ZYJ
MA9^*M3FUK35-R+JSO[AX&\NT*0IP2"DAY8\>E '?JRNH96#*>A!R*6N<\!$G
MP/I9))/EMR3_ +;5T= !1110 4444 %%%% !1110 5YQ\:]&N-5\"&:U1I'L
MIUG95&3LP0WY9!_.O1Z1E#*58 J1@@C@T >?^!_B%X=N/!=C]JU2WMKBUMUC
MN(Y7VE2HQD>H.,TWP7\1;KQIXCU6QM=.5--M@QAO0QR1G"[AZGD_A5G4/A!X
M,U*]:ZDTQH78[F6"4HI/T%=3HNA:9X>L!9:59QVT .2J#[Q]2>YH \<^#&H6
M&B:UXAT[5YHK34C*.9V"E@I;<,GW.?QI]C/!KO[10O=$82VMO&3<31?=;$>T
MG\R!7HWB/X<>%_%-U]JU+3@;D_>FB8HS?4CK6CX=\*:+X5M6M]'LDMU?[[]6
M?ZD\F@9Y;X!5W^,7C58SAR)PI]#YHQ4/P2U+3M&NM>TW5)HK34C,"?M#!2P7
M((R?0_SKU;3/".C:1KM[K-G;%+Z]W>?(7)W9.X\?6L[Q%\-?"WBB[-WJ.G#[
M2WWY87*,_P!<=:!'GFB30ZY^T1<:AHI$EE#&QN)H_NM^[VD_BV/RS4OPKB1O
MBOXPE*@NDDRJ?3,W/\J]3\/>%]'\+69MM(LDMT8Y=ARSGW/4U'I'A'1M#U:^
MU.PMC'=7S%IW+D[B6W'CZT >0_$:.[MOC1IEP;]=.$L,8M[R5-R1GD=/K^6:
MGU'2?MGCC0X]8\>6MWJ<$J/;)#;9S\P.-R\ DCO7K?B'PMHWBFS6UU>R2X1#
ME&Z,A]B.169X<^''ACPM=_:]-L,7.,++,Y=E^A/2@9YU:W4&A_M%:A+J\BPI
M<(?(FE.%^9 %Y/3H17=_\)IX8F\?0Z+!;+=ZI(@ NX(ED"]3@OVP.?QK5\2^
M"M!\71QC5[%97C&$E4E74>F1VJ+PSX#\.^$6>32;$1S.-IF=B[X],GM0(\V\
M*7EO9?'KQ*UW<1P*ZNH,KA03E>.>]6[WQ5KGB/XC:CX?TO4K+08+0%7N9(@9
MI<8S@GZ]/05VFL_#+PMKVM_VO?6+&[+*S-'(5#D="0.IX%+K_P -?"_B34_[
M1O[%OM1QODAD*%\?WL=: /,? *"/XYWT?]JOJK)%(IO7(S*0@R>...GX5I?"
M_P#Y+!XP_P!U_P#T;7HFG> ?#>D:S!JNG:>MM=01^4AB8A=N,'([U9TKPAHV
MBZU>ZO8VQCO+W(G<N3NR<]/K0!J:C:_;M,NK3IYT31Y^HQ7B?P?\067A*[U?
MPUKTZV5TLX*&;Y5)'!&?R(]J]UKF?$G@#PWXJE$VJ:>KW &/.C)1R/0D=: .
M9U[XLQ6WBS3M$\/6T.KM.X2=D<_*2> I'!P,DU2\;>+]6/Q#L_"NDSV6FNT:
ML^H7,88C<"<+GITKLO#?P_\ #?A24SZ7IZK<$8\Z1B[@>@)Z4[Q-X#\/>+98
MIM5LR\\0VK-$Y1\>F1VH \<DMY;7XX>'H+GQ ^M7"2IYL[;<(2&^08XQ6]&B
MO^TNVY0=L!89['9UKO+?X9^%+.XL+BVTWR9K%M\,B.0V[.<L>Y^M:2^$=&7Q
M2?$@MC_:A789=YQC&.G3I0,\R\=@#XZ^%"!R=F3^)JO)<PZ'^T9)<ZQ(L4,\
M1$$LG"C<H"\_@17JNH>$=&U37[/6[NV+W]GCR9-Y&W'M3?$O@W0O%L*1ZQ9+
M,T?W)%.UU]@1VH$8\_C7PNWCRTT:.W2\U290$NH(UD$?4X+=L"O)O"%OJT'C
M[Q'8P^(8-%OS*V]KB,-YPWDX!/H"#^->T>&? 'ASPE*TVDV 2=AM,TC%W ]
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ J*Y_X]9O]QOY5+45S_QZS?[C?RH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MMK"WN=5@M4M'GF.FVPE=FW  '*D  9-=S6'J</B*/4_M6DSVDUN\7EM:W;%
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M2('7/H1D5,H2CN7&I&?PLDHHHJ"PHHHH **** "BBB@ HHHH **** "BBB@
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M][[_ ,!FH_X2ZP_Y][[_ ,!FK?HH P/^$NL/^?>^_P# 9J/^$NL/^?>^_P#
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M[U#_ , VKURBNO\ M'$_S?D<']C8+^3\7_F>1_V%IW_/WJ'_ (!M1_86G?\
M/WJ'_@&U>N44?VCB?YOR#^QL%_)^+_S/(_["T[_G[U#_ , VH_L+3O\ G[U#
M_P  VKURBC^T<3_-^0?V-@OY/Q?^9Y'_ &%IW_/WJ'_@&U-DT.Q$3&.YOV<#
MY5-HP!->O44?VCB?YOR!Y-@OY/Q?^9Y]X0U1=#L)X+Z&[W/+N0)$S#&*Z+_A
M+K#_ )][[_P&:K^HPS2W&GM$I*QW&Y\'H-IK0KEJU'5FYRW9W4*,:%-4H;(P
M/^$NL/\ GWOO_ 9J/^$NL/\ GWOO_ 9JWZ*S-C _X2ZP_P"?>^_\!FH_X2ZP
M_P"?>^_\!FK?HH P/^$NL/\ GWOO_ 9J/^$NL/\ GWOO_ 9JWZ* ,#_A+K#_
M )][[_P&:O-?!%E=>'_'&JZQ?6\WV6Z601^7&6;YG!&1CT%>TT52DTFEU)E!
M2:;Z&!_PEUA_S[WW_@,U'_"76'_/O??^ S5OT5)1CV?B.SO;N.VCANU=\X+P
ME1^=;%4)H9FUVSF53Y*02JYSP"2F/Y&K] !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ',>--?
MFT.RL1;7,%M/=W0A$LR%U1=K,QVCD]!^=6_"U_+J.F/<2ZK:ZCF0A9+>(QA<
M8^4@\@Y]:?KW]HQ-97-A8P7RPRDS0O@2;2.#&3P"#^8JIX8TV\@O]8U6\MEL
MVU&9'6U5@VQ50+EB.-QQDT =)1110 4444 %%%% !1110 4444 %<M'XAU.7
MQU!I3V'V;3W@E9'D(+S,A R .B\\>M=36%=Z;=2^-=,U)$!M8+2:*1L\AF*X
MX_ T 8%QXFUK[#?^(8'MQI5C=-";0QY>2-&VN^_LV<X'3BN[5@RA@<@C(->?
MSZ%K:Z5J7AB&R5K2^NWD6_\ -&U(G?<P*]=P^88[\5Z JA$5%X51@4 +1110
M 4444 %%%% !1110 57OKE[.QFN(K:6YD1<K#%C<Y]!FK%% '%6GBS44\$ZY
MK&I1007=C//$L2G*(5.%!/?DC)J;PAK-WJMQ(+C7K"^*1 O!!;M$Z$]^>H]Z
M?9Z1JMIH&MQ0P6S7=QJ$UQ!'<?-'(K," WID _2FZ?8ZCJ?BZUUJZTP:9%9V
MCVX0R!GE9B/3^%<<?6@#KJ*** "BBB@ HHHH **** "LK6FUAA;6^D"*-I9"
M)KF4;A"@!.0O<DX%:M<WXQ;7FL8+;0[9Y/.DQ<RQ2JDD<?\ L$\;CTSVH R/
M^$JU:*&ZT[?;7&H)J<>G07BH1&Q=0Y)7^\HW9 [BM+3M>N;#5+_2=;GBEEMU
MCEBN(TV>8C[NJ]B"A_2LW^R+^3P_91V6@_V?+I5['=0VTEPKFXQD/EA_$0QY
M/>KUCHEQK&KW^KZM:&T$R10P6Y<,RJFXDL1QDESQ[4 =;1110 4444 %%%%
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M%<0K-!(DL3C*NC @CV(H \[;^V[>;4);&&[:]DN'F DB8KS:#:1D8^^",>H
MJW8-K5Y+;6YNK];.2Z >0(ZN%\ERPW, <;@G;@G -=Y10!YMC5XY;FXDEU".
MYDM8$\SR9"&5)7#9VCY3C;R.?FSBNA%WJG_"&0WR170O(&\QX6&Z25%<Y7H"
M=RCC(!Y&>:ZBFNZ11M)(RHBC+,QP * .!MW\2SQK#?+<EK>X@1F\OB7S'#LP
M]D'RYJGI]AJ5O9375JVI1W%K8Q!%*-^\D61\J01\W';WKT"WU?3;N-Y+:_M9
MD0@,T<RL 3TS@U9CECF3?$ZNA)&Y3D<'!_6@# \2K<V4UKK-C;RW$\(:!XHE
MRSH_ X] VUOH#6:?#TTMK)9KN6>QM5:&7!PUPS>8SCWW#_QZNTHH YO1DN+R
MPU'5[FVE@N;]<+!(I#QHJX52/7)8_B*P8!J^CZ1;1(=2ECDL8C(N#F)]X4X(
M4E0%)R ,\9KT*D#*V=I!P<'!Z&@#S9[C6+C39H;Y]36WV7"0&*%R\CY78&XR
M1@M@MP:V=9AU*.ST&2PMY#=6]O+T3.QO)QS[^F>]=<\L<;(KNJLYPH)P6/M3
MB0H))P!R2: .'MVU2\OHK:VNM5_LQY4#32HR2?<)<9(R!G'/8\"L^;5M7ALM
M]]=7\-Q&L*VX2,X;,A5C)Q@$@#KCCD5Z/'(DL:R1NKHPR&4Y!K+G70;G6428
MV,FI1@%49E,@QR..O% ''F[\3LM]^\NUN=DHD1(G(0[P$*9&W[O]TG/>M_Q)
MIMU)IVD6MJQN)([Z(M)<QF48 ;+. 1D?B*Z*&Y@N"?)FCDV@$[&!QGI3WD2*
M-I)&5$499F. !0!PMQX8O(-8TL1R0L\LUS/-(MIF",E%  3)QG'<TGB"T-M=
MR[89&G-HL:H; S07.,G:-O,9SQU YS7:6>H6>HQ&6RNX+F-3@M#(' /IQ5F@
M#GM1,GF>'EFC\J)IE\Q,YVR!#M7/?G/Y5C^'-^F:@0BWLEMY;FZ-Q8[)(W+\
M %5R^<GNW SFNSN4@> FY"&)/G)?HN.<^V*E#*4#A@5(R"#QB@#B]/@EMO%K
MM;+=.TUU,URMQ:!5C0]&23'(Z8&X_05I,VKCQ4+$&;["S?:O/ ^4*%V^43[M
MD_05J_VSI?D-/_:-IY*OL9_.7:&]"<]:LV]S!=PK-;31S1-T>-@P/XB@#E-<
MC63Q!:_9;.<7:7<4KG[.2LZA<9\P<*%!/''3IS4&OJ;N_NI!:7$INK2.*R<0
M/\L@D).>/EP<')QQ7:>;'YOE;U\S;NV9YQZX]*AEU"S@@>>:[@CA1MC2/( J
MMZ$^M '/^)AJW[L64UVGE6%Q*?LX/SS*J[ >.><\=ZSV?5K:Y\BZN-3.G&2-
MI9D1FD&8@2!M&=N_.<=.E=>^HV,<D,;WENKSC,2F0 R?[OK^%67=8T9W8*JC
M)8G  H X2-_$4L'VF66_62&*W:) F!)F7#%@!R=G4=NM48--U!/M4EN^I13V
ML%ZR$*WS2>9N0 D?,#P<#@UWW]K:;]C^V?;[7[-NV^=YJ[,^F<XS4K7UHEQ%
M;O<PK-*,QQEP&<>H'>@#CH;_ %&/6[G[;+?_ &4PR-(Z1N@@4)G.-I4]\%3G
MU%:?B2TNK^3019+&Y6Z+E[B$R(%\I^6 (]NXY-;L5W:7<DT$5Q#,\1VRHKAB
MOL1VJQ0!F:%I)T>SDB:59))9FF?RTV("QZ*N3@?C5*6SUHZ\)D=OL/F X^V8
M^7O\GE_INKH** .+\1VTCZK?K]EFEFN;:!+&18BP2178GY@,+@E22<<?2I/$
M!2:]$T]I<7-N;*XMD"V[MB;<O;'&<'#=..M=A10!Y];V=[%)';36UPVK+>"9
M[A8B08O) )#_ '?5<9ZU#;PR6>@7T%H+AX(;: VTES:B"07(;Y4X W<[>>>3
MU->CTR2&.;;YB*^Q@ZY&<$=#0!G7.F:?K-U:W<\+M-8RDQ%E*X;C/7J/TK4H
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH Y_P 4Q;TL92EXOD3EUN+6(2M"=I&3'@[@<D<#
M(S7/Q_VDEG$)X+ZWMRD[0?8(7C:28OE&=!DKD9.#\O7->@44 <,UWX@"_9)8
M[W[;]IWNT<9\L1^0.C=,;\\>M+'#J%JUJEU+K,A-I"\!A9F)N"3Y@D/0#[O#
M< 9Q7<44 <)HS:P;N?\ M.74-OE2?:52.3A]XV[">.G39QCKS75Z[%)-H&H1
M1(SR/;NJJHR2<&M"B@#S:RM]3#K+;1WDNVSBB=Y;,P&-A(A*@8&[C.3@XQUY
MH@AUNTTZ:+24U%+H?:C<+,K; #*Q0QYXW8.1M[=:])HH \\DDUC^S_*!U-[=
MYW\N0+,I4!. ?^6A&[IG S[5/;7NO*EM!<1Z@;B5K-L^4VT*#^]R>@]P37>4
M4 <;XH;6AK2?97NDMQ"/LYMXW?,N[G<%XZ?W_EZU/I4-UIVC:Z$@O&NA<RR*
MF3E\@$;"V1CZ9KJZ* //-+75#J<4MS'>/9V\Z3(TRR':/*;?R_S=<>G/05UN
MI:JL6D1W4=K<SP7,?6&(LRAERI*CGT'M6J_W&^E)'_JD_P!T4 97AM9+?1;.
MRFBDCFA@0N&4@#/;/0D=ZP=,3[+80:5<Z/<7&I)=/(\IB(3)9B)O-Q@\$<9S
MVQ7:T4 >?Z5I^KF2WLY1?6]H6B#^63&=NQ]PR.1\V*T9[;4[SP58BZAFGGBF
M1[F!A\\T:N<KCN2 #[XKKZ* .&OTN]0U.:_T>WO+6$PQP22"%H7D/F G"D \
M+GYL=^*0IJ4%Q)!>/JYL(Y9UMFMR[2ELC9D]2N,X+<>M=U10!Y[<KK5Q%<Q,
MFHO>2).MS'(I\DQ%#L"_P[NGW><YS766UQ!)H<L,D,LOV>#RIX0AW,0G*@=_
M2M:HXOX_]XT <1:&:XTK4KZ'3YHKZ6*.&&U-JZ+ F=JXW ;F7)8GVKJM-CM-
M+2#1K=2IA@#@!3@C."<^I.:T:C_Y>#_N?UH Q(]+6/QE=72PR!+BP"23;CRV
M\\ ]L#L*Q5B.@Z-)'%I$LL@U2<VO[AY%A#,<2D $D8/XY_&NYHH X![>U2.P
MTB*ROA;M%$9[YK*0NX5]P0 +\O/)SC /Y=3?WUM/H=[-]DFO(HB\;6ZQDM(R
MG!4#OR*UJCB^Z?\ >/\ .@#A;1"+N#6+FSN9$DFD:Z@2SD C8QJJ!4(RP"J0
M6QU/:J]GI>H6U@EA<6D[7TQLFAD"%EC6,J7!?HN,-UZY]Z]&HH XCPW87D.N
MVJA9%M+&VFA8R6QB8EG4KN8DB0_*W*\<^]=O110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
24444 %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>54
<FILENAME>g4i5nix4zlkt000010.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g4i5nix4zlkt000010.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %Q J # 2(  A$! Q$!_\0
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MOTN7BE!'(^8L 14?Q$6]?Q/X173I(H[PW$WDO,I*!MJ]0.<4HTE[3E;T_P"
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MEU-Y/=:HDB7D;?>*QEN",Y  R*&@N=6T_P ;75UJNHG^S;N9K1$N758R 3G
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M()[D#H/>O-=;N;[5O&$&C1_;M6L;?3DEC6TO5MS<,>/-+@@-]!W_ !J*ZO\
MQ%8>#-(6]O)XKA=:2%)([I7:2 Y(5V0D'T.?2A4-KO<3J;GKE4KG5(K74K6Q
M>&Y:2YW;'CA9HUQ_>8<+^->>:UXCOO!VK^);.:XGF6\MQ=:7YCEMKL=I1?0
MG./:IT&J:/XC\$:7<:E>2-)#*;L/,Q\U]N3NYYP3@9]*2H]7_6EQ^TZ'I-%>
M+^5=ZAX-\3ZO<:MJ1N-/OI1:!;IPL>&';//7'/3'%;,D]SXE\2>&=(U"]N8[
M.;2%O95AE,9GE([E<'CK^=-T+=0]IY'I]8]]XGTO3=?L]%NYFCN[Q=T.4.T\
MD %N@)(Q7-> )KG_ (2+Q392ZC<WL-I<I%"T\I<JHW<?I@_2LGQ[HI\0_$/3
MM.24Q3/IDCPR XVR*S%3],BE&DN?ED^GZ YOENCT"77[&'Q FB.TGVU[<W(
M0[=@..OKQTJK:^+]&NO#DFO"X:/3XRP9Y4*G(.,8ZDYZ>M>>^&M;N-<^(=G)
M>Q-%J%KI4MK=JPQ^\1CD_CD&N8L;+6)/!]MJ\\,=SH.F7I=K(G_79;YV/L.G
M/OVS6JPT=F^WZD>U?0]VT;6+?7=-CO[2.=+>3[AFC*%AZ@'M[UG:YXWT+P]>
M+:7]R_V@KO:.*)I"B^K8' HN_%$5OHUAJ&FZ7?:G;72YC6QB#%%QW&>/3ZUQ
M]W%JB>(M3UC2AI^[4[!3>6>HR[)K)0N,LH[8[5E"FFVY;%RDTM#MM1\6Z)IF
MCV^J3WJM:W./(,0+F7/90.34F@^)=+\26\DVFSE_*;;+&Z%'0^ZGFO/O"EQI
M&E?#?2=7UJW\^6TN)3IJ\[V9F. @]21^%=1X*TBZANM4US4S#'J.J2*[VT+!
MA @^ZI(ZMZTYTHQ3\@C)MHZ.34XHM7ATTPW)EEC,@D6%C$ .Q?H#QTJ[7&:C
M>W:?%O1[-+F9;633Y7> .0C,"V"5Z$UP@6]NOAIJ/B&;5]3:_LKQA;-]J8+&
M-ZCIGGJ>OM1&CS6U[?C<'4L>IZUXJTS0;NVM+LSO=7 +1PV\#2N0.IPHZ5M
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M_MDV1R;C@#GJ.A(R:UJ*;J3;NV+E78P]:\(Z-KUREU>V[_:%3R_.AE:-BO\
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MA. ?PJ[J_BC1]$6W-[=_-<#,,<2-(\@]0J@DCWJ$^,_#XT-=8_M*,V32>4&
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MQ/>ZI=:MXCT^X%_:@IMM+:QLLB\7:?FDDVDD>O(X)KUN.-(HDBC4*B*%51T
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M * -U_W_ %H_X7M8_P#0!NO^_P"M>)T4?5*78/K%3N>V?\+VL?\ H W7_?\
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M@#=?]_UH_P"%[6/_ $ ;K_O^M>)T4?5*78/K%3N>V?\ "]K'_H W7_?]:/\
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MSHW+ZC\Z %HI-R^H_.C<OJ/SH ]+\#74+:!;VT^H:288;QI9(+NZ>TGM<_\
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MHI-R^H_.C<OJ/SH #T-;7B;_ )"D'_7C:_\ HE*Q"RX/(_.MKQ.P_M6#D?\
M'A:]_P#IBE2_B0UL8]%)N7U'YT;E]1^=4(6BDW+ZC\Z-R^H_.@!::_\ JV^A
MI=R^H_.C<O\ >'YT >P7-Q;V/B2]\13:_I[:4^EB#['%>!Y)G\D)L\L?[0JO
MI;:-'?1W"76CJT>EZ>KQR^2-QY\T[G! (_B !8\=*\FROJ*,KZBL/8:6N:^U
MUV/:]+MM);6X(-*31?L\FM3B[2=8V,L?6(0Y!R!_L]#U[UGZ=>Z*@T73YAI
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MS]T,#CVI>V?\H_9KN>6VMA/>PS26\:O'"%W_ #J,;C@8!///IFI&T:]AUO\
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MF0,N>QP0:Q?[-T'_ *%[3/\ P&3_ .)K<U'_ (]#_O"LBN>&QM+<B_LW0?\
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MT?V;H/\ T+VF?^ R?_$U+2/Q&Y'93_*D S^S-"_Z%W3/_ 9/_B:/[,T+&?\
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M1_9N@_\ 0O:9_P" R?\ Q-2T4 1?V;H/_0O:9_X#)_\ $T?V;H/_ $+VF?\
M@,G_ ,34M% $7]FZ#_T+VF?^ R?_ !-']FZ#_P!"]IG_ (#)_P#$U+10 2:?
MHIA@#Z%IS*JD(IMTP@SR!QQSS47]FZ#_ -"]IG_@,G_Q-69/]5#]#_.HZ2 B
M_LW0?^A>TS_P&3_XFC^S=!_Z%[3/_ 9/_B:EHI@)#::-;N7AT+3XW*E2R0(#
M@C!' Z$<4L]KI%RRM<:)82LB!%,D",54= ,CH/2BBE8"+^S=!_Z%[3/_  &3
M_P")H_LW0?\ H7=,_P# 9/\ XFI:*8$7]FZ#_P!"]IG_ (#)_P#$T?V;H/\
MT+NF?^ R?_$U+10 ]XM,DLX[1]'LVM8SN2$Q*44^H7& >35?^S=!_P"A>TS_
M ,!D_P#B:XW7KFZ$WB2_2\N(I](^R_8XTE*I\P5CN0</O+%><].,5W###$>]
M) 0_V;H/_0O:9_X#)_\ $T?V;H/_ $+NF?\ @,G_ ,34M%,"+^S=!_Z%[3/_
M  &3_P")H_LW0?\ H7M,_P# 9/\ XFI:* $-IHS0) ="T\PHQ98S FU2>I Q
MC)P/RJ/^S=!_Z%[3/_ 9/_B:EHI6 B_LW0?^A>TS_P !D_\ B:/[-T'_ *%[
M3/\ P&3_ .)J6BF MK8:+'=PO#H6GQ2JX*2);H&4^H('6NAK"MO^/J+_ 'A6
M[653<N!4U'_CT/\ O"LBMV<D1<>M5=S>OZ40=D$EJ9E%:>YO7]*-S>OZ57,3
M8S**T]S>OZ4;F]?THY@L9E%:>YO7]*-S>OZ4<P6,RBM/<WK^E&YO7]*.8+&3
M-%'<020S('BD0HZ'HRD8(/U%$<:0Q)%&H2.-0J*.@ & *TYKF.WB:6>:.&)?
MO/(P51^)XIZR;E#*P92,@C!!%',%C,HK3W-Z_I1N;U_2CF"QF45I[F]?THW-
MZ_I1S!8S**T]S>OZ4;F]?THY@L9E%:>YO7]*-S>OZ4<P6,RI)O\ 6#_=7^57
M]S>OZ4YV.1SV':CF'8RJ*T]S>OZ4;F]?THYA6,RBM/<WK^E&YO7]*.8+&916
MGN;U_2C<WK^E',%C,I#@@@]#P:U-S>OZ4;SZ_I1S!8P&TK3FL;>Q:SB-K;,C
M018XC*'*%?0CM4)T#1SJ/]H'3K?[7YGF^9M_C_OXZ;O]K&:W(-4L;J;R;?4+
M2:7KLBF1F_('-2_;(!=?93<P_:"-PAWKOQZ[>M',.QS\V@:/<7_VZ;3K=[K<
M',C+]YAT8CH2/4C-:.?>K[7D"7"6SW,*SN,I$SJ'8>R]34FYO7]*.85C,HK3
MW-Z_I1N;U_2CF"QF45I[F]?THW-Z_I1S!8S**T]S>OZ4;F]?THY@L9E20]7_
M -QJO[F]?TIR,?FY_A/:AR'8RJ*T]S>OZ4;F]?THYA6,RBM/<WK^E&YO7]*.
M8+&916GN;U_2C<WK^E',%C,HK3W-Z_I1N;U_2CF"QCR6\$TT$TL2O);L7A8]
M48@J2/P)'XU7@TG3K5[=X+.&-K?S/)91RGF'+\]]QY.>];YEVE0SJ"QPH.!D
M]<#UI=S>OZ4<P6.?ETC39[2:UELX7@FE,\B$<-(3DOZAL\Y%3VMK;V5K';6L
M*0P1C"1H,!16L]S''%)+)/$D<>=[LP"ICKD]OQJ"35;*&XMX)+R%9;D9A7</
MW@[$?7MZT<P[%:BM/<WK^E&YO7]*.85C,HK3W-Z_I1N;U_2CF"QF45I[F]?T
MHW-Z_I1S!8S**T]S>OZ4;F]?THY@L4)/]5#]#_.HZU68[5Y[>E-W-Z_I0I#L
M9E%:>YO7]*-S>OZ4<PK&916GN;U_2C<WK^E',%C,HK3W-Z_I1N;U_2CF"QF4
M5I[F]?THW-Z_I1S!8YZYT?3;R^BOKFR@ENH<;)67D8.1]<'D9SCM5[-:#744
M<T<+SQ++)GRXV8!GQUP.I_"G[V]?THY@L9E%:>YO7]*-S>OZ4<P6,RBM/<WK
M^E&YO7]*.8+&916GN;U_2C<WK^E',%C,HK3W-Z_I1N;U_2CF"Q1MO^/J+_>%
M;M4XV/F+SW]*N5$W=EQ1%<?ZK\:J5;G!,7'K578WI1'8&)12[&]*-C>E,0E%
M+L;THV-Z4 )12[&]*-C>E "44NQO2C8WI0!S/C+4M'TNVL)]4MX;FX\\K8V\
M\@2-I2I!9RWRA0I)+'..W.*M^$K6"R\+V4%O>V]Y& [>=;']T69V8K'Z(I)4
M#L *VS%N&&0-]0#0(RHP$P/0#% "44NQO2C8WI0 E%+L;THV-Z4 )12[&]*-
MC>E "44NQO2C8WI0 E.?J/H/Y4FQO2G.K9Z=A0 RBEV-Z4;&]* $HI=C>E&Q
MO2@!**78WI1L;TH 2FR?ZJ3_ '3_ "I^QO2C8WI0!Y3H]G-;Z7X'FU&'38-+
M+P.EY:6Q6>.;;^[25B>%<_*6'4X' ;-:&BR^'H= M+76;99O$*WH^TP(G^FM
M=>;G>#PVWH=V=NSVXKT;RSC&WCTQ1L.[=M^;&,]\4K#N>=6LF@0:3J5OXB@2
M?6SJ$S30A,W<SF4F$Q=&(V;-I4@ #M@UZ)SWZTNPY#;>0, ]Q1L;TIB$HI=C
M>E&QO2@!**78WI1L;TH 2BEV-Z4;&]* $IR?Q?[II-C>E.56^;C^$T ,HI=C
M>E&QO2@!**78WI1L;TH 2BEV-Z4;&]* $HI=C>E&QO2@#E]<L8O^$S\+7Y\U
MIOM,L2AI"41?L\A.%Z DXR>O%9V@:I>ZAXGO+&YU2Z;3-LXTR8*$-X V)#O[
MF(_*N,9'S<XKN=C?W:/+/'RCCIQTI >:6]K:6%A!%<*!H]MXIN/M)G8N@7#A
M&D+9R/,*\MWP35G0O#\VH.NH6DT<6G)?RM:*=R@0+<&12JCY75N=H;A>"M>A
M;#@C;P>HQUI=C>E%@&T4NQO2C8WI3 2BEV-Z4;&]* $HI=C>E&QO2@!**78W
MI1L;TH 5ONI]/ZTVGLK;5X[4W8WI0 E%+L;THV-Z4 )12[&]*-C>E "44NQO
M2C8WI0 E%+L;THV-Z4 >;^)Q;_VCXEBG53K$_P!B_LC*YD;&W'E'KQ)O+8Z=
M3Q7I#??/UHV-D';R.A]*-C>E "44NQO2C8WI0 E%+L;THV-Z4 )12[&]*-C>
ME "44NQO2C8WI0 L?^M7ZU>JE&K>8O'>KM3(I%34?^/0_P"\*R*U]1_X]#_O
M"LBM*>Q$MPHHHJR0HHHH **** "BBB@"IJ&IVFEQ1O=R,OFOY<2(C.\C8)PJ
MJ"2< G@=!4MI=V]]:17=K*LUO*NY)%Z,*I:S*\4,)6RN[B-V9));(_O[<%3\
MZ#K[''(S4/A.SN;#PS9VEU$8I(MX5'QO";V*;\<;]I&[WS2Z@;-%%%, HHHH
M **** "BBB@ J2;_ %@_W5_E4=23?ZP?[J_RI=0(Z***8!1110 4444 %!.
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MNX>N>.:[1CEB?>D@$HHHI@%%%% !1110 4444 2VW_'U%_O"MVL*V_X^HO\
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MO_?C_.C[&_\ ?C_.K5%',PLBK]C?^_'^='V-_P"_'^=6J*.9A9%7[&_]^/\
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MF?8W_OQ_G5QONI]/ZTVE=A9%7[&_]^/\Z/L;_P!^/\ZM44^9A9%7[&_]^/\
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MM=1A<RJB[F^<CE1A2.O0&MS1/M.J>';/Q)>>(+JRN)Y?-DS(/LT2^9M\DQG
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MNZ)&44_R9?\ GD__ 'R:/)E_YY/_ -\FBZ 913_)E_YY/_WR:/)E_P">3_\
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M3_\ ?)HN@&44_P F7_GD_P#WR:/)E_YY/_WR:+H!E-?_ %3_ .Z?Y5+Y,O\
MSR?_ +Y-'DR_\\G_ .^31= >5Z)9FWLO!<UU9:58VDKPNFI6J'SFDV_+%(<#
M DY!.2">.X-:6CGP\-#M)]9*G7Q> 7)C/^F_:O-^Z,?/CIQ]W9[5Z ;0F,1F
MVS&,80Q_*,=.*3['^_\ /^R#SL8\WROGQZ9QFE89P%M_8']E:A-XA,9UE+^7
MSBK?Z6'$I\H0X^;&W9M"\$?C7?\ /?K0;/=,LS6@,RC"R&++ >QQD4_R9?\
MGD__ 'R:: 913_)E_P">3_\ ?)H\F7_GD_\ WR:+H0RBG^3+_P \G_[Y-'DR
M_P#/)_\ ODT70#**?Y,O_/)_^^31Y,O_ #R?_ODT70#*DAZO_N-2>3+_ ,\G
M_P"^34D4,H+YC?[A_AH;&B"BG^3+_P \G_[Y-'DR_P#/)_\ ODT70AE%/\F7
M_GD__?)H\F7_ )Y/_P!\FBZ 913_ "9?^>3_ /?)H\F7_GD__?)HN@&44_R9
M?^>3_P#?)H\F7_GD_P#WR:+H#F-:M5'B_P ,W9FG9C<RQK$9#Y:CR)"2%_O'
MU.>G&*I:'K%[J/B6^TV;4V-G$LPL9TC56O/FPY#8P3"?EXZ]3G%=F;>0E28&
M)4Y4E.GTI!:%0@6UP$^YB/&W/7'I2&>=P06UM806MU(7TM/$]PETUU)O5AAM
MGFLW4%]O7C.*FT?1)M13S[*98]-6_=8F$AYMXK@R1A1@Y7.X+@KP>XP*[XV9
M:-HVM<H^=ZF/(;/7([TX6\BJ%6%E4#  3  HL@&'K13_ "9?^>3_ /?)H\F7
M_GD__?)IW0AE%/\ )E_YY/\ ]\FCR9?^>3_]\FBZ 913_)E_YY/_ -\FCR9?
M^>3_ /?)HN@&44_R9?\ GD__ 'R:/)E_YY/_ -\FBZ 63_50_0_SJ.IY(9?*
MB_=OP#GY?>H_)E_YY/\ ]\FA,!E%/\F7_GD__?)H\F7_ )Y/_P!\FBZ 913_
M "9?^>3_ /?)H\F7_GD__?)HN@&44_R9?^>3_P#?)H\F7_GD_P#WR:+H!E%/
M\F7_ )Y/_P!\FCR9?^>3_P#?)HN@/._$GV?[?XC><I_:Z?8_[)W']Z,XQY7?
MF3?G'XUZ$WWS]:&M"TB2-;;I$SL<QY*YZX/:G>3+_P \G_[Y-"&,HI_DR_\
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MB@ R?4TYR<CD]!3:<_4?0?RH ;D^IHR?4T44 &3ZFC)]3110 9/J:,GU-%%
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M:,GU-%% !D^IHR?4T44 &3ZFC)]3110 ^,GS5Y/6KM48_P#6K]:O5,BD0W)
MARS!1GJ353?'_P ]8_\ OJIM1_X]#_O"LBJ@KHF3U-'?'_SUC_[ZHWQ_\]8_
M^^JSJ*OE)N:.^/\ YZQ_]]4;X_\ GK'_ -]5G44<H7-'?'_SUC_[ZHWQ_P#/
M6/\ [ZK.HHY0N:.^/_GK'_WU1OC_ .>L?_?59U%'*%S1WQ_\]8_^^J-\?_/6
M/_OJN=U/5#82V=O#:27=Y>2,D$*.J9VKN8EFX  _F*ETO48=6T^.\A5T5BR-
M&^-R.K%64XXR"".*7*@N;N^/_GK'_P!]4;X_^>L?_?59U%/E"YH[X_\ GK'_
M -]4;X_^>L?_ 'U6=11RA<T=\?\ SUC_ .^J-\?_ #UC_P"^JSJ*.4+FCOC_
M .>L?_?5&^/_ )ZQ_P#?59U%'*%S1WQ_\]8_^^J<[Q[AF5!P._M694DW^L'^
MZO\ *ERA<N[X_P#GK'_WU1OC_P">L?\ WU6=13Y0N:.^/_GK'_WU1OC_ .>L
M?_?59U%'*%S1WQ_\]8_^^J-\?_/6/_OJLZBCE"YH[X_^>L?_ 'U1OC_YZQ_]
M]5G4A.%)]!FCE"YI>9'_ ,]4_P"^J/,C_P">J?\ ?5<5:>*IIK;2KRYT6:UL
M=4DCBMY_M*.0TGW-RCD ^V<5-!XE:Z1+JVTB\GTR2;REO(RI+?-MWB/[Q3/\
M7ISC%*R'<Z_?'_SUC_[ZHWQ_\]8_^^JY$^)6<33VFDW=WI\$S0274+*265MK
M%(\[G4'()'H< UNT<HKFCOC_ .>L?_?5&^/_ )ZQ_P#?59U%/E"YH[X_^>L?
M_?5&^/\ YZQ_]]5G44<H7-'?'_SUC_[ZHWQ_\]8_^^JSJ*.4+FCOC_YZQ_\
M?5.1X_F_>I]T]ZS*DAZO_N-2<0N7=\?_ #UC_P"^J-\?_/6/_OJLZBGRA<T=
M\?\ SUC_ .^J-\?_ #UC_P"^JSJ*.4+FCOC_ .>L?_?5&^/_ )ZQ_P#?59U%
M'*%S1WQ_\]8_^^J-\?\ SUC_ .^JSJ*.4+FCOC_YZQ_]]4>9'_SU3_OJN;NM
M<M[77;#2#%/)<7C, ZH?+CPC,-S'C)"G '-2IK.F2!3'?0OO61E"G)(C.).!
MS\IX/OQ2Y4%S?\R/_GJG_?5&^/\ YZQ_]]5QT/BR"ZTY+FVL;IY9KYK&WMI
M(WD=<DD[ON# )YY '3/%5SXP4S6X%F8T,@AG24GS%E\WRF1=H*DJ<,22,@C%
M%D.YW.^/_GK'_P!]4;X_^>L?_?59W0T4^45S1WQ_\]8_^^J-\?\ SUC_ .^J
MSJ*.4+FCOC_YZQ_]]4;X_P#GK'_WU6=11RA<T=\?_/6/_OJC?'_SUC_[ZK.H
MHY0N:;/'L3]XG0]_>F[X_P#GK'_WU5*3_50_0_SJ.DHA<T=\?_/6/_OJC?'_
M ,]8_P#OJLZBGRA<T=\?_/6/_OJC?'_SUC_[ZK.HHY0N:.^/_GK'_P!]4;X_
M^>L?_?59U%'*%S1WQ_\ /6/_ +ZHWQ_\]8_^^JYK6M>MM$6V\Z*>9[B9(D6)
M"<;G"[F/15!8=>O:E\0:W;>'-(EU"Z!=4945%."[,< 9[?7T%*R"YTGF1_\
M/5/^^J-\?_/6/_OJN<37]+\TV\E_;1W21>9+#YH)0!=S<]\#GUQSBI9M7TVV
M3?/?V\:F$7 +. #&2 &^A) 'KFCE07-[S(_^>J?]]4;X_P#GK'_WU7.'Q#HP
MBMI/[3MMETQ6 A_]800" .N02,CM6ETI\H7-'?'_ ,]8_P#OJC?'_P ]8_\
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M^QI_SU/_ 'S_ /7H^QI_SU/_ 'S_ /7HYD%F5*DF_P!8/]U?Y5/]C3_GJ?\
MOG_Z]/DM59@?,(^4#[OM1S*X691HJW]C3_GJ?^^?_KT?8T_YZG_OG_Z]',@L
MRI15O[&G_/4_]\__ %Z/L:?\]3_WS_\ 7HYD%F5**M_8T_YZG_OG_P"O1]C3
M_GJ?^^?_ *]',@LRI2,,HP'4@BKGV-/^>I_[Y_\ KT?8T_YZG_OG_P"O1S(+
M,X'3?!7]CP^'[RQAM%U.P58[L$DQSH1AR"1PXZJP [@\&KNG:9K^DZ?;Z-92
MV26=O)B*^9B91#OW;?**X+X^7.['?':NQ^QI_P ]3_WS_P#7H^QI_P ]3_WS
M_P#7I70:G'V^EZ[I=I/I>EO9):O/))!>2,QDMTD<NP,>W#L"S '('3(KI:M_
M8T_YZG_OG_Z]'V-/^>I_[Y_^O3N@LRI15O[&G_/4_P#?/_UZ/L:?\]3_ -\_
M_7HYD%F5**M_8T_YZG_OG_Z]'V-/^>I_[Y_^O1S(+,J45;^QI_SU/_?/_P!>
MC[&G_/4_]\__ %Z.9!9E2I(>K_[C5/\ 8T_YZG_OG_Z].CM5!;]X>5(^[0Y(
M$F4J*M_8T_YZG_OG_P"O1]C3_GJ?^^?_ *]',@LRI15O[&G_ #U/_?/_ ->C
M[&G_ #U/_?/_ ->CF0694HJW]C3_ )ZG_OG_ .O1]C3_ )ZG_OG_ .O1S(+,
MJ45;^QI_SU/_ 'S_ /7H^QI_SU/_ 'S_ /7HYD%F8>HV$UYJ>C7",HCLKAY9
M QY(:)D&/?+"LK1=!O\ 3O$M[K,QM2=3W&ZBC_Y8%3^[V''S9'W\XRV#78_8
MT_YZG_OG_P"O1]C3_GJ?^^?_ *]%T%F<:= OX4%Q UN]U!K,VHQ1NY"21R!E
M*%L':VUCS@\BK>D^'HK=/M.H1Q2ZA)=273M&S;$9VW!1TW!>,$CKR,5T_P!C
M3_GJ?^^?_KT?8T_YZG_OG_Z]%T%F5**M_8T_YZG_ +Y_^O1]C3_GJ?\ OG_Z
M]',@LRI15O[&G_/4_P#?/_UZ/L:?\]3_ -\__7HYD%F5**M_8T_YZG_OG_Z]
M'V-/^>I_[Y_^O1S(+,J45;^QI_SU/_?/_P!>C[&G_/4_]\__ %Z.9!9D$G^J
MA^A_G4=7GM5*1CS#P#_#[TS[&G_/4_\ ?/\ ]>A20694HJW]C3_GJ?\ OG_Z
M]'V-/^>I_P"^?_KT<R"S*E%6_L:?\]3_ -\__7H^QI_SU/\ WS_]>CF0694H
MJW]C3_GJ?^^?_KT?8T_YZG_OG_Z]',@LS!U[3YM4TL6L#(KBY@E.\X&$E5S^
M.%-5]<T6?4+:Y%O>W#232PN(9Y?W*!)4<[0!D'"GOWKIOL:?\]3_ -\__7H^
MQI_SU/\ WS_]>BZ"S.%L_"EQ;ZUOF"7%DNHRWZ227LO&\L<>3]S<-Q&[.".U
M5%\$7PTYT:[1[BWNX6LL2O'_ *+"6\N,NO*M\['(S@A:]%^QI_SU/_?/_P!>
MC[&G_/4_]\__ %Z7NAJ<7I'ANYLM9M-1DCBC*FZ>9?M,D[EI1&JG>XR3B/D\
M#I74U;^QI_SU/_?/_P!>C[&G_/4_]\__ %Z::"S*E%6_L:?\]3_WS_\ 7H^Q
MI_SU/_?/_P!>CF0694HJW]C3_GJ?^^?_ *]'V-/^>I_[Y_\ KT<R"S*E%6_L
M:?\ /4_]\_\ UZ/L:?\ /4_]\_\ UZ.9!9D-M_Q]1?[PK=K+AM56>-A(3A@<
M;:U*SF[LN)%<?ZK\:J5;N/\ 5?C52B.P/<****9(4444 %%%% !1110!A3ZW
M=V_BR#3)+$1V#VD\_P!I9P7D:/9D*HZ ;NIY)[=S4T/Q#J-[=:7]OAM4@UBS
M>[M1!NW0A=IV.2<,2K@Y&.01BMFXTN.YUJSU)Y#FV@F@\K'#B39G)]MGZUGZ
M/X8&E75K+)J,UW'8V[6MC$\:KY$;$9R1]]L*JY..!TR2:6HS?HHHIB"BBB@
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MUJ]4R+B5[R3R[?=MW<CC-9_VS_ID/^^JNZC_ ,>A_P!X5D5<$FB)/4M?;/\
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M *9#_OJJM%/E079:^V?],A_WU1]L_P"F0_[ZJK11RH+LM?;/^F0_[ZH^V?\
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M_3(?]]5#)_JH?H?YU'244%V6OMG_ $R'_?5'VS_ID/\ OJJM%/E079:^V?\
M3(?]]4?;/^F0_P"^JJUS_BW7ET?3Q!#=V]MJ%VD@MY)V 6,*N6D.>N.,#N2!
MZTK(+LZK[9_TR'_?5'VS_ID/^^JX:;Q/!_P@8FCU6-M6?1C<QE6!=I!$26';
M.X'\0:E3Q1?6LJ0:E80(RK:22R13EPD4S%-QRH^97 SVP<YXHT#4[3[9_P!,
MA_WU1]L_Z9#_ +ZKBD\4ZG>3LFG:3;RQ_9YKM'FN2F^))#&,84\O@D=AWHA\
M9/=6K:I;6"MH\4T,,LKRXF!D"'*IC!"^8H.3D\XH]T-3M?MG_3(?]]4?;/\
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MS:DF_P!8/]U?Y5>PO_/./_O@4YPNX?(G0?PCTI<P[&716EA?^><?_? HPO\
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M"C"_\\X_^^!1S!8S:DAZO_N-5["_\\X_^^!3D"Y;Y$^Z?X12<AV,NBM+"_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
+ "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>55
<FILENAME>g4i5nix4zlkt000015.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g4i5nix4zlkt000015.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $R J # 2(  A$! Q$!_\0
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M8D\<6%W;7GARW0PNLMKIMP[^<FTY)!&/3J1TKU6ZM+>^MGM[N".>%QAHY%#
M_@:S+3PGH%@93:Z3:PF5#&Y2/!*G@C/O1&HE#E!QUN>,(;5-<53Y_P#PAKZQ
MQG[A<#_T'G\JZ77H]$D^,.S7#"+ V:<2MB,MCY<]L?7BO1V\-Z*VD+I+:9;'
M3U;<+?9\H.<Y^M<Y-X(^T^.VU*X@M)='-B+80/R<@8'!&,>^:OVL6[^1/(T<
M5IHMUC\?)I)SHXMSY6TG9NYQC]?PQ5ZUT:UL?@_+K%A;;=3GM6$MRN2^POA@
M#V&T5Z=!H6E6VF2:;!I]O'92@AX50!6SUSZU8M;"TL;%+*VMXXK5%VK$H^4#
MTQ4NMV&H'AMIIL%S8:/+9WGAJPGBEC9)H[F07+-D<.N#SG_ZW%:7BZWT^P\1
MZMJYFT?5XW<)<V%W(5GB( !"=_RKTV'PAX=@O!=Q:-9).K;@XB'!]13[CPKH
M%W?F^N-(M);HMN,CQ DGU/K5>V5[AR.QYQXJ@T^ZO;#6K>XTMGBTV,G2-3?I
M&5RNWU.#^E0:O>VE_P"'_ T]G9"RM_M^U8 Q8)AUS@GG&<UZCJ'AG1-6G6>_
MTNUN)4 57>,$@#H*EN-#TJZ2T2>PMW2S8/;J4&(B.A4=NE2JJL@Y&>:(NB77
MQ-U\>+3#A%46BW3839[9XZ8Q]3659A!X+\=+8%CHXF7[+G.W[XZ9]MOZ5Z[J
M?A[1]9='U'3;:Y=!A6D0$@?6I6T;3&TIM+-C!]@8;6MP@"$=>E'M5^7X!R'C
MVNZ'IVE^!?#.J6=N(K^6:)Y+@$[F)&>3]0,>E>PZJ<Z%>D][:3_T$TRYT'2K
MNPM[&XL()+6W*F&)E^5".!BK[QI+$T3J&C92K*>A![5,ZG-8I1L>"R/,OPCT
MI%.+9]383Y)"D<X#8YQFM[0-+B/C72[FTNO#=N"CH]MIMP[F=-ISE2.N/7%>
MG0:'I5KI9TR&PMUL6SF#8"ASUXJ'3O#&AZ3<_:;#2K6WFP1YB1@,,]>:MUDT
M_F3R,\@N[JXT"P\0>"HMQEN;Y%M1CK&YY_3;^9JYXGL%T[Q?HNE3K8-96NGJ
MD"ZB[);LW.XDKW)_IFO5Y_#^D76JQZG/I]O)?1XV3LGS#'3GVJ74M'T[6(5B
MU&R@ND4Y42H#CZ>E'ME?8.0\GL; V7AWQBT-_I4EO+;!C:Z=,TB0MSZCH1[F
MDN-/M;_P=X3=M3TZ"ZMH'D2TU%L13KNYS^7ZUZE;^&]%M+">QM],MHK6X&)H
MUC #CW]:9<>%=!N[.WM)]*M9(+9=L*-'P@]!1[97_KL'(8?PUU"SO_#UP;33
M(K#R[EEEC@8M&SX&67/0=.*RW_Y+BW_8._\ 9:] L[*UT^U6VL[>."!/NQQJ
M% J'^R-/_M7^U/LD7V[9Y?G[?FV^F:CG7,WW*MHCQKP]H&EWW@'Q'J5S:K+>
M0/((I&)S'@ C'IR:]+^'DCR^ M(9V+$1%<GT#$#]*UK?0=)M+"XL+>P@CM;@
MDS1*ORN3US5JRLK;3K..TLX$@MXAA(T& HIU*G,FA1C8\OTC0M-USXG>)TU.
MU6Y2$[D1R< G S]:Q]&U&RT[X:ZE'?V O[8:KY<5N[E5#8!!)'..,U[%;Z3I
M]I?W-];VD4=U<_ZZ55^9_K4$7AS1H;">QCTRV%K.^^6+RQM=O4CUI^U77R%R
M'E&B>3'\3=#^S1Z1!N1PZZ5*SI@HW#$]_I5_3-!/B&W\:VL1VW4>I>=:OW61
M=Q'Y]/QKT6T\+:%83036FE6L,L!+1.D8!4D8//TJY9Z78Z?+<RV=K'#)<OYD
MS(,&1O4T2K+H"AW/,/!VK'6_B)-?R K<-I&R=2,;9%*JP_,?K7+:1975IHL7
MBFW3[2FF:BWG6KC*[3CYQ[]L_0]J]SMM"TJSU">_MK""*[G!$LJ)AGSR<TMG
MHFF:?9S6=I8PPVTQ)EB5?E<D8.1[T_;);(.1DFEZE;:OIMO?V<@>"= RGT]C
M[CI7FFAZ%INM_$[Q.NI6J7*0ON1'^Z"2!G'K7I>G:78Z1:?9=/M8[: ,6\N,
M8&3U--MM)T^SO[F^M[2**ZN?]=*JX9_K6<9J-[%-7M<\6\H7OB;Q$FHKHAN3
M<,F=7F>-D7D#R\<=,?I4VJ0/9^"/#5G>:C%=Z3_:#B>6U=F38#PN2!T^>O6]
M1\,Z)J\XGU#2[6XF QO>,;OSJ<Z/IK:9_9IL+<V(&!!Y8V#\*T]LM">0\W\2
MKX=M/#.NGPB\(N&@A%V+1R4$6_KZ9ZY]NM8GB&#PG%X.TE] :#^VB\6SR&)F
M+8^;=[Y_^M7L.GZ%I6E6\D%AI]M;Q2_ZQ4C&'^OK5>S\*Z!I]Y]KM-(M(;@'
M(D6(9!]O2A54NX.#9P&M7LG@GQT^K2+MCU33F\P*.//5?_B@/^^C6#J>FW&F
M?#;17EX34;[[3>%\A3N'R!R.<8YKV75-#TO6TC34[&&Z6,DH)5SM)ZXJQ-8V
MEQ9?8IK:*2UVA?*= 5P.@Q259*V@.!Y9X:TY$\<Z;=V=YX=MOW;J]MIEP[F9
M=I/((Z_4CI4OPST'3-0N=7U"[M$FN;;4"(7?_EG@DY'OFO0=.\,Z)I%P;C3]
M+M;>8@CS$C ;!]ZL:?I.GZ4LRV%I%;B9S)((UQN8]S1*K=.PU Y7XLG'@*X(
M[31G_P >K%UVR\.^&/!6GM_8<-U)?&$'S7959]I.Z1AZ9->CZCIMEJUFUIJ%
MM'<6[$$QR#()'2DNM+L+ZP%C=6D,UJ  (G4%1CI4QJ620.-W<\D\+^5'\5+%
M;=-*B#6SAUTJ1FB/RD\D]^G3CI5#PY%X5DL_$AUXP?:UDD^SB1B& YY0>N[T
MYKU^R\,Z'IUQ#<6>EVL$T(81O&@!4'KS7,^&?A]#:PZ@NOV=C>&6[,T'&[:I
M]R!CZ5K[6+N_0GD9P4YN#\,O#/VC=C^U#Y6[^YDXQ[9S707BZ+<_%C5E\5&+
M[.ELOV87)Q'C _\ KX]\]Z]*O-$TN_M[>WNK""6&W8-#&R#;&1TP.U,U+P_I
M&L2QRZCIUM<R1_<:6,$BI]LOS'R,\ET,6@\)^/A8$FS'^H)SS'\VWKSTQ5F]
MM)+3P%X3\3VJ_O\ 3"OF$=XV;O[9_G7J*^'](2*\B73K=8[T8N5"8$O&.1]*
MI:_HDDW@ZYT718+:+?%Y,4<G$:*3SV/;./>CVJ;^?Z6#DT.<\!?\3[Q)KOBM
MU/ES2"VM=PY" #/_ ++^M.^(VH:=%>Z1976E6EY<3,YAEOI2D$(X!+8Z]JZC
MPOHB^'O#EGIN59XDS(R]&<\L?SJUJ>CZ=K,*PZE90W4:G*B5,X/M4<ZY[]!\
MKY;'E'@RUL[SQ/XDLY(-/DLY+,%X;-B]N2"#\N>N#^N<4>&=#TV[^%.K7\MA
M#+>IY^V8IEAM&1S[5ZG9>'](TZ9I;+3K>WD>(0LT: 93TJ6PTG3]+LFL[*SB
M@MF)+1(ORDGKQ[U3K=O(2@>/@V$7P?E?2S -2=4&H&$CS/+\P_?[XZ?A2:=I
ML,FHZ!<6-YX:L98IX]IM;F0S39QE64CJ>>N.M>MV/AW1M,6=;+3+:!;@8F"1
MC#CT/M[5#:>$O#]C>+=VNCV<5PIW+(L8R#ZCTI^V6H<C."T30M-UOXG^)UU*
MU2Y2%]R(_P!T$D#./6O0_$&J)H7AZ]U!L 6\)*#U;HH_/%36VDZ?9W]S?6]I
M%%=7/^NE5?F?ZT_4=-LM6LVM+^VCN+=B"8Y!D$CI6<IJ4E?8I*R/$19Z]+\/
MY+%O#4[QS2_;SJ'FC.>N[;U^[6KXJUI=;\">%K]W&_[6J3$GHRC#$_EG\:]@
M6&-8! L:B(+L"8XVXQCZ5D'PCX?.GK8'2+7[(LIF$6SY0Y&"?KBM/;)N[1/(
MSCOB3XETG4_#O]C:;=17U]=RH(X[=M^,'.<C\OQJA,Z^$_B7I-WJY\NUDTZ.
MW$YY565-IY^H_6O1=.\,Z'I,WG6&E6MO+V=(QN'XU;O]-LM4M_L]_:0W,6<[
M)4# &I52*7*MA\K>IS/B/6=-\0Z#JNBZ1?17=_)9/(L<#;N!CN.,GTK-\!>+
M]!M?!=I;7>H06D]FA26.9MIZDY [Y]J['3-!TG1MW]FZ?;VI?[QB0 G\:KW/
MA+P]>79N[C1[.2<G)=HADGU/K2YH6Y>@[.]S1L;V#4K&"]M7+P3H'C8@C(/3
M@U8IJ(D:*D:JJ*,*JC  ]!3JR*"BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M^7L2<>@XZ5BVSHC%/=V)M)\2C4+O4H+F!+7[%\Q_>[R5Y!;IC'RGN?PKE?\
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M&+&X!A(JJ>=S9 %=UIES<WFFV]S=V9LYY5W-;L^XQYZ GUQC/H?6@"W1110
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MOS1T?PU_Y%3_ +>'_I785PWP\-]_PC'^CK;F/SW_ -8S YX]!75YU7^Y9?\
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MRP*DTP$I+H,'YUVG//7IS44&B:FLV&TZZ#/+&^FN3Q91B9F96.?E^3''.>E
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MO.O680J'^TK@L,@'=Z5]+@OAG_7<^9QGQ0_KL6Y/^1F;_K]_]GKUBO)9 _\
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M9YGH/_(Q:?\ ]?"_SI\G_(<?_KZ/_H==K;>!=.M+J*YAN[X21,'4ET/(_P"
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MHX?]7_P(_P S0!)1110 4444 %%%% !5'2_]7<_]?4O_ *%5ZJ.E_P"KN?\
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MN-3A^Q2V<EC-Y9CF<%V4YPQ4?=!P<>H[UT-4--T/2]'>Y?3K""U>Y?S)FB0
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MRK*=XVGH3C<*]-\/" >&M+%JLJVXM(O*$WWPNP8W>^.M $C_ /(=A_Z]I/\
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MQD5Z;0!1M/\ D*:A_O1_^@U:N$DDMI4AE\J5D(23;NV-C@X[XJK:?\A34/\
M>C_]!JQ=W(L[.:Y:.658D+E(4+NV!G"@=3[4 >1^#[I]/\>BRN;F;4KN662&
M;5+K3B&E*AQM20RG:N48 *N#M->Q5Y1X=NKO5_'T-_=:7/:*D\_V=9/#[1E8
MVR<F<MPS=3QU)'>O5Z "LKQ);W=UX=O8K+5&TN<QDB\6/S#$!RQ ]< UJUFZ
M]J8TC2)KO['<W9 VK#;P&5B3P,J.<>M 'G_PKOXFU"[L8X9%)A\YIY[$Q37!
MROSM(TKL_# X(&,BO4J\T^&HNIM6NKR_LFMKN6S19%.AFS";2 $$A8[P!P!@
M<#/:O2Z "N1^(T%Y+X7>6WUBYTZ&%PTXMH3))<*?E$0PRD;F('!%==7*^/=8
MN-,\/216>EW%_=W(*PK'9-<QJ00<NH_,>I% %#X7W\5UH=S!#:I:QV\H58EL
MA;$ J#DC>Y8G^\3DUU>L_P#((N?]RN9^'$31Z=J+O"\;S71E<OI)L"[$#)VE
MCN^M=-K/_((N?]R@"U+]U?\ ?'\ZDJ.7[J_[X_G4E !1110 4444 >;>*_"=
MUI^F^+]8M=0OKB;4K<+';1YS'\PSLQSGZ5AVD'B63Q)H<=V-0%OH=X^F!_FV
MW0\N4^<WJ-@A&3W)KT;7_%^G>';R"UNX;Z:6:)Y\6MLTVR-"-SMMZ 9%74\0
M:/);I.NIVAC>W^U+^]&3%C._'7&.<T >6>&-*UG3= \(3S6LD$T]Z)IVBDGE
M<J+67YIE?[IW8^4<9Q6[XPMM8UWPQX5%C<W?VZ2X6<SI"T!WK;2NI=/X 7"@
MJ?7%=M9>(-'U&&TEM-3M)5O$WVX$HW2#V7K]1CBK<E[:0W45K+=01W$V?+B:
M0!WQZ#J?PH \;CU;Q<MYJ_BFVT^^6ZO],66"SEC=EME$ZQXVXQO"!GQC//2H
M]:U_Q;K/A>UM+V.8)<VS,3;Z=(YNG6?&QCM'E$( V< '/'I7LT&H65T\B6]W
M;S-& 76.0,5STS@\5R@^)FCOIM_?I;W;V]H[J'0(PF"2+&67#=-SC&<$@9Z8
MR <CK/BCQ9HK%=+L+HE]6NRRBR9TEC650 3@D94L>, ]0>,5TNAZSXHF\7)'
M?Y;3+BYOH%B^QE/)6%AY;E^^X$CG@XXKMH[RUFN9;:*YA>>''F1*X+)GID=1
M^-3T >,7NA:G,WB2_DL&=)->A2*0R3-,4%U"W$9^3RP 3N'H:U)/&7BSR;F*
M&RN3=6L$XN2VG/M1Q=*JLO $FV%BV%)SBO4Z* /,M,U[QE>W-A$CN]N3=R"Y
MDTXQ->1Q;#&"IQY18LR]L@9 K#M?&_CQ_#DUU<1,EREY$IC33I&EVE6+1A=@
M7[P !/N"V<&O::* /*]9\6>+[=-=>TBN/M$%R(X[3^S6(@M]X F$F")"5)..
M<>G'+(?$_C>6&UNF"JD-M:S311V#-]I+W#1N,D J0F&( X/M7J]% 'DVI^+?
M&,&D:C/;+.UVE_Y,L']ELHL8MS@,KX(EW (<@'&ZMF^N]9O]'\%7T\<@O'NU
MENA;(X4?N).6! (&<<$=:] HH \<EUKQO/H]O)>:A=VY\O3K^2:UTP[HA([+
M+$5&2P7"L1C/)!&*D?QAX\^W^((1:^7]GXM4:R<E1YR(K#Y<,&1B3\Q]L8KU
M^B@#S ^)?%UKJ&FV<_FW"IJLUI.\6G-NN8@RA'_NJN&.3D=,C."*R=+O/%]L
M(Y8+JZ@;^PO/@LI+-C TL<LA="3]UBH').3N'H*]EIDL4<\,D,J*\<BE71AD
M,#P0: ,'P9JU[KWAY=8N_ECO97FM8B@4QP$XC!]3@9S[UT-1P016MO';P1I%
M#$H2.-!A54#  '8 5)0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !4</\ J_\ @1_F:DJ.'_5_\"/\S0!)1110 4444 %%%% !5'2_]7<_]?4O
M_H57JY#3/%MLL^I[[2X32[6ZN%FU1R@@5D)+#[V[ Z9QC/% '7T5S3>/_"Z6
M27;:J@B>1H@#%)OWJNXJ4V[@=I!Y'3FHS\0_#:WE]!)>M&EE'#+).T3>4RRX
MV%6 YSD?GQWH Z=_N-]*K:7_ ,@FR_ZX)_Z"*Q;OQSH,0N8(;U)KR.W>9;?:
MR[RL?F;-Q& VWG;U'I6IH%Q]J\.:7<[=OFVD4FW.<90'% $U]I>GZFJ+J%C;
M7:QG*">)7"GVR.*+'2]/TM'33[&VM%<Y98(EC#'U.!S5NB@ HHK$\4>);;PK
MI(O[BWN+G=($2&W4,[<$D@$] JLQ]A0!<O=#TG4IA-?Z7974H7:'G@5R!Z9(
MZ58M+.UL+=;>SMH;>!<[8X4"*,]>!Q7+7_Q!LK&_N(_[/O)["UB@FN;^'88X
MDESL8C=N(XY(!P*FF\=64,VI2&RO&TO36>.ZU%57RDD1=S*!G<<=,@8R<4 =
M5169HNJSZM;-+/I5YIQ&"J76S+J1D$;2?Q!Y%:= &9<^'-#O+A[BZT;3YYI#
MEY);5&9C[DC)K1CC2&)(HD5(T4*J*,!0.@ ]*=10!1?_ )#L/_7M)_Z$E7JY
MK7M>_LCQ#I]O!87.H7EU;S>7;VVT':I0LQ+$ #IWY)Q4P\::!]N:QDOUBO$C
M+R0NC93";V4D#;O"\E02: -^BN3F^)/AA+:">&^>YCFNHK4&"!V*M(,J2,9V
MD#J.O;-69/'GAF**65M43;%,;=ML3L?,&=R@!<G&#G&<=\4 :MI_R%-0_P!Z
M/_T&KU<]H.M0:KKVM1VVUX(A;/'.CY659(]P(]JZ&@ HHHH **I:OJ<&C:3=
M:C<AC%;QERJ#+-Z*/<G 'N:YUO'T,ECH\UEI%]=W&I^<$M4*+)$T7^L5MS
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M@8QT["N[HHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M4PWFKW&I$8"/-&BE5 QCY0,GU)K3J/R5]7_[[-'DKZO_ -]F@"2BH_)7U?\
M[[-'DKZO_P!]F@#G]=\/3:KK^G:A:7UQI]U9P2JES"BN"'*Y1E8$$<9'N*H/
M\/+>6XG:75KV2WEEEN1;E4PMQ)$8VER!GHS';T!/X5U_DKZO_P!]FCR5]7_[
M[- ')-\/K78ABU&YBFB%D8I JG:UJ"%.",'(8Y%.?P%$MM:BSU6[M;JUN+F>
M*Y1$8@3DF12I!&.>#U&!75^2OJ__ 'V:/)7U?_OLT 8'ACPQ;^&[N^2T,OV=
MX[>*,2$'Y8X]O7N?6NCJ/R5]7_[[-'DKZO\ ]]F@"2BH_)7U?_OLT>2OJ_\
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M(/S'!SRQJ2@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
L* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>56
<FILENAME>g4i5nix4zlkt000016.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g4i5nix4zlkt000016.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &$ J # 2(  A$! Q$!_\0
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M!..I/I6E9>,=5O\ 0+N:/2(TU6SN#;7$,DP6)#UW;O[N* .UHKS*\\;W6L>
M_$;JHL]1T[$4DEO)N3GHR-]*R9/$.L6O@>XTF[OI/[7L'MW%R&PT\#D$-^I!
MH ]CS17D6K^)M4LOB'JVC6ER_GWT4,-IYK8B@+ ;F_WO0=Z],TFP.CZ/%;27
M,MR\29DFE.6<]S0!H9I:\RT'2+SQW;W>NZEJU];%KAX[**TF*+"JG )'<G%3
M:C\09=)N+NRLXH;V+1T47TUQ,$DE..1&.Y H ]$,B D%U! R03VIP(89!!!Z
M$5Y#K^H)J?B2_O;9V^SW'AUY4[=:V-.\6WUJNAZ#IUG!+.-/AFD:XEV;U(QA
M/[QH ]'HI%)*@D8..12T %%%% !17G?Q6\07^AVVCK9ZC_9\=W="*>XV[MB^
MM,^&WB;4M8U?6]/EU&/5M/L9 L-^$"%B?X2._P!: /1Z*** "BBB@ HHHH *
M**Q_$7B*U\-V45Q<I)(9I1%''&,L['H!0!L45RMOXXMY+2ZDFTZ\AN+6X\B:
MV"[W4XR#QVJEJGBZZOK>QL]&AFMKV^N/)#SQX,2@99P#UXH [>BN,\':KJ+:
MCKNE:G>B\73)5"W93:6!!)! ],5SMYXH\0"QC\5+?)#I[7XMXK#RP1)%D@L6
MZYX- 'JM%>8S^(/$,MK'XECOTALGOEMX-/\ +!$D9;;N+=<]ZMWGBK6+_P :
M:1:Z84AT=KAHIG*Y:X*CDK_L@]Z /0Z*** "BBB@#G?&^GZKJWA2\T_1V1+J
MY CWNV-JD\_I7 ZA\(;K3;31KS0-2NI]2TR5'CBNYLQ ?Q;>.*]@HH ;'N,:
MEQAB!N ]:=110 4444 %%(V2I X..M<C-X>\5-/*\7BQTC9B40VR':/3I0!U
M]%<8?#OC'MXN_.U3_"F'P]XT[>+E_&U7_"@#MJ*X<^'O'';Q;%^-JO\ A3?^
M$?\ 'G;Q9;_C:C_"@#NJ*X3^P?B!V\5VA^MJ/\*!H?Q!'_,SV1_[=O\ ZU '
M=T5PW]C?$ ?\S)8'ZVW_ -:G#2?B .OB#3C_ -NY_P * -+7O#D^K>)-"U.*
M9433I6D=2.6R,4R_\+-?^,O[8DE7[,VGM9M'CD[B>?UJD-,\?C_F.:8?^V!I
MXT_QZ/\ F,:6?^V+4 9WA[PAK.A7-K8_9M(FT^V<[+IHOWI3.0,>OO67??#7
M6;N6]MFNK62">]%V+R4%IL Y">P'K73_ &+QZ/\ F*:0?^V+4X6OCP?\Q#1C
M]8GH JW_ ('GO]2\13M=(L>J6B0(,<HR@<G\J</#FN:EI&AQ:K-:I=Z;=K*S
M0@[715('XFK/D>/!_P O>BGV\MZ-GCP?\M=%;_@+T 5+_P *(M]XHU*_F#V6
MHV@3RU'S+M'^-,^%.EW=GX22_P!2>274+]O,DDD^\4'" _05=/\ PGF,%=$;
MZAZ3=X]486'1,>@W_P"- &?=>&_%%CXKU34]"NK)(M2"!S<)DQ%>X'?K4A^'
MAA\-?9+>^)U878OOMCKP\X.>1Z=JM&;Q^/\ EVT8_P# G_QIIN?B /\ EQT<
M_P# V_QH I/X4\0:X;Z]URXM8[M[&2RMHH!E4#_>8GN35^Y\'W-Q)X;/VE%3
M2X&BF&/OY0+Q^5,-Y\0!_P PW23_ -M&_P :3[?\0!_S"-+/_;8_XT 9:>"_
M$DMC!X;N[ZU?08)E<3;?WSHK9"8[?6NI\.:#+HMYJ\KR*R7MT9HU7^!<  ?I
M63_:7Q '71--/TG/^-+_ &IX]'70; _2X_\ KT :WBC0I==CTY8I5C-K>1W#
M9'4*>E9&I>!3<?$'3_$EI<B&*-MUU;GI*P!"L/>E_M?QX/\ F7;(_2Y'^-']
ML^.A_P RS:G_ +>A_C0!2?X>7'V"[:&\6'5%U!KZRND&#'G'RGU!]*Z37/#Y
M\3>%6TO4I D\B*3)'T60<AA^-8_]M^.A_P RO;'Z7:_XTO\ ;OCG_H5(/_ Q
M: *R^'O%VKVDNC:]?V(THQ&)Y+>,^;,,8!_V:?X<\-ZUI=W!;W5II'V2VC*+
M<Q1?O9 !A3_LG'4U-_;WC?OX2A_\#%IW]O\ C0#_ )%",_2]2@"#3?!%W9)I
M(-TA:QOKBZ)Q]X2 X_+--T3PIJZ>,!KFH_8K5HXVC86(*BZR>&<=!BK(\0^,
M?XO!X_"\2G?\))XL'7P<_P"%VE '8T5R \2^)^_@Z?\ "Z2E'B?Q'W\'77_@
M2E '745R)\4^(!U\'W?_ ($)3#XNUT?\R=>_]_UH [&BN,_X3+6QU\'7_P#W
M]6FGQMK Z^#M1_!UH [6BN(;QUJBKG_A#]4/L"*[&UF:XMHY7C:)G4$HW5?8
MT 34444 %%%(>G% '-ZSX<GU+Q;HFL),JQ:?OWH1RVZL'5? FI3V]\;:ZC9Y
M=2%\(')"2J !L;'TK4GN/'@N)1!9Z0T(;]V69LE??FHS=_$ ?\P[23_VT;_&
M@#*MOA[J'_"/^)+2:XMH[C6G20+"F$AP,8]_K5GQ5\/9->L]':UNA;WUBL<<
MKX^6:-<94^O(XJU]N^( _P"85I1_[:G_ !I/[1^( _Y@VF'Z3'_&@!E]X!&J
M:WKEU>2J8+^&-8=HP\,B='!]<UTN@V^HVNC0VVK3)<748V-*H^^!T)]ZYT:I
MX^'70M//TG_^O2_VMX\[^'[(_2X_^O0!4@\->*O#EW=6_AR\LGTNZG,RK=J2
MUN6Y8#^\*KR^"=8T[6+V[TY-,OTU K+/]LCYCE P2OJI]*T_[8\=C_F6[0_]
MO(_QI/[:\=?]"Q;?^!0_QH ;J?@JZU#5;B\$\,:S:6;(HBX"L>X'I5'6O!FM
M:CI^G:3&-/-M!#&GVME(FMV7&2I[YK1_MSQS_P!"K;_^!:_XT?V[XX_Z%.'_
M ,#%H [&",Q01QEBY10I8]3@=:DKC!KWC7OX1B_"]2M/0]4\07MV\>JZ"MA"
M%RL@N%?)],"@#H**** .$^)7AG5O$,6DR:5#;3O977G/#<-A7'I4/@_PIJ]I
MXPU+Q'JEO9Z>+F%8([*S.4 '\1[9KT&B@ HHHH **** "BBB@ KB?&%GJ^I^
M)M"@TP+&MLSW+SRQ[XP<$ $5VU<OXY\;V'@71/[0O$>5W;9#"AP7;Z]J *]G
MX#MY-/E76+F2ZO;BX-S//$QCRQ[#'8>E-OO!<ML--F\/72V]S8/(4^U9E#!Q
M@YR:H>#?BYH'BJPEFGFCTVXB;#0W$@Y'8@UTW_"8>'/^@U8_]_A0!FZ3X4O-
M,B\LZ@LHNF>347:/YIW;^Z?X0/2LVP\ WRI;:;J6I1SZ+9.[P0)'M9V.=I<]
M]N372?\ "8>'/^@W8_\ ?X4?\)AX<_Z#=C_W^% '.V'@2_)L;+5M1BN=*TXL
M;>"./:SYR!O/? -.L/ACIFF^++36+:>98+6-EBMBY*JQZG_ZU=!_PF'AS_H-
M6/\ W^%<!J_QYT+3/%']E16TES;(X22[C<;<GN/4"@#UJBHK:XCN[:*XA;=%
M*@=#Z@\BI: "BBB@ HHHH *R=<O=5LX4_LK3TNYF)SYC[54#U-:U<SXT379]
M*6TT2$-Y[;;F3?M=(^^WW- &;%X\GU"RTU--TW?J5[YG[B5\+'Y>=Q)';(XK
M3T?QKI.HZ8ES=W4%A.&:.6">559&7@_A7/'1M5TZ?1=8TO1U!LX'MI+ R_-@
M]&W8Y.>M&F?"G1+ZR%SXETV*YU.:1I9"'.$W'.WCKB@#O;/4;+449[*[AN%4
MX)B<,!^56:\E^!]O%:6WB2V@79%%J<B(OH < 5IW7C&/0_B?J%IJM[(E@;-'
MAC"%@&SSTH ]'S17D7_"67][X5\:ZE97TAC@N0EFY&#&I('%6+D:IX(TC2O$
M,.M7=[:SR1)>6MT0P82?Q+Z$&@#U6BO.O'-YK5AK>A7EOJ9CL9[R.$6J+]X$
M<EC7HM !1110 4444 %%%% !45S=06<+37,R0Q+U=VP!^-2U0UC1K'7M-DT_
M4H!/:R??C)QF@!D'B'1KJ98K?5+.61ONHDRDG\*TJ\+U[PCH?A7XK>$HM%LE
MM5E):3:Q.XY]Z]1\>7=U8>"-4N[*4Q7$4.Y''4&@#H\T5Y%J_P 1+>Y\*:'#
MIFHRC5))K993Y9&[(^?)K0N[:^\1_$[4]+;6;VRMK.TBDA6V8#YF R30!Z;1
M7!>&[W4]:M=<\-7VI2+?:;-Y OX1AV0CY3Z;O6HO!QO+#QKJVB0ZG=:CIEK"
MC-)<$,8YCU4'Z4 >A4444 %%%% !1110 4444 4[W5=/TXJ+V]@MB_W?-D"Y
M^F:++5M/U$L+*]M[@IRPBD#8^N*S/$7@O0/%<D#ZU8+=- "(]S$8SUZ5Y_\
M#'2;+0_BEXTT[3X?)M(1$(X\YVB@#UZEKS>Y\91Z'\4=2L]5O9$L/L:-#&$+
M ,<9Z5F/XKO;WPEXTU*QOY#'!=;+1RN#&I(''YF@#UNBO*[I=3\#Z1I?B&'6
MKN]M)7B2\M;LA@P?^)<="#2_$.ZBL)/MJ>(=0@U*14^PVD0_=AB1C/'0]\T
M>IT56TYIWTVU:Y*F<Q*9"O0MCG'XU9H **** "BBB@ HHHH 0D*"2< <DUEG
MQ-H2L5;5[$,#@@SKU_.M-T$B,C#*L,$>U>*?%CX=>%]#\#7^K:=I:0WJRH1*
MK'C+#- 'M:.LB!T8,K#((/!IU97AG_D6-,_Z]D_E6K0 4444 %%%% !1110
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M^!?_ "3> 9)Q<2@9_P!ZO2Z "N5\>>!K+QWH8L+J1H9(VWPS*,[&^G>NJHH
M\Z\&?!_0/"]C+'=Q1ZG<2MEIIDQ@=@!73?\ "$>&?^@):?\ ?%;]% &!_P (
M1X9_Z MI_P!\4?\ "$>&?^@+:?\ ?%;]% &!_P (1X9_Z EI_P!\5Y_J_P
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M>Z@;NLEJX(_2J^I?&'PE:Z/=7=KJ"W$\2_);A2K.W8<T <[)!XR3X@P^&/\
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M% !574O^05>?]<'_ /035JJNI?\ (*O/^N#_ /H)H \^^!?_ "3B'_KYE_\
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MQBA:&/RQMC;J@QT-6JS]#:\?0K%M0&+PP(9A_M8YJ/7=?T_PYIKW^HR,D"$
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MZYL3&-HP>V*=0!Y)\"[<VEEXBMVE:4Q:DZ&1S\S8XR?>MS3?^2VZQ_V#(_\
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MQ>H_$K2=/UB[TL6E_<W%H0)OL\!<*3VS2Z=\2M)U#6+33#:7]M<79(A^T0%
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M.#7=5YI;^=\,==%J^7\)W\O[E^IL93_"?]@_I7I2LKJ&4AE(R".A% "T444
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M9Z;:^'4N9((D23R;Z-R   2!GI7I\;,T:LR[6(R5]* '4444 %%%% !1110
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MNQJKJ7_(+O/^N#_^@F@#S[X%<?#>$#H+B4#_ +ZKTNO-/@7_ ,DXA_Z^9?\
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MDY8'\<UUE !1110!7N+&TNV4W%M%*5^Z70'%>8^ 8HX/C#XYCBC6.,>3A5&
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M\DXA_P"OF7_T(UZ77FGP+_Y)Q#_U\R_^A&O2Z "BBB@ HHHH **** "BBB@
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MQG>X@(CDV-@!!W_*I/L/QD_Z"ND?]^16==>%OBO=ZU9ZM+J6E&[LU982(P
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MIH9KJ7399(3^[9W4E:N_VYI(_P"8E9_]_E_QK'_X5WX5QC^R8_\ OIO\:/\
MA7?A7_H$Q?\ ?1_QH V/[=TG_H)V?_?Y?\:3^WM'_P"@I9_]_P!?\:R?^%>>
M%O\ H$1?]]'_ !H_X5[X6_Z!$/YG_&@!-3@\&ZO=Q76H2Z9//%PKO,N?7!YY
MJ2Z_X1*\%T)[C3G^U*JS?OU^<+T[]J9_PKWPK_T!X/U_QIW_  K_ ,+#_F#P
M?K0!%#;^"X-(ETJ.32Q92G,D7G*0Q]3S5G2KGPKHEI]ETZ\TZWASG:LZ\G\Z
MC_X0#PO_ - >#]:7_A ?"_\ T![?\C0!'JJ>#=;FAEU*?3+B2+[C/.N1[=>E
M/N'\'W0N!<7.F2+<PK!,K3+AXUZ*1GH*=_P@?AC_ * ]O^5*/ GA@?\ ,'MO
M^^: *,-EX%M[:>VBETQ(9P!(@N!@@=.]7=)N?">A6AM=.O=-MXBVXA9UY/J3
MFG?\(-X9_P"@-;?]\TO_  @_AK.?['M?^^: *VKGP9KWE'4[G3+DQ'*%YUR/
MUJ8W7A$S>:;S3-WD?9O]>N/+_NXSTJ3_ (0GPU_T!K7_ +XI?^$*\-_] >U_
M[XH HV,7@?3;6XMK2;2HX;@;9E$ZG>/0\]*ETB;P=H,+Q:9>:9;*YW-MG7)/
MUS5K_A#/#@_Y@UI_WQ2_\(;X<_Z ]I_W[% $_P#PDVA?]!BP_P# A?\ &C_A
M)M"_Z#%A_P"!"_XU /!WAT?\P:S_ ._8I?\ A$/#O_0'L_\ OT* )O\ A)M"
M_P"@S8?^!"_XUGQ7W@Z*[FNHKO2EGF&))%E3+#\ZM_\ "(^'O^@-9_\ ?H4?
M\(CX>_Z UEQ_TR% %">?P3<1Q1S7&DND)RBF5<+^M27FI>#]02%;N]TN982#
M&&D7Y?I5S_A$_#__ $!K+_OR*7_A%/#XZ:-9?]^10 @\4^'D4*-8L  , "9<
M52BU7P=;WTEY%>Z6ES*,/(LBY(J__P (KH&,?V/9?]^5I?\ A%]!QC^Q[+_O
MPO\ A0!E3W_@>YB2&:ZTIXXP0BEU^4'KBFS7O@6=($FN=*=8/]4K2#Y:V/\
MA&="_P"@18_]^%_PI?\ A&]$SG^R+'_OPO\ A0!7'B[PVJA1K-B% P )1Q5*
M/6/!<5])?1WNF+=.,/*'7)%:W_".:)_T";+_ +\+_A1_PCFB<_\ $HL>>O\
MHZ_X4 8T^J^"+BS6UFN]->W#[PA88#>M+>:SX)OK>*"ZO--EBB(,:,PPN/2M
M@>'=% _Y!%C_ . Z_P"%+_PCVB_] FQ_\!U_PH HKXQ\,Q(J)J]FJ@8 #C %
M._X37PU_T&;3_OX*N?\ "/:+_P! FQ_\!U_PH_X1[1?^@38_^ Z_X4 4?^$X
M\,_]!FU_[[JO>>+?"-_:2VMWJ=G-!*NUT9L@BM;_ (1[1?\ H$V/_@.O^%'_
M  CVB_\ 0)L?_ =?\* .4L[[X>:?826=M=6*022+(Z[\[F!R,GVI&U#X>-K8
MU=[NS>^#;Q(SDX;&,XZ9KK/^$>T;_H$V/_@.O^%'_"/:+_T";'_P'7_"@#DS
MJ?P[.M?VP;FQ^W9W>9GJ?7'K6S_PGWA;'_(9MOSK3_X1[1?^@38_^ Z_X4?\
M(_HW_0)LO^_"_P"% '(6NI_#FRU*;4;>YLDN9@0S@GOUQZ9J&YO/AI=Q6\<T
M]FRV^1#\Q^3/7%=K_P (_HW_ $";+_OPO^%+_P (_HW_ $"K+_OPO^% '$W-
M_P##:\AM8KB[MGCM5V1J7;A<YQ[UN1>/_"$$*1Q:M;)&@VJJ@X K:_X1_1O^
M@59?]^%_PH_L#1O^@59?]^%_PH XW5-<^'.L7T5]?W5I-/%C#D'G'3/K5?Q#
MXT\"P:/JMW&UK>S30@20'.)@.@KNO[ T?_H%67_?A?\ "J&L^#M&UC1[K3C8
MV]NMPFPRQ0J&7W!QUH XKP/XG\ >*]+;0K*S6WEN?GELI5)9B/XMW?%>C:3H
M]AHEG]ETZV2"'.XA>Y]2>]9OAOP1H'A6V2+2]/BC=1S,RYD8^N:Z&@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M ?NB6&K&^NFC$)C14W$L><YQC'I5'7M=N]*O$6W2WG41-*\'/FE%!+/GHJC
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
? **** "BBB@ HHHH **** "BBB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>57
<FILENAME>g4i5nix4zlkt000049.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g4i5nix4zlkt000049.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" )- A # 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#T3P;X-\+W
MG@;P_=77AO1Y[B;3;>2666QB9Y&,:DLQ*Y)).236W_P@G@__ *%30_\ P70_
M_$T>!/\ DGGAG_L%6O\ Z*6N@H Y_P#X03P?_P!"IH?_ (+H?_B:/^$$\'_]
M"IH?_@NA_P#B:Z"B@#G_ /A!/!__ $*FA_\ @NA_^)H_X03P?_T*FA_^"Z'_
M .)KH** .?\ ^$$\'_\ 0J:'_P""Z'_XFC_A!/!__0J:'_X+H?\ XFN@HH Y
M_P#X03P?_P!"IH?_ (+H?_B:/^$$\'_]"IH?_@NA_P#B:Z"B@#G_ /A!/!__
M $*FA_\ @NA_^)H_X03P?_T*FA_^"Z'_ .)KH** .?\ ^$$\'_\ 0J:'_P""
MZ'_XFC_A!/!__0J:'_X+H?\ XFN@HH Y_P#X03P?_P!"IH?_ (+H?_B:/^$$
M\'_]"IH?_@NA_P#B:Z"B@#G_ /A!/!__ $*FA_\ @NA_^)H_X03P?_T*FA_^
M"Z'_ .)KH** .?\ ^$$\'_\ 0J:'_P""Z'_XFC_A!/!__0J:'_X+H?\ XFN@
MHH Y_P#X03P?_P!"IH?_ (+H?_B:/^$$\'_]"IH?_@NA_P#B:Z"B@#G_ /A!
M/!__ $*FA_\ @NA_^)H_X03P?_T*FA_^"Z'_ .)KH** .?\ ^$$\'_\ 0J:'
M_P""Z'_XFC_A!/!__0J:'_X+H?\ XFN@HH Y_P#X03P?_P!"IH?_ (+H?_B:
M/^$$\'_]"IH?_@NA_P#B:Z"B@#G_ /A!/!__ $*FA_\ @NA_^)H_X03P?_T*
MFA_^"Z'_ .)KH** .?\ ^$$\'_\ 0J:'_P""Z'_XFC_A!/!__0J:'_X+H?\
MXFN@HH Y_P#X03P?_P!"IH?_ (+H?_B:/^$$\'_]"IH?_@NA_P#B:Z"B@#G_
M /A!/!__ $*FA_\ @NA_^)H_X03P?_T*FA_^"Z'_ .)KH** .?\ ^$$\'_\
M0J:'_P""Z'_XFC_A!/!__0J:'_X+H?\ XFN@HH Y_P#X03P?_P!"IH?_ (+H
M?_B:/^$$\'_]"IH?_@NA_P#B:Z"B@#G_ /A!/!__ $*FA_\ @NA_^)H_X03P
M?_T*FA_^"Z'_ .)KH** .?\ ^$$\'_\ 0J:'_P""Z'_XFC_A!/!__0J:'_X+
MH?\ XFN@HH Y_P#X03P?_P!"IH?_ (+H?_B:/^$$\'_]"IH?_@NA_P#B:Z"B
M@#G_ /A!/!__ $*FA_\ @NA_^)H_X03P?_T*FA_^"Z'_ .)KH** .?\ ^$$\
M'_\ 0J:'_P""Z'_XFC_A!/!__0J:'_X+H?\ XFN@HH Y_P#X03P?_P!"IH?_
M (+H?_B:/^$$\'_]"IH?_@NA_P#B:Z"B@#G_ /A!/!__ $*FA_\ @NA_^)H_
MX03P?_T*FA_^"Z'_ .)KH** .?\ ^$$\'_\ 0J:'_P""Z'_XFC_A!/!__0J:
M'_X+H?\ XFN@HH Y_P#X03P?_P!"IH?_ (+H?_B:/^$$\'_]"IH?_@NA_P#B
M:Z"B@#G_ /A!/!__ $*FA_\ @NA_^)H_X03P?_T*FA_^"Z'_ .)KH** .?\
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M9:'I6V\>[M)(")&0KY*[P/,((Y*@CWY% $=KXO\ %GB_QWK&G:!J7]G1:;/
M(;>YT]PDL66,IE+1%D8X& 2GH.>:Z/X@>.+W1=7T?PQH20MKFL2!$EF7<EM&
M3M\PKW/4CM\ISGH<7X>+<P_%'QE>3Z9JMO:ZG*CVDUQI\\22!=Y/S,@"]1][
M&>U3_$KPGJ\GC#P_XVT6U:^DTDJMU9QX\QX58L2@)PS89QCKDC&: .FN=/\
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M'0;3MXR.G:MW5?BAI>B:[?Z+<:;J\]W869O)'BCB*O$ "6SO&, D_,%Z8')
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M);((+$\?0PS@9Z]\4 +16%XCT*\\00K:1ZW?Z5:[27DTZ01SN^1M^<@X4<Y
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M,C3P';*J,"0%D)*Y(Y S[5'IGPVO+&]U_1]7T2]U;2M0O#<VMS#JK10 L?\
MEO")4)VX4E@K'CC.!7L]% 'C/B3PAXDG\>>(=0LM#N)[*[T%],MY5N(1ND**
M <-*&"\=3S[&HK_P)XFN?A-X4TR+2S_:FCWRSSVC3Q NH9^5;=L_B'4U[710
M!#:R336T<D\!MY&&3$6#%/8D<9]<9&>A/6N3U&UU6:^UFVU;PZFO:!=3(UK
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M .QK7_GK??\ @?/_ /%T?V-:_P#/6^_\#Y__ (NM"B@#/_L:U_YZWW_@?/\
M_%T?V-:_\];[_P #Y_\ XNM"B@#/_L:U_P">M]_X'S__ !=']C6O_/6^_P#
M^?\ ^+K0HH S_P"QK7_GK??^!\__ ,71_8UK_P ];[_P/G_^+K0HH S_ .QK
M7_GK??\ @?/_ /%T?V-:_P#/6^_\#Y__ (NM"B@#/_L:U_YZWW_@?/\ _%T?
MV-:_\];[_P #Y_\ XNM"B@#/_L:U_P">M]_X'S__ !=']C6O_/6^_P# ^?\
M^+K0HH S_P"QK7_GK??^!\__ ,71_8UK_P ];[_P/G_^+K0HH S_ .QK7_GK
M??\ @?/_ /%T?V-:_P#/6^_\#Y__ (NM"B@#/_L:U_YZWW_@?/\ _%T?V-:_
M\];[_P #Y_\ XNM"B@#/_L:U_P">M]_X'S__ !=']C6O_/6^_P# ^?\ ^+K0
MHH S_P"QK7_GK??^!\__ ,71_8UK_P ];[_P/G_^+K0HH S_ .QK7_GK??\
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MT :%%9_]G77_ $&;[_OB#_XW1_9UU_T&;[_OB#_XW0!H45G_ -G77_09OO\
MOB#_ .-T?V==?]!F^_[X@_\ C= &A16?_9UU_P!!F^_[X@_^-T?V==?]!F^_
M[X@_^-T :%%9_P#9UU_T&;[_ +X@_P#C=']G77_09OO^^(/_ (W0!H45G_V=
M=?\ 09OO^^(/_C=']G77_09OO^^(/_C= &A16?\ V==?]!F^_P"^(/\ XW1_
M9UU_T&;[_OB#_P"-T :%%9_]G77_ $&;[_OB#_XW1_9UU_T&;[_OB#_XW0!H
M45G_ -G77_09OO\ OB#_ .-T?V==?]!F^_[X@_\ C= &A16?_9UU_P!!F^_[
MX@_^-T?V==?]!F^_[X@_^-T :%%8UAJMK_;UWHAU"YN;V")96$L:A0.,JI50
M"0'C)'82)ZULT %%%% !7/\ CO\ Y)YXF_[!5U_Z*:N@KG_'?_)//$W_ &"K
MK_T4U !X$_Y)YX9_[!5K_P"BEKH*Y?PG?6VF?"S0K^\E$5M;:+;S2N03M585
M).!ST%6/#_BC^W)I(I-)OM/;!>+[3L82(-N3E&8*1O7Y20>>,X. #H**Q-(\
M466LV.H7D%O?11V-P\$BSVK)(Q50V5C^^<AA@$!CZ=*2P\307,U_!>V5YI<]
MC"MQ-'>B/_5-NPX:-V4CY&'7(QR* -RBL71_$L&KW'V<V5[93/"+F%+N-5,T
M).-Z[6..2,JV&&1E1D5M4 <_X[_Y)YXF_P"P5=?^BFKH*Y_QW_R3SQ-_V"KK
M_P!%-704 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !6/XA\2:?X;LEFNY5-Q,?+M+53^\N9?X8T'<DD
M#/09YJQK5U>VVAZA<:5;I=ZA# [00$\/(%RJGGUQQD5XIX1^&GBOQ;XE7Q9X
MZOKVS>-]T$$<IBGX/ &W_5)[##'GIU(!Z;/H=UIGAVUOHA]HUJQE:_F,0YN9
M&SYZ#V92RJ#T(C_NBNHM;J"^LX+NVD66WGC66*1>C*PR"/J#6+_PANE_\_6N
M?^#Z]_\ CU:NEZ9::/IT.GV*.EM""$5Y6D(R23\S$D\D]30!;HHHH *Y_P =
M_P#)//$W_8*NO_135T%<_P"._P#DGGB;_L%77_HIJ *OA:6&'X4Z))<V[W,"
MZ);F2%(O,,B^2N5"?Q9';O6'X'U6VC\27.B:#>IJ6AA))MR2&;[$04"*9<DD
M."^%;YAY9P<<#IO G_)//#/_ &"K7_T4M;R1I'NV(J[CN; QD^I]Z .(\&>(
M-&FE\6W4>K6#01ZH\TDJW"%5C\J,!R<\+E6YSC@UE3V5WKMOXRAT;75URQU'
M3"L,X,3>7<8<>2LD8 *X(.W^'=D_>);TZB@#B;"_MO$?C71[W2Y%EMM/TV<7
M+)R(I)3%MB;T<;&)4X(XR!D5VU%% '&?$*#76\(>(Y+?4=.CT\:9<%H)+!WE
M*^4VX"03  GG!V<>AKI/)U?_ )_K'_P#?_X[6=X[_P"2>>)O^P5=?^BFKH*
M,_R=8_Y_K'_P"?\ ^.T>3K'_ #_6/_@$_P#\=K0HH S_ "=8_P"?ZQ_\ G_^
M.T>3K'_/]8_^ 3__ !VM"B@#/\G6/^?ZQ_\  )__ ([1Y.L?\_UC_P" 3_\
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MK0HH S_)UC_G^L?_  "?_P".T>3K'_/]8_\ @$__ ,=K0HH S_)UC_G^L?\
MP"?_ ..T>3K'_/\ 6/\ X!/_ /':T** ,_R=8_Y_K'_P"?\ ^.T>3K'_ #_6
M/_@$_P#\=K0HH S_ "=8_P"?ZQ_\ G_^.T>3K'_/]8_^ 3__ !VM"B@#/\G6
M/^?ZQ_\  )__ ([1Y.L?\_UC_P" 3_\ QVM"B@#/\G6/^?ZQ_P# )_\ X[1Y
M.L?\_P!8_P#@$_\ \=K+\2:[$DL?AVPO477-0_=Q1QMF2",_?F([!5#$9X+
M#O2^&Y%TNZN/#$LK%[-?-LC(^YI+1C\O)Y.QLQGV"$_>H T_)UC_ )_K'_P"
M?_X[1Y.L?\_UC_X!/_\ ':T** ,_R=8_Y_K'_P  G_\ CM'DZQ_S_6/_ (!/
M_P#':T** ,_R=8_Y_K'_ , G_P#CM'DZQ_S_ %C_ . 3_P#QVM"B@#/\G6/^
M?ZQ_\ G_ /CM'DZQ_P _UC_X!/\ _':T** ,_P G6/\ G^L?_ )__CM'DZQ_
MS_6/_@$__P =K0HH S_)UC_G^L?_  "?_P".T>3K'_/]8_\ @$__ ,=K0HH
MS_)UC_G^L?\ P"?_ ..T>3K'_/\ 6/\ X!/_ /':T** ,_R=8_Y_K'_P"?\
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MQ_\  Q__ (U2>=K'_/C8_P#@8_\ \:H T**S_.UC_GQL?_ Q_P#XU2^=J_\
MSXV/_@8__P :H OT5G^=K'_/C8_^!C__ !JCSM8_Y\;'_P #'_\ C5 &A15#
MSM7_ .?&Q_\  Q__ (U2>=K'_/C8_P#@8_\ \:H T**S_.UC_GQL?_ Q_P#X
MU2^=J_\ SXV/_@8__P :H OT5G^=K'_/C8_^!C__ !JCSM8_Y\;'_P #'_\
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M;EM?%%YKFE7\FF:/:FTD9998M3EE9H'&'3:;=<\A&'(Y1>V:W?.U?_GQL?\
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MZ*:N@H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MH77_ $!K[_ON#_XY6A10!G_VA=?] :^_[[@_^.4O]H77_0&OO^^X?_CE7Z*
M,_\ M"Z_Z U]_P!]P?\ QRC^T+K_ * U]_WW!_\ '*T** *']H77_0&OO^^X
M?_CE)_:%U_T!K[_ON#_XY6A10!G_ -H77_0&OO\ ON#_ ..4O]H77_0&OO\
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M01YO2MVUMHK.TAM8 5AAC6- S%B% P,DY)X'4\T 4H[R:*-8X]$O$1 %55:
M #V'F=*=_:-U_P! :^_[[@_^.5H44 9_]HW7_0&OO^^X/_CE']HW7_0&OO\
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M[_P G_\ B* -"BL_^V;7_GE??^ $_P#\12_VQ:_\\K[_ , 9O_B* +]%9_\
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M[9M?^>5]_P" $_\ \10!H45G_P!LVO\ SROO_ "?_P"(H_MFU_YY7W_@!/\
M_$4 :%%9_P#;-K_SROO_   G_P#B*/[9M?\ GE??^ $__P 10!H45G_VS:_\
M\K[_ , )_P#XBC^V;7_GE??^ $__ ,10!H45G_VS:_\ /*^_\ )__B*/[9M?
M^>5]_P" $_\ \10!H45G_P!LVO\ SROO_ "?_P"(H_MFU_YY7W_@!/\ _$4
M:%%9_P#;-K_SROO_   G_P#B*/[9M?\ GE??^ $__P 10!H45G_VS:_\\K[_
M , )_P#XBC^V;7_GE??^ $__ ,10!H45G_VS:_\ /*^_\ )__B*/[9M?^>5]
M_P" $_\ \10!H45G_P!LVO\ SROO_ "?_P"(H_MFU_YY7W_@!/\ _$4 :%%9
M_P#;-K_SROO_   G_P#B*/[9M?\ GE??^ $__P 10!H45G_VS:_\\K[_ , )
M_P#XBC^V;7_GE??^ $__ ,10!H45G_VS:_\ /*^_\ )__B*/[9M?^>5]_P"
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MD- N"JZIH]_9,3@M"RSJOU/RG\A7=W_P]TN92U@[V,@!V!"2BGY2O (( V(
M%92 J;2IBA:+DM3^'E_!)N_LRPU2-=J1^9;Q2,%'*C:P4#NF%*C! !C1D-F
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MAO;_ % JTZH3Y:$;NA/+$[N6('T]?0J* "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBN5\7^++;1+5(H[L)*[CSY8E\Q[:'+;Y O()&Q^#V21L,(G%
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M//#/_8*M?_12ULWINEL9S8K$]V$)A69B$+8X#$<@9K&\"?\ )//#/_8*M?\
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MG[HGD#.?GC)_$>F[CZ;KF/'O@VU\<>%KC2I]J3C]Y:SD?ZJ4=#]#R#[$]\4
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M*PP5! !7MM,T*[A$]OIUA(A)&1;KPP)5@>.""""#R""#4O\ 86D?] JQ_P#
M=/\ "N*G\+ZYX9>.?0+IYXMPW1JB@@J,+E,JA!4!<#:!@+\B>4]IJZ1X_L;K
MS$U15L)$YW,3LP-V[)(!7;L?.X#A')"M',D0!T']A:1_T"K'_P !T_PI?["T
MC_H%6/\ X#I_A5^B@#/_ +"TC_H%6/\ X#I_A1_86D?] JQ_\!T_PK0HH H?
MV%I'_0*L?_ =/\*3^PM(_P"@58_^ Z?X5H5G:IKFFZ/"TE[=1QD8^0L-W.X@
MX[#".2QP J.Q("L0 +_86D?] JQ_\!T_PJ*YTWP_90M/=66F01*"S22Q1JH
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M37M1@@&F7#&SCCMS$P$39!+1%\'OAL\\$5TG]GW/_08OO^^(?_C= %^BL_\
ML^Z_Z#-]_P!\0?\ QNC^S[K_ *#-]_WQ!_\ &Z -"BJ']GW7_09OO^^(?_C=
M)_9]U_T&;[_OB#_XW0!Y+\<? \[I%XXT/=%J6G[6NC%PQ1?NRC_:3 S_ +/^
M[7<_#7QS!X[\+1WN434(,17L(/W9,?> _NMU'XCL:Z!],GD1D?5KQT8$,K1P
M$$'L?W=?.^L6%]\$?B3#>V,UU_PCNH\,R;2QCR-Z<C;O4\CCH0,\F@#Z9HK)
MLXFU"R@O+37KR:VN(Q)%(J0X96&01^[]*G_L^Z_Z#-]_WQ#_ /&Z +]%9_\
M9]U_T&;[_OB#_P"-T?V?=?\ 09OO^^(/_C= &A15#^S[K_H,WW_?$/\ \;I/
M[/NO^@S??]\0?_&Z -"BL_\ L^Z_Z#-]_P!\0?\ QNE_L^Z_Z#-]_P!\0_\
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M 4DC8F" F"BL HC@2#I8]+FBC6./5;M(T 556. !0.@ \OI3O[/N?^@Q>_\
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M ([_ .2>>)O^P5=?^BFKH*Y_QW_R3SQ-_P!@JZ_]%-0 >!/^2>>&?^P5:_\
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MB@ HHHH **** "BBB@ KG_'?_)//$W_8*NO_ $4U=!7/^._^2>>)O^P5=?\
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M)Y.L?\_UC_X!O_\ ':T** ,_R=8_Y_K'_P  W_\ CM+Y.K_\_P!8_P#@&_\
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MA10!G^3K'_/]8_\ @$__ ,=H\G6/^?ZQ_P# )_\ X[6A10!G^3K'_/\ 6/\
MX!/_ /':/)UC_G^L?_ )_P#X[6A10!G^3K'_ #_6/_@$_P#\=H\G6/\ G^L?
M_ )__CM:%% &?Y.L?\_UC_X!/_\ ':/)UC_G^L?_  "?_P".UH44 9_DZQ_S
M_6/_ (!/_P#':/)UC_G^L?\ P"?_ ..UH44 9_DZQ_S_ %C_ . 3_P#QVCR=
M8_Y_K'_P"?\ ^.UH44 9_DZQ_P _UC_X!/\ _':/)UC_ )_K'_P"?_X[6A10
M!G^3K'_/]8_^ 3__ !VCR=8_Y_K'_P  G_\ CM:%% &?Y.L?\_UC_P" 3_\
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ML?\ P-?_ .-4>=K'_/C8_P#@:_\ \:H T**S_.UC_GQL?_ U_P#XU1YVL?\
M/C8_^!K_ /QJ@#0HK/\ .UC_ )\;'_P-?_XU1YVL?\^-C_X&O_\ &J -"BL_
MSM8_Y\;'_P #7_\ C5'G:Q_SXV/_ (&O_P#&J -"BL_SM8_Y\;'_ ,#7_P#C
M5'G:Q_SXV/\ X&O_ /&J -"BL_SM8_Y\;'_P-?\ ^-4>=K'_ #XV/_@:_P#\
M:H T**S_ #M8_P"?&Q_\#7_^-4>=K'_/C8_^!K__ !J@#0HK/\[6/^?&Q_\
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M_P!]P?\ QRM"B@#/_M&Z_P"@-??]]P?_ !RC^T;K_H#7W_?<'_QRM"B@#/\
M[1NO^@-??]]P?_'*/[1NO^@-??\ ?<'_ ,<K0HH S_[1NO\ H#7W_?<'_P <
MH_M&Z_Z U]_WW!_\<K0HH S_ .T;K_H#7W_?<'_QRC^T;K_H#7W_ 'W!_P#'
M*T** ,_^T;K_ * U]_WW!_\ '*/[1NO^@-??]]P?_'*T** ,_P#M&Z_Z U]_
MWW!_\<H_M&Z_Z U]_P!]P?\ QRM"B@#/_M&Z_P"@-??]]P?_ !RC^T;K_H#7
MW_?<'_QRM"B@#/\ [1NO^@-??]]P?_'*/[1NO^@-??\ ?<'_ ,<K0HH S_[1
MNO\ H#7W_?<'_P <H_M&Z_Z U]_WW!_\<K0HH S_ .T;K_H#7W_?<'_QRC^T
M;K_H#7W_ 'W!_P#'*T** ,_^T;K_ * U]_WW!_\ '*/[1NO^@-??]]P?_'*T
M** ,_P#M&Z_Z U]_WW!_\<H_M&Z_Z U]_P!]P?\ QRM"B@#/_M&Z_P"@-??]
M]P?_ !RC^T;K_H#7W_?<'_QRM"B@#/\ [1NO^@-??]]P?_'*/[1NO^@-??\
M?<'_ ,<K0HH S_[1NO\ H#7W_?<'_P <H_M&Z_Z U]_WW!_\<K0HH @M;B6<
M,9+.>VQT$I0Y^FUC4]%% !1110 5S_CO_DGGB;_L%77_ **:N@KG_'?_ "3S
MQ-_V"KK_ -%-0 >!/^2>>&?^P5:_^BEKH*Y_P)_R3SPS_P!@JU_]%+6KJEG+
MJ&DWEE#=RVDMQ"\27$1P\1((##IR.O44 6$ECEW>7(K[&VMM.=I]#[T^O./!
M&FZ;87EWHT]@FE:L8Y$D73W9(;J,; 7210I+*?7#KO/8[C2DO8O#?_"<'2M$
MFT*ZM]+%Q;VRQQB&4*) +A?+8J&)X(X.$4G))"@'JE%<3I^GVGAOQEHUAI,2
MQ6]_IL[72IG$KQ&+;*Q_B<^8P+'EL\DX&.VH Y_QW_R3SQ-_V"KK_P!%-705
MQGQ"UZSM_"'B/3WAU$SMIEPH:/3;AXLM$V,RJA0#GDEL#OC%=)_;%M_SROO_
M  !F_P#B* +]%9_]LVO_ #ROO_ "?_XBE_MBU_YY7W_@#-_\10!?HK/_ +9M
M?^>5]_X 3_\ Q%']LVO_ #ROO_ "?_XB@#0HJA_;%K_SROO_  !F_P#B*3^V
M;7_GE??^ $__ ,10!H45G_VS:_\ /*^_\ )__B*7^V+7_GE??^ ,W_Q% %^B
ML_\ MFU_YY7W_@!/_P#$4?VS:_\ /*^_\ )__B* -"BJ']L6O_/*^_\  &;_
M .(I/[9M?^>5]_X 3_\ Q% &A371)8VCD171@596&00>H(JC_;-K_P \K[_P
M G_^(I?[8M?^>5]_X S?_$4 >$>./ >K_#+7#XU\$NR6*'-Q; %O)4_>!'\4
M1_->/3(]8\ ?$#3/'NC"YM2(;Z( 75FS9:)O4>JGL?ZUNMJUG(A1X+UE88*F
MPF((/_ *\!\;^#[WP'X@3QEX#2]AMHR7N+8VDJK /XOO* 8CW';Z= #Z/HKA
M? WQ1TCQGI2RHD\.HQ*/M-I'!)*4/]X%5.5/8UU7]LVO_/*^_P# "?\ ^(H
MT**S_P"V;7_GE??^ $__ ,11_;-K_P \K[_P G_^(H T**S_ .V;7_GE??\
M@!/_ /$4?VS:_P#/*^_\ )__ (B@#0HK/_MFU_YY7W_@!/\ _$4?VS:_\\K[
M_P  )_\ XB@#0HK/_MFU_P">5]_X 3__ !%']LVO_/*^_P# "?\ ^(H T**S
M_P"V;7_GE??^ $__ ,11_;-K_P \K[_P G_^(H T**S_ .V;7_GE??\ @!/_
M /$4?VS:_P#/*^_\ )__ (B@#0HK/_MFU_YY7W_@!/\ _$4?VS:_\\K[_P
M)_\ XB@#0HK/_MFU_P">5]_X 3__ !%']LVO_/*^_P# "?\ ^(H T**S_P"V
M;7_GE??^ $__ ,11_;-K_P \K[_P G_^(H T**S_ .V;7_GE??\ @!/_ /$4
M?VS:_P#/*^_\ )__ (B@#0HK/_MFU_YY7W_@!/\ _$4?VS:_\\K[_P  )_\
MXB@#0HK/_MFU_P">5]_X 3__ !%']LVO_/*^_P# "?\ ^(H T**S_P"V;7_G
ME??^ $__ ,11_;-K_P \K[_P G_^(H T**S_ .V;7_GE??\ @!/_ /$4?VS:
M_P#/*^_\ )__ (B@#0HK/_MFU_YY7W_@!/\ _$4?VS:_\\K[_P  )_\ XB@#
M0HK/_MFU_P">5]_X 3__ !%']LVO_/*^_P# "?\ ^(H T**S_P"V;7_GE??^
M $__ ,11_;-K_P \K[_P G_^(H T**KVMY%=AC$LZ[<9\V!X_P MP&?PJQ0
M4444 %<_X[_Y)YXF_P"P5=?^BFKH*Y_QW_R3SQ-_V"KK_P!%-0 >!/\ DGGA
MG_L%6O\ Z*6MF\M(;^RGL[@,T,Z&-PKE3@C!P000?<5C>!/^2>>&?^P5:_\
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MJ/M-H3U_VT]5)_$=#V)[J@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M .!"?XUH44 4/[=TC_H*V/\ X$)_C2?V[I'_ $%;'_P(3_&M"B@#/_MW2/\
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M<T 7?[>T?_H*V/\ X$)_C1_;VC_]!6Q_\"$_QJY#<0W*;X)HY4_O(P8?I4E
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M?7%3T44 %%%% !7/^._^2>>)O^P5=?\ HIJZ"N?\=_\ )//$W_8*NO\ T4U
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MX2O([.Y^SR6]PVH0/="96:-@<+)'M(*'IUW'T%>AT4 <_P#8_&'_ $'=#_\
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M[&M?^>M]_P"!\_\ \70!H45G_P!C6O\ SUOO_ ^?_P"+H_L:U_YZWW_@?/\
M_%T :%%9_P#8UK_SUOO_  /G_P#BZ/[&M?\ GK??^!\__P 70!H45G_V-:_\
M];[_ ,#Y_P#XNC^QK7_GK??^!\__ ,70!H45G_V-:_\ /6^_\#Y__BZ/[&M?
M^>M]_P"!\_\ \70!H45G_P!C6O\ SUOO_ ^?_P"+H_L:U_YZWW_@?/\ _%T
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M +&M?^>M]_X'S_\ Q=']C6O_ #UOO_ ^?_XN@#0HK/\ [&M?^>M]_P"!\_\
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M_P!4_E^9MW>7YF-F_;\VS.['.,4^/7]*F\02Z%%>QR:G##Y\MNF28TR!EB.
M>1P3G!!QBN"D\T>#)+!C_P 35_$^P*6^;?\ ;?-!_P"_.&_W>>E=/,1_PM.S
M7()&C3''I^^B_P _A0!:O?&GA_3_ !-;>'+F_P!NKW(4Q6RPR.2#G&652HZ'
MJ1@<UO5Q5WHNHZ'XM@UC3M=O9TU2]5+O2[IU:)E*XW0@ %"BKN/7(7D\5VM
M!6;<:_I5KKEGHLU[&NIWBL\-L,EV5026./NC@\G .#BM*N7\1$?\)CX07(R;
MJX('_;N_/^?6@#1OO$^D:;J$=E=W+QR.ZQ[_ ")#$KM]U&E"[$8\85F!Y''(
MS:O]6LM,'^ES^62A< (S%@"JX  ))+.H"CDE@ ":YKQIJOA[RQX=U+5=.L3=
ME)[G[1<)&1$KAB<$C+,5P/Q/:MVS#7FH7UZO  6WMRZD@ #<6QP?O.5(X^Y0
M ZP\0Z5J.GW-]!=;+>U9DN6N8V@,!4 L'60*4P"#R!P<U+I&L6&NZ5#J>F7
MGLYMWER[2H;!*GA@#U!K"\'#4XK_ ,0V^JFSGN([Y6-[:QF,3[HD(#*6;:47
M:N,],=\DTO"[/)\/$AMV/F7=Y<PHZ'D![F0%P?9<MWZ4 ;M]XMT73;:&XNKJ
M18)HEF$B6TKK'&>CR%5/EJ><,^ <'T.)M4\2Z3H_D_;;HKYR-*OEQ/+B-<;I
M&V [4&1ESA1D9-9GB_5='TK26TNYO]/T^;4XFMHC<RI&JKMP7.XC(4'IW.!W
MK,TN;3M/\17TXG0Z0OA^V-G,S_(T$32B0ANXPT9)'9E/<4 =1J/B'2-)EL(K
MV_BBEU"58;1!EFF8XQM R<<C)Z#(R>:@\2>+=#\(6<-WKM\+2&:3RHV\MW+-
M@G&$!/0=:Y!8I[;X:>"8+P%)Q=Z:I1^OWUP"/4#M[5N>,O#]S>[=<L?$E[I%
MYIUNYAVLIMCG!;S4(^8':!UXP#C(H ZFWGCNK:*XB),<J!T+*5.",C(/(^AJ
M3H,FJVGS3W&FVLUU#Y%Q)"CRQ9_U;D E?P/%6: ,K3/$FC:S975[I^H0SVEK
M*T4UPIQ&K* 6^8\$ $<C(]Z72O$6F:S<7%O9RRBXMPIE@N+:2"10W1MDBJVT
MX/.,<5D>%/*>Y\5F38T8UF3<6P1Q%%U^G]*H67B'0]4\0:AK>F:G87M['8FU
MM;6"=7D=5<DLP4D@,Y51GV_O4 ;U_P"+]#TQ2UU=R*BEO,=+:618@&*%I"JD
M1KN5@&; .UL'@XM:GK^E://8V]_>QPSW\P@M8CDM*YXP ,G'(R>@R,GFL+Q=
MI^HVG@"YM],N[)?L]JQN1>0EEND5?G4L&7;OP06Y/)Q@\@\6R-)H>@-+$())
M-5L"8?[I\Q25_#GMVH ZJ:YA@D@CD?#SOY<8P3N;:6Q^2D_A6;8^)](U+4CI
M]M<N;G89$62"2,3(#@O&S*%D7I\R$CD'/(J4H;K7F+KF"U@VC/(9Y#SD>H51
M^$AKFI=8T'6?&-O%:ZOIYO-,6:WMK>.=#*\[J V$!SM100>,9)Z;: .BLO$N
MDZCJ+V%K=%[A2X&8G5)-AVOY;D!9-IX;:3@\'%/T_7]*U74;^PL+V.XN=/94
MNECR1$QSA2W0G@Y .1CG%<-I1+Z'\-K2+_C]AEW3KGYE$5O(D^1[.P4^Y ZF
MN@TYF_X3[Q280&D6SLP!_M8F(!_3N/ZT ;/]OZ:=;.CQW#37Z@&2.&)Y!#D$
MCS&4%8\@'&\C/;-:5>5>"Y-1TBP\)S0:J;U=;GE_M*RDA0%)BC/+(& W[TD4
MJV]F'. %P /5: *FIZG8Z-IT^H:E=1VMI NZ260X"C^I)X '))P*@DU[3H](
MM]4\V1[6Y17@\J"2224,,C;&JER<<X R "3P#4NKD+HE^Q;:!;2$DG&/E-8.
MBZIIVB?#;1=3U.:&WM[?38#YDA"X)C48!..3TH VK/7M,O\ 1FU>VNE>Q169
MY-K IMSN#*1N!&#D$9]JAC\3Z1)K":4MQ)]JD9TC)MY!'(Z@ED60KL9EP<J&
M)&U@1D'&!H+:?>Z>8=-OK2];4-3:ZOGLY5ECC)_>%-R\'A8T/^]D]:L^(5U2
M'Q7X<FC:RN-,-V8OL;1,LL;F)_WRONP=JAAC;@!CWP5 -N/7]*F\02Z%%>QR
M:G##Y\MNF28TR!EB. >1P3G!!QBIKK5;*R\_SYMI@C620!&8X8E5  &69B"
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MP^?+;IDF-,@98C@'D<$YP0<8K@I/-'@R2P8_\35_$^P*6^;?]M\T'_OSAO\
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M-B\)>&X+Y;Z'P]I4=XK^8+A+*,2!\YW;L9SGO6Q10!4_LO3_ .T_[3^P6O\
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M,XW XS@?D*2XT#1KN_AO[G2+":\@"B&XDMD:2,*<KM8C(P>1CI6C10 4444
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MH^GW[Q@A&NK9)2H/4#<#BEDT'1Y=*32I-)L7TY,;;1K9#"N#GA,8Z\]*T**
M*5_H^F:K:)::CIMG>6T;!DAN(%D12 0"%8$ @$C\:9<:%I%WIL6FW.E6,UA#
MCR[62W1HDP,#"$8&!TXK0HH 9##%;01P01)%#&H1(T4*JJ.  !T%/HHH S8?
M#VB6U]/?0:/I\5Y<!A-<):HLDH8Y;<P&3D]<]:@M/"/AJPF\ZS\.Z3;R[2F^
M&RC1MI&",A>A!P:V:* ,[4= T;6'B?5-)L+YH01$UU;)*4SUQN!QT'2I=1TG
M3M8MEM]4T^UOH%<.(KJ%95# $9PP(S@GGWJY10!!;65I91I':VL,")&L2+%&
M%"HN=J@#H!DX';-9T7A+PW!?+?0^'M*CO%?S!<)91B0/G.[=C.<]ZV** *G]
MEZ?_ &G_ &G]@M?[0V>7]J\E?-V?W=^,X]LU"=!T9M7&K-I-@=2'2\-LGG=-
MOW\;NG'7IQ6C10!5L],L-.>X>QL;:V:XD,L[01*AE<]6; Y/N:R?'?\ R3SQ
M-_V"KK_T4U=!7/\ CO\ Y)YXF_[!5U_Z*:@ \"?\D\\,_P#8*M?_ $4M=!7/
M^!/^2>>&?^P5:_\ HI:Z"@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M8@\#(SD '0?;/&'_ $ M#_\ !S-_\BT?;/&'_0"T/_P<S?\ R+5RP6XU7PY
M-47R9[B$>:+2Y<8SW610C D8/ &.GO7#>$O$FJ6>B>&-,M],NM3O-5T][QKV
M^U([-Z[=P+-O<#YAT7 )& <L5 .M^V>,/^@%H?\ X.9O_D6C[9XP_P"@%H?_
M (.9O_D6LZU\:7NLZ?!/H&BQWL_V&&\N();T0[!(&VQHVU@S_(W7:.G//'8
MDJ"01D=#VH P/MGC#_H!:'_X.9O_ )%H^V>,/^@%H?\ X.9O_D6N@HH Y_[9
MXP_Z 6A_^#F;_P"1:/MGC#_H!:'_ .#F;_Y%KH** .?^V>,/^@%H?_@YF_\
MD6C[9XP_Z 6A_P#@YF_^1:Z"B@#G_MGC#_H!:'_X.9O_ )%H^V>,/^@%H?\
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M_'?_ "3SQ-_V"KK_ -%-705S_CO_ ))YXF_[!5U_Z*:@#H**** "N?\ '?\
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M ,BUY!_PTU_U*/\ Y4O_ +51_P --?\ 4H_^5+_[50!Z_P#;/&'_ $ M#_\
M!S-_\BT?;/&'_0"T/_P<S?\ R+7D'_#37_4H_P#E2_\ M5'_  TU_P!2C_Y4
MO_M5 'K_ -L\8?\ 0"T/_P ',W_R+1]L\8?] +0__!S-_P#(M>0?\--?]2C_
M .5+_P"U4?\ #37_ %*/_E2_^U4 >O\ VSQA_P! +0__  <S?_(M'VSQA_T
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M_P#;/&'_ $ M#_\ !S-_\BT?;/&'_0"T/_P<S?\ R+7D'_#37_4H_P#E2_\
MM5'_  TU_P!2C_Y4O_M5 'K_ -L\8?\ 0"T/_P ',W_R+1]L\8?] +0__!S-
M_P#(M>0?\--?]2C_ .5+_P"U4?\ #37_ %*/_E2_^U4 >O\ VSQA_P! +0__
M  <S?_(M'VSQA_T M#_\',W_ ,BUY!_PTU_U*/\ Y4O_ +51_P --?\ 4H_^
M5+_[50!Z_P#;/&'_ $ M#_\ !S-_\BT?;/&'_0"T/_P<S?\ R+7D'_#37_4H
M_P#E2_\ M5'_  TU_P!2C_Y4O_M5 'K_ -L\8?\ 0"T/_P ',W_R+1]L\8?]
M +0__!S-_P#(M>0?\--?]2C_ .5+_P"U4?\ #37_ %*/_E2_^U4 >O\ VSQA
M_P! +0__  <S?_(M9MMI>N66JS:E:>&="MKF?)F\C7;A(Y6)R7>,6P1GY^^0
M6]Z\R_X::_ZE'_RI?_:J/^&FO^I1_P#*E_\ :J /7_MGC#_H!:'_ .#F;_Y%
MH^V>,/\ H!:'_P"#F;_Y%KR#_AIK_J4?_*E_]JH_X::_ZE'_ ,J7_P!JH ]?
M^V>,/^@%H?\ X.9O_D6C[9XP_P"@%H?_ (.9O_D6O(/^&FO^I1_\J7_VJC_A
MIK_J4?\ RI?_ &J@#U_[9XP_Z 6A_P#@YF_^1:/MGC#_ * 6A_\ @YF_^1:\
M@_X::_ZE'_RI?_:J/^&FO^I1_P#*E_\ :J /7_MGC#_H!:'_ .#F;_Y%H^V>
M,/\ H!:'_P"#F;_Y%KR#_AIK_J4?_*E_]JH_X::_ZE'_ ,J7_P!JH ]?^V>,
M/^@%H?\ X.9O_D6L:RT'6=/O/M-MX=TM2)&D6%O$MVT",Q))6%H#&IR3C"C&
M>,5YS_PTU_U*/_E2_P#M5'_#37_4H_\ E2_^U4 >J6,/B?3_ #O(T+2"TSEW
M>;Q!<RL3Z;GMR0!V4<#L!5O[9XP_Z 6A_P#@YF_^1:\@_P"&FO\ J4?_ "I?
M_:J/^&FO^I1_\J7_ -JH ]?^V>,/^@%H?_@YF_\ D6C[9XP_Z 6A_P#@YF_^
M1:\@_P"&FO\ J4?_ "I?_:J/^&FO^I1_\J7_ -JH ]?^V>,/^@%H?_@YF_\
MD6C[9XP_Z 6A_P#@YF_^1:\@_P"&FO\ J4?_ "I?_:J/^&FO^I1_\J7_ -JH
M ]?^V>,/^@%H?_@YF_\ D6C[9XP_Z 6A_P#@YF_^1:\@_P"&FO\ J4?_ "I?
M_:J/^&FO^I1_\J7_ -JH ]?^V>,/^@%H?_@YF_\ D6C[9XP_Z 6A_P#@YF_^
M1:\@_P"&FO\ J4?_ "I?_:J/^&FO^I1_\J7_ -JH ]?^V>,/^@%H?_@YF_\
MD6C[9XP_Z 6A_P#@YF_^1:\@_P"&FO\ J4?_ "I?_:J/^&FO^I1_\J7_ -JH
M ]?^V>,/^@%H?_@YF_\ D6C[9XP_Z 6A_P#@YF_^1:\@_P"&FO\ J4?_ "I?
M_:J/^&FO^I1_\J7_ -JH ]?^V>,/^@%H?_@YF_\ D6C[9XP_Z 6A_P#@YF_^
M1:\@_P"&FO\ J4?_ "I?_:J/^&FO^I1_\J7_ -JH ]?^V>,/^@%H?_@YF_\
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$@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>58
<FILENAME>g4i5nix4zlkt000036.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g4i5nix4zlkt000036.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %E J # 2(  A$! Q$!_\0
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M_BIX<TWQ9<Z!/;W)*'RWN(X]RB3'W=HY/IQWKHP^%K8EM48N32N[=A.26YZ
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MCCT1FNDN?L#HQOY9^3RH,1P>O][%=?11S,.1'&6NDWX5;B6&X^TQM9",F0\
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M= *6BO,.X**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ IDH+1.
M25(Y&13Z@O+B*ULIIY[B.WB1"6FD8*J>Y)H \O\ A[_:MK>Z?97E]XF18U=6
ML[G2?*M%P#@"0KG:/X>?05ZO7C7A+0K_ $SQEH=W=:E'=QW:22"X.KM.L[;&
M#!(SUYP^>@!([5[+0 45YKJ_C"[7Q!?_ &>:[@^SV%XEM:M;.%:2,*1*21@\
M[L<XP/\ :K3T;4;C28]3BM7U#7X84MI8P)EEE+2 E@&8@8X#8SQNXH N> /^
M01J7_87O/_1S5U=<9\.+AYO#U[,]K-"\FJ7;-$^-R$RM\IP<9%=AYA_YYO\
MI_C0 2=%_P!X4^H)'.%_=/\ >'I4GF'_ )Y/^G^-  G\7^]0OWW^O]*8CG+_
M +I_O>U"N=[_ +I^OMZ"@ 4?N,?[7]:5@<R?05&KGR/]4_WO0>M>6_&+QC>:
M7;6^EZ)?207TC[[D0_ZQ(\?+R/NY/X\5TX3#2Q-94HM*_5[+U#5Z)79H^-=8
MEUO6T\*:8GGJ'4W@#<2-C(B)'\(X9_; [UVNA:+'HUD4W^;<RMYEQ.1@R/\
MT Z =A7%_";2Q;^%H-7N897U*^D=I9I!EB-Q[GUZD]_RKT7S#_SR?]/\:G$V
M53V<7>,+I>?>7S_*R.B<U"'LHZ?S=[]O1?B]>UI*8GWG_P![^E'F'_GD_P"G
M^-1I(=TG[I_O>WH*P.<DDZ+_ +PHE_U9_"F/(<+^Z?[P]*260^6?W3]O3UH
MD?[R?[W]*:PXF^G]*:\AW)^ZD^][>AIK.<3?NGZ>@]* 'L.6_P!T4Z/[TG^]
M_05"TARW[F3[H[#WI\;G=)^Z?[_MZ4 3TR7F,_4?SI/,/_/)_P!/\:9+(?+/
M[I^H]/6@">F)_K)/J/Y"CS#_ ,\W_3_&HT<^9)^Z?DCT]!0!(O\ KG^@_K3#
M_J9/]XTBN?.?]T_('I3"Y\F3]T_WCV% $D@^:3_KG_C01S^*U'*YW2_NG_U?
MH/>EW$MCRV'*<D"@"S1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M:R.6]PIB?>D_WOZ4^F)]Z3_>_I0 2=%_WA1+_JS]1_.B3HO^\*)?]6?J/YT
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M6D"0J[]6"@#)_*KM !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MR>?XQU-!@ 2[<8],"N4M[-8%WEMSG]*TO$&LOK'B.[NGC4/*V\G& ,U4),:
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MAJ4[;E!!9>7XR,C/49I+[X4:+<6;Q6M]K%K,2-LPU*=]N"">"^.1D?C7>44
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M]CAU)]^"/QJ[!IRVVHW%U%(RI<*-\('R[Q_&/0D<'UP*NT4!9!1110,****
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MK'3[+3+86UA:0VT();RX4"KD]3@59HHH **** "BBB@ HHHH **** "BBB@
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M455TR&XMM+M8+N59;B.)5DD7HQ ZU:J#H"BBB@##UG4)[#4(7C)9%M9Y#%G
M=EVXS^=,_MC4/MGV'[/;_:?.";MYV &,OGUSQBM>XL;:[<-/$'8(T8))^ZV,
MC]!2?8+7[5]J\D>=N#;\GJ%VC]#BM5*%M4*S,%O%,OV>"<01[2J-+&"S,-S[
M3R!A1W&>M-CUZ_@A\MXUN)R]P^5C<C8DA4+\H.#[GBM9O#^EL #:#: !M#L
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M/.>.M;-5!I=F+[[8(?W^=V=QQG&,XSC..^*MUG)Q>PT%%%%2,**** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH *0 #H /I2T4 4-;,PT.^\B-I)3"P5%&2217$^#?!5Q;K-J.H
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
( !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>59
<FILENAME>nk-20191231.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Instance Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2020-03-25T06:28:30.9214960+00:00 -->
<!-- Version            : 5.0.1.369 -->
<!-- Package ID         : 997a9244481146b697c7b584a5c14c7f -->
<!-- Copyright (c) 2020 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xbrli:xbrl xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2019-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:exch="http://xbrl.sec.gov/exch/2019-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:srt="http://fasb.org/srt/2019-01-31" xmlns:srt-types="http://fasb.org/srt-types/2019-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31" xmlns:us-types="http://fasb.org/us-types/2019-01-31" xmlns:nk="http://www.nantkwest.com/20191231" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:schemaRef xlink:type="simple" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xlink:href="nk-20191231.xsd" />
  <xbrli:unit id="U_xbrlishares">
    <xbrli:measure>xbrli:shares</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="U_iso4217USD">
    <xbrli:measure>iso4217:USD</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="U_iso4217USD_xbrlishares">
    <xbrli:divide>
      <xbrli:unitNumerator>
        <xbrli:measure>iso4217:USD</xbrli:measure>
      </xbrli:unitNumerator>
      <xbrli:unitDenominator>
        <xbrli:measure>xbrli:shares</xbrli:measure>
      </xbrli:unitDenominator>
    </xbrli:divide>
  </xbrli:unit>
  <xbrli:unit id="U_xbrlipure">
    <xbrli:measure>xbrli:pure</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="U_nkProduct">
    <xbrli:measure>nk:Product</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="U_nkSecurity">
    <xbrli:measure>nk:Security</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="U_nkPatient">
    <xbrli:measure>nk:Patient</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="U_utrsqft">
    <xbrli:measure>utr:sqft</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="U_iso4217USD_utrsqft">
    <xbrli:divide>
      <xbrli:unitNumerator>
        <xbrli:measure>iso4217:USD</xbrli:measure>
      </xbrli:unitNumerator>
      <xbrli:unitDenominator>
        <xbrli:measure>utr:sqft</xbrli:measure>
      </xbrli:unitDenominator>
    </xbrli:divide>
  </xbrli:unit>
  <xbrli:unit id="U_nkOfficer">
    <xbrli:measure>nk:Officer</xbrli:measure>
  </xbrli:unit>
  <xbrli:context id="C_0001326110_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_20200320">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-03-20</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_20190630">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_20180101_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_20170101_20171231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20161231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20161231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20161231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20161231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_20161231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20170101_20171231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20170101_20171231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20170101_20171231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20170101_20171231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20171231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20171231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20171231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20171231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_20171231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20180101_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20180101_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20180101_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20180101_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201409Member_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20180101_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201409Member_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20180101_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201409Member_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20180101_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201409Member_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20180101_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201409Member_20180101_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201602Member_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201602Member_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201602Member_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201602Member_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201602Member_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_srtTitleOfIndividualAxis_nkChairmanAndChiefExecutiveOfficerMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nk:ChairmanAndChiefExecutiveOfficerMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_srtRangeAxis_srtMinimumMember_us-gaapVariableInterestEntitiesByClassificationOfEntityAxis_us-gaapVariableInterestEntityPrimaryBeneficiaryMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:VariableInterestEntitiesByClassificationOfEntityAxis">us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_srtRangeAxis_srtMaximumMember_us-gaapVariableInterestEntitiesByClassificationOfEntityAxis_us-gaapVariableInterestEntityPrimaryBeneficiaryMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:VariableInterestEntitiesByClassificationOfEntityAxis">us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_srtRangeAxis_srtMinimumMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapBuildingMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapSoftwareAndSoftwareDevelopmentCostsMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapPropertyPlantAndEquipmentByTypeAxis_nkLaboratoryEquipmentMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nk:LaboratoryEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapPropertyPlantAndEquipmentByTypeAxis_nkITEquipmentMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nk:ITEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20190401_20190630">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-04-01</xbrli:startDate>
      <xbrli:endDate>2019-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20180101_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20170101_20171231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_srtRangeAxis_srtMinimumMember_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_srtRangeAxis_srtMaximumMember_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_srtRangeAxis_srtMinimumMember_srtStatementGeographicalAxis_stprCA_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_srtRangeAxis_srtMaximumMember_srtStatementGeographicalAxis_stprCA_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_20151130">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-11-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_nkIntrexonLicenseAgreementMember_20100201_20100228">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">nk:IntrexonLicenseAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2010-02-01</xbrli:startDate>
      <xbrli:endDate>2010-02-28</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20180101_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20170101_20171231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapRestrictedStockUnitsRSUMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapRestrictedStockUnitsRSUMember_20180101_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapRestrictedStockUnitsRSUMember_20170101_20171231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapWarrantMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapWarrantMember_20180101_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapWarrantMember_20170101_20171231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201602Member_20190101">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-01-01</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201602Member_us-gaapInitialApplicationPeriodCumulativeEffectTransitionAxis_nkDifferenceBetweenLeaseGuidanceInEffectBeforeAndAfterTopic842Member_20190101">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:InitialApplicationPeriodCumulativeEffectTransitionAxis">nk:DifferenceBetweenLeaseGuidanceInEffectBeforeAndAfterTopic842Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-01-01</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201602Member_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20190101">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-01-01</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapConstructionInProgressMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapConstructionInProgressMember_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapBuildingMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapBuildingMember_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapEquipmentMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapEquipmentMember_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapSoftwareAndSoftwareDevelopmentCostsMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapSoftwareAndSoftwareDevelopmentCostsMember_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201602Member_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_srtRestatementAxis_srtRestatementAdjustmentMember_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201602Member_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20190101">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-01-01</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201602Member_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20190101">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-01-01</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_srtRestatementAxis_srtRestatementAdjustmentMember_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201602Member_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapBuildingMember_20190101">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-01-01</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201602Member_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapBuildingMember_20190101">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-01-01</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_srtRestatementAxis_srtRestatementAdjustmentMember_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201602Member_20190101">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-01-01</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_nkTechnologyLicenseMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">nk:TechnologyLicenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_nkTechnologyLicenseMember_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">nk:TechnologyLicenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_20170331">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapDebtInstrumentAxis_nkTwoThousandAndEighteenNoteAndWarrantPurchaseAgreementMember_20180601_20180630">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nk:TwoThousandAndEighteenNoteAndWarrantPurchaseAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-06-01</xbrli:startDate>
      <xbrli:endDate>2018-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapDebtInstrumentAxis_nkTwoThousandAndEighteenNoteAndWarrantPurchaseAgreementMember_20180901_20180930">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nk:TwoThousandAndEighteenNoteAndWarrantPurchaseAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-09-01</xbrli:startDate>
      <xbrli:endDate>2018-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapDebtInstrumentAxis_nkTwoThousandAndEighteenNoteAndWarrantPurchaseAgreementMember_20180630">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nk:TwoThousandAndEighteenNoteAndWarrantPurchaseAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapDebtInstrumentAxis_nkTwoThousandAndEighteenNoteAndWarrantPurchaseAgreementMember_20180930">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nk:TwoThousandAndEighteenNoteAndWarrantPurchaseAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapDebtInstrumentAxis_nkTwoThousandAndEighteenNoteAndWarrantPurchaseAgreementMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20190131">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nk:TwoThousandAndEighteenNoteAndWarrantPurchaseAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-01-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapDebtInstrumentAxis_nkTwoThousandAndEighteenNoteAndWarrantPurchaseAgreementMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190531">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nk:TwoThousandAndEighteenNoteAndWarrantPurchaseAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-05-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapDebtInstrumentAxis_nkTwoThousandAndEighteenNoteAndWarrantPurchaseAgreementMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nk:TwoThousandAndEighteenNoteAndWarrantPurchaseAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapBalanceSheetLocationAxis_nkCurrentAssetsMember_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">nk:CurrentAssetsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapBalanceSheetLocationAxis_nkCurrentAssetsMember_us-gaapInvestmentTypeAxis_us-gaapForeignGovernmentDebtMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">nk:CurrentAssetsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ForeignGovernmentDebtMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapBalanceSheetLocationAxis_nkCurrentAssetsMember_us-gaapUnderlyingAssetClassAxis_us-gaapAgencySecuritiesMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">nk:CurrentAssetsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:UnderlyingAssetClassAxis">us-gaap:AgencySecuritiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapBalanceSheetLocationAxis_nkCurrentAssetsMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">nk:CurrentAssetsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapBalanceSheetLocationAxis_nkNoncurrentAssetsMember_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">nk:NoncurrentAssetsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapBalanceSheetLocationAxis_nkNoncurrentAssetsMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">nk:NoncurrentAssetsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapBalanceSheetLocationAxis_nkCurrentAssetsMember_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">nk:CurrentAssetsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapBalanceSheetLocationAxis_nkCurrentAssetsMember_us-gaapInvestmentTypeAxis_us-gaapForeignGovernmentDebtMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">nk:CurrentAssetsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ForeignGovernmentDebtMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapBalanceSheetLocationAxis_nkCurrentAssetsMember_us-gaapUnderlyingAssetClassAxis_us-gaapAgencySecuritiesMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">nk:CurrentAssetsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:UnderlyingAssetClassAxis">us-gaap:AgencySecuritiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapBalanceSheetLocationAxis_nkCurrentAssetsMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">nk:CurrentAssetsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapBalanceSheetLocationAxis_nkNoncurrentAssetsMember_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">nk:NoncurrentAssetsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapBalanceSheetLocationAxis_nkNoncurrentAssetsMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">nk:NoncurrentAssetsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapBalanceSheetLocationAxis_nkCurrentAssetsMember_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">nk:CurrentAssetsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapBalanceSheetLocationAxis_nkCurrentAssetsMember_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">nk:CurrentAssetsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapBalanceSheetLocationAxis_nkNoncurrentAssetsMember_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">nk:NoncurrentAssetsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapBalanceSheetLocationAxis_nkNoncurrentAssetsMember_us-gaapUnderlyingAssetClassAxis_us-gaapAgencySecuritiesMember_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">nk:NoncurrentAssetsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:UnderlyingAssetClassAxis">us-gaap:AgencySecuritiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapBalanceSheetLocationAxis_nkNoncurrentAssetsMember_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">nk:NoncurrentAssetsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapFairValueByAssetClassAxis_us-gaapNotesReceivableMember_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:NotesReceivableMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_srtRangeAxis_srtMaximumMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_srtRangeAxis_srtMinimumMember_20180101_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_srtRangeAxis_srtMaximumMember_20180101_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapUnderlyingAssetClassAxis_us-gaapAgencySecuritiesMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:UnderlyingAssetClassAxis">us-gaap:AgencySecuritiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapUnderlyingAssetClassAxis_us-gaapAgencySecuritiesMember_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:UnderlyingAssetClassAxis">us-gaap:AgencySecuritiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapFinancialInstrumentAxis_us-gaapDebtSecuritiesMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapBalanceSheetLocationAxis_nkCurrentAssetsMember_us-gaapFairValueByAssetClassAxis_us-gaapCashAndCashEquivalentsMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">nk:CurrentAssetsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapBalanceSheetLocationAxis_nkCurrentAssetsMember_us-gaapFairValueByAssetClassAxis_us-gaapCashAndCashEquivalentsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">nk:CurrentAssetsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapBalanceSheetLocationAxis_nkCurrentAssetsMember_us-gaapFairValueByAssetClassAxis_us-gaapCashAndCashEquivalentsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">nk:CurrentAssetsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapBalanceSheetLocationAxis_nkCurrentAssetsMember_us-gaapFairValueByAssetClassAxis_us-gaapCashAndCashEquivalentsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">nk:CurrentAssetsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapBalanceSheetLocationAxis_nkCurrentAssetsMember_us-gaapFairValueByAssetClassAxis_us-gaapCorporateDebtSecuritiesMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">nk:CurrentAssetsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapBalanceSheetLocationAxis_nkCurrentAssetsMember_us-gaapFairValueByAssetClassAxis_us-gaapCorporateDebtSecuritiesMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">nk:CurrentAssetsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapBalanceSheetLocationAxis_nkCurrentAssetsMember_us-gaapFairValueByAssetClassAxis_us-gaapCorporateDebtSecuritiesMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">nk:CurrentAssetsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapBalanceSheetLocationAxis_nkCurrentAssetsMember_us-gaapFairValueByAssetClassAxis_us-gaapCorporateDebtSecuritiesMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">nk:CurrentAssetsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapBalanceSheetLocationAxis_nkCurrentAssetsMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapForeignGovernmentDebtMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">nk:CurrentAssetsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ForeignGovernmentDebtMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapBalanceSheetLocationAxis_nkCurrentAssetsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapForeignGovernmentDebtMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">nk:CurrentAssetsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ForeignGovernmentDebtMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapBalanceSheetLocationAxis_nkCurrentAssetsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapForeignGovernmentDebtMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">nk:CurrentAssetsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ForeignGovernmentDebtMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapBalanceSheetLocationAxis_nkCurrentAssetsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapForeignGovernmentDebtMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">nk:CurrentAssetsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ForeignGovernmentDebtMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapBalanceSheetLocationAxis_nkCurrentAssetsMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapUnderlyingAssetClassAxis_us-gaapAgencySecuritiesMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">nk:CurrentAssetsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:UnderlyingAssetClassAxis">us-gaap:AgencySecuritiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapBalanceSheetLocationAxis_nkCurrentAssetsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapUnderlyingAssetClassAxis_us-gaapAgencySecuritiesMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">nk:CurrentAssetsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:UnderlyingAssetClassAxis">us-gaap:AgencySecuritiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapBalanceSheetLocationAxis_nkCurrentAssetsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapUnderlyingAssetClassAxis_us-gaapAgencySecuritiesMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">nk:CurrentAssetsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:UnderlyingAssetClassAxis">us-gaap:AgencySecuritiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapBalanceSheetLocationAxis_nkCurrentAssetsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapUnderlyingAssetClassAxis_us-gaapAgencySecuritiesMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">nk:CurrentAssetsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:UnderlyingAssetClassAxis">us-gaap:AgencySecuritiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapBalanceSheetLocationAxis_nkNoncurrentAssetsMember_us-gaapFairValueByAssetClassAxis_us-gaapCorporateDebtSecuritiesMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">nk:NoncurrentAssetsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapBalanceSheetLocationAxis_nkNoncurrentAssetsMember_us-gaapFairValueByAssetClassAxis_us-gaapCorporateDebtSecuritiesMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">nk:NoncurrentAssetsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapBalanceSheetLocationAxis_nkNoncurrentAssetsMember_us-gaapFairValueByAssetClassAxis_us-gaapCorporateDebtSecuritiesMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">nk:NoncurrentAssetsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapBalanceSheetLocationAxis_nkNoncurrentAssetsMember_us-gaapFairValueByAssetClassAxis_us-gaapCorporateDebtSecuritiesMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">nk:NoncurrentAssetsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapBalanceSheetLocationAxis_nkCurrentAssetsMember_us-gaapFairValueByAssetClassAxis_us-gaapCashAndCashEquivalentsMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">nk:CurrentAssetsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapBalanceSheetLocationAxis_nkCurrentAssetsMember_us-gaapFairValueByAssetClassAxis_us-gaapCashAndCashEquivalentsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">nk:CurrentAssetsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapBalanceSheetLocationAxis_nkCurrentAssetsMember_us-gaapFairValueByAssetClassAxis_us-gaapCashAndCashEquivalentsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">nk:CurrentAssetsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapBalanceSheetLocationAxis_nkCurrentAssetsMember_us-gaapFairValueByAssetClassAxis_us-gaapCashAndCashEquivalentsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">nk:CurrentAssetsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapBalanceSheetLocationAxis_nkCurrentAssetsMember_us-gaapFairValueByAssetClassAxis_us-gaapCorporateDebtSecuritiesMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">nk:CurrentAssetsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapBalanceSheetLocationAxis_nkCurrentAssetsMember_us-gaapFairValueByAssetClassAxis_us-gaapCorporateDebtSecuritiesMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">nk:CurrentAssetsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapBalanceSheetLocationAxis_nkCurrentAssetsMember_us-gaapFairValueByAssetClassAxis_us-gaapCorporateDebtSecuritiesMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">nk:CurrentAssetsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapBalanceSheetLocationAxis_nkCurrentAssetsMember_us-gaapFairValueByAssetClassAxis_us-gaapCorporateDebtSecuritiesMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">nk:CurrentAssetsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapBalanceSheetLocationAxis_nkNoncurrentAssetsMember_us-gaapFairValueByAssetClassAxis_us-gaapCorporateDebtSecuritiesMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">nk:NoncurrentAssetsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapBalanceSheetLocationAxis_nkNoncurrentAssetsMember_us-gaapFairValueByAssetClassAxis_us-gaapCorporateDebtSecuritiesMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">nk:NoncurrentAssetsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapBalanceSheetLocationAxis_nkNoncurrentAssetsMember_us-gaapFairValueByAssetClassAxis_us-gaapCorporateDebtSecuritiesMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">nk:NoncurrentAssetsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapBalanceSheetLocationAxis_nkNoncurrentAssetsMember_us-gaapFairValueByAssetClassAxis_us-gaapCorporateDebtSecuritiesMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">nk:NoncurrentAssetsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapBalanceSheetLocationAxis_nkNoncurrentAssetsMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapUnderlyingAssetClassAxis_us-gaapAgencySecuritiesMember_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">nk:NoncurrentAssetsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:UnderlyingAssetClassAxis">us-gaap:AgencySecuritiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapBalanceSheetLocationAxis_nkNoncurrentAssetsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapUnderlyingAssetClassAxis_us-gaapAgencySecuritiesMember_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">nk:NoncurrentAssetsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:UnderlyingAssetClassAxis">us-gaap:AgencySecuritiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapBalanceSheetLocationAxis_nkNoncurrentAssetsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapUnderlyingAssetClassAxis_us-gaapAgencySecuritiesMember_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">nk:NoncurrentAssetsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:UnderlyingAssetClassAxis">us-gaap:AgencySecuritiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapBalanceSheetLocationAxis_nkNoncurrentAssetsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapUnderlyingAssetClassAxis_us-gaapAgencySecuritiesMember_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">nk:NoncurrentAssetsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:UnderlyingAssetClassAxis">us-gaap:AgencySecuritiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapRelatedPartyTransactionAxis_nkAltorBioScienceCorporationMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nk:AltorBioScienceCorporationMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapRelatedPartyTransactionAxis_nkAltorBioScienceCorporationMember_20180101_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nk:AltorBioScienceCorporationMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapRelatedPartyTransactionAxis_nkAltorBioScienceCorporationMember_20170101_20171231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nk:AltorBioScienceCorporationMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_deiLegalEntityAxis_nkViractaTherapeuticsIncMember_srtRangeAxis_srtMinimumMember_20170501_20170531">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nk:ViractaTherapeuticsIncMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-05-01</xbrli:startDate>
      <xbrli:endDate>2017-05-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_deiLegalEntityAxis_nkViractaTherapeuticsIncMember_srtRangeAxis_srtMaximumMember_20170501_20170531">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nk:ViractaTherapeuticsIncMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-05-01</xbrli:startDate>
      <xbrli:endDate>2017-05-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_deiLegalEntityAxis_nkViractaTherapeuticsIncMember_20170501_20170531">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nk:ViractaTherapeuticsIncMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-05-01</xbrli:startDate>
      <xbrli:endDate>2017-05-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis_nkGeorgSpeyerHausAndDRKBlutspendedienstBadenWurttembergHessengGmbHLicenseAgreementMember_20150101_20151231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">nk:GeorgSpeyerHausAndDRKBlutspendedienstBadenWurttembergHessengGmbHLicenseAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapOtherCommitmentsAxis_nkRushUniversityMedicalCenterLicenseAgreementMember_20040101_20041231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">nk:RushUniversityMedicalCenterLicenseAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2004-01-01</xbrli:startDate>
      <xbrli:endDate>2004-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapOtherCommitmentsAxis_nkRushUniversityMedicalCenterLicenseAgreementMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">nk:RushUniversityMedicalCenterLicenseAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapOtherCommitmentsAxis_nkRushUniversityMedicalCenterLicenseAgreementMember_20180101_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">nk:RushUniversityMedicalCenterLicenseAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapOtherCommitmentsAxis_nkRushUniversityMedicalCenterLicenseAgreementMember_20170101_20171231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">nk:RushUniversityMedicalCenterLicenseAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_nkIntrexonLicenseAgreementMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">nk:IntrexonLicenseAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_nkIntrexonLicenseAgreementMember_20180101_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">nk:IntrexonLicenseAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_nkIntrexonLicenseAgreementMember_20170101_20171231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">nk:IntrexonLicenseAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_nkIntrexonLicenseAgreementMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_nkINDFilingMember_20100201_20100228">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">nk:IntrexonLicenseAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">nk:INDFilingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2010-02-01</xbrli:startDate>
      <xbrli:endDate>2010-02-28</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_nkIntrexonLicenseAgreementMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_nkPhaseTwoMember_20100201_20100228">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">nk:IntrexonLicenseAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">nk:PhaseTwoMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2010-02-01</xbrli:startDate>
      <xbrli:endDate>2010-02-28</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_nkIntrexonLicenseAgreementMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_nkPhaseThreeMember_20100201_20100228">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">nk:IntrexonLicenseAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">nk:PhaseThreeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2010-02-01</xbrli:startDate>
      <xbrli:endDate>2010-02-28</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_nkIntrexonLicenseAgreementMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_nkCommercialSaleRelatedToLicensedProductsMember_20100201_20100228">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">nk:IntrexonLicenseAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">nk:CommercialSaleRelatedToLicensedProductsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2010-02-01</xbrli:startDate>
      <xbrli:endDate>2010-02-28</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapIncomeStatementLocationAxis_us-gaapSellingGeneralAndAdministrativeExpensesMember_20180701_20180930">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-07-01</xbrli:startDate>
      <xbrli:endDate>2018-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapReinsurancePolicyTypeAxis_nkDirectorsAndOfficersInsurancePolicyMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ReinsurancePolicyTypeAxis">nk:DirectorsAndOfficersInsurancePolicyMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_20190809_20190809">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-08-09</xbrli:startDate>
      <xbrli:endDate>2019-08-09</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapBalanceSheetLocationAxis_us-gaapPrepaidExpensesAndOtherCurrentAssetsMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapBalanceSheetLocationAxis_us-gaapPrepaidExpensesAndOtherCurrentAssetsMember_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_20190101">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-01-01</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapIncomeStatementLocationAxis_us-gaapOperatingExpenseMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapRelatedPartyTransactionAxis_nkNantBioScienceMember_20180801_20180831">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nk:NantBioScienceMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-08-01</xbrli:startDate>
      <xbrli:endDate>2018-08-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_srtStatementGeographicalAxis_nkElSegundoCaliforniaMember_us-gaapRelatedPartyTransactionAxis_nkDougStLLCMember_20160930">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nk:DougStLLCMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">nk:ElSegundoCaliforniaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapRelatedPartyTransactionAxis_nkDougStLLCMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nk:DougStLLCMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapRelatedPartyTransactionAxis_nkDougStLLCMember_20160901_20160930">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nk:DougStLLCMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-09-01</xbrli:startDate>
      <xbrli:endDate>2016-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapLeaseArrangementTypeAxis_nkCommitmentWoburnMassachusettsMember_20160331">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">nk:CommitmentWoburnMassachusettsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapLeaseArrangementTypeAxis_nkCommitmentWoburnMassachusettsMember_20160301_20160331">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">nk:CommitmentWoburnMassachusettsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-03-01</xbrli:startDate>
      <xbrli:endDate>2016-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapLeaseArrangementTypeAxis_nkCommitmentWoburnMassachusettsMember_20160630">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">nk:CommitmentWoburnMassachusettsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapLeaseArrangementTypeAxis_nkCommitmentWoburnMassachusettsMember_20160601_20160630">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">nk:CommitmentWoburnMassachusettsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-06-01</xbrli:startDate>
      <xbrli:endDate>2016-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapLeaseArrangementTypeAxis_nkCommitmentWoburnMassachusettsMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">nk:CommitmentWoburnMassachusettsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapLeaseArrangementTypeAxis_nkCommitmentWoburnMassachusettsMember_20190831">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">nk:CommitmentWoburnMassachusettsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-08-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapLeaseArrangementTypeAxis_nkCommitmentWoburnMassachusettsMember_20190801_20190831">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">nk:CommitmentWoburnMassachusettsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-08-01</xbrli:startDate>
      <xbrli:endDate>2019-08-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapRelatedPartyTransactionAxis_nkNantWorksLimitedLiabilityCompanyMember_20151130">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nk:NantWorksLimitedLiabilityCompanyMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-11-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapRelatedPartyTransactionAxis_nkNantWorksLimitedLiabilityCompanyMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nk:NantWorksLimitedLiabilityCompanyMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapRelatedPartyTransactionAxis_nkNantWorksLimitedLiabilityCompanyMember_20151101_20151130">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nk:NantWorksLimitedLiabilityCompanyMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-11-01</xbrli:startDate>
      <xbrli:endDate>2015-11-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapLeaseArrangementTypeAxis_nkCommitmentSanDiegoMember_20150630">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">nk:CommitmentSanDiegoMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapLeaseArrangementTypeAxis_nkCommitmentSanDiegoMember_20150601_20150630">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">nk:CommitmentSanDiegoMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-06-01</xbrli:startDate>
      <xbrli:endDate>2015-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_20181101_20181130">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-11-01</xbrli:startDate>
      <xbrli:endDate>2018-11-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapRelatedPartyTransactionAxis_nkNantHealthLabsIncMember_20180301_20180331">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nk:NantHealthLabsIncMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-03-01</xbrli:startDate>
      <xbrli:endDate>2018-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapRelatedPartyTransactionAxis_nkNantHealthLabsIncMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nk:NantHealthLabsIncMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapRelatedPartyTransactionAxis_nkNantHealthLabsIncMember_20180101_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nk:NantHealthLabsIncMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapRelatedPartyTransactionAxis_nkNantHealthLabsIncMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nk:NantHealthLabsIncMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapRelatedPartyTransactionAxis_nkNantHealthLabsIncMember_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nk:NantHealthLabsIncMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_srtStatementGeographicalAxis_stprCA_us-gaapRelatedPartyTransactionAxis_nkImmunoOncologyClinicIncMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nk:ImmunoOncologyClinicIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_srtStatementGeographicalAxis_stprCA_us-gaapRelatedPartyTransactionAxis_nkImmunoOncologyClinicIncMember_20190701_20190731">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nk:ImmunoOncologyClinicIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-07-01</xbrli:startDate>
      <xbrli:endDate>2019-07-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_srtStatementGeographicalAxis_stprCA_us-gaapRelatedPartyTransactionAxis_nkImmunoOncologyClinicIncMember_20191001_20191031">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nk:ImmunoOncologyClinicIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-10-01</xbrli:startDate>
      <xbrli:endDate>2019-10-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_srtStatementGeographicalAxis_stprCA_us-gaapRelatedPartyTransactionAxis_nkImmunoOncologyClinicIncMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nk:ImmunoOncologyClinicIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_srtStatementGeographicalAxis_stprCA_us-gaapRelatedPartyTransactionAxis_nkImmunoOncologyClinicIncMember_20180101_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nk:ImmunoOncologyClinicIncMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_srtStatementGeographicalAxis_stprCA_us-gaapRelatedPartyTransactionAxis_nkImmunoOncologyClinicIncMember_20170101_20171231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nk:ImmunoOncologyClinicIncMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_srtStatementGeographicalAxis_stprCA_us-gaapRelatedPartyTransactionAxis_nkImmunoOncologyClinicIncMember_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nk:ImmunoOncologyClinicIncMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_srtStatementGeographicalAxis_nkSanDiegoCaliforniaMember_us-gaapRelatedPartyTransactionAxis_nkTensorcomIncMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nk:TensorcomIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">nk:SanDiegoCaliforniaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_srtStatementGeographicalAxis_nkSanDiegoCaliforniaMember_us-gaapRelatedPartyTransactionAxis_nkTensorcomIncMember_20170430">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nk:TensorcomIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">nk:SanDiegoCaliforniaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-04-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_srtStatementGeographicalAxis_nkSanDiegoCaliforniaMember_us-gaapRelatedPartyTransactionAxis_nkTensorcomIncMember_20170401_20170430">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nk:TensorcomIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">nk:SanDiegoCaliforniaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-04-01</xbrli:startDate>
      <xbrli:endDate>2017-04-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_srtStatementGeographicalAxis_nkSanDiegoCaliforniaMember_us-gaapIncomeStatementLocationAxis_us-gaapOtherIncomeMember_us-gaapRelatedPartyTransactionAxis_nkTensorcomIncMember_20180101_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherIncomeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nk:TensorcomIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">nk:SanDiegoCaliforniaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_srtStatementGeographicalAxis_nkSanDiegoCaliforniaMember_us-gaapIncomeStatementLocationAxis_us-gaapOtherIncomeMember_us-gaapRelatedPartyTransactionAxis_nkTensorcomIncMember_20170101_20171231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherIncomeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nk:TensorcomIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">nk:SanDiegoCaliforniaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_srtStatementGeographicalAxis_nkSanDiegoCaliforniaMember_us-gaapRelatedPartyTransactionAxis_nkTensorcomIncMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nk:TensorcomIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">nk:SanDiegoCaliforniaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_srtStatementGeographicalAxis_nkSanDiegoCaliforniaMember_us-gaapRelatedPartyTransactionAxis_nkTensorcomIncMember_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nk:TensorcomIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">nk:SanDiegoCaliforniaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_us-gaapRelatedPartyTransactionAxis_nkDougStLLCMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nk:DougStLLCMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_us-gaapRelatedPartyTransactionAxis_nkDougStLLCMember_20180101_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nk:DougStLLCMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_us-gaapRelatedPartyTransactionAxis_nkDougStLLCMember_20170101_20171231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nk:DougStLLCMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapRelatedPartyTransactionAxis_nkDougStLLCMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nk:DougStLLCMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapRelatedPartyTransactionAxis_nkDougStLLCMember_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nk:DougStLLCMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapRelatedPartyTransactionAxis_nkNantBioScienceMember_20171231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nk:NantBioScienceMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapIncomeStatementLocationAxis_us-gaapOtherIncomeMember_us-gaapRelatedPartyTransactionAxis_nkNantBioScienceMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nk:NantBioScienceMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherIncomeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapIncomeStatementLocationAxis_us-gaapOtherIncomeMember_us-gaapRelatedPartyTransactionAxis_nkNantBioScienceMember_20180101_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nk:NantBioScienceMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherIncomeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapIncomeStatementLocationAxis_us-gaapOtherIncomeMember_us-gaapRelatedPartyTransactionAxis_nkNantBioScienceMember_20170101_20171231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nk:NantBioScienceMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherIncomeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapBalanceSheetLocationAxis_us-gaapPrepaidExpensesAndOtherCurrentAssetsMember_us-gaapRelatedPartyTransactionAxis_nkNantBioScienceMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nk:NantBioScienceMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapBalanceSheetLocationAxis_us-gaapPrepaidExpensesAndOtherCurrentAssetsMember_us-gaapRelatedPartyTransactionAxis_nkNantBioScienceMember_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nk:NantBioScienceMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapRelatedPartyTransactionAxis_nkNantBioScienceMember_20160301_20160331">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nk:NantBioScienceMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-03-01</xbrli:startDate>
      <xbrli:endDate>2016-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapRelatedPartyTransactionAxis_nkNantBioScienceMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nk:NantBioScienceMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapRelatedPartyTransactionAxis_nkNantBioScienceMember_20180101_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nk:NantBioScienceMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapRelatedPartyTransactionAxis_nkNantBioScienceMember_20170101_20171231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nk:NantBioScienceMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapRelatedPartyTransactionAxis_nkNantBioScienceMember_20160401_20160430">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nk:NantBioScienceMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-04-01</xbrli:startDate>
      <xbrli:endDate>2016-04-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapRelatedPartyTransactionAxis_nkNantBioScienceMember_20170401_20170430">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nk:NantBioScienceMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-04-01</xbrli:startDate>
      <xbrli:endDate>2017-04-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapRelatedPartyTransactionAxis_nkNantBioScienceMember_20190501_20190531">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nk:NantBioScienceMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-05-01</xbrli:startDate>
      <xbrli:endDate>2019-05-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapBalanceSheetLocationAxis_us-gaapPrepaidExpensesAndOtherCurrentAssetsMember_us-gaapRelatedPartyTransactionAxis_nkNantBioScienceMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nk:NantBioScienceMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapBalanceSheetLocationAxis_us-gaapPrepaidExpensesAndOtherCurrentAssetsMember_us-gaapRelatedPartyTransactionAxis_nkNantBioScienceMember_20180101_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nk:NantBioScienceMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapRelatedPartyTransactionAxis_nkNantWorksLimitedLiabilityCompanyMember_20180501_20180531">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nk:NantWorksLimitedLiabilityCompanyMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-05-01</xbrli:startDate>
      <xbrli:endDate>2018-05-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapRelatedPartyTransactionAxis_nkNantWorksLimitedLiabilityCompanyMember_us-gaapTypeOfArrangementAxis_nkSharedServicesAgreementMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nk:NantWorksLimitedLiabilityCompanyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nk:SharedServicesAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapRelatedPartyTransactionAxis_nkNantWorksLimitedLiabilityCompanyMember_us-gaapTypeOfArrangementAxis_nkSharedServicesAgreementMember_20180101_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nk:NantWorksLimitedLiabilityCompanyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nk:SharedServicesAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapRelatedPartyTransactionAxis_nkNantWorksLimitedLiabilityCompanyMember_us-gaapTypeOfArrangementAxis_nkSharedServicesAgreementMember_20170101_20171231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nk:NantWorksLimitedLiabilityCompanyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nk:SharedServicesAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapRelatedPartyTransactionAxis_nkNantWorksLimitedLiabilityCompanyMember_us-gaapTransactionTypeAxis_nkReimbursementsMember_us-gaapTypeOfArrangementAxis_nkSharedServicesAgreementMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">nk:ReimbursementsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nk:NantWorksLimitedLiabilityCompanyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nk:SharedServicesAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapRelatedPartyTransactionAxis_nkNantWorksLimitedLiabilityCompanyMember_us-gaapTransactionTypeAxis_nkReimbursementsMember_us-gaapTypeOfArrangementAxis_nkSharedServicesAgreementMember_20180101_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">nk:ReimbursementsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nk:NantWorksLimitedLiabilityCompanyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nk:SharedServicesAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapRelatedPartyTransactionAxis_nkNantWorksLimitedLiabilityCompanyMember_us-gaapTransactionTypeAxis_nkReimbursementsMember_us-gaapTypeOfArrangementAxis_nkSharedServicesAgreementMember_20170101_20171231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">nk:ReimbursementsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nk:NantWorksLimitedLiabilityCompanyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nk:SharedServicesAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapRelatedPartyTransactionAxis_nkNantWorksLimitedLiabilityCompanyMember_us-gaapTransactionTypeAxis_nkReimbursementsMember_us-gaapTypeOfArrangementAxis_nkSharedServicesAgreementMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">nk:ReimbursementsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nk:NantWorksLimitedLiabilityCompanyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nk:SharedServicesAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapRelatedPartyTransactionAxis_nkNantWorksLimitedLiabilityCompanyMember_us-gaapTransactionTypeAxis_nkReimbursementsMember_us-gaapTypeOfArrangementAxis_nkSharedServicesAgreementMember_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">nk:ReimbursementsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nk:NantWorksLimitedLiabilityCompanyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nk:SharedServicesAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_us-gaapRelatedPartyTransactionAxis_nkNantWorksLimitedLiabilityCompanyMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nk:NantWorksLimitedLiabilityCompanyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_us-gaapRelatedPartyTransactionAxis_nkNantWorksLimitedLiabilityCompanyMember_20180101_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nk:NantWorksLimitedLiabilityCompanyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_us-gaapRelatedPartyTransactionAxis_nkNantWorksLimitedLiabilityCompanyMember_20170101_20171231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nk:NantWorksLimitedLiabilityCompanyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapRelatedPartyTransactionAxis_nkNantOmicsLLCMember_20150601_20150630">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nk:NantOmicsLLCMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-06-01</xbrli:startDate>
      <xbrli:endDate>2015-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapRelatedPartyTransactionAxis_nkNantOmicsLLCMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nk:NantOmicsLLCMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapRelatedPartyTransactionAxis_nkNantOmicsLLCMember_20180101_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nk:NantOmicsLLCMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapRelatedPartyTransactionAxis_nkNantOmicsLLCMember_20170101_20171231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nk:NantOmicsLLCMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapRelatedPartyTransactionAxis_nkNantOmicsLLCMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nk:NantOmicsLLCMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapRelatedPartyTransactionAxis_nkNantOmicsLLCMember_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nk:NantOmicsLLCMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapRelatedPartyTransactionAxis_nkImmunityBioMember_20181101_20181130">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nk:ImmunityBioMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-11-01</xbrli:startDate>
      <xbrli:endDate>2018-11-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapRelatedPartyTransactionAxis_nkVivaBioCellSPAMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nk:VivaBioCellSPAMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapRelatedPartyTransactionAxis_nkVivaBioCellSPAMember_20180101_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nk:VivaBioCellSPAMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapRelatedPartyTransactionAxis_nkVivaBioCellSPAMember_20170101_20171231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nk:VivaBioCellSPAMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapRelatedPartyTransactionAxis_nkImmunityBioMember_20150601_20150630">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nk:ImmunityBioMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-06-01</xbrli:startDate>
      <xbrli:endDate>2015-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapRelatedPartyTransactionAxis_nkImmunityBioMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nk:ImmunityBioMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapRelatedPartyTransactionAxis_nkImmunityBioMember_20180101_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nk:ImmunityBioMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapRelatedPartyTransactionAxis_nkImmunityBioMember_20170101_20171231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nk:ImmunityBioMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapRelatedPartyTransactionAxis_nkImmunityBioMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nk:ImmunityBioMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapRelatedPartyTransactionAxis_nkImmunityBioMember_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nk:ImmunityBioMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_20151102_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-11-02</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapAwardTypeAxis_nkOutstandingOfficerWarrantsMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nk:OutstandingOfficerWarrantsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapPlanNameAxis_nkTwoThousandFourteenEquityIncentivePlanMember_us-gaapStatementClassOfStockAxis_us-gaapCommonClassAMember_20140331">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nk:TwoThousandFourteenEquityIncentivePlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapPlanNameAxis_nkTwoThousandFourteenEquityIncentivePlanMember_us-gaapStatementClassOfStockAxis_us-gaapCommonClassAMember_20140301_20140331">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nk:TwoThousandFourteenEquityIncentivePlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-03-01</xbrli:startDate>
      <xbrli:endDate>2014-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapPlanNameAxis_nkTwoThousandFifteenEquityIncentivePlanMember_20190601_20190630">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nk:TwoThousandFifteenEquityIncentivePlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-06-01</xbrli:startDate>
      <xbrli:endDate>2019-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapPlanNameAxis_nkTwoThousandFifteenEquityIncentivePlanMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nk:TwoThousandFifteenEquityIncentivePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapPlanNameAxis_nkTwoThousandFifteenEquityIncentivePlanMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nk:TwoThousandFifteenEquityIncentivePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_srtTitleOfIndividualAxis_srtOfficerMember_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:OfficerMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_srtTitleOfIndividualAxis_srtOfficerMember_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_20180101_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:OfficerMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_srtTitleOfIndividualAxis_srtOfficerMember_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_20170101_20171231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:OfficerMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20180101_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20170101_20171231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapAwardTypeAxis_nkEmployeeRestrictedStockUnitMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nk:EmployeeRestrictedStockUnitMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapAwardTypeAxis_nkEmployeeRestrictedStockUnitMember_20180101_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nk:EmployeeRestrictedStockUnitMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapAwardTypeAxis_nkEmployeeRestrictedStockUnitMember_20170101_20171231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nk:EmployeeRestrictedStockUnitMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapAwardTypeAxis_nkNonEmployeeRestrictedStockUnitMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nk:NonEmployeeRestrictedStockUnitMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapAwardTypeAxis_nkNonEmployeeRestrictedStockUnitMember_20180101_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nk:NonEmployeeRestrictedStockUnitMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapAwardTypeAxis_nkNonEmployeeRestrictedStockUnitMember_20170101_20171231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nk:NonEmployeeRestrictedStockUnitMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapIncomeStatementLocationAxis_us-gaapSellingGeneralAndAdministrativeExpensesMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapIncomeStatementLocationAxis_us-gaapSellingGeneralAndAdministrativeExpensesMember_20180101_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapIncomeStatementLocationAxis_us-gaapSellingGeneralAndAdministrativeExpensesMember_20170101_20171231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20161231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20171231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20160101_20161231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_nkExercisePriceRangeOneMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">nk:ExercisePriceRangeOneMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_nkExercisePriceRangeTwoMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">nk:ExercisePriceRangeTwoMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_nkExercisePriceRangeThreeMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">nk:ExercisePriceRangeThreeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_nkExercisePriceRangeFourMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">nk:ExercisePriceRangeFourMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_nkExercisePriceRangeFiveMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">nk:ExercisePriceRangeFiveMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_nkExercisePriceRangeOneMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">nk:ExercisePriceRangeOneMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_nkExercisePriceRangeTwoMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">nk:ExercisePriceRangeTwoMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_nkExercisePriceRangeThreeMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">nk:ExercisePriceRangeThreeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_nkExercisePriceRangeFourMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">nk:ExercisePriceRangeFourMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_nkExercisePriceRangeFiveMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">nk:ExercisePriceRangeFiveMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapAwardTypeAxis_nkKeyExecutivesStockOptionsMember_20180101_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nk:KeyExecutivesStockOptionsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapAwardTypeAxis_nkKeyExecutivesStockOptionsMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nk:KeyExecutivesStockOptionsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapAwardTypeAxis_nkKeyExecutivesStockOptionsMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nk:KeyExecutivesStockOptionsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapAwardTypeAxis_nkNonEmployeeStockOptionsMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nk:NonEmployeeStockOptionsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapAwardTypeAxis_nkNonEmployeeStockOptionsMember_20180101_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nk:NonEmployeeStockOptionsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapAwardTypeAxis_nkNonEmployeeStockOptionsMember_20170101_20171231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nk:NonEmployeeStockOptionsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_srtRangeAxis_srtMinimumMember_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20180101_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_srtRangeAxis_srtMaximumMember_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20180101_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20161231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20170101_20171231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20171231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20180101_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapAwardTypeAxis_nkEmployeeRestrictedStockUnitMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nk:EmployeeRestrictedStockUnitMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapAwardTypeAxis_nkNonEmployeeRestrictedStockUnitMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nk:NonEmployeeRestrictedStockUnitMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapWarrantMember_20161231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapWarrantMember_20170101_20171231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapWarrantMember_20171231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapWarrantMember_20180101_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapWarrantMember_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapWarrantMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapWarrantMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_srtRangeAxis_srtMaximumMember_20170101_20171231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapIncomeTaxAuthorityAxis_us-gaapForeignCountryMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapIncomeTaxAuthorityAxis_us-gaapForeignCountryMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_us-gaapTaxCreditCarryforwardAxis_us-gaapResearchMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_srtStatementGeographicalAxis_stprCA_us-gaapTaxCreditCarryforwardAxis_us-gaapResearchMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_us-gaapTaxCreditCarryforwardAxis_us-gaapResearchMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_us-gaapTaxCreditCarryforwardAxis_us-gaapResearchMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_20190101_20190331">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_20190401_20190630">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-04-01</xbrli:startDate>
      <xbrli:endDate>2019-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_20190701_20190930">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-07-01</xbrli:startDate>
      <xbrli:endDate>2019-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_20191001_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-10-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_20180101_20180331">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_20180401_20180630">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-04-01</xbrli:startDate>
      <xbrli:endDate>2018-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_20180701_20180930">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-07-01</xbrli:startDate>
      <xbrli:endDate>2018-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_20181001_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-10-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapRetirementPlanNameAxis_nkFourHundredOneKPlanMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RetirementPlanNameAxis">nk:FourHundredOneKPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapRetirementPlanNameAxis_nkFourHundredOneKPlanMember_20180101_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RetirementPlanNameAxis">nk:FourHundredOneKPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapRetirementPlanNameAxis_nkFourHundredOneKPlanMember_20170101_20171231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RetirementPlanNameAxis">nk:FourHundredOneKPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20200129">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-01-29</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001326110_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <dei:DocumentType id="F_000000" contextRef="C_0001326110_20190101_20191231">10-K</dei:DocumentType>
  <dei:AmendmentFlag id="F_000001" contextRef="C_0001326110_20190101_20191231">false</dei:AmendmentFlag>
  <dei:DocumentPeriodEndDate id="F_000002" contextRef="C_0001326110_20190101_20191231">2019-12-31</dei:DocumentPeriodEndDate>
  <dei:DocumentFiscalYearFocus id="F_000003" contextRef="C_0001326110_20190101_20191231">2019</dei:DocumentFiscalYearFocus>
  <dei:DocumentFiscalPeriodFocus id="F_000004" contextRef="C_0001326110_20190101_20191231">FY</dei:DocumentFiscalPeriodFocus>
  <dei:TradingSymbol id="F_000005" contextRef="C_0001326110_20190101_20191231">NK</dei:TradingSymbol>
  <dei:EntityRegistrantName id="F_000006" contextRef="C_0001326110_20190101_20191231">NANTKWEST, INC.</dei:EntityRegistrantName>
  <dei:EntityCentralIndexKey id="F_000007" contextRef="C_0001326110_20190101_20191231">0001326110</dei:EntityCentralIndexKey>
  <dei:CurrentFiscalYearEndDate id="F_000008" contextRef="C_0001326110_20190101_20191231">--12-31</dei:CurrentFiscalYearEndDate>
  <dei:EntityWellKnownSeasonedIssuer id="F_000009" contextRef="C_0001326110_20190101_20191231">No</dei:EntityWellKnownSeasonedIssuer>
  <dei:EntityCurrentReportingStatus id="F_000010" contextRef="C_0001326110_20190101_20191231">Yes</dei:EntityCurrentReportingStatus>
  <dei:EntityVoluntaryFilers id="F_000011" contextRef="C_0001326110_20190101_20191231">No</dei:EntityVoluntaryFilers>
  <dei:EntityFilerCategory id="F_000012" contextRef="C_0001326110_20190101_20191231">Non-accelerated Filer</dei:EntityFilerCategory>
  <dei:EntityEmergingGrowthCompany id="F_000013" contextRef="C_0001326110_20190101_20191231">true</dei:EntityEmergingGrowthCompany>
  <dei:EntitySmallBusiness id="F_000014" contextRef="C_0001326110_20190101_20191231">true</dei:EntitySmallBusiness>
  <dei:EntityExTransitionPeriod id="F_000015" contextRef="C_0001326110_20190101_20191231">true</dei:EntityExTransitionPeriod>
  <dei:EntityShellCompany id="F_000016" contextRef="C_0001326110_20190101_20191231">false</dei:EntityShellCompany>
  <dei:EntityCommonStockSharesOutstanding id="F_000017" contextRef="C_0001326110_20200320" decimals="INF" unitRef="U_xbrlishares">98483161</dei:EntityCommonStockSharesOutstanding>
  <dei:EntityPublicFloat id="F_000018" contextRef="C_0001326110_20190630" decimals="-5" unitRef="U_iso4217USD">28800000</dei:EntityPublicFloat>
  <dei:Security12bTitle id="F_000019" contextRef="C_0001326110_20190101_20191231">Common Stock, par value $0.0001 per share</dei:Security12bTitle>
  <dei:EntityFileNumber id="F_000020" contextRef="C_0001326110_20190101_20191231">001-37507</dei:EntityFileNumber>
  <dei:EntityIncorporationStateCountryCode id="F_000021" contextRef="C_0001326110_20190101_20191231">DE</dei:EntityIncorporationStateCountryCode>
  <dei:EntityTaxIdentificationNumber id="F_000022" contextRef="C_0001326110_20190101_20191231">43-1979754</dei:EntityTaxIdentificationNumber>
  <dei:EntityInteractiveDataCurrent id="F_000023" contextRef="C_0001326110_20190101_20191231">Yes</dei:EntityInteractiveDataCurrent>
  <dei:SecurityExchangeName id="F_000024" contextRef="C_0001326110_20190101_20191231">NASDAQ</dei:SecurityExchangeName>
  <dei:EntityAddressAddressLine1 id="F_000025" contextRef="C_0001326110_20190101_20191231">3530 John Hopkins Court</dei:EntityAddressAddressLine1>
  <dei:EntityAddressCityOrTown id="F_000026" contextRef="C_0001326110_20190101_20191231">San Diego</dei:EntityAddressCityOrTown>
  <dei:EntityAddressStateOrProvince id="F_000027" contextRef="C_0001326110_20190101_20191231">CA</dei:EntityAddressStateOrProvince>
  <dei:EntityAddressPostalZipCode id="F_000028" contextRef="C_0001326110_20190101_20191231">92121</dei:EntityAddressPostalZipCode>
  <dei:CityAreaCode id="F_000029" contextRef="C_0001326110_20190101_20191231">858</dei:CityAreaCode>
  <dei:LocalPhoneNumber id="F_000030" contextRef="C_0001326110_20190101_20191231">633-0300</dei:LocalPhoneNumber>
  <dei:DocumentAnnualReport id="F_000031" contextRef="C_0001326110_20190101_20191231">true</dei:DocumentAnnualReport>
  <dei:DocumentTransitionReport id="F_000032" contextRef="C_0001326110_20190101_20191231">false</dei:DocumentTransitionReport>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="F_000033" contextRef="C_0001326110_20191231" decimals="-3" unitRef="U_iso4217USD">15508000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="F_000034" contextRef="C_0001326110_20181231" decimals="-3" unitRef="U_iso4217USD">16821000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent id="F_000035" contextRef="C_0001326110_20191231" decimals="-3" unitRef="U_iso4217USD">4105000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent id="F_000036" contextRef="C_0001326110_20181231" decimals="-3" unitRef="U_iso4217USD">13900000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent id="F_000037" contextRef="C_0001326110_20191231" decimals="-3" unitRef="U_iso4217USD">36144000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
  <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent id="F_000038" contextRef="C_0001326110_20181231" decimals="-3" unitRef="U_iso4217USD">57328000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
  <us-gaap:HeldToMaturitySecuritiesCurrent id="F_000039" contextRef="C_0001326110_20191231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:HeldToMaturitySecuritiesCurrent>
  <us-gaap:HeldToMaturitySecuritiesCurrent id="F_000040" contextRef="C_0001326110_20181231" decimals="-3" unitRef="U_iso4217USD">723000</us-gaap:HeldToMaturitySecuritiesCurrent>
  <us-gaap:AssetsCurrent id="F_000041" contextRef="C_0001326110_20191231" decimals="-3" unitRef="U_iso4217USD">55757000</us-gaap:AssetsCurrent>
  <us-gaap:AssetsCurrent id="F_000042" contextRef="C_0001326110_20181231" decimals="-3" unitRef="U_iso4217USD">88772000</us-gaap:AssetsCurrent>
  <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent id="F_000043" contextRef="C_0001326110_20191231" decimals="-3" unitRef="U_iso4217USD">1497000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
  <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent id="F_000044" contextRef="C_0001326110_20181231" decimals="-3" unitRef="U_iso4217USD">5701000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
  <us-gaap:PropertyPlantAndEquipmentNet id="F_000045" contextRef="C_0001326110_20191231" decimals="-3" unitRef="U_iso4217USD">60501000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:PropertyPlantAndEquipmentNet id="F_000046" contextRef="C_0001326110_20181231" decimals="-3" unitRef="U_iso4217USD">76885000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:OperatingLeaseRightOfUseAsset id="F_000047" contextRef="C_0001326110_20191231" decimals="-3" unitRef="U_iso4217USD">11729000</us-gaap:OperatingLeaseRightOfUseAsset>
  <us-gaap:OperatingLeaseRightOfUseAsset id="F_000048" contextRef="C_0001326110_20181231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:OperatingLeaseRightOfUseAsset>
  <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount id="F_000049" contextRef="C_0001326110_20191231" decimals="-3" unitRef="U_iso4217USD">9253000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount>
  <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount id="F_000050" contextRef="C_0001326110_20181231" decimals="-3" unitRef="U_iso4217USD">8500000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount>
  <us-gaap:IntangibleAssetsNetExcludingGoodwill id="F_000051" contextRef="C_0001326110_20191231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:IntangibleAssetsNetExcludingGoodwill>
  <us-gaap:IntangibleAssetsNetExcludingGoodwill id="F_000052" contextRef="C_0001326110_20181231" decimals="-3" unitRef="U_iso4217USD">565000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
  <us-gaap:OtherAssetsNoncurrent id="F_000053" contextRef="C_0001326110_20191231" decimals="-3" unitRef="U_iso4217USD">4386000</us-gaap:OtherAssetsNoncurrent>
  <us-gaap:OtherAssetsNoncurrent id="F_000054" contextRef="C_0001326110_20181231" decimals="-3" unitRef="U_iso4217USD">1527000</us-gaap:OtherAssetsNoncurrent>
  <us-gaap:Assets id="F_000055" contextRef="C_0001326110_20191231" decimals="-3" unitRef="U_iso4217USD">143123000</us-gaap:Assets>
  <us-gaap:Assets id="F_000056" contextRef="C_0001326110_20181231" decimals="-3" unitRef="U_iso4217USD">181950000</us-gaap:Assets>
  <us-gaap:AccountsPayableCurrent id="F_000057" contextRef="C_0001326110_20191231" decimals="-3" unitRef="U_iso4217USD">1749000</us-gaap:AccountsPayableCurrent>
  <us-gaap:AccountsPayableCurrent id="F_000058" contextRef="C_0001326110_20181231" decimals="-3" unitRef="U_iso4217USD">2793000</us-gaap:AccountsPayableCurrent>
  <us-gaap:AccruedLiabilitiesCurrent id="F_000059" contextRef="C_0001326110_20191231" decimals="-3" unitRef="U_iso4217USD">5343000</us-gaap:AccruedLiabilitiesCurrent>
  <us-gaap:AccruedLiabilitiesCurrent id="F_000060" contextRef="C_0001326110_20181231" decimals="-3" unitRef="U_iso4217USD">21104000</us-gaap:AccruedLiabilitiesCurrent>
  <us-gaap:DueToRelatedPartiesCurrent id="F_000061" contextRef="C_0001326110_20191231" decimals="-3" unitRef="U_iso4217USD">486000</us-gaap:DueToRelatedPartiesCurrent>
  <us-gaap:DueToRelatedPartiesCurrent id="F_000062" contextRef="C_0001326110_20181231" decimals="-3" unitRef="U_iso4217USD">1696000</us-gaap:DueToRelatedPartiesCurrent>
  <us-gaap:OtherLiabilitiesCurrent id="F_000063" contextRef="C_0001326110_20191231" decimals="-3" unitRef="U_iso4217USD">3981000</us-gaap:OtherLiabilitiesCurrent>
  <us-gaap:OtherLiabilitiesCurrent id="F_000064" contextRef="C_0001326110_20181231" decimals="-3" unitRef="U_iso4217USD">1667000</us-gaap:OtherLiabilitiesCurrent>
  <us-gaap:LiabilitiesCurrent id="F_000065" contextRef="C_0001326110_20191231" decimals="-3" unitRef="U_iso4217USD">11559000</us-gaap:LiabilitiesCurrent>
  <us-gaap:LiabilitiesCurrent id="F_000066" contextRef="C_0001326110_20181231" decimals="-3" unitRef="U_iso4217USD">27260000</us-gaap:LiabilitiesCurrent>
  <us-gaap:OperatingLeaseLiabilityNoncurrent id="F_000067" contextRef="C_0001326110_20191231" decimals="-3" unitRef="U_iso4217USD">10885000</us-gaap:OperatingLeaseLiabilityNoncurrent>
  <us-gaap:OperatingLeaseLiabilityNoncurrent id="F_000068" contextRef="C_0001326110_20181231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:OperatingLeaseLiabilityNoncurrent>
  <nk:FinancingObligationNoncurrent id="F_000069" contextRef="C_0001326110_20191231" decimals="-3" unitRef="U_iso4217USD">0</nk:FinancingObligationNoncurrent>
  <nk:FinancingObligationNoncurrent id="F_000070" contextRef="C_0001326110_20181231" decimals="-3" unitRef="U_iso4217USD">5945000</nk:FinancingObligationNoncurrent>
  <us-gaap:DeferredRentCreditNoncurrent id="F_000071" contextRef="C_0001326110_20191231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:DeferredRentCreditNoncurrent>
  <us-gaap:DeferredRentCreditNoncurrent id="F_000072" contextRef="C_0001326110_20181231" decimals="-3" unitRef="U_iso4217USD">2739000</us-gaap:DeferredRentCreditNoncurrent>
  <us-gaap:Liabilities id="F_000073" contextRef="C_0001326110_20191231" decimals="-3" unitRef="U_iso4217USD">22444000</us-gaap:Liabilities>
  <us-gaap:Liabilities id="F_000074" contextRef="C_0001326110_20181231" decimals="-3" unitRef="U_iso4217USD">35944000</us-gaap:Liabilities>
  <us-gaap:CommitmentsAndContingencies id="F_000075" contextRef="C_0001326110_20191231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:CommitmentsAndContingencies>
  <us-gaap:CommitmentsAndContingencies id="F_000076" contextRef="C_0001326110_20181231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:CommitmentsAndContingencies>
  <us-gaap:CommonStockValue id="F_000077" contextRef="C_0001326110_20191231" decimals="-3" unitRef="U_iso4217USD">10000</us-gaap:CommonStockValue>
  <us-gaap:CommonStockValue id="F_000078" contextRef="C_0001326110_20181231" decimals="-3" unitRef="U_iso4217USD">8000</us-gaap:CommonStockValue>
  <us-gaap:AdditionalPaidInCapitalCommonStock id="F_000079" contextRef="C_0001326110_20191231" decimals="-3" unitRef="U_iso4217USD">782965000</us-gaap:AdditionalPaidInCapitalCommonStock>
  <us-gaap:AdditionalPaidInCapitalCommonStock id="F_000080" contextRef="C_0001326110_20181231" decimals="-3" unitRef="U_iso4217USD">741246000</us-gaap:AdditionalPaidInCapitalCommonStock>
  <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax id="F_000081" contextRef="C_0001326110_20191231" decimals="-3" unitRef="U_iso4217USD">-105000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
  <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax id="F_000082" contextRef="C_0001326110_20181231" decimals="-3" unitRef="U_iso4217USD">-267000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
  <us-gaap:RetainedEarningsAccumulatedDeficit id="F_000083" contextRef="C_0001326110_20191231" decimals="-3" unitRef="U_iso4217USD">-662191000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:RetainedEarningsAccumulatedDeficit id="F_000084" contextRef="C_0001326110_20181231" decimals="-3" unitRef="U_iso4217USD">-594981000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:StockholdersEquity id="F_000085" contextRef="C_0001326110_20191231" decimals="-3" unitRef="U_iso4217USD">120679000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="F_000086" contextRef="C_0001326110_20181231" decimals="-3" unitRef="U_iso4217USD">146006000</us-gaap:StockholdersEquity>
  <us-gaap:LiabilitiesAndStockholdersEquity id="F_000087" contextRef="C_0001326110_20191231" decimals="-3" unitRef="U_iso4217USD">143123000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:LiabilitiesAndStockholdersEquity id="F_000088" contextRef="C_0001326110_20181231" decimals="-3" unitRef="U_iso4217USD">181950000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:CommonStockParOrStatedValuePerShare id="F_000089" contextRef="C_0001326110_20191231" decimals="INF" unitRef="U_iso4217USD_xbrlishares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockParOrStatedValuePerShare id="F_000090" contextRef="C_0001326110_20181231" decimals="INF" unitRef="U_iso4217USD_xbrlishares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockSharesAuthorized id="F_000091" contextRef="C_0001326110_20191231" decimals="INF" unitRef="U_xbrlishares">500000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesAuthorized id="F_000092" contextRef="C_0001326110_20181231" decimals="INF" unitRef="U_xbrlishares">500000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesIssued id="F_000093" contextRef="C_0001326110_20191231" decimals="INF" unitRef="U_xbrlishares">98460404</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesIssued id="F_000094" contextRef="C_0001326110_20181231" decimals="INF" unitRef="U_xbrlishares">79087734</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesOutstanding id="F_000095" contextRef="C_0001326110_20191231" decimals="INF" unitRef="U_xbrlishares">98460404</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockSharesOutstanding id="F_000096" contextRef="C_0001326110_20181231" decimals="INF" unitRef="U_xbrlishares">79087734</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:Revenues id="F_000097" contextRef="C_0001326110_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">43000</us-gaap:Revenues>
  <us-gaap:Revenues id="F_000098" contextRef="C_0001326110_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">47000</us-gaap:Revenues>
  <us-gaap:Revenues id="F_000099" contextRef="C_0001326110_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">45000</us-gaap:Revenues>
  <us-gaap:ResearchAndDevelopmentExpense id="F_000100" contextRef="C_0001326110_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">49785000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense id="F_000101" contextRef="C_0001326110_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">55718000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense id="F_000102" contextRef="C_0001326110_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">42044000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:SellingGeneralAndAdministrativeExpense id="F_000103" contextRef="C_0001326110_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">18065000</us-gaap:SellingGeneralAndAdministrativeExpense>
  <us-gaap:SellingGeneralAndAdministrativeExpense id="F_000104" contextRef="C_0001326110_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">42718000</us-gaap:SellingGeneralAndAdministrativeExpense>
  <us-gaap:SellingGeneralAndAdministrativeExpense id="F_000105" contextRef="C_0001326110_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">57121000</us-gaap:SellingGeneralAndAdministrativeExpense>
  <us-gaap:OperatingExpenses id="F_000106" contextRef="C_0001326110_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">67850000</us-gaap:OperatingExpenses>
  <us-gaap:OperatingExpenses id="F_000107" contextRef="C_0001326110_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">98436000</us-gaap:OperatingExpenses>
  <us-gaap:OperatingExpenses id="F_000108" contextRef="C_0001326110_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">99165000</us-gaap:OperatingExpenses>
  <us-gaap:OperatingIncomeLoss id="F_000109" contextRef="C_0001326110_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-67807000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss id="F_000110" contextRef="C_0001326110_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">-98389000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss id="F_000111" contextRef="C_0001326110_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">-99120000</us-gaap:OperatingIncomeLoss>
  <us-gaap:InvestmentIncomeNet id="F_000112" contextRef="C_0001326110_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">1642000</us-gaap:InvestmentIncomeNet>
  <us-gaap:InvestmentIncomeNet id="F_000113" contextRef="C_0001326110_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">1857000</us-gaap:InvestmentIncomeNet>
  <us-gaap:InvestmentIncomeNet id="F_000114" contextRef="C_0001326110_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">2665000</us-gaap:InvestmentIncomeNet>
  <us-gaap:FinanceLeaseInterestExpense id="F_000115" contextRef="C_0001326110_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">19000</us-gaap:FinanceLeaseInterestExpense>
  <us-gaap:FinanceLeaseInterestExpense id="F_000116" contextRef="C_0001326110_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">433000</us-gaap:FinanceLeaseInterestExpense>
  <us-gaap:FinanceLeaseInterestExpense id="F_000117" contextRef="C_0001326110_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">618000</us-gaap:FinanceLeaseInterestExpense>
  <us-gaap:OtherNonoperatingIncomeExpense id="F_000118" contextRef="C_0001326110_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">298000</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:OtherNonoperatingIncomeExpense id="F_000119" contextRef="C_0001326110_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">236000</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:OtherNonoperatingIncomeExpense id="F_000120" contextRef="C_0001326110_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">157000</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:NonoperatingIncomeExpense id="F_000121" contextRef="C_0001326110_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">1921000</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:NonoperatingIncomeExpense id="F_000122" contextRef="C_0001326110_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">1660000</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:NonoperatingIncomeExpense id="F_000123" contextRef="C_0001326110_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">2204000</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest id="F_000124" contextRef="C_0001326110_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-65886000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest id="F_000125" contextRef="C_0001326110_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">-96729000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest id="F_000126" contextRef="C_0001326110_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">-96916000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
  <us-gaap:IncomeTaxExpenseBenefit id="F_000127" contextRef="C_0001326110_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-97000</us-gaap:IncomeTaxExpenseBenefit>
  <us-gaap:IncomeTaxExpenseBenefit id="F_000128" contextRef="C_0001326110_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">-503000</us-gaap:IncomeTaxExpenseBenefit>
  <us-gaap:IncomeTaxExpenseBenefit id="F_000129" contextRef="C_0001326110_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">-493000</us-gaap:IncomeTaxExpenseBenefit>
  <us-gaap:NetIncomeLoss id="F_000130" contextRef="C_0001326110_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-65789000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss id="F_000131" contextRef="C_0001326110_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">-96226000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss id="F_000132" contextRef="C_0001326110_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">-96423000</us-gaap:NetIncomeLoss>
  <us-gaap:EarningsPerShareBasicAndDiluted id="F_000133" contextRef="C_0001326110_20190101_20191231" decimals="2" unitRef="U_iso4217USD_xbrlishares">-0.70</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted id="F_000134" contextRef="C_0001326110_20180101_20181231" decimals="2" unitRef="U_iso4217USD_xbrlishares">-1.22</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted id="F_000135" contextRef="C_0001326110_20170101_20171231" decimals="2" unitRef="U_iso4217USD_xbrlishares">-1.20</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted id="F_000136" contextRef="C_0001326110_20190101_20191231" decimals="0" unitRef="U_xbrlishares">94210087</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted id="F_000137" contextRef="C_0001326110_20180101_20181231" decimals="0" unitRef="U_xbrlishares">79132220</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted id="F_000138" contextRef="C_0001326110_20170101_20171231" decimals="0" unitRef="U_xbrlishares">80583910</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax id="F_000139" contextRef="C_0001326110_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">158000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax>
  <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax id="F_000140" contextRef="C_0001326110_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">114000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax>
  <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax id="F_000141" contextRef="C_0001326110_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">-65000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax>
  <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax id="F_000142" contextRef="C_0001326110_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-4000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
  <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax id="F_000143" contextRef="C_0001326110_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
  <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax id="F_000144" contextRef="C_0001326110_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">32000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
  <us-gaap:OtherComprehensiveIncomeLossNetOfTax id="F_000145" contextRef="C_0001326110_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">162000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
  <us-gaap:OtherComprehensiveIncomeLossNetOfTax id="F_000146" contextRef="C_0001326110_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">114000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
  <us-gaap:OtherComprehensiveIncomeLossNetOfTax id="F_000147" contextRef="C_0001326110_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">-97000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
  <us-gaap:ComprehensiveIncomeNetOfTax id="F_000148" contextRef="C_0001326110_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-65627000</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:ComprehensiveIncomeNetOfTax id="F_000149" contextRef="C_0001326110_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">-96112000</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:ComprehensiveIncomeNetOfTax id="F_000150" contextRef="C_0001326110_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">-96520000</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:CommonStockSharesIssued id="F_000151" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20161231" decimals="INF" unitRef="U_xbrlishares">81983937</us-gaap:CommonStockSharesIssued>
  <us-gaap:StockholdersEquity id="F_000152" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20161231" decimals="-3" unitRef="U_iso4217USD">8000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="F_000153" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20161231" decimals="-3" unitRef="U_iso4217USD">680757000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="F_000154" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20161231" decimals="-3" unitRef="U_iso4217USD">-284000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="F_000155" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20161231" decimals="-3" unitRef="U_iso4217USD">-387063000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="F_000156" contextRef="C_0001326110_20161231" decimals="-3" unitRef="U_iso4217USD">293418000</us-gaap:StockholdersEquity>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="F_000157" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="F_000158" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">36997000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="F_000159" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="F_000160" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="F_000161" contextRef="C_0001326110_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">36997000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <nk:StockIssuedDuringPeriodSharesWarrantsExercised id="F_000162" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20170101_20171231" decimals="INF" unitRef="U_xbrlishares">47226</nk:StockIssuedDuringPeriodSharesWarrantsExercised>
  <us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants id="F_000163" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants>
  <us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants id="F_000164" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">61000</us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants>
  <us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants id="F_000165" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants>
  <us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants id="F_000166" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants>
  <us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants id="F_000167" contextRef="C_0001326110_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">61000</us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised id="F_000168" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20170101_20171231" decimals="INF" unitRef="U_xbrlishares">614136</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised id="F_000169" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised id="F_000170" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">1154000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised id="F_000171" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised id="F_000172" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised id="F_000173" contextRef="C_0001326110_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">1154000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross id="F_000174" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20170101_20171231" decimals="INF" unitRef="U_xbrlishares">244209</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
  <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross id="F_000175" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
  <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross id="F_000176" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
  <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross id="F_000177" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
  <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross id="F_000178" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
  <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross id="F_000179" contextRef="C_0001326110_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
  <us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation id="F_000180" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20170101_20171231" decimals="INF" unitRef="U_xbrlishares">234020</us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation>
  <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation id="F_000181" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
  <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation id="F_000182" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">1039000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
  <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation id="F_000183" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
  <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation id="F_000184" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
  <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation id="F_000185" contextRef="C_0001326110_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">1039000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
  <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares id="F_000186" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20170101_20171231" decimals="INF" unitRef="U_xbrlishares">3633610</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
  <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue id="F_000187" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
  <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue id="F_000188" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
  <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue id="F_000189" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
  <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue id="F_000190" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">15227000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
  <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue id="F_000191" contextRef="C_0001326110_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">15227000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
  <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax id="F_000192" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
  <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax id="F_000193" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
  <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax id="F_000194" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">-97000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
  <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax id="F_000195" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
  <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax id="F_000196" contextRef="C_0001326110_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">-97000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
  <us-gaap:NetIncomeLoss id="F_000197" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss id="F_000198" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss id="F_000199" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss id="F_000200" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">-96423000</us-gaap:NetIncomeLoss>
  <us-gaap:CommonStockSharesIssued id="F_000201" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20171231" decimals="INF" unitRef="U_xbrlishares">79021878</us-gaap:CommonStockSharesIssued>
  <us-gaap:StockholdersEquity id="F_000202" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20171231" decimals="-3" unitRef="U_iso4217USD">8000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="F_000203" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20171231" decimals="-3" unitRef="U_iso4217USD">717930000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="F_000204" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20171231" decimals="-3" unitRef="U_iso4217USD">-381000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="F_000205" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20171231" decimals="-3" unitRef="U_iso4217USD">-498713000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="F_000206" contextRef="C_0001326110_20171231" decimals="-3" unitRef="U_iso4217USD">218844000</us-gaap:StockholdersEquity>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="F_000207" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="F_000208" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">23382000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="F_000209" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="F_000210" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="F_000211" contextRef="C_0001326110_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">23382000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <nk:StockIssuedDuringPeriodSharesWarrantsExercised id="F_000212" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20180101_20181231" decimals="INF" unitRef="U_xbrlishares">93254</nk:StockIssuedDuringPeriodSharesWarrantsExercised>
  <us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants id="F_000213" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants>
  <us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants id="F_000214" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">57000</us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants>
  <us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants id="F_000215" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants>
  <us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants id="F_000216" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants>
  <us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants id="F_000217" contextRef="C_0001326110_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">57000</us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants>
  <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross id="F_000218" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20180101_20181231" decimals="INF" unitRef="U_xbrlishares">172330</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
  <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross id="F_000219" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
  <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross id="F_000220" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
  <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross id="F_000221" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
  <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross id="F_000222" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
  <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross id="F_000223" contextRef="C_0001326110_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
  <us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation id="F_000224" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20180101_20181231" decimals="INF" unitRef="U_xbrlishares">61379</us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation>
  <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation id="F_000225" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
  <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation id="F_000226" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">123000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
  <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation id="F_000227" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
  <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation id="F_000228" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
  <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation id="F_000229" contextRef="C_0001326110_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">123000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
  <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares id="F_000230" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20180101_20181231" decimals="INF" unitRef="U_xbrlishares">138349</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
  <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue id="F_000231" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
  <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue id="F_000232" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
  <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue id="F_000233" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
  <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue id="F_000234" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">228000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
  <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue id="F_000235" contextRef="C_0001326110_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">228000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
  <us-gaap:NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification id="F_000236" contextRef="C_0001326110_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201409Member_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification>
  <us-gaap:NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification id="F_000237" contextRef="C_0001326110_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201409Member_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification>
  <us-gaap:NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification id="F_000238" contextRef="C_0001326110_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201409Member_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification>
  <us-gaap:NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification id="F_000239" contextRef="C_0001326110_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201409Member_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">186000</us-gaap:NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification>
  <us-gaap:NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification id="F_000240" contextRef="C_0001326110_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201409Member_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">186000</us-gaap:NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification>
  <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax id="F_000241" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
  <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax id="F_000242" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
  <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax id="F_000243" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">114000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
  <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax id="F_000244" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
  <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax id="F_000245" contextRef="C_0001326110_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">114000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
  <us-gaap:NetIncomeLoss id="F_000246" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss id="F_000247" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss id="F_000248" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss id="F_000249" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">-96226000</us-gaap:NetIncomeLoss>
  <us-gaap:CommonStockSharesIssued id="F_000250" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20181231" decimals="INF" unitRef="U_xbrlishares">79087734</us-gaap:CommonStockSharesIssued>
  <us-gaap:StockholdersEquity id="F_000251" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20181231" decimals="-3" unitRef="U_iso4217USD">8000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="F_000252" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20181231" decimals="-3" unitRef="U_iso4217USD">741246000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="F_000253" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20181231" decimals="-3" unitRef="U_iso4217USD">-267000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="F_000254" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20181231" decimals="-3" unitRef="U_iso4217USD">-594981000</us-gaap:StockholdersEquity>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="F_000255" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="F_000256" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">2627000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="F_000257" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="F_000258" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="F_000259" contextRef="C_0001326110_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">2627000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <nk:StockIssuedDuringPeriodSharesWarrantsExercised id="F_000260" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190101_20191231" decimals="INF" unitRef="U_xbrlishares">17589250</nk:StockIssuedDuringPeriodSharesWarrantsExercised>
  <us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants id="F_000261" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">2000</us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants>
  <us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants id="F_000262" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">35149000</us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants>
  <us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants id="F_000263" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants>
  <us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants id="F_000264" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants>
  <us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants id="F_000265" contextRef="C_0001326110_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">35151000</us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised id="F_000266" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190101_20191231" decimals="INF" unitRef="U_xbrlishares">1986300</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised id="F_000267" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised id="F_000268" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">4070000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised id="F_000269" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised id="F_000270" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised id="F_000271" contextRef="C_0001326110_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">4070000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross id="F_000272" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190101_20191231" decimals="INF" unitRef="U_xbrlishares">395051</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
  <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross id="F_000273" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
  <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross id="F_000274" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
  <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross id="F_000275" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
  <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross id="F_000276" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
  <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross id="F_000277" contextRef="C_0001326110_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
  <us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation id="F_000278" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190101_20191231" decimals="INF" unitRef="U_xbrlishares">124345</us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation>
  <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation id="F_000279" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
  <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation id="F_000280" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">127000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
  <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation id="F_000281" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
  <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation id="F_000282" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
  <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation id="F_000283" contextRef="C_0001326110_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">127000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
  <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares id="F_000284" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190101_20191231" decimals="INF" unitRef="U_xbrlishares">473586</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
  <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue id="F_000285" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
  <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue id="F_000286" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
  <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue id="F_000287" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
  <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue id="F_000288" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">501000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
  <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue id="F_000289" contextRef="C_0001326110_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">501000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
  <us-gaap:NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification id="F_000290" contextRef="C_0001326110_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201602Member_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification>
  <us-gaap:NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification id="F_000291" contextRef="C_0001326110_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201602Member_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification>
  <us-gaap:NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification id="F_000292" contextRef="C_0001326110_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201602Member_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification>
  <us-gaap:NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification id="F_000293" contextRef="C_0001326110_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201602Member_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-920000</us-gaap:NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification>
  <us-gaap:NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification id="F_000294" contextRef="C_0001326110_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201602Member_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-920000</us-gaap:NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification>
  <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax id="F_000295" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
  <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax id="F_000296" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
  <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax id="F_000297" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">162000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
  <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax id="F_000298" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
  <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax id="F_000299" contextRef="C_0001326110_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">162000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
  <us-gaap:NetIncomeLoss id="F_000300" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss id="F_000301" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss id="F_000302" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss id="F_000303" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-65789000</us-gaap:NetIncomeLoss>
  <us-gaap:CommonStockSharesIssued id="F_000304" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191231" decimals="INF" unitRef="U_xbrlishares">98460404</us-gaap:CommonStockSharesIssued>
  <us-gaap:StockholdersEquity id="F_000305" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191231" decimals="-3" unitRef="U_iso4217USD">10000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="F_000306" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20191231" decimals="-3" unitRef="U_iso4217USD">782965000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="F_000307" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20191231" decimals="-3" unitRef="U_iso4217USD">-105000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="F_000308" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20191231" decimals="-3" unitRef="U_iso4217USD">-662191000</us-gaap:StockholdersEquity>
  <us-gaap:ProfitLoss id="F_000309" contextRef="C_0001326110_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-65789000</us-gaap:ProfitLoss>
  <us-gaap:ProfitLoss id="F_000310" contextRef="C_0001326110_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">-96226000</us-gaap:ProfitLoss>
  <us-gaap:ProfitLoss id="F_000311" contextRef="C_0001326110_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">-96423000</us-gaap:ProfitLoss>
  <us-gaap:DepreciationDepletionAndAmortization id="F_000312" contextRef="C_0001326110_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">9012000</us-gaap:DepreciationDepletionAndAmortization>
  <us-gaap:DepreciationDepletionAndAmortization id="F_000313" contextRef="C_0001326110_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">9555000</us-gaap:DepreciationDepletionAndAmortization>
  <us-gaap:DepreciationDepletionAndAmortization id="F_000314" contextRef="C_0001326110_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">5566000</us-gaap:DepreciationDepletionAndAmortization>
  <us-gaap:ShareBasedCompensation id="F_000315" contextRef="C_0001326110_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">2627000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation id="F_000316" contextRef="C_0001326110_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">23382000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation id="F_000317" contextRef="C_0001326110_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">36997000</us-gaap:ShareBasedCompensation>
  <nk:OperatingLeaseRightOfUseAssetNonCashLeaseExpense id="F_000318" contextRef="C_0001326110_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">2604000</nk:OperatingLeaseRightOfUseAssetNonCashLeaseExpense>
  <nk:OperatingLeaseRightOfUseAssetNonCashLeaseExpense id="F_000319" contextRef="C_0001326110_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">0</nk:OperatingLeaseRightOfUseAssetNonCashLeaseExpense>
  <nk:OperatingLeaseRightOfUseAssetNonCashLeaseExpense id="F_000320" contextRef="C_0001326110_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">0</nk:OperatingLeaseRightOfUseAssetNonCashLeaseExpense>
  <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments id="F_000321" contextRef="C_0001326110_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
  <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments id="F_000322" contextRef="C_0001326110_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">-463000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
  <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments id="F_000323" contextRef="C_0001326110_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">-1597000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
  <nk:NonCashInterestIncomeExpenseFromOperatingActivities id="F_000324" contextRef="C_0001326110_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-246000</nk:NonCashInterestIncomeExpenseFromOperatingActivities>
  <nk:NonCashInterestIncomeExpenseFromOperatingActivities id="F_000325" contextRef="C_0001326110_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">-291000</nk:NonCashInterestIncomeExpenseFromOperatingActivities>
  <nk:NonCashInterestIncomeExpenseFromOperatingActivities id="F_000326" contextRef="C_0001326110_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">-720000</nk:NonCashInterestIncomeExpenseFromOperatingActivities>
  <us-gaap:AssetImpairmentCharges id="F_000327" contextRef="C_0001326110_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">869000</us-gaap:AssetImpairmentCharges>
  <us-gaap:AssetImpairmentCharges id="F_000328" contextRef="C_0001326110_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:AssetImpairmentCharges>
  <us-gaap:AssetImpairmentCharges id="F_000329" contextRef="C_0001326110_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:AssetImpairmentCharges>
  <us-gaap:GainLossOnDispositionOfAssets1 id="F_000330" contextRef="C_0001326110_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:GainLossOnDispositionOfAssets1>
  <us-gaap:GainLossOnDispositionOfAssets1 id="F_000331" contextRef="C_0001326110_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">-209000</us-gaap:GainLossOnDispositionOfAssets1>
  <us-gaap:GainLossOnDispositionOfAssets1 id="F_000332" contextRef="C_0001326110_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">-64000</us-gaap:GainLossOnDispositionOfAssets1>
  <us-gaap:DeferredIncomeTaxExpenseBenefit id="F_000333" contextRef="C_0001326110_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
  <us-gaap:DeferredIncomeTaxExpenseBenefit id="F_000334" contextRef="C_0001326110_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">-498000</us-gaap:DeferredIncomeTaxExpenseBenefit>
  <us-gaap:DeferredIncomeTaxExpenseBenefit id="F_000335" contextRef="C_0001326110_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">-497000</us-gaap:DeferredIncomeTaxExpenseBenefit>
  <us-gaap:MarketableSecuritiesGainLoss id="F_000336" contextRef="C_0001326110_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-4000</us-gaap:MarketableSecuritiesGainLoss>
  <us-gaap:MarketableSecuritiesGainLoss id="F_000337" contextRef="C_0001326110_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">3000</us-gaap:MarketableSecuritiesGainLoss>
  <us-gaap:MarketableSecuritiesGainLoss id="F_000338" contextRef="C_0001326110_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">32000</us-gaap:MarketableSecuritiesGainLoss>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets id="F_000339" contextRef="C_0001326110_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-9276000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets id="F_000340" contextRef="C_0001326110_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">9818000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets id="F_000341" contextRef="C_0001326110_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">-156000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <nk:IncreaseDecreaseInOperatingLeaseRightOfUseAssetNet id="F_000342" contextRef="C_0001326110_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">800000</nk:IncreaseDecreaseInOperatingLeaseRightOfUseAssetNet>
  <nk:IncreaseDecreaseInOperatingLeaseRightOfUseAssetNet id="F_000343" contextRef="C_0001326110_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">0</nk:IncreaseDecreaseInOperatingLeaseRightOfUseAssetNet>
  <nk:IncreaseDecreaseInOperatingLeaseRightOfUseAssetNet id="F_000344" contextRef="C_0001326110_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">0</nk:IncreaseDecreaseInOperatingLeaseRightOfUseAssetNet>
  <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets id="F_000345" contextRef="C_0001326110_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">4063000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
  <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets id="F_000346" contextRef="C_0001326110_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">1151000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
  <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets id="F_000347" contextRef="C_0001326110_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">-458000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
  <nk:IncreaseDecreaseInAccountsPayableCurrent id="F_000348" contextRef="C_0001326110_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">41000</nk:IncreaseDecreaseInAccountsPayableCurrent>
  <nk:IncreaseDecreaseInAccountsPayableCurrent id="F_000349" contextRef="C_0001326110_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">-1100000</nk:IncreaseDecreaseInAccountsPayableCurrent>
  <nk:IncreaseDecreaseInAccountsPayableCurrent id="F_000350" contextRef="C_0001326110_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">150000</nk:IncreaseDecreaseInAccountsPayableCurrent>
  <us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities id="F_000351" contextRef="C_0001326110_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-12020000</us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities>
  <us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities id="F_000352" contextRef="C_0001326110_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">12708000</us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities>
  <us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities id="F_000353" contextRef="C_0001326110_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">-299000</us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities>
  <us-gaap:IncreaseDecreaseInDueToRelatedPartiesCurrent id="F_000354" contextRef="C_0001326110_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-1093000</us-gaap:IncreaseDecreaseInDueToRelatedPartiesCurrent>
  <us-gaap:IncreaseDecreaseInDueToRelatedPartiesCurrent id="F_000355" contextRef="C_0001326110_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">-685000</us-gaap:IncreaseDecreaseInDueToRelatedPartiesCurrent>
  <us-gaap:IncreaseDecreaseInDueToRelatedPartiesCurrent id="F_000356" contextRef="C_0001326110_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">1562000</us-gaap:IncreaseDecreaseInDueToRelatedPartiesCurrent>
  <nk:IncreaseDecreaseInOperatingLeaseLiability id="F_000357" contextRef="C_0001326110_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-2276000</nk:IncreaseDecreaseInOperatingLeaseLiability>
  <nk:IncreaseDecreaseInOperatingLeaseLiability id="F_000358" contextRef="C_0001326110_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">0</nk:IncreaseDecreaseInOperatingLeaseLiability>
  <nk:IncreaseDecreaseInOperatingLeaseLiability id="F_000359" contextRef="C_0001326110_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">0</nk:IncreaseDecreaseInOperatingLeaseLiability>
  <us-gaap:IncreaseDecreaseInDeferredRevenue id="F_000360" contextRef="C_0001326110_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:IncreaseDecreaseInDeferredRevenue>
  <us-gaap:IncreaseDecreaseInDeferredRevenue id="F_000361" contextRef="C_0001326110_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">-508000</us-gaap:IncreaseDecreaseInDeferredRevenue>
  <us-gaap:IncreaseDecreaseInDeferredRevenue id="F_000362" contextRef="C_0001326110_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">1201000</us-gaap:IncreaseDecreaseInDeferredRevenue>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities id="F_000363" contextRef="C_0001326110_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-61362000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities id="F_000364" contextRef="C_0001326110_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">-63381000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities id="F_000365" contextRef="C_0001326110_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">-48780000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment id="F_000366" contextRef="C_0001326110_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">4182000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment id="F_000367" contextRef="C_0001326110_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">13102000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment id="F_000368" contextRef="C_0001326110_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">34815000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment id="F_000369" contextRef="C_0001326110_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
  <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment id="F_000370" contextRef="C_0001326110_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">412000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
  <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment id="F_000371" contextRef="C_0001326110_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
  <us-gaap:PaymentsToAcquireHeldToMaturitySecurities id="F_000372" contextRef="C_0001326110_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:PaymentsToAcquireHeldToMaturitySecurities>
  <us-gaap:PaymentsToAcquireHeldToMaturitySecurities id="F_000373" contextRef="C_0001326110_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">723000</us-gaap:PaymentsToAcquireHeldToMaturitySecurities>
  <us-gaap:PaymentsToAcquireHeldToMaturitySecurities id="F_000374" contextRef="C_0001326110_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:PaymentsToAcquireHeldToMaturitySecurities>
  <nk:PaymentsToAcquireInvestmentsInEquitySecurities id="F_000375" contextRef="C_0001326110_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">3000</nk:PaymentsToAcquireInvestmentsInEquitySecurities>
  <nk:PaymentsToAcquireInvestmentsInEquitySecurities id="F_000376" contextRef="C_0001326110_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">0</nk:PaymentsToAcquireInvestmentsInEquitySecurities>
  <nk:PaymentsToAcquireInvestmentsInEquitySecurities id="F_000377" contextRef="C_0001326110_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">8500000</nk:PaymentsToAcquireInvestmentsInEquitySecurities>
  <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt id="F_000378" contextRef="C_0001326110_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">86618000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
  <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt id="F_000379" contextRef="C_0001326110_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">94770000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
  <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt id="F_000380" contextRef="C_0001326110_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">111355000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
  <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities id="F_000381" contextRef="C_0001326110_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">112259000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
  <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities id="F_000382" contextRef="C_0001326110_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">165284000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
  <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities id="F_000383" contextRef="C_0001326110_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">254222000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities id="F_000384" contextRef="C_0001326110_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">21456000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities id="F_000385" contextRef="C_0001326110_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">57101000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities id="F_000386" contextRef="C_0001326110_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">99552000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:RepaymentsOfLongTermCapitalLeaseObligations id="F_000387" contextRef="C_0001326110_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:RepaymentsOfLongTermCapitalLeaseObligations>
  <us-gaap:RepaymentsOfLongTermCapitalLeaseObligations id="F_000388" contextRef="C_0001326110_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">477000</us-gaap:RepaymentsOfLongTermCapitalLeaseObligations>
  <us-gaap:RepaymentsOfLongTermCapitalLeaseObligations id="F_000389" contextRef="C_0001326110_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">19932000</us-gaap:RepaymentsOfLongTermCapitalLeaseObligations>
  <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions id="F_000390" contextRef="C_0001326110_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">39221000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
  <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions id="F_000391" contextRef="C_0001326110_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">57000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
  <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions id="F_000392" contextRef="C_0001326110_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">1215000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
  <us-gaap:PaymentsForRepurchaseOfCommonStock id="F_000393" contextRef="C_0001326110_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">501000</us-gaap:PaymentsForRepurchaseOfCommonStock>
  <us-gaap:PaymentsForRepurchaseOfCommonStock id="F_000394" contextRef="C_0001326110_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">228000</us-gaap:PaymentsForRepurchaseOfCommonStock>
  <us-gaap:PaymentsForRepurchaseOfCommonStock id="F_000395" contextRef="C_0001326110_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">15227000</us-gaap:PaymentsForRepurchaseOfCommonStock>
  <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation id="F_000396" contextRef="C_0001326110_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">127000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
  <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation id="F_000397" contextRef="C_0001326110_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">123000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
  <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation id="F_000398" contextRef="C_0001326110_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">1039000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities id="F_000399" contextRef="C_0001326110_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">38593000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities id="F_000400" contextRef="C_0001326110_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">-771000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities id="F_000401" contextRef="C_0001326110_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">-34983000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect id="F_000402" contextRef="C_0001326110_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-1313000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect id="F_000403" contextRef="C_0001326110_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">-7051000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect id="F_000404" contextRef="C_0001326110_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">15789000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations id="F_000405" contextRef="C_0001326110_20181231" decimals="-3" unitRef="U_iso4217USD">17000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations id="F_000406" contextRef="C_0001326110_20171231" decimals="-3" unitRef="U_iso4217USD">24051000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations id="F_000407" contextRef="C_0001326110_20161231" decimals="-3" unitRef="U_iso4217USD">8262000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations id="F_000408" contextRef="C_0001326110_20191231" decimals="-3" unitRef="U_iso4217USD">15687000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="F_000409" contextRef="C_0001326110_20171231" decimals="-3" unitRef="U_iso4217USD">23872000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent id="F_000410" contextRef="C_0001326110_20191231" decimals="-3" unitRef="U_iso4217USD">179000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
  <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent id="F_000411" contextRef="C_0001326110_20181231" decimals="-3" unitRef="U_iso4217USD">179000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
  <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent id="F_000412" contextRef="C_0001326110_20171231" decimals="-3" unitRef="U_iso4217USD">179000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
  <us-gaap:InterestPaidNet id="F_000413" contextRef="C_0001326110_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">19000</us-gaap:InterestPaidNet>
  <us-gaap:InterestPaidNet id="F_000414" contextRef="C_0001326110_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">475000</us-gaap:InterestPaidNet>
  <us-gaap:InterestPaidNet id="F_000415" contextRef="C_0001326110_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">668000</us-gaap:InterestPaidNet>
  <us-gaap:IncomeTaxesPaidNet id="F_000416" contextRef="C_0001326110_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">3000</us-gaap:IncomeTaxesPaidNet>
  <us-gaap:IncomeTaxesPaidNet id="F_000417" contextRef="C_0001326110_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">4000</us-gaap:IncomeTaxesPaidNet>
  <us-gaap:IncomeTaxesPaidNet id="F_000418" contextRef="C_0001326110_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">3000</us-gaap:IncomeTaxesPaidNet>
  <nk:NoncashPropertyAndEquipmentPurchasesAcquiredUnderCapitalLease id="F_000419" contextRef="C_0001326110_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">0</nk:NoncashPropertyAndEquipmentPurchasesAcquiredUnderCapitalLease>
  <nk:NoncashPropertyAndEquipmentPurchasesAcquiredUnderCapitalLease id="F_000420" contextRef="C_0001326110_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">0</nk:NoncashPropertyAndEquipmentPurchasesAcquiredUnderCapitalLease>
  <nk:NoncashPropertyAndEquipmentPurchasesAcquiredUnderCapitalLease id="F_000421" contextRef="C_0001326110_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">19448000</nk:NoncashPropertyAndEquipmentPurchasesAcquiredUnderCapitalLease>
  <us-gaap:CapitalExpendituresIncurredButNotYetPaid id="F_000422" contextRef="C_0001326110_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">74000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
  <us-gaap:CapitalExpendituresIncurredButNotYetPaid id="F_000423" contextRef="C_0001326110_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">4664000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
  <us-gaap:CapitalExpendituresIncurredButNotYetPaid id="F_000424" contextRef="C_0001326110_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">9500000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
  <us-gaap:DebtConversionConvertedInstrumentAmount1 id="F_000425" contextRef="C_0001326110_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">751000</us-gaap:DebtConversionConvertedInstrumentAmount1>
  <us-gaap:DebtConversionConvertedInstrumentAmount1 id="F_000426" contextRef="C_0001326110_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:DebtConversionConvertedInstrumentAmount1>
  <us-gaap:DebtConversionConvertedInstrumentAmount1 id="F_000427" contextRef="C_0001326110_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:DebtConversionConvertedInstrumentAmount1>
  <us-gaap:UnrealizedGainLossOnInvestments id="F_000428" contextRef="C_0001326110_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">258000</us-gaap:UnrealizedGainLossOnInvestments>
  <us-gaap:UnrealizedGainLossOnInvestments id="F_000429" contextRef="C_0001326110_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">123000</us-gaap:UnrealizedGainLossOnInvestments>
  <us-gaap:UnrealizedGainLossOnInvestments id="F_000430" contextRef="C_0001326110_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">-97000</us-gaap:UnrealizedGainLossOnInvestments>
  <us-gaap:StockIssued1 id="F_000431" contextRef="C_0001326110_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">29000</us-gaap:StockIssued1>
  <us-gaap:StockIssued1 id="F_000432" contextRef="C_0001326110_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">94000</us-gaap:StockIssued1>
  <us-gaap:StockIssued1 id="F_000433" contextRef="C_0001326110_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">16000</us-gaap:StockIssued1>
  <dei:DocumentsIncorporatedByReferenceTextBlock id="F_000434" contextRef="C_0001326110_20190101_20191231">
&lt;p style="text-align:center;margin-top:3pt;margin-bottom:0pt;text-indent:2.5%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;DOCUMENTS INCORPORATED BY REFERENCE&lt;/p&gt;
&lt;p style="margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As noted herein, the information called for by Part&amp;#160;III is incorporated by reference to specified portions of the Registrant&amp;#8217;s definitive proxy statement to be filed in conjunction with the Registrant&amp;#8217;s 2020 Annual Meeting of Stockholders, which is expected to be filed not later than 120&amp;#160;days after the Registrant&amp;#8217;s fiscal year ended December&amp;#160;31, 2019.&lt;/p&gt;</dei:DocumentsIncorporatedByReferenceTextBlock>
  <nk:DescriptionOfBusinessDisclosureTextBlock id="F_000435" contextRef="C_0001326110_20190101_20191231">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;1. &amp;#160;&amp;#160;&amp;#160;&amp;#160;Description of Business&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Organization&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;NantKwest, Inc., or NantKwest, was incorporated in Illinois on October&amp;#160;7, 2002 under the name ZelleRx Corporation. On January&amp;#160;22, 2010, the company changed its name to Conkwest, Inc., and on July&amp;#160;10, 2015, the company changed its name to NantKwest, Inc. In March&amp;#160;2014, the company redomesticated from the State of Illinois to the State of Delaware and the Illinois company ceased to exist. We are a pioneering clinical-stage immunotherapy biotechnology company headquartered in San Diego, California with certain operations in Culver City and El Segundo, California and Woburn, Massachusetts. In these notes, the terms &amp;#8220;we,&amp;#8221; &amp;#8220;our,&amp;#8221; &amp;#8220;the company&amp;#8221; and &amp;#8220;us&amp;#8221; refer to NantKwest.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;We are focused on harnessing the power of the innate immune system by using its natural killer cells, or NK&amp;#160;cells, to treat cancer and viral infectious diseases. A critical aspect of our strategy is to invest significantly in innovating new therapeutic candidates, based upon our proprietary activated NK, or aNK, cell platform, and conducting clinical testing and scale manufacturing of our most promising biologic product candidates.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;We hold the exclusive right to commercialize aNK&amp;#160;cells, a commercially viable NK&amp;#160;cell line, and a wide range of genetically modified derivatives capable of killing cancer and virally infected cells. We own corresponding United States, or U.S., and foreign composition and methods-of-use patents and applications covering the cells, improvements, methods of expansion and manufacture and use of aNK&amp;#160;cells and their improvements as therapeutics to treat a spectrum of clinical conditions.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;We also license exclusive commercial rights to a high-affinity CD16 receptor expressing enhancement of our aNK&amp;#160;cell platform, covered in a portfolio of U.S. and foreign composition and methods-of-use patents and applications covering both the clinical use as a therapeutic to treat cancers in combination with antibody products, as well as the non-clinical use in laboratory testing of monoclonal antibodies. We have non-exclusively licensed or sub-licensed our high-affinity CD16 bearing aNK&amp;#160;cell platform and corresponding intellectual property to numerous pharmaceutical and biotechnology companies for such non-clinical uses.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Liquidity&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December&amp;#160;31, 2019, the company had an accumulated deficit of approximately $662.2&amp;#160;million. We also had negative cash flow from operations of approximately $61.4&amp;#160;million during the year ended December&amp;#160;31, 2019. The company expects that it will likely need additional capital to further fund development of, and seek regulatory approvals for, our product candidates, and to begin to commercialize any approved products.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;We are currently focused primarily on the development of immunotherapeutic treatments for cancers and debilitating viral infections using targeted cancer and viral killing cell lines, and we believe such activities will result in the company&amp;#8217;s continued incurrence of significant research and development and other expenses related to those programs. If the clinical trials for any of the company&amp;#8217;s product candidates fail or produce unsuccessful results and those product candidates do not gain regulatory approval, or if any of our product candidates, if approved, fail to achieve market acceptance, we may never become profitable. Even if the company achieves profitability in the future, it may not be able to sustain profitability in subsequent periods. We intend to cover our future operating expenses through cash and cash equivalents and marketable debt securities on hand and through a combination of equity offerings, debt financings, government or other third party funding, marketing and distribution arrangements and other collaborations, strategic alliances, and licensing arrangements. Additional financing may not be available to us when needed and, if available, financing may not be obtained on terms favorable to the company or its stockholders.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;While we expect our existing cash, and cash equivalents and marketable debt securities, together with the ability to borrow from affiliated entities, will enable us to fund operations and capital expenditure requirements for at least the next 12&amp;#160;months, we may not have sufficient funds to reach commercialization. Failure to obtain adequate financing when needed may require us to delay, reduce, limit, or terminate some or all of our development programs or future commercialization efforts or grant rights to develop and market product candidates that we might otherwise prefer to develop and market ourselves, which could adversely affect our ability to operate as a going concern. If we raise additional funds from the issuance of equity securities, substantial dilution to existing stockholders may result. If we raise additional funds by incurring debt financing, the terms of the debt may involve significant cash payment obligations, as well as covenants and specific financial ratios that may restrict our ability to operate our business.&lt;/p&gt;</nk:DescriptionOfBusinessDisclosureTextBlock>
  <us-gaap:SignificantAccountingPoliciesTextBlock id="F_000436" contextRef="C_0001326110_20190101_20191231">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2. &amp;#160;&amp;#160;&amp;#160;&amp;#160;Summary of Significant Accounting Policies&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Basis of Presentation&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America, or U.S.&amp;#160;GAAP.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The consolidated financial statements have been prepared assuming the company will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business, and do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or amounts and classification of liabilities that may result from the outcome of the uncertainty discussed in the Liquidity section of Note&amp;#160;1. We believe our existing cash, cash equivalents, and investments in marketable debt securities, and our ability to borrow from affiliated entities, will be sufficient to fund operations through at least the next 12&amp;#160;months following the issuance date of the financial statements based upon our Chairman and CEO&amp;#8217;s intent and ability to support the company&amp;#8217;s operations with additional funds, including loans from affiliated entities, as required. We may also seek to sell additional equity, through one or more follow-on public offerings, or in separate financings, or obtain a credit facility. However, we may not be able to secure such financing in a timely manner or on favorable terms. Without additional funds, we may choose to delay or reduce our operating or investment expenditures. Further, because of the risk and uncertainties associated with the commercialization of the company&amp;#8217;s product candidates in development, we may need additional funds to meet our needs sooner than planned. To date, the company&amp;#8217;s primary sources of capital were its initial public offering and the concurrent private placement of common shares. In addition, during the year ended December&amp;#160;31, 2019, our Chairman and CEO exercised warrants and options resulting in aggregate cash proceeds of $39.2&amp;#160;million.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Principles of Consolidation&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The consolidated financial statements include the accounts of NantKwest and its wholly owned subsidiaries. All intercompany amounts have been eliminated.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;We apply the variable interest model under Accounting Standards Codification, or ASC Topic&amp;#160;810,&amp;#160;&lt;font style="font-style:italic;"&gt;Consolidation&lt;/font&gt;, to any entity in which we hold an equity investment or to which we have the power to direct the entity&apos;s most significant economic activities and the ability to participate in the entity&apos;s economics. If the entity is within the scope of the variable interest model and meets the definition of a variable interest entity, or VIE, we consider whether we must consolidate the VIE or provide additional disclosures regarding our involvement with the VIE. If we determine that we are the primary beneficiary of the VIE, we will consolidate the VIE. This analysis is performed at the initial investment in the entity or upon any reconsideration event.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;For entities we hold as an equity investment that are not consolidated under the VIE Model, we consider whether our investment constitutes ownership of a majority of the voting interests in the entity and therefore should be considered for consolidation under the voting interest model.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unconsolidated equity investments in the common stock or in-substance common stock of an entity under which we are able to exercise significant influence, but not control, are accounted for using the equity method. Our ability to exercise significant influence is generally indicated by ownership of 20 to 50 percent interest in the voting securities of the entity.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;All other unconsolidated equity investments on which we are not able to exercise significant influence will be subsequently measured at fair value with unrealized holding gains and losses included in other income, net on the consolidated statements of operations. In the instance the equity investment does not have a readily determinable fair value and does not qualify for the practical expedient to estimate fair value in accordance with ASC&amp;#160;820, &lt;font style="font-style:italic;"&gt;Fair Value Measurement&lt;/font&gt;, or ASC&amp;#160;820, we will apply the measurement alternative under ASC&amp;#160;321, &lt;font style="font-style:italic;"&gt;Investments&amp;#8212;Equity Securities&lt;/font&gt;, or ASC&amp;#160;321, pursuant to which we will measure the investment at its cost less impairment, adjusted for observable price changes in an orderly market for an identical or similar investment of the same issuer.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;We own non-marketable equity securities that are accounted for using the measurement alternative under ASC&amp;#160;321 because the preferred stock held by us is not considered in-substance common stock and such preferred stock does not have a readily determinable fair value. All investments are reviewed on a regular basis for possible impairment. If an investment&apos;s fair value is determined to be less than its net carrying value, the investment is written down to its fair value. Such an evaluation is judgmental and dependent on specific facts and circumstances. Factors considered in determining whether an impairment indicator is present include:&amp;#160;the investees&amp;#8217; earnings performance and clinical trial performance, change in the investees&amp;#8217; industry and geographic area in which it operates, offers to purchase or sell the security for a price less than the cost of the investment, issues that raise concerns about the investee&apos;s ability to continue as a going concern, and any other information that we may be aware of related to the investment. Factors considered in determining whether an observable price change has occurred include:&amp;#160;the price at which the investee issues equity instruments similar to those of our investment and the rights and preferences of those equity instruments compared to ours.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Use of Estimates&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. On an ongoing basis, we evaluate our estimates, including those related to valuation of equity-based awards, deferred income taxes and related valuation allowances, preclinical and clinical trial accruals, impairment assessments, useful lives of long-lived assets, loss contingencies, and fair value measurements. We base our estimates on historical experience and on various other market-specific and relevant assumptions that we believe to be reasonable under the circumstances. Actual results could differ from those estimates.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Risks and Uncertainties&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Contingencies&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;We record accruals for loss contingencies to the extent that we conclude it is probable that a liability has been incurred and the amount of the related loss can be reasonably estimated. We evaluate, on a quarterly basis, developments in legal proceedings and other matters that could cause a change in the potential amount of the liability recorded or of the range of potential losses disclosed. Additionally, we record our rights to insurance recoveries, limited to the extent of incurred or probable losses, as a receivable when such recoveries have been agreed to with our third-party insurers and when receipt is deemed probable. This includes instances when our third-party insurers have agreed to pay, on our behalf, certain legal defense costs and settlement amounts directly to applicable law firms and a settlement fund.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Concentration of Credit Risk and Other Risks and Uncertainties&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Financial instruments that potentially subject us to concentrations of risk consist principally of cash and cash equivalents and marketable debt securities.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Our cash and cash equivalents are held by one major financial institution in the U.S. and one in Korea.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Product candidates developed by us will require approvals or clearances from the U.S. Food and Drug Administration, or FDA, or international regulatory agencies prior to commercial sales. There can be no assurance that any of our product candidates will receive any of the required approvals or clearances. If we were to be denied approval or clearance or any such approval or clearance was to be delayed, it would have a material adverse impact on us.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Cash, Cash Equivalents and Marketable Debt Securities&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;We invest our excess funds in investment grade short- to intermediate-term corporate debt securities, commercial paper, government sponsored securities, and foreign government bonds. We consider all highly liquid investments purchased with original maturities of three&amp;#160;months or less to be cash equivalents and all investments purchased with original maturities of greater than three&amp;#160;months as marketable debt securities, classified as available-for-sale. Marketable debt securities with remaining maturities of 12&amp;#160;months or less are classified as short-term and marketable debt securities with remaining maturities greater than 12&amp;#160;months are classified as long-term. All marketable debt securities are reported at fair value and any unrealized gains and losses are reported as a component of accumulated other comprehensive income (loss), net of tax, on the consolidated statements of stockholders&amp;#8217; equity, with the exception of unrealized losses believed to be other-than-temporary, which are recorded in investment income, net, on the consolidated statements of operations. Realized gains and losses are included in investment income, net, on the consolidated statements of operations. Realized gains and losses from sale of the securities and the amounts, net of tax, reclassified out of accumulated other comprehensive loss, if any, are determined on a specific identification basis.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;We periodically evaluate whether declines in fair values of our investments below their book value are other-than-temporary. This evaluation consists of several qualitative and quantitative factors regarding the severity and duration of the unrealized loss, as well as our ability and intent to hold the investment until a forecasted recovery occurs. Additionally, we assess whether or not we have plans to sell the security or whether or not it is more likely than not we will be required to sell any investment before recovery of its amortized cost basis. Factors considered include quoted market prices, recent financial results and operating trends, implied values from any recent transactions or offers of investee securities, credit quality of debt instrument issuers, other publicly available information that may affect the value of our investments, duration and severity of the decline in value, and our strategy and intentions for holding the investment. There were no other-than-temporary impairments recorded in the years ended December&amp;#160;31, 2019, 2018 and 2017.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;We minimize credit risk associated with our cash and cash equivalents by periodically evaluating the credit quality of our primary financial institutions. While we maintain cash deposits in FDIC insured financial institutions in excess of federally insured limits, we do not believe that we are exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held. We have not experienced any losses on such accounts.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;We have funded a certificate of deposit (CD) as a substitute letter of credit for one of our leased properties. This CD is reported as long term restricted cash and is included in other assets on the consolidated balance sheets as the landlord is the beneficiary of the account and we are not able to access the funds during the term of the lease.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Property, Plant and Equipment&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property, plant and equipment is stated at historical cost less accumulated depreciation. Historical cost includes expenditures that are directly attributable to the acquisition of the items. All repairs and maintenance are charged to net loss during the financial period in which they are incurred. Depreciation of property, plant and equipment is calculated using the straight-line method over the estimated useful lives of the assets, as follows:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Buildings&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.36%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; 39 years&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Software&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.36%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; 3 years&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Laboratory equipment&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.36%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; 5 years&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Furniture &amp;amp; fixtures&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.36%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; 5 years&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;IT equipment&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.36%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; 3 years&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.36%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; The lesser of the lease term or the life of the asset&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Upon disposal or impairment of property, plant and equipment, the cost and related accumulated depreciation is removed from the consolidated financial statements and the net amount, less any proceeds, is included in the consolidated statements of operations.&lt;/p&gt;&lt;/div&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Intangible Assets&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Intangible assets, which consisted of the cost of reacquiring a technology license during 2015, were amortized using the straight-line method over an estimated useful life of 4&amp;#160;years. As of December 31, 2019, our intangible assets were fully amortized.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Patents&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Patent costs, including related legal costs, are expensed as incurred and recorded in selling, general and administrative expenses on the consolidated statements of operations.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Impairments&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Long-lived assets include property, plant and equipment and intangible assets. We review long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability is measured by comparison of the carrying amount to the future net cash flows that the assets are expected to generate. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the projected undiscounted future cash flows arising from the assets using a discount rate determined by management to be commensurate with the risk inherent to our current business model.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;During the second quarter of 2019, we determined that certain bioreactor laboratory equipment could no longer be utilized in the production process. As a result, we recorded an impairment charge totaling $0.9&amp;#160;million, which is included in research and development expense on the consolidated statements of operations. There were no impairment losses recognized during the years ended December&amp;#160;31, 2018 and 2017.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Fair Value of Financial Instruments&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The accounting standard for fair value measurements provides a framework for measuring fair value and requires disclosures regarding fair value measurements. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date, based on our principal or, in absence of a principal, most advantageous market for the specific asset or liability.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;We use a three-tier fair value hierarchy to classify and disclose all assets and liabilities measured at fair value on a recurring basis, as well as assets and liabilities measured at fair value on a non-recurring basis, in periods subsequent to their initial measurement. The hierarchy requires us to use observable inputs when available, and to minimize the use of unobservable inputs, when determining fair value.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The three tiers are defined as follows:&lt;/p&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:4.54%;white-space:nowrap"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:4.54%;white-space:nowrap"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-family:&apos;Times New Roman&apos;;font-size:15pt;line-height:11pt;"&gt;&amp;#x2022;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level&amp;#160;1&amp;#8212; Observable inputs that reflect quoted market prices (unadjusted) for identical assets or liabilities in active markets at the measurement date. Since valuations are based on quoted prices that are readily and regularly available in an active market, valuation of these products does not entail a significant degree of judgment. Our Level 1 assets consist of bank deposits and money market funds.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:4.54%;white-space:nowrap"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:4.54%;white-space:nowrap"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-family:&apos;Times New Roman&apos;;font-size:15pt;line-height:11pt;"&gt;&amp;#x2022;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level&amp;#160;2&amp;#8212; Observable inputs other than quoted prices in active markets that are observable either directly or indirectly in the marketplace for identical or similar assets and liabilities. Our Level 2 assets consist of corporate debt securities including commercial paper, government sponsored securities and corporate bonds, as well as foreign municipal securities.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:4.54%;white-space:nowrap"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:4.54%;white-space:nowrap"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-family:&apos;Times New Roman&apos;;font-size:15pt;line-height:11pt;"&gt;&amp;#x2022;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level&amp;#160;3&amp;#8212; Valuations based on inputs that are unobservable and significant to the overall fair value measurement.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;During the years ended December&amp;#160;31, 2019, 2018 and 2017, no transfers were made into or out of the Level&amp;#160;1,&amp;#160;2 or 3 categories. We will continue to review the fair value inputs on a quarterly basis.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;We utilize a third-party pricing service to assist in obtaining fair value pricing for our investments in marketable debt securities. Inputs are documented in accordance with the fair value disclosure hierarchy.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Preclinical and Clinical Trial Accruals&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As part of the process of preparing the financial statements, we are required to estimate expenses resulting from obligations under contracts with vendors, clinical research organizations and consultants. The financial terms of these contracts vary and may result in payment flows that do not match the periods over which materials or services are provided under such contracts.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;We estimate clinical trial and research agreement related expenses based on the services performed, pursuant to contracts with research institutions and clinical research organizations and other vendors that conduct clinical trials and research on our behalf. In accruing clinical and research related fees, we estimate the time period over which services will be performed and activity expended in each period. If the actual timing of the performance of services or the level of effort varies from the estimate, we will adjust the accrual accordingly. Payments made under these arrangements in advance of the receipt of the related services are recorded as prepaid expenses until the services are rendered.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Transactions with Related Parties&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As outlined in Note&amp;#160;9&lt;font style="font-style:italic;"&gt; &amp;#8211; Related Party Agreements&lt;/font&gt;, we have various agreements with different related parties. Some are billed and settled in cash monthly. Others are billed quarterly and settled in cash the following month. Monthly accruals are made for all quarterly billing arrangements.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Lease Obligations&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;We adopted FASB ASC Topic&amp;#160;842, &lt;font style="font-style:italic;"&gt;Leases&lt;/font&gt;, or ASC&amp;#160;842, effective January&amp;#160;1, 2019. For contracts entered into on or after the effective date, we determine if an arrangement is, or contains, a lease at lease inception. Our assessment is based on:&amp;#160;(1)&amp;#160;whether the contract involves the use of a distinct identified asset; (2)&amp;#160;whether we obtain the right to substantially all of the economic benefit from the use of the asset throughout the period; and (3)&amp;#160;whether we have the right to direct the use of the asset. At inception of a lease, we allocate the consideration in the contract to each lease component based on its relative stand-alone price to determine the lease payments. Leases entered into prior to January&amp;#160;1, 2019, which were accounted for under ASC&amp;#160;840, &lt;font style="font-style:italic;"&gt;Leases&lt;/font&gt;, were not reassessed as we elected the package of practical expedients permitted under the transition guidance within the new standard, which among other things, allowed us to carry forward the historical lease classification. We determine the lease term by assuming the exercise of renewal options that are reasonably assured. The exercise of lease renewal options is at our sole discretion. Several of our leases have renewal options, however, exercise of renewal is only assured for the El&amp;#160;Segundo current Good Manufacturing Practices, or cGMP, facility, where we have made significant improvements.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;For all leases at the lease commencement date, a right-of-use asset and a lease liability are recognized. The right-of-use asset represents the right to use the leased asset for the lease term. At lease commencement, leases are classified as either finance leases or operating leases. A lease is classified as a finance lease if any one of the following criteria are met:&amp;#160;(1)&amp;#160;the lease transfers ownership of the underlying asset by the end of the lease term; (2)&amp;#160;the lease contains an option to purchase the underlying asset that is reasonably certain to be exercised; (3)&amp;#160;the lease term is for a major part of the remaining economic life of the underlying asset; (4)&amp;#160;the present value of the sum of the lease payments and any guaranteed residual value that is not already included in the lease payments equals or exceeds substantially all of the fair value of the underlying asset; or (5)&amp;#160;the underlying asset is of such a specialized nature that it is expected to have no alternative use to the lessor at the end of the lease term. A lease is classified as an operating lease if it does not meet any one of these criteria.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;We do not currently have any leases classified as finance leases. Our operating leases are included in operating lease right-of-use assets, net, other current liabilities, and operating lease liabilities on the consolidated balance sheets. At the commencement date, operating lease right-of-use assets and operating lease liabilities are determined based on the present value of lease payments to be made over the lease term. Operating lease right-of-use assets also include any rent paid prior to the commencement date, less any lease incentives received, and initial direct costs incurred. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term. We have elected to combine our lease components (e.g., fixed payments including rent, real estate taxes and insurance costs) with non-lease components (e.g., common-area maintenance costs and equipment maintenance costs) and as such, we account for lease and non-lease components as a single component. Lease expense also includes amounts relating to variable lease payments. Variable lease payments include amounts relating to common area maintenance and real estate taxes.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;We also elected not to recognize right-of-use assets and lease liabilities for qualifying short-term leases with an initial lease term of 12&amp;#160;months or less at lease inception. Such leases are expensed on a straight-line basis over the lease term.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The depreciable life of operating right-of-use-assets and leasehold improvements is limited by the expected lease term.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Income Taxes&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;We recognize deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the financial reporting and tax basis of assets and liabilities, as well as for operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using the tax rates that are expected to apply to taxable income for the years in which those tax assets and liabilities are expected to be realized or settled. We record valuation allowances to reduce deferred tax assets to the amount we believe is more likely than not to be realized.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;We recognize uncertain tax positions when the position will be more likely than not upheld on examination by the taxing authorities based solely upon the technical merits of the positions. We recognize interest and penalties, if any, related to unrecognized income tax uncertainties in income tax expense. We did not have any accrued interest or penalties associated with uncertain tax positions as of December&amp;#160;31, 2019 and 2018.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;We are subject to U.S. federal income tax, as well as income tax in Korea, California and other states. The federal returns for tax years 2016 through 2019 remain open to examination; the California returns remain subject to examination for tax years 2015 through 2019. Carryforward attributes that were generated in years where the statute of limitations is closed may still be adjusted upon examination by the Internal Revenue Service or other respective tax authority. All other state jurisdictions remain open to examination. No income tax returns are currently under examination by taxing authorities.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Stock Repurchases&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In November&amp;#160;2015, the board of directors approved the 2015 Share Repurchase Program (Note&amp;#160;10) allowing the CEO or CFO, on behalf of the company, to repurchase from time to time, in the open market or in privately negotiated transactions, up to $50.0&amp;#160;million of our outstanding shares of common stock, exclusive of any commissions, markups or expenses. The timing and amounts of any purchases were and will continue to be based on market conditions and other factors, including price, regulatory requirements and other corporate considerations. The 2015 Share Repurchase Program does not require the purchase of any minimum number of shares and may be suspended, modified or discontinued at any time without prior notice. We have financed, and expect to continue to finance, the purchases with existing cash balances. As it is the intent for the repurchased shares to be retired, we have elected to account for the shares repurchased under the constructive retirement method. For shares repurchased in excess of par, we allocate the purchase price in excess of par value to accumulated deficit.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Revenue Recognition&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Beginning January&amp;#160;1, 2018, we adopted the provisions of FASB ASC Topic&amp;#160;606, &lt;font style="font-style:italic;"&gt;Revenue from Contracts with Customers&lt;/font&gt;, or ASC&amp;#160;606. This guidance requires that entities recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. We adopted ASC&amp;#160;606 on January&amp;#160;1, 2018 by recording the cumulative effect of the adoption to accumulated deficit. We applied the new guidance to contracts that were not complete as of January&amp;#160;1, 2018. Implementation of ASC&amp;#160;606 did not have a material impact on our consolidated financial statements.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;We derive substantially all of our revenue from non-exclusive license agreements with a limited number of pharmaceutical and biotechnology companies granting them the right to use our cell lines and intellectual property for non-clinical use. These agreements generally include upfront fees and annual research license fees for such use, as well as commercial license fees for sales of the licensee products developed or manufactured using our intellectual property and cell lines.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account in ASC&amp;#160;606. A contract&amp;#8217;s transaction price is allocated to each distinct performance obligation based on relative standalone selling price and recognized as revenue when, or as, the performance obligation is satisfied.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Under the company&amp;#8217;s license agreements with customers, the company typically promises to provide a license to use certain cell lines and related patents, the related know-how, and future research and development data that affect the license. We have concluded that these promises represent one performance obligation due to the highly interrelated nature of the promises. We provide the cell lines and know-how immediately upon entering into the contracts. The research and development data is provided throughout the term of the contract when and if available.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Our license agreement with Intrexon (Note&amp;#160;7) included a nonrefundable upfront payment of $0.4&amp;#160;million, received when we entered into the contract in 2010. In this instance, we determined that under ASC&amp;#160;606 it would be appropriate to recognize the initial milestone payment at a point in time, when we transferred the license. In this case, the intellectual property provided under the contract is functional intellectual property under ASC&amp;#160;606 and was determined to be a distinct performance obligation in the context of the arrangement. Prior to adoption, the upfront payment had been initially recorded as deferred revenue and was being recognized into revenue on a straight-line basis. As a result, upon adoption of ASC&amp;#160;606, we adjusted our accumulated deficit for the effects of recognizing revenue upfront for the initial milestone. The adjustment to accumulated deficit upon adoption was not material.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The license agreements may include nonrefundable upfront payments, event-based milestone payments, sales-based royalty payments, or some combination of these. The event-based milestone payments represent variable consideration and we use the most likely amount method to estimate this variable consideration. Given the high degree of uncertainly around achievement of these milestones, we do not recognize revenue from these milestone payments until the uncertainty associated with these payments is resolved. We currently estimate variable consideration related to milestone payments to be zero and, as such, no revenue has been recognized for milestone payments. We recognize revenue from sales-based royalty payments when or as the sales occur. On a quarterly basis, we re-evaluate our estimate of milestone variable consideration to determine whether any amount should be included in the transaction price and recorded in revenue prospectively.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Upon adoption, we changed our accounting policy from accounting for milestones payments under the milestone method to accounting for variable consideration as discussed above. The change in accounting policy did not change any amounts in the financial statements because of the significant uncertainty surrounding the estimate of variable consideration for milestone payments.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;To date, we have generated minimal revenue related to the non-clinical use of our cells lines and intellectual property. We have no products approved for commercial sale and we have not generated any revenue from product sales. If we fail to complete the development of our product candidates in a timely manner or fail to obtain regulatory approval for them, we may never be able to generate substantial future revenue.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Research and Development Costs&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Major components of research and development costs include cash compensation and other personnel-related expenses, stock-based compensation, depreciation and amortization expense on research and development property and equipment and intangible assets, costs of preclinical studies, clinical trials and related clinical manufacturing, costs of drug development, costs of materials and supplies, facilities cost, overhead costs, regulatory and compliance costs, and fees paid to consultants and other entities that conduct certain research and development activities on our behalf. Costs incurred in research and development are expensed as incurred.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Included in research and development costs are clinical trial and research expenses based on the services performed pursuant to contracts with research institutions and clinical research organizations and other vendors that conduct clinical trials and research on our behalf. We record accruals for estimated costs under these contracts. When evaluating the adequacy of the accrued liabilities, we analyze the progress of the studies or clinical trials, including the phase or completion of events, invoices received, contracted costs and purchase orders. Significant judgments and estimates are made in determining the accrued balances at the end of any reporting period based on the facts and circumstances known at that time. Although we do not expect the estimates to be materially different from the amounts actually incurred, if the estimates of the status and timing of services performed differs from the actual status and timing of services performed, we may report amounts that are too high or too low in any particular period. Actual results could differ from our estimates.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Stock-Based Compensation&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;We account for stock-based compensation under the provisions of ASC Topic&amp;#160;718, &lt;font style="font-style:italic;"&gt;Compensation&amp;#8212;Stock Compensation&lt;/font&gt;, or ASC&amp;#160;718, which applies to share-based payments issued to employees and nonemployees in exchange for goods or services. Under ASC&amp;#160;718, the fair value of an equity-classified award is estimated on the grant date without regard to service or performance conditions. The grant date fair values for options and warrants are estimated using the Black-Scholes-Merton option pricing model, and the grant date fair values for restricted stock units, or RSUs, are based upon the closing market price of our common stock on the date of grant.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;We use the straight-line method to recognize stock-based compensation expense for our outstanding share awards that do not contain a performance condition. For awards subject to performance-based vesting conditions, we assess the probability of the individual milestones under the award being achieved and stock-based compensation expense is recognized over the service period commencing once management believes the performance criteria is probable of being met. For awards with service or performance conditions, we recognize the effect of forfeitures in compensation cost in the period that the award was forfeited.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Litigation Costs&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;We expense legal fees as they are incurred.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Comprehensive Income (Loss)&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Comprehensive income or loss is defined as the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. Comprehensive income or loss is composed of net income (loss) and other comprehensive income (loss). Our other comprehensive income or loss consists of unrealized gains and losses on marketable debt securities classified as available-for-sale, net of income taxes.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Basic and Diluted Net Loss per Share of Common Stock&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Basic net loss per share is calculated by dividing the net loss by the weighted-average number of common shares outstanding for the period. Diluted loss per share is computed similarly to basic loss per share except that the denominator is increased to include the number of additional shares that would have been outstanding if the potential common shares had been issued and if the additional common shares were dilutive.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;For all periods presented, potentially dilutive securities are excluded from the computation of fully diluted loss per share as their effect is anti-dilutive. The following table details those securities that have been excluded from the computation of potentially dilutive securities:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.1%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December&amp;#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2017&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding options&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,506,950&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,493,250&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,693,250&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding RSUs&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,139,428&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;867,911&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;888,189&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding warrants&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;17,589,250&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;17,721,088&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,646,378&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;24,950,411&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;24,302,527&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amounts in the table above reflect the common stock equivalents of the noted instruments.&lt;/p&gt;&lt;/div&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Segment and Geographic Information&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating segments are defined as components of an enterprise (business activity from which it earns revenue and incurs expenses) for which discrete financial information is available and regularly reviewed by the chief operating decision maker in deciding how to allocate resources and in assessing performance. Our chief operating decision maker is the company&amp;#8217;s CEO. We view our operations and manage our business as a single operating and reporting segment. As of December&amp;#160;31, 2019 and 2018, the majority of our assets were held in the U.S. For the years ended December&amp;#160;31, 2019, 2018 and 2017, all of our revenue was derived in the U.S.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Recent Accounting Pronouncements&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Application of New or Revised Accounting Standards &amp;#8211; Adopted&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;We adopted ASC&amp;#160;842 on January&amp;#160;1, 2019, using the simplified transition approach which allowed us to not recast the comparative periods presented when transitioning to the new lease standard, while including required disclosures under ASC&amp;#160;840 for all periods presented under ASC&amp;#160;840. In addition, we elected the package of practical expedients permitted under the transition guidance, which among other things, allowed us to not reassess&amp;#160;(1)&amp;#160;whether a contract is or contains a lease, and (2)&amp;#160;the classification of existing leases.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The adoption of ASC&amp;#160;842 had a substantial impact on our balance sheet. The most significant impacts were (i)&amp;#160;the recognition of $13.5&amp;#160;million of operating lease right-of-use assets, net, and $16.4&amp;#160;million of operating lease liabilities, and (ii)&amp;#160;the derecognition of assets and liabilities associated with the build-to-suit leases under ASC&amp;#160;840 (resulting in the derecognition of property, plant and equipment, net, of $6.6&amp;#160;million and net adjustments to related liabilities of $5.7&amp;#160;million). The build-to-suit leases were recorded as normal operating leases under ASC&amp;#160;842. The difference between the excess of build-to-suit related liabilities and assets of $0.9&amp;#160;million was recorded as an increase to our accumulated deficit. The cumulative-effect adjustment had no tax impact due to the valuation allowance against the gross deferred tax asset less reversing deferred tax liabilities. Adoption of this standard had no material impact on our results of operations and cash flows.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In August&amp;#160;2018, the FASB issued ASU&amp;#160;2018&amp;#8209;15, &lt;font style="font-style:italic;"&gt;Intangibles&amp;#8212;Goodwill and Other&amp;#8212;Internal-Use Software (Subtopic 350-40): Customer&amp;#8217;s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract&lt;/font&gt; (ASU&amp;#160;2018&amp;#8209;15). This update aligns guidance for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs to develop or obtain internal-use software (and hosting arrangements that include an internal-use software license). Capitalized implementation costs will be amortized over the term of the hosting arrangement and expense related to the capitalized implementation costs will be presented in the same line item in the statements of operations as the fees associated with the service contract. As permitted by the standard, we elected to early adopt ASU&amp;#160;2018&amp;#8209;15 on a prospective basis as of October&amp;#160;1, 2019. The adoption did not have a material effect on our consolidated financial statements.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Application of New or Revised Accounting Standards &amp;#8211; Not Yet Adopted&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In December&amp;#160;2019, the FASB issued ASU&amp;#160;2019-12,&amp;#160;&lt;font style="font-style:italic;"&gt;Simplifying the Accounting for Income Taxes&lt;/font&gt;. The amendments in this update include removing the exception to the incremental approach for intraperiod tax allocation when there is a loss from continuing operations and income, or a gain, from other items (e.g., discontinued operations or other comprehensive income), and the exception to the general methodology for calculating income taxes in an interim period when a year-to-date loss exceeds the anticipated loss for the year. We are currently evaluating the impact that these amendments will have on our consolidated financial statements and we intend to early adopt these amendments on January&amp;#160;1, 2020. We do not expect that the adoption of these amendments will have a significant impact on our consolidated financial statements.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In June&amp;#160;2016, the FASB issued ASU&amp;#160;2016&amp;#8209;13,&amp;#160;&lt;font style="font-style:italic;"&gt;Financial Instruments&amp;#8212;Credit Losses (Topic 326):&amp;#160;Measurement of Credit Losses on Financial Instruments&lt;/font&gt;. The new guidance supersedes existing U.S. GAAP for measuring and recording of credit losses on financial assets measured at amortized cost by replacing the incurred-loss model with an expected-loss model. Accordingly, these financial assets will be presented at the net amount expected to be collected. This new standard also requires that credit losses related to available-for-sale debt securities be recorded as an allowance through net income rather than reducing the carrying amount under the current, other-than-temporary-impairment model. The new guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December&amp;#160;15, 2019, but may be adopted earlier. With certain exceptions, adjustments are to be applied using a modified-retrospective approach by reflecting adjustments through a cumulative-effect impact on retained earnings as of the beginning of the fiscal year of adoption. In May&amp;#160;2019, the FASB issued ASU&amp;#160;2019-05,&amp;#160;&lt;font style="font-style:italic;"&gt;Financial Instruments&amp;#8212;Credit Losses (Topic&amp;#160;326):&amp;#160;Targeted Transition Relief&lt;/font&gt;, which provides companies with an option to irrevocably elect the fair value option for certain financial assets previously measured at amortized cost basis upon adoption of Topic&amp;#160;326. We are currently evaluating the impact that this new standard and its related amendments will have on our consolidated financial statements and we intend to adopt the standard on January&amp;#160;1, 2021. However, as the impact is dependent upon the investments held as of the adoption date, it is not possible for us to quantify the impact until the date of adoption.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other recent authoritative guidance issued by the FASB (including technical corrections to the ASC), the American Institute of Certified Public Accountants, and the Securities and Exchange Commission during the three&amp;#160;months ended December&amp;#160;31, 2019 did not, or are not expected to, have a material effect on our consolidated financial statements.&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
  <us-gaap:SupplementalBalanceSheetDisclosuresTextBlock id="F_000437" contextRef="C_0001326110_20190101_20191231">
&lt;p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;3. &amp;#160;&amp;#160;&amp;#160;&amp;#160;Financial Statement Details&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Prepaid expenses and other current assets&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December&amp;#160;31, 2019 and 2018, prepaid expenses and other current assets were made up of (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December&amp;#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Prepaid preclinical and clinical trial services - with&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&amp;nbsp; related party (Note 9)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,021&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Insurance premium financing asset&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;757&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;339&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Prepaid supplies - with related party (Note 9)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;467&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;532&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Prepaid services&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;440&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;230&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Prepaid rent&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;392&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;536&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Prepaid insurance&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;372&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;343&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Prepaid equipment maintenance&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;251&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;329&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Interest receivable - marketable debt securities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;222&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;473&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Prepaid license fees&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;78&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;104&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Insurance claim receivables&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;34&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,882&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Due from related parties&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;47&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;90&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;24&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;42&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,105&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13,900&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;
&lt;p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Property, plant and equipment, net&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December&amp;#160;31, 2019 and 2018, property, plant and equipment, net, was made up of (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December&amp;#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Construction in progress&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,480&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;33,406&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,087&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Buildings&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;22,690&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;59,356&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Equipment&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21,434&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;20,878&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Software&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,195&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,264&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Furniture &amp;amp; fixtures&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;383&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;381&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;79,108&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;88,446&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accumulated depreciation&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(18,607&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(11,561&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;60,501&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;76,885&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Depreciation expense related to property, plant and equipment was $8.4&amp;#160;million, $7.3&amp;#160;million and $3.3&amp;#160;million for the years ended December&amp;#160;31, 2019, 2018 and 2017, respectively.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As a result of adoption of ASC&amp;#160;842 (Note&amp;#160;2), we&amp;#160;(i)&amp;#160;reclassified $32.0&amp;#160;million of assets from buildings to leasehold improvements, and (ii)&amp;#160;derecognized $6.6&amp;#160;million of assets associated with build-to-suit leases under ASC&amp;#160;840.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The impact of adoption of ASC&amp;#160;842 on property, plant, and equipment at December&amp;#160;31, 2018 was as follows&amp;#160;(in&amp;#160;thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.24%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31, 2018&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.24%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Adoption of&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;ASC 842&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Increase&amp;#160;(Decrease)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.24%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;January 1, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,087&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;32,014&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;36,101&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Buildings&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;59,356&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(39,893&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;19,463&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property, plant and equipment, gross&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;88,446&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(7,879&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;80,567&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accumulated depreciation&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(11,561&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,293&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(10,268&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property, plant and equipment, net&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;76,885&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(6,586&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;70,299&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Intangible assets, net&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December&amp;#160;31, 2019 and 2018, intangible assets were made up of (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December&amp;#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Technology license&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,042&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,042&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less accumulated amortization&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(9,042&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(8,477&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;565&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Our intangible assets were fully amortized as of March&amp;#160;31, 2019. Amortization expense was $0.6&amp;#160;million, $2.3&amp;#160;million and $2.3&amp;#160;million for the years ended December&amp;#160;31, 2019, 2018 and 2017, respectively. Amortization for the company&amp;#8217;s technology license is included in research and development expense on the consolidated statements of operations.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Other assets&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December&amp;#160;31, 2019 and 2018, other assets were made up of (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December&amp;#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Prepaid preclinical and clinical trial services - with&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&amp;nbsp; related party (Note 9)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,075&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Restricted cash&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;179&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;179&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Security deposit&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;113&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;113&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Prepaid rent&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,205&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;19&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;30&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,386&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,527&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Restricted cash is comprised of a certificate of deposit that serves as collateral for a letter of credit required by our landlord as a security deposit related to our facility in San Diego, California.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Accrued expenses&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December&amp;#160;31, 2019 and 2018, accrued expenses were made up of (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December&amp;#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued bonus&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,002&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,079&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued compensation&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,064&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;943&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued professional and service fees&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;975&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;912&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued laboratory equipment and supplies&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;640&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;678&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued preclinical and clinical trial costs&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;281&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;704&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued franchise, sales/use and property taxes&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;200&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;250&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Litigation settlement accruals&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,000&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued construction costs&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,341&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;181&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;197&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,343&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21,104&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;
&lt;p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Other current liabilities&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December&amp;#160;31, 2019 and 2018, other current liabilities were made up of (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December&amp;#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating lease liability - current portion (including&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;   amounts with related parties, Note 9)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,206&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Financing obligation - current portion&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;757&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;965&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred rent - current portion&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;598&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;18&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;104&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,981&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,667&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;
&lt;p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Investment income, net&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net investment income is as follows for the years ended December&amp;#160;31, 2019, 2018 and 2017 (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.1%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;For the Year Ended December&amp;#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2017&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Interest income&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,643&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,317&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,225&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Investment accretion income (amortization expense), net&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(463&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1,597&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net realized (losses) gains on investments&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(4&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;37&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,642&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,857&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,665&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Interest income includes interest from marketable debt securities, notes receivable, other assets, and interest from bank deposits. We did not recognize an impairment loss on any investments during the years ended December&amp;#160;31, 2019, 2018 and 2017.&lt;/p&gt;</us-gaap:SupplementalBalanceSheetDisclosuresTextBlock>
  <us-gaap:CostAndEquityMethodInvestmentsDisclosureTextBlock id="F_000438" contextRef="C_0001326110_20190101_20191231">
&lt;p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;4. &amp;#160;&amp;#160;&amp;#160;&amp;#160;Viracta Investment and Convertible Notes&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In March&amp;#160;2017, we participated in a Series&amp;#160;B convertible preferred stock financing and invested $8.5&amp;#160;million in Viracta Therapeutics, Inc., or Viracta, a clinical stage drug development company. In May&amp;#160;2017, we executed an exclusive worldwide license with Viracta to develop and commercialize Viracta&amp;#8217;s proprietary histone deacetylase inhibitor drug candidate for use in combination with natural killer cell therapy and possibly additional therapies. See Note&amp;#160;7&lt;font style="font-style:italic;"&gt; &amp;#8211; Collaboration and License Agreements &amp;#8211; Royalties and In-licensing Agreements &amp;#8211; Viracta License Agreement&lt;/font&gt; for further information.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In June&amp;#160;2018, Viracta executed a 2018&amp;#160;Note and Warrant Purchase Agreement with existing and new investors, including us. The initial closing under the Purchase Agreement occurred in June&amp;#160;2018, at which point we purchased a convertible note for $0.4&amp;#160;million, which under certain circumstances was convertible into preferred stock of Viracta, and a warrant to purchase Viracta&amp;#8217;s common shares. The convertible note accrued interest at 8% and had a one-year maturity date. In September&amp;#160;2018, a milestone closing under the Purchase Agreement occurred, at which point we purchased an additional convertible note for $0.4&amp;#160;million, which under certain circumstances was convertible into preferred stock of Viracta, and a warrant to purchase Viracta&amp;#8217;s common shares. The convertible note accrued interest at 8% and had a one-year maturity date. We classified the convertible notes as held-to-maturity notes receivable on the consolidated balance sheets. Effective January&amp;#160;31, 2019, the notes, together with accrued interest then outstanding, were converted to Series&amp;#160;B preferred stock resulting in an increase to our investment in Viracta&amp;#8217;s Series&amp;#160;B convertible preferred stock of $0.8&amp;#160;million. In May&amp;#160;2019, we exercised warrants to acquire 253,120&amp;#160;shares of Viracta common stock. At December&amp;#160;31, 2019, our investment in Viracta totaled $9.3&amp;#160;million.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Based on the level of equity investment at risk, Viracta is not a VIE and therefore is not consolidated under the VIE Model. In addition, we do not hold a controlling financial interest in Viracta and therefore we do not consolidate Viracta under the voting interest model. As the preferred stock is not considered in-substance common stock, the investment is not within the scope of accounting for the investment under the equity method. As the preferred stock does not have a readily determinable fair value and does not qualify for the practical expedient to estimate fair value in accordance with ASC&amp;#160;820, we have elected to apply the measurement alternative under ASC&amp;#160;321, pursuant to which we measure our investment in Viracta at cost, less impairment, adjusted for observable price changes in an orderly market for an identical or similar investment of the same issuer.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December&amp;#160;31, 2019, our qualitative impairment assessment did not indicate there were events or changes in circumstances that may have had a significant adverse effect on the fair value of the investment. We have not recorded any impairments as of December&amp;#160;31, 2019, or on a cumulative basis. Further, we have not identified any downward or upward adjustments due to observable price changes in the investment as of December&amp;#160;31, 2019, or on a cumulative basis. Our investment in Viracta is reflected in equity investment on the consolidated balance sheets.&lt;/p&gt;</us-gaap:CostAndEquityMethodInvestmentsDisclosureTextBlock>
  <us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock id="F_000439" contextRef="C_0001326110_20190101_20191231">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;5. &amp;#160;&amp;#160;&amp;#160;&amp;#160;Financial Instruments &amp;#8211; Investments in Debt Securities&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;At December&amp;#160;31, 2019, our investments in debt securities are detailed below (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="18" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.1%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&amp;#160;31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Remaining&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Contractual&amp;#160;Life&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in years)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amortized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cost&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gains&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Losses&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Value&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Current:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Available-for-sale:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Corporate debt securities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.2&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;32,382&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(3&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;32,389&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Foreign government bonds&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.3&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,007&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,007&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Government sponsored securities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.5&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,752&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(4&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,748&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Current portion&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.2&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;36,141&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(7&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;36,144&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Noncurrent:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Available-for-sale:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Corporate debt securities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.7&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,501&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(4&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,497&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Noncurrent portion&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.7&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,501&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(4&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,497&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.94%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.3&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;37,642&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(11&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;37,641&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;At December&amp;#160;31, 2018, our investments in debt securities are detailed below (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.42%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&amp;#160;31, 2018&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amortized&amp;#160;Cost&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gains&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Losses&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair&amp;#160;Value&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Current:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Available-for-sale:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Corporate debt securities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;57,463&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(136&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;57,328&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total available-for-sale&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;57,463&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(136&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;57,328&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Held-to-maturity, notes receivable (Note 4)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;723&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;723&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Current portion&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;58,186&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(136&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;58,051&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Noncurrent:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Available-for-sale:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Corporate debt securities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,067&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(76&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,991&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Government sponsored securities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,756&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(46&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,710&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Noncurrent portion&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,823&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(122&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,701&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;64,009&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(258&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;63,752&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accumulated unrealized losses on debt securities classified as available-for-sale that have been in a continuous loss position for less than 12&amp;#160;months and for more than 12&amp;#160;months at December&amp;#160;31, 2019 and 2018 were as follows (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.42%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&amp;#160;31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less than 12 months&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;More than 12 months&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Estimated&amp;#160;Fair&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Value&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross&amp;#160;Unrealized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Losses&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Estimated&amp;#160;Fair&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Value&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross&amp;#160;Unrealized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Losses&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Corporate debt securities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11,021&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(3&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,497&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(4&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Government sponsored securities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,748&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(4&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11,021&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(3&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,245&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(8&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.42%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&amp;#160;31, 2018&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less than 12 months&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;More than 12 months&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Estimated&amp;#160;Fair&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Value&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross&amp;#160;Unrealized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Losses&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Estimated&amp;#160;Fair&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Value&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross&amp;#160;Unrealized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Losses&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Corporate debt securities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;32,010&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(26&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;26,663&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(186&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Government sponsored securities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,710&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(46&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;32,010&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(26&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;29,373&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(232&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;At December&amp;#160;31, 2019, 14 of the securities were in an unrealized loss position. We evaluated our securities for other-than-temporary impairment and concluded that the decline in value was primarily caused by current economic and market conditions. We do not intend to sell the investments and it is not more likely than not that we will be required to sell the investments before recovery of their amortized cost bases. Therefore, we did not recognize any other-than-temporary impairment loss during the years ended December&amp;#160;31, 2019, 2018 and 2017.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;We recorded realized gains and losses on sales of available-for-sale debt securities as follows (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.92%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Realized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gains&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.92%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Realized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Losses&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.92%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Realized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gains (Losses)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(8&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(4&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2017&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;52&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(15&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;37&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock>
  <us-gaap:FairValueMeasurementInputsDisclosureTextBlock id="F_000440" contextRef="C_0001326110_20190101_20191231">
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;6. &amp;#160;&amp;#160;&amp;#160;&amp;#160;Fair Value Measurements&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair value is defined as an exit price that would be received from the sale of an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Authoritative guidance establishes a three-level hierarchy for disclosure that is based on the extent and level of judgment used to estimate the fair value of assets and liabilities.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Recurring Valuations&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Financial assets and liabilities measured at fair value on a recurring basis are summarized below at December&amp;#160;31, 2019 and 2018 (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.42%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Value Measurements at December&amp;#160;31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 1&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 2&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 3&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Assets:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Current:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash and cash equivalents&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15,508&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15,508&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Corporate debt securities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;32,389&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;32,389&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Foreign government bonds&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,007&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,007&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Government sponsored securities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,748&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,748&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Noncurrent:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Corporate debt securities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,497&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,497&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total assets measured at fair value&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;53,149&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15,508&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;37,641&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.42%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Value Measurements at December&amp;#160;31, 2018&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 1&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 2&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 3&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Assets:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Current:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash and cash equivalents&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;16,821&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;16,821&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Corporate debt securities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;57,328&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;57,328&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Noncurrent:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Corporate debt securities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,991&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,991&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Government sponsored securities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,710&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,710&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total assets measured at fair value&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;79,850&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;16,821&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;63,029&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;
&lt;p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Non-recurring Valuations&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Non-financial assets and liabilities are recognized at fair value subsequent to initial recognition when they are deemed to be other-than-temporarily impaired. There were no material non-financial assets and liabilities deemed to be other-than-temporarily impaired and measured at fair value on a non-recurring basis for the years ended December&amp;#160;31, 2019, 2018 and 2017.&lt;/p&gt;</us-gaap:FairValueMeasurementInputsDisclosureTextBlock>
  <nk:CollaborationAndLicenseAgreementsTextBlock id="F_000441" contextRef="C_0001326110_20190101_20191231">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;7. &amp;#160;&amp;#160;&amp;#160;&amp;#160;Collaboration and License Agreements&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Collaborative Arrangements&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;A collaborative arrangement is a contractual arrangement that involves a joint operating activity. These arrangements involve two or more parties who are&amp;#160;(i)&amp;#160;active participants in the activity, and (ii)&amp;#160;exposed to significant risks and rewards dependent on the commercial success of the activity.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In January&amp;#160;2020, we entered into a Cost Sharing Agreement with ImmunityBio as further described in Note 15 &amp;#8211; &lt;font style="font-style:italic;"&gt;Subsequent Events&lt;/font&gt;.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Exclusive Co-Development Agreement&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In August&amp;#160;2016, we entered into an exclusive Co-Development Agreement, or the Co-Development Agreement, with Altor BioScience, LLC, or Altor. Altor is a related party, as it is a wholly owned subsidiary of ImmunityBio (Note&amp;#160;9). Under the Co-Development Agreement, the parties agreed to exclusively collaborate on the development of certain therapeutic applications combining our proprietary NK&amp;#160;cells with Altor&apos;s N&amp;#8209;801 and/or N&amp;#8209;803 products with respect to certain technologies and intellectual property rights as may be agreed between the parties for the purpose of jointly developing therapeutic applications of certain effector cell lines.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;We are the lead developer for each product developed by the parties pursuant to the Co-Development Agreement unless otherwise agreed to under a given project plan. Under the terms of the Co-Development Agreement, both parties granted a co-exclusive, royalty free, fully paid-up, worldwide license, with the right to sublicense (only to a third-party contractor assisting with research and development activities under this Co-Development Agreement and subject to prior consent, not to be unreasonably withheld), under the intellectual property, or IP, including the parties interest in the joint IP, solely to conduct any development activities agreed to by the steering committee as set forth in any development plan. Unless otherwise mutually agreed by the parties in the development plan for a project, we are responsible for all costs and expenses incurred by either party related to conducting clinical trials and other activities under each development program, including costs associated with patient enrollment, materials and supplies, third-party staffing and regulatory filings. Altor supplies free of charge, sufficient amounts of Altor products for all pre-clinical requirements and certain clinical requirements for up to 400&amp;#160;patients in phase&amp;#160;I and/or phase&amp;#160;II clinical trials, as required under the development plan for a project per the Co-Development Agreement.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Each company owns an undivided interest in and to all rights, title and interest in and to the joint product rights. The Co-Development Agreement expires upon the fifth anniversary of the effective date. We have dosed patients with N&amp;#8209;803, an IL&amp;#8209;15 superagonist, in several phase&amp;#160;Ib/II trials during the years ended December&amp;#160;31, 2019, 2018 and 2017. No charges for supplies by Altor were incurred in association with the above trials during the years ended December&amp;#160;31, 2019, 2018 and 2017.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Royalties and In-licensing Agreements&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Viracta License Agreement&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In May&amp;#160;2017, we entered into an agreement with Viracta under which we were granted exclusive worldwide rights to Viracta&amp;#8217;s phase&amp;#160;II drug candidate, VRx&amp;#8209;3996, for use in combination with our platform of NK&amp;#160;cell therapies. In consideration for the license, we are obligated to pay to Viracta&amp;#160;(i)&amp;#160;mid-single digit percentage royalties of net sales of licensed products for therapeutic use; and (ii)&amp;#160;milestone payments ranging from $10.0&amp;#160;million to $25.0&amp;#160;million for various regulatory approvals and cumulative net sales levels. We may terminate the agreement, in its sole discretion, in whole or on a product by product and/or country by country basis, at any time upon 90&amp;#160;days&amp;#8217;&amp;#160;prior written notice. In addition, either party may terminate the agreement in the event of a material breach or for bankruptcy of the other party.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus, or GSH, and DRK-Blutspendedienst Baden-Wurttenberg-Hessen gGmbH, or BSD, License Agreement&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In August&amp;#160;2015, we entered into a license agreement with GSH and BSD under which we were granted an exclusive license to certain GSH&amp;#8209;BSD patents, materials and know-how that specifically targets ErbB2 expressing cancers. In addition, GSH granted us an exclusive license to certain GSH only technology and materials. In consideration for the licenses, we agreed to pay initial and annual licensing fees, regulatory and commercial milestones and low single-digit percentage royalties on net sales of licensed products. We paid $1.1&amp;#160;million for the initial license fees, which was included in research and development expenses on the consolidated statements of operations for the year ended December&amp;#160;31, 2015. Annual license fees under the agreement began in 2018. In October&amp;#160;2018, we terminated this agreement in accordance with the terms of the agreement.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Fox Chase Cancer Center License Agreement&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In 2004 and amended in 2008, we entered into an exclusive license agreement with Fox Chase Cancer Center, or Fox Chase, for the exclusive, worldwide right to certain patents and know-how pertaining to CD16 receptor bearing NK&amp;#8209;92&amp;#160;cell lines. In consideration for this exclusive license, we agreed to pay Fox Chase&amp;#160;(i)&amp;#160;low single-digit percentage royalties on net sales of licensed products for therapeutic and diagnostic use; and (ii)&amp;#160;mid-twenties percentage royalties on any compensation we receive from sublicensees.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Rush University Medical Center License Agreement&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In 2004, we entered into a 12-year licensing agreement with Rush University Medical Center for the exclusive rights to license and grant sublicenses of certain intellectual property related to clinical use of NK&amp;#8209;92. We are required to pay low to mid-single digit percentage royalties on net sales depending upon the various fields of studies and other factors. We were required to pay a minimum annual royalty of $25,000. The Rush University Medical Center License Agreement also provides for payments in the aggregate amount of $2.5&amp;#160;million upon the company achieving various milestones, including upon&amp;#160;(i)&amp;#160;the completion of phase&amp;#160;II clinical trial associated with the licensed intellectual property; (ii)&amp;#160;the approval by the FDA of a new drug application for a licensed product; and (iii)&amp;#160;the first year that sales of the licensed product equals or exceeds $0.3&amp;#160;million. The license had a term of 12&amp;#160;years from 2006, the year in which royalty payments were first made, and included customary termination rights for both parties. Beginning in 2018, this license converted to a perpetual, irrevocable, fully paid, royalty-free, exclusive license.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;During the years ended December&amp;#160;31, 2019, 2018 and 2017, we recorded royalty expense of $0, $4,200 and $25,000, respectively, related to the Rush University Medical Center License Agreement. Royalty expense is included in selling, general and administrative on the consolidated statements of operations. No milestones were met during the years ended December&amp;#160;31, 2019, 2018 and 2017.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Out-Licensing Agreement&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Intrexon License Agreement&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In February&amp;#160;2010, we entered into a 17-year license agreement with Intrexon Corporation, or Intrexon, pursuant to which we granted to Intrexon a non-exclusive, worldwide, sublicensable license to research and sell products under certain patents relating to modified NK&amp;#8209;92&amp;#160;cells that express Intrexon&amp;#8217;s proprietary gene sequences for use as a therapeutic and prophylactic agent in humans in specified therapeutic areas. In consideration for the license agreement, Intrexon paid us a one-time fee of $0.4&amp;#160;million. Prior to adoption of ASC&amp;#160;606, this upfront payment had initially been recorded as deferred revenue and was being recognized into revenue on a straight-line basis. Upon adoption of ASC&amp;#160;606, we adjusted our accumulated deficit in an amount equal to the then remaining deferred revenue after concluding that under ASC&amp;#160;606 the upfront payment would have been recognized when the license was transferred in 2010. Intrexon will pay the following milestone payments:&amp;#160;$0.1&amp;#160;million upon the first IND filing; $0.1&amp;#160;million upon the commencement of the first phase&amp;#160;II clinical trial; $0.4&amp;#160;million upon the commencement of the first phase&amp;#160;III clinical trial; and $0.5&amp;#160;million upon the first commercial sale relating to the licensed products. Intrexon is obligated to pay us a low single digit percentage royalty based on net sales of the licensed products by Intrexon and a mid-teen percentage royalty based on revenues received by Intrexon in connection with sublicenses of the licensed products. No milestone payments were due or received in the years ended December&amp;#160;31, 2019, 2018 and 2017, and, therefore, we recorded no milestone revenue for any of those years on the consolidated statements of operations.&lt;/p&gt;</nk:CollaborationAndLicenseAgreementsTextBlock>
  <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock id="F_000442" contextRef="C_0001326110_20190101_20191231">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;8. &amp;#160;&amp;#160;&amp;#160;&amp;#160;Commitments and Contingencies&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Contingencies&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;We record accruals for loss contingencies to the extent that we conclude it is probable that a liability has been incurred and the amount of the related loss can be reasonably estimated. We evaluate, on a quarterly basis, developments in legal proceedings and other matters that could cause a change in the potential amount of the liability recorded or of the range of potential losses disclosed. Additionally, we record our rights to insurance recoveries, limited to the extent of incurred or probable losses, as a receivable when such recoveries have been agreed to with our third-party insurers and when receipt is deemed probable. This includes instances where our third-party insurers have agreed to pay, on our behalf, certain legal defense costs and settlement amounts directly to applicable law firms and a settlement fund.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Securities Litigation&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In March&amp;#160;2016, a putative securities class action complaint captioned &lt;font style="font-style:italic;"&gt;Sudunagunta v. NantKwest, Inc., et al.&lt;/font&gt;, No. 16&amp;#8209;cv&amp;#8209;01947 was filed in federal district court for the Central District of California related to the company&amp;#8217;s restatement of certain interim financial statements for the periods ended June&amp;#160;30, 2015 and September&amp;#160;30, 2015. A number of similar putative class actions were filed in federal and state court in California. The actions originally filed in state court were removed to federal court, and the various related actions were consolidated. Plaintiffs asserted causes of action for alleged violations of Sections&amp;#160;11 and 15 of the Securities Act of 1933 and Sections&amp;#160;10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule&amp;#160;10b&amp;#8209;5 promulgated thereunder. Plaintiffs sought unspecified damages, costs and attorneys&amp;#8217; fees, and equitable/injunctive or other relief on behalf of putative classes of persons who purchased or acquired the company&amp;#8217;s securities during various time periods from July&amp;#160;28, 2015 through March&amp;#160;11, 2016. In September&amp;#160;2017, the court denied defendants&apos; motion to dismiss the third amended consolidated complaint. On August&amp;#160;13, 2018, the district court granted plaintiffs&amp;#8217; motions for class certification and to strike plaintiffs&amp;#8217; claims under the Securities Exchange Act of 1934 and Rule&amp;#160;10b&amp;#8209;5. On August&amp;#160;24, 2018, at the district court&amp;#8217;s direction, plaintiffs filed a fourth amended consolidated complaint. On August&amp;#160;27, 2018, defendants petitioned the U.S. Court of Appeals for the Ninth Circuit to authorize interlocutory appeal of the class certification order. On September&amp;#160;7, 2018, defendants answered the fourth amended consolidated complaint. On September&amp;#160;21, 2018, the parties informed the Ninth Circuit that they had reached a settlement in principle, and the parties moved to stay appellate proceedings. On September&amp;#160;24, 2018, the parties notified the district court that they had reached a settlement in principle. On November&amp;#160;9, 2018, the plaintiffs filed an unopposed motion for preliminary approval of the settlement and notice to class members. On January&amp;#160;9, 2019, the district court granted the motion for preliminary approval. A final approval hearing was held on April&amp;#160;29, 2019, and the district court granted final approval and entered judgment on May&amp;#160;31, 2019.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Under the terms of the settlement, we paid $12.0&amp;#160;million to the plaintiffs as full and complete settlement of the litigation. We were responsible for $1.2&amp;#160;million of the settlement amount, which was recognized in selling, general and administrative expense during the third quarter of 2018, while the remaining $10.8&amp;#160;million was fully funded by our insurance carriers under our directors&amp;#8217; and officers&amp;#8217; insurance policy. We and the insurance carriers paid the settlement amount into a settlement fund in January&amp;#160;2019. Subsequent to receiving final approval of the settlement on May&amp;#160;13, 2019, the aforementioned settlement accrual, associated insurance claim receivable and restricted cash were released and are no longer reflected on our consolidated balance sheets as of December&amp;#160;31, 2019.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Stipulation of Settlement&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In early April&amp;#160;2019, following board approval, which occurred in late March&amp;#160;2019, we entered into a settlement agreement, or the Stipulation of Settlement, with three&amp;#160;stockholders of the company, each of whom had submitted a stockholder demand for the board to take action to remedy purported harm to the company resulting from certain alleged wrongful conduct concerning, among other things, disclosures about Dr.&amp;#160;Soon-Shiong&amp;#8217;s compensation and a related-party lease agreement. The Stipulation of Settlement called for us to adopt certain governance changes, and for the three&amp;#160;stockholders to file a stockholder derivative action in the Superior Court of the State of California, County of San Diego, followed by an application for court approval of the Stipulation of Settlement. On May&amp;#160;31, 2019, the court entered an order preliminarily approving the Stipulation of Settlement and scheduling the final settlement hearing for August&amp;#160;9, 2019. Pursuant to the Stipulation of Settlement, we have provided stockholders with notice of the settlement and the final settlement hearing.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Under the terms of the Stipulation of Settlement, which received final approval by the court on August&amp;#160;9, 2019, we paid an attorney&amp;#8217;s fee of $0.5&amp;#160;million to the plaintiffs as part of the settlement. Of that amount, we were responsible for half, which was recognized in selling, general and administrative expense on the consolidated statements of operations during the first quarter of 2019, while the other half was funded by our insurance carrier. We and the insurance carrier paid the settlement amount into a settlement fund in June&amp;#160;2019. Subsequent to receiving final approval of the settlement on August&amp;#160;9, 2019, the aforementioned settlement accrual, associated insurance claim receivable and restricted cash were released and are no longer reflected on our consolidated balance sheets as of December&amp;#160;31, 2019.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Insurance Recoveries&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;We have reflected our right to insurance recoveries, limited to the extent of incurred or probable losses, as a receivable when such recoveries have been agreed to with our third-party insurers and receipt is deemed probable. This includes instances where our third-party insurers have agreed to pay, on our behalf, certain legal defense costs and settlement amounts directly to applicable law firms and a settlement fund. The amount of such receivable recorded at December&amp;#160;31, 2019 and 2018 was $34,000 and $10.9&amp;#160;million, respectively, and is included in prepaid expenses and other current assets on our consolidated balance sheets.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Contractual Obligations - Leases&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;We adopted ASC&amp;#160;842, as of January&amp;#160;1, 2019, using the simplified transition approach discussed in further detail in Note&amp;#160;2. As a result, prior periods were not recast. The following disclosures relate to our lease balances as of January&amp;#160;1, 2019 and December&amp;#160;31, 2019, under ASC&amp;#160;842 (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.26%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.36%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;January 1, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.36%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.26%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating lease right-of-use assets, net&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.36%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13,532&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.36%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11,729&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.26%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other current liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.36%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,960&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.36%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,206&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.26%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating lease liability, less current portion&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.36%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13,407&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.36%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,885&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As a result of new agreements entered into subsequent to our adoption of ASC&amp;#160;842, we recognized an increase of $0.8&amp;#160;million in both operating lease right-of-use assets and operating lease liabilities during the year ended December&amp;#160;31, 2019.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Substantially all of our operating lease right-of-use assets and operating lease liabilities relate to facilities leases. We lease:&amp;#160;(i)&amp;#160;a&amp;#160;research facility and office space in San Diego, California; (ii)&amp;#160;a research and manufacturing space in Culver City, California, from a related party; (iii)&amp;#160;a research and manufacturing facility in El Segundo, California, also from a related party; (iv)&amp;#160;a research facility in Torrance, California, and (v)&amp;#160;a research facility in Woburn, Massachusetts. See Note&amp;#160;9 &amp;#8211; &lt;font style="font-style:italic;"&gt;Related Party Agreements&lt;/font&gt; for further information.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating lease expense of $5.1&amp;#160;million, including variable lease costs of $1.2&amp;#160;million, was recorded in operating expenses on the consolidated statements of operations for year ended December&amp;#160;31, 2019. The weighted-average remaining lease term as of January&amp;#160;1, 2019 and December&amp;#160;31, 2019 was 5.4&amp;#160;years and 4.5&amp;#160;years, respectively. The weighted-average discount rate as of January&amp;#160;1, 2019 and December&amp;#160;31, 2019 was 9%. For the year ended December&amp;#160;31, 2019, cash outflows from operating leases, excluding variable lease costs, was $4.4&amp;#160;million.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Future minimum lease payments at December&amp;#160;31, 2019 are presented in the following table (in thousands). Common area maintenance costs and taxes are not included in these payments.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:81.8%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Years ending December 31:&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.18%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Leases (a)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:81.8%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,271&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:81.8%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,753&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:81.8%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2022&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,671&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:81.8%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2023&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,546&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:81.8%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2024&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,083&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:81.8%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,729&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:81.8%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total future minimum lease payments&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;17,053&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:81.8%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less: Interest&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,962&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:81.8%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Present value of operating lease liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14,091&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;margin-right:75.93%;text-indent:0%;font-size:5pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:4.54%;white-space:nowrap"&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:4.54%;white-space:nowrap"&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;font-size:10pt;"&gt;(a)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating lease payments include $3.3&amp;#160;million related to options to extend lease terms that are reasonably certain of being exercised.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In August&amp;#160;2018, NantBio, Inc., or NantBio, a related party (Note&amp;#160;9) assigned an agreement to us for the use of a third-party research facility, which provides us with the exclusive right to use and access to a portion of the third party&amp;#8217;s laboratory and vivarium premises. In conjunction with the assignment, we reimbursed NantBio for upfront payments, which it had made to the third party of $0.9&amp;#160;million, and paid $0.5&amp;#160;million directly to the third party for an aggregate value of $1.4&amp;#160;million. The assigned agreement is for a term of ten&amp;#160;years and expires in June&amp;#160;2027. The agreement may be terminated by us at any time, with or without cause. In case of termination of the agreement, the third party will reimburse us for a pro-rata amount based upon the passage of time.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In September&amp;#160;2016, we entered into a lease agreement with 605&amp;#160;Doug St,&amp;#160;LLC, a related party (Note&amp;#160;9), for approximately 24,250&amp;#160;square feet in El Segundo, California, which has been converted to a research and development laboratory and a cGMP manufacturing facility. The lease runs from July&amp;#160;2016 through July&amp;#160;2023. We have the option to extend the lease for an additional three&amp;#160;year term through July&amp;#160;2026. The monthly rent is $0.1&amp;#160;million with annual increases of 3% beginning in July&amp;#160;2017.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In March&amp;#160;2016, we entered into a lease agreement for an approximately 7,893&amp;#160;square foot facility in Woburn, Massachusetts, for a research and development laboratory, related office and other related uses. The initial lease term runs for 48&amp;#160;months from April&amp;#160;29, 2016 through May&amp;#160;31, 2020. In June&amp;#160;2016, the lease was amended to add 260&amp;#160;square feet, for a total of 8,153&amp;#160;square feet. Base rent for the initial term of the lease is $19,000&amp;#160;per&amp;#160;month with a $1&amp;#160;per&amp;#160;square foot annual increase on each anniversary date. In August&amp;#160;2019, we exercised our right pursuant to the lease agreement to extend the term of the lease for an additional two&amp;#160;years through May&amp;#160;31, 2022. Consequently, we recognized an increase of $0.6&amp;#160;million in both operating lease right-of-use assets and operating lease liabilities on the consolidated balance sheets.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In November&amp;#160;2015, we entered into a facility license agreement with NantWorks LLC, or NantWorks, a related party (Note&amp;#160;9), for approximately 9,500&amp;#160;square feet of office space in Culver City, California, which has been converted to a research and development laboratory and a cGMP manufacturing facility. The license was effective in May&amp;#160;2015 and extends through December&amp;#160;2020. The monthly rent is $47,000, with annual increases of 3% beginning in January&amp;#160;2017.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In June&amp;#160;2015, we entered into a lease agreement for an approximately 44,700&amp;#160;square foot facility in San Diego, California, for a research and development laboratory, related office and other related uses. The term of the lease extends for seven&amp;#160;years commencing on August&amp;#160;1, 2016. The base rent is $0.2&amp;#160;million per month with 3% annual increases on each anniversary date.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Prior to adopting ASC&amp;#160;842 on January&amp;#160;1, 2019, we recognized rent expense under operating leases on a straight-line basis. Fixed rent expense under ASC&amp;#160;840 for the years ended December&amp;#160;31, 2018 and 2017 was $2.8&amp;#160;million and $2.7&amp;#160;million, respectively.&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
  <us-gaap:RelatedPartyTransactionsDisclosureTextBlock id="F_000443" contextRef="C_0001326110_20190101_20191231">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;9. &amp;#160;&amp;#160;&amp;#160;&amp;#160;Related Party Agreements&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Our Chairman and CEO founded and has a controlling interest in NantWorks, which is a collection of multiple companies in the healthcare and technology space. As described below, we have entered into arrangements with NantWorks, and certain affiliates of NantWorks, to facilitate the development of new genetically modified NK&amp;#160;cells for our product pipeline.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Share Repurchase&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In November&amp;#160;2018, we entered into a share repurchase agreement with an immediate family member of a director of the company, pursuant to which we repurchased 138,349&amp;#160;of our common shares for a total of $0.2&amp;#160;million under our existing share repurchase program.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;NantHealth Labs, Inc.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In March&amp;#160;2018, we entered into an agreement with NantHealth Labs, Inc., or NantHealth Labs, to obtain blood-based tumor profiling services. NantHealth Labs is a related party, as it is a wholly owned subsidiary of NantHealth, Inc., a majority owned subsidiary of NantWorks. We are obligated to pay NantHealth Labs fixed, per-patient fees. The agreement has an initial term of five&amp;#160;years and renews automatically for successive one-year periods, unless terminated earlier. During the years ended December&amp;#160;31, 2019 and 2018, $10,000 and $0.3&amp;#160;million, respectively, has been recognized in research and development expense on the consolidated statements of operations. At December&amp;#160;31, 2018, we owed NantHealth Labs $49,300, which is included in due to related parties on the consolidated balance sheets. At December&amp;#160;31, 2019, no balances were due between the parties.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Immuno-Oncology Clinic, Inc.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Beginning in 2017, we entered into multiple agreements with Immuno-Oncology Clinic, Inc., or the Clinic, to conduct various clinical trials. The Clinic was formerly known as John Lee, M.D. and Leonard Sender, M.D., Inc., a professional medical corporation, dba&amp;#160;Chan Soon-Shiong Institutes for Medicine, in El Segundo, California. The Clinic is a related party as it is owned by one officer of NantKwest and NantWorks manages the administrative operations of the Clinic. Prior to June&amp;#160;30, 2019, one of the company&amp;#8217;s officers was an investigator or sub-investigator for all of the company&amp;#8217;s trials conducted at the Clinic.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In July&amp;#160;2019, we entered into a new agreement with the Clinic which superseded our existing agreements with the Clinic, effective as of July&amp;#160;1, 2019. The new agreement covers clinical trial and research related activities on a non-exclusive basis relating to our existing clinical trials, commenced prior to July&amp;#160;1, 2019, and prospective clinical trials and research projects. The new agreement also specifies certain services and related costs that are excluded from the new agreement. Prior to commencing any work under the new agreement, the parties have agreed to execute written work orders setting forth the terms and conditions related to specific services to be performed, including financial terms. For existing clinical trials, commenced prior to July&amp;#160;1, 2019, fees incurred for services performed after July&amp;#160;1, 2019 are covered under the new agreement and applied towards the below-mentioned prepayments. The initial term of the new agreement is for one year, but the agreement allows for an automatic renewal and additional extensions beyond the initial term. In July&amp;#160;2019, we executed a clinical trial work order under the new agreement with the Clinic for an open-label, phase&amp;#160;I study of PD&amp;#8209;L1.t&amp;#8209;haNK for infusion in subjects with locally advanced or metastatic solid cancers.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In consideration of the services to be performed under the new agreement, we agreed to make payments of $7.5&amp;#160;million to the Clinic, of which $3.75&amp;#160;million and $1.875&amp;#160;million were paid in July&amp;#160;2019 and October&amp;#160;2019, respectively. The prepayments constitute a prepayment by us for services to be performed by the Clinic. Under the term of the new agreement, the outstanding balance of our prepayment shall be increased on a quarterly basis by an interest credit computed in accordance with terms specified in the new agreement.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;To the extent any portion of the prepayments remain unearned by the Clinic on the third anniversary of the new agreement, we may elect at our sole discretion either to&amp;#160;(i)&amp;#160;not extend the term of the new agreement and have the Clinic reimburse us for the total amount of any remaining unused portion of the prepayments, or (ii)&amp;#160;extend the term of the new agreement for up to three additional one year periods, at which time the Clinic will reimburse us for the total amount of any remaining unused portion of the prepayments plus interest if reimbursement is not made within 60&amp;#160;days of expiration. The Clinic may terminate this agreement upon each anniversary date upon sixty&amp;#160;(60)&amp;#160;days prior written notice and reimbursement in full to us of any outstanding unearned balance of the prepayments, provided that any such termination by the Clinic will not apply with respect to any work orders still in effect at the time of such termination.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;During the years ended December&amp;#160;31, 2019, 2018 and 2017, expense of $1.1&amp;#160;million, $2.7&amp;#160;million and $0.8&amp;#160;million, respectively, has been recognized in research and development expense on the consolidated statements of operations. At December&amp;#160;31, 2019 and 2018, we owed the Clinic $0.1&amp;#160;million and $0.6&amp;#160;million, respectively, for services excluded from the new agreement, which are included in due to related parties on the consolidated balance sheets, and as of December&amp;#160;31, 2019, we had a prepaid balance with the Clinic of $5.1&amp;#160;million, which is included in prepaid expenses and other currents assets, and other assets, on the consolidated balance sheets. We anticipate that the remaining prepayment amount as of December&amp;#160;31, 2019 will be utilized in future periods as the Clinic provides additional services pursuant to the new agreement.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Tensorcom, LLC&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In April&amp;#160;2017, we entered into a sublease agreement with Tensorcom, LLC, or Tensorcom, for a portion of our San Diego, California, research and development laboratory and office space. The lease ran from May&amp;#160;1, 2017 through April&amp;#160;30, 2018. Tensorcom is a related party, as it is an affiliate of NantWorks. The sublease included a portion of the premises consisting of approximately 6,557&amp;#160;rentable square feet of space. The monthly base rent was $25,000&amp;#160;per month. For the years ended December&amp;#160;31, 2018 and 2017, $0.1&amp;#160;million and $0.2&amp;#160;million, respectively, was recognized in other income on the consolidated statements of operations under the sublease agreement. At December&amp;#160;31, 2019 and 2018, there were no balances due between the parties.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;605&amp;#160;Doug&amp;#160;St,&amp;#160;LLC&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In September&amp;#160;2016, we entered into a lease agreement with 605&amp;#160;Doug&amp;#160;St,&amp;#160;LLC, an entity owned by our Chairman and CEO, for approximately 24,250&amp;#160;square feet in El Segundo, California, which has been converted to a research and development laboratory and a cGMP laboratory manufacturing facility. The lease runs from July&amp;#160;2016 through July&amp;#160;2023. We have the option to extend the lease for an additional three-year term through July&amp;#160;2026. The monthly rent is $0.1&amp;#160;million with annual increases of 3% beginning in July&amp;#160;2017. Lease expense for this facility is recorded in research and development expense on the consolidated statements of operations and was $0.9&amp;#160;million, $0.2&amp;#160;million and $0.2&amp;#160;million, respectively, for the years ended December&amp;#160;31, 2019, 2018 and 2017. At December&amp;#160;31, 2019 and 2018, no balances were due between the parties.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;NantBio, Inc.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In August&amp;#160;2018, NantBio assigned an agreement to us for the use of a third-party research facility, which provides us with the exclusive right to use and access to a portion of the third party&amp;#8217;s laboratory and vivarium premises. NantBio is a related party as it is an affiliate of NantWorks. In conjunction with the assignment, we reimbursed NantBio for upfront payments which it had made to the third party of $0.9&amp;#160;million and paid $0.5&amp;#160;million directly to the third party for an aggregate value of $1.4&amp;#160;million. The assigned agreement is for a term of ten&amp;#160;years and expires in June&amp;#160;2027. The agreement may be terminated by us at any time, with or without cause. In case of termination of the agreement, the third party will reimburse us for a pro-rata amount based upon the passage of time.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In January&amp;#160;2018, we entered into a laboratory services agreement with NantBio. The agreement, effective December&amp;#160;2017, included a sublease of approximately 1,965&amp;#160;square feet of laboratory and office space at our San Diego, California, research facility. This sublease was terminated effective December&amp;#160;31, 2019, pursuant to the terms of the agreement. We recognized $0.1&amp;#160;million, $0.1&amp;#160;million and $10,000, respectively, in other income on the consolidated statements of operations for the years ended December&amp;#160;31, 2019, 2018 and 2017. At December&amp;#160;31, 2019 and 2018, NantBio owed us $8,400 and $49,000, respectively, which is included in prepaid expenses and other current assets on the consolidated balance sheets.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In March&amp;#160;2016, NantBio and the National Cancer Institute entered into a cooperative research and development agreement. The initial five-year agreement covers NantBio and its affiliates, including us. Under the agreement, the parties are collaborating on the preclinical and clinical development of proprietary recombinant natural killer cells and monoclonal antibodies in monotherapy and in combination immunotherapies. We benefited from the preclinical and clinical research conducted during the first four years under this agreement. In each of April&amp;#160;2016, April&amp;#160;2017, August&amp;#160;2018, and May&amp;#160;2019, we paid $0.6&amp;#160;million to the National Cancer Institute as a prepayment for services under the agreement. We recognize research and development expense related to this agreement ratably over a 12-month period for each funding year and recorded $0.6&amp;#160;million, of expense associated with the agreement in each of the years ended December&amp;#160;31, 2019, 2018 and 2017. At December&amp;#160;31, 2019 and 2018, we had balances of $0.1&amp;#160;million and $0.1&amp;#160;million, respectively, included in prepaid expenses and other current assets related to this agreement, on the consolidated balance sheets.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;NantWorks&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In May&amp;#160;2018, we entered into an assignment agreement with NantWorks and a third-party construction firm. In connection with the agreement, we assigned our deposit of $0.4&amp;#160;million with the third-party firm to NantWorks for which NantWorks reimbursed us. This assignment represented unutilized deposits that NantKwest had previously made with the construction company, for which NantWorks can now utilize in applying such funds to future planned construction projects.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Under the NantWorks shared services agreement executed in November&amp;#160;2015, but effective August&amp;#160;2015, NantWorks provides corporate, general and administrative, manufacturing strategy, research and development, regulatory and clinical trial strategy, and other support services. We are charged for the services at cost plus reasonable allocations for indirect costs that relate to the employees providing the services. For the years ended December&amp;#160;31, 2019, 2018 and 2017, we recorded $2.1&amp;#160;million, $2.8&amp;#160;million and $3.6&amp;#160;million, respectively, to selling, general and administrative expense, and $1.5&amp;#160;million, $3.3&amp;#160;million and $3.2&amp;#160;million, respectively, in research and development expense under this arrangement on the consolidated statements of operations. These amounts exclude certain general and administrative expenses provided by third party vendors directly for our benefit, which have been reimbursed to NantWorks based on those vendors&amp;#8217; invoiced amounts without markup by NantWorks.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In June&amp;#160;2016, we amended the existing shared services agreement with NantWorks whereby we can provide support services to NantWorks and/or any of its affiliates. For the years ended December&amp;#160;31, 2019, 2018 and 2017, we recorded expense reimbursements of $1.2&amp;#160;million, $0.6&amp;#160;million and $0.4&amp;#160;million, respectively, to selling, general and administrative expense and $2.3&amp;#160;million, $2.6&amp;#160;million and $1.0&amp;#160;million, respectively, to research and development expense.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;At December&amp;#160;31, 2019 and 2018, we owed NantWorks a net amount of $0.4&amp;#160;million and $1.1&amp;#160;million, respectively, for all agreements between the two affiliates, which is included in due to related parties on the consolidated balance sheets.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In November&amp;#160;2015, we entered into a facility license agreement with NantWorks, which became effective May&amp;#160;2015, for approximately 9,500&amp;#160;square feet in Culver City, California, which has been converted to a research and development laboratory and a cGMP manufacturing facility. Lease expense for this facility is recorded in research and development expense on the consolidated statements of operations and was $0.6&amp;#160;million, $0.2&amp;#160;million, and $0.2&amp;#160;million for the years ended December&amp;#160;31, 2019, 2018 and 2017.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;NantOmics, LLC&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In June&amp;#160;2015, we entered into an agreement, as amended in May&amp;#160;2018, with NantOmics, LLC, or NantOmics, which is a related party, as it is an affiliate of NantWorks. Pursuant to this agreement we obtain genomic sequencing and proteomic analysis services, as well as related data management and bioinformatics services, exclusively from NantOmics. We will have rights to use the data and results generated from NantOmics&amp;#8217; services in connection with the performance of the particular oncology trial with respect to which the services were performed, but NantOmics owns the data and results, as well as any other intellectual property it creates in performing these services on our behalf. We are obligated to pay NantOmics a fixed, per sample fee, determined based on the type of services being provided. The agreement has an initial term of five&amp;#160;years and renews automatically for successive one-year periods, unless terminated earlier. For the years ended December&amp;#160;31, 2019, 2018 and 2017, we recorded operating expense of $0.1&amp;#160;million, $0.1&amp;#160;million and $0.1&amp;#160;million, respectively, to research and development under this arrangement on the consolidated statements of operations. At December&amp;#160;31, 2018, we owed NantOmics $24,000, which is included in due to related parties on the consolidated balance sheets. At December&amp;#160;31, 2019, no balances were due between the parties.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;ImmunityBio&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;ImmunityBio, Inc., or ImmunityBio, is a related party, as it is an affiliate of NantWorks. ImmunityBio was formerly known as NantCell, Inc.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In January&amp;#160;2020, we entered into a cost sharing agreement with ImmunityBio as further described in Note&amp;#160;15&amp;#160;&amp;#8209;&amp;#160;&lt;font style="font-style:italic;"&gt;Subsequent Events&lt;/font&gt;.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In November&amp;#160;2018, we entered into an agreement with Etubics Corporation, or Etubics, a subsidiary of ImmunityBio. Pursuant to this agreement we sold used laboratory equipment to Etubics for $0.3&amp;#160;million. In conjunction with this sale, we recognized a loss on disposal of related laboratory equipment of $0.1&amp;#160;million, which was included in other income, net on the consolidated statements of operations.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In February&amp;#160;2017, we entered into a research grant agreement with VivaBioCell S.p.A., or VBC, a subsidiary of ImmunityBio. VBC conducted research and development activities related to our NK&amp;#160;cell lines using VBC&amp;#8217;s proprietary technology. For the years ended December&amp;#160;31, 2018 and 2017, $0.1&amp;#160;million and $0.6&amp;#160;million, respectively, was recognized in research and development expense on the consolidated statements of operations. No expense was incurred for the year ended December&amp;#160;31, 2019.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In August&amp;#160;2016, we entered into an exclusive Co-Development Agreement with Altor as described in Note&amp;#160;7&amp;#160;&amp;#8211;&amp;#160;&lt;font style="font-style:italic;"&gt;Collaboration and License Agreements&lt;/font&gt;. Altor is a related party as it is a wholly owned subsidiary of ImmunityBio. No charges for supplies by Altor were incurred in association with the trials during the years ended December&amp;#160;31, 2019, 2018 and 2017.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In June&amp;#160;2015, we also entered into a supply agreement with ImmunityBio pursuant to which we have the right to purchase ImmunityBio&amp;#8217;s proprietary bioreactors, made according to specifications mutually agreed to with ImmunityBio. We also have the right to purchase reagents and consumables associated with such equipment from ImmunityBio. When an upfront payment is made, it is included in prepaid expenses on the consolidated balance sheets until the product is received. The agreement has an initial term of five&amp;#160;years and renews automatically for successive one-year periods unless terminated earlier.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;At December&amp;#160;31, 2019 and 2018, we had $1.8&amp;#160;million and $1.1&amp;#160;million, respectively, in capitalized equipment purchased from ImmunityBio, which is included in property, plant and equipment, net, on the consolidated balance sheets. During the years ended December&amp;#160;31, 2019, 2018 and 2017, we recorded research and development expense associated with reagents and consumables purchased from ImmunityBio of $0.1&amp;#160;million, $0.1&amp;#160;million and $0.3&amp;#160;million, respectively, on the consolidated statements of operations.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;At December&amp;#160;31, 2019 and 2018, we had $0.5&amp;#160;million and $0.5&amp;#160;million, respectively, included in prepaid expenses and other current assets on the consolidated balance sheets related to consumables purchased from ImmunityBio. At December&amp;#160;31, 2019 and December&amp;#160;31, 2018, no balances were due between the parties.&lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
  <us-gaap:StockholdersEquityNoteDisclosureTextBlock id="F_000444" contextRef="C_0001326110_20190101_20191231">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;10. &amp;#160;&amp;#160;&amp;#160;&amp;#160;Stockholders&amp;#8217; Equity&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Stock Repurchase &amp;#8211; &lt;font style="font-style:normal;"&gt;In November&amp;#160;2015, the board of directors approved a share repurchase program, or the 2015 Share Repurchase Program, allowing the CEO or CFO, on behalf of the company, to repurchase from time to time, in the open market or in privately negotiated transactions, up to $50.0&amp;#160;million of our outstanding shares of common stock, exclusive of any commissions, markups or expenses. The timing and amounts of any purchases were and will continue to be based on market conditions and other factors, including price, regulatory requirements and other corporate considerations. The 2015&amp;#160;Share Repurchase Program does not require the purchase of any minimum number of shares and may be suspended, modified, or discontinued at any time without prior notice. We have financed, and expect to continue to finance, the purchases with existing cash balances. The shares are formally retired through board approval upon repurchase.&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;To date, we have repurchased 6,403,489&amp;#160;shares of our common stock under the 2015&amp;#160;Share Repurchase Program at a total cost of $31.7&amp;#160;million. In addition, we have paid approximately $0.1&amp;#160;million of broker commissions on repurchases. We repurchased 473,586&amp;#160;shares, 138,349&amp;#160;shares (Note&amp;#160;9), and 3,633,610&amp;#160;shares during the years ended December&amp;#160;31, 2019, 2018 and 2017, respectively, for a total of $0.5&amp;#160;million, $0.2&amp;#160;million, and $15.2&amp;#160;million, respectively. At December&amp;#160;31, 2019, $18.3&amp;#160;million remained authorized for repurchase under the 2015 Share Repurchase Program.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Common Stock Reserved for Future Issuance&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;We are authorized to issue up to 500,000,000&amp;#160;shares of our common stock, par value $0.0001&amp;#160;per share at December&amp;#160;31, 2019. As of December&amp;#160;31, 2019, there were 98,460,404&amp;#160;shares of our common stock issued and outstanding.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table summarizes the common shares reserved for issuance on exercise or vesting of various awards at December&amp;#160;31, 2019:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:60%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding stock options&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.64%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,506,950&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding RSUs&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.64%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,139,428&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:78.44%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding warrants&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.9%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.64%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:78.44%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total shares reserved for future issuance&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.9%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.64%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,646,378&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
  <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock id="F_000445" contextRef="C_0001326110_20190101_20191231">
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;11. &amp;#160;&amp;#160;&amp;#160;&amp;#160;Stock-Based Compensation&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;2014 Equity Incentive Plan &amp;#8211; &lt;font style="font-style:normal;"&gt;In March&amp;#160;2014, the company&amp;#8217;s board of directors and stockholders approved the 2014 Equity Incentive Plan, or 2014&amp;#160;Plan, under which 11,109,000&amp;#160;shares of Class&amp;#160;A common stock were reserved for the granting of incentive stock options, within the meaning of Section&amp;#160;422 of the Internal Revenue Code, or IRC, non-statutory stock options, stock appreciation rights, restricted stock awards, restricted stock units and performance awards to employees, directors and consultants. Recipients of stock awards are eligible to purchase shares of our common stock at an exercise price equal to no less than the estimated fair market value of such stock on the date of grant. The maximum term of awards granted under the 2014&amp;#160;Plan is ten&amp;#160;years. Stock awards are generally not exercisable prior to the applicable vesting date, unless otherwise accelerated under the terms of the applicable stock plan agreement. Unvested shares of our common stock issued in connection with an early exercise allowed by the company may be repurchased by us upon termination of the optionee&amp;#8217;s service.&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;2015 Equity Incentive Plan &amp;#8211; &lt;font style="font-style:normal;"&gt;In July&amp;#160;2015, the company&amp;#8217;s board of directors adopted and the company&amp;#8217;s stockholders approved the 2015 Equity Incentive Plan, or 2015&amp;#160;Plan. In April&amp;#160;2019, the company&amp;#8217;s board of directors adopted, and in June&amp;#160;2019 the company&amp;#8217;s stockholders approved, an amendment to the 2015&amp;#160;Plan to reserve a further 3,000,000&amp;#160;shares of common stock for issuance pursuant to the 2015&amp;#160;Plan. The 2015&amp;#160;Plan, as amended, permits the grant of incentive stock options to the company&amp;#8217;s employees, and for the grant of non-statutory stock options, restricted stock, restricted stock units, stock appreciation rights, performance units and performance shares to the company&amp;#8217;s employees, directors and consultants.&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December&amp;#160;31, 2019 there were approximately 4.3&amp;#160;million shares of common stock reserved for future grants pursuant to the 2015&amp;#160;Plan. In addition, the shares reserved for future grants under the 2015&amp;#160;Plan include shares subject to stock options or similar awards granted under the 2014&amp;#160;Plan that expire or terminate without having been exercised in full and shares issued pursuant to awards granted under the 2014&amp;#160;Plan that are forfeited to or repurchased by us (provided that the maximum number of shares that may be added to the 2015&amp;#160;Plan pursuant to this provision is approximately 2.3&amp;#160;million shares as of December&amp;#160;31, 2019).&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Stock-Based Compensation&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table presents all stock-based compensation as included on the consolidated statements of operations (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.1%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;For the Year Ended December&amp;#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2017&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock-based compensation expense:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Warrants for common stock to an officer&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;17,817&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;31,584&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Employee stock options&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,309&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,057&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,267&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Employee RSUs&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;938&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,193&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;894&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Non-employee RSUs&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;380&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;315&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;252&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,627&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;23,382&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;36,997&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock-based compensation expense in operating expenses:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;499&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;460&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;102&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Selling, general and administrative&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,128&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;22,922&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;36,895&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,627&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;23,382&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;36,997&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;
&lt;p style="margin-top:8pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Stock Options&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table summarizes stock option activity under all equity incentive plans for the years ended December&amp;#160;31, 2019, 2018 and 2017:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Number of&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Shares&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercise&amp;#160;Price&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Aggregate&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Intrinsic&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Value&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Remaining&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Contractual&amp;#160;Life&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in years)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding at December 31, 2016&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,307,386&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7.14&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;19,100&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.4&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options exercised&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(614,136&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.88&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding at December 31, 2017&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,693,250&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7.71&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11,920&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.3&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options granted&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;800,000&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3.07&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding at December 31, 2018&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,493,250&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7.14&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;563&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4.8&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options exercised&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1,986,300&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.06&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding at December 31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,506,950&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9.37&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,710&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.8&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Vested and Exercisable at December 31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,973,614&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10.22&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,326&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.5&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The vested and exercisable shares at December&amp;#160;31, 2018 and 2017 were 5,577,531 and 5,114,656, respectively.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table provides a summary of options outstanding and vested as of December&amp;#160;31, 2019:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.56%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercise Prices&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Number&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&amp;#160;Remaining&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Contractual Life&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in years)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Number&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercisable&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&amp;#160;Remaining&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Contractual Life&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in years)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.56%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$0.42&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;589,660&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4.9&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;589,660&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4.9&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.56%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$1.76&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;699,060&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.0&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;699,060&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.0&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.56%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$2.00&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;962,780&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.1&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;962,780&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.1&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.56%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$3.07&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;800,000&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8.7&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;266,664&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8.7&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.56%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$25.00&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,455,450&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.22%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.6&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,455,450&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.22%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.6&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.56%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,506,950&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.22%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.8&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,973,614&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.22%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.5&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The aggregate intrinsic value of stock options exercised during the years ended December&amp;#160;31, 2019, 2018 and 2017 was $0.2&amp;#160;million, $0.6&amp;#160;million and $1.7&amp;#160;million, respectively. The cash received from exercised options was $4.1&amp;#160;million, $0 and $1.2&amp;#160;million, respectively, for the years ended December&amp;#160;31, 2019, 2018 and 2017.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;During the year ended December&amp;#160;31, 2018, the company granted 800,000&amp;#160;stock options to key executives. These options have an exercise price of $3.07&amp;#160;per share, which was equal to the closing price of the company&amp;#8217;s common stock on the date of grant, and 25% vest on the one-year anniversary of the date of grant with the remaining options vesting ratably each month over the following three&amp;#160;years. No stock options were granted to employees during the years ended December&amp;#160;31, 2019 and 2017. No stock options were granted to non-employees during the years ended December&amp;#160;31, 2019, 2018 and 2017.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The total unrecognized compensation cost related to non-vested stock options as of December&amp;#160;31, 2019 is $1.1&amp;#160;million, which is expected to be recognized over a weighted-average period of 2.7&amp;#160;years.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The company uses a Black-Scholes option-pricing model to determine the fair value of stock-based compensation under ASC&amp;#160;Topic&amp;#160;718,&amp;#160;&lt;font style="font-style:italic;"&gt;Stock Compensation&lt;/font&gt;. The assumptions used for employee stock options granted during the year ended December&amp;#160;31, 2018, are presented in the table below:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:60%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected term (years)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.0 - 6.1&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.8%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;75.9%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Dividend yield&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-average measurement date fair value&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$2.09&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The assumed dividend yield was based on the company&amp;#8217;s expectation of not paying dividends in the foreseeable future. The estimated volatility was based on a weighted-average calculation of the company&amp;#8217;s common stock together with a peer group of comparable companies whose share prices are publicly available. The risk-free interest rate assumption was based on the U.S.&amp;#160;Treasury&amp;#8217;s rates for U.S.&amp;#160;Treasury zero-coupon bonds with maturities similar to those of the expected term of the award being valued. The weighted-average expected life of options was estimated using the average of the contractual term and the weighted-average vesting term of the options.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Restricted Stock Units&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table summarizes the restricted stock units, or RSUs, activity under the 2015&amp;#160;Plan:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Number of&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;RSUs&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Grant Date&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Value&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unvested balance at December 31, 2016&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;814,456&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13.98&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Granted&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;615,983&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4.50&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Vested&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(244,209&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15.82&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Forfeited/canceled&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(298,041&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10.28&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unvested balance at December 31, 2017&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;888,189&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8.14&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Granted&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;487,472&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3.57&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Vested&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(172,330&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.16&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Forfeited/canceled&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(335,420&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.27&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unvested balance at December 31, 2018&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;867,911&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.69&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Granted&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;749,793&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.12&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Vested&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(395,051&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8.83&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Forfeited/canceled&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(83,225&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7.29&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unvested balance at December 31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,139,428&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.88%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.23&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;We may grant RSUs to both employees and directors of the company and to employees of related parties that provide shared services to the company under the company&amp;#8217;s shared services agreement with NantWorks (Note&amp;#160;9). During the years ended December&amp;#160;31, 2018 and 2017, we granted 90,906&amp;#160;RSUs and 77,250&amp;#160;RSUs, respectively, to non-employees. All of the RSUs granted to non-employees during these periods were granted to employees of related companies under our shared services agreement with NantWorks (Note&amp;#160;9). There were no new grants made to non-employees during the year ended December&amp;#160;31, 2019.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December&amp;#160;31, 2019, there was $1.4&amp;#160;million of unrecognized stock-based compensation expense related to RSUs that is expected to be recognized over a weighted-average period of 1.7&amp;#160;years. Of that amount, $1.3&amp;#160;million of unrecognized expense is related to employee grants with a remaining weighted-average period of 1.8&amp;#160;years and $0.1&amp;#160;million of unrecognized expense is related to non-employee grants with a remaining weighted-average period of 0.8&amp;#160;years.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Warrants&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table summarizes the company&amp;#8217;s warrant activity:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:60%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding at December 31, 2016&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;17,768,314&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Warrants exercised&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(47,226&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding at December 31, 2017&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;17,721,088&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Warrants exercised&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(93,254&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Warrants expired&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(38,584&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding at December 31, 2018&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;17,589,250&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Warrants exercised&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(17,589,250&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding at December 31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Vested and exercisable at December 31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;During the years ended December&amp;#160;31, 2019, 2018 and 2017, cash proceeds recognized from exercises of warrants were $35.2&amp;#160;million, $0.1&amp;#160;million and $0.1&amp;#160;million, respectively.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Common Stock Reserved for Future Grants under the 2015 Equity Incentive Plan&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;At December&amp;#160;31, 2019, there were approximately 4.3&amp;#160;million shares of common stock reserved for future grants of equity awards.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
  <us-gaap:IncomeTaxDisclosureTextBlock id="F_000446" contextRef="C_0001326110_20190101_20191231">
&lt;p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;12. &amp;#160;&amp;#160;&amp;#160;&amp;#160;Income Taxes&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The amount of loss before taxes is as follows (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.1%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;For the Year Ended December&amp;#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2017&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;U.S. loss before taxes&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(65,286&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(94,423&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(94,734&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Foreign loss before taxes&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(600&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2,306&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2,182&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Loss before income taxes&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(65,886&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(96,729&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(96,916&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Income tax benefit for the years ended December&amp;#160;31, 2019, 2018 and 2017 consists of the following (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.78%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.84%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;For the Year Ended December&amp;#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.78%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.8%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.8%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2017&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.78%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Current:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.48%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.78%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Federal&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.48%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.78%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;State&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.48%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.78%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Foreign&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.48%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.78%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total Current&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.48%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.78%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.48%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.78%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Federal&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.48%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(79&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.78%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;State&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.48%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(21&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(8&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.78%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Foreign&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.48%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(498&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(497&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.78%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total Deferred&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(100&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(506&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(497&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.78%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Income tax benefit&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.48%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(97&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(503&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(493&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The components that comprise the company&amp;#8217;s net deferred tax assets at December&amp;#160;31, 2019 and 2018 consist of the following (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.44%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.94%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December&amp;#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.44%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred tax assets:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.4%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net operating loss carryforwards&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;78,377&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.4%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;61,915&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock compensation&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,536&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.4%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;79,281&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating lease liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,884&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.4%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Depreciation and amortization&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,042&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.4%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Tax credits&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;898&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.4%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;845&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued compensation&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;775&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.4%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;795&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Leases and other accrued liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;453&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.4%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,909&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.44%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued legal expenses&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.4%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;308&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total deferred tax assets&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;94,965&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.4%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;146,053&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred tax liabilities:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.4%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Foreign intangibles&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.4%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating lease right-of-use assets&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(3,233&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.4%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.44%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Depreciation and amortization&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.4%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1,279&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.44%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total deferred tax liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(3,233&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.4%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1,280&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net deferred tax assets&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;91,732&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.4%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;144,773&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.44%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Valuation allowance&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(91,732&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.4%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(144,773&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.44%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net deferred tax liability&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.4%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;A reconciliation of the federal statutory income tax rate to the company&amp;#8217;s effective income tax rate is as follows:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:55.54%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="12" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.08%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;For the Year Ended December&amp;#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:55.54%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.02%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2017&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.02%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.54%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Tax computed at federal statutory rate&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.34%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21.0&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.34%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21.0&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.34%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;34.0&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.54%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;State income taxes, net of federal tax benefit&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.34%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(19.4&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.34%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.2&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.34%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.3&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.54%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Tax rate adjustment&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.34%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.1&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.34%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(0.3&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.34%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4.8&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.54%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Tax Cuts and Jobs Act&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.34%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.34%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.34%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(53.4&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.54%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development credits&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.34%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.2&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.34%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.1&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.34%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.6&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.54%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock-based compensation&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.34%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(82.5&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.34%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(0.1&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.34%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(0.3&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.54%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.34%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(0.1&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.34%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.3&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.34%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.8&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:55.54%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Valuation allowance&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.34%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;80.5&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.02%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.34%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(26.7&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.02%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.34%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8.7&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.02%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:55.54%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Effective income tax rate&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.34%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(0.2&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.02%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.34%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.5&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.02%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.34%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.5&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.02%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On December&amp;#160;22, 2017, the Tax Cuts and Jobs Act, or the TCJA, was enacted into law. The TCJA made significant changes to U.S. tax laws, including, but not limited to, the following:&amp;#160;(a)&amp;#160;reducing the federal corporate income tax rate from 35% to a flat 21%, effective January&amp;#160;1, 2018; (b)&amp;#160;eliminating the federal corporate alternative minimum tax, or AMT, and changing how existing AMT credits can be realized; and (c)&amp;#160;eliminating several business deductions and credits, including deductions for certain executive compensation in excess of $1.0&amp;#160;million.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As a result of the rate reduction, the company reduced the deferred tax asset balance as of December&amp;#160;31, 2017 by $51.7&amp;#160;million. Due to the company&amp;#8217;s full valuation allowance position, we also reduced the valuation allowance by the same amount.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In December&amp;#160;2017, the Securities and Exchange Commission issued Staff Accounting Bulletin&amp;#160;No.&amp;#160;118, or SAB&amp;#160;118, which provides guidance on accounting for the income tax effects of the TCJA. SAB&amp;#160;118 provides a measurement period that should not extend beyond one year from the TCJA enactment date for companies to complete the accounting related to the TCJA under ASC&amp;#160;Topic&amp;#160;740, &lt;font style="font-style:italic;"&gt;Income Taxes&lt;/font&gt;, or ASC&amp;#160;740. In accordance with SAB&amp;#160;118, a company must reflect the income tax effects of those aspects of the TCJA for which the accounting under ASC&amp;#160;740 is complete. To the extent that a company&amp;#8217;s accounting for TCJA-related income tax effects is incomplete, but the company is able to determine a reasonable estimate, it must record a provisional estimate in its financial statements. If a company cannot determine a provisional estimate to be included in its financial statements, it should continue to apply ASC&amp;#160;740 on the basis of the provisions of the tax laws that were in effect immediately before enactment of the TCJA. We completed our evaluation of the potential impacts of IRC&amp;#160;Section&amp;#160;162(m) as amended by the TJCA on our December&amp;#160;31, 2018 consolidated financial statements, resulting in no adjustment for the years ended December&amp;#160;31, 2019, 2018 and 2017.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Pursuant to IRC&amp;#160;Sections&amp;#160;382 and 383, annual use of the company&apos;s net operating loss and research and development credit carryforwards may be limited in the event a cumulative change in ownership of more than 50% occurs within a three-year period. We completed an IRC&amp;#160;Section&amp;#160;382/383 analysis through March&amp;#160;2019 regarding the limitation of net operating loss and research and development credit carryforwards. As a result, we derecognized a portion of the deferred tax assets for net operating losses and federal and state research and development credits of $0.8&amp;#160;million from our deferred tax asset schedule as of December&amp;#160;31, 2019. There is no impact to tax expense for the derecognition of the net operating losses and federal and state research and development credits due to the valuation allowance recorded against the deferred tax assets. Additionally, we have not recognized the deferred tax asset for research and development credits carryforwards as of December&amp;#160;31, 2019 and 2018 because we are a part of a controlled group of affiliated companies with common ownership and cannot complete our calculation of the credit until the time that all members of the controlled group complete their analysis and calculation of qualified research expenditures. We do not expect that the unrecognized tax benefits will change within 12&amp;#160;months of this reporting date. Due to the existence of the valuation allowance, future changes in our unrecognized tax benefits will not impact the company&apos;s effective tax rate.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In assessing the realization of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income and tax planning strategies in making this assessment. Based on the level of historical operating results and the uncertainty of the economic conditions, we have recorded a full valuation allowance of $91.7&amp;#160;million at December&amp;#160;31, 2019. The change in the valuation allowance for the year ended December&amp;#160;31, 2019 was a decrease of $53.0&amp;#160;million which was mainly driven by the reversal of deferred tax assets related to stock compensation that will not be realized. The portion of the valuation allowance for deferred tax assets for which subsequently recognized tax benefits will be credited directly to contributed capital is $0.2&amp;#160;million.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;We have not incurred any material interest or penalties as of the current reporting date with respect to income tax matters. We do not expect that there will be unrecognized tax benefits of a significant nature that will increase or decrease within 12&amp;#160;months of the reporting date. We are subject to U.S. federal income tax, as well as income tax in California and other states. The federal returns for tax years 2016 through 2019 remain open to examination and the California returns remain subject to examination for tax years 2015 through 2019. Carryforward attributes that were generated in years where the statute of limitations is closed may still be adjusted upon examination by the Internal Revenue Service or other respective tax authority. All other state jurisdictions remain open to examination.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;At December&amp;#160;31, 2019, the company has federal net operating losses, or NOLs, of approximately $291.8&amp;#160;million, state NOLs of $255.7&amp;#160;million, and foreign NOLs of $0.2&amp;#160;million. The federal NOL carryforwards begin to expire in 2024, the state NOL carryforwards begin to expire in 2030 and the foreign NOL carryforwards begin to expire in 2022. At December&amp;#160;31, 2019, the company also had federal research tax credit carryforwards of approximately $8.5&amp;#160;million and California research tax credits of $5.7&amp;#160;million. The federal research tax credit carryforwards begin to expire in 2034 and the state research tax credit carryforwards begin to expire in 2031.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table summarizes the changes to the amount of unrecognized tax benefits (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:60%;"&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrecognized tax benefits at December 31, 2017&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,577&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Increase for prior year tax positions&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;798&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Increase for current year tax positions&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,608&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrecognized tax benefits at December 31, 2018&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11,983&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Decrease for prior year tax positions&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(7&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Increase for current year tax positions&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,680&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrecognized tax benefits at December 31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15,656&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Included in the balance of unrecognized tax benefits at December&amp;#160;31, 2019, is $14.1&amp;#160;million that, if recognized, would not impact our income tax benefit or effective tax rate as long as the deferred tax asset remains subject to a full valuation allowance. We do not expect any significant increases or decreases to our unrecognized tax benefits within the next 12&amp;#160;months.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
  <us-gaap:QuarterlyFinancialInformationTextBlock id="F_000447" contextRef="C_0001326110_20190101_20191231">
&lt;p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;13. &amp;#160;&amp;#160;&amp;#160;&amp;#160;Summarized Quarterly Data (Unaudited)&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following financial information reflects all normal recurring adjustments that are, in the opinion of management, necessary for a fair statement of the results of the interim periods.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The table below presents unaudited quarterly data for fiscal 2019 and 2018 (in thousands, except for share and per share amounts):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;1st Quarter&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2nd Quarter&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;3rd Quarter&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;4th Quarter&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Revenue&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;17&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating expenses&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;18,340&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;17,313&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;16,077&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;16,120&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating loss&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(18,335&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(17,296&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(16,065&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(16,111&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net loss&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(17,885&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(16,682&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(15,581&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(15,641&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net loss per share - basic and diluted&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(0.22&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(0.17&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(0.16&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(0.16&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Shares used in calculating net loss per share - basic and&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&amp;nbsp; diluted&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;81,261,302&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;98,594,355&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;98,331,695&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;98,419,166&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;1st Quarter&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2nd Quarter&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;3rd Quarter&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;4th Quarter&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Revenue&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;31&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating expenses&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;28,289&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;28,282&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;24,139&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;17,726&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating loss&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(28,284&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(28,278&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(24,108&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(17,719&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;) &lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net loss&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(27,519&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(27,732&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(23,635&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(17,340&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;) &lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net loss per share - basic and diluted&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(0.35&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(0.35&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(0.30&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(0.22&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;) &lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Shares used in calculating net loss per share - basic and&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&amp;nbsp; diluted&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;79,036,614&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;79,107,208&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;79,204,765&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;79,177,962&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;</us-gaap:QuarterlyFinancialInformationTextBlock>
  <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock id="F_000448" contextRef="C_0001326110_20190101_20191231">
&lt;p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;14. &amp;#160;&amp;#160;&amp;#160;&amp;#160;Employee Benefits&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Defined Contribution Benefit Plan &amp;#8211; &lt;font style="font-style:normal;"&gt;In December&amp;#160;2015, the company adopted a 401(k) retirement and savings plan, or the 401(k) Plan, covering all employees. The 401(k)&amp;#160;Plan allows employees to make pre- and post-tax contributions up to the maximum allowable amount set by the Internal Revenue Service. The company, at its discretion, may make certain contributions to the 401(k)&amp;#160;Plan. We made contributions of $0.6&amp;#160;million, $0.5&amp;#160;million and $0.4&amp;#160;million during the years ended December&amp;#160;31, 2019, 2018 and 2017, respectively.&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Compensated Absences &amp;#8211; &lt;font style="font-style:normal;"&gt;Under our vacation policy, salaried employees are provided unlimited vacation leave. Therefore, we do not record an accrual for paid leave related to these employees since we are unable to reasonably estimate the compensated absences that these employees will take.&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
  <us-gaap:SubsequentEventsTextBlock id="F_000449" contextRef="C_0001326110_20190101_20191231">
&lt;p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;15. &amp;#160;&amp;#160;&amp;#160;&amp;#160;Subsequent Events&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Collaborative Arrangement&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;A collaborative arrangement is a contractual arrangement that involves a joint operating activity. These arrangements involve two or more parties who are&amp;#160;(i)&amp;#160;active participants in the activity, and (ii)&amp;#160;exposed to significant risks and rewards dependent on the commercial success of the activity.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Cost Allocation Agreement&lt;font style="font-style:normal;"&gt;&amp;#8212; On January&amp;#160;29, 2020, we entered into a Cost Allocation Agreement, or the Agreement, with ImmunityBio, Inc. and its subsidiaries, or ImmunityBio. The Agreement is effective as of October&amp;#160;1, 2019. ImmunityBio is a related party, as it is an affiliate of NantWorks (Note&amp;#160;9). Simultaneously, we and ImmunityBio entered into Work Order Number One under the Agreement. Under the Agreement and Work Order Number One, the parties agreed to conduct a joint study, the clinical research trial being conducted pursuant to the protocol titled QUILT&amp;#160;3.063:&lt;/font&gt;&amp;#160;A phase&amp;#160;2 study of combination therapy with an IL-15 superagonist&amp;#160;(N&amp;#8209;803), off-the-shelf CD16&amp;#8209;targeted natural killer cells&amp;#160;(haNK), and avelumab without cytotoxic chemotherapy in subjects with Merkel Cell Carcinoma&amp;#160;(MCC) that has progressed on or after treatment with a checkpoint inhibitor&lt;font style="font-style:normal;"&gt;. The ImmunityBio study drug included in the joint study is ImmunityBio&amp;#8217;s proprietary IL-15 superagonist known as N&amp;#8209;803 and our study drug is our proprietary &amp;#8220;off-the-shelf&amp;#8221; CD16-targeted natural killer cell therapy known as haNK.&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;We will act as the sponsor of this joint study for purposes of regulatory matters, including submissions, correspondence, and communications. Additionally, we are designated as the contracting party to execute agreements with third and related parties relating to the joint study under Work Order Number One. We and ImmunityBio will split certain joint study costs equally related to Work Order Number One, in accordance with the terms of the Agreement. Shared joint study costs include cost related to conducting the joint study development activities, such as personnel related costs, as well as all costs associated to regulatory matters. Costs and expenses incurred in connection with the development, manufacturing, supply, delivery, and pre-patient administration dosing mechanism of each party&amp;#8217;s study drug, are excluded from the shared joint study costs. We expect that the joint study cost sharing component under the Agreement related to Work Order Number One will total approximately $2.1&amp;#160;million, subject to change dependent on clinical trial enrollments and progress. At December&amp;#160;31, 2019, there was minimal joint research activity under the Agreement and we incurred approximately $0.1&amp;#160;million in costs related to the joint study that are subject to joint cost sharing under the Agreement and are recorded in research in research and development expense on the consolidated statements of operations.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Under the agreement, each of ImmunityBio and the company will receive exclusive rights to any new intellectual property developed that relates solely to its respective study drug, and the parties will have joint co-equal rights in any other intellectual property. The Agreement expires upon the second anniversary of the effective date with the option to renew for additional successive one-year terms, but work orders for any joint studies still in process at the time of termination will continue until the applicable study is completed.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Coronavirus Pandemic&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Due to the global viral outbreak caused by Coronavirus Disease&amp;#160;2019&amp;#160;(COVID&amp;#8209;19) in 2020, there have been resulting effects which could negatively impact our financial condition or operations, including significant stock market exchange volatility, including various temporary volatility trading halts which commenced initially on March&amp;#160;9,&amp;#160;2020 due to market declines, various temporary business closures and event cancellations, and other effects including strains on hospitals and health provider resources which could result in clinical trial disruptions as the broader economic impact of COVID&amp;#8209;19 develops. The ultimate impact of these matters to us and our financial condition and operations is presently unknown. The accompanying consolidated financial statements as of and for the year ended December&amp;#160;31,&amp;#160;2019 do not reflect the effects of these subsequent events.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
  <nk:LiquidityPolicyTextBlock id="F_000450" contextRef="C_0001326110_20190101_20191231">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Liquidity&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December&amp;#160;31, 2019, the company had an accumulated deficit of approximately $662.2&amp;#160;million. We also had negative cash flow from operations of approximately $61.4&amp;#160;million during the year ended December&amp;#160;31, 2019. The company expects that it will likely need additional capital to further fund development of, and seek regulatory approvals for, our product candidates, and to begin to commercialize any approved products.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;We are currently focused primarily on the development of immunotherapeutic treatments for cancers and debilitating viral infections using targeted cancer and viral killing cell lines, and we believe such activities will result in the company&amp;#8217;s continued incurrence of significant research and development and other expenses related to those programs. If the clinical trials for any of the company&amp;#8217;s product candidates fail or produce unsuccessful results and those product candidates do not gain regulatory approval, or if any of our product candidates, if approved, fail to achieve market acceptance, we may never become profitable. Even if the company achieves profitability in the future, it may not be able to sustain profitability in subsequent periods. We intend to cover our future operating expenses through cash and cash equivalents and marketable debt securities on hand and through a combination of equity offerings, debt financings, government or other third party funding, marketing and distribution arrangements and other collaborations, strategic alliances, and licensing arrangements. Additional financing may not be available to us when needed and, if available, financing may not be obtained on terms favorable to the company or its stockholders.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;While we expect our existing cash, and cash equivalents and marketable debt securities, together with the ability to borrow from affiliated entities, will enable us to fund operations and capital expenditure requirements for at least the next 12&amp;#160;months, we may not have sufficient funds to reach commercialization. Failure to obtain adequate financing when needed may require us to delay, reduce, limit, or terminate some or all of our development programs or future commercialization efforts or grant rights to develop and market product candidates that we might otherwise prefer to develop and market ourselves, which could adversely affect our ability to operate as a going concern. If we raise additional funds from the issuance of equity securities, substantial dilution to existing stockholders may result. If we raise additional funds by incurring debt financing, the terms of the debt may involve significant cash payment obligations, as well as covenants and specific financial ratios that may restrict our ability to operate our business.&lt;/p&gt;</nk:LiquidityPolicyTextBlock>
  <us-gaap:BasisOfAccountingPolicyPolicyTextBlock id="F_000451" contextRef="C_0001326110_20190101_20191231">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Basis of Presentation&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America, or U.S.&amp;#160;GAAP.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The consolidated financial statements have been prepared assuming the company will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business, and do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or amounts and classification of liabilities that may result from the outcome of the uncertainty discussed in the Liquidity section of Note&amp;#160;1. We believe our existing cash, cash equivalents, and investments in marketable debt securities, and our ability to borrow from affiliated entities, will be sufficient to fund operations through at least the next 12&amp;#160;months following the issuance date of the financial statements based upon our Chairman and CEO&amp;#8217;s intent and ability to support the company&amp;#8217;s operations with additional funds, including loans from affiliated entities, as required. We may also seek to sell additional equity, through one or more follow-on public offerings, or in separate financings, or obtain a credit facility. However, we may not be able to secure such financing in a timely manner or on favorable terms. Without additional funds, we may choose to delay or reduce our operating or investment expenditures. Further, because of the risk and uncertainties associated with the commercialization of the company&amp;#8217;s product candidates in development, we may need additional funds to meet our needs sooner than planned. To date, the company&amp;#8217;s primary sources of capital were its initial public offering and the concurrent private placement of common shares. In addition, during the year ended December&amp;#160;31, 2019, our Chairman and CEO exercised warrants and options resulting in aggregate cash proceeds of $39.2&amp;#160;million.&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
  <us-gaap:ConsolidationPolicyTextBlock id="F_000452" contextRef="C_0001326110_20190101_20191231">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Principles of Consolidation&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The consolidated financial statements include the accounts of NantKwest and its wholly owned subsidiaries. All intercompany amounts have been eliminated.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;We apply the variable interest model under Accounting Standards Codification, or ASC Topic&amp;#160;810,&amp;#160;&lt;font style="font-style:italic;"&gt;Consolidation&lt;/font&gt;, to any entity in which we hold an equity investment or to which we have the power to direct the entity&apos;s most significant economic activities and the ability to participate in the entity&apos;s economics. If the entity is within the scope of the variable interest model and meets the definition of a variable interest entity, or VIE, we consider whether we must consolidate the VIE or provide additional disclosures regarding our involvement with the VIE. If we determine that we are the primary beneficiary of the VIE, we will consolidate the VIE. This analysis is performed at the initial investment in the entity or upon any reconsideration event.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;For entities we hold as an equity investment that are not consolidated under the VIE Model, we consider whether our investment constitutes ownership of a majority of the voting interests in the entity and therefore should be considered for consolidation under the voting interest model.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unconsolidated equity investments in the common stock or in-substance common stock of an entity under which we are able to exercise significant influence, but not control, are accounted for using the equity method. Our ability to exercise significant influence is generally indicated by ownership of 20 to 50 percent interest in the voting securities of the entity.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;All other unconsolidated equity investments on which we are not able to exercise significant influence will be subsequently measured at fair value with unrealized holding gains and losses included in other income, net on the consolidated statements of operations. In the instance the equity investment does not have a readily determinable fair value and does not qualify for the practical expedient to estimate fair value in accordance with ASC&amp;#160;820, &lt;font style="font-style:italic;"&gt;Fair Value Measurement&lt;/font&gt;, or ASC&amp;#160;820, we will apply the measurement alternative under ASC&amp;#160;321, &lt;font style="font-style:italic;"&gt;Investments&amp;#8212;Equity Securities&lt;/font&gt;, or ASC&amp;#160;321, pursuant to which we will measure the investment at its cost less impairment, adjusted for observable price changes in an orderly market for an identical or similar investment of the same issuer.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;We own non-marketable equity securities that are accounted for using the measurement alternative under ASC&amp;#160;321 because the preferred stock held by us is not considered in-substance common stock and such preferred stock does not have a readily determinable fair value. All investments are reviewed on a regular basis for possible impairment. If an investment&apos;s fair value is determined to be less than its net carrying value, the investment is written down to its fair value. Such an evaluation is judgmental and dependent on specific facts and circumstances. Factors considered in determining whether an impairment indicator is present include:&amp;#160;the investees&amp;#8217; earnings performance and clinical trial performance, change in the investees&amp;#8217; industry and geographic area in which it operates, offers to purchase or sell the security for a price less than the cost of the investment, issues that raise concerns about the investee&apos;s ability to continue as a going concern, and any other information that we may be aware of related to the investment. Factors considered in determining whether an observable price change has occurred include:&amp;#160;the price at which the investee issues equity instruments similar to those of our investment and the rights and preferences of those equity instruments compared to ours.&lt;/p&gt;</us-gaap:ConsolidationPolicyTextBlock>
  <us-gaap:UseOfEstimates id="F_000453" contextRef="C_0001326110_20190101_20191231">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Use of Estimates&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. On an ongoing basis, we evaluate our estimates, including those related to valuation of equity-based awards, deferred income taxes and related valuation allowances, preclinical and clinical trial accruals, impairment assessments, useful lives of long-lived assets, loss contingencies, and fair value measurements. We base our estimates on historical experience and on various other market-specific and relevant assumptions that we believe to be reasonable under the circumstances. Actual results could differ from those estimates.&lt;/p&gt;</us-gaap:UseOfEstimates>
  <us-gaap:UnusualRisksAndUncertaintiesTextBlock id="F_000454" contextRef="C_0001326110_20190101_20191231">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Risks and Uncertainties&lt;/p&gt;</us-gaap:UnusualRisksAndUncertaintiesTextBlock>
  <us-gaap:CommitmentsAndContingenciesPolicyTextBlock id="F_000455" contextRef="C_0001326110_20190101_20191231">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Contingencies&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;We record accruals for loss contingencies to the extent that we conclude it is probable that a liability has been incurred and the amount of the related loss can be reasonably estimated. We evaluate, on a quarterly basis, developments in legal proceedings and other matters that could cause a change in the potential amount of the liability recorded or of the range of potential losses disclosed. Additionally, we record our rights to insurance recoveries, limited to the extent of incurred or probable losses, as a receivable when such recoveries have been agreed to with our third-party insurers and when receipt is deemed probable. This includes instances when our third-party insurers have agreed to pay, on our behalf, certain legal defense costs and settlement amounts directly to applicable law firms and a settlement fund.&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesPolicyTextBlock>
  <us-gaap:ConcentrationRiskCreditRisk id="F_000456" contextRef="C_0001326110_20190101_20191231">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Concentration of Credit Risk and Other Risks and Uncertainties&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Financial instruments that potentially subject us to concentrations of risk consist principally of cash and cash equivalents and marketable debt securities.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Our cash and cash equivalents are held by one major financial institution in the U.S. and one in Korea.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Product candidates developed by us will require approvals or clearances from the U.S. Food and Drug Administration, or FDA, or international regulatory agencies prior to commercial sales. There can be no assurance that any of our product candidates will receive any of the required approvals or clearances. If we were to be denied approval or clearance or any such approval or clearance was to be delayed, it would have a material adverse impact on us.&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
  <nk:CashCashEquivalentsAndMarketableSecuritiesPolicyTextBlock id="F_000457" contextRef="C_0001326110_20190101_20191231">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Cash, Cash Equivalents and Marketable Debt Securities&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;We invest our excess funds in investment grade short- to intermediate-term corporate debt securities, commercial paper, government sponsored securities, and foreign government bonds. We consider all highly liquid investments purchased with original maturities of three&amp;#160;months or less to be cash equivalents and all investments purchased with original maturities of greater than three&amp;#160;months as marketable debt securities, classified as available-for-sale. Marketable debt securities with remaining maturities of 12&amp;#160;months or less are classified as short-term and marketable debt securities with remaining maturities greater than 12&amp;#160;months are classified as long-term. All marketable debt securities are reported at fair value and any unrealized gains and losses are reported as a component of accumulated other comprehensive income (loss), net of tax, on the consolidated statements of stockholders&amp;#8217; equity, with the exception of unrealized losses believed to be other-than-temporary, which are recorded in investment income, net, on the consolidated statements of operations. Realized gains and losses are included in investment income, net, on the consolidated statements of operations. Realized gains and losses from sale of the securities and the amounts, net of tax, reclassified out of accumulated other comprehensive loss, if any, are determined on a specific identification basis.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;We periodically evaluate whether declines in fair values of our investments below their book value are other-than-temporary. This evaluation consists of several qualitative and quantitative factors regarding the severity and duration of the unrealized loss, as well as our ability and intent to hold the investment until a forecasted recovery occurs. Additionally, we assess whether or not we have plans to sell the security or whether or not it is more likely than not we will be required to sell any investment before recovery of its amortized cost basis. Factors considered include quoted market prices, recent financial results and operating trends, implied values from any recent transactions or offers of investee securities, credit quality of debt instrument issuers, other publicly available information that may affect the value of our investments, duration and severity of the decline in value, and our strategy and intentions for holding the investment. There were no other-than-temporary impairments recorded in the years ended December&amp;#160;31, 2019, 2018 and 2017.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;We minimize credit risk associated with our cash and cash equivalents by periodically evaluating the credit quality of our primary financial institutions. While we maintain cash deposits in FDIC insured financial institutions in excess of federally insured limits, we do not believe that we are exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held. We have not experienced any losses on such accounts.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;We have funded a certificate of deposit (CD) as a substitute letter of credit for one of our leased properties. This CD is reported as long term restricted cash and is included in other assets on the consolidated balance sheets as the landlord is the beneficiary of the account and we are not able to access the funds during the term of the lease.&lt;/p&gt;</nk:CashCashEquivalentsAndMarketableSecuritiesPolicyTextBlock>
  <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock id="F_000458" contextRef="C_0001326110_20190101_20191231">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Property, Plant and Equipment&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property, plant and equipment is stated at historical cost less accumulated depreciation. Historical cost includes expenditures that are directly attributable to the acquisition of the items. All repairs and maintenance are charged to net loss during the financial period in which they are incurred. Depreciation of property, plant and equipment is calculated using the straight-line method over the estimated useful lives of the assets, as follows:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Buildings&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.36%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; 39 years&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Software&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.36%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; 3 years&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Laboratory equipment&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.36%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; 5 years&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Furniture &amp;amp; fixtures&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.36%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; 5 years&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;IT equipment&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.36%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; 3 years&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.36%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; The lesser of the lease term or the life of the asset&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Upon disposal or impairment of property, plant and equipment, the cost and related accumulated depreciation is removed from the consolidated financial statements and the net amount, less any proceeds, is included in the consolidated statements of operations.&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
  <us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy id="F_000459" contextRef="C_0001326110_20190101_20191231">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Intangible Assets&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Intangible assets, which consisted of the cost of reacquiring a technology license during 2015, were amortized using the straight-line method over an estimated useful life of 4&amp;#160;years. As of December 31, 2019, our intangible assets were fully amortized.&lt;/p&gt;</us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy>
  <us-gaap:LegalCostsPolicyTextBlock id="F_000460" contextRef="C_0001326110_20190101_20191231">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Patents&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Patent costs, including related legal costs, are expensed as incurred and recorded in selling, general and administrative expenses on the consolidated statements of operations.&lt;/p&gt;</us-gaap:LegalCostsPolicyTextBlock>
  <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock id="F_000461" contextRef="C_0001326110_20190101_20191231">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Impairments&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Long-lived assets include property, plant and equipment and intangible assets. We review long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability is measured by comparison of the carrying amount to the future net cash flows that the assets are expected to generate. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the projected undiscounted future cash flows arising from the assets using a discount rate determined by management to be commensurate with the risk inherent to our current business model.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;During the second quarter of 2019, we determined that certain bioreactor laboratory equipment could no longer be utilized in the production process. As a result, we recorded an impairment charge totaling $0.9&amp;#160;million, which is included in research and development expense on the consolidated statements of operations. There were no impairment losses recognized during the years ended December&amp;#160;31, 2018 and 2017.&lt;/p&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock>
  <us-gaap:FairValueOfFinancialInstrumentsPolicy id="F_000462" contextRef="C_0001326110_20190101_20191231">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Fair Value of Financial Instruments&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The accounting standard for fair value measurements provides a framework for measuring fair value and requires disclosures regarding fair value measurements. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date, based on our principal or, in absence of a principal, most advantageous market for the specific asset or liability.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;We use a three-tier fair value hierarchy to classify and disclose all assets and liabilities measured at fair value on a recurring basis, as well as assets and liabilities measured at fair value on a non-recurring basis, in periods subsequent to their initial measurement. The hierarchy requires us to use observable inputs when available, and to minimize the use of unobservable inputs, when determining fair value.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The three tiers are defined as follows:&lt;/p&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:4.54%;white-space:nowrap"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:4.54%;white-space:nowrap"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-family:&apos;Times New Roman&apos;;font-size:15pt;line-height:11pt;"&gt;&amp;#x2022;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level&amp;#160;1&amp;#8212; Observable inputs that reflect quoted market prices (unadjusted) for identical assets or liabilities in active markets at the measurement date. Since valuations are based on quoted prices that are readily and regularly available in an active market, valuation of these products does not entail a significant degree of judgment. Our Level 1 assets consist of bank deposits and money market funds.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:4.54%;white-space:nowrap"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:4.54%;white-space:nowrap"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-family:&apos;Times New Roman&apos;;font-size:15pt;line-height:11pt;"&gt;&amp;#x2022;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level&amp;#160;2&amp;#8212; Observable inputs other than quoted prices in active markets that are observable either directly or indirectly in the marketplace for identical or similar assets and liabilities. Our Level 2 assets consist of corporate debt securities including commercial paper, government sponsored securities and corporate bonds, as well as foreign municipal securities.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:4.54%;white-space:nowrap"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:4.54%;white-space:nowrap"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-family:&apos;Times New Roman&apos;;font-size:15pt;line-height:11pt;"&gt;&amp;#x2022;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level&amp;#160;3&amp;#8212; Valuations based on inputs that are unobservable and significant to the overall fair value measurement.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;During the years ended December&amp;#160;31, 2019, 2018 and 2017, no transfers were made into or out of the Level&amp;#160;1,&amp;#160;2 or 3 categories. We will continue to review the fair value inputs on a quarterly basis.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;We utilize a third-party pricing service to assist in obtaining fair value pricing for our investments in marketable debt securities. Inputs are documented in accordance with the fair value disclosure hierarchy.&lt;/p&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
  <nk:PreclinicalAndClinicalTrialAccrualsPolicyTextBlock id="F_000463" contextRef="C_0001326110_20190101_20191231">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Preclinical and Clinical Trial Accruals&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As part of the process of preparing the financial statements, we are required to estimate expenses resulting from obligations under contracts with vendors, clinical research organizations and consultants. The financial terms of these contracts vary and may result in payment flows that do not match the periods over which materials or services are provided under such contracts.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;We estimate clinical trial and research agreement related expenses based on the services performed, pursuant to contracts with research institutions and clinical research organizations and other vendors that conduct clinical trials and research on our behalf. In accruing clinical and research related fees, we estimate the time period over which services will be performed and activity expended in each period. If the actual timing of the performance of services or the level of effort varies from the estimate, we will adjust the accrual accordingly. Payments made under these arrangements in advance of the receipt of the related services are recorded as prepaid expenses until the services are rendered.&lt;/p&gt;</nk:PreclinicalAndClinicalTrialAccrualsPolicyTextBlock>
  <nk:RelatedPartyTransactionsPolicyPolicyTextBlock id="F_000464" contextRef="C_0001326110_20190101_20191231">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Transactions with Related Parties&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As outlined in Note&amp;#160;9&lt;font style="font-style:italic;"&gt; &amp;#8211; Related Party Agreements&lt;/font&gt;, we have various agreements with different related parties. Some are billed and settled in cash monthly. Others are billed quarterly and settled in cash the following month. Monthly accruals are made for all quarterly billing arrangements.&lt;/p&gt;</nk:RelatedPartyTransactionsPolicyPolicyTextBlock>
  <us-gaap:LesseeLeasesPolicyTextBlock id="F_000465" contextRef="C_0001326110_20190101_20191231">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Lease Obligations&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;We adopted FASB ASC Topic&amp;#160;842, &lt;font style="font-style:italic;"&gt;Leases&lt;/font&gt;, or ASC&amp;#160;842, effective January&amp;#160;1, 2019. For contracts entered into on or after the effective date, we determine if an arrangement is, or contains, a lease at lease inception. Our assessment is based on:&amp;#160;(1)&amp;#160;whether the contract involves the use of a distinct identified asset; (2)&amp;#160;whether we obtain the right to substantially all of the economic benefit from the use of the asset throughout the period; and (3)&amp;#160;whether we have the right to direct the use of the asset. At inception of a lease, we allocate the consideration in the contract to each lease component based on its relative stand-alone price to determine the lease payments. Leases entered into prior to January&amp;#160;1, 2019, which were accounted for under ASC&amp;#160;840, &lt;font style="font-style:italic;"&gt;Leases&lt;/font&gt;, were not reassessed as we elected the package of practical expedients permitted under the transition guidance within the new standard, which among other things, allowed us to carry forward the historical lease classification. We determine the lease term by assuming the exercise of renewal options that are reasonably assured. The exercise of lease renewal options is at our sole discretion. Several of our leases have renewal options, however, exercise of renewal is only assured for the El&amp;#160;Segundo current Good Manufacturing Practices, or cGMP, facility, where we have made significant improvements.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;For all leases at the lease commencement date, a right-of-use asset and a lease liability are recognized. The right-of-use asset represents the right to use the leased asset for the lease term. At lease commencement, leases are classified as either finance leases or operating leases. A lease is classified as a finance lease if any one of the following criteria are met:&amp;#160;(1)&amp;#160;the lease transfers ownership of the underlying asset by the end of the lease term; (2)&amp;#160;the lease contains an option to purchase the underlying asset that is reasonably certain to be exercised; (3)&amp;#160;the lease term is for a major part of the remaining economic life of the underlying asset; (4)&amp;#160;the present value of the sum of the lease payments and any guaranteed residual value that is not already included in the lease payments equals or exceeds substantially all of the fair value of the underlying asset; or (5)&amp;#160;the underlying asset is of such a specialized nature that it is expected to have no alternative use to the lessor at the end of the lease term. A lease is classified as an operating lease if it does not meet any one of these criteria.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;We do not currently have any leases classified as finance leases. Our operating leases are included in operating lease right-of-use assets, net, other current liabilities, and operating lease liabilities on the consolidated balance sheets. At the commencement date, operating lease right-of-use assets and operating lease liabilities are determined based on the present value of lease payments to be made over the lease term. Operating lease right-of-use assets also include any rent paid prior to the commencement date, less any lease incentives received, and initial direct costs incurred. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term. We have elected to combine our lease components (e.g., fixed payments including rent, real estate taxes and insurance costs) with non-lease components (e.g., common-area maintenance costs and equipment maintenance costs) and as such, we account for lease and non-lease components as a single component. Lease expense also includes amounts relating to variable lease payments. Variable lease payments include amounts relating to common area maintenance and real estate taxes.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;We also elected not to recognize right-of-use assets and lease liabilities for qualifying short-term leases with an initial lease term of 12&amp;#160;months or less at lease inception. Such leases are expensed on a straight-line basis over the lease term.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The depreciable life of operating right-of-use-assets and leasehold improvements is limited by the expected lease term.&lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
  <us-gaap:IncomeTaxPolicyTextBlock id="F_000466" contextRef="C_0001326110_20190101_20191231">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Income Taxes&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;We recognize deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the financial reporting and tax basis of assets and liabilities, as well as for operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using the tax rates that are expected to apply to taxable income for the years in which those tax assets and liabilities are expected to be realized or settled. We record valuation allowances to reduce deferred tax assets to the amount we believe is more likely than not to be realized.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;We recognize uncertain tax positions when the position will be more likely than not upheld on examination by the taxing authorities based solely upon the technical merits of the positions. We recognize interest and penalties, if any, related to unrecognized income tax uncertainties in income tax expense. We did not have any accrued interest or penalties associated with uncertain tax positions as of December&amp;#160;31, 2019 and 2018.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;We are subject to U.S. federal income tax, as well as income tax in Korea, California and other states. The federal returns for tax years 2016 through 2019 remain open to examination; the California returns remain subject to examination for tax years 2015 through 2019. Carryforward attributes that were generated in years where the statute of limitations is closed may still be adjusted upon examination by the Internal Revenue Service or other respective tax authority. All other state jurisdictions remain open to examination. No income tax returns are currently under examination by taxing authorities.&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
  <nk:StockRepurchasesPolicyTextBlock id="F_000467" contextRef="C_0001326110_20190101_20191231">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Stock Repurchases&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In November&amp;#160;2015, the board of directors approved the 2015 Share Repurchase Program (Note&amp;#160;10) allowing the CEO or CFO, on behalf of the company, to repurchase from time to time, in the open market or in privately negotiated transactions, up to $50.0&amp;#160;million of our outstanding shares of common stock, exclusive of any commissions, markups or expenses. The timing and amounts of any purchases were and will continue to be based on market conditions and other factors, including price, regulatory requirements and other corporate considerations. The 2015 Share Repurchase Program does not require the purchase of any minimum number of shares and may be suspended, modified or discontinued at any time without prior notice. We have financed, and expect to continue to finance, the purchases with existing cash balances. As it is the intent for the repurchased shares to be retired, we have elected to account for the shares repurchased under the constructive retirement method. For shares repurchased in excess of par, we allocate the purchase price in excess of par value to accumulated deficit.&lt;/p&gt;</nk:StockRepurchasesPolicyTextBlock>
  <us-gaap:RevenueRecognitionPolicyTextBlock id="F_000468" contextRef="C_0001326110_20190101_20191231">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Revenue Recognition&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Beginning January&amp;#160;1, 2018, we adopted the provisions of FASB ASC Topic&amp;#160;606, &lt;font style="font-style:italic;"&gt;Revenue from Contracts with Customers&lt;/font&gt;, or ASC&amp;#160;606. This guidance requires that entities recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. We adopted ASC&amp;#160;606 on January&amp;#160;1, 2018 by recording the cumulative effect of the adoption to accumulated deficit. We applied the new guidance to contracts that were not complete as of January&amp;#160;1, 2018. Implementation of ASC&amp;#160;606 did not have a material impact on our consolidated financial statements.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;We derive substantially all of our revenue from non-exclusive license agreements with a limited number of pharmaceutical and biotechnology companies granting them the right to use our cell lines and intellectual property for non-clinical use. These agreements generally include upfront fees and annual research license fees for such use, as well as commercial license fees for sales of the licensee products developed or manufactured using our intellectual property and cell lines.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account in ASC&amp;#160;606. A contract&amp;#8217;s transaction price is allocated to each distinct performance obligation based on relative standalone selling price and recognized as revenue when, or as, the performance obligation is satisfied.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Under the company&amp;#8217;s license agreements with customers, the company typically promises to provide a license to use certain cell lines and related patents, the related know-how, and future research and development data that affect the license. We have concluded that these promises represent one performance obligation due to the highly interrelated nature of the promises. We provide the cell lines and know-how immediately upon entering into the contracts. The research and development data is provided throughout the term of the contract when and if available.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Our license agreement with Intrexon (Note&amp;#160;7) included a nonrefundable upfront payment of $0.4&amp;#160;million, received when we entered into the contract in 2010. In this instance, we determined that under ASC&amp;#160;606 it would be appropriate to recognize the initial milestone payment at a point in time, when we transferred the license. In this case, the intellectual property provided under the contract is functional intellectual property under ASC&amp;#160;606 and was determined to be a distinct performance obligation in the context of the arrangement. Prior to adoption, the upfront payment had been initially recorded as deferred revenue and was being recognized into revenue on a straight-line basis. As a result, upon adoption of ASC&amp;#160;606, we adjusted our accumulated deficit for the effects of recognizing revenue upfront for the initial milestone. The adjustment to accumulated deficit upon adoption was not material.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The license agreements may include nonrefundable upfront payments, event-based milestone payments, sales-based royalty payments, or some combination of these. The event-based milestone payments represent variable consideration and we use the most likely amount method to estimate this variable consideration. Given the high degree of uncertainly around achievement of these milestones, we do not recognize revenue from these milestone payments until the uncertainty associated with these payments is resolved. We currently estimate variable consideration related to milestone payments to be zero and, as such, no revenue has been recognized for milestone payments. We recognize revenue from sales-based royalty payments when or as the sales occur. On a quarterly basis, we re-evaluate our estimate of milestone variable consideration to determine whether any amount should be included in the transaction price and recorded in revenue prospectively.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Upon adoption, we changed our accounting policy from accounting for milestones payments under the milestone method to accounting for variable consideration as discussed above. The change in accounting policy did not change any amounts in the financial statements because of the significant uncertainty surrounding the estimate of variable consideration for milestone payments.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;To date, we have generated minimal revenue related to the non-clinical use of our cells lines and intellectual property. We have no products approved for commercial sale and we have not generated any revenue from product sales. If we fail to complete the development of our product candidates in a timely manner or fail to obtain regulatory approval for them, we may never be able to generate substantial future revenue.&lt;/p&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
  <us-gaap:ResearchAndDevelopmentExpensePolicy id="F_000469" contextRef="C_0001326110_20190101_20191231">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Research and Development Costs&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Major components of research and development costs include cash compensation and other personnel-related expenses, stock-based compensation, depreciation and amortization expense on research and development property and equipment and intangible assets, costs of preclinical studies, clinical trials and related clinical manufacturing, costs of drug development, costs of materials and supplies, facilities cost, overhead costs, regulatory and compliance costs, and fees paid to consultants and other entities that conduct certain research and development activities on our behalf. Costs incurred in research and development are expensed as incurred.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Included in research and development costs are clinical trial and research expenses based on the services performed pursuant to contracts with research institutions and clinical research organizations and other vendors that conduct clinical trials and research on our behalf. We record accruals for estimated costs under these contracts. When evaluating the adequacy of the accrued liabilities, we analyze the progress of the studies or clinical trials, including the phase or completion of events, invoices received, contracted costs and purchase orders. Significant judgments and estimates are made in determining the accrued balances at the end of any reporting period based on the facts and circumstances known at that time. Although we do not expect the estimates to be materially different from the amounts actually incurred, if the estimates of the status and timing of services performed differs from the actual status and timing of services performed, we may report amounts that are too high or too low in any particular period. Actual results could differ from our estimates.&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
  <us-gaap:CompensationRelatedCostsPolicyTextBlock id="F_000470" contextRef="C_0001326110_20190101_20191231">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Stock-Based Compensation&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;We account for stock-based compensation under the provisions of ASC Topic&amp;#160;718, &lt;font style="font-style:italic;"&gt;Compensation&amp;#8212;Stock Compensation&lt;/font&gt;, or ASC&amp;#160;718, which applies to share-based payments issued to employees and nonemployees in exchange for goods or services. Under ASC&amp;#160;718, the fair value of an equity-classified award is estimated on the grant date without regard to service or performance conditions. The grant date fair values for options and warrants are estimated using the Black-Scholes-Merton option pricing model, and the grant date fair values for restricted stock units, or RSUs, are based upon the closing market price of our common stock on the date of grant.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;We use the straight-line method to recognize stock-based compensation expense for our outstanding share awards that do not contain a performance condition. For awards subject to performance-based vesting conditions, we assess the probability of the individual milestones under the award being achieved and stock-based compensation expense is recognized over the service period commencing once management believes the performance criteria is probable of being met. For awards with service or performance conditions, we recognize the effect of forfeitures in compensation cost in the period that the award was forfeited.&lt;/p&gt;</us-gaap:CompensationRelatedCostsPolicyTextBlock>
  <nk:LitigationCostsPolicyTextBlock id="F_000471" contextRef="C_0001326110_20190101_20191231">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Litigation Costs&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;We expense legal fees as they are incurred.&lt;/p&gt;</nk:LitigationCostsPolicyTextBlock>
  <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock id="F_000472" contextRef="C_0001326110_20190101_20191231">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Comprehensive Income (Loss)&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Comprehensive income or loss is defined as the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. Comprehensive income or loss is composed of net income (loss) and other comprehensive income (loss). Our other comprehensive income or loss consists of unrealized gains and losses on marketable debt securities classified as available-for-sale, net of income taxes.&lt;/p&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
  <us-gaap:EarningsPerSharePolicyTextBlock id="F_000473" contextRef="C_0001326110_20190101_20191231">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Basic and Diluted Net Loss per Share of Common Stock&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Basic net loss per share is calculated by dividing the net loss by the weighted-average number of common shares outstanding for the period. Diluted loss per share is computed similarly to basic loss per share except that the denominator is increased to include the number of additional shares that would have been outstanding if the potential common shares had been issued and if the additional common shares were dilutive.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;For all periods presented, potentially dilutive securities are excluded from the computation of fully diluted loss per share as their effect is anti-dilutive. The following table details those securities that have been excluded from the computation of potentially dilutive securities:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.1%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December&amp;#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2017&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding options&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,506,950&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,493,250&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,693,250&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding RSUs&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,139,428&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;867,911&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;888,189&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding warrants&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;17,589,250&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;17,721,088&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,646,378&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;24,950,411&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;24,302,527&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amounts in the table above reflect the common stock equivalents of the noted instruments.&lt;/p&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
  <us-gaap:SegmentReportingPolicyPolicyTextBlock id="F_000474" contextRef="C_0001326110_20190101_20191231">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Segment and Geographic Information&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating segments are defined as components of an enterprise (business activity from which it earns revenue and incurs expenses) for which discrete financial information is available and regularly reviewed by the chief operating decision maker in deciding how to allocate resources and in assessing performance. Our chief operating decision maker is the company&amp;#8217;s CEO. We view our operations and manage our business as a single operating and reporting segment. As of December&amp;#160;31, 2019 and 2018, the majority of our assets were held in the U.S. For the years ended December&amp;#160;31, 2019, 2018 and 2017, all of our revenue was derived in the U.S.&lt;/p&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
  <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock id="F_000475" contextRef="C_0001326110_20190101_20191231">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Recent Accounting Pronouncements&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Application of New or Revised Accounting Standards &amp;#8211; Adopted&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;We adopted ASC&amp;#160;842 on January&amp;#160;1, 2019, using the simplified transition approach which allowed us to not recast the comparative periods presented when transitioning to the new lease standard, while including required disclosures under ASC&amp;#160;840 for all periods presented under ASC&amp;#160;840. In addition, we elected the package of practical expedients permitted under the transition guidance, which among other things, allowed us to not reassess&amp;#160;(1)&amp;#160;whether a contract is or contains a lease, and (2)&amp;#160;the classification of existing leases.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The adoption of ASC&amp;#160;842 had a substantial impact on our balance sheet. The most significant impacts were (i)&amp;#160;the recognition of $13.5&amp;#160;million of operating lease right-of-use assets, net, and $16.4&amp;#160;million of operating lease liabilities, and (ii)&amp;#160;the derecognition of assets and liabilities associated with the build-to-suit leases under ASC&amp;#160;840 (resulting in the derecognition of property, plant and equipment, net, of $6.6&amp;#160;million and net adjustments to related liabilities of $5.7&amp;#160;million). The build-to-suit leases were recorded as normal operating leases under ASC&amp;#160;842. The difference between the excess of build-to-suit related liabilities and assets of $0.9&amp;#160;million was recorded as an increase to our accumulated deficit. The cumulative-effect adjustment had no tax impact due to the valuation allowance against the gross deferred tax asset less reversing deferred tax liabilities. Adoption of this standard had no material impact on our results of operations and cash flows.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In August&amp;#160;2018, the FASB issued ASU&amp;#160;2018&amp;#8209;15, &lt;font style="font-style:italic;"&gt;Intangibles&amp;#8212;Goodwill and Other&amp;#8212;Internal-Use Software (Subtopic 350-40): Customer&amp;#8217;s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract&lt;/font&gt; (ASU&amp;#160;2018&amp;#8209;15). This update aligns guidance for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs to develop or obtain internal-use software (and hosting arrangements that include an internal-use software license). Capitalized implementation costs will be amortized over the term of the hosting arrangement and expense related to the capitalized implementation costs will be presented in the same line item in the statements of operations as the fees associated with the service contract. As permitted by the standard, we elected to early adopt ASU&amp;#160;2018&amp;#8209;15 on a prospective basis as of October&amp;#160;1, 2019. The adoption did not have a material effect on our consolidated financial statements.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Application of New or Revised Accounting Standards &amp;#8211; Not Yet Adopted&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In December&amp;#160;2019, the FASB issued ASU&amp;#160;2019-12,&amp;#160;&lt;font style="font-style:italic;"&gt;Simplifying the Accounting for Income Taxes&lt;/font&gt;. The amendments in this update include removing the exception to the incremental approach for intraperiod tax allocation when there is a loss from continuing operations and income, or a gain, from other items (e.g., discontinued operations or other comprehensive income), and the exception to the general methodology for calculating income taxes in an interim period when a year-to-date loss exceeds the anticipated loss for the year. We are currently evaluating the impact that these amendments will have on our consolidated financial statements and we intend to early adopt these amendments on January&amp;#160;1, 2020. We do not expect that the adoption of these amendments will have a significant impact on our consolidated financial statements.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In June&amp;#160;2016, the FASB issued ASU&amp;#160;2016&amp;#8209;13,&amp;#160;&lt;font style="font-style:italic;"&gt;Financial Instruments&amp;#8212;Credit Losses (Topic 326):&amp;#160;Measurement of Credit Losses on Financial Instruments&lt;/font&gt;. The new guidance supersedes existing U.S. GAAP for measuring and recording of credit losses on financial assets measured at amortized cost by replacing the incurred-loss model with an expected-loss model. Accordingly, these financial assets will be presented at the net amount expected to be collected. This new standard also requires that credit losses related to available-for-sale debt securities be recorded as an allowance through net income rather than reducing the carrying amount under the current, other-than-temporary-impairment model. The new guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December&amp;#160;15, 2019, but may be adopted earlier. With certain exceptions, adjustments are to be applied using a modified-retrospective approach by reflecting adjustments through a cumulative-effect impact on retained earnings as of the beginning of the fiscal year of adoption. In May&amp;#160;2019, the FASB issued ASU&amp;#160;2019-05,&amp;#160;&lt;font style="font-style:italic;"&gt;Financial Instruments&amp;#8212;Credit Losses (Topic&amp;#160;326):&amp;#160;Targeted Transition Relief&lt;/font&gt;, which provides companies with an option to irrevocably elect the fair value option for certain financial assets previously measured at amortized cost basis upon adoption of Topic&amp;#160;326. We are currently evaluating the impact that this new standard and its related amendments will have on our consolidated financial statements and we intend to adopt the standard on January&amp;#160;1, 2021. However, as the impact is dependent upon the investments held as of the adoption date, it is not possible for us to quantify the impact until the date of adoption.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other recent authoritative guidance issued by the FASB (including technical corrections to the ASC), the American Institute of Certified Public Accountants, and the Securities and Exchange Commission during the three&amp;#160;months ended December&amp;#160;31, 2019 did not, or are not expected to, have a material effect on our consolidated financial statements.&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
  <us-gaap:InvestmentPolicyTextBlock id="F_000476" contextRef="C_0001326110_20190101_20191231">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Based on the level of equity investment at risk, Viracta is not a VIE and therefore is not consolidated under the VIE Model. In addition, we do not hold a controlling financial interest in Viracta and therefore we do not consolidate Viracta under the voting interest model. As the preferred stock is not considered in-substance common stock, the investment is not within the scope of accounting for the investment under the equity method. As the preferred stock does not have a readily determinable fair value and does not qualify for the practical expedient to estimate fair value in accordance with ASC&amp;#160;820, we have elected to apply the measurement alternative under ASC&amp;#160;321, pursuant to which we measure our investment in Viracta at cost, less impairment, adjusted for observable price changes in an orderly market for an identical or similar investment of the same issuer.&lt;/p&gt;</us-gaap:InvestmentPolicyTextBlock>
  <nk:PropertyPlantAndEquipmentUsefulLifeTableTextBlock id="F_000477" contextRef="C_0001326110_20190101_20191231">Depreciation of property, plant and equipment is calculated using the straight-line method over the estimated useful lives of the assets, as follows:
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Buildings&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.36%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; 39 years&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Software&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.36%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; 3 years&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Laboratory equipment&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.36%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; 5 years&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Furniture &amp;amp; fixtures&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.36%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; 5 years&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;IT equipment&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.36%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; 3 years&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.36%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; The lesser of the lease term or the life of the asset&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;</nk:PropertyPlantAndEquipmentUsefulLifeTableTextBlock>
  <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock id="F_000478" contextRef="C_0001326110_20190101_20191231">The following table details those securities that have been excluded from the computation of potentially dilutive securities:
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.1%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December&amp;#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2017&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding options&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,506,950&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,493,250&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,693,250&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding RSUs&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,139,428&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;867,911&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;888,189&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding warrants&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;17,589,250&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;17,721,088&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,646,378&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;24,950,411&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;24,302,527&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amounts in the table above reflect the common stock equivalents of the noted instruments.&lt;/p&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
  <nk:PrepaidExpensesAndOtherCurrentAssetsTableTextBlock id="F_000479" contextRef="C_0001326110_20190101_20191231">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December&amp;#160;31, 2019 and 2018, prepaid expenses and other current assets were made up of (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December&amp;#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Prepaid preclinical and clinical trial services - with&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&amp;nbsp; related party (Note 9)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,021&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Insurance premium financing asset&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;757&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;339&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Prepaid supplies - with related party (Note 9)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;467&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;532&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Prepaid services&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;440&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;230&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Prepaid rent&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;392&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;536&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Prepaid insurance&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;372&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;343&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Prepaid equipment maintenance&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;251&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;329&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Interest receivable - marketable debt securities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;222&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;473&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Prepaid license fees&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;78&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;104&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Insurance claim receivables&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;34&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,882&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Due from related parties&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;47&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;90&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;24&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;42&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,105&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13,900&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;</nk:PrepaidExpensesAndOtherCurrentAssetsTableTextBlock>
  <us-gaap:PropertyPlantAndEquipmentTextBlock id="F_000480" contextRef="C_0001326110_20190101_20191231">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December&amp;#160;31, 2019 and 2018, property, plant and equipment, net, was made up of (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December&amp;#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Construction in progress&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,480&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;33,406&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,087&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Buildings&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;22,690&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;59,356&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Equipment&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21,434&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;20,878&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Software&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,195&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,264&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Furniture &amp;amp; fixtures&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;383&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;381&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;79,108&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;88,446&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accumulated depreciation&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(18,607&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(11,561&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;60,501&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;76,885&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
  <nk:ScheduleOfImpactOfAdoptionOnPropertyPlantAndEquipmentTableTextBlock id="F_000481" contextRef="C_0001326110_20190101_20191231">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The impact of adoption of ASC&amp;#160;842 on property, plant, and equipment at December&amp;#160;31, 2018 was as follows&amp;#160;(in&amp;#160;thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.24%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31, 2018&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.24%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Adoption of&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;ASC 842&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Increase&amp;#160;(Decrease)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.24%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;January 1, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,087&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;32,014&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;36,101&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Buildings&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;59,356&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(39,893&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;19,463&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property, plant and equipment, gross&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;88,446&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(7,879&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;80,567&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accumulated depreciation&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(11,561&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,293&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(10,268&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property, plant and equipment, net&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;76,885&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(6,586&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;70,299&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</nk:ScheduleOfImpactOfAdoptionOnPropertyPlantAndEquipmentTableTextBlock>
  <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock id="F_000482" contextRef="C_0001326110_20190101_20191231">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December&amp;#160;31, 2019 and 2018, intangible assets were made up of (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December&amp;#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Technology license&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,042&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,042&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less accumulated amortization&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(9,042&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(8,477&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;565&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
  <us-gaap:ScheduleOfOtherAssetsNoncurrentTextBlock id="F_000483" contextRef="C_0001326110_20190101_20191231">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December&amp;#160;31, 2019 and 2018, other assets were made up of (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December&amp;#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Prepaid preclinical and clinical trial services - with&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&amp;nbsp; related party (Note 9)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,075&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Restricted cash&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;179&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;179&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Security deposit&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;113&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;113&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Prepaid rent&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,205&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;19&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;30&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,386&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,527&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;</us-gaap:ScheduleOfOtherAssetsNoncurrentTextBlock>
  <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock id="F_000484" contextRef="C_0001326110_20190101_20191231">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December&amp;#160;31, 2019 and 2018, accrued expenses were made up of (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December&amp;#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued bonus&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,002&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,079&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued compensation&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,064&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;943&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued professional and service fees&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;975&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;912&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued laboratory equipment and supplies&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;640&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;678&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued preclinical and clinical trial costs&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;281&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;704&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued franchise, sales/use and property taxes&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;200&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;250&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Litigation settlement accruals&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,000&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued construction costs&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,341&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;181&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;197&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,343&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21,104&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
  <us-gaap:OtherCurrentLiabilitiesTableTextBlock id="F_000485" contextRef="C_0001326110_20190101_20191231">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December&amp;#160;31, 2019 and 2018, other current liabilities were made up of (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December&amp;#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating lease liability - current portion (including&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;   amounts with related parties, Note 9)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,206&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Financing obligation - current portion&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;757&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;965&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred rent - current portion&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;598&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;18&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;104&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,981&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,667&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;</us-gaap:OtherCurrentLiabilitiesTableTextBlock>
  <us-gaap:InvestmentIncomeTextBlock id="F_000486" contextRef="C_0001326110_20190101_20191231">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net investment income is as follows for the years ended December&amp;#160;31, 2019, 2018 and 2017 (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.1%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;For the Year Ended December&amp;#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2017&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Interest income&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,643&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,317&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,225&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Investment accretion income (amortization expense), net&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(463&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1,597&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net realized (losses) gains on investments&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(4&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;37&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,642&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,857&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,665&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;</us-gaap:InvestmentIncomeTextBlock>
  <us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock id="F_000487" contextRef="C_0001326110_20190101_20191231">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;At December&amp;#160;31, 2019, our investments in debt securities are detailed below (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="18" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.1%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&amp;#160;31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Remaining&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Contractual&amp;#160;Life&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in years)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amortized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cost&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gains&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Losses&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Value&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Current:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Available-for-sale:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Corporate debt securities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.2&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;32,382&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(3&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;32,389&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Foreign government bonds&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.3&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,007&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,007&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Government sponsored securities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.5&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,752&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(4&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,748&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Current portion&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.2&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;36,141&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(7&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;36,144&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Noncurrent:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Available-for-sale:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Corporate debt securities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.7&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,501&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(4&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,497&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Noncurrent portion&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.7&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,501&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(4&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,497&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.94%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.3&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;37,642&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(11&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;37,641&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;At December&amp;#160;31, 2018, our investments in debt securities are detailed below (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.42%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&amp;#160;31, 2018&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amortized&amp;#160;Cost&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gains&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Losses&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair&amp;#160;Value&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Current:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Available-for-sale:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Corporate debt securities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;57,463&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(136&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;57,328&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total available-for-sale&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;57,463&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(136&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;57,328&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Held-to-maturity, notes receivable (Note 4)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;723&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;723&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Current portion&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;58,186&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(136&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;58,051&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Noncurrent:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Available-for-sale:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Corporate debt securities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,067&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(76&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,991&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Government sponsored securities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,756&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(46&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,710&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Noncurrent portion&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,823&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(122&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,701&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;64,009&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(258&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;63,752&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;</us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock>
  <us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueTableTextBlock id="F_000488" contextRef="C_0001326110_20190101_20191231">
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accumulated unrealized losses on debt securities classified as available-for-sale that have been in a continuous loss position for less than 12&amp;#160;months and for more than 12&amp;#160;months at December&amp;#160;31, 2019 and 2018 were as follows (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.42%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&amp;#160;31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less than 12 months&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;More than 12 months&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Estimated&amp;#160;Fair&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Value&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross&amp;#160;Unrealized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Losses&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Estimated&amp;#160;Fair&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Value&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross&amp;#160;Unrealized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Losses&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Corporate debt securities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11,021&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(3&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,497&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(4&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Government sponsored securities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,748&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(4&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11,021&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(3&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,245&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(8&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.42%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&amp;#160;31, 2018&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less than 12 months&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;More than 12 months&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Estimated&amp;#160;Fair&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Value&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross&amp;#160;Unrealized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Losses&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Estimated&amp;#160;Fair&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Value&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross&amp;#160;Unrealized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Losses&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Corporate debt securities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;32,010&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(26&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;26,663&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(186&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Government sponsored securities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,710&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(46&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;32,010&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(26&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;29,373&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(232&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueTableTextBlock>
  <us-gaap:ScheduleOfRealizedGainLossTableTextBlock id="F_000489" contextRef="C_0001326110_20190101_20191231">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;We recorded realized gains and losses on sales of available-for-sale debt securities as follows (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.92%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Realized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gains&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.92%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Realized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Losses&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.92%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Realized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gains (Losses)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(8&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(4&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2017&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;52&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(15&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;37&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"&gt;&amp;nbsp;&lt;/p&gt;</us-gaap:ScheduleOfRealizedGainLossTableTextBlock>
  <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock id="F_000490" contextRef="C_0001326110_20190101_20191231">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Financial assets and liabilities measured at fair value on a recurring basis are summarized below at December&amp;#160;31, 2019 and 2018 (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.42%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Value Measurements at December&amp;#160;31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 1&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 2&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 3&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Assets:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Current:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash and cash equivalents&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15,508&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15,508&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Corporate debt securities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;32,389&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;32,389&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Foreign government bonds&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,007&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,007&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Government sponsored securities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,748&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,748&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Noncurrent:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Corporate debt securities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,497&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,497&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total assets measured at fair value&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;53,149&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15,508&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;37,641&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.42%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Value Measurements at December&amp;#160;31, 2018&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 1&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 2&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 3&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Assets:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Current:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash and cash equivalents&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;16,821&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;16,821&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Corporate debt securities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;57,328&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;57,328&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Noncurrent:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Corporate debt securities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,991&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,991&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Government sponsored securities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,710&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,710&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total assets measured at fair value&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;79,850&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;16,821&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;63,029&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
  <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock id="F_000491" contextRef="C_0001326110_20190101_20191231">The following disclosures relate to our lease balances as of January&amp;#160;1, 2019 and December&amp;#160;31, 2019, under ASC&amp;#160;842 (in thousands):
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.26%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.36%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;January 1, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.36%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.26%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating lease right-of-use assets, net&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.36%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13,532&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.36%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11,729&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.26%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other current liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.36%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,960&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.36%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,206&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.26%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating lease liability, less current portion&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.36%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13,407&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.36%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,885&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
  <us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock id="F_000492" contextRef="C_0001326110_20190101_20191231">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Future minimum lease payments at December&amp;#160;31, 2019 are presented in the following table (in thousands). Common area maintenance costs and taxes are not included in these payments.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:81.8%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Years ending December 31:&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.18%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Leases (a)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:81.8%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,271&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:81.8%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,753&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:81.8%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2022&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,671&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:81.8%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2023&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,546&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:81.8%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2024&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,083&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:81.8%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,729&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:81.8%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total future minimum lease payments&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;17,053&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:81.8%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less: Interest&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,962&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:81.8%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Present value of operating lease liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14,091&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;margin-right:75.93%;text-indent:0%;font-size:5pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:4.54%;white-space:nowrap"&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:4.54%;white-space:nowrap"&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;font-size:10pt;"&gt;(a)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating lease payments include $3.3&amp;#160;million related to options to extend lease terms that are reasonably certain of being exercised.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;</us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock>
  <nk:ScheduleOfCommonStockReservedForIssuanceTableTextBlock id="F_000493" contextRef="C_0001326110_20180101_20181231">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table summarizes the common shares reserved for issuance on exercise or vesting of various awards at December&amp;#160;31, 2019:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:60%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding stock options&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.64%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,506,950&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding RSUs&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.64%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,139,428&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:78.44%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding warrants&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.9%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.64%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:78.44%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total shares reserved for future issuance&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.9%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.64%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,646,378&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</nk:ScheduleOfCommonStockReservedForIssuanceTableTextBlock>
  <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock id="F_000494" contextRef="C_0001326110_20190101_20191231">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table presents all stock-based compensation as included on the consolidated statements of operations (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.1%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;For the Year Ended December&amp;#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2017&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock-based compensation expense:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Warrants for common stock to an officer&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;17,817&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;31,584&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Employee stock options&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,309&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,057&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,267&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Employee RSUs&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;938&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,193&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;894&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Non-employee RSUs&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;380&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;315&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;252&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,627&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;23,382&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;36,997&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock-based compensation expense in operating expenses:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;499&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;460&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;102&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Selling, general and administrative&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,128&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;22,922&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;36,895&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,627&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;23,382&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;36,997&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
  <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock id="F_000495" contextRef="C_0001326110_20190101_20191231">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table summarizes stock option activity under all equity incentive plans for the years ended December&amp;#160;31, 2019, 2018 and 2017:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Number of&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Shares&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercise&amp;#160;Price&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Aggregate&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Intrinsic&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Value&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Remaining&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Contractual&amp;#160;Life&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in years)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding at December 31, 2016&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,307,386&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7.14&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;19,100&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.4&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options exercised&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(614,136&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.88&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding at December 31, 2017&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,693,250&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7.71&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11,920&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.3&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options granted&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;800,000&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3.07&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding at December 31, 2018&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,493,250&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7.14&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;563&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4.8&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options exercised&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1,986,300&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.06&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding at December 31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,506,950&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9.37&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,710&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.8&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Vested and Exercisable at December 31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,973,614&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10.22&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,326&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.5&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
  <us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock id="F_000496" contextRef="C_0001326110_20190101_20191231">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table provides a summary of options outstanding and vested as of December&amp;#160;31, 2019:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.56%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercise Prices&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Number&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&amp;#160;Remaining&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Contractual Life&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in years)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Number&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercisable&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&amp;#160;Remaining&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Contractual Life&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in years)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.56%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$0.42&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;589,660&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4.9&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;589,660&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4.9&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.56%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$1.76&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;699,060&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.0&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;699,060&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.0&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.56%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$2.00&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;962,780&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.1&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;962,780&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.1&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.56%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$3.07&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;800,000&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8.7&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;266,664&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8.7&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.56%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$25.00&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,455,450&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.22%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.6&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,455,450&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.22%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.6&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.56%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,506,950&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.22%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.8&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,973,614&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.22%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.5&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;</us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock>
  <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock id="F_000497" contextRef="C_0001326110_20190101_20191231">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The company uses a Black-Scholes option-pricing model to determine the fair value of stock-based compensation under ASC&amp;#160;Topic&amp;#160;718,&amp;#160;&lt;font style="font-style:italic;"&gt;Stock Compensation&lt;/font&gt;. The assumptions used for employee stock options granted during the year ended December&amp;#160;31, 2018, are presented in the table below:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:60%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected term (years)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.0 - 6.1&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.8%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;75.9%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Dividend yield&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-average measurement date fair value&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$2.09&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
  <us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock id="F_000498" contextRef="C_0001326110_20190101_20191231">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table summarizes the restricted stock units, or RSUs, activity under the 2015&amp;#160;Plan:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Number of&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;RSUs&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Grant Date&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Value&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unvested balance at December 31, 2016&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;814,456&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13.98&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Granted&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;615,983&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4.50&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Vested&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(244,209&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15.82&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Forfeited/canceled&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(298,041&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10.28&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unvested balance at December 31, 2017&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;888,189&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8.14&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Granted&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;487,472&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3.57&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Vested&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(172,330&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.16&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Forfeited/canceled&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(335,420&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.27&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unvested balance at December 31, 2018&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;867,911&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.69&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Granted&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;749,793&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.12&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Vested&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(395,051&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8.83&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Forfeited/canceled&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(83,225&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7.29&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unvested balance at December 31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,139,428&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.88%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.23&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;</us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock>
  <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock id="F_000499" contextRef="C_0001326110_20190101_20191231">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table summarizes the company&amp;#8217;s warrant activity:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:60%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding at December 31, 2016&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;17,768,314&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Warrants exercised&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(47,226&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding at December 31, 2017&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;17,721,088&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Warrants exercised&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(93,254&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Warrants expired&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(38,584&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding at December 31, 2018&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;17,589,250&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Warrants exercised&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(17,589,250&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding at December 31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Vested and exercisable at December 31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
  <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock id="F_000500" contextRef="C_0001326110_20190101_20191231">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The amount of loss before taxes is as follows (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.1%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;For the Year Ended December&amp;#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2017&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;U.S. loss before taxes&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(65,286&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(94,423&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(94,734&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Foreign loss before taxes&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(600&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2,306&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2,182&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Loss before income taxes&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(65,886&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(96,729&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(96,916&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;</us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
  <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock id="F_000501" contextRef="C_0001326110_20190101_20191231">
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Income tax benefit for the years ended December&amp;#160;31, 2019, 2018 and 2017 consists of the following (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.78%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.84%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;For the Year Ended December&amp;#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.78%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.8%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.8%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2017&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.78%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Current:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.48%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.78%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Federal&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.48%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.78%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;State&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.48%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.78%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Foreign&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.48%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.78%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total Current&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.48%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.78%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.48%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.78%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Federal&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.48%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(79&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.78%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;State&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.48%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(21&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(8&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.78%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Foreign&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.48%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(498&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(497&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.78%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total Deferred&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(100&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(506&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(497&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.78%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Income tax benefit&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.48%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(97&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(503&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(493&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
  <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock id="F_000502" contextRef="C_0001326110_20190101_20191231">
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The components that comprise the company&amp;#8217;s net deferred tax assets at December&amp;#160;31, 2019 and 2018 consist of the following (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.44%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.94%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December&amp;#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.44%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred tax assets:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.4%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net operating loss carryforwards&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;78,377&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.4%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;61,915&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock compensation&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,536&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.4%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;79,281&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating lease liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,884&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.4%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Depreciation and amortization&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,042&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.4%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Tax credits&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;898&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.4%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;845&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued compensation&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;775&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.4%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;795&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Leases and other accrued liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;453&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.4%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,909&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.44%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued legal expenses&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.4%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;308&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total deferred tax assets&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;94,965&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.4%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;146,053&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred tax liabilities:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.4%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Foreign intangibles&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.4%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating lease right-of-use assets&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(3,233&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.4%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.44%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Depreciation and amortization&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.4%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1,279&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.44%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total deferred tax liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(3,233&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.4%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1,280&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net deferred tax assets&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;91,732&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.4%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;144,773&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.44%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Valuation allowance&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(91,732&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.4%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(144,773&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.44%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net deferred tax liability&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.4%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
  <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock id="F_000503" contextRef="C_0001326110_20190101_20191231">
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;A reconciliation of the federal statutory income tax rate to the company&amp;#8217;s effective income tax rate is as follows:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:55.54%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="12" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.08%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;For the Year Ended December&amp;#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:55.54%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.02%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2017&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.02%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.54%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Tax computed at federal statutory rate&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.34%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21.0&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.34%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21.0&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.34%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;34.0&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.54%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;State income taxes, net of federal tax benefit&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.34%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(19.4&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.34%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.2&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.34%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.3&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.54%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Tax rate adjustment&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.34%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.1&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.34%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(0.3&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.34%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4.8&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.54%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Tax Cuts and Jobs Act&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.34%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.34%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.34%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(53.4&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.54%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development credits&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.34%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.2&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.34%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.1&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.34%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.6&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.54%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock-based compensation&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.34%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(82.5&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.34%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(0.1&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.34%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(0.3&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.54%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.34%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(0.1&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.34%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.3&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.34%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.8&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:55.54%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Valuation allowance&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.34%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;80.5&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.02%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.34%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(26.7&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.02%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.34%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8.7&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.02%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:55.54%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Effective income tax rate&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.34%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(0.2&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.02%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.34%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.5&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.02%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.34%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.5&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.02%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
  <us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock id="F_000504" contextRef="C_0001326110_20190101_20191231">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table summarizes the changes to the amount of unrecognized tax benefits (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:60%;"&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrecognized tax benefits at December 31, 2017&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,577&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Increase for prior year tax positions&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;798&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Increase for current year tax positions&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,608&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrecognized tax benefits at December 31, 2018&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11,983&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Decrease for prior year tax positions&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(7&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Increase for current year tax positions&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,680&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrecognized tax benefits at December 31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15,656&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;</us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock>
  <us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock id="F_000505" contextRef="C_0001326110_20190101_20191231">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The table below presents unaudited quarterly data for fiscal 2019 and 2018 (in thousands, except for share and per share amounts):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;1st Quarter&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2nd Quarter&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;3rd Quarter&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;4th Quarter&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Revenue&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;17&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating expenses&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;18,340&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;17,313&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;16,077&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;16,120&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating loss&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(18,335&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(17,296&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(16,065&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(16,111&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net loss&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(17,885&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(16,682&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(15,581&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(15,641&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net loss per share - basic and diluted&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(0.22&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(0.17&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(0.16&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(0.16&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Shares used in calculating net loss per share - basic and&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&amp;nbsp; diluted&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;81,261,302&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;98,594,355&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;98,331,695&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;98,419,166&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;1st Quarter&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2nd Quarter&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;3rd Quarter&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;4th Quarter&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Revenue&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;31&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating expenses&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;28,289&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;28,282&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;24,139&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;17,726&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating loss&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(28,284&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(28,278&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(24,108&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(17,719&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;) &lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net loss&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(27,519&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(27,732&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(23,635&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(17,340&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;) &lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net loss per share - basic and diluted&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(0.35&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(0.35&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(0.30&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(0.22&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;) &lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Shares used in calculating net loss per share - basic and&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&amp;nbsp; diluted&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;79,036,614&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;79,107,208&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;79,204,765&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;79,177,962&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;</us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock>
  <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions id="F_000506" contextRef="C_0001326110_srtTitleOfIndividualAxis_nkChairmanAndChiefExecutiveOfficerMember_20190101_20191231" decimals="-5" unitRef="U_iso4217USD">39200000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
  <us-gaap:EquityMethodInvestmentOwnershipPercentage id="F_000507" contextRef="C_0001326110_srtRangeAxis_srtMinimumMember_us-gaapVariableInterestEntitiesByClassificationOfEntityAxis_us-gaapVariableInterestEntityPrimaryBeneficiaryMember_20191231" decimals="INF" unitRef="U_xbrlipure">0.20</us-gaap:EquityMethodInvestmentOwnershipPercentage>
  <us-gaap:EquityMethodInvestmentOwnershipPercentage id="F_000508" contextRef="C_0001326110_srtRangeAxis_srtMaximumMember_us-gaapVariableInterestEntitiesByClassificationOfEntityAxis_us-gaapVariableInterestEntityPrimaryBeneficiaryMember_20191231" decimals="INF" unitRef="U_xbrlipure">0.50</us-gaap:EquityMethodInvestmentOwnershipPercentage>
  <nk:CashAndCashEquivalentsOriginalMaturities id="F_000509" contextRef="C_0001326110_20190101_20191231">P3M</nk:CashAndCashEquivalentsOriginalMaturities>
  <nk:MarketableSecuritiesOriginalMaturities id="F_000510" contextRef="C_0001326110_srtRangeAxis_srtMinimumMember_20190101_20191231">P3M</nk:MarketableSecuritiesOriginalMaturities>
  <nk:MaximumOriginalMaturityPeriodOfShortTermMarketableSecurities id="F_000511" contextRef="C_0001326110_20190101_20191231">P12M</nk:MaximumOriginalMaturityPeriodOfShortTermMarketableSecurities>
  <nk:MinimumOriginalMaturityPeriodOfLongTermMarketableSecurities id="F_000512" contextRef="C_0001326110_20190101_20191231">P12M</nk:MinimumOriginalMaturityPeriodOfLongTermMarketableSecurities>
  <us-gaap:OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet id="F_000513" contextRef="C_0001326110_20190101_20191231" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet>
  <us-gaap:OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet id="F_000514" contextRef="C_0001326110_20180101_20181231" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet>
  <us-gaap:OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet id="F_000515" contextRef="C_0001326110_20170101_20171231" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet>
  <us-gaap:PropertyPlantAndEquipmentUsefulLife id="F_000516" contextRef="C_0001326110_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapBuildingMember_20190101_20191231">P39Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
  <us-gaap:PropertyPlantAndEquipmentUsefulLife id="F_000517" contextRef="C_0001326110_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapSoftwareAndSoftwareDevelopmentCostsMember_20190101_20191231">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
  <us-gaap:PropertyPlantAndEquipmentUsefulLife id="F_000518" contextRef="C_0001326110_us-gaapPropertyPlantAndEquipmentByTypeAxis_nkLaboratoryEquipmentMember_20190101_20191231">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
  <us-gaap:PropertyPlantAndEquipmentUsefulLife id="F_000519" contextRef="C_0001326110_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20190101_20191231">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
  <us-gaap:PropertyPlantAndEquipmentUsefulLife id="F_000520" contextRef="C_0001326110_us-gaapPropertyPlantAndEquipmentByTypeAxis_nkITEquipmentMember_20190101_20191231">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
  <us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives id="F_000521" contextRef="C_0001326110_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20190101_20191231">The lesser of the lease term or the life of the asset</us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives>
  <us-gaap:FiniteLivedIntangibleAssetUsefulLife id="F_000522" contextRef="C_0001326110_20190101_20191231">P4Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
  <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse id="F_000523" contextRef="C_0001326110_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20190401_20190630" decimals="-5" unitRef="U_iso4217USD">900000</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
  <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse id="F_000524" contextRef="C_0001326110_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20180101_20181231" decimals="-6" unitRef="U_iso4217USD">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
  <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse id="F_000525" contextRef="C_0001326110_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20170101_20171231" decimals="-6" unitRef="U_iso4217USD">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
  <nk:FairValueInputsTransfersIntoOrOutOfLevelOneLevelTwoOrLevelThreeCategories id="F_000526" contextRef="C_0001326110_20191231" decimals="INF" unitRef="U_iso4217USD">0</nk:FairValueInputsTransfersIntoOrOutOfLevelOneLevelTwoOrLevelThreeCategories>
  <nk:FairValueInputsTransfersIntoOrOutOfLevelOneLevelTwoOrLevelThreeCategories id="F_000527" contextRef="C_0001326110_20181231" decimals="INF" unitRef="U_iso4217USD">0</nk:FairValueInputsTransfersIntoOrOutOfLevelOneLevelTwoOrLevelThreeCategories>
  <nk:FairValueInputsTransfersIntoOrOutOfLevelOneLevelTwoOrLevelThreeCategories id="F_000528" contextRef="C_0001326110_20171231" decimals="INF" unitRef="U_iso4217USD">0</nk:FairValueInputsTransfersIntoOrOutOfLevelOneLevelTwoOrLevelThreeCategories>
  <us-gaap:LeasePracticalExpedientsPackage id="F_000529" contextRef="C_0001326110_20190101_20191231">true</us-gaap:LeasePracticalExpedientsPackage>
  <us-gaap:LesseeOperatingLeaseDescription id="F_000530" contextRef="C_0001326110_20190101_20191231">elected not to recognize right-of-use assets and lease liabilities for qualifying short-term leases with an initial lease term of 12 months or less at lease inception</us-gaap:LesseeOperatingLeaseDescription>
  <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued id="F_000531" contextRef="C_0001326110_20191231" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
  <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued id="F_000532" contextRef="C_0001326110_20181231" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
  <us-gaap:OpenTaxYear id="F_000533" contextRef="C_0001326110_srtRangeAxis_srtMinimumMember_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20190101_20191231">2016</us-gaap:OpenTaxYear>
  <us-gaap:OpenTaxYear id="F_000534" contextRef="C_0001326110_srtRangeAxis_srtMaximumMember_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20190101_20191231">2019</us-gaap:OpenTaxYear>
  <us-gaap:OpenTaxYear id="F_000535" contextRef="C_0001326110_srtRangeAxis_srtMinimumMember_srtStatementGeographicalAxis_stprCA_20190101_20191231">2015</us-gaap:OpenTaxYear>
  <us-gaap:OpenTaxYear id="F_000536" contextRef="C_0001326110_srtRangeAxis_srtMaximumMember_srtStatementGeographicalAxis_stprCA_20190101_20191231">2019</us-gaap:OpenTaxYear>
  <us-gaap:StockRepurchaseProgramAuthorizedAmount1 id="F_000537" contextRef="C_0001326110_20151130" decimals="INF" unitRef="U_iso4217USD">50000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
  <nk:NonrefundableUpfrontPayment id="F_000538" contextRef="C_0001326110_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_nkIntrexonLicenseAgreementMember_20100201_20100228" decimals="-5" unitRef="U_iso4217USD">400000</nk:NonrefundableUpfrontPayment>
  <nk:VariableConsiderationRelatedToMilestonePayment id="F_000539" contextRef="C_0001326110_20190101_20191231" decimals="-6" unitRef="U_iso4217USD">0</nk:VariableConsiderationRelatedToMilestonePayment>
  <us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized id="F_000540" contextRef="C_0001326110_20190101_20191231" decimals="-6" unitRef="U_iso4217USD">0</us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized>
  <nk:NumberOfProductsApprovedForCommercialSale id="F_000541" contextRef="C_0001326110_20191231" decimals="INF" unitRef="U_nkProduct">0</nk:NumberOfProductsApprovedForCommercialSale>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="F_000542" contextRef="C_0001326110_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20190101_20191231" decimals="INF" unitRef="U_xbrlishares">4506950</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="F_000543" contextRef="C_0001326110_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20180101_20181231" decimals="INF" unitRef="U_xbrlishares">6493250</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="F_000544" contextRef="C_0001326110_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20170101_20171231" decimals="INF" unitRef="U_xbrlishares">5693250</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="F_000545" contextRef="C_0001326110_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapRestrictedStockUnitsRSUMember_20190101_20191231" decimals="INF" unitRef="U_xbrlishares">1139428</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="F_000546" contextRef="C_0001326110_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapRestrictedStockUnitsRSUMember_20180101_20181231" decimals="INF" unitRef="U_xbrlishares">867911</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="F_000547" contextRef="C_0001326110_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapRestrictedStockUnitsRSUMember_20170101_20171231" decimals="INF" unitRef="U_xbrlishares">888189</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="F_000548" contextRef="C_0001326110_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapWarrantMember_20190101_20191231" decimals="INF" unitRef="U_xbrlishares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="F_000549" contextRef="C_0001326110_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapWarrantMember_20180101_20181231" decimals="INF" unitRef="U_xbrlishares">17589250</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="F_000550" contextRef="C_0001326110_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapWarrantMember_20170101_20171231" decimals="INF" unitRef="U_xbrlishares">17721088</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="F_000551" contextRef="C_0001326110_20190101_20191231" decimals="INF" unitRef="U_xbrlishares">5646378</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="F_000552" contextRef="C_0001326110_20180101_20181231" decimals="INF" unitRef="U_xbrlishares">24950411</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="F_000553" contextRef="C_0001326110_20170101_20171231" decimals="INF" unitRef="U_xbrlishares">24302527</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:OperatingLeaseRightOfUseAsset id="F_000554" contextRef="C_0001326110_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201602Member_20190101" decimals="-5" unitRef="U_iso4217USD">13500000</us-gaap:OperatingLeaseRightOfUseAsset>
  <us-gaap:OperatingLeaseLiability id="F_000555" contextRef="C_0001326110_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201602Member_20190101" decimals="-5" unitRef="U_iso4217USD">16400000</us-gaap:OperatingLeaseLiability>
  <us-gaap:PropertyPlantAndEquipmentNet id="F_000556" contextRef="C_0001326110_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201602Member_us-gaapInitialApplicationPeriodCumulativeEffectTransitionAxis_nkDifferenceBetweenLeaseGuidanceInEffectBeforeAndAfterTopic842Member_20190101" decimals="-5" unitRef="U_iso4217USD">-6600000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:Liabilities id="F_000557" contextRef="C_0001326110_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201602Member_us-gaapInitialApplicationPeriodCumulativeEffectTransitionAxis_nkDifferenceBetweenLeaseGuidanceInEffectBeforeAndAfterTopic842Member_20190101" decimals="-5" unitRef="U_iso4217USD">-5700000</us-gaap:Liabilities>
  <us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption id="F_000558" contextRef="C_0001326110_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201602Member_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20190101" decimals="-5" unitRef="U_iso4217USD">-900000</us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption>
  <nk:PrepaidPreclinicalAndClinicalTrialServicesWithRelatedParty id="F_000559" contextRef="C_0001326110_20191231" decimals="-3" unitRef="U_iso4217USD">1021000</nk:PrepaidPreclinicalAndClinicalTrialServicesWithRelatedParty>
  <nk:PrepaidPreclinicalAndClinicalTrialServicesWithRelatedParty id="F_000560" contextRef="C_0001326110_20181231" decimals="-3" unitRef="U_iso4217USD">0</nk:PrepaidPreclinicalAndClinicalTrialServicesWithRelatedParty>
  <nk:InsurancePremiumFinancingAsset id="F_000561" contextRef="C_0001326110_20191231" decimals="-3" unitRef="U_iso4217USD">757000</nk:InsurancePremiumFinancingAsset>
  <nk:InsurancePremiumFinancingAsset id="F_000562" contextRef="C_0001326110_20181231" decimals="-3" unitRef="U_iso4217USD">339000</nk:InsurancePremiumFinancingAsset>
  <nk:PrepaidSuppliesWithRelatedParty id="F_000563" contextRef="C_0001326110_20191231" decimals="-3" unitRef="U_iso4217USD">467000</nk:PrepaidSuppliesWithRelatedParty>
  <nk:PrepaidSuppliesWithRelatedParty id="F_000564" contextRef="C_0001326110_20181231" decimals="-3" unitRef="U_iso4217USD">532000</nk:PrepaidSuppliesWithRelatedParty>
  <nk:PrepaidServices id="F_000565" contextRef="C_0001326110_20191231" decimals="-3" unitRef="U_iso4217USD">440000</nk:PrepaidServices>
  <nk:PrepaidServices id="F_000566" contextRef="C_0001326110_20181231" decimals="-3" unitRef="U_iso4217USD">230000</nk:PrepaidServices>
  <us-gaap:PrepaidRent id="F_000567" contextRef="C_0001326110_20191231" decimals="-3" unitRef="U_iso4217USD">392000</us-gaap:PrepaidRent>
  <us-gaap:PrepaidRent id="F_000568" contextRef="C_0001326110_20181231" decimals="-3" unitRef="U_iso4217USD">536000</us-gaap:PrepaidRent>
  <us-gaap:PrepaidInsurance id="F_000569" contextRef="C_0001326110_20191231" decimals="-3" unitRef="U_iso4217USD">372000</us-gaap:PrepaidInsurance>
  <us-gaap:PrepaidInsurance id="F_000570" contextRef="C_0001326110_20181231" decimals="-3" unitRef="U_iso4217USD">343000</us-gaap:PrepaidInsurance>
  <nk:PrepaidEquipmentMaintenance id="F_000571" contextRef="C_0001326110_20191231" decimals="-3" unitRef="U_iso4217USD">251000</nk:PrepaidEquipmentMaintenance>
  <nk:PrepaidEquipmentMaintenance id="F_000572" contextRef="C_0001326110_20181231" decimals="-3" unitRef="U_iso4217USD">329000</nk:PrepaidEquipmentMaintenance>
  <us-gaap:InterestReceivableCurrent id="F_000573" contextRef="C_0001326110_20191231" decimals="-3" unitRef="U_iso4217USD">222000</us-gaap:InterestReceivableCurrent>
  <us-gaap:InterestReceivableCurrent id="F_000574" contextRef="C_0001326110_20181231" decimals="-3" unitRef="U_iso4217USD">473000</us-gaap:InterestReceivableCurrent>
  <nk:PrepaidLicenseFees id="F_000575" contextRef="C_0001326110_20191231" decimals="-3" unitRef="U_iso4217USD">78000</nk:PrepaidLicenseFees>
  <nk:PrepaidLicenseFees id="F_000576" contextRef="C_0001326110_20181231" decimals="-3" unitRef="U_iso4217USD">104000</nk:PrepaidLicenseFees>
  <us-gaap:InsuranceSettlementsReceivableCurrent id="F_000577" contextRef="C_0001326110_20191231" decimals="-3" unitRef="U_iso4217USD">34000</us-gaap:InsuranceSettlementsReceivableCurrent>
  <us-gaap:InsuranceSettlementsReceivableCurrent id="F_000578" contextRef="C_0001326110_20181231" decimals="-3" unitRef="U_iso4217USD">10882000</us-gaap:InsuranceSettlementsReceivableCurrent>
  <us-gaap:DueFromRelatedPartiesCurrent id="F_000579" contextRef="C_0001326110_20191231" decimals="-3" unitRef="U_iso4217USD">47000</us-gaap:DueFromRelatedPartiesCurrent>
  <us-gaap:DueFromRelatedPartiesCurrent id="F_000580" contextRef="C_0001326110_20181231" decimals="-3" unitRef="U_iso4217USD">90000</us-gaap:DueFromRelatedPartiesCurrent>
  <us-gaap:OtherAssetsCurrent id="F_000581" contextRef="C_0001326110_20191231" decimals="-3" unitRef="U_iso4217USD">24000</us-gaap:OtherAssetsCurrent>
  <us-gaap:OtherAssetsCurrent id="F_000582" contextRef="C_0001326110_20181231" decimals="-3" unitRef="U_iso4217USD">42000</us-gaap:OtherAssetsCurrent>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000583" contextRef="C_0001326110_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapConstructionInProgressMember_20191231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000584" contextRef="C_0001326110_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapConstructionInProgressMember_20181231" decimals="-3" unitRef="U_iso4217USD">2480000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000585" contextRef="C_0001326110_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20191231" decimals="-3" unitRef="U_iso4217USD">33406000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000586" contextRef="C_0001326110_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20181231" decimals="-3" unitRef="U_iso4217USD">4087000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000587" contextRef="C_0001326110_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapBuildingMember_20191231" decimals="-3" unitRef="U_iso4217USD">22690000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000588" contextRef="C_0001326110_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapBuildingMember_20181231" decimals="-3" unitRef="U_iso4217USD">59356000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000589" contextRef="C_0001326110_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapEquipmentMember_20191231" decimals="-3" unitRef="U_iso4217USD">21434000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000590" contextRef="C_0001326110_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapEquipmentMember_20181231" decimals="-3" unitRef="U_iso4217USD">20878000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000591" contextRef="C_0001326110_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapSoftwareAndSoftwareDevelopmentCostsMember_20191231" decimals="-3" unitRef="U_iso4217USD">1195000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000592" contextRef="C_0001326110_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapSoftwareAndSoftwareDevelopmentCostsMember_20181231" decimals="-3" unitRef="U_iso4217USD">1264000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000593" contextRef="C_0001326110_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20191231" decimals="-3" unitRef="U_iso4217USD">383000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000594" contextRef="C_0001326110_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20181231" decimals="-3" unitRef="U_iso4217USD">381000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000595" contextRef="C_0001326110_20191231" decimals="-3" unitRef="U_iso4217USD">79108000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000596" contextRef="C_0001326110_20181231" decimals="-3" unitRef="U_iso4217USD">88446000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment id="F_000597" contextRef="C_0001326110_20191231" decimals="-3" unitRef="U_iso4217USD">18607000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
  <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment id="F_000598" contextRef="C_0001326110_20181231" decimals="-3" unitRef="U_iso4217USD">11561000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
  <us-gaap:Depreciation id="F_000599" contextRef="C_0001326110_20190101_20191231" decimals="-5" unitRef="U_iso4217USD">8400000</us-gaap:Depreciation>
  <us-gaap:Depreciation id="F_000600" contextRef="C_0001326110_20180101_20181231" decimals="-5" unitRef="U_iso4217USD">7300000</us-gaap:Depreciation>
  <us-gaap:Depreciation id="F_000601" contextRef="C_0001326110_20170101_20171231" decimals="-5" unitRef="U_iso4217USD">3300000</us-gaap:Depreciation>
  <nk:LesseseOperatingLeaseReclassificationOfAssetsFromBuildingsToLeaseholdImprovements id="F_000602" contextRef="C_0001326110_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201602Member_20191231" decimals="-5" unitRef="U_iso4217USD">32000000</nk:LesseseOperatingLeaseReclassificationOfAssetsFromBuildingsToLeaseholdImprovements>
  <nk:DerecognizedBuildToSuitLeaseAssets id="F_000603" contextRef="C_0001326110_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201602Member_20191231" decimals="-5" unitRef="U_iso4217USD">6600000</nk:DerecognizedBuildToSuitLeaseAssets>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000604" contextRef="C_0001326110_srtRestatementAxis_srtRestatementAdjustmentMember_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201602Member_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20190101" decimals="-3" unitRef="U_iso4217USD">32014000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000605" contextRef="C_0001326110_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201602Member_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20190101" decimals="-3" unitRef="U_iso4217USD">36101000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000606" contextRef="C_0001326110_srtRestatementAxis_srtRestatementAdjustmentMember_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201602Member_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapBuildingMember_20190101" decimals="-3" unitRef="U_iso4217USD">-39893000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000607" contextRef="C_0001326110_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201602Member_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapBuildingMember_20190101" decimals="-3" unitRef="U_iso4217USD">19463000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000608" contextRef="C_0001326110_srtRestatementAxis_srtRestatementAdjustmentMember_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201602Member_20190101" decimals="-3" unitRef="U_iso4217USD">-7879000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000609" contextRef="C_0001326110_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201602Member_20190101" decimals="-3" unitRef="U_iso4217USD">80567000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment id="F_000610" contextRef="C_0001326110_srtRestatementAxis_srtRestatementAdjustmentMember_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201602Member_20190101" decimals="-3" unitRef="U_iso4217USD">-1293000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
  <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment id="F_000611" contextRef="C_0001326110_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201602Member_20190101" decimals="-3" unitRef="U_iso4217USD">10268000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
  <us-gaap:PropertyPlantAndEquipmentNet id="F_000612" contextRef="C_0001326110_srtRestatementAxis_srtRestatementAdjustmentMember_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201602Member_20190101" decimals="-3" unitRef="U_iso4217USD">-6586000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:PropertyPlantAndEquipmentNet id="F_000613" contextRef="C_0001326110_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201602Member_20190101" decimals="-3" unitRef="U_iso4217USD">70299000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:FiniteLivedIntangibleAssetsGross id="F_000614" contextRef="C_0001326110_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_nkTechnologyLicenseMember_20191231" decimals="-3" unitRef="U_iso4217USD">9042000</us-gaap:FiniteLivedIntangibleAssetsGross>
  <us-gaap:FiniteLivedIntangibleAssetsGross id="F_000615" contextRef="C_0001326110_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_nkTechnologyLicenseMember_20181231" decimals="-3" unitRef="U_iso4217USD">9042000</us-gaap:FiniteLivedIntangibleAssetsGross>
  <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization id="F_000616" contextRef="C_0001326110_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_nkTechnologyLicenseMember_20191231" decimals="-3" unitRef="U_iso4217USD">9042000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
  <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization id="F_000617" contextRef="C_0001326110_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_nkTechnologyLicenseMember_20181231" decimals="-3" unitRef="U_iso4217USD">8477000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
  <us-gaap:IntangibleAssetsNetExcludingGoodwill id="F_000618" contextRef="C_0001326110_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_nkTechnologyLicenseMember_20191231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:IntangibleAssetsNetExcludingGoodwill>
  <us-gaap:IntangibleAssetsNetExcludingGoodwill id="F_000619" contextRef="C_0001326110_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_nkTechnologyLicenseMember_20181231" decimals="-3" unitRef="U_iso4217USD">565000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
  <us-gaap:AmortizationOfIntangibleAssets id="F_000620" contextRef="C_0001326110_20190101_20191231" decimals="-5" unitRef="U_iso4217USD">600000</us-gaap:AmortizationOfIntangibleAssets>
  <us-gaap:AmortizationOfIntangibleAssets id="F_000621" contextRef="C_0001326110_20180101_20181231" decimals="-5" unitRef="U_iso4217USD">2300000</us-gaap:AmortizationOfIntangibleAssets>
  <us-gaap:AmortizationOfIntangibleAssets id="F_000622" contextRef="C_0001326110_20170101_20171231" decimals="-5" unitRef="U_iso4217USD">2300000</us-gaap:AmortizationOfIntangibleAssets>
  <nk:PrepaidPreclinicalAndClinicalTrialServicesWithRelatedPartyInOtherAssets id="F_000623" contextRef="C_0001326110_20191231" decimals="-3" unitRef="U_iso4217USD">4075000</nk:PrepaidPreclinicalAndClinicalTrialServicesWithRelatedPartyInOtherAssets>
  <nk:PrepaidPreclinicalAndClinicalTrialServicesWithRelatedPartyInOtherAssets id="F_000624" contextRef="C_0001326110_20181231" decimals="-3" unitRef="U_iso4217USD">0</nk:PrepaidPreclinicalAndClinicalTrialServicesWithRelatedPartyInOtherAssets>
  <us-gaap:SecurityDeposit id="F_000625" contextRef="C_0001326110_20191231" decimals="-3" unitRef="U_iso4217USD">113000</us-gaap:SecurityDeposit>
  <us-gaap:SecurityDeposit id="F_000626" contextRef="C_0001326110_20181231" decimals="-3" unitRef="U_iso4217USD">113000</us-gaap:SecurityDeposit>
  <us-gaap:PrepaidExpenseNoncurrent id="F_000627" contextRef="C_0001326110_20191231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:PrepaidExpenseNoncurrent>
  <us-gaap:PrepaidExpenseNoncurrent id="F_000628" contextRef="C_0001326110_20181231" decimals="-3" unitRef="U_iso4217USD">1205000</us-gaap:PrepaidExpenseNoncurrent>
  <us-gaap:OtherAssetsMiscellaneousNoncurrent id="F_000629" contextRef="C_0001326110_20191231" decimals="-3" unitRef="U_iso4217USD">19000</us-gaap:OtherAssetsMiscellaneousNoncurrent>
  <us-gaap:OtherAssetsMiscellaneousNoncurrent id="F_000630" contextRef="C_0001326110_20181231" decimals="-3" unitRef="U_iso4217USD">30000</us-gaap:OtherAssetsMiscellaneousNoncurrent>
  <us-gaap:AccruedBonusesCurrent id="F_000631" contextRef="C_0001326110_20191231" decimals="-3" unitRef="U_iso4217USD">2002000</us-gaap:AccruedBonusesCurrent>
  <us-gaap:AccruedBonusesCurrent id="F_000632" contextRef="C_0001326110_20181231" decimals="-3" unitRef="U_iso4217USD">2079000</us-gaap:AccruedBonusesCurrent>
  <us-gaap:AccruedSalariesCurrent id="F_000633" contextRef="C_0001326110_20191231" decimals="-3" unitRef="U_iso4217USD">1064000</us-gaap:AccruedSalariesCurrent>
  <us-gaap:AccruedSalariesCurrent id="F_000634" contextRef="C_0001326110_20181231" decimals="-3" unitRef="U_iso4217USD">943000</us-gaap:AccruedSalariesCurrent>
  <us-gaap:AccruedProfessionalFeesCurrent id="F_000635" contextRef="C_0001326110_20191231" decimals="-3" unitRef="U_iso4217USD">975000</us-gaap:AccruedProfessionalFeesCurrent>
  <us-gaap:AccruedProfessionalFeesCurrent id="F_000636" contextRef="C_0001326110_20181231" decimals="-3" unitRef="U_iso4217USD">912000</us-gaap:AccruedProfessionalFeesCurrent>
  <nk:AccruedLaboratoryEquipmentAndSupplies id="F_000637" contextRef="C_0001326110_20191231" decimals="-3" unitRef="U_iso4217USD">640000</nk:AccruedLaboratoryEquipmentAndSupplies>
  <nk:AccruedLaboratoryEquipmentAndSupplies id="F_000638" contextRef="C_0001326110_20181231" decimals="-3" unitRef="U_iso4217USD">678000</nk:AccruedLaboratoryEquipmentAndSupplies>
  <nk:AccruedPreclinicalAndClinicalTrialCosts id="F_000639" contextRef="C_0001326110_20191231" decimals="-3" unitRef="U_iso4217USD">281000</nk:AccruedPreclinicalAndClinicalTrialCosts>
  <nk:AccruedPreclinicalAndClinicalTrialCosts id="F_000640" contextRef="C_0001326110_20181231" decimals="-3" unitRef="U_iso4217USD">704000</nk:AccruedPreclinicalAndClinicalTrialCosts>
  <nk:AccruedFranchiseSalesUseAndPropertyTaxes id="F_000641" contextRef="C_0001326110_20191231" decimals="-3" unitRef="U_iso4217USD">200000</nk:AccruedFranchiseSalesUseAndPropertyTaxes>
  <nk:AccruedFranchiseSalesUseAndPropertyTaxes id="F_000642" contextRef="C_0001326110_20181231" decimals="-3" unitRef="U_iso4217USD">250000</nk:AccruedFranchiseSalesUseAndPropertyTaxes>
  <us-gaap:LitigationReserveCurrent id="F_000643" contextRef="C_0001326110_20191231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:LitigationReserveCurrent>
  <us-gaap:LitigationReserveCurrent id="F_000644" contextRef="C_0001326110_20181231" decimals="-3" unitRef="U_iso4217USD">12000000</us-gaap:LitigationReserveCurrent>
  <us-gaap:ConstructionPayableCurrent id="F_000645" contextRef="C_0001326110_20191231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:ConstructionPayableCurrent>
  <us-gaap:ConstructionPayableCurrent id="F_000646" contextRef="C_0001326110_20181231" decimals="-3" unitRef="U_iso4217USD">3341000</us-gaap:ConstructionPayableCurrent>
  <us-gaap:OtherAccruedLiabilitiesCurrent id="F_000647" contextRef="C_0001326110_20191231" decimals="-3" unitRef="U_iso4217USD">181000</us-gaap:OtherAccruedLiabilitiesCurrent>
  <us-gaap:OtherAccruedLiabilitiesCurrent id="F_000648" contextRef="C_0001326110_20181231" decimals="-3" unitRef="U_iso4217USD">197000</us-gaap:OtherAccruedLiabilitiesCurrent>
  <us-gaap:OperatingLeaseLiabilityCurrent id="F_000649" contextRef="C_0001326110_20191231" decimals="-3" unitRef="U_iso4217USD">3206000</us-gaap:OperatingLeaseLiabilityCurrent>
  <us-gaap:OperatingLeaseLiabilityCurrent id="F_000650" contextRef="C_0001326110_20181231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:OperatingLeaseLiabilityCurrent>
  <nk:FinancingObligationCurrent id="F_000651" contextRef="C_0001326110_20191231" decimals="-3" unitRef="U_iso4217USD">757000</nk:FinancingObligationCurrent>
  <nk:FinancingObligationCurrent id="F_000652" contextRef="C_0001326110_20181231" decimals="-3" unitRef="U_iso4217USD">965000</nk:FinancingObligationCurrent>
  <us-gaap:DeferredRentCreditCurrent id="F_000653" contextRef="C_0001326110_20191231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:DeferredRentCreditCurrent>
  <us-gaap:DeferredRentCreditCurrent id="F_000654" contextRef="C_0001326110_20181231" decimals="-3" unitRef="U_iso4217USD">598000</us-gaap:DeferredRentCreditCurrent>
  <us-gaap:OtherSundryLiabilitiesCurrent id="F_000655" contextRef="C_0001326110_20191231" decimals="-3" unitRef="U_iso4217USD">18000</us-gaap:OtherSundryLiabilitiesCurrent>
  <us-gaap:OtherSundryLiabilitiesCurrent id="F_000656" contextRef="C_0001326110_20181231" decimals="-3" unitRef="U_iso4217USD">104000</us-gaap:OtherSundryLiabilitiesCurrent>
  <us-gaap:InvestmentIncomeInterest id="F_000657" contextRef="C_0001326110_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">1643000</us-gaap:InvestmentIncomeInterest>
  <us-gaap:InvestmentIncomeInterest id="F_000658" contextRef="C_0001326110_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">2317000</us-gaap:InvestmentIncomeInterest>
  <us-gaap:InvestmentIncomeInterest id="F_000659" contextRef="C_0001326110_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">4225000</us-gaap:InvestmentIncomeInterest>
  <us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium id="F_000660" contextRef="C_0001326110_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">3000</us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium>
  <us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium id="F_000661" contextRef="C_0001326110_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">-463000</us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium>
  <us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium id="F_000662" contextRef="C_0001326110_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">-1597000</us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium>
  <us-gaap:RealizedInvestmentGainsLosses id="F_000663" contextRef="C_0001326110_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-4000</us-gaap:RealizedInvestmentGainsLosses>
  <us-gaap:RealizedInvestmentGainsLosses id="F_000664" contextRef="C_0001326110_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">3000</us-gaap:RealizedInvestmentGainsLosses>
  <us-gaap:RealizedInvestmentGainsLosses id="F_000665" contextRef="C_0001326110_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">37000</us-gaap:RealizedInvestmentGainsLosses>
  <us-gaap:ImpairmentOfInvestments id="F_000666" contextRef="C_0001326110_20190101_20191231" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:ImpairmentOfInvestments>
  <us-gaap:ImpairmentOfInvestments id="F_000667" contextRef="C_0001326110_20180101_20181231" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:ImpairmentOfInvestments>
  <us-gaap:ImpairmentOfInvestments id="F_000668" contextRef="C_0001326110_20170101_20171231" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:ImpairmentOfInvestments>
  <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount id="F_000669" contextRef="C_0001326110_20170331" decimals="-5" unitRef="U_iso4217USD">8500000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount>
  <nk:PurchaseOfConvertibleNoteUponConversion id="F_000670" contextRef="C_0001326110_us-gaapDebtInstrumentAxis_nkTwoThousandAndEighteenNoteAndWarrantPurchaseAgreementMember_20180601_20180630" decimals="-5" unitRef="U_iso4217USD">400000</nk:PurchaseOfConvertibleNoteUponConversion>
  <nk:PurchaseOfConvertibleNoteUponConversion id="F_000671" contextRef="C_0001326110_us-gaapDebtInstrumentAxis_nkTwoThousandAndEighteenNoteAndWarrantPurchaseAgreementMember_20180901_20180930" decimals="-5" unitRef="U_iso4217USD">400000</nk:PurchaseOfConvertibleNoteUponConversion>
  <us-gaap:DebtInstrumentInterestRateEffectivePercentage id="F_000672" contextRef="C_0001326110_us-gaapDebtInstrumentAxis_nkTwoThousandAndEighteenNoteAndWarrantPurchaseAgreementMember_20180630" decimals="2" unitRef="U_xbrlipure">0.08</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
  <us-gaap:DebtInstrumentInterestRateEffectivePercentage id="F_000673" contextRef="C_0001326110_us-gaapDebtInstrumentAxis_nkTwoThousandAndEighteenNoteAndWarrantPurchaseAgreementMember_20180930" decimals="2" unitRef="U_xbrlipure">0.08</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
  <us-gaap:DebtInstrumentTerm id="F_000674" contextRef="C_0001326110_us-gaapDebtInstrumentAxis_nkTwoThousandAndEighteenNoteAndWarrantPurchaseAgreementMember_20180601_20180630">P1Y</us-gaap:DebtInstrumentTerm>
  <us-gaap:DebtInstrumentTerm id="F_000675" contextRef="C_0001326110_us-gaapDebtInstrumentAxis_nkTwoThousandAndEighteenNoteAndWarrantPurchaseAgreementMember_20180901_20180930">P1Y</us-gaap:DebtInstrumentTerm>
  <us-gaap:PreferredStockValue id="F_000676" contextRef="C_0001326110_us-gaapDebtInstrumentAxis_nkTwoThousandAndEighteenNoteAndWarrantPurchaseAgreementMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20190131" decimals="-5" unitRef="U_iso4217USD">800000</us-gaap:PreferredStockValue>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights id="F_000677" contextRef="C_0001326110_us-gaapDebtInstrumentAxis_nkTwoThousandAndEighteenNoteAndWarrantPurchaseAgreementMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190531" decimals="INF" unitRef="U_xbrlishares">253120</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount id="F_000678" contextRef="C_0001326110_us-gaapDebtInstrumentAxis_nkTwoThousandAndEighteenNoteAndWarrantPurchaseAgreementMember_20191231" decimals="-5" unitRef="U_iso4217USD">9300000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount>
  <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis id="F_000679" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_nkCurrentAssetsMember_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_20191231" decimals="-3" unitRef="U_iso4217USD">32382000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
  <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis id="F_000680" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_nkCurrentAssetsMember_us-gaapInvestmentTypeAxis_us-gaapForeignGovernmentDebtMember_20191231" decimals="-3" unitRef="U_iso4217USD">1007000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
  <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis id="F_000681" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_nkCurrentAssetsMember_us-gaapUnderlyingAssetClassAxis_us-gaapAgencySecuritiesMember_20191231" decimals="-3" unitRef="U_iso4217USD">2752000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
  <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis id="F_000682" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_nkCurrentAssetsMember_20191231" decimals="-3" unitRef="U_iso4217USD">36141000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
  <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis id="F_000683" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_nkNoncurrentAssetsMember_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_20191231" decimals="-3" unitRef="U_iso4217USD">1501000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
  <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis id="F_000684" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_nkNoncurrentAssetsMember_20191231" decimals="-3" unitRef="U_iso4217USD">1501000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
  <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis id="F_000685" contextRef="C_0001326110_20191231" decimals="-3" unitRef="U_iso4217USD">37642000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
  <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax id="F_000686" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_nkCurrentAssetsMember_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_20191231" decimals="-3" unitRef="U_iso4217USD">10000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
  <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax id="F_000687" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_nkCurrentAssetsMember_us-gaapInvestmentTypeAxis_us-gaapForeignGovernmentDebtMember_20191231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
  <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax id="F_000688" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_nkCurrentAssetsMember_us-gaapUnderlyingAssetClassAxis_us-gaapAgencySecuritiesMember_20191231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
  <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax id="F_000689" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_nkCurrentAssetsMember_20191231" decimals="-3" unitRef="U_iso4217USD">10000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
  <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax id="F_000690" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_nkNoncurrentAssetsMember_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_20191231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
  <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax id="F_000691" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_nkNoncurrentAssetsMember_20191231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
  <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax id="F_000692" contextRef="C_0001326110_20191231" decimals="-3" unitRef="U_iso4217USD">10000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
  <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax id="F_000693" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_nkCurrentAssetsMember_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_20191231" decimals="-3" unitRef="U_iso4217USD">3000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
  <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax id="F_000694" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_nkCurrentAssetsMember_us-gaapInvestmentTypeAxis_us-gaapForeignGovernmentDebtMember_20191231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
  <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax id="F_000695" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_nkCurrentAssetsMember_us-gaapUnderlyingAssetClassAxis_us-gaapAgencySecuritiesMember_20191231" decimals="-3" unitRef="U_iso4217USD">4000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
  <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax id="F_000696" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_nkCurrentAssetsMember_20191231" decimals="-3" unitRef="U_iso4217USD">7000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
  <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax id="F_000697" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_nkNoncurrentAssetsMember_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_20191231" decimals="-3" unitRef="U_iso4217USD">4000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
  <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax id="F_000698" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_nkNoncurrentAssetsMember_20191231" decimals="-3" unitRef="U_iso4217USD">4000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
  <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax id="F_000699" contextRef="C_0001326110_20191231" decimals="-3" unitRef="U_iso4217USD">11000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
  <us-gaap:AvailableForSaleSecuritiesDebtSecurities id="F_000700" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_nkCurrentAssetsMember_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_20191231" decimals="-3" unitRef="U_iso4217USD">32389000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
  <us-gaap:AvailableForSaleSecuritiesDebtSecurities id="F_000701" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_nkCurrentAssetsMember_us-gaapInvestmentTypeAxis_us-gaapForeignGovernmentDebtMember_20191231" decimals="-3" unitRef="U_iso4217USD">1007000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
  <us-gaap:AvailableForSaleSecuritiesDebtSecurities id="F_000702" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_nkCurrentAssetsMember_us-gaapUnderlyingAssetClassAxis_us-gaapAgencySecuritiesMember_20191231" decimals="-3" unitRef="U_iso4217USD">2748000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
  <us-gaap:AvailableForSaleSecuritiesDebtSecurities id="F_000703" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_nkCurrentAssetsMember_20191231" decimals="-3" unitRef="U_iso4217USD">36144000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
  <us-gaap:AvailableForSaleSecuritiesDebtSecurities id="F_000704" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_nkNoncurrentAssetsMember_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_20191231" decimals="-3" unitRef="U_iso4217USD">1497000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
  <us-gaap:AvailableForSaleSecuritiesDebtSecurities id="F_000705" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_nkNoncurrentAssetsMember_20191231" decimals="-3" unitRef="U_iso4217USD">1497000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
  <us-gaap:AvailableForSaleSecuritiesDebtSecurities id="F_000706" contextRef="C_0001326110_20191231" decimals="-3" unitRef="U_iso4217USD">37641000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
  <nk:AvailableForSaleSecuritiesDebtSecuritiesPeriod id="F_000707" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_nkCurrentAssetsMember_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_20190101_20191231">P2M12D</nk:AvailableForSaleSecuritiesDebtSecuritiesPeriod>
  <nk:AvailableForSaleSecuritiesDebtSecuritiesPeriod id="F_000708" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_nkCurrentAssetsMember_us-gaapInvestmentTypeAxis_us-gaapForeignGovernmentDebtMember_20190101_20191231">P3M18D</nk:AvailableForSaleSecuritiesDebtSecuritiesPeriod>
  <nk:AvailableForSaleSecuritiesDebtSecuritiesPeriod id="F_000709" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_nkCurrentAssetsMember_us-gaapUnderlyingAssetClassAxis_us-gaapAgencySecuritiesMember_20190101_20191231">P6M</nk:AvailableForSaleSecuritiesDebtSecuritiesPeriod>
  <nk:AvailableForSaleSecuritiesDebtSecuritiesPeriod id="F_000710" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_nkCurrentAssetsMember_20190101_20191231">P2M12D</nk:AvailableForSaleSecuritiesDebtSecuritiesPeriod>
  <nk:AvailableForSaleSecuritiesDebtSecuritiesPeriod id="F_000711" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_nkNoncurrentAssetsMember_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_20190101_20191231">P1Y8M12D</nk:AvailableForSaleSecuritiesDebtSecuritiesPeriod>
  <nk:AvailableForSaleSecuritiesDebtSecuritiesPeriod id="F_000712" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_nkNoncurrentAssetsMember_20190101_20191231">P1Y8M12D</nk:AvailableForSaleSecuritiesDebtSecuritiesPeriod>
  <nk:AvailableForSaleSecuritiesDebtSecuritiesPeriod id="F_000713" contextRef="C_0001326110_20190101_20191231">P3M18D</nk:AvailableForSaleSecuritiesDebtSecuritiesPeriod>
  <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis id="F_000714" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_nkCurrentAssetsMember_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_20181231" decimals="-3" unitRef="U_iso4217USD">57463000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
  <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis id="F_000715" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_nkCurrentAssetsMember_20181231" decimals="-3" unitRef="U_iso4217USD">57463000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
  <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis id="F_000716" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_nkNoncurrentAssetsMember_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_20181231" decimals="-3" unitRef="U_iso4217USD">3067000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
  <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis id="F_000717" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_nkNoncurrentAssetsMember_us-gaapUnderlyingAssetClassAxis_us-gaapAgencySecuritiesMember_20181231" decimals="-3" unitRef="U_iso4217USD">2756000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
  <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis id="F_000718" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_nkNoncurrentAssetsMember_20181231" decimals="-3" unitRef="U_iso4217USD">5823000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
  <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax id="F_000719" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_nkCurrentAssetsMember_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_20181231" decimals="-3" unitRef="U_iso4217USD">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
  <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax id="F_000720" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_nkCurrentAssetsMember_20181231" decimals="-3" unitRef="U_iso4217USD">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
  <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax id="F_000721" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_nkNoncurrentAssetsMember_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_20181231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
  <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax id="F_000722" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_nkNoncurrentAssetsMember_us-gaapUnderlyingAssetClassAxis_us-gaapAgencySecuritiesMember_20181231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
  <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax id="F_000723" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_nkNoncurrentAssetsMember_20181231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
  <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax id="F_000724" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_nkCurrentAssetsMember_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_20181231" decimals="-3" unitRef="U_iso4217USD">136000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
  <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax id="F_000725" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_nkCurrentAssetsMember_20181231" decimals="-3" unitRef="U_iso4217USD">136000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
  <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax id="F_000726" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_nkNoncurrentAssetsMember_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_20181231" decimals="-3" unitRef="U_iso4217USD">76000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
  <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax id="F_000727" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_nkNoncurrentAssetsMember_us-gaapUnderlyingAssetClassAxis_us-gaapAgencySecuritiesMember_20181231" decimals="-3" unitRef="U_iso4217USD">46000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
  <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax id="F_000728" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_nkNoncurrentAssetsMember_20181231" decimals="-3" unitRef="U_iso4217USD">122000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
  <us-gaap:AvailableForSaleSecuritiesDebtSecurities id="F_000729" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_nkCurrentAssetsMember_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_20181231" decimals="-3" unitRef="U_iso4217USD">57328000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
  <us-gaap:AvailableForSaleSecuritiesDebtSecurities id="F_000730" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_nkCurrentAssetsMember_20181231" decimals="-3" unitRef="U_iso4217USD">57328000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
  <us-gaap:AvailableForSaleSecuritiesDebtSecurities id="F_000731" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_nkNoncurrentAssetsMember_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_20181231" decimals="-3" unitRef="U_iso4217USD">2991000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
  <us-gaap:AvailableForSaleSecuritiesDebtSecurities id="F_000732" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_nkNoncurrentAssetsMember_us-gaapUnderlyingAssetClassAxis_us-gaapAgencySecuritiesMember_20181231" decimals="-3" unitRef="U_iso4217USD">2710000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
  <us-gaap:AvailableForSaleSecuritiesDebtSecurities id="F_000733" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_nkNoncurrentAssetsMember_20181231" decimals="-3" unitRef="U_iso4217USD">5701000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
  <us-gaap:HeldToMaturitySecurities id="F_000734" contextRef="C_0001326110_us-gaapFairValueByAssetClassAxis_us-gaapNotesReceivableMember_20181231" decimals="-3" unitRef="U_iso4217USD">723000</us-gaap:HeldToMaturitySecurities>
  <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain id="F_000735" contextRef="C_0001326110_us-gaapFairValueByAssetClassAxis_us-gaapNotesReceivableMember_20181231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain>
  <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss id="F_000736" contextRef="C_0001326110_us-gaapFairValueByAssetClassAxis_us-gaapNotesReceivableMember_20181231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss>
  <us-gaap:HeldToMaturitySecuritiesFairValue id="F_000737" contextRef="C_0001326110_us-gaapFairValueByAssetClassAxis_us-gaapNotesReceivableMember_20181231" decimals="-3" unitRef="U_iso4217USD">723000</us-gaap:HeldToMaturitySecuritiesFairValue>
  <nk:DebtSecuritiesAvailableForSaleAndHeldToMaturityAmortizedCost id="F_000738" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_nkCurrentAssetsMember_20181231" decimals="-3" unitRef="U_iso4217USD">58186000</nk:DebtSecuritiesAvailableForSaleAndHeldToMaturityAmortizedCost>
  <nk:DebtSecuritiesAvailableForSaleAndHeldToMaturityAmortizedCost id="F_000739" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_nkNoncurrentAssetsMember_20181231" decimals="-3" unitRef="U_iso4217USD">64009000</nk:DebtSecuritiesAvailableForSaleAndHeldToMaturityAmortizedCost>
  <nk:DebtSecuritiesAvailableForSaleAndHeldToMaturityAmortizedCostAccumulatedGrossUnrealizedGainBeforeTax id="F_000740" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_nkCurrentAssetsMember_20181231" decimals="-3" unitRef="U_iso4217USD">1000</nk:DebtSecuritiesAvailableForSaleAndHeldToMaturityAmortizedCostAccumulatedGrossUnrealizedGainBeforeTax>
  <nk:DebtSecuritiesAvailableForSaleAndHeldToMaturityAmortizedCostAccumulatedGrossUnrealizedGainBeforeTax id="F_000741" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_nkNoncurrentAssetsMember_20181231" decimals="-3" unitRef="U_iso4217USD">1000</nk:DebtSecuritiesAvailableForSaleAndHeldToMaturityAmortizedCostAccumulatedGrossUnrealizedGainBeforeTax>
  <nk:DebtSecuritiesAvailableForSaleAndHeldToMaturityAmortizedCostAccumulatedGrossUnrealizedLossBeforeTax id="F_000742" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_nkCurrentAssetsMember_20181231" decimals="-3" unitRef="U_iso4217USD">136000</nk:DebtSecuritiesAvailableForSaleAndHeldToMaturityAmortizedCostAccumulatedGrossUnrealizedLossBeforeTax>
  <nk:DebtSecuritiesAvailableForSaleAndHeldToMaturityAmortizedCostAccumulatedGrossUnrealizedLossBeforeTax id="F_000743" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_nkNoncurrentAssetsMember_20181231" decimals="-3" unitRef="U_iso4217USD">258000</nk:DebtSecuritiesAvailableForSaleAndHeldToMaturityAmortizedCostAccumulatedGrossUnrealizedLossBeforeTax>
  <nk:DebtSecuritiesAvailableForSaleAndHeldToMaturityFairValue id="F_000744" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_nkCurrentAssetsMember_20181231" decimals="-3" unitRef="U_iso4217USD">58051000</nk:DebtSecuritiesAvailableForSaleAndHeldToMaturityFairValue>
  <nk:DebtSecuritiesAvailableForSaleAndHeldToMaturityFairValue id="F_000745" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_nkNoncurrentAssetsMember_20181231" decimals="-3" unitRef="U_iso4217USD">63752000</nk:DebtSecuritiesAvailableForSaleAndHeldToMaturityFairValue>
  <nk:AvailableForSaleSecuritiesPeriodOfUnrealizedLossPositions id="F_000746" contextRef="C_0001326110_srtRangeAxis_srtMinimumMember_20190101_20191231">P12M</nk:AvailableForSaleSecuritiesPeriodOfUnrealizedLossPositions>
  <nk:AvailableForSaleSecuritiesPeriodOfUnrealizedLossPositions id="F_000747" contextRef="C_0001326110_srtRangeAxis_srtMaximumMember_20190101_20191231">P12M</nk:AvailableForSaleSecuritiesPeriodOfUnrealizedLossPositions>
  <nk:AvailableForSaleSecuritiesPeriodOfUnrealizedLossPositions id="F_000748" contextRef="C_0001326110_srtRangeAxis_srtMinimumMember_20180101_20181231">P12M</nk:AvailableForSaleSecuritiesPeriodOfUnrealizedLossPositions>
  <nk:AvailableForSaleSecuritiesPeriodOfUnrealizedLossPositions id="F_000749" contextRef="C_0001326110_srtRangeAxis_srtMaximumMember_20180101_20181231">P12M</nk:AvailableForSaleSecuritiesPeriodOfUnrealizedLossPositions>
  <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months id="F_000750" contextRef="C_0001326110_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_20191231" decimals="-3" unitRef="U_iso4217USD">11021000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
  <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months id="F_000751" contextRef="C_0001326110_us-gaapUnderlyingAssetClassAxis_us-gaapAgencySecuritiesMember_20191231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
  <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months id="F_000752" contextRef="C_0001326110_20191231" decimals="-3" unitRef="U_iso4217USD">11021000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
  <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss id="F_000753" contextRef="C_0001326110_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_20191231" decimals="-3" unitRef="U_iso4217USD">3000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
  <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss id="F_000754" contextRef="C_0001326110_us-gaapUnderlyingAssetClassAxis_us-gaapAgencySecuritiesMember_20191231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
  <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss id="F_000755" contextRef="C_0001326110_20191231" decimals="-3" unitRef="U_iso4217USD">3000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
  <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger id="F_000756" contextRef="C_0001326110_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_20191231" decimals="-3" unitRef="U_iso4217USD">1497000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
  <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger id="F_000757" contextRef="C_0001326110_us-gaapUnderlyingAssetClassAxis_us-gaapAgencySecuritiesMember_20191231" decimals="-3" unitRef="U_iso4217USD">2748000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
  <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger id="F_000758" contextRef="C_0001326110_20191231" decimals="-3" unitRef="U_iso4217USD">4245000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
  <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss id="F_000759" contextRef="C_0001326110_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_20191231" decimals="-3" unitRef="U_iso4217USD">4000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
  <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss id="F_000760" contextRef="C_0001326110_us-gaapUnderlyingAssetClassAxis_us-gaapAgencySecuritiesMember_20191231" decimals="-3" unitRef="U_iso4217USD">4000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
  <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss id="F_000761" contextRef="C_0001326110_20191231" decimals="-3" unitRef="U_iso4217USD">8000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
  <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months id="F_000762" contextRef="C_0001326110_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_20181231" decimals="-3" unitRef="U_iso4217USD">32010000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
  <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months id="F_000763" contextRef="C_0001326110_us-gaapUnderlyingAssetClassAxis_us-gaapAgencySecuritiesMember_20181231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
  <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months id="F_000764" contextRef="C_0001326110_20181231" decimals="-3" unitRef="U_iso4217USD">32010000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
  <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss id="F_000765" contextRef="C_0001326110_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_20181231" decimals="-3" unitRef="U_iso4217USD">26000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
  <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss id="F_000766" contextRef="C_0001326110_us-gaapUnderlyingAssetClassAxis_us-gaapAgencySecuritiesMember_20181231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
  <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss id="F_000767" contextRef="C_0001326110_20181231" decimals="-3" unitRef="U_iso4217USD">26000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
  <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger id="F_000768" contextRef="C_0001326110_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_20181231" decimals="-3" unitRef="U_iso4217USD">26663000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
  <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger id="F_000769" contextRef="C_0001326110_us-gaapUnderlyingAssetClassAxis_us-gaapAgencySecuritiesMember_20181231" decimals="-3" unitRef="U_iso4217USD">2710000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
  <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger id="F_000770" contextRef="C_0001326110_20181231" decimals="-3" unitRef="U_iso4217USD">29373000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
  <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss id="F_000771" contextRef="C_0001326110_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_20181231" decimals="-3" unitRef="U_iso4217USD">186000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
  <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss id="F_000772" contextRef="C_0001326110_us-gaapUnderlyingAssetClassAxis_us-gaapAgencySecuritiesMember_20181231" decimals="-3" unitRef="U_iso4217USD">46000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
  <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss id="F_000773" contextRef="C_0001326110_20181231" decimals="-3" unitRef="U_iso4217USD">232000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
  <us-gaap:AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1 id="F_000774" contextRef="C_0001326110_us-gaapFinancialInstrumentAxis_us-gaapDebtSecuritiesMember_20191231" decimals="INF" unitRef="U_nkSecurity">14</us-gaap:AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1>
  <us-gaap:AvailableForSaleSecuritiesGrossRealizedGains id="F_000775" contextRef="C_0001326110_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">4000</us-gaap:AvailableForSaleSecuritiesGrossRealizedGains>
  <us-gaap:AvailableForSaleSecuritiesGrossRealizedGains id="F_000776" contextRef="C_0001326110_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">3000</us-gaap:AvailableForSaleSecuritiesGrossRealizedGains>
  <us-gaap:AvailableForSaleSecuritiesGrossRealizedGains id="F_000777" contextRef="C_0001326110_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">52000</us-gaap:AvailableForSaleSecuritiesGrossRealizedGains>
  <us-gaap:AvailableForSaleSecuritiesGrossRealizedLosses id="F_000778" contextRef="C_0001326110_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">8000</us-gaap:AvailableForSaleSecuritiesGrossRealizedLosses>
  <us-gaap:AvailableForSaleSecuritiesGrossRealizedLosses id="F_000779" contextRef="C_0001326110_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:AvailableForSaleSecuritiesGrossRealizedLosses>
  <us-gaap:AvailableForSaleSecuritiesGrossRealizedLosses id="F_000780" contextRef="C_0001326110_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">15000</us-gaap:AvailableForSaleSecuritiesGrossRealizedLosses>
  <us-gaap:AvailableForSaleSecuritiesGrossRealizedGainLossNet id="F_000781" contextRef="C_0001326110_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-4000</us-gaap:AvailableForSaleSecuritiesGrossRealizedGainLossNet>
  <us-gaap:AvailableForSaleSecuritiesGrossRealizedGainLossNet id="F_000782" contextRef="C_0001326110_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">3000</us-gaap:AvailableForSaleSecuritiesGrossRealizedGainLossNet>
  <us-gaap:AvailableForSaleSecuritiesGrossRealizedGainLossNet id="F_000783" contextRef="C_0001326110_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">37000</us-gaap:AvailableForSaleSecuritiesGrossRealizedGainLossNet>
  <us-gaap:AssetsFairValueDisclosure id="F_000784" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_nkCurrentAssetsMember_us-gaapFairValueByAssetClassAxis_us-gaapCashAndCashEquivalentsMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231" decimals="-3" unitRef="U_iso4217USD">15508000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure id="F_000785" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_nkCurrentAssetsMember_us-gaapFairValueByAssetClassAxis_us-gaapCashAndCashEquivalentsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231" decimals="-3" unitRef="U_iso4217USD">15508000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure id="F_000786" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_nkCurrentAssetsMember_us-gaapFairValueByAssetClassAxis_us-gaapCashAndCashEquivalentsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure id="F_000787" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_nkCurrentAssetsMember_us-gaapFairValueByAssetClassAxis_us-gaapCashAndCashEquivalentsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure id="F_000788" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_nkCurrentAssetsMember_us-gaapFairValueByAssetClassAxis_us-gaapCorporateDebtSecuritiesMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231" decimals="-3" unitRef="U_iso4217USD">32389000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure id="F_000789" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_nkCurrentAssetsMember_us-gaapFairValueByAssetClassAxis_us-gaapCorporateDebtSecuritiesMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure id="F_000790" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_nkCurrentAssetsMember_us-gaapFairValueByAssetClassAxis_us-gaapCorporateDebtSecuritiesMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231" decimals="-3" unitRef="U_iso4217USD">32389000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure id="F_000791" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_nkCurrentAssetsMember_us-gaapFairValueByAssetClassAxis_us-gaapCorporateDebtSecuritiesMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure id="F_000792" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_nkCurrentAssetsMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapForeignGovernmentDebtMember_20191231" decimals="-3" unitRef="U_iso4217USD">1007000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure id="F_000793" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_nkCurrentAssetsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapForeignGovernmentDebtMember_20191231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure id="F_000794" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_nkCurrentAssetsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapForeignGovernmentDebtMember_20191231" decimals="-3" unitRef="U_iso4217USD">1007000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure id="F_000795" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_nkCurrentAssetsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapForeignGovernmentDebtMember_20191231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure id="F_000796" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_nkCurrentAssetsMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapUnderlyingAssetClassAxis_us-gaapAgencySecuritiesMember_20191231" decimals="-3" unitRef="U_iso4217USD">2748000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure id="F_000797" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_nkCurrentAssetsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapUnderlyingAssetClassAxis_us-gaapAgencySecuritiesMember_20191231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure id="F_000798" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_nkCurrentAssetsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapUnderlyingAssetClassAxis_us-gaapAgencySecuritiesMember_20191231" decimals="-3" unitRef="U_iso4217USD">2748000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure id="F_000799" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_nkCurrentAssetsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapUnderlyingAssetClassAxis_us-gaapAgencySecuritiesMember_20191231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure id="F_000800" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_nkNoncurrentAssetsMember_us-gaapFairValueByAssetClassAxis_us-gaapCorporateDebtSecuritiesMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231" decimals="-3" unitRef="U_iso4217USD">1497000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure id="F_000801" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_nkNoncurrentAssetsMember_us-gaapFairValueByAssetClassAxis_us-gaapCorporateDebtSecuritiesMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure id="F_000802" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_nkNoncurrentAssetsMember_us-gaapFairValueByAssetClassAxis_us-gaapCorporateDebtSecuritiesMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231" decimals="-3" unitRef="U_iso4217USD">1497000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure id="F_000803" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_nkNoncurrentAssetsMember_us-gaapFairValueByAssetClassAxis_us-gaapCorporateDebtSecuritiesMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure id="F_000804" contextRef="C_0001326110_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231" decimals="-3" unitRef="U_iso4217USD">53149000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure id="F_000805" contextRef="C_0001326110_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231" decimals="-3" unitRef="U_iso4217USD">15508000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure id="F_000806" contextRef="C_0001326110_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231" decimals="-3" unitRef="U_iso4217USD">37641000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure id="F_000807" contextRef="C_0001326110_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure id="F_000808" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_nkCurrentAssetsMember_us-gaapFairValueByAssetClassAxis_us-gaapCashAndCashEquivalentsMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20181231" decimals="-3" unitRef="U_iso4217USD">16821000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure id="F_000809" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_nkCurrentAssetsMember_us-gaapFairValueByAssetClassAxis_us-gaapCashAndCashEquivalentsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20181231" decimals="-3" unitRef="U_iso4217USD">16821000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure id="F_000810" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_nkCurrentAssetsMember_us-gaapFairValueByAssetClassAxis_us-gaapCashAndCashEquivalentsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20181231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure id="F_000811" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_nkCurrentAssetsMember_us-gaapFairValueByAssetClassAxis_us-gaapCashAndCashEquivalentsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20181231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure id="F_000812" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_nkCurrentAssetsMember_us-gaapFairValueByAssetClassAxis_us-gaapCorporateDebtSecuritiesMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20181231" decimals="-3" unitRef="U_iso4217USD">57328000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure id="F_000813" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_nkCurrentAssetsMember_us-gaapFairValueByAssetClassAxis_us-gaapCorporateDebtSecuritiesMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20181231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure id="F_000814" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_nkCurrentAssetsMember_us-gaapFairValueByAssetClassAxis_us-gaapCorporateDebtSecuritiesMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20181231" decimals="-3" unitRef="U_iso4217USD">57328000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure id="F_000815" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_nkCurrentAssetsMember_us-gaapFairValueByAssetClassAxis_us-gaapCorporateDebtSecuritiesMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20181231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure id="F_000816" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_nkNoncurrentAssetsMember_us-gaapFairValueByAssetClassAxis_us-gaapCorporateDebtSecuritiesMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20181231" decimals="-3" unitRef="U_iso4217USD">2991000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure id="F_000817" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_nkNoncurrentAssetsMember_us-gaapFairValueByAssetClassAxis_us-gaapCorporateDebtSecuritiesMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20181231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure id="F_000818" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_nkNoncurrentAssetsMember_us-gaapFairValueByAssetClassAxis_us-gaapCorporateDebtSecuritiesMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20181231" decimals="-3" unitRef="U_iso4217USD">2991000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure id="F_000819" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_nkNoncurrentAssetsMember_us-gaapFairValueByAssetClassAxis_us-gaapCorporateDebtSecuritiesMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20181231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure id="F_000820" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_nkNoncurrentAssetsMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapUnderlyingAssetClassAxis_us-gaapAgencySecuritiesMember_20181231" decimals="-3" unitRef="U_iso4217USD">2710000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure id="F_000821" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_nkNoncurrentAssetsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapUnderlyingAssetClassAxis_us-gaapAgencySecuritiesMember_20181231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure id="F_000822" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_nkNoncurrentAssetsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapUnderlyingAssetClassAxis_us-gaapAgencySecuritiesMember_20181231" decimals="-3" unitRef="U_iso4217USD">2710000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure id="F_000823" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_nkNoncurrentAssetsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapUnderlyingAssetClassAxis_us-gaapAgencySecuritiesMember_20181231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure id="F_000824" contextRef="C_0001326110_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20181231" decimals="-3" unitRef="U_iso4217USD">79850000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure id="F_000825" contextRef="C_0001326110_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20181231" decimals="-3" unitRef="U_iso4217USD">16821000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure id="F_000826" contextRef="C_0001326110_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20181231" decimals="-3" unitRef="U_iso4217USD">63029000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure id="F_000827" contextRef="C_0001326110_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20181231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:AssetsFairValueDisclosure>
  <nk:MaximumNumberOfPatientsInPhaseOneAndTwoForClinicalTrials id="F_000828" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_nkAltorBioScienceCorporationMember_20190101_20191231" decimals="INF" unitRef="U_nkPatient">400</nk:MaximumNumberOfPatientsInPhaseOneAndTwoForClinicalTrials>
  <nk:SuppliesAndMilestoneChargesForConductingClinicalTrials id="F_000829" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_nkAltorBioScienceCorporationMember_20190101_20191231" decimals="INF" unitRef="U_iso4217USD">0</nk:SuppliesAndMilestoneChargesForConductingClinicalTrials>
  <nk:SuppliesAndMilestoneChargesForConductingClinicalTrials id="F_000830" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_nkAltorBioScienceCorporationMember_20180101_20181231" decimals="INF" unitRef="U_iso4217USD">0</nk:SuppliesAndMilestoneChargesForConductingClinicalTrials>
  <nk:SuppliesAndMilestoneChargesForConductingClinicalTrials id="F_000831" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_nkAltorBioScienceCorporationMember_20170101_20171231" decimals="INF" unitRef="U_iso4217USD">0</nk:SuppliesAndMilestoneChargesForConductingClinicalTrials>
  <nk:MilestonePaymentAmount id="F_000832" contextRef="C_0001326110_deiLegalEntityAxis_nkViractaTherapeuticsIncMember_srtRangeAxis_srtMinimumMember_20170501_20170531" decimals="INF" unitRef="U_iso4217USD">10000000</nk:MilestonePaymentAmount>
  <nk:MilestonePaymentAmount id="F_000833" contextRef="C_0001326110_deiLegalEntityAxis_nkViractaTherapeuticsIncMember_srtRangeAxis_srtMaximumMember_20170501_20170531" decimals="INF" unitRef="U_iso4217USD">25000000</nk:MilestonePaymentAmount>
  <nk:LicenseAgreementTerminationNoticePeriod id="F_000834" contextRef="C_0001326110_deiLegalEntityAxis_nkViractaTherapeuticsIncMember_20170501_20170531">P90D</nk:LicenseAgreementTerminationNoticePeriod>
  <nk:PaymentsForInitialLicenseFees id="F_000835" contextRef="C_0001326110_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis_nkGeorgSpeyerHausAndDRKBlutspendedienstBadenWurttembergHessengGmbHLicenseAgreementMember_20150101_20151231" decimals="-5" unitRef="U_iso4217USD">1100000</nk:PaymentsForInitialLicenseFees>
  <nk:PeriodOfLicenseAgreement id="F_000836" contextRef="C_0001326110_us-gaapOtherCommitmentsAxis_nkRushUniversityMedicalCenterLicenseAgreementMember_20040101_20041231">P12Y</nk:PeriodOfLicenseAgreement>
  <nk:MinimumAnnualRoyaltyPayment id="F_000837" contextRef="C_0001326110_us-gaapOtherCommitmentsAxis_nkRushUniversityMedicalCenterLicenseAgreementMember_20040101_20041231" decimals="INF" unitRef="U_iso4217USD">25000</nk:MinimumAnnualRoyaltyPayment>
  <us-gaap:CostOfGoodsAndServicesSold id="F_000838" contextRef="C_0001326110_us-gaapOtherCommitmentsAxis_nkRushUniversityMedicalCenterLicenseAgreementMember_20040101_20041231" decimals="-5" unitRef="U_iso4217USD">2500000</us-gaap:CostOfGoodsAndServicesSold>
  <nk:MinimumSalesMilestoneOfLicenseForFirstYear id="F_000839" contextRef="C_0001326110_us-gaapOtherCommitmentsAxis_nkRushUniversityMedicalCenterLicenseAgreementMember_20040101_20041231" decimals="INF" unitRef="U_iso4217USD">300000</nk:MinimumSalesMilestoneOfLicenseForFirstYear>
  <us-gaap:RoyaltyExpense id="F_000840" contextRef="C_0001326110_us-gaapOtherCommitmentsAxis_nkRushUniversityMedicalCenterLicenseAgreementMember_20190101_20191231" decimals="0" unitRef="U_iso4217USD">0</us-gaap:RoyaltyExpense>
  <us-gaap:RoyaltyExpense id="F_000841" contextRef="C_0001326110_us-gaapOtherCommitmentsAxis_nkRushUniversityMedicalCenterLicenseAgreementMember_20180101_20181231" decimals="0" unitRef="U_iso4217USD">4200</us-gaap:RoyaltyExpense>
  <us-gaap:RoyaltyExpense id="F_000842" contextRef="C_0001326110_us-gaapOtherCommitmentsAxis_nkRushUniversityMedicalCenterLicenseAgreementMember_20170101_20171231" decimals="0" unitRef="U_iso4217USD">25000</us-gaap:RoyaltyExpense>
  <us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized id="F_000843" contextRef="C_0001326110_us-gaapOtherCommitmentsAxis_nkRushUniversityMedicalCenterLicenseAgreementMember_20190101_20191231" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized>
  <us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized id="F_000844" contextRef="C_0001326110_us-gaapOtherCommitmentsAxis_nkRushUniversityMedicalCenterLicenseAgreementMember_20180101_20181231" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized>
  <us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized id="F_000845" contextRef="C_0001326110_us-gaapOtherCommitmentsAxis_nkRushUniversityMedicalCenterLicenseAgreementMember_20170101_20171231" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized>
  <nk:LicenseAgreementTerm id="F_000846" contextRef="C_0001326110_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_nkIntrexonLicenseAgreementMember_20100201_20100228">P17Y</nk:LicenseAgreementTerm>
  <nk:AgreementOneTimeFee id="F_000847" contextRef="C_0001326110_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_nkIntrexonLicenseAgreementMember_20100201_20100228" decimals="-5" unitRef="U_iso4217USD">400000</nk:AgreementOneTimeFee>
  <nk:MilestonePaymentAmount id="F_000848" contextRef="C_0001326110_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_nkIntrexonLicenseAgreementMember_20190101_20191231" decimals="INF" unitRef="U_iso4217USD">0</nk:MilestonePaymentAmount>
  <nk:MilestonePaymentAmount id="F_000849" contextRef="C_0001326110_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_nkIntrexonLicenseAgreementMember_20180101_20181231" decimals="INF" unitRef="U_iso4217USD">0</nk:MilestonePaymentAmount>
  <nk:MilestonePaymentAmount id="F_000850" contextRef="C_0001326110_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_nkIntrexonLicenseAgreementMember_20170101_20171231" decimals="INF" unitRef="U_iso4217USD">0</nk:MilestonePaymentAmount>
  <us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized id="F_000851" contextRef="C_0001326110_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_nkIntrexonLicenseAgreementMember_20190101_20191231" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized>
  <us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized id="F_000852" contextRef="C_0001326110_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_nkIntrexonLicenseAgreementMember_20180101_20181231" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized>
  <us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized id="F_000853" contextRef="C_0001326110_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_nkIntrexonLicenseAgreementMember_20170101_20171231" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized>
  <nk:MilestonePaymentAmount id="F_000854" contextRef="C_0001326110_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_nkIntrexonLicenseAgreementMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_nkINDFilingMember_20100201_20100228" decimals="-5" unitRef="U_iso4217USD">100000</nk:MilestonePaymentAmount>
  <nk:MilestonePaymentAmount id="F_000855" contextRef="C_0001326110_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_nkIntrexonLicenseAgreementMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_nkPhaseTwoMember_20100201_20100228" decimals="-5" unitRef="U_iso4217USD">100000</nk:MilestonePaymentAmount>
  <nk:MilestonePaymentAmount id="F_000856" contextRef="C_0001326110_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_nkIntrexonLicenseAgreementMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_nkPhaseThreeMember_20100201_20100228" decimals="-5" unitRef="U_iso4217USD">400000</nk:MilestonePaymentAmount>
  <nk:MilestonePaymentAmount id="F_000857" contextRef="C_0001326110_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_nkIntrexonLicenseAgreementMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_nkCommercialSaleRelatedToLicensedProductsMember_20100201_20100228" decimals="-5" unitRef="U_iso4217USD">500000</nk:MilestonePaymentAmount>
  <us-gaap:LitigationSettlementAmountAwardedToOtherParty id="F_000858" contextRef="C_0001326110_20190101_20191231" decimals="-5" unitRef="U_iso4217USD">12000000</us-gaap:LitigationSettlementAmountAwardedToOtherParty>
  <us-gaap:LitigationSettlementAmountAwardedToOtherParty id="F_000859" contextRef="C_0001326110_us-gaapIncomeStatementLocationAxis_us-gaapSellingGeneralAndAdministrativeExpensesMember_20180701_20180930" decimals="-5" unitRef="U_iso4217USD">1200000</us-gaap:LitigationSettlementAmountAwardedToOtherParty>
  <us-gaap:LitigationSettlementAmountAwardedToOtherParty id="F_000860" contextRef="C_0001326110_us-gaapReinsurancePolicyTypeAxis_nkDirectorsAndOfficersInsurancePolicyMember_20190101_20191231" decimals="-5" unitRef="U_iso4217USD">10800000</us-gaap:LitigationSettlementAmountAwardedToOtherParty>
  <us-gaap:LegalFees id="F_000861" contextRef="C_0001326110_20190809_20190809" decimals="-5" unitRef="U_iso4217USD">500000</us-gaap:LegalFees>
  <us-gaap:InsuranceSettlementsReceivable id="F_000862" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_us-gaapPrepaidExpensesAndOtherCurrentAssetsMember_20191231" decimals="-3" unitRef="U_iso4217USD">34000000</us-gaap:InsuranceSettlementsReceivable>
  <us-gaap:InsuranceSettlementsReceivable id="F_000863" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_us-gaapPrepaidExpensesAndOtherCurrentAssetsMember_20181231" decimals="-5" unitRef="U_iso4217USD">10900000</us-gaap:InsuranceSettlementsReceivable>
  <us-gaap:OperatingLeaseRightOfUseAsset id="F_000864" contextRef="C_0001326110_20190101" decimals="-3" unitRef="U_iso4217USD">13532000</us-gaap:OperatingLeaseRightOfUseAsset>
  <us-gaap:OperatingLeaseLiabilityCurrent id="F_000865" contextRef="C_0001326110_20190101" decimals="-3" unitRef="U_iso4217USD">2960000</us-gaap:OperatingLeaseLiabilityCurrent>
  <us-gaap:OperatingLeaseLiabilityNoncurrent id="F_000866" contextRef="C_0001326110_20190101" decimals="-3" unitRef="U_iso4217USD">13407000</us-gaap:OperatingLeaseLiabilityNoncurrent>
  <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability id="F_000867" contextRef="C_0001326110_20190101_20191231" decimals="-5" unitRef="U_iso4217USD">800000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
  <us-gaap:OperatingLeaseCost id="F_000868" contextRef="C_0001326110_us-gaapIncomeStatementLocationAxis_us-gaapOperatingExpenseMember_20190101_20191231" decimals="-5" unitRef="U_iso4217USD">5100000</us-gaap:OperatingLeaseCost>
  <us-gaap:VariableLeaseCost id="F_000869" contextRef="C_0001326110_us-gaapIncomeStatementLocationAxis_us-gaapOperatingExpenseMember_20190101_20191231" decimals="-5" unitRef="U_iso4217USD">1200000</us-gaap:VariableLeaseCost>
  <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 id="F_000870" contextRef="C_0001326110_20190101">P5Y4M24D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
  <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 id="F_000871" contextRef="C_0001326110_20191231">P4Y6M</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
  <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent id="F_000872" contextRef="C_0001326110_20190101" decimals="2" unitRef="U_xbrlipure">0.09</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
  <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent id="F_000873" contextRef="C_0001326110_20191231" decimals="2" unitRef="U_xbrlipure">0.09</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
  <us-gaap:OperatingLeasePayments id="F_000874" contextRef="C_0001326110_20190101_20191231" decimals="-5" unitRef="U_iso4217USD">4400000</us-gaap:OperatingLeasePayments>
  <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths id="F_000875" contextRef="C_0001326110_20191231" decimals="-3" unitRef="U_iso4217USD">4271000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
  <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo id="F_000876" contextRef="C_0001326110_20191231" decimals="-3" unitRef="U_iso4217USD">3753000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
  <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree id="F_000877" contextRef="C_0001326110_20191231" decimals="-3" unitRef="U_iso4217USD">3671000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
  <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour id="F_000878" contextRef="C_0001326110_20191231" decimals="-3" unitRef="U_iso4217USD">2546000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
  <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive id="F_000879" contextRef="C_0001326110_20191231" decimals="-3" unitRef="U_iso4217USD">1083000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
  <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive id="F_000880" contextRef="C_0001326110_20191231" decimals="-3" unitRef="U_iso4217USD">1729000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
  <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue id="F_000881" contextRef="C_0001326110_20191231" decimals="-3" unitRef="U_iso4217USD">17053000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
  <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount id="F_000882" contextRef="C_0001326110_20191231" decimals="-3" unitRef="U_iso4217USD">2962000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
  <us-gaap:OperatingLeaseLiability id="F_000883" contextRef="C_0001326110_20191231" decimals="-3" unitRef="U_iso4217USD">14091000</us-gaap:OperatingLeaseLiability>
  <nk:OperatingLeasePaymentsRelatedToOptionsToExtendLeaseTerms id="F_000884" contextRef="C_0001326110_20190101_20191231" decimals="-5" unitRef="U_iso4217USD">3300000</nk:OperatingLeasePaymentsRelatedToOptionsToExtendLeaseTerms>
  <nk:RelatedPartyTransactionReimbursedUpfrontPaymentToThirdParty id="F_000885" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_nkNantBioScienceMember_20180801_20180831" decimals="-5" unitRef="U_iso4217USD">900000</nk:RelatedPartyTransactionReimbursedUpfrontPaymentToThirdParty>
  <nk:RelatedPartyTransactionAmountPaidToRelatedParty id="F_000886" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_nkNantBioScienceMember_20180801_20180831" decimals="-5" unitRef="U_iso4217USD">500000</nk:RelatedPartyTransactionAmountPaidToRelatedParty>
  <us-gaap:RelatedPartyTransactionAmountsOfTransaction id="F_000887" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_nkNantBioScienceMember_20180801_20180831" decimals="-5" unitRef="U_iso4217USD">1400000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
  <nk:RelatedPartyTransactionInitialTermOfAgreement id="F_000888" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_nkNantBioScienceMember_20180801_20180831">P10Y</nk:RelatedPartyTransactionInitialTermOfAgreement>
  <nk:RelatedPartyAgreementExpirationMonthAndYear id="F_000889" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_nkNantBioScienceMember_20180801_20180831">2027-06</nk:RelatedPartyAgreementExpirationMonthAndYear>
  <nk:NumberOfSquareFootOfFacilityLeased id="F_000890" contextRef="C_0001326110_srtStatementGeographicalAxis_nkElSegundoCaliforniaMember_us-gaapRelatedPartyTransactionAxis_nkDougStLLCMember_20160930" decimals="INF" unitRef="U_utrsqft">24250</nk:NumberOfSquareFootOfFacilityLeased>
  <us-gaap:LesseeOperatingLeaseDescription id="F_000891" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_nkDougStLLCMember_20190101_20191231">The lease runs from July 2016 through July 2023. We have the option to extend the lease for an additional three year term through July 2026. The monthly rent is $0.1 million with annual increases of 3% beginning in July 2017.</us-gaap:LesseeOperatingLeaseDescription>
  <nk:PeriodOfExtendedLeaseTerm id="F_000892" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_nkDougStLLCMember_20160901_20160930">P3Y</nk:PeriodOfExtendedLeaseTerm>
  <nk:BaseMonthlyRent id="F_000893" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_nkDougStLLCMember_20160901_20160930" decimals="-5" unitRef="U_iso4217USD">100000</nk:BaseMonthlyRent>
  <nk:AnnualPercentageIncreasesToBaseRent id="F_000894" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_nkDougStLLCMember_20160901_20160930" decimals="2" unitRef="U_xbrlipure">0.03</nk:AnnualPercentageIncreasesToBaseRent>
  <nk:AnnualPercentageIncreasesToBaseRentCommencementDate id="F_000895" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_nkDougStLLCMember_20160901_20160930">2017-07-31</nk:AnnualPercentageIncreasesToBaseRentCommencementDate>
  <nk:NumberOfSquareFootOfFacilityLeased id="F_000896" contextRef="C_0001326110_us-gaapLeaseArrangementTypeAxis_nkCommitmentWoburnMassachusettsMember_20160331" decimals="0" unitRef="U_utrsqft">7893</nk:NumberOfSquareFootOfFacilityLeased>
  <us-gaap:LesseeOperatingLeaseTermOfContract id="F_000897" contextRef="C_0001326110_us-gaapLeaseArrangementTypeAxis_nkCommitmentWoburnMassachusettsMember_20160331">P48M</us-gaap:LesseeOperatingLeaseTermOfContract>
  <nk:LeaseCommencementDate id="F_000898" contextRef="C_0001326110_us-gaapLeaseArrangementTypeAxis_nkCommitmentWoburnMassachusettsMember_20160301_20160331">2016-04-29</nk:LeaseCommencementDate>
  <us-gaap:LeaseExpirationDate1 id="F_000899" contextRef="C_0001326110_us-gaapLeaseArrangementTypeAxis_nkCommitmentWoburnMassachusettsMember_20160301_20160331">2020-05-31</us-gaap:LeaseExpirationDate1>
  <nk:AdditionToNumberOfSquareFootOfFacilityLeased id="F_000900" contextRef="C_0001326110_us-gaapLeaseArrangementTypeAxis_nkCommitmentWoburnMassachusettsMember_20160630" decimals="INF" unitRef="U_utrsqft">260</nk:AdditionToNumberOfSquareFootOfFacilityLeased>
  <nk:NumberOfSquareFootOfFacilityLeased id="F_000901" contextRef="C_0001326110_us-gaapLeaseArrangementTypeAxis_nkCommitmentWoburnMassachusettsMember_20160630" decimals="INF" unitRef="U_utrsqft">8153</nk:NumberOfSquareFootOfFacilityLeased>
  <nk:BaseMonthlyRent id="F_000902" contextRef="C_0001326110_us-gaapLeaseArrangementTypeAxis_nkCommitmentWoburnMassachusettsMember_20160601_20160630" decimals="0" unitRef="U_iso4217USD">19000</nk:BaseMonthlyRent>
  <nk:AnnualBaseRentIncreasePerSquareFoot id="F_000903" contextRef="C_0001326110_us-gaapLeaseArrangementTypeAxis_nkCommitmentWoburnMassachusettsMember_20160601_20160630" decimals="INF" unitRef="U_iso4217USD_utrsqft">1</nk:AnnualBaseRentIncreasePerSquareFoot>
  <nk:PeriodOfLicenseAgreementDescription id="F_000904" contextRef="C_0001326110_us-gaapLeaseArrangementTypeAxis_nkCommitmentWoburnMassachusettsMember_20190101_20191231">In June 2016, the lease was amended to add 260 square feet, for a total of 8,153 square feet. Base rent for the initial term of the lease is $19,000 per month with a $1 per square foot annual increase on each anniversary date.</nk:PeriodOfLicenseAgreementDescription>
  <us-gaap:LesseeOperatingLeaseRenewalTerm id="F_000905" contextRef="C_0001326110_us-gaapLeaseArrangementTypeAxis_nkCommitmentWoburnMassachusettsMember_20190831">P2Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
  <nk:LeaseAgreementExtendedPeriod id="F_000906" contextRef="C_0001326110_us-gaapLeaseArrangementTypeAxis_nkCommitmentWoburnMassachusettsMember_20190801_20190831">2022-05-31</nk:LeaseAgreementExtendedPeriod>
  <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability id="F_000907" contextRef="C_0001326110_us-gaapLeaseArrangementTypeAxis_nkCommitmentWoburnMassachusettsMember_20190101_20191231" decimals="-5" unitRef="U_iso4217USD">600000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
  <nk:NumberOfSquareFootOfFacilityLeased id="F_000908" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_nkNantWorksLimitedLiabilityCompanyMember_20151130" decimals="INF" unitRef="U_utrsqft">9500</nk:NumberOfSquareFootOfFacilityLeased>
  <us-gaap:LesseeOperatingLeaseDescription id="F_000909" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_nkNantWorksLimitedLiabilityCompanyMember_20190101_20191231">The license was effective in May 2015 and extends through December 2020. The monthly rent is $47,000, with annual increases of 3% beginning in January 2017.</us-gaap:LesseeOperatingLeaseDescription>
  <nk:BaseMonthlyRent id="F_000910" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_nkNantWorksLimitedLiabilityCompanyMember_20151101_20151130" decimals="0" unitRef="U_iso4217USD">47000</nk:BaseMonthlyRent>
  <nk:AnnualPercentageIncreasesToBaseRent id="F_000911" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_nkNantWorksLimitedLiabilityCompanyMember_20151101_20151130" decimals="2" unitRef="U_xbrlipure">0.03</nk:AnnualPercentageIncreasesToBaseRent>
  <nk:AnnualPercentageIncreasesToBaseRentCommencementDate id="F_000912" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_nkNantWorksLimitedLiabilityCompanyMember_20151101_20151130">2017-01-31</nk:AnnualPercentageIncreasesToBaseRentCommencementDate>
  <nk:NumberOfSquareFootOfFacilityLeased id="F_000913" contextRef="C_0001326110_us-gaapLeaseArrangementTypeAxis_nkCommitmentSanDiegoMember_20150630" decimals="0" unitRef="U_utrsqft">44700</nk:NumberOfSquareFootOfFacilityLeased>
  <us-gaap:LesseeOperatingLeaseTermOfContract id="F_000914" contextRef="C_0001326110_us-gaapLeaseArrangementTypeAxis_nkCommitmentSanDiegoMember_20150630">P7Y</us-gaap:LesseeOperatingLeaseTermOfContract>
  <nk:BaseMonthlyRent id="F_000915" contextRef="C_0001326110_us-gaapLeaseArrangementTypeAxis_nkCommitmentSanDiegoMember_20150601_20150630" decimals="-5" unitRef="U_iso4217USD">200000</nk:BaseMonthlyRent>
  <nk:AnnualPercentageIncreasesToBaseRent id="F_000916" contextRef="C_0001326110_us-gaapLeaseArrangementTypeAxis_nkCommitmentSanDiegoMember_20150601_20150630" decimals="2" unitRef="U_xbrlipure">0.03</nk:AnnualPercentageIncreasesToBaseRent>
  <us-gaap:OperatingLeasesRentExpenseNet id="F_000917" contextRef="C_0001326110_20180101_20181231" decimals="-5" unitRef="U_iso4217USD">2800000</us-gaap:OperatingLeasesRentExpenseNet>
  <us-gaap:OperatingLeasesRentExpenseNet id="F_000918" contextRef="C_0001326110_20170101_20171231" decimals="-5" unitRef="U_iso4217USD">2700000</us-gaap:OperatingLeasesRentExpenseNet>
  <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares id="F_000919" contextRef="C_0001326110_20181101_20181130" decimals="INF" unitRef="U_xbrlishares">138349</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
  <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue id="F_000920" contextRef="C_0001326110_20181101_20181130" decimals="-5" unitRef="U_iso4217USD">200000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
  <nk:RelatedPartyTransactionInitialTermOfAgreement id="F_000921" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_nkNantHealthLabsIncMember_20180301_20180331">P5Y</nk:RelatedPartyTransactionInitialTermOfAgreement>
  <nk:RelatedPartyAgreementRenewalTerm id="F_000922" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_nkNantHealthLabsIncMember_20180301_20180331">P1Y</nk:RelatedPartyAgreementRenewalTerm>
  <us-gaap:ResearchAndDevelopmentExpense id="F_000923" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_nkNantHealthLabsIncMember_20190101_20191231" decimals="0" unitRef="U_iso4217USD">10000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense id="F_000924" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_nkNantHealthLabsIncMember_20180101_20181231" decimals="-5" unitRef="U_iso4217USD">300000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:DueToRelatedPartiesCurrent id="F_000925" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_nkNantHealthLabsIncMember_20191231" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:DueToRelatedPartiesCurrent>
  <us-gaap:DueToRelatedPartiesCurrent id="F_000926" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_nkNantHealthLabsIncMember_20181231" decimals="0" unitRef="U_iso4217USD">49300</us-gaap:DueToRelatedPartiesCurrent>
  <nk:NumberOfOfficers id="F_000927" contextRef="C_0001326110_srtStatementGeographicalAxis_stprCA_us-gaapRelatedPartyTransactionAxis_nkImmunoOncologyClinicIncMember_20191231" decimals="INF" unitRef="U_nkOfficer">1</nk:NumberOfOfficers>
  <nk:InitialTermOfAgreement id="F_000928" contextRef="C_0001326110_srtStatementGeographicalAxis_stprCA_us-gaapRelatedPartyTransactionAxis_nkImmunoOncologyClinicIncMember_20190701_20190731">P1Y</nk:InitialTermOfAgreement>
  <us-gaap:RelatedPartyTransactionAmountsOfTransaction id="F_000929" contextRef="C_0001326110_srtStatementGeographicalAxis_stprCA_us-gaapRelatedPartyTransactionAxis_nkImmunoOncologyClinicIncMember_20190701_20190731" decimals="-5" unitRef="U_iso4217USD">7500000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
  <nk:RelatedPartyInstallmentPayment id="F_000930" contextRef="C_0001326110_srtStatementGeographicalAxis_stprCA_us-gaapRelatedPartyTransactionAxis_nkImmunoOncologyClinicIncMember_20190701_20190731" decimals="-4" unitRef="U_iso4217USD">3750000</nk:RelatedPartyInstallmentPayment>
  <nk:RelatedPartyInstallmentPayment id="F_000931" contextRef="C_0001326110_srtStatementGeographicalAxis_stprCA_us-gaapRelatedPartyTransactionAxis_nkImmunoOncologyClinicIncMember_20191001_20191031" decimals="-3" unitRef="U_iso4217USD">1875000</nk:RelatedPartyInstallmentPayment>
  <nk:RelatedPartyTransactionAgreementExtensionDescription id="F_000932" contextRef="C_0001326110_srtStatementGeographicalAxis_stprCA_us-gaapRelatedPartyTransactionAxis_nkImmunoOncologyClinicIncMember_20190101_20191231">To the extent any portion of the prepayments remain unearned by the Clinic on the third anniversary of the new agreement, we may elect at our sole discretion either to (i) not extend the term of the new agreement and have the Clinic reimburse us for the total amount of any remaining unused portion of the prepayments, or (ii) extend the term of the new agreement for up to three additional one year periods, at which time the Clinic will reimburse us for the total amount of any remaining unused portion of the prepayments plus interest if reimbursement is not made within 60 days of expiration.</nk:RelatedPartyTransactionAgreementExtensionDescription>
  <nk:NewAgreementTerminationNoticePeriod id="F_000933" contextRef="C_0001326110_srtStatementGeographicalAxis_stprCA_us-gaapRelatedPartyTransactionAxis_nkImmunoOncologyClinicIncMember_20190101_20191231">P60D</nk:NewAgreementTerminationNoticePeriod>
  <us-gaap:ResearchAndDevelopmentExpense id="F_000934" contextRef="C_0001326110_srtStatementGeographicalAxis_stprCA_us-gaapRelatedPartyTransactionAxis_nkImmunoOncologyClinicIncMember_20190101_20191231" decimals="-5" unitRef="U_iso4217USD">1100000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense id="F_000935" contextRef="C_0001326110_srtStatementGeographicalAxis_stprCA_us-gaapRelatedPartyTransactionAxis_nkImmunoOncologyClinicIncMember_20180101_20181231" decimals="-5" unitRef="U_iso4217USD">2700000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense id="F_000936" contextRef="C_0001326110_srtStatementGeographicalAxis_stprCA_us-gaapRelatedPartyTransactionAxis_nkImmunoOncologyClinicIncMember_20170101_20171231" decimals="-5" unitRef="U_iso4217USD">800000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:DueToRelatedPartiesCurrent id="F_000937" contextRef="C_0001326110_srtStatementGeographicalAxis_stprCA_us-gaapRelatedPartyTransactionAxis_nkImmunoOncologyClinicIncMember_20191231" decimals="-5" unitRef="U_iso4217USD">100000</us-gaap:DueToRelatedPartiesCurrent>
  <us-gaap:DueToRelatedPartiesCurrent id="F_000938" contextRef="C_0001326110_srtStatementGeographicalAxis_stprCA_us-gaapRelatedPartyTransactionAxis_nkImmunoOncologyClinicIncMember_20181231" decimals="-5" unitRef="U_iso4217USD">600000</us-gaap:DueToRelatedPartiesCurrent>
  <nk:PrepaidBalanceIncludedInPrepaidExpensesAndOtherCurrentAssetsAndOtherAssets id="F_000939" contextRef="C_0001326110_srtStatementGeographicalAxis_stprCA_us-gaapRelatedPartyTransactionAxis_nkImmunoOncologyClinicIncMember_20191231" decimals="-5" unitRef="U_iso4217USD">5100000</nk:PrepaidBalanceIncludedInPrepaidExpensesAndOtherCurrentAssetsAndOtherAssets>
  <us-gaap:RelatedPartyTransactionDescriptionOfTransaction id="F_000940" contextRef="C_0001326110_srtStatementGeographicalAxis_nkSanDiegoCaliforniaMember_us-gaapRelatedPartyTransactionAxis_nkTensorcomIncMember_20190101_20191231">The lease ran from May 1, 2017 through April 30, 2018.</us-gaap:RelatedPartyTransactionDescriptionOfTransaction>
  <nk:NumberOfSquareFootOfFacilityLeased id="F_000941" contextRef="C_0001326110_srtStatementGeographicalAxis_nkSanDiegoCaliforniaMember_us-gaapRelatedPartyTransactionAxis_nkTensorcomIncMember_20170430" decimals="INF" unitRef="U_utrsqft">6557</nk:NumberOfSquareFootOfFacilityLeased>
  <nk:BaseMonthlyRent id="F_000942" contextRef="C_0001326110_srtStatementGeographicalAxis_nkSanDiegoCaliforniaMember_us-gaapRelatedPartyTransactionAxis_nkTensorcomIncMember_20170401_20170430" decimals="0" unitRef="U_iso4217USD">25000</nk:BaseMonthlyRent>
  <us-gaap:OperatingLeasesIncomeStatementSubleaseRevenue id="F_000943" contextRef="C_0001326110_srtStatementGeographicalAxis_nkSanDiegoCaliforniaMember_us-gaapIncomeStatementLocationAxis_us-gaapOtherIncomeMember_us-gaapRelatedPartyTransactionAxis_nkTensorcomIncMember_20180101_20181231" decimals="-5" unitRef="U_iso4217USD">100000</us-gaap:OperatingLeasesIncomeStatementSubleaseRevenue>
  <us-gaap:OperatingLeasesIncomeStatementSubleaseRevenue id="F_000944" contextRef="C_0001326110_srtStatementGeographicalAxis_nkSanDiegoCaliforniaMember_us-gaapIncomeStatementLocationAxis_us-gaapOtherIncomeMember_us-gaapRelatedPartyTransactionAxis_nkTensorcomIncMember_20170101_20171231" decimals="-5" unitRef="U_iso4217USD">200000</us-gaap:OperatingLeasesIncomeStatementSubleaseRevenue>
  <us-gaap:RelatedPartyTransactionDueFromToRelatedParty id="F_000945" contextRef="C_0001326110_srtStatementGeographicalAxis_nkSanDiegoCaliforniaMember_us-gaapRelatedPartyTransactionAxis_nkTensorcomIncMember_20191231" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:RelatedPartyTransactionDueFromToRelatedParty>
  <us-gaap:RelatedPartyTransactionDueFromToRelatedParty id="F_000946" contextRef="C_0001326110_srtStatementGeographicalAxis_nkSanDiegoCaliforniaMember_us-gaapRelatedPartyTransactionAxis_nkTensorcomIncMember_20181231" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:RelatedPartyTransactionDueFromToRelatedParty>
  <us-gaap:RelatedPartyTransactionDescriptionOfTransaction id="F_000947" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_nkDougStLLCMember_20190101_20191231">The lease runs from July 2016 through July 2023.</us-gaap:RelatedPartyTransactionDescriptionOfTransaction>
  <us-gaap:OperatingLeaseExpense id="F_000948" contextRef="C_0001326110_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_us-gaapRelatedPartyTransactionAxis_nkDougStLLCMember_20190101_20191231" decimals="-5" unitRef="U_iso4217USD">900000</us-gaap:OperatingLeaseExpense>
  <us-gaap:OperatingLeaseExpense id="F_000949" contextRef="C_0001326110_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_us-gaapRelatedPartyTransactionAxis_nkDougStLLCMember_20180101_20181231" decimals="-5" unitRef="U_iso4217USD">200000</us-gaap:OperatingLeaseExpense>
  <us-gaap:OperatingLeaseExpense id="F_000950" contextRef="C_0001326110_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_us-gaapRelatedPartyTransactionAxis_nkDougStLLCMember_20170101_20171231" decimals="-5" unitRef="U_iso4217USD">200000</us-gaap:OperatingLeaseExpense>
  <us-gaap:RelatedPartyTransactionDueFromToRelatedParty id="F_000951" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_nkDougStLLCMember_20191231" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:RelatedPartyTransactionDueFromToRelatedParty>
  <us-gaap:RelatedPartyTransactionDueFromToRelatedParty id="F_000952" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_nkDougStLLCMember_20181231" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:RelatedPartyTransactionDueFromToRelatedParty>
  <nk:RelatedPartyTransactionReimbursedUpfrontPaymentToRelatedParty id="F_000953" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_nkNantBioScienceMember_20180801_20180831" decimals="-5" unitRef="U_iso4217USD">900000</nk:RelatedPartyTransactionReimbursedUpfrontPaymentToRelatedParty>
  <nk:RelatedPartyTransactionAmountPaidToThirdParty id="F_000954" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_nkNantBioScienceMember_20180801_20180831" decimals="-5" unitRef="U_iso4217USD">500000</nk:RelatedPartyTransactionAmountPaidToThirdParty>
  <nk:NumberOfSquareFootOfFacilityLeased id="F_000955" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_nkNantBioScienceMember_20171231" decimals="INF" unitRef="U_utrsqft">1965</nk:NumberOfSquareFootOfFacilityLeased>
  <us-gaap:OperatingLeasesIncomeStatementSubleaseRevenue id="F_000956" contextRef="C_0001326110_us-gaapIncomeStatementLocationAxis_us-gaapOtherIncomeMember_us-gaapRelatedPartyTransactionAxis_nkNantBioScienceMember_20190101_20191231" decimals="-5" unitRef="U_iso4217USD">100000</us-gaap:OperatingLeasesIncomeStatementSubleaseRevenue>
  <us-gaap:OperatingLeasesIncomeStatementSubleaseRevenue id="F_000957" contextRef="C_0001326110_us-gaapIncomeStatementLocationAxis_us-gaapOtherIncomeMember_us-gaapRelatedPartyTransactionAxis_nkNantBioScienceMember_20180101_20181231" decimals="-5" unitRef="U_iso4217USD">100000</us-gaap:OperatingLeasesIncomeStatementSubleaseRevenue>
  <us-gaap:OperatingLeasesIncomeStatementSubleaseRevenue id="F_000958" contextRef="C_0001326110_us-gaapIncomeStatementLocationAxis_us-gaapOtherIncomeMember_us-gaapRelatedPartyTransactionAxis_nkNantBioScienceMember_20170101_20171231" decimals="0" unitRef="U_iso4217USD">10000</us-gaap:OperatingLeasesIncomeStatementSubleaseRevenue>
  <us-gaap:RelatedPartyTransactionDueFromToRelatedParty id="F_000959" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_us-gaapPrepaidExpensesAndOtherCurrentAssetsMember_us-gaapRelatedPartyTransactionAxis_nkNantBioScienceMember_20191231" decimals="0" unitRef="U_iso4217USD">8400</us-gaap:RelatedPartyTransactionDueFromToRelatedParty>
  <us-gaap:RelatedPartyTransactionDueFromToRelatedParty id="F_000960" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_us-gaapPrepaidExpensesAndOtherCurrentAssetsMember_us-gaapRelatedPartyTransactionAxis_nkNantBioScienceMember_20181231" decimals="0" unitRef="U_iso4217USD">49000</us-gaap:RelatedPartyTransactionDueFromToRelatedParty>
  <nk:RelatedPartyTransactionInitialTermOfAgreement id="F_000961" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_nkNantBioScienceMember_20160301_20160331">P5Y</nk:RelatedPartyTransactionInitialTermOfAgreement>
  <nk:ResearchAndDevelopmentExpenseRatablePaymentPeriod id="F_000962" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_nkNantBioScienceMember_20190101_20191231">P12M</nk:ResearchAndDevelopmentExpenseRatablePaymentPeriod>
  <us-gaap:ResearchAndDevelopmentExpense id="F_000963" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_nkNantBioScienceMember_20190101_20191231" decimals="-5" unitRef="U_iso4217USD">600000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense id="F_000964" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_nkNantBioScienceMember_20180101_20181231" decimals="-5" unitRef="U_iso4217USD">600000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense id="F_000965" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_nkNantBioScienceMember_20170101_20171231" decimals="-5" unitRef="U_iso4217USD">600000</us-gaap:ResearchAndDevelopmentExpense>
  <nk:PrepaymentOfFundingAmount id="F_000966" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_nkNantBioScienceMember_20160401_20160430" decimals="-5" unitRef="U_iso4217USD">600000</nk:PrepaymentOfFundingAmount>
  <nk:PrepaymentOfFundingAmount id="F_000967" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_nkNantBioScienceMember_20170401_20170430" decimals="-5" unitRef="U_iso4217USD">600000</nk:PrepaymentOfFundingAmount>
  <nk:PrepaymentOfFundingAmount id="F_000968" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_nkNantBioScienceMember_20180801_20180831" decimals="-5" unitRef="U_iso4217USD">600000</nk:PrepaymentOfFundingAmount>
  <nk:PrepaymentOfFundingAmount id="F_000969" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_nkNantBioScienceMember_20190501_20190531" decimals="-5" unitRef="U_iso4217USD">600000</nk:PrepaymentOfFundingAmount>
  <us-gaap:ResearchAndDevelopmentExpense id="F_000970" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_us-gaapPrepaidExpensesAndOtherCurrentAssetsMember_us-gaapRelatedPartyTransactionAxis_nkNantBioScienceMember_20190101_20191231" decimals="-5" unitRef="U_iso4217USD">100000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense id="F_000971" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_us-gaapPrepaidExpensesAndOtherCurrentAssetsMember_us-gaapRelatedPartyTransactionAxis_nkNantBioScienceMember_20180101_20181231" decimals="-5" unitRef="U_iso4217USD">100000</us-gaap:ResearchAndDevelopmentExpense>
  <nk:TransferOfDepositAmountToThirdParty id="F_000972" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_nkNantWorksLimitedLiabilityCompanyMember_20180501_20180531" decimals="-5" unitRef="U_iso4217USD">400000</nk:TransferOfDepositAmountToThirdParty>
  <us-gaap:SellingGeneralAndAdministrativeExpense id="F_000973" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_nkNantWorksLimitedLiabilityCompanyMember_us-gaapTypeOfArrangementAxis_nkSharedServicesAgreementMember_20190101_20191231" decimals="-5" unitRef="U_iso4217USD">2100000</us-gaap:SellingGeneralAndAdministrativeExpense>
  <us-gaap:SellingGeneralAndAdministrativeExpense id="F_000974" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_nkNantWorksLimitedLiabilityCompanyMember_us-gaapTypeOfArrangementAxis_nkSharedServicesAgreementMember_20180101_20181231" decimals="-5" unitRef="U_iso4217USD">2800000</us-gaap:SellingGeneralAndAdministrativeExpense>
  <us-gaap:SellingGeneralAndAdministrativeExpense id="F_000975" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_nkNantWorksLimitedLiabilityCompanyMember_us-gaapTypeOfArrangementAxis_nkSharedServicesAgreementMember_20170101_20171231" decimals="-5" unitRef="U_iso4217USD">3600000</us-gaap:SellingGeneralAndAdministrativeExpense>
  <us-gaap:ResearchAndDevelopmentExpense id="F_000976" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_nkNantWorksLimitedLiabilityCompanyMember_us-gaapTypeOfArrangementAxis_nkSharedServicesAgreementMember_20190101_20191231" decimals="-5" unitRef="U_iso4217USD">1500000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense id="F_000977" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_nkNantWorksLimitedLiabilityCompanyMember_us-gaapTypeOfArrangementAxis_nkSharedServicesAgreementMember_20180101_20181231" decimals="-5" unitRef="U_iso4217USD">3300000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense id="F_000978" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_nkNantWorksLimitedLiabilityCompanyMember_us-gaapTypeOfArrangementAxis_nkSharedServicesAgreementMember_20170101_20171231" decimals="-5" unitRef="U_iso4217USD">3200000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:SellingGeneralAndAdministrativeExpense id="F_000979" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_nkNantWorksLimitedLiabilityCompanyMember_us-gaapTransactionTypeAxis_nkReimbursementsMember_us-gaapTypeOfArrangementAxis_nkSharedServicesAgreementMember_20190101_20191231" decimals="-5" unitRef="U_iso4217USD">1200000</us-gaap:SellingGeneralAndAdministrativeExpense>
  <us-gaap:SellingGeneralAndAdministrativeExpense id="F_000980" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_nkNantWorksLimitedLiabilityCompanyMember_us-gaapTransactionTypeAxis_nkReimbursementsMember_us-gaapTypeOfArrangementAxis_nkSharedServicesAgreementMember_20180101_20181231" decimals="-5" unitRef="U_iso4217USD">600000</us-gaap:SellingGeneralAndAdministrativeExpense>
  <us-gaap:SellingGeneralAndAdministrativeExpense id="F_000981" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_nkNantWorksLimitedLiabilityCompanyMember_us-gaapTransactionTypeAxis_nkReimbursementsMember_us-gaapTypeOfArrangementAxis_nkSharedServicesAgreementMember_20170101_20171231" decimals="-5" unitRef="U_iso4217USD">400000</us-gaap:SellingGeneralAndAdministrativeExpense>
  <us-gaap:ResearchAndDevelopmentExpense id="F_000982" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_nkNantWorksLimitedLiabilityCompanyMember_us-gaapTransactionTypeAxis_nkReimbursementsMember_us-gaapTypeOfArrangementAxis_nkSharedServicesAgreementMember_20190101_20191231" decimals="-5" unitRef="U_iso4217USD">2300000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense id="F_000983" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_nkNantWorksLimitedLiabilityCompanyMember_us-gaapTransactionTypeAxis_nkReimbursementsMember_us-gaapTypeOfArrangementAxis_nkSharedServicesAgreementMember_20180101_20181231" decimals="-5" unitRef="U_iso4217USD">2600000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense id="F_000984" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_nkNantWorksLimitedLiabilityCompanyMember_us-gaapTransactionTypeAxis_nkReimbursementsMember_us-gaapTypeOfArrangementAxis_nkSharedServicesAgreementMember_20170101_20171231" decimals="-5" unitRef="U_iso4217USD">1000000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:DueToRelatedPartiesCurrent id="F_000985" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_nkNantWorksLimitedLiabilityCompanyMember_us-gaapTransactionTypeAxis_nkReimbursementsMember_us-gaapTypeOfArrangementAxis_nkSharedServicesAgreementMember_20191231" decimals="-5" unitRef="U_iso4217USD">400000</us-gaap:DueToRelatedPartiesCurrent>
  <us-gaap:DueToRelatedPartiesCurrent id="F_000986" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_nkNantWorksLimitedLiabilityCompanyMember_us-gaapTransactionTypeAxis_nkReimbursementsMember_us-gaapTypeOfArrangementAxis_nkSharedServicesAgreementMember_20181231" decimals="-5" unitRef="U_iso4217USD">1100000</us-gaap:DueToRelatedPartiesCurrent>
  <us-gaap:OperatingLeaseExpense id="F_000987" contextRef="C_0001326110_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_us-gaapRelatedPartyTransactionAxis_nkNantWorksLimitedLiabilityCompanyMember_20190101_20191231" decimals="-5" unitRef="U_iso4217USD">600000</us-gaap:OperatingLeaseExpense>
  <us-gaap:OperatingLeaseExpense id="F_000988" contextRef="C_0001326110_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_us-gaapRelatedPartyTransactionAxis_nkNantWorksLimitedLiabilityCompanyMember_20180101_20181231" decimals="-5" unitRef="U_iso4217USD">200000</us-gaap:OperatingLeaseExpense>
  <us-gaap:OperatingLeaseExpense id="F_000989" contextRef="C_0001326110_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_us-gaapRelatedPartyTransactionAxis_nkNantWorksLimitedLiabilityCompanyMember_20170101_20171231" decimals="-5" unitRef="U_iso4217USD">200000</us-gaap:OperatingLeaseExpense>
  <nk:RelatedPartyTransactionInitialTermOfAgreement id="F_000990" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_nkNantOmicsLLCMember_20150601_20150630">P5Y</nk:RelatedPartyTransactionInitialTermOfAgreement>
  <nk:RelatedPartyAgreementRenewalTerm id="F_000991" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_nkNantOmicsLLCMember_20150601_20150630">P1Y</nk:RelatedPartyAgreementRenewalTerm>
  <us-gaap:ResearchAndDevelopmentExpense id="F_000992" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_nkNantOmicsLLCMember_20190101_20191231" decimals="-5" unitRef="U_iso4217USD">100000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense id="F_000993" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_nkNantOmicsLLCMember_20180101_20181231" decimals="-5" unitRef="U_iso4217USD">100000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense id="F_000994" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_nkNantOmicsLLCMember_20170101_20171231" decimals="-5" unitRef="U_iso4217USD">100000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:DueToRelatedPartiesCurrent id="F_000995" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_nkNantOmicsLLCMember_20191231" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:DueToRelatedPartiesCurrent>
  <us-gaap:DueToRelatedPartiesCurrent id="F_000996" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_nkNantOmicsLLCMember_20181231" decimals="0" unitRef="U_iso4217USD">24000</us-gaap:DueToRelatedPartiesCurrent>
  <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment id="F_000997" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_nkImmunityBioMember_20181101_20181130" decimals="-5" unitRef="U_iso4217USD">300000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
  <us-gaap:GainLossOnSaleOfPropertyPlantEquipment id="F_000998" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_nkImmunityBioMember_20181101_20181130" decimals="-5" unitRef="U_iso4217USD">100000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
  <us-gaap:ResearchAndDevelopmentExpense id="F_000999" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_nkVivaBioCellSPAMember_20190101_20191231" decimals="-6" unitRef="U_iso4217USD">0</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense id="F_001000" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_nkVivaBioCellSPAMember_20180101_20181231" decimals="-5" unitRef="U_iso4217USD">100000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense id="F_001001" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_nkVivaBioCellSPAMember_20170101_20171231" decimals="-5" unitRef="U_iso4217USD">600000</us-gaap:ResearchAndDevelopmentExpense>
  <nk:RelatedPartyTransactionInitialTermOfAgreement id="F_001002" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_nkImmunityBioMember_20150601_20150630">P5Y</nk:RelatedPartyTransactionInitialTermOfAgreement>
  <nk:RelatedPartyAgreementRenewalTerm id="F_001003" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_nkImmunityBioMember_20150601_20150630">P1Y</nk:RelatedPartyAgreementRenewalTerm>
  <us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty id="F_001004" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_nkImmunityBioMember_20190101_20191231" decimals="-5" unitRef="U_iso4217USD">1800000</us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty>
  <us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty id="F_001005" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_nkImmunityBioMember_20180101_20181231" decimals="-5" unitRef="U_iso4217USD">1100000</us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty>
  <us-gaap:ResearchAndDevelopmentExpense id="F_001006" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_nkImmunityBioMember_20190101_20191231" decimals="-5" unitRef="U_iso4217USD">100000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense id="F_001007" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_nkImmunityBioMember_20180101_20181231" decimals="-5" unitRef="U_iso4217USD">100000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense id="F_001008" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_nkImmunityBioMember_20170101_20171231" decimals="-5" unitRef="U_iso4217USD">300000</us-gaap:ResearchAndDevelopmentExpense>
  <nk:PrepaidExpensesAndOtherAssetsCurrentWithRelatedParty id="F_001009" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_nkImmunityBioMember_20191231" decimals="-5" unitRef="U_iso4217USD">500000</nk:PrepaidExpensesAndOtherAssetsCurrentWithRelatedParty>
  <nk:PrepaidExpensesAndOtherAssetsCurrentWithRelatedParty id="F_001010" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_nkImmunityBioMember_20181231" decimals="-5" unitRef="U_iso4217USD">500000</nk:PrepaidExpensesAndOtherAssetsCurrentWithRelatedParty>
  <us-gaap:RelatedPartyTransactionDueFromToRelatedParty id="F_001011" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_nkImmunityBioMember_20191231" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:RelatedPartyTransactionDueFromToRelatedParty>
  <us-gaap:RelatedPartyTransactionDueFromToRelatedParty id="F_001012" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_nkImmunityBioMember_20181231" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:RelatedPartyTransactionDueFromToRelatedParty>
  <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares id="F_001013" contextRef="C_0001326110_20151102_20191231" decimals="INF" unitRef="U_xbrlishares">6403489</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
  <nk:StockRepurchasedAndRetiredExcludingCommissionDuringPeriodValue id="F_001014" contextRef="C_0001326110_20151102_20191231" decimals="-5" unitRef="U_iso4217USD">31700000</nk:StockRepurchasedAndRetiredExcludingCommissionDuringPeriodValue>
  <us-gaap:SalesCommissionsAndFees id="F_001015" contextRef="C_0001326110_20151102_20191231" decimals="-5" unitRef="U_iso4217USD">100000</us-gaap:SalesCommissionsAndFees>
  <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares id="F_001016" contextRef="C_0001326110_20190101_20191231" decimals="INF" unitRef="U_xbrlishares">473586</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
  <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares id="F_001017" contextRef="C_0001326110_20180101_20181231" decimals="INF" unitRef="U_xbrlishares">138349</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
  <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares id="F_001018" contextRef="C_0001326110_20170101_20171231" decimals="INF" unitRef="U_xbrlishares">3633610</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
  <nk:StockRepurchasedAndRetiredExcludingCommissionDuringPeriodValue id="F_001019" contextRef="C_0001326110_20190101_20191231" decimals="-5" unitRef="U_iso4217USD">500000</nk:StockRepurchasedAndRetiredExcludingCommissionDuringPeriodValue>
  <nk:StockRepurchasedAndRetiredExcludingCommissionDuringPeriodValue id="F_001020" contextRef="C_0001326110_20180101_20181231" decimals="-5" unitRef="U_iso4217USD">200000</nk:StockRepurchasedAndRetiredExcludingCommissionDuringPeriodValue>
  <nk:StockRepurchasedAndRetiredExcludingCommissionDuringPeriodValue id="F_001021" contextRef="C_0001326110_20170101_20171231" decimals="-5" unitRef="U_iso4217USD">15200000</nk:StockRepurchasedAndRetiredExcludingCommissionDuringPeriodValue>
  <us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1 id="F_001022" contextRef="C_0001326110_20191231" decimals="INF" unitRef="U_iso4217USD">18300000</us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1>
  <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance id="F_001023" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20191231" decimals="INF" unitRef="U_xbrlishares">4506950</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
  <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance id="F_001024" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20191231" decimals="INF" unitRef="U_xbrlishares">1139428</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
  <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance id="F_001025" contextRef="C_0001326110_us-gaapAwardTypeAxis_nkOutstandingOfficerWarrantsMember_20191231" decimals="INF" unitRef="U_xbrlishares">0</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
  <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance id="F_001026" contextRef="C_0001326110_20191231" decimals="INF" unitRef="U_xbrlishares">5646378</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized id="F_001027" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapPlanNameAxis_nkTwoThousandFourteenEquityIncentivePlanMember_us-gaapStatementClassOfStockAxis_us-gaapCommonClassAMember_20140331" decimals="INF" unitRef="U_xbrlishares">11109000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod id="F_001028" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapPlanNameAxis_nkTwoThousandFourteenEquityIncentivePlanMember_us-gaapStatementClassOfStockAxis_us-gaapCommonClassAMember_20140301_20140331">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized id="F_001029" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapPlanNameAxis_nkTwoThousandFifteenEquityIncentivePlanMember_20190601_20190630" decimals="INF" unitRef="U_xbrlishares">3000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant id="F_001030" contextRef="C_0001326110_us-gaapPlanNameAxis_nkTwoThousandFifteenEquityIncentivePlanMember_20191231" decimals="INF" unitRef="U_xbrlishares">4300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
  <nk:ShareBasedCompensationArrangementByShareBasedPaymentAwardPossibleIncreaseInNumberOfSharesReservedForIssuance id="F_001031" contextRef="C_0001326110_us-gaapPlanNameAxis_nkTwoThousandFifteenEquityIncentivePlanMember_20190101_20191231" decimals="-5" unitRef="U_xbrlishares">2300000</nk:ShareBasedCompensationArrangementByShareBasedPaymentAwardPossibleIncreaseInNumberOfSharesReservedForIssuance>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_001032" contextRef="C_0001326110_srtTitleOfIndividualAxis_srtOfficerMember_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_001033" contextRef="C_0001326110_srtTitleOfIndividualAxis_srtOfficerMember_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">17817000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_001034" contextRef="C_0001326110_srtTitleOfIndividualAxis_srtOfficerMember_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">31584000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_001035" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">1309000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_001036" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">4057000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_001037" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">4267000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_001038" contextRef="C_0001326110_us-gaapAwardTypeAxis_nkEmployeeRestrictedStockUnitMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">938000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_001039" contextRef="C_0001326110_us-gaapAwardTypeAxis_nkEmployeeRestrictedStockUnitMember_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">1193000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_001040" contextRef="C_0001326110_us-gaapAwardTypeAxis_nkEmployeeRestrictedStockUnitMember_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">894000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_001041" contextRef="C_0001326110_us-gaapAwardTypeAxis_nkNonEmployeeRestrictedStockUnitMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">380000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_001042" contextRef="C_0001326110_us-gaapAwardTypeAxis_nkNonEmployeeRestrictedStockUnitMember_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">315000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_001043" contextRef="C_0001326110_us-gaapAwardTypeAxis_nkNonEmployeeRestrictedStockUnitMember_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">252000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_001044" contextRef="C_0001326110_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">2627000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_001045" contextRef="C_0001326110_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">23382000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_001046" contextRef="C_0001326110_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">36997000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_001047" contextRef="C_0001326110_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">499000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_001048" contextRef="C_0001326110_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">460000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_001049" contextRef="C_0001326110_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">102000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_001050" contextRef="C_0001326110_us-gaapIncomeStatementLocationAxis_us-gaapSellingGeneralAndAdministrativeExpensesMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">2128000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_001051" contextRef="C_0001326110_us-gaapIncomeStatementLocationAxis_us-gaapSellingGeneralAndAdministrativeExpensesMember_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">22922000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_001052" contextRef="C_0001326110_us-gaapIncomeStatementLocationAxis_us-gaapSellingGeneralAndAdministrativeExpensesMember_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">36895000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber id="F_001053" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20161231" decimals="INF" unitRef="U_xbrlishares">6307386</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised id="F_001054" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20170101_20171231" decimals="INF" unitRef="U_xbrlishares">614136</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber id="F_001055" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20171231" decimals="INF" unitRef="U_xbrlishares">5693250</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross id="F_001056" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20180101_20181231" decimals="INF" unitRef="U_xbrlishares">800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber id="F_001057" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20181231" decimals="INF" unitRef="U_xbrlishares">6493250</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised id="F_001058" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20190101_20191231" decimals="INF" unitRef="U_xbrlishares">1986300</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber id="F_001059" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20191231" decimals="INF" unitRef="U_xbrlishares">4506950</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber id="F_001060" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20191231" decimals="INF" unitRef="U_xbrlishares">3973614</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice id="F_001061" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20161231" decimals="2" unitRef="U_iso4217USD_xbrlishares">7.14</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice id="F_001062" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20170101_20171231" decimals="2" unitRef="U_iso4217USD_xbrlishares">1.88</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice id="F_001063" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20171231" decimals="2" unitRef="U_iso4217USD_xbrlishares">7.71</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice id="F_001064" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20180101_20181231" decimals="2" unitRef="U_iso4217USD_xbrlishares">3.07</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice id="F_001065" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20181231" decimals="2" unitRef="U_iso4217USD_xbrlishares">7.14</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice id="F_001066" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20190101_20191231" decimals="2" unitRef="U_iso4217USD_xbrlishares">2.06</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice id="F_001067" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20191231" decimals="2" unitRef="U_iso4217USD_xbrlishares">9.37</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice id="F_001068" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20191231" decimals="2" unitRef="U_iso4217USD_xbrlishares">10.22</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue id="F_001069" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20161231" decimals="-3" unitRef="U_iso4217USD">19100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue id="F_001070" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20171231" decimals="-3" unitRef="U_iso4217USD">11920000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue id="F_001071" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20181231" decimals="-3" unitRef="U_iso4217USD">563000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue id="F_001072" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20191231" decimals="-3" unitRef="U_iso4217USD">5710000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue id="F_001073" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20191231" decimals="-3" unitRef="U_iso4217USD">5326000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 id="F_001074" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20160101_20161231">P6Y4M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 id="F_001075" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20170101_20171231">P5Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 id="F_001076" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20180101_20181231">P4Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 id="F_001077" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20190101_20191231">P5Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1 id="F_001078" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20190101_20191231">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
  <nk:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableOutstandingNumber id="F_001079" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20181231" decimals="INF" unitRef="U_xbrlishares">5577531</nk:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableOutstandingNumber>
  <nk:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableOutstandingNumber id="F_001080" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20171231" decimals="INF" unitRef="U_xbrlishares">5114656</nk:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableOutstandingNumber>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1 id="F_001081" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_nkExercisePriceRangeOneMember_20191231" decimals="2" unitRef="U_iso4217USD_xbrlishares">0.42</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1 id="F_001082" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_nkExercisePriceRangeTwoMember_20191231" decimals="2" unitRef="U_iso4217USD_xbrlishares">1.76</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1 id="F_001083" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_nkExercisePriceRangeThreeMember_20191231" decimals="2" unitRef="U_iso4217USD_xbrlishares">2.00</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1 id="F_001084" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_nkExercisePriceRangeFourMember_20191231" decimals="2" unitRef="U_iso4217USD_xbrlishares">3.07</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1 id="F_001085" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_nkExercisePriceRangeFiveMember_20191231" decimals="2" unitRef="U_iso4217USD_xbrlishares">25.00</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions id="F_001086" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_nkExercisePriceRangeOneMember_20191231" decimals="INF" unitRef="U_xbrlishares">589660</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions id="F_001087" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_nkExercisePriceRangeTwoMember_20191231" decimals="INF" unitRef="U_xbrlishares">699060</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions id="F_001088" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_nkExercisePriceRangeThreeMember_20191231" decimals="INF" unitRef="U_xbrlishares">962780</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions id="F_001089" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_nkExercisePriceRangeFourMember_20191231" decimals="INF" unitRef="U_xbrlishares">800000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions id="F_001090" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_nkExercisePriceRangeFiveMember_20191231" decimals="INF" unitRef="U_xbrlishares">1455450</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions id="F_001091" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20191231" decimals="INF" unitRef="U_xbrlishares">4506950</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 id="F_001092" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_nkExercisePriceRangeOneMember_20190101_20191231">P4Y10M24D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 id="F_001093" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_nkExercisePriceRangeTwoMember_20190101_20191231">P5Y</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 id="F_001094" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_nkExercisePriceRangeThreeMember_20190101_20191231">P5Y1M6D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 id="F_001095" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_nkExercisePriceRangeFourMember_20190101_20191231">P8Y8M12D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 id="F_001096" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_nkExercisePriceRangeFiveMember_20190101_20191231">P5Y7M6D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 id="F_001097" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20190101_20191231">P5Y9M18D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber id="F_001098" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_nkExercisePriceRangeOneMember_20191231" decimals="INF" unitRef="U_xbrlishares">589660</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber id="F_001099" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_nkExercisePriceRangeTwoMember_20191231" decimals="INF" unitRef="U_xbrlishares">699060</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber id="F_001100" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_nkExercisePriceRangeThreeMember_20191231" decimals="INF" unitRef="U_xbrlishares">962780</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber id="F_001101" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_nkExercisePriceRangeFourMember_20191231" decimals="INF" unitRef="U_xbrlishares">266664</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber id="F_001102" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_nkExercisePriceRangeFiveMember_20191231" decimals="INF" unitRef="U_xbrlishares">1455450</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber id="F_001103" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20191231" decimals="INF" unitRef="U_xbrlishares">3973614</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1 id="F_001104" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_nkExercisePriceRangeOneMember_20190101_20191231">P4Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1 id="F_001105" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_nkExercisePriceRangeTwoMember_20190101_20191231">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1 id="F_001106" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_nkExercisePriceRangeThreeMember_20190101_20191231">P5Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1 id="F_001107" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_nkExercisePriceRangeFourMember_20190101_20191231">P8Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1 id="F_001108" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_nkExercisePriceRangeFiveMember_20190101_20191231">P5Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue id="F_001109" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20190101_20191231" decimals="-5" unitRef="U_iso4217USD">200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue id="F_001110" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20180101_20181231" decimals="-5" unitRef="U_iso4217USD">600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue id="F_001111" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20170101_20171231" decimals="-5" unitRef="U_iso4217USD">1700000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
  <us-gaap:ProceedsFromStockOptionsExercised id="F_001112" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20190101_20191231" decimals="-5" unitRef="U_iso4217USD">4100000</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:ProceedsFromStockOptionsExercised id="F_001113" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20180101_20181231" decimals="-6" unitRef="U_iso4217USD">0</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:ProceedsFromStockOptionsExercised id="F_001114" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20170101_20171231" decimals="-5" unitRef="U_iso4217USD">1200000</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod id="F_001115" contextRef="C_0001326110_us-gaapAwardTypeAxis_nkKeyExecutivesStockOptionsMember_20180101_20181231" decimals="INF" unitRef="U_xbrlishares">800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1 id="F_001116" contextRef="C_0001326110_us-gaapAwardTypeAxis_nkKeyExecutivesStockOptionsMember_20191231" decimals="2" unitRef="U_iso4217USD_xbrlishares">3.07</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage id="F_001117" contextRef="C_0001326110_us-gaapAwardTypeAxis_nkKeyExecutivesStockOptionsMember_20190101_20191231" decimals="INF" unitRef="U_xbrlipure">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 id="F_001118" contextRef="C_0001326110_us-gaapAwardTypeAxis_nkKeyExecutivesStockOptionsMember_20190101_20191231">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod id="F_001119" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20190101_20191231" decimals="INF" unitRef="U_xbrlishares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod id="F_001120" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20170101_20171231" decimals="INF" unitRef="U_xbrlishares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod id="F_001121" contextRef="C_0001326110_us-gaapAwardTypeAxis_nkNonEmployeeStockOptionsMember_20190101_20191231" decimals="INF" unitRef="U_xbrlishares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod id="F_001122" contextRef="C_0001326110_us-gaapAwardTypeAxis_nkNonEmployeeStockOptionsMember_20180101_20181231" decimals="INF" unitRef="U_xbrlishares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod id="F_001123" contextRef="C_0001326110_us-gaapAwardTypeAxis_nkNonEmployeeStockOptionsMember_20170101_20171231" decimals="INF" unitRef="U_xbrlishares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions id="F_001124" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20191231" decimals="-5" unitRef="U_iso4217USD">1100000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 id="F_001125" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20190101_20191231">P2Y8M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 id="F_001126" contextRef="C_0001326110_srtRangeAxis_srtMinimumMember_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20180101_20181231">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 id="F_001127" contextRef="C_0001326110_srtRangeAxis_srtMaximumMember_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20180101_20181231">P6Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate id="F_001128" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20180101_20181231" decimals="3" unitRef="U_xbrlipure">0.028</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate id="F_001129" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20180101_20181231" decimals="3" unitRef="U_xbrlipure">0.759</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate id="F_001130" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20180101_20181231" decimals="2" unitRef="U_xbrlipure">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <nk:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsPrice id="F_001131" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20181231" decimals="2" unitRef="U_iso4217USD_xbrlishares">2.09</nk:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsPrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber id="F_001132" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20161231" decimals="INF" unitRef="U_xbrlishares">814456</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod id="F_001133" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20170101_20171231" decimals="INF" unitRef="U_xbrlishares">615983</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod id="F_001134" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20170101_20171231" decimals="INF" unitRef="U_xbrlishares">244209</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod id="F_001135" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20170101_20171231" decimals="INF" unitRef="U_xbrlishares">298041</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber id="F_001136" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20171231" decimals="INF" unitRef="U_xbrlishares">888189</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod id="F_001137" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20180101_20181231" decimals="INF" unitRef="U_xbrlishares">487472</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod id="F_001138" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20180101_20181231" decimals="INF" unitRef="U_xbrlishares">172330</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod id="F_001139" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20180101_20181231" decimals="INF" unitRef="U_xbrlishares">335420</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber id="F_001140" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20181231" decimals="INF" unitRef="U_xbrlishares">867911</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod id="F_001141" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20190101_20191231" decimals="INF" unitRef="U_xbrlishares">749793</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod id="F_001142" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20190101_20191231" decimals="INF" unitRef="U_xbrlishares">395051</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod id="F_001143" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20190101_20191231" decimals="INF" unitRef="U_xbrlishares">83225</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber id="F_001144" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20191231" decimals="INF" unitRef="U_xbrlishares">1139428</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue id="F_001145" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20161231" decimals="2" unitRef="U_iso4217USD_xbrlishares">13.98</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue id="F_001146" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20170101_20171231" decimals="2" unitRef="U_iso4217USD_xbrlishares">4.50</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue id="F_001147" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20170101_20171231" decimals="2" unitRef="U_iso4217USD_xbrlishares">15.82</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue id="F_001148" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20170101_20171231" decimals="2" unitRef="U_iso4217USD_xbrlishares">10.28</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue id="F_001149" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20171231" decimals="2" unitRef="U_iso4217USD_xbrlishares">8.14</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue id="F_001150" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20180101_20181231" decimals="2" unitRef="U_iso4217USD_xbrlishares">3.57</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue id="F_001151" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20180101_20181231" decimals="2" unitRef="U_iso4217USD_xbrlishares">6.16</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue id="F_001152" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20180101_20181231" decimals="2" unitRef="U_iso4217USD_xbrlishares">6.27</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue id="F_001153" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20181231" decimals="2" unitRef="U_iso4217USD_xbrlishares">6.69</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue id="F_001154" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20190101_20191231" decimals="2" unitRef="U_iso4217USD_xbrlishares">1.12</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue id="F_001155" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20190101_20191231" decimals="2" unitRef="U_iso4217USD_xbrlishares">8.83</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue id="F_001156" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20190101_20191231" decimals="2" unitRef="U_iso4217USD_xbrlishares">7.29</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue id="F_001157" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20191231" decimals="2" unitRef="U_iso4217USD_xbrlishares">2.23</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod id="F_001158" contextRef="C_0001326110_us-gaapAwardTypeAxis_nkNonEmployeeRestrictedStockUnitMember_20190101_20191231" decimals="INF" unitRef="U_xbrlishares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod id="F_001159" contextRef="C_0001326110_us-gaapAwardTypeAxis_nkNonEmployeeRestrictedStockUnitMember_20180101_20181231" decimals="INF" unitRef="U_xbrlishares">90906</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod id="F_001160" contextRef="C_0001326110_us-gaapAwardTypeAxis_nkNonEmployeeRestrictedStockUnitMember_20170101_20171231" decimals="INF" unitRef="U_xbrlishares">77250</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions id="F_001161" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20191231" decimals="-5" unitRef="U_iso4217USD">1400000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 id="F_001162" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20190101_20191231">P1Y8M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions id="F_001163" contextRef="C_0001326110_us-gaapAwardTypeAxis_nkEmployeeRestrictedStockUnitMember_20191231" decimals="-5" unitRef="U_iso4217USD">1300000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 id="F_001164" contextRef="C_0001326110_us-gaapAwardTypeAxis_nkEmployeeRestrictedStockUnitMember_20190101_20191231">P1Y9M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions id="F_001165" contextRef="C_0001326110_us-gaapAwardTypeAxis_nkNonEmployeeRestrictedStockUnitMember_20191231" decimals="-5" unitRef="U_iso4217USD">100000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 id="F_001166" contextRef="C_0001326110_us-gaapAwardTypeAxis_nkNonEmployeeRestrictedStockUnitMember_20190101_20191231">P9M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
  <us-gaap:ClassOfWarrantOrRightOutstanding id="F_001167" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapWarrantMember_20161231" decimals="INF" unitRef="U_xbrlishares">17768314</us-gaap:ClassOfWarrantOrRightOutstanding>
  <nk:StockIssuedDuringPeriodSharesWarrantsExercised id="F_001168" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapWarrantMember_20170101_20171231" decimals="INF" unitRef="U_xbrlishares">47226</nk:StockIssuedDuringPeriodSharesWarrantsExercised>
  <us-gaap:ClassOfWarrantOrRightOutstanding id="F_001169" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapWarrantMember_20171231" decimals="INF" unitRef="U_xbrlishares">17721088</us-gaap:ClassOfWarrantOrRightOutstanding>
  <nk:StockIssuedDuringPeriodSharesWarrantsExercised id="F_001170" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapWarrantMember_20180101_20181231" decimals="INF" unitRef="U_xbrlishares">93254</nk:StockIssuedDuringPeriodSharesWarrantsExercised>
  <nk:StockIssuedDuringPeriodSharesWarrantsExpired id="F_001171" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapWarrantMember_20180101_20181231" decimals="INF" unitRef="U_xbrlishares">38584</nk:StockIssuedDuringPeriodSharesWarrantsExpired>
  <us-gaap:ClassOfWarrantOrRightOutstanding id="F_001172" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapWarrantMember_20181231" decimals="INF" unitRef="U_xbrlishares">17589250</us-gaap:ClassOfWarrantOrRightOutstanding>
  <nk:StockIssuedDuringPeriodSharesWarrantsExercised id="F_001173" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapWarrantMember_20190101_20191231" decimals="INF" unitRef="U_xbrlishares">17589250</nk:StockIssuedDuringPeriodSharesWarrantsExercised>
  <us-gaap:ClassOfWarrantOrRightOutstanding id="F_001174" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapWarrantMember_20191231" decimals="INF" unitRef="U_xbrlishares">0</us-gaap:ClassOfWarrantOrRightOutstanding>
  <nk:ClassOfWarrantOrVestedAndExercisable id="F_001175" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapWarrantMember_20191231" decimals="INF" unitRef="U_xbrlishares">0</nk:ClassOfWarrantOrVestedAndExercisable>
  <us-gaap:ProceedsFromWarrantExercises id="F_001176" contextRef="C_0001326110_20190101_20191231" decimals="-5" unitRef="U_iso4217USD">35200000</us-gaap:ProceedsFromWarrantExercises>
  <us-gaap:ProceedsFromWarrantExercises id="F_001177" contextRef="C_0001326110_20180101_20181231" decimals="-5" unitRef="U_iso4217USD">100000</us-gaap:ProceedsFromWarrantExercises>
  <us-gaap:ProceedsFromWarrantExercises id="F_001178" contextRef="C_0001326110_20170101_20171231" decimals="-5" unitRef="U_iso4217USD">100000</us-gaap:ProceedsFromWarrantExercises>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic id="F_001179" contextRef="C_0001326110_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-65286000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic id="F_001180" contextRef="C_0001326110_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">-94423000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic id="F_001181" contextRef="C_0001326110_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">-94734000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign id="F_001182" contextRef="C_0001326110_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-600000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign id="F_001183" contextRef="C_0001326110_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">-2306000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign id="F_001184" contextRef="C_0001326110_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">-2182000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
  <us-gaap:CurrentFederalTaxExpenseBenefit id="F_001185" contextRef="C_0001326110_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:CurrentFederalTaxExpenseBenefit>
  <us-gaap:CurrentFederalTaxExpenseBenefit id="F_001186" contextRef="C_0001326110_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:CurrentFederalTaxExpenseBenefit>
  <us-gaap:CurrentFederalTaxExpenseBenefit id="F_001187" contextRef="C_0001326110_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:CurrentFederalTaxExpenseBenefit>
  <us-gaap:CurrentStateAndLocalTaxExpenseBenefit id="F_001188" contextRef="C_0001326110_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">3000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
  <us-gaap:CurrentStateAndLocalTaxExpenseBenefit id="F_001189" contextRef="C_0001326110_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">3000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
  <us-gaap:CurrentStateAndLocalTaxExpenseBenefit id="F_001190" contextRef="C_0001326110_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">4000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
  <us-gaap:CurrentForeignTaxExpenseBenefit id="F_001191" contextRef="C_0001326110_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:CurrentForeignTaxExpenseBenefit>
  <us-gaap:CurrentForeignTaxExpenseBenefit id="F_001192" contextRef="C_0001326110_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:CurrentForeignTaxExpenseBenefit>
  <us-gaap:CurrentForeignTaxExpenseBenefit id="F_001193" contextRef="C_0001326110_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:CurrentForeignTaxExpenseBenefit>
  <us-gaap:CurrentIncomeTaxExpenseBenefit id="F_001194" contextRef="C_0001326110_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">3000</us-gaap:CurrentIncomeTaxExpenseBenefit>
  <us-gaap:CurrentIncomeTaxExpenseBenefit id="F_001195" contextRef="C_0001326110_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">3000</us-gaap:CurrentIncomeTaxExpenseBenefit>
  <us-gaap:CurrentIncomeTaxExpenseBenefit id="F_001196" contextRef="C_0001326110_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">4000</us-gaap:CurrentIncomeTaxExpenseBenefit>
  <us-gaap:DeferredFederalIncomeTaxExpenseBenefit id="F_001197" contextRef="C_0001326110_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-79000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
  <us-gaap:DeferredFederalIncomeTaxExpenseBenefit id="F_001198" contextRef="C_0001326110_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
  <us-gaap:DeferredFederalIncomeTaxExpenseBenefit id="F_001199" contextRef="C_0001326110_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
  <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit id="F_001200" contextRef="C_0001326110_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-21000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
  <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit id="F_001201" contextRef="C_0001326110_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">-8000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
  <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit id="F_001202" contextRef="C_0001326110_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
  <us-gaap:DeferredForeignIncomeTaxExpenseBenefit id="F_001203" contextRef="C_0001326110_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
  <us-gaap:DeferredForeignIncomeTaxExpenseBenefit id="F_001204" contextRef="C_0001326110_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">-498000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
  <us-gaap:DeferredForeignIncomeTaxExpenseBenefit id="F_001205" contextRef="C_0001326110_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">-497000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
  <nk:DeferredIncomeTaxExpenseBenefitNet id="F_001206" contextRef="C_0001326110_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-100000</nk:DeferredIncomeTaxExpenseBenefitNet>
  <nk:DeferredIncomeTaxExpenseBenefitNet id="F_001207" contextRef="C_0001326110_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">-506000</nk:DeferredIncomeTaxExpenseBenefitNet>
  <nk:DeferredIncomeTaxExpenseBenefitNet id="F_001208" contextRef="C_0001326110_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">-497000</nk:DeferredIncomeTaxExpenseBenefitNet>
  <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards id="F_001209" contextRef="C_0001326110_20191231" decimals="-3" unitRef="U_iso4217USD">78377000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
  <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards id="F_001210" contextRef="C_0001326110_20181231" decimals="-3" unitRef="U_iso4217USD">61915000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
  <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost id="F_001211" contextRef="C_0001326110_20191231" decimals="-3" unitRef="U_iso4217USD">8536000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
  <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost id="F_001212" contextRef="C_0001326110_20181231" decimals="-3" unitRef="U_iso4217USD">79281000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
  <nk:DeferredTaxAssetsOperatingLeaseLiabilities id="F_001213" contextRef="C_0001326110_20191231" decimals="-3" unitRef="U_iso4217USD">3884000</nk:DeferredTaxAssetsOperatingLeaseLiabilities>
  <nk:DeferredTaxAssetsOperatingLeaseLiabilities id="F_001214" contextRef="C_0001326110_20181231" decimals="-3" unitRef="U_iso4217USD">0</nk:DeferredTaxAssetsOperatingLeaseLiabilities>
  <nk:DeferredTaxAssetsDeferredDepreciationAndAmortization id="F_001215" contextRef="C_0001326110_20191231" decimals="-3" unitRef="U_iso4217USD">2042000</nk:DeferredTaxAssetsDeferredDepreciationAndAmortization>
  <nk:DeferredTaxAssetsDeferredDepreciationAndAmortization id="F_001216" contextRef="C_0001326110_20181231" decimals="-3" unitRef="U_iso4217USD">0</nk:DeferredTaxAssetsDeferredDepreciationAndAmortization>
  <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards id="F_001217" contextRef="C_0001326110_20191231" decimals="-3" unitRef="U_iso4217USD">898000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
  <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards id="F_001218" contextRef="C_0001326110_20181231" decimals="-3" unitRef="U_iso4217USD">845000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
  <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation id="F_001219" contextRef="C_0001326110_20191231" decimals="-3" unitRef="U_iso4217USD">775000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation>
  <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation id="F_001220" contextRef="C_0001326110_20181231" decimals="-3" unitRef="U_iso4217USD">795000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation>
  <nk:DeferredTaxAssetsLeasesAndOtherAccruedLiabilities id="F_001221" contextRef="C_0001326110_20191231" decimals="-3" unitRef="U_iso4217USD">453000</nk:DeferredTaxAssetsLeasesAndOtherAccruedLiabilities>
  <nk:DeferredTaxAssetsLeasesAndOtherAccruedLiabilities id="F_001222" contextRef="C_0001326110_20181231" decimals="-3" unitRef="U_iso4217USD">2909000</nk:DeferredTaxAssetsLeasesAndOtherAccruedLiabilities>
  <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLegalSettlements id="F_001223" contextRef="C_0001326110_20191231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLegalSettlements>
  <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLegalSettlements id="F_001224" contextRef="C_0001326110_20181231" decimals="-3" unitRef="U_iso4217USD">308000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLegalSettlements>
  <us-gaap:DeferredTaxAssetsGross id="F_001225" contextRef="C_0001326110_20191231" decimals="-3" unitRef="U_iso4217USD">94965000</us-gaap:DeferredTaxAssetsGross>
  <us-gaap:DeferredTaxAssetsGross id="F_001226" contextRef="C_0001326110_20181231" decimals="-3" unitRef="U_iso4217USD">146053000</us-gaap:DeferredTaxAssetsGross>
  <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets id="F_001227" contextRef="C_0001326110_20191231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
  <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets id="F_001228" contextRef="C_0001326110_20181231" decimals="-3" unitRef="U_iso4217USD">1000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
  <nk:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets id="F_001229" contextRef="C_0001326110_20191231" decimals="-3" unitRef="U_iso4217USD">3233000</nk:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets>
  <nk:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets id="F_001230" contextRef="C_0001326110_20181231" decimals="-3" unitRef="U_iso4217USD">0</nk:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets>
  <nk:DeferredTaxLiabilitiesDeferredDepreciationAndAmortization id="F_001231" contextRef="C_0001326110_20191231" decimals="-3" unitRef="U_iso4217USD">0</nk:DeferredTaxLiabilitiesDeferredDepreciationAndAmortization>
  <nk:DeferredTaxLiabilitiesDeferredDepreciationAndAmortization id="F_001232" contextRef="C_0001326110_20181231" decimals="-3" unitRef="U_iso4217USD">1279000</nk:DeferredTaxLiabilitiesDeferredDepreciationAndAmortization>
  <us-gaap:DeferredIncomeTaxLiabilities id="F_001233" contextRef="C_0001326110_20191231" decimals="-3" unitRef="U_iso4217USD">3233000</us-gaap:DeferredIncomeTaxLiabilities>
  <us-gaap:DeferredIncomeTaxLiabilities id="F_001234" contextRef="C_0001326110_20181231" decimals="-3" unitRef="U_iso4217USD">1280000</us-gaap:DeferredIncomeTaxLiabilities>
  <us-gaap:DeferredTaxAssetsLiabilitiesNet id="F_001235" contextRef="C_0001326110_20191231" decimals="-3" unitRef="U_iso4217USD">91732000</us-gaap:DeferredTaxAssetsLiabilitiesNet>
  <us-gaap:DeferredTaxAssetsLiabilitiesNet id="F_001236" contextRef="C_0001326110_20181231" decimals="-3" unitRef="U_iso4217USD">144773000</us-gaap:DeferredTaxAssetsLiabilitiesNet>
  <us-gaap:DeferredTaxAssetsValuationAllowance id="F_001237" contextRef="C_0001326110_20191231" decimals="-3" unitRef="U_iso4217USD">91732000</us-gaap:DeferredTaxAssetsValuationAllowance>
  <us-gaap:DeferredTaxAssetsValuationAllowance id="F_001238" contextRef="C_0001326110_20181231" decimals="-3" unitRef="U_iso4217USD">144773000</us-gaap:DeferredTaxAssetsValuationAllowance>
  <us-gaap:DeferredTaxLiabilities id="F_001239" contextRef="C_0001326110_20191231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:DeferredTaxLiabilities>
  <us-gaap:DeferredTaxLiabilities id="F_001240" contextRef="C_0001326110_20181231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:DeferredTaxLiabilities>
  <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate id="F_001241" contextRef="C_0001326110_20190101_20191231" decimals="INF" unitRef="U_xbrlipure">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
  <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate id="F_001242" contextRef="C_0001326110_20180101_20181231" decimals="INF" unitRef="U_xbrlipure">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
  <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate id="F_001243" contextRef="C_0001326110_20170101_20171231" decimals="INF" unitRef="U_xbrlipure">0.340</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
  <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes id="F_001244" contextRef="C_0001326110_20190101_20191231" decimals="3" unitRef="U_xbrlipure">-0.194</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
  <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes id="F_001245" contextRef="C_0001326110_20180101_20181231" decimals="3" unitRef="U_xbrlipure">0.062</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
  <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes id="F_001246" contextRef="C_0001326110_20170101_20171231" decimals="3" unitRef="U_xbrlipure">0.053</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
  <us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlements id="F_001247" contextRef="C_0001326110_20190101_20191231" decimals="3" unitRef="U_xbrlipure">0.001</us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlements>
  <us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlements id="F_001248" contextRef="C_0001326110_20180101_20181231" decimals="3" unitRef="U_xbrlipure">-0.003</us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlements>
  <us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlements id="F_001249" contextRef="C_0001326110_20170101_20171231" decimals="3" unitRef="U_xbrlipure">0.048</us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlements>
  <nk:EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsAct id="F_001250" contextRef="C_0001326110_20190101_20191231" decimals="2" unitRef="U_xbrlipure">0.00</nk:EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsAct>
  <nk:EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsAct id="F_001251" contextRef="C_0001326110_20180101_20181231" decimals="2" unitRef="U_xbrlipure">0.00</nk:EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsAct>
  <nk:EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsAct id="F_001252" contextRef="C_0001326110_20170101_20171231" decimals="3" unitRef="U_xbrlipure">-0.534</nk:EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsAct>
  <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment id="F_001253" contextRef="C_0001326110_20190101_20191231" decimals="3" unitRef="U_xbrlipure">0.002</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment>
  <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment id="F_001254" contextRef="C_0001326110_20180101_20181231" decimals="3" unitRef="U_xbrlipure">0.001</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment>
  <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment id="F_001255" contextRef="C_0001326110_20170101_20171231" decimals="3" unitRef="U_xbrlipure">0.006</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment>
  <nk:EffectiveIncomeTaxRateReconciliationStockBasedCompensationContribution id="F_001256" contextRef="C_0001326110_20190101_20191231" decimals="3" unitRef="U_xbrlipure">-0.825</nk:EffectiveIncomeTaxRateReconciliationStockBasedCompensationContribution>
  <nk:EffectiveIncomeTaxRateReconciliationStockBasedCompensationContribution id="F_001257" contextRef="C_0001326110_20180101_20181231" decimals="3" unitRef="U_xbrlipure">-0.001</nk:EffectiveIncomeTaxRateReconciliationStockBasedCompensationContribution>
  <nk:EffectiveIncomeTaxRateReconciliationStockBasedCompensationContribution id="F_001258" contextRef="C_0001326110_20170101_20171231" decimals="3" unitRef="U_xbrlipure">-0.003</nk:EffectiveIncomeTaxRateReconciliationStockBasedCompensationContribution>
  <us-gaap:EffectiveIncomeTaxRateReconciliationDeductionsOther id="F_001259" contextRef="C_0001326110_20190101_20191231" decimals="3" unitRef="U_xbrlipure">-0.001</us-gaap:EffectiveIncomeTaxRateReconciliationDeductionsOther>
  <us-gaap:EffectiveIncomeTaxRateReconciliationDeductionsOther id="F_001260" contextRef="C_0001326110_20180101_20181231" decimals="3" unitRef="U_xbrlipure">0.003</us-gaap:EffectiveIncomeTaxRateReconciliationDeductionsOther>
  <us-gaap:EffectiveIncomeTaxRateReconciliationDeductionsOther id="F_001261" contextRef="C_0001326110_20170101_20171231" decimals="3" unitRef="U_xbrlipure">0.008</us-gaap:EffectiveIncomeTaxRateReconciliationDeductionsOther>
  <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance id="F_001262" contextRef="C_0001326110_20190101_20191231" decimals="3" unitRef="U_xbrlipure">0.805</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
  <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance id="F_001263" contextRef="C_0001326110_20180101_20181231" decimals="3" unitRef="U_xbrlipure">-0.267</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
  <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance id="F_001264" contextRef="C_0001326110_20170101_20171231" decimals="3" unitRef="U_xbrlipure">0.087</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
  <us-gaap:EffectiveIncomeTaxRateContinuingOperations id="F_001265" contextRef="C_0001326110_20190101_20191231" decimals="3" unitRef="U_xbrlipure">-0.002</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
  <us-gaap:EffectiveIncomeTaxRateContinuingOperations id="F_001266" contextRef="C_0001326110_20180101_20181231" decimals="3" unitRef="U_xbrlipure">0.005</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
  <us-gaap:EffectiveIncomeTaxRateContinuingOperations id="F_001267" contextRef="C_0001326110_20170101_20171231" decimals="3" unitRef="U_xbrlipure">0.005</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
  <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate id="F_001268" contextRef="C_0001326110_srtRangeAxis_srtMaximumMember_20170101_20171231" decimals="INF" unitRef="U_xbrlipure">0.35</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
  <nk:TaxCutsAndJobsActOf2017IncompleteAccountingChangeInTaxRateMinimumAmountForEliminationOfSeveralBusinessDeductionsAndCreditsIncludingDeductionsForCertainExecutiveCompensation id="F_001269" contextRef="C_0001326110_20191231" decimals="INF" unitRef="U_iso4217USD">1000000</nk:TaxCutsAndJobsActOf2017IncompleteAccountingChangeInTaxRateMinimumAmountForEliminationOfSeveralBusinessDeductionsAndCreditsIncludingDeductionsForCertainExecutiveCompensation>
  <nk:TaxCutsAndJobsActOf2017IncompleteAccountingChangeInTaxRateReductionInDeferredTaxAssets id="F_001270" contextRef="C_0001326110_20171231" decimals="-5" unitRef="U_iso4217USD">51700000</nk:TaxCutsAndJobsActOf2017IncompleteAccountingChangeInTaxRateReductionInDeferredTaxAssets>
  <nk:ResearchAndDevelopmentCumulativeChangeInOwnershipPercentage id="F_001271" contextRef="C_0001326110_20190101_20191231" decimals="2" unitRef="U_xbrlipure">0.50</nk:ResearchAndDevelopmentCumulativeChangeInOwnershipPercentage>
  <nk:PeriodOfCumulativeOwnershipChange id="F_001272" contextRef="C_0001326110_20190101_20191231">P3Y</nk:PeriodOfCumulativeOwnershipChange>
  <nk:DerecognizedDeferredTaxAssets id="F_001273" contextRef="C_0001326110_20191231" decimals="-5" unitRef="U_iso4217USD">800000</nk:DerecognizedDeferredTaxAssets>
  <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount id="F_001274" contextRef="C_0001326110_20190101_20191231" decimals="-5" unitRef="U_iso4217USD">-53000000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
  <us-gaap:IncomeTaxEffectsAllocatedDirectlyToEquityEquityTransactions id="F_001275" contextRef="C_0001326110_20190101_20191231" decimals="-5" unitRef="U_iso4217USD">200000</us-gaap:IncomeTaxEffectsAllocatedDirectlyToEquityEquityTransactions>
  <us-gaap:OperatingLossCarryforwards id="F_001276" contextRef="C_0001326110_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20191231" decimals="-5" unitRef="U_iso4217USD">291800000</us-gaap:OperatingLossCarryforwards>
  <us-gaap:OperatingLossCarryforwards id="F_001277" contextRef="C_0001326110_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20191231" decimals="-5" unitRef="U_iso4217USD">255700000</us-gaap:OperatingLossCarryforwards>
  <us-gaap:OperatingLossCarryforwards id="F_001278" contextRef="C_0001326110_us-gaapIncomeTaxAuthorityAxis_us-gaapForeignCountryMember_20191231" decimals="-5" unitRef="U_iso4217USD">200000</us-gaap:OperatingLossCarryforwards>
  <nk:NetOperatingLossCarryforwardsExpirationDate id="F_001279" contextRef="C_0001326110_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20190101_20191231">2024</nk:NetOperatingLossCarryforwardsExpirationDate>
  <nk:NetOperatingLossCarryforwardsExpirationDate id="F_001280" contextRef="C_0001326110_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20190101_20191231">2030</nk:NetOperatingLossCarryforwardsExpirationDate>
  <nk:NetOperatingLossCarryforwardsExpirationDate id="F_001281" contextRef="C_0001326110_us-gaapIncomeTaxAuthorityAxis_us-gaapForeignCountryMember_20190101_20191231">2022</nk:NetOperatingLossCarryforwardsExpirationDate>
  <us-gaap:TaxCreditCarryforwardAmount id="F_001282" contextRef="C_0001326110_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_us-gaapTaxCreditCarryforwardAxis_us-gaapResearchMember_20191231" decimals="-5" unitRef="U_iso4217USD">8500000</us-gaap:TaxCreditCarryforwardAmount>
  <us-gaap:TaxCreditCarryforwardAmount id="F_001283" contextRef="C_0001326110_srtStatementGeographicalAxis_stprCA_us-gaapTaxCreditCarryforwardAxis_us-gaapResearchMember_20191231" decimals="-5" unitRef="U_iso4217USD">5700000</us-gaap:TaxCreditCarryforwardAmount>
  <nk:TaxCreditCarryforwardExpirationPeriod id="F_001284" contextRef="C_0001326110_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_us-gaapTaxCreditCarryforwardAxis_us-gaapResearchMember_20190101_20191231">2034</nk:TaxCreditCarryforwardExpirationPeriod>
  <nk:TaxCreditCarryforwardExpirationPeriod id="F_001285" contextRef="C_0001326110_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_us-gaapTaxCreditCarryforwardAxis_us-gaapResearchMember_20190101_20191231">2031</nk:TaxCreditCarryforwardExpirationPeriod>
  <us-gaap:UnrecognizedTaxBenefits id="F_001286" contextRef="C_0001326110_20171231" decimals="-3" unitRef="U_iso4217USD">6577000</us-gaap:UnrecognizedTaxBenefits>
  <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions id="F_001287" contextRef="C_0001326110_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">798000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
  <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions id="F_001288" contextRef="C_0001326110_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">4608000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
  <us-gaap:UnrecognizedTaxBenefits id="F_001289" contextRef="C_0001326110_20181231" decimals="-3" unitRef="U_iso4217USD">11983000</us-gaap:UnrecognizedTaxBenefits>
  <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions id="F_001290" contextRef="C_0001326110_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">7000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
  <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions id="F_001291" contextRef="C_0001326110_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">3680000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
  <us-gaap:UnrecognizedTaxBenefits id="F_001292" contextRef="C_0001326110_20191231" decimals="-3" unitRef="U_iso4217USD">15656000</us-gaap:UnrecognizedTaxBenefits>
  <nk:UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRate id="F_001293" contextRef="C_0001326110_20191231" decimals="-5" unitRef="U_iso4217USD">14100000</nk:UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRate>
  <us-gaap:Revenues id="F_001294" contextRef="C_0001326110_20190101_20190331" decimals="-3" unitRef="U_iso4217USD">5000</us-gaap:Revenues>
  <us-gaap:Revenues id="F_001295" contextRef="C_0001326110_20190401_20190630" decimals="-3" unitRef="U_iso4217USD">17000</us-gaap:Revenues>
  <us-gaap:Revenues id="F_001296" contextRef="C_0001326110_20190701_20190930" decimals="-3" unitRef="U_iso4217USD">12000</us-gaap:Revenues>
  <us-gaap:Revenues id="F_001297" contextRef="C_0001326110_20191001_20191231" decimals="-3" unitRef="U_iso4217USD">9000</us-gaap:Revenues>
  <us-gaap:OperatingExpenses id="F_001298" contextRef="C_0001326110_20190101_20190331" decimals="-3" unitRef="U_iso4217USD">18340000</us-gaap:OperatingExpenses>
  <us-gaap:OperatingExpenses id="F_001299" contextRef="C_0001326110_20190401_20190630" decimals="-3" unitRef="U_iso4217USD">17313000</us-gaap:OperatingExpenses>
  <us-gaap:OperatingExpenses id="F_001300" contextRef="C_0001326110_20190701_20190930" decimals="-3" unitRef="U_iso4217USD">16077000</us-gaap:OperatingExpenses>
  <us-gaap:OperatingExpenses id="F_001301" contextRef="C_0001326110_20191001_20191231" decimals="-3" unitRef="U_iso4217USD">16120000</us-gaap:OperatingExpenses>
  <us-gaap:OperatingIncomeLoss id="F_001302" contextRef="C_0001326110_20190101_20190331" decimals="-3" unitRef="U_iso4217USD">-18335000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss id="F_001303" contextRef="C_0001326110_20190401_20190630" decimals="-3" unitRef="U_iso4217USD">-17296000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss id="F_001304" contextRef="C_0001326110_20190701_20190930" decimals="-3" unitRef="U_iso4217USD">-16065000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss id="F_001305" contextRef="C_0001326110_20191001_20191231" decimals="-3" unitRef="U_iso4217USD">-16111000</us-gaap:OperatingIncomeLoss>
  <us-gaap:NetIncomeLoss id="F_001306" contextRef="C_0001326110_20190101_20190331" decimals="-3" unitRef="U_iso4217USD">-17885000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss id="F_001307" contextRef="C_0001326110_20190401_20190630" decimals="-3" unitRef="U_iso4217USD">-16682000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss id="F_001308" contextRef="C_0001326110_20190701_20190930" decimals="-3" unitRef="U_iso4217USD">-15581000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss id="F_001309" contextRef="C_0001326110_20191001_20191231" decimals="-3" unitRef="U_iso4217USD">-15641000</us-gaap:NetIncomeLoss>
  <us-gaap:EarningsPerShareBasicAndDiluted id="F_001310" contextRef="C_0001326110_20190101_20190331" decimals="2" unitRef="U_iso4217USD_xbrlishares">-0.22</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted id="F_001311" contextRef="C_0001326110_20190401_20190630" decimals="2" unitRef="U_iso4217USD_xbrlishares">-0.17</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted id="F_001312" contextRef="C_0001326110_20190701_20190930" decimals="2" unitRef="U_iso4217USD_xbrlishares">-0.16</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted id="F_001313" contextRef="C_0001326110_20191001_20191231" decimals="2" unitRef="U_iso4217USD_xbrlishares">-0.16</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted id="F_001314" contextRef="C_0001326110_20190101_20190331" decimals="0" unitRef="U_xbrlishares">81261302</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted id="F_001315" contextRef="C_0001326110_20190401_20190630" decimals="0" unitRef="U_xbrlishares">98594355</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted id="F_001316" contextRef="C_0001326110_20190701_20190930" decimals="0" unitRef="U_xbrlishares">98331695</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted id="F_001317" contextRef="C_0001326110_20191001_20191231" decimals="0" unitRef="U_xbrlishares">98419166</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:Revenues id="F_001318" contextRef="C_0001326110_20180101_20180331" decimals="-3" unitRef="U_iso4217USD">5000</us-gaap:Revenues>
  <us-gaap:Revenues id="F_001319" contextRef="C_0001326110_20180401_20180630" decimals="-3" unitRef="U_iso4217USD">4000</us-gaap:Revenues>
  <us-gaap:Revenues id="F_001320" contextRef="C_0001326110_20180701_20180930" decimals="-3" unitRef="U_iso4217USD">31000</us-gaap:Revenues>
  <us-gaap:Revenues id="F_001321" contextRef="C_0001326110_20181001_20181231" decimals="-3" unitRef="U_iso4217USD">7000</us-gaap:Revenues>
  <us-gaap:OperatingExpenses id="F_001322" contextRef="C_0001326110_20180101_20180331" decimals="-3" unitRef="U_iso4217USD">28289000</us-gaap:OperatingExpenses>
  <us-gaap:OperatingExpenses id="F_001323" contextRef="C_0001326110_20180401_20180630" decimals="-3" unitRef="U_iso4217USD">28282000</us-gaap:OperatingExpenses>
  <us-gaap:OperatingExpenses id="F_001324" contextRef="C_0001326110_20180701_20180930" decimals="-3" unitRef="U_iso4217USD">24139000</us-gaap:OperatingExpenses>
  <us-gaap:OperatingExpenses id="F_001325" contextRef="C_0001326110_20181001_20181231" decimals="-3" unitRef="U_iso4217USD">17726000</us-gaap:OperatingExpenses>
  <us-gaap:OperatingIncomeLoss id="F_001326" contextRef="C_0001326110_20180101_20180331" decimals="-3" unitRef="U_iso4217USD">-28284000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss id="F_001327" contextRef="C_0001326110_20180401_20180630" decimals="-3" unitRef="U_iso4217USD">-28278000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss id="F_001328" contextRef="C_0001326110_20180701_20180930" decimals="-3" unitRef="U_iso4217USD">-24108000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss id="F_001329" contextRef="C_0001326110_20181001_20181231" decimals="-3" unitRef="U_iso4217USD">-17719000</us-gaap:OperatingIncomeLoss>
  <us-gaap:NetIncomeLoss id="F_001330" contextRef="C_0001326110_20180101_20180331" decimals="-3" unitRef="U_iso4217USD">-27519000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss id="F_001331" contextRef="C_0001326110_20180401_20180630" decimals="-3" unitRef="U_iso4217USD">-27732000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss id="F_001332" contextRef="C_0001326110_20180701_20180930" decimals="-3" unitRef="U_iso4217USD">-23635000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss id="F_001333" contextRef="C_0001326110_20181001_20181231" decimals="-3" unitRef="U_iso4217USD">-17340000</us-gaap:NetIncomeLoss>
  <us-gaap:EarningsPerShareBasicAndDiluted id="F_001334" contextRef="C_0001326110_20180101_20180331" decimals="2" unitRef="U_iso4217USD_xbrlishares">-0.35</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted id="F_001335" contextRef="C_0001326110_20180401_20180630" decimals="2" unitRef="U_iso4217USD_xbrlishares">-0.35</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted id="F_001336" contextRef="C_0001326110_20180701_20180930" decimals="2" unitRef="U_iso4217USD_xbrlishares">-0.30</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted id="F_001337" contextRef="C_0001326110_20181001_20181231" decimals="2" unitRef="U_iso4217USD_xbrlishares">-0.22</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted id="F_001338" contextRef="C_0001326110_20180101_20180331" decimals="0" unitRef="U_xbrlishares">79036614</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted id="F_001339" contextRef="C_0001326110_20180401_20180630" decimals="0" unitRef="U_xbrlishares">79107208</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted id="F_001340" contextRef="C_0001326110_20180701_20180930" decimals="0" unitRef="U_xbrlishares">79204765</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted id="F_001341" contextRef="C_0001326110_20181001_20181231" decimals="0" unitRef="U_xbrlishares">79177962</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount id="F_001342" contextRef="C_0001326110_us-gaapRetirementPlanNameAxis_nkFourHundredOneKPlanMember_20190101_20191231" decimals="-5" unitRef="U_iso4217USD">600000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
  <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount id="F_001343" contextRef="C_0001326110_us-gaapRetirementPlanNameAxis_nkFourHundredOneKPlanMember_20180101_20181231" decimals="-5" unitRef="U_iso4217USD">500000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
  <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount id="F_001344" contextRef="C_0001326110_us-gaapRetirementPlanNameAxis_nkFourHundredOneKPlanMember_20170101_20171231" decimals="-5" unitRef="U_iso4217USD">400000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
  <nk:ExpectJointStudyCost id="F_001345" contextRef="C_0001326110_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20200129" decimals="-5" unitRef="U_iso4217USD">2100000</nk:ExpectJointStudyCost>
  <us-gaap:ResearchAndDevelopmentExpense id="F_001346" contextRef="C_0001326110_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20190101_20191231" decimals="-5" unitRef="U_iso4217USD">100000</us-gaap:ResearchAndDevelopmentExpense>
</xbrli:xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>60
<FILENAME>nk-20191231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2020-03-25T06:28:30.9214960+00:00 -->
<!-- Version            : 5.0.1.369 -->
<!-- Package ID         : 997a9244481146b697c7b584a5c14c7f -->
<!-- Copyright (c) 2020 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:srt-types="http://fasb.org/srt-types/2019-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:srt="http://fasb.org/srt/2019-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:nk="http://www.nantkwest.com/20191231" xmlns:currency="http://xbrl.sec.gov/currency/2019-01-31" xmlns:us-types="http://fasb.org/us-types/2019-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2019-01-31" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.nantkwest.com/20191231" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd" namespace="http://xbrl.sec.gov/country/2017-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd" namespace="http://xbrl.sec.gov/currency/2019-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd" namespace="http://xbrl.sec.gov/dei/2019-01-31" />
  <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
  <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/exch/2019/exch-2019-01-31.xsd" namespace="http://xbrl.sec.gov/exch/2019-01-31" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/role/negated" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/role/net" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd" namespace="http://xbrl.sec.gov/naics/2017-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd" namespace="http://xbrl.sec.gov/sic/2011-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd" namespace="http://fasb.org/srt/2019-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd" namespace="http://fasb.org/srt-roles/2019-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd" namespace="http://fasb.org/srt-types/2019-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd" namespace="http://xbrl.sec.gov/stpr/2018-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd" namespace="http://fasb.org/us-gaap/2019-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd" namespace="http://fasb.org/us-roles/2019-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd" namespace="http://fasb.org/us-types/2019-01-31" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType id="TemplateLink" roleURI="http://www.nantkwest.com/20191231/role/TemplateLink" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>00000 - Document - Template Link</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="nk-20191231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:title="Calculation Links, all" xlink:type="simple" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="nk-20191231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:title="Definition Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="nk-20191231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="nk-20191231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://www.nantkwest.com/20191231/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nantkwest.com/20191231/taxonomy/role/StatementConsolidatedBalanceSheets" id="Role_StatementConsolidatedBalanceSheets">
        <link:definition>100010 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nantkwest.com/20191231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical" id="Role_StatementConsolidatedBalanceSheetsParenthetical">
        <link:definition>100020 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nantkwest.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfOperations" id="Role_StatementConsolidatedStatementsOfOperations">
        <link:definition>100030 - Statement - Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nantkwest.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveLoss" id="Role_StatementConsolidatedStatementsOfComprehensiveLoss">
        <link:definition>100040 - Statement - Consolidated Statements of Comprehensive Loss</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nantkwest.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity" id="Role_StatementConsolidatedStatementsOfStockholdersEquity">
        <link:definition>100050 - Statement - Consolidated Statements of Stockholders&apos; Equity</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nantkwest.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" id="Role_StatementConsolidatedStatementsOfCashFlows">
        <link:definition>100060 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureDescriptionOfBusiness" id="Role_DisclosureDescriptionOfBusiness">
        <link:definition>100070 - Disclosure - Description of Business</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies" id="Role_DisclosureSummaryOfSignificantAccountingPolicies">
        <link:definition>100080 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureFinancialStatementDetails" id="Role_DisclosureFinancialStatementDetails">
        <link:definition>100090 - Disclosure - Financial Statement Details</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureViractaInvestmentAndConvertibleNotes" id="Role_DisclosureViractaInvestmentAndConvertibleNotes">
        <link:definition>100100 - Disclosure - Viracta Investment and Convertible Notes</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureFinancialInstrumentsInvestmentsInDebtSecurities" id="Role_DisclosureFinancialInstrumentsInvestmentsInDebtSecurities">
        <link:definition>100110 - Disclosure - Financial Instruments Investments in Debt Securities</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureFairValueMeasurements" id="Role_DisclosureFairValueMeasurements">
        <link:definition>100120 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureCollaborationAndLicenseAgreements" id="Role_DisclosureCollaborationAndLicenseAgreements">
        <link:definition>100130 - Disclosure - Collaboration and License Agreements</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureCommitmentAndContingencies" id="Role_DisclosureCommitmentAndContingencies">
        <link:definition>100140 - Disclosure - Commitment and Contingencies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureRelatedPartyAgreements" id="Role_DisclosureRelatedPartyAgreements">
        <link:definition>100150 - Disclosure - Related Party Agreements</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureStockholdersEquity" id="Role_DisclosureStockholdersEquity">
        <link:definition>100160 - Disclosure - Stockholders&apos; Equity</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureStockBasedCompensation" id="Role_DisclosureStockBasedCompensation">
        <link:definition>100170 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureIncomeTaxes" id="Role_DisclosureIncomeTaxes">
        <link:definition>100180 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureSummarizedQuarterlyDataUnaudited" id="Role_DisclosureSummarizedQuarterlyDataUnaudited">
        <link:definition>100190 - Disclosure - Summarized Quarterly Data (Unaudited)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureEmployeeBenefits" id="Role_DisclosureEmployeeBenefits">
        <link:definition>100200 - Disclosure - Employee Benefits</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureSubsequentEvents" id="Role_DisclosureSubsequentEvents">
        <link:definition>100210 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>100220 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesTables">
        <link:definition>100230 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureFinancialStatementDetailsTables" id="Role_DisclosureFinancialStatementDetailsTables">
        <link:definition>100240 - Disclosure - Financial Statement Details (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureFinancialInstrumentsInvestmentsInDebtSecuritiesTables" id="Role_DisclosureFinancialInstrumentsInvestmentsInDebtSecuritiesTables">
        <link:definition>100250 - Disclosure - Financial Instruments Investments in Debt Securities (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureFairValueMeasurementsTables" id="Role_DisclosureFairValueMeasurementsTables">
        <link:definition>100260 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureCommitmentAndContingenciesTables" id="Role_DisclosureCommitmentAndContingenciesTables">
        <link:definition>100270 - Disclosure - Commitment and Contingencies (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureStockholdersEquityTables" id="Role_DisclosureStockholdersEquityTables">
        <link:definition>100280 - Disclosure - Stockholders&apos; Equity (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureStockBasedCompensationTables" id="Role_DisclosureStockBasedCompensationTables">
        <link:definition>100290 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureIncomeTaxesTables" id="Role_DisclosureIncomeTaxesTables">
        <link:definition>100300 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureSummarizedQuarterlyDataUnauditedTables" id="Role_DisclosureSummarizedQuarterlyDataUnauditedTables">
        <link:definition>100310 - Disclosure - Summarized Quarterly Data (Unaudited) (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureDescriptionOfBusinessAdditionalInformationDetail" id="Role_DisclosureDescriptionOfBusinessAdditionalInformationDetail">
        <link:definition>100320 - Disclosure - Description of Business - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail">
        <link:definition>100330 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentDetail" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentDetail">
        <link:definition>100340 - Disclosure - Summary of Significant Accounting Policies - Schedule of Estimated Useful Lives of Property, Plant and Equipment (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSecuritiesExcludedFromComputationOfPotentiallyDilutiveSecuritiesDetail" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesSecuritiesExcludedFromComputationOfPotentiallyDilutiveSecuritiesDetail">
        <link:definition>100350 - Disclosure - Summary of Significant Accounting Policies - Securities Excluded from the Computation of Potentially Dilutive Securities (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureFinancialStatementDetailsPrepaidExpensesAndOtherCurrentAssetsDetail" id="Role_DisclosureFinancialStatementDetailsPrepaidExpensesAndOtherCurrentAssetsDetail">
        <link:definition>100360 - Disclosure - Financial Statement Details - Prepaid Expenses and Other Current Assets (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureFinancialStatementDetailsPropertyPlantAndEquipmentNetDetail" id="Role_DisclosureFinancialStatementDetailsPropertyPlantAndEquipmentNetDetail">
        <link:definition>100370 - Disclosure - Financial Statement Details - Property, Plant and Equipment, Net (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureFinancialStatementDetailsAdditionalInformationDetail" id="Role_DisclosureFinancialStatementDetailsAdditionalInformationDetail">
        <link:definition>100380 - Disclosure - Financial Statement Details - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureFinancialStatementDetailsImpactOfAdoptionOfASC842OnPropertyPlantAndEquipmentDetail" id="Role_DisclosureFinancialStatementDetailsImpactOfAdoptionOfASC842OnPropertyPlantAndEquipmentDetail">
        <link:definition>100390 - Disclosure - Financial Statement Details - Impact of Adoption of ASC 842 on Property, Plant and Equipment (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureFinancialStatementDetailsIntangibleAssetsNetDetail" id="Role_DisclosureFinancialStatementDetailsIntangibleAssetsNetDetail">
        <link:definition>100400 - Disclosure - Financial Statement Details - Intangible Assets, Net (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureFinancialStatementDetailsOtherAssetsDetail" id="Role_DisclosureFinancialStatementDetailsOtherAssetsDetail">
        <link:definition>100410 - Disclosure - Financial Statement Details - Other Assets (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureFinancialStatementDetailsAccruedExpensesDetail" id="Role_DisclosureFinancialStatementDetailsAccruedExpensesDetail">
        <link:definition>100420 - Disclosure - Financial Statement Details - Accrued Expenses (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureFinancialStatementDetailsOtherCurrentLiabilitiesDetail" id="Role_DisclosureFinancialStatementDetailsOtherCurrentLiabilitiesDetail">
        <link:definition>100430 - Disclosure - Financial Statement Details - Other Current Liabilities (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureFinancialStatementDetailsInvestmentIncomeNetDetail" id="Role_DisclosureFinancialStatementDetailsInvestmentIncomeNetDetail">
        <link:definition>100440 - Disclosure - Financial Statement Details - Investment Income, Net (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureViractaInvestmentAndConvertibleNotesAdditionalInformationDetail" id="Role_DisclosureViractaInvestmentAndConvertibleNotesAdditionalInformationDetail">
        <link:definition>100450 - Disclosure - Viracta Investment and Convertible Notes - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureFinancialInstrumentsInvestmentsInDebtSecuritiesScheduleOfInvestmentsInDebtSecuritiesDetail" id="Role_DisclosureFinancialInstrumentsInvestmentsInDebtSecuritiesScheduleOfInvestmentsInDebtSecuritiesDetail">
        <link:definition>100460 - Disclosure - Financial Instruments Investments in Debt Securities - Schedule of Investments in Debt Securities (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureFinancialInstrumentsInvestmentsInDebtSecuritiesAdditionalInformationDetail" id="Role_DisclosureFinancialInstrumentsInvestmentsInDebtSecuritiesAdditionalInformationDetail">
        <link:definition>100470 - Disclosure - Financial Instruments Investments in Debt Securities - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureFinancialInstrumentsInvestmentsInDebtSecuritiesAccumulatedUnrealizedLossesOnDebtSecuritiesClassifiedAsAvailableForSaleInContinuousLossPositionDetail" id="Role_DisclosureFinancialInstrumentsInvestmentsInDebtSecuritiesAccumulatedUnrealizedLossesOnDebtSecuritiesClassifiedAsAvailableForSaleInContinuousLossPositionDetail">
        <link:definition>100480 - Disclosure - Financial Instruments Investments in Debt Securities - Accumulated Unrealized Losses on Debt Securities Classified as Available-for-Sale in Continuous Loss Position (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureFinancialInstrumentsInvestmentsInDebtSecuritiesScheduleOfRealizedGainsAndLossesOnSalesOfAvailableForSaleDebtSecuritiesDetail" id="Role_DisclosureFinancialInstrumentsInvestmentsInDebtSecuritiesScheduleOfRealizedGainsAndLossesOnSalesOfAvailableForSaleDebtSecuritiesDetail">
        <link:definition>100490 - Disclosure - Financial Instruments Investments in Debt Securities - Schedule of Realized Gains and Losses on Sales of Available-for-Sale Debt Securities (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail" id="Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail">
        <link:definition>100500 - Disclosure - Fair Value Measurements - Summary of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail" id="Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail">
        <link:definition>100510 - Disclosure - Collaboration and License Agreements - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureCommitmentAndContingenciesAdditionalInformationDetail" id="Role_DisclosureCommitmentAndContingenciesAdditionalInformationDetail">
        <link:definition>100520 - Disclosure - Commitment and Contingencies - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureCommitmentAndContingenciesScheduleOfLeaseBalancesDetail" id="Role_DisclosureCommitmentAndContingenciesScheduleOfLeaseBalancesDetail">
        <link:definition>100530 - Disclosure - Commitment and Contingencies - Schedule of Lease Balances (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureCommitmentAndContingenciesSummaryOfFutureMinimumLeasePaymentsDetail" id="Role_DisclosureCommitmentAndContingenciesSummaryOfFutureMinimumLeasePaymentsDetail">
        <link:definition>100540 - Disclosure - Commitment and Contingencies - Summary of Future Minimum Lease Payments (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureCommitmentAndContingenciesSummaryOfFutureMinimumLeasePaymentsParentheticalDetail" id="Role_DisclosureCommitmentAndContingenciesSummaryOfFutureMinimumLeasePaymentsParentheticalDetail">
        <link:definition>100550 - Disclosure - Commitment and Contingencies - Summary of Future Minimum Lease Payments (Parenthetical) (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureRelatedPartyAgreementsAdditionalInformationDetail" id="Role_DisclosureRelatedPartyAgreementsAdditionalInformationDetail">
        <link:definition>100560 - Disclosure - Related Party Agreements - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" id="Role_DisclosureStockholdersEquityAdditionalInformationDetail">
        <link:definition>100570 - Disclosure - Stockholders&apos; Equity - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureStockholdersEquitySummaryOfCommonSharesReservedForIssuanceDetail" id="Role_DisclosureStockholdersEquitySummaryOfCommonSharesReservedForIssuanceDetail">
        <link:definition>100580 - Disclosure - Stockholders&apos; Equity - Summary of Common Shares Reserved for Issuance (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail" id="Role_DisclosureStockBasedCompensationAdditionalInformationDetail">
        <link:definition>100590 - Disclosure - Stock-Based Compensation - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureStockBasedCompensationStockBasedCompensationExpensesRelatedToStatementOfOperationsDetail" id="Role_DisclosureStockBasedCompensationStockBasedCompensationExpensesRelatedToStatementOfOperationsDetail">
        <link:definition>100600 - Disclosure - Stock-Based Compensation - Stock Based Compensation Expenses Related to Statement of Operations (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureStockBasedCompensationStockOptionActivityDetail" id="Role_DisclosureStockBasedCompensationStockOptionActivityDetail">
        <link:definition>100610 - Disclosure - Stock-Based Compensation - Stock Option Activity (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfOptionsOutstandingAndVestedPricingOfExercisePricesDetail" id="Role_DisclosureStockBasedCompensationSummaryOfOptionsOutstandingAndVestedPricingOfExercisePricesDetail">
        <link:definition>100620 - Disclosure - Stock-Based Compensation - Summary of Options Outstanding and Vested Pricing of Exercise Prices (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureStockBasedCompensationBlackScholesOptionPricingModelToDetermineFairValueOfAssumptionsUsedForEmployeeStockOptionsGrantedDetail" id="Role_DisclosureStockBasedCompensationBlackScholesOptionPricingModelToDetermineFairValueOfAssumptionsUsedForEmployeeStockOptionsGrantedDetail">
        <link:definition>100630 - Disclosure - Stock-Based Compensation - Black-Scholes Option-Pricing Model to Determine Fair Value of Assumptions Used for Employee Stock Options Granted (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureStockBasedCompensationRestrictedStockUnitsRsusActivityDetail" id="Role_DisclosureStockBasedCompensationRestrictedStockUnitsRsusActivityDetail">
        <link:definition>100640 - Disclosure - Stock-Based Compensation - Restricted Stock Units (RSUs) Activity (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfWarrantActivityDetail" id="Role_DisclosureStockBasedCompensationSummaryOfWarrantActivityDetail">
        <link:definition>100650 - Disclosure - Stock-Based Compensation - Summary of Warrant Activity (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureIncomeTaxesSummaryOfLossBeforeTaxesDetail" id="Role_DisclosureIncomeTaxesSummaryOfLossBeforeTaxesDetail">
        <link:definition>100660 - Disclosure - Income Taxes - Summary of Loss Before Taxes (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureIncomeTaxesSummaryOfIncomeTaxBenefitDetail" id="Role_DisclosureIncomeTaxesSummaryOfIncomeTaxBenefitDetail">
        <link:definition>100670 - Disclosure - Income Taxes - Summary of Income Tax Benefit (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsAndLiabilitiesDetail" id="Role_DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsAndLiabilitiesDetail">
        <link:definition>100680 - Disclosure - Income Taxes - Components of Net Deferred Tax Assets and Liabilities (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateDetail" id="Role_DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateDetail">
        <link:definition>100690 - Disclosure - Income Taxes - Reconciliation of Federal Statutory Income Tax Rate (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail" id="Role_DisclosureIncomeTaxesAdditionalInformationDetail">
        <link:definition>100700 - Disclosure - Income Taxes - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureIncomeTaxesSummarizesOfChangesInUnrecognizedTaxBenefitsDetail" id="Role_DisclosureIncomeTaxesSummarizesOfChangesInUnrecognizedTaxBenefitsDetail">
        <link:definition>100710 - Disclosure - Income Taxes - Summarizes of Changes in Unrecognized Tax Benefits (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureSummaryOfQuarterlyDataUnauditedDetail" id="Role_DisclosureSummaryOfQuarterlyDataUnauditedDetail">
        <link:definition>100720 - Disclosure - Summary of Quarterly Data (Unaudited) (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureEmployeeBenefitsAdditionalInformationDetail" id="Role_DisclosureEmployeeBenefitsAdditionalInformationDetail">
        <link:definition>100730 - Disclosure - Employee Benefits - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail" id="Role_DisclosureSubsequentEventsAdditionalInformationDetail">
        <link:definition>100740 - Disclosure - Subsequent Events - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="nk_FinancingObligationNoncurrent" name="FinancingObligationNoncurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="nk_StockIssuedDuringPeriodSharesWarrantsExercised" name="StockIssuedDuringPeriodSharesWarrantsExercised" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="nk_OperatingLeaseRightOfUseAssetNonCashLeaseExpense" name="OperatingLeaseRightOfUseAssetNonCashLeaseExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="nk_NonCashInterestIncomeExpenseFromOperatingActivities" name="NonCashInterestIncomeExpenseFromOperatingActivities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="nk_IncreaseDecreaseInOperatingLeaseRightOfUseAssetNet" name="IncreaseDecreaseInOperatingLeaseRightOfUseAssetNet" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="nk_IncreaseDecreaseInAccountsPayableCurrent" name="IncreaseDecreaseInAccountsPayableCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="nk_IncreaseDecreaseInOperatingLeaseLiability" name="IncreaseDecreaseInOperatingLeaseLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="nk_PaymentsToAcquireInvestmentsInEquitySecurities" name="PaymentsToAcquireInvestmentsInEquitySecurities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="nk_NoncashPropertyAndEquipmentPurchasesAcquiredUnderCapitalLease" name="NoncashPropertyAndEquipmentPurchasesAcquiredUnderCapitalLease" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="nk_DescriptionOfBusinessDisclosureTextBlock" name="DescriptionOfBusinessDisclosureTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="nk_FinancialStatementDetailsAbstract" name="FinancialStatementDetailsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="nk_CashEquivalentsAndMarketableSecuritiesAbstract" name="CashEquivalentsAndMarketableSecuritiesAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="nk_CollaborationAndLicenseAgreementsTextBlock" name="CollaborationAndLicenseAgreementsTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="nk_LiquidityPolicyTextBlock" name="LiquidityPolicyTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="nk_CashCashEquivalentsAndMarketableSecuritiesPolicyTextBlock" name="CashCashEquivalentsAndMarketableSecuritiesPolicyTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="nk_PreclinicalAndClinicalTrialAccrualsPolicyTextBlock" name="PreclinicalAndClinicalTrialAccrualsPolicyTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="nk_RelatedPartyTransactionsPolicyPolicyTextBlock" name="RelatedPartyTransactionsPolicyPolicyTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="nk_StockRepurchasesPolicyTextBlock" name="StockRepurchasesPolicyTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="nk_LitigationCostsPolicyTextBlock" name="LitigationCostsPolicyTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="nk_PropertyPlantAndEquipmentUsefulLifeTableTextBlock" name="PropertyPlantAndEquipmentUsefulLifeTableTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="nk_PrepaidExpensesAndOtherCurrentAssetsTableTextBlock" name="PrepaidExpensesAndOtherCurrentAssetsTableTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="nk_ScheduleOfImpactOfAdoptionOnPropertyPlantAndEquipmentTableTextBlock" name="ScheduleOfImpactOfAdoptionOnPropertyPlantAndEquipmentTableTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="nk_ScheduleOfCommonStockReservedForIssuanceTableTextBlock" name="ScheduleOfCommonStockReservedForIssuanceTableTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="nk_AccountingPoliciesLineItems" name="AccountingPoliciesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="nk_AccountingPoliciesTable" name="AccountingPoliciesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="nk_ChairmanAndChiefExecutiveOfficerMember" name="ChairmanAndChiefExecutiveOfficerMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="nk_IntrexonLicenseAgreementMember" name="IntrexonLicenseAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="nk_DifferenceBetweenLeaseGuidanceInEffectBeforeAndAfterTopic842Member" name="DifferenceBetweenLeaseGuidanceInEffectBeforeAndAfterTopic842Member" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="nk_CashAndCashEquivalentsOriginalMaturities" name="CashAndCashEquivalentsOriginalMaturities" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="nk_MarketableSecuritiesOriginalMaturities" name="MarketableSecuritiesOriginalMaturities" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="nk_MinimumOriginalMaturityPeriodOfLongTermMarketableSecurities" name="MinimumOriginalMaturityPeriodOfLongTermMarketableSecurities" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="nk_MaximumOriginalMaturityPeriodOfShortTermMarketableSecurities" name="MaximumOriginalMaturityPeriodOfShortTermMarketableSecurities" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="nk_LaboratoryEquipmentMember" name="LaboratoryEquipmentMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="nk_ITEquipmentMember" name="ITEquipmentMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="nk_FairValueInputsTransfersIntoOrOutOfLevelOneLevelTwoOrLevelThreeCategories" name="FairValueInputsTransfersIntoOrOutOfLevelOneLevelTwoOrLevelThreeCategories" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="nk_NonrefundableUpfrontPayment" name="NonrefundableUpfrontPayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="nk_VariableConsiderationRelatedToMilestonePayment" name="VariableConsiderationRelatedToMilestonePayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="nk_NumberOfProductsApprovedForCommercialSale" name="NumberOfProductsApprovedForCommercialSale" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <xsd:element id="nk_PrepaidPreclinicalAndClinicalTrialServicesWithRelatedParty" name="PrepaidPreclinicalAndClinicalTrialServicesWithRelatedParty" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="nk_InsurancePremiumFinancingAsset" name="InsurancePremiumFinancingAsset" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="nk_PrepaidSuppliesWithRelatedParty" name="PrepaidSuppliesWithRelatedParty" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="nk_PrepaidServices" name="PrepaidServices" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="nk_PrepaidEquipmentMaintenance" name="PrepaidEquipmentMaintenance" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="nk_PrepaidLicenseFees" name="PrepaidLicenseFees" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="nk_FinancialStatementDetailsLineItems" name="FinancialStatementDetailsLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="nk_FinancialStatementDetailsTable" name="FinancialStatementDetailsTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="nk_LesseseOperatingLeaseReclassificationOfAssetsFromBuildingsToLeaseholdImprovements" name="LesseseOperatingLeaseReclassificationOfAssetsFromBuildingsToLeaseholdImprovements" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="nk_DerecognizedBuildToSuitLeaseAssets" name="DerecognizedBuildToSuitLeaseAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="nk_TechnologyLicenseMember" name="TechnologyLicenseMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="nk_PrepaidPreclinicalAndClinicalTrialServicesWithRelatedPartyInOtherAssets" name="PrepaidPreclinicalAndClinicalTrialServicesWithRelatedPartyInOtherAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="nk_AccruedLaboratoryEquipmentAndSupplies" name="AccruedLaboratoryEquipmentAndSupplies" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="nk_AccruedPreclinicalAndClinicalTrialCosts" name="AccruedPreclinicalAndClinicalTrialCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="nk_AccruedFranchiseSalesUseAndPropertyTaxes" name="AccruedFranchiseSalesUseAndPropertyTaxes" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="nk_FinancingObligationCurrent" name="FinancingObligationCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="nk_TwoThousandAndEighteenNoteAndWarrantPurchaseAgreementMember" name="TwoThousandAndEighteenNoteAndWarrantPurchaseAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="nk_PurchaseOfConvertibleNoteUponConversion" name="PurchaseOfConvertibleNoteUponConversion" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="nk_DebtSecuritiesAvailableForSaleAndHeldToMaturityAmortizedCost" name="DebtSecuritiesAvailableForSaleAndHeldToMaturityAmortizedCost" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="nk_DebtSecuritiesAvailableForSaleAndHeldToMaturityAmortizedCostAccumulatedGrossUnrealizedGainBeforeTax" name="DebtSecuritiesAvailableForSaleAndHeldToMaturityAmortizedCostAccumulatedGrossUnrealizedGainBeforeTax" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="nk_DebtSecuritiesAvailableForSaleAndHeldToMaturityAmortizedCostAccumulatedGrossUnrealizedLossBeforeTax" name="DebtSecuritiesAvailableForSaleAndHeldToMaturityAmortizedCostAccumulatedGrossUnrealizedLossBeforeTax" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="nk_DebtSecuritiesAvailableForSaleAndHeldToMaturityFairValue" name="DebtSecuritiesAvailableForSaleAndHeldToMaturityFairValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="nk_CurrentAssetsMember" name="CurrentAssetsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="nk_NoncurrentAssetsMember" name="NoncurrentAssetsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="nk_AvailableForSaleSecuritiesDebtSecuritiesPeriod" name="AvailableForSaleSecuritiesDebtSecuritiesPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="nk_AvailableForSaleSecuritiesAndHeldToMaturityGrossUnrealizedGain" name="AvailableForSaleSecuritiesAndHeldToMaturityGrossUnrealizedGain" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="nk_AvailableForSaleSecuritiesAndHeldToMaturityGrossUnrealizedLosses" name="AvailableForSaleSecuritiesAndHeldToMaturityGrossUnrealizedLosses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="nk_AvailableForSaleDebtSecuritiesAmortizedCost" name="AvailableForSaleDebtSecuritiesAmortizedCost" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="nk_AvailableForSaleSecuritiesPeriodOfUnrealizedLossPositions" name="AvailableForSaleSecuritiesPeriodOfUnrealizedLossPositions" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="nk_MaximumNumberOfPatientsInPhaseOneAndTwoForClinicalTrials" name="MaximumNumberOfPatientsInPhaseOneAndTwoForClinicalTrials" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="nk_LicensingAgreementAbstract" name="LicensingAgreementAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="nk_LicensingAgreementLineItems" name="LicensingAgreementLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="nk_LicensingAgreementTable" name="LicensingAgreementTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="nk_AltorBioScienceCorporationMember" name="AltorBioScienceCorporationMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="nk_ViractaTherapeuticsIncMember" name="ViractaTherapeuticsIncMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="nk_GeorgSpeyerHausAndDRKBlutspendedienstBadenWurttembergHessengGmbHLicenseAgreementMember" name="GeorgSpeyerHausAndDRKBlutspendedienstBadenWurttembergHessengGmbHLicenseAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="nk_RushUniversityMedicalCenterLicenseAgreementMember" name="RushUniversityMedicalCenterLicenseAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="nk_INDFilingMember" name="INDFilingMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="nk_PhaseTwoMember" name="PhaseTwoMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="nk_PhaseThreeMember" name="PhaseThreeMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="nk_CommercialSaleRelatedToLicensedProductsMember" name="CommercialSaleRelatedToLicensedProductsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="nk_SuppliesAndMilestoneChargesForConductingClinicalTrials" name="SuppliesAndMilestoneChargesForConductingClinicalTrials" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="nk_MilestonePaymentAmount" name="MilestonePaymentAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="nk_LicenseAgreementTerminationNoticePeriod" name="LicenseAgreementTerminationNoticePeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="nk_PaymentsForInitialLicenseFees" name="PaymentsForInitialLicenseFees" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="nk_PeriodOfLicenseAgreement" name="PeriodOfLicenseAgreement" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="nk_MinimumAnnualRoyaltyPayment" name="MinimumAnnualRoyaltyPayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="nk_MinimumSalesMilestoneOfLicenseForFirstYear" name="MinimumSalesMilestoneOfLicenseForFirstYear" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="nk_AgreementOneTimeFee" name="AgreementOneTimeFee" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="nk_LicenseAgreementTerm" name="LicenseAgreementTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="nk_CommitmentsAndContingenciesLineItems" name="CommitmentsAndContingenciesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="nk_CommitmentsAndContingenciesTable" name="CommitmentsAndContingenciesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="nk_DirectorsAndOfficersInsurancePolicyMember" name="DirectorsAndOfficersInsurancePolicyMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="nk_NantBioScienceMember" name="NantBioScienceMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="nk_DougStLLCMember" name="DougStLLCMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="nk_ElSegundoCaliforniaMember" name="ElSegundoCaliforniaMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="nk_CommitmentWoburnMassachusettsMember" name="CommitmentWoburnMassachusettsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="nk_NantWorksLimitedLiabilityCompanyMember" name="NantWorksLimitedLiabilityCompanyMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="nk_CommitmentSanDiegoMember" name="CommitmentSanDiegoMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="nk_OperatingLeasePaymentsRelatedToOptionsToExtendLeaseTerms" name="OperatingLeasePaymentsRelatedToOptionsToExtendLeaseTerms" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="nk_RelatedPartyTransactionReimbursedUpfrontPaymentToThirdParty" name="RelatedPartyTransactionReimbursedUpfrontPaymentToThirdParty" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="nk_RelatedPartyTransactionAmountPaidToRelatedParty" name="RelatedPartyTransactionAmountPaidToRelatedParty" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="nk_RelatedPartyTransactionInitialTermOfAgreement" name="RelatedPartyTransactionInitialTermOfAgreement" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="nk_RelatedPartyAgreementExpirationMonthAndYear" name="RelatedPartyAgreementExpirationMonthAndYear" type="xbrli:gYearMonthItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="nk_PeriodOfExtendedLeaseTerm" name="PeriodOfExtendedLeaseTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="nk_BaseMonthlyRent" name="BaseMonthlyRent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="nk_AnnualPercentageIncreasesToBaseRent" name="AnnualPercentageIncreasesToBaseRent" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="nk_AnnualPercentageIncreasesToBaseRentCommencementDate" name="AnnualPercentageIncreasesToBaseRentCommencementDate" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="nk_NumberOfSquareFootOfFacilityLeased" name="NumberOfSquareFootOfFacilityLeased" type="num:areaItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <xsd:element id="nk_PeriodOfLicenseAgreementDescription" name="PeriodOfLicenseAgreementDescription" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="nk_LeaseCommencementDate" name="LeaseCommencementDate" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="nk_AdditionToNumberOfSquareFootOfFacilityLeased" name="AdditionToNumberOfSquareFootOfFacilityLeased" type="num:areaItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <xsd:element id="nk_AnnualBaseRentIncreasePerSquareFoot" name="AnnualBaseRentIncreasePerSquareFoot" type="srt-types:perUnitItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="nk_LeaseAgreementExtendedPeriod" name="LeaseAgreementExtendedPeriod" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="nk_NantHealthLabsIncMember" name="NantHealthLabsIncMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="nk_ImmunoOncologyClinicIncMember" name="ImmunoOncologyClinicIncMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="nk_TensorcomIncMember" name="TensorcomIncMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="nk_SanDiegoCaliforniaMember" name="SanDiegoCaliforniaMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="nk_ReimbursementsMember" name="ReimbursementsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="nk_SharedServicesAgreementMember" name="SharedServicesAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="nk_NantOmicsLLCMember" name="NantOmicsLLCMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="nk_ImmunityBioMember" name="ImmunityBioMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="nk_VivaBioCellSPAMember" name="VivaBioCellSPAMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="nk_RelatedPartyAgreementRenewalTerm" name="RelatedPartyAgreementRenewalTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="nk_NumberOfOfficers" name="NumberOfOfficers" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <xsd:element id="nk_InitialTermOfAgreement" name="InitialTermOfAgreement" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="nk_RelatedPartyInstallmentPayment" name="RelatedPartyInstallmentPayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="nk_RelatedPartyTransactionAgreementExtensionDescription" name="RelatedPartyTransactionAgreementExtensionDescription" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="nk_NewAgreementTerminationNoticePeriod" name="NewAgreementTerminationNoticePeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="nk_PrepaidBalanceIncludedInPrepaidExpensesAndOtherCurrentAssetsAndOtherAssets" name="PrepaidBalanceIncludedInPrepaidExpensesAndOtherCurrentAssetsAndOtherAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="nk_RelatedPartyTransactionReimbursedUpfrontPaymentToRelatedParty" name="RelatedPartyTransactionReimbursedUpfrontPaymentToRelatedParty" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="nk_RelatedPartyTransactionAmountPaidToThirdParty" name="RelatedPartyTransactionAmountPaidToThirdParty" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="nk_ResearchAndDevelopmentExpenseRatablePaymentPeriod" name="ResearchAndDevelopmentExpenseRatablePaymentPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="nk_PrepaymentOfFundingAmount" name="PrepaymentOfFundingAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="nk_TransferOfDepositAmountToThirdParty" name="TransferOfDepositAmountToThirdParty" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="nk_PrepaidExpensesAndOtherAssetsCurrentWithRelatedParty" name="PrepaidExpensesAndOtherAssetsCurrentWithRelatedParty" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="nk_StockRepurchasedAndRetiredExcludingCommissionDuringPeriodValue" name="StockRepurchasedAndRetiredExcludingCommissionDuringPeriodValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="nk_OutstandingOfficerWarrantsMember" name="OutstandingOfficerWarrantsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="nk_TwoThousandFourteenEquityIncentivePlanMember" name="TwoThousandFourteenEquityIncentivePlanMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="nk_TwoThousandFifteenEquityIncentivePlanMember" name="TwoThousandFifteenEquityIncentivePlanMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="nk_KeyExecutivesStockOptionsMember" name="KeyExecutivesStockOptionsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="nk_NonEmployeeStockOptionsMember" name="NonEmployeeStockOptionsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="nk_NonEmployeeRestrictedStockUnitMember" name="NonEmployeeRestrictedStockUnitMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="nk_EmployeeRestrictedStockUnitMember" name="EmployeeRestrictedStockUnitMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="nk_ShareBasedCompensationArrangementByShareBasedPaymentAwardPossibleIncreaseInNumberOfSharesReservedForIssuance" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardPossibleIncreaseInNumberOfSharesReservedForIssuance" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="nk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="nk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableOutstandingNumber" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableOutstandingNumber" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <xsd:element id="nk_ExercisePriceRangeOneMember" name="ExercisePriceRangeOneMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="nk_ExercisePriceRangeTwoMember" name="ExercisePriceRangeTwoMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="nk_ExercisePriceRangeThreeMember" name="ExercisePriceRangeThreeMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="nk_ExercisePriceRangeFourMember" name="ExercisePriceRangeFourMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="nk_ExercisePriceRangeFiveMember" name="ExercisePriceRangeFiveMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="nk_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsPrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsPrice" type="num:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <xsd:element id="nk_StockIssuedDuringPeriodSharesWarrantsExpired" name="StockIssuedDuringPeriodSharesWarrantsExpired" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="nk_ClassOfWarrantOrVestedAndExercisable" name="ClassOfWarrantOrVestedAndExercisable" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <xsd:element id="nk_WarrantLineItems" name="WarrantLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="nk_WarrantTable" name="WarrantTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="nk_DeferredIncomeTaxExpenseBenefitNet" name="DeferredIncomeTaxExpenseBenefitNet" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="nk_DeferredTaxAssetsOperatingLeaseLiabilities" name="DeferredTaxAssetsOperatingLeaseLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="nk_DeferredTaxAssetsDeferredDepreciationAndAmortization" name="DeferredTaxAssetsDeferredDepreciationAndAmortization" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="nk_DeferredTaxAssetsLeasesAndOtherAccruedLiabilities" name="DeferredTaxAssetsLeasesAndOtherAccruedLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="nk_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" name="DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="nk_DeferredTaxLiabilitiesDeferredDepreciationAndAmortization" name="DeferredTaxLiabilitiesDeferredDepreciationAndAmortization" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="nk_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsAct" name="EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsAct" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="nk_EffectiveIncomeTaxRateReconciliationStockBasedCompensationContribution" name="EffectiveIncomeTaxRateReconciliationStockBasedCompensationContribution" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="nk_TaxCutsAndJobsActOf2017IncompleteAccountingChangeInTaxRateMinimumAmountForEliminationOfSeveralBusinessDeductionsAndCreditsIncludingDeductionsForCertainExecutiveCompensation" name="TaxCutsAndJobsActOf2017IncompleteAccountingChangeInTaxRateMinimumAmountForEliminationOfSeveralBusinessDeductionsAndCreditsIncludingDeductionsForCertainExecutiveCompensation" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="nk_TaxCutsAndJobsActOf2017IncompleteAccountingChangeInTaxRateReductionInDeferredTaxAssets" name="TaxCutsAndJobsActOf2017IncompleteAccountingChangeInTaxRateReductionInDeferredTaxAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="nk_IncomeTaxLineItems" name="IncomeTaxLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="nk_IncomeTaxTable" name="IncomeTaxTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="nk_ResearchAndDevelopmentCumulativeChangeInOwnershipPercentage" name="ResearchAndDevelopmentCumulativeChangeInOwnershipPercentage" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="nk_PeriodOfCumulativeOwnershipChange" name="PeriodOfCumulativeOwnershipChange" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="nk_DerecognizedDeferredTaxAssets" name="DerecognizedDeferredTaxAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="nk_NetOperatingLossCarryforwardsExpirationDate" name="NetOperatingLossCarryforwardsExpirationDate" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="nk_TaxCreditCarryforwardExpirationPeriod" name="TaxCreditCarryforwardExpirationPeriod" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="nk_UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRate" name="UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRate" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="nk_FourHundredOneKPlanMember" name="FourHundredOneKPlanMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="nk_ExpectJointStudyCost" name="ExpectJointStudyCost" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>61
<FILENAME>nk-20191231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2020-03-25T06:28:30.9214960+00:00 -->
<!-- Version            : 5.0.1.369 -->
<!-- Package ID         : 997a9244481146b697c7b584a5c14c7f -->
<!-- Copyright (c) 2020 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef xlink:type="simple" xlink:href="nk-20191231.xsd#TemplateLink" roleURI="http://www.nantkwest.com/20191231/role/TemplateLink" />
  <link:roleRef roleURI="http://www.nantkwest.com/20191231/taxonomy/role/StatementConsolidatedBalanceSheets" xlink:href="nk-20191231.xsd#Role_StatementConsolidatedBalanceSheets" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.nantkwest.com/20191231/taxonomy/role/StatementConsolidatedBalanceSheets">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HeldToMaturitySecuritiesCurrent" xlink:type="locator" xlink:label="us-gaap_HeldToMaturitySecuritiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:type="locator" xlink:label="us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets" xlink:type="locator" xlink:label="us-gaap_Assets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:type="locator" xlink:label="us-gaap_DueToRelatedPartiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:type="locator" xlink:label="us-gaap_DeferredRentCreditNoncurrent" />
    <link:loc xlink:href="nk-20191231.xsd#nk_FinancingObligationNoncurrent" xlink:type="locator" xlink:label="nk_FinancingObligationNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue" xlink:type="locator" xlink:label="us-gaap_CommonStockValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities" xlink:type="locator" xlink:label="us-gaap_Liabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="10060.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="10070.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="10080.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="10090.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="nk_FinancingObligationNoncurrent" order="10100.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_DeferredRentCreditNoncurrent" order="10110.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="10120.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="10130.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_DueToRelatedPartiesCurrent" order="10140.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent" order="10150.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="10160.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" order="10170.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10180.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="10190.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" order="10200.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" order="10210.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent" order="10220.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="10230.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="10240.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" order="10250.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_HeldToMaturitySecuritiesCurrent" order="10260.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.nantkwest.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfOperations" xlink:href="nk-20191231.xsd#Role_StatementConsolidatedStatementsOfOperations" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.nantkwest.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfOperations">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpenses" xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues" xlink:type="locator" xlink:label="us-gaap_Revenues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseInterestExpense" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseInterestExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentIncomeNet" xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="10020.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_OperatingIncomeLoss" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_NonoperatingIncomeExpense" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_InvestmentIncomeNet" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_FinanceLeaseInterestExpense" order="10060.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="10070.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_Revenues" order="10080.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="10090.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="10100.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" order="10110.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.nantkwest.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveLoss" xlink:href="nk-20191231.xsd#Role_StatementConsolidatedStatementsOfComprehensiveLoss" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.nantkwest.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveLoss">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" order="10040.00" priority="2" use="optional" weight="-1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.nantkwest.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" xlink:href="nk-20191231.xsd#Role_StatementConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.nantkwest.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue" />
    <link:loc xlink:href="nk-20191231.xsd#nk_IncreaseDecreaseInOperatingLeaseLiability" xlink:type="locator" xlink:label="nk_IncreaseDecreaseInOperatingLeaseLiability" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" />
    <link:loc xlink:href="nk-20191231.xsd#nk_IncreaseDecreaseInAccountsPayableCurrent" xlink:type="locator" xlink:label="nk_IncreaseDecreaseInAccountsPayableCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" />
    <link:loc xlink:href="nk-20191231.xsd#nk_IncreaseDecreaseInOperatingLeaseRightOfUseAssetNet" xlink:type="locator" xlink:label="nk_IncreaseDecreaseInOperatingLeaseRightOfUseAssetNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MarketableSecuritiesGainLoss" xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesGainLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1" xlink:type="locator" xlink:label="us-gaap_GainLossOnDispositionOfAssets1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:type="locator" xlink:label="us-gaap_AssetImpairmentCharges" />
    <link:loc xlink:href="nk-20191231.xsd#nk_NonCashInterestIncomeExpenseFromOperatingActivities" xlink:type="locator" xlink:label="nk_NonCashInterestIncomeExpenseFromOperatingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:type="locator" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" />
    <link:loc xlink:href="nk-20191231.xsd#nk_OperatingLeaseRightOfUseAssetNonCashLeaseExpense" xlink:type="locator" xlink:label="nk_OperatingLeaseRightOfUseAssetNonCashLeaseExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProfitLoss" xlink:type="locator" xlink:label="us-gaap_ProfitLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" />
    <link:loc xlink:href="nk-20191231.xsd#nk_PaymentsToAcquireInvestmentsInEquitySecurities" xlink:type="locator" xlink:label="nk_PaymentsToAcquireInvestmentsInEquitySecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireHeldToMaturitySecurities" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireHeldToMaturitySecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:type="locator" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" xlink:type="locator" xlink:label="us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" order="10040.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_PaymentsForRepurchaseOfCommonStock" order="10060.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" order="10070.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="10080.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" order="10090.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireHeldToMaturitySecurities" order="10100.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="nk_PaymentsToAcquireInvestmentsInEquitySecurities" order="10110.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" order="10120.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" order="10130.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ProfitLoss" order="10140.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="10150.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="10160.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="nk_OperatingLeaseRightOfUseAssetNonCashLeaseExpense" order="10170.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" order="10180.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="nk_NonCashInterestIncomeExpenseFromOperatingActivities" order="10190.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AssetImpairmentCharges" order="10200.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_GainLossOnDispositionOfAssets1" order="10210.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" order="10220.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_MarketableSecuritiesGainLoss" order="10230.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="10240.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="nk_IncreaseDecreaseInOperatingLeaseRightOfUseAssetNet" order="10250.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" order="10260.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="nk_IncreaseDecreaseInAccountsPayableCurrent" order="10270.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" order="10280.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent" order="10290.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="nk_IncreaseDecreaseInOperatingLeaseLiability" order="10300.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue" order="10310.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureFinancialStatementDetailsPrepaidExpensesAndOtherCurrentAssetsDetail" xlink:href="nk-20191231.xsd#Role_DisclosureFinancialStatementDetailsPrepaidExpensesAndOtherCurrentAssetsDetail" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureFinancialStatementDetailsPrepaidExpensesAndOtherCurrentAssetsDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DueFromRelatedPartiesCurrent" xlink:type="locator" xlink:label="us-gaap_DueFromRelatedPartiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InsuranceSettlementsReceivableCurrent" xlink:type="locator" xlink:label="us-gaap_InsuranceSettlementsReceivableCurrent" />
    <link:loc xlink:href="nk-20191231.xsd#nk_PrepaidLicenseFees" xlink:type="locator" xlink:label="nk_PrepaidLicenseFees" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestReceivableCurrent" xlink:type="locator" xlink:label="us-gaap_InterestReceivableCurrent" />
    <link:loc xlink:href="nk-20191231.xsd#nk_PrepaidEquipmentMaintenance" xlink:type="locator" xlink:label="nk_PrepaidEquipmentMaintenance" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidInsurance" xlink:type="locator" xlink:label="us-gaap_PrepaidInsurance" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidRent" xlink:type="locator" xlink:label="us-gaap_PrepaidRent" />
    <link:loc xlink:href="nk-20191231.xsd#nk_PrepaidServices" xlink:type="locator" xlink:label="nk_PrepaidServices" />
    <link:loc xlink:href="nk-20191231.xsd#nk_PrepaidSuppliesWithRelatedParty" xlink:type="locator" xlink:label="nk_PrepaidSuppliesWithRelatedParty" />
    <link:loc xlink:href="nk-20191231.xsd#nk_InsurancePremiumFinancingAsset" xlink:type="locator" xlink:label="nk_InsurancePremiumFinancingAsset" />
    <link:loc xlink:href="nk-20191231.xsd#nk_PrepaidPreclinicalAndClinicalTrialServicesWithRelatedParty" xlink:type="locator" xlink:label="nk_PrepaidPreclinicalAndClinicalTrialServicesWithRelatedParty" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="nk_PrepaidPreclinicalAndClinicalTrialServicesWithRelatedParty" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="nk_InsurancePremiumFinancingAsset" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="nk_PrepaidSuppliesWithRelatedParty" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="nk_PrepaidServices" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidRent" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidInsurance" order="10060.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="nk_PrepaidEquipmentMaintenance" order="10070.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_InterestReceivableCurrent" order="10080.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="nk_PrepaidLicenseFees" order="10090.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_InsuranceSettlementsReceivableCurrent" order="10100.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_DueFromRelatedPartiesCurrent" order="10110.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent" order="10120.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureFinancialStatementDetailsPropertyPlantAndEquipmentNetDetail" xlink:href="nk-20191231.xsd#Role_DisclosureFinancialStatementDetailsPropertyPlantAndEquipmentNetDetail" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureFinancialStatementDetailsPropertyPlantAndEquipmentNetDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="10020.00" priority="2" use="optional" weight="-1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureFinancialStatementDetailsIntangibleAssetsNetDetail" xlink:href="nk-20191231.xsd#Role_DisclosureFinancialStatementDetailsIntangibleAssetsNetDetail" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureFinancialStatementDetailsIntangibleAssetsNetDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" order="10020.00" priority="2" use="optional" weight="-1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureFinancialStatementDetailsOtherAssetsDetail" xlink:href="nk-20191231.xsd#Role_DisclosureFinancialStatementDetailsOtherAssetsDetail" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureFinancialStatementDetailsOtherAssetsDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsMiscellaneousNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsMiscellaneousNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseNoncurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SecurityDeposit" xlink:type="locator" xlink:label="us-gaap_SecurityDeposit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" />
    <link:loc xlink:href="nk-20191231.xsd#nk_PrepaidPreclinicalAndClinicalTrialServicesWithRelatedPartyInOtherAssets" xlink:type="locator" xlink:label="nk_PrepaidPreclinicalAndClinicalTrialServicesWithRelatedPartyInOtherAssets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="nk_PrepaidPreclinicalAndClinicalTrialServicesWithRelatedPartyInOtherAssets" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_SecurityDeposit" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_PrepaidExpenseNoncurrent" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsMiscellaneousNoncurrent" order="10050.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureFinancialStatementDetailsAccruedExpensesDetail" xlink:href="nk-20191231.xsd#Role_DisclosureFinancialStatementDetailsAccruedExpensesDetail" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureFinancialStatementDetailsAccruedExpensesDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConstructionPayableCurrent" xlink:type="locator" xlink:label="us-gaap_ConstructionPayableCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LitigationReserveCurrent" xlink:type="locator" xlink:label="us-gaap_LitigationReserveCurrent" />
    <link:loc xlink:href="nk-20191231.xsd#nk_AccruedFranchiseSalesUseAndPropertyTaxes" xlink:type="locator" xlink:label="nk_AccruedFranchiseSalesUseAndPropertyTaxes" />
    <link:loc xlink:href="nk-20191231.xsd#nk_AccruedPreclinicalAndClinicalTrialCosts" xlink:type="locator" xlink:label="nk_AccruedPreclinicalAndClinicalTrialCosts" />
    <link:loc xlink:href="nk-20191231.xsd#nk_AccruedLaboratoryEquipmentAndSupplies" xlink:type="locator" xlink:label="nk_AccruedLaboratoryEquipmentAndSupplies" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedSalariesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedSalariesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedBonusesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedBonusesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedBonusesCurrent" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedSalariesCurrent" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="nk_AccruedLaboratoryEquipmentAndSupplies" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="nk_AccruedPreclinicalAndClinicalTrialCosts" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="nk_AccruedFranchiseSalesUseAndPropertyTaxes" order="10060.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_LitigationReserveCurrent" order="10070.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_ConstructionPayableCurrent" order="10080.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="10090.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureFinancialStatementDetailsOtherCurrentLiabilitiesDetail" xlink:href="nk-20191231.xsd#Role_DisclosureFinancialStatementDetailsOtherCurrentLiabilitiesDetail" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureFinancialStatementDetailsOtherCurrentLiabilitiesDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherSundryLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_OtherSundryLiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredRentCreditCurrent" xlink:type="locator" xlink:label="us-gaap_DeferredRentCreditCurrent" />
    <link:loc xlink:href="nk-20191231.xsd#nk_FinancingObligationCurrent" xlink:type="locator" xlink:label="nk_FinancingObligationCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="nk_FinancingObligationCurrent" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_DeferredRentCreditCurrent" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherSundryLiabilitiesCurrent" order="10040.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureFinancialStatementDetailsInvestmentIncomeNetDetail" xlink:href="nk-20191231.xsd#Role_DisclosureFinancialStatementDetailsInvestmentIncomeNetDetail" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureFinancialStatementDetailsInvestmentIncomeNetDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RealizedInvestmentGainsLosses" xlink:type="locator" xlink:label="us-gaap_RealizedInvestmentGainsLosses" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInterest" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentIncomeNet" xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeNet" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InvestmentIncomeNet" xlink:to="us-gaap_InvestmentIncomeInterest" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InvestmentIncomeNet" xlink:to="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InvestmentIncomeNet" xlink:to="us-gaap_RealizedInvestmentGainsLosses" order="10030.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureFinancialInstrumentsInvestmentsInDebtSecuritiesScheduleOfInvestmentsInDebtSecuritiesDetail" xlink:href="nk-20191231.xsd#Role_DisclosureFinancialInstrumentsInvestmentsInDebtSecuritiesScheduleOfInvestmentsInDebtSecuritiesDetail" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureFinancialInstrumentsInvestmentsInDebtSecuritiesScheduleOfInvestmentsInDebtSecuritiesDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HeldToMaturitySecuritiesFairValue" xlink:type="locator" xlink:label="us-gaap_HeldToMaturitySecuritiesFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" xlink:type="locator" xlink:label="us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" xlink:type="locator" xlink:label="us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HeldToMaturitySecurities" xlink:type="locator" xlink:label="us-gaap_HeldToMaturitySecurities" />
    <link:loc xlink:href="nk-20191231.xsd#nk_DebtSecuritiesAvailableForSaleAndHeldToMaturityFairValue" xlink:type="locator" xlink:label="nk_DebtSecuritiesAvailableForSaleAndHeldToMaturityFairValue" />
    <link:loc xlink:href="nk-20191231.xsd#nk_DebtSecuritiesAvailableForSaleAndHeldToMaturityAmortizedCostAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="locator" xlink:label="nk_DebtSecuritiesAvailableForSaleAndHeldToMaturityAmortizedCostAccumulatedGrossUnrealizedLossBeforeTax" />
    <link:loc xlink:href="nk-20191231.xsd#nk_DebtSecuritiesAvailableForSaleAndHeldToMaturityAmortizedCostAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="locator" xlink:label="nk_DebtSecuritiesAvailableForSaleAndHeldToMaturityAmortizedCostAccumulatedGrossUnrealizedGainBeforeTax" />
    <link:loc xlink:href="nk-20191231.xsd#nk_DebtSecuritiesAvailableForSaleAndHeldToMaturityAmortizedCost" xlink:type="locator" xlink:label="nk_DebtSecuritiesAvailableForSaleAndHeldToMaturityAmortizedCost" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="nk_DebtSecuritiesAvailableForSaleAndHeldToMaturityAmortizedCost" xlink:to="nk_DebtSecuritiesAvailableForSaleAndHeldToMaturityAmortizedCostAccumulatedGrossUnrealizedGainBeforeTax" order="10010.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="nk_DebtSecuritiesAvailableForSaleAndHeldToMaturityAmortizedCost" xlink:to="nk_DebtSecuritiesAvailableForSaleAndHeldToMaturityAmortizedCostAccumulatedGrossUnrealizedLossBeforeTax" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="nk_DebtSecuritiesAvailableForSaleAndHeldToMaturityAmortizedCost" xlink:to="nk_DebtSecuritiesAvailableForSaleAndHeldToMaturityFairValue" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_HeldToMaturitySecurities" xlink:to="us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" order="10040.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_HeldToMaturitySecurities" xlink:to="us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_HeldToMaturitySecurities" xlink:to="us-gaap_HeldToMaturitySecuritiesFairValue" order="10060.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="10070.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="10080.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="10090.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureFinancialInstrumentsInvestmentsInDebtSecuritiesScheduleOfRealizedGainsAndLossesOnSalesOfAvailableForSaleDebtSecuritiesDetail" xlink:href="nk-20191231.xsd#Role_DisclosureFinancialInstrumentsInvestmentsInDebtSecuritiesScheduleOfRealizedGainsAndLossesOnSalesOfAvailableForSaleDebtSecuritiesDetail" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureFinancialInstrumentsInvestmentsInDebtSecuritiesScheduleOfRealizedGainsAndLossesOnSalesOfAvailableForSaleDebtSecuritiesDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesGrossRealizedGains" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesGrossRealizedGains" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossNet" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossNet" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossNet" xlink:to="us-gaap_AvailableForSaleSecuritiesGrossRealizedGains" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossNet" xlink:to="us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses" order="10020.00" priority="2" use="optional" weight="-1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureCommitmentAndContingenciesSummaryOfFutureMinimumLeasePaymentsDetail" xlink:href="nk-20191231.xsd#Role_DisclosureCommitmentAndContingenciesSummaryOfFutureMinimumLeasePaymentsDetail" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureCommitmentAndContingenciesSummaryOfFutureMinimumLeasePaymentsDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeaseLiability" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="10060.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" order="10070.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" order="10080.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureIncomeTaxesSummaryOfLossBeforeTaxesDetail" xlink:href="nk-20191231.xsd#Role_DisclosureIncomeTaxesSummaryOfLossBeforeTaxesDetail" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureIncomeTaxesSummaryOfLossBeforeTaxesDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" order="10020.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureIncomeTaxesSummaryOfIncomeTaxBenefitDetail" xlink:href="nk-20191231.xsd#Role_DisclosureIncomeTaxesSummaryOfIncomeTaxBenefitDetail" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureIncomeTaxesSummaryOfIncomeTaxBenefitDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" />
    <link:loc xlink:href="nk-20191231.xsd#nk_DeferredIncomeTaxExpenseBenefitNet" xlink:type="locator" xlink:label="nk_DeferredIncomeTaxExpenseBenefitNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="nk_DeferredIncomeTaxExpenseBenefitNet" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="nk_DeferredIncomeTaxExpenseBenefitNet" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="nk_DeferredIncomeTaxExpenseBenefitNet" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="nk_DeferredIncomeTaxExpenseBenefitNet" xlink:to="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit" order="10060.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" order="10070.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentForeignTaxExpenseBenefit" order="10080.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsAndLiabilitiesDetail" xlink:href="nk-20191231.xsd#Role_DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsAndLiabilitiesDetail" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsAndLiabilitiesDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLegalSettlements" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLegalSettlements" />
    <link:loc xlink:href="nk-20191231.xsd#nk_DeferredTaxAssetsLeasesAndOtherAccruedLiabilities" xlink:type="locator" xlink:label="nk_DeferredTaxAssetsLeasesAndOtherAccruedLiabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" />
    <link:loc xlink:href="nk-20191231.xsd#nk_DeferredTaxAssetsDeferredDepreciationAndAmortization" xlink:type="locator" xlink:label="nk_DeferredTaxAssetsDeferredDepreciationAndAmortization" />
    <link:loc xlink:href="nk-20191231.xsd#nk_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:type="locator" xlink:label="nk_DeferredTaxAssetsOperatingLeaseLiabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
    <link:loc xlink:href="nk-20191231.xsd#nk_DeferredTaxLiabilitiesDeferredDepreciationAndAmortization" xlink:type="locator" xlink:label="nk_DeferredTaxLiabilitiesDeferredDepreciationAndAmortization" />
    <link:loc xlink:href="nk-20191231.xsd#nk_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" xlink:type="locator" xlink:label="nk_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxLiabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilities" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" order="10010.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsGross" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredIncomeTaxLiabilities" order="10040.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="nk_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" order="10060.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="nk_DeferredTaxLiabilitiesDeferredDepreciationAndAmortization" order="10070.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="10080.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="10090.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="nk_DeferredTaxAssetsOperatingLeaseLiabilities" order="10100.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="nk_DeferredTaxAssetsDeferredDepreciationAndAmortization" order="10110.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" order="10120.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" order="10130.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="nk_DeferredTaxAssetsLeasesAndOtherAccruedLiabilities" order="10140.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLegalSettlements" order="10150.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateDetail" xlink:href="nk-20191231.xsd#Role_DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateDetail" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther" />
    <link:loc xlink:href="nk-20191231.xsd#nk_EffectiveIncomeTaxRateReconciliationStockBasedCompensationContribution" xlink:type="locator" xlink:label="nk_EffectiveIncomeTaxRateReconciliationStockBasedCompensationContribution" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" />
    <link:loc xlink:href="nk-20191231.xsd#nk_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsAct" xlink:type="locator" xlink:label="nk_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsAct" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="nk_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsAct" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="nk_EffectiveIncomeTaxRateReconciliationStockBasedCompensationContribution" order="10060.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther" order="10070.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="10080.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>62
<FILENAME>nk-20191231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2020-03-25T06:28:30.9224972+00:00 -->
<!-- Version            : 5.0.1.369 -->
<!-- Package ID         : 997a9244481146b697c7b584a5c14c7f -->
<!-- Copyright (c) 2020 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
  <link:roleRef xlink:type="simple" xlink:href="nk-20191231.xsd#TemplateLink" roleURI="http://www.nantkwest.com/20191231/role/TemplateLink" />
  <link:roleRef roleURI="http://www.nantkwest.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity" xlink:href="nk-20191231.xsd#Role_StatementConsolidatedStatementsOfStockholdersEquity" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.nantkwest.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification" xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:type="locator" xlink:label="us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:type="locator" xlink:label="us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <link:loc xlink:href="nk-20191231.xsd#nk_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:type="locator" xlink:label="nk_StockIssuedDuringPeriodSharesWarrantsExercised" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" xlink:type="locator" xlink:label="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdate201602Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingStandardsUpdate201409Member" xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdate201409Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:type="locator" xlink:label="us-gaap_TypeOfAdoptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:type="locator" xlink:label="us-gaap_TypeOfAdoptionMember_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:type="locator" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" order="10180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember_2" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201409Member" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201602Member" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="10280.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="10300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="10420.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" order="10560.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="nk_StockIssuedDuringPeriodSharesWarrantsExercised" order="10580.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="10700.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="10720.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" order="10840.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" order="10860.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" order="10980.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" order="11000.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" order="11120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" order="11140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification" order="11260.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" order="11400.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="11540.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" xlink:href="nk-20191231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" xlink:type="locator" xlink:label="us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities" xlink:type="locator" xlink:label="us-gaap_Liabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <link:loc xlink:href="nk-20191231.xsd#nk_NumberOfProductsApprovedForCommercialSale" xlink:type="locator" xlink:label="nk_NumberOfProductsApprovedForCommercialSale" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" />
    <link:loc xlink:href="nk-20191231.xsd#nk_VariableConsiderationRelatedToMilestonePayment" xlink:type="locator" xlink:label="nk_VariableConsiderationRelatedToMilestonePayment" />
    <link:loc xlink:href="nk-20191231.xsd#nk_NonrefundableUpfrontPayment" xlink:type="locator" xlink:label="nk_NonrefundableUpfrontPayment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:type="locator" xlink:label="us-gaap_StockRepurchaseProgramAuthorizedAmount1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OpenTaxYear" xlink:type="locator" xlink:label="us-gaap_OpenTaxYear" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseDescription" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseDescription" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeasePracticalExpedientsPackage" xlink:type="locator" xlink:label="us-gaap_LeasePracticalExpedientsPackage" />
    <link:loc xlink:href="nk-20191231.xsd#nk_FairValueInputsTransfersIntoOrOutOfLevelOneLevelTwoOrLevelThreeCategories" xlink:type="locator" xlink:label="nk_FairValueInputsTransfersIntoOrOutOfLevelOneLevelTwoOrLevelThreeCategories" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:type="locator" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet" xlink:type="locator" xlink:label="us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet" />
    <link:loc xlink:href="nk-20191231.xsd#nk_MinimumOriginalMaturityPeriodOfLongTermMarketableSecurities" xlink:type="locator" xlink:label="nk_MinimumOriginalMaturityPeriodOfLongTermMarketableSecurities" />
    <link:loc xlink:href="nk-20191231.xsd#nk_MaximumOriginalMaturityPeriodOfShortTermMarketableSecurities" xlink:type="locator" xlink:label="nk_MaximumOriginalMaturityPeriodOfShortTermMarketableSecurities" />
    <link:loc xlink:href="nk-20191231.xsd#nk_MarketableSecuritiesOriginalMaturities" xlink:type="locator" xlink:label="nk_MarketableSecuritiesOriginalMaturities" />
    <link:loc xlink:href="nk-20191231.xsd#nk_CashAndCashEquivalentsOriginalMaturities" xlink:type="locator" xlink:label="nk_CashAndCashEquivalentsOriginalMaturities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="nk-20191231.xsd#nk_DifferenceBetweenLeaseGuidanceInEffectBeforeAndAfterTopic842Member" xlink:type="locator" xlink:label="nk_DifferenceBetweenLeaseGuidanceInEffectBeforeAndAfterTopic842Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain" xlink:type="locator" xlink:label="us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain" xlink:type="locator" xlink:label="us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis" xlink:type="locator" xlink:label="us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdate201602Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:type="locator" xlink:label="us-gaap_TypeOfAdoptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:type="locator" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" />
    <link:loc xlink:href="nk-20191231.xsd#nk_IntrexonLicenseAgreementMember" xlink:type="locator" xlink:label="nk_IntrexonLicenseAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
    <link:loc xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_CA" xlink:type="locator" xlink:label="stpr_CA" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementGeographicalAxis" xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DomesticCountryMember" xlink:type="locator" xlink:label="us-gaap_DomesticCountryMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:type="locator" xlink:label="us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassificationOfVariableInterestEntityDomain" xlink:type="locator" xlink:label="us-gaap_ClassificationOfVariableInterestEntityDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassificationOfVariableInterestEntityDomain" xlink:type="locator" xlink:label="us-gaap_ClassificationOfVariableInterestEntityDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis" xlink:type="locator" xlink:label="us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis" />
    <link:loc xlink:href="nk-20191231.xsd#nk_ChairmanAndChiefExecutiveOfficerMember" xlink:type="locator" xlink:label="nk_ChairmanAndChiefExecutiveOfficerMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualAxis" xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" />
    <link:loc xlink:href="nk-20191231.xsd#nk_AccountingPoliciesTable" xlink:type="locator" xlink:label="nk_AccountingPoliciesTable" />
    <link:loc xlink:href="nk-20191231.xsd#nk_AccountingPoliciesLineItems" xlink:type="locator" xlink:label="nk_AccountingPoliciesLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="nk_AccountingPoliciesLineItems" xlink:to="nk_AccountingPoliciesTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nk_AccountingPoliciesTable" xlink:to="srt_TitleOfIndividualAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="nk_ChairmanAndChiefExecutiveOfficerMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nk_AccountingPoliciesTable" xlink:to="us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis" xlink:to="us-gaap_ClassificationOfVariableInterestEntityDomain_2" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis" xlink:to="us-gaap_ClassificationOfVariableInterestEntityDomain" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassificationOfVariableInterestEntityDomain" xlink:to="us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nk_AccountingPoliciesTable" xlink:to="srt_RangeAxis" order="10180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_2" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nk_AccountingPoliciesTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10340.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_2" order="10350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="10370.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="10390.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nk_AccountingPoliciesTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="10520.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain_2" order="10530.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="10550.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" order="10570.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nk_AccountingPoliciesTable" xlink:to="srt_StatementGeographicalAxis" order="10600.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain_2" order="10610.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="10630.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="stpr_CA" order="10650.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nk_AccountingPoliciesTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="10680.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2" order="10690.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="10710.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="nk_IntrexonLicenseAgreementMember" order="10730.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nk_AccountingPoliciesTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" order="10740.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" order="10770.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201602Member" order="10790.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nk_AccountingPoliciesTable" xlink:to="us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis" order="10880.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis" xlink:to="us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_2" order="10890.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis" xlink:to="us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain" order="10910.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain" xlink:to="nk_DifferenceBetweenLeaseGuidanceInEffectBeforeAndAfterTopic842Member" order="10930.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nk_AccountingPoliciesTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10960.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10990.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="11010.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nk_AccountingPoliciesLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" order="11040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nk_AccountingPoliciesLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" order="11090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nk_AccountingPoliciesLineItems" xlink:to="nk_CashAndCashEquivalentsOriginalMaturities" order="11160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nk_AccountingPoliciesLineItems" xlink:to="nk_MarketableSecuritiesOriginalMaturities" order="11180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nk_AccountingPoliciesLineItems" xlink:to="nk_MaximumOriginalMaturityPeriodOfShortTermMarketableSecurities" order="11200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nk_AccountingPoliciesLineItems" xlink:to="nk_MinimumOriginalMaturityPeriodOfLongTermMarketableSecurities" order="11220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nk_AccountingPoliciesLineItems" xlink:to="us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet" order="11270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nk_AccountingPoliciesLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife" order="11360.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nk_AccountingPoliciesLineItems" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" order="11410.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nk_AccountingPoliciesLineItems" xlink:to="nk_FairValueInputsTransfersIntoOrOutOfLevelOneLevelTwoOrLevelThreeCategories" order="11500.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nk_AccountingPoliciesLineItems" xlink:to="us-gaap_LeasePracticalExpedientsPackage" order="11590.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nk_AccountingPoliciesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseDescription" order="11640.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nk_AccountingPoliciesLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" order="11690.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nk_AccountingPoliciesLineItems" xlink:to="us-gaap_OpenTaxYear" order="11760.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nk_AccountingPoliciesLineItems" xlink:to="us-gaap_StockRepurchaseProgramAuthorizedAmount1" order="11870.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nk_AccountingPoliciesLineItems" xlink:to="nk_NonrefundableUpfrontPayment" order="11920.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nk_AccountingPoliciesLineItems" xlink:to="nk_VariableConsiderationRelatedToMilestonePayment" order="11970.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nk_AccountingPoliciesLineItems" xlink:to="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" order="11990.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nk_AccountingPoliciesLineItems" xlink:to="nk_NumberOfProductsApprovedForCommercialSale" order="12040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nk_AccountingPoliciesLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="12090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nk_AccountingPoliciesLineItems" xlink:to="us-gaap_OperatingLeaseLiability" order="12110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nk_AccountingPoliciesLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="12130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nk_AccountingPoliciesLineItems" xlink:to="us-gaap_Liabilities" order="12150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nk_AccountingPoliciesLineItems" xlink:to="us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" order="12170.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentDetail" xlink:href="nk-20191231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <link:loc xlink:href="nk-20191231.xsd#nk_ITEquipmentMember" xlink:type="locator" xlink:label="nk_ITEquipmentMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" />
    <link:loc xlink:href="nk-20191231.xsd#nk_LaboratoryEquipmentMember" xlink:type="locator" xlink:label="nk_LaboratoryEquipmentMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:type="locator" xlink:label="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BuildingMember" xlink:type="locator" xlink:label="us-gaap_BuildingMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_BuildingMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="nk_LaboratoryEquipmentMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="nk_ITEquipmentMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="10220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" order="10320.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSecuritiesExcludedFromComputationOfPotentiallyDilutiveSecuritiesDetail" xlink:href="nk-20191231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesSecuritiesExcludedFromComputationOfPotentiallyDilutiveSecuritiesDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSecuritiesExcludedFromComputationOfPotentiallyDilutiveSecuritiesDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantMember" xlink:type="locator" xlink:label="us-gaap_WarrantMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_WarrantMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="10290.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureFinancialStatementDetailsPropertyPlantAndEquipmentNetDetail" xlink:href="nk-20191231.xsd#Role_DisclosureFinancialStatementDetailsPropertyPlantAndEquipmentNetDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureFinancialStatementDetailsPropertyPlantAndEquipmentNetDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:type="locator" xlink:label="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquipmentMember" xlink:type="locator" xlink:label="us-gaap_EquipmentMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BuildingMember" xlink:type="locator" xlink:label="us-gaap_BuildingMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:type="locator" xlink:label="us-gaap_ConstructionInProgressMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="10030.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10060.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ConstructionInProgressMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_BuildingMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_EquipmentMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="10240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="10520.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10560.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureFinancialStatementDetailsAdditionalInformationDetail" xlink:href="nk-20191231.xsd#Role_DisclosureFinancialStatementDetailsAdditionalInformationDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureFinancialStatementDetailsAdditionalInformationDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ImpairmentOfInvestments" xlink:type="locator" xlink:label="us-gaap_ImpairmentOfInvestments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:type="locator" xlink:label="us-gaap_AmortizationOfIntangibleAssets" />
    <link:loc xlink:href="nk-20191231.xsd#nk_DerecognizedBuildToSuitLeaseAssets" xlink:type="locator" xlink:label="nk_DerecognizedBuildToSuitLeaseAssets" />
    <link:loc xlink:href="nk-20191231.xsd#nk_LesseseOperatingLeaseReclassificationOfAssetsFromBuildingsToLeaseholdImprovements" xlink:type="locator" xlink:label="nk_LesseseOperatingLeaseReclassificationOfAssetsFromBuildingsToLeaseholdImprovements" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Depreciation" xlink:type="locator" xlink:label="us-gaap_Depreciation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdate201602Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:type="locator" xlink:label="us-gaap_TypeOfAdoptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:type="locator" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" />
    <link:loc xlink:href="nk-20191231.xsd#nk_FinancialStatementDetailsTable" xlink:type="locator" xlink:label="nk_FinancialStatementDetailsTable" />
    <link:loc xlink:href="nk-20191231.xsd#nk_FinancialStatementDetailsLineItems" xlink:type="locator" xlink:label="nk_FinancialStatementDetailsLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="nk_FinancialStatementDetailsLineItems" xlink:to="nk_FinancialStatementDetailsTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nk_FinancialStatementDetailsTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201602Member" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nk_FinancialStatementDetailsLineItems" xlink:to="us-gaap_Depreciation" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nk_FinancialStatementDetailsLineItems" xlink:to="nk_LesseseOperatingLeaseReclassificationOfAssetsFromBuildingsToLeaseholdImprovements" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nk_FinancialStatementDetailsLineItems" xlink:to="nk_DerecognizedBuildToSuitLeaseAssets" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nk_FinancialStatementDetailsLineItems" xlink:to="us-gaap_AmortizationOfIntangibleAssets" order="10280.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nk_FinancialStatementDetailsLineItems" xlink:to="us-gaap_ImpairmentOfInvestments" order="10370.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureFinancialStatementDetailsImpactOfAdoptionOfASC842OnPropertyPlantAndEquipmentDetail" xlink:href="nk-20191231.xsd#Role_DisclosureFinancialStatementDetailsImpactOfAdoptionOfASC842OnPropertyPlantAndEquipmentDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureFinancialStatementDetailsImpactOfAdoptionOfASC842OnPropertyPlantAndEquipmentDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RestatementAdjustmentMember" xlink:type="locator" xlink:label="srt_RestatementAdjustmentMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RestatementDomain" xlink:type="locator" xlink:label="srt_RestatementDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RestatementDomain" xlink:type="locator" xlink:label="srt_RestatementDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RestatementAxis" xlink:type="locator" xlink:label="srt_RestatementAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BuildingMember" xlink:type="locator" xlink:label="us-gaap_BuildingMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdate201602Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:type="locator" xlink:label="us-gaap_TypeOfAdoptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:type="locator" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" />
    <link:loc xlink:href="nk-20191231.xsd#nk_FinancialStatementDetailsTable" xlink:type="locator" xlink:label="nk_FinancialStatementDetailsTable" />
    <link:loc xlink:href="nk-20191231.xsd#nk_FinancialStatementDetailsLineItems" xlink:type="locator" xlink:label="nk_FinancialStatementDetailsLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="nk_FinancialStatementDetailsLineItems" xlink:to="nk_FinancialStatementDetailsTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nk_FinancialStatementDetailsTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201602Member" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nk_FinancialStatementDetailsTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_BuildingMember" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nk_FinancialStatementDetailsTable" xlink:to="srt_RestatementAxis" order="10200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementDomain_2" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementDomain" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RestatementDomain" xlink:to="srt_RestatementAdjustmentMember" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nk_FinancialStatementDetailsLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="10280.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nk_FinancialStatementDetailsLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="10460.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nk_FinancialStatementDetailsLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10520.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureFinancialStatementDetailsIntangibleAssetsNetDetail" xlink:href="nk-20191231.xsd#Role_DisclosureFinancialStatementDetailsIntangibleAssetsNetDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureFinancialStatementDetailsIntangibleAssetsNetDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross" />
    <link:loc xlink:href="nk-20191231.xsd#nk_TechnologyLicenseMember" xlink:type="locator" xlink:label="nk_TechnologyLicenseMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" order="10030.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="10060.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="nk_TechnologyLicenseMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross" order="10180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" order="10220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" order="10260.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureViractaInvestmentAndConvertibleNotesAdditionalInformationDetail" xlink:href="nk-20191231.xsd#Role_DisclosureViractaInvestmentAndConvertibleNotesAdditionalInformationDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureViractaInvestmentAndConvertibleNotesAdditionalInformationDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockValue" xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentTerm" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage" />
    <link:loc xlink:href="nk-20191231.xsd#nk_PurchaseOfConvertibleNoteUponConversion" xlink:type="locator" xlink:label="nk_PurchaseOfConvertibleNoteUponConversion" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:type="locator" xlink:label="us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:type="locator" xlink:label="us-gaap_SeriesBPreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="nk-20191231.xsd#nk_TwoThousandAndEighteenNoteAndWarrantPurchaseAgreementMember" xlink:type="locator" xlink:label="nk_TwoThousandAndEighteenNoteAndWarrantPurchaseAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfInvestmentsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfInvestmentsTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfInvestmentsLineItems" xlink:type="locator" xlink:label="us-gaap_ScheduleOfInvestmentsLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ScheduleOfInvestmentsLineItems" xlink:to="us-gaap_ScheduleOfInvestmentsTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfInvestmentsTable" xlink:to="us-gaap_DebtInstrumentAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="nk_TwoThousandAndEighteenNoteAndWarrantPurchaseAgreementMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfInvestmentsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_2" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfInvestmentsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10260.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfInvestmentsLineItems" xlink:to="us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" order="10340.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfInvestmentsLineItems" xlink:to="nk_PurchaseOfConvertibleNoteUponConversion" order="10390.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfInvestmentsLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage" order="10430.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfInvestmentsLineItems" xlink:to="us-gaap_DebtInstrumentTerm" order="10470.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfInvestmentsLineItems" xlink:to="us-gaap_PreferredStockValue" order="10510.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfInvestmentsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="10550.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureFinancialInstrumentsInvestmentsInDebtSecuritiesScheduleOfInvestmentsInDebtSecuritiesDetail" xlink:href="nk-20191231.xsd#Role_DisclosureFinancialInstrumentsInvestmentsInDebtSecuritiesScheduleOfInvestmentsInDebtSecuritiesDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureFinancialInstrumentsInvestmentsInDebtSecuritiesScheduleOfInvestmentsInDebtSecuritiesDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain" />
    <link:loc xlink:href="nk-20191231.xsd#nk_AvailableForSaleDebtSecuritiesAmortizedCost" xlink:type="locator" xlink:label="nk_AvailableForSaleDebtSecuritiesAmortizedCost" />
    <link:loc xlink:href="nk-20191231.xsd#nk_DebtSecuritiesAvailableForSaleAndHeldToMaturityFairValue" xlink:type="locator" xlink:label="nk_DebtSecuritiesAvailableForSaleAndHeldToMaturityFairValue" />
    <link:loc xlink:href="nk-20191231.xsd#nk_DebtSecuritiesAvailableForSaleAndHeldToMaturityAmortizedCostAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="locator" xlink:label="nk_DebtSecuritiesAvailableForSaleAndHeldToMaturityAmortizedCostAccumulatedGrossUnrealizedLossBeforeTax" />
    <link:loc xlink:href="nk-20191231.xsd#nk_DebtSecuritiesAvailableForSaleAndHeldToMaturityAmortizedCostAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="locator" xlink:label="nk_DebtSecuritiesAvailableForSaleAndHeldToMaturityAmortizedCostAccumulatedGrossUnrealizedGainBeforeTax" />
    <link:loc xlink:href="nk-20191231.xsd#nk_DebtSecuritiesAvailableForSaleAndHeldToMaturityAmortizedCost" xlink:type="locator" xlink:label="nk_DebtSecuritiesAvailableForSaleAndHeldToMaturityAmortizedCost" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HeldToMaturitySecuritiesFairValue" xlink:type="locator" xlink:label="us-gaap_HeldToMaturitySecuritiesFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" xlink:type="locator" xlink:label="us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" xlink:type="locator" xlink:label="us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HeldToMaturitySecurities" xlink:type="locator" xlink:label="us-gaap_HeldToMaturitySecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAndHeldToMaturitySecurities" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesAndHeldToMaturitySecurities" />
    <link:loc xlink:href="nk-20191231.xsd#nk_AvailableForSaleSecuritiesAndHeldToMaturityGrossUnrealizedLosses" xlink:type="locator" xlink:label="nk_AvailableForSaleSecuritiesAndHeldToMaturityGrossUnrealizedLosses" />
    <link:loc xlink:href="nk-20191231.xsd#nk_AvailableForSaleSecuritiesAndHeldToMaturityGrossUnrealizedGain" xlink:type="locator" xlink:label="nk_AvailableForSaleSecuritiesAndHeldToMaturityGrossUnrealizedGain" />
    <link:loc xlink:href="nk-20191231.xsd#nk_AvailableForSaleSecuritiesDebtSecuritiesPeriod" xlink:type="locator" xlink:label="nk_AvailableForSaleSecuritiesDebtSecuritiesPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NotesReceivableMember" xlink:type="locator" xlink:label="us-gaap_NotesReceivableMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByAssetClassAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_CorporateDebtSecuritiesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:type="locator" xlink:label="us-gaap_FinancialInstrumentAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignGovernmentDebtMember" xlink:type="locator" xlink:label="us-gaap_ForeignGovernmentDebtMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeCategorizationMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeCategorizationMember_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AgencySecuritiesMember" xlink:type="locator" xlink:label="us-gaap_AgencySecuritiesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnderlyingAssetClassDomain" xlink:type="locator" xlink:label="us-gaap_UnderlyingAssetClassDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnderlyingAssetClassDomain" xlink:type="locator" xlink:label="us-gaap_UnderlyingAssetClassDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnderlyingAssetClassAxis" xlink:type="locator" xlink:label="us-gaap_UnderlyingAssetClassAxis" />
    <link:loc xlink:href="nk-20191231.xsd#nk_NoncurrentAssetsMember" xlink:type="locator" xlink:label="nk_NoncurrentAssetsMember" />
    <link:loc xlink:href="nk-20191231.xsd#nk_CurrentAssetsMember" xlink:type="locator" xlink:label="nk_CurrentAssetsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" order="10100.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="us-gaap_BalanceSheetLocationAxis" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain_2" order="10140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" order="10160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="nk_CurrentAssetsMember" order="10180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="nk_NoncurrentAssetsMember" order="10200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="us-gaap_UnderlyingAssetClassAxis" order="10290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_UnderlyingAssetClassAxis" xlink:to="us-gaap_UnderlyingAssetClassDomain_2" order="10300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_UnderlyingAssetClassAxis" xlink:to="us-gaap_UnderlyingAssetClassDomain" order="10320.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_UnderlyingAssetClassDomain" xlink:to="us-gaap_AgencySecuritiesMember" order="10340.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="us-gaap_InvestmentTypeAxis" order="10350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember_2" order="10360.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" order="10380.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_ForeignGovernmentDebtMember" order="10400.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="10410.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2" order="10420.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="10440.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CorporateDebtSecuritiesMember" order="10460.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="11170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_2" order="11180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="11200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_NotesReceivableMember" order="11220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" order="11650.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="11910.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="12170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="12430.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="nk_AvailableForSaleSecuritiesDebtSecuritiesPeriod" order="12720.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="nk_AvailableForSaleSecuritiesAndHeldToMaturityGrossUnrealizedGain" order="12980.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="nk_AvailableForSaleSecuritiesAndHeldToMaturityGrossUnrealizedLosses" order="13240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesAndHeldToMaturitySecurities" order="13500.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_HeldToMaturitySecurities" order="14940.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" order="15220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" order="15500.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_HeldToMaturitySecuritiesFairValue" order="15780.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="nk_DebtSecuritiesAvailableForSaleAndHeldToMaturityAmortizedCost" order="16090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="nk_DebtSecuritiesAvailableForSaleAndHeldToMaturityAmortizedCostAccumulatedGrossUnrealizedGainBeforeTax" order="16370.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="nk_DebtSecuritiesAvailableForSaleAndHeldToMaturityAmortizedCostAccumulatedGrossUnrealizedLossBeforeTax" order="16650.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="nk_DebtSecuritiesAvailableForSaleAndHeldToMaturityFairValue" order="16930.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="nk_AvailableForSaleDebtSecuritiesAmortizedCost" order="17240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain" order="17520.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" order="17800.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureFinancialInstrumentsInvestmentsInDebtSecuritiesAdditionalInformationDetail" xlink:href="nk-20191231.xsd#Role_DisclosureFinancialInstrumentsInvestmentsInDebtSecuritiesAdditionalInformationDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureFinancialInstrumentsInvestmentsInDebtSecuritiesAdditionalInformationDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1" xlink:type="locator" xlink:label="us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1" />
    <link:loc xlink:href="nk-20191231.xsd#nk_AvailableForSaleSecuritiesPeriodOfUnrealizedLossPositions" xlink:type="locator" xlink:label="nk_AvailableForSaleSecuritiesPeriodOfUnrealizedLossPositions" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:type="locator" xlink:label="us-gaap_FinancialInstrumentAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_DebtSecuritiesMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="srt_RangeAxis" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="nk_AvailableForSaleSecuritiesPeriodOfUnrealizedLossPositions" order="10260.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1" order="10410.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureFinancialInstrumentsInvestmentsInDebtSecuritiesAccumulatedUnrealizedLossesOnDebtSecuritiesClassifiedAsAvailableForSaleInContinuousLossPositionDetail" xlink:href="nk-20191231.xsd#Role_DisclosureFinancialInstrumentsInvestmentsInDebtSecuritiesAccumulatedUnrealizedLossesOnDebtSecuritiesClassifiedAsAvailableForSaleInContinuousLossPositionDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureFinancialInstrumentsInvestmentsInDebtSecuritiesAccumulatedUnrealizedLossesOnDebtSecuritiesClassifiedAsAvailableForSaleInContinuousLossPositionDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_CorporateDebtSecuritiesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:type="locator" xlink:label="us-gaap_FinancialInstrumentAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AgencySecuritiesMember" xlink:type="locator" xlink:label="us-gaap_AgencySecuritiesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnderlyingAssetClassDomain" xlink:type="locator" xlink:label="us-gaap_UnderlyingAssetClassDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnderlyingAssetClassAxis" xlink:type="locator" xlink:label="us-gaap_UnderlyingAssetClassAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="us-gaap_UnderlyingAssetClassAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_UnderlyingAssetClassAxis" xlink:to="us-gaap_UnderlyingAssetClassDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_UnderlyingAssetClassDomain" xlink:to="us-gaap_AgencySecuritiesMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CorporateDebtSecuritiesMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" order="10300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" order="10440.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" order="10580.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" order="10720.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail" xlink:href="nk-20191231.xsd#Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_AssetsFairValueDisclosure" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_CorporateDebtSecuritiesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsMember" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByAssetClassAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignGovernmentDebtMember" xlink:type="locator" xlink:label="us-gaap_ForeignGovernmentDebtMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeCategorizationMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AgencySecuritiesMember" xlink:type="locator" xlink:label="us-gaap_AgencySecuritiesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnderlyingAssetClassDomain" xlink:type="locator" xlink:label="us-gaap_UnderlyingAssetClassDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnderlyingAssetClassAxis" xlink:type="locator" xlink:label="us-gaap_UnderlyingAssetClassAxis" />
    <link:loc xlink:href="nk-20191231.xsd#nk_NoncurrentAssetsMember" xlink:type="locator" xlink:label="nk_NoncurrentAssetsMember" />
    <link:loc xlink:href="nk-20191231.xsd#nk_CurrentAssetsMember" xlink:type="locator" xlink:label="nk_CurrentAssetsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="10140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_2" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_BalanceSheetLocationAxis" order="10300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" order="10330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="nk_CurrentAssetsMember" order="10350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="nk_NoncurrentAssetsMember" order="10430.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_UnderlyingAssetClassAxis" order="10440.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_UnderlyingAssetClassAxis" xlink:to="us-gaap_UnderlyingAssetClassDomain" order="10470.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_UnderlyingAssetClassDomain" xlink:to="us-gaap_AgencySecuritiesMember" order="10490.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_InvestmentTypeAxis" order="10500.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" order="10530.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_ForeignGovernmentDebtMember" order="10550.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="10560.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="10590.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_CashAndCashEquivalentsMember" order="10610.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_CorporateDebtSecuritiesMember" order="10630.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" order="11200.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail" xlink:href="nk-20191231.xsd#Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail">
    <link:loc xlink:href="nk-20191231.xsd#nk_AgreementOneTimeFee" xlink:type="locator" xlink:label="nk_AgreementOneTimeFee" />
    <link:loc xlink:href="nk-20191231.xsd#nk_LicenseAgreementTerm" xlink:type="locator" xlink:label="nk_LicenseAgreementTerm" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RoyaltyExpense" xlink:type="locator" xlink:label="us-gaap_RoyaltyExpense" />
    <link:loc xlink:href="nk-20191231.xsd#nk_MinimumSalesMilestoneOfLicenseForFirstYear" xlink:type="locator" xlink:label="nk_MinimumSalesMilestoneOfLicenseForFirstYear" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:type="locator" xlink:label="us-gaap_CostOfGoodsAndServicesSold" />
    <link:loc xlink:href="nk-20191231.xsd#nk_MinimumAnnualRoyaltyPayment" xlink:type="locator" xlink:label="nk_MinimumAnnualRoyaltyPayment" />
    <link:loc xlink:href="nk-20191231.xsd#nk_PeriodOfLicenseAgreement" xlink:type="locator" xlink:label="nk_PeriodOfLicenseAgreement" />
    <link:loc xlink:href="nk-20191231.xsd#nk_PaymentsForInitialLicenseFees" xlink:type="locator" xlink:label="nk_PaymentsForInitialLicenseFees" />
    <link:loc xlink:href="nk-20191231.xsd#nk_LicenseAgreementTerminationNoticePeriod" xlink:type="locator" xlink:label="nk_LicenseAgreementTerminationNoticePeriod" />
    <link:loc xlink:href="nk-20191231.xsd#nk_MilestonePaymentAmount" xlink:type="locator" xlink:label="nk_MilestonePaymentAmount" />
    <link:loc xlink:href="nk-20191231.xsd#nk_SuppliesAndMilestoneChargesForConductingClinicalTrials" xlink:type="locator" xlink:label="nk_SuppliesAndMilestoneChargesForConductingClinicalTrials" />
    <link:loc xlink:href="nk-20191231.xsd#nk_MaximumNumberOfPatientsInPhaseOneAndTwoForClinicalTrials" xlink:type="locator" xlink:label="nk_MaximumNumberOfPatientsInPhaseOneAndTwoForClinicalTrials" />
    <link:loc xlink:href="nk-20191231.xsd#nk_IntrexonLicenseAgreementMember" xlink:type="locator" xlink:label="nk_IntrexonLicenseAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
    <link:loc xlink:href="nk-20191231.xsd#nk_CommercialSaleRelatedToLicensedProductsMember" xlink:type="locator" xlink:label="nk_CommercialSaleRelatedToLicensedProductsMember" />
    <link:loc xlink:href="nk-20191231.xsd#nk_PhaseThreeMember" xlink:type="locator" xlink:label="nk_PhaseThreeMember" />
    <link:loc xlink:href="nk-20191231.xsd#nk_PhaseTwoMember" xlink:type="locator" xlink:label="nk_PhaseTwoMember" />
    <link:loc xlink:href="nk-20191231.xsd#nk_INDFilingMember" xlink:type="locator" xlink:label="nk_INDFilingMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" />
    <link:loc xlink:href="nk-20191231.xsd#nk_RushUniversityMedicalCenterLicenseAgreementMember" xlink:type="locator" xlink:label="nk_RushUniversityMedicalCenterLicenseAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCommitmentsDomain" xlink:type="locator" xlink:label="us-gaap_OtherCommitmentsDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCommitmentsDomain" xlink:type="locator" xlink:label="us-gaap_OtherCommitmentsDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCommitmentsAxis" xlink:type="locator" xlink:label="us-gaap_OtherCommitmentsAxis" />
    <link:loc xlink:href="nk-20191231.xsd#nk_GeorgSpeyerHausAndDRKBlutspendedienstBadenWurttembergHessengGmbHLicenseAgreementMember" xlink:type="locator" xlink:label="nk_GeorgSpeyerHausAndDRKBlutspendedienstBadenWurttembergHessengGmbHLicenseAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="nk-20191231.xsd#nk_ViractaTherapeuticsIncMember" xlink:type="locator" xlink:label="nk_ViractaTherapeuticsIncMember" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain_2" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <link:loc xlink:href="nk-20191231.xsd#nk_AltorBioScienceCorporationMember" xlink:type="locator" xlink:label="nk_AltorBioScienceCorporationMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" />
    <link:loc xlink:href="nk-20191231.xsd#nk_LicensingAgreementTable" xlink:type="locator" xlink:label="nk_LicensingAgreementTable" />
    <link:loc xlink:href="nk-20191231.xsd#nk_LicensingAgreementLineItems" xlink:type="locator" xlink:label="nk_LicensingAgreementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="nk_LicensingAgreementLineItems" xlink:to="nk_LicensingAgreementTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nk_LicensingAgreementTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="nk_AltorBioScienceCorporationMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nk_LicensingAgreementTable" xlink:to="dei_LegalEntityAxis" order="10160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain_2" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="nk_ViractaTherapeuticsIncMember" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nk_LicensingAgreementTable" xlink:to="srt_RangeAxis" order="10220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nk_LicensingAgreementTable" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" order="10300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_2" order="10310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" order="10330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="nk_GeorgSpeyerHausAndDRKBlutspendedienstBadenWurttembergHessengGmbHLicenseAgreementMember" order="10350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nk_LicensingAgreementTable" xlink:to="us-gaap_OtherCommitmentsAxis" order="10360.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="us-gaap_OtherCommitmentsDomain_2" order="10370.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="us-gaap_OtherCommitmentsDomain" order="10390.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsDomain" xlink:to="nk_RushUniversityMedicalCenterLicenseAgreementMember" order="10410.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nk_LicensingAgreementTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" order="10560.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_2" order="10570.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" order="10590.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="nk_INDFilingMember" order="10610.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="nk_PhaseTwoMember" order="10630.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="nk_PhaseThreeMember" order="10650.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="nk_CommercialSaleRelatedToLicensedProductsMember" order="10670.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nk_LicensingAgreementTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="10680.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="10710.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="nk_IntrexonLicenseAgreementMember" order="10730.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nk_LicensingAgreementLineItems" xlink:to="nk_MaximumNumberOfPatientsInPhaseOneAndTwoForClinicalTrials" order="10900.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nk_LicensingAgreementLineItems" xlink:to="nk_SuppliesAndMilestoneChargesForConductingClinicalTrials" order="10950.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nk_LicensingAgreementLineItems" xlink:to="nk_MilestonePaymentAmount" order="11040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nk_LicensingAgreementLineItems" xlink:to="nk_LicenseAgreementTerminationNoticePeriod" order="11080.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nk_LicensingAgreementLineItems" xlink:to="nk_PaymentsForInitialLicenseFees" order="11130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nk_LicensingAgreementLineItems" xlink:to="nk_PeriodOfLicenseAgreement" order="11180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nk_LicensingAgreementLineItems" xlink:to="nk_MinimumAnnualRoyaltyPayment" order="11200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nk_LicensingAgreementLineItems" xlink:to="us-gaap_CostOfGoodsAndServicesSold" order="11220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nk_LicensingAgreementLineItems" xlink:to="nk_MinimumSalesMilestoneOfLicenseForFirstYear" order="11240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nk_LicensingAgreementLineItems" xlink:to="us-gaap_RoyaltyExpense" order="11290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nk_LicensingAgreementLineItems" xlink:to="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" order="11350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nk_LicensingAgreementLineItems" xlink:to="nk_LicenseAgreementTerm" order="11440.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nk_LicensingAgreementLineItems" xlink:to="nk_AgreementOneTimeFee" order="11520.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureCommitmentAndContingenciesAdditionalInformationDetail" xlink:href="nk-20191231.xsd#Role_DisclosureCommitmentAndContingenciesAdditionalInformationDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureCommitmentAndContingenciesAdditionalInformationDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesRentExpenseNet" />
    <link:loc xlink:href="nk-20191231.xsd#nk_LeaseAgreementExtendedPeriod" xlink:type="locator" xlink:label="nk_LeaseAgreementExtendedPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm" />
    <link:loc xlink:href="nk-20191231.xsd#nk_PeriodOfLicenseAgreementDescription" xlink:type="locator" xlink:label="nk_PeriodOfLicenseAgreementDescription" />
    <link:loc xlink:href="nk-20191231.xsd#nk_AnnualBaseRentIncreasePerSquareFoot" xlink:type="locator" xlink:label="nk_AnnualBaseRentIncreasePerSquareFoot" />
    <link:loc xlink:href="nk-20191231.xsd#nk_AdditionToNumberOfSquareFootOfFacilityLeased" xlink:type="locator" xlink:label="nk_AdditionToNumberOfSquareFootOfFacilityLeased" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseExpirationDate1" xlink:type="locator" xlink:label="us-gaap_LeaseExpirationDate1" />
    <link:loc xlink:href="nk-20191231.xsd#nk_LeaseCommencementDate" xlink:type="locator" xlink:label="nk_LeaseCommencementDate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" />
    <link:loc xlink:href="nk-20191231.xsd#nk_AnnualPercentageIncreasesToBaseRentCommencementDate" xlink:type="locator" xlink:label="nk_AnnualPercentageIncreasesToBaseRentCommencementDate" />
    <link:loc xlink:href="nk-20191231.xsd#nk_AnnualPercentageIncreasesToBaseRent" xlink:type="locator" xlink:label="nk_AnnualPercentageIncreasesToBaseRent" />
    <link:loc xlink:href="nk-20191231.xsd#nk_BaseMonthlyRent" xlink:type="locator" xlink:label="nk_BaseMonthlyRent" />
    <link:loc xlink:href="nk-20191231.xsd#nk_PeriodOfExtendedLeaseTerm" xlink:type="locator" xlink:label="nk_PeriodOfExtendedLeaseTerm" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseDescription" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseDescription" />
    <link:loc xlink:href="nk-20191231.xsd#nk_NumberOfSquareFootOfFacilityLeased" xlink:type="locator" xlink:label="nk_NumberOfSquareFootOfFacilityLeased" />
    <link:loc xlink:href="nk-20191231.xsd#nk_RelatedPartyAgreementExpirationMonthAndYear" xlink:type="locator" xlink:label="nk_RelatedPartyAgreementExpirationMonthAndYear" />
    <link:loc xlink:href="nk-20191231.xsd#nk_RelatedPartyTransactionInitialTermOfAgreement" xlink:type="locator" xlink:label="nk_RelatedPartyTransactionInitialTermOfAgreement" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction" />
    <link:loc xlink:href="nk-20191231.xsd#nk_RelatedPartyTransactionAmountPaidToRelatedParty" xlink:type="locator" xlink:label="nk_RelatedPartyTransactionAmountPaidToRelatedParty" />
    <link:loc xlink:href="nk-20191231.xsd#nk_RelatedPartyTransactionReimbursedUpfrontPaymentToThirdParty" xlink:type="locator" xlink:label="nk_RelatedPartyTransactionReimbursedUpfrontPaymentToThirdParty" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:type="locator" xlink:label="us-gaap_OperatingLeasePayments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableLeaseCost" xlink:type="locator" xlink:label="us-gaap_VariableLeaseCost" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseCost" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="locator" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InsuranceSettlementsReceivable" xlink:type="locator" xlink:label="us-gaap_InsuranceSettlementsReceivable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LegalFees" xlink:type="locator" xlink:label="us-gaap_LegalFees" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:type="locator" xlink:label="us-gaap_LitigationSettlementAmountAwardedToOtherParty" />
    <link:loc xlink:href="nk-20191231.xsd#nk_CommitmentSanDiegoMember" xlink:type="locator" xlink:label="nk_CommitmentSanDiegoMember" />
    <link:loc xlink:href="nk-20191231.xsd#nk_NantWorksLimitedLiabilityCompanyMember" xlink:type="locator" xlink:label="nk_NantWorksLimitedLiabilityCompanyMember" />
    <link:loc xlink:href="nk-20191231.xsd#nk_CommitmentWoburnMassachusettsMember" xlink:type="locator" xlink:label="nk_CommitmentWoburnMassachusettsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseArrangementTypeDomain" xlink:type="locator" xlink:label="us-gaap_LeaseArrangementTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseArrangementTypeDomain" xlink:type="locator" xlink:label="us-gaap_LeaseArrangementTypeDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseArrangementTypeAxis" xlink:type="locator" xlink:label="us-gaap_LeaseArrangementTypeAxis" />
    <link:loc xlink:href="nk-20191231.xsd#nk_ElSegundoCaliforniaMember" xlink:type="locator" xlink:label="nk_ElSegundoCaliforniaMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementGeographicalAxis" xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" />
    <link:loc xlink:href="nk-20191231.xsd#nk_DougStLLCMember" xlink:type="locator" xlink:label="nk_DougStLLCMember" />
    <link:loc xlink:href="nk-20191231.xsd#nk_NantBioScienceMember" xlink:type="locator" xlink:label="nk_NantBioScienceMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpenseMember" xlink:type="locator" xlink:label="us-gaap_OperatingExpenseMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:type="locator" xlink:label="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationAxis" />
    <link:loc xlink:href="nk-20191231.xsd#nk_DirectorsAndOfficersInsurancePolicyMember" xlink:type="locator" xlink:label="nk_DirectorsAndOfficersInsurancePolicyMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReinsurancePolicyDomain" xlink:type="locator" xlink:label="us-gaap_ReinsurancePolicyDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReinsurancePolicyDomain" xlink:type="locator" xlink:label="us-gaap_ReinsurancePolicyDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReinsurancePolicyTypeAxis" xlink:type="locator" xlink:label="us-gaap_ReinsurancePolicyTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:loc xlink:href="nk-20191231.xsd#nk_CommitmentsAndContingenciesTable" xlink:type="locator" xlink:label="nk_CommitmentsAndContingenciesTable" />
    <link:loc xlink:href="nk-20191231.xsd#nk_CommitmentsAndContingenciesLineItems" xlink:type="locator" xlink:label="nk_CommitmentsAndContingenciesLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="nk_CommitmentsAndContingenciesLineItems" xlink:to="nk_CommitmentsAndContingenciesTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nk_CommitmentsAndContingenciesTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nk_CommitmentsAndContingenciesTable" xlink:to="us-gaap_ReinsurancePolicyTypeAxis" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ReinsurancePolicyTypeAxis" xlink:to="us-gaap_ReinsurancePolicyDomain_2" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ReinsurancePolicyTypeAxis" xlink:to="us-gaap_ReinsurancePolicyDomain" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ReinsurancePolicyDomain" xlink:to="nk_DirectorsAndOfficersInsurancePolicyMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nk_CommitmentsAndContingenciesTable" xlink:to="us-gaap_BalanceSheetLocationAxis" order="10160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_OperatingExpenseMember" order="10270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nk_CommitmentsAndContingenciesTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="10300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="10330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="nk_NantBioScienceMember" order="10350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="nk_DougStLLCMember" order="10490.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nk_CommitmentsAndContingenciesTable" xlink:to="srt_StatementGeographicalAxis" order="10600.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="10630.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="nk_ElSegundoCaliforniaMember" order="10650.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nk_CommitmentsAndContingenciesTable" xlink:to="us-gaap_LeaseArrangementTypeAxis" order="10660.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LeaseArrangementTypeAxis" xlink:to="us-gaap_LeaseArrangementTypeDomain_2" order="10670.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LeaseArrangementTypeAxis" xlink:to="us-gaap_LeaseArrangementTypeDomain" order="10690.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseArrangementTypeDomain" xlink:to="nk_CommitmentWoburnMassachusettsMember" order="10710.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="nk_NantWorksLimitedLiabilityCompanyMember" order="10990.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseArrangementTypeDomain" xlink:to="nk_CommitmentSanDiegoMember" order="11050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nk_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_LitigationSettlementAmountAwardedToOtherParty" order="11140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nk_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_LegalFees" order="11230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nk_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_InsuranceSettlementsReceivable" order="11280.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nk_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" order="11350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nk_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_OperatingLeaseCost" order="11400.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nk_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_VariableLeaseCost" order="11460.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nk_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="11520.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nk_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="11580.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nk_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_OperatingLeasePayments" order="11640.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nk_CommitmentsAndContingenciesLineItems" xlink:to="nk_RelatedPartyTransactionReimbursedUpfrontPaymentToThirdParty" order="11730.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nk_CommitmentsAndContingenciesLineItems" xlink:to="nk_RelatedPartyTransactionAmountPaidToRelatedParty" order="11750.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nk_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_RelatedPartyTransactionAmountsOfTransaction" order="11770.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nk_CommitmentsAndContingenciesLineItems" xlink:to="nk_RelatedPartyTransactionInitialTermOfAgreement" order="11790.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nk_CommitmentsAndContingenciesLineItems" xlink:to="nk_RelatedPartyAgreementExpirationMonthAndYear" order="11810.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nk_CommitmentsAndContingenciesLineItems" xlink:to="nk_NumberOfSquareFootOfFacilityLeased" order="11860.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nk_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseDescription" order="11880.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nk_CommitmentsAndContingenciesLineItems" xlink:to="nk_PeriodOfExtendedLeaseTerm" order="11900.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nk_CommitmentsAndContingenciesLineItems" xlink:to="nk_BaseMonthlyRent" order="11920.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nk_CommitmentsAndContingenciesLineItems" xlink:to="nk_AnnualPercentageIncreasesToBaseRent" order="11940.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nk_CommitmentsAndContingenciesLineItems" xlink:to="nk_AnnualPercentageIncreasesToBaseRentCommencementDate" order="11960.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nk_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" order="12030.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nk_CommitmentsAndContingenciesLineItems" xlink:to="nk_LeaseCommencementDate" order="12050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nk_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_LeaseExpirationDate1" order="12070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nk_CommitmentsAndContingenciesLineItems" xlink:to="nk_AdditionToNumberOfSquareFootOfFacilityLeased" order="12090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nk_CommitmentsAndContingenciesLineItems" xlink:to="nk_AnnualBaseRentIncreasePerSquareFoot" order="12150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nk_CommitmentsAndContingenciesLineItems" xlink:to="nk_PeriodOfLicenseAgreementDescription" order="12170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nk_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm" order="12190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nk_CommitmentsAndContingenciesLineItems" xlink:to="nk_LeaseAgreementExtendedPeriod" order="12210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nk_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_OperatingLeasesRentExpenseNet" order="12520.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureRelatedPartyAgreementsAdditionalInformationDetail" xlink:href="nk-20191231.xsd#Role_DisclosureRelatedPartyAgreementsAdditionalInformationDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureRelatedPartyAgreementsAdditionalInformationDetail">
    <link:loc xlink:href="nk-20191231.xsd#nk_PrepaidExpensesAndOtherAssetsCurrentWithRelatedParty" xlink:type="locator" xlink:label="nk_PrepaidExpensesAndOtherAssetsCurrentWithRelatedParty" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" />
    <link:loc xlink:href="nk-20191231.xsd#nk_SuppliesAndMilestoneChargesForConductingClinicalTrials" xlink:type="locator" xlink:label="nk_SuppliesAndMilestoneChargesForConductingClinicalTrials" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:type="locator" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" />
    <link:loc xlink:href="nk-20191231.xsd#nk_TransferOfDepositAmountToThirdParty" xlink:type="locator" xlink:label="nk_TransferOfDepositAmountToThirdParty" />
    <link:loc xlink:href="nk-20191231.xsd#nk_PrepaymentOfFundingAmount" xlink:type="locator" xlink:label="nk_PrepaymentOfFundingAmount" />
    <link:loc xlink:href="nk-20191231.xsd#nk_ResearchAndDevelopmentExpenseRatablePaymentPeriod" xlink:type="locator" xlink:label="nk_ResearchAndDevelopmentExpenseRatablePaymentPeriod" />
    <link:loc xlink:href="nk-20191231.xsd#nk_RelatedPartyAgreementExpirationMonthAndYear" xlink:type="locator" xlink:label="nk_RelatedPartyAgreementExpirationMonthAndYear" />
    <link:loc xlink:href="nk-20191231.xsd#nk_RelatedPartyTransactionAmountPaidToThirdParty" xlink:type="locator" xlink:label="nk_RelatedPartyTransactionAmountPaidToThirdParty" />
    <link:loc xlink:href="nk-20191231.xsd#nk_RelatedPartyTransactionReimbursedUpfrontPaymentToRelatedParty" xlink:type="locator" xlink:label="nk_RelatedPartyTransactionReimbursedUpfrontPaymentToRelatedParty" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseExpense" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseExpense" />
    <link:loc xlink:href="nk-20191231.xsd#nk_AnnualPercentageIncreasesToBaseRentCommencementDate" xlink:type="locator" xlink:label="nk_AnnualPercentageIncreasesToBaseRentCommencementDate" />
    <link:loc xlink:href="nk-20191231.xsd#nk_AnnualPercentageIncreasesToBaseRent" xlink:type="locator" xlink:label="nk_AnnualPercentageIncreasesToBaseRent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionDueFromToRelatedParty" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDueFromToRelatedParty" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesIncomeStatementSubleaseRevenue" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesIncomeStatementSubleaseRevenue" />
    <link:loc xlink:href="nk-20191231.xsd#nk_BaseMonthlyRent" xlink:type="locator" xlink:label="nk_BaseMonthlyRent" />
    <link:loc xlink:href="nk-20191231.xsd#nk_NumberOfSquareFootOfFacilityLeased" xlink:type="locator" xlink:label="nk_NumberOfSquareFootOfFacilityLeased" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionDescriptionOfTransaction" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDescriptionOfTransaction" />
    <link:loc xlink:href="nk-20191231.xsd#nk_PrepaidBalanceIncludedInPrepaidExpensesAndOtherCurrentAssetsAndOtherAssets" xlink:type="locator" xlink:label="nk_PrepaidBalanceIncludedInPrepaidExpensesAndOtherCurrentAssetsAndOtherAssets" />
    <link:loc xlink:href="nk-20191231.xsd#nk_NewAgreementTerminationNoticePeriod" xlink:type="locator" xlink:label="nk_NewAgreementTerminationNoticePeriod" />
    <link:loc xlink:href="nk-20191231.xsd#nk_RelatedPartyTransactionAgreementExtensionDescription" xlink:type="locator" xlink:label="nk_RelatedPartyTransactionAgreementExtensionDescription" />
    <link:loc xlink:href="nk-20191231.xsd#nk_RelatedPartyInstallmentPayment" xlink:type="locator" xlink:label="nk_RelatedPartyInstallmentPayment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction" />
    <link:loc xlink:href="nk-20191231.xsd#nk_InitialTermOfAgreement" xlink:type="locator" xlink:label="nk_InitialTermOfAgreement" />
    <link:loc xlink:href="nk-20191231.xsd#nk_NumberOfOfficers" xlink:type="locator" xlink:label="nk_NumberOfOfficers" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:type="locator" xlink:label="us-gaap_DueToRelatedPartiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:loc xlink:href="nk-20191231.xsd#nk_RelatedPartyAgreementRenewalTerm" xlink:type="locator" xlink:label="nk_RelatedPartyAgreementRenewalTerm" />
    <link:loc xlink:href="nk-20191231.xsd#nk_RelatedPartyTransactionInitialTermOfAgreement" xlink:type="locator" xlink:label="nk_RelatedPartyTransactionInitialTermOfAgreement" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:type="locator" xlink:label="us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:type="locator" xlink:label="us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" />
    <link:loc xlink:href="nk-20191231.xsd#nk_AltorBioScienceCorporationMember" xlink:type="locator" xlink:label="nk_AltorBioScienceCorporationMember" />
    <link:loc xlink:href="nk-20191231.xsd#nk_VivaBioCellSPAMember" xlink:type="locator" xlink:label="nk_VivaBioCellSPAMember" />
    <link:loc xlink:href="nk-20191231.xsd#nk_ImmunityBioMember" xlink:type="locator" xlink:label="nk_ImmunityBioMember" />
    <link:loc xlink:href="nk-20191231.xsd#nk_NantOmicsLLCMember" xlink:type="locator" xlink:label="nk_NantOmicsLLCMember" />
    <link:loc xlink:href="nk-20191231.xsd#nk_SharedServicesAgreementMember" xlink:type="locator" xlink:label="nk_SharedServicesAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="nk-20191231.xsd#nk_ReimbursementsMember" xlink:type="locator" xlink:label="nk_ReimbursementsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransactionDomain" xlink:type="locator" xlink:label="us-gaap_TransactionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransactionDomain" xlink:type="locator" xlink:label="us-gaap_TransactionDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransactionTypeAxis" xlink:type="locator" xlink:label="us-gaap_TransactionTypeAxis" />
    <link:loc xlink:href="nk-20191231.xsd#nk_NantWorksLimitedLiabilityCompanyMember" xlink:type="locator" xlink:label="nk_NantWorksLimitedLiabilityCompanyMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:type="locator" xlink:label="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationAxis" />
    <link:loc xlink:href="nk-20191231.xsd#nk_NantBioScienceMember" xlink:type="locator" xlink:label="nk_NantBioScienceMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:loc xlink:href="nk-20191231.xsd#nk_ElSegundoCaliforniaMember" xlink:type="locator" xlink:label="nk_ElSegundoCaliforniaMember" />
    <link:loc xlink:href="nk-20191231.xsd#nk_DougStLLCMember" xlink:type="locator" xlink:label="nk_DougStLLCMember" />
    <link:loc xlink:href="nk-20191231.xsd#nk_SanDiegoCaliforniaMember" xlink:type="locator" xlink:label="nk_SanDiegoCaliforniaMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherIncomeMember" xlink:type="locator" xlink:label="us-gaap_OtherIncomeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:loc xlink:href="nk-20191231.xsd#nk_TensorcomIncMember" xlink:type="locator" xlink:label="nk_TensorcomIncMember" />
    <link:loc xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_CA" xlink:type="locator" xlink:label="stpr_CA" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementGeographicalAxis" xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" />
    <link:loc xlink:href="nk-20191231.xsd#nk_ImmunoOncologyClinicIncMember" xlink:type="locator" xlink:label="nk_ImmunoOncologyClinicIncMember" />
    <link:loc xlink:href="nk-20191231.xsd#nk_NantHealthLabsIncMember" xlink:type="locator" xlink:label="nk_NantHealthLabsIncMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="nk_NantHealthLabsIncMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="nk_ImmunoOncologyClinicIncMember" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="srt_StatementGeographicalAxis" order="10220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="stpr_CA" order="10270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="nk_TensorcomIncMember" order="11010.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="11100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="11130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_OtherIncomeMember" order="11150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="nk_SanDiegoCaliforniaMember" order="11210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="nk_DougStLLCMember" order="11350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="nk_ElSegundoCaliforniaMember" order="11530.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="11590.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="nk_NantBioScienceMember" order="11650.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_BalanceSheetLocationAxis" order="11840.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" order="11870.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" order="11890.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="nk_NantWorksLimitedLiabilityCompanyMember" order="12210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_TransactionTypeAxis" order="12320.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TransactionTypeAxis" xlink:to="us-gaap_TransactionDomain_2" order="12330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TransactionTypeAxis" xlink:to="us-gaap_TransactionDomain" order="12350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransactionDomain" xlink:to="nk_ReimbursementsMember" order="12370.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="12420.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_2" order="12430.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="12450.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="nk_SharedServicesAgreementMember" order="12470.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="nk_NantOmicsLLCMember" order="12750.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="nk_ImmunityBioMember" order="12870.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="nk_VivaBioCellSPAMember" order="12950.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="nk_AltorBioScienceCorporationMember" order="13010.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" order="13240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" order="13260.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="nk_RelatedPartyTransactionInitialTermOfAgreement" order="13310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="nk_RelatedPartyAgreementRenewalTerm" order="13350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="13390.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_DueToRelatedPartiesCurrent" order="13430.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="nk_NumberOfOfficers" order="13500.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="nk_InitialTermOfAgreement" order="13550.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionAmountsOfTransaction" order="13600.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="nk_RelatedPartyInstallmentPayment" order="13620.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="nk_RelatedPartyTransactionAgreementExtensionDescription" order="13690.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="nk_NewAgreementTerminationNoticePeriod" order="13710.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="nk_PrepaidBalanceIncludedInPrepaidExpensesAndOtherCurrentAssetsAndOtherAssets" order="13880.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionDescriptionOfTransaction" order="13970.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="nk_NumberOfSquareFootOfFacilityLeased" order="14010.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="nk_BaseMonthlyRent" order="14050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_OperatingLeasesIncomeStatementSubleaseRevenue" order="14090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionDueFromToRelatedParty" order="14130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="nk_AnnualPercentageIncreasesToBaseRent" order="14380.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="nk_AnnualPercentageIncreasesToBaseRentCommencementDate" order="14440.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_OperatingLeaseExpense" order="14500.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="nk_RelatedPartyTransactionReimbursedUpfrontPaymentToRelatedParty" order="14650.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="nk_RelatedPartyTransactionAmountPaidToThirdParty" order="14670.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="nk_RelatedPartyAgreementExpirationMonthAndYear" order="14730.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="nk_ResearchAndDevelopmentExpenseRatablePaymentPeriod" order="15110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="nk_PrepaymentOfFundingAmount" order="15230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="nk_TransferOfDepositAmountToThirdParty" order="15400.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" order="15460.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" order="16210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" order="16230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="nk_SuppliesAndMilestoneChargesForConductingClinicalTrials" order="16370.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" order="16530.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="nk_PrepaidExpensesAndOtherAssetsCurrentWithRelatedParty" order="16650.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureStockholdersEquitySummaryOfCommonSharesReservedForIssuanceDetail" xlink:href="nk-20191231.xsd#Role_DisclosureStockholdersEquitySummaryOfCommonSharesReservedForIssuanceDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureStockholdersEquitySummaryOfCommonSharesReservedForIssuanceDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:loc xlink:href="nk-20191231.xsd#nk_OutstandingOfficerWarrantsMember" xlink:type="locator" xlink:label="nk_OutstandingOfficerWarrantsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_AwardTypeAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="nk_OutstandingOfficerWarrantsMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="10160.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail" xlink:href="nk-20191231.xsd#Role_DisclosureStockBasedCompensationAdditionalInformationDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:type="locator" xlink:label="us-gaap_ProceedsFromWarrantExercises" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
    <link:loc xlink:href="nk-20191231.xsd#nk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableOutstandingNumber" xlink:type="locator" xlink:label="nk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableOutstandingNumber" />
    <link:loc xlink:href="nk-20191231.xsd#nk_ShareBasedCompensationArrangementByShareBasedPaymentAwardPossibleIncreaseInNumberOfSharesReservedForIssuance" xlink:type="locator" xlink:label="nk_ShareBasedCompensationArrangementByShareBasedPaymentAwardPossibleIncreaseInNumberOfSharesReservedForIssuance" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <link:loc xlink:href="nk-20191231.xsd#nk_EmployeeRestrictedStockUnitMember" xlink:type="locator" xlink:label="nk_EmployeeRestrictedStockUnitMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <link:loc xlink:href="nk-20191231.xsd#nk_NonEmployeeRestrictedStockUnitMember" xlink:type="locator" xlink:label="nk_NonEmployeeRestrictedStockUnitMember" />
    <link:loc xlink:href="nk-20191231.xsd#nk_NonEmployeeStockOptionsMember" xlink:type="locator" xlink:label="nk_NonEmployeeStockOptionsMember" />
    <link:loc xlink:href="nk-20191231.xsd#nk_KeyExecutivesStockOptionsMember" xlink:type="locator" xlink:label="nk_KeyExecutivesStockOptionsMember" />
    <link:loc xlink:href="nk-20191231.xsd#nk_TwoThousandFifteenEquityIncentivePlanMember" xlink:type="locator" xlink:label="nk_TwoThousandFifteenEquityIncentivePlanMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonClassAMember" xlink:type="locator" xlink:label="us-gaap_CommonClassAMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="nk-20191231.xsd#nk_TwoThousandFourteenEquityIncentivePlanMember" xlink:type="locator" xlink:label="nk_TwoThousandFourteenEquityIncentivePlanMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_2" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="nk_TwoThousandFourteenEquityIncentivePlanMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassAMember" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="nk_TwoThousandFifteenEquityIncentivePlanMember" order="10390.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="nk_KeyExecutivesStockOptionsMember" order="10670.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="nk_NonEmployeeStockOptionsMember" order="10770.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="nk_NonEmployeeRestrictedStockUnitMember" order="10890.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="10910.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="nk_EmployeeRestrictedStockUnitMember" order="10950.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" order="11100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" order="11120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" order="11170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="11220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="nk_ShareBasedCompensationArrangementByShareBasedPaymentAwardPossibleIncreaseInNumberOfSharesReservedForIssuance" order="11240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="nk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableOutstandingNumber" order="11290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" order="11360.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="11420.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" order="11510.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" order="11590.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" order="11670.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="11750.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" order="12020.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="12040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="12090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" order="12150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ProceedsFromWarrantExercises" order="12660.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureStockBasedCompensationStockBasedCompensationExpensesRelatedToStatementOfOperationsDetail" xlink:href="nk-20191231.xsd#Role_DisclosureStockBasedCompensationStockBasedCompensationExpensesRelatedToStatementOfOperationsDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureStockBasedCompensationStockBasedCompensationExpensesRelatedToStatementOfOperationsDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_OfficerMember" xlink:type="locator" xlink:label="srt_OfficerMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualAxis" xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" />
    <link:loc xlink:href="nk-20191231.xsd#nk_NonEmployeeRestrictedStockUnitMember" xlink:type="locator" xlink:label="nk_NonEmployeeRestrictedStockUnitMember" />
    <link:loc xlink:href="nk-20191231.xsd#nk_EmployeeRestrictedStockUnitMember" xlink:type="locator" xlink:label="nk_EmployeeRestrictedStockUnitMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockCompensationPlanMember" xlink:type="locator" xlink:label="us-gaap_StockCompensationPlanMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_AwardTypeAxis" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_StockCompensationPlanMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="nk_EmployeeRestrictedStockUnitMember" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="nk_NonEmployeeRestrictedStockUnitMember" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="srt_TitleOfIndividualAxis" order="10240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="10270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_OfficerMember" order="10290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="10320.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureStockBasedCompensationStockOptionActivityDetail" xlink:href="nk-20191231.xsd#Role_DisclosureStockBasedCompensationStockOptionActivityDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureStockBasedCompensationStockOptionActivityDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <link:loc xlink:href="nk-20191231.xsd#nk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:type="locator" xlink:label="nk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" order="10300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="10500.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="10600.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="10700.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" order="11300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" order="11430.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="11630.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="11730.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="11830.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" order="12430.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="nk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" order="12560.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="12760.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" order="13160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" order="13290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="13490.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" order="13890.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfOptionsOutstandingAndVestedPricingOfExercisePricesDetail" xlink:href="nk-20191231.xsd#Role_DisclosureStockBasedCompensationSummaryOfOptionsOutstandingAndVestedPricingOfExercisePricesDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfOptionsOutstandingAndVestedPricingOfExercisePricesDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" />
    <link:loc xlink:href="nk-20191231.xsd#nk_ExercisePriceRangeFiveMember" xlink:type="locator" xlink:label="nk_ExercisePriceRangeFiveMember" />
    <link:loc xlink:href="nk-20191231.xsd#nk_ExercisePriceRangeFourMember" xlink:type="locator" xlink:label="nk_ExercisePriceRangeFourMember" />
    <link:loc xlink:href="nk-20191231.xsd#nk_ExercisePriceRangeThreeMember" xlink:type="locator" xlink:label="nk_ExercisePriceRangeThreeMember" />
    <link:loc xlink:href="nk-20191231.xsd#nk_ExercisePriceRangeTwoMember" xlink:type="locator" xlink:label="nk_ExercisePriceRangeTwoMember" />
    <link:loc xlink:href="nk-20191231.xsd#nk_ExercisePriceRangeOneMember" xlink:type="locator" xlink:label="nk_ExercisePriceRangeOneMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="us-gaap_AwardTypeAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_2" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="nk_ExercisePriceRangeOneMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="nk_ExercisePriceRangeTwoMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="nk_ExercisePriceRangeThreeMember" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="nk_ExercisePriceRangeFourMember" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="nk_ExercisePriceRangeFiveMember" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" order="10260.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" order="10400.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" order="10540.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="10680.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" order="10820.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureStockBasedCompensationBlackScholesOptionPricingModelToDetermineFairValueOfAssumptionsUsedForEmployeeStockOptionsGrantedDetail" xlink:href="nk-20191231.xsd#Role_DisclosureStockBasedCompensationBlackScholesOptionPricingModelToDetermineFairValueOfAssumptionsUsedForEmployeeStockOptionsGrantedDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureStockBasedCompensationBlackScholesOptionPricingModelToDetermineFairValueOfAssumptionsUsedForEmployeeStockOptionsGrantedDetail">
    <link:loc xlink:href="nk-20191231.xsd#nk_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsPrice" xlink:type="locator" xlink:label="nk_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsPrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="10200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="10240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="10260.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="10280.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="nk_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsPrice" order="10300.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureStockBasedCompensationRestrictedStockUnitsRsusActivityDetail" xlink:href="nk-20191231.xsd#Role_DisclosureStockBasedCompensationRestrictedStockUnitsRsusActivityDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureStockBasedCompensationRestrictedStockUnitsRsusActivityDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="10180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="10240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="10300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="10360.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="10990.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="11050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" order="11110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" order="11170.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfWarrantActivityDetail" xlink:href="nk-20191231.xsd#Role_DisclosureStockBasedCompensationSummaryOfWarrantActivityDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfWarrantActivityDetail">
    <link:loc xlink:href="nk-20191231.xsd#nk_ClassOfWarrantOrVestedAndExercisable" xlink:type="locator" xlink:label="nk_ClassOfWarrantOrVestedAndExercisable" />
    <link:loc xlink:href="nk-20191231.xsd#nk_StockIssuedDuringPeriodSharesWarrantsExpired" xlink:type="locator" xlink:label="nk_StockIssuedDuringPeriodSharesWarrantsExpired" />
    <link:loc xlink:href="nk-20191231.xsd#nk_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:type="locator" xlink:label="nk_StockIssuedDuringPeriodSharesWarrantsExercised" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantMember" xlink:type="locator" xlink:label="us-gaap_WarrantMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="nk-20191231.xsd#nk_WarrantTable" xlink:type="locator" xlink:label="nk_WarrantTable" />
    <link:loc xlink:href="nk-20191231.xsd#nk_WarrantLineItems" xlink:type="locator" xlink:label="nk_WarrantLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="nk_WarrantLineItems" xlink:to="nk_WarrantTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nk_WarrantTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_WarrantMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nk_WarrantLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" order="10300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nk_WarrantLineItems" xlink:to="nk_StockIssuedDuringPeriodSharesWarrantsExercised" order="10340.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nk_WarrantLineItems" xlink:to="nk_StockIssuedDuringPeriodSharesWarrantsExpired" order="10380.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nk_WarrantLineItems" xlink:to="nk_ClassOfWarrantOrVestedAndExercisable" order="10660.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail" xlink:href="nk-20191231.xsd#Role_DisclosureIncomeTaxesAdditionalInformationDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail">
    <link:loc xlink:href="nk-20191231.xsd#nk_UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRate" xlink:type="locator" xlink:label="nk_UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRate" />
    <link:loc xlink:href="nk-20191231.xsd#nk_TaxCreditCarryforwardExpirationPeriod" xlink:type="locator" xlink:label="nk_TaxCreditCarryforwardExpirationPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardAmount" />
    <link:loc xlink:href="nk-20191231.xsd#nk_NetOperatingLossCarryforwardsExpirationDate" xlink:type="locator" xlink:label="nk_NetOperatingLossCarryforwardsExpirationDate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwards" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OpenTaxYear" xlink:type="locator" xlink:label="us-gaap_OpenTaxYear" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxEffectsAllocatedDirectlyToEquityEquityTransactions" xlink:type="locator" xlink:label="us-gaap_IncomeTaxEffectsAllocatedDirectlyToEquityEquityTransactions" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="locator" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
    <link:loc xlink:href="nk-20191231.xsd#nk_DerecognizedDeferredTaxAssets" xlink:type="locator" xlink:label="nk_DerecognizedDeferredTaxAssets" />
    <link:loc xlink:href="nk-20191231.xsd#nk_PeriodOfCumulativeOwnershipChange" xlink:type="locator" xlink:label="nk_PeriodOfCumulativeOwnershipChange" />
    <link:loc xlink:href="nk-20191231.xsd#nk_ResearchAndDevelopmentCumulativeChangeInOwnershipPercentage" xlink:type="locator" xlink:label="nk_ResearchAndDevelopmentCumulativeChangeInOwnershipPercentage" />
    <link:loc xlink:href="nk-20191231.xsd#nk_TaxCutsAndJobsActOf2017IncompleteAccountingChangeInTaxRateReductionInDeferredTaxAssets" xlink:type="locator" xlink:label="nk_TaxCutsAndJobsActOf2017IncompleteAccountingChangeInTaxRateReductionInDeferredTaxAssets" />
    <link:loc xlink:href="nk-20191231.xsd#nk_TaxCutsAndJobsActOf2017IncompleteAccountingChangeInTaxRateMinimumAmountForEliminationOfSeveralBusinessDeductionsAndCreditsIncludingDeductionsForCertainExecutiveCompensation" xlink:type="locator" xlink:label="nk_TaxCutsAndJobsActOf2017IncompleteAccountingChangeInTaxRateMinimumAmountForEliminationOfSeveralBusinessDeductionsAndCreditsIncludingDeductionsForCertainExecutiveCompensation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchMember" xlink:type="locator" xlink:label="us-gaap_ResearchMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCountryMember" xlink:type="locator" xlink:label="us-gaap_ForeignCountryMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:type="locator" xlink:label="us-gaap_StateAndLocalJurisdictionMember" />
    <link:loc xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_CA" xlink:type="locator" xlink:label="stpr_CA" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementGeographicalAxis" xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DomesticCountryMember" xlink:type="locator" xlink:label="us-gaap_DomesticCountryMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="nk-20191231.xsd#nk_IncomeTaxTable" xlink:type="locator" xlink:label="nk_IncomeTaxTable" />
    <link:loc xlink:href="nk-20191231.xsd#nk_IncomeTaxLineItems" xlink:type="locator" xlink:label="nk_IncomeTaxLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="nk_IncomeTaxLineItems" xlink:to="nk_IncomeTaxTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nk_IncomeTaxTable" xlink:to="srt_RangeAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nk_IncomeTaxTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nk_IncomeTaxTable" xlink:to="srt_StatementGeographicalAxis" order="10200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="stpr_CA" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" order="10470.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_ForeignCountryMember" order="10490.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nk_IncomeTaxTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" order="10560.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_2" order="10570.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" order="10590.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_ResearchMember" order="10610.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nk_IncomeTaxLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="10700.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nk_IncomeTaxLineItems" xlink:to="nk_TaxCutsAndJobsActOf2017IncompleteAccountingChangeInTaxRateMinimumAmountForEliminationOfSeveralBusinessDeductionsAndCreditsIncludingDeductionsForCertainExecutiveCompensation" order="10760.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nk_IncomeTaxLineItems" xlink:to="nk_TaxCutsAndJobsActOf2017IncompleteAccountingChangeInTaxRateReductionInDeferredTaxAssets" order="10820.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nk_IncomeTaxLineItems" xlink:to="nk_ResearchAndDevelopmentCumulativeChangeInOwnershipPercentage" order="10910.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nk_IncomeTaxLineItems" xlink:to="nk_PeriodOfCumulativeOwnershipChange" order="10950.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nk_IncomeTaxLineItems" xlink:to="nk_DerecognizedDeferredTaxAssets" order="10990.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nk_IncomeTaxLineItems" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="11060.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nk_IncomeTaxLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" order="11100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nk_IncomeTaxLineItems" xlink:to="us-gaap_IncomeTaxEffectsAllocatedDirectlyToEquityEquityTransactions" order="11140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nk_IncomeTaxLineItems" xlink:to="us-gaap_OpenTaxYear" order="11210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nk_IncomeTaxLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" order="11320.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nk_IncomeTaxLineItems" xlink:to="nk_NetOperatingLossCarryforwardsExpirationDate" order="11420.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nk_IncomeTaxLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" order="11520.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nk_IncomeTaxLineItems" xlink:to="nk_TaxCreditCarryforwardExpirationPeriod" order="11720.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nk_IncomeTaxLineItems" xlink:to="nk_UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRate" order="11950.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureEmployeeBenefitsAdditionalInformationDetail" xlink:href="nk-20191231.xsd#Role_DisclosureEmployeeBenefitsAdditionalInformationDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureEmployeeBenefitsAdditionalInformationDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" />
    <link:loc xlink:href="nk-20191231.xsd#nk_FourHundredOneKPlanMember" xlink:type="locator" xlink:label="nk_FourHundredOneKPlanMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_RetirementPlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_RetirementPlanNameDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanNameAxis" xlink:type="locator" xlink:label="us-gaap_RetirementPlanNameAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedContributionPlanTable" xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanDisclosureLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DefinedContributionPlanTable" xlink:to="us-gaap_RetirementPlanNameAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RetirementPlanNameAxis" xlink:to="us-gaap_RetirementPlanNameDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RetirementPlanNameAxis" xlink:to="us-gaap_RetirementPlanNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RetirementPlanNameDomain" xlink:to="nk_FourHundredOneKPlanMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" order="10120.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail" xlink:href="nk-20191231.xsd#Role_DisclosureSubsequentEventsAdditionalInformationDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:loc xlink:href="nk-20191231.xsd#nk_ExpectJointStudyCost" xlink:type="locator" xlink:label="nk_ExpectJointStudyCost" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventMember" xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementMember" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTable" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:type="locator" xlink:label="us-gaap_SubsequentEventLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_CollaborativeArrangementMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_2" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="nk_ExpectJointStudyCost" order="10200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="10220.00" priority="2" use="optional" />
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>63
<FILENAME>nk-20191231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2020-03-25T06:28:30.9224972+00:00 -->
<!-- Version            : 5.0.1.369 -->
<!-- Package ID         : 997a9244481146b697c7b584a5c14c7f -->
<!-- Copyright (c) 2020 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/label/axisDefault" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd#axisDefault" xlink:type="simple" />
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Year Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Year Focus</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Period Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Period Focus</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" />
    <link:label xml:lang="en-US" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current Fiscal Year End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Current Fiscal Year End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:type="locator" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Well-known Seasoned Issuer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Well Known Seasoned Issuer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Current Reporting Status</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Current Reporting Status</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityVoluntaryFilers" xlink:type="locator" xlink:label="dei_EntityVoluntaryFilers" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Voluntary Filers</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Voluntary Filers</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory" xlink:type="locator" xlink:label="dei_EntityFilerCategory" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFilerCategory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Filer Category</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFilerCategory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Filer Category</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness" xlink:type="locator" xlink:label="dei_EntitySmallBusiness" />
    <link:label xml:lang="en-US" xlink:label="dei_EntitySmallBusiness_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Small Business</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntitySmallBusiness_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Small Business</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityExTransitionPeriod" xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Ex Transition Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Ex Transition Period</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany" xlink:type="locator" xlink:label="dei_EntityShellCompany" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityShellCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Shell Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityShellCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Shell Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Common Stock, Shares Outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Common Stock Shares Outstanding</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityPublicFloat" xlink:type="locator" xlink:label="dei_EntityPublicFloat" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityPublicFloat_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Public Float</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityPublicFloat_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Public Float</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of 12(b) Security</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation, State or Country Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Interactive Data Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Interactive Data Current</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Address Line1</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address City Or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address State Or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentAnnualReport" xlink:type="locator" xlink:label="dei_DocumentAnnualReport" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentAnnualReport_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Annual Report</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentAnnualReport_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Annual Report</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport" xlink:type="locator" xlink:label="dei_DocumentTransitionReport" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentTransitionReport_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Transition Report</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentTransitionReport_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Transition Report</link:label>
    <link:loc xlink:href="nk-20191231.xsd#nk_FinancingObligationNoncurrent" xlink:type="locator" xlink:label="nk_FinancingObligationNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="nk_FinancingObligationNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Financing obligation noncurrent.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nk_FinancingObligationNoncurrent" xlink:to="nk_FinancingObligationNoncurrent_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Financial Position [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ASSETS</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current assets:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents At Carrying Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid expenses and other current assets (including related parties)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense And Other Assets Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable debt securities, available-for-sale</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Securities Debt Securities Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HeldToMaturitySecuritiesCurrent" xlink:type="locator" xlink:label="us-gaap_HeldToMaturitySecuritiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_HeldToMaturitySecuritiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Notes receivable, held-to-maturity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_HeldToMaturitySecuritiesCurrent" xlink:to="us-gaap_HeldToMaturitySecuritiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_HeldToMaturitySecuritiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Held To Maturity Securities Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable debt securities, noncurrent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Securities Debt Securities Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property, plant and equipment, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease right-of-use assets, net (including related parties)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Right Of Use Asset</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:type="locator" xlink:label="us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity investment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:to="us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Equity Securities Without Readily Determinable Fair Value Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intangible assets, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Intangible Assets Net Excluding Goodwill</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other assets (including related parties)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets" xlink:type="locator" xlink:label="us-gaap_Assets" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Assets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Assets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities And Stockholders Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current liabilities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:type="locator" xlink:label="us-gaap_DueToRelatedPartiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DueToRelatedPartiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Due to related parties</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DueToRelatedPartiesCurrent" xlink:to="us-gaap_DueToRelatedPartiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DueToRelatedPartiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Due To Related Parties Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other current liabilities (including related parties)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Liabilities Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liability, less current portion (including related parties)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Liability Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_FinancingObligationNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financing obligation, less current portion</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_FinancingObligationNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Financing Obligation Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:type="locator" xlink:label="us-gaap_DeferredRentCreditNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredRentCreditNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred rent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRentCreditNoncurrent" xlink:to="us-gaap_DeferredRentCreditNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredRentCreditNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Rent Credit Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities" xlink:type="locator" xlink:label="us-gaap_Liabilities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Liabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Liabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and contingencies (Note 8)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders&#8217; equity:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue" xlink:type="locator" xlink:label="us-gaap_CommonStockValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, $0.0001 par value; 500,000,000 shares authorized; 98,460,404 and 79,087,734 issued and outstanding as of December 31, 2019 and December 31, 2018</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional paid-in capital</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid In Capital Common Stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated other comprehensive loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Other Comprehensive Income Loss Net Of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated deficit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings Accumulated Deficit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total stockholders&#8217; equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities and stockholders&#8217; equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities And Stockholders Equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, par value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Par Or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares authorized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues" xlink:type="locator" xlink:label="us-gaap_Revenues" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Revenues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Revenues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revenues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating expenses:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development (including amounts with related parties)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Selling, general and administrative (including amounts with related parties)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Selling General And Administrative Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpenses" xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total operating expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Loss from operations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Income Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other income (expense):</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Nonoperating Income Expense [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentIncomeNet" xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentIncomeNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investment income, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeNet" xlink:to="us-gaap_InvestmentIncomeNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentIncomeNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Investment Income Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseInterestExpense" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseInterestExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinanceLeaseInterestExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Interest expense (including amounts with related parties)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseInterestExpense" xlink:to="us-gaap_FinanceLeaseInterestExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinanceLeaseInterestExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease Interest Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other income, net (including amounts with related parties)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Nonoperating Income Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total other income</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Nonoperating Income Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Loss before income taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Income tax benefit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Expense Benefit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Income Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per share:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveVerboseLabel">Basic and diluted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share Basic And Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average number of shares during the period:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number Of Shares Outstanding Diluted Disclosure Items [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basic and diluted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number Of Share Outstanding Basic And Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Income And Comprehensive Income [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other comprehensive income (loss), net of income taxes:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income Loss Net Of Tax Period Increase Decrease [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net unrealized gains (losses) on available-for-sale securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Reclassification of net realized gains (losses) on available-for-sale securities included in net loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income Loss Reclassification Adjustment From A O C I For Sale Of Securities Net Of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total other comprehensive income (loss)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income Loss Net Of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Comprehensive loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income Net Of Tax</link:label>
    <link:loc xlink:href="nk-20191231.xsd#nk_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:type="locator" xlink:label="nk_StockIssuedDuringPeriodSharesWarrantsExercised" />
    <link:label xml:lang="en-US" xlink:label="nk_StockIssuedDuringPeriodSharesWarrantsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period shares warrants exercised.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nk_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:to="nk_StockIssuedDuringPeriodSharesWarrantsExercised_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Stockholders Equity [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Equity Components [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Component</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Equity Component [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional Paid-in Capital</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid In Capital [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Other Comprehensive Income [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Deficit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:type="locator" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustments for New Accounting Pronouncements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments For New Accounting Pronouncements [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:type="locator" xlink:label="us-gaap_TypeOfAdoptionMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TypeOfAdoptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Type of Adoption</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_TypeOfAdoptionMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TypeOfAdoptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Type Of Adoption [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingStandardsUpdate201409Member" xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdate201409Member" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountingStandardsUpdate201409Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounting Standards Update 2014-09</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdate201409Member" xlink:to="us-gaap_AccountingStandardsUpdate201409Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountingStandardsUpdate201409Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update201409 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdate201602Member" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountingStandardsUpdate201602Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounting Standards Update 2016-02</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdate201602Member" xlink:to="us-gaap_AccountingStandardsUpdate201602Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountingStandardsUpdate201602Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update201602 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning Balance, Shares</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" xlink:type="locator" xlink:label="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of warrants</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" xlink:to="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock And Warrants Issued During Period Value Preferred Stock And Warrants</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_StockIssuedDuringPeriodSharesWarrantsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of warrants, Shares</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_StockIssuedDuringPeriodSharesWarrantsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Warrants Exercised</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of stock options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Stock Options Exercised</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of stock options, Shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Stock Options Exercised</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting of restricted stock units (RSUs)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Restricted Stock Award Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting of restricted stock units (RSUs), Shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Restricted Stock Award Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Net share settlement for restricted stock unit vesting and option/warrant exercises</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments Related To Tax Withholding For Share Based Compensation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Net share settlement for restricted stock unit vesting and option/warrant exercises, Shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:to="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Shares Paid For Tax Withholding For Share Based Compensation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:type="locator" xlink:label="us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Repurchase of common stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:to="us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Repurchased And Retired During Period Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:type="locator" xlink:label="us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Repurchase of common stock, Shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:to="us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Repurchased And Retired During Period Shares</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification" xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cumulative effect of the adoption of the new standard</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification" xlink:to="us-gaap_NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">New Accounting Pronouncement Or Change In Accounting Principle Effect Of Adoption Quantification</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other comprehensive income (loss)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending Balance, Shares</link:label>
    <link:loc xlink:href="nk-20191231.xsd#nk_OperatingLeaseRightOfUseAssetNonCashLeaseExpense" xlink:type="locator" xlink:label="nk_OperatingLeaseRightOfUseAssetNonCashLeaseExpense" />
    <link:label xml:lang="en-US" xlink:label="nk_OperatingLeaseRightOfUseAssetNonCashLeaseExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating lease right of use asset non cash lease expense.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nk_OperatingLeaseRightOfUseAssetNonCashLeaseExpense" xlink:to="nk_OperatingLeaseRightOfUseAssetNonCashLeaseExpense_lbl" />
    <link:loc xlink:href="nk-20191231.xsd#nk_NonCashInterestIncomeExpenseFromOperatingActivities" xlink:type="locator" xlink:label="nk_NonCashInterestIncomeExpenseFromOperatingActivities" />
    <link:label xml:lang="en-US" xlink:label="nk_NonCashInterestIncomeExpenseFromOperatingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Non cash interest (income) expense from operating activities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nk_NonCashInterestIncomeExpenseFromOperatingActivities" xlink:to="nk_NonCashInterestIncomeExpenseFromOperatingActivities_lbl" />
    <link:loc xlink:href="nk-20191231.xsd#nk_IncreaseDecreaseInOperatingLeaseRightOfUseAssetNet" xlink:type="locator" xlink:label="nk_IncreaseDecreaseInOperatingLeaseRightOfUseAssetNet" />
    <link:label xml:lang="en-US" xlink:label="nk_IncreaseDecreaseInOperatingLeaseRightOfUseAssetNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase decrease in operating lease right of use asset net.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nk_IncreaseDecreaseInOperatingLeaseRightOfUseAssetNet" xlink:to="nk_IncreaseDecreaseInOperatingLeaseRightOfUseAssetNet_lbl" />
    <link:loc xlink:href="nk-20191231.xsd#nk_IncreaseDecreaseInAccountsPayableCurrent" xlink:type="locator" xlink:label="nk_IncreaseDecreaseInAccountsPayableCurrent" />
    <link:label xml:lang="en-US" xlink:label="nk_IncreaseDecreaseInAccountsPayableCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase (decrease) in accounts payable current.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nk_IncreaseDecreaseInAccountsPayableCurrent" xlink:to="nk_IncreaseDecreaseInAccountsPayableCurrent_lbl" />
    <link:loc xlink:href="nk-20191231.xsd#nk_IncreaseDecreaseInOperatingLeaseLiability" xlink:type="locator" xlink:label="nk_IncreaseDecreaseInOperatingLeaseLiability" />
    <link:label xml:lang="en-US" xlink:label="nk_IncreaseDecreaseInOperatingLeaseLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase (decrease) in operating lease liability.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nk_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="nk_IncreaseDecreaseInOperatingLeaseLiability_lbl" />
    <link:loc xlink:href="nk-20191231.xsd#nk_PaymentsToAcquireInvestmentsInEquitySecurities" xlink:type="locator" xlink:label="nk_PaymentsToAcquireInvestmentsInEquitySecurities" />
    <link:label xml:lang="en-US" xlink:label="nk_PaymentsToAcquireInvestmentsInEquitySecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Payments to acquire investments in equity securities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nk_PaymentsToAcquireInvestmentsInEquitySecurities" xlink:to="nk_PaymentsToAcquireInvestmentsInEquitySecurities_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Cash Flows [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProfitLoss" xlink:type="locator" xlink:label="us-gaap_ProfitLoss" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProfitLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProfitLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Profit Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation and amortization</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation Depletion And Amortization</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_OperatingLeaseRightOfUseAssetNonCashLeaseExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-cash lease expense related to operating lease right-of-use assets</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_OperatingLeaseRightOfUseAssetNonCashLeaseExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Right Of Use Asset Non Cash Lease Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:type="locator" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Amortization of net premiums and discounts on marketable debt securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accretion Amortization Of Discounts And Premiums Investments</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_NonCashInterestIncomeExpenseFromOperatingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Non-cash interest items, net</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_NonCashInterestIncomeExpenseFromOperatingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Non Cash Interest Income Expense From Operating Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:type="locator" xlink:label="us-gaap_AssetImpairmentCharges" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetImpairmentCharges_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loss on impairment of assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetImpairmentCharges" xlink:to="us-gaap_AssetImpairmentCharges_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetImpairmentCharges_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Asset Impairment Charges</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1" xlink:type="locator" xlink:label="us-gaap_GainLossOnDispositionOfAssets1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GainLossOnDispositionOfAssets1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Loss on disposal of assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnDispositionOfAssets1" xlink:to="us-gaap_GainLossOnDispositionOfAssets1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GainLossOnDispositionOfAssets1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Gain Loss On Disposition Of Assets1</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred income tax benefit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Income Tax Expense Benefit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MarketableSecuritiesGainLoss" xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesGainLoss" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MarketableSecuritiesGainLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Gains (losses) on sales of marketable debt securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesGainLoss" xlink:to="us-gaap_MarketableSecuritiesGainLoss_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MarketableSecuritiesGainLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities Gain Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in operating assets and liabilities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Operating Capital [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Prepaid expenses and other current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Prepaid Deferred Expense And Other Assets</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_IncreaseDecreaseInOperatingLeaseRightOfUseAssetNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Operating lease right-of-use assets, net</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_IncreaseDecreaseInOperatingLeaseRightOfUseAssetNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Operating Lease Right Of Use Asset Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Other assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Other Noncurrent Assets</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_IncreaseDecreaseInAccountsPayableCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_IncreaseDecreaseInAccountsPayableCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Accounts Payable Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses and other liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Other Accounts Payable And Accrued Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Due to related parties</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent" xlink:to="us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Due To Related Parties Current</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_IncreaseDecreaseInOperatingLeaseLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liabilities</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_IncreaseDecreaseInOperatingLeaseLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Operating Lease Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred rent and revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Deferred Revenue</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in operating activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Operating Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investing activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Investing Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchases of property, plant and equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments To Acquire Property Plant And Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from sales of property, plant and equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Sale Of Property Plant And Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireHeldToMaturitySecurities" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireHeldToMaturitySecurities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquireHeldToMaturitySecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchases of debt securities, held-to-maturity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireHeldToMaturitySecurities" xlink:to="us-gaap_PaymentsToAcquireHeldToMaturitySecurities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquireHeldToMaturitySecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments To Acquire Held To Maturity Securities</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_PaymentsToAcquireInvestmentsInEquitySecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchases of investments in equity securities</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_PaymentsToAcquireInvestmentsInEquitySecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments To Acquire Investments In Equity Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchases of marketable debt securities, available-for-sale</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments To Acquire Available For Sale Securities Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sales/maturities of marketable debt securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Sale And Maturity Of Marketable Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by investing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Investing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financing activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Financing Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" xlink:type="locator" xlink:label="us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Principal payments of financing/capital lease obligations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" xlink:to="us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Repayments Of Long Term Capital Lease Obligations</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from exercises of stock options and warrants</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:to="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:type="locator" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Repurchases of common stock with commissions</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="us-gaap_PaymentsForRepurchaseOfCommonStock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments For Repurchase Of Common Stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Net share settlement for restricted stock unit vesting and warrant and option exercises</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments Related To Tax Withholding For Share Based Compensation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by (used in) financing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Financing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net (decrease) increase in cash, cash equivalents, and restricted cash</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash, cash equivalents and restricted cash, beginning of period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash, cash equivalents and restricted cash, end of period</link:label>
    <link:loc xlink:href="nk-20191231.xsd#nk_NoncashPropertyAndEquipmentPurchasesAcquiredUnderCapitalLease" xlink:type="locator" xlink:label="nk_NoncashPropertyAndEquipmentPurchasesAcquiredUnderCapitalLease" />
    <link:label xml:lang="en-US" xlink:label="nk_NoncashPropertyAndEquipmentPurchasesAcquiredUnderCapitalLease_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Noncash property and equipment purchases acquired under capital lease.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nk_NoncashPropertyAndEquipmentPurchasesAcquiredUnderCapitalLease" xlink:to="nk_NoncashPropertyAndEquipmentPurchasesAcquiredUnderCapitalLease_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reconciliation of cash, cash equivalents, and restricted cash at end of period:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Restricted cash included in other assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash And Cash Equivalents Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplemental disclosure of cash flow information:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestPaidNet" xlink:type="locator" xlink:label="us-gaap_InterestPaidNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InterestPaidNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InterestPaidNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Interest Paid Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxesPaidNet" xlink:type="locator" xlink:label="us-gaap_IncomeTaxesPaidNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaidNet" xlink:to="us-gaap_IncomeTaxesPaidNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Taxes Paid Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="locator" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplemental disclosure of non-cash investing and financing activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Noncash Investing And Financing Items [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_NoncashPropertyAndEquipmentPurchasesAcquiredUnderCapitalLease_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment purchases acquired under capital lease</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_NoncashPropertyAndEquipmentPurchasesAcquiredUnderCapitalLease_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Noncash Property And Equipment Purchases Acquired Under Capital Lease</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="locator" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment purchases included in accounts payable, accrued expenses, and other liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Capital Expenditures Incurred But Not Yet Paid</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:type="locator" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of Viracta convertible notes and accrued interest into investment in equity securities of Viracta (Note 4)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Conversion Converted Instrument Amount1</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:type="locator" xlink:label="us-gaap_UnrealizedGainLossOnInvestments" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrealizedGainLossOnInvestments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized gains (losses) on marketable debt securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrealizedGainLossOnInvestments" xlink:to="us-gaap_UnrealizedGainLossOnInvestments_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrealizedGainLossOnInvestments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Unrealized Gain Loss On Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssued1" xlink:type="locator" xlink:label="us-gaap_StockIssued1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssued1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cashless exercises of stock options and warrants</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssued1" xlink:to="us-gaap_StockIssued1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssued1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued1</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="locator" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Documents Incorporated by Reference</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Documents Incorporated By Reference [Text Block]</link:label>
    <link:loc xlink:href="nk-20191231.xsd#nk_DescriptionOfBusinessDisclosureTextBlock" xlink:type="locator" xlink:label="nk_DescriptionOfBusinessDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="nk_DescriptionOfBusinessDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Description of business disclosure.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nk_DescriptionOfBusinessDisclosureTextBlock" xlink:to="nk_DescriptionOfBusinessDisclosureTextBlock_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Organization Consolidation And Presentation Of Financial Statements [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="nk_DescriptionOfBusinessDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Description of Business</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_DescriptionOfBusinessDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Description Of Business Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Policies [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Significant Accounting Policies</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:href="nk-20191231.xsd#nk_FinancialStatementDetailsAbstract" xlink:type="locator" xlink:label="nk_FinancialStatementDetailsAbstract" />
    <link:label xml:lang="en-US" xlink:label="nk_FinancialStatementDetailsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Financial statement details.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nk_FinancialStatementDetailsAbstract" xlink:to="nk_FinancialStatementDetailsAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="nk_FinancialStatementDetailsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Financial Statement Details [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:type="locator" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial Statement Details</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:to="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Supplemental Balance Sheet Disclosures [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:type="locator" xlink:label="us-gaap_InvestmentsAllOtherInvestmentsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentsAllOtherInvestmentsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Investments All Other Investments [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:to="us-gaap_InvestmentsAllOtherInvestmentsAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostAndEquityMethodInvestmentsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_CostAndEquityMethodInvestmentsDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CostAndEquityMethodInvestmentsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Viracta Investment and Convertible Notes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostAndEquityMethodInvestmentsDisclosureTextBlock" xlink:to="us-gaap_CostAndEquityMethodInvestmentsDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CostAndEquityMethodInvestmentsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cost And Equity Method Investments Disclosure [Text Block]</link:label>
    <link:loc xlink:href="nk-20191231.xsd#nk_CashEquivalentsAndMarketableSecuritiesAbstract" xlink:type="locator" xlink:label="nk_CashEquivalentsAndMarketableSecuritiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="nk_CashEquivalentsAndMarketableSecuritiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Cash equivalents and marketable securities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nk_CashEquivalentsAndMarketableSecuritiesAbstract" xlink:to="nk_CashEquivalentsAndMarketableSecuritiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="nk_CashEquivalentsAndMarketableSecuritiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Equivalents And Marketable Securities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial Instruments Investments in Debt Securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:to="us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Cash Equivalents And Marketable Securities [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementInputsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementInputsDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementInputsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementInputsDisclosureTextBlock" xlink:to="us-gaap_FairValueMeasurementInputsDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementInputsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement Inputs Disclosure [Text Block]</link:label>
    <link:loc xlink:href="nk-20191231.xsd#nk_CollaborationAndLicenseAgreementsTextBlock" xlink:type="locator" xlink:label="nk_CollaborationAndLicenseAgreementsTextBlock" />
    <link:label xml:lang="en-US" xlink:label="nk_CollaborationAndLicenseAgreementsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaboration and license agreements.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nk_CollaborationAndLicenseAgreementsTextBlock" xlink:to="nk_CollaborationAndLicenseAgreementsTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="nk_CollaborationAndLicenseAgreementsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration and License Agreements</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_CollaborationAndLicenseAgreementsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration And License Agreements [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies Disclosure [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and contingencies</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party Agreements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract" xlink:type="locator" xlink:label="us-gaap_EquityAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Equity [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders&apos; Equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-Based Compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Compensation Related Costs Share Based Payments [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_QuarterlyFinancialInformationDisclosureAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_QuarterlyFinancialInformationDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Quarterly Financial Information Disclosure [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:to="us-gaap_QuarterlyFinancialInformationDisclosureAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_QuarterlyFinancialInformationTextBlock" xlink:type="locator" xlink:label="us-gaap_QuarterlyFinancialInformationTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_QuarterlyFinancialInformationTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summarized Quarterly Data (Unaudited)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_QuarterlyFinancialInformationTextBlock" xlink:to="us-gaap_QuarterlyFinancialInformationTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_QuarterlyFinancialInformationTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Quarterly Financial Information [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Compensation And Retirement Disclosure [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee Benefits</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pension And Other Postretirement Benefits Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Events</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:href="nk-20191231.xsd#nk_LiquidityPolicyTextBlock" xlink:type="locator" xlink:label="nk_LiquidityPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="nk_LiquidityPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Liquidity.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nk_LiquidityPolicyTextBlock" xlink:to="nk_LiquidityPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="nk_LiquidityPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liquidity</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_LiquidityPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liquidity Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basis of Presentation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Basis Of Accounting Policy Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_ConsolidationPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Principles of Consolidation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Consolidation Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UseOfEstimates" xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Use of Estimates</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Use Of Estimates</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnusualRisksAndUncertaintiesTextBlock" xlink:type="locator" xlink:label="us-gaap_UnusualRisksAndUncertaintiesTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnusualRisksAndUncertaintiesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risks and Uncertainties</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnusualRisksAndUncertaintiesTextBlock" xlink:to="us-gaap_UnusualRisksAndUncertaintiesTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnusualRisksAndUncertaintiesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Unusual Risks And Uncertainties [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingenciesPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contingencies</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingenciesPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration of Credit Risk and Other Risks and Uncertainties</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk Credit Risk</link:label>
    <link:loc xlink:href="nk-20191231.xsd#nk_CashCashEquivalentsAndMarketableSecuritiesPolicyTextBlock" xlink:type="locator" xlink:label="nk_CashCashEquivalentsAndMarketableSecuritiesPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="nk_CashCashEquivalentsAndMarketableSecuritiesPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Cash, cash equivalents and marketable securities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nk_CashCashEquivalentsAndMarketableSecuritiesPolicyTextBlock" xlink:to="nk_CashCashEquivalentsAndMarketableSecuritiesPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="nk_CashCashEquivalentsAndMarketableSecuritiesPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash, Cash Equivalents and Marketable Debt Securities</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_CashCashEquivalentsAndMarketableSecuritiesPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Cash Equivalents And Marketable Securities Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property, Plant and Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intangible Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:to="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Goodwill And Intangible Assets Intangible Assets Policy</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LegalCostsPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_LegalCostsPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LegalCostsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Patents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LegalCostsPolicyTextBlock" xlink:to="us-gaap_LegalCostsPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LegalCostsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Legal Costs Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Impairment Or Disposal Of Long Lived Assets Including Intangible Assets Policy Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="locator" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value of Financial Instruments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Of Financial Instruments Policy</link:label>
    <link:loc xlink:href="nk-20191231.xsd#nk_PreclinicalAndClinicalTrialAccrualsPolicyTextBlock" xlink:type="locator" xlink:label="nk_PreclinicalAndClinicalTrialAccrualsPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="nk_PreclinicalAndClinicalTrialAccrualsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Preclinical and clinical trial accruals policy text block.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nk_PreclinicalAndClinicalTrialAccrualsPolicyTextBlock" xlink:to="nk_PreclinicalAndClinicalTrialAccrualsPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="nk_PreclinicalAndClinicalTrialAccrualsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preclinical and Clinical Trial Accruals</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_PreclinicalAndClinicalTrialAccrualsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preclinical And Clinical Trial Accruals Policy [Text Block]</link:label>
    <link:loc xlink:href="nk-20191231.xsd#nk_RelatedPartyTransactionsPolicyPolicyTextBlock" xlink:type="locator" xlink:label="nk_RelatedPartyTransactionsPolicyPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="nk_RelatedPartyTransactionsPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Related party transactions policy.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nk_RelatedPartyTransactionsPolicyPolicyTextBlock" xlink:to="nk_RelatedPartyTransactionsPolicyPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="nk_RelatedPartyTransactionsPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Transactions with Related Parties</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_RelatedPartyTransactionsPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions Policy Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease Obligations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Leases Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Policy [Text Block]</link:label>
    <link:loc xlink:href="nk-20191231.xsd#nk_StockRepurchasesPolicyTextBlock" xlink:type="locator" xlink:label="nk_StockRepurchasesPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="nk_StockRepurchasesPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock repurchases policy.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nk_StockRepurchasesPolicyTextBlock" xlink:to="nk_StockRepurchasesPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="nk_StockRepurchasesPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Repurchases</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_StockRepurchasesPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Repurchases Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue Recognition</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revenue Recognition Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expense Policy</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-Based Compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Compensation Related Costs Policy [Text Block]</link:label>
    <link:loc xlink:href="nk-20191231.xsd#nk_LitigationCostsPolicyTextBlock" xlink:type="locator" xlink:label="nk_LitigationCostsPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="nk_LitigationCostsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Litigation costs.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nk_LitigationCostsPolicyTextBlock" xlink:to="nk_LitigationCostsPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="nk_LitigationCostsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Litigation Costs</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_LitigationCostsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Litigation Costs Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Comprehensive Income (Loss)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income Policy Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basic and Diluted Net Loss Per Share of Common Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Segment and Geographic Information</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting Policy Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recent Accounting Pronouncements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">New Accounting Pronouncements Policy Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_InvestmentPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investment in Viracta</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentPolicyTextBlock" xlink:to="us-gaap_InvestmentPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Investment Policy [Text Block]</link:label>
    <link:loc xlink:href="nk-20191231.xsd#nk_PropertyPlantAndEquipmentUsefulLifeTableTextBlock" xlink:type="locator" xlink:label="nk_PropertyPlantAndEquipmentUsefulLifeTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="nk_PropertyPlantAndEquipmentUsefulLifeTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Property plant and equipment useful life.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nk_PropertyPlantAndEquipmentUsefulLifeTableTextBlock" xlink:to="nk_PropertyPlantAndEquipmentUsefulLifeTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="nk_PropertyPlantAndEquipmentUsefulLifeTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Estimated Useful Lives of Property, Plant and Equipment</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_PropertyPlantAndEquipmentUsefulLifeTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Useful Life Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Securities Excluded from the Computation of Potentially Dilutive Securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:href="nk-20191231.xsd#nk_PrepaidExpensesAndOtherCurrentAssetsTableTextBlock" xlink:type="locator" xlink:label="nk_PrepaidExpensesAndOtherCurrentAssetsTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="nk_PrepaidExpensesAndOtherCurrentAssetsTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Prepaid expenses and other current assets.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nk_PrepaidExpensesAndOtherCurrentAssetsTableTextBlock" xlink:to="nk_PrepaidExpensesAndOtherCurrentAssetsTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="nk_PrepaidExpensesAndOtherCurrentAssetsTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid Expenses and Other Current Assets</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_PrepaidExpensesAndOtherCurrentAssetsTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expenses And Other Current Assets Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property, Plant and Equipment, Net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment [Text Block]</link:label>
    <link:loc xlink:href="nk-20191231.xsd#nk_ScheduleOfImpactOfAdoptionOnPropertyPlantAndEquipmentTableTextBlock" xlink:type="locator" xlink:label="nk_ScheduleOfImpactOfAdoptionOnPropertyPlantAndEquipmentTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="nk_ScheduleOfImpactOfAdoptionOnPropertyPlantAndEquipmentTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of impact of adoption on property, plant and equipment.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nk_ScheduleOfImpactOfAdoptionOnPropertyPlantAndEquipmentTableTextBlock" xlink:to="nk_ScheduleOfImpactOfAdoptionOnPropertyPlantAndEquipmentTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="nk_ScheduleOfImpactOfAdoptionOnPropertyPlantAndEquipmentTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impact of Adoption of ASC 842 on Property, Plant and Equipment</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_ScheduleOfImpactOfAdoptionOnPropertyPlantAndEquipmentTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Impact Of Adoption On Property Plant And Equipment Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intangible Assets, Net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Finite Lived Intangible Assets Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock" xlink:to="us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Other Assets Noncurrent [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued Expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Accrued Liabilities Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_OtherCurrentLiabilitiesTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherCurrentLiabilitiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other Current Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:to="us-gaap_OtherCurrentLiabilitiesTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherCurrentLiabilitiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Current Liabilities Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentIncomeTextBlock" xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentIncomeTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investment Income, Net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeTextBlock" xlink:to="us-gaap_InvestmentIncomeTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentIncomeTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Investment Income [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Investments in Debt Securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Available For Sale Securities Reconciliation Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueTableTextBlock" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Unrealized Losses on Debt Securities Classified as Available-for-Sale in Continuous Loss Position</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueTableTextBlock" xlink:to="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Securities Continuous Unrealized Loss Position Fair Value Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfRealizedGainLossTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfRealizedGainLossTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfRealizedGainLossTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Realized Gains and Losses on Sales of Available-for-Sale Debt Securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRealizedGainLossTableTextBlock" xlink:to="us-gaap_ScheduleOfRealizedGainLossTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfRealizedGainLossTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Realized Gain Loss Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Fair Value Assets And Liabilities Measured On Recurring Basis Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Lease Balances</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Maturity Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Future Minimum Lease Payments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:to="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Future Minimum Rental Payments For Operating Leases Table [Text Block]</link:label>
    <link:loc xlink:href="nk-20191231.xsd#nk_ScheduleOfCommonStockReservedForIssuanceTableTextBlock" xlink:type="locator" xlink:label="nk_ScheduleOfCommonStockReservedForIssuanceTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="nk_ScheduleOfCommonStockReservedForIssuanceTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of common stock reserved for issuance .</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nk_ScheduleOfCommonStockReservedForIssuanceTableTextBlock" xlink:to="nk_ScheduleOfCommonStockReservedForIssuanceTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="nk_ScheduleOfCommonStockReservedForIssuanceTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary Of Common Stock Reserved For Issuance</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_ScheduleOfCommonStockReservedForIssuanceTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Common Stock Reserved For Issuance Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Based Compensation Expenses Included on Operations Statement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summarizes Stock Option Activity Under Equity Intensive Plan</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Compensation Stock Options Activity Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Options Outstanding and Vested</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Compensation Shares Authorized Under Stock Option Plans By Exercise Price Range [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average of Fair Value of Options Under Black-Scholes Option-Pricing Model</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Payment Award Stock Options Valuation Assumptions Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Stock Units (RSUs) Activity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:to="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Nonvested Restricted Stock Shares Activity Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Warrant Activity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Stockholders Equity Note Warrants Or Rights [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Loss Before Taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Income Before Income Tax Domestic And Foreign Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Income Tax Benefit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Components Of Income Tax Expense Benefit Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Components of Net Deferred Tax Assets and Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Deferred Tax Assets And Liabilities Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reconciliation of Federal Statutory Income Tax Rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Effective Income Tax Rate Reconciliation Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summarizes of Changes in Unrecognized Tax Benefits</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:to="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Unrecognized Tax Benefits Roll Forward Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Quarterly Data (Unaudited)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:to="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Quarterly Financial Information Table [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net cash used in operating activities</link:label>
    <link:loc xlink:href="nk-20191231.xsd#nk_AccountingPoliciesLineItems" xlink:type="locator" xlink:label="nk_AccountingPoliciesLineItems" />
    <link:label xml:lang="en-US" xlink:label="nk_AccountingPoliciesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Accounting policies.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nk_AccountingPoliciesLineItems" xlink:to="nk_AccountingPoliciesLineItems_lbl" />
    <link:loc xlink:href="nk-20191231.xsd#nk_AccountingPoliciesTable" xlink:type="locator" xlink:label="nk_AccountingPoliciesTable" />
    <link:label xml:lang="en-US" xlink:label="nk_AccountingPoliciesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Accounting policies.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nk_AccountingPoliciesTable" xlink:to="nk_AccountingPoliciesTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="nk_AccountingPoliciesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounting Policies [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_AccountingPoliciesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Policies [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualAxis" xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_TitleOfIndividualAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of Individual</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_TitleOfIndividualAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Title Of Individual [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:label xml:lang="en-US" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of Individual</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Title Of Individual With Relationship To Entity [Domain]</link:label>
    <link:loc xlink:href="nk-20191231.xsd#nk_ChairmanAndChiefExecutiveOfficerMember" xlink:type="locator" xlink:label="nk_ChairmanAndChiefExecutiveOfficerMember" />
    <link:label xml:lang="en-US" xlink:label="nk_ChairmanAndChiefExecutiveOfficerMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Chairman and Chief Executive Officer.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nk_ChairmanAndChiefExecutiveOfficerMember" xlink:to="nk_ChairmanAndChiefExecutiveOfficerMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="nk_ChairmanAndChiefExecutiveOfficerMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Chairman and Chief Executive Officer</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_ChairmanAndChiefExecutiveOfficerMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Chairman And Chief Executive Officer [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis" xlink:type="locator" xlink:label="us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Variable Interest Entities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis" xlink:to="us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Variable Interest Entities By Classification Of Entity [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassificationOfVariableInterestEntityDomain" xlink:type="locator" xlink:label="us-gaap_ClassificationOfVariableInterestEntityDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassificationOfVariableInterestEntityDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Variable Interest Entity, Classification</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassificationOfVariableInterestEntityDomain" xlink:to="us-gaap_ClassificationOfVariableInterestEntityDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassificationOfVariableInterestEntityDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Classification Of Variable Interest Entity [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:type="locator" xlink:label="us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">VIE</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:to="us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Variable Interest Entity Primary Beneficiary [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_RangeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_RangeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Range [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:label xml:lang="en-US" xlink:label="srt_RangeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_RangeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Range [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:label xml:lang="en-US" xlink:label="srt_MinimumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_MinimumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Minimum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:label xml:lang="en-US" xlink:label="srt_MaximumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_MaximumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Maximum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expense [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Authority</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Authority</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DomesticCountryMember" xlink:type="locator" xlink:label="us-gaap_DomesticCountryMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Domestic Country [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementGeographicalAxis" xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_StatementGeographicalAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Geographical</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_StatementGeographicalAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Geographical [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" />
    <link:label xml:lang="en-US" xlink:label="srt_SegmentGeographicalDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Geographical</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_SegmentGeographicalDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_SegmentGeographicalDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Segment Geographical [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_CA" xlink:type="locator" xlink:label="stpr_CA" />
    <link:label xml:lang="en-US" xlink:label="stpr_CA_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">California</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="stpr_CA" xlink:to="stpr_CA_lbl" />
    <link:label xml:lang="en-US" xlink:label="stpr_CA_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">CALIFORNIA</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finite-Lived Intangible Assets by Major Class</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finite Lived Intangible Assets By Major Class [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finite-Lived Intangible Assets, Major Class Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finite Lived Intangible Assets Major Class Name [Domain]</link:label>
    <link:loc xlink:href="nk-20191231.xsd#nk_IntrexonLicenseAgreementMember" xlink:type="locator" xlink:label="nk_IntrexonLicenseAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="nk_IntrexonLicenseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Intrexon license agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nk_IntrexonLicenseAgreementMember" xlink:to="nk_IntrexonLicenseAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="nk_IntrexonLicenseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intrexon Corporation</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_IntrexonLicenseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Intrexon License Agreement [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis" xlink:type="locator" xlink:label="us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Initial Application Period Cumulative Effect Transition</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis" xlink:to="us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Initial Application Period Cumulative Effect Transition [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain" xlink:type="locator" xlink:label="us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Initial Application Period Cumulative Effect Transition</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain" xlink:to="us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Initial Application Period Cumulative Effect Transition [Domain]</link:label>
    <link:loc xlink:href="nk-20191231.xsd#nk_DifferenceBetweenLeaseGuidanceInEffectBeforeAndAfterTopic842Member" xlink:type="locator" xlink:label="nk_DifferenceBetweenLeaseGuidanceInEffectBeforeAndAfterTopic842Member" />
    <link:label xml:lang="en-US" xlink:label="nk_DifferenceBetweenLeaseGuidanceInEffectBeforeAndAfterTopic842Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Difference between lease guidance in effect before and after Topic 842.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nk_DifferenceBetweenLeaseGuidanceInEffectBeforeAndAfterTopic842Member" xlink:to="nk_DifferenceBetweenLeaseGuidanceInEffectBeforeAndAfterTopic842Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="nk_DifferenceBetweenLeaseGuidanceInEffectBeforeAndAfterTopic842Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Difference between Lease Guidance in Effect before and after Topic 842</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_DifferenceBetweenLeaseGuidanceInEffectBeforeAndAfterTopic842Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Difference Between Lease Guidance In Effect Before And After Topic842 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_AccountingPoliciesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounting Policies [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_AccountingPoliciesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Policies [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Proceeds from exercise of stock options and warrants</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Percentage of ownership interest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Equity Method Investment Ownership Percentage</link:label>
    <link:loc xlink:href="nk-20191231.xsd#nk_CashAndCashEquivalentsOriginalMaturities" xlink:type="locator" xlink:label="nk_CashAndCashEquivalentsOriginalMaturities" />
    <link:label xml:lang="en-US" xlink:label="nk_CashAndCashEquivalentsOriginalMaturities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Cash and cash equivalents original maturities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nk_CashAndCashEquivalentsOriginalMaturities" xlink:to="nk_CashAndCashEquivalentsOriginalMaturities_lbl" />
    <link:loc xlink:href="nk-20191231.xsd#nk_MarketableSecuritiesOriginalMaturities" xlink:type="locator" xlink:label="nk_MarketableSecuritiesOriginalMaturities" />
    <link:label xml:lang="en-US" xlink:label="nk_MarketableSecuritiesOriginalMaturities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Marketable securities original maturities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nk_MarketableSecuritiesOriginalMaturities" xlink:to="nk_MarketableSecuritiesOriginalMaturities_lbl" />
    <link:loc xlink:href="nk-20191231.xsd#nk_MinimumOriginalMaturityPeriodOfLongTermMarketableSecurities" xlink:type="locator" xlink:label="nk_MinimumOriginalMaturityPeriodOfLongTermMarketableSecurities" />
    <link:label xml:lang="en-US" xlink:label="nk_MinimumOriginalMaturityPeriodOfLongTermMarketableSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Minimum original maturity period of long term marketable securities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nk_MinimumOriginalMaturityPeriodOfLongTermMarketableSecurities" xlink:to="nk_MinimumOriginalMaturityPeriodOfLongTermMarketableSecurities_lbl" />
    <link:loc xlink:href="nk-20191231.xsd#nk_MaximumOriginalMaturityPeriodOfShortTermMarketableSecurities" xlink:type="locator" xlink:label="nk_MaximumOriginalMaturityPeriodOfShortTermMarketableSecurities" />
    <link:label xml:lang="en-US" xlink:label="nk_MaximumOriginalMaturityPeriodOfShortTermMarketableSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Maximum original maturity period of short term marketable securities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nk_MaximumOriginalMaturityPeriodOfShortTermMarketableSecurities" xlink:to="nk_MaximumOriginalMaturityPeriodOfShortTermMarketableSecurities_lbl" />
    <link:label xml:lang="en-US" xlink:label="nk_CashAndCashEquivalentsOriginalMaturities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents original maturities</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_CashAndCashEquivalentsOriginalMaturities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents Original Maturities</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_MarketableSecuritiesOriginalMaturities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable securities original maturities</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_MarketableSecuritiesOriginalMaturities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities Original Maturities</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_MaximumOriginalMaturityPeriodOfShortTermMarketableSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum original maturity period of short-term marketable securities</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_MaximumOriginalMaturityPeriodOfShortTermMarketableSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Maximum Original Maturity Period Of Short Term Marketable Securities</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_MinimumOriginalMaturityPeriodOfLongTermMarketableSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum original maturity period of long-term marketable securities</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_MinimumOriginalMaturityPeriodOfLongTermMarketableSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Minimum Original Maturity Period Of Long Term Marketable Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet" xlink:type="locator" xlink:label="us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other than temporary impairments for marketable securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet" xlink:to="us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Than Temporary Impairment Losses Investments Portion Recognized In Earnings Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Property Plant And Equipment [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Property Plant And Equipment [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property, Plant and Equipment, Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment By Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property, Plant and Equipment, Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BuildingMember" xlink:type="locator" xlink:label="us-gaap_BuildingMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BuildingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Buildings</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BuildingMember" xlink:to="us-gaap_BuildingMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BuildingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Building [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:type="locator" xlink:label="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Software</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:to="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Software And Software Development Costs [Member]</link:label>
    <link:loc xlink:href="nk-20191231.xsd#nk_LaboratoryEquipmentMember" xlink:type="locator" xlink:label="nk_LaboratoryEquipmentMember" />
    <link:label xml:lang="en-US" xlink:label="nk_LaboratoryEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Laboratory equipment.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nk_LaboratoryEquipmentMember" xlink:to="nk_LaboratoryEquipmentMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="nk_LaboratoryEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Laboratory Equipment</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_LaboratoryEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Laboratory Equipment [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Furniture And Fixtures</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Furniture And Fixtures [Member]</link:label>
    <link:loc xlink:href="nk-20191231.xsd#nk_ITEquipmentMember" xlink:type="locator" xlink:label="nk_ITEquipmentMember" />
    <link:label xml:lang="en-US" xlink:label="nk_ITEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">IT equipment.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nk_ITEquipmentMember" xlink:to="nk_ITEquipmentMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="nk_ITEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">IT Equipment</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_ITEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">I T Equipment [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leasehold Improvements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property Plant And Equipment [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment estimated useful lives</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Useful Life</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment estimated useful lives, term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:to="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Estimated Useful Lives</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated useful lives of intangible assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finite Lived Intangible Asset Useful Life</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:type="locator" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment charge/losses of long-lived assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Impairment Of Long Lived Assets Held For Use</link:label>
    <link:loc xlink:href="nk-20191231.xsd#nk_FairValueInputsTransfersIntoOrOutOfLevelOneLevelTwoOrLevelThreeCategories" xlink:type="locator" xlink:label="nk_FairValueInputsTransfersIntoOrOutOfLevelOneLevelTwoOrLevelThreeCategories" />
    <link:label xml:lang="en-US" xlink:label="nk_FairValueInputsTransfersIntoOrOutOfLevelOneLevelTwoOrLevelThreeCategories_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair value inputs, transfers into level 1, 2 or 3 categories.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nk_FairValueInputsTransfersIntoOrOutOfLevelOneLevelTwoOrLevelThreeCategories" xlink:to="nk_FairValueInputsTransfersIntoOrOutOfLevelOneLevelTwoOrLevelThreeCategories_lbl" />
    <link:label xml:lang="en-US" xlink:label="nk_FairValueInputsTransfersIntoOrOutOfLevelOneLevelTwoOrLevelThreeCategories_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value inputs, transfers into or out of Level 1, 2 or 3 categories</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_FairValueInputsTransfersIntoOrOutOfLevelOneLevelTwoOrLevelThreeCategories_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Inputs Transfers Into Or Out Of Level One Level Two Or Level Three Categories</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeasePracticalExpedientsPackage" xlink:type="locator" xlink:label="us-gaap_LeasePracticalExpedientsPackage" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeasePracticalExpedientsPackage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease practical expedients package</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasePracticalExpedientsPackage" xlink:to="us-gaap_LeasePracticalExpedientsPackage_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeasePracticalExpedientsPackage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lease Practical Expedients Package</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseDescription" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseDescription" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseDescription_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease, description</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseDescription" xlink:to="us-gaap_LesseeOperatingLeaseDescription_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseDescription_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Description</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued interest or penalties associated with uncertain tax positions</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OpenTaxYear" xlink:type="locator" xlink:label="us-gaap_OpenTaxYear" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OpenTaxYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax year open for examination</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OpenTaxYear" xlink:to="us-gaap_OpenTaxYear_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OpenTaxYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Open Tax Year</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:type="locator" xlink:label="us-gaap_StockRepurchaseProgramAuthorizedAmount1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockRepurchaseProgramAuthorizedAmount1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total amount authorized for repurchase</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:to="us-gaap_StockRepurchaseProgramAuthorizedAmount1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockRepurchaseProgramAuthorizedAmount1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Repurchase Program Authorized Amount1</link:label>
    <link:loc xlink:href="nk-20191231.xsd#nk_NonrefundableUpfrontPayment" xlink:type="locator" xlink:label="nk_NonrefundableUpfrontPayment" />
    <link:label xml:lang="en-US" xlink:label="nk_NonrefundableUpfrontPayment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Nonrefundable upfront payment.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nk_NonrefundableUpfrontPayment" xlink:to="nk_NonrefundableUpfrontPayment_lbl" />
    <link:label xml:lang="en-US" xlink:label="nk_NonrefundableUpfrontPayment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Nonrefundable upfront payment</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_NonrefundableUpfrontPayment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Nonrefundable Upfront Payment</link:label>
    <link:loc xlink:href="nk-20191231.xsd#nk_VariableConsiderationRelatedToMilestonePayment" xlink:type="locator" xlink:label="nk_VariableConsiderationRelatedToMilestonePayment" />
    <link:label xml:lang="en-US" xlink:label="nk_VariableConsiderationRelatedToMilestonePayment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Variable consideration related to milestone payment.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nk_VariableConsiderationRelatedToMilestonePayment" xlink:to="nk_VariableConsiderationRelatedToMilestonePayment_lbl" />
    <link:label xml:lang="en-US" xlink:label="nk_VariableConsiderationRelatedToMilestonePayment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Variable consideration related to milestone payment</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_VariableConsiderationRelatedToMilestonePayment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Variable Consideration Related To Milestone Payment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue recognized for milestone payment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xlink:to="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revenue Recognition Milestone Method Revenue Recognized</link:label>
    <link:loc xlink:href="nk-20191231.xsd#nk_NumberOfProductsApprovedForCommercialSale" xlink:type="locator" xlink:label="nk_NumberOfProductsApprovedForCommercialSale" />
    <link:label xml:lang="en-US" xlink:label="nk_NumberOfProductsApprovedForCommercialSale_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of products approved for commercial sale.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nk_NumberOfProductsApprovedForCommercialSale" xlink:to="nk_NumberOfProductsApprovedForCommercialSale_lbl" />
    <link:label xml:lang="en-US" xlink:label="nk_NumberOfProductsApprovedForCommercialSale_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of products approved for commercial sale</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_NumberOfProductsApprovedForCommercialSale_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Products Approved For Commercial Sale</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities, Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee Stock Option</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Stock Option [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Outstanding RSUs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock Units R S U [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantMember" xlink:type="locator" xlink:label="us-gaap_WarrantMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WarrantMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Outstanding Warrants</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WarrantMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Warrant [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive securities excluded from computation of earnings per share, amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Operating lease right-of-use assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Liability</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_Liabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" xlink:type="locator" xlink:label="us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Build-to-suit related liabilities and assets adjust as accumulated deficit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" xlink:to="us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cumulative Effect Of New Accounting Principle In Period Of Adoption</link:label>
    <link:loc xlink:href="nk-20191231.xsd#nk_PrepaidPreclinicalAndClinicalTrialServicesWithRelatedParty" xlink:type="locator" xlink:label="nk_PrepaidPreclinicalAndClinicalTrialServicesWithRelatedParty" />
    <link:label xml:lang="en-US" xlink:label="nk_PrepaidPreclinicalAndClinicalTrialServicesWithRelatedParty_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Prepaid preclinical and clinical trial services with related party.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nk_PrepaidPreclinicalAndClinicalTrialServicesWithRelatedParty" xlink:to="nk_PrepaidPreclinicalAndClinicalTrialServicesWithRelatedParty_lbl" />
    <link:loc xlink:href="nk-20191231.xsd#nk_InsurancePremiumFinancingAsset" xlink:type="locator" xlink:label="nk_InsurancePremiumFinancingAsset" />
    <link:label xml:lang="en-US" xlink:label="nk_InsurancePremiumFinancingAsset_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Insurance premium financing asset.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nk_InsurancePremiumFinancingAsset" xlink:to="nk_InsurancePremiumFinancingAsset_lbl" />
    <link:loc xlink:href="nk-20191231.xsd#nk_PrepaidSuppliesWithRelatedParty" xlink:type="locator" xlink:label="nk_PrepaidSuppliesWithRelatedParty" />
    <link:label xml:lang="en-US" xlink:label="nk_PrepaidSuppliesWithRelatedParty_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Prepaid supplies with related party.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nk_PrepaidSuppliesWithRelatedParty" xlink:to="nk_PrepaidSuppliesWithRelatedParty_lbl" />
    <link:loc xlink:href="nk-20191231.xsd#nk_PrepaidServices" xlink:type="locator" xlink:label="nk_PrepaidServices" />
    <link:label xml:lang="en-US" xlink:label="nk_PrepaidServices_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Prepaid services.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nk_PrepaidServices" xlink:to="nk_PrepaidServices_lbl" />
    <link:loc xlink:href="nk-20191231.xsd#nk_PrepaidEquipmentMaintenance" xlink:type="locator" xlink:label="nk_PrepaidEquipmentMaintenance" />
    <link:label xml:lang="en-US" xlink:label="nk_PrepaidEquipmentMaintenance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Prepaid equipment maintenance.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nk_PrepaidEquipmentMaintenance" xlink:to="nk_PrepaidEquipmentMaintenance_lbl" />
    <link:loc xlink:href="nk-20191231.xsd#nk_PrepaidLicenseFees" xlink:type="locator" xlink:label="nk_PrepaidLicenseFees" />
    <link:label xml:lang="en-US" xlink:label="nk_PrepaidLicenseFees_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Prepaid license fees.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nk_PrepaidLicenseFees" xlink:to="nk_PrepaidLicenseFees_lbl" />
    <link:label xml:lang="en-US" xlink:label="nk_PrepaidPreclinicalAndClinicalTrialServicesWithRelatedParty_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid preclinical and clinical trial services - with related party (Note 9)</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_PrepaidPreclinicalAndClinicalTrialServicesWithRelatedParty_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Preclinical And Clinical Trial Services With Related Party</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_InsurancePremiumFinancingAsset_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Insurance premium financing asset</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_InsurancePremiumFinancingAsset_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Insurance Premium Financing Asset</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_PrepaidSuppliesWithRelatedParty_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid supplies - with related party (Note 9)</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_PrepaidSuppliesWithRelatedParty_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Supplies With Related Party</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_PrepaidServices_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid services</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_PrepaidServices_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Services</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidRent" xlink:type="locator" xlink:label="us-gaap_PrepaidRent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PrepaidRent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid rent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidRent" xlink:to="us-gaap_PrepaidRent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PrepaidRent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Rent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidInsurance" xlink:type="locator" xlink:label="us-gaap_PrepaidInsurance" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PrepaidInsurance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid insurance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidInsurance" xlink:to="us-gaap_PrepaidInsurance_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PrepaidInsurance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Insurance</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_PrepaidEquipmentMaintenance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid equipment maintenance</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_PrepaidEquipmentMaintenance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Equipment Maintenance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestReceivableCurrent" xlink:type="locator" xlink:label="us-gaap_InterestReceivableCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InterestReceivableCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest receivable - marketable debt securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestReceivableCurrent" xlink:to="us-gaap_InterestReceivableCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InterestReceivableCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Interest Receivable Current</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_PrepaidLicenseFees_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid license fees</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_PrepaidLicenseFees_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid License Fees</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InsuranceSettlementsReceivableCurrent" xlink:type="locator" xlink:label="us-gaap_InsuranceSettlementsReceivableCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InsuranceSettlementsReceivableCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Insurance claim receivables</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InsuranceSettlementsReceivableCurrent" xlink:to="us-gaap_InsuranceSettlementsReceivableCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InsuranceSettlementsReceivableCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Insurance Settlements Receivable Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DueFromRelatedPartiesCurrent" xlink:type="locator" xlink:label="us-gaap_DueFromRelatedPartiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DueFromRelatedPartiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Due from related parties</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DueFromRelatedPartiesCurrent" xlink:to="us-gaap_DueFromRelatedPartiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DueFromRelatedPartiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Due From Related Parties Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets Current</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total prepaid expenses and other current assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:type="locator" xlink:label="us-gaap_ConstructionInProgressMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConstructionInProgressMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Construction in Progress</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConstructionInProgressMember" xlink:to="us-gaap_ConstructionInProgressMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConstructionInProgressMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Construction In Progress [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquipmentMember" xlink:type="locator" xlink:label="us-gaap_EquipmentMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquipmentMember" xlink:to="us-gaap_EquipmentMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Equipment [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property, plant and equipment, gross</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accumulated depreciation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Depreciation Depletion And Amortization Property Plant And Equipment</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Property, plant and equipment, net</link:label>
    <link:loc xlink:href="nk-20191231.xsd#nk_FinancialStatementDetailsLineItems" xlink:type="locator" xlink:label="nk_FinancialStatementDetailsLineItems" />
    <link:label xml:lang="en-US" xlink:label="nk_FinancialStatementDetailsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Financial statement details.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nk_FinancialStatementDetailsLineItems" xlink:to="nk_FinancialStatementDetailsLineItems_lbl" />
    <link:loc xlink:href="nk-20191231.xsd#nk_FinancialStatementDetailsTable" xlink:type="locator" xlink:label="nk_FinancialStatementDetailsTable" />
    <link:label xml:lang="en-US" xlink:label="nk_FinancialStatementDetailsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Financial statement details.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nk_FinancialStatementDetailsTable" xlink:to="nk_FinancialStatementDetailsTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="nk_FinancialStatementDetailsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial Statement Details [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_FinancialStatementDetailsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Financial Statement Details [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_FinancialStatementDetailsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial Statement Details [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_FinancialStatementDetailsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Financial Statement Details [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Depreciation" xlink:type="locator" xlink:label="us-gaap_Depreciation" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Depreciation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation expense related to property, plant and equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Depreciation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation</link:label>
    <link:loc xlink:href="nk-20191231.xsd#nk_LesseseOperatingLeaseReclassificationOfAssetsFromBuildingsToLeaseholdImprovements" xlink:type="locator" xlink:label="nk_LesseseOperatingLeaseReclassificationOfAssetsFromBuildingsToLeaseholdImprovements" />
    <link:label xml:lang="en-US" xlink:label="nk_LesseseOperatingLeaseReclassificationOfAssetsFromBuildingsToLeaseholdImprovements_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Lessese, operating lease, reclassification of assets from buildings to leasehold improvements.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nk_LesseseOperatingLeaseReclassificationOfAssetsFromBuildingsToLeaseholdImprovements" xlink:to="nk_LesseseOperatingLeaseReclassificationOfAssetsFromBuildingsToLeaseholdImprovements_lbl" />
    <link:loc xlink:href="nk-20191231.xsd#nk_DerecognizedBuildToSuitLeaseAssets" xlink:type="locator" xlink:label="nk_DerecognizedBuildToSuitLeaseAssets" />
    <link:label xml:lang="en-US" xlink:label="nk_DerecognizedBuildToSuitLeaseAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Derecognized build to suit lease assets.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nk_DerecognizedBuildToSuitLeaseAssets" xlink:to="nk_DerecognizedBuildToSuitLeaseAssets_lbl" />
    <link:label xml:lang="en-US" xlink:label="nk_LesseseOperatingLeaseReclassificationOfAssetsFromBuildingsToLeaseholdImprovements_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reclassification of assets from buildings to leasehold improvements</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_LesseseOperatingLeaseReclassificationOfAssetsFromBuildingsToLeaseholdImprovements_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessese Operating Lease Reclassification Of Assets From Buildings To Leasehold Improvements</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_DerecognizedBuildToSuitLeaseAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Derecognized build-to-suit lease assets</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_DerecognizedBuildToSuitLeaseAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Derecognized Build To Suit Lease Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RestatementAxis" xlink:type="locator" xlink:label="srt_RestatementAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_RestatementAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restatement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_RestatementAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Restatement [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RestatementDomain" xlink:type="locator" xlink:label="srt_RestatementDomain" />
    <link:label xml:lang="en-US" xlink:label="srt_RestatementDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restatement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RestatementDomain" xlink:to="srt_RestatementDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_RestatementDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Restatement [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RestatementAdjustmentMember" xlink:type="locator" xlink:label="srt_RestatementAdjustmentMember" />
    <link:label xml:lang="en-US" xlink:label="srt_RestatementAdjustmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restatement Adjustment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RestatementAdjustmentMember" xlink:to="srt_RestatementAdjustmentMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_RestatementAdjustmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Restatement Adjustment [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Finite Lived Intangible Assets [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Finite Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:href="nk-20191231.xsd#nk_TechnologyLicenseMember" xlink:type="locator" xlink:label="nk_TechnologyLicenseMember" />
    <link:label xml:lang="en-US" xlink:label="nk_TechnologyLicenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Technology license.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nk_TechnologyLicenseMember" xlink:to="nk_TechnologyLicenseMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="nk_TechnologyLicenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Technology License</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_TechnologyLicenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Technology License [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finite Lived Intangible Assets [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finite Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total intangible assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finite Lived Intangible Assets Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less accumulated amortization</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finite Lived Intangible Assets Accumulated Amortization</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Intangible assets, net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:type="locator" xlink:label="us-gaap_AmortizationOfIntangibleAssets" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortization expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amortization Of Intangible Assets</link:label>
    <link:loc xlink:href="nk-20191231.xsd#nk_PrepaidPreclinicalAndClinicalTrialServicesWithRelatedPartyInOtherAssets" xlink:type="locator" xlink:label="nk_PrepaidPreclinicalAndClinicalTrialServicesWithRelatedPartyInOtherAssets" />
    <link:label xml:lang="en-US" xlink:label="nk_PrepaidPreclinicalAndClinicalTrialServicesWithRelatedPartyInOtherAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Prepaid preclinical and clinical trial services with related party in other assets.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nk_PrepaidPreclinicalAndClinicalTrialServicesWithRelatedPartyInOtherAssets" xlink:to="nk_PrepaidPreclinicalAndClinicalTrialServicesWithRelatedPartyInOtherAssets_lbl" />
    <link:label xml:lang="en-US" xlink:label="nk_PrepaidPreclinicalAndClinicalTrialServicesWithRelatedPartyInOtherAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid preclinical and clinical trial services - with related party (Note 9)</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_PrepaidPreclinicalAndClinicalTrialServicesWithRelatedPartyInOtherAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Preclinical And Clinical Trial Services With Related Party In Other Assets</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted cash</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SecurityDeposit" xlink:type="locator" xlink:label="us-gaap_SecurityDeposit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SecurityDeposit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security deposit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SecurityDeposit" xlink:to="us-gaap_SecurityDeposit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SecurityDeposit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Deposit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseNoncurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PrepaidExpenseNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid rent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseNoncurrent" xlink:to="us-gaap_PrepaidExpenseNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PrepaidExpenseNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsMiscellaneousNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsMiscellaneousNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherAssetsMiscellaneousNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsMiscellaneousNoncurrent" xlink:to="us-gaap_OtherAssetsMiscellaneousNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherAssetsMiscellaneousNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets Miscellaneous Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Assets Noncurrent</link:label>
    <link:loc xlink:href="nk-20191231.xsd#nk_AccruedLaboratoryEquipmentAndSupplies" xlink:type="locator" xlink:label="nk_AccruedLaboratoryEquipmentAndSupplies" />
    <link:label xml:lang="en-US" xlink:label="nk_AccruedLaboratoryEquipmentAndSupplies_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued laboratory equipment and supplies.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nk_AccruedLaboratoryEquipmentAndSupplies" xlink:to="nk_AccruedLaboratoryEquipmentAndSupplies_lbl" />
    <link:loc xlink:href="nk-20191231.xsd#nk_AccruedPreclinicalAndClinicalTrialCosts" xlink:type="locator" xlink:label="nk_AccruedPreclinicalAndClinicalTrialCosts" />
    <link:label xml:lang="en-US" xlink:label="nk_AccruedPreclinicalAndClinicalTrialCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued preclinical and clinical trial costs.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nk_AccruedPreclinicalAndClinicalTrialCosts" xlink:to="nk_AccruedPreclinicalAndClinicalTrialCosts_lbl" />
    <link:loc xlink:href="nk-20191231.xsd#nk_AccruedFranchiseSalesUseAndPropertyTaxes" xlink:type="locator" xlink:label="nk_AccruedFranchiseSalesUseAndPropertyTaxes" />
    <link:label xml:lang="en-US" xlink:label="nk_AccruedFranchiseSalesUseAndPropertyTaxes_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued franchise, sales/use and property taxes.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nk_AccruedFranchiseSalesUseAndPropertyTaxes" xlink:to="nk_AccruedFranchiseSalesUseAndPropertyTaxes_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedBonusesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedBonusesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedBonusesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued bonus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedBonusesCurrent" xlink:to="us-gaap_AccruedBonusesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedBonusesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Bonuses Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedSalariesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedSalariesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedSalariesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedSalariesCurrent" xlink:to="us-gaap_AccruedSalariesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedSalariesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Salaries Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued professional and service fees</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Professional Fees Current</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_AccruedLaboratoryEquipmentAndSupplies_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued laboratory equipment and supplies</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_AccruedLaboratoryEquipmentAndSupplies_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Laboratory Equipment And Supplies</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_AccruedPreclinicalAndClinicalTrialCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued preclinical and clinical trial costs</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_AccruedPreclinicalAndClinicalTrialCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Preclinical And Clinical Trial Costs</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_AccruedFranchiseSalesUseAndPropertyTaxes_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued franchise, sales/use and property taxes</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_AccruedFranchiseSalesUseAndPropertyTaxes_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Franchise Sales Use And Property Taxes</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LitigationReserveCurrent" xlink:type="locator" xlink:label="us-gaap_LitigationReserveCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LitigationReserveCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Litigation settlement accruals</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LitigationReserveCurrent" xlink:to="us-gaap_LitigationReserveCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LitigationReserveCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Litigation Reserve Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConstructionPayableCurrent" xlink:type="locator" xlink:label="us-gaap_ConstructionPayableCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConstructionPayableCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued construction costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConstructionPayableCurrent" xlink:to="us-gaap_ConstructionPayableCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConstructionPayableCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Construction Payable Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Accrued Liabilities Current</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accrued Liabilities Current</link:label>
    <link:loc xlink:href="nk-20191231.xsd#nk_FinancingObligationCurrent" xlink:type="locator" xlink:label="nk_FinancingObligationCurrent" />
    <link:label xml:lang="en-US" xlink:label="nk_FinancingObligationCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Financing obligation current.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nk_FinancingObligationCurrent" xlink:to="nk_FinancingObligationCurrent_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liability - current portion (including amounts with related parties, Note 9)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Liability Current</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_FinancingObligationCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financing obligation - current portion</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_FinancingObligationCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Financing Obligation Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredRentCreditCurrent" xlink:type="locator" xlink:label="us-gaap_DeferredRentCreditCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredRentCreditCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred rent - current portion</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRentCreditCurrent" xlink:to="us-gaap_DeferredRentCreditCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredRentCreditCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Rent Credit Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherSundryLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_OtherSundryLiabilitiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherSundryLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherSundryLiabilitiesCurrent" xlink:to="us-gaap_OtherSundryLiabilitiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherSundryLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Sundry Liabilities Current</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other current liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInterest" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest income</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Investment Income Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investment accretion income (amortization expense), net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:to="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Investment Income Net Amortization Of Discount And Premium</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RealizedInvestmentGainsLosses" xlink:type="locator" xlink:label="us-gaap_RealizedInvestmentGainsLosses" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RealizedInvestmentGainsLosses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net realized (losses) gains on investments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RealizedInvestmentGainsLosses" xlink:to="us-gaap_RealizedInvestmentGainsLosses_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RealizedInvestmentGainsLosses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Realized Investment Gains Losses</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentIncomeNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Investment income, net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ImpairmentOfInvestments" xlink:type="locator" xlink:label="us-gaap_ImpairmentOfInvestments" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ImpairmentOfInvestments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment loss on recognized investments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfInvestments" xlink:to="us-gaap_ImpairmentOfInvestments_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ImpairmentOfInvestments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Impairment Of Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfInvestmentsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfInvestmentsTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfInvestmentsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Investments [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfInvestmentsTable" xlink:to="us-gaap_ScheduleOfInvestmentsTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfInvestmentsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Investments [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Instrument</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Instrument, Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_DebtInstrumentNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Name [Domain]</link:label>
    <link:loc xlink:href="nk-20191231.xsd#nk_TwoThousandAndEighteenNoteAndWarrantPurchaseAgreementMember" xlink:type="locator" xlink:label="nk_TwoThousandAndEighteenNoteAndWarrantPurchaseAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="nk_TwoThousandAndEighteenNoteAndWarrantPurchaseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">2018 Note and Warrant Purchase Agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nk_TwoThousandAndEighteenNoteAndWarrantPurchaseAgreementMember" xlink:to="nk_TwoThousandAndEighteenNoteAndWarrantPurchaseAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="nk_TwoThousandAndEighteenNoteAndWarrantPurchaseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2018 Note and Warrant Purchase Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_TwoThousandAndEighteenNoteAndWarrantPurchaseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand And Eighteen Note And Warrant Purchase Agreement [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Class Of Stock [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Stock [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:type="locator" xlink:label="us-gaap_SeriesBPreferredStockMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SeriesBPreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series B Preferred Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesBPreferredStockMember" xlink:to="us-gaap_SeriesBPreferredStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SeriesBPreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Series B Preferred Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfInvestmentsLineItems" xlink:type="locator" xlink:label="us-gaap_ScheduleOfInvestmentsLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfInvestmentsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Investments [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfInvestmentsLineItems" xlink:to="us-gaap_ScheduleOfInvestmentsLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfInvestmentsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Investments [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Equity securities</link:label>
    <link:loc xlink:href="nk-20191231.xsd#nk_PurchaseOfConvertibleNoteUponConversion" xlink:type="locator" xlink:label="nk_PurchaseOfConvertibleNoteUponConversion" />
    <link:label xml:lang="en-US" xlink:label="nk_PurchaseOfConvertibleNoteUponConversion_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Purchase of convertible note upon conversion.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nk_PurchaseOfConvertibleNoteUponConversion" xlink:to="nk_PurchaseOfConvertibleNoteUponConversion_lbl" />
    <link:label xml:lang="en-US" xlink:label="nk_PurchaseOfConvertibleNoteUponConversion_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchase of convertible note</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_PurchaseOfConvertibleNoteUponConversion_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Purchase Of Convertible Note Upon Conversion</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible note accrued interest rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Interest Rate Effective Percentage</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentTerm" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt instrument maturity date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTerm" xlink:to="us-gaap_DebtInstrumentTerm_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockValue" xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants exercised to acquire shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights</link:label>
    <link:loc xlink:href="nk-20191231.xsd#nk_DebtSecuritiesAvailableForSaleAndHeldToMaturityAmortizedCost" xlink:type="locator" xlink:label="nk_DebtSecuritiesAvailableForSaleAndHeldToMaturityAmortizedCost" />
    <link:label xml:lang="en-US" xlink:label="nk_DebtSecuritiesAvailableForSaleAndHeldToMaturityAmortizedCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Debt securities available for sale and held to maturity amortized cost.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nk_DebtSecuritiesAvailableForSaleAndHeldToMaturityAmortizedCost" xlink:to="nk_DebtSecuritiesAvailableForSaleAndHeldToMaturityAmortizedCost_lbl" />
    <link:loc xlink:href="nk-20191231.xsd#nk_DebtSecuritiesAvailableForSaleAndHeldToMaturityAmortizedCostAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="locator" xlink:label="nk_DebtSecuritiesAvailableForSaleAndHeldToMaturityAmortizedCostAccumulatedGrossUnrealizedGainBeforeTax" />
    <link:label xml:lang="en-US" xlink:label="nk_DebtSecuritiesAvailableForSaleAndHeldToMaturityAmortizedCostAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Debt securities available for sale and held to maturity amortized cost accumulated gross unrealized gain before tax.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nk_DebtSecuritiesAvailableForSaleAndHeldToMaturityAmortizedCostAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="nk_DebtSecuritiesAvailableForSaleAndHeldToMaturityAmortizedCostAccumulatedGrossUnrealizedGainBeforeTax_lbl" />
    <link:loc xlink:href="nk-20191231.xsd#nk_DebtSecuritiesAvailableForSaleAndHeldToMaturityAmortizedCostAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="locator" xlink:label="nk_DebtSecuritiesAvailableForSaleAndHeldToMaturityAmortizedCostAccumulatedGrossUnrealizedLossBeforeTax" />
    <link:label xml:lang="en-US" xlink:label="nk_DebtSecuritiesAvailableForSaleAndHeldToMaturityAmortizedCostAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Debt securities available for sale and held to maturity amortized cost accumulated gross unrealized loss before tax.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nk_DebtSecuritiesAvailableForSaleAndHeldToMaturityAmortizedCostAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="nk_DebtSecuritiesAvailableForSaleAndHeldToMaturityAmortizedCostAccumulatedGrossUnrealizedLossBeforeTax_lbl" />
    <link:loc xlink:href="nk-20191231.xsd#nk_DebtSecuritiesAvailableForSaleAndHeldToMaturityFairValue" xlink:type="locator" xlink:label="nk_DebtSecuritiesAvailableForSaleAndHeldToMaturityFairValue" />
    <link:label xml:lang="en-US" xlink:label="nk_DebtSecuritiesAvailableForSaleAndHeldToMaturityFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Debt securities available for sale and held to maturity fair value.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nk_DebtSecuritiesAvailableForSaleAndHeldToMaturityFairValue" xlink:to="nk_DebtSecuritiesAvailableForSaleAndHeldToMaturityFairValue_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAbstract" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Securities [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Available For Sale Securities [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Available For Sale Securities [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BalanceSheetLocationAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Balance Sheet Location</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BalanceSheetLocationAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BalanceSheetLocationDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Balance Sheet Location</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_BalanceSheetLocationDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BalanceSheetLocationDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:href="nk-20191231.xsd#nk_CurrentAssetsMember" xlink:type="locator" xlink:label="nk_CurrentAssetsMember" />
    <link:label xml:lang="en-US" xlink:label="nk_CurrentAssetsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Current assets.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nk_CurrentAssetsMember" xlink:to="nk_CurrentAssetsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="nk_CurrentAssetsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current Assets</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_CurrentAssetsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Current Assets [Member]</link:label>
    <link:loc xlink:href="nk-20191231.xsd#nk_NoncurrentAssetsMember" xlink:type="locator" xlink:label="nk_NoncurrentAssetsMember" />
    <link:label xml:lang="en-US" xlink:label="nk_NoncurrentAssetsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Noncurrent assets.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nk_NoncurrentAssetsMember" xlink:to="nk_NoncurrentAssetsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="nk_NoncurrentAssetsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Noncurrent Assets</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_NoncurrentAssetsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Noncurrent Assets [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnderlyingAssetClassAxis" xlink:type="locator" xlink:label="us-gaap_UnderlyingAssetClassAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnderlyingAssetClassAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Underlying Asset Class</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnderlyingAssetClassAxis" xlink:to="us-gaap_UnderlyingAssetClassAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnderlyingAssetClassAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Underlying Asset Class [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnderlyingAssetClassDomain" xlink:type="locator" xlink:label="us-gaap_UnderlyingAssetClassDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnderlyingAssetClassDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Underlying Asset Class</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnderlyingAssetClassDomain" xlink:to="us-gaap_UnderlyingAssetClassDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnderlyingAssetClassDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Underlying Asset Class [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AgencySecuritiesMember" xlink:type="locator" xlink:label="us-gaap_AgencySecuritiesMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AgencySecuritiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Government Sponsored Securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AgencySecuritiesMember" xlink:to="us-gaap_AgencySecuritiesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AgencySecuritiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Agency Securities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investment Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Investment Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeCategorizationMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentTypeCategorizationMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_InvestmentTypeCategorizationMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentTypeCategorizationMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Investment Type Categorization [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignGovernmentDebtMember" xlink:type="locator" xlink:label="us-gaap_ForeignGovernmentDebtMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ForeignGovernmentDebtMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign Government Bonds</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignGovernmentDebtMember" xlink:to="us-gaap_ForeignGovernmentDebtMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ForeignGovernmentDebtMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Foreign Government Debt [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:type="locator" xlink:label="us-gaap_FinancialInstrumentAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial Instrument</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instrument [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial Instruments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Transfers And Servicing Of Financial Instruments Types Of Financial Instruments [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_CorporateDebtSecuritiesMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CorporateDebtSecuritiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Corporate Debt Securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CorporateDebtSecuritiesMember" xlink:to="us-gaap_CorporateDebtSecuritiesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CorporateDebtSecuritiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByAssetClassAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueByAssetClassAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Asset Class</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueByAssetClassAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueByAssetClassAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value By Asset Class [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Asset Class</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation By Asset Class [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NotesReceivableMember" xlink:type="locator" xlink:label="us-gaap_NotesReceivableMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NotesReceivableMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Notes Receivable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesReceivableMember" xlink:to="us-gaap_NotesReceivableMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NotesReceivableMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Notes Receivable [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Available For Sale Securities [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Available For Sale Securities [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Available-for-sale, Amortized Cost</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Debt Securities Amortized Cost Basis</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Available-for-sale, Unrealized Gains</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Available-for-sale, Unrealized Losses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Available-for-sale, Fair Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Securities Debt Securities</link:label>
    <link:loc xlink:href="nk-20191231.xsd#nk_AvailableForSaleSecuritiesDebtSecuritiesPeriod" xlink:type="locator" xlink:label="nk_AvailableForSaleSecuritiesDebtSecuritiesPeriod" />
    <link:label xml:lang="en-US" xlink:label="nk_AvailableForSaleSecuritiesDebtSecuritiesPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Available for sale securities debt securities period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nk_AvailableForSaleSecuritiesDebtSecuritiesPeriod" xlink:to="nk_AvailableForSaleSecuritiesDebtSecuritiesPeriod_lbl" />
    <link:loc xlink:href="nk-20191231.xsd#nk_AvailableForSaleSecuritiesAndHeldToMaturityGrossUnrealizedGain" xlink:type="locator" xlink:label="nk_AvailableForSaleSecuritiesAndHeldToMaturityGrossUnrealizedGain" />
    <link:label xml:lang="en-US" xlink:label="nk_AvailableForSaleSecuritiesAndHeldToMaturityGrossUnrealizedGain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Available for sale securities and held to maturity gross unrealized gain.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nk_AvailableForSaleSecuritiesAndHeldToMaturityGrossUnrealizedGain" xlink:to="nk_AvailableForSaleSecuritiesAndHeldToMaturityGrossUnrealizedGain_lbl" />
    <link:loc xlink:href="nk-20191231.xsd#nk_AvailableForSaleSecuritiesAndHeldToMaturityGrossUnrealizedLosses" xlink:type="locator" xlink:label="nk_AvailableForSaleSecuritiesAndHeldToMaturityGrossUnrealizedLosses" />
    <link:label xml:lang="en-US" xlink:label="nk_AvailableForSaleSecuritiesAndHeldToMaturityGrossUnrealizedLosses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Available for sale securities and held to maturity gross unrealized losses.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nk_AvailableForSaleSecuritiesAndHeldToMaturityGrossUnrealizedLosses" xlink:to="nk_AvailableForSaleSecuritiesAndHeldToMaturityGrossUnrealizedLosses_lbl" />
    <link:label xml:lang="en-US" xlink:label="nk_AvailableForSaleSecuritiesDebtSecuritiesPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Available-for-sale, Weighted- Average Remaining Contractual Life</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_AvailableForSaleSecuritiesDebtSecuritiesPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Securities Debt Securities Period</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_AvailableForSaleSecuritiesAndHeldToMaturityGrossUnrealizedGain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Available-for-sale and held-to-maturity, Unrealized Gains</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_AvailableForSaleSecuritiesAndHeldToMaturityGrossUnrealizedGain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Securities And Held To Maturity Gross Unrealized Gain</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_AvailableForSaleSecuritiesAndHeldToMaturityGrossUnrealizedLosses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Available-for-sale and held-to-maturity, Unrealized Losses</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_AvailableForSaleSecuritiesAndHeldToMaturityGrossUnrealizedLosses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Securities And Held To Maturity Gross Unrealized Losses</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAndHeldToMaturitySecurities" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesAndHeldToMaturitySecurities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesAndHeldToMaturitySecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Available-for-sale and held-to-maturity, Fair Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesAndHeldToMaturitySecurities" xlink:to="us-gaap_AvailableForSaleSecuritiesAndHeldToMaturitySecurities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesAndHeldToMaturitySecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Securities And Held To Maturity Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HeldToMaturitySecurities" xlink:type="locator" xlink:label="us-gaap_HeldToMaturitySecurities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_HeldToMaturitySecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Held-to-maturity, Amortized Cost</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_HeldToMaturitySecurities" xlink:to="us-gaap_HeldToMaturitySecurities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_HeldToMaturitySecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Held To Maturity Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" xlink:type="locator" xlink:label="us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Held-to-maturity, Unrealized Gains</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" xlink:to="us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Held To Maturity Securities Accumulated Unrecognized Holding Gain</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" xlink:type="locator" xlink:label="us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Held-to-maturity, Unrealized Losses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" xlink:to="us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Held To Maturity Securities Accumulated Unrecognized Holding Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HeldToMaturitySecuritiesFairValue" xlink:type="locator" xlink:label="us-gaap_HeldToMaturitySecuritiesFairValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_HeldToMaturitySecuritiesFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Held-to-maturity, Fair Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_HeldToMaturitySecuritiesFairValue" xlink:to="us-gaap_HeldToMaturitySecuritiesFairValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_HeldToMaturitySecuritiesFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Held To Maturity Securities Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_DebtSecuritiesAvailableForSaleAndHeldToMaturityAmortizedCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Available-for-sale and held-to-maturity, Amortized Cost</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_DebtSecuritiesAvailableForSaleAndHeldToMaturityAmortizedCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities Available For Sale And Held To Maturity Amortized Cost</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_DebtSecuritiesAvailableForSaleAndHeldToMaturityAmortizedCostAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Available-for-sale and held-to-maturity, Unrealized Gains</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_DebtSecuritiesAvailableForSaleAndHeldToMaturityAmortizedCostAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities Available For Sale And Held To Maturity Amortized Cost Accumulated Gross Unrealized Gain Before Tax</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_DebtSecuritiesAvailableForSaleAndHeldToMaturityAmortizedCostAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Available-for-sale and held-to-maturity, Unrealized Losses</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_DebtSecuritiesAvailableForSaleAndHeldToMaturityAmortizedCostAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities Available For Sale And Held To Maturity Amortized Cost Accumulated Gross Unrealized Loss Before Tax</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_DebtSecuritiesAvailableForSaleAndHeldToMaturityFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Available-for-sale and held-to-maturity, Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_DebtSecuritiesAvailableForSaleAndHeldToMaturityFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities Available For Sale And Held To Maturity Fair Value</link:label>
    <link:loc xlink:href="nk-20191231.xsd#nk_AvailableForSaleDebtSecuritiesAmortizedCost" xlink:type="locator" xlink:label="nk_AvailableForSaleDebtSecuritiesAmortizedCost" />
    <link:label xml:lang="en-US" xlink:label="nk_AvailableForSaleDebtSecuritiesAmortizedCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Available for sale debt securities amortized cost.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nk_AvailableForSaleDebtSecuritiesAmortizedCost" xlink:to="nk_AvailableForSaleDebtSecuritiesAmortizedCost_lbl" />
    <link:label xml:lang="en-US" xlink:label="nk_AvailableForSaleDebtSecuritiesAmortizedCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortized Cost</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_AvailableForSaleDebtSecuritiesAmortizedCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Debt Securities Amortized Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized Gains</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Debt Securities Gross Unrealized Gain</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Unrealized Losses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Debt Securities Gross Unrealized Loss</link:label>
    <link:loc xlink:href="nk-20191231.xsd#nk_AvailableForSaleSecuritiesPeriodOfUnrealizedLossPositions" xlink:type="locator" xlink:label="nk_AvailableForSaleSecuritiesPeriodOfUnrealizedLossPositions" />
    <link:label xml:lang="en-US" xlink:label="nk_AvailableForSaleSecuritiesPeriodOfUnrealizedLossPositions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Available for sale securities period of unrealized loss positions.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nk_AvailableForSaleSecuritiesPeriodOfUnrealizedLossPositions" xlink:to="nk_AvailableForSaleSecuritiesPeriodOfUnrealizedLossPositions_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtSecuritiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesMember" xlink:to="us-gaap_DebtSecuritiesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtSecuritiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_AvailableForSaleSecuritiesPeriodOfUnrealizedLossPositions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Available-for-sale securities, period of unrealized loss positions</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_AvailableForSaleSecuritiesPeriodOfUnrealizedLossPositions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Securities Period Of Unrealized Loss Positions</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Available-for-Sale Investments, Less than 12 months, Estimated Fair Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Available-for-Sale Investments, Less than 12 months, Gross Unrealized Losses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Available-for-Sale Investments, More than 12 months, Estimated Fair Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Available-for-Sale Investments, More than 12 months, Gross Unrealized Losses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1" xlink:type="locator" xlink:label="us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of available-for-sale securities in unrealized loss positions</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1" xlink:to="us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Availableforsale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions1</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesRealizedGainLossAbstract" xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesRealizedGainLossAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtSecuritiesRealizedGainLossAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities Realized Gain Loss [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesRealizedGainLossAbstract" xlink:to="us-gaap_DebtSecuritiesRealizedGainLossAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesGrossRealizedGains" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesGrossRealizedGains" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesGrossRealizedGains_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Available-for-sale Securities, Gross Realized Gains</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesGrossRealizedGains" xlink:to="us-gaap_AvailableForSaleSecuritiesGrossRealizedGains_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesGrossRealizedGains_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Securities Gross Realized Gains</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Available-for-sale Securities, Gross Realized Losses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses" xlink:to="us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Securities Gross Realized Losses</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossNet" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Available for Sale Securities, Net Realized Gains (Losses)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossNet" xlink:to="us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Securities Gross Realized Gain Loss Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy and NAV</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value By Fair Value Hierarchy Level [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy and NAV</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurements Fair Value Hierarchy [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 1</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Inputs Level1 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 2</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Inputs Level2 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 3</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Inputs Level3 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Frequency</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value By Measurement Frequency [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Frequency</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement Frequency [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value, Measurements, Recurring</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurements Recurring [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsMember" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsMember" xlink:to="us-gaap_CashAndCashEquivalentsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_AssetsFairValueDisclosure" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets measured at fair value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets Fair Value Disclosure</link:label>
    <link:loc xlink:href="nk-20191231.xsd#nk_MaximumNumberOfPatientsInPhaseOneAndTwoForClinicalTrials" xlink:type="locator" xlink:label="nk_MaximumNumberOfPatientsInPhaseOneAndTwoForClinicalTrials" />
    <link:label xml:lang="en-US" xlink:label="nk_MaximumNumberOfPatientsInPhaseOneAndTwoForClinicalTrials_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Maximum number of patients in phase one and two for clinical trials.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nk_MaximumNumberOfPatientsInPhaseOneAndTwoForClinicalTrials" xlink:to="nk_MaximumNumberOfPatientsInPhaseOneAndTwoForClinicalTrials_lbl" />
    <link:loc xlink:href="nk-20191231.xsd#nk_LicensingAgreementAbstract" xlink:type="locator" xlink:label="nk_LicensingAgreementAbstract" />
    <link:label xml:lang="en-US" xlink:label="nk_LicensingAgreementAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Licensing agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nk_LicensingAgreementAbstract" xlink:to="nk_LicensingAgreementAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="nk_LicensingAgreementAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Licensing Agreement [Abstract]</link:label>
    <link:loc xlink:href="nk-20191231.xsd#nk_LicensingAgreementLineItems" xlink:type="locator" xlink:label="nk_LicensingAgreementLineItems" />
    <link:label xml:lang="en-US" xlink:label="nk_LicensingAgreementLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Licensing agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nk_LicensingAgreementLineItems" xlink:to="nk_LicensingAgreementLineItems_lbl" />
    <link:loc xlink:href="nk-20191231.xsd#nk_LicensingAgreementTable" xlink:type="locator" xlink:label="nk_LicensingAgreementTable" />
    <link:label xml:lang="en-US" xlink:label="nk_LicensingAgreementTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Licensing agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nk_LicensingAgreementTable" xlink:to="nk_LicensingAgreementTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="nk_LicensingAgreementTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Licensing Agreement [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_LicensingAgreementTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Licensing Agreement [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party Transaction</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party Transaction</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="us-gaap_RelatedPartyTransactionDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction [Domain]</link:label>
    <link:loc xlink:href="nk-20191231.xsd#nk_AltorBioScienceCorporationMember" xlink:type="locator" xlink:label="nk_AltorBioScienceCorporationMember" />
    <link:label xml:lang="en-US" xlink:label="nk_AltorBioScienceCorporationMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Altor BioScience Corporation.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nk_AltorBioScienceCorporationMember" xlink:to="nk_AltorBioScienceCorporationMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="nk_AltorBioScienceCorporationMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Altor</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_AltorBioScienceCorporationMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Altor Bio Science Corporation [Member]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <link:label xml:lang="en-US" xlink:label="dei_LegalEntityAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Legal Entity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LegalEntityAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Legal Entity [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity [Domain]</link:label>
    <link:loc xlink:href="nk-20191231.xsd#nk_ViractaTherapeuticsIncMember" xlink:type="locator" xlink:label="nk_ViractaTherapeuticsIncMember" />
    <link:label xml:lang="en-US" xlink:label="nk_ViractaTherapeuticsIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Viracta Therapeutics, Inc.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nk_ViractaTherapeuticsIncMember" xlink:to="nk_ViractaTherapeuticsIncMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="nk_ViractaTherapeuticsIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Viracta Therapeutics, Inc.</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_ViractaTherapeuticsIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Viracta Therapeutics Inc [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Indefinite-lived Intangible Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Indefinite Lived Intangible Assets By Major Class [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Indefinite-lived Intangible Assets, Major Class Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Indefinite Lived Intangible Assets Major Class Name [Domain]</link:label>
    <link:loc xlink:href="nk-20191231.xsd#nk_GeorgSpeyerHausAndDRKBlutspendedienstBadenWurttembergHessengGmbHLicenseAgreementMember" xlink:type="locator" xlink:label="nk_GeorgSpeyerHausAndDRKBlutspendedienstBadenWurttembergHessengGmbHLicenseAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="nk_GeorgSpeyerHausAndDRKBlutspendedienstBadenWurttembergHessengGmbHLicenseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Georg-Speyer-Haus and DRK-Blutspendedienst Baden-Wurttemberg-HessenGmbH license agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nk_GeorgSpeyerHausAndDRKBlutspendedienstBadenWurttembergHessengGmbHLicenseAgreementMember" xlink:to="nk_GeorgSpeyerHausAndDRKBlutspendedienstBadenWurttembergHessengGmbHLicenseAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="nk_GeorgSpeyerHausAndDRKBlutspendedienstBadenWurttembergHessengGmbHLicenseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">GSH-BSD</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_GeorgSpeyerHausAndDRKBlutspendedienstBadenWurttembergHessengGmbHLicenseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Georg Speyer Haus And D R K Blutspendedienst Baden Wurttemberg Hesseng Gmb H License Agreement [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCommitmentsAxis" xlink:type="locator" xlink:label="us-gaap_OtherCommitmentsAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherCommitmentsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other Commitments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="us-gaap_OtherCommitmentsAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherCommitmentsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Commitments [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCommitmentsDomain" xlink:type="locator" xlink:label="us-gaap_OtherCommitmentsDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherCommitmentsDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other Commitments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentsDomain" xlink:to="us-gaap_OtherCommitmentsDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherCommitmentsDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Commitments [Domain]</link:label>
    <link:loc xlink:href="nk-20191231.xsd#nk_RushUniversityMedicalCenterLicenseAgreementMember" xlink:type="locator" xlink:label="nk_RushUniversityMedicalCenterLicenseAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="nk_RushUniversityMedicalCenterLicenseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Rush university medical center license agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nk_RushUniversityMedicalCenterLicenseAgreementMember" xlink:to="nk_RushUniversityMedicalCenterLicenseAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="nk_RushUniversityMedicalCenterLicenseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Rush University Medical Center License Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_RushUniversityMedicalCenterLicenseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Rush University Medical Center License Agreement [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Arrangement, Contract to Perform for Others, Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Arrangement Contract To Perform For Others By Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Arrangement, Contract to Perform for Others, Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Arrangement Contract To Perform For Others Type [Domain]</link:label>
    <link:loc xlink:href="nk-20191231.xsd#nk_INDFilingMember" xlink:type="locator" xlink:label="nk_INDFilingMember" />
    <link:label xml:lang="en-US" xlink:label="nk_INDFilingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">IND filing.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nk_INDFilingMember" xlink:to="nk_INDFilingMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="nk_INDFilingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">First IND Filing</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_INDFilingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">I N D Filing [Member]</link:label>
    <link:loc xlink:href="nk-20191231.xsd#nk_PhaseTwoMember" xlink:type="locator" xlink:label="nk_PhaseTwoMember" />
    <link:label xml:lang="en-US" xlink:label="nk_PhaseTwoMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Phase two.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nk_PhaseTwoMember" xlink:to="nk_PhaseTwoMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="nk_PhaseTwoMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">First Phase II Clinical Trial</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_PhaseTwoMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Phase Two [Member]</link:label>
    <link:loc xlink:href="nk-20191231.xsd#nk_PhaseThreeMember" xlink:type="locator" xlink:label="nk_PhaseThreeMember" />
    <link:label xml:lang="en-US" xlink:label="nk_PhaseThreeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Phase three.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nk_PhaseThreeMember" xlink:to="nk_PhaseThreeMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="nk_PhaseThreeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">First Phase III Clinical Trial</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_PhaseThreeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Phase Three [Member]</link:label>
    <link:loc xlink:href="nk-20191231.xsd#nk_CommercialSaleRelatedToLicensedProductsMember" xlink:type="locator" xlink:label="nk_CommercialSaleRelatedToLicensedProductsMember" />
    <link:label xml:lang="en-US" xlink:label="nk_CommercialSaleRelatedToLicensedProductsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Commercial sale related to licensed products.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nk_CommercialSaleRelatedToLicensedProductsMember" xlink:to="nk_CommercialSaleRelatedToLicensedProductsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="nk_CommercialSaleRelatedToLicensedProductsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commercial Sale Related to Licensed Products</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_CommercialSaleRelatedToLicensedProductsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commercial Sale Related To Licensed Products [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_LicensingAgreementLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Licensing Agreement [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_LicensingAgreementLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Licensing Agreement [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_MaximumNumberOfPatientsInPhaseOneAndTwoForClinicalTrials_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum number of patients in phase 1 and 2 for clinical trials</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_MaximumNumberOfPatientsInPhaseOneAndTwoForClinicalTrials_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Maximum Number Of Patients In Phase One And Two For Clinical Trials</link:label>
    <link:loc xlink:href="nk-20191231.xsd#nk_SuppliesAndMilestoneChargesForConductingClinicalTrials" xlink:type="locator" xlink:label="nk_SuppliesAndMilestoneChargesForConductingClinicalTrials" />
    <link:label xml:lang="en-US" xlink:label="nk_SuppliesAndMilestoneChargesForConductingClinicalTrials_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Supplies and milestone charges for conducting clinical trials.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nk_SuppliesAndMilestoneChargesForConductingClinicalTrials" xlink:to="nk_SuppliesAndMilestoneChargesForConductingClinicalTrials_lbl" />
    <link:label xml:lang="en-US" xlink:label="nk_SuppliesAndMilestoneChargesForConductingClinicalTrials_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplies and milestone charges for conducting clinical trials</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_SuppliesAndMilestoneChargesForConductingClinicalTrials_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Supplies And Milestone Charges For Conducting Clinical Trials</link:label>
    <link:loc xlink:href="nk-20191231.xsd#nk_MilestonePaymentAmount" xlink:type="locator" xlink:label="nk_MilestonePaymentAmount" />
    <link:label xml:lang="en-US" xlink:label="nk_MilestonePaymentAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Milestone payment amount.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nk_MilestonePaymentAmount" xlink:to="nk_MilestonePaymentAmount_lbl" />
    <link:loc xlink:href="nk-20191231.xsd#nk_LicenseAgreementTerminationNoticePeriod" xlink:type="locator" xlink:label="nk_LicenseAgreementTerminationNoticePeriod" />
    <link:label xml:lang="en-US" xlink:label="nk_LicenseAgreementTerminationNoticePeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">License agreement termination notice period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nk_LicenseAgreementTerminationNoticePeriod" xlink:to="nk_LicenseAgreementTerminationNoticePeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="nk_MilestonePaymentAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Milestone Payment Amount</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_MilestonePaymentAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Milestone Payment Amount</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_LicenseAgreementTerminationNoticePeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License agreement termination notice period</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_LicenseAgreementTerminationNoticePeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">License Agreement Termination Notice Period</link:label>
    <link:loc xlink:href="nk-20191231.xsd#nk_PaymentsForInitialLicenseFees" xlink:type="locator" xlink:label="nk_PaymentsForInitialLicenseFees" />
    <link:label xml:lang="en-US" xlink:label="nk_PaymentsForInitialLicenseFees_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Payments for initial license fees.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nk_PaymentsForInitialLicenseFees" xlink:to="nk_PaymentsForInitialLicenseFees_lbl" />
    <link:label xml:lang="en-US" xlink:label="nk_PaymentsForInitialLicenseFees_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payments for initial license fees</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_PaymentsForInitialLicenseFees_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments For Initial License Fees</link:label>
    <link:loc xlink:href="nk-20191231.xsd#nk_PeriodOfLicenseAgreement" xlink:type="locator" xlink:label="nk_PeriodOfLicenseAgreement" />
    <link:label xml:lang="en-US" xlink:label="nk_PeriodOfLicenseAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Period of license agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nk_PeriodOfLicenseAgreement" xlink:to="nk_PeriodOfLicenseAgreement_lbl" />
    <link:loc xlink:href="nk-20191231.xsd#nk_MinimumAnnualRoyaltyPayment" xlink:type="locator" xlink:label="nk_MinimumAnnualRoyaltyPayment" />
    <link:label xml:lang="en-US" xlink:label="nk_MinimumAnnualRoyaltyPayment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Minimum annual royalty payment.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nk_MinimumAnnualRoyaltyPayment" xlink:to="nk_MinimumAnnualRoyaltyPayment_lbl" />
    <link:loc xlink:href="nk-20191231.xsd#nk_MinimumSalesMilestoneOfLicenseForFirstYear" xlink:type="locator" xlink:label="nk_MinimumSalesMilestoneOfLicenseForFirstYear" />
    <link:label xml:lang="en-US" xlink:label="nk_MinimumSalesMilestoneOfLicenseForFirstYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Minimum sales milestone of license for first year.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nk_MinimumSalesMilestoneOfLicenseForFirstYear" xlink:to="nk_MinimumSalesMilestoneOfLicenseForFirstYear_lbl" />
    <link:label xml:lang="en-US" xlink:label="nk_PeriodOfLicenseAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Period of license agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_PeriodOfLicenseAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Period Of License Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_MinimumAnnualRoyaltyPayment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum annual royalty payment</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_MinimumAnnualRoyaltyPayment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Minimum Annual Royalty Payment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:type="locator" xlink:label="us-gaap_CostOfGoodsAndServicesSold" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CostOfGoodsAndServicesSold_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payments in license agreement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfGoodsAndServicesSold" xlink:to="us-gaap_CostOfGoodsAndServicesSold_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CostOfGoodsAndServicesSold_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cost Of Goods And Services Sold</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_MinimumSalesMilestoneOfLicenseForFirstYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum sales milestone of license for first year</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_MinimumSalesMilestoneOfLicenseForFirstYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Minimum Sales Milestone Of License For First Year</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RoyaltyExpense" xlink:type="locator" xlink:label="us-gaap_RoyaltyExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RoyaltyExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Royalty expense earned or paid</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RoyaltyExpense" xlink:to="us-gaap_RoyaltyExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RoyaltyExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Royalty Expense</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Milestone payments</link:label>
    <link:loc xlink:href="nk-20191231.xsd#nk_AgreementOneTimeFee" xlink:type="locator" xlink:label="nk_AgreementOneTimeFee" />
    <link:label xml:lang="en-US" xlink:label="nk_AgreementOneTimeFee_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Agreement one time fee.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nk_AgreementOneTimeFee" xlink:to="nk_AgreementOneTimeFee_lbl" />
    <link:loc xlink:href="nk-20191231.xsd#nk_LicenseAgreementTerm" xlink:type="locator" xlink:label="nk_LicenseAgreementTerm" />
    <link:label xml:lang="en-US" xlink:label="nk_LicenseAgreementTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">License agreement term.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nk_LicenseAgreementTerm" xlink:to="nk_LicenseAgreementTerm_lbl" />
    <link:label xml:lang="en-US" xlink:label="nk_LicenseAgreementTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License agreement term (years)</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_LicenseAgreementTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">License Agreement Term</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_AgreementOneTimeFee_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Agreement one time fee</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_AgreementOneTimeFee_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Agreement One Time Fee</link:label>
    <link:loc xlink:href="nk-20191231.xsd#nk_CommitmentsAndContingenciesLineItems" xlink:type="locator" xlink:label="nk_CommitmentsAndContingenciesLineItems" />
    <link:label xml:lang="en-US" xlink:label="nk_CommitmentsAndContingenciesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Commitments and contingencies.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nk_CommitmentsAndContingenciesLineItems" xlink:to="nk_CommitmentsAndContingenciesLineItems_lbl" />
    <link:loc xlink:href="nk-20191231.xsd#nk_CommitmentsAndContingenciesTable" xlink:type="locator" xlink:label="nk_CommitmentsAndContingenciesTable" />
    <link:label xml:lang="en-US" xlink:label="nk_CommitmentsAndContingenciesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Commitments and Contingencies Table.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nk_CommitmentsAndContingenciesTable" xlink:to="nk_CommitmentsAndContingenciesTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="nk_CommitmentsAndContingenciesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments And Contingencies [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_CommitmentsAndContingenciesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Selling, General and Administrative</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Selling General And Administrative Expenses [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReinsurancePolicyTypeAxis" xlink:type="locator" xlink:label="us-gaap_ReinsurancePolicyTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ReinsurancePolicyTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reinsurance Policy, Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReinsurancePolicyTypeAxis" xlink:to="us-gaap_ReinsurancePolicyTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ReinsurancePolicyTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Reinsurance Policy Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReinsurancePolicyDomain" xlink:type="locator" xlink:label="us-gaap_ReinsurancePolicyDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ReinsurancePolicyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reinsurance Policy</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReinsurancePolicyDomain" xlink:to="us-gaap_ReinsurancePolicyDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ReinsurancePolicyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Reinsurance Policy [Domain]</link:label>
    <link:loc xlink:href="nk-20191231.xsd#nk_DirectorsAndOfficersInsurancePolicyMember" xlink:type="locator" xlink:label="nk_DirectorsAndOfficersInsurancePolicyMember" />
    <link:label xml:lang="en-US" xlink:label="nk_DirectorsAndOfficersInsurancePolicyMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Directors and officers insurance policy.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nk_DirectorsAndOfficersInsurancePolicyMember" xlink:to="nk_DirectorsAndOfficersInsurancePolicyMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="nk_DirectorsAndOfficersInsurancePolicyMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Directors and Officers Insurance Policy</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_DirectorsAndOfficersInsurancePolicyMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Directors And Officers Insurance Policy [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:type="locator" xlink:label="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid Expenses and Other Current Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:to="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expenses And Other Current Assets [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpenseMember" xlink:type="locator" xlink:label="us-gaap_OperatingExpenseMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating Expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenseMember" xlink:to="us-gaap_OperatingExpenseMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expense [Member]</link:label>
    <link:loc xlink:href="nk-20191231.xsd#nk_NantBioScienceMember" xlink:type="locator" xlink:label="nk_NantBioScienceMember" />
    <link:label xml:lang="en-US" xlink:label="nk_NantBioScienceMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">NantBioScience.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nk_NantBioScienceMember" xlink:to="nk_NantBioScienceMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="nk_NantBioScienceMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">NantBioScience</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_NantBioScienceMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Nant Bio Science [Member]</link:label>
    <link:loc xlink:href="nk-20191231.xsd#nk_DougStLLCMember" xlink:type="locator" xlink:label="nk_DougStLLCMember" />
    <link:label xml:lang="en-US" xlink:label="nk_DougStLLCMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Doug St LLC.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nk_DougStLLCMember" xlink:to="nk_DougStLLCMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="nk_DougStLLCMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Doug St, LLC</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_DougStLLCMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Doug St L L C [Member]</link:label>
    <link:loc xlink:href="nk-20191231.xsd#nk_ElSegundoCaliforniaMember" xlink:type="locator" xlink:label="nk_ElSegundoCaliforniaMember" />
    <link:label xml:lang="en-US" xlink:label="nk_ElSegundoCaliforniaMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">El Segundo, California.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nk_ElSegundoCaliforniaMember" xlink:to="nk_ElSegundoCaliforniaMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="nk_ElSegundoCaliforniaMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">El Segundo California</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_ElSegundoCaliforniaMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">El Segundo California [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseArrangementTypeAxis" xlink:type="locator" xlink:label="us-gaap_LeaseArrangementTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseArrangementTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease Arrangement, Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseArrangementTypeAxis" xlink:to="us-gaap_LeaseArrangementTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseArrangementTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lease Arrangement Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseArrangementTypeDomain" xlink:type="locator" xlink:label="us-gaap_LeaseArrangementTypeDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseArrangementTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease Arrangement, Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseArrangementTypeDomain" xlink:to="us-gaap_LeaseArrangementTypeDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseArrangementTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lease Arrangement Type [Domain]</link:label>
    <link:loc xlink:href="nk-20191231.xsd#nk_CommitmentWoburnMassachusettsMember" xlink:type="locator" xlink:label="nk_CommitmentWoburnMassachusettsMember" />
    <link:label xml:lang="en-US" xlink:label="nk_CommitmentWoburnMassachusettsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Commitment Woburn Massachusetts.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nk_CommitmentWoburnMassachusettsMember" xlink:to="nk_CommitmentWoburnMassachusettsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="nk_CommitmentWoburnMassachusettsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Woburn, Massachusetts</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_CommitmentWoburnMassachusettsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitment Woburn Massachusetts [Member]</link:label>
    <link:loc xlink:href="nk-20191231.xsd#nk_NantWorksLimitedLiabilityCompanyMember" xlink:type="locator" xlink:label="nk_NantWorksLimitedLiabilityCompanyMember" />
    <link:label xml:lang="en-US" xlink:label="nk_NantWorksLimitedLiabilityCompanyMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Nant Works LLC.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nk_NantWorksLimitedLiabilityCompanyMember" xlink:to="nk_NantWorksLimitedLiabilityCompanyMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="nk_NantWorksLimitedLiabilityCompanyMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">NantWorks</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_NantWorksLimitedLiabilityCompanyMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Nant Works Limited Liability Company [Member]</link:label>
    <link:loc xlink:href="nk-20191231.xsd#nk_CommitmentSanDiegoMember" xlink:type="locator" xlink:label="nk_CommitmentSanDiegoMember" />
    <link:label xml:lang="en-US" xlink:label="nk_CommitmentSanDiegoMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Commitment; San Diego.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nk_CommitmentSanDiegoMember" xlink:to="nk_CommitmentSanDiegoMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="nk_CommitmentSanDiegoMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitment; San Diego</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_CommitmentSanDiegoMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitment San Diego [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_CommitmentsAndContingenciesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments And Contingencies [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_CommitmentsAndContingenciesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:type="locator" xlink:label="us-gaap_LitigationSettlementAmountAwardedToOtherParty" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LitigationSettlementAmountAwardedToOtherParty_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Litigation settlement amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:to="us-gaap_LitigationSettlementAmountAwardedToOtherParty_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LitigationSettlementAmountAwardedToOtherParty_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Litigation Settlement Amount Awarded To Other Party</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LegalFees" xlink:type="locator" xlink:label="us-gaap_LegalFees" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LegalFees_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Attorney&apos;s fee to plaintiffs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LegalFees" xlink:to="us-gaap_LegalFees_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LegalFees_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Legal Fees</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InsuranceSettlementsReceivable" xlink:type="locator" xlink:label="us-gaap_InsuranceSettlementsReceivable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InsuranceSettlementsReceivable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Insurance claim receivable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InsuranceSettlementsReceivable" xlink:to="us-gaap_InsuranceSettlementsReceivable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InsuranceSettlementsReceivable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Insurance Settlements Receivable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsAndLiabilitiesLesseeAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsAndLiabilitiesLesseeAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsAndLiabilitiesLesseeAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets And Liabilities Lessee [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAndLiabilitiesLesseeAbstract" xlink:to="us-gaap_AssetsAndLiabilitiesLesseeAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel">Operating lease right-of-use assets, net</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Other current liabilities</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Operating lease liability, less current portion</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="locator" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase in operating lease right-of-use assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Right Of Use Asset Obtained In Exchange For Operating Lease Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseCost" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableLeaseCost" xlink:type="locator" xlink:label="us-gaap_VariableLeaseCost" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_VariableLeaseCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Variable lease costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableLeaseCost" xlink:to="us-gaap_VariableLeaseCost_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_VariableLeaseCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Variable Lease Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average remaining lease term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Weighted Average Remaining Lease Term1</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average discount rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Weighted Average Discount Rate Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:type="locator" xlink:label="us-gaap_OperatingLeasePayments" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash outflows from operating leases excluding variable lease cost</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Payments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2020</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due Next Twelve Months</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2021</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due Year Two</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2022</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due Year Three</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2023</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due Year Four</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2024</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due Year Five</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Thereafter</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due After Year Five</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total future minimum lease payments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Less: Interest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Undiscounted Excess Amount</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Present value of operating lease liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total future minimum lease payments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases Future Minimum Payments Due</link:label>
    <link:loc xlink:href="nk-20191231.xsd#nk_OperatingLeasePaymentsRelatedToOptionsToExtendLeaseTerms" xlink:type="locator" xlink:label="nk_OperatingLeasePaymentsRelatedToOptionsToExtendLeaseTerms" />
    <link:label xml:lang="en-US" xlink:label="nk_OperatingLeasePaymentsRelatedToOptionsToExtendLeaseTerms_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating lease payments related to options to extend lease terms.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nk_OperatingLeasePaymentsRelatedToOptionsToExtendLeaseTerms" xlink:to="nk_OperatingLeasePaymentsRelatedToOptionsToExtendLeaseTerms_lbl" />
    <link:label xml:lang="en-US" xlink:label="nk_OperatingLeasePaymentsRelatedToOptionsToExtendLeaseTerms_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease payments related to options to extend lease terms</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_OperatingLeasePaymentsRelatedToOptionsToExtendLeaseTerms_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Payments Related To Options To Extend Lease Terms</link:label>
    <link:loc xlink:href="nk-20191231.xsd#nk_RelatedPartyTransactionReimbursedUpfrontPaymentToThirdParty" xlink:type="locator" xlink:label="nk_RelatedPartyTransactionReimbursedUpfrontPaymentToThirdParty" />
    <link:label xml:lang="en-US" xlink:label="nk_RelatedPartyTransactionReimbursedUpfrontPaymentToThirdParty_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Related party transaction, Reimbursed upfront payment to third party.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nk_RelatedPartyTransactionReimbursedUpfrontPaymentToThirdParty" xlink:to="nk_RelatedPartyTransactionReimbursedUpfrontPaymentToThirdParty_lbl" />
    <link:loc xlink:href="nk-20191231.xsd#nk_RelatedPartyTransactionAmountPaidToRelatedParty" xlink:type="locator" xlink:label="nk_RelatedPartyTransactionAmountPaidToRelatedParty" />
    <link:label xml:lang="en-US" xlink:label="nk_RelatedPartyTransactionAmountPaidToRelatedParty_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Related party transaction, amount paid to related party.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nk_RelatedPartyTransactionAmountPaidToRelatedParty" xlink:to="nk_RelatedPartyTransactionAmountPaidToRelatedParty_lbl" />
    <link:loc xlink:href="nk-20191231.xsd#nk_RelatedPartyTransactionInitialTermOfAgreement" xlink:type="locator" xlink:label="nk_RelatedPartyTransactionInitialTermOfAgreement" />
    <link:label xml:lang="en-US" xlink:label="nk_RelatedPartyTransactionInitialTermOfAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Related party transaction initial term of agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nk_RelatedPartyTransactionInitialTermOfAgreement" xlink:to="nk_RelatedPartyTransactionInitialTermOfAgreement_lbl" />
    <link:loc xlink:href="nk-20191231.xsd#nk_RelatedPartyAgreementExpirationMonthAndYear" xlink:type="locator" xlink:label="nk_RelatedPartyAgreementExpirationMonthAndYear" />
    <link:label xml:lang="en-US" xlink:label="nk_RelatedPartyAgreementExpirationMonthAndYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Related party agreement expiration month and year.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nk_RelatedPartyAgreementExpirationMonthAndYear" xlink:to="nk_RelatedPartyAgreementExpirationMonthAndYear_lbl" />
    <link:label xml:lang="en-US" xlink:label="nk_RelatedPartyTransactionReimbursedUpfrontPaymentToThirdParty_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reimbursed upfront payment to third-party</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_RelatedPartyTransactionReimbursedUpfrontPaymentToThirdParty_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction Reimbursed Upfront Payment To Third Party</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_RelatedPartyTransactionAmountPaidToRelatedParty_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related party transaction, amount paid to third-party</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_RelatedPartyTransactionAmountPaidToRelatedParty_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction Amount Paid To Related Party</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related party transaction, aggregate value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:to="us-gaap_RelatedPartyTransactionAmountsOfTransaction_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction Amounts Of Transaction</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_RelatedPartyTransactionInitialTermOfAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Initial term of agreement entered into with the related party by the entity</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_RelatedPartyTransactionInitialTermOfAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction Initial Term Of Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_RelatedPartyAgreementExpirationMonthAndYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related party agreement expiration date</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_RelatedPartyAgreementExpirationMonthAndYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Agreement Expiration Month And Year</link:label>
    <link:loc xlink:href="nk-20191231.xsd#nk_PeriodOfExtendedLeaseTerm" xlink:type="locator" xlink:label="nk_PeriodOfExtendedLeaseTerm" />
    <link:label xml:lang="en-US" xlink:label="nk_PeriodOfExtendedLeaseTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Period of extended lease term.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nk_PeriodOfExtendedLeaseTerm" xlink:to="nk_PeriodOfExtendedLeaseTerm_lbl" />
    <link:loc xlink:href="nk-20191231.xsd#nk_BaseMonthlyRent" xlink:type="locator" xlink:label="nk_BaseMonthlyRent" />
    <link:label xml:lang="en-US" xlink:label="nk_BaseMonthlyRent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Base monthly rent.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nk_BaseMonthlyRent" xlink:to="nk_BaseMonthlyRent_lbl" />
    <link:loc xlink:href="nk-20191231.xsd#nk_AnnualPercentageIncreasesToBaseRent" xlink:type="locator" xlink:label="nk_AnnualPercentageIncreasesToBaseRent" />
    <link:label xml:lang="en-US" xlink:label="nk_AnnualPercentageIncreasesToBaseRent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Annual percentage increases to base rent.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nk_AnnualPercentageIncreasesToBaseRent" xlink:to="nk_AnnualPercentageIncreasesToBaseRent_lbl" />
    <link:loc xlink:href="nk-20191231.xsd#nk_AnnualPercentageIncreasesToBaseRentCommencementDate" xlink:type="locator" xlink:label="nk_AnnualPercentageIncreasesToBaseRentCommencementDate" />
    <link:label xml:lang="en-US" xlink:label="nk_AnnualPercentageIncreasesToBaseRentCommencementDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Annual percentage increases to base rent commencement date.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nk_AnnualPercentageIncreasesToBaseRentCommencementDate" xlink:to="nk_AnnualPercentageIncreasesToBaseRentCommencementDate_lbl" />
    <link:loc xlink:href="nk-20191231.xsd#nk_NumberOfSquareFootOfFacilityLeased" xlink:type="locator" xlink:label="nk_NumberOfSquareFootOfFacilityLeased" />
    <link:label xml:lang="en-US" xlink:label="nk_NumberOfSquareFootOfFacilityLeased_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of square foot of facility leased.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nk_NumberOfSquareFootOfFacilityLeased" xlink:to="nk_NumberOfSquareFootOfFacilityLeased_lbl" />
    <link:label xml:lang="en-US" xlink:label="nk_NumberOfSquareFootOfFacilityLeased_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of square foot of facility leased</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_NumberOfSquareFootOfFacilityLeased_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Square Foot Of Facility Leased</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseDescription_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Period of agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_PeriodOfExtendedLeaseTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Optional extended lease term</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_PeriodOfExtendedLeaseTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Period Of Extended Lease Term</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_BaseMonthlyRent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Base rent - monthly</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_BaseMonthlyRent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Base Monthly Rent</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_AnnualPercentageIncreasesToBaseRent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of annual increase of base rent</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_AnnualPercentageIncreasesToBaseRent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Annual Percentage Increases To Base Rent</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_AnnualPercentageIncreasesToBaseRentCommencementDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Annual percentage increases to base rent commencement date</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_AnnualPercentageIncreasesToBaseRentCommencementDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Annual Percentage Increases To Base Rent Commencement Date</link:label>
    <link:loc xlink:href="nk-20191231.xsd#nk_PeriodOfLicenseAgreementDescription" xlink:type="locator" xlink:label="nk_PeriodOfLicenseAgreementDescription" />
    <link:label xml:lang="en-US" xlink:label="nk_PeriodOfLicenseAgreementDescription_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Period of license agreement description.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nk_PeriodOfLicenseAgreementDescription" xlink:to="nk_PeriodOfLicenseAgreementDescription_lbl" />
    <link:loc xlink:href="nk-20191231.xsd#nk_LeaseCommencementDate" xlink:type="locator" xlink:label="nk_LeaseCommencementDate" />
    <link:label xml:lang="en-US" xlink:label="nk_LeaseCommencementDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Lease commencement date.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nk_LeaseCommencementDate" xlink:to="nk_LeaseCommencementDate_lbl" />
    <link:loc xlink:href="nk-20191231.xsd#nk_AdditionToNumberOfSquareFootOfFacilityLeased" xlink:type="locator" xlink:label="nk_AdditionToNumberOfSquareFootOfFacilityLeased" />
    <link:label xml:lang="en-US" xlink:label="nk_AdditionToNumberOfSquareFootOfFacilityLeased_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Addition to number of square foot of facility leased.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nk_AdditionToNumberOfSquareFootOfFacilityLeased" xlink:to="nk_AdditionToNumberOfSquareFootOfFacilityLeased_lbl" />
    <link:loc xlink:href="nk-20191231.xsd#nk_AnnualBaseRentIncreasePerSquareFoot" xlink:type="locator" xlink:label="nk_AnnualBaseRentIncreasePerSquareFoot" />
    <link:label xml:lang="en-US" xlink:label="nk_AnnualBaseRentIncreasePerSquareFoot_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Annual base rent increase per square foot.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nk_AnnualBaseRentIncreasePerSquareFoot" xlink:to="nk_AnnualBaseRentIncreasePerSquareFoot_lbl" />
    <link:loc xlink:href="nk-20191231.xsd#nk_LeaseAgreementExtendedPeriod" xlink:type="locator" xlink:label="nk_LeaseAgreementExtendedPeriod" />
    <link:label xml:lang="en-US" xlink:label="nk_LeaseAgreementExtendedPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Lease agreement extended period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nk_LeaseAgreementExtendedPeriod" xlink:to="nk_LeaseAgreementExtendedPeriod_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Initial term of lease arrangement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Term Of Contract</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_LeaseCommencementDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease commencement date</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_LeaseCommencementDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lease Commencement Date</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseExpirationDate1" xlink:type="locator" xlink:label="us-gaap_LeaseExpirationDate1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseExpirationDate1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease expiration date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseExpirationDate1" xlink:to="us-gaap_LeaseExpirationDate1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseExpirationDate1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lease Expiration Date1</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_AdditionToNumberOfSquareFootOfFacilityLeased_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Addition to number of square foot of facility leased</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_AdditionToNumberOfSquareFootOfFacilityLeased_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Addition To Number Of Square Foot Of Facility Leased</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_AnnualBaseRentIncreasePerSquareFoot_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Annual increase of base rent</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_AnnualBaseRentIncreasePerSquareFoot_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Annual Base Rent Increase Per Square Foot</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_PeriodOfLicenseAgreementDescription_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Period of agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_PeriodOfLicenseAgreementDescription_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Period Of License Agreement Description</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Optional extended lease term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Renewal Term</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_LeaseAgreementExtendedPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease agreement extended lease period</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_LeaseAgreementExtendedPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lease Agreement Extended Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesRentExpenseNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasesRentExpenseNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Rent expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesRentExpenseNet" xlink:to="us-gaap_OperatingLeasesRentExpenseNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasesRentExpenseNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases Rent Expense Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Related Party Transactions By Related Party [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Related Party Transactions By Related Party [Table]</link:label>
    <link:loc xlink:href="nk-20191231.xsd#nk_NantHealthLabsIncMember" xlink:type="locator" xlink:label="nk_NantHealthLabsIncMember" />
    <link:label xml:lang="en-US" xlink:label="nk_NantHealthLabsIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Nant Health Labs, Inc.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nk_NantHealthLabsIncMember" xlink:to="nk_NantHealthLabsIncMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="nk_NantHealthLabsIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">NantHealth Labs, Inc.</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_NantHealthLabsIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Nant Health Labs Inc [Member]</link:label>
    <link:loc xlink:href="nk-20191231.xsd#nk_ImmunoOncologyClinicIncMember" xlink:type="locator" xlink:label="nk_ImmunoOncologyClinicIncMember" />
    <link:label xml:lang="en-US" xlink:label="nk_ImmunoOncologyClinicIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Immuno Oncology Clinic Inc.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nk_ImmunoOncologyClinicIncMember" xlink:to="nk_ImmunoOncologyClinicIncMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="nk_ImmunoOncologyClinicIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Immuno-Oncology Clinic, Inc.</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_ImmunoOncologyClinicIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Immuno Oncology Clinic Inc [Member]</link:label>
    <link:loc xlink:href="nk-20191231.xsd#nk_TensorcomIncMember" xlink:type="locator" xlink:label="nk_TensorcomIncMember" />
    <link:label xml:lang="en-US" xlink:label="nk_TensorcomIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Tensorcom, Inc.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nk_TensorcomIncMember" xlink:to="nk_TensorcomIncMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="nk_TensorcomIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tensorcom, Inc</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_TensorcomIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Tensorcom Inc [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherIncomeMember" xlink:type="locator" xlink:label="us-gaap_OtherIncomeMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherIncomeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other Income</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherIncomeMember" xlink:to="us-gaap_OtherIncomeMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherIncomeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Income [Member]</link:label>
    <link:loc xlink:href="nk-20191231.xsd#nk_SanDiegoCaliforniaMember" xlink:type="locator" xlink:label="nk_SanDiegoCaliforniaMember" />
    <link:label xml:lang="en-US" xlink:label="nk_SanDiegoCaliforniaMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">San Diego California.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nk_SanDiegoCaliforniaMember" xlink:to="nk_SanDiegoCaliforniaMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="nk_SanDiegoCaliforniaMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">San Diego California</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_SanDiegoCaliforniaMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">San Diego California [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransactionTypeAxis" xlink:type="locator" xlink:label="us-gaap_TransactionTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TransactionTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Transaction Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransactionTypeAxis" xlink:to="us-gaap_TransactionTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TransactionTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Transaction Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransactionDomain" xlink:type="locator" xlink:label="us-gaap_TransactionDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TransactionDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Transaction</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransactionDomain" xlink:to="us-gaap_TransactionDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TransactionDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Transaction [Domain]</link:label>
    <link:loc xlink:href="nk-20191231.xsd#nk_ReimbursementsMember" xlink:type="locator" xlink:label="nk_ReimbursementsMember" />
    <link:label xml:lang="en-US" xlink:label="nk_ReimbursementsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Reimbursements.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nk_ReimbursementsMember" xlink:to="nk_ReimbursementsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="nk_ReimbursementsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reimbursements</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_ReimbursementsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Reimbursements [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Type Of Arrangement [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Arrangements And Nonarrangement Transactions [Member]</link:label>
    <link:loc xlink:href="nk-20191231.xsd#nk_SharedServicesAgreementMember" xlink:type="locator" xlink:label="nk_SharedServicesAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="nk_SharedServicesAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Shared services agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nk_SharedServicesAgreementMember" xlink:to="nk_SharedServicesAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="nk_SharedServicesAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shared Services Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_SharedServicesAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Shared Services Agreement [Member]</link:label>
    <link:loc xlink:href="nk-20191231.xsd#nk_NantOmicsLLCMember" xlink:type="locator" xlink:label="nk_NantOmicsLLCMember" />
    <link:label xml:lang="en-US" xlink:label="nk_NantOmicsLLCMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">NantOmics, LLC.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nk_NantOmicsLLCMember" xlink:to="nk_NantOmicsLLCMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="nk_NantOmicsLLCMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">NantOmics</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_NantOmicsLLCMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Nant Omics L L C [Member]</link:label>
    <link:loc xlink:href="nk-20191231.xsd#nk_ImmunityBioMember" xlink:type="locator" xlink:label="nk_ImmunityBioMember" />
    <link:label xml:lang="en-US" xlink:label="nk_ImmunityBioMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Immunity Bio.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nk_ImmunityBioMember" xlink:to="nk_ImmunityBioMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="nk_ImmunityBioMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ImmunityBio</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_ImmunityBioMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Immunity Bio [Member]</link:label>
    <link:loc xlink:href="nk-20191231.xsd#nk_VivaBioCellSPAMember" xlink:type="locator" xlink:label="nk_VivaBioCellSPAMember" />
    <link:label xml:lang="en-US" xlink:label="nk_VivaBioCellSPAMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">VivaBioCell S.p.A.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nk_VivaBioCellSPAMember" xlink:to="nk_VivaBioCellSPAMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="nk_VivaBioCellSPAMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">VivaBioCell S.p.A.</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_VivaBioCellSPAMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Viva Bio Cell S P A [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party Transaction [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Repurchase of common stock, shares</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Repurchase of common stock, value</link:label>
    <link:loc xlink:href="nk-20191231.xsd#nk_RelatedPartyAgreementRenewalTerm" xlink:type="locator" xlink:label="nk_RelatedPartyAgreementRenewalTerm" />
    <link:label xml:lang="en-US" xlink:label="nk_RelatedPartyAgreementRenewalTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Related party agreement renewal term.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nk_RelatedPartyAgreementRenewalTerm" xlink:to="nk_RelatedPartyAgreementRenewalTerm_lbl" />
    <link:label xml:lang="en-US" xlink:label="nk_RelatedPartyAgreementRenewalTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related party, agreement renewal term</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_RelatedPartyAgreementRenewalTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Agreement Renewal Term</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Research and development</link:label>
    <link:loc xlink:href="nk-20191231.xsd#nk_NumberOfOfficers" xlink:type="locator" xlink:label="nk_NumberOfOfficers" />
    <link:label xml:lang="en-US" xlink:label="nk_NumberOfOfficers_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of officers.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nk_NumberOfOfficers" xlink:to="nk_NumberOfOfficers_lbl" />
    <link:label xml:lang="en-US" xlink:label="nk_NumberOfOfficers_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of officers</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_NumberOfOfficers_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Officers</link:label>
    <link:loc xlink:href="nk-20191231.xsd#nk_InitialTermOfAgreement" xlink:type="locator" xlink:label="nk_InitialTermOfAgreement" />
    <link:label xml:lang="en-US" xlink:label="nk_InitialTermOfAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Initial term of agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nk_InitialTermOfAgreement" xlink:to="nk_InitialTermOfAgreement_lbl" />
    <link:label xml:lang="en-US" xlink:label="nk_InitialTermOfAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Initial term of agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_InitialTermOfAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Initial Term Of Agreement</link:label>
    <link:loc xlink:href="nk-20191231.xsd#nk_RelatedPartyInstallmentPayment" xlink:type="locator" xlink:label="nk_RelatedPartyInstallmentPayment" />
    <link:label xml:lang="en-US" xlink:label="nk_RelatedPartyInstallmentPayment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Related party installment payment.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nk_RelatedPartyInstallmentPayment" xlink:to="nk_RelatedPartyInstallmentPayment_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Estimated cost for new agreement with clinic</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_RelatedPartyInstallmentPayment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related party transaction installment payment</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_RelatedPartyInstallmentPayment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Installment Payment</link:label>
    <link:loc xlink:href="nk-20191231.xsd#nk_RelatedPartyTransactionAgreementExtensionDescription" xlink:type="locator" xlink:label="nk_RelatedPartyTransactionAgreementExtensionDescription" />
    <link:label xml:lang="en-US" xlink:label="nk_RelatedPartyTransactionAgreementExtensionDescription_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Related party transaction agreement extension description.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nk_RelatedPartyTransactionAgreementExtensionDescription" xlink:to="nk_RelatedPartyTransactionAgreementExtensionDescription_lbl" />
    <link:loc xlink:href="nk-20191231.xsd#nk_NewAgreementTerminationNoticePeriod" xlink:type="locator" xlink:label="nk_NewAgreementTerminationNoticePeriod" />
    <link:label xml:lang="en-US" xlink:label="nk_NewAgreementTerminationNoticePeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">New agreement termination notice period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nk_NewAgreementTerminationNoticePeriod" xlink:to="nk_NewAgreementTerminationNoticePeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="nk_RelatedPartyTransactionAgreementExtensionDescription_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Prepayments remain unearned extension description</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_RelatedPartyTransactionAgreementExtensionDescription_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction Agreement Extension Description</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_NewAgreementTerminationNoticePeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Notice period to terminate new agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_NewAgreementTerminationNoticePeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">New Agreement Termination Notice Period</link:label>
    <link:loc xlink:href="nk-20191231.xsd#nk_PrepaidBalanceIncludedInPrepaidExpensesAndOtherCurrentAssetsAndOtherAssets" xlink:type="locator" xlink:label="nk_PrepaidBalanceIncludedInPrepaidExpensesAndOtherCurrentAssetsAndOtherAssets" />
    <link:label xml:lang="en-US" xlink:label="nk_PrepaidBalanceIncludedInPrepaidExpensesAndOtherCurrentAssetsAndOtherAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Prepaid balance included in prepaid expenses and other current assets and other assets.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nk_PrepaidBalanceIncludedInPrepaidExpensesAndOtherCurrentAssetsAndOtherAssets" xlink:to="nk_PrepaidBalanceIncludedInPrepaidExpensesAndOtherCurrentAssetsAndOtherAssets_lbl" />
    <link:label xml:lang="en-US" xlink:label="nk_PrepaidBalanceIncludedInPrepaidExpensesAndOtherCurrentAssetsAndOtherAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid balance included in prepaid expenses and other current assets and other assets</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_PrepaidBalanceIncludedInPrepaidExpensesAndOtherCurrentAssetsAndOtherAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Balance Included In Prepaid Expenses And Other Current Assets And Other Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionDescriptionOfTransaction" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDescriptionOfTransaction" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionDescriptionOfTransaction_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Period of agreement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionDescriptionOfTransaction" xlink:to="us-gaap_RelatedPartyTransactionDescriptionOfTransaction_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionDescriptionOfTransaction_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction Description Of Transaction</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesIncomeStatementSubleaseRevenue" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesIncomeStatementSubleaseRevenue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasesIncomeStatementSubleaseRevenue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sublease revenue recognized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesIncomeStatementSubleaseRevenue" xlink:to="us-gaap_OperatingLeasesIncomeStatementSubleaseRevenue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasesIncomeStatementSubleaseRevenue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases Income Statement Sublease Revenue</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionDueFromToRelatedParty" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDueFromToRelatedParty" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionDueFromToRelatedParty_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Due between parties</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionDueFromToRelatedParty" xlink:to="us-gaap_RelatedPartyTransactionDueFromToRelatedParty_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionDueFromToRelatedParty_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction Due From To Related Party</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseExpense" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Expense</link:label>
    <link:loc xlink:href="nk-20191231.xsd#nk_RelatedPartyTransactionReimbursedUpfrontPaymentToRelatedParty" xlink:type="locator" xlink:label="nk_RelatedPartyTransactionReimbursedUpfrontPaymentToRelatedParty" />
    <link:label xml:lang="en-US" xlink:label="nk_RelatedPartyTransactionReimbursedUpfrontPaymentToRelatedParty_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Related party transaction reimbursed upfront payment to related party.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nk_RelatedPartyTransactionReimbursedUpfrontPaymentToRelatedParty" xlink:to="nk_RelatedPartyTransactionReimbursedUpfrontPaymentToRelatedParty_lbl" />
    <link:loc xlink:href="nk-20191231.xsd#nk_RelatedPartyTransactionAmountPaidToThirdParty" xlink:type="locator" xlink:label="nk_RelatedPartyTransactionAmountPaidToThirdParty" />
    <link:label xml:lang="en-US" xlink:label="nk_RelatedPartyTransactionAmountPaidToThirdParty_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Related party transaction, amount paid to third-party.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nk_RelatedPartyTransactionAmountPaidToThirdParty" xlink:to="nk_RelatedPartyTransactionAmountPaidToThirdParty_lbl" />
    <link:label xml:lang="en-US" xlink:label="nk_RelatedPartyTransactionReimbursedUpfrontPaymentToRelatedParty_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related party transaction,reimbursement payment to a related-party</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_RelatedPartyTransactionReimbursedUpfrontPaymentToRelatedParty_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction Reimbursed Upfront Payment To Related Party</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_RelatedPartyTransactionAmountPaidToThirdParty_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related party transaction, amount paid to third-party</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_RelatedPartyTransactionAmountPaidToThirdParty_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction Amount Paid To Third Party</link:label>
    <link:loc xlink:href="nk-20191231.xsd#nk_ResearchAndDevelopmentExpenseRatablePaymentPeriod" xlink:type="locator" xlink:label="nk_ResearchAndDevelopmentExpenseRatablePaymentPeriod" />
    <link:label xml:lang="en-US" xlink:label="nk_ResearchAndDevelopmentExpenseRatablePaymentPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Research and development expense ratable payment period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nk_ResearchAndDevelopmentExpenseRatablePaymentPeriod" xlink:to="nk_ResearchAndDevelopmentExpenseRatablePaymentPeriod_lbl" />
    <link:loc xlink:href="nk-20191231.xsd#nk_PrepaymentOfFundingAmount" xlink:type="locator" xlink:label="nk_PrepaymentOfFundingAmount" />
    <link:label xml:lang="en-US" xlink:label="nk_PrepaymentOfFundingAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Prepayment of funding amount.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nk_PrepaymentOfFundingAmount" xlink:to="nk_PrepaymentOfFundingAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="nk_ResearchAndDevelopmentExpenseRatablePaymentPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development expense, ratable payment period</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_ResearchAndDevelopmentExpenseRatablePaymentPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expense Ratable Payment Period</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_PrepaymentOfFundingAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepayment for services amount</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_PrepaymentOfFundingAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Prepayment Of Funding Amount</link:label>
    <link:loc xlink:href="nk-20191231.xsd#nk_TransferOfDepositAmountToThirdParty" xlink:type="locator" xlink:label="nk_TransferOfDepositAmountToThirdParty" />
    <link:label xml:lang="en-US" xlink:label="nk_TransferOfDepositAmountToThirdParty_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Transfer of deposit amount to third party.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nk_TransferOfDepositAmountToThirdParty" xlink:to="nk_TransferOfDepositAmountToThirdParty_lbl" />
    <link:label xml:lang="en-US" xlink:label="nk_TransferOfDepositAmountToThirdParty_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Transfer of deposit amount to third party</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_TransferOfDepositAmountToThirdParty_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Transfer Of Deposit Amount To Third Party</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Selling, general and administrative expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:type="locator" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loss on disposal of assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Gain Loss On Sale Of Property Plant Equipment</link:label>
    <link:loc xlink:href="nk-20191231.xsd#nk_PrepaidExpensesAndOtherAssetsCurrentWithRelatedParty" xlink:type="locator" xlink:label="nk_PrepaidExpensesAndOtherAssetsCurrentWithRelatedParty" />
    <link:label xml:lang="en-US" xlink:label="nk_PrepaidExpensesAndOtherAssetsCurrentWithRelatedParty_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Prepaid expenses and other assets current with related party.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nk_PrepaidExpensesAndOtherAssetsCurrentWithRelatedParty" xlink:to="nk_PrepaidExpensesAndOtherAssetsCurrentWithRelatedParty_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related parties, capitalized equipment amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" xlink:to="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction Purchases From Related Party</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_PrepaidExpensesAndOtherAssetsCurrentWithRelatedParty_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid expenses and other current assets</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_PrepaidExpensesAndOtherAssetsCurrentWithRelatedParty_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expenses And Other Assets Current With Related Party</link:label>
    <link:loc xlink:href="nk-20191231.xsd#nk_StockRepurchasedAndRetiredExcludingCommissionDuringPeriodValue" xlink:type="locator" xlink:label="nk_StockRepurchasedAndRetiredExcludingCommissionDuringPeriodValue" />
    <link:label xml:lang="en-US" xlink:label="nk_StockRepurchasedAndRetiredExcludingCommissionDuringPeriodValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock repurchased and retired excluding commission during period value.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nk_StockRepurchasedAndRetiredExcludingCommissionDuringPeriodValue" xlink:to="nk_StockRepurchasedAndRetiredExcludingCommissionDuringPeriodValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="nk_StockRepurchasedAndRetiredExcludingCommissionDuringPeriodValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Repurchase of common stock excluding commissions, value</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_StockRepurchasedAndRetiredExcludingCommissionDuringPeriodValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Repurchased And Retired Excluding Commission During Period Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SalesCommissionsAndFees" xlink:type="locator" xlink:label="us-gaap_SalesCommissionsAndFees" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SalesCommissionsAndFees_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Broker commissions on repurchases</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesCommissionsAndFees" xlink:to="us-gaap_SalesCommissionsAndFees_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SalesCommissionsAndFees_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sales Commissions And Fees</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:type="locator" xlink:label="us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Remaining authorized repurchase amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:to="us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Repurchase Program Remaining Authorized Repurchase Amount1</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Stock By Class [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Stock By Class [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AwardTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AwardTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Award Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Outstanding Stock Options</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Outstanding RSUs</link:label>
    <link:loc xlink:href="nk-20191231.xsd#nk_OutstandingOfficerWarrantsMember" xlink:type="locator" xlink:label="nk_OutstandingOfficerWarrantsMember" />
    <link:label xml:lang="en-US" xlink:label="nk_OutstandingOfficerWarrantsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Outstanding officer warrants.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nk_OutstandingOfficerWarrantsMember" xlink:to="nk_OutstandingOfficerWarrantsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="nk_OutstandingOfficerWarrantsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Outstanding Warrants</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_OutstandingOfficerWarrantsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Outstanding Officer Warrants [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class Of Stock [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Stock [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total shares reserved for future issuance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Capital Shares Reserved For Future Issuance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Domain]</link:label>
    <link:loc xlink:href="nk-20191231.xsd#nk_TwoThousandFourteenEquityIncentivePlanMember" xlink:type="locator" xlink:label="nk_TwoThousandFourteenEquityIncentivePlanMember" />
    <link:label xml:lang="en-US" xlink:label="nk_TwoThousandFourteenEquityIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand fourteen equity incentive plan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nk_TwoThousandFourteenEquityIncentivePlanMember" xlink:to="nk_TwoThousandFourteenEquityIncentivePlanMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="nk_TwoThousandFourteenEquityIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2014 Equity Incentive Plan</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_TwoThousandFourteenEquityIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Fourteen Equity Incentive Plan [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonClassAMember" xlink:type="locator" xlink:label="us-gaap_CommonClassAMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonClassAMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Class A</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonClassAMember" xlink:to="us-gaap_CommonClassAMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonClassAMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Class A [Member]</link:label>
    <link:loc xlink:href="nk-20191231.xsd#nk_TwoThousandFifteenEquityIncentivePlanMember" xlink:type="locator" xlink:label="nk_TwoThousandFifteenEquityIncentivePlanMember" />
    <link:label xml:lang="en-US" xlink:label="nk_TwoThousandFifteenEquityIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand fifteen equity incentive plan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nk_TwoThousandFifteenEquityIncentivePlanMember" xlink:to="nk_TwoThousandFifteenEquityIncentivePlanMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="nk_TwoThousandFifteenEquityIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2015 Equity Incentive Plan</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_TwoThousandFifteenEquityIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Fifteen Equity Incentive Plan [Member]</link:label>
    <link:loc xlink:href="nk-20191231.xsd#nk_KeyExecutivesStockOptionsMember" xlink:type="locator" xlink:label="nk_KeyExecutivesStockOptionsMember" />
    <link:label xml:lang="en-US" xlink:label="nk_KeyExecutivesStockOptionsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Key executives stock options.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nk_KeyExecutivesStockOptionsMember" xlink:to="nk_KeyExecutivesStockOptionsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="nk_KeyExecutivesStockOptionsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Key Executives Stock Options</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_KeyExecutivesStockOptionsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Key Executives Stock Options [Member]</link:label>
    <link:loc xlink:href="nk-20191231.xsd#nk_NonEmployeeStockOptionsMember" xlink:type="locator" xlink:label="nk_NonEmployeeStockOptionsMember" />
    <link:label xml:lang="en-US" xlink:label="nk_NonEmployeeStockOptionsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Non employee stock options.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nk_NonEmployeeStockOptionsMember" xlink:to="nk_NonEmployeeStockOptionsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="nk_NonEmployeeStockOptionsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non Employee Stock Options</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_NonEmployeeStockOptionsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Non Employee Stock Options [Member]</link:label>
    <link:loc xlink:href="nk-20191231.xsd#nk_NonEmployeeRestrictedStockUnitMember" xlink:type="locator" xlink:label="nk_NonEmployeeRestrictedStockUnitMember" />
    <link:label xml:lang="en-US" xlink:label="nk_NonEmployeeRestrictedStockUnitMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Non employee restricted stock unit.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nk_NonEmployeeRestrictedStockUnitMember" xlink:to="nk_NonEmployeeRestrictedStockUnitMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="nk_NonEmployeeRestrictedStockUnitMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non Employee Restricted Stock Units</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_NonEmployeeRestrictedStockUnitMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Non Employee Restricted Stock Unit [Member]</link:label>
    <link:loc xlink:href="nk-20191231.xsd#nk_EmployeeRestrictedStockUnitMember" xlink:type="locator" xlink:label="nk_EmployeeRestrictedStockUnitMember" />
    <link:label xml:lang="en-US" xlink:label="nk_EmployeeRestrictedStockUnitMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Employee restricted stock unit.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nk_EmployeeRestrictedStockUnitMember" xlink:to="nk_EmployeeRestrictedStockUnitMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="nk_EmployeeRestrictedStockUnitMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee Restricted Stock Units</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_EmployeeRestrictedStockUnitMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Restricted Stock Unit [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock reserved for issuance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based compensation, expiration period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional common shares reserved for future issuance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized</link:label>
    <link:loc xlink:href="nk-20191231.xsd#nk_ShareBasedCompensationArrangementByShareBasedPaymentAwardPossibleIncreaseInNumberOfSharesReservedForIssuance" xlink:type="locator" xlink:label="nk_ShareBasedCompensationArrangementByShareBasedPaymentAwardPossibleIncreaseInNumberOfSharesReservedForIssuance" />
    <link:label xml:lang="en-US" xlink:label="nk_ShareBasedCompensationArrangementByShareBasedPaymentAwardPossibleIncreaseInNumberOfSharesReservedForIssuance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of additional shares that may be added to shares reserved for issuance under an established share-based compensation plan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nk_ShareBasedCompensationArrangementByShareBasedPaymentAwardPossibleIncreaseInNumberOfSharesReservedForIssuance" xlink:to="nk_ShareBasedCompensationArrangementByShareBasedPaymentAwardPossibleIncreaseInNumberOfSharesReservedForIssuance_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock reserved for future grants</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_ShareBasedCompensationArrangementByShareBasedPaymentAwardPossibleIncreaseInNumberOfSharesReservedForIssuance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional Shares that may be added to shares reserved for issuance</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_ShareBasedCompensationArrangementByShareBasedPaymentAwardPossibleIncreaseInNumberOfSharesReservedForIssuance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Possible Increase In Number Of Shares Reserved For Issuance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockCompensationPlanMember" xlink:type="locator" xlink:label="us-gaap_StockCompensationPlanMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockCompensationPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants For Common Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockCompensationPlanMember" xlink:to="us-gaap_StockCompensationPlanMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockCompensationPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Compensation Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_EmployeeRestrictedStockUnitMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Employee RSUs</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_NonEmployeeRestrictedStockUnitMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Non-employee RSUs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_OfficerMember" xlink:type="locator" xlink:label="srt_OfficerMember" />
    <link:label xml:lang="en-US" xlink:label="srt_OfficerMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Officer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_OfficerMember" xlink:to="srt_OfficerMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_OfficerMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Officer [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Allocated Share Based Compensation Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Roll Forward</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Stock Options, Beginning Balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Stock Options, Options exercised</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel">Stock Options, Options granted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Stock Options, Ending Balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Stock Options, Vested and Exercisable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price Rollforward</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Weighted Average Exercise Price, Outstanding Beginning balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price, Options exercised</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price, Options granted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted Average Exercise Price, Outstanding Ending balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price, Vested and Exercisable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="nk-20191231.xsd#nk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:type="locator" xlink:label="nk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" />
    <link:label xml:lang="en-US" xlink:label="nk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share-based payment award, options, aggregate intrinsic value.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:to="nk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="nk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Aggregate Intrinsic Value [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Aggregate Intrinsic Value, Outstanding, Beginning balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Aggregate Intrinsic Value, Outstanding, Ending balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value, Vested and Exercisable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Remaining Contractual Life</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Remaining Contractual Life, Outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Remaining Contractual Life, Vested and Exercisable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1</link:label>
    <link:loc xlink:href="nk-20191231.xsd#nk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableOutstandingNumber" xlink:type="locator" xlink:label="nk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableOutstandingNumber" />
    <link:label xml:lang="en-US" xlink:label="nk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">As of the balance sheet date, the number of shares into which fully vested and exercisable stock options outstanding can be converted under the option plan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableOutstandingNumber" xlink:to="nk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableOutstandingNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="nk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock options, vested and exercisable</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Exercisable Outstanding Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Share Based Compensation Shares Authorized Under Stock Option Plans By Exercise Price Range [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Compensation Shares Authorized Under Stock Option Plans By Exercise Price Range [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise Price Range</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Shares Authorized Under Stock Option Plans By Exercise Price Range [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise Price Range</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Domain]</link:label>
    <link:loc xlink:href="nk-20191231.xsd#nk_ExercisePriceRangeOneMember" xlink:type="locator" xlink:label="nk_ExercisePriceRangeOneMember" />
    <link:label xml:lang="en-US" xlink:label="nk_ExercisePriceRangeOneMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Exercise price range one.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nk_ExercisePriceRangeOneMember" xlink:to="nk_ExercisePriceRangeOneMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="nk_ExercisePriceRangeOneMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">$0.42</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_ExercisePriceRangeOneMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Exercise Price Range One [Member]</link:label>
    <link:loc xlink:href="nk-20191231.xsd#nk_ExercisePriceRangeTwoMember" xlink:type="locator" xlink:label="nk_ExercisePriceRangeTwoMember" />
    <link:label xml:lang="en-US" xlink:label="nk_ExercisePriceRangeTwoMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Exercise price range two.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nk_ExercisePriceRangeTwoMember" xlink:to="nk_ExercisePriceRangeTwoMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="nk_ExercisePriceRangeTwoMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">$1.76</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_ExercisePriceRangeTwoMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Exercise Price Range Two [Member]</link:label>
    <link:loc xlink:href="nk-20191231.xsd#nk_ExercisePriceRangeThreeMember" xlink:type="locator" xlink:label="nk_ExercisePriceRangeThreeMember" />
    <link:label xml:lang="en-US" xlink:label="nk_ExercisePriceRangeThreeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Exercise price range three.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nk_ExercisePriceRangeThreeMember" xlink:to="nk_ExercisePriceRangeThreeMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="nk_ExercisePriceRangeThreeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">$2.00</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_ExercisePriceRangeThreeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Exercise Price Range Three [Member]</link:label>
    <link:loc xlink:href="nk-20191231.xsd#nk_ExercisePriceRangeFourMember" xlink:type="locator" xlink:label="nk_ExercisePriceRangeFourMember" />
    <link:label xml:lang="en-US" xlink:label="nk_ExercisePriceRangeFourMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Exercise price range four.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nk_ExercisePriceRangeFourMember" xlink:to="nk_ExercisePriceRangeFourMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="nk_ExercisePriceRangeFourMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">$3.07</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_ExercisePriceRangeFourMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Exercise Price Range Four [Member]</link:label>
    <link:loc xlink:href="nk-20191231.xsd#nk_ExercisePriceRangeFiveMember" xlink:type="locator" xlink:label="nk_ExercisePriceRangeFiveMember" />
    <link:label xml:lang="en-US" xlink:label="nk_ExercisePriceRangeFiveMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Exercise price range five.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nk_ExercisePriceRangeFiveMember" xlink:to="nk_ExercisePriceRangeFiveMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="nk_ExercisePriceRangeFiveMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">$25.00</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_ExercisePriceRangeFiveMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Exercise Price Range Five [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise Prices</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options Outstanding, Number Outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options Outstanding, Weighted- Average Remaining Contractual Life (in years)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Options Outstanding, Number Exercisable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Options Outstanding, Weighted- Average Remaining Contractual Life (in years)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate intrinsic value of stock options exercised</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Cash received from exercised options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Stock Options Exercised</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares granted to employee</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Exercise price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based compensation arrangement, award vesting rights, percentage</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Award Vesting Rights Percentage</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Remaining vesting period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized compensation cost related to non-vested stock options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average period for recognition</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1</link:label>
    <link:loc xlink:href="nk-20191231.xsd#nk_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsPrice" xlink:type="locator" xlink:label="nk_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsPrice" />
    <link:label xml:lang="en-US" xlink:label="nk_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsPrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award fair value assumptions price.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nk_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsPrice" xlink:to="nk_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsPrice_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected term (years)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Dividend yield</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsPrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average measurement date fair value</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsPrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Number of Shares, Unvested, Beginning balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel">Number of Shares, Granted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of Shares, Vested</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of Shares, Forfeited/Canceled</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Number of Shares, Unvested, Ending balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Weighted-Average Grant Date Fair Value, Unvested, beginning balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Grant Date Fair Value, Granted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Grant Date Fair Value, Vested</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Grant Date Fair Value, Forfeited/Canceled</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted-Average Grant Date Fair Value, Unvested, ending balance</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Grants of restricted stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized compensation cost related to non-vested stock options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Share Based Awards Other Than Options</link:label>
    <link:loc xlink:href="nk-20191231.xsd#nk_StockIssuedDuringPeriodSharesWarrantsExpired" xlink:type="locator" xlink:label="nk_StockIssuedDuringPeriodSharesWarrantsExpired" />
    <link:label xml:lang="en-US" xlink:label="nk_StockIssuedDuringPeriodSharesWarrantsExpired_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period shares warrants expired.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nk_StockIssuedDuringPeriodSharesWarrantsExpired" xlink:to="nk_StockIssuedDuringPeriodSharesWarrantsExpired_lbl" />
    <link:loc xlink:href="nk-20191231.xsd#nk_ClassOfWarrantOrVestedAndExercisable" xlink:type="locator" xlink:label="nk_ClassOfWarrantOrVestedAndExercisable" />
    <link:label xml:lang="en-US" xlink:label="nk_ClassOfWarrantOrVestedAndExercisable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Vested and exercisable.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nk_ClassOfWarrantOrVestedAndExercisable" xlink:to="nk_ClassOfWarrantOrVestedAndExercisable_lbl" />
    <link:loc xlink:href="nk-20191231.xsd#nk_WarrantLineItems" xlink:type="locator" xlink:label="nk_WarrantLineItems" />
    <link:label xml:lang="en-US" xlink:label="nk_WarrantLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Warrant.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nk_WarrantLineItems" xlink:to="nk_WarrantLineItems_lbl" />
    <link:loc xlink:href="nk-20191231.xsd#nk_WarrantTable" xlink:type="locator" xlink:label="nk_WarrantTable" />
    <link:label xml:lang="en-US" xlink:label="nk_WarrantTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Warrant.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nk_WarrantTable" xlink:to="nk_WarrantTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="nk_WarrantTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrant [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_WarrantTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Warrant [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_WarrantLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrant [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_WarrantLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Warrant [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Number of shares Warrants, Beginning Balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Or Right Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_StockIssuedDuringPeriodSharesWarrantsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of shares Warrants exercised</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_StockIssuedDuringPeriodSharesWarrantsExpired_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of shares Warrants expired</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_StockIssuedDuringPeriodSharesWarrantsExpired_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Warrants Expired</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Number of shares Warrants, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_ClassOfWarrantOrVestedAndExercisable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares Warrants, Vested and exercisable Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_ClassOfWarrantOrVestedAndExercisable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Or Vested And Exercisable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:type="locator" xlink:label="us-gaap_ProceedsFromWarrantExercises" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from exercises of warrants</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Warrant Exercises</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U.S. loss before taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Loss From Continuing Operations Before Income Taxes Domestic</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign loss before taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Loss From Continuing Operations Before Income Taxes Foreign</link:label>
    <link:loc xlink:href="nk-20191231.xsd#nk_DeferredIncomeTaxExpenseBenefitNet" xlink:type="locator" xlink:label="nk_DeferredIncomeTaxExpenseBenefitNet" />
    <link:label xml:lang="en-US" xlink:label="nk_DeferredIncomeTaxExpenseBenefitNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred income tax expense benefit, net.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nk_DeferredIncomeTaxExpenseBenefitNet" xlink:to="nk_DeferredIncomeTaxExpenseBenefitNet_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:type="locator" xlink:label="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Current Federal State And Local Tax Expense Benefit [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Current Federal Tax Expense Benefit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Current State And Local Tax Expense Benefit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentForeignTaxExpenseBenefit" xlink:to="us-gaap_CurrentForeignTaxExpenseBenefit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Current Foreign Tax Expense Benefit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Current Income Tax Expense Benefit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:type="locator" xlink:label="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Federal State And Local Tax Expense Benefit [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Federal Income Tax Expense Benefit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred State And Local Income Tax Expense Benefit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredForeignIncomeTaxExpenseBenefit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Foreign Income Tax Expense Benefit</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_DeferredIncomeTaxExpenseBenefitNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total Deferred</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_DeferredIncomeTaxExpenseBenefitNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Income Tax Expense Benefit Net</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Income tax benefit</link:label>
    <link:loc xlink:href="nk-20191231.xsd#nk_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:type="locator" xlink:label="nk_DeferredTaxAssetsOperatingLeaseLiabilities" />
    <link:label xml:lang="en-US" xlink:label="nk_DeferredTaxAssetsOperatingLeaseLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets operating lease liabilities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nk_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:to="nk_DeferredTaxAssetsOperatingLeaseLiabilities_lbl" />
    <link:loc xlink:href="nk-20191231.xsd#nk_DeferredTaxAssetsDeferredDepreciationAndAmortization" xlink:type="locator" xlink:label="nk_DeferredTaxAssetsDeferredDepreciationAndAmortization" />
    <link:label xml:lang="en-US" xlink:label="nk_DeferredTaxAssetsDeferredDepreciationAndAmortization_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets deferred depreciation and amortization.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nk_DeferredTaxAssetsDeferredDepreciationAndAmortization" xlink:to="nk_DeferredTaxAssetsDeferredDepreciationAndAmortization_lbl" />
    <link:loc xlink:href="nk-20191231.xsd#nk_DeferredTaxAssetsLeasesAndOtherAccruedLiabilities" xlink:type="locator" xlink:label="nk_DeferredTaxAssetsLeasesAndOtherAccruedLiabilities" />
    <link:label xml:lang="en-US" xlink:label="nk_DeferredTaxAssetsLeasesAndOtherAccruedLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets leases and other accrued liabilities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nk_DeferredTaxAssetsLeasesAndOtherAccruedLiabilities" xlink:to="nk_DeferredTaxAssetsLeasesAndOtherAccruedLiabilities_lbl" />
    <link:loc xlink:href="nk-20191231.xsd#nk_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" xlink:type="locator" xlink:label="nk_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" />
    <link:label xml:lang="en-US" xlink:label="nk_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax liabilities operating lease right of use assets.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nk_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" xlink:to="nk_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets_lbl" />
    <link:loc xlink:href="nk-20191231.xsd#nk_DeferredTaxLiabilitiesDeferredDepreciationAndAmortization" xlink:type="locator" xlink:label="nk_DeferredTaxLiabilitiesDeferredDepreciationAndAmortization" />
    <link:label xml:lang="en-US" xlink:label="nk_DeferredTaxLiabilitiesDeferredDepreciationAndAmortization_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax liabilities deferred depreciation and amortization.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nk_DeferredTaxLiabilitiesDeferredDepreciationAndAmortization" xlink:to="nk_DeferredTaxLiabilitiesDeferredDepreciationAndAmortization_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax assets:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Net [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforwards</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Operating Loss Carryforwards</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_DeferredTaxAssetsOperatingLeaseLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liabilities</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_DeferredTaxAssetsOperatingLeaseLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Operating Lease Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_DeferredTaxAssetsDeferredDepreciationAndAmortization_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation and amortization</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_DeferredTaxAssetsDeferredDepreciationAndAmortization_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Deferred Depreciation And Amortization</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax credits</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Tax Credit Carryforwards</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Compensation</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_DeferredTaxAssetsLeasesAndOtherAccruedLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leases and other accrued liabilities</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_DeferredTaxAssetsLeasesAndOtherAccruedLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Leases And Other Accrued Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLegalSettlements" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLegalSettlements" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLegalSettlements_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued legal expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLegalSettlements" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLegalSettlements_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLegalSettlements_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Legal Settlements</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total deferred tax assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax liabilities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesNetAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities Net [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Foreign intangibles</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:to="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Operating lease right-of-use assets</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities Operating Lease Right Of Use Assets</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_DeferredTaxLiabilitiesDeferredDepreciationAndAmortization_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Depreciation and amortization</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_DeferredTaxLiabilitiesDeferredDepreciationAndAmortization_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities Deferred Depreciation And Amortization</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxLiabilities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel">Total deferred tax liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Income Tax Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net deferred tax assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Liabilities Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Valuation allowance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Valuation Allowance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel">Net deferred tax liability</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities</link:label>
    <link:loc xlink:href="nk-20191231.xsd#nk_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsAct" xlink:type="locator" xlink:label="nk_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsAct" />
    <link:label xml:lang="en-US" xlink:label="nk_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsAct_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Effective income tax rate reconciliation Tax Cuts and Jobs Act.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nk_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsAct" xlink:to="nk_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsAct_lbl" />
    <link:loc xlink:href="nk-20191231.xsd#nk_EffectiveIncomeTaxRateReconciliationStockBasedCompensationContribution" xlink:type="locator" xlink:label="nk_EffectiveIncomeTaxRateReconciliationStockBasedCompensationContribution" />
    <link:label xml:lang="en-US" xlink:label="nk_EffectiveIncomeTaxRateReconciliationStockBasedCompensationContribution_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Effective income tax rate reconciliation stock based compensation contribution.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nk_EffectiveIncomeTaxRateReconciliationStockBasedCompensationContribution" xlink:to="nk_EffectiveIncomeTaxRateReconciliationStockBasedCompensationContribution_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Tax computed at federal statutory rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State income taxes, net of federal tax benefit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation State And Local Income Taxes</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax rate adjustment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Tax Settlements</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsAct_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax Cuts and Jobs Act</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsAct_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Tax Cuts And Jobs Act</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development credits</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_EffectiveIncomeTaxRateReconciliationStockBasedCompensationContribution_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_EffectiveIncomeTaxRateReconciliationStockBasedCompensationContribution_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Stock Based Compensation Contribution</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Deductions Other</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Valuation allowance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Effective income tax rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Continuing Operations</link:label>
    <link:loc xlink:href="nk-20191231.xsd#nk_TaxCutsAndJobsActOf2017IncompleteAccountingChangeInTaxRateMinimumAmountForEliminationOfSeveralBusinessDeductionsAndCreditsIncludingDeductionsForCertainExecutiveCompensation" xlink:type="locator" xlink:label="nk_TaxCutsAndJobsActOf2017IncompleteAccountingChangeInTaxRateMinimumAmountForEliminationOfSeveralBusinessDeductionsAndCreditsIncludingDeductionsForCertainExecutiveCompensation" />
    <link:label xml:lang="en-US" xlink:label="nk_TaxCutsAndJobsActOf2017IncompleteAccountingChangeInTaxRateMinimumAmountForEliminationOfSeveralBusinessDeductionsAndCreditsIncludingDeductionsForCertainExecutiveCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Tax cuts and jobs act of 2017 incomplete accounting change in tax rate minimum amount for elimination of several business deductions and credits including deductions for certain executive compensation.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nk_TaxCutsAndJobsActOf2017IncompleteAccountingChangeInTaxRateMinimumAmountForEliminationOfSeveralBusinessDeductionsAndCreditsIncludingDeductionsForCertainExecutiveCompensation" xlink:to="nk_TaxCutsAndJobsActOf2017IncompleteAccountingChangeInTaxRateMinimumAmountForEliminationOfSeveralBusinessDeductionsAndCreditsIncludingDeductionsForCertainExecutiveCompensation_lbl" />
    <link:loc xlink:href="nk-20191231.xsd#nk_TaxCutsAndJobsActOf2017IncompleteAccountingChangeInTaxRateReductionInDeferredTaxAssets" xlink:type="locator" xlink:label="nk_TaxCutsAndJobsActOf2017IncompleteAccountingChangeInTaxRateReductionInDeferredTaxAssets" />
    <link:label xml:lang="en-US" xlink:label="nk_TaxCutsAndJobsActOf2017IncompleteAccountingChangeInTaxRateReductionInDeferredTaxAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Tax Cuts and Jobs Act of 2017 incomplete accounting change in tax rate reduction in deferred tax assets.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nk_TaxCutsAndJobsActOf2017IncompleteAccountingChangeInTaxRateReductionInDeferredTaxAssets" xlink:to="nk_TaxCutsAndJobsActOf2017IncompleteAccountingChangeInTaxRateReductionInDeferredTaxAssets_lbl" />
    <link:loc xlink:href="nk-20191231.xsd#nk_IncomeTaxLineItems" xlink:type="locator" xlink:label="nk_IncomeTaxLineItems" />
    <link:label xml:lang="en-US" xlink:label="nk_IncomeTaxLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Income tax.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nk_IncomeTaxLineItems" xlink:to="nk_IncomeTaxLineItems_lbl" />
    <link:loc xlink:href="nk-20191231.xsd#nk_IncomeTaxTable" xlink:type="locator" xlink:label="nk_IncomeTaxTable" />
    <link:label xml:lang="en-US" xlink:label="nk_IncomeTaxTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Income tax.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nk_IncomeTaxTable" xlink:to="nk_IncomeTaxTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="nk_IncomeTaxTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_IncomeTaxTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:type="locator" xlink:label="us-gaap_StateAndLocalJurisdictionMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">State And Local Jurisdiction [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCountryMember" xlink:type="locator" xlink:label="us-gaap_ForeignCountryMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ForeignCountryMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCountryMember" xlink:to="us-gaap_ForeignCountryMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ForeignCountryMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Foreign Country [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TaxCreditCarryforwardAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax Credit Carryforward</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TaxCreditCarryforwardAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax Credit Carryforward, Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchMember" xlink:type="locator" xlink:label="us-gaap_ResearchMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research Tax Credits</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchMember" xlink:to="us-gaap_ResearchMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_IncomeTaxLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_IncomeTaxLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Corporate tax rate</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_TaxCutsAndJobsActOf2017IncompleteAccountingChangeInTaxRateMinimumAmountForEliminationOfSeveralBusinessDeductionsAndCreditsIncludingDeductionsForCertainExecutiveCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum Amount for elimination of several business deductions and credits, including deductions for certain executive compensation</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_TaxCutsAndJobsActOf2017IncompleteAccountingChangeInTaxRateMinimumAmountForEliminationOfSeveralBusinessDeductionsAndCreditsIncludingDeductionsForCertainExecutiveCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Tax Cuts And Jobs Act Of2017 Incomplete Accounting Change In Tax Rate Minimum Amount For Elimination Of Several Business Deductions And Credits Including Deductions For Certain Executive Compensation</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_TaxCutsAndJobsActOf2017IncompleteAccountingChangeInTaxRateReductionInDeferredTaxAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reduction in deferred tax asset balance</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_TaxCutsAndJobsActOf2017IncompleteAccountingChangeInTaxRateReductionInDeferredTaxAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Tax Cuts And Jobs Act Of2017 Incomplete Accounting Change In Tax Rate Reduction In Deferred Tax Assets</link:label>
    <link:loc xlink:href="nk-20191231.xsd#nk_ResearchAndDevelopmentCumulativeChangeInOwnershipPercentage" xlink:type="locator" xlink:label="nk_ResearchAndDevelopmentCumulativeChangeInOwnershipPercentage" />
    <link:label xml:lang="en-US" xlink:label="nk_ResearchAndDevelopmentCumulativeChangeInOwnershipPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Research and development cumulative change in ownership Percentage.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nk_ResearchAndDevelopmentCumulativeChangeInOwnershipPercentage" xlink:to="nk_ResearchAndDevelopmentCumulativeChangeInOwnershipPercentage_lbl" />
    <link:loc xlink:href="nk-20191231.xsd#nk_PeriodOfCumulativeOwnershipChange" xlink:type="locator" xlink:label="nk_PeriodOfCumulativeOwnershipChange" />
    <link:label xml:lang="en-US" xlink:label="nk_PeriodOfCumulativeOwnershipChange_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Period of cumulative ownership change.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nk_PeriodOfCumulativeOwnershipChange" xlink:to="nk_PeriodOfCumulativeOwnershipChange_lbl" />
    <link:loc xlink:href="nk-20191231.xsd#nk_DerecognizedDeferredTaxAssets" xlink:type="locator" xlink:label="nk_DerecognizedDeferredTaxAssets" />
    <link:label xml:lang="en-US" xlink:label="nk_DerecognizedDeferredTaxAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Derecognized deferred tax assets.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nk_DerecognizedDeferredTaxAssets" xlink:to="nk_DerecognizedDeferredTaxAssets_lbl" />
    <link:label xml:lang="en-US" xlink:label="nk_ResearchAndDevelopmentCumulativeChangeInOwnershipPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cumulative change in ownership</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_ResearchAndDevelopmentCumulativeChangeInOwnershipPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Cumulative Change In Ownership Percentage</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_PeriodOfCumulativeOwnershipChange_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Period of cumulative ownership change</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_PeriodOfCumulativeOwnershipChange_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Period Of Cumulative Ownership Change</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_DerecognizedDeferredTaxAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Derecognized deferred tax assets</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_DerecognizedDeferredTaxAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Derecognized Deferred Tax Assets</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax assets valuation allowance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="locator" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Deferred tax assets change in valuation allowance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Valuation Allowance Deferred Tax Asset Change In Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxEffectsAllocatedDirectlyToEquityEquityTransactions" xlink:type="locator" xlink:label="us-gaap_IncomeTaxEffectsAllocatedDirectlyToEquityEquityTransactions" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxEffectsAllocatedDirectlyToEquityEquityTransactions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax benefits credited to contributed capital</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxEffectsAllocatedDirectlyToEquityEquityTransactions" xlink:to="us-gaap_IncomeTaxEffectsAllocatedDirectlyToEquityEquityTransactions_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxEffectsAllocatedDirectlyToEquityEquityTransactions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Effects Allocated Directly To Equity Equity Transactions</link:label>
    <link:loc xlink:href="nk-20191231.xsd#nk_NetOperatingLossCarryforwardsExpirationDate" xlink:type="locator" xlink:label="nk_NetOperatingLossCarryforwardsExpirationDate" />
    <link:label xml:lang="en-US" xlink:label="nk_NetOperatingLossCarryforwardsExpirationDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Net operating loss carryforwards expiration date.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nk_NetOperatingLossCarryforwardsExpirationDate" xlink:to="nk_NetOperatingLossCarryforwardsExpirationDate_lbl" />
    <link:loc xlink:href="nk-20191231.xsd#nk_TaxCreditCarryforwardExpirationPeriod" xlink:type="locator" xlink:label="nk_TaxCreditCarryforwardExpirationPeriod" />
    <link:label xml:lang="en-US" xlink:label="nk_TaxCreditCarryforwardExpirationPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Tax credit carryforward expiration period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nk_TaxCreditCarryforwardExpirationPeriod" xlink:to="nk_TaxCreditCarryforwardExpirationPeriod_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwards" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforwards</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_NetOperatingLossCarryforwardsExpirationDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforwards expiration date</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_NetOperatingLossCarryforwardsExpirationDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Operating Loss Carryforwards Expiration Date</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax credit carryforwards</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAmount" xlink:to="us-gaap_TaxCreditCarryforwardAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward Amount</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_TaxCreditCarryforwardExpirationPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax credit carryforward expiration period</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_TaxCreditCarryforwardExpirationPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward Expiration Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefits" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Unrecognized tax benefits at beginning balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase for prior year tax positions</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Decrease for prior year tax positions</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase for current year tax positions</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Unrecognized tax benefits at ending balance</link:label>
    <link:loc xlink:href="nk-20191231.xsd#nk_UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRate" xlink:type="locator" xlink:label="nk_UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRate" />
    <link:label xml:lang="en-US" xlink:label="nk_UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">The total amount of unrecognized tax benefits that, if recognized, would not affect the effective tax rate.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nk_UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRate" xlink:to="nk_UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRate_lbl" />
    <link:label xml:lang="en-US" xlink:label="nk_UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized tax benefits that would not impact effective tax rate</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits That Would Not Impact Effective Tax Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_QuarterlyFinancialDataAbstract" xlink:type="locator" xlink:label="us-gaap_QuarterlyFinancialDataAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_QuarterlyFinancialDataAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Quarterly Financial Data [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_QuarterlyFinancialDataAbstract" xlink:to="us-gaap_QuarterlyFinancialDataAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Operating expenses</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Operating loss</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net loss per share - basic and diluted</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Shares used in calculating net loss per share - basic and diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedContributionPlanTable" xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DefinedContributionPlanTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Defined Contribution Plan [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanTable" xlink:to="us-gaap_DefinedContributionPlanTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DefinedContributionPlanTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanNameAxis" xlink:type="locator" xlink:label="us-gaap_RetirementPlanNameAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetirementPlanNameAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Retirement Plan Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetirementPlanNameAxis" xlink:to="us-gaap_RetirementPlanNameAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetirementPlanNameAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Retirement Plan Name [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_RetirementPlanNameDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetirementPlanNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Retirement Plan Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetirementPlanNameDomain" xlink:to="us-gaap_RetirementPlanNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetirementPlanNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Retirement Plan Name [Domain]</link:label>
    <link:loc xlink:href="nk-20191231.xsd#nk_FourHundredOneKPlanMember" xlink:type="locator" xlink:label="nk_FourHundredOneKPlanMember" />
    <link:label xml:lang="en-US" xlink:label="nk_FourHundredOneKPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Four hundred one K plan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nk_FourHundredOneKPlanMember" xlink:to="nk_FourHundredOneKPlanMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="nk_FourHundredOneKPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">401(k) Plan</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_FourHundredOneKPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Four Hundred One K Plan [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanDisclosureLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DefinedContributionPlanDisclosureLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Defined Contribution Plan Disclosure [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanDisclosureLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DefinedContributionPlanDisclosureLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan Disclosure [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee benefit plan, company contributions</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan Employer Discretionary Contribution Amount</link:label>
    <link:loc xlink:href="nk-20191231.xsd#nk_ExpectJointStudyCost" xlink:type="locator" xlink:label="nk_ExpectJointStudyCost" />
    <link:label xml:lang="en-US" xlink:label="nk_ExpectJointStudyCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Expect joint study cost.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nk_ExpectJointStudyCost" xlink:to="nk_ExpectJointStudyCost_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTable" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementMember" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CollaborativeArrangementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementMember" xlink:to="us-gaap_CollaborativeArrangementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CollaborativeArrangementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventMember" xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:type="locator" xlink:label="us-gaap_SubsequentEventLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_ExpectJointStudyCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expect joint study cost</link:label>
    <link:label xml:lang="en-US" xlink:label="nk_ExpectJointStudyCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Expect Joint Study Cost</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>64
<FILENAME>nk-20191231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2020-03-25T06:28:30.9224972+00:00 -->
<!-- Version            : 5.0.1.369 -->
<!-- Package ID         : 997a9244481146b697c7b584a5c14c7f -->
<!-- Copyright (c) 2020 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.nantkwest.com/20191231/role/TemplateLink" xlink:href="nk-20191231.xsd#TemplateLink" xlink:type="simple" />
  <link:roleRef roleURI="http://www.nantkwest.com/20191231/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="nk-20191231.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.nantkwest.com/20191231/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="locator" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport" xlink:type="locator" xlink:label="dei_DocumentTransitionReport" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentAnnualReport" xlink:type="locator" xlink:label="dei_DocumentAnnualReport" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityPublicFloat" xlink:type="locator" xlink:label="dei_EntityPublicFloat" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany" xlink:type="locator" xlink:label="dei_EntityShellCompany" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityExTransitionPeriod" xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness" xlink:type="locator" xlink:label="dei_EntitySmallBusiness" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory" xlink:type="locator" xlink:label="dei_EntityFilerCategory" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityVoluntaryFilers" xlink:type="locator" xlink:label="dei_EntityVoluntaryFilers" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:type="locator" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="10550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus" order="10610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityVoluntaryFilers" order="10670.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory" order="10730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="10790.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness" order="10850.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityExTransitionPeriod" order="10910.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany" order="10970.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding" order="11030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityPublicFloat" order="11090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="11150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="11210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="11270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="11330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent" order="11390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="11450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="11510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="11570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="11630.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="11690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="11750.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="11810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentAnnualReport" order="11870.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport" order="11930.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock" order="11990.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nantkwest.com/20191231/taxonomy/role/StatementConsolidatedBalanceSheets" xlink:href="nk-20191231.xsd#Role_StatementConsolidatedBalanceSheets" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.nantkwest.com/20191231/taxonomy/role/StatementConsolidatedBalanceSheets">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue" xlink:type="locator" xlink:label="us-gaap_CommonStockValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities" xlink:type="locator" xlink:label="us-gaap_Liabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:type="locator" xlink:label="us-gaap_DeferredRentCreditNoncurrent" />
    <link:loc xlink:href="nk-20191231.xsd#nk_FinancingObligationNoncurrent" xlink:type="locator" xlink:label="nk_FinancingObligationNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:type="locator" xlink:label="us-gaap_DueToRelatedPartiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets" xlink:type="locator" xlink:label="us-gaap_Assets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:type="locator" xlink:label="us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HeldToMaturitySecuritiesCurrent" xlink:type="locator" xlink:label="us-gaap_HeldToMaturitySecuritiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="10470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" order="10510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_HeldToMaturitySecuritiesCurrent" order="10550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="10590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" order="10630.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10670.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="10710.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" order="10750.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" order="10790.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="10830.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="10870.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="10910.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="10990.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="11070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="11110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DueToRelatedPartiesCurrent" order="11150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherLiabilitiesCurrent" order="11190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="11230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="11270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="nk_FinancingObligationNoncurrent" order="11310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_DeferredRentCreditNoncurrent" order="11350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" order="11390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="11430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="11470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="11550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="11590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="11630.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="11670.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="11710.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="11750.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nantkwest.com/20191231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical" xlink:href="nk-20191231.xsd#Role_StatementConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.nantkwest.com/20191231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nantkwest.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfOperations" xlink:href="nk-20191231.xsd#Role_StatementConsolidatedStatementsOfOperations" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.nantkwest.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfOperations">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseInterestExpense" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseInterestExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentIncomeNet" xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpenses" xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues" xlink:type="locator" xlink:label="us-gaap_Revenues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_Revenues" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" order="10360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="10420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="10480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract" order="10540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InvestmentIncomeNet" order="10660.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_FinanceLeaseInterestExpense" order="10720.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="10780.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" order="10840.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="10900.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="10960.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss" order="11020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareAbstract" order="11080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" order="11200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveVerboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" order="11260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" order="11380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nantkwest.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveLoss" xlink:href="nk-20191231.xsd#Role_StatementConsolidatedStatementsOfComprehensiveLoss" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.nantkwest.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveLoss">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_NetIncomeLoss" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nantkwest.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity" xlink:href="nk-20191231.xsd#Role_StatementConsolidatedStatementsOfStockholdersEquity" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.nantkwest.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification" xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:type="locator" xlink:label="us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:type="locator" xlink:label="us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <link:loc xlink:href="nk-20191231.xsd#nk_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:type="locator" xlink:label="nk_StockIssuedDuringPeriodSharesWarrantsExercised" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" xlink:type="locator" xlink:label="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdate201602Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingStandardsUpdate201409Member" xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdate201409Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:type="locator" xlink:label="us-gaap_TypeOfAdoptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:type="locator" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201409Member" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201602Member" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" order="10550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="nk_StockIssuedDuringPeriodSharesWarrantsExercised" order="10570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="10690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="10710.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" order="10830.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" order="10850.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" order="10970.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" order="10990.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" order="11110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" order="11130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification" order="11250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" order="11390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="11530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_li0l2" order="11670.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued_li0l2" order="11690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nantkwest.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" xlink:href="nk-20191231.xsd#Role_StatementConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.nantkwest.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssued1" xlink:type="locator" xlink:label="us-gaap_StockIssued1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:type="locator" xlink:label="us-gaap_UnrealizedGainLossOnInvestments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:type="locator" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="locator" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid" />
    <link:loc xlink:href="nk-20191231.xsd#nk_NoncashPropertyAndEquipmentPurchasesAcquiredUnderCapitalLease" xlink:type="locator" xlink:label="nk_NoncashPropertyAndEquipmentPurchasesAcquiredUnderCapitalLease" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="locator" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxesPaidNet" xlink:type="locator" xlink:label="us-gaap_IncomeTaxesPaidNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestPaidNet" xlink:type="locator" xlink:label="us-gaap_InterestPaidNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:type="locator" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" xlink:type="locator" xlink:label="us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" />
    <link:loc xlink:href="nk-20191231.xsd#nk_PaymentsToAcquireInvestmentsInEquitySecurities" xlink:type="locator" xlink:label="nk_PaymentsToAcquireInvestmentsInEquitySecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireHeldToMaturitySecurities" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireHeldToMaturitySecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue" />
    <link:loc xlink:href="nk-20191231.xsd#nk_IncreaseDecreaseInOperatingLeaseLiability" xlink:type="locator" xlink:label="nk_IncreaseDecreaseInOperatingLeaseLiability" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" />
    <link:loc xlink:href="nk-20191231.xsd#nk_IncreaseDecreaseInAccountsPayableCurrent" xlink:type="locator" xlink:label="nk_IncreaseDecreaseInAccountsPayableCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" />
    <link:loc xlink:href="nk-20191231.xsd#nk_IncreaseDecreaseInOperatingLeaseRightOfUseAssetNet" xlink:type="locator" xlink:label="nk_IncreaseDecreaseInOperatingLeaseRightOfUseAssetNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MarketableSecuritiesGainLoss" xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesGainLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1" xlink:type="locator" xlink:label="us-gaap_GainLossOnDispositionOfAssets1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:type="locator" xlink:label="us-gaap_AssetImpairmentCharges" />
    <link:loc xlink:href="nk-20191231.xsd#nk_NonCashInterestIncomeExpenseFromOperatingActivities" xlink:type="locator" xlink:label="nk_NonCashInterestIncomeExpenseFromOperatingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:type="locator" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" />
    <link:loc xlink:href="nk-20191231.xsd#nk_OperatingLeaseRightOfUseAssetNonCashLeaseExpense" xlink:type="locator" xlink:label="nk_OperatingLeaseRightOfUseAssetNonCashLeaseExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProfitLoss" xlink:type="locator" xlink:label="us-gaap_ProfitLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" order="10440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="10500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="10620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="10680.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="nk_OperatingLeaseRightOfUseAssetNonCashLeaseExpense" order="10740.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" order="10800.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="nk_NonCashInterestIncomeExpenseFromOperatingActivities" order="10860.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AssetImpairmentCharges" order="10920.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainLossOnDispositionOfAssets1" order="10980.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" order="11040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_MarketableSecuritiesGainLoss" order="11100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="11160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="11280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="nk_IncreaseDecreaseInOperatingLeaseRightOfUseAssetNet" order="11340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" order="11400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="nk_IncreaseDecreaseInAccountsPayableCurrent" order="11460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" order="11520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent" order="11580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="nk_IncreaseDecreaseInOperatingLeaseLiability" order="11640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue" order="11700.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="11760.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="11820.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="11940.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" order="12000.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireHeldToMaturitySecurities" order="12060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="nk_PaymentsToAcquireInvestmentsInEquitySecurities" order="12120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" order="12180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" order="12240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="12300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="12360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" order="12480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" order="12540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsForRepurchaseOfCommonStock" order="12600.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" order="12660.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="12720.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" order="12780.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" order="12840.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_li0l2" order="12900.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" order="12960.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="13080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" order="13140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" order="13200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="13260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_InterestPaidNet" order="13500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_IncomeTaxesPaidNet" order="13560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract" order="13620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="nk_NoncashPropertyAndEquipmentPurchasesAcquiredUnderCapitalLease" order="13740.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid" order="13800.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1" order="13860.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_UnrealizedGainLossOnInvestments" order="13920.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_StockIssued1" order="13980.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureDescriptionOfBusiness" xlink:href="nk-20191231.xsd#Role_DisclosureDescriptionOfBusiness" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureDescriptionOfBusiness">
    <link:loc xlink:href="nk-20191231.xsd#nk_DescriptionOfBusinessDisclosureTextBlock" xlink:type="locator" xlink:label="nk_DescriptionOfBusinessDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="nk_DescriptionOfBusinessDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies" xlink:href="nk-20191231.xsd#Role_DisclosureSummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureFinancialStatementDetails" xlink:href="nk-20191231.xsd#Role_DisclosureFinancialStatementDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureFinancialStatementDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:type="locator" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" />
    <link:loc xlink:href="nk-20191231.xsd#nk_FinancialStatementDetailsAbstract" xlink:type="locator" xlink:label="nk_FinancialStatementDetailsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nk_FinancialStatementDetailsAbstract" xlink:to="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureViractaInvestmentAndConvertibleNotes" xlink:href="nk-20191231.xsd#Role_DisclosureViractaInvestmentAndConvertibleNotes" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureViractaInvestmentAndConvertibleNotes">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostAndEquityMethodInvestmentsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_CostAndEquityMethodInvestmentsDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:type="locator" xlink:label="us-gaap_InvestmentsAllOtherInvestmentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:to="us-gaap_CostAndEquityMethodInvestmentsDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureFinancialInstrumentsInvestmentsInDebtSecurities" xlink:href="nk-20191231.xsd#Role_DisclosureFinancialInstrumentsInvestmentsInDebtSecurities" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureFinancialInstrumentsInvestmentsInDebtSecurities">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" />
    <link:loc xlink:href="nk-20191231.xsd#nk_CashEquivalentsAndMarketableSecuritiesAbstract" xlink:type="locator" xlink:label="nk_CashEquivalentsAndMarketableSecuritiesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nk_CashEquivalentsAndMarketableSecuritiesAbstract" xlink:to="us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureFairValueMeasurements" xlink:href="nk-20191231.xsd#Role_DisclosureFairValueMeasurements" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureFairValueMeasurements">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementInputsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementInputsDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueMeasurementInputsDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureCollaborationAndLicenseAgreements" xlink:href="nk-20191231.xsd#Role_DisclosureCollaborationAndLicenseAgreements" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureCollaborationAndLicenseAgreements">
    <link:loc xlink:href="nk-20191231.xsd#nk_CollaborationAndLicenseAgreementsTextBlock" xlink:type="locator" xlink:label="nk_CollaborationAndLicenseAgreementsTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="nk_CollaborationAndLicenseAgreementsTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureCommitmentAndContingencies" xlink:href="nk-20191231.xsd#Role_DisclosureCommitmentAndContingencies" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureCommitmentAndContingencies">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureRelatedPartyAgreements" xlink:href="nk-20191231.xsd#Role_DisclosureRelatedPartyAgreements" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureRelatedPartyAgreements">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureStockholdersEquity" xlink:href="nk-20191231.xsd#Role_DisclosureStockholdersEquity" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureStockholdersEquity">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract" xlink:type="locator" xlink:label="us-gaap_EquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureStockBasedCompensation" xlink:href="nk-20191231.xsd#Role_DisclosureStockBasedCompensation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureStockBasedCompensation">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureIncomeTaxes" xlink:href="nk-20191231.xsd#Role_DisclosureIncomeTaxes" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureIncomeTaxes">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureSummarizedQuarterlyDataUnaudited" xlink:href="nk-20191231.xsd#Role_DisclosureSummarizedQuarterlyDataUnaudited" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureSummarizedQuarterlyDataUnaudited">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_QuarterlyFinancialInformationTextBlock" xlink:type="locator" xlink:label="us-gaap_QuarterlyFinancialInformationTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_QuarterlyFinancialInformationDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:to="us-gaap_QuarterlyFinancialInformationTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureEmployeeBenefits" xlink:href="nk-20191231.xsd#Role_DisclosureEmployeeBenefits" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureEmployeeBenefits">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureSubsequentEvents" xlink:href="nk-20191231.xsd#Role_DisclosureSubsequentEvents" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureSubsequentEvents">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="nk-20191231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_InvestmentPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" />
    <link:loc xlink:href="nk-20191231.xsd#nk_LitigationCostsPolicyTextBlock" xlink:type="locator" xlink:label="nk_LitigationCostsPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" />
    <link:loc xlink:href="nk-20191231.xsd#nk_StockRepurchasesPolicyTextBlock" xlink:type="locator" xlink:label="nk_StockRepurchasesPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" />
    <link:loc xlink:href="nk-20191231.xsd#nk_RelatedPartyTransactionsPolicyPolicyTextBlock" xlink:type="locator" xlink:label="nk_RelatedPartyTransactionsPolicyPolicyTextBlock" />
    <link:loc xlink:href="nk-20191231.xsd#nk_PreclinicalAndClinicalTrialAccrualsPolicyTextBlock" xlink:type="locator" xlink:label="nk_PreclinicalAndClinicalTrialAccrualsPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="locator" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LegalCostsPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_LegalCostsPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
    <link:loc xlink:href="nk-20191231.xsd#nk_CashCashEquivalentsAndMarketableSecuritiesPolicyTextBlock" xlink:type="locator" xlink:label="nk_CashCashEquivalentsAndMarketableSecuritiesPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnusualRisksAndUncertaintiesTextBlock" xlink:type="locator" xlink:label="us-gaap_UnusualRisksAndUncertaintiesTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UseOfEstimates" xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_ConsolidationPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
    <link:loc xlink:href="nk-20191231.xsd#nk_LiquidityPolicyTextBlock" xlink:type="locator" xlink:label="nk_LiquidityPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="nk_LiquidityPolicyTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConsolidationPolicyTextBlock" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UnusualRisksAndUncertaintiesTextBlock" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesPolicyTextBlock" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="nk_CashCashEquivalentsAndMarketableSecuritiesPolicyTextBlock" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LegalCostsPolicyTextBlock" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="nk_PreclinicalAndClinicalTrialAccrualsPolicyTextBlock" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="nk_RelatedPartyTransactionsPolicyPolicyTextBlock" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="nk_StockRepurchasesPolicyTextBlock" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="nk_LitigationCostsPolicyTextBlock" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="10470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="10510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InvestmentPolicyTextBlock" order="10530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" xlink:href="nk-20191231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
    <link:loc xlink:href="nk-20191231.xsd#nk_PropertyPlantAndEquipmentUsefulLifeTableTextBlock" xlink:type="locator" xlink:label="nk_PropertyPlantAndEquipmentUsefulLifeTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="nk_PropertyPlantAndEquipmentUsefulLifeTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureFinancialStatementDetailsTables" xlink:href="nk-20191231.xsd#Role_DisclosureFinancialStatementDetailsTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureFinancialStatementDetailsTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentIncomeTextBlock" xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_OtherCurrentLiabilitiesTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" />
    <link:loc xlink:href="nk-20191231.xsd#nk_ScheduleOfImpactOfAdoptionOnPropertyPlantAndEquipmentTableTextBlock" xlink:type="locator" xlink:label="nk_ScheduleOfImpactOfAdoptionOnPropertyPlantAndEquipmentTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" />
    <link:loc xlink:href="nk-20191231.xsd#nk_PrepaidExpensesAndOtherCurrentAssetsTableTextBlock" xlink:type="locator" xlink:label="nk_PrepaidExpensesAndOtherCurrentAssetsTableTextBlock" />
    <link:loc xlink:href="nk-20191231.xsd#nk_FinancialStatementDetailsAbstract" xlink:type="locator" xlink:label="nk_FinancialStatementDetailsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nk_FinancialStatementDetailsAbstract" xlink:to="nk_PrepaidExpensesAndOtherCurrentAssetsTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nk_FinancialStatementDetailsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nk_FinancialStatementDetailsAbstract" xlink:to="nk_ScheduleOfImpactOfAdoptionOnPropertyPlantAndEquipmentTableTextBlock" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nk_FinancialStatementDetailsAbstract" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nk_FinancialStatementDetailsAbstract" xlink:to="us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nk_FinancialStatementDetailsAbstract" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nk_FinancialStatementDetailsAbstract" xlink:to="us-gaap_OtherCurrentLiabilitiesTableTextBlock" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nk_FinancialStatementDetailsAbstract" xlink:to="us-gaap_InvestmentIncomeTextBlock" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureFinancialInstrumentsInvestmentsInDebtSecuritiesTables" xlink:href="nk-20191231.xsd#Role_DisclosureFinancialInstrumentsInvestmentsInDebtSecuritiesTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureFinancialInstrumentsInvestmentsInDebtSecuritiesTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfRealizedGainLossTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfRealizedGainLossTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueTableTextBlock" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" />
    <link:loc xlink:href="nk-20191231.xsd#nk_CashEquivalentsAndMarketableSecuritiesAbstract" xlink:type="locator" xlink:label="nk_CashEquivalentsAndMarketableSecuritiesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nk_CashEquivalentsAndMarketableSecuritiesAbstract" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nk_CashEquivalentsAndMarketableSecuritiesAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueTableTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nk_CashEquivalentsAndMarketableSecuritiesAbstract" xlink:to="us-gaap_ScheduleOfRealizedGainLossTableTextBlock" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureFairValueMeasurementsTables" xlink:href="nk-20191231.xsd#Role_DisclosureFairValueMeasurementsTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureFairValueMeasurementsTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureCommitmentAndContingenciesTables" xlink:href="nk-20191231.xsd#Role_DisclosureCommitmentAndContingenciesTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureCommitmentAndContingenciesTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureStockholdersEquityTables" xlink:href="nk-20191231.xsd#Role_DisclosureStockholdersEquityTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureStockholdersEquityTables">
    <link:loc xlink:href="nk-20191231.xsd#nk_ScheduleOfCommonStockReservedForIssuanceTableTextBlock" xlink:type="locator" xlink:label="nk_ScheduleOfCommonStockReservedForIssuanceTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract" xlink:type="locator" xlink:label="us-gaap_EquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="nk_ScheduleOfCommonStockReservedForIssuanceTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureStockBasedCompensationTables" xlink:href="nk-20191231.xsd#Role_DisclosureStockBasedCompensationTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureStockBasedCompensationTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureIncomeTaxesTables" xlink:href="nk-20191231.xsd#Role_DisclosureIncomeTaxesTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureIncomeTaxesTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureSummarizedQuarterlyDataUnauditedTables" xlink:href="nk-20191231.xsd#Role_DisclosureSummarizedQuarterlyDataUnauditedTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureSummarizedQuarterlyDataUnauditedTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_QuarterlyFinancialInformationDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:to="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureDescriptionOfBusinessAdditionalInformationDetail" xlink:href="nk-20191231.xsd#Role_DisclosureDescriptionOfBusinessAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureDescriptionOfBusinessAdditionalInformationDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" xlink:href="nk-20191231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" xlink:type="locator" xlink:label="us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities" xlink:type="locator" xlink:label="us-gaap_Liabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <link:loc xlink:href="nk-20191231.xsd#nk_NumberOfProductsApprovedForCommercialSale" xlink:type="locator" xlink:label="nk_NumberOfProductsApprovedForCommercialSale" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" />
    <link:loc xlink:href="nk-20191231.xsd#nk_VariableConsiderationRelatedToMilestonePayment" xlink:type="locator" xlink:label="nk_VariableConsiderationRelatedToMilestonePayment" />
    <link:loc xlink:href="nk-20191231.xsd#nk_NonrefundableUpfrontPayment" xlink:type="locator" xlink:label="nk_NonrefundableUpfrontPayment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:type="locator" xlink:label="us-gaap_StockRepurchaseProgramAuthorizedAmount1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OpenTaxYear" xlink:type="locator" xlink:label="us-gaap_OpenTaxYear" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseDescription" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseDescription" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeasePracticalExpedientsPackage" xlink:type="locator" xlink:label="us-gaap_LeasePracticalExpedientsPackage" />
    <link:loc xlink:href="nk-20191231.xsd#nk_FairValueInputsTransfersIntoOrOutOfLevelOneLevelTwoOrLevelThreeCategories" xlink:type="locator" xlink:label="nk_FairValueInputsTransfersIntoOrOutOfLevelOneLevelTwoOrLevelThreeCategories" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:type="locator" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet" xlink:type="locator" xlink:label="us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet" />
    <link:loc xlink:href="nk-20191231.xsd#nk_MinimumOriginalMaturityPeriodOfLongTermMarketableSecurities" xlink:type="locator" xlink:label="nk_MinimumOriginalMaturityPeriodOfLongTermMarketableSecurities" />
    <link:loc xlink:href="nk-20191231.xsd#nk_MaximumOriginalMaturityPeriodOfShortTermMarketableSecurities" xlink:type="locator" xlink:label="nk_MaximumOriginalMaturityPeriodOfShortTermMarketableSecurities" />
    <link:loc xlink:href="nk-20191231.xsd#nk_MarketableSecuritiesOriginalMaturities" xlink:type="locator" xlink:label="nk_MarketableSecuritiesOriginalMaturities" />
    <link:loc xlink:href="nk-20191231.xsd#nk_CashAndCashEquivalentsOriginalMaturities" xlink:type="locator" xlink:label="nk_CashAndCashEquivalentsOriginalMaturities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" />
    <link:loc xlink:href="nk-20191231.xsd#nk_AccountingPoliciesLineItems" xlink:type="locator" xlink:label="nk_AccountingPoliciesLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="nk-20191231.xsd#nk_DifferenceBetweenLeaseGuidanceInEffectBeforeAndAfterTopic842Member" xlink:type="locator" xlink:label="nk_DifferenceBetweenLeaseGuidanceInEffectBeforeAndAfterTopic842Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain" xlink:type="locator" xlink:label="us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis" xlink:type="locator" xlink:label="us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdate201602Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:type="locator" xlink:label="us-gaap_TypeOfAdoptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:type="locator" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" />
    <link:loc xlink:href="nk-20191231.xsd#nk_IntrexonLicenseAgreementMember" xlink:type="locator" xlink:label="nk_IntrexonLicenseAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
    <link:loc xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_CA" xlink:type="locator" xlink:label="stpr_CA" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementGeographicalAxis" xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DomesticCountryMember" xlink:type="locator" xlink:label="us-gaap_DomesticCountryMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:type="locator" xlink:label="us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassificationOfVariableInterestEntityDomain" xlink:type="locator" xlink:label="us-gaap_ClassificationOfVariableInterestEntityDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis" xlink:type="locator" xlink:label="us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis" />
    <link:loc xlink:href="nk-20191231.xsd#nk_ChairmanAndChiefExecutiveOfficerMember" xlink:type="locator" xlink:label="nk_ChairmanAndChiefExecutiveOfficerMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualAxis" xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" />
    <link:loc xlink:href="nk-20191231.xsd#nk_AccountingPoliciesTable" xlink:type="locator" xlink:label="nk_AccountingPoliciesTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="nk_AccountingPoliciesTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nk_AccountingPoliciesTable" xlink:to="srt_TitleOfIndividualAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="nk_ChairmanAndChiefExecutiveOfficerMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nk_AccountingPoliciesTable" xlink:to="us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis" xlink:to="us-gaap_ClassificationOfVariableInterestEntityDomain" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassificationOfVariableInterestEntityDomain" xlink:to="us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nk_AccountingPoliciesTable" xlink:to="srt_RangeAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nk_AccountingPoliciesTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="10360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nk_AccountingPoliciesTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="10030.08" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="10540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" order="10560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nk_AccountingPoliciesTable" xlink:to="srt_StatementGeographicalAxis" order="10030.10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="10620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="stpr_CA" order="10640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nk_AccountingPoliciesTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="10030.12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="10700.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="nk_IntrexonLicenseAgreementMember" order="10720.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nk_AccountingPoliciesTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" order="10030.14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" order="10760.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201602Member" order="10780.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nk_AccountingPoliciesTable" xlink:to="us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis" order="10030.16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis" xlink:to="us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain" order="10900.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain" xlink:to="nk_DifferenceBetweenLeaseGuidanceInEffectBeforeAndAfterTopic842Member" order="10920.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nk_AccountingPoliciesTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10030.18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10980.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="11000.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nk_AccountingPoliciesTable" xlink:to="nk_AccountingPoliciesLineItems" order="11020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nk_AccountingPoliciesLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" order="11030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nk_AccountingPoliciesLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" order="11080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nk_AccountingPoliciesLineItems" xlink:to="nk_CashAndCashEquivalentsOriginalMaturities" order="11150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nk_AccountingPoliciesLineItems" xlink:to="nk_MarketableSecuritiesOriginalMaturities" order="11170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nk_AccountingPoliciesLineItems" xlink:to="nk_MaximumOriginalMaturityPeriodOfShortTermMarketableSecurities" order="11190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nk_AccountingPoliciesLineItems" xlink:to="nk_MinimumOriginalMaturityPeriodOfLongTermMarketableSecurities" order="11210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nk_AccountingPoliciesLineItems" xlink:to="us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet" order="11260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nk_AccountingPoliciesLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife" order="11350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nk_AccountingPoliciesLineItems" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" order="11400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nk_AccountingPoliciesLineItems" xlink:to="nk_FairValueInputsTransfersIntoOrOutOfLevelOneLevelTwoOrLevelThreeCategories" order="11490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nk_AccountingPoliciesLineItems" xlink:to="us-gaap_LeasePracticalExpedientsPackage" order="11580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nk_AccountingPoliciesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseDescription" order="11630.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nk_AccountingPoliciesLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" order="11680.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nk_AccountingPoliciesLineItems" xlink:to="us-gaap_OpenTaxYear" order="11750.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nk_AccountingPoliciesLineItems" xlink:to="us-gaap_StockRepurchaseProgramAuthorizedAmount1" order="11860.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nk_AccountingPoliciesLineItems" xlink:to="nk_NonrefundableUpfrontPayment" order="11910.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nk_AccountingPoliciesLineItems" xlink:to="nk_VariableConsiderationRelatedToMilestonePayment" order="11960.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nk_AccountingPoliciesLineItems" xlink:to="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" order="11980.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nk_AccountingPoliciesLineItems" xlink:to="nk_NumberOfProductsApprovedForCommercialSale" order="12030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nk_AccountingPoliciesLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="12080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nk_AccountingPoliciesLineItems" xlink:to="us-gaap_OperatingLeaseLiability" order="12100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nk_AccountingPoliciesLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="12120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nk_AccountingPoliciesLineItems" xlink:to="us-gaap_Liabilities" order="12140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nk_AccountingPoliciesLineItems" xlink:to="us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" order="12160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentDetail" xlink:href="nk-20191231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <link:loc xlink:href="nk-20191231.xsd#nk_ITEquipmentMember" xlink:type="locator" xlink:label="nk_ITEquipmentMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" />
    <link:loc xlink:href="nk-20191231.xsd#nk_LaboratoryEquipmentMember" xlink:type="locator" xlink:label="nk_LaboratoryEquipmentMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:type="locator" xlink:label="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BuildingMember" xlink:type="locator" xlink:label="us-gaap_BuildingMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_BuildingMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="nk_LaboratoryEquipmentMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="nk_ITEquipmentMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSecuritiesExcludedFromComputationOfPotentiallyDilutiveSecuritiesDetail" xlink:href="nk-20191231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesSecuritiesExcludedFromComputationOfPotentiallyDilutiveSecuritiesDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSecuritiesExcludedFromComputationOfPotentiallyDilutiveSecuritiesDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantMember" xlink:type="locator" xlink:label="us-gaap_WarrantMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_WarrantMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureFinancialStatementDetailsPrepaidExpensesAndOtherCurrentAssetsDetail" xlink:href="nk-20191231.xsd#Role_DisclosureFinancialStatementDetailsPrepaidExpensesAndOtherCurrentAssetsDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureFinancialStatementDetailsPrepaidExpensesAndOtherCurrentAssetsDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DueFromRelatedPartiesCurrent" xlink:type="locator" xlink:label="us-gaap_DueFromRelatedPartiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InsuranceSettlementsReceivableCurrent" xlink:type="locator" xlink:label="us-gaap_InsuranceSettlementsReceivableCurrent" />
    <link:loc xlink:href="nk-20191231.xsd#nk_PrepaidLicenseFees" xlink:type="locator" xlink:label="nk_PrepaidLicenseFees" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestReceivableCurrent" xlink:type="locator" xlink:label="us-gaap_InterestReceivableCurrent" />
    <link:loc xlink:href="nk-20191231.xsd#nk_PrepaidEquipmentMaintenance" xlink:type="locator" xlink:label="nk_PrepaidEquipmentMaintenance" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidInsurance" xlink:type="locator" xlink:label="us-gaap_PrepaidInsurance" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidRent" xlink:type="locator" xlink:label="us-gaap_PrepaidRent" />
    <link:loc xlink:href="nk-20191231.xsd#nk_PrepaidServices" xlink:type="locator" xlink:label="nk_PrepaidServices" />
    <link:loc xlink:href="nk-20191231.xsd#nk_PrepaidSuppliesWithRelatedParty" xlink:type="locator" xlink:label="nk_PrepaidSuppliesWithRelatedParty" />
    <link:loc xlink:href="nk-20191231.xsd#nk_InsurancePremiumFinancingAsset" xlink:type="locator" xlink:label="nk_InsurancePremiumFinancingAsset" />
    <link:loc xlink:href="nk-20191231.xsd#nk_PrepaidPreclinicalAndClinicalTrialServicesWithRelatedParty" xlink:type="locator" xlink:label="nk_PrepaidPreclinicalAndClinicalTrialServicesWithRelatedParty" />
    <link:loc xlink:href="nk-20191231.xsd#nk_FinancialStatementDetailsAbstract" xlink:type="locator" xlink:label="nk_FinancialStatementDetailsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nk_FinancialStatementDetailsAbstract" xlink:to="nk_PrepaidPreclinicalAndClinicalTrialServicesWithRelatedParty" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nk_FinancialStatementDetailsAbstract" xlink:to="nk_InsurancePremiumFinancingAsset" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nk_FinancialStatementDetailsAbstract" xlink:to="nk_PrepaidSuppliesWithRelatedParty" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nk_FinancialStatementDetailsAbstract" xlink:to="nk_PrepaidServices" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nk_FinancialStatementDetailsAbstract" xlink:to="us-gaap_PrepaidRent" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nk_FinancialStatementDetailsAbstract" xlink:to="us-gaap_PrepaidInsurance" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nk_FinancialStatementDetailsAbstract" xlink:to="nk_PrepaidEquipmentMaintenance" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nk_FinancialStatementDetailsAbstract" xlink:to="us-gaap_InterestReceivableCurrent" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nk_FinancialStatementDetailsAbstract" xlink:to="nk_PrepaidLicenseFees" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nk_FinancialStatementDetailsAbstract" xlink:to="us-gaap_InsuranceSettlementsReceivableCurrent" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nk_FinancialStatementDetailsAbstract" xlink:to="us-gaap_DueFromRelatedPartiesCurrent" order="10530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nk_FinancialStatementDetailsAbstract" xlink:to="us-gaap_OtherAssetsCurrent" order="10570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nk_FinancialStatementDetailsAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="10610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureFinancialStatementDetailsPropertyPlantAndEquipmentNetDetail" xlink:href="nk-20191231.xsd#Role_DisclosureFinancialStatementDetailsPropertyPlantAndEquipmentNetDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureFinancialStatementDetailsPropertyPlantAndEquipmentNetDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:type="locator" xlink:label="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquipmentMember" xlink:type="locator" xlink:label="us-gaap_EquipmentMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BuildingMember" xlink:type="locator" xlink:label="us-gaap_BuildingMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:type="locator" xlink:label="us-gaap_ConstructionInProgressMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:loc xlink:href="nk-20191231.xsd#nk_FinancialStatementDetailsAbstract" xlink:type="locator" xlink:label="nk_FinancialStatementDetailsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nk_FinancialStatementDetailsAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="10040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ConstructionInProgressMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_BuildingMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_EquipmentMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="10510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureFinancialStatementDetailsAdditionalInformationDetail" xlink:href="nk-20191231.xsd#Role_DisclosureFinancialStatementDetailsAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureFinancialStatementDetailsAdditionalInformationDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ImpairmentOfInvestments" xlink:type="locator" xlink:label="us-gaap_ImpairmentOfInvestments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:type="locator" xlink:label="us-gaap_AmortizationOfIntangibleAssets" />
    <link:loc xlink:href="nk-20191231.xsd#nk_DerecognizedBuildToSuitLeaseAssets" xlink:type="locator" xlink:label="nk_DerecognizedBuildToSuitLeaseAssets" />
    <link:loc xlink:href="nk-20191231.xsd#nk_LesseseOperatingLeaseReclassificationOfAssetsFromBuildingsToLeaseholdImprovements" xlink:type="locator" xlink:label="nk_LesseseOperatingLeaseReclassificationOfAssetsFromBuildingsToLeaseholdImprovements" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Depreciation" xlink:type="locator" xlink:label="us-gaap_Depreciation" />
    <link:loc xlink:href="nk-20191231.xsd#nk_FinancialStatementDetailsLineItems" xlink:type="locator" xlink:label="nk_FinancialStatementDetailsLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdate201602Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:type="locator" xlink:label="us-gaap_TypeOfAdoptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:type="locator" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" />
    <link:loc xlink:href="nk-20191231.xsd#nk_FinancialStatementDetailsTable" xlink:type="locator" xlink:label="nk_FinancialStatementDetailsTable" />
    <link:loc xlink:href="nk-20191231.xsd#nk_FinancialStatementDetailsAbstract" xlink:type="locator" xlink:label="nk_FinancialStatementDetailsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nk_FinancialStatementDetailsAbstract" xlink:to="nk_FinancialStatementDetailsTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nk_FinancialStatementDetailsTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201602Member" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nk_FinancialStatementDetailsTable" xlink:to="nk_FinancialStatementDetailsLineItems" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nk_FinancialStatementDetailsLineItems" xlink:to="us-gaap_Depreciation" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nk_FinancialStatementDetailsLineItems" xlink:to="nk_LesseseOperatingLeaseReclassificationOfAssetsFromBuildingsToLeaseholdImprovements" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nk_FinancialStatementDetailsLineItems" xlink:to="nk_DerecognizedBuildToSuitLeaseAssets" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nk_FinancialStatementDetailsLineItems" xlink:to="us-gaap_AmortizationOfIntangibleAssets" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nk_FinancialStatementDetailsLineItems" xlink:to="us-gaap_ImpairmentOfInvestments" order="10360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureFinancialStatementDetailsImpactOfAdoptionOfASC842OnPropertyPlantAndEquipmentDetail" xlink:href="nk-20191231.xsd#Role_DisclosureFinancialStatementDetailsImpactOfAdoptionOfASC842OnPropertyPlantAndEquipmentDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureFinancialStatementDetailsImpactOfAdoptionOfASC842OnPropertyPlantAndEquipmentDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <link:loc xlink:href="nk-20191231.xsd#nk_FinancialStatementDetailsLineItems" xlink:type="locator" xlink:label="nk_FinancialStatementDetailsLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RestatementAdjustmentMember" xlink:type="locator" xlink:label="srt_RestatementAdjustmentMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RestatementDomain" xlink:type="locator" xlink:label="srt_RestatementDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RestatementAxis" xlink:type="locator" xlink:label="srt_RestatementAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BuildingMember" xlink:type="locator" xlink:label="us-gaap_BuildingMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdate201602Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:type="locator" xlink:label="us-gaap_TypeOfAdoptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:type="locator" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" />
    <link:loc xlink:href="nk-20191231.xsd#nk_FinancialStatementDetailsTable" xlink:type="locator" xlink:label="nk_FinancialStatementDetailsTable" />
    <link:loc xlink:href="nk-20191231.xsd#nk_FinancialStatementDetailsAbstract" xlink:type="locator" xlink:label="nk_FinancialStatementDetailsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nk_FinancialStatementDetailsAbstract" xlink:to="nk_FinancialStatementDetailsTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nk_FinancialStatementDetailsTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201602Member" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nk_FinancialStatementDetailsTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_BuildingMember" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nk_FinancialStatementDetailsTable" xlink:to="srt_RestatementAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementDomain" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RestatementDomain" xlink:to="srt_RestatementAdjustmentMember" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nk_FinancialStatementDetailsTable" xlink:to="nk_FinancialStatementDetailsLineItems" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nk_FinancialStatementDetailsLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nk_FinancialStatementDetailsLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nk_FinancialStatementDetailsLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureFinancialStatementDetailsIntangibleAssetsNetDetail" xlink:href="nk-20191231.xsd#Role_DisclosureFinancialStatementDetailsIntangibleAssetsNetDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureFinancialStatementDetailsIntangibleAssetsNetDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems" />
    <link:loc xlink:href="nk-20191231.xsd#nk_TechnologyLicenseMember" xlink:type="locator" xlink:label="nk_TechnologyLicenseMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" />
    <link:loc xlink:href="nk-20191231.xsd#nk_FinancialStatementDetailsAbstract" xlink:type="locator" xlink:label="nk_FinancialStatementDetailsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nk_FinancialStatementDetailsAbstract" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" order="10040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="nk_TechnologyLicenseMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsLineItems" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureFinancialStatementDetailsOtherAssetsDetail" xlink:href="nk-20191231.xsd#Role_DisclosureFinancialStatementDetailsOtherAssetsDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureFinancialStatementDetailsOtherAssetsDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsMiscellaneousNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsMiscellaneousNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseNoncurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SecurityDeposit" xlink:type="locator" xlink:label="us-gaap_SecurityDeposit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" />
    <link:loc xlink:href="nk-20191231.xsd#nk_PrepaidPreclinicalAndClinicalTrialServicesWithRelatedPartyInOtherAssets" xlink:type="locator" xlink:label="nk_PrepaidPreclinicalAndClinicalTrialServicesWithRelatedPartyInOtherAssets" />
    <link:loc xlink:href="nk-20191231.xsd#nk_FinancialStatementDetailsAbstract" xlink:type="locator" xlink:label="nk_FinancialStatementDetailsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nk_FinancialStatementDetailsAbstract" xlink:to="nk_PrepaidPreclinicalAndClinicalTrialServicesWithRelatedPartyInOtherAssets" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nk_FinancialStatementDetailsAbstract" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nk_FinancialStatementDetailsAbstract" xlink:to="us-gaap_SecurityDeposit" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nk_FinancialStatementDetailsAbstract" xlink:to="us-gaap_PrepaidExpenseNoncurrent" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nk_FinancialStatementDetailsAbstract" xlink:to="us-gaap_OtherAssetsMiscellaneousNoncurrent" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nk_FinancialStatementDetailsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureFinancialStatementDetailsAccruedExpensesDetail" xlink:href="nk-20191231.xsd#Role_DisclosureFinancialStatementDetailsAccruedExpensesDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureFinancialStatementDetailsAccruedExpensesDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConstructionPayableCurrent" xlink:type="locator" xlink:label="us-gaap_ConstructionPayableCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LitigationReserveCurrent" xlink:type="locator" xlink:label="us-gaap_LitigationReserveCurrent" />
    <link:loc xlink:href="nk-20191231.xsd#nk_AccruedFranchiseSalesUseAndPropertyTaxes" xlink:type="locator" xlink:label="nk_AccruedFranchiseSalesUseAndPropertyTaxes" />
    <link:loc xlink:href="nk-20191231.xsd#nk_AccruedPreclinicalAndClinicalTrialCosts" xlink:type="locator" xlink:label="nk_AccruedPreclinicalAndClinicalTrialCosts" />
    <link:loc xlink:href="nk-20191231.xsd#nk_AccruedLaboratoryEquipmentAndSupplies" xlink:type="locator" xlink:label="nk_AccruedLaboratoryEquipmentAndSupplies" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedSalariesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedSalariesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedBonusesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedBonusesCurrent" />
    <link:loc xlink:href="nk-20191231.xsd#nk_FinancialStatementDetailsAbstract" xlink:type="locator" xlink:label="nk_FinancialStatementDetailsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nk_FinancialStatementDetailsAbstract" xlink:to="us-gaap_AccruedBonusesCurrent" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nk_FinancialStatementDetailsAbstract" xlink:to="us-gaap_AccruedSalariesCurrent" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nk_FinancialStatementDetailsAbstract" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nk_FinancialStatementDetailsAbstract" xlink:to="nk_AccruedLaboratoryEquipmentAndSupplies" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nk_FinancialStatementDetailsAbstract" xlink:to="nk_AccruedPreclinicalAndClinicalTrialCosts" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nk_FinancialStatementDetailsAbstract" xlink:to="nk_AccruedFranchiseSalesUseAndPropertyTaxes" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nk_FinancialStatementDetailsAbstract" xlink:to="us-gaap_LitigationReserveCurrent" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nk_FinancialStatementDetailsAbstract" xlink:to="us-gaap_ConstructionPayableCurrent" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nk_FinancialStatementDetailsAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="10420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nk_FinancialStatementDetailsAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="10460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureFinancialStatementDetailsOtherCurrentLiabilitiesDetail" xlink:href="nk-20191231.xsd#Role_DisclosureFinancialStatementDetailsOtherCurrentLiabilitiesDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureFinancialStatementDetailsOtherCurrentLiabilitiesDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherSundryLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_OtherSundryLiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredRentCreditCurrent" xlink:type="locator" xlink:label="us-gaap_DeferredRentCreditCurrent" />
    <link:loc xlink:href="nk-20191231.xsd#nk_FinancingObligationCurrent" xlink:type="locator" xlink:label="nk_FinancingObligationCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <link:loc xlink:href="nk-20191231.xsd#nk_FinancialStatementDetailsAbstract" xlink:type="locator" xlink:label="nk_FinancialStatementDetailsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nk_FinancialStatementDetailsAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nk_FinancialStatementDetailsAbstract" xlink:to="nk_FinancingObligationCurrent" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nk_FinancialStatementDetailsAbstract" xlink:to="us-gaap_DeferredRentCreditCurrent" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nk_FinancialStatementDetailsAbstract" xlink:to="us-gaap_OtherSundryLiabilitiesCurrent" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nk_FinancialStatementDetailsAbstract" xlink:to="us-gaap_OtherLiabilitiesCurrent" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureFinancialStatementDetailsInvestmentIncomeNetDetail" xlink:href="nk-20191231.xsd#Role_DisclosureFinancialStatementDetailsInvestmentIncomeNetDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureFinancialStatementDetailsInvestmentIncomeNetDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentIncomeNet" xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RealizedInvestmentGainsLosses" xlink:type="locator" xlink:label="us-gaap_RealizedInvestmentGainsLosses" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInterest" />
    <link:loc xlink:href="nk-20191231.xsd#nk_FinancialStatementDetailsAbstract" xlink:type="locator" xlink:label="nk_FinancialStatementDetailsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nk_FinancialStatementDetailsAbstract" xlink:to="us-gaap_InvestmentIncomeInterest" order="10040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nk_FinancialStatementDetailsAbstract" xlink:to="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nk_FinancialStatementDetailsAbstract" xlink:to="us-gaap_RealizedInvestmentGainsLosses" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nk_FinancialStatementDetailsAbstract" xlink:to="us-gaap_InvestmentIncomeNet" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureViractaInvestmentAndConvertibleNotesAdditionalInformationDetail" xlink:href="nk-20191231.xsd#Role_DisclosureViractaInvestmentAndConvertibleNotesAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureViractaInvestmentAndConvertibleNotesAdditionalInformationDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockValue" xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentTerm" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage" />
    <link:loc xlink:href="nk-20191231.xsd#nk_PurchaseOfConvertibleNoteUponConversion" xlink:type="locator" xlink:label="nk_PurchaseOfConvertibleNoteUponConversion" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:type="locator" xlink:label="us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfInvestmentsLineItems" xlink:type="locator" xlink:label="us-gaap_ScheduleOfInvestmentsLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:type="locator" xlink:label="us-gaap_SeriesBPreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="nk-20191231.xsd#nk_TwoThousandAndEighteenNoteAndWarrantPurchaseAgreementMember" xlink:type="locator" xlink:label="nk_TwoThousandAndEighteenNoteAndWarrantPurchaseAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfInvestmentsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfInvestmentsTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:type="locator" xlink:label="us-gaap_InvestmentsAllOtherInvestmentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:to="us-gaap_ScheduleOfInvestmentsTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfInvestmentsTable" xlink:to="us-gaap_DebtInstrumentAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="nk_TwoThousandAndEighteenNoteAndWarrantPurchaseAgreementMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfInvestmentsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfInvestmentsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfInvestmentsTable" xlink:to="us-gaap_ScheduleOfInvestmentsLineItems" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfInvestmentsLineItems" xlink:to="us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfInvestmentsLineItems" xlink:to="nk_PurchaseOfConvertibleNoteUponConversion" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfInvestmentsLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage" order="10420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfInvestmentsLineItems" xlink:to="us-gaap_DebtInstrumentTerm" order="10460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfInvestmentsLineItems" xlink:to="us-gaap_PreferredStockValue" order="10500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfInvestmentsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="10540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureFinancialInstrumentsInvestmentsInDebtSecuritiesScheduleOfInvestmentsInDebtSecuritiesDetail" xlink:href="nk-20191231.xsd#Role_DisclosureFinancialInstrumentsInvestmentsInDebtSecuritiesScheduleOfInvestmentsInDebtSecuritiesDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureFinancialInstrumentsInvestmentsInDebtSecuritiesScheduleOfInvestmentsInDebtSecuritiesDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain" />
    <link:loc xlink:href="nk-20191231.xsd#nk_AvailableForSaleDebtSecuritiesAmortizedCost" xlink:type="locator" xlink:label="nk_AvailableForSaleDebtSecuritiesAmortizedCost" />
    <link:loc xlink:href="nk-20191231.xsd#nk_DebtSecuritiesAvailableForSaleAndHeldToMaturityFairValue" xlink:type="locator" xlink:label="nk_DebtSecuritiesAvailableForSaleAndHeldToMaturityFairValue" />
    <link:loc xlink:href="nk-20191231.xsd#nk_DebtSecuritiesAvailableForSaleAndHeldToMaturityAmortizedCostAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="locator" xlink:label="nk_DebtSecuritiesAvailableForSaleAndHeldToMaturityAmortizedCostAccumulatedGrossUnrealizedLossBeforeTax" />
    <link:loc xlink:href="nk-20191231.xsd#nk_DebtSecuritiesAvailableForSaleAndHeldToMaturityAmortizedCostAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="locator" xlink:label="nk_DebtSecuritiesAvailableForSaleAndHeldToMaturityAmortizedCostAccumulatedGrossUnrealizedGainBeforeTax" />
    <link:loc xlink:href="nk-20191231.xsd#nk_DebtSecuritiesAvailableForSaleAndHeldToMaturityAmortizedCost" xlink:type="locator" xlink:label="nk_DebtSecuritiesAvailableForSaleAndHeldToMaturityAmortizedCost" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HeldToMaturitySecuritiesFairValue" xlink:type="locator" xlink:label="us-gaap_HeldToMaturitySecuritiesFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" xlink:type="locator" xlink:label="us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" xlink:type="locator" xlink:label="us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HeldToMaturitySecurities" xlink:type="locator" xlink:label="us-gaap_HeldToMaturitySecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAndHeldToMaturitySecurities" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesAndHeldToMaturitySecurities" />
    <link:loc xlink:href="nk-20191231.xsd#nk_AvailableForSaleSecuritiesAndHeldToMaturityGrossUnrealizedLosses" xlink:type="locator" xlink:label="nk_AvailableForSaleSecuritiesAndHeldToMaturityGrossUnrealizedLosses" />
    <link:loc xlink:href="nk-20191231.xsd#nk_AvailableForSaleSecuritiesAndHeldToMaturityGrossUnrealizedGain" xlink:type="locator" xlink:label="nk_AvailableForSaleSecuritiesAndHeldToMaturityGrossUnrealizedGain" />
    <link:loc xlink:href="nk-20191231.xsd#nk_AvailableForSaleSecuritiesDebtSecuritiesPeriod" xlink:type="locator" xlink:label="nk_AvailableForSaleSecuritiesDebtSecuritiesPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NotesReceivableMember" xlink:type="locator" xlink:label="us-gaap_NotesReceivableMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByAssetClassAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_CorporateDebtSecuritiesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:type="locator" xlink:label="us-gaap_FinancialInstrumentAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignGovernmentDebtMember" xlink:type="locator" xlink:label="us-gaap_ForeignGovernmentDebtMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeCategorizationMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AgencySecuritiesMember" xlink:type="locator" xlink:label="us-gaap_AgencySecuritiesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnderlyingAssetClassDomain" xlink:type="locator" xlink:label="us-gaap_UnderlyingAssetClassDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnderlyingAssetClassAxis" xlink:type="locator" xlink:label="us-gaap_UnderlyingAssetClassAxis" />
    <link:loc xlink:href="nk-20191231.xsd#nk_NoncurrentAssetsMember" xlink:type="locator" xlink:label="nk_NoncurrentAssetsMember" />
    <link:loc xlink:href="nk-20191231.xsd#nk_CurrentAssetsMember" xlink:type="locator" xlink:label="nk_CurrentAssetsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAbstract" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesAbstract" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="us-gaap_BalanceSheetLocationAxis" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="nk_CurrentAssetsMember" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="nk_NoncurrentAssetsMember" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="us-gaap_UnderlyingAssetClassAxis" order="10120.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_UnderlyingAssetClassAxis" xlink:to="us-gaap_UnderlyingAssetClassDomain" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_UnderlyingAssetClassDomain" xlink:to="us-gaap_AgencySecuritiesMember" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="us-gaap_InvestmentTypeAxis" order="10120.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_ForeignGovernmentDebtMember" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="10120.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CorporateDebtSecuritiesMember" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="10120.08" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="11190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_NotesReceivableMember" order="11210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" order="11630.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" order="11640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="11900.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="12160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="12420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="nk_AvailableForSaleSecuritiesDebtSecuritiesPeriod" order="12710.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="nk_AvailableForSaleSecuritiesAndHeldToMaturityGrossUnrealizedGain" order="12970.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="nk_AvailableForSaleSecuritiesAndHeldToMaturityGrossUnrealizedLosses" order="13230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesAndHeldToMaturitySecurities" order="13490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_HeldToMaturitySecurities" order="14930.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" order="15210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" order="15490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_HeldToMaturitySecuritiesFairValue" order="15770.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="nk_DebtSecuritiesAvailableForSaleAndHeldToMaturityAmortizedCost" order="16080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="nk_DebtSecuritiesAvailableForSaleAndHeldToMaturityAmortizedCostAccumulatedGrossUnrealizedGainBeforeTax" order="16360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="nk_DebtSecuritiesAvailableForSaleAndHeldToMaturityAmortizedCostAccumulatedGrossUnrealizedLossBeforeTax" order="16640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="nk_DebtSecuritiesAvailableForSaleAndHeldToMaturityFairValue" order="16920.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="nk_AvailableForSaleDebtSecuritiesAmortizedCost" order="17230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain" order="17510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" order="17790.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureFinancialInstrumentsInvestmentsInDebtSecuritiesAdditionalInformationDetail" xlink:href="nk-20191231.xsd#Role_DisclosureFinancialInstrumentsInvestmentsInDebtSecuritiesAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureFinancialInstrumentsInvestmentsInDebtSecuritiesAdditionalInformationDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1" xlink:type="locator" xlink:label="us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1" />
    <link:loc xlink:href="nk-20191231.xsd#nk_AvailableForSaleSecuritiesPeriodOfUnrealizedLossPositions" xlink:type="locator" xlink:label="nk_AvailableForSaleSecuritiesPeriodOfUnrealizedLossPositions" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:type="locator" xlink:label="us-gaap_FinancialInstrumentAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" />
    <link:loc xlink:href="nk-20191231.xsd#nk_CashEquivalentsAndMarketableSecuritiesAbstract" xlink:type="locator" xlink:label="nk_CashEquivalentsAndMarketableSecuritiesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nk_CashEquivalentsAndMarketableSecuritiesAbstract" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_DebtSecuritiesMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="srt_RangeAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="nk_AvailableForSaleSecuritiesPeriodOfUnrealizedLossPositions" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureFinancialInstrumentsInvestmentsInDebtSecuritiesAccumulatedUnrealizedLossesOnDebtSecuritiesClassifiedAsAvailableForSaleInContinuousLossPositionDetail" xlink:href="nk-20191231.xsd#Role_DisclosureFinancialInstrumentsInvestmentsInDebtSecuritiesAccumulatedUnrealizedLossesOnDebtSecuritiesClassifiedAsAvailableForSaleInContinuousLossPositionDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureFinancialInstrumentsInvestmentsInDebtSecuritiesAccumulatedUnrealizedLossesOnDebtSecuritiesClassifiedAsAvailableForSaleInContinuousLossPositionDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_CorporateDebtSecuritiesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:type="locator" xlink:label="us-gaap_FinancialInstrumentAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AgencySecuritiesMember" xlink:type="locator" xlink:label="us-gaap_AgencySecuritiesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnderlyingAssetClassDomain" xlink:type="locator" xlink:label="us-gaap_UnderlyingAssetClassDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnderlyingAssetClassAxis" xlink:type="locator" xlink:label="us-gaap_UnderlyingAssetClassAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" />
    <link:loc xlink:href="nk-20191231.xsd#nk_CashEquivalentsAndMarketableSecuritiesAbstract" xlink:type="locator" xlink:label="nk_CashEquivalentsAndMarketableSecuritiesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nk_CashEquivalentsAndMarketableSecuritiesAbstract" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="us-gaap_UnderlyingAssetClassAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_UnderlyingAssetClassAxis" xlink:to="us-gaap_UnderlyingAssetClassDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_UnderlyingAssetClassDomain" xlink:to="us-gaap_AgencySecuritiesMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CorporateDebtSecuritiesMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" order="10570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" order="10710.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureFinancialInstrumentsInvestmentsInDebtSecuritiesScheduleOfRealizedGainsAndLossesOnSalesOfAvailableForSaleDebtSecuritiesDetail" xlink:href="nk-20191231.xsd#Role_DisclosureFinancialInstrumentsInvestmentsInDebtSecuritiesScheduleOfRealizedGainsAndLossesOnSalesOfAvailableForSaleDebtSecuritiesDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureFinancialInstrumentsInvestmentsInDebtSecuritiesScheduleOfRealizedGainsAndLossesOnSalesOfAvailableForSaleDebtSecuritiesDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossNet" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesGrossRealizedGains" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesGrossRealizedGains" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesRealizedGainLossAbstract" xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesRealizedGainLossAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesRealizedGainLossAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesGrossRealizedGains" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesRealizedGainLossAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesRealizedGainLossAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossNet" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail" xlink:href="nk-20191231.xsd#Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_AssetsFairValueDisclosure" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_CorporateDebtSecuritiesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsMember" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByAssetClassAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignGovernmentDebtMember" xlink:type="locator" xlink:label="us-gaap_ForeignGovernmentDebtMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeCategorizationMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AgencySecuritiesMember" xlink:type="locator" xlink:label="us-gaap_AgencySecuritiesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnderlyingAssetClassDomain" xlink:type="locator" xlink:label="us-gaap_UnderlyingAssetClassDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnderlyingAssetClassAxis" xlink:type="locator" xlink:label="us-gaap_UnderlyingAssetClassAxis" />
    <link:loc xlink:href="nk-20191231.xsd#nk_NoncurrentAssetsMember" xlink:type="locator" xlink:label="nk_NoncurrentAssetsMember" />
    <link:loc xlink:href="nk-20191231.xsd#nk_CurrentAssetsMember" xlink:type="locator" xlink:label="nk_CurrentAssetsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_BalanceSheetLocationAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="nk_CurrentAssetsMember" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="nk_NoncurrentAssetsMember" order="10420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_UnderlyingAssetClassAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_UnderlyingAssetClassAxis" xlink:to="us-gaap_UnderlyingAssetClassDomain" order="10460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_UnderlyingAssetClassDomain" xlink:to="us-gaap_AgencySecuritiesMember" order="10480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_InvestmentTypeAxis" order="10030.08" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" order="10520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_ForeignGovernmentDebtMember" order="10540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="10030.10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="10580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_CashAndCashEquivalentsMember" order="10600.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_CorporateDebtSecuritiesMember" order="10620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="11180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" order="11190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail" xlink:href="nk-20191231.xsd#Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail">
    <link:loc xlink:href="nk-20191231.xsd#nk_AgreementOneTimeFee" xlink:type="locator" xlink:label="nk_AgreementOneTimeFee" />
    <link:loc xlink:href="nk-20191231.xsd#nk_LicenseAgreementTerm" xlink:type="locator" xlink:label="nk_LicenseAgreementTerm" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RoyaltyExpense" xlink:type="locator" xlink:label="us-gaap_RoyaltyExpense" />
    <link:loc xlink:href="nk-20191231.xsd#nk_MinimumSalesMilestoneOfLicenseForFirstYear" xlink:type="locator" xlink:label="nk_MinimumSalesMilestoneOfLicenseForFirstYear" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:type="locator" xlink:label="us-gaap_CostOfGoodsAndServicesSold" />
    <link:loc xlink:href="nk-20191231.xsd#nk_MinimumAnnualRoyaltyPayment" xlink:type="locator" xlink:label="nk_MinimumAnnualRoyaltyPayment" />
    <link:loc xlink:href="nk-20191231.xsd#nk_PeriodOfLicenseAgreement" xlink:type="locator" xlink:label="nk_PeriodOfLicenseAgreement" />
    <link:loc xlink:href="nk-20191231.xsd#nk_PaymentsForInitialLicenseFees" xlink:type="locator" xlink:label="nk_PaymentsForInitialLicenseFees" />
    <link:loc xlink:href="nk-20191231.xsd#nk_LicenseAgreementTerminationNoticePeriod" xlink:type="locator" xlink:label="nk_LicenseAgreementTerminationNoticePeriod" />
    <link:loc xlink:href="nk-20191231.xsd#nk_MilestonePaymentAmount" xlink:type="locator" xlink:label="nk_MilestonePaymentAmount" />
    <link:loc xlink:href="nk-20191231.xsd#nk_SuppliesAndMilestoneChargesForConductingClinicalTrials" xlink:type="locator" xlink:label="nk_SuppliesAndMilestoneChargesForConductingClinicalTrials" />
    <link:loc xlink:href="nk-20191231.xsd#nk_MaximumNumberOfPatientsInPhaseOneAndTwoForClinicalTrials" xlink:type="locator" xlink:label="nk_MaximumNumberOfPatientsInPhaseOneAndTwoForClinicalTrials" />
    <link:loc xlink:href="nk-20191231.xsd#nk_LicensingAgreementLineItems" xlink:type="locator" xlink:label="nk_LicensingAgreementLineItems" />
    <link:loc xlink:href="nk-20191231.xsd#nk_IntrexonLicenseAgreementMember" xlink:type="locator" xlink:label="nk_IntrexonLicenseAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
    <link:loc xlink:href="nk-20191231.xsd#nk_CommercialSaleRelatedToLicensedProductsMember" xlink:type="locator" xlink:label="nk_CommercialSaleRelatedToLicensedProductsMember" />
    <link:loc xlink:href="nk-20191231.xsd#nk_PhaseThreeMember" xlink:type="locator" xlink:label="nk_PhaseThreeMember" />
    <link:loc xlink:href="nk-20191231.xsd#nk_PhaseTwoMember" xlink:type="locator" xlink:label="nk_PhaseTwoMember" />
    <link:loc xlink:href="nk-20191231.xsd#nk_INDFilingMember" xlink:type="locator" xlink:label="nk_INDFilingMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" />
    <link:loc xlink:href="nk-20191231.xsd#nk_RushUniversityMedicalCenterLicenseAgreementMember" xlink:type="locator" xlink:label="nk_RushUniversityMedicalCenterLicenseAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCommitmentsDomain" xlink:type="locator" xlink:label="us-gaap_OtherCommitmentsDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCommitmentsAxis" xlink:type="locator" xlink:label="us-gaap_OtherCommitmentsAxis" />
    <link:loc xlink:href="nk-20191231.xsd#nk_GeorgSpeyerHausAndDRKBlutspendedienstBadenWurttembergHessengGmbHLicenseAgreementMember" xlink:type="locator" xlink:label="nk_GeorgSpeyerHausAndDRKBlutspendedienstBadenWurttembergHessengGmbHLicenseAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="nk-20191231.xsd#nk_ViractaTherapeuticsIncMember" xlink:type="locator" xlink:label="nk_ViractaTherapeuticsIncMember" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <link:loc xlink:href="nk-20191231.xsd#nk_AltorBioScienceCorporationMember" xlink:type="locator" xlink:label="nk_AltorBioScienceCorporationMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" />
    <link:loc xlink:href="nk-20191231.xsd#nk_LicensingAgreementTable" xlink:type="locator" xlink:label="nk_LicensingAgreementTable" />
    <link:loc xlink:href="nk-20191231.xsd#nk_LicensingAgreementAbstract" xlink:type="locator" xlink:label="nk_LicensingAgreementAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nk_LicensingAgreementAbstract" xlink:to="nk_LicensingAgreementTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nk_LicensingAgreementTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="nk_AltorBioScienceCorporationMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nk_LicensingAgreementTable" xlink:to="dei_LegalEntityAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="nk_ViractaTherapeuticsIncMember" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nk_LicensingAgreementTable" xlink:to="srt_RangeAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nk_LicensingAgreementTable" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="nk_GeorgSpeyerHausAndDRKBlutspendedienstBadenWurttembergHessengGmbHLicenseAgreementMember" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nk_LicensingAgreementTable" xlink:to="us-gaap_OtherCommitmentsAxis" order="10030.08" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="us-gaap_OtherCommitmentsDomain" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsDomain" xlink:to="nk_RushUniversityMedicalCenterLicenseAgreementMember" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nk_LicensingAgreementTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" order="10030.10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" order="10580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="nk_INDFilingMember" order="10600.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="nk_PhaseTwoMember" order="10620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="nk_PhaseThreeMember" order="10640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="nk_CommercialSaleRelatedToLicensedProductsMember" order="10660.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nk_LicensingAgreementTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="10030.12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="10700.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="nk_IntrexonLicenseAgreementMember" order="10720.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nk_LicensingAgreementTable" xlink:to="nk_LicensingAgreementLineItems" order="10880.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nk_LicensingAgreementLineItems" xlink:to="nk_MaximumNumberOfPatientsInPhaseOneAndTwoForClinicalTrials" order="10890.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nk_LicensingAgreementLineItems" xlink:to="nk_SuppliesAndMilestoneChargesForConductingClinicalTrials" order="10940.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nk_LicensingAgreementLineItems" xlink:to="nk_MilestonePaymentAmount" order="11030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nk_LicensingAgreementLineItems" xlink:to="nk_LicenseAgreementTerminationNoticePeriod" order="11070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nk_LicensingAgreementLineItems" xlink:to="nk_PaymentsForInitialLicenseFees" order="11120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nk_LicensingAgreementLineItems" xlink:to="nk_PeriodOfLicenseAgreement" order="11170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nk_LicensingAgreementLineItems" xlink:to="nk_MinimumAnnualRoyaltyPayment" order="11190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nk_LicensingAgreementLineItems" xlink:to="us-gaap_CostOfGoodsAndServicesSold" order="11210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nk_LicensingAgreementLineItems" xlink:to="nk_MinimumSalesMilestoneOfLicenseForFirstYear" order="11230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nk_LicensingAgreementLineItems" xlink:to="us-gaap_RoyaltyExpense" order="11280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nk_LicensingAgreementLineItems" xlink:to="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" order="11340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nk_LicensingAgreementLineItems" xlink:to="nk_LicenseAgreementTerm" order="11430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nk_LicensingAgreementLineItems" xlink:to="nk_AgreementOneTimeFee" order="11510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureCommitmentAndContingenciesAdditionalInformationDetail" xlink:href="nk-20191231.xsd#Role_DisclosureCommitmentAndContingenciesAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureCommitmentAndContingenciesAdditionalInformationDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesRentExpenseNet" />
    <link:loc xlink:href="nk-20191231.xsd#nk_LeaseAgreementExtendedPeriod" xlink:type="locator" xlink:label="nk_LeaseAgreementExtendedPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm" />
    <link:loc xlink:href="nk-20191231.xsd#nk_PeriodOfLicenseAgreementDescription" xlink:type="locator" xlink:label="nk_PeriodOfLicenseAgreementDescription" />
    <link:loc xlink:href="nk-20191231.xsd#nk_AnnualBaseRentIncreasePerSquareFoot" xlink:type="locator" xlink:label="nk_AnnualBaseRentIncreasePerSquareFoot" />
    <link:loc xlink:href="nk-20191231.xsd#nk_AdditionToNumberOfSquareFootOfFacilityLeased" xlink:type="locator" xlink:label="nk_AdditionToNumberOfSquareFootOfFacilityLeased" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseExpirationDate1" xlink:type="locator" xlink:label="us-gaap_LeaseExpirationDate1" />
    <link:loc xlink:href="nk-20191231.xsd#nk_LeaseCommencementDate" xlink:type="locator" xlink:label="nk_LeaseCommencementDate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" />
    <link:loc xlink:href="nk-20191231.xsd#nk_AnnualPercentageIncreasesToBaseRentCommencementDate" xlink:type="locator" xlink:label="nk_AnnualPercentageIncreasesToBaseRentCommencementDate" />
    <link:loc xlink:href="nk-20191231.xsd#nk_AnnualPercentageIncreasesToBaseRent" xlink:type="locator" xlink:label="nk_AnnualPercentageIncreasesToBaseRent" />
    <link:loc xlink:href="nk-20191231.xsd#nk_BaseMonthlyRent" xlink:type="locator" xlink:label="nk_BaseMonthlyRent" />
    <link:loc xlink:href="nk-20191231.xsd#nk_PeriodOfExtendedLeaseTerm" xlink:type="locator" xlink:label="nk_PeriodOfExtendedLeaseTerm" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseDescription" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseDescription" />
    <link:loc xlink:href="nk-20191231.xsd#nk_NumberOfSquareFootOfFacilityLeased" xlink:type="locator" xlink:label="nk_NumberOfSquareFootOfFacilityLeased" />
    <link:loc xlink:href="nk-20191231.xsd#nk_RelatedPartyAgreementExpirationMonthAndYear" xlink:type="locator" xlink:label="nk_RelatedPartyAgreementExpirationMonthAndYear" />
    <link:loc xlink:href="nk-20191231.xsd#nk_RelatedPartyTransactionInitialTermOfAgreement" xlink:type="locator" xlink:label="nk_RelatedPartyTransactionInitialTermOfAgreement" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction" />
    <link:loc xlink:href="nk-20191231.xsd#nk_RelatedPartyTransactionAmountPaidToRelatedParty" xlink:type="locator" xlink:label="nk_RelatedPartyTransactionAmountPaidToRelatedParty" />
    <link:loc xlink:href="nk-20191231.xsd#nk_RelatedPartyTransactionReimbursedUpfrontPaymentToThirdParty" xlink:type="locator" xlink:label="nk_RelatedPartyTransactionReimbursedUpfrontPaymentToThirdParty" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:type="locator" xlink:label="us-gaap_OperatingLeasePayments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableLeaseCost" xlink:type="locator" xlink:label="us-gaap_VariableLeaseCost" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseCost" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="locator" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InsuranceSettlementsReceivable" xlink:type="locator" xlink:label="us-gaap_InsuranceSettlementsReceivable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LegalFees" xlink:type="locator" xlink:label="us-gaap_LegalFees" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:type="locator" xlink:label="us-gaap_LitigationSettlementAmountAwardedToOtherParty" />
    <link:loc xlink:href="nk-20191231.xsd#nk_CommitmentsAndContingenciesLineItems" xlink:type="locator" xlink:label="nk_CommitmentsAndContingenciesLineItems" />
    <link:loc xlink:href="nk-20191231.xsd#nk_CommitmentSanDiegoMember" xlink:type="locator" xlink:label="nk_CommitmentSanDiegoMember" />
    <link:loc xlink:href="nk-20191231.xsd#nk_NantWorksLimitedLiabilityCompanyMember" xlink:type="locator" xlink:label="nk_NantWorksLimitedLiabilityCompanyMember" />
    <link:loc xlink:href="nk-20191231.xsd#nk_CommitmentWoburnMassachusettsMember" xlink:type="locator" xlink:label="nk_CommitmentWoburnMassachusettsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseArrangementTypeDomain" xlink:type="locator" xlink:label="us-gaap_LeaseArrangementTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseArrangementTypeAxis" xlink:type="locator" xlink:label="us-gaap_LeaseArrangementTypeAxis" />
    <link:loc xlink:href="nk-20191231.xsd#nk_ElSegundoCaliforniaMember" xlink:type="locator" xlink:label="nk_ElSegundoCaliforniaMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementGeographicalAxis" xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" />
    <link:loc xlink:href="nk-20191231.xsd#nk_DougStLLCMember" xlink:type="locator" xlink:label="nk_DougStLLCMember" />
    <link:loc xlink:href="nk-20191231.xsd#nk_NantBioScienceMember" xlink:type="locator" xlink:label="nk_NantBioScienceMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpenseMember" xlink:type="locator" xlink:label="us-gaap_OperatingExpenseMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:type="locator" xlink:label="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationAxis" />
    <link:loc xlink:href="nk-20191231.xsd#nk_DirectorsAndOfficersInsurancePolicyMember" xlink:type="locator" xlink:label="nk_DirectorsAndOfficersInsurancePolicyMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReinsurancePolicyDomain" xlink:type="locator" xlink:label="us-gaap_ReinsurancePolicyDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReinsurancePolicyTypeAxis" xlink:type="locator" xlink:label="us-gaap_ReinsurancePolicyTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:loc xlink:href="nk-20191231.xsd#nk_CommitmentsAndContingenciesTable" xlink:type="locator" xlink:label="nk_CommitmentsAndContingenciesTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="nk_CommitmentsAndContingenciesTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nk_CommitmentsAndContingenciesTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nk_CommitmentsAndContingenciesTable" xlink:to="us-gaap_ReinsurancePolicyTypeAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReinsurancePolicyTypeAxis" xlink:to="us-gaap_ReinsurancePolicyDomain" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReinsurancePolicyDomain" xlink:to="nk_DirectorsAndOfficersInsurancePolicyMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nk_CommitmentsAndContingenciesTable" xlink:to="us-gaap_BalanceSheetLocationAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_OperatingExpenseMember" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nk_CommitmentsAndContingenciesTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="nk_NantBioScienceMember" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="nk_DougStLLCMember" order="10480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nk_CommitmentsAndContingenciesTable" xlink:to="srt_StatementGeographicalAxis" order="10030.08" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="10620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="nk_ElSegundoCaliforniaMember" order="10640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nk_CommitmentsAndContingenciesTable" xlink:to="us-gaap_LeaseArrangementTypeAxis" order="10030.10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseArrangementTypeAxis" xlink:to="us-gaap_LeaseArrangementTypeDomain" order="10680.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseArrangementTypeDomain" xlink:to="nk_CommitmentWoburnMassachusettsMember" order="10700.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="nk_NantWorksLimitedLiabilityCompanyMember" order="10980.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseArrangementTypeDomain" xlink:to="nk_CommitmentSanDiegoMember" order="11040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nk_CommitmentsAndContingenciesTable" xlink:to="nk_CommitmentsAndContingenciesLineItems" order="11120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nk_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_LitigationSettlementAmountAwardedToOtherParty" order="11130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nk_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_LegalFees" order="11220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nk_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_InsuranceSettlementsReceivable" order="11270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nk_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" order="11340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nk_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_OperatingLeaseCost" order="11390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nk_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_VariableLeaseCost" order="11450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nk_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="11510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nk_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="11570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nk_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_OperatingLeasePayments" order="11630.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nk_CommitmentsAndContingenciesLineItems" xlink:to="nk_RelatedPartyTransactionReimbursedUpfrontPaymentToThirdParty" order="11720.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nk_CommitmentsAndContingenciesLineItems" xlink:to="nk_RelatedPartyTransactionAmountPaidToRelatedParty" order="11740.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nk_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_RelatedPartyTransactionAmountsOfTransaction" order="11760.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nk_CommitmentsAndContingenciesLineItems" xlink:to="nk_RelatedPartyTransactionInitialTermOfAgreement" order="11780.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nk_CommitmentsAndContingenciesLineItems" xlink:to="nk_RelatedPartyAgreementExpirationMonthAndYear" order="11800.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nk_CommitmentsAndContingenciesLineItems" xlink:to="nk_NumberOfSquareFootOfFacilityLeased" order="11850.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nk_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseDescription" order="11870.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nk_CommitmentsAndContingenciesLineItems" xlink:to="nk_PeriodOfExtendedLeaseTerm" order="11890.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nk_CommitmentsAndContingenciesLineItems" xlink:to="nk_BaseMonthlyRent" order="11910.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nk_CommitmentsAndContingenciesLineItems" xlink:to="nk_AnnualPercentageIncreasesToBaseRent" order="11930.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nk_CommitmentsAndContingenciesLineItems" xlink:to="nk_AnnualPercentageIncreasesToBaseRentCommencementDate" order="11950.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nk_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" order="12020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nk_CommitmentsAndContingenciesLineItems" xlink:to="nk_LeaseCommencementDate" order="12040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nk_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_LeaseExpirationDate1" order="12060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nk_CommitmentsAndContingenciesLineItems" xlink:to="nk_AdditionToNumberOfSquareFootOfFacilityLeased" order="12080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nk_CommitmentsAndContingenciesLineItems" xlink:to="nk_AnnualBaseRentIncreasePerSquareFoot" order="12140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nk_CommitmentsAndContingenciesLineItems" xlink:to="nk_PeriodOfLicenseAgreementDescription" order="12160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nk_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm" order="12180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nk_CommitmentsAndContingenciesLineItems" xlink:to="nk_LeaseAgreementExtendedPeriod" order="12200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nk_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_OperatingLeasesRentExpenseNet" order="12510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureCommitmentAndContingenciesScheduleOfLeaseBalancesDetail" xlink:href="nk-20191231.xsd#Role_DisclosureCommitmentAndContingenciesScheduleOfLeaseBalancesDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureCommitmentAndContingenciesScheduleOfLeaseBalancesDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsAndLiabilitiesLesseeAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsAndLiabilitiesLesseeAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAndLiabilitiesLesseeAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAndLiabilitiesLesseeAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAndLiabilitiesLesseeAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureCommitmentAndContingenciesSummaryOfFutureMinimumLeasePaymentsDetail" xlink:href="nk-20191231.xsd#Role_DisclosureCommitmentAndContingenciesSummaryOfFutureMinimumLeasePaymentsDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureCommitmentAndContingenciesSummaryOfFutureMinimumLeasePaymentsDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureCommitmentAndContingenciesSummaryOfFutureMinimumLeasePaymentsParentheticalDetail" xlink:href="nk-20191231.xsd#Role_DisclosureCommitmentAndContingenciesSummaryOfFutureMinimumLeasePaymentsParentheticalDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureCommitmentAndContingenciesSummaryOfFutureMinimumLeasePaymentsParentheticalDetail">
    <link:loc xlink:href="nk-20191231.xsd#nk_OperatingLeasePaymentsRelatedToOptionsToExtendLeaseTerms" xlink:type="locator" xlink:label="nk_OperatingLeasePaymentsRelatedToOptionsToExtendLeaseTerms" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="nk_OperatingLeasePaymentsRelatedToOptionsToExtendLeaseTerms" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureRelatedPartyAgreementsAdditionalInformationDetail" xlink:href="nk-20191231.xsd#Role_DisclosureRelatedPartyAgreementsAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureRelatedPartyAgreementsAdditionalInformationDetail">
    <link:loc xlink:href="nk-20191231.xsd#nk_PrepaidExpensesAndOtherAssetsCurrentWithRelatedParty" xlink:type="locator" xlink:label="nk_PrepaidExpensesAndOtherAssetsCurrentWithRelatedParty" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" />
    <link:loc xlink:href="nk-20191231.xsd#nk_SuppliesAndMilestoneChargesForConductingClinicalTrials" xlink:type="locator" xlink:label="nk_SuppliesAndMilestoneChargesForConductingClinicalTrials" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:type="locator" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" />
    <link:loc xlink:href="nk-20191231.xsd#nk_TransferOfDepositAmountToThirdParty" xlink:type="locator" xlink:label="nk_TransferOfDepositAmountToThirdParty" />
    <link:loc xlink:href="nk-20191231.xsd#nk_PrepaymentOfFundingAmount" xlink:type="locator" xlink:label="nk_PrepaymentOfFundingAmount" />
    <link:loc xlink:href="nk-20191231.xsd#nk_ResearchAndDevelopmentExpenseRatablePaymentPeriod" xlink:type="locator" xlink:label="nk_ResearchAndDevelopmentExpenseRatablePaymentPeriod" />
    <link:loc xlink:href="nk-20191231.xsd#nk_RelatedPartyAgreementExpirationMonthAndYear" xlink:type="locator" xlink:label="nk_RelatedPartyAgreementExpirationMonthAndYear" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction_li0l2" />
    <link:loc xlink:href="nk-20191231.xsd#nk_RelatedPartyTransactionAmountPaidToThirdParty" xlink:type="locator" xlink:label="nk_RelatedPartyTransactionAmountPaidToThirdParty" />
    <link:loc xlink:href="nk-20191231.xsd#nk_RelatedPartyTransactionReimbursedUpfrontPaymentToRelatedParty" xlink:type="locator" xlink:label="nk_RelatedPartyTransactionReimbursedUpfrontPaymentToRelatedParty" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseExpense" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseExpense" />
    <link:loc xlink:href="nk-20191231.xsd#nk_AnnualPercentageIncreasesToBaseRentCommencementDate" xlink:type="locator" xlink:label="nk_AnnualPercentageIncreasesToBaseRentCommencementDate" />
    <link:loc xlink:href="nk-20191231.xsd#nk_AnnualPercentageIncreasesToBaseRent" xlink:type="locator" xlink:label="nk_AnnualPercentageIncreasesToBaseRent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionDueFromToRelatedParty" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDueFromToRelatedParty" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesIncomeStatementSubleaseRevenue" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesIncomeStatementSubleaseRevenue" />
    <link:loc xlink:href="nk-20191231.xsd#nk_BaseMonthlyRent" xlink:type="locator" xlink:label="nk_BaseMonthlyRent" />
    <link:loc xlink:href="nk-20191231.xsd#nk_NumberOfSquareFootOfFacilityLeased" xlink:type="locator" xlink:label="nk_NumberOfSquareFootOfFacilityLeased" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionDescriptionOfTransaction" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDescriptionOfTransaction" />
    <link:loc xlink:href="nk-20191231.xsd#nk_PrepaidBalanceIncludedInPrepaidExpensesAndOtherCurrentAssetsAndOtherAssets" xlink:type="locator" xlink:label="nk_PrepaidBalanceIncludedInPrepaidExpensesAndOtherCurrentAssetsAndOtherAssets" />
    <link:loc xlink:href="nk-20191231.xsd#nk_NewAgreementTerminationNoticePeriod" xlink:type="locator" xlink:label="nk_NewAgreementTerminationNoticePeriod" />
    <link:loc xlink:href="nk-20191231.xsd#nk_RelatedPartyTransactionAgreementExtensionDescription" xlink:type="locator" xlink:label="nk_RelatedPartyTransactionAgreementExtensionDescription" />
    <link:loc xlink:href="nk-20191231.xsd#nk_RelatedPartyInstallmentPayment" xlink:type="locator" xlink:label="nk_RelatedPartyInstallmentPayment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction" />
    <link:loc xlink:href="nk-20191231.xsd#nk_InitialTermOfAgreement" xlink:type="locator" xlink:label="nk_InitialTermOfAgreement" />
    <link:loc xlink:href="nk-20191231.xsd#nk_NumberOfOfficers" xlink:type="locator" xlink:label="nk_NumberOfOfficers" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:type="locator" xlink:label="us-gaap_DueToRelatedPartiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:loc xlink:href="nk-20191231.xsd#nk_RelatedPartyAgreementRenewalTerm" xlink:type="locator" xlink:label="nk_RelatedPartyAgreementRenewalTerm" />
    <link:loc xlink:href="nk-20191231.xsd#nk_RelatedPartyTransactionInitialTermOfAgreement" xlink:type="locator" xlink:label="nk_RelatedPartyTransactionInitialTermOfAgreement" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:type="locator" xlink:label="us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:type="locator" xlink:label="us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
    <link:loc xlink:href="nk-20191231.xsd#nk_AltorBioScienceCorporationMember" xlink:type="locator" xlink:label="nk_AltorBioScienceCorporationMember" />
    <link:loc xlink:href="nk-20191231.xsd#nk_VivaBioCellSPAMember" xlink:type="locator" xlink:label="nk_VivaBioCellSPAMember" />
    <link:loc xlink:href="nk-20191231.xsd#nk_ImmunityBioMember" xlink:type="locator" xlink:label="nk_ImmunityBioMember" />
    <link:loc xlink:href="nk-20191231.xsd#nk_NantOmicsLLCMember" xlink:type="locator" xlink:label="nk_NantOmicsLLCMember" />
    <link:loc xlink:href="nk-20191231.xsd#nk_SharedServicesAgreementMember" xlink:type="locator" xlink:label="nk_SharedServicesAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="nk-20191231.xsd#nk_ReimbursementsMember" xlink:type="locator" xlink:label="nk_ReimbursementsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransactionDomain" xlink:type="locator" xlink:label="us-gaap_TransactionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransactionTypeAxis" xlink:type="locator" xlink:label="us-gaap_TransactionTypeAxis" />
    <link:loc xlink:href="nk-20191231.xsd#nk_NantWorksLimitedLiabilityCompanyMember" xlink:type="locator" xlink:label="nk_NantWorksLimitedLiabilityCompanyMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:type="locator" xlink:label="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationAxis" />
    <link:loc xlink:href="nk-20191231.xsd#nk_NantBioScienceMember" xlink:type="locator" xlink:label="nk_NantBioScienceMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:loc xlink:href="nk-20191231.xsd#nk_ElSegundoCaliforniaMember" xlink:type="locator" xlink:label="nk_ElSegundoCaliforniaMember" />
    <link:loc xlink:href="nk-20191231.xsd#nk_DougStLLCMember" xlink:type="locator" xlink:label="nk_DougStLLCMember" />
    <link:loc xlink:href="nk-20191231.xsd#nk_SanDiegoCaliforniaMember" xlink:type="locator" xlink:label="nk_SanDiegoCaliforniaMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherIncomeMember" xlink:type="locator" xlink:label="us-gaap_OtherIncomeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:loc xlink:href="nk-20191231.xsd#nk_TensorcomIncMember" xlink:type="locator" xlink:label="nk_TensorcomIncMember" />
    <link:loc xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_CA" xlink:type="locator" xlink:label="stpr_CA" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementGeographicalAxis" xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" />
    <link:loc xlink:href="nk-20191231.xsd#nk_ImmunoOncologyClinicIncMember" xlink:type="locator" xlink:label="nk_ImmunoOncologyClinicIncMember" />
    <link:loc xlink:href="nk-20191231.xsd#nk_NantHealthLabsIncMember" xlink:type="locator" xlink:label="nk_NantHealthLabsIncMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="nk_NantHealthLabsIncMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="nk_ImmunoOncologyClinicIncMember" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="srt_StatementGeographicalAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="stpr_CA" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="nk_TensorcomIncMember" order="11000.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="11120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_OtherIncomeMember" order="11140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="nk_SanDiegoCaliforniaMember" order="11200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="nk_DougStLLCMember" order="11340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="nk_ElSegundoCaliforniaMember" order="11520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="11580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="nk_NantBioScienceMember" order="11640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_BalanceSheetLocationAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" order="11860.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" order="11880.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="nk_NantWorksLimitedLiabilityCompanyMember" order="12200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_TransactionTypeAxis" order="10030.08" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransactionTypeAxis" xlink:to="us-gaap_TransactionDomain" order="12340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransactionDomain" xlink:to="nk_ReimbursementsMember" order="12360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10030.10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="12440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="nk_SharedServicesAgreementMember" order="12460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="nk_NantOmicsLLCMember" order="12740.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="nk_ImmunityBioMember" order="12860.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="nk_VivaBioCellSPAMember" order="12940.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="nk_AltorBioScienceCorporationMember" order="13000.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionLineItems" order="13220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" order="13230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" order="13250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="nk_RelatedPartyTransactionInitialTermOfAgreement" order="13300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="nk_RelatedPartyAgreementRenewalTerm" order="13340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="13380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_DueToRelatedPartiesCurrent" order="13420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="nk_NumberOfOfficers" order="13490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="nk_InitialTermOfAgreement" order="13540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionAmountsOfTransaction" order="13590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="nk_RelatedPartyInstallmentPayment" order="13610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="nk_RelatedPartyTransactionAgreementExtensionDescription" order="13680.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="nk_NewAgreementTerminationNoticePeriod" order="13700.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="nk_PrepaidBalanceIncludedInPrepaidExpensesAndOtherCurrentAssetsAndOtherAssets" order="13870.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionDescriptionOfTransaction" order="13960.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="nk_NumberOfSquareFootOfFacilityLeased" order="14000.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="nk_BaseMonthlyRent" order="14040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_OperatingLeasesIncomeStatementSubleaseRevenue" order="14080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionDueFromToRelatedParty" order="14120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="nk_AnnualPercentageIncreasesToBaseRent" order="14370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="nk_AnnualPercentageIncreasesToBaseRentCommencementDate" order="14430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_OperatingLeaseExpense" order="14490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="nk_RelatedPartyTransactionReimbursedUpfrontPaymentToRelatedParty" order="14640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="nk_RelatedPartyTransactionAmountPaidToThirdParty" order="14660.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionAmountsOfTransaction_li0l2" order="14680.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="nk_RelatedPartyAgreementExpirationMonthAndYear" order="14720.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="nk_ResearchAndDevelopmentExpenseRatablePaymentPeriod" order="15100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="nk_PrepaymentOfFundingAmount" order="15220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="nk_TransferOfDepositAmountToThirdParty" order="15390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" order="15450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" order="16200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" order="16220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="nk_SuppliesAndMilestoneChargesForConductingClinicalTrials" order="16360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" order="16520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="nk_PrepaidExpensesAndOtherAssetsCurrentWithRelatedParty" order="16640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" xlink:href="nk-20191231.xsd#Role_DisclosureStockholdersEquityAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:type="locator" xlink:label="us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SalesCommissionsAndFees" xlink:type="locator" xlink:label="us-gaap_SalesCommissionsAndFees" />
    <link:loc xlink:href="nk-20191231.xsd#nk_StockRepurchasedAndRetiredExcludingCommissionDuringPeriodValue" xlink:type="locator" xlink:label="nk_StockRepurchasedAndRetiredExcludingCommissionDuringPeriodValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:type="locator" xlink:label="us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:type="locator" xlink:label="us-gaap_StockRepurchaseProgramAuthorizedAmount1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract" xlink:type="locator" xlink:label="us-gaap_EquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_StockRepurchaseProgramAuthorizedAmount1" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="nk_StockRepurchasedAndRetiredExcludingCommissionDuringPeriodValue" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_SalesCommissionsAndFees" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="10530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="10550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="10570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="10590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureStockholdersEquitySummaryOfCommonSharesReservedForIssuanceDetail" xlink:href="nk-20191231.xsd#Role_DisclosureStockholdersEquitySummaryOfCommonSharesReservedForIssuanceDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureStockholdersEquitySummaryOfCommonSharesReservedForIssuanceDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" />
    <link:loc xlink:href="nk-20191231.xsd#nk_OutstandingOfficerWarrantsMember" xlink:type="locator" xlink:label="nk_OutstandingOfficerWarrantsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract" xlink:type="locator" xlink:label="us-gaap_EquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_AwardTypeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="nk_OutstandingOfficerWarrantsMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfStockLineItems" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail" xlink:href="nk-20191231.xsd#Role_DisclosureStockBasedCompensationAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:type="locator" xlink:label="us-gaap_ProceedsFromWarrantExercises" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
    <link:loc xlink:href="nk-20191231.xsd#nk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableOutstandingNumber" xlink:type="locator" xlink:label="nk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableOutstandingNumber" />
    <link:loc xlink:href="nk-20191231.xsd#nk_ShareBasedCompensationArrangementByShareBasedPaymentAwardPossibleIncreaseInNumberOfSharesReservedForIssuance" xlink:type="locator" xlink:label="nk_ShareBasedCompensationArrangementByShareBasedPaymentAwardPossibleIncreaseInNumberOfSharesReservedForIssuance" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:href="nk-20191231.xsd#nk_EmployeeRestrictedStockUnitMember" xlink:type="locator" xlink:label="nk_EmployeeRestrictedStockUnitMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <link:loc xlink:href="nk-20191231.xsd#nk_NonEmployeeRestrictedStockUnitMember" xlink:type="locator" xlink:label="nk_NonEmployeeRestrictedStockUnitMember" />
    <link:loc xlink:href="nk-20191231.xsd#nk_NonEmployeeStockOptionsMember" xlink:type="locator" xlink:label="nk_NonEmployeeStockOptionsMember" />
    <link:loc xlink:href="nk-20191231.xsd#nk_KeyExecutivesStockOptionsMember" xlink:type="locator" xlink:label="nk_KeyExecutivesStockOptionsMember" />
    <link:loc xlink:href="nk-20191231.xsd#nk_TwoThousandFifteenEquityIncentivePlanMember" xlink:type="locator" xlink:label="nk_TwoThousandFifteenEquityIncentivePlanMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonClassAMember" xlink:type="locator" xlink:label="us-gaap_CommonClassAMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="nk-20191231.xsd#nk_TwoThousandFourteenEquityIncentivePlanMember" xlink:type="locator" xlink:label="nk_TwoThousandFourteenEquityIncentivePlanMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="nk_TwoThousandFourteenEquityIncentivePlanMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassAMember" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="nk_TwoThousandFifteenEquityIncentivePlanMember" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="nk_KeyExecutivesStockOptionsMember" order="10660.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="nk_NonEmployeeStockOptionsMember" order="10760.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="nk_NonEmployeeRestrictedStockUnitMember" order="10880.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="10900.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="nk_EmployeeRestrictedStockUnitMember" order="10940.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="11080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" order="11090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" order="11110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" order="11160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="11210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="nk_ShareBasedCompensationArrangementByShareBasedPaymentAwardPossibleIncreaseInNumberOfSharesReservedForIssuance" order="11230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="nk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableOutstandingNumber" order="11280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" order="11350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="11410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" order="11500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" order="11580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" order="11660.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="11740.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" order="12010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="12030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="12080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" order="12140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ProceedsFromWarrantExercises" order="12650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureStockBasedCompensationStockBasedCompensationExpensesRelatedToStatementOfOperationsDetail" xlink:href="nk-20191231.xsd#Role_DisclosureStockBasedCompensationStockBasedCompensationExpensesRelatedToStatementOfOperationsDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureStockBasedCompensationStockBasedCompensationExpensesRelatedToStatementOfOperationsDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_OfficerMember" xlink:type="locator" xlink:label="srt_OfficerMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualAxis" xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" />
    <link:loc xlink:href="nk-20191231.xsd#nk_NonEmployeeRestrictedStockUnitMember" xlink:type="locator" xlink:label="nk_NonEmployeeRestrictedStockUnitMember" />
    <link:loc xlink:href="nk-20191231.xsd#nk_EmployeeRestrictedStockUnitMember" xlink:type="locator" xlink:label="nk_EmployeeRestrictedStockUnitMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockCompensationPlanMember" xlink:type="locator" xlink:label="us-gaap_StockCompensationPlanMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_AwardTypeAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_StockCompensationPlanMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="nk_EmployeeRestrictedStockUnitMember" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="nk_NonEmployeeRestrictedStockUnitMember" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="srt_TitleOfIndividualAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_OfficerMember" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureStockBasedCompensationStockOptionActivityDetail" xlink:href="nk-20191231.xsd#Role_DisclosureStockBasedCompensationStockOptionActivityDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureStockBasedCompensationStockOptionActivityDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <link:loc xlink:href="nk-20191231.xsd#nk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:type="locator" xlink:label="nk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="10590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="10690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_li0l2" order="10790.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" order="11290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" order="11420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="11620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="11720.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="11820.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_li0l2" order="11920.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" order="12420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="nk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" order="12550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="12750.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_li0l2" order="12850.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" order="13150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" order="13280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="13480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" order="13880.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfOptionsOutstandingAndVestedPricingOfExercisePricesDetail" xlink:href="nk-20191231.xsd#Role_DisclosureStockBasedCompensationSummaryOfOptionsOutstandingAndVestedPricingOfExercisePricesDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfOptionsOutstandingAndVestedPricingOfExercisePricesDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" />
    <link:loc xlink:href="nk-20191231.xsd#nk_ExercisePriceRangeFiveMember" xlink:type="locator" xlink:label="nk_ExercisePriceRangeFiveMember" />
    <link:loc xlink:href="nk-20191231.xsd#nk_ExercisePriceRangeFourMember" xlink:type="locator" xlink:label="nk_ExercisePriceRangeFourMember" />
    <link:loc xlink:href="nk-20191231.xsd#nk_ExercisePriceRangeThreeMember" xlink:type="locator" xlink:label="nk_ExercisePriceRangeThreeMember" />
    <link:loc xlink:href="nk-20191231.xsd#nk_ExercisePriceRangeTwoMember" xlink:type="locator" xlink:label="nk_ExercisePriceRangeTwoMember" />
    <link:loc xlink:href="nk-20191231.xsd#nk_ExercisePriceRangeOneMember" xlink:type="locator" xlink:label="nk_ExercisePriceRangeOneMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="us-gaap_AwardTypeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="nk_ExercisePriceRangeOneMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="nk_ExercisePriceRangeTwoMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="nk_ExercisePriceRangeThreeMember" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="nk_ExercisePriceRangeFourMember" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="nk_ExercisePriceRangeFiveMember" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" order="10530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="10670.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" order="10810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureStockBasedCompensationBlackScholesOptionPricingModelToDetermineFairValueOfAssumptionsUsedForEmployeeStockOptionsGrantedDetail" xlink:href="nk-20191231.xsd#Role_DisclosureStockBasedCompensationBlackScholesOptionPricingModelToDetermineFairValueOfAssumptionsUsedForEmployeeStockOptionsGrantedDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureStockBasedCompensationBlackScholesOptionPricingModelToDetermineFairValueOfAssumptionsUsedForEmployeeStockOptionsGrantedDetail">
    <link:loc xlink:href="nk-20191231.xsd#nk_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsPrice" xlink:type="locator" xlink:label="nk_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsPrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="nk_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsPrice" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureStockBasedCompensationRestrictedStockUnitsRsusActivityDetail" xlink:href="nk-20191231.xsd#Role_DisclosureStockBasedCompensationRestrictedStockUnitsRsusActivityDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureStockBasedCompensationRestrictedStockUnitsRsusActivityDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_li0l2" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="10980.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="11040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" order="11100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" order="11160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_li0l2" order="11220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfWarrantActivityDetail" xlink:href="nk-20191231.xsd#Role_DisclosureStockBasedCompensationSummaryOfWarrantActivityDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfWarrantActivityDetail">
    <link:loc xlink:href="nk-20191231.xsd#nk_ClassOfWarrantOrVestedAndExercisable" xlink:type="locator" xlink:label="nk_ClassOfWarrantOrVestedAndExercisable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_li0l2" />
    <link:loc xlink:href="nk-20191231.xsd#nk_StockIssuedDuringPeriodSharesWarrantsExpired" xlink:type="locator" xlink:label="nk_StockIssuedDuringPeriodSharesWarrantsExpired" />
    <link:loc xlink:href="nk-20191231.xsd#nk_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:type="locator" xlink:label="nk_StockIssuedDuringPeriodSharesWarrantsExercised" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
    <link:loc xlink:href="nk-20191231.xsd#nk_WarrantLineItems" xlink:type="locator" xlink:label="nk_WarrantLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantMember" xlink:type="locator" xlink:label="us-gaap_WarrantMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="nk-20191231.xsd#nk_WarrantTable" xlink:type="locator" xlink:label="nk_WarrantTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract" xlink:type="locator" xlink:label="us-gaap_EquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="nk_WarrantTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nk_WarrantTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_WarrantMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nk_WarrantTable" xlink:to="nk_WarrantLineItems" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nk_WarrantLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nk_WarrantLineItems" xlink:to="nk_StockIssuedDuringPeriodSharesWarrantsExercised" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nk_WarrantLineItems" xlink:to="nk_StockIssuedDuringPeriodSharesWarrantsExpired" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nk_WarrantLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_li0l2" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nk_WarrantLineItems" xlink:to="nk_ClassOfWarrantOrVestedAndExercisable" order="10650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureIncomeTaxesSummaryOfLossBeforeTaxesDetail" xlink:href="nk-20191231.xsd#Role_DisclosureIncomeTaxesSummaryOfLossBeforeTaxesDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureIncomeTaxesSummaryOfLossBeforeTaxesDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureIncomeTaxesSummaryOfIncomeTaxBenefitDetail" xlink:href="nk-20191231.xsd#Role_DisclosureIncomeTaxesSummaryOfIncomeTaxBenefitDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureIncomeTaxesSummaryOfIncomeTaxBenefitDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <link:loc xlink:href="nk-20191231.xsd#nk_DeferredIncomeTaxExpenseBenefitNet" xlink:type="locator" xlink:label="nk_DeferredIncomeTaxExpenseBenefitNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:type="locator" xlink:label="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:type="locator" xlink:label="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_CurrentForeignTaxExpenseBenefit" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" order="10570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" order="10630.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" order="10690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="nk_DeferredIncomeTaxExpenseBenefitNet" order="10750.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="10810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsAndLiabilitiesDetail" xlink:href="nk-20191231.xsd#Role_DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsAndLiabilitiesDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsAndLiabilitiesDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxLiabilities" />
    <link:loc xlink:href="nk-20191231.xsd#nk_DeferredTaxLiabilitiesDeferredDepreciationAndAmortization" xlink:type="locator" xlink:label="nk_DeferredTaxLiabilitiesDeferredDepreciationAndAmortization" />
    <link:loc xlink:href="nk-20191231.xsd#nk_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" xlink:type="locator" xlink:label="nk_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLegalSettlements" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLegalSettlements" />
    <link:loc xlink:href="nk-20191231.xsd#nk_DeferredTaxAssetsLeasesAndOtherAccruedLiabilities" xlink:type="locator" xlink:label="nk_DeferredTaxAssetsLeasesAndOtherAccruedLiabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" />
    <link:loc xlink:href="nk-20191231.xsd#nk_DeferredTaxAssetsDeferredDepreciationAndAmortization" xlink:type="locator" xlink:label="nk_DeferredTaxAssetsDeferredDepreciationAndAmortization" />
    <link:loc xlink:href="nk-20191231.xsd#nk_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:type="locator" xlink:label="nk_DeferredTaxAssetsOperatingLeaseLiabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetAbstract" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="nk_DeferredTaxAssetsOperatingLeaseLiabilities" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="nk_DeferredTaxAssetsDeferredDepreciationAndAmortization" order="10360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" order="10440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="nk_DeferredTaxAssetsLeasesAndOtherAccruedLiabilities" order="10480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLegalSettlements" order="10520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" order="10560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesNetAbstract" order="10600.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" order="10680.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="nk_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" order="10720.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="nk_DeferredTaxLiabilitiesDeferredDepreciationAndAmortization" order="10760.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredIncomeTaxLiabilities" order="10800.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" order="10840.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="10880.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxLiabilities" order="10920.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateDetail" xlink:href="nk-20191231.xsd#Role_DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther" />
    <link:loc xlink:href="nk-20191231.xsd#nk_EffectiveIncomeTaxRateReconciliationStockBasedCompensationContribution" xlink:type="locator" xlink:label="nk_EffectiveIncomeTaxRateReconciliationStockBasedCompensationContribution" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" />
    <link:loc xlink:href="nk-20191231.xsd#nk_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsAct" xlink:type="locator" xlink:label="nk_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsAct" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="nk_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsAct" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="nk_EffectiveIncomeTaxRateReconciliationStockBasedCompensationContribution" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="10510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" order="10570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail" xlink:href="nk-20191231.xsd#Role_DisclosureIncomeTaxesAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail">
    <link:loc xlink:href="nk-20191231.xsd#nk_UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRate" xlink:type="locator" xlink:label="nk_UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRate" />
    <link:loc xlink:href="nk-20191231.xsd#nk_TaxCreditCarryforwardExpirationPeriod" xlink:type="locator" xlink:label="nk_TaxCreditCarryforwardExpirationPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardAmount" />
    <link:loc xlink:href="nk-20191231.xsd#nk_NetOperatingLossCarryforwardsExpirationDate" xlink:type="locator" xlink:label="nk_NetOperatingLossCarryforwardsExpirationDate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwards" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OpenTaxYear" xlink:type="locator" xlink:label="us-gaap_OpenTaxYear" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxEffectsAllocatedDirectlyToEquityEquityTransactions" xlink:type="locator" xlink:label="us-gaap_IncomeTaxEffectsAllocatedDirectlyToEquityEquityTransactions" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="locator" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
    <link:loc xlink:href="nk-20191231.xsd#nk_DerecognizedDeferredTaxAssets" xlink:type="locator" xlink:label="nk_DerecognizedDeferredTaxAssets" />
    <link:loc xlink:href="nk-20191231.xsd#nk_PeriodOfCumulativeOwnershipChange" xlink:type="locator" xlink:label="nk_PeriodOfCumulativeOwnershipChange" />
    <link:loc xlink:href="nk-20191231.xsd#nk_ResearchAndDevelopmentCumulativeChangeInOwnershipPercentage" xlink:type="locator" xlink:label="nk_ResearchAndDevelopmentCumulativeChangeInOwnershipPercentage" />
    <link:loc xlink:href="nk-20191231.xsd#nk_TaxCutsAndJobsActOf2017IncompleteAccountingChangeInTaxRateReductionInDeferredTaxAssets" xlink:type="locator" xlink:label="nk_TaxCutsAndJobsActOf2017IncompleteAccountingChangeInTaxRateReductionInDeferredTaxAssets" />
    <link:loc xlink:href="nk-20191231.xsd#nk_TaxCutsAndJobsActOf2017IncompleteAccountingChangeInTaxRateMinimumAmountForEliminationOfSeveralBusinessDeductionsAndCreditsIncludingDeductionsForCertainExecutiveCompensation" xlink:type="locator" xlink:label="nk_TaxCutsAndJobsActOf2017IncompleteAccountingChangeInTaxRateMinimumAmountForEliminationOfSeveralBusinessDeductionsAndCreditsIncludingDeductionsForCertainExecutiveCompensation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <link:loc xlink:href="nk-20191231.xsd#nk_IncomeTaxLineItems" xlink:type="locator" xlink:label="nk_IncomeTaxLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchMember" xlink:type="locator" xlink:label="us-gaap_ResearchMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCountryMember" xlink:type="locator" xlink:label="us-gaap_ForeignCountryMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:type="locator" xlink:label="us-gaap_StateAndLocalJurisdictionMember" />
    <link:loc xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_CA" xlink:type="locator" xlink:label="stpr_CA" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementGeographicalAxis" xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DomesticCountryMember" xlink:type="locator" xlink:label="us-gaap_DomesticCountryMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="nk-20191231.xsd#nk_IncomeTaxTable" xlink:type="locator" xlink:label="nk_IncomeTaxTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="nk_IncomeTaxTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nk_IncomeTaxTable" xlink:to="srt_RangeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nk_IncomeTaxTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nk_IncomeTaxTable" xlink:to="srt_StatementGeographicalAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="stpr_CA" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" order="10460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_ForeignCountryMember" order="10480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nk_IncomeTaxTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" order="10580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_ResearchMember" order="10600.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nk_IncomeTaxTable" xlink:to="nk_IncomeTaxLineItems" order="10680.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nk_IncomeTaxLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="10690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nk_IncomeTaxLineItems" xlink:to="nk_TaxCutsAndJobsActOf2017IncompleteAccountingChangeInTaxRateMinimumAmountForEliminationOfSeveralBusinessDeductionsAndCreditsIncludingDeductionsForCertainExecutiveCompensation" order="10750.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nk_IncomeTaxLineItems" xlink:to="nk_TaxCutsAndJobsActOf2017IncompleteAccountingChangeInTaxRateReductionInDeferredTaxAssets" order="10810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nk_IncomeTaxLineItems" xlink:to="nk_ResearchAndDevelopmentCumulativeChangeInOwnershipPercentage" order="10900.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nk_IncomeTaxLineItems" xlink:to="nk_PeriodOfCumulativeOwnershipChange" order="10940.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nk_IncomeTaxLineItems" xlink:to="nk_DerecognizedDeferredTaxAssets" order="10980.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nk_IncomeTaxLineItems" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="11050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nk_IncomeTaxLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" order="11090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nk_IncomeTaxLineItems" xlink:to="us-gaap_IncomeTaxEffectsAllocatedDirectlyToEquityEquityTransactions" order="11130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nk_IncomeTaxLineItems" xlink:to="us-gaap_OpenTaxYear" order="11200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nk_IncomeTaxLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" order="11310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nk_IncomeTaxLineItems" xlink:to="nk_NetOperatingLossCarryforwardsExpirationDate" order="11410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nk_IncomeTaxLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" order="11510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nk_IncomeTaxLineItems" xlink:to="nk_TaxCreditCarryforwardExpirationPeriod" order="11710.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nk_IncomeTaxLineItems" xlink:to="nk_UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRate" order="11940.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureIncomeTaxesSummarizesOfChangesInUnrecognizedTaxBenefitsDetail" xlink:href="nk-20191231.xsd#Role_DisclosureIncomeTaxesSummarizesOfChangesInUnrecognizedTaxBenefitsDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureIncomeTaxesSummarizesOfChangesInUnrecognizedTaxBenefitsDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefits_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefits" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefits" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefits_li0l2" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureSummaryOfQuarterlyDataUnauditedDetail" xlink:href="nk-20191231.xsd#Role_DisclosureSummaryOfQuarterlyDataUnauditedDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureSummaryOfQuarterlyDataUnauditedDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpenses" xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues" xlink:type="locator" xlink:label="us-gaap_Revenues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_QuarterlyFinancialDataAbstract" xlink:type="locator" xlink:label="us-gaap_QuarterlyFinancialDataAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_QuarterlyFinancialDataAbstract" xlink:to="us-gaap_Revenues" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_QuarterlyFinancialDataAbstract" xlink:to="us-gaap_OperatingExpenses" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_QuarterlyFinancialDataAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_QuarterlyFinancialDataAbstract" xlink:to="us-gaap_NetIncomeLoss" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_QuarterlyFinancialDataAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_QuarterlyFinancialDataAbstract" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureEmployeeBenefitsAdditionalInformationDetail" xlink:href="nk-20191231.xsd#Role_DisclosureEmployeeBenefitsAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureEmployeeBenefitsAdditionalInformationDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanDisclosureLineItems" />
    <link:loc xlink:href="nk-20191231.xsd#nk_FourHundredOneKPlanMember" xlink:type="locator" xlink:label="nk_FourHundredOneKPlanMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_RetirementPlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanNameAxis" xlink:type="locator" xlink:label="us-gaap_RetirementPlanNameAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedContributionPlanTable" xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_DefinedContributionPlanTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPlanTable" xlink:to="us-gaap_RetirementPlanNameAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RetirementPlanNameAxis" xlink:to="us-gaap_RetirementPlanNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RetirementPlanNameDomain" xlink:to="nk_FourHundredOneKPlanMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPlanTable" xlink:to="us-gaap_DefinedContributionPlanDisclosureLineItems" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail" xlink:href="nk-20191231.xsd#Role_DisclosureSubsequentEventsAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.nantkwest.com/20191231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:loc xlink:href="nk-20191231.xsd#nk_ExpectJointStudyCost" xlink:type="locator" xlink:label="nk_ExpectJointStudyCost" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:type="locator" xlink:label="us-gaap_SubsequentEventLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventMember" xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementMember" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTable" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_CollaborativeArrangementMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventLineItems" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="nk_ExpectJointStudyCost" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6814871616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Summary of Income Tax Benefit (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract', window );"><strong>Current:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentForeignTaxExpenseBenefit', window );">Foreign</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total Current</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract', window );"><strong>Deferred:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Federal</a></td>
<td class="num">(79)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">State</a></td>
<td class="num">(21)<span></span>
</td>
<td class="num">(8)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit', window );">Foreign</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(498)<span></span>
</td>
<td class="num">(497)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_DeferredIncomeTaxExpenseBenefitNet', window );">Total Deferred</a></td>
<td class="num">(100)<span></span>
</td>
<td class="num">(506)<span></span>
</td>
<td class="num">(497)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit</a></td>
<td class="num">$ (97)<span></span>
</td>
<td class="num">$ (503)<span></span>
</td>
<td class="num">$ (493)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nk_DeferredIncomeTaxExpenseBenefitNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred income tax expense benefit, net.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nk_DeferredIncomeTaxExpenseBenefitNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentForeignTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentForeignTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredForeignIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109238882&amp;loc=d3e38679-109324<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6814171648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Black-Scholes Option-Pricing Model to Determine Fair Value of Assumptions Used for Employee Stock Options Granted (Detail) - Employee Stock Option<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2018 </div>
<div>$ / shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">2.80%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">75.90%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsPrice', window );">Weighted-average measurement date fair value</a></td>
<td class="nump">$ 2.09<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (years)</a></td>
<td class="text">6 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (years)</a></td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nk_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award fair value assumptions price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nk_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6922066400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Additional Information (Detail) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from exercises of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35.2<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=nk_TwoThousandFifteenEquityIncentivePlanMember', window );">2015 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Common stock reserved for future grants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_ShareBasedCompensationArrangementByShareBasedPaymentAwardPossibleIncreaseInNumberOfSharesReservedForIssuance', window );">Additional Shares that may be added to shares reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableOutstandingNumber', window );">Stock options, vested and exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,577,531<span></span>
</td>
<td class="nump">5,114,656<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Aggregate intrinsic value of stock options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.2<span></span>
</td>
<td class="nump">$ 0.6<span></span>
</td>
<td class="nump">$ 1.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Cash received from exercised options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.1<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 1.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Shares granted to employee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation cost related to non-vested stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-average period for recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option | 2014 Equity Incentive Plan | Common Class A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Common stock reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,109,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Share-based compensation, expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option | 2015 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Additional common shares reserved for future issuance</a></td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=nk_KeyExecutivesStockOptionsMember', window );">Key Executives Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Shares granted to employee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.07<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Share-based compensation arrangement, award vesting rights, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Remaining vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=nk_NonEmployeeStockOptionsMember', window );">Non Employee Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Shares granted to employee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=nk_NonEmployeeRestrictedStockUnitMember', window );">Non Employee Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-average period for recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Grants of restricted stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">90,906<span></span>
</td>
<td class="nump">77,250<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized compensation cost related to non-vested stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Outstanding RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-average period for recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Grants of restricted stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">749,793<span></span>
</td>
<td class="nump">487,472<span></span>
</td>
<td class="nump">615,983<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized compensation cost related to non-vested stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=nk_EmployeeRestrictedStockUnitMember', window );">Employee Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-average period for recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized compensation cost related to non-vested stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>As of the balance sheet date, the number of shares into which fully vested and exercisable stock options outstanding can be converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nk_ShareBasedCompensationArrangementByShareBasedPaymentAwardPossibleIncreaseInNumberOfSharesReservedForIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares that may be added to shares reserved for issuance under an established share-based compensation plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nk_ShareBasedCompensationArrangementByShareBasedPaymentAwardPossibleIncreaseInNumberOfSharesReservedForIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price as of the balance sheet date for those equity-based payment arrangements exercisable and outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=nk_TwoThousandFifteenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=nk_TwoThousandFifteenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=nk_TwoThousandFourteenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=nk_TwoThousandFourteenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=nk_KeyExecutivesStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=nk_KeyExecutivesStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=nk_NonEmployeeStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=nk_NonEmployeeStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=nk_NonEmployeeRestrictedStockUnitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=nk_NonEmployeeRestrictedStockUnitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=nk_EmployeeRestrictedStockUnitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=nk_EmployeeRestrictedStockUnitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6900010080">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Statement Details - Accrued Expenses (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_FinancialStatementDetailsAbstract', window );"><strong>Financial Statement Details [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedBonusesCurrent', window );">Accrued bonus</a></td>
<td class="nump">$ 2,002<span></span>
</td>
<td class="nump">$ 2,079<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedSalariesCurrent', window );">Accrued compensation</a></td>
<td class="nump">1,064<span></span>
</td>
<td class="nump">943<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued professional and service fees</a></td>
<td class="nump">975<span></span>
</td>
<td class="nump">912<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_AccruedLaboratoryEquipmentAndSupplies', window );">Accrued laboratory equipment and supplies</a></td>
<td class="nump">640<span></span>
</td>
<td class="nump">678<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_AccruedPreclinicalAndClinicalTrialCosts', window );">Accrued preclinical and clinical trial costs</a></td>
<td class="nump">281<span></span>
</td>
<td class="nump">704<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_AccruedFranchiseSalesUseAndPropertyTaxes', window );">Accrued franchise, sales/use and property taxes</a></td>
<td class="nump">200<span></span>
</td>
<td class="nump">250<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationReserveCurrent', window );">Litigation settlement accruals</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">12,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConstructionPayableCurrent', window );">Accrued construction costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,341<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">181<span></span>
</td>
<td class="nump">197<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued Liabilities Current</a></td>
<td class="nump">$ 5,343<span></span>
</td>
<td class="nump">$ 21,104<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nk_AccruedFranchiseSalesUseAndPropertyTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued franchise, sales/use and property taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nk_AccruedFranchiseSalesUseAndPropertyTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nk_AccruedLaboratoryEquipmentAndSupplies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued laboratory equipment and supplies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nk_AccruedLaboratoryEquipmentAndSupplies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nk_AccruedPreclinicalAndClinicalTrialCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued preclinical and clinical trial costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nk_AccruedPreclinicalAndClinicalTrialCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nk_FinancialStatementDetailsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Financial statement details.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nk_FinancialStatementDetailsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedBonusesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6935-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6911-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedBonusesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedSalariesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedSalariesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConstructionPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for the acquisition of merchandise, materials, supplies and services pertaining to construction projects such as a housing development or factory expansion not classified as trade payables. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConstructionPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationReserveCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of reserve for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs, which is expected to be paid within one year of the date of the statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 55<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=116646759&amp;loc=d3e15243-108350<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationReserveCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6911608192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments Investments in Debt Securities - Schedule of Investments in Debt Securities (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Available-for-sale, Amortized Cost</a></td>
<td class="nump">$ 37,642<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Available-for-sale, Unrealized Gains</a></td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Available-for-sale, Unrealized Losses</a></td>
<td class="num">(11)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale, Fair Value</a></td>
<td class="nump">$ 37,641<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_AvailableForSaleSecuritiesDebtSecuritiesPeriod', window );">Available-for-sale, Weighted- Average Remaining Contractual Life</a></td>
<td class="text">3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_NotesReceivableMember', window );">Notes Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecurities', window );">Held-to-maturity, Amortized Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 723<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain', window );">Held-to-maturity, Unrealized Gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss', window );">Held-to-maturity, Unrealized Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesFairValue', window );">Held-to-maturity, Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">723<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=nk_CurrentAssetsMember', window );">Current Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Available-for-sale, Amortized Cost</a></td>
<td class="nump">$ 36,141<span></span>
</td>
<td class="nump">57,463<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Available-for-sale, Unrealized Gains</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Available-for-sale, Unrealized Losses</a></td>
<td class="num">(7)<span></span>
</td>
<td class="num">(136)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale, Fair Value</a></td>
<td class="nump">$ 36,144<span></span>
</td>
<td class="nump">57,328<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_AvailableForSaleSecuritiesDebtSecuritiesPeriod', window );">Available-for-sale, Weighted- Average Remaining Contractual Life</a></td>
<td class="text">2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_DebtSecuritiesAvailableForSaleAndHeldToMaturityAmortizedCost', window );">Available-for-sale and held-to-maturity, Amortized Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58,186<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_DebtSecuritiesAvailableForSaleAndHeldToMaturityAmortizedCostAccumulatedGrossUnrealizedGainBeforeTax', window );">Available-for-sale and held-to-maturity, Unrealized Gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_DebtSecuritiesAvailableForSaleAndHeldToMaturityAmortizedCostAccumulatedGrossUnrealizedLossBeforeTax', window );">Available-for-sale and held-to-maturity, Unrealized Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(136)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_DebtSecuritiesAvailableForSaleAndHeldToMaturityFairValue', window );">Available-for-sale and held-to-maturity, Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58,051<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=nk_CurrentAssetsMember', window );">Current Assets | Corporate Debt Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Available-for-sale, Amortized Cost</a></td>
<td class="nump">$ 32,382<span></span>
</td>
<td class="nump">57,463<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Available-for-sale, Unrealized Gains</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Available-for-sale, Unrealized Losses</a></td>
<td class="num">(3)<span></span>
</td>
<td class="num">(136)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale, Fair Value</a></td>
<td class="nump">$ 32,389<span></span>
</td>
<td class="nump">57,328<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_AvailableForSaleSecuritiesDebtSecuritiesPeriod', window );">Available-for-sale, Weighted- Average Remaining Contractual Life</a></td>
<td class="text">2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=nk_CurrentAssetsMember', window );">Current Assets | Foreign Government Bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Available-for-sale, Amortized Cost</a></td>
<td class="nump">$ 1,007<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Available-for-sale, Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Available-for-sale, Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale, Fair Value</a></td>
<td class="nump">$ 1,007<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_AvailableForSaleSecuritiesDebtSecuritiesPeriod', window );">Available-for-sale, Weighted- Average Remaining Contractual Life</a></td>
<td class="text">3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=nk_CurrentAssetsMember', window );">Current Assets | Government Sponsored Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Available-for-sale, Amortized Cost</a></td>
<td class="nump">$ 2,752<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Available-for-sale, Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Available-for-sale, Unrealized Losses</a></td>
<td class="num">(4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale, Fair Value</a></td>
<td class="nump">$ 2,748<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_AvailableForSaleSecuritiesDebtSecuritiesPeriod', window );">Available-for-sale, Weighted- Average Remaining Contractual Life</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=nk_NoncurrentAssetsMember', window );">Noncurrent Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Available-for-sale, Amortized Cost</a></td>
<td class="nump">$ 1,501<span></span>
</td>
<td class="nump">5,823<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Available-for-sale, Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Available-for-sale, Unrealized Losses</a></td>
<td class="num">(4)<span></span>
</td>
<td class="num">(122)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale, Fair Value</a></td>
<td class="nump">$ 1,497<span></span>
</td>
<td class="nump">5,701<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_AvailableForSaleSecuritiesDebtSecuritiesPeriod', window );">Available-for-sale, Weighted- Average Remaining Contractual Life</a></td>
<td class="text">1 year 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_DebtSecuritiesAvailableForSaleAndHeldToMaturityAmortizedCost', window );">Available-for-sale and held-to-maturity, Amortized Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">64,009<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_DebtSecuritiesAvailableForSaleAndHeldToMaturityAmortizedCostAccumulatedGrossUnrealizedGainBeforeTax', window );">Available-for-sale and held-to-maturity, Unrealized Gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_DebtSecuritiesAvailableForSaleAndHeldToMaturityAmortizedCostAccumulatedGrossUnrealizedLossBeforeTax', window );">Available-for-sale and held-to-maturity, Unrealized Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(258)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_DebtSecuritiesAvailableForSaleAndHeldToMaturityFairValue', window );">Available-for-sale and held-to-maturity, Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63,752<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=nk_NoncurrentAssetsMember', window );">Noncurrent Assets | Corporate Debt Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Available-for-sale, Amortized Cost</a></td>
<td class="nump">$ 1,501<span></span>
</td>
<td class="nump">3,067<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Available-for-sale, Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Available-for-sale, Unrealized Losses</a></td>
<td class="num">(4)<span></span>
</td>
<td class="num">(76)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale, Fair Value</a></td>
<td class="nump">$ 1,497<span></span>
</td>
<td class="nump">2,991<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_AvailableForSaleSecuritiesDebtSecuritiesPeriod', window );">Available-for-sale, Weighted- Average Remaining Contractual Life</a></td>
<td class="text">1 year 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=nk_NoncurrentAssetsMember', window );">Noncurrent Assets | Government Sponsored Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Available-for-sale, Amortized Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,756<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Available-for-sale, Unrealized Gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Available-for-sale, Unrealized Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(46)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale, Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,710<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nk_AvailableForSaleSecuritiesDebtSecuritiesPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Available for sale securities debt securities period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nk_AvailableForSaleSecuritiesDebtSecuritiesPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nk_DebtSecuritiesAvailableForSaleAndHeldToMaturityAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt securities available for sale and held to maturity amortized cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nk_DebtSecuritiesAvailableForSaleAndHeldToMaturityAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nk_DebtSecuritiesAvailableForSaleAndHeldToMaturityAmortizedCostAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt securities available for sale and held to maturity amortized cost accumulated gross unrealized gain before tax.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nk_DebtSecuritiesAvailableForSaleAndHeldToMaturityAmortizedCostAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nk_DebtSecuritiesAvailableForSaleAndHeldToMaturityAmortizedCostAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt securities available for sale and held to maturity amortized cost accumulated gross unrealized loss before tax.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nk_DebtSecuritiesAvailableForSaleAndHeldToMaturityAmortizedCostAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nk_DebtSecuritiesAvailableForSaleAndHeldToMaturityFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt securities available for sale and held to maturity fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nk_DebtSecuritiesAvailableForSaleAndHeldToMaturityFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942338&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942338&amp;loc=SL82898722-210454<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=d3e26610-111562<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at amortized cost (held-to-maturity).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=d3e26610-111562<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27232-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrecognized gain on investment in debt security measured at amortized cost (held-to-maturity).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27232-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at amortized cost (held-to-maturity).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27232-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at amortized cost (held-to-maturity).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27232-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_NotesReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_NotesReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=nk_CurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=nk_CurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_ForeignGovernmentDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_ForeignGovernmentDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnderlyingAssetClassAxis=us-gaap_AgencySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnderlyingAssetClassAxis=us-gaap_AgencySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=nk_NoncurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=nk_NoncurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6814520672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments Investments in Debt Securities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_CashEquivalentsAndMarketableSecuritiesAbstract', window );"><strong>Cash Equivalents And Marketable Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock', window );">Schedule of Investments in Debt Securities</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At December&#160;31, 2019, our investments in debt securities are detailed below (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="18" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contractual&#160;Life</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in years)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cost</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gains</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Losses</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current:</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Available-for-sale:</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt securities</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.2</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32,382</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32,389</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Foreign government bonds</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.3</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,007</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,007</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Government sponsored securities</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.5</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,752</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,748</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current portion</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.2</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36,141</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(7</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36,144</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Noncurrent:</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Available-for-sale:</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt securities</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.7</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,501</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,497</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Noncurrent portion</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.7</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,501</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,497</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.94%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.3</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37,642</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(11</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37,641</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At December&#160;31, 2018, our investments in debt securities are detailed below (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="14" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.42%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2018</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized&#160;Cost</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gains</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Losses</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair&#160;Value</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current:</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Available-for-sale:</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt securities</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">57,463</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(136</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">57,328</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total available-for-sale</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">57,463</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(136</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">57,328</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Held-to-maturity, notes receivable (Note 4)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">723</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">723</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current portion</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">58,186</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(136</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">58,051</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Noncurrent:</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Available-for-sale:</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt securities</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,067</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(76</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,991</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Government sponsored securities</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,756</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(46</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,710</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Noncurrent portion</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,823</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(122</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,701</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">64,009</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(258</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">63,752</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueTableTextBlock', window );">Accumulated Unrealized Losses on Debt Securities Classified as Available-for-Sale in Continuous Loss Position</a></td>
<td class="text">
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulated unrealized losses on debt securities classified as available-for-sale that have been in a continuous loss position for less than 12&#160;months and for more than 12&#160;months at December&#160;31, 2019 and 2018 were as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="14" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.42%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Less than 12 months</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">More than 12 months</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Estimated&#160;Fair</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross&#160;Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Losses</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Estimated&#160;Fair</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross&#160;Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Losses</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt securities</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,021</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,497</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Government sponsored securities</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,748</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,021</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,245</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(8</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="14" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.42%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2018</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Less than 12 months</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">More than 12 months</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Estimated&#160;Fair</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross&#160;Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Losses</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Estimated&#160;Fair</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross&#160;Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Losses</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt securities</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32,010</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(26</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26,663</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(186</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Government sponsored securities</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,710</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(46</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32,010</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(26</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29,373</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(232</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRealizedGainLossTableTextBlock', window );">Schedule of Realized Gains and Losses on Sales of Available-for-Sale Debt Securities</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We recorded realized gains and losses on sales of available-for-sale debt securities as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;">
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.92%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Realized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gains</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.92%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Realized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Losses</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.92%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Net</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Realized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gains (Losses)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(8</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">52</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(15</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nk_CashEquivalentsAndMarketableSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash equivalents and marketable securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nk_CashEquivalentsAndMarketableSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of fair value of investments in debt and equity securities in an unrealized loss position categorized neither as held-to-maturity nor trading securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRealizedGainLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the proceeds from sales of available-for-sale securities and the gross realized gains and gross realized losses that have been included in earnings as a result of those sales.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27357-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRealizedGainLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6814391104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text">
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">15. &#160;&#160;&#160;&#160;Subsequent Events</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Collaborative Arrangement</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A collaborative arrangement is a contractual arrangement that involves a joint operating activity. These arrangements involve two or more parties who are&#160;(i)&#160;active participants in the activity, and (ii)&#160;exposed to significant risks and rewards dependent on the commercial success of the activity.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Cost Allocation Agreement<font style="font-style:normal;">&#8212; On January&#160;29, 2020, we entered into a Cost Allocation Agreement, or the Agreement, with ImmunityBio, Inc. and its subsidiaries, or ImmunityBio. The Agreement is effective as of October&#160;1, 2019. ImmunityBio is a related party, as it is an affiliate of NantWorks (Note&#160;9). Simultaneously, we and ImmunityBio entered into Work Order Number One under the Agreement. Under the Agreement and Work Order Number One, the parties agreed to conduct a joint study, the clinical research trial being conducted pursuant to the protocol titled QUILT&#160;3.063:</font>&#160;A phase&#160;2 study of combination therapy with an IL-15 superagonist&#160;(N&#8209;803), off-the-shelf CD16&#8209;targeted natural killer cells&#160;(haNK), and avelumab without cytotoxic chemotherapy in subjects with Merkel Cell Carcinoma&#160;(MCC) that has progressed on or after treatment with a checkpoint inhibitor<font style="font-style:normal;">. The ImmunityBio study drug included in the joint study is ImmunityBio&#8217;s proprietary IL-15 superagonist known as N&#8209;803 and our study drug is our proprietary &#8220;off-the-shelf&#8221; CD16-targeted natural killer cell therapy known as haNK.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We will act as the sponsor of this joint study for purposes of regulatory matters, including submissions, correspondence, and communications. Additionally, we are designated as the contracting party to execute agreements with third and related parties relating to the joint study under Work Order Number One. We and ImmunityBio will split certain joint study costs equally related to Work Order Number One, in accordance with the terms of the Agreement. Shared joint study costs include cost related to conducting the joint study development activities, such as personnel related costs, as well as all costs associated to regulatory matters. Costs and expenses incurred in connection with the development, manufacturing, supply, delivery, and pre-patient administration dosing mechanism of each party&#8217;s study drug, are excluded from the shared joint study costs. We expect that the joint study cost sharing component under the Agreement related to Work Order Number One will total approximately $2.1&#160;million, subject to change dependent on clinical trial enrollments and progress. At December&#160;31, 2019, there was minimal joint research activity under the Agreement and we incurred approximately $0.1&#160;million in costs related to the joint study that are subject to joint cost sharing under the Agreement and are recorded in research in research and development expense on the consolidated statements of operations.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the agreement, each of ImmunityBio and the company will receive exclusive rights to any new intellectual property developed that relates solely to its respective study drug, and the parties will have joint co-equal rights in any other intellectual property. The Agreement expires upon the second anniversary of the effective date with the option to renew for additional successive one-year terms, but work orders for any joint studies still in process at the time of termination will continue until the applicable study is completed.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Coronavirus Pandemic</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Due to the global viral outbreak caused by Coronavirus Disease&#160;2019&#160;(COVID&#8209;19) in 2020, there have been resulting effects which could negatively impact our financial condition or operations, including significant stock market exchange volatility, including various temporary volatility trading halts which commenced initially on March&#160;9,&#160;2020 due to market declines, various temporary business closures and event cancellations, and other effects including strains on hospitals and health provider resources which could result in clinical trial disruptions as the broader economic impact of COVID&#8209;19 develops. The ultimate impact of these matters to us and our financial condition and operations is presently unknown. The accompanying consolidated financial statements as of and for the year ended December&#160;31,&#160;2019 do not reflect the effects of these subsequent events.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6894405472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business - Additional Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">$ (662,191)<span></span>
</td>
<td class="num">$ (594,981)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">$ (61,362)<span></span>
</td>
<td class="num">$ (63,381)<span></span>
</td>
<td class="num">$ (48,780)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6894152432">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Statement Details - Prepaid Expenses and Other Current Assets (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_FinancialStatementDetailsAbstract', window );"><strong>Financial Statement Details [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_PrepaidPreclinicalAndClinicalTrialServicesWithRelatedParty', window );">Prepaid preclinical and clinical trial services - with related party (Note 9)</a></td>
<td class="nump">$ 1,021<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_InsurancePremiumFinancingAsset', window );">Insurance premium financing asset</a></td>
<td class="nump">757<span></span>
</td>
<td class="nump">339<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_PrepaidSuppliesWithRelatedParty', window );">Prepaid supplies - with related party (Note 9)</a></td>
<td class="nump">467<span></span>
</td>
<td class="nump">532<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_PrepaidServices', window );">Prepaid services</a></td>
<td class="nump">440<span></span>
</td>
<td class="nump">230<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidRent', window );">Prepaid rent</a></td>
<td class="nump">392<span></span>
</td>
<td class="nump">536<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidInsurance', window );">Prepaid insurance</a></td>
<td class="nump">372<span></span>
</td>
<td class="nump">343<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_PrepaidEquipmentMaintenance', window );">Prepaid equipment maintenance</a></td>
<td class="nump">251<span></span>
</td>
<td class="nump">329<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestReceivableCurrent', window );">Interest receivable - marketable debt securities</a></td>
<td class="nump">222<span></span>
</td>
<td class="nump">473<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_PrepaidLicenseFees', window );">Prepaid license fees</a></td>
<td class="nump">78<span></span>
</td>
<td class="nump">104<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InsuranceSettlementsReceivableCurrent', window );">Insurance claim receivables</a></td>
<td class="nump">34<span></span>
</td>
<td class="nump">10,882<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueFromRelatedPartiesCurrent', window );">Due from related parties</a></td>
<td class="nump">47<span></span>
</td>
<td class="nump">90<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other</a></td>
<td class="nump">24<span></span>
</td>
<td class="nump">42<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Total prepaid expenses and other current assets</a></td>
<td class="nump">$ 4,105<span></span>
</td>
<td class="nump">$ 13,900<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nk_FinancialStatementDetailsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Financial statement details.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nk_FinancialStatementDetailsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nk_InsurancePremiumFinancingAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Insurance premium financing asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nk_InsurancePremiumFinancingAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nk_PrepaidEquipmentMaintenance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Prepaid equipment maintenance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nk_PrepaidEquipmentMaintenance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nk_PrepaidLicenseFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Prepaid license fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nk_PrepaidLicenseFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nk_PrepaidPreclinicalAndClinicalTrialServicesWithRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Prepaid preclinical and clinical trial services with related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nk_PrepaidPreclinicalAndClinicalTrialServicesWithRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nk_PrepaidServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Prepaid services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nk_PrepaidServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nk_PrepaidSuppliesWithRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Prepaid supplies with related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nk_PrepaidSuppliesWithRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueFromRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of receivables to be collected from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth, at the financial statement date. which are usually due within one year (or one business cycle).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueFromRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InsuranceSettlementsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount due in settlement of a claim for reimbursement from an insurance company when the Company has suffered a loss covered under an insurance policy.   For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InsuranceSettlementsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of current interest earned but not received. Also called accrued interest or accrued interest receivable. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidInsurance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=68074540&amp;loc=d3e5865-108316<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6787-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=68074540&amp;loc=d3e5879-108316<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidInsurance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for rent that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=68074540&amp;loc=d3e5879-108316<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6787-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=68074540&amp;loc=d3e5865-108316<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6898428592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">11. &#160;&#160;&#160;&#160;Stock-Based Compensation</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">2014 Equity Incentive Plan &#8211; <font style="font-style:normal;">In March&#160;2014, the company&#8217;s board of directors and stockholders approved the 2014 Equity Incentive Plan, or 2014&#160;Plan, under which 11,109,000&#160;shares of Class&#160;A common stock were reserved for the granting of incentive stock options, within the meaning of Section&#160;422 of the Internal Revenue Code, or IRC, non-statutory stock options, stock appreciation rights, restricted stock awards, restricted stock units and performance awards to employees, directors and consultants. Recipients of stock awards are eligible to purchase shares of our common stock at an exercise price equal to no less than the estimated fair market value of such stock on the date of grant. The maximum term of awards granted under the 2014&#160;Plan is ten&#160;years. Stock awards are generally not exercisable prior to the applicable vesting date, unless otherwise accelerated under the terms of the applicable stock plan agreement. Unvested shares of our common stock issued in connection with an early exercise allowed by the company may be repurchased by us upon termination of the optionee&#8217;s service.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">2015 Equity Incentive Plan &#8211; <font style="font-style:normal;">In July&#160;2015, the company&#8217;s board of directors adopted and the company&#8217;s stockholders approved the 2015 Equity Incentive Plan, or 2015&#160;Plan. In April&#160;2019, the company&#8217;s board of directors adopted, and in June&#160;2019 the company&#8217;s stockholders approved, an amendment to the 2015&#160;Plan to reserve a further 3,000,000&#160;shares of common stock for issuance pursuant to the 2015&#160;Plan. The 2015&#160;Plan, as amended, permits the grant of incentive stock options to the company&#8217;s employees, and for the grant of non-statutory stock options, restricted stock, restricted stock units, stock appreciation rights, performance units and performance shares to the company&#8217;s employees, directors and consultants.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2019 there were approximately 4.3&#160;million shares of common stock reserved for future grants pursuant to the 2015&#160;Plan. In addition, the shares reserved for future grants under the 2015&#160;Plan include shares subject to stock options or similar awards granted under the 2014&#160;Plan that expire or terminate without having been exercised in full and shares issued pursuant to awards granted under the 2014&#160;Plan that are forfeited to or repurchased by us (provided that the maximum number of shares that may be added to the 2015&#160;Plan pursuant to this provision is approximately 2.3&#160;million shares as of December&#160;31, 2019).</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Stock-Based Compensation</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table presents all stock-based compensation as included on the consolidated statements of operations (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the Year Ended December&#160;31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense:</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrants for common stock to an officer</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,817</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31,584</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Employee stock options</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,309</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,057</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,267</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Employee RSUs</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">938</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,193</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">894</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-employee RSUs</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">380</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">315</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">252</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,627</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,382</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36,997</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense in operating expenses:</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">499</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">460</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">102</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Selling, general and administrative</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,128</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,922</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36,895</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,627</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,382</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36,997</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></div>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Stock Options</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes stock option activity under all equity incentive plans for the years ended December&#160;31, 2019, 2018 and 2017:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise&#160;Price</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Intrinsic</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contractual&#160;Life</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in years)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at December 31, 2016</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,307,386</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.14</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,100</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.4</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options exercised</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(614,136</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.88</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at December 31, 2017</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,693,250</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.71</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,920</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.3</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options granted</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">800,000</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.07</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at December 31, 2018</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,493,250</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.14</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">563</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.8</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options exercised</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,986,300</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.06</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at December 31, 2019</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,506,950</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.37</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,710</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.8</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested and Exercisable at December 31, 2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,973,614</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.22</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,326</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.5</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></div>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The vested and exercisable shares at December&#160;31, 2018 and 2017 were 5,577,531 and 5,114,656, respectively.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table provides a summary of options outstanding and vested as of December&#160;31, 2019:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.56%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise Prices</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Outstanding</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average&#160;Remaining</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contractual Life</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in years)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercisable</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average&#160;Remaining</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contractual Life</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in years)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.56%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$0.42</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">589,660</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.9</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">589,660</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.9</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$1.76</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">699,060</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.0</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">699,060</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.0</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$2.00</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">962,780</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.1</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">962,780</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.1</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$3.07</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">800,000</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.7</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">266,664</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.7</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$25.00</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,455,450</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.22%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.6</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,455,450</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.22%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.6</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.56%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,506,950</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.22%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.8</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,973,614</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.22%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.5</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></div>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The aggregate intrinsic value of stock options exercised during the years ended December&#160;31, 2019, 2018 and 2017 was $0.2&#160;million, $0.6&#160;million and $1.7&#160;million, respectively. The cash received from exercised options was $4.1&#160;million, $0 and $1.2&#160;million, respectively, for the years ended December&#160;31, 2019, 2018 and 2017.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the year ended December&#160;31, 2018, the company granted 800,000&#160;stock options to key executives. These options have an exercise price of $3.07&#160;per share, which was equal to the closing price of the company&#8217;s common stock on the date of grant, and 25% vest on the one-year anniversary of the date of grant with the remaining options vesting ratably each month over the following three&#160;years. No stock options were granted to employees during the years ended December&#160;31, 2019 and 2017. No stock options were granted to non-employees during the years ended December&#160;31, 2019, 2018 and 2017.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The total unrecognized compensation cost related to non-vested stock options as of December&#160;31, 2019 is $1.1&#160;million, which is expected to be recognized over a weighted-average period of 2.7&#160;years.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The company uses a Black-Scholes option-pricing model to determine the fair value of stock-based compensation under ASC&#160;Topic&#160;718,&#160;<font style="font-style:italic;">Stock Compensation</font>. The assumptions used for employee stock options granted during the year ended December&#160;31, 2018, are presented in the table below:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:60%;">
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term (years)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.0 - 6.1</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.8%</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75.9%</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dividend yield</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0%</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average measurement date fair value</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$2.09</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></div>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The assumed dividend yield was based on the company&#8217;s expectation of not paying dividends in the foreseeable future. The estimated volatility was based on a weighted-average calculation of the company&#8217;s common stock together with a peer group of comparable companies whose share prices are publicly available. The risk-free interest rate assumption was based on the U.S.&#160;Treasury&#8217;s rates for U.S.&#160;Treasury zero-coupon bonds with maturities similar to those of the expected term of the award being valued. The weighted-average expected life of options was estimated using the average of the contractual term and the weighted-average vesting term of the options.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Restricted Stock Units</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes the restricted stock units, or RSUs, activity under the 2015&#160;Plan:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">RSUs</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Outstanding</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Grant Date</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested balance at December 31, 2016</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">814,456</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13.98</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">615,983</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.50</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(244,209</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15.82</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited/canceled</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(298,041</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.28</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested balance at December 31, 2017</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">888,189</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.14</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">487,472</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.57</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(172,330</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.16</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited/canceled</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(335,420</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.27</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested balance at December 31, 2018</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">867,911</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.69</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">749,793</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.12</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(395,051</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.83</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited/canceled</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(83,225</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.29</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested balance at December 31, 2019</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,139,428</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.88%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.23</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></div>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may grant RSUs to both employees and directors of the company and to employees of related parties that provide shared services to the company under the company&#8217;s shared services agreement with NantWorks (Note&#160;9). During the years ended December&#160;31, 2018 and 2017, we granted 90,906&#160;RSUs and 77,250&#160;RSUs, respectively, to non-employees. All of the RSUs granted to non-employees during these periods were granted to employees of related companies under our shared services agreement with NantWorks (Note&#160;9). There were no new grants made to non-employees during the year ended December&#160;31, 2019.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2019, there was $1.4&#160;million of unrecognized stock-based compensation expense related to RSUs that is expected to be recognized over a weighted-average period of 1.7&#160;years. Of that amount, $1.3&#160;million of unrecognized expense is related to employee grants with a remaining weighted-average period of 1.8&#160;years and $0.1&#160;million of unrecognized expense is related to non-employee grants with a remaining weighted-average period of 0.8&#160;years.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Warrants</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes the company&#8217;s warrant activity:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:60%;">
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at December 31, 2016</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,768,314</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrants exercised</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(47,226</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at December 31, 2017</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,721,088</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrants exercised</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(93,254</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrants expired</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(38,584</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at December 31, 2018</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,589,250</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrants exercised</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(17,589,250</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at December 31, 2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested and exercisable at December 31, 2019</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></div>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the years ended December&#160;31, 2019, 2018 and 2017, cash proceeds recognized from exercises of warrants were $35.2&#160;million, $0.1&#160;million and $0.1&#160;million, respectively.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Common Stock Reserved for Future Grants under the 2015 Equity Incentive Plan</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At December&#160;31, 2019, there were approximately 4.3&#160;million shares of common stock reserved for future grants of equity awards.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6898460400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and License Agreements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_CollaborationAndLicenseAgreementsTextBlock', window );">Collaboration and License Agreements</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">7. &#160;&#160;&#160;&#160;Collaboration and License Agreements</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Collaborative Arrangements</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A collaborative arrangement is a contractual arrangement that involves a joint operating activity. These arrangements involve two or more parties who are&#160;(i)&#160;active participants in the activity, and (ii)&#160;exposed to significant risks and rewards dependent on the commercial success of the activity.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In January&#160;2020, we entered into a Cost Sharing Agreement with ImmunityBio as further described in Note 15 &#8211; <font style="font-style:italic;">Subsequent Events</font>.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Exclusive Co-Development Agreement</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August&#160;2016, we entered into an exclusive Co-Development Agreement, or the Co-Development Agreement, with Altor BioScience, LLC, or Altor. Altor is a related party, as it is a wholly owned subsidiary of ImmunityBio (Note&#160;9). Under the Co-Development Agreement, the parties agreed to exclusively collaborate on the development of certain therapeutic applications combining our proprietary NK&#160;cells with Altor's N&#8209;801 and/or N&#8209;803 products with respect to certain technologies and intellectual property rights as may be agreed between the parties for the purpose of jointly developing therapeutic applications of certain effector cell lines.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are the lead developer for each product developed by the parties pursuant to the Co-Development Agreement unless otherwise agreed to under a given project plan. Under the terms of the Co-Development Agreement, both parties granted a co-exclusive, royalty free, fully paid-up, worldwide license, with the right to sublicense (only to a third-party contractor assisting with research and development activities under this Co-Development Agreement and subject to prior consent, not to be unreasonably withheld), under the intellectual property, or IP, including the parties interest in the joint IP, solely to conduct any development activities agreed to by the steering committee as set forth in any development plan. Unless otherwise mutually agreed by the parties in the development plan for a project, we are responsible for all costs and expenses incurred by either party related to conducting clinical trials and other activities under each development program, including costs associated with patient enrollment, materials and supplies, third-party staffing and regulatory filings. Altor supplies free of charge, sufficient amounts of Altor products for all pre-clinical requirements and certain clinical requirements for up to 400&#160;patients in phase&#160;I and/or phase&#160;II clinical trials, as required under the development plan for a project per the Co-Development Agreement.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Each company owns an undivided interest in and to all rights, title and interest in and to the joint product rights. The Co-Development Agreement expires upon the fifth anniversary of the effective date. We have dosed patients with N&#8209;803, an IL&#8209;15 superagonist, in several phase&#160;Ib/II trials during the years ended December&#160;31, 2019, 2018 and 2017. No charges for supplies by Altor were incurred in association with the above trials during the years ended December&#160;31, 2019, 2018 and 2017.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Royalties and In-licensing Agreements</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Viracta License Agreement</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In May&#160;2017, we entered into an agreement with Viracta under which we were granted exclusive worldwide rights to Viracta&#8217;s phase&#160;II drug candidate, VRx&#8209;3996, for use in combination with our platform of NK&#160;cell therapies. In consideration for the license, we are obligated to pay to Viracta&#160;(i)&#160;mid-single digit percentage royalties of net sales of licensed products for therapeutic use; and (ii)&#160;milestone payments ranging from $10.0&#160;million to $25.0&#160;million for various regulatory approvals and cumulative net sales levels. We may terminate the agreement, in its sole discretion, in whole or on a product by product and/or country by country basis, at any time upon 90&#160;days&#8217;&#160;prior written notice. In addition, either party may terminate the agreement in the event of a material breach or for bankruptcy of the other party.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus, or GSH, and DRK-Blutspendedienst Baden-Wurttenberg-Hessen gGmbH, or BSD, License Agreement</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August&#160;2015, we entered into a license agreement with GSH and BSD under which we were granted an exclusive license to certain GSH&#8209;BSD patents, materials and know-how that specifically targets ErbB2 expressing cancers. In addition, GSH granted us an exclusive license to certain GSH only technology and materials. In consideration for the licenses, we agreed to pay initial and annual licensing fees, regulatory and commercial milestones and low single-digit percentage royalties on net sales of licensed products. We paid $1.1&#160;million for the initial license fees, which was included in research and development expenses on the consolidated statements of operations for the year ended December&#160;31, 2015. Annual license fees under the agreement began in 2018. In October&#160;2018, we terminated this agreement in accordance with the terms of the agreement.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Fox Chase Cancer Center License Agreement</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2004 and amended in 2008, we entered into an exclusive license agreement with Fox Chase Cancer Center, or Fox Chase, for the exclusive, worldwide right to certain patents and know-how pertaining to CD16 receptor bearing NK&#8209;92&#160;cell lines. In consideration for this exclusive license, we agreed to pay Fox Chase&#160;(i)&#160;low single-digit percentage royalties on net sales of licensed products for therapeutic and diagnostic use; and (ii)&#160;mid-twenties percentage royalties on any compensation we receive from sublicensees.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Rush University Medical Center License Agreement</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2004, we entered into a 12-year licensing agreement with Rush University Medical Center for the exclusive rights to license and grant sublicenses of certain intellectual property related to clinical use of NK&#8209;92. We are required to pay low to mid-single digit percentage royalties on net sales depending upon the various fields of studies and other factors. We were required to pay a minimum annual royalty of $25,000. The Rush University Medical Center License Agreement also provides for payments in the aggregate amount of $2.5&#160;million upon the company achieving various milestones, including upon&#160;(i)&#160;the completion of phase&#160;II clinical trial associated with the licensed intellectual property; (ii)&#160;the approval by the FDA of a new drug application for a licensed product; and (iii)&#160;the first year that sales of the licensed product equals or exceeds $0.3&#160;million. The license had a term of 12&#160;years from 2006, the year in which royalty payments were first made, and included customary termination rights for both parties. Beginning in 2018, this license converted to a perpetual, irrevocable, fully paid, royalty-free, exclusive license.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the years ended December&#160;31, 2019, 2018 and 2017, we recorded royalty expense of $0, $4,200 and $25,000, respectively, related to the Rush University Medical Center License Agreement. Royalty expense is included in selling, general and administrative on the consolidated statements of operations. No milestones were met during the years ended December&#160;31, 2019, 2018 and 2017.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Out-Licensing Agreement</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Intrexon License Agreement</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February&#160;2010, we entered into a 17-year license agreement with Intrexon Corporation, or Intrexon, pursuant to which we granted to Intrexon a non-exclusive, worldwide, sublicensable license to research and sell products under certain patents relating to modified NK&#8209;92&#160;cells that express Intrexon&#8217;s proprietary gene sequences for use as a therapeutic and prophylactic agent in humans in specified therapeutic areas. In consideration for the license agreement, Intrexon paid us a one-time fee of $0.4&#160;million. Prior to adoption of ASC&#160;606, this upfront payment had initially been recorded as deferred revenue and was being recognized into revenue on a straight-line basis. Upon adoption of ASC&#160;606, we adjusted our accumulated deficit in an amount equal to the then remaining deferred revenue after concluding that under ASC&#160;606 the upfront payment would have been recognized when the license was transferred in 2010. Intrexon will pay the following milestone payments:&#160;$0.1&#160;million upon the first IND filing; $0.1&#160;million upon the commencement of the first phase&#160;II clinical trial; $0.4&#160;million upon the commencement of the first phase&#160;III clinical trial; and $0.5&#160;million upon the first commercial sale relating to the licensed products. Intrexon is obligated to pay us a low single digit percentage royalty based on net sales of the licensed products by Intrexon and a mid-teen percentage royalty based on revenues received by Intrexon in connection with sublicenses of the licensed products. No milestone payments were due or received in the years ended December&#160;31, 2019, 2018 and 2017, and, therefore, we recorded no milestone revenue for any of those years on the consolidated statements of operations.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nk_CollaborationAndLicenseAgreementsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration and license agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nk_CollaborationAndLicenseAgreementsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6898466384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Statement Details<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_FinancialStatementDetailsAbstract', window );"><strong>Financial Statement Details [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock', window );">Financial Statement Details</a></td>
<td class="text">
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">3. &#160;&#160;&#160;&#160;Financial Statement Details</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Prepaid expenses and other current assets</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2019 and 2018, prepaid expenses and other current assets were made up of (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid preclinical and clinical trial services - with</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; related party (Note 9)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,021</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Insurance premium financing asset</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">757</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">339</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid supplies - with related party (Note 9)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">467</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">532</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid services</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">440</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">230</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid rent</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">392</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">536</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid insurance</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">372</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">343</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid equipment maintenance</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">251</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">329</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest receivable - marketable debt securities</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">222</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">473</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid license fees</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">78</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">104</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Insurance claim receivables</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,882</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Due from related parties</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">90</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,105</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,900</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></div>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Property, plant and equipment, net</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2019 and 2018, property, plant and equipment, net, was made up of (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Construction in progress</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,480</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33,406</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,087</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Buildings</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,690</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">59,356</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Equipment</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,434</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,878</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Software</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,195</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,264</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furniture &amp; fixtures</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">383</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">381</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">79,108</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">88,446</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulated depreciation</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(18,607</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(11,561</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">60,501</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">76,885</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></div>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation expense related to property, plant and equipment was $8.4&#160;million, $7.3&#160;million and $3.3&#160;million for the years ended December&#160;31, 2019, 2018 and 2017, respectively.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a result of adoption of ASC&#160;842 (Note&#160;2), we&#160;(i)&#160;reclassified $32.0&#160;million of assets from buildings to leasehold improvements, and (ii)&#160;derecognized $6.6&#160;million of assets associated with build-to-suit leases under ASC&#160;840.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The impact of adoption of ASC&#160;842 on property, plant, and equipment at December&#160;31, 2018 was as follows&#160;(in&#160;thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.24%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2018</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.24%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Adoption of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ASC 842</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Increase&#160;(Decrease)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.24%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">January 1, 2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,087</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32,014</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36,101</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Buildings</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">59,356</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(39,893</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,463</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property, plant and equipment, gross</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">88,446</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(7,879</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">80,567</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulated depreciation</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(11,561</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,293</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(10,268</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property, plant and equipment, net</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">76,885</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,586</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70,299</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Intangible assets, net</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2019 and 2018, intangible assets were made up of (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Technology license</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,042</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,042</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less accumulated amortization</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(9,042</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(8,477</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">565</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></div>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our intangible assets were fully amortized as of March&#160;31, 2019. Amortization expense was $0.6&#160;million, $2.3&#160;million and $2.3&#160;million for the years ended December&#160;31, 2019, 2018 and 2017, respectively. Amortization for the company&#8217;s technology license is included in research and development expense on the consolidated statements of operations.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Other assets</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2019 and 2018, other assets were made up of (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid preclinical and clinical trial services - with</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; related party (Note 9)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,075</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted cash</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">179</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">179</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Security deposit</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">113</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">113</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid rent</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,205</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,386</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,527</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></div>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted cash is comprised of a certificate of deposit that serves as collateral for a letter of credit required by our landlord as a security deposit related to our facility in San Diego, California.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Accrued expenses</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2019 and 2018, accrued expenses were made up of (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued bonus</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,002</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,079</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued compensation</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,064</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">943</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued professional and service fees</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">975</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">912</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued laboratory equipment and supplies</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">640</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">678</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued preclinical and clinical trial costs</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">281</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">704</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued franchise, sales/use and property taxes</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">200</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">250</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Litigation settlement accruals</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,000</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued construction costs</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,341</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">181</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">197</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,343</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,104</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></div>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Other current liabilities</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2019 and 2018, other current liabilities were made up of (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease liability - current portion (including</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">   amounts with related parties, Note 9)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,206</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financing obligation - current portion</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">757</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">965</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred rent - current portion</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">598</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">104</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,981</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,667</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></div>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Investment income, net</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net investment income is as follows for the years ended December&#160;31, 2019, 2018 and 2017 (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the Year Ended December&#160;31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest income</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,643</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,317</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,225</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Investment accretion income (amortization expense), net</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(463</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,597</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net realized (losses) gains on investments</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,642</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,857</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,665</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></div>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest income includes interest from marketable debt securities, notes receivable, other assets, and interest from bank deposits. We did not recognize an impairment loss on any investments during the years ended December&#160;31, 2019, 2018 and 2017.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nk_FinancialStatementDetailsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Financial statement details.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nk_FinancialStatementDetailsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -URI http://asc.fasb.org/topic&amp;trid=2122208<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalBalanceSheetDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6909890352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_IncomeTaxLineItems', window );"><strong>Income Tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Corporate tax rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">34.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_TaxCutsAndJobsActOf2017IncompleteAccountingChangeInTaxRateMinimumAmountForEliminationOfSeveralBusinessDeductionsAndCreditsIncludingDeductionsForCertainExecutiveCompensation', window );">Minimum Amount for elimination of several business deductions and credits, including deductions for certain executive compensation</a></td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_TaxCutsAndJobsActOf2017IncompleteAccountingChangeInTaxRateReductionInDeferredTaxAssets', window );">Reduction in deferred tax asset balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 51,700,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_ResearchAndDevelopmentCumulativeChangeInOwnershipPercentage', window );">Cumulative change in ownership</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_PeriodOfCumulativeOwnershipChange', window );">Period of cumulative ownership change</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_DerecognizedDeferredTaxAssets', window );">Derecognized deferred tax assets</a></td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Deferred tax assets valuation allowance</a></td>
<td class="nump">91,732,000<span></span>
</td>
<td class="nump">$ 144,773,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Deferred tax assets change in valuation allowance</a></td>
<td class="nump">53,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxEffectsAllocatedDirectlyToEquityEquityTransactions', window );">Tax benefits credited to contributed capital</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRate', window );">Unrecognized tax benefits that would not impact effective tax rate</a></td>
<td class="nump">14,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_CA', window );">California | Research Tax Credits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_IncomeTaxLineItems', window );"><strong>Income Tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforwards</a></td>
<td class="nump">5,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_IncomeTaxLineItems', window );"><strong>Income Tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 291,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_NetOperatingLossCarryforwardsExpirationDate', window );">Net operating loss carryforwards expiration date</a></td>
<td class="text">2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal | Research Tax Credits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_IncomeTaxLineItems', window );"><strong>Income Tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforwards</a></td>
<td class="nump">$ 8,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_TaxCreditCarryforwardExpirationPeriod', window );">Tax credit carryforward expiration period</a></td>
<td class="text">2034<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_IncomeTaxLineItems', window );"><strong>Income Tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 255,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_NetOperatingLossCarryforwardsExpirationDate', window );">Net operating loss carryforwards expiration date</a></td>
<td class="text">2030<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State | Research Tax Credits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_IncomeTaxLineItems', window );"><strong>Income Tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_TaxCreditCarryforwardExpirationPeriod', window );">Tax credit carryforward expiration period</a></td>
<td class="text">2031<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Foreign</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_IncomeTaxLineItems', window );"><strong>Income Tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_NetOperatingLossCarryforwardsExpirationDate', window );">Net operating loss carryforwards expiration date</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_IncomeTaxLineItems', window );"><strong>Income Tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Corporate tax rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | California</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_IncomeTaxLineItems', window );"><strong>Income Tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OpenTaxYear', window );">Tax year open for examination</a></td>
<td class="text">2019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_IncomeTaxLineItems', window );"><strong>Income Tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OpenTaxYear', window );">Tax year open for examination</a></td>
<td class="text">2019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | California</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_IncomeTaxLineItems', window );"><strong>Income Tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OpenTaxYear', window );">Tax year open for examination</a></td>
<td class="text">2015<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_IncomeTaxLineItems', window );"><strong>Income Tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OpenTaxYear', window );">Tax year open for examination</a></td>
<td class="text">2016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nk_DerecognizedDeferredTaxAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Derecognized deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nk_DerecognizedDeferredTaxAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nk_IncomeTaxLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income tax.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nk_IncomeTaxLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nk_NetOperatingLossCarryforwardsExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net operating loss carryforwards expiration date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nk_NetOperatingLossCarryforwardsExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nk_PeriodOfCumulativeOwnershipChange">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of cumulative ownership change.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nk_PeriodOfCumulativeOwnershipChange</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nk_ResearchAndDevelopmentCumulativeChangeInOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research and development cumulative change in ownership Percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nk_ResearchAndDevelopmentCumulativeChangeInOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nk_TaxCreditCarryforwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax credit carryforward expiration period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nk_TaxCreditCarryforwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nk_TaxCutsAndJobsActOf2017IncompleteAccountingChangeInTaxRateMinimumAmountForEliminationOfSeveralBusinessDeductionsAndCreditsIncludingDeductionsForCertainExecutiveCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax cuts and jobs act of 2017 incomplete accounting change in tax rate minimum amount for elimination of several business deductions and credits including deductions for certain executive compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nk_TaxCutsAndJobsActOf2017IncompleteAccountingChangeInTaxRateMinimumAmountForEliminationOfSeveralBusinessDeductionsAndCreditsIncludingDeductionsForCertainExecutiveCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nk_TaxCutsAndJobsActOf2017IncompleteAccountingChangeInTaxRateReductionInDeferredTaxAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax Cuts and Jobs Act of 2017 incomplete accounting change in tax rate reduction in deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nk_TaxCutsAndJobsActOf2017IncompleteAccountingChangeInTaxRateReductionInDeferredTaxAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nk_UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of unrecognized tax benefits that, if recognized, would not affect the effective tax rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nk_UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxEffectsAllocatedDirectlyToEquityEquityTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The tax effect of an increase or decrease in contributed capital (for example, deductible expenditures reported as a reduction of the proceeds from issuing capital stock) during the period charged or credited directly to shareholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109238882&amp;loc=d3e39076-109324<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109238882&amp;loc=d3e38679-109324<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxEffectsAllocatedDirectlyToEquityEquityTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OpenTaxYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax year that remains open to examination under enacted tax laws, in CCYY format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OpenTaxYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>us-types:gYearListItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=116821951&amp;loc=d3e32123-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_CA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_CA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6900367264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events - Additional Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Jan. 29, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development (including amounts with related parties)</a></td>
<td class="nump">$ 49,785<span></span>
</td>
<td class="nump">$ 55,718<span></span>
</td>
<td class="nump">$ 42,044<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development (including amounts with related parties)</a></td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative Arrangement | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_ExpectJointStudyCost', window );">Expect joint study cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,100<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nk_ExpectJointStudyCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expect joint study cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nk_ExpectJointStudyCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6898500560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitment and Contingencies - Summary of Future Minimum Lease Payments (Parenthetical) (Detail)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments And Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_OperatingLeasePaymentsRelatedToOptionsToExtendLeaseTerms', window );">Operating lease payments related to options to extend lease terms</a></td>
<td class="nump">$ 3.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nk_OperatingLeasePaymentsRelatedToOptionsToExtendLeaseTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating lease payments related to options to extend lease terms.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nk_OperatingLeasePaymentsRelatedToOptionsToExtendLeaseTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6898373744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_DescriptionOfBusinessDisclosureTextBlock', window );">Description of Business</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1. &#160;&#160;&#160;&#160;Description of Business</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Organization</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NantKwest, Inc., or NantKwest, was incorporated in Illinois on October&#160;7, 2002 under the name ZelleRx Corporation. On January&#160;22, 2010, the company changed its name to Conkwest, Inc., and on July&#160;10, 2015, the company changed its name to NantKwest, Inc. In March&#160;2014, the company redomesticated from the State of Illinois to the State of Delaware and the Illinois company ceased to exist. We are a pioneering clinical-stage immunotherapy biotechnology company headquartered in San Diego, California with certain operations in Culver City and El Segundo, California and Woburn, Massachusetts. In these notes, the terms &#8220;we,&#8221; &#8220;our,&#8221; &#8220;the company&#8221; and &#8220;us&#8221; refer to NantKwest.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are focused on harnessing the power of the innate immune system by using its natural killer cells, or NK&#160;cells, to treat cancer and viral infectious diseases. A critical aspect of our strategy is to invest significantly in innovating new therapeutic candidates, based upon our proprietary activated NK, or aNK, cell platform, and conducting clinical testing and scale manufacturing of our most promising biologic product candidates.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We hold the exclusive right to commercialize aNK&#160;cells, a commercially viable NK&#160;cell line, and a wide range of genetically modified derivatives capable of killing cancer and virally infected cells. We own corresponding United States, or U.S., and foreign composition and methods-of-use patents and applications covering the cells, improvements, methods of expansion and manufacture and use of aNK&#160;cells and their improvements as therapeutics to treat a spectrum of clinical conditions.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We also license exclusive commercial rights to a high-affinity CD16 receptor expressing enhancement of our aNK&#160;cell platform, covered in a portfolio of U.S. and foreign composition and methods-of-use patents and applications covering both the clinical use as a therapeutic to treat cancers in combination with antibody products, as well as the non-clinical use in laboratory testing of monoclonal antibodies. We have non-exclusively licensed or sub-licensed our high-affinity CD16 bearing aNK&#160;cell platform and corresponding intellectual property to numerous pharmaceutical and biotechnology companies for such non-clinical uses.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Liquidity</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2019, the company had an accumulated deficit of approximately $662.2&#160;million. We also had negative cash flow from operations of approximately $61.4&#160;million during the year ended December&#160;31, 2019. The company expects that it will likely need additional capital to further fund development of, and seek regulatory approvals for, our product candidates, and to begin to commercialize any approved products.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are currently focused primarily on the development of immunotherapeutic treatments for cancers and debilitating viral infections using targeted cancer and viral killing cell lines, and we believe such activities will result in the company&#8217;s continued incurrence of significant research and development and other expenses related to those programs. If the clinical trials for any of the company&#8217;s product candidates fail or produce unsuccessful results and those product candidates do not gain regulatory approval, or if any of our product candidates, if approved, fail to achieve market acceptance, we may never become profitable. Even if the company achieves profitability in the future, it may not be able to sustain profitability in subsequent periods. We intend to cover our future operating expenses through cash and cash equivalents and marketable debt securities on hand and through a combination of equity offerings, debt financings, government or other third party funding, marketing and distribution arrangements and other collaborations, strategic alliances, and licensing arrangements. Additional financing may not be available to us when needed and, if available, financing may not be obtained on terms favorable to the company or its stockholders.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">While we expect our existing cash, and cash equivalents and marketable debt securities, together with the ability to borrow from affiliated entities, will enable us to fund operations and capital expenditure requirements for at least the next 12&#160;months, we may not have sufficient funds to reach commercialization. Failure to obtain adequate financing when needed may require us to delay, reduce, limit, or terminate some or all of our development programs or future commercialization efforts or grant rights to develop and market product candidates that we might otherwise prefer to develop and market ourselves, which could adversely affect our ability to operate as a going concern. If we raise additional funds from the issuance of equity securities, substantial dilution to existing stockholders may result. If we raise additional funds by incurring debt financing, the terms of the debt may involve significant cash payment obligations, as well as covenants and specific financial ratios that may restrict our ability to operate our business.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nk_DescriptionOfBusinessDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of business disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nk_DescriptionOfBusinessDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6895463696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and License Agreements - Additional Information (Detail)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="5">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>May 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 28, 2010 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>Patient</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2004 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_LicensingAgreementLineItems', window );"><strong>Licensing Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized', window );">Milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=nk_IntrexonLicenseAgreementMember', window );">Intrexon Corporation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_LicensingAgreementLineItems', window );"><strong>Licensing Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_MilestonePaymentAmount', window );">Milestone Payment Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized', window );">Milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_LicenseAgreementTerm', window );">License agreement term (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">17 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_AgreementOneTimeFee', window );">Agreement one time fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=nk_INDFilingMember', window );">First IND Filing | Intrexon Corporation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_LicensingAgreementLineItems', window );"><strong>Licensing Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_MilestonePaymentAmount', window );">Milestone Payment Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=nk_PhaseTwoMember', window );">First Phase II Clinical Trial | Intrexon Corporation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_LicensingAgreementLineItems', window );"><strong>Licensing Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_MilestonePaymentAmount', window );">Milestone Payment Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=nk_PhaseThreeMember', window );">First Phase III Clinical Trial | Intrexon Corporation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_LicensingAgreementLineItems', window );"><strong>Licensing Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_MilestonePaymentAmount', window );">Milestone Payment Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=nk_CommercialSaleRelatedToLicensedProductsMember', window );">Commercial Sale Related to Licensed Products | Intrexon Corporation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_LicensingAgreementLineItems', window );"><strong>Licensing Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_MilestonePaymentAmount', window );">Milestone Payment Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsAxis=nk_RushUniversityMedicalCenterLicenseAgreementMember', window );">Rush University Medical Center License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_LicensingAgreementLineItems', window );"><strong>Licensing Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_PeriodOfLicenseAgreement', window );">Period of license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_MinimumAnnualRoyaltyPayment', window );">Minimum annual royalty payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Payments in license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_MinimumSalesMilestoneOfLicenseForFirstYear', window );">Minimum sales milestone of license for first year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Royalty expense earned or paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,200<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized', window );">Milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=nk_GeorgSpeyerHausAndDRKBlutspendedienstBadenWurttembergHessengGmbHLicenseAgreementMember', window );">GSH-BSD</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_LicensingAgreementLineItems', window );"><strong>Licensing Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_PaymentsForInitialLicenseFees', window );">Payments for initial license fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nk_ViractaTherapeuticsIncMember', window );">Viracta Therapeutics, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_LicensingAgreementLineItems', window );"><strong>Licensing Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_LicenseAgreementTerminationNoticePeriod', window );">License agreement termination notice period</a></td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nk_ViractaTherapeuticsIncMember', window );">Viracta Therapeutics, Inc. | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_LicensingAgreementLineItems', window );"><strong>Licensing Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_MilestonePaymentAmount', window );">Milestone Payment Amount</a></td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nk_ViractaTherapeuticsIncMember', window );">Viracta Therapeutics, Inc. | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_LicensingAgreementLineItems', window );"><strong>Licensing Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_MilestonePaymentAmount', window );">Milestone Payment Amount</a></td>
<td class="nump">$ 25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=nk_AltorBioScienceCorporationMember', window );">Altor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_LicensingAgreementLineItems', window );"><strong>Licensing Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_MaximumNumberOfPatientsInPhaseOneAndTwoForClinicalTrials', window );">Maximum number of patients in phase 1 and 2 for clinical trials | Patient</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_SuppliesAndMilestoneChargesForConductingClinicalTrials', window );">Supplies and milestone charges for conducting clinical trials</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nk_AgreementOneTimeFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Agreement one time fee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nk_AgreementOneTimeFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nk_LicenseAgreementTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License agreement term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nk_LicenseAgreementTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nk_LicenseAgreementTerminationNoticePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License agreement termination notice period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nk_LicenseAgreementTerminationNoticePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nk_LicensingAgreementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Licensing agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nk_LicensingAgreementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nk_MaximumNumberOfPatientsInPhaseOneAndTwoForClinicalTrials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum number of patients in phase one and two for clinical trials.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nk_MaximumNumberOfPatientsInPhaseOneAndTwoForClinicalTrials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nk_MilestonePaymentAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone payment amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nk_MilestonePaymentAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nk_MinimumAnnualRoyaltyPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum annual royalty payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nk_MinimumAnnualRoyaltyPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nk_MinimumSalesMilestoneOfLicenseForFirstYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum sales milestone of license for first year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nk_MinimumSalesMilestoneOfLicenseForFirstYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nk_PaymentsForInitialLicenseFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments for initial license fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nk_PaymentsForInitialLicenseFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nk_PeriodOfLicenseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of license agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nk_PeriodOfLicenseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nk_SuppliesAndMilestoneChargesForConductingClinicalTrials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Supplies and milestone charges for conducting clinical trials.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nk_SuppliesAndMilestoneChargesForConductingClinicalTrials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of consideration recognized during the period for the milestone or milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=nk_IntrexonLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=nk_IntrexonLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=nk_INDFilingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=nk_INDFilingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=nk_PhaseTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=nk_PhaseTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=nk_PhaseThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=nk_PhaseThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=nk_CommercialSaleRelatedToLicensedProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=nk_CommercialSaleRelatedToLicensedProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsAxis=nk_RushUniversityMedicalCenterLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsAxis=nk_RushUniversityMedicalCenterLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=nk_GeorgSpeyerHausAndDRKBlutspendedienstBadenWurttembergHessengGmbHLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=nk_GeorgSpeyerHausAndDRKBlutspendedienstBadenWurttembergHessengGmbHLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nk_ViractaTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nk_ViractaTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=nk_AltorBioScienceCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=nk_AltorBioScienceCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6900430032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">$ 43<span></span>
</td>
<td class="nump">$ 47<span></span>
</td>
<td class="nump">$ 45<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development (including amounts with related parties)</a></td>
<td class="nump">49,785<span></span>
</td>
<td class="nump">55,718<span></span>
</td>
<td class="nump">42,044<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative (including amounts with related parties)</a></td>
<td class="nump">18,065<span></span>
</td>
<td class="nump">42,718<span></span>
</td>
<td class="nump">57,121<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">67,850<span></span>
</td>
<td class="nump">98,436<span></span>
</td>
<td class="nump">99,165<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(67,807)<span></span>
</td>
<td class="num">(98,389)<span></span>
</td>
<td class="num">(99,120)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeNet', window );">Investment income, net</a></td>
<td class="nump">1,642<span></span>
</td>
<td class="nump">1,857<span></span>
</td>
<td class="nump">2,665<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestExpense', window );">Interest expense (including amounts with related parties)</a></td>
<td class="num">(19)<span></span>
</td>
<td class="num">(433)<span></span>
</td>
<td class="num">(618)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income, net (including amounts with related parties)</a></td>
<td class="nump">298<span></span>
</td>
<td class="nump">236<span></span>
</td>
<td class="nump">157<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income</a></td>
<td class="nump">1,921<span></span>
</td>
<td class="nump">1,660<span></span>
</td>
<td class="nump">2,204<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="num">(65,886)<span></span>
</td>
<td class="num">(96,729)<span></span>
</td>
<td class="num">(96,916)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit</a></td>
<td class="nump">97<span></span>
</td>
<td class="nump">503<span></span>
</td>
<td class="nump">493<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (65,789)<span></span>
</td>
<td class="num">$ (96,226)<span></span>
</td>
<td class="num">$ (96,423)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net loss per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Basic and diluted</a></td>
<td class="num">$ (0.70)<span></span>
</td>
<td class="num">$ (1.22)<span></span>
</td>
<td class="num">$ (1.20)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract', window );"><strong>Weighted-average number of shares during the period:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Basic and diluted</a></td>
<td class="nump">94,210,087<span></span>
</td>
<td class="nump">79,132,220<span></span>
</td>
<td class="nump">80,583,910<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918638-209977<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68072869&amp;loc=d3e41242-110953<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109238882&amp;loc=d3e38679-109324<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(a),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=68048583&amp;loc=d3e3636-108311<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6898402128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summarized Quarterly Data (Unaudited) (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract', window );"><strong>Quarterly Financial Information Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock', window );">Summary of Quarterly Data (Unaudited)</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The table below presents unaudited quarterly data for fiscal 2019 and 2018 (in thousands, except for share and per share amounts):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1st Quarter</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2nd Quarter</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">3rd Quarter</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">4th Quarter</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenue</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating expenses</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,340</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,313</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,077</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,120</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating loss</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(18,335</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(17,296</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(16,065</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(16,111</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(17,885</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(16,682</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(15,581</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(15,641</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per share - basic and diluted</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.22</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.17</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.16</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.16</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shares used in calculating net loss per share - basic and</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; diluted</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">81,261,302</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">98,594,355</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">98,331,695</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">98,419,166</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1st Quarter</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2nd Quarter</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">3rd Quarter</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">4th Quarter</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenue</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating expenses</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28,289</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28,282</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,139</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,726</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating loss</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(28,284</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(28,278</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(24,108</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(17,719</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">) </p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(27,519</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(27,732</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(23,635</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(17,340</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">) </p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per share - basic and diluted</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.35</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.35</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.30</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.22</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">) </p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shares used in calculating net loss per share - basic and</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; diluted</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">79,036,614</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">79,107,208</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">79,204,765</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">79,177,962</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of quarterly financial data. Includes, but is not limited to, financial information for fiscal quarters, cumulative effect of a change in accounting principle and earnings per share data.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118952077&amp;loc=d3e1280-108306<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6894153904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Securities Excluded from the Computation of Potentially Dilutive Securities (Detail) - shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share, amount</a></td>
<td class="nump">5,646,378<span></span>
</td>
<td class="nump">24,950,411<span></span>
</td>
<td class="nump">24,302,527<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share, amount</a></td>
<td class="nump">4,506,950<span></span>
</td>
<td class="nump">6,493,250<span></span>
</td>
<td class="nump">5,693,250<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Outstanding RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share, amount</a></td>
<td class="nump">1,139,428<span></span>
</td>
<td class="nump">867,911<span></span>
</td>
<td class="nump">888,189<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Outstanding Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share, amount</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">17,589,250<span></span>
</td>
<td class="nump">17,721,088<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6898433120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitment and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments And Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and contingencies</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">8. &#160;&#160;&#160;&#160;Commitments and Contingencies</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Contingencies</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We record accruals for loss contingencies to the extent that we conclude it is probable that a liability has been incurred and the amount of the related loss can be reasonably estimated. We evaluate, on a quarterly basis, developments in legal proceedings and other matters that could cause a change in the potential amount of the liability recorded or of the range of potential losses disclosed. Additionally, we record our rights to insurance recoveries, limited to the extent of incurred or probable losses, as a receivable when such recoveries have been agreed to with our third-party insurers and when receipt is deemed probable. This includes instances where our third-party insurers have agreed to pay, on our behalf, certain legal defense costs and settlement amounts directly to applicable law firms and a settlement fund.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Securities Litigation</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March&#160;2016, a putative securities class action complaint captioned <font style="font-style:italic;">Sudunagunta v. NantKwest, Inc., et al.</font>, No. 16&#8209;cv&#8209;01947 was filed in federal district court for the Central District of California related to the company&#8217;s restatement of certain interim financial statements for the periods ended June&#160;30, 2015 and September&#160;30, 2015. A number of similar putative class actions were filed in federal and state court in California. The actions originally filed in state court were removed to federal court, and the various related actions were consolidated. Plaintiffs asserted causes of action for alleged violations of Sections&#160;11 and 15 of the Securities Act of 1933 and Sections&#160;10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule&#160;10b&#8209;5 promulgated thereunder. Plaintiffs sought unspecified damages, costs and attorneys&#8217; fees, and equitable/injunctive or other relief on behalf of putative classes of persons who purchased or acquired the company&#8217;s securities during various time periods from July&#160;28, 2015 through March&#160;11, 2016. In September&#160;2017, the court denied defendants' motion to dismiss the third amended consolidated complaint. On August&#160;13, 2018, the district court granted plaintiffs&#8217; motions for class certification and to strike plaintiffs&#8217; claims under the Securities Exchange Act of 1934 and Rule&#160;10b&#8209;5. On August&#160;24, 2018, at the district court&#8217;s direction, plaintiffs filed a fourth amended consolidated complaint. On August&#160;27, 2018, defendants petitioned the U.S. Court of Appeals for the Ninth Circuit to authorize interlocutory appeal of the class certification order. On September&#160;7, 2018, defendants answered the fourth amended consolidated complaint. On September&#160;21, 2018, the parties informed the Ninth Circuit that they had reached a settlement in principle, and the parties moved to stay appellate proceedings. On September&#160;24, 2018, the parties notified the district court that they had reached a settlement in principle. On November&#160;9, 2018, the plaintiffs filed an unopposed motion for preliminary approval of the settlement and notice to class members. On January&#160;9, 2019, the district court granted the motion for preliminary approval. A final approval hearing was held on April&#160;29, 2019, and the district court granted final approval and entered judgment on May&#160;31, 2019.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the terms of the settlement, we paid $12.0&#160;million to the plaintiffs as full and complete settlement of the litigation. We were responsible for $1.2&#160;million of the settlement amount, which was recognized in selling, general and administrative expense during the third quarter of 2018, while the remaining $10.8&#160;million was fully funded by our insurance carriers under our directors&#8217; and officers&#8217; insurance policy. We and the insurance carriers paid the settlement amount into a settlement fund in January&#160;2019. Subsequent to receiving final approval of the settlement on May&#160;13, 2019, the aforementioned settlement accrual, associated insurance claim receivable and restricted cash were released and are no longer reflected on our consolidated balance sheets as of December&#160;31, 2019.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Stipulation of Settlement</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In early April&#160;2019, following board approval, which occurred in late March&#160;2019, we entered into a settlement agreement, or the Stipulation of Settlement, with three&#160;stockholders of the company, each of whom had submitted a stockholder demand for the board to take action to remedy purported harm to the company resulting from certain alleged wrongful conduct concerning, among other things, disclosures about Dr.&#160;Soon-Shiong&#8217;s compensation and a related-party lease agreement. The Stipulation of Settlement called for us to adopt certain governance changes, and for the three&#160;stockholders to file a stockholder derivative action in the Superior Court of the State of California, County of San Diego, followed by an application for court approval of the Stipulation of Settlement. On May&#160;31, 2019, the court entered an order preliminarily approving the Stipulation of Settlement and scheduling the final settlement hearing for August&#160;9, 2019. Pursuant to the Stipulation of Settlement, we have provided stockholders with notice of the settlement and the final settlement hearing.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the terms of the Stipulation of Settlement, which received final approval by the court on August&#160;9, 2019, we paid an attorney&#8217;s fee of $0.5&#160;million to the plaintiffs as part of the settlement. Of that amount, we were responsible for half, which was recognized in selling, general and administrative expense on the consolidated statements of operations during the first quarter of 2019, while the other half was funded by our insurance carrier. We and the insurance carrier paid the settlement amount into a settlement fund in June&#160;2019. Subsequent to receiving final approval of the settlement on August&#160;9, 2019, the aforementioned settlement accrual, associated insurance claim receivable and restricted cash were released and are no longer reflected on our consolidated balance sheets as of December&#160;31, 2019.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Insurance Recoveries</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have reflected our right to insurance recoveries, limited to the extent of incurred or probable losses, as a receivable when such recoveries have been agreed to with our third-party insurers and receipt is deemed probable. This includes instances where our third-party insurers have agreed to pay, on our behalf, certain legal defense costs and settlement amounts directly to applicable law firms and a settlement fund. The amount of such receivable recorded at December&#160;31, 2019 and 2018 was $34,000 and $10.9&#160;million, respectively, and is included in prepaid expenses and other current assets on our consolidated balance sheets.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Contractual Obligations - Leases</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We adopted ASC&#160;842, as of January&#160;1, 2019, using the simplified transition approach discussed in further detail in Note&#160;2. As a result, prior periods were not recast. The following disclosures relate to our lease balances as of January&#160;1, 2019 and December&#160;31, 2019, under ASC&#160;842 (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.36%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">January 1, 2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.36%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease right-of-use assets, net</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.36%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,532</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.36%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,729</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other current liabilities</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.36%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,960</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.36%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,206</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease liability, less current portion</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.36%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,407</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.36%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,885</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></div>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a result of new agreements entered into subsequent to our adoption of ASC&#160;842, we recognized an increase of $0.8&#160;million in both operating lease right-of-use assets and operating lease liabilities during the year ended December&#160;31, 2019.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Substantially all of our operating lease right-of-use assets and operating lease liabilities relate to facilities leases. We lease:&#160;(i)&#160;a&#160;research facility and office space in San Diego, California; (ii)&#160;a research and manufacturing space in Culver City, California, from a related party; (iii)&#160;a research and manufacturing facility in El Segundo, California, also from a related party; (iv)&#160;a research facility in Torrance, California, and (v)&#160;a research facility in Woburn, Massachusetts. See Note&#160;9 &#8211; <font style="font-style:italic;">Related Party Agreements</font> for further information.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease expense of $5.1&#160;million, including variable lease costs of $1.2&#160;million, was recorded in operating expenses on the consolidated statements of operations for year ended December&#160;31, 2019. The weighted-average remaining lease term as of January&#160;1, 2019 and December&#160;31, 2019 was 5.4&#160;years and 4.5&#160;years, respectively. The weighted-average discount rate as of January&#160;1, 2019 and December&#160;31, 2019 was 9%. For the year ended December&#160;31, 2019, cash outflows from operating leases, excluding variable lease costs, was $4.4&#160;million.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Future minimum lease payments at December&#160;31, 2019 are presented in the following table (in thousands). Common area maintenance costs and taxes are not included in these payments.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:81.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Years ending December 31:</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Operating</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Leases (a)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:81.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,271</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:81.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,753</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:81.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,671</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:81.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,546</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:81.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2024</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,083</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:81.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thereafter</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,729</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:81.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total future minimum lease payments</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,053</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:81.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: Interest</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,962</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:81.8%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Present value of operating lease liabilities</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,091</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table>
<p style="border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;margin-right:75.93%;text-indent:0%;font-size:5pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:2pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:2pt;margin-bottom:0pt;font-size:10pt;">(a)</p></td>
<td valign="top">
<p style="margin-top:2pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease payments include $3.3&#160;million related to options to extend lease terms that are reasonably certain of being exercised.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></div>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August&#160;2018, NantBio, Inc., or NantBio, a related party (Note&#160;9) assigned an agreement to us for the use of a third-party research facility, which provides us with the exclusive right to use and access to a portion of the third party&#8217;s laboratory and vivarium premises. In conjunction with the assignment, we reimbursed NantBio for upfront payments, which it had made to the third party of $0.9&#160;million, and paid $0.5&#160;million directly to the third party for an aggregate value of $1.4&#160;million. The assigned agreement is for a term of ten&#160;years and expires in June&#160;2027. The agreement may be terminated by us at any time, with or without cause. In case of termination of the agreement, the third party will reimburse us for a pro-rata amount based upon the passage of time.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In September&#160;2016, we entered into a lease agreement with 605&#160;Doug St,&#160;LLC, a related party (Note&#160;9), for approximately 24,250&#160;square feet in El Segundo, California, which has been converted to a research and development laboratory and a cGMP manufacturing facility. The lease runs from July&#160;2016 through July&#160;2023. We have the option to extend the lease for an additional three&#160;year term through July&#160;2026. The monthly rent is $0.1&#160;million with annual increases of 3% beginning in July&#160;2017.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March&#160;2016, we entered into a lease agreement for an approximately 7,893&#160;square foot facility in Woburn, Massachusetts, for a research and development laboratory, related office and other related uses. The initial lease term runs for 48&#160;months from April&#160;29, 2016 through May&#160;31, 2020. In June&#160;2016, the lease was amended to add 260&#160;square feet, for a total of 8,153&#160;square feet. Base rent for the initial term of the lease is $19,000&#160;per&#160;month with a $1&#160;per&#160;square foot annual increase on each anniversary date. In August&#160;2019, we exercised our right pursuant to the lease agreement to extend the term of the lease for an additional two&#160;years through May&#160;31, 2022. Consequently, we recognized an increase of $0.6&#160;million in both operating lease right-of-use assets and operating lease liabilities on the consolidated balance sheets.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In November&#160;2015, we entered into a facility license agreement with NantWorks LLC, or NantWorks, a related party (Note&#160;9), for approximately 9,500&#160;square feet of office space in Culver City, California, which has been converted to a research and development laboratory and a cGMP manufacturing facility. The license was effective in May&#160;2015 and extends through December&#160;2020. The monthly rent is $47,000, with annual increases of 3% beginning in January&#160;2017.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June&#160;2015, we entered into a lease agreement for an approximately 44,700&#160;square foot facility in San Diego, California, for a research and development laboratory, related office and other related uses. The term of the lease extends for seven&#160;years commencing on August&#160;1, 2016. The base rent is $0.2&#160;million per month with 3% annual increases on each anniversary date.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prior to adopting ASC&#160;842 on January&#160;1, 2019, we recognized rent expense under operating leases on a straight-line basis. Fixed rent expense under ASC&#160;840 for the years ended December&#160;31, 2018 and 2017 was $2.8&#160;million and $2.7&#160;million, respectively.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6814507872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Viracta Investment and Convertible Notes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsAllOtherInvestmentsAbstract', window );"><strong>Investments All Other Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostAndEquityMethodInvestmentsDisclosureTextBlock', window );">Viracta Investment and Convertible Notes</a></td>
<td class="text">
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">4. &#160;&#160;&#160;&#160;Viracta Investment and Convertible Notes</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March&#160;2017, we participated in a Series&#160;B convertible preferred stock financing and invested $8.5&#160;million in Viracta Therapeutics, Inc., or Viracta, a clinical stage drug development company. In May&#160;2017, we executed an exclusive worldwide license with Viracta to develop and commercialize Viracta&#8217;s proprietary histone deacetylase inhibitor drug candidate for use in combination with natural killer cell therapy and possibly additional therapies. See Note&#160;7<font style="font-style:italic;"> &#8211; Collaboration and License Agreements &#8211; Royalties and In-licensing Agreements &#8211; Viracta License Agreement</font> for further information.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June&#160;2018, Viracta executed a 2018&#160;Note and Warrant Purchase Agreement with existing and new investors, including us. The initial closing under the Purchase Agreement occurred in June&#160;2018, at which point we purchased a convertible note for $0.4&#160;million, which under certain circumstances was convertible into preferred stock of Viracta, and a warrant to purchase Viracta&#8217;s common shares. The convertible note accrued interest at 8% and had a one-year maturity date. In September&#160;2018, a milestone closing under the Purchase Agreement occurred, at which point we purchased an additional convertible note for $0.4&#160;million, which under certain circumstances was convertible into preferred stock of Viracta, and a warrant to purchase Viracta&#8217;s common shares. The convertible note accrued interest at 8% and had a one-year maturity date. We classified the convertible notes as held-to-maturity notes receivable on the consolidated balance sheets. Effective January&#160;31, 2019, the notes, together with accrued interest then outstanding, were converted to Series&#160;B preferred stock resulting in an increase to our investment in Viracta&#8217;s Series&#160;B convertible preferred stock of $0.8&#160;million. In May&#160;2019, we exercised warrants to acquire 253,120&#160;shares of Viracta common stock. At December&#160;31, 2019, our investment in Viracta totaled $9.3&#160;million.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Based on the level of equity investment at risk, Viracta is not a VIE and therefore is not consolidated under the VIE Model. In addition, we do not hold a controlling financial interest in Viracta and therefore we do not consolidate Viracta under the voting interest model. As the preferred stock is not considered in-substance common stock, the investment is not within the scope of accounting for the investment under the equity method. As the preferred stock does not have a readily determinable fair value and does not qualify for the practical expedient to estimate fair value in accordance with ASC&#160;820, we have elected to apply the measurement alternative under ASC&#160;321, pursuant to which we measure our investment in Viracta at cost, less impairment, adjusted for observable price changes in an orderly market for an identical or similar investment of the same issuer.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2019, our qualitative impairment assessment did not indicate there were events or changes in circumstances that may have had a significant adverse effect on the fair value of the investment. We have not recorded any impairments as of December&#160;31, 2019, or on a cumulative basis. Further, we have not identified any downward or upward adjustments due to observable price changes in the investment as of December&#160;31, 2019, or on a cumulative basis. Our investment in Viracta is reflected in equity investment on the consolidated balance sheets.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostAndEquityMethodInvestmentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for cost method and equity method investments included basis, impairment losses, recognized or unrecognized gains (losses).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostAndEquityMethodInvestmentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAllOtherInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAllOtherInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6814503600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">12. &#160;&#160;&#160;&#160;Income Taxes</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The amount of loss before taxes is as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the Year Ended December&#160;31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. loss before taxes</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(65,286</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(94,423</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(94,734</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Foreign loss before taxes</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(600</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,306</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,182</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss before income taxes</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(65,886</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(96,729</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(96,916</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></div>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Income tax benefit for the years ended December&#160;31, 2019, 2018 and 2017 consists of the following (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.84%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the Year Ended December&#160;31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.8%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.8%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current:</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.48%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Federal</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Foreign</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.48%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total Current</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.48%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred:</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.48%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Federal</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(79</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(21</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(8</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Foreign</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.48%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(498</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(497</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total Deferred</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(100</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(506</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(497</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.78%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Income tax benefit</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.48%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(97</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(503</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(493</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></div>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The components that comprise the company&#8217;s net deferred tax assets at December&#160;31, 2019 and 2018 consist of the following (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.94%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax assets:</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net operating loss carryforwards</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">78,377</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61,915</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock compensation</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,536</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">79,281</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease liabilities</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,884</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation and amortization</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,042</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tax credits</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">898</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">845</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued compensation</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">775</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">795</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leases and other accrued liabilities</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">453</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,909</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued legal expenses</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">308</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred tax assets</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">94,965</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">146,053</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax liabilities:</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Foreign intangibles</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease right-of-use assets</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,233</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation and amortization</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,279</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred tax liabilities</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,233</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,280</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net deferred tax assets</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">91,732</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">144,773</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Valuation allowance</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(91,732</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(144,773</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.44%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net deferred tax liability</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.4%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></div>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A reconciliation of the federal statutory income tax rate to the company&#8217;s effective income tax rate is as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:55.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="12" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.08%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the Year Ended December&#160;31,</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:55.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.02%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.02%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tax computed at federal statutory rate</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.34%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.0</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.34%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.0</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.34%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34.0</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State income taxes, net of federal tax benefit</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.34%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(19.4</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.34%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.2</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.34%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.3</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tax rate adjustment</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.34%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.1</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.34%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.3</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.34%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.8</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tax Cuts and Jobs Act</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.34%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.34%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.34%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(53.4</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development credits</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.34%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.2</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.34%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.1</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.34%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.6</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.34%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(82.5</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.34%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.1</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.34%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.3</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.34%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.1</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.34%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.3</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.34%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.8</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:55.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Valuation allowance</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.34%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">80.5</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.34%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(26.7</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.34%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.7</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:55.54%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Effective income tax rate</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.34%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.2</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.02%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.34%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.5</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.02%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.34%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.5</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.02%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On December&#160;22, 2017, the Tax Cuts and Jobs Act, or the TCJA, was enacted into law. The TCJA made significant changes to U.S. tax laws, including, but not limited to, the following:&#160;(a)&#160;reducing the federal corporate income tax rate from 35% to a flat 21%, effective January&#160;1, 2018; (b)&#160;eliminating the federal corporate alternative minimum tax, or AMT, and changing how existing AMT credits can be realized; and (c)&#160;eliminating several business deductions and credits, including deductions for certain executive compensation in excess of $1.0&#160;million.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a result of the rate reduction, the company reduced the deferred tax asset balance as of December&#160;31, 2017 by $51.7&#160;million. Due to the company&#8217;s full valuation allowance position, we also reduced the valuation allowance by the same amount.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December&#160;2017, the Securities and Exchange Commission issued Staff Accounting Bulletin&#160;No.&#160;118, or SAB&#160;118, which provides guidance on accounting for the income tax effects of the TCJA. SAB&#160;118 provides a measurement period that should not extend beyond one year from the TCJA enactment date for companies to complete the accounting related to the TCJA under ASC&#160;Topic&#160;740, <font style="font-style:italic;">Income Taxes</font>, or ASC&#160;740. In accordance with SAB&#160;118, a company must reflect the income tax effects of those aspects of the TCJA for which the accounting under ASC&#160;740 is complete. To the extent that a company&#8217;s accounting for TCJA-related income tax effects is incomplete, but the company is able to determine a reasonable estimate, it must record a provisional estimate in its financial statements. If a company cannot determine a provisional estimate to be included in its financial statements, it should continue to apply ASC&#160;740 on the basis of the provisions of the tax laws that were in effect immediately before enactment of the TCJA. We completed our evaluation of the potential impacts of IRC&#160;Section&#160;162(m) as amended by the TJCA on our December&#160;31, 2018 consolidated financial statements, resulting in no adjustment for the years ended December&#160;31, 2019, 2018 and 2017.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to IRC&#160;Sections&#160;382 and 383, annual use of the company's net operating loss and research and development credit carryforwards may be limited in the event a cumulative change in ownership of more than 50% occurs within a three-year period. We completed an IRC&#160;Section&#160;382/383 analysis through March&#160;2019 regarding the limitation of net operating loss and research and development credit carryforwards. As a result, we derecognized a portion of the deferred tax assets for net operating losses and federal and state research and development credits of $0.8&#160;million from our deferred tax asset schedule as of December&#160;31, 2019. There is no impact to tax expense for the derecognition of the net operating losses and federal and state research and development credits due to the valuation allowance recorded against the deferred tax assets. Additionally, we have not recognized the deferred tax asset for research and development credits carryforwards as of December&#160;31, 2019 and 2018 because we are a part of a controlled group of affiliated companies with common ownership and cannot complete our calculation of the credit until the time that all members of the controlled group complete their analysis and calculation of qualified research expenditures. We do not expect that the unrecognized tax benefits will change within 12&#160;months of this reporting date. Due to the existence of the valuation allowance, future changes in our unrecognized tax benefits will not impact the company's effective tax rate.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In assessing the realization of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income and tax planning strategies in making this assessment. Based on the level of historical operating results and the uncertainty of the economic conditions, we have recorded a full valuation allowance of $91.7&#160;million at December&#160;31, 2019. The change in the valuation allowance for the year ended December&#160;31, 2019 was a decrease of $53.0&#160;million which was mainly driven by the reversal of deferred tax assets related to stock compensation that will not be realized. The portion of the valuation allowance for deferred tax assets for which subsequently recognized tax benefits will be credited directly to contributed capital is $0.2&#160;million.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have not incurred any material interest or penalties as of the current reporting date with respect to income tax matters. We do not expect that there will be unrecognized tax benefits of a significant nature that will increase or decrease within 12&#160;months of the reporting date. We are subject to U.S. federal income tax, as well as income tax in California and other states. The federal returns for tax years 2016 through 2019 remain open to examination and the California returns remain subject to examination for tax years 2015 through 2019. Carryforward attributes that were generated in years where the statute of limitations is closed may still be adjusted upon examination by the Internal Revenue Service or other respective tax authority. All other state jurisdictions remain open to examination.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At December&#160;31, 2019, the company has federal net operating losses, or NOLs, of approximately $291.8&#160;million, state NOLs of $255.7&#160;million, and foreign NOLs of $0.2&#160;million. The federal NOL carryforwards begin to expire in 2024, the state NOL carryforwards begin to expire in 2030 and the foreign NOL carryforwards begin to expire in 2022. At December&#160;31, 2019, the company also had federal research tax credit carryforwards of approximately $8.5&#160;million and California research tax credits of $5.7&#160;million. The federal research tax credit carryforwards begin to expire in 2034 and the state research tax credit carryforwards begin to expire in 2031.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes the changes to the amount of unrecognized tax benefits (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:60%;">
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unrecognized tax benefits at December 31, 2017</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,577</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Increase for prior year tax positions</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">798</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Increase for current year tax positions</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,608</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unrecognized tax benefits at December 31, 2018</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,983</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Decrease for prior year tax positions</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(7</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Increase for current year tax positions</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,680</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unrecognized tax benefits at December 31, 2019</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,656</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></div>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Included in the balance of unrecognized tax benefits at December&#160;31, 2019, is $14.1&#160;million that, if recognized, would not impact our income tax benefit or effective tax rate as long as the deferred tax asset remains subject to a full valuation allowance. We do not expect any significant increases or decreases to our unrecognized tax benefits within the next 12&#160;months.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6894467632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Reconciliation of Federal Statutory Income Tax Rate (Detail)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Tax computed at federal statutory rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">34.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State income taxes, net of federal tax benefit</a></td>
<td class="num">(19.40%)<span></span>
</td>
<td class="nump">6.20%<span></span>
</td>
<td class="nump">5.30%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements', window );">Tax rate adjustment</a></td>
<td class="nump">0.10%<span></span>
</td>
<td class="num">(0.30%)<span></span>
</td>
<td class="nump">4.80%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsAct', window );">Tax Cuts and Jobs Act</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="num">(53.40%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment', window );">Research and development credits</a></td>
<td class="nump">0.20%<span></span>
</td>
<td class="nump">0.10%<span></span>
</td>
<td class="nump">0.60%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_EffectiveIncomeTaxRateReconciliationStockBasedCompensationContribution', window );">Stock-based compensation</a></td>
<td class="num">(82.50%)<span></span>
</td>
<td class="num">(0.10%)<span></span>
</td>
<td class="num">(0.30%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther', window );">Other</a></td>
<td class="num">(0.10%)<span></span>
</td>
<td class="nump">0.30%<span></span>
</td>
<td class="nump">0.80%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="nump">80.50%<span></span>
</td>
<td class="num">(26.70%)<span></span>
</td>
<td class="nump">8.70%<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective income tax rate</a></td>
<td class="num">(0.20%)<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nk_EffectiveIncomeTaxRateReconciliationStockBasedCompensationContribution">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective income tax rate reconciliation stock based compensation contribution.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nk_EffectiveIncomeTaxRateReconciliationStockBasedCompensationContribution</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nk_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsAct">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective income tax rate reconciliation Tax Cuts and Jobs Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nk_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsAct</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other deductions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research and development expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to income tax settlements. Including, but not limited to, domestic tax settlement, foreign tax settlement, state and local tax settlement, and other tax settlements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6814490512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefits - Additional Information (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanNameAxis=nk_FourHundredOneKPlanMember', window );">401(k) Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanDisclosureLineItems', window );"><strong>Defined Contribution Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount', window );">Employee benefit plan, company contributions</a></td>
<td class="nump">$ 0.6<span></span>
</td>
<td class="nump">$ 0.5<span></span>
</td>
<td class="nump">$ 0.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of discretionary contributions made by an employer to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanNameAxis=nk_FourHundredOneKPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanNameAxis=nk_FourHundredOneKPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6817519120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement Of Income And Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (65,789)<span></span>
</td>
<td class="num">$ (96,226)<span></span>
</td>
<td class="num">$ (96,423)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive income (loss), net of income taxes:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax', window );">Net unrealized gains (losses) on available-for-sale securities</a></td>
<td class="nump">158<span></span>
</td>
<td class="nump">114<span></span>
</td>
<td class="num">(65)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax', window );">Reclassification of net realized gains (losses) on available-for-sale securities included in net loss</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(32)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Total other comprehensive income (loss)</a></td>
<td class="nump">162<span></span>
</td>
<td class="nump">114<span></span>
</td>
<td class="num">(97)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (65,627)<span></span>
</td>
<td class="num">$ (96,112)<span></span>
</td>
<td class="num">$ (96,520)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e557-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments, of unrealized holding gain (loss) on available-for-sale securities and unrealized holding gain (loss) related to transfers of securities into the available-for-sale classification and out of the held-to-maturity classification.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=118951672&amp;loc=d3e1436-108581<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of reclassification adjustment from accumulated other comprehensive income for unrealized gain (loss) realized upon the sale of available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e689-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e637-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27357-111563<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17A<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL34724391-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6908664384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Mar. 20, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">NK<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">NANTKWEST, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001326110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98,483,161<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.0001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-37507<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">43-1979754<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">3530 John Hopkins Court<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">San Diego<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92121<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">858<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">633-0300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text">
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;text-indent:2.5%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">DOCUMENTS INCORPORATED BY REFERENCE</p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As noted herein, the information called for by Part&#160;III is incorporated by reference to specified portions of the Registrant&#8217;s definitive proxy statement to be filed in conjunction with the Registrant&#8217;s 2020 Annual Meeting of Stockholders, which is expected to be filed not later than 120&#160;days after the Registrant&#8217;s fiscal year ended December&#160;31, 2019.</p><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 20-F, 40-F<br> -Number 240<br> -Section 15<br> -Subsection d-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1-<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6919885024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Agreements - Additional Information (Detail)<br></strong></div></th>
<th class="th" colspan="13">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1">50 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Oct. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 30, 2018 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th">
<div>Apr. 30, 2017 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Sep. 30, 2016 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Apr. 30, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th">
<div>Nov. 30, 2015 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>Officer </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($) </div>
<div>ft&#178; </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>Officer </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares', window );">Repurchase of common stock, shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">138,349<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">473,586<span></span>
</td>
<td class="nump">138,349<span></span>
</td>
<td class="nump">3,633,610<span></span>
</td>
<td class="nump">6,403,489<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue', window );">Repurchase of common stock, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 501,000<span></span>
</td>
<td class="nump">$ 228,000<span></span>
</td>
<td class="nump">$ 15,227,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49,785,000<span></span>
</td>
<td class="nump">55,718,000<span></span>
</td>
<td class="nump">42,044,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrent', window );">Due to related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">486,000<span></span>
</td>
<td class="nump">1,696,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 486,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,065,000<span></span>
</td>
<td class="nump">42,718,000<span></span>
</td>
<td class="nump">57,121,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Proceeds from sales of property, plant and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">412,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=nk_NantHealthLabsIncMember', window );">NantHealth Labs, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_RelatedPartyTransactionInitialTermOfAgreement', window );">Initial term of agreement entered into with the related party by the entity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_RelatedPartyAgreementRenewalTerm', window );">Related party, agreement renewal term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrent', window );">Due to related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">49,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=nk_ImmunoOncologyClinicIncMember', window );">Immuno-Oncology Clinic, Inc. | California</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100,000<span></span>
</td>
<td class="nump">2,700,000<span></span>
</td>
<td class="nump">800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrent', window );">Due to related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_NumberOfOfficers', window );">Number of officers | Officer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_InitialTermOfAgreement', window );">Initial term of agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Estimated cost for new agreement with clinic</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_RelatedPartyInstallmentPayment', window );">Related party transaction installment payment</a></td>
<td class="nump">$ 1,875,000<span></span>
</td>
<td class="nump">3,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_RelatedPartyTransactionAgreementExtensionDescription', window );">Prepayments remain unearned extension description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">To the extent any portion of the prepayments remain unearned by the Clinic on the third anniversary of the new agreement, we may elect at our sole discretion either to (i) not extend the term of the new agreement and have the Clinic reimburse us for the total amount of any remaining unused portion of the prepayments, or (ii) extend the term of the new agreement for up to three additional one year periods, at which time the Clinic will reimburse us for the total amount of any remaining unused portion of the prepayments plus interest if reimbursement is not made within 60 days of expiration.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_NewAgreementTerminationNoticePeriod', window );">Notice period to terminate new agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_PrepaidBalanceIncludedInPrepaidExpensesAndOtherCurrentAssetsAndOtherAssets', window );">Prepaid balance included in prepaid expenses and other current assets and other assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,100,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Related party transaction, aggregate value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=nk_TensorcomIncMember', window );">Tensorcom, Inc | San Diego California</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionDescriptionOfTransaction', window );">Period of agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The lease ran from May 1, 2017 through April 30, 2018.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_NumberOfSquareFootOfFacilityLeased', window );">Number of square foot of facility leased | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,557<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_BaseMonthlyRent', window );">Base rent - monthly</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionDueFromToRelatedParty', window );">Due between parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=nk_TensorcomIncMember', window );">Tensorcom, Inc | San Diego California | Other Income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesIncomeStatementSubleaseRevenue', window );">Sublease revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=nk_DougStLLCMember', window );">Doug St, LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionDescriptionOfTransaction', window );">Period of agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The lease runs from July 2016 through July 2023.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_BaseMonthlyRent', window );">Base rent - monthly</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionDueFromToRelatedParty', window );">Due between parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_AnnualPercentageIncreasesToBaseRent', window );">Percentage of annual increase of base rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_AnnualPercentageIncreasesToBaseRentCommencementDate', window );">Annual percentage increases to base rent commencement date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jul. 31,  2017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=nk_DougStLLCMember', window );">Doug St, LLC | Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Lease expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">900,000<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=nk_DougStLLCMember', window );">Doug St, LLC | El Segundo California</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_NumberOfSquareFootOfFacilityLeased', window );">Number of square foot of facility leased | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=nk_NantBioScienceMember', window );">NantBioScience</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_RelatedPartyTransactionInitialTermOfAgreement', window );">Initial term of agreement entered into with the related party by the entity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Estimated cost for new agreement with clinic</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_NumberOfSquareFootOfFacilityLeased', window );">Number of square foot of facility leased | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,965<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_RelatedPartyTransactionReimbursedUpfrontPaymentToRelatedParty', window );">Related party transaction,reimbursement payment to a related-party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_RelatedPartyTransactionAmountPaidToThirdParty', window );">Related party transaction, amount paid to third-party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Related party transaction, aggregate value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_RelatedPartyAgreementExpirationMonthAndYear', window );">Related party agreement expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2027-06<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_ResearchAndDevelopmentExpenseRatablePaymentPeriod', window );">Research and development expense, ratable payment period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_PrepaymentOfFundingAmount', window );">Prepayment for services amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=nk_NantBioScienceMember', window );">NantBioScience | Prepaid Expenses and Other Current Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionDueFromToRelatedParty', window );">Due between parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,400<span></span>
</td>
<td class="nump">49,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,400<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=nk_NantBioScienceMember', window );">NantBioScience | Other Income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesIncomeStatementSubleaseRevenue', window );">Sublease revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=nk_NantWorksLimitedLiabilityCompanyMember', window );">NantWorks</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_NumberOfSquareFootOfFacilityLeased', window );">Number of square foot of facility leased | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_BaseMonthlyRent', window );">Base rent - monthly</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 47,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_AnnualPercentageIncreasesToBaseRent', window );">Percentage of annual increase of base rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_AnnualPercentageIncreasesToBaseRentCommencementDate', window );">Annual percentage increases to base rent commencement date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jan. 31,  2017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_TransferOfDepositAmountToThirdParty', window );">Transfer of deposit amount to third party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=nk_NantWorksLimitedLiabilityCompanyMember', window );">NantWorks | Shared Services Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
<td class="nump">3,300,000<span></span>
</td>
<td class="nump">3,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,100,000<span></span>
</td>
<td class="nump">2,800,000<span></span>
</td>
<td class="nump">3,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=nk_NantWorksLimitedLiabilityCompanyMember', window );">NantWorks | Reimbursements | Shared Services Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,300,000<span></span>
</td>
<td class="nump">2,600,000<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrent', window );">Due to related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="nump">1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200,000<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=nk_NantWorksLimitedLiabilityCompanyMember', window );">NantWorks | Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Lease expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=nk_NantOmicsLLCMember', window );">NantOmics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_RelatedPartyTransactionInitialTermOfAgreement', window );">Initial term of agreement entered into with the related party by the entity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_RelatedPartyAgreementRenewalTerm', window );">Related party, agreement renewal term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrent', window );">Due to related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">24,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=nk_ImmunityBioMember', window );">ImmunityBio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_RelatedPartyTransactionInitialTermOfAgreement', window );">Initial term of agreement entered into with the related party by the entity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_RelatedPartyAgreementRenewalTerm', window );">Related party, agreement renewal term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionDueFromToRelatedParty', window );">Due between parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Proceeds from sales of property, plant and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Loss on disposal of assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty', window );">Related parties, capitalized equipment amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,800,000<span></span>
</td>
<td class="nump">1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_PrepaidExpensesAndOtherAssetsCurrentWithRelatedParty', window );">Prepaid expenses and other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=nk_VivaBioCellSPAMember', window );">VivaBioCell S.p.A.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=nk_AltorBioScienceCorporationMember', window );">Altor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_SuppliesAndMilestoneChargesForConductingClinicalTrials', window );">Supplies and milestone charges for conducting clinical trials</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nk_AnnualPercentageIncreasesToBaseRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Annual percentage increases to base rent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nk_AnnualPercentageIncreasesToBaseRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nk_AnnualPercentageIncreasesToBaseRentCommencementDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Annual percentage increases to base rent commencement date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nk_AnnualPercentageIncreasesToBaseRentCommencementDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nk_BaseMonthlyRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Base monthly rent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nk_BaseMonthlyRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nk_InitialTermOfAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Initial term of agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nk_InitialTermOfAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nk_NewAgreementTerminationNoticePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>New agreement termination notice period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nk_NewAgreementTerminationNoticePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nk_NumberOfOfficers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of officers.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nk_NumberOfOfficers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nk_NumberOfSquareFootOfFacilityLeased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of square foot of facility leased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nk_NumberOfSquareFootOfFacilityLeased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nk_PrepaidBalanceIncludedInPrepaidExpensesAndOtherCurrentAssetsAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Prepaid balance included in prepaid expenses and other current assets and other assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nk_PrepaidBalanceIncludedInPrepaidExpensesAndOtherCurrentAssetsAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nk_PrepaidExpensesAndOtherAssetsCurrentWithRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Prepaid expenses and other assets current with related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nk_PrepaidExpensesAndOtherAssetsCurrentWithRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nk_PrepaymentOfFundingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Prepayment of funding amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nk_PrepaymentOfFundingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nk_RelatedPartyAgreementExpirationMonthAndYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Related party agreement expiration month and year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nk_RelatedPartyAgreementExpirationMonthAndYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearMonthItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nk_RelatedPartyAgreementRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Related party agreement renewal term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nk_RelatedPartyAgreementRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nk_RelatedPartyInstallmentPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Related party installment payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nk_RelatedPartyInstallmentPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nk_RelatedPartyTransactionAgreementExtensionDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Related party transaction agreement extension description.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nk_RelatedPartyTransactionAgreementExtensionDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nk_RelatedPartyTransactionAmountPaidToThirdParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Related party transaction, amount paid to third-party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nk_RelatedPartyTransactionAmountPaidToThirdParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nk_RelatedPartyTransactionInitialTermOfAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Related party transaction initial term of agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nk_RelatedPartyTransactionInitialTermOfAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nk_RelatedPartyTransactionReimbursedUpfrontPaymentToRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Related party transaction reimbursed upfront payment to related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nk_RelatedPartyTransactionReimbursedUpfrontPaymentToRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nk_ResearchAndDevelopmentExpenseRatablePaymentPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research and development expense ratable payment period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nk_ResearchAndDevelopmentExpenseRatablePaymentPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nk_SuppliesAndMilestoneChargesForConductingClinicalTrials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Supplies and milestone charges for conducting clinical trials.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nk_SuppliesAndMilestoneChargesForConductingClinicalTrials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nk_TransferOfDepositAmountToThirdParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Transfer of deposit amount to third party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nk_TransferOfDepositAmountToThirdParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesIncomeStatementSubleaseRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of revenue recognized for the period under subleasing arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 55<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=77891322&amp;loc=d3e41620-112719<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesIncomeStatementSubleaseRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transactions with related party during the financial reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39622-107864<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAmountsOfTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionDescriptionOfTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A description of the related party transaction, including transactions to which no amounts or nominal amounts were ascribed and such other information deemed necessary to an understanding of the effects of the transactions on the financial statements. Examples of common related party transactions are, sales, purchases and transfers of realty and personal property, services received or furnished, loans and leases to and from top management and affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=119202524&amp;loc=SL77919370-209981<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=77911099&amp;loc=d3e36975-112693<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918703-209980<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 40<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=77888430&amp;loc=SL77919784-209982<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionDescriptionOfTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionDueFromToRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Receivables to be collected from (obligations owed to) related parties, net as of the balance sheet date where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionDueFromToRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchases during the period (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=68048583&amp;loc=d3e3636-108311<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased and retired during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedAndRetiredDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased and retired during the period. The excess of the purchase price over par value can be charged against retained earnings (once the excess is fully allocated to additional paid in capital).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedAndRetiredDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=nk_NantHealthLabsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=nk_NantHealthLabsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=nk_ImmunoOncologyClinicIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=nk_ImmunoOncologyClinicIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_CA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_CA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=nk_TensorcomIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=nk_TensorcomIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=nk_SanDiegoCaliforniaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=nk_SanDiegoCaliforniaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_OtherIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=nk_DougStLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=nk_DougStLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=nk_ElSegundoCaliforniaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=nk_ElSegundoCaliforniaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=nk_NantBioScienceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=nk_NantBioScienceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=nk_NantWorksLimitedLiabilityCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=nk_NantWorksLimitedLiabilityCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nk_SharedServicesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nk_SharedServicesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TransactionTypeAxis=nk_ReimbursementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TransactionTypeAxis=nk_ReimbursementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=nk_NantOmicsLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=nk_NantOmicsLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=nk_ImmunityBioMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=nk_ImmunityBioMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=nk_VivaBioCellSPAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=nk_VivaBioCellSPAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=nk_AltorBioScienceCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=nk_AltorBioScienceCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6814490656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2. &#160;&#160;&#160;&#160;Summary of Significant Accounting Policies</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Basis of Presentation</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America, or U.S.&#160;GAAP.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The consolidated financial statements have been prepared assuming the company will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business, and do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or amounts and classification of liabilities that may result from the outcome of the uncertainty discussed in the Liquidity section of Note&#160;1. We believe our existing cash, cash equivalents, and investments in marketable debt securities, and our ability to borrow from affiliated entities, will be sufficient to fund operations through at least the next 12&#160;months following the issuance date of the financial statements based upon our Chairman and CEO&#8217;s intent and ability to support the company&#8217;s operations with additional funds, including loans from affiliated entities, as required. We may also seek to sell additional equity, through one or more follow-on public offerings, or in separate financings, or obtain a credit facility. However, we may not be able to secure such financing in a timely manner or on favorable terms. Without additional funds, we may choose to delay or reduce our operating or investment expenditures. Further, because of the risk and uncertainties associated with the commercialization of the company&#8217;s product candidates in development, we may need additional funds to meet our needs sooner than planned. To date, the company&#8217;s primary sources of capital were its initial public offering and the concurrent private placement of common shares. In addition, during the year ended December&#160;31, 2019, our Chairman and CEO exercised warrants and options resulting in aggregate cash proceeds of $39.2&#160;million.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Principles of Consolidation</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The consolidated financial statements include the accounts of NantKwest and its wholly owned subsidiaries. All intercompany amounts have been eliminated.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We apply the variable interest model under Accounting Standards Codification, or ASC Topic&#160;810,&#160;<font style="font-style:italic;">Consolidation</font>, to any entity in which we hold an equity investment or to which we have the power to direct the entity's most significant economic activities and the ability to participate in the entity's economics. If the entity is within the scope of the variable interest model and meets the definition of a variable interest entity, or VIE, we consider whether we must consolidate the VIE or provide additional disclosures regarding our involvement with the VIE. If we determine that we are the primary beneficiary of the VIE, we will consolidate the VIE. This analysis is performed at the initial investment in the entity or upon any reconsideration event.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For entities we hold as an equity investment that are not consolidated under the VIE Model, we consider whether our investment constitutes ownership of a majority of the voting interests in the entity and therefore should be considered for consolidation under the voting interest model.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unconsolidated equity investments in the common stock or in-substance common stock of an entity under which we are able to exercise significant influence, but not control, are accounted for using the equity method. Our ability to exercise significant influence is generally indicated by ownership of 20 to 50 percent interest in the voting securities of the entity.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All other unconsolidated equity investments on which we are not able to exercise significant influence will be subsequently measured at fair value with unrealized holding gains and losses included in other income, net on the consolidated statements of operations. In the instance the equity investment does not have a readily determinable fair value and does not qualify for the practical expedient to estimate fair value in accordance with ASC&#160;820, <font style="font-style:italic;">Fair Value Measurement</font>, or ASC&#160;820, we will apply the measurement alternative under ASC&#160;321, <font style="font-style:italic;">Investments&#8212;Equity Securities</font>, or ASC&#160;321, pursuant to which we will measure the investment at its cost less impairment, adjusted for observable price changes in an orderly market for an identical or similar investment of the same issuer.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We own non-marketable equity securities that are accounted for using the measurement alternative under ASC&#160;321 because the preferred stock held by us is not considered in-substance common stock and such preferred stock does not have a readily determinable fair value. All investments are reviewed on a regular basis for possible impairment. If an investment's fair value is determined to be less than its net carrying value, the investment is written down to its fair value. Such an evaluation is judgmental and dependent on specific facts and circumstances. Factors considered in determining whether an impairment indicator is present include:&#160;the investees&#8217; earnings performance and clinical trial performance, change in the investees&#8217; industry and geographic area in which it operates, offers to purchase or sell the security for a price less than the cost of the investment, issues that raise concerns about the investee's ability to continue as a going concern, and any other information that we may be aware of related to the investment. Factors considered in determining whether an observable price change has occurred include:&#160;the price at which the investee issues equity instruments similar to those of our investment and the rights and preferences of those equity instruments compared to ours.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Use of Estimates</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. On an ongoing basis, we evaluate our estimates, including those related to valuation of equity-based awards, deferred income taxes and related valuation allowances, preclinical and clinical trial accruals, impairment assessments, useful lives of long-lived assets, loss contingencies, and fair value measurements. We base our estimates on historical experience and on various other market-specific and relevant assumptions that we believe to be reasonable under the circumstances. Actual results could differ from those estimates.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Risks and Uncertainties</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Contingencies</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We record accruals for loss contingencies to the extent that we conclude it is probable that a liability has been incurred and the amount of the related loss can be reasonably estimated. We evaluate, on a quarterly basis, developments in legal proceedings and other matters that could cause a change in the potential amount of the liability recorded or of the range of potential losses disclosed. Additionally, we record our rights to insurance recoveries, limited to the extent of incurred or probable losses, as a receivable when such recoveries have been agreed to with our third-party insurers and when receipt is deemed probable. This includes instances when our third-party insurers have agreed to pay, on our behalf, certain legal defense costs and settlement amounts directly to applicable law firms and a settlement fund.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Concentration of Credit Risk and Other Risks and Uncertainties</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially subject us to concentrations of risk consist principally of cash and cash equivalents and marketable debt securities.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our cash and cash equivalents are held by one major financial institution in the U.S. and one in Korea.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Product candidates developed by us will require approvals or clearances from the U.S. Food and Drug Administration, or FDA, or international regulatory agencies prior to commercial sales. There can be no assurance that any of our product candidates will receive any of the required approvals or clearances. If we were to be denied approval or clearance or any such approval or clearance was to be delayed, it would have a material adverse impact on us.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Cash, Cash Equivalents and Marketable Debt Securities</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We invest our excess funds in investment grade short- to intermediate-term corporate debt securities, commercial paper, government sponsored securities, and foreign government bonds. We consider all highly liquid investments purchased with original maturities of three&#160;months or less to be cash equivalents and all investments purchased with original maturities of greater than three&#160;months as marketable debt securities, classified as available-for-sale. Marketable debt securities with remaining maturities of 12&#160;months or less are classified as short-term and marketable debt securities with remaining maturities greater than 12&#160;months are classified as long-term. All marketable debt securities are reported at fair value and any unrealized gains and losses are reported as a component of accumulated other comprehensive income (loss), net of tax, on the consolidated statements of stockholders&#8217; equity, with the exception of unrealized losses believed to be other-than-temporary, which are recorded in investment income, net, on the consolidated statements of operations. Realized gains and losses are included in investment income, net, on the consolidated statements of operations. Realized gains and losses from sale of the securities and the amounts, net of tax, reclassified out of accumulated other comprehensive loss, if any, are determined on a specific identification basis.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We periodically evaluate whether declines in fair values of our investments below their book value are other-than-temporary. This evaluation consists of several qualitative and quantitative factors regarding the severity and duration of the unrealized loss, as well as our ability and intent to hold the investment until a forecasted recovery occurs. Additionally, we assess whether or not we have plans to sell the security or whether or not it is more likely than not we will be required to sell any investment before recovery of its amortized cost basis. Factors considered include quoted market prices, recent financial results and operating trends, implied values from any recent transactions or offers of investee securities, credit quality of debt instrument issuers, other publicly available information that may affect the value of our investments, duration and severity of the decline in value, and our strategy and intentions for holding the investment. There were no other-than-temporary impairments recorded in the years ended December&#160;31, 2019, 2018 and 2017.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We minimize credit risk associated with our cash and cash equivalents by periodically evaluating the credit quality of our primary financial institutions. While we maintain cash deposits in FDIC insured financial institutions in excess of federally insured limits, we do not believe that we are exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held. We have not experienced any losses on such accounts.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have funded a certificate of deposit (CD) as a substitute letter of credit for one of our leased properties. This CD is reported as long term restricted cash and is included in other assets on the consolidated balance sheets as the landlord is the beneficiary of the account and we are not able to access the funds during the term of the lease.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Property, Plant and Equipment</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property, plant and equipment is stated at historical cost less accumulated depreciation. Historical cost includes expenditures that are directly attributable to the acquisition of the items. All repairs and maintenance are charged to net loss during the financial period in which they are incurred. Depreciation of property, plant and equipment is calculated using the straight-line method over the estimated useful lives of the assets, as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Buildings</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> 39 years</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Software</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> 3 years</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Laboratory equipment</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> 5 years</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furniture &amp; fixtures</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> 5 years</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">IT equipment</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> 3 years</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> The lesser of the lease term or the life of the asset</p></td>
</tr>
</table>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Upon disposal or impairment of property, plant and equipment, the cost and related accumulated depreciation is removed from the consolidated financial statements and the net amount, less any proceeds, is included in the consolidated statements of operations.</p></div>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Intangible Assets</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intangible assets, which consisted of the cost of reacquiring a technology license during 2015, were amortized using the straight-line method over an estimated useful life of 4&#160;years. As of December 31, 2019, our intangible assets were fully amortized.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Patents</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Patent costs, including related legal costs, are expensed as incurred and recorded in selling, general and administrative expenses on the consolidated statements of operations.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Impairments</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Long-lived assets include property, plant and equipment and intangible assets. We review long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability is measured by comparison of the carrying amount to the future net cash flows that the assets are expected to generate. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the projected undiscounted future cash flows arising from the assets using a discount rate determined by management to be commensurate with the risk inherent to our current business model.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the second quarter of 2019, we determined that certain bioreactor laboratory equipment could no longer be utilized in the production process. As a result, we recorded an impairment charge totaling $0.9&#160;million, which is included in research and development expense on the consolidated statements of operations. There were no impairment losses recognized during the years ended December&#160;31, 2018 and 2017.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Fair Value of Financial Instruments</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accounting standard for fair value measurements provides a framework for measuring fair value and requires disclosures regarding fair value measurements. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date, based on our principal or, in absence of a principal, most advantageous market for the specific asset or liability.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We use a three-tier fair value hierarchy to classify and disclose all assets and liabilities measured at fair value on a recurring basis, as well as assets and liabilities measured at fair value on a non-recurring basis, in periods subsequent to their initial measurement. The hierarchy requires us to use observable inputs when available, and to minimize the use of unobservable inputs, when determining fair value.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The three tiers are defined as follows:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:15pt;line-height:11pt;">&#x2022;</p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level&#160;1&#8212; Observable inputs that reflect quoted market prices (unadjusted) for identical assets or liabilities in active markets at the measurement date. Since valuations are based on quoted prices that are readily and regularly available in an active market, valuation of these products does not entail a significant degree of judgment. Our Level 1 assets consist of bank deposits and money market funds.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:15pt;line-height:11pt;">&#x2022;</p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level&#160;2&#8212; Observable inputs other than quoted prices in active markets that are observable either directly or indirectly in the marketplace for identical or similar assets and liabilities. Our Level 2 assets consist of corporate debt securities including commercial paper, government sponsored securities and corporate bonds, as well as foreign municipal securities.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:15pt;line-height:11pt;">&#x2022;</p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level&#160;3&#8212; Valuations based on inputs that are unobservable and significant to the overall fair value measurement.</p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the years ended December&#160;31, 2019, 2018 and 2017, no transfers were made into or out of the Level&#160;1,&#160;2 or 3 categories. We will continue to review the fair value inputs on a quarterly basis.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We utilize a third-party pricing service to assist in obtaining fair value pricing for our investments in marketable debt securities. Inputs are documented in accordance with the fair value disclosure hierarchy.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Preclinical and Clinical Trial Accruals</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As part of the process of preparing the financial statements, we are required to estimate expenses resulting from obligations under contracts with vendors, clinical research organizations and consultants. The financial terms of these contracts vary and may result in payment flows that do not match the periods over which materials or services are provided under such contracts.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We estimate clinical trial and research agreement related expenses based on the services performed, pursuant to contracts with research institutions and clinical research organizations and other vendors that conduct clinical trials and research on our behalf. In accruing clinical and research related fees, we estimate the time period over which services will be performed and activity expended in each period. If the actual timing of the performance of services or the level of effort varies from the estimate, we will adjust the accrual accordingly. Payments made under these arrangements in advance of the receipt of the related services are recorded as prepaid expenses until the services are rendered.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Transactions with Related Parties</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As outlined in Note&#160;9<font style="font-style:italic;"> &#8211; Related Party Agreements</font>, we have various agreements with different related parties. Some are billed and settled in cash monthly. Others are billed quarterly and settled in cash the following month. Monthly accruals are made for all quarterly billing arrangements.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Lease Obligations</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We adopted FASB ASC Topic&#160;842, <font style="font-style:italic;">Leases</font>, or ASC&#160;842, effective January&#160;1, 2019. For contracts entered into on or after the effective date, we determine if an arrangement is, or contains, a lease at lease inception. Our assessment is based on:&#160;(1)&#160;whether the contract involves the use of a distinct identified asset; (2)&#160;whether we obtain the right to substantially all of the economic benefit from the use of the asset throughout the period; and (3)&#160;whether we have the right to direct the use of the asset. At inception of a lease, we allocate the consideration in the contract to each lease component based on its relative stand-alone price to determine the lease payments. Leases entered into prior to January&#160;1, 2019, which were accounted for under ASC&#160;840, <font style="font-style:italic;">Leases</font>, were not reassessed as we elected the package of practical expedients permitted under the transition guidance within the new standard, which among other things, allowed us to carry forward the historical lease classification. We determine the lease term by assuming the exercise of renewal options that are reasonably assured. The exercise of lease renewal options is at our sole discretion. Several of our leases have renewal options, however, exercise of renewal is only assured for the El&#160;Segundo current Good Manufacturing Practices, or cGMP, facility, where we have made significant improvements.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For all leases at the lease commencement date, a right-of-use asset and a lease liability are recognized. The right-of-use asset represents the right to use the leased asset for the lease term. At lease commencement, leases are classified as either finance leases or operating leases. A lease is classified as a finance lease if any one of the following criteria are met:&#160;(1)&#160;the lease transfers ownership of the underlying asset by the end of the lease term; (2)&#160;the lease contains an option to purchase the underlying asset that is reasonably certain to be exercised; (3)&#160;the lease term is for a major part of the remaining economic life of the underlying asset; (4)&#160;the present value of the sum of the lease payments and any guaranteed residual value that is not already included in the lease payments equals or exceeds substantially all of the fair value of the underlying asset; or (5)&#160;the underlying asset is of such a specialized nature that it is expected to have no alternative use to the lessor at the end of the lease term. A lease is classified as an operating lease if it does not meet any one of these criteria.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We do not currently have any leases classified as finance leases. Our operating leases are included in operating lease right-of-use assets, net, other current liabilities, and operating lease liabilities on the consolidated balance sheets. At the commencement date, operating lease right-of-use assets and operating lease liabilities are determined based on the present value of lease payments to be made over the lease term. Operating lease right-of-use assets also include any rent paid prior to the commencement date, less any lease incentives received, and initial direct costs incurred. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term. We have elected to combine our lease components (e.g., fixed payments including rent, real estate taxes and insurance costs) with non-lease components (e.g., common-area maintenance costs and equipment maintenance costs) and as such, we account for lease and non-lease components as a single component. Lease expense also includes amounts relating to variable lease payments. Variable lease payments include amounts relating to common area maintenance and real estate taxes.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We also elected not to recognize right-of-use assets and lease liabilities for qualifying short-term leases with an initial lease term of 12&#160;months or less at lease inception. Such leases are expensed on a straight-line basis over the lease term.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The depreciable life of operating right-of-use-assets and leasehold improvements is limited by the expected lease term.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Income Taxes</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We recognize deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the financial reporting and tax basis of assets and liabilities, as well as for operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using the tax rates that are expected to apply to taxable income for the years in which those tax assets and liabilities are expected to be realized or settled. We record valuation allowances to reduce deferred tax assets to the amount we believe is more likely than not to be realized.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We recognize uncertain tax positions when the position will be more likely than not upheld on examination by the taxing authorities based solely upon the technical merits of the positions. We recognize interest and penalties, if any, related to unrecognized income tax uncertainties in income tax expense. We did not have any accrued interest or penalties associated with uncertain tax positions as of December&#160;31, 2019 and 2018.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are subject to U.S. federal income tax, as well as income tax in Korea, California and other states. The federal returns for tax years 2016 through 2019 remain open to examination; the California returns remain subject to examination for tax years 2015 through 2019. Carryforward attributes that were generated in years where the statute of limitations is closed may still be adjusted upon examination by the Internal Revenue Service or other respective tax authority. All other state jurisdictions remain open to examination. No income tax returns are currently under examination by taxing authorities.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Stock Repurchases</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In November&#160;2015, the board of directors approved the 2015 Share Repurchase Program (Note&#160;10) allowing the CEO or CFO, on behalf of the company, to repurchase from time to time, in the open market or in privately negotiated transactions, up to $50.0&#160;million of our outstanding shares of common stock, exclusive of any commissions, markups or expenses. The timing and amounts of any purchases were and will continue to be based on market conditions and other factors, including price, regulatory requirements and other corporate considerations. The 2015 Share Repurchase Program does not require the purchase of any minimum number of shares and may be suspended, modified or discontinued at any time without prior notice. We have financed, and expect to continue to finance, the purchases with existing cash balances. As it is the intent for the repurchased shares to be retired, we have elected to account for the shares repurchased under the constructive retirement method. For shares repurchased in excess of par, we allocate the purchase price in excess of par value to accumulated deficit.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Revenue Recognition</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Beginning January&#160;1, 2018, we adopted the provisions of FASB ASC Topic&#160;606, <font style="font-style:italic;">Revenue from Contracts with Customers</font>, or ASC&#160;606. This guidance requires that entities recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. We adopted ASC&#160;606 on January&#160;1, 2018 by recording the cumulative effect of the adoption to accumulated deficit. We applied the new guidance to contracts that were not complete as of January&#160;1, 2018. Implementation of ASC&#160;606 did not have a material impact on our consolidated financial statements.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We derive substantially all of our revenue from non-exclusive license agreements with a limited number of pharmaceutical and biotechnology companies granting them the right to use our cell lines and intellectual property for non-clinical use. These agreements generally include upfront fees and annual research license fees for such use, as well as commercial license fees for sales of the licensee products developed or manufactured using our intellectual property and cell lines.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account in ASC&#160;606. A contract&#8217;s transaction price is allocated to each distinct performance obligation based on relative standalone selling price and recognized as revenue when, or as, the performance obligation is satisfied.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the company&#8217;s license agreements with customers, the company typically promises to provide a license to use certain cell lines and related patents, the related know-how, and future research and development data that affect the license. We have concluded that these promises represent one performance obligation due to the highly interrelated nature of the promises. We provide the cell lines and know-how immediately upon entering into the contracts. The research and development data is provided throughout the term of the contract when and if available.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our license agreement with Intrexon (Note&#160;7) included a nonrefundable upfront payment of $0.4&#160;million, received when we entered into the contract in 2010. In this instance, we determined that under ASC&#160;606 it would be appropriate to recognize the initial milestone payment at a point in time, when we transferred the license. In this case, the intellectual property provided under the contract is functional intellectual property under ASC&#160;606 and was determined to be a distinct performance obligation in the context of the arrangement. Prior to adoption, the upfront payment had been initially recorded as deferred revenue and was being recognized into revenue on a straight-line basis. As a result, upon adoption of ASC&#160;606, we adjusted our accumulated deficit for the effects of recognizing revenue upfront for the initial milestone. The adjustment to accumulated deficit upon adoption was not material.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The license agreements may include nonrefundable upfront payments, event-based milestone payments, sales-based royalty payments, or some combination of these. The event-based milestone payments represent variable consideration and we use the most likely amount method to estimate this variable consideration. Given the high degree of uncertainly around achievement of these milestones, we do not recognize revenue from these milestone payments until the uncertainty associated with these payments is resolved. We currently estimate variable consideration related to milestone payments to be zero and, as such, no revenue has been recognized for milestone payments. We recognize revenue from sales-based royalty payments when or as the sales occur. On a quarterly basis, we re-evaluate our estimate of milestone variable consideration to determine whether any amount should be included in the transaction price and recorded in revenue prospectively.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Upon adoption, we changed our accounting policy from accounting for milestones payments under the milestone method to accounting for variable consideration as discussed above. The change in accounting policy did not change any amounts in the financial statements because of the significant uncertainty surrounding the estimate of variable consideration for milestone payments.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To date, we have generated minimal revenue related to the non-clinical use of our cells lines and intellectual property. We have no products approved for commercial sale and we have not generated any revenue from product sales. If we fail to complete the development of our product candidates in a timely manner or fail to obtain regulatory approval for them, we may never be able to generate substantial future revenue.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Research and Development Costs</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Major components of research and development costs include cash compensation and other personnel-related expenses, stock-based compensation, depreciation and amortization expense on research and development property and equipment and intangible assets, costs of preclinical studies, clinical trials and related clinical manufacturing, costs of drug development, costs of materials and supplies, facilities cost, overhead costs, regulatory and compliance costs, and fees paid to consultants and other entities that conduct certain research and development activities on our behalf. Costs incurred in research and development are expensed as incurred.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Included in research and development costs are clinical trial and research expenses based on the services performed pursuant to contracts with research institutions and clinical research organizations and other vendors that conduct clinical trials and research on our behalf. We record accruals for estimated costs under these contracts. When evaluating the adequacy of the accrued liabilities, we analyze the progress of the studies or clinical trials, including the phase or completion of events, invoices received, contracted costs and purchase orders. Significant judgments and estimates are made in determining the accrued balances at the end of any reporting period based on the facts and circumstances known at that time. Although we do not expect the estimates to be materially different from the amounts actually incurred, if the estimates of the status and timing of services performed differs from the actual status and timing of services performed, we may report amounts that are too high or too low in any particular period. Actual results could differ from our estimates.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Stock-Based Compensation</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We account for stock-based compensation under the provisions of ASC Topic&#160;718, <font style="font-style:italic;">Compensation&#8212;Stock Compensation</font>, or ASC&#160;718, which applies to share-based payments issued to employees and nonemployees in exchange for goods or services. Under ASC&#160;718, the fair value of an equity-classified award is estimated on the grant date without regard to service or performance conditions. The grant date fair values for options and warrants are estimated using the Black-Scholes-Merton option pricing model, and the grant date fair values for restricted stock units, or RSUs, are based upon the closing market price of our common stock on the date of grant.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We use the straight-line method to recognize stock-based compensation expense for our outstanding share awards that do not contain a performance condition. For awards subject to performance-based vesting conditions, we assess the probability of the individual milestones under the award being achieved and stock-based compensation expense is recognized over the service period commencing once management believes the performance criteria is probable of being met. For awards with service or performance conditions, we recognize the effect of forfeitures in compensation cost in the period that the award was forfeited.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Litigation Costs</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expense legal fees as they are incurred.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Comprehensive Income (Loss)</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Comprehensive income or loss is defined as the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. Comprehensive income or loss is composed of net income (loss) and other comprehensive income (loss). Our other comprehensive income or loss consists of unrealized gains and losses on marketable debt securities classified as available-for-sale, net of income taxes.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Basic and Diluted Net Loss per Share of Common Stock</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic net loss per share is calculated by dividing the net loss by the weighted-average number of common shares outstanding for the period. Diluted loss per share is computed similarly to basic loss per share except that the denominator is increased to include the number of additional shares that would have been outstanding if the potential common shares had been issued and if the additional common shares were dilutive.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For all periods presented, potentially dilutive securities are excluded from the computation of fully diluted loss per share as their effect is anti-dilutive. The following table details those securities that have been excluded from the computation of potentially dilutive securities:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding options</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,506,950</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,493,250</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,693,250</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding RSUs</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,139,428</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">867,911</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">888,189</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding warrants</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,589,250</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,721,088</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,646,378</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,950,411</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,302,527</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amounts in the table above reflect the common stock equivalents of the noted instruments.</p></div>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Segment and Geographic Information</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating segments are defined as components of an enterprise (business activity from which it earns revenue and incurs expenses) for which discrete financial information is available and regularly reviewed by the chief operating decision maker in deciding how to allocate resources and in assessing performance. Our chief operating decision maker is the company&#8217;s CEO. We view our operations and manage our business as a single operating and reporting segment. As of December&#160;31, 2019 and 2018, the majority of our assets were held in the U.S. For the years ended December&#160;31, 2019, 2018 and 2017, all of our revenue was derived in the U.S.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Recent Accounting Pronouncements</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Application of New or Revised Accounting Standards &#8211; Adopted</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We adopted ASC&#160;842 on January&#160;1, 2019, using the simplified transition approach which allowed us to not recast the comparative periods presented when transitioning to the new lease standard, while including required disclosures under ASC&#160;840 for all periods presented under ASC&#160;840. In addition, we elected the package of practical expedients permitted under the transition guidance, which among other things, allowed us to not reassess&#160;(1)&#160;whether a contract is or contains a lease, and (2)&#160;the classification of existing leases.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The adoption of ASC&#160;842 had a substantial impact on our balance sheet. The most significant impacts were (i)&#160;the recognition of $13.5&#160;million of operating lease right-of-use assets, net, and $16.4&#160;million of operating lease liabilities, and (ii)&#160;the derecognition of assets and liabilities associated with the build-to-suit leases under ASC&#160;840 (resulting in the derecognition of property, plant and equipment, net, of $6.6&#160;million and net adjustments to related liabilities of $5.7&#160;million). The build-to-suit leases were recorded as normal operating leases under ASC&#160;842. The difference between the excess of build-to-suit related liabilities and assets of $0.9&#160;million was recorded as an increase to our accumulated deficit. The cumulative-effect adjustment had no tax impact due to the valuation allowance against the gross deferred tax asset less reversing deferred tax liabilities. Adoption of this standard had no material impact on our results of operations and cash flows.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August&#160;2018, the FASB issued ASU&#160;2018&#8209;15, <font style="font-style:italic;">Intangibles&#8212;Goodwill and Other&#8212;Internal-Use Software (Subtopic 350-40): Customer&#8217;s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract</font> (ASU&#160;2018&#8209;15). This update aligns guidance for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs to develop or obtain internal-use software (and hosting arrangements that include an internal-use software license). Capitalized implementation costs will be amortized over the term of the hosting arrangement and expense related to the capitalized implementation costs will be presented in the same line item in the statements of operations as the fees associated with the service contract. As permitted by the standard, we elected to early adopt ASU&#160;2018&#8209;15 on a prospective basis as of October&#160;1, 2019. The adoption did not have a material effect on our consolidated financial statements.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Application of New or Revised Accounting Standards &#8211; Not Yet Adopted</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December&#160;2019, the FASB issued ASU&#160;2019-12,&#160;<font style="font-style:italic;">Simplifying the Accounting for Income Taxes</font>. The amendments in this update include removing the exception to the incremental approach for intraperiod tax allocation when there is a loss from continuing operations and income, or a gain, from other items (e.g., discontinued operations or other comprehensive income), and the exception to the general methodology for calculating income taxes in an interim period when a year-to-date loss exceeds the anticipated loss for the year. We are currently evaluating the impact that these amendments will have on our consolidated financial statements and we intend to early adopt these amendments on January&#160;1, 2020. We do not expect that the adoption of these amendments will have a significant impact on our consolidated financial statements.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June&#160;2016, the FASB issued ASU&#160;2016&#8209;13,&#160;<font style="font-style:italic;">Financial Instruments&#8212;Credit Losses (Topic 326):&#160;Measurement of Credit Losses on Financial Instruments</font>. The new guidance supersedes existing U.S. GAAP for measuring and recording of credit losses on financial assets measured at amortized cost by replacing the incurred-loss model with an expected-loss model. Accordingly, these financial assets will be presented at the net amount expected to be collected. This new standard also requires that credit losses related to available-for-sale debt securities be recorded as an allowance through net income rather than reducing the carrying amount under the current, other-than-temporary-impairment model. The new guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December&#160;15, 2019, but may be adopted earlier. With certain exceptions, adjustments are to be applied using a modified-retrospective approach by reflecting adjustments through a cumulative-effect impact on retained earnings as of the beginning of the fiscal year of adoption. In May&#160;2019, the FASB issued ASU&#160;2019-05,&#160;<font style="font-style:italic;">Financial Instruments&#8212;Credit Losses (Topic&#160;326):&#160;Targeted Transition Relief</font>, which provides companies with an option to irrevocably elect the fair value option for certain financial assets previously measured at amortized cost basis upon adoption of Topic&#160;326. We are currently evaluating the impact that this new standard and its related amendments will have on our consolidated financial statements and we intend to adopt the standard on January&#160;1, 2021. However, as the impact is dependent upon the investments held as of the adoption date, it is not possible for us to quantify the impact until the date of adoption.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other recent authoritative guidance issued by the FASB (including technical corrections to the ASC), the American Institute of Certified Public Accountants, and the Securities and Exchange Commission during the three&#160;months ended December&#160;31, 2019 did not, or are not expected to, have a material effect on our consolidated financial statements.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6914380304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitment and Contingencies - Additional Information (Detail)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="7">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Aug. 09, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Aug. 31, 2019</div></th>
<th class="th">
<div>Aug. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2016 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Jun. 30, 2016 </div>
<div>USD ($) </div>
<div>ft&#178; </div>
<div>$ / ft&#178;</div>
</th>
<th class="th">
<div>Mar. 31, 2016 </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Nov. 30, 2015 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Jun. 30, 2015 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Sep. 30, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th"><div>Jan. 01, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty', window );">Litigation settlement amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LegalFees', window );">Attorney's fee to plaintiffs</a></td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Increase in operating lease right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 4 months 24 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Cash outflows from operating leases excluding variable lease cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDescription', window );">Period of agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">elected not to recognize right-of-use assets and lease liabilities for qualifying short-term leases with an initial lease term of 12 months or less at lease inception<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesRentExpenseNet', window );">Rent expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,800,000<span></span>
</td>
<td class="nump">$ 2,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseArrangementTypeAxis=nk_CommitmentWoburnMassachusettsMember', window );">Woburn, Massachusetts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Increase in operating lease right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_NumberOfSquareFootOfFacilityLeased', window );">Number of square foot of facility leased | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,153<span></span>
</td>
<td class="nump">7,893<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_BaseMonthlyRent', window );">Base rent - monthly</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Initial term of lease arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">48 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_LeaseCommencementDate', window );">Lease commencement date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Apr. 29,  2016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseExpirationDate1', window );">Lease expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">May 31,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_AdditionToNumberOfSquareFootOfFacilityLeased', window );">Addition to number of square foot of facility leased | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">260<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_AnnualBaseRentIncreasePerSquareFoot', window );">Annual increase of base rent | $ / ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_PeriodOfLicenseAgreementDescription', window );">Period of agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">In June 2016, the lease was amended to add 260 square feet, for a total of 8,153 square feet. Base rent for the initial term of the lease is $19,000 per month with a $1 per square foot annual increase on each anniversary date.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Optional extended lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_LeaseAgreementExtendedPeriod', window );">Lease agreement extended lease period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">May 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseArrangementTypeAxis=nk_CommitmentSanDiegoMember', window );">Commitment; San Diego</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_NumberOfSquareFootOfFacilityLeased', window );">Number of square foot of facility leased | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_BaseMonthlyRent', window );">Base rent - monthly</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_AnnualPercentageIncreasesToBaseRent', window );">Percentage of annual increase of base rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Initial term of lease arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=nk_NantBioScienceMember', window );">NantBioScience</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_RelatedPartyTransactionReimbursedUpfrontPaymentToThirdParty', window );">Reimbursed upfront payment to third-party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_RelatedPartyTransactionAmountPaidToRelatedParty', window );">Related party transaction, amount paid to third-party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Related party transaction, aggregate value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_RelatedPartyTransactionInitialTermOfAgreement', window );">Initial term of agreement entered into with the related party by the entity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_RelatedPartyAgreementExpirationMonthAndYear', window );">Related party agreement expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2027-06<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_NumberOfSquareFootOfFacilityLeased', window );">Number of square foot of facility leased | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,965<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=nk_DougStLLCMember', window );">Doug St, LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDescription', window );">Period of agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The lease runs from July 2016 through July 2023. We have the option to extend the lease for an additional three year term through July 2026. The monthly rent is $0.1 million with annual increases of 3% beginning in July 2017.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_PeriodOfExtendedLeaseTerm', window );">Optional extended lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_BaseMonthlyRent', window );">Base rent - monthly</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_AnnualPercentageIncreasesToBaseRent', window );">Percentage of annual increase of base rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_AnnualPercentageIncreasesToBaseRentCommencementDate', window );">Annual percentage increases to base rent commencement date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jul. 31,  2017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=nk_DougStLLCMember', window );">Doug St, LLC | El Segundo California</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_NumberOfSquareFootOfFacilityLeased', window );">Number of square foot of facility leased | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=nk_NantWorksLimitedLiabilityCompanyMember', window );">NantWorks</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_NumberOfSquareFootOfFacilityLeased', window );">Number of square foot of facility leased | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDescription', window );">Period of agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The license was effective in May 2015 and extends through December 2020. The monthly rent is $47,000, with annual increases of 3% beginning in January 2017.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_BaseMonthlyRent', window );">Base rent - monthly</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 47,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_AnnualPercentageIncreasesToBaseRent', window );">Percentage of annual increase of base rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_AnnualPercentageIncreasesToBaseRentCommencementDate', window );">Annual percentage increases to base rent commencement date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jan. 31,  2017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember', window );">Prepaid Expenses and Other Current Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InsuranceSettlementsReceivable', window );">Insurance claim receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34,000,000<span></span>
</td>
<td class="nump">$ 10,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReinsurancePolicyTypeAxis=nk_DirectorsAndOfficersInsurancePolicyMember', window );">Directors and Officers Insurance Policy</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty', window );">Litigation settlement amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, General and Administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty', window );">Litigation settlement amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OperatingExpenseMember', window );">Operating Expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nk_AdditionToNumberOfSquareFootOfFacilityLeased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Addition to number of square foot of facility leased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nk_AdditionToNumberOfSquareFootOfFacilityLeased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nk_AnnualBaseRentIncreasePerSquareFoot">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Annual base rent increase per square foot.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nk_AnnualBaseRentIncreasePerSquareFoot</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>srt-types:perUnitItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nk_AnnualPercentageIncreasesToBaseRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Annual percentage increases to base rent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nk_AnnualPercentageIncreasesToBaseRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nk_AnnualPercentageIncreasesToBaseRentCommencementDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Annual percentage increases to base rent commencement date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nk_AnnualPercentageIncreasesToBaseRentCommencementDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nk_BaseMonthlyRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Base monthly rent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nk_BaseMonthlyRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nk_CommitmentsAndContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nk_CommitmentsAndContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nk_LeaseAgreementExtendedPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lease agreement extended period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nk_LeaseAgreementExtendedPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nk_LeaseCommencementDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lease commencement date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nk_LeaseCommencementDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nk_NumberOfSquareFootOfFacilityLeased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of square foot of facility leased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nk_NumberOfSquareFootOfFacilityLeased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nk_PeriodOfExtendedLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of extended lease term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nk_PeriodOfExtendedLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nk_PeriodOfLicenseAgreementDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of license agreement description.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nk_PeriodOfLicenseAgreementDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nk_RelatedPartyAgreementExpirationMonthAndYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Related party agreement expiration month and year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nk_RelatedPartyAgreementExpirationMonthAndYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearMonthItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nk_RelatedPartyTransactionAmountPaidToRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Related party transaction, amount paid to related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nk_RelatedPartyTransactionAmountPaidToRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nk_RelatedPartyTransactionInitialTermOfAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Related party transaction initial term of agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nk_RelatedPartyTransactionInitialTermOfAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nk_RelatedPartyTransactionReimbursedUpfrontPaymentToThirdParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Related party transaction, Reimbursed upfront payment to third party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nk_RelatedPartyTransactionReimbursedUpfrontPaymentToThirdParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InsuranceSettlementsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount due in settlement of a claim for reimbursement from an insurance company when the Company has suffered a loss covered under an insurance policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InsuranceSettlementsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseExpirationDate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date which lease or group of leases is set to expire, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseExpirationDate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LegalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of lessee's operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount awarded to other party in judgment or settlement of litigation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementAmountAwardedToOtherParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesRentExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Rental expense for the reporting period incurred under operating leases, including minimum and any contingent rent expense, net of related sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41499-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesRentExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transactions with related party during the financial reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39622-107864<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAmountsOfTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseArrangementTypeAxis=nk_CommitmentWoburnMassachusettsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseArrangementTypeAxis=nk_CommitmentWoburnMassachusettsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseArrangementTypeAxis=nk_CommitmentSanDiegoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseArrangementTypeAxis=nk_CommitmentSanDiegoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=nk_NantBioScienceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=nk_NantBioScienceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=nk_DougStLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=nk_DougStLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=nk_ElSegundoCaliforniaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=nk_ElSegundoCaliforniaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=nk_NantWorksLimitedLiabilityCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=nk_NantWorksLimitedLiabilityCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReinsurancePolicyTypeAxis=nk_DirectorsAndOfficersInsurancePolicyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReinsurancePolicyTypeAxis=nk_DirectorsAndOfficersInsurancePolicyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OperatingExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_OperatingExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6909016704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Restricted Stock Units (RSUs) Activity (Detail) - Outstanding RSUs - $ / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of Shares, Unvested, Beginning balance</a></td>
<td class="nump">867,911<span></span>
</td>
<td class="nump">888,189<span></span>
</td>
<td class="nump">814,456<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of Shares, Granted</a></td>
<td class="nump">749,793<span></span>
</td>
<td class="nump">487,472<span></span>
</td>
<td class="nump">615,983<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Number of Shares, Vested</a></td>
<td class="num">(395,051)<span></span>
</td>
<td class="num">(172,330)<span></span>
</td>
<td class="num">(244,209)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Number of Shares, Forfeited/Canceled</a></td>
<td class="num">(83,225)<span></span>
</td>
<td class="num">(335,420)<span></span>
</td>
<td class="num">(298,041)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of Shares, Unvested, Ending balance</a></td>
<td class="nump">1,139,428<span></span>
</td>
<td class="nump">867,911<span></span>
</td>
<td class="nump">888,189<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted-Average Grant Date Fair Value, Unvested, beginning balance</a></td>
<td class="nump">$ 6.69<span></span>
</td>
<td class="nump">$ 8.14<span></span>
</td>
<td class="nump">$ 13.98<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-Average Grant Date Fair Value, Granted</a></td>
<td class="nump">1.12<span></span>
</td>
<td class="nump">3.57<span></span>
</td>
<td class="nump">4.50<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-Average Grant Date Fair Value, Vested</a></td>
<td class="nump">8.83<span></span>
</td>
<td class="nump">6.16<span></span>
</td>
<td class="nump">15.82<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Weighted-Average Grant Date Fair Value, Forfeited/Canceled</a></td>
<td class="nump">7.29<span></span>
</td>
<td class="nump">6.27<span></span>
</td>
<td class="nump">10.28<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted-Average Grant Date Fair Value, Unvested, ending balance</a></td>
<td class="nump">$ 2.23<span></span>
</td>
<td class="nump">$ 6.69<span></span>
</td>
<td class="nump">$ 8.14<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6911897840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Stock Based Compensation Expenses Related to Statement of Operations (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 2,627<span></span>
</td>
<td class="nump">$ 23,382<span></span>
</td>
<td class="nump">$ 36,997<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_StockCompensationPlanMember', window );">Warrants For Common Stock | Officer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">17,817<span></span>
</td>
<td class="nump">31,584<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">1,309<span></span>
</td>
<td class="nump">4,057<span></span>
</td>
<td class="nump">4,267<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=nk_EmployeeRestrictedStockUnitMember', window );">Employee RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">938<span></span>
</td>
<td class="nump">1,193<span></span>
</td>
<td class="nump">894<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=nk_NonEmployeeRestrictedStockUnitMember', window );">Non-employee RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">380<span></span>
</td>
<td class="nump">315<span></span>
</td>
<td class="nump">252<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">499<span></span>
</td>
<td class="nump">460<span></span>
</td>
<td class="nump">102<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, General and Administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 2,128<span></span>
</td>
<td class="nump">$ 22,922<span></span>
</td>
<td class="nump">$ 36,895<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_StockCompensationPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_StockCompensationPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_OfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_OfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=nk_EmployeeRestrictedStockUnitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=nk_EmployeeRestrictedStockUnitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=nk_NonEmployeeRestrictedStockUnitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=nk_NonEmployeeRestrictedStockUnitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6912445280">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Components of Net Deferred Tax Assets and Liabilities (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 78,377<span></span>
</td>
<td class="nump">$ 61,915<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock compensation</a></td>
<td class="nump">8,536<span></span>
</td>
<td class="nump">79,281<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_DeferredTaxAssetsOperatingLeaseLiabilities', window );">Operating lease liabilities</a></td>
<td class="nump">3,884<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_DeferredTaxAssetsDeferredDepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">2,042<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards', window );">Tax credits</a></td>
<td class="nump">898<span></span>
</td>
<td class="nump">845<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation', window );">Accrued compensation</a></td>
<td class="nump">775<span></span>
</td>
<td class="nump">795<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_DeferredTaxAssetsLeasesAndOtherAccruedLiabilities', window );">Leases and other accrued liabilities</a></td>
<td class="nump">453<span></span>
</td>
<td class="nump">2,909<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLegalSettlements', window );">Accrued legal expenses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">308<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">94,965<span></span>
</td>
<td class="nump">146,053<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesNetAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets', window );">Foreign intangibles</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets', window );">Operating lease right-of-use assets</a></td>
<td class="num">(3,233)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_DeferredTaxLiabilitiesDeferredDepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,279)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="num">(3,233)<span></span>
</td>
<td class="num">(1,280)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred tax assets</a></td>
<td class="nump">91,732<span></span>
</td>
<td class="nump">144,773<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(91,732)<span></span>
</td>
<td class="num">(144,773)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Net deferred tax liability</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nk_DeferredTaxAssetsDeferredDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets deferred depreciation and amortization.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nk_DeferredTaxAssetsDeferredDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nk_DeferredTaxAssetsLeasesAndOtherAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets leases and other accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nk_DeferredTaxAssetsLeasesAndOtherAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nk_DeferredTaxAssetsOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets operating lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nk_DeferredTaxAssetsOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nk_DeferredTaxLiabilitiesDeferredDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred tax liabilities deferred depreciation and amortization.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nk_DeferredTaxLiabilitiesDeferredDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nk_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred tax liabilities operating lease right of use assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nk_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(15)(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117330534&amp;loc=d3e28680-109314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from employee compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117330534&amp;loc=d3e28680-109314<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117330534&amp;loc=d3e28680-109314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLegalSettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from the estimated loss from legal settlements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117330534&amp;loc=d3e28680-109314<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLegalSettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=116821951&amp;loc=d3e31931-109318<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=117330534&amp;loc=d3e28680-109314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6893677040">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Statement Details - Other Assets (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_FinancialStatementDetailsAbstract', window );"><strong>Financial Statement Details [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_PrepaidPreclinicalAndClinicalTrialServicesWithRelatedPartyInOtherAssets', window );">Prepaid preclinical and clinical trial services - with related party (Note 9)</a></td>
<td class="nump">$ 4,075<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent', window );">Restricted cash</a></td>
<td class="nump">179<span></span>
</td>
<td class="nump">179<span></span>
</td>
<td class="nump">$ 179<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SecurityDeposit', window );">Security deposit</a></td>
<td class="nump">113<span></span>
</td>
<td class="nump">113<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseNoncurrent', window );">Prepaid rent</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,205<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsMiscellaneousNoncurrent', window );">Other</a></td>
<td class="nump">19<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other Assets Noncurrent</a></td>
<td class="nump">$ 4,386<span></span>
</td>
<td class="nump">$ 1,527<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nk_FinancialStatementDetailsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Financial statement details.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nk_FinancialStatementDetailsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nk_PrepaidPreclinicalAndClinicalTrialServicesWithRelatedPartyInOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Prepaid preclinical and clinical trial services with related party in other assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nk_PrepaidPreclinicalAndClinicalTrialServicesWithRelatedPartyInOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsMiscellaneousNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other miscellaneous assets expected to be realized or consumed after one year or normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsMiscellaneousNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of amounts paid in advance for expenses which will be charged against earnings in periods after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6812-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=116631420&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecurityDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8,17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecurityDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6908906800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Viracta Investment and Convertible Notes - Additional Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>May 31, 2019</div></th>
<th class="th"><div>Jan. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule Of Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount', window );">Equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,253<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,500<span></span>
</td>
<td class="nump">$ 8,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=nk_TwoThousandAndEighteenNoteAndWarrantPurchaseAgreementMember', window );">2018 Note and Warrant Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule Of Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount', window );">Equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_PurchaseOfConvertibleNoteUponConversion', window );">Purchase of convertible note</a></td>
<td class="nump">$ 400<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Convertible note accrued interest rate</a></td>
<td class="nump">8.00%<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt instrument maturity date</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=nk_TwoThousandAndEighteenNoteAndWarrantPurchaseAgreementMember', window );">2018 Note and Warrant Purchase Agreement | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule Of Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants exercised to acquire shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">253,120<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=nk_TwoThousandAndEighteenNoteAndWarrantPurchaseAgreementMember', window );">2018 Note and Warrant Purchase Agreement | Series B Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule Of Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nk_PurchaseOfConvertibleNoteUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase of convertible note upon conversion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nk_PurchaseOfConvertibleNoteUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109500613&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security without readily determinable fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116654751&amp;loc=SL75117539-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInvestmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInvestmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=nk_TwoThousandAndEighteenNoteAndWarrantPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=nk_TwoThousandAndEighteenNoteAndWarrantPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6681589120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Summary of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial assets and liabilities measured at fair value on a recurring basis are summarized below at December&#160;31, 2019 and 2018 (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="14" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.42%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value Measurements at December&#160;31, 2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Assets:</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current:</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,508</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,508</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt securities</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32,389</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32,389</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Foreign government bonds</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,007</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,007</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Government sponsored securities</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,748</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,748</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Noncurrent:</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt securities</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,497</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,497</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total assets measured at fair value</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">53,149</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,508</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37,641</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;">
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="14" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.42%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value Measurements at December&#160;31, 2018</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Assets:</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current:</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,821</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,821</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt securities</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">57,328</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">57,328</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Noncurrent:</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt securities</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,991</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,991</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Government sponsored securities</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,710</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,710</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total assets measured at fair value</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">79,850</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,821</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">63,029</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6894112864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_LiquidityPolicyTextBlock', window );">Liquidity</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Liquidity</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2019, the company had an accumulated deficit of approximately $662.2&#160;million. We also had negative cash flow from operations of approximately $61.4&#160;million during the year ended December&#160;31, 2019. The company expects that it will likely need additional capital to further fund development of, and seek regulatory approvals for, our product candidates, and to begin to commercialize any approved products.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are currently focused primarily on the development of immunotherapeutic treatments for cancers and debilitating viral infections using targeted cancer and viral killing cell lines, and we believe such activities will result in the company&#8217;s continued incurrence of significant research and development and other expenses related to those programs. If the clinical trials for any of the company&#8217;s product candidates fail or produce unsuccessful results and those product candidates do not gain regulatory approval, or if any of our product candidates, if approved, fail to achieve market acceptance, we may never become profitable. Even if the company achieves profitability in the future, it may not be able to sustain profitability in subsequent periods. We intend to cover our future operating expenses through cash and cash equivalents and marketable debt securities on hand and through a combination of equity offerings, debt financings, government or other third party funding, marketing and distribution arrangements and other collaborations, strategic alliances, and licensing arrangements. Additional financing may not be available to us when needed and, if available, financing may not be obtained on terms favorable to the company or its stockholders.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">While we expect our existing cash, and cash equivalents and marketable debt securities, together with the ability to borrow from affiliated entities, will enable us to fund operations and capital expenditure requirements for at least the next 12&#160;months, we may not have sufficient funds to reach commercialization. Failure to obtain adequate financing when needed may require us to delay, reduce, limit, or terminate some or all of our development programs or future commercialization efforts or grant rights to develop and market product candidates that we might otherwise prefer to develop and market ourselves, which could adversely affect our ability to operate as a going concern. If we raise additional funds from the issuance of equity securities, substantial dilution to existing stockholders may result. If we raise additional funds by incurring debt financing, the terms of the debt may involve significant cash payment obligations, as well as covenants and specific financial ratios that may restrict our ability to operate our business.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Basis of Presentation</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America, or U.S.&#160;GAAP.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The consolidated financial statements have been prepared assuming the company will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business, and do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or amounts and classification of liabilities that may result from the outcome of the uncertainty discussed in the Liquidity section of Note&#160;1. We believe our existing cash, cash equivalents, and investments in marketable debt securities, and our ability to borrow from affiliated entities, will be sufficient to fund operations through at least the next 12&#160;months following the issuance date of the financial statements based upon our Chairman and CEO&#8217;s intent and ability to support the company&#8217;s operations with additional funds, including loans from affiliated entities, as required. We may also seek to sell additional equity, through one or more follow-on public offerings, or in separate financings, or obtain a credit facility. However, we may not be able to secure such financing in a timely manner or on favorable terms. Without additional funds, we may choose to delay or reduce our operating or investment expenditures. Further, because of the risk and uncertainties associated with the commercialization of the company&#8217;s product candidates in development, we may need additional funds to meet our needs sooner than planned. To date, the company&#8217;s primary sources of capital were its initial public offering and the concurrent private placement of common shares. In addition, during the year ended December&#160;31, 2019, our Chairman and CEO exercised warrants and options resulting in aggregate cash proceeds of $39.2&#160;million.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Principles of Consolidation</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The consolidated financial statements include the accounts of NantKwest and its wholly owned subsidiaries. All intercompany amounts have been eliminated.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We apply the variable interest model under Accounting Standards Codification, or ASC Topic&#160;810,&#160;<font style="font-style:italic;">Consolidation</font>, to any entity in which we hold an equity investment or to which we have the power to direct the entity's most significant economic activities and the ability to participate in the entity's economics. If the entity is within the scope of the variable interest model and meets the definition of a variable interest entity, or VIE, we consider whether we must consolidate the VIE or provide additional disclosures regarding our involvement with the VIE. If we determine that we are the primary beneficiary of the VIE, we will consolidate the VIE. This analysis is performed at the initial investment in the entity or upon any reconsideration event.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For entities we hold as an equity investment that are not consolidated under the VIE Model, we consider whether our investment constitutes ownership of a majority of the voting interests in the entity and therefore should be considered for consolidation under the voting interest model.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unconsolidated equity investments in the common stock or in-substance common stock of an entity under which we are able to exercise significant influence, but not control, are accounted for using the equity method. Our ability to exercise significant influence is generally indicated by ownership of 20 to 50 percent interest in the voting securities of the entity.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All other unconsolidated equity investments on which we are not able to exercise significant influence will be subsequently measured at fair value with unrealized holding gains and losses included in other income, net on the consolidated statements of operations. In the instance the equity investment does not have a readily determinable fair value and does not qualify for the practical expedient to estimate fair value in accordance with ASC&#160;820, <font style="font-style:italic;">Fair Value Measurement</font>, or ASC&#160;820, we will apply the measurement alternative under ASC&#160;321, <font style="font-style:italic;">Investments&#8212;Equity Securities</font>, or ASC&#160;321, pursuant to which we will measure the investment at its cost less impairment, adjusted for observable price changes in an orderly market for an identical or similar investment of the same issuer.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We own non-marketable equity securities that are accounted for using the measurement alternative under ASC&#160;321 because the preferred stock held by us is not considered in-substance common stock and such preferred stock does not have a readily determinable fair value. All investments are reviewed on a regular basis for possible impairment. If an investment's fair value is determined to be less than its net carrying value, the investment is written down to its fair value. Such an evaluation is judgmental and dependent on specific facts and circumstances. Factors considered in determining whether an impairment indicator is present include:&#160;the investees&#8217; earnings performance and clinical trial performance, change in the investees&#8217; industry and geographic area in which it operates, offers to purchase or sell the security for a price less than the cost of the investment, issues that raise concerns about the investee's ability to continue as a going concern, and any other information that we may be aware of related to the investment. Factors considered in determining whether an observable price change has occurred include:&#160;the price at which the investee issues equity instruments similar to those of our investment and the rights and preferences of those equity instruments compared to ours.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Use of Estimates</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. On an ongoing basis, we evaluate our estimates, including those related to valuation of equity-based awards, deferred income taxes and related valuation allowances, preclinical and clinical trial accruals, impairment assessments, useful lives of long-lived assets, loss contingencies, and fair value measurements. We base our estimates on historical experience and on various other market-specific and relevant assumptions that we believe to be reasonable under the circumstances. Actual results could differ from those estimates.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnusualRisksAndUncertaintiesTextBlock', window );">Risks and Uncertainties</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Risks and Uncertainties</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesPolicyTextBlock', window );">Contingencies</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Contingencies</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We record accruals for loss contingencies to the extent that we conclude it is probable that a liability has been incurred and the amount of the related loss can be reasonably estimated. We evaluate, on a quarterly basis, developments in legal proceedings and other matters that could cause a change in the potential amount of the liability recorded or of the range of potential losses disclosed. Additionally, we record our rights to insurance recoveries, limited to the extent of incurred or probable losses, as a receivable when such recoveries have been agreed to with our third-party insurers and when receipt is deemed probable. This includes instances when our third-party insurers have agreed to pay, on our behalf, certain legal defense costs and settlement amounts directly to applicable law firms and a settlement fund.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk and Other Risks and Uncertainties</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Concentration of Credit Risk and Other Risks and Uncertainties</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially subject us to concentrations of risk consist principally of cash and cash equivalents and marketable debt securities.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our cash and cash equivalents are held by one major financial institution in the U.S. and one in Korea.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Product candidates developed by us will require approvals or clearances from the U.S. Food and Drug Administration, or FDA, or international regulatory agencies prior to commercial sales. There can be no assurance that any of our product candidates will receive any of the required approvals or clearances. If we were to be denied approval or clearance or any such approval or clearance was to be delayed, it would have a material adverse impact on us.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_CashCashEquivalentsAndMarketableSecuritiesPolicyTextBlock', window );">Cash, Cash Equivalents and Marketable Debt Securities</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Cash, Cash Equivalents and Marketable Debt Securities</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We invest our excess funds in investment grade short- to intermediate-term corporate debt securities, commercial paper, government sponsored securities, and foreign government bonds. We consider all highly liquid investments purchased with original maturities of three&#160;months or less to be cash equivalents and all investments purchased with original maturities of greater than three&#160;months as marketable debt securities, classified as available-for-sale. Marketable debt securities with remaining maturities of 12&#160;months or less are classified as short-term and marketable debt securities with remaining maturities greater than 12&#160;months are classified as long-term. All marketable debt securities are reported at fair value and any unrealized gains and losses are reported as a component of accumulated other comprehensive income (loss), net of tax, on the consolidated statements of stockholders&#8217; equity, with the exception of unrealized losses believed to be other-than-temporary, which are recorded in investment income, net, on the consolidated statements of operations. Realized gains and losses are included in investment income, net, on the consolidated statements of operations. Realized gains and losses from sale of the securities and the amounts, net of tax, reclassified out of accumulated other comprehensive loss, if any, are determined on a specific identification basis.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We periodically evaluate whether declines in fair values of our investments below their book value are other-than-temporary. This evaluation consists of several qualitative and quantitative factors regarding the severity and duration of the unrealized loss, as well as our ability and intent to hold the investment until a forecasted recovery occurs. Additionally, we assess whether or not we have plans to sell the security or whether or not it is more likely than not we will be required to sell any investment before recovery of its amortized cost basis. Factors considered include quoted market prices, recent financial results and operating trends, implied values from any recent transactions or offers of investee securities, credit quality of debt instrument issuers, other publicly available information that may affect the value of our investments, duration and severity of the decline in value, and our strategy and intentions for holding the investment. There were no other-than-temporary impairments recorded in the years ended December&#160;31, 2019, 2018 and 2017.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We minimize credit risk associated with our cash and cash equivalents by periodically evaluating the credit quality of our primary financial institutions. While we maintain cash deposits in FDIC insured financial institutions in excess of federally insured limits, we do not believe that we are exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held. We have not experienced any losses on such accounts.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have funded a certificate of deposit (CD) as a substitute letter of credit for one of our leased properties. This CD is reported as long term restricted cash and is included in other assets on the consolidated balance sheets as the landlord is the beneficiary of the account and we are not able to access the funds during the term of the lease.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property, Plant and Equipment</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Property, Plant and Equipment</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property, plant and equipment is stated at historical cost less accumulated depreciation. Historical cost includes expenditures that are directly attributable to the acquisition of the items. All repairs and maintenance are charged to net loss during the financial period in which they are incurred. Depreciation of property, plant and equipment is calculated using the straight-line method over the estimated useful lives of the assets, as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Buildings</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> 39 years</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Software</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> 3 years</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Laboratory equipment</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> 5 years</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furniture &amp; fixtures</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> 5 years</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">IT equipment</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> 3 years</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> The lesser of the lease term or the life of the asset</p></td>
</tr>
</table>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></div>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Upon disposal or impairment of property, plant and equipment, the cost and related accumulated depreciation is removed from the consolidated financial statements and the net amount, less any proceeds, is included in the consolidated statements of operations.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy', window );">Intangible Assets</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Intangible Assets</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intangible assets, which consisted of the cost of reacquiring a technology license during 2015, were amortized using the straight-line method over an estimated useful life of 4&#160;years. As of December 31, 2019, our intangible assets were fully amortized.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LegalCostsPolicyTextBlock', window );">Patents</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Patents</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Patent costs, including related legal costs, are expensed as incurred and recorded in selling, general and administrative expenses on the consolidated statements of operations.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock', window );">Impairments</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Impairments</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Long-lived assets include property, plant and equipment and intangible assets. We review long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability is measured by comparison of the carrying amount to the future net cash flows that the assets are expected to generate. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the projected undiscounted future cash flows arising from the assets using a discount rate determined by management to be commensurate with the risk inherent to our current business model.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the second quarter of 2019, we determined that certain bioreactor laboratory equipment could no longer be utilized in the production process. As a result, we recorded an impairment charge totaling $0.9&#160;million, which is included in research and development expense on the consolidated statements of operations. There were no impairment losses recognized during the years ended December&#160;31, 2018 and 2017.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Fair Value of Financial Instruments</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accounting standard for fair value measurements provides a framework for measuring fair value and requires disclosures regarding fair value measurements. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date, based on our principal or, in absence of a principal, most advantageous market for the specific asset or liability.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We use a three-tier fair value hierarchy to classify and disclose all assets and liabilities measured at fair value on a recurring basis, as well as assets and liabilities measured at fair value on a non-recurring basis, in periods subsequent to their initial measurement. The hierarchy requires us to use observable inputs when available, and to minimize the use of unobservable inputs, when determining fair value.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The three tiers are defined as follows:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:15pt;line-height:11pt;">&#x2022;</p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level&#160;1&#8212; Observable inputs that reflect quoted market prices (unadjusted) for identical assets or liabilities in active markets at the measurement date. Since valuations are based on quoted prices that are readily and regularly available in an active market, valuation of these products does not entail a significant degree of judgment. Our Level 1 assets consist of bank deposits and money market funds.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:15pt;line-height:11pt;">&#x2022;</p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level&#160;2&#8212; Observable inputs other than quoted prices in active markets that are observable either directly or indirectly in the marketplace for identical or similar assets and liabilities. Our Level 2 assets consist of corporate debt securities including commercial paper, government sponsored securities and corporate bonds, as well as foreign municipal securities.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:15pt;line-height:11pt;">&#x2022;</p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level&#160;3&#8212; Valuations based on inputs that are unobservable and significant to the overall fair value measurement.</p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the years ended December&#160;31, 2019, 2018 and 2017, no transfers were made into or out of the Level&#160;1,&#160;2 or 3 categories. We will continue to review the fair value inputs on a quarterly basis.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We utilize a third-party pricing service to assist in obtaining fair value pricing for our investments in marketable debt securities. Inputs are documented in accordance with the fair value disclosure hierarchy.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_PreclinicalAndClinicalTrialAccrualsPolicyTextBlock', window );">Preclinical and Clinical Trial Accruals</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Preclinical and Clinical Trial Accruals</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As part of the process of preparing the financial statements, we are required to estimate expenses resulting from obligations under contracts with vendors, clinical research organizations and consultants. The financial terms of these contracts vary and may result in payment flows that do not match the periods over which materials or services are provided under such contracts.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We estimate clinical trial and research agreement related expenses based on the services performed, pursuant to contracts with research institutions and clinical research organizations and other vendors that conduct clinical trials and research on our behalf. In accruing clinical and research related fees, we estimate the time period over which services will be performed and activity expended in each period. If the actual timing of the performance of services or the level of effort varies from the estimate, we will adjust the accrual accordingly. Payments made under these arrangements in advance of the receipt of the related services are recorded as prepaid expenses until the services are rendered.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_RelatedPartyTransactionsPolicyPolicyTextBlock', window );">Transactions with Related Parties</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Transactions with Related Parties</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As outlined in Note&#160;9<font style="font-style:italic;"> &#8211; Related Party Agreements</font>, we have various agreements with different related parties. Some are billed and settled in cash monthly. Others are billed quarterly and settled in cash the following month. Monthly accruals are made for all quarterly billing arrangements.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Lease Obligations</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Lease Obligations</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We adopted FASB ASC Topic&#160;842, <font style="font-style:italic;">Leases</font>, or ASC&#160;842, effective January&#160;1, 2019. For contracts entered into on or after the effective date, we determine if an arrangement is, or contains, a lease at lease inception. Our assessment is based on:&#160;(1)&#160;whether the contract involves the use of a distinct identified asset; (2)&#160;whether we obtain the right to substantially all of the economic benefit from the use of the asset throughout the period; and (3)&#160;whether we have the right to direct the use of the asset. At inception of a lease, we allocate the consideration in the contract to each lease component based on its relative stand-alone price to determine the lease payments. Leases entered into prior to January&#160;1, 2019, which were accounted for under ASC&#160;840, <font style="font-style:italic;">Leases</font>, were not reassessed as we elected the package of practical expedients permitted under the transition guidance within the new standard, which among other things, allowed us to carry forward the historical lease classification. We determine the lease term by assuming the exercise of renewal options that are reasonably assured. The exercise of lease renewal options is at our sole discretion. Several of our leases have renewal options, however, exercise of renewal is only assured for the El&#160;Segundo current Good Manufacturing Practices, or cGMP, facility, where we have made significant improvements.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For all leases at the lease commencement date, a right-of-use asset and a lease liability are recognized. The right-of-use asset represents the right to use the leased asset for the lease term. At lease commencement, leases are classified as either finance leases or operating leases. A lease is classified as a finance lease if any one of the following criteria are met:&#160;(1)&#160;the lease transfers ownership of the underlying asset by the end of the lease term; (2)&#160;the lease contains an option to purchase the underlying asset that is reasonably certain to be exercised; (3)&#160;the lease term is for a major part of the remaining economic life of the underlying asset; (4)&#160;the present value of the sum of the lease payments and any guaranteed residual value that is not already included in the lease payments equals or exceeds substantially all of the fair value of the underlying asset; or (5)&#160;the underlying asset is of such a specialized nature that it is expected to have no alternative use to the lessor at the end of the lease term. A lease is classified as an operating lease if it does not meet any one of these criteria.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We do not currently have any leases classified as finance leases. Our operating leases are included in operating lease right-of-use assets, net, other current liabilities, and operating lease liabilities on the consolidated balance sheets. At the commencement date, operating lease right-of-use assets and operating lease liabilities are determined based on the present value of lease payments to be made over the lease term. Operating lease right-of-use assets also include any rent paid prior to the commencement date, less any lease incentives received, and initial direct costs incurred. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term. We have elected to combine our lease components (e.g., fixed payments including rent, real estate taxes and insurance costs) with non-lease components (e.g., common-area maintenance costs and equipment maintenance costs) and as such, we account for lease and non-lease components as a single component. Lease expense also includes amounts relating to variable lease payments. Variable lease payments include amounts relating to common area maintenance and real estate taxes.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We also elected not to recognize right-of-use assets and lease liabilities for qualifying short-term leases with an initial lease term of 12&#160;months or less at lease inception. Such leases are expensed on a straight-line basis over the lease term.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The depreciable life of operating right-of-use-assets and leasehold improvements is limited by the expected lease term.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Income Taxes</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We recognize deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the financial reporting and tax basis of assets and liabilities, as well as for operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using the tax rates that are expected to apply to taxable income for the years in which those tax assets and liabilities are expected to be realized or settled. We record valuation allowances to reduce deferred tax assets to the amount we believe is more likely than not to be realized.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We recognize uncertain tax positions when the position will be more likely than not upheld on examination by the taxing authorities based solely upon the technical merits of the positions. We recognize interest and penalties, if any, related to unrecognized income tax uncertainties in income tax expense. We did not have any accrued interest or penalties associated with uncertain tax positions as of December&#160;31, 2019 and 2018.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are subject to U.S. federal income tax, as well as income tax in Korea, California and other states. The federal returns for tax years 2016 through 2019 remain open to examination; the California returns remain subject to examination for tax years 2015 through 2019. Carryforward attributes that were generated in years where the statute of limitations is closed may still be adjusted upon examination by the Internal Revenue Service or other respective tax authority. All other state jurisdictions remain open to examination. No income tax returns are currently under examination by taxing authorities.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_StockRepurchasesPolicyTextBlock', window );">Stock Repurchases</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Stock Repurchases</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In November&#160;2015, the board of directors approved the 2015 Share Repurchase Program (Note&#160;10) allowing the CEO or CFO, on behalf of the company, to repurchase from time to time, in the open market or in privately negotiated transactions, up to $50.0&#160;million of our outstanding shares of common stock, exclusive of any commissions, markups or expenses. The timing and amounts of any purchases were and will continue to be based on market conditions and other factors, including price, regulatory requirements and other corporate considerations. The 2015 Share Repurchase Program does not require the purchase of any minimum number of shares and may be suspended, modified or discontinued at any time without prior notice. We have financed, and expect to continue to finance, the purchases with existing cash balances. As it is the intent for the repurchased shares to be retired, we have elected to account for the shares repurchased under the constructive retirement method. For shares repurchased in excess of par, we allocate the purchase price in excess of par value to accumulated deficit.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Revenue Recognition</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Beginning January&#160;1, 2018, we adopted the provisions of FASB ASC Topic&#160;606, <font style="font-style:italic;">Revenue from Contracts with Customers</font>, or ASC&#160;606. This guidance requires that entities recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. We adopted ASC&#160;606 on January&#160;1, 2018 by recording the cumulative effect of the adoption to accumulated deficit. We applied the new guidance to contracts that were not complete as of January&#160;1, 2018. Implementation of ASC&#160;606 did not have a material impact on our consolidated financial statements.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We derive substantially all of our revenue from non-exclusive license agreements with a limited number of pharmaceutical and biotechnology companies granting them the right to use our cell lines and intellectual property for non-clinical use. These agreements generally include upfront fees and annual research license fees for such use, as well as commercial license fees for sales of the licensee products developed or manufactured using our intellectual property and cell lines.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account in ASC&#160;606. A contract&#8217;s transaction price is allocated to each distinct performance obligation based on relative standalone selling price and recognized as revenue when, or as, the performance obligation is satisfied.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the company&#8217;s license agreements with customers, the company typically promises to provide a license to use certain cell lines and related patents, the related know-how, and future research and development data that affect the license. We have concluded that these promises represent one performance obligation due to the highly interrelated nature of the promises. We provide the cell lines and know-how immediately upon entering into the contracts. The research and development data is provided throughout the term of the contract when and if available.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our license agreement with Intrexon (Note&#160;7) included a nonrefundable upfront payment of $0.4&#160;million, received when we entered into the contract in 2010. In this instance, we determined that under ASC&#160;606 it would be appropriate to recognize the initial milestone payment at a point in time, when we transferred the license. In this case, the intellectual property provided under the contract is functional intellectual property under ASC&#160;606 and was determined to be a distinct performance obligation in the context of the arrangement. Prior to adoption, the upfront payment had been initially recorded as deferred revenue and was being recognized into revenue on a straight-line basis. As a result, upon adoption of ASC&#160;606, we adjusted our accumulated deficit for the effects of recognizing revenue upfront for the initial milestone. The adjustment to accumulated deficit upon adoption was not material.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The license agreements may include nonrefundable upfront payments, event-based milestone payments, sales-based royalty payments, or some combination of these. The event-based milestone payments represent variable consideration and we use the most likely amount method to estimate this variable consideration. Given the high degree of uncertainly around achievement of these milestones, we do not recognize revenue from these milestone payments until the uncertainty associated with these payments is resolved. We currently estimate variable consideration related to milestone payments to be zero and, as such, no revenue has been recognized for milestone payments. We recognize revenue from sales-based royalty payments when or as the sales occur. On a quarterly basis, we re-evaluate our estimate of milestone variable consideration to determine whether any amount should be included in the transaction price and recorded in revenue prospectively.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Upon adoption, we changed our accounting policy from accounting for milestones payments under the milestone method to accounting for variable consideration as discussed above. The change in accounting policy did not change any amounts in the financial statements because of the significant uncertainty surrounding the estimate of variable consideration for milestone payments.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To date, we have generated minimal revenue related to the non-clinical use of our cells lines and intellectual property. We have no products approved for commercial sale and we have not generated any revenue from product sales. If we fail to complete the development of our product candidates in a timely manner or fail to obtain regulatory approval for them, we may never be able to generate substantial future revenue.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Costs</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Research and Development Costs</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Major components of research and development costs include cash compensation and other personnel-related expenses, stock-based compensation, depreciation and amortization expense on research and development property and equipment and intangible assets, costs of preclinical studies, clinical trials and related clinical manufacturing, costs of drug development, costs of materials and supplies, facilities cost, overhead costs, regulatory and compliance costs, and fees paid to consultants and other entities that conduct certain research and development activities on our behalf. Costs incurred in research and development are expensed as incurred.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Included in research and development costs are clinical trial and research expenses based on the services performed pursuant to contracts with research institutions and clinical research organizations and other vendors that conduct clinical trials and research on our behalf. We record accruals for estimated costs under these contracts. When evaluating the adequacy of the accrued liabilities, we analyze the progress of the studies or clinical trials, including the phase or completion of events, invoices received, contracted costs and purchase orders. Significant judgments and estimates are made in determining the accrued balances at the end of any reporting period based on the facts and circumstances known at that time. Although we do not expect the estimates to be materially different from the amounts actually incurred, if the estimates of the status and timing of services performed differs from the actual status and timing of services performed, we may report amounts that are too high or too low in any particular period. Actual results could differ from our estimates.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsPolicyTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Stock-Based Compensation</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We account for stock-based compensation under the provisions of ASC Topic&#160;718, <font style="font-style:italic;">Compensation&#8212;Stock Compensation</font>, or ASC&#160;718, which applies to share-based payments issued to employees and nonemployees in exchange for goods or services. Under ASC&#160;718, the fair value of an equity-classified award is estimated on the grant date without regard to service or performance conditions. The grant date fair values for options and warrants are estimated using the Black-Scholes-Merton option pricing model, and the grant date fair values for restricted stock units, or RSUs, are based upon the closing market price of our common stock on the date of grant.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We use the straight-line method to recognize stock-based compensation expense for our outstanding share awards that do not contain a performance condition. For awards subject to performance-based vesting conditions, we assess the probability of the individual milestones under the award being achieved and stock-based compensation expense is recognized over the service period commencing once management believes the performance criteria is probable of being met. For awards with service or performance conditions, we recognize the effect of forfeitures in compensation cost in the period that the award was forfeited.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_LitigationCostsPolicyTextBlock', window );">Litigation Costs</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Litigation Costs</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expense legal fees as they are incurred.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Income (Loss)</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Comprehensive Income (Loss)</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Comprehensive income or loss is defined as the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. Comprehensive income or loss is composed of net income (loss) and other comprehensive income (loss). Our other comprehensive income or loss consists of unrealized gains and losses on marketable debt securities classified as available-for-sale, net of income taxes.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Basic and Diluted Net Loss Per Share of Common Stock</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Basic and Diluted Net Loss per Share of Common Stock</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic net loss per share is calculated by dividing the net loss by the weighted-average number of common shares outstanding for the period. Diluted loss per share is computed similarly to basic loss per share except that the denominator is increased to include the number of additional shares that would have been outstanding if the potential common shares had been issued and if the additional common shares were dilutive.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For all periods presented, potentially dilutive securities are excluded from the computation of fully diluted loss per share as their effect is anti-dilutive. The following table details those securities that have been excluded from the computation of potentially dilutive securities:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding options</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,506,950</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,493,250</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,693,250</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding RSUs</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,139,428</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">867,911</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">888,189</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding warrants</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,589,250</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,721,088</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,646,378</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,950,411</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,302,527</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amounts in the table above reflect the common stock equivalents of the noted instruments.</p></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment and Geographic Information</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Segment and Geographic Information</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating segments are defined as components of an enterprise (business activity from which it earns revenue and incurs expenses) for which discrete financial information is available and regularly reviewed by the chief operating decision maker in deciding how to allocate resources and in assessing performance. Our chief operating decision maker is the company&#8217;s CEO. We view our operations and manage our business as a single operating and reporting segment. As of December&#160;31, 2019 and 2018, the majority of our assets were held in the U.S. For the years ended December&#160;31, 2019, 2018 and 2017, all of our revenue was derived in the U.S.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Recent Accounting Pronouncements</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Application of New or Revised Accounting Standards &#8211; Adopted</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We adopted ASC&#160;842 on January&#160;1, 2019, using the simplified transition approach which allowed us to not recast the comparative periods presented when transitioning to the new lease standard, while including required disclosures under ASC&#160;840 for all periods presented under ASC&#160;840. In addition, we elected the package of practical expedients permitted under the transition guidance, which among other things, allowed us to not reassess&#160;(1)&#160;whether a contract is or contains a lease, and (2)&#160;the classification of existing leases.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The adoption of ASC&#160;842 had a substantial impact on our balance sheet. The most significant impacts were (i)&#160;the recognition of $13.5&#160;million of operating lease right-of-use assets, net, and $16.4&#160;million of operating lease liabilities, and (ii)&#160;the derecognition of assets and liabilities associated with the build-to-suit leases under ASC&#160;840 (resulting in the derecognition of property, plant and equipment, net, of $6.6&#160;million and net adjustments to related liabilities of $5.7&#160;million). The build-to-suit leases were recorded as normal operating leases under ASC&#160;842. The difference between the excess of build-to-suit related liabilities and assets of $0.9&#160;million was recorded as an increase to our accumulated deficit. The cumulative-effect adjustment had no tax impact due to the valuation allowance against the gross deferred tax asset less reversing deferred tax liabilities. Adoption of this standard had no material impact on our results of operations and cash flows.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August&#160;2018, the FASB issued ASU&#160;2018&#8209;15, <font style="font-style:italic;">Intangibles&#8212;Goodwill and Other&#8212;Internal-Use Software (Subtopic 350-40): Customer&#8217;s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract</font> (ASU&#160;2018&#8209;15). This update aligns guidance for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs to develop or obtain internal-use software (and hosting arrangements that include an internal-use software license). Capitalized implementation costs will be amortized over the term of the hosting arrangement and expense related to the capitalized implementation costs will be presented in the same line item in the statements of operations as the fees associated with the service contract. As permitted by the standard, we elected to early adopt ASU&#160;2018&#8209;15 on a prospective basis as of October&#160;1, 2019. The adoption did not have a material effect on our consolidated financial statements.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Application of New or Revised Accounting Standards &#8211; Not Yet Adopted</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December&#160;2019, the FASB issued ASU&#160;2019-12,&#160;<font style="font-style:italic;">Simplifying the Accounting for Income Taxes</font>. The amendments in this update include removing the exception to the incremental approach for intraperiod tax allocation when there is a loss from continuing operations and income, or a gain, from other items (e.g., discontinued operations or other comprehensive income), and the exception to the general methodology for calculating income taxes in an interim period when a year-to-date loss exceeds the anticipated loss for the year. We are currently evaluating the impact that these amendments will have on our consolidated financial statements and we intend to early adopt these amendments on January&#160;1, 2020. We do not expect that the adoption of these amendments will have a significant impact on our consolidated financial statements.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June&#160;2016, the FASB issued ASU&#160;2016&#8209;13,&#160;<font style="font-style:italic;">Financial Instruments&#8212;Credit Losses (Topic 326):&#160;Measurement of Credit Losses on Financial Instruments</font>. The new guidance supersedes existing U.S. GAAP for measuring and recording of credit losses on financial assets measured at amortized cost by replacing the incurred-loss model with an expected-loss model. Accordingly, these financial assets will be presented at the net amount expected to be collected. This new standard also requires that credit losses related to available-for-sale debt securities be recorded as an allowance through net income rather than reducing the carrying amount under the current, other-than-temporary-impairment model. The new guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December&#160;15, 2019, but may be adopted earlier. With certain exceptions, adjustments are to be applied using a modified-retrospective approach by reflecting adjustments through a cumulative-effect impact on retained earnings as of the beginning of the fiscal year of adoption. In May&#160;2019, the FASB issued ASU&#160;2019-05,&#160;<font style="font-style:italic;">Financial Instruments&#8212;Credit Losses (Topic&#160;326):&#160;Targeted Transition Relief</font>, which provides companies with an option to irrevocably elect the fair value option for certain financial assets previously measured at amortized cost basis upon adoption of Topic&#160;326. We are currently evaluating the impact that this new standard and its related amendments will have on our consolidated financial statements and we intend to adopt the standard on January&#160;1, 2021. However, as the impact is dependent upon the investments held as of the adoption date, it is not possible for us to quantify the impact until the date of adoption.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other recent authoritative guidance issued by the FASB (including technical corrections to the ASC), the American Institute of Certified Public Accountants, and the Securities and Exchange Commission during the three&#160;months ended December&#160;31, 2019 did not, or are not expected to, have a material effect on our consolidated financial statements.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentPolicyTextBlock', window );">Investment in Viracta</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Based on the level of equity investment at risk, Viracta is not a VIE and therefore is not consolidated under the VIE Model. In addition, we do not hold a controlling financial interest in Viracta and therefore we do not consolidate Viracta under the voting interest model. As the preferred stock is not considered in-substance common stock, the investment is not within the scope of accounting for the investment under the equity method. As the preferred stock does not have a readily determinable fair value and does not qualify for the practical expedient to estimate fair value in accordance with ASC&#160;820, we have elected to apply the measurement alternative under ASC&#160;321, pursuant to which we measure our investment in Viracta at cost, less impairment, adjusted for observable price changes in an orderly market for an identical or similar investment of the same issuer.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nk_CashCashEquivalentsAndMarketableSecuritiesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash, cash equivalents and marketable securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nk_CashCashEquivalentsAndMarketableSecuritiesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nk_LiquidityPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Liquidity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nk_LiquidityPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nk_LitigationCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Litigation costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nk_LitigationCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nk_PreclinicalAndClinicalTrialAccrualsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Preclinical and clinical trial accruals policy text block.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nk_PreclinicalAndClinicalTrialAccrualsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nk_RelatedPartyTransactionsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Related party transactions policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nk_RelatedPartyTransactionsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nk_StockRepurchasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock repurchases policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nk_StockRepurchasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 450<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6491354&amp;loc=d3e6052-115624<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 450<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491354&amp;loc=d3e6049-115624<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=68068213&amp;loc=d3e12565-110249<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18726-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=108315417&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.3A-02)<br> -URI http://asc.fasb.org/extlink&amp;oid=116822174&amp;loc=d3e355033-122828<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.3A-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=116822174&amp;loc=d3e355100-122828<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118260190&amp;loc=d3e13279-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for intangible assets. This accounting policy may address both intangible assets subject to amortization and those that are not. The following also may be disclosed: (1) a description of intangible assets (2) the estimated useful lives of those assets (3) the amortization method used (4) how the entity assesses and measures impairment of such assets (5) how future cash flows are estimated (6) how the fair values of such asset are determined.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the impairment and disposal of long-lived assets including goodwill and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32847-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116657188&amp;loc=SL116659661-227067<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32840-109319<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=116821951&amp;loc=d3e32247-109318<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=116821951&amp;loc=d3e32280-109318<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65884525&amp;loc=d3e40913-109327<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment in financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for legal costs incurred to protect or defend the entity's assets and rights, or to obtain assets, including monetary damages, or to obtain rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section S99<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=27011672&amp;loc=d3e149975-122751<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18726-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LegalCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnusualRisksAndUncertaintiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the nature of the unusual risk or uncertainty, if estimable, such as the threat of expropriation of its assets by a foreign government, rapid technological obsolescence in the industry, risk of natural disaster from earthquake or weather events, and availability of or continuation of a labor force at a reasonable cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnusualRisksAndUncertaintiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6898381600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">10. &#160;&#160;&#160;&#160;Stockholders&#8217; Equity</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Stock Repurchase &#8211; <font style="font-style:normal;">In November&#160;2015, the board of directors approved a share repurchase program, or the 2015 Share Repurchase Program, allowing the CEO or CFO, on behalf of the company, to repurchase from time to time, in the open market or in privately negotiated transactions, up to $50.0&#160;million of our outstanding shares of common stock, exclusive of any commissions, markups or expenses. The timing and amounts of any purchases were and will continue to be based on market conditions and other factors, including price, regulatory requirements and other corporate considerations. The 2015&#160;Share Repurchase Program does not require the purchase of any minimum number of shares and may be suspended, modified, or discontinued at any time without prior notice. We have financed, and expect to continue to finance, the purchases with existing cash balances. The shares are formally retired through board approval upon repurchase.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To date, we have repurchased 6,403,489&#160;shares of our common stock under the 2015&#160;Share Repurchase Program at a total cost of $31.7&#160;million. In addition, we have paid approximately $0.1&#160;million of broker commissions on repurchases. We repurchased 473,586&#160;shares, 138,349&#160;shares (Note&#160;9), and 3,633,610&#160;shares during the years ended December&#160;31, 2019, 2018 and 2017, respectively, for a total of $0.5&#160;million, $0.2&#160;million, and $15.2&#160;million, respectively. At December&#160;31, 2019, $18.3&#160;million remained authorized for repurchase under the 2015 Share Repurchase Program.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Common Stock Reserved for Future Issuance</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are authorized to issue up to 500,000,000&#160;shares of our common stock, par value $0.0001&#160;per share at December&#160;31, 2019. As of December&#160;31, 2019, there were 98,460,404&#160;shares of our common stock issued and outstanding.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes the common shares reserved for issuance on exercise or vesting of various awards at December&#160;31, 2019:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:60%;">
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding stock options</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,506,950</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding RSUs</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,139,428</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:78.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding warrants</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.9%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.64%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:78.44%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total shares reserved for future issuance</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.9%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.64%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,646,378</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6814475184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementInputsDisclosureTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">6. &#160;&#160;&#160;&#160;Fair Value Measurements</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fair value is defined as an exit price that would be received from the sale of an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Authoritative guidance establishes a three-level hierarchy for disclosure that is based on the extent and level of judgment used to estimate the fair value of assets and liabilities.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Recurring Valuations</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial assets and liabilities measured at fair value on a recurring basis are summarized below at December&#160;31, 2019 and 2018 (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="14" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.42%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value Measurements at December&#160;31, 2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Assets:</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current:</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,508</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,508</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt securities</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32,389</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32,389</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Foreign government bonds</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,007</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,007</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Government sponsored securities</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,748</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,748</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Noncurrent:</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt securities</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,497</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,497</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total assets measured at fair value</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">53,149</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,508</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37,641</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;">
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="14" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.42%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value Measurements at December&#160;31, 2018</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Assets:</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current:</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,821</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,821</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt securities</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">57,328</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">57,328</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Noncurrent:</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt securities</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,991</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,991</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Government sponsored securities</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,710</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,710</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total assets measured at fair value</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">79,850</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,821</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">63,029</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></div>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Non-recurring Valuations</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-financial assets and liabilities are recognized at fair value subsequent to initial recognition when they are deemed to be other-than-temporarily impaired. There were no material non-financial assets and liabilities deemed to be other-than-temporarily impaired and measured at fair value on a non-recurring basis for the years ended December&#160;31, 2019, 2018 and 2017.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementInputsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of the fair value measurement of assets and liabilities, which includes financial instruments measured at fair value that are classified in shareholders' equity, which may be measured on a recurring or nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -URI http://asc.fasb.org/topic&amp;trid=2155941<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementInputsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6661407088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Stock Based Compensation Expenses Included on Operations Statement</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table presents all stock-based compensation as included on the consolidated statements of operations (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the Year Ended December&#160;31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense:</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrants for common stock to an officer</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,817</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31,584</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Employee stock options</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,309</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,057</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,267</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Employee RSUs</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">938</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,193</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">894</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-employee RSUs</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">380</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">315</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">252</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,627</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,382</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36,997</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense in operating expenses:</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">499</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">460</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">102</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Selling, general and administrative</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,128</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,922</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36,895</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,627</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,382</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36,997</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summarizes Stock Option Activity Under Equity Intensive Plan</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes stock option activity under all equity incentive plans for the years ended December&#160;31, 2019, 2018 and 2017:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise&#160;Price</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Intrinsic</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contractual&#160;Life</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in years)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at December 31, 2016</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,307,386</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.14</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,100</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.4</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options exercised</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(614,136</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.88</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at December 31, 2017</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,693,250</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.71</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,920</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.3</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options granted</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">800,000</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.07</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at December 31, 2018</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,493,250</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.14</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">563</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.8</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options exercised</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,986,300</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.06</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at December 31, 2019</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,506,950</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.37</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,710</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.8</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested and Exercisable at December 31, 2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,973,614</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.22</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,326</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.5</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock', window );">Summary of Options Outstanding and Vested</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table provides a summary of options outstanding and vested as of December&#160;31, 2019:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.56%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise Prices</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Outstanding</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average&#160;Remaining</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contractual Life</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in years)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercisable</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average&#160;Remaining</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contractual Life</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in years)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.56%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$0.42</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">589,660</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.9</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">589,660</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.9</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$1.76</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">699,060</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.0</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">699,060</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.0</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$2.00</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">962,780</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.1</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">962,780</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.1</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$3.07</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">800,000</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.7</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">266,664</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.7</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$25.00</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,455,450</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.22%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.6</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,455,450</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.22%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.6</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.56%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,506,950</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.22%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.8</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,973,614</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.22%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.5</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Weighted Average of Fair Value of Options Under Black-Scholes Option-Pricing Model</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The company uses a Black-Scholes option-pricing model to determine the fair value of stock-based compensation under ASC&#160;Topic&#160;718,&#160;<font style="font-style:italic;">Stock Compensation</font>. The assumptions used for employee stock options granted during the year ended December&#160;31, 2018, are presented in the table below:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:60%;">
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term (years)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.0 - 6.1</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.8%</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75.9%</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dividend yield</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0%</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average measurement date fair value</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$2.09</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock', window );">Restricted Stock Units (RSUs) Activity</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes the restricted stock units, or RSUs, activity under the 2015&#160;Plan:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">RSUs</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Outstanding</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Grant Date</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested balance at December 31, 2016</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">814,456</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13.98</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">615,983</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.50</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(244,209</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15.82</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited/canceled</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(298,041</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.28</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested balance at December 31, 2017</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">888,189</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.14</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">487,472</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.57</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(172,330</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.16</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited/canceled</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(335,420</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.27</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested balance at December 31, 2018</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">867,911</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.69</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">749,793</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.12</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(395,051</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.83</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited/canceled</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(83,225</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.29</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested balance at December 31, 2019</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,139,428</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.88%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.23</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Summary of Warrant Activity</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes the company&#8217;s warrant activity:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:60%;">
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at December 31, 2016</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,768,314</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrants exercised</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(47,226</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at December 31, 2017</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,721,088</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrants exercised</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(93,254</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrants expired</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(38,584</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at December 31, 2018</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,589,250</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrants exercised</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(17,589,250</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at December 31, 2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested and exercisable at December 31, 2019</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6784392&amp;loc=d3e188667-122775<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6912271792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Additional Information (Detail)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Feb. 28, 2010 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>Product</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 01, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 30, 2015 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_AccountingPoliciesLineItems', window );"><strong>Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions', window );">Proceeds from exercise of stock options and warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 39,221,000<span></span>
</td>
<td class="nump">$ 57,000<span></span>
</td>
<td class="nump">$ 1,215,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_CashAndCashEquivalentsOriginalMaturities', window );">Cash and cash equivalents original maturities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_MaximumOriginalMaturityPeriodOfShortTermMarketableSecurities', window );">Maximum original maturity period of short-term marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_MinimumOriginalMaturityPeriodOfLongTermMarketableSecurities', window );">Minimum original maturity period of long-term marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet', window );">Other than temporary impairments for marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated useful lives of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_FairValueInputsTransfersIntoOrOutOfLevelOneLevelTwoOrLevelThreeCategories', window );">Fair value inputs, transfers into or out of Level 1, 2 or 3 categories</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasePracticalExpedientsPackage', window );">Lease practical expedients package</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDescription', window );">Operating lease, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">elected not to recognize right-of-use assets and lease liabilities for qualifying short-term leases with an initial lease term of 12 months or less at lease inception<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued', window );">Accrued interest or penalties associated with uncertain tax positions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Total amount authorized for repurchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_VariableConsiderationRelatedToMilestonePayment', window );">Variable consideration related to milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized', window );">Revenue recognized for milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_NumberOfProductsApprovedForCommercialSale', window );">Number of products approved for commercial sale | Product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,729,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,532,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,091,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,501,000<span></span>
</td>
<td class="nump">76,885,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,444,000<span></span>
</td>
<td class="nump">35,944,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member', window );">Accounting Standards Update 2016-02</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_AccountingPoliciesLineItems', window );"><strong>Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70,299,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member', window );">Accounting Standards Update 2016-02 | Accumulated Deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_AccountingPoliciesLineItems', window );"><strong>Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption', window );">Build-to-suit related liabilities and assets adjust as accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(900,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member', window );">Accounting Standards Update 2016-02 | Difference between Lease Guidance in Effect before and after Topic 842</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_AccountingPoliciesLineItems', window );"><strong>Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,600,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (5,700,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=nk_IntrexonLicenseAgreementMember', window );">Intrexon Corporation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_AccountingPoliciesLineItems', window );"><strong>Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_NonrefundableUpfrontPayment', window );">Nonrefundable upfront payment</a></td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized', window );">Revenue recognized for milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_AccountingPoliciesLineItems', window );"><strong>Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Impairment charge/losses of long-lived assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_AccountingPoliciesLineItems', window );"><strong>Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_MarketableSecuritiesOriginalMaturities', window );">Marketable securities original maturities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | California</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_AccountingPoliciesLineItems', window );"><strong>Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OpenTaxYear', window );">Tax year open for examination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2015<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_AccountingPoliciesLineItems', window );"><strong>Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OpenTaxYear', window );">Tax year open for examination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | California</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_AccountingPoliciesLineItems', window );"><strong>Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OpenTaxYear', window );">Tax year open for examination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_AccountingPoliciesLineItems', window );"><strong>Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OpenTaxYear', window );">Tax year open for examination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis=us-gaap_VariableInterestEntityPrimaryBeneficiaryMember', window );">VIE | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_AccountingPoliciesLineItems', window );"><strong>Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Percentage of ownership interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis=us-gaap_VariableInterestEntityPrimaryBeneficiaryMember', window );">VIE | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_AccountingPoliciesLineItems', window );"><strong>Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Percentage of ownership interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=nk_ChairmanAndChiefExecutiveOfficerMember', window );">Chairman and Chief Executive Officer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_AccountingPoliciesLineItems', window );"><strong>Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions', window );">Proceeds from exercise of stock options and warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 39,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nk_AccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accounting policies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nk_AccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nk_CashAndCashEquivalentsOriginalMaturities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash and cash equivalents original maturities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nk_CashAndCashEquivalentsOriginalMaturities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nk_FairValueInputsTransfersIntoOrOutOfLevelOneLevelTwoOrLevelThreeCategories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value inputs, transfers into level 1, 2 or 3 categories.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nk_FairValueInputsTransfersIntoOrOutOfLevelOneLevelTwoOrLevelThreeCategories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nk_MarketableSecuritiesOriginalMaturities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Marketable securities original maturities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nk_MarketableSecuritiesOriginalMaturities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nk_MaximumOriginalMaturityPeriodOfShortTermMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum original maturity period of short term marketable securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nk_MaximumOriginalMaturityPeriodOfShortTermMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nk_MinimumOriginalMaturityPeriodOfLongTermMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum original maturity period of long term marketable securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nk_MinimumOriginalMaturityPeriodOfLongTermMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nk_NonrefundableUpfrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Nonrefundable upfront payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nk_NonrefundableUpfrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nk_NumberOfProductsApprovedForCommercialSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of products approved for commercial sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nk_NumberOfProductsApprovedForCommercialSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nk_VariableConsiderationRelatedToMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Variable consideration related to milestone payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nk_VariableConsiderationRelatedToMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) to equity or (increase) decrease to net assets, resulting from the cumulative effect adjustment of a new accounting principle applied in the period of adoption.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2921-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 220<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114873921&amp;loc=SL114875236-224282<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasePracticalExpedientsPackage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether practical expedients are elected for not reassessing whether any expired or existing contract is or contains lease, lease classification for expired or existing lease, and initial direct cost for any existing lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (j)<br> -URI http://asc.fasb.org/extlink&amp;oid=119364159&amp;loc=SL77916155-209984<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=119364159&amp;loc=SL77916155-209984<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasePracticalExpedientsPackage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of lessee's operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OpenTaxYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax year that remains open to examination under enacted tax laws, in CCYY format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OpenTaxYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>us-types:gYearListItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of other than temporary impairment (OTTI) losses on equity securities, OTTI related to credit losses on debt securities, and OTTI losses on debt securities when the entity intends to sell the securities or it is more likely than not that the entity will be required to sell the securities before recovery of its amortized cost basis. Additionally, this item includes OTTI losses recognized during the period on investments accounted for under the cost method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of consideration recognized during the period for the milestone or milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramAuthorizedAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis=nk_DifferenceBetweenLeaseGuidanceInEffectBeforeAndAfterTopic842Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis=nk_DifferenceBetweenLeaseGuidanceInEffectBeforeAndAfterTopic842Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=nk_IntrexonLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=nk_IntrexonLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_CA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_CA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis=us-gaap_VariableInterestEntityPrimaryBeneficiaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis=us-gaap_VariableInterestEntityPrimaryBeneficiaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=nk_ChairmanAndChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=nk_ChairmanAndChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6900307088">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Statement Details - Property, Plant and Equipment, Net (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">$ 79,108<span></span>
</td>
<td class="nump">$ 88,446<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation</a></td>
<td class="num">(18,607)<span></span>
</td>
<td class="num">(11,561)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">60,501<span></span>
</td>
<td class="nump">76,885<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in Progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,480<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">33,406<span></span>
</td>
<td class="nump">4,087<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember', window );">Buildings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">22,690<span></span>
</td>
<td class="nump">59,356<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">21,434<span></span>
</td>
<td class="nump">20,878<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember', window );">Software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">1,195<span></span>
</td>
<td class="nump">1,264<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture And Fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">$ 383<span></span>
</td>
<td class="nump">$ 381<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6900185856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (65,789)<span></span>
</td>
<td class="num">$ (96,226)<span></span>
</td>
<td class="num">$ (96,423)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">9,012<span></span>
</td>
<td class="nump">9,555<span></span>
</td>
<td class="nump">5,566<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">2,627<span></span>
</td>
<td class="nump">23,382<span></span>
</td>
<td class="nump">36,997<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_OperatingLeaseRightOfUseAssetNonCashLeaseExpense', window );">Non-cash lease expense related to operating lease right-of-use assets</a></td>
<td class="nump">2,604<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Amortization of net premiums and discounts on marketable debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">463<span></span>
</td>
<td class="nump">1,597<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_NonCashInterestIncomeExpenseFromOperatingActivities', window );">Non-cash interest items, net</a></td>
<td class="nump">246<span></span>
</td>
<td class="nump">291<span></span>
</td>
<td class="nump">720<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Loss on impairment of assets</a></td>
<td class="nump">869<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets1', window );">Loss on disposal of assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">209<span></span>
</td>
<td class="nump">64<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred income tax benefit</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(498)<span></span>
</td>
<td class="num">(497)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesGainLoss', window );">Gains (losses) on sales of marketable debt securities</a></td>
<td class="nump">4<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="num">(32)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">9,276<span></span>
</td>
<td class="num">(9,818)<span></span>
</td>
<td class="nump">156<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_IncreaseDecreaseInOperatingLeaseRightOfUseAssetNet', window );">Operating lease right-of-use assets, net</a></td>
<td class="num">(800)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets', window );">Other assets</a></td>
<td class="num">(4,063)<span></span>
</td>
<td class="num">(1,151)<span></span>
</td>
<td class="nump">458<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_IncreaseDecreaseInAccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">41<span></span>
</td>
<td class="num">(1,100)<span></span>
</td>
<td class="nump">150<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities', window );">Accrued expenses and other liabilities</a></td>
<td class="num">(12,020)<span></span>
</td>
<td class="nump">12,708<span></span>
</td>
<td class="num">(299)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent', window );">Due to related parties</a></td>
<td class="num">(1,093)<span></span>
</td>
<td class="num">(685)<span></span>
</td>
<td class="nump">1,562<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="num">(2,276)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">Deferred rent and revenue</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(508)<span></span>
</td>
<td class="nump">1,201<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(61,362)<span></span>
</td>
<td class="num">(63,381)<span></span>
</td>
<td class="num">(48,780)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property, plant and equipment</a></td>
<td class="num">(4,182)<span></span>
</td>
<td class="num">(13,102)<span></span>
</td>
<td class="num">(34,815)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Proceeds from sales of property, plant and equipment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">412<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireHeldToMaturitySecurities', window );">Purchases of debt securities, held-to-maturity</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(723)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_PaymentsToAcquireInvestmentsInEquitySecurities', window );">Purchases of investments in equity securities</a></td>
<td class="num">(3)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(8,500)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchases of marketable debt securities, available-for-sale</a></td>
<td class="num">(86,618)<span></span>
</td>
<td class="num">(94,770)<span></span>
</td>
<td class="num">(111,355)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Sales/maturities of marketable debt securities</a></td>
<td class="nump">112,259<span></span>
</td>
<td class="nump">165,284<span></span>
</td>
<td class="nump">254,222<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by investing activities</a></td>
<td class="nump">21,456<span></span>
</td>
<td class="nump">57,101<span></span>
</td>
<td class="nump">99,552<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations', window );">Principal payments of financing/capital lease obligations</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(477)<span></span>
</td>
<td class="num">(19,932)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions', window );">Proceeds from exercises of stock options and warrants</a></td>
<td class="nump">39,221<span></span>
</td>
<td class="nump">57<span></span>
</td>
<td class="nump">1,215<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Repurchases of common stock with commissions</a></td>
<td class="num">(501)<span></span>
</td>
<td class="num">(228)<span></span>
</td>
<td class="num">(15,227)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Net share settlement for restricted stock unit vesting and warrant and option exercises</a></td>
<td class="num">(127)<span></span>
</td>
<td class="num">(123)<span></span>
</td>
<td class="num">(1,039)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by (used in) financing activities</a></td>
<td class="nump">38,593<span></span>
</td>
<td class="num">(771)<span></span>
</td>
<td class="num">(34,983)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">Net (decrease) increase in cash, cash equivalents, and restricted cash</a></td>
<td class="num">(1,313)<span></span>
</td>
<td class="num">(7,051)<span></span>
</td>
<td class="nump">15,789<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash, cash equivalents and restricted cash, beginning of period</a></td>
<td class="nump">17,000<span></span>
</td>
<td class="nump">24,051<span></span>
</td>
<td class="nump">8,262<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash, cash equivalents and restricted cash, end of period</a></td>
<td class="nump">15,687<span></span>
</td>
<td class="nump">17,000<span></span>
</td>
<td class="nump">24,051<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract', window );"><strong>Reconciliation of cash, cash equivalents, and restricted cash at end of period:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">15,508<span></span>
</td>
<td class="nump">16,821<span></span>
</td>
<td class="nump">23,872<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent', window );">Restricted cash included in other assets</a></td>
<td class="nump">179<span></span>
</td>
<td class="nump">179<span></span>
</td>
<td class="nump">179<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash, cash equivalents and restricted cash, end of period</a></td>
<td class="nump">15,687<span></span>
</td>
<td class="nump">17,000<span></span>
</td>
<td class="nump">24,051<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest</a></td>
<td class="nump">19<span></span>
</td>
<td class="nump">475<span></span>
</td>
<td class="nump">668<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Income taxes</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Supplemental disclosure of non-cash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_NoncashPropertyAndEquipmentPurchasesAcquiredUnderCapitalLease', window );">Property and equipment purchases acquired under capital lease</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">19,448<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Property and equipment purchases included in accounts payable, accrued expenses, and other liabilities</a></td>
<td class="nump">74<span></span>
</td>
<td class="nump">4,664<span></span>
</td>
<td class="nump">9,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Conversion of Viracta convertible notes and accrued interest into investment in equity securities of Viracta (Note 4)</a></td>
<td class="nump">751<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Unrealized gains (losses) on marketable debt securities</a></td>
<td class="nump">258<span></span>
</td>
<td class="nump">123<span></span>
</td>
<td class="num">(97)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssued1', window );">Cashless exercises of stock options and warrants</a></td>
<td class="nump">$ 29<span></span>
</td>
<td class="nump">$ 94<span></span>
</td>
<td class="nump">$ 16<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nk_IncreaseDecreaseInAccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) in accounts payable current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nk_IncreaseDecreaseInAccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nk_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) in operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nk_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nk_IncreaseDecreaseInOperatingLeaseRightOfUseAssetNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in operating lease right of use asset net.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nk_IncreaseDecreaseInOperatingLeaseRightOfUseAssetNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nk_NonCashInterestIncomeExpenseFromOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non cash interest (income) expense from operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nk_NonCashInterestIncomeExpenseFromOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nk_NoncashPropertyAndEquipmentPurchasesAcquiredUnderCapitalLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Noncash property and equipment purchases acquired under capital lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nk_NoncashPropertyAndEquipmentPurchasesAcquiredUnderCapitalLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nk_OperatingLeaseRightOfUseAssetNonCashLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating lease right of use asset non cash lease expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nk_OperatingLeaseRightOfUseAssetNonCashLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nk_PaymentsToAcquireInvestmentsInEquitySecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments to acquire investments in equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nk_PaymentsToAcquireInvestmentsInEquitySecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfAssets1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of obligations to be paid to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management; an entity and its principal owners, management, or member of their immediate families, affiliates, or other parties with the ability to exert significant influence.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in other obligations or expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized and realized gain (loss) on investment in marketable security, including other-than-temporary impairment (OTTI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireHeldToMaturitySecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow through purchase of long-term held-to-maturity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireHeldToMaturitySecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities  (held-to-maturity or available-for-sale) during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=116874947&amp;loc=SL4591551-111686<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3000-108585<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=116874947&amp;loc=SL4591552-111686<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the obligation for a lease meeting the criteria for capitalization (with maturities exceeding one year or beyond the operating cycle of the entity, if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermCapitalLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6812-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=116631420&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value of stock issued in noncash financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of investments, not including unrealized gains or losses on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity, held at each balance sheet date and included in earnings for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6814189120">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stockholders' Equity - Summary of Common Shares Reserved for Issuance (Detail)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total shares reserved for future issuance</a></td>
<td class="nump">5,646,378<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Outstanding Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total shares reserved for future issuance</a></td>
<td class="nump">4,506,950<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Outstanding RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total shares reserved for future issuance</a></td>
<td class="nump">1,139,428<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=nk_OutstandingOfficerWarrantsMember', window );">Outstanding Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total shares reserved for future issuance</a></td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=nk_OutstandingOfficerWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=nk_OutstandingOfficerWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6817416176">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement Of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">500,000,000<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">98,460,404<span></span>
</td>
<td class="nump">79,087,734<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">98,460,404<span></span>
</td>
<td class="nump">79,087,734<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6894883984">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitment and Contingencies - Summary of Future Minimum Lease Payments (Detail)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments And Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2020</a></td>
<td class="nump">$ 4,271<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2021</a></td>
<td class="nump">3,753<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2022</a></td>
<td class="nump">3,671<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2023</a></td>
<td class="nump">2,546<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2024</a></td>
<td class="nump">1,083<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">1,729<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total future minimum lease payments</a></td>
<td class="nump">17,053<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: Interest</a></td>
<td class="nump">2,962<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of operating lease liabilities</a></td>
<td class="nump">$ 14,091<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due after fifth fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in next fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fifth fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fourth fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in third fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>115
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6908420800">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Summary of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail) - Fair Value, Measurements, Recurring - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets measured at fair value</a></td>
<td class="nump">$ 53,149<span></span>
</td>
<td class="nump">$ 79,850<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Current Assets | Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets measured at fair value</a></td>
<td class="nump">15,508<span></span>
</td>
<td class="nump">16,821<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Current Assets | Corporate Debt Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets measured at fair value</a></td>
<td class="nump">32,389<span></span>
</td>
<td class="nump">57,328<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Current Assets | Foreign Government Bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets measured at fair value</a></td>
<td class="nump">1,007<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Current Assets | Government Sponsored Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets measured at fair value</a></td>
<td class="nump">2,748<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Noncurrent Assets | Corporate Debt Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets measured at fair value</a></td>
<td class="nump">1,497<span></span>
</td>
<td class="nump">2,991<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Noncurrent Assets | Government Sponsored Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets measured at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,710<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets measured at fair value</a></td>
<td class="nump">15,508<span></span>
</td>
<td class="nump">16,821<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Current Assets | Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets measured at fair value</a></td>
<td class="nump">15,508<span></span>
</td>
<td class="nump">16,821<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Current Assets | Corporate Debt Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets measured at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Current Assets | Foreign Government Bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets measured at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Current Assets | Government Sponsored Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets measured at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Noncurrent Assets | Corporate Debt Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets measured at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Noncurrent Assets | Government Sponsored Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets measured at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets measured at fair value</a></td>
<td class="nump">37,641<span></span>
</td>
<td class="nump">63,029<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Current Assets | Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets measured at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Current Assets | Corporate Debt Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets measured at fair value</a></td>
<td class="nump">32,389<span></span>
</td>
<td class="nump">57,328<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Current Assets | Foreign Government Bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets measured at fair value</a></td>
<td class="nump">1,007<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Current Assets | Government Sponsored Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets measured at fair value</a></td>
<td class="nump">2,748<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Noncurrent Assets | Corporate Debt Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets measured at fair value</a></td>
<td class="nump">1,497<span></span>
</td>
<td class="nump">2,991<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Noncurrent Assets | Government Sponsored Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets measured at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,710<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets measured at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Current Assets | Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets measured at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Current Assets | Corporate Debt Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets measured at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Current Assets | Foreign Government Bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets measured at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Current Assets | Government Sponsored Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets measured at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Noncurrent Assets | Corporate Debt Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets measured at fair value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Noncurrent Assets | Government Sponsored Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets measured at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=nk_CurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=nk_CurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CashAndCashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CashAndCashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_ForeignGovernmentDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_ForeignGovernmentDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnderlyingAssetClassAxis=us-gaap_AgencySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnderlyingAssetClassAxis=us-gaap_AgencySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=nk_NoncurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=nk_NoncurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>116
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6910696768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Summarizes of Changes in Unrecognized Tax Benefits (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits at beginning balance</a></td>
<td class="nump">$ 11,983<span></span>
</td>
<td class="nump">$ 6,577<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions', window );">Increase for prior year tax positions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">798<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions', window );">Decrease for prior year tax positions</a></td>
<td class="num">(7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Increase for current year tax positions</a></td>
<td class="nump">3,680<span></span>
</td>
<td class="nump">4,608<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits at ending balance</a></td>
<td class="nump">$ 15,656<span></span>
</td>
<td class="nump">$ 11,983<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=116821951&amp;loc=SL37586934-109318<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>117
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6908655696">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Statement Details - Impact of Adoption of ASC 842 on Property, Plant and Equipment (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Jan. 01, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_FinancialStatementDetailsLineItems', window );"><strong>Financial Statement Details [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">$ 79,108<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 88,446<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation</a></td>
<td class="num">(18,607)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11,561)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">60,501<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">76,885<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_FinancialStatementDetailsLineItems', window );"><strong>Financial Statement Details [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">33,406<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,087<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember', window );">Buildings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_FinancialStatementDetailsLineItems', window );"><strong>Financial Statement Details [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">$ 22,690<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 59,356<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member', window );">Accounting Standards Update 2016-02</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_FinancialStatementDetailsLineItems', window );"><strong>Financial Statement Details [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 80,567<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10,268)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70,299<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member', window );">Accounting Standards Update 2016-02 | Restatement Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_FinancialStatementDetailsLineItems', window );"><strong>Financial Statement Details [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,879)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,293<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,586)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member', window );">Accounting Standards Update 2016-02 | Leasehold Improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_FinancialStatementDetailsLineItems', window );"><strong>Financial Statement Details [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,101<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member', window );">Accounting Standards Update 2016-02 | Leasehold Improvements | Restatement Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_FinancialStatementDetailsLineItems', window );"><strong>Financial Statement Details [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,014<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member', window );">Accounting Standards Update 2016-02 | Buildings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_FinancialStatementDetailsLineItems', window );"><strong>Financial Statement Details [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,463<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member', window );">Accounting Standards Update 2016-02 | Buildings | Restatement Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_FinancialStatementDetailsLineItems', window );"><strong>Financial Statement Details [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (39,893)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nk_FinancialStatementDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Financial statement details.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nk_FinancialStatementDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_RestatementAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_RestatementAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>118
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6814675104">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Statement Details - Other Current Liabilities (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Jan. 01, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_FinancialStatementDetailsAbstract', window );"><strong>Financial Statement Details [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liability - current portion (including amounts with related parties, Note 9)</a></td>
<td class="nump">$ 3,206<span></span>
</td>
<td class="nump">$ 2,960<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_FinancingObligationCurrent', window );">Financing obligation - current portion</a></td>
<td class="nump">757<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">965<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRentCreditCurrent', window );">Deferred rent - current portion</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">598<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherSundryLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">104<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">$ 3,981<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,667<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nk_FinancialStatementDetailsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Financial statement details.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nk_FinancialStatementDetailsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nk_FinancingObligationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Financing obligation current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nk_FinancingObligationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRentCreditCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For a classified balance sheet, the cumulative difference as of the balance sheet date between the payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense, by the lessor or lessee, respectively, within one year of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902458&amp;loc=d3e39927-112707<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRentCreditCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6904-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherSundryLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Obligations not otherwise itemized or categorized in the footnotes to the financial statements that are due within one year or operating cycle, if longer, from the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=99376301&amp;loc=d3e1243-112600<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherSundryLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>119
<FILENAME>0001564590-20-012816-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001564590-20-012816-xbrl.zip
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MAUM 3@&!] M(H$%Q0'Y@+\Q4Z_8[B?,),G#[;H1E#]!SB1/T-JK6[!:01[0
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M^E@C8GLFOO(6J*+@Y6 Z+6R=N2"%&AHF[!$K?_V=%J7A_^)J&@LP:!#?7,Z
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M/:/5:(&,EF(65CJW3 N.:"8J#/Y:G7&>G&DO_$7^[@#OBAT;(T,ZWO-Y\&_
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MO,#ZD5G.I$47L:3XH^2B O*)L3A,^2+TO@G!5#&=!4I?9(C!#LCC %B^ #T
MA0<#W.DPRD,'2B'D4<)S<P"EDQ3U&FT7];7E%GC8S@>RXT<(%P?CD?T4/1+X
M1I>TX\2NO3+8-4,'N+@HU(**'Z(ID+V>X:*2B#G[D3/13R!%3P:A8$2&CW*
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M3N,/;SS%-XC,X#%#_QX1O:G$B;61]-7K]LB;<^2C Q N6+83WAY_.2*G@;0
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M.IJB6=3/'%]ST?C"WQ9,GM*D04_30@U#M;!URH<,<6(UV(**AAIW@=E1'38
MS:N-K062V:>KQP\X!;GQ9"WTD3+%N]O>>@8W86K3B&UZ(:-^P.B0_*=F @TM
MU9,@'2UQ_(EJVE&W.")8/$J:-!%DXLJ.>O[KQE*A^!E?O&FY2I<-#+.+EV-3
M]3-,]*!-UESQ!X9X%KS'(?HL@\&)F&<BC0UE^NM/K;\&_Y!=IT7Z%2T CU66
M\<(<-;!.:7]@V>)ET31=9H#^TOBI'?/*5R8.<2+C#VB!4EGXP&DQ_0@94V@Z
MS(BSYOI(] -U ^TK0/!3$3',;7G3F1S<RPV 7TA8_-2)!X4D60@0[BV._<!%
MX\H-\,J73\CFQP 0/2-IS,@,3TV=(>1C$@\):*+PG0I&& 0^(>K8;/ <;,I8
M.M<,[-PJ,H(LA3B"ZB=AOH.@Y60<ICA_@,XZ>CWS1\6OSB!?G3 ^Z#;WXRJ1
MJ>?2Z#TD3FZXH%EHB#1:W$1M]$,38^T0=_X SK'.,[40"Z[K'S'(DD3AP=MP
M3CT].,2+;3!!/,DL,'_2PAP[W,KH [8,/..S2JGP@DQNS*A%9.#44WJ/TFE4
M;*2823 2O46_L]AMHB*UYR6?!"I/E^P-8P*.F ,-(&(X(C3 U@X-*:091]CN
M\RGR,/]&]!4Z18.IU[AE</>%S3B4CZ+IOMH46,S B[SEK#$#A+Q@R"(.7!U]
M5@%H?D;71\5)]LBFL$^6G]3[&PZ(^@($B5W]N>_NGF\S$Q+NMR_W9]CSGS+
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MSO>0&";I?AW.5;X&&PF,$7M3DA5\3XPC]G,X_*X@9+ZA3YZ. XH?47R7\F,
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M8"RZSA:#(;-%[2#P.B ]3'*G#T_>DPV+L,/'$2D*RHGCMG5NY;GDN&WM(#1
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M*%V.#X[I5C[:!V#'[(ROR.*X;EZ\ I8MM#\LNW]!0W$>KC4[(GAD-"DQ9F-
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MP',5"XE]2_U$A',AW7"ED8+/5Y^ORW&9C@;B[.<P4>57@[>6N*O\?>:]+?\
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MM10 L(>]24.!JKN8$!=EH!:EXU3)'3I#PZF2=X,[M"[)ULDCDBF9-2E3&S%
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M=Z V1:'6XP5_QQX(M%QK!J"MH9<8/XGC5$4MTB-76@D_IFOU%$L,LI6P#8:
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M&!%8RGLT7;-AF:GD3AE+NABQW )=I1%R  Z&YBH8MFR,L-,[QZ4R=FH^AX;
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M=2P+0WR@%]6YCN_/5:;1>Z,MUL*O.J:/D\$-5[EU=?7YNKQT;*P##Q?,P5[
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MCLM9F";B0]0K!^!S& ;GGQ?0PILU.WUMN[2)\64.>Q9WU/J@<DI"APIVCK[
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MO(<V*\46'HV"RK!PIVCU_EY1,Y:@/P/"40QNHH4EE>VQH5BDO%, 7KGR[&"
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M-^ *>>GJ]03&_Z)\:%S^TT-5$;>4$_&"+:ZQA Y&\Y=W/_W4_^E=\1 UC*N
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M+8_RU"[G'&*AHXRFLU,U9ZEY/>\M#G/9TYJ6^K:4G]BEH&]2V-X7-:K:DG-
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M!2_EL??<Y>L%C\6T_<6>]-\,;8L-^O9<_.^,.:&'_YBR6R=A+_N]07DE3$$
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M"$_SA"SR,'%P-N$/D*R8!XXVF2@<\-?VK(.8@V =0<Q/T/!5F46I*#X2 1I
M^: %BF4Q)B%T#I/OS[TK4,?8N08UY+$?>?CD@6[#I02V"ZG<I&4)/-QA/P2.
M^^7JD[N* OA;HG"%-@6E>QUY7!@<CZ<\7OLAEQKK^/$."5\MG&07\PQ>/&9O
M/[TK)Q1<3]\M_YR"G2W_PLG%L>?SJ[VM#]+EN_(E/@EY>:<]20"$5^/7DF*=
M),G62J0R'!GR8*Z].R*7Z[AW;XH ^PSV%PR\^+TO#:?P!4'NP*B]/B$ZS^H8
MBA'HCJ$:J'#\OW_1?\%<'@3HVL,L%'^KH$'\K<(1%U\W+H(/%3E :!(XFX2_
MSO_QALGH8M+7NR89<S+PK"]BU#8N!OQ8V#]06O9*6+%O3=TA8_?F(VJK5<_4
M3WJS:A70UEJDMC=_L672Z[,K-J%C0.J'PO22[BYRQF]^\N5J"?$7KK- Y(/N
M.CCKIN9 B37JF_HNL<:@-_O&6""(, QI^-=%PBB"C)LH@"@\\-,[8STK(@L*
M,9Y!):;CWOQ2MJ#PPGBVH/#B >DW_\:'L7CLSN>!9ZQ'141!4<4S:$.?8HK:
M,:"8PCQ,_MC-RZZYDV0Q7\/X9-%!F7HTUL\B#J%@XQETY>6@UY\;B\1STPA5
MBE*E*)9\8!G'5J@A"N=D<8HJ;*NJD9,50[)L)5K"K5.V<>ZP&B2_6Y*7=\!P
M>,*YJ)U89BFPDZPXP4JWM;.](+;]\(JZ(]<)W"PHGGM6"5\:77.X,)9U=P[;
M</CW=1QE&[R%^'DL1B?OY ,4MZLHX;*>4-8+)K)T)5L$OAO<,>?&\0/\C7R5
MN#H7I!75[,_J[[U//:W.)Q;$O?T6>(]$%.)47\S^C\?1E0LO O=<1#CGXA5A
M5K/83_%%$A\$S(EE#22^DYHTOE7QH#YT;IW88PN., J7P9.OMX="\>O 7XI;
MZC6X):Y9DI<'Y3\L( M!4MU45&?B +#(+ZUZ4EX/J0]3/>RL,K/9?;1QJW3J
M8?IYSUPBO"5(&<Z9+-;Z/?33I%UE=%K5JE VT P8.#PU4:6PQ11(K<UP"BP&
MPO_;I]_A'PY6:*.)D%5R^)M!WQZ76O%KX(14/P:^Q/2B^K''W2$SF?3F,R/:
MCBI)7D2!=]]PH WK1WF,-3&C":S1:,#<PQ0 '(,7M2XI#7NS$[J3;T=_ULBM
M'NQ^R;"8&+C_D&EOVPLCW77E73]F:9*"\P=Z8(:=?.XPW&A[2.QD$AK$3@9B
M5RS =\5BOY6!>5=>][_$ALWW6X6][7[CGS!A],\')(R(D;N47%6!?AN3J[^'
M:L/MP@F<T.7,28O-C4SM::S[$(0C6=7)T^:\*:MZ))=WLM<<U8R8 M9@RYU]
M(&#M:[DTLT?6:&RNF:/R*W.P(,HARJE=3UX:BQ$QS?%S+8<021@+'O&,Z9M!
M'BD2!3&<&@C+?\F>.\:6P1/WTPX$$TQ3S5A(CN\JA4_LL36?#8U%AS3%'"R(
M,$@-3(T%B2>>^,S&7NW'-9)V=#[G:&BD]T^1=#1V(81XF]:@3+!,1BSF=I7
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M$O;2[HW**V# @1^%^/,L!-6+KD,8* "61NZ7JX63*%QYF#@I7LB_XK]Y 3K
M(-49=<]/Q/>N^F*!EQ6WC&Y )APFWYQ[5P[\[5SG,H8CL'O3<F1"=WKLXU+>
MVEE'69A:./SAZ>'GHX0!:0/-9267(R&"#ERQ=OP09>?HV&8[8Q/*^++?LR\=
MCBZ^EPRIOS>DLT1Z=A^1ED+II^"^N \4\GL2AA.+&6F/DH(Y8\LH"*);8:;0
MS6!)MH:!PU.3@U1T*R>".6C<_?3N]8D9>58/18Q ]U#D:TD/]/L7_1?,Y4&
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M/G3,D&EX;9\+]7#,VN<_F+-AY"P5TTT@J5D= &T=Q4XL9:+5(Y9J%E[$4J=
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MVIK==7'%^5,J=@T4NPAX8K&0I[A+(5]\QKT%"Q[RI9_6G,"AE6>#LFE$($W
M0CIB7?6S7MGSWLA8;#JC)W6WH^N@?]4 T]09\6\ %MVFB4FO[D:FI"4-T!)B
M"](#PJ+S;#'NU=U<E+2D 5K2;;:@LN%G+AL6W5\<[\\L2=<P+%,S&K12:Q(8
M1!?F8-%MIZK?LXU%AK3$&"RZ[521'A 6Q!:8U^M?'(.3FM2>UB.6:+-EZHSX
M-P"+;K/$J'=IUQO2D@YI2;?9@JIMGWFA]EV6)LP)/?;W:)&PMRX5U;9@J98R
M>UW"HMMNU<-/_B!MZ9"V=-N](CT@+(@UB#4,!,-H;2'6(#T@+#K/&J_&0]K
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M2</J;#;!W3X H(0X%PLG\0LDBQ$4G^2>C03EEL?B'>7\,G^]!NJ%Y\/]%QP
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M'.Y$[O>\C]TBE?RL9ZZ9J&8 6[V&@<-3I=>M9<5%#D!DV!"JPSSY2OB349;
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MT182+MSPXB_11H*:0P@W<7Y&<XBG7E ;]ZM.I*:40ITYGN=,RC48$)A^F 5
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M\ROQT UHS57J?!5JD,](PK(-7HH#6#M?_76VEK=",\*<=93AG/"4+>[$-1]
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MJ#O-!14>R: OR(^CCR;J P$5AQU\=N%Y:I_<^NF*?5BOLQ  ^,&/+/#XW)Y
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M@SGV0U!^[1G_>/?N6VF/85IP9@&X!*T=S '(OK-,403 (TP%_'(Z\)GNEXW
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M+SC\VOA$.N[1])XS9SE_\,<@"[./LPMY_ >W9GRE/GW/.;5WJ',J^5PZ7!M
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M_JPL,:@ 74ZOX I!I+.^G.JP(B0;3$P (4PGR[E:?/!*RC\D:5:&Q[Z.3A]
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M^9S;I2V8R$<JJ^E0&@^Z1!92Q,+4!#70*%$IKBFF2Z97BA7@5(81:$?6'!I
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M*T+0?9I4Z;S2'"?#PN949A\8U9%.^@80@\F?@9ZZ"FMGYVA/0Y6,!ZN0Y_:
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MU-EQ,CO&1$+4CFKZK?I.D?=I3ETJCUMMIPU?3J$J.!-J8JFC+>$3]E&TXK?
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MDAMC:4GKRWC:-JT3<H?R45@]JA759-?;%O:C9JPLF,/SQ]) S<7<_E9^6:_
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MYM@C(<3F65A)3S7!0[%7$T&@GURSR]&6QWQ1 6O',5]M'>$U]$^Z(YA?219
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ML#][**'1WDR;V!Y,)JG J4TZQ?THF$/+[O^H44[BVT+$F7CM>['(*XX4L)5
M<.E9B='!0ED#;27[?1V7+"-MDA&F"A8#%H.64\71<,1L43D*K\E"P"3!NY])
MHNTDT?-/SJO.CF1!N8\F*NY[2:=$L](V&:F0B_T?,?6.HB3+1/;:NPK".//0
MIV@<C5G%;GBNX:Q?W/&^Y/R6*+\:X%6.03X=LP9:$OOVUG[NYE]$:BPHFA9,
M2DQ*3$JUQ8M)Z;G"9<Q)+1$N)B=:># Y-04O)J<'R:GJZ@!FIQJF<M[GE>7Q
M %6$+^ZQ(:H I+8VQ$N.--RU9PJ/:Z"(XXX5(3RN83NX4 7?IZ$XJ8YK8&9C
M9J.%!S,;,QLSVX/,=G92=483,QMQ3<K,1@L/9C9F-F:V!SO*C$;[5OJWA-EX
MQ-ZA1NQMG9=7'JOW97(MILM(?)Q=W 1A!&_U+DF_!)'X(B;+%,?R?1:3))Z$
M48CE]N4A?>[TO=-V3=^[R.\=I)<L4S>U6/[;FXIQ[F5V73TI8?)WN5QW,?7&
M(DIN>>#>^L"]<P(#]X;#SBF-% .V_8WMWZT<$'RS-\:LJ<-)H)B_=U9I"_R3
M ?GY>T\"]PE(;N<4&G)7Y;"/JC"IQS0^$B15/YW(C$49'2(S6\XZY\.ZCVRI
M2GO^@<\@IL?;3C/-?OV+&Y$&5Z*=+_]9S(,PEB+5SM>_E'])@TF^#*+"GOL0
MSEJZ&\"[<2>"-*NZK0K;LC2MHKV(]84\+S4"CXVFVB-]H3K<BFD[F>(RR:IN
MY<L<43..8%!8]S<"Z=]CTZZHG<K_%VC-1$/S4"VNHP 3LT1]06&6J#W2;6>)
M#]C(CX;J89IH&DVPPXGII%7J]%T0INTDDG\$T5+0T$WL;"+61'FKJM')-B^6
MIE%9WN?E,@6B>[.G@+S ^-5N*W"H0<\H2M-8&;K'0'>ZF^'$Z)%$[R7-!D:&
MR:F62+!ZJRMT3$YU1H_)B2PR3$Y4D&#U5E?HF)SJC!Z3$UEDF)RH(,'JK:[0
M,3G5&3TF)[+(,#E108+56UVA8W*J,WI,3@?,5GGVQ+@#9:OT!IU3\@C91H;'
M\M/'62"O4W%R%]L15%* 69W5#AEE)C X),%AL2&+#%,+%2181H@BP]1"&!P6
M&[+(,+5008)EA"@R3"V$P6&Q(8L,4PL5)%A&B"+#U$(8'!8;LL@PM5!!@F6$
M*#),+83!8;$Y8,9%7?J#]$\[@Q/R$%TFZ2))@URLCC@DF[W$Q@ 5)%BK$47F
M,<; LS0(HP17M].GBA-+$%EDMK&,(RX'FVW.T+#0/(S,7ZD"LB?;-%)\!GU_
M<,9\0PR5&B@UYANRT+14:)AO:@!2KTL5I;:*30T4&G,-66A:*C3,-34 Z6A
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M)V>9D46&R8H($$Q6=87NH&3%Z#$W,3+,3:2 8.U65^B8F^J,'G,36628FX@
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M-85415&PR,0;\X^WGF:&KMNLHHKZY=/.\($D'0Y?OVQFXH KE6O4R[_7.7\
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M,A'!(L\%U( #JB$3%J (Z &P $70@@.J00@+4 3T %B (FC! =4@A 4H GH
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M$8'$#?"[0>P,51KFD&KG:J@7^(HX0."KIN %OMK+5UJ/ACD$7U%5+_ 5<8#
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M (&7:@@:M*INM6QI<4#3G=_93-';)PPV42UP&U4<4D]Q*ZJ J;9>!(FJMS0
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MY.2"AT4B D2>FG6  :V0 PCP C1 ;B!R%!T""RB%'$" %J !<@,!6J"#!8!
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MU;)\F#7/C1NJE6?I9M*MI#6$?E4!4.3)R>Q+D $$!-44O$!0>V.7>K\](&$
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M!"P0RT'!+G1N*@[(-7MDSIP540N4TM4_:04F"=><T82E:'=>:(9,5@H, 3T
M0\C)$%VJL,BC&36P4F (Z $80DZ&Z&A4<9%'-6I@ID 1T -0A)P4,: *BSR:
M@0(H8H!<SIAG!'S6"OLQ8X[/?)I14_ VKAL"%I(3N#YLZ<,156R@)X2P %]
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M0#Q>JWL:('9D /%HK?CW@YAZI$=#Z%ON,"I1]L?KQ%.V[!M!:<=!\<#;AFN
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MF1I(V+;D]-2%B0=#_[__:6S _Y)_W_\74$L#!!0    ( "B!>5!UKW]&6!X
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MOM<$TK@P7R71F6B?#LK@H-\UEL^OX-SY09@B@_>)[/!*8K [(4]=GOO$E<F
M^,Q3L#+AXF2E/ EUN"!>2O6/>&\&Q05.;D4IMF;>O4^$8BM@.#EQI(<TA6V]
M2SK#]I)ZKK?8A,8LNRZM+#9O==K=69S0U)OFV_N>.72FZ()V"(0/;I<$5(#S
MR!%+[98T 3:%>?U "!FJD;?:],_QKP??NQZXDLN,)>%8/>XE#Z13)]K659=+
M<UW0 'Y_^J#D0L]8>^5G5V?5=VGV?WBSI>=S1!VY2R\O'V!,Y3/(\&=X<R<Z
M6%RQV[85"@.GCY!4N7F?>8WZ82W/^\A//&@BF!Z:@N]1>"KWWF?N24*0ZN]8
M>CO1KL+9R@.V_RF3;G&1>$?;X#!E #5P%[NSF7IY%+C@/'E]5#ZQ&">HZJ-'
M&S=E2L?O5DFKNR.3&FRW/9]KRI2>[UOEX[V=CKV9JK\W790Y%Y@[>U-69-XL
MF-Q>+F.BJM0\/O+JE7Y+-ZV&P<YX[-&VK&7BAGDU#X4A5C(EZ'NB&193AFR#
M54]G3H-GD+?OL0B/*7VF#Q34/E9=ZA:VJF*,R]RZ)_(F8CK/BCEZ#[Z!UF@1
MF&A\PO-'\;8U8 QN\-ZJM1*5TSRL&^7V=3I4DC^_U*%^O]O?/5TJD1%3N44;
MK7[S-QWK((S;5RD26]@OJ@79 X8R.T25Q09O#9VYPF/GQ+NWB3P*//;8.KQ4
MFG7D]'#FN73?B(1#LR5F:(VA;1OL@IWEJQ[&/)Y^PQY;W*_Q!K/?D2\]A8N[
MOYV[ON!K3!UP74 #Q3ER,/W#9T(H/A:_RVTZNOAM]?A[_7GX76$WKQ_O?+Y\
MH$0%W<3F*[ &4\,8RS0T]5W4H:)YW$]N+JZ(*Y_SR)XIS7\VCW(UK<.$GB4\
M_]54NN49U#+*T]_-HSU[<# ^6!FJNQ,=-<R%+]I5,H_K:$M2WL&/CI".EX@M
M,%>'*:FD'\9*N5_:M?;^K&3RYVIA2>8GFUY5I<;PIU_GY\WY3#T;%*;L T<!
M9T-!C<%-7(9%V93DG5.9.!&Y96?8ZH'V2+3QG9^<S&).*\M-%%YXL>D,;"=R
M[[P-<L4F=T2^%L08P36P.8H-=6X@MC"QF$ OKPCCXG\P8CG&&]4PIA\:Q" C
MC9Q2/",K.0+CE5I9D3&L:45<9D;K3*R90U)Z/R1(1B=/^7CJEC@LG,ONQ#>#
M-2X84D-V)BJBAS,X/')!&+:%QU0BC^#..T\N5JAT+OE;U8TKF.?RWB JDAA/
M;B>OM,P\'BX\?W$OKJ_'.;GD/YM'^:5[CQ<^=;PQ<LG<8Y2@+ \U .9QDPS[
M/[Q'G]&OB'-D+WV.1=E240MJ'H=R1/SAL>]@I8%\'+__M)&O-B&Z*8Z?)M#F
M\9F(YQ[1"X(77I7X\N7F\9*]J1 M:.+H1/B^Z\R[?!:8.@I(.AGQ7-V]OC$>
MF-ZYK$@_=X?)"H8GQT[V@O',FRT)RU[&VPK%_G=5$.VX101THNRN8NMJ^]\E
M8<1 CH;IO+#@;EG)1)<_S4),ZN7SFH3;9*#M,M-,>G':JDJ:YX7\I(I?F^LH
M4A(8/)R8O'PHI03 1"G*MWI5Q[J;NY1^%CX;,R#U)TY4S ?$ &MG@18XRB$/
ML]2YNJV7<-D(-)S4849?!X"O+;(&5*O-".@N=6L3AEP+AHM5,VH+7UZ;_^CL
MR_V?/F+XRO/$='Z%;.5<JM$6AZB;0";B!1#T(J?)VL=I4SG<=2';#.B+!U'T
M1WYDMU>I9T6A:0H8O18U\YJK8KLZ1BEE8#0B^Q"9#-"_A(.L?=& !LQQ)D;R
M%Y?T/H#?\]I2#:XG)UY),'WG]KQJ84S34[D$_QTC5RROH5;A*%!EL7G+V,EJ
MY5-O2FUUT3K80R[PHP$RCZL9&&Z/V=ZJP$I9B7GT1^&/JOA==;EYO,0K=17@
MR!V!*BTSCP?UJER<+Z?B/)<&R#RNI)F:KHC-"S'NLA+SZ%=F">;V<^*5V*ML
M@7G4?R-/" @<8]>]OSW+GR4M*S./A]*P S@H^$<0:JD-3V3@3%S!1_YDM/N6
M7_PDW]/4FY$ KSY(MJ_1L(GL&=>5Q;EC*3HH8Z(LW2/!&>=87O O6;MVJVO>
M8O8&_VAZ6JX1J(F*'6;Y.0\T _Q1UX<ESX0V>?@C^EB:-Z@7C#T/F-W="&R]
M0=1B&Z4IDO\#UB6U8=1X$ZZJTEYU!\>(V7)SY$(F=_;6X<Z)'"EW2.4I#X6>
M-3L=*AIKA!25T_F53V5&O>SQZQJ /1)SE-Y[.K_ :WF/->"A3-<;@1K#>N.,
MJ3G;'YCY< ;0),)M67=O9H[<@W$RE=0=%O(9V\MG.77*2Q7R1 I7#E/JD?E,
M;I%ML>R/*DU](44A.0J7/F&JK5Q41P]GWDHVE5'LRO.93"<6O/P,7A2 D2<L
MGQ6KS$+6H([9/)-Y:Y:U5<SC^&]X$S\\Q=7 #<]99;G4@IG'V8U'+U=KU]M@
M7,V7!LAHKL#?@I6I#=.,(EWN:U4R5P-K'H^-&=Q+[E107&Y;.O)T*K@1"N.9
MG X6"O!\DX!$-_Q^('"T/)@PH<EHJW-"X^U="<]+WC;,!.)?K,U,\$2!O;9/
MWYG_T!Z<+18,+^0V*Y7!($YLY:KD,XCLO)D7#TOM3)E#CK_!R%4.(LPNS"9<
M4I%RE@)EZZM[&S;6J_KV$;D.R<6W8.-@(0W,3FGN!DDMB'DVL$AN(>U +<A>
M<%1,2* !V@>NI%NO8RH-LQ<\@5.KY2D%8QY/G2UCG-?S#&;O56 F%=-;V]P:
MS,F),^@'5?N5#:SR&J7_@IUT.")P<:*5NCH[GARR:U?'/)=H+-\1F<Y#2J>L
M;'*,;R$U@C5NW@SI+5P*+GXWSJ\*2<Q<]LU^ZT#RBUWLQ7/,F-QFL[V5S*L<
MADO/,<5S(FZ2=]2:0.Y/-##B!O@( L+9&VW1K<34NQUM:NQ-$+G 5/3A J\9
MMDDP@U GS#,:2:.\0QK5W=^N46).MA'"9UP:*(J^XCYV2HJ!W+M7\D&+Z?RA
M^/Q3E[JF=$V3_/IE_'4;4&T1[$\O7<[GV):AZ7@>N4-"OI7F47G70?$#'\>^
M.M3Q5^^1GR5!FXZ5,TZL"5>UFO"AG-:"-R_SAC#RZ*?UIB]LQG530933^<G1
M\4?%YMK% H,ME;O;<I-R*1<Y$QHR'^5Y4IO?5QZ[=$ETM&HZO\=/8'/<<Y^#
M5\EA@*D<=#*F1YVQ4F >G#X"O$FA3%>'F8 %9+R[DN[*>(]IKVC>'[O1O5_O
MHNZ8T,+4O+W4ZK&;TK\-WE(.34=A!5968MP:+"8RLPK+?S5X'59^(&L<O(0C
MAVVH==,?%#.^).ODLF[]F:Z&*(RS_=$]UH3^F.Z D?R%UQI $X^NI1]#K31+
M&B!3K(O>>M]@D3CZ'N=CQ-AF[C$9?>1)IH?TI=]65=(]H9)"O+9XY82B>B5-
M=D)U]C1F0V#CF)0O;$3J"3R$D2 ^6R+QA^>[SHTG)JLUX(H]U'#2C!C? L'^
MZ+[<8OG=IPX 3BG^6_%84@V >=L7,NIGB[]ZA(I[X3N;]%LUY64F2NK70\D:
MMY=XA?[ROU!+ P04    "  H@7E069KEFK(6  ![<0$ $P   &YK+3(P,3DQ
M,C,Q7V-A;"YX;6SE75ESX[@1?D]5_H/B?4DJD2UYKK5K)RE;MB=*>493LF>3
M/&W1)"0A0Q%:'K*UOSX-D!(IB0<.$B2\\S"V);+1_:'1W0 :C9_^\;)T>VOD
M!YAX'T^&IX.3'O)LXF!O_O$D"OI68&-\\H^___$//_VIW^_=W(V_]*[L$*_1
M#0YLEP21C_[\\/DOO?]<3^][]]C[_F0%J'=#[&B)O+#7[RW"<'5Y=O;\_'SJ
MS+ 7$#<*H;'@U";+LUZ_OR4]\I%%O^C=6"'JL7^7O?/!^: _>-,_?_<X>']Y
M_N/EF\'IQ?GP[<7[P5\'@\O!($/@YUB*7N;?9>_=Z>!T>/KF_47FP:^6_=V:
MH][X)O/@Q<4'Z^+\[=NW/PZ';]\_O;_X8']X>O?C6^N=/7QK?YAE.26KC8_G
MB[#W9_LOC$60U_.0ZZ)-[PY[EF=CR^T];"7]6V_LV:>]*]?M3>EK06^* N2O
MD7.:4'4!MTMW"QYTB1>P/S^>9-![>?+=4^+/S\X'@S=GVZ=/DL=?CIY_?L.>
M'EY<7)RQ;W>/!CCO02 [//O/Y_L'>X&65A^Z*@1): ,!O@S8A_?$9GW$P5>O
M\ GZ5W_[6)]^U!^>]]\,3U\"YP30Z/5B/'SBHBF:]1COE^%FA3Z>!'BY<BE+
M[+.%CV8?3[SO0&1X,3R/2?SPB. 9T*%[)C*E\FTZWN,8>BC\_HR"D.G@]N4S
M^NC9_MMG.?P(4 RM%^*1Y28F_1 "73HJ1H0. ^S G\ZUY5*4'Q8(A4&Y8%,@
M\@L_D7W$LI+8EFM'+NM)*N;>\^@E1)Z#G"T5RGDCHC)^MARYQ-X3/6F/*<[,
M"IZ8]H YFEO6BK5YAMPPV'["8.H/AHD2_9!\_,L_D>L\DL]6&/DXW#P@F_[$
M*!A%O@^\[0/E4MTF_O9#UWI"+C.!?*3.-,ASM;8P\.6B.^(_6"Y*V;A!3Z&2
M?,*D=<C[U4<K"SNW+ROD!>C*<R;A OE700#Z(R$C%SD=<HVL8 '-TQ^WOT9X
M#7A[87 5CBS?WX#G_=ER(R0B&2=!';)E,/U"/%N\EPH(Z.!][(''FV,8!4G[
M*+Q]L=V(1D.?"'&>L>N*B,)'3X=D5"NR9NO?.%R0*)PBR\'NY@:%R%]"X$+'
MOX5]IBY72Q*)]9Q"(UHT<X5\\'G>_!Y!X,$BL<GL6Q#WC9"&EA/28QD),!%N
MOH)'#6'D4^A7U-]^$1.EG$Z7?)J<,9&AKD5J61_6@K>*FQ1G4J._N<?6$W9E
M8Y]"$CKXOXG0(YDB.N5POEJ^I AE5+3HB&W[$7+4^J&$B"89J#,*OEH;:C'D
M!,BEH$6/T Q!<\Z43KK@)P[E+&8YG7))#B>LWO=?DN40;SYY<O&<33G%^*JF
MH3]VV&KH1C+"K2:F0R:UP=K6*)VBT,(><FXMWP,( QAST3)BA@]4%]M82 H>
M:IILS[9=YHU&9+GRT0+FJ7B-QIY-ENB>!'0",9D]6B^"1DF,M!9Y'3 L,(XM
M]RO,R,?>R%KAT'*!MR7Q'D)B?Q<2D8.:EGE]VJ#X%/[H71T<L_86Q'60'\33
M-Q&>\][6A3,.EVR-PW-&Q*/&%(&+0$)A:BD9S198TO1JYQ. 4M.9:EK[$F76
MJJ]\>Z\AR[>WC<"O1PO5^[L.R1-G0;1<,FI]'*+E]OV93Y8B/"9LD().(3X\
M_/%D.!@,!Z>#P4EOY6-"%XX_GIR?]*( &"6KV&*=])X174%@FV\#4Z4O'4HI
M&N>_#S3RGDI!>&,>"/Q*L._"4J'?OE:A>6*/%(9WKQ8&T2@SQ>3]:\6$9W*1
MPO#!/!CRXI=\E[B;(J;R_OCJY.68UZ?B7[P:\:M7:'92@]RO16J^];)4<K,#
MP<,%HGW+G[OHF8IN=M17+GK1@G4JO8'A'I_T97L.J?@&!GY\XA?N&J6R&QCM
M'6SVD<-O<J0T,'XKD5)BPSB%PL 8KAB*\MR 5&@# [EBH2MR.U*I#8S?BJ56
MR-S9(7)N8&Q7C A?ZE8JO('A7<D@R$_!2Z4U,*++S[C)KE[QY5"F(!@8V%6"
MP)4BFT)@8'!7"8%P)G0*A['Q7@D<E8GOJ?B2@>!/9X?2W\/?C1^\V'T83&:)
MUX=OMQ"(GL HI]:YHQ@%[.K8<4:N2WTH\J!5%RS,E0.A!0Y"RL,:)99':!>:
MDZ*>[)0 P?"CCN0&K9%+6, L(50%(:TY3TFK0GO4.2_KP7^-O$B,U?0=;?FJ
M$%61+4#QYHB$BE11TB%-O/"+V&0)0F;D@S&2$*64C)Z3'VMHD@ZQ&$3!-/K<
MUW7P78LBM:Q#D_VVZ3:AE*7)OJY'9VA[C]9+@M8U.*"96/IA(0E]_%.\[B D
MC',V(KJ'LXL'KM&,^&C') IN7\"I0L 'P]7?C"&"8/-#>!,B#9=U03QVQ3%H
MB TM8Q"%<II[\&+[DX%\28BFOC(Z:8H3NIRA+I4=U>^*W#J,2-[R;!9LHU.K
M- -8XNN-3M:J#H1(1;AF=)*6D/BET;947E9GS)$0#E43**-SL\JB:I(W^34Z
M,XM3VIQ5":F,K,[H>_$:#>%>2S(Z.XL+ -X50N5LK0XL9>\EWF;'@<J*=B'1
M3B]L'W.M:WVO(/MYBFS7"@(\PW$9K2OG?U$<A]#8[VHR&B=[3I-9)M-$XLQ?
M@TQH6R,M8+]X>RX5)(Z8BP6M'=.:F6H;X[KAT2M9,^LQC9UD/ 1,!OQ2,NT[
M:1XI26$_&+TN)"BZZ-D9 Q-QA P/)S0UVU^C%Y2:P%<Q9I!:6>IW+;"V@L6=
M2Y[K":@/B74[D-YQJV=;RJ<K4S<H_CGVTB,V;*U"<'.IBIAP29MCF@4'OW@8
M%:.G:5OP$+):2E2)T6U'TCC;<?] $UTN.#KGHR:X0#,U:*=\72LA<BWV6)JD
M+%ZKCIMD[7;BX' !9\J)).%V>B=))][:W-RT8K7.XFM!A_2?+?\["NF02$.@
M3Q;V1&>AY71TEI*K(<&EDI0.>;;H3;P;'*Q(P.HU3&:Q<@Q%Q*FBI*T<YW@)
M6N^SF&UA^7,QAU1$0=C"@9&DH>%V#W%O^XQ.#'9FB=T8P>TX92GK*G2)V!1H
M22!B^<V*-8!>AL&\(E@>,$E+'"V#=)=9K'<D6Q#NO7*G$7< ^TH@I5"*K)9"
M9Z#DZ!I:=>@4%]IEL JEF1=0T&.1859N8]8B_.[&^@$18T9%Q,PR#SU-A:S!
M#XCZR.Q;FKBT$7)8B@Y=Y@"HMB=B)K,\ARTHC"AQ+3);&V99'LF5_6N$?51^
M,$I(8E'2PK;MJ(6,J1Q[A\==.2V;*-%6>JGHO)92_Q03;6/T36:%1]-5QETI
MV5;ZLAXQ!:CJE#)9^'DD,"N@Y\UI.2V(&J@%4/;5\FWH1 #8F*)5Y-L+X(.E
M*\@4O^6AIGN4CH,@HBF&DQG#.?CF.<B'(![XQ&OJX/+AIQH)EC0Y9L]XGZQR
M#E+RC^L&&-%SC&V5].ID=D^\^2/RETEA018ZIV6V!$^Z"9#5M%5/IP/08VOL
M(.=Z _,$9^SMRHF)S1MEJ+8H91P]U"UE+M46I91< Y"AJNOJKH,2$5/ V\<V
M^)FDA,3^!YDGOR(?$^=P$7-75P1^65C>'$W!9]W.9L@6\O.Z.6M_I[NEOB!R
MVFEV&DM7H<XU=T;GQW06ZES_:72JC$3X022C*?44&'.!:C@@-_O@EAJR'',_
MPP]TU8*/^#J U-FOKJ-6-N/(08UGQ4CJU-AKP4ED ='HRM\UZU/Q<K+4633#
MU4EB9T'JH)KA,$EO'DD5(G\M8(GO+1I=N5QB$6H?K=VVLM$5S-5@X,L.,+K,
MN1I E4&CB371Y2"12O@QNF"ZFNK(9G=)E5OONA.KUBVI/$"I(NV&8U65VVET
MF78U2*J2=J6*N+\2=:G,SS:ZYKL:-N6)^%)UX%^)UL@>PY J'&\X9I+G=:2*
MRAL.5;%Z%1S)DBH];SA(0F?R4H!^=X&VTJG+%#<#:Z'5C1O7/6_GKV=56]V@
M9TYL[P!Z\[N+NSG.WJ?H=+;@&IV9NR2(?)3L.5KNKC3"#;W@UPWV+\T)ME'/
M*.NLXD>W,)64CFBDO3:K2]0KD*[*6/GWXO#6P3IX6\L1L8@MB"B7:2BGH^<8
M.2@+S1%Y0&'HHF0#WT9X+5B^0)"@^"&C6&WOL<V6HQ#_0:*<%_4@&R^C*:)9
M2$06P=TV^6>87H/-H7TE!F4^!3W''A@#.QT3.ZEP^*Y&CJ?"QZ4RK\GV] /R
MUZ#U@@,E?4NZW6BU<I.++3.FC;=$3R45B>(@29\GJ_UI0E-\T2@76U5$9-&"
M'S8\B&U6+'>4_/KH4]>==(4:D%(-:!P;Y?<?"H^9<G+MQ_DB4A/E?C0Z$5X<
MJJI!:G2RNK3F%)M2HS/*Y?'8N3BCK^$0E#\WMC ZGUL-@$PD*)6V;2@*57&\
MT1=Q2&I$R33+Z)LZI%5C;[9L=#:UM$9P+6,8?9V')#3EBU;*UWH8B$CIO>TB
MB= =7&TO.&/Q!87UKK+SMM/YU?5*0?04SHN6$1N?//G%M92^J:]-3054\IO_
MY(N71RNEU*HT@E<KE]/I@GWFD)/P]XWAJR-B8-0W0-5O4>V$<X.HW_+FF&:F
M,-]=LT^K)-]Q5U;,OP:+!ER!YM_C-<V!V.<CH\>R)3EEJ.NPXR5\"?NE:EJ:
M=D$/E6A7(.,3(<XS=ET1J?CHM6^<A>0F(KUFM,]J );" ?M*O%1F<EFG=RHD
MVW&O=,RWWBRES\ B<B$F0B0*TBQIR:RE0FKZ]U_E9"FFH:70>'Q69 ,Q+#UJ
M),+XT:MZ2DT>U)8ZJ"@EUP<B5#5F*6R3P+DO'JFS-6VW>B9^3-40%/=1:]?:
M%4JFFI5PT%5&!S252,D,4J.S%+@1.;+ 1B<C<(M=[#&-3D;@EI\G^E'.2NA$
MY)X<=MIFVM<9O9>2[G@$G\^[-G]]= )-^MQ!,24]MUE[X%$BFZW5"M\VR$-%
MAQ3W %Q<MQ,<),0+,C(4TQ".=I,^O:-;_PL<(%K&*?C&MH*WZ^&/U@MW2C4_
M.5E.2\*O$0FXXVYN:K)\WEM/Q*=M;W;["+3^:)*8*,9E%2U=5Y,QP,@,!0'S
M1#191D)[JRAIE ;4T_+E+&(1!8W<7Q,/(@,%Y@\):.1=S1UQ>Z(V L-J"4EE
M3Q@]190!X&@<&3TEE$&@T!X:/4OD0H+?TQD]8Q3$HCHV,3J771 -CI#2Z*1V
M(9-1/ $P.IE="(.RB9S1.>Q"*%1-S)53V3NQL)0MV)"1LO;MX:HF.K[05"Z#
MK@6GA\AS_$T-ZTW%A'3>4T^/C8W@)PYEZET4$Q%>6-@=[4RO?A'@J(* ENW#
M_#)&,NI104G;9F@-6M[-26R5=(2_,XR>RW+@4#&RC)[("JA!B:DS>@8K,A+*
MO9;RY+43L5A:.#PNZUM[$GD%^8['8,7\:TFWLES\&TT9W3)!2PH'M*:PV,6H
M%83T)%(? 9E?U3XM:B^65RU!O@VYMT>U581+:;34<XH]TP4_4"85X8'>Z#A(
M4GJN465TA,0)3(5!58Z06@D-QFP%+KE'+'.E&+T9*ZUJ_V OD!/1"^Q*'E()
M(1ICHV.A1OURZMCO+;T_+7LUF,#V+S=-+3O:!]SL\Y YK</.,WWS_,04T+%_
MC6;$IS=CJ(@OV6"7L:'&42LV!PUV )O8;=)+P(+PV@JPT@BIIJU#XJ*;.>\L
M[/]LN9%0>5,.8FW*E%$UJF4VF7L4\7_&=P/?"YYM56FENRC00=<\"G$K;:)0
MAXP2&P8'@_[ )$ $OM^6T"A4(M^T)'OVK48'K(N3CN C[(1U<:(5'PV"MSF/
MK0L=HJ_[I1926K^8R02@#^R0D0LSK>*<<7)&;WI51C*DGJA,:DNL]:&L#Z6#
MVR!-S/.L Z3<865BDJ?LE)_4OL(AE2C:F9'7)I"%3M+$7-,&<"Q>C34S&55T
MV7V:&7#TMK%XCV?BL<3UR:P<<IW[(#4R:OA.21U(M+J7PDS4-&.@ZMI0R27<
MQNIX 4NLQQH0-:';,4EI!PAF4\A0[YY?$L"$RS/E];71^1E: 3O.6C"AX."(
M+)<X3(X4CHA'4Y81N MP!!1@?S.9W44P\T"?L8>7T9*E,W^U-LQW2/CE&MOK
MAGNM0R =%380:"<JR$K?L1.AJUF(_/\BR[_#:Z&=1\D&M%07X62M2;$[+#&)
M_,8D9K2[)O$C--Q8)R?$.R?S,VE,8DJZ2_)^ 1O_^(S<-?H,]G@A% G+M]$E
M!)J0N-7C<#6<@^M #WWSG"33EQ8^L^'1JR7]J[;N*FY ?]\%>V&/I')RDVQ_
MLB$J/5'N4Z/G9@IP%0YP([=FI6T[KP*5>BVC-V1U0+:+<(RNLJ,-J3CZ-7IO
M5A=6\>3(Z*U;;5"QF;/197QT0'6PMJ*\":MS(3(^*,:*5NT6SO8VE:6V 86I
M=F-1D9]M+2=7*3.T>7KA:[S$&=&R#K$^$B]A*\/T'?R)YT)I["JMZ#F_*\S?
M#?P2A-AN&(:TF8[B</L2^A88(^R!(H_!0K(J[_ F:#WP-Y<[S-T@&^U["QTH
MDYJTSNAI:/>!WEDYY=EMV^Y\]]DU\M ,RU1($2?;78=>P+>.2P/BXCN)9@$'
MR2T,"2,B=KB2E)9+$&(F6-49EJA$2\+6(%4508VRW2$8_/5(54Q*9P7!1&-V
M@T!>+%Z*.J7;TYP:9>2CJ[4?8VVJLQ\K*$H<=(L)%U#DS!WC)*31)M2 >14E
M?3,*)3$X^6\OP"R6CO!WQBL(M$MQX!QA1N[RB)FAG J255;1R(T<953X_*&1
M6S?J&E,1#QF]2</I H^M:W'T:_1.C#0>57,<HS==Y+6D<#YKZJ;*B"Q7Q*,;
M19,9*[\:&PGX+KZ%DZJ TB4"-;75N?4:*6$T3L!VC, OV\\2I4WN0:$LLMLP
M+#>X1W-Z)7,8NJP^KU!N9%TM2D_@=@W'.4/02,%-'X+S.0&Z.J?6)3A3I82?
ML37UG,0Z!;<P:L@&[7U=<P\+M=P66DFI=<OW-S/B/UN^HZSHN235-7G[P0U:
M^<C&6UBS]6%EE9F+M+H$^6D)"H.PA&"W1]_#PO+1-?#L9!_@+9?4;/NM()?V
M) F"^D9C&5D5?=YSXPT,2U'Z-<FR/YZF-"*=S.A=<0Q,)3&J2&O6N@QGGPAQ
MGK%++PD<>Z'ES?&3F[!U^+>D+LHVIA.371@K:);YZ+1B4]B96R7SD5!HA7M:
MKR<>[*Y+GBW/%CH-P46N%;DR>B%X%+^25'LV1-TP=&$-I$*VG(7#PJXPL\9@
M#4#DC3,CMR%$!W 9*(D=-7+CH08<\GVBV;7[N.*&?)V0#8>,WH7@Q4LZ@#9Z
M3T(9':Y9DM$;%!7A;9GY+9L%&UU^3P&36I9*E OR=1L\P26W'1J Q^\$#3&S
M,S0P&4=MB.4NA:=XO(9PN &3D[]#DL+V&J)GKN%5O<F6@F)0ODXCNL2UGYK"
M)1E"MY22,$4V\6SH==;D9):DYM",E"@D_F;WZ-0*D5I&@D)3G4M(D)%%PQK:
M[6R&[!"OT5[[^\R.%C#[0[3D;*WKHK4WK6/-D8?I&^1$-CL6QFQEW9@<D1?>
M<>)IY2$D]O><6-L+??P4"6REU=585WKW"Z$6@O; DXLR!A^\S0(,_@U:(Y>L
MEDBL0%3=+3>B$S2*C%CNU+_(4W!E\Y[ D*3=E1Z'#R5SKV2H=T7J_"1ML?T5
MM7:Z@L156.JLZP:DLKGV<,D[^JPN?C[5]N<$$AB0FKO:Z,-#S>-7;#N,WN=K
M'KA#IV/T=J <7/)QB9$'D_3IEDB8:O0^8J-ZQS,E,GJ?L7E%/)HH&[WIV#Q>
M0HLMS9VH2KZ@_SV!_O_]_U!+ P04    "  H@7E0.[^-=QE"  "HS00 $P
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M[23H*/OOEZ/3X]/CU\?O7I^>3X[?_W+Z\9=WQV\N3D_/+CZ<_M_CXU^.CTL
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MAJ]4'01%9S]=I-DKK\XH)G3^>8&JV8V55[T 7<V %-_^</PK!JO .;^GZ2;
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M(F[\G_0G 18V00%S\,YYPA&=;"7&R8;Q2GJDX&GRP\E8L?FQE.9UA6.1/0H
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M\HQ9Y%";F#<.'RA;(Z)W98S\%N*G&$49>K?ADCJ>7!RZ?I#75;I<9<,SNZQ
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MSR@D,CX@.WOD+?S0CQ,J\9_11D+"12P0L!I+D(L7J% .Q05M"R"-M,#KIC>
MZ6 /B'=#WB U5]O!R,3L#EB%E0^4ZG*L( (Q)YN'7Z"5>\=BSC-C8J76QI)-
M[6*DG70;*Y7R7098^$*SJG:IR#%H4%Q8?4S=>4:\A57:%+DFNJOJG>K.E.8L
M?]*=[#+1YF8+\KXY,/2AQXBWH&B:R"FO?X^;6+>X8;.W&B=:B+:I]B_ K(3%
MC&+&% CNXZ:OLW<:4Y.VORN=IP>!065;U=?@MZ#$**0&?[6KR)A2H)*IW?/*
ML0*) U/26[R@K.*1T6>9SQF,6QW5-I1)XW/6X[8X F/JG_5U1]6'<S#2S5%(
MFUZ=K<$M+517O#MU5W'CNYKE$%XFVWQ5G",B:]<JVQ )9U-)-J@ZPA.IR(IN
M#7+E=\-'60$J<_4Q 1^$8%@OJ]FDV\3>#S=8L#8K;6.NWM*!TK9X>D:^T<6Y
M1,GOE#EA2:T?4=Y4)<VPNC^Z'RV]D%R1W,0HUJW1*EADG@PU@:)(@V%(99(B
M8\@@161=-FI!]OM!J0!=4XP+MIA=GU@>6^JSQQDK!GD_@BH ,%[H-@\HVA9U
M)1\8(\Q]-G9G1&NUCH(-'\VU'HBQ@:>V"J-^D$I5:^4;1O^@5(;F\D4%T6:7
MJQ<@>J]J%"-U4#HR;[$N1O[05$.AVFJ,'2]&VNV6Q]NPX/1X:%IQ395#1O @
M==_J\I*,Z*$IN; "H8P/0]-QN2JZ%N3K#LCL3;MI++C+R!_4*6@2]UL%D1G]
M0]O]S86M"[H-CL>49@?<*S1>4&]DK?S*M[FT.OG"T/,UUEPC'XX]N"9N=51S
M'LZ\CFW^[B=S@9*68J UUJZX3R.7-G:+;\B!A!(L#AN<K2G:BXUKU42!JUBW
MST1VWN$X'H>TP<]X>A]A(OF2U7U CM6GOU)_R5L/%PI132T/["+D93ND ANR
M($(D@L":DU,/(9$7(OBD90=X2M\4UVB)8W\==R-0&Y<+$KRB.16QF:>+O'32
MT*/M=-;]"/E%=/5X@?K"5>UZU[Q_<!+JO%^[Y4 M2P3@OM3ZX&5_GZSJS74P
M^Z\_+:^*-N\<ZJOE"@B[&@"'+A<ZNUST6Q\N1?3RAI\(,;CJ3T&\DX/XF!*9
MGG$^:^(G?CI: 5O3N\2@_AK][G5FKI/=_Z$>M)C>Y7OK!&*RR8+4HZ&I/#G"
MV^]@V%M:RH3PO8=^M'>!YMM\/)"D:4-;UL!X>P=T5(J:07>BX#:,$R<(,GUV
MTYD8C&L5D$-'EQKN=VJK(]8_IT'";TIJ .4Y&Z9BG8GJL*4V^&ACT8,L:Q,4
M-;NUX6D)VY^-@.2\1X%=,KG '#I3U=BH$NS^^8"6:ZNM1Q;V 25^A+SK-"+:
M97Y7_>X$,.T4!-8<.A_G1%4$%4Z$P86__0(R-2O,<(6C)5X;5B E:]O!@#'[
MW7]V",0K% 2/]R,0-M5#X;?98I&2D[,BH$#35XP3JLH^7OAN#"T(7S40[A>A
MV\E[1-$SN0GC0F* $&F!H>),EI)AJ>[^%8=.*3V6R4>!JK-@T"^+7E65D6F.
M,[G2&"K0NK0U  1N\[5A-.,0Z*!4#U7"O=HL>1[.[0^V#V=E^Y1-+%*[NW+X
M$'H]'7HW''HW:.W=8&GWFX9',GRC<X&SIX>50;V5-O55!%E0/UR)9XE*N]SM
M(]#*9W_PH?."%%KT=EZ8$)F (P*1@ 7MY:J![5R,-VR,D?MFAI_?QLDRHBS\
MF/U$T?M8;NI&/OOC:L2#4O%5@:4\-,13T1 O,Z/@,=F^ 9ZM\BA)Z*YK@2&D
M+OR&G""9WSE/,12;VM$ZW<2'EGGZ6N8]NG/DI322M :5^'*U]1=H)VG!"32N
MX1VD2PX_+*5M<L DXLXK-O ..G(.#+@"N1V]=7JJ0&YP?BOL3L/-EZ\Q#70D
M$]RB^QC364'=X><M5GZJNZ"%VF+EI^9F,',7*R^><\;TSI!\FJO>SZQ<[XLY
MPEQ6#5:X5W<1'HV]\4XL:),%[YBS;U9D] Y C#4:?5F98G-S[T5$6VVW%)-K
M#DMNHW%R/L#3RN588AP8EOK=W/'HQ/BV*=*O[/8.?R<?K7AOR^[P=_+1?%6U
M_PY_)Q^'=_XA+4:T5]11+Q$JPYH*?KPSYQ7>U%VI*;2KFM;]?DJGVKO]<0D^
M45++A)JKT;5'&.*&>$U&H>D].^4?X^H8VH(C9Y8<Y,98XA*] K'0C!=V'/2>
M6%%FA/F"0#2<'O/D/S!&F*_\0=6>W?R3@E:#>R0(>UBV$WT*4BW0Z2&D5J=4
M%=1>#&MAV]/9-I2_TVUZ%Z?\KC$, 91V6'#C5/<#7B<WUMFFC!GF5D(7889X
M&Y1W[X9U2+@2PAGQULK&QC/1DJG/R+?6K--(?E/%A8)V[=J^]'V_7R2C(/9<
MM[-5.K&M<NU\J$=;H.G7N_>#6_^V.D",=-T6#E4W?4NY)L:080E]WH);!?WV
MMDNOHU]FW;2"309W!NM!?M:7S2L8<F&MU:!-8>!I)7,VL,=T4]>T,X-[)G79
M^\"RH8P=P[HQVD1!=<'8@AL6Q.X!#P*HI][9NV%=#%V;ZIV=#=.N5E.!NR![
M>$_*CG75"\[H#A]3]^*HJ9K/.#$XE4FHQ_*9P:W8A?D [E>QX<;YR> TR88.
M(P75IX/; US=7@KZSX9U7Q3N)\ZN/(P/P_(\L;!20 .F#3/>ZXZK[(D9O VW
M&!\&)QQ$.ZP5+-$=JZ?VT=G0.:_@B 5I*&*&2V#SQ((A_(JVPDZ?63S"' <$
MQY@>]63UF"X63K2B[<@7"QSF@1E4@8J>D4<.PVT<I]1P*]#X4]9D^:;0W >T
M,S$**J.L$:&87CE+/W&"/:1NTH00LT%MF\/-I5($@(.K)(W3)$Z<3$5=^XF_
M9Y&3P,*X[6 4%5M,(M\EHB%CVC>R4>.'QV]"91:; *F@Y1,Y>WB%\E,P7I8#
MVOCI: "BI&82W:[49.;11!HBT_/\JU*L[N6*?6?]/AS]<"(O^R=+7 @]JB5]
M=18(7OZJG_D/G!.;7U4!9X8!L,;8SD"U5<6R(WJYN@J<..Y0.ZP"C HZLOG6
ML^]K=SQW734 +;7 FHFI+ !6P?875^:K?@?CVC-F8OFNIL2C:MF"^Q><C%&Z
MO0E<64E:^&170;1>KWC,I0/:5$Y-%;M:5/^"919X+?IF&=>[CS',?',5]\4O
M\#)G?. V^*NV4NUO%<_S<Y1NPRF.%GDI"4&SE AT<^Q0(.R5]%%A_I7UD?OT
MDVAL?@SK6=<,1ZFA(T^_K19:7W'X3!8,Y9(IGF!RY,I_O\)Q\A4G?T?) W+Q
M+/3_B3P&*1^4V9(G<R?,+T$0FS0B:82YH>ZBR.VR-. ^2K,;91?_S]EE<!OR
M=TQ6CY/5NSPG@EPXZX_H]TZ,V-HUF%G-[9(2;8C\V$+(:%F1_?,[(;#(P@7M
M4[GS*N/44SO&3TT8/_BS>1*S8%0PR^0CH(]WN98]2I,Y49W)[O]&]+RH= 3H
M6R7>Z"_WY!F''BBIZT^H36I]5+XC2A4Y:<\H<HHOY$/@NU(;GD:?=WT:@,9[
M?BONJ22;-RL'8@ ',!MV0/&@V"Q%=K/=ADGDA['OPAN**\%'K!-S![1^S^_^
MT"N+ 69?R;.S./WQBG!1QZ-[',<^06*3BW$;%MEJ=5$@?;-*""6CS^LV_J-G
MQP_HPA,",E&JY(RVXF %!YEU:%<54,K$)C2,UH!9"H6@VB!G4BOVFM8=!MU7
M5=UGUV_C"L\+K MM.YR7$X16U1 1A[)8S0>J"X9E=5<4M2H88)S^"ZV(#N2F
M-'LC%L:J%0J\N^L//)GC-"8*V8T_31 *-W9/^DXGT] W)JSM*P2BDJ"BS,N6
M.>5&\.-3-5IU*!0\\*YJM));:)/V7T8 &D#7 *33_L9I)'N#MX-48BT0#M#4
M$90J"UM5@:";6:';>'O<(=C[Y88L'P*6&P*6A?G=);RYZZ1&G(0Z'.]$(J=E
MS*8ES%HBFZICLKONE9<7P2WI2-L5[WT(8S8YR-2F,&8SCMRV^LKB3G47/N7+
ML*A4VBNHJTB-T!YAS"538 26R=.=^=$N#!ICQ6'/;T:V?4V:>CC4#:85UD9;
M=TD=KOW?;FG"S>8P1J_N\P[+**B_VZI,E3:T? <?^U:S<D&U!:T(%*37M+H-
M"GY94%I/ ;]:G#\%MSX<N,7MQ2N89D'35].2!"\.28)\CGG&,?-ONY[L5O(C
M,8IVS2>Z%4.M3)43"L28J?L=;>T.;8I&8^P=P-6L50#L1TP6O#U]:5M7>7@O
M8[5N^[9-K(8%G3,>#T A52LJ0 D0!9_?F5^BN!\^<^3?%$S2WCG=ULVXFZ55
M</1\ (\GB5JKJIQ"QO\7+5[EI\T6C!V"K4ZMJ*A,X2[X:4&K^G[XJ:BJ0-$Z
M_OBEWG&J:V0PCK^T9T1GJ.#J+XS7+_6^TUC<J&"^!<$-_;\Q]@MP%?QY;T_5
MN.I/-TT=UKT;)KB( QA/U[WER(Z05EQ.'A(&UZ"30*2*\/8@"V NBX,*=$%Q
M[YP0!8*]XR@I449^VZ6*?/3'NM0E?XI&Q:"^<)OX"0U!N@T]_]GW4B<H&J;0
M59_[RPG^%"9$@O!G6 B!548?;])$P^ !IM(.+*EZ$ E26;G8DIR")3!R@3$B
MO>60Z#6$1"^N1H: +'A!P(I*-M1W+Q4JW- .3@5=.QW=[RC6Y*C CUP+((VT
M0$]2(QBU"91<S^ZUJDM^&D]WS4;TR=VE5XQ4!(PIZ]J*\/YS7%8!5\C46E(N
M^V)@9?ZEU.WUXG(Q^Y .F%,.6I:ER7,UM)-N8_(EWP6/@:J),?F4?7  J'X:
MT^_%/!%2E]JM/4#6BM3N(3@\)&53-%HTC,D#-8AA/+GP)^;+;L-23TX'$&^F
M/"E,=PZN.==B@W^!<<MH?;K=O5)'9ILSB#' 7"'>Q7F&*UU\C&KS9;$"RP"O
MUY;E@',KDF;$/.0W\<@E[PBZ1:2&,C3!-CU"H1)WDZN/[^>C+)&;A5+0CTH1
MU3NAU ^(GC/RNKS"(7E/N@F1(!,4+21TE-&#M=$UXM?TEC*$. D[5;D<0N@9
MX<9MR=M@V9Q,",2CIS@C1:H_MQLB-O"R_<R.9K,(S<CMJ:]M3@<D;5B#TD'5
MQ^,&))3W(ZI93<@15X&%#7NKYNC4WPU;25D&'')N3(U8C5HK2&4*@#+6RT3+
M"C[OY1D;PVH@9D9PF__J,$68V"4UY!!#GO3!%$=TH(&LWL+.!JZW*YW\?1'5
MXV0#A[=OG<\1CM64GV^:7EDX-JW<@KSK-"H2B_,T^\ZM6T6@V[!;A!J2]CBY
M93RC\O=&Z^VPA<$A=>.0\G!(>=AW$8OS^]#;YM#;IK^B"(?>-B;5Y#_TMCGT
MMGDQO6WLJP33HONR,),!5T?F>X'TP^W=>IW'YP=&=S,0L&X/!T[V;(%BK2(&
MS.I>Y2Z_E905FCWP6IWUGU6N-;^-DD;?C?I5*E<*/2R-I*61[!!FM4</*Z1H
MA2#1$<7R?!SP\NBXO<$B['3(MTOE"JB(>2NX>VYN:7Z%$8C]W-%U_1!./YC+
M="N%"D\$\8;Y[TX.S.\E3+Y@L 7):CVSHH;W3^T3/H%5J(8DD&)%S@:\(NU;
MO@/;9:9"%:O!WP93?U9BNE@XT8J6_=W=AH0I.7>HOD9^'T^W%#B)A9AEX6!R
MEF-G&BW(LSMD0QH=7\'];C,F7E9G--_>CLK]+N#N2B4:JKLK]9B#J@%E?2=
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M?\E47?O@U\VLW!+GT+TY$J!0@&'YX^!]E& )6WEH_K:;*UC>OJ/S&#-P]88
M&]:N"73O[B+%>.GP7=1TNOR!Q;RDH<?MY1BPX?AW:4 /KFY?MO<8R3I[ZY?T
M+-L08M^IA7C Y<_OQMV&QKVV\,:H2,V>]C8>;^!#3+<VDOPJV$I/I[M_UV3;
ML2G+V:YC!0,HSOP>.\@"'K.0;Q9'^L:>=X.ZJ;C"WK253=Y]FC:F?(J+V_[?
MU]SZ[9%G/RH%4F,BZL\R=Y07+&,O'SE )N:W-_C\"A'Z6X*_)K<PR' "HXLL
MV\-4;13J%6*2''N$.AN7*-[Q[Q00%(B 0\X?!G)<86GS><L+.J $_$V-$HL'
MPCPT;^ .ISF=;.9!+K]0'I9A=#S<*=/=*;'(4"4>X("^1,4(35C6=+Y2@@S9
ML!<0OV"T3_(@??D8(^(G:I%P\,LF]FX)<^;[)0[@0+[X?!\3>-1(WED=:1K<
MGELSI%,RWWK J>*UG]:OFABW(<J90S,44,#XXL[=#. 1\WAF;:1E:'MN?+Z%
MZ0,9$#ZE^&O^>(JWNR!1=.<>$2:&[A3IS+T+-,#A@,#SQ<^'*<*2=O.4#F3&
MA+U N-T&")WLLSB!F>(DI?6K)I9NB'+F\ P%%#"^^'DW WC$/)Y9&VD9VF(^
M?[Y+@R2+Z1L:?DZFF,P[?M\H=1S(<Y?&GT&%)0X)??'M 5JPC+E\I  96-]B
MWGZ$"&G-6YJ_:91':I+<)6T*XMO<I-/Z>-@V?ED:Z1C9XG8AWFYQ<IOC\/?;
MQX!\P'J?L[>Q9!:DN&DX*,EHGVI LKL-1 8*&.H1X+B@!NQ+!$@1B-7,Z3=9
MJ)<G)9KLQ=#U_A[%X4>$ ^F7-AV_:&+TFB!G <$Q  /QQ?F[+(\'#>.5E9&&
M@6VX[2T,]RF!?/_A_B[.D?1]@</?TS-G6XZ#^V54+, ;\/[#F_MO00$XO]_V
MFAX/F<8G,PNGK0D'3/I4F]Y7^^V]ZE%__?=,-V"Y'*=[W8!CS.^MO58_V.6N
M6\4G"Q_N;X\:UYZ[7B0A3G<X915%Z(DG/,7[)$_))"E2O#(Y(LK$Y(.BG?EY
M _6(G0>3A)T"@0THN"\!(,<C5C2JYYRA?KH$6W)4V0NGN^#Y(H+DCYN8%^G1
M&0IZA9C0T2/46? 0/- $]&S(&*,*2UO/6UJ0*2,VQQGB(P&O61;D@;AMHSK
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MR!> K/P$_Y.;&\>5S($.N/_#.*ED1BTU!T1U0'4'E?*@TJZXY='6O_8C,W:
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M\]$2Z(<[?/9F7W 7Q)&X29(5309/]VE*_)V_N=><?JD+UGV-J0CDZO4M50-
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M^1S\)T[9'4W5?10EL?H3.P48!Q-L!G[,T$$%7Y3JNW\!3 -^.]F/:;@.V]C
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M-:L-2<ZHEO2!Z.#;*DPWY,V=GCL*2(WGYN/^W+Q\BZ"F,=JLOQ3'>^L-8-H
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MS%.RKH@CR'NQWD!$%R%W^'.,R.02)U M@%6%:CF1&HB3,"]4 &%=!S(<,B5
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M*)T2[0?%)_P$TX3=N[_=X23#['*RQ$O220]-A@G"<F;SDXSB%(M!-':-YYE
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M/,$,PWSY">:P2#),U6J[3_.43.*NTC?(3YT&#_TL =N?O8T0!:CG9N@O ">
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M.LH;NC/^S#9&RPA"&Z2O.@(IB@\</YC*55KZH6#N0F0X7!Q2 H85<+1VL<-
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M:J)D''6)>A>!DAF($9DQU6YC$^Z7V;F4;:0F^YL4A/TV)P$9<+<3+_/Y ?U
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M%J$II'..&E-OE@0YH-B!2"+H3"K&&ZCXQ;I6DFF:X*7(0940"PBUX"NCU\\
MG^O](4/O$-(=_9YV!_$YXZO;FO#^6)55PJH060C!,/H9T_,(RZI(-Q7<4MB_
MY&E5/C[],LUR,"*GIOP"+-[C_S<ZP+HRF/>N!<8J':P"&^1&0&0O'], OG&T
M\^?YM06&##@8L7#$K5"43(W+-=4^S2JRTP5P;,U"YAH^2(]2_!!W9S-Q4 +
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M"^-TM,Q2UJ!%6Y#ZFU5).LM6K["^20'E*X05V"85=MGD\[SI/TMK<$I27(/
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M*1XS2HPJE%'B[[KNE1T8OM2AA3FA:1*D41KG@)2DYMGG7*P2Z9CHGW[X\<<
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M$MF68J4KORM]'#<M'VU+X9G/(Q;50O83,XICM"N3%<RWDWS86Q\S6YCR0LA
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MBX7EJ  ZRVL<@7\KHOBBLB%-F9U:D@[K%B&?GE5I;$XS[4CLI.1E1Y*"<O>
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ME?Z-"<!2"[5 ^]%'#523:>:V_FPK$$/?!"4".1$JJ8DJ2-156P[NBDL-HL3
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M !NVUZ5Y6T&U9]P@3_SPE\ .%0"V#"'P2L82L.8\ =LV3B>X>9J/H&1\$;]
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M )ZNW(>]L7>)=SNZDXA9^;0UB'A<!'YX+2=7=1B_S91ZF\#3EER(R=A[PSG
M&,Y_V1N#UZ_,)'Y KH5-&)M5W_>'YLZP[8O (RK2\X!PYC_M#\\=<C=D3WUU
M\0]_*[3R-21ZE9[N)1'6&^P"62U\VAN+OV&;Z!'#C08$+GWIX_[$561C1+<V
MLH)4!09 ;NMH],;T[T3._,,A-O(3,CQRK3-O/2^ :M):(GU<#B.$;BR/W$3_
MB0SWVC&INY3[HEC[?7\;@XSG&O:M8Z+7?R#@(2M]W!N;CVAC>60LQX?<#:J_
M[8%)HFFHNGXZ[)ZQS<M=X:,>W3W1AHJ4X WY&??!;R#0.[MT_W=@-O-YCZQ&
MD "/><W'/;!Y3H8Q0TQL@]LL+7S4I\^4< +VDX;?]"&\\0MRSY^II%AQ7SD*
M'^79ROKPS]U5CJ3AKA)RY(\E!W[^22;^C;=[@ZJ'GU=;RTZ-X;6+=Y6\Q*/A
M*OBP:R+W[S^=O'MW\NZ7=^]^>K,G.Y%>[/[^T^E/;P*/,(/WE&W#IO]&/>DN
M,N^B>=>R&?+H$T,&A;\Y9C@*>YSA\6F:>-2(I!27D_?3QJ6D4Q@R7V9D"J9!
MBLWIAVEB4[#L4CS>3U3:5MOA#):)"MV:2U2*R]E$A6[]-9A!,U&IV^+32/'Y
M,%')V^RI2N'Y.&E!7'([,EPF+8D+/N,4E4\3E<.-3G^&SJ1%<>'U)D7E\Z0%
M<-7;6PK-ETD+W_SK*0-ETI*W^0T\ 8G<%*8,4BZP@6$R4?%;#D5)(3F9M.S-
MA@ZED)Q.6N:V1'\QE"8MA&L#_%)\WD]:_M:%;3)X)BZ*\R&X*2QGDQ;'E3'4
M*38?)BV7*X+A&3*3EL5U:0TI/!\G+8JK$U48.!,5Q/E$HQ2.3Q,5P.6$L!22
MSQ.5N]5)? R6B0K=^B3,%)HO$Q6X@.Q:AI4"^?L?;TM0$>/J3YD)X:'VI7._
MQ+0N@F6&4S=LFG;_M$7(3T,3&]+!^8D,F@S.P69KR%T2<;<VO.=P_0+OYXUA
M[*.P.V3[7O*38OQ=_.,_[BSCV;+) 43>N6.&_L MMLFN\J[_'9"-Q!.6QT^K
M/8BP^XRZS6$HKA^1;Y";BGEMN([E;+SS%1$" :W%8%ZAM;6RN (D(=14S"HS
M[L+?(I=ZX5VT143DOR JWG;H#GO>/?(7ZZ7Q"IDBF+22^9JF%8G;!\,R;YU+
M8V\1>SGC; =-D8.:BEEE!OS-L .N .+Z;X>1 9 P8QXJJG"W_- 4(/*4J D:
M64$L ")?H4M02T;%/#)Z05"=J.'S*K:/'JE2)O^U_'OLK/CSS?GH-,^D:-$X
M?_X1%U!R-HMGV]I$?F(07^TT5*"[V"/Z'.!L[I!!+,MX<0]B$',04[RS 74)
MFKY6LA)47W9CO9:$DG,:H"5^1*'N?S!<P2DT45%D&[D!N8QU6H<&(HKF0)_U
MO ?C8#S;2&P"E12&.;TB5D(3%<6SJ+QU=9Q3"TTEN\SS2I?VEET5?Z%,FD8#
M"NJR:@(J>+]U?,/96.3@Q>,C__IU90<T"N@KQN8/R^9*KH714S&S:)_&[Z1D
M&_]N^5L<^(_(,"W[<(5\Y.Z(340XO3$L-[R:G.^H)(),M\,@ZBVNL-+F8OW=
MB]9&W-HJ$5(QEP<7$R;\PX-M1'43"?1[>J>YATVEF8X2:?9B6':X)[#[9-B(
M;9\K].RSOXD)$Q'JZF2XB(&0_U %K[\BVUSB;X8?QE@PS 2X;R4UIATGLCI0
MTFID!=H;EGG]ND<.$5*.F=&P G/D(J?$'V1X6^K!(?^A8NN%X$U].OZEX;H'
M(IWASCD^@LKE@XC)6D- '>_B3*OE-GUW6JS3TMP/.'J#%?.2\M ;[+E5:-JX
M?HE8JK6>+_<MF[J$3.G$L21C/8-@^"06!DM9W9.0P;AQZ5V&VA2.(P=J8(N,
M93#K&:$%1K#59M<]YQN^YVK.Y ?Y44G8-^QQX2/C,&9OXRPU? IZH%D!-/EJ
M=$^AY\>IQ3W'\L:G(.";@.K@KV4@3D'F-X'(Y^/7O5@!X'16/^^PN@53%_/)
M8QU#1+Y 'Y/9(.J)X'^4U;WP@_#3=S6:]2X,%6'UX\"/Q\JO"=5@A1'T-L3
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M72,"+])Y#7FJ+7!BC@O<YG-AL:%Z%\MJ]%AAL).-P::W3I !6\;ORF#36QT
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MH6[&(9CTX/)-%(Q*F0=::GTCKJZ0MW*MJ 3.^B+P+ =YWKEI6M%LL@"']0Y
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M9,AB)/=\'CH^.HI"-:.Z@LB\0F2)">9T@<F?;10*%(=6R28:X:^H>UD=P\#
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M$2_)?RU?8!X-1$3]&LYF\6S'I@> HQ8"2G9'KG5#LJX'D>W10FGV&<FT05K
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M=RX30R]6N[B)RE"S@-8PJZ<!WB?7]A/:!(Z)+PW;6F/7L0S0[FCXOJ^"CF1
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M[;.XTZH@!/6?*WF#H=(N>B"![ZF*CU7P7'C/$1>3+80&G M46#:2@<?W$)F
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M89>8N@E\,IF$-4'7%"]Q)8XWV_"\Q3KDJ_QJP3.O:@)@-TU&AL2IL[^'5:.
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M#)Y^X*X<,0H2^%DX71'*4#@ZJ2 KE[/C\"/'[>)09AV:$-K+\',"])P /2=
M\Z9#"1\VZ5G173F94Z4GGBK==0/-^=-21<*<5#TG5<])U9I K5QD]'(UF$H/
MSSZO=7+6J/[:RQHF:JZ%>W19X':OS+3[K?8+<\89-^U.JSW#G/7"3KO/:K]
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M2P$"% ,4    "  H@7E0=:]_1E@>   &70$ #P              @ %W4P(
M;FLM,C Q.3$R,S$N>'-D4$L! A0#%     @ *(%Y4%F:Y9JR%@  >W$! !,
M             ( !_'$" &YK+3(P,3DQ,C,Q7V-A;"YX;6Q02P$"% ,4
M"  H@7E0.[^-=QE"  "HS00 $P              @ '?B ( ;FLM,C Q.3$R
M,S%?9&5F+GAM;%!+ 0(4 Q0    ( "B!>5#'_ (H"+<  '+]"@ 3
M      "  2G+ @!N:RTR,#$Y,3(S,5]L86(N>&UL4$L! A0#%     @ *(%Y
M4.JVC74:<   '(T( !,              ( !8H(# &YK+3(P,3DQ,C,Q7W!R
;92YX;6Q02P4&      8 !@!^ 0  K?(#

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>120
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6661347520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments Investments in Debt Securities - Additional Information (Detail) - Security<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_AvailableForSaleSecuritiesPeriodOfUnrealizedLossPositions', window );">Available-for-sale securities, period of unrealized loss positions</a></td>
<td class="text">12 months<span></span>
</td>
<td class="text">12 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_AvailableForSaleSecuritiesPeriodOfUnrealizedLossPositions', window );">Available-for-sale securities, period of unrealized loss positions</a></td>
<td class="text">12 months<span></span>
</td>
<td class="text">12 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_DebtSecuritiesMember', window );">Debt Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1', window );">Number of available-for-sale securities in unrealized loss positions</a></td>
<td class="nump">14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nk_AvailableForSaleSecuritiesPeriodOfUnrealizedLossPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Available for sale securities period of unrealized loss positions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nk_AvailableForSaleSecuritiesPeriodOfUnrealizedLossPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of investment positions in available-for-sale investments in a continuous unrealized loss position for which an other-than-temporary impairment (OTTI) has not been recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27290-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_DebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_DebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>121
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6900062608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Summary of Loss Before Taxes (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">U.S. loss before taxes</a></td>
<td class="num">$ (65,286)<span></span>
</td>
<td class="num">$ (94,423)<span></span>
</td>
<td class="num">$ (94,734)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">Foreign loss before taxes</a></td>
<td class="num">(600)<span></span>
</td>
<td class="num">(2,306)<span></span>
</td>
<td class="num">(2,182)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="num">$ (65,886)<span></span>
</td>
<td class="num">$ (96,729)<span></span>
</td>
<td class="num">$ (96,916)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68072869&amp;loc=d3e41242-110953<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>122
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6920058080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Options Outstanding and Vested Pricing of Exercise Prices (Detail) - Employee Stock Option<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2019 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding, Number Outstanding</a></td>
<td class="nump">4,506,950<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Options Outstanding, Weighted- Average Remaining Contractual Life (in years)</a></td>
<td class="text">5 years 9 months 18 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Options Outstanding, Number Exercisable</a></td>
<td class="nump">3,973,614<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Options Outstanding, Weighted- Average Remaining Contractual Life (in years)</a></td>
<td class="text">5 years 6 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">$0.42</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Exercise Prices | $ / shares</a></td>
<td class="nump">$ 0.42<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding, Number Outstanding</a></td>
<td class="nump">589,660<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Options Outstanding, Weighted- Average Remaining Contractual Life (in years)</a></td>
<td class="text">4 years 10 months 24 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Options Outstanding, Number Exercisable</a></td>
<td class="nump">589,660<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Options Outstanding, Weighted- Average Remaining Contractual Life (in years)</a></td>
<td class="text">4 years 10 months 24 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">$1.76</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Exercise Prices | $ / shares</a></td>
<td class="nump">$ 1.76<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding, Number Outstanding</a></td>
<td class="nump">699,060<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Options Outstanding, Weighted- Average Remaining Contractual Life (in years)</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Options Outstanding, Number Exercisable</a></td>
<td class="nump">699,060<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Options Outstanding, Weighted- Average Remaining Contractual Life (in years)</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">$2.00</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Exercise Prices | $ / shares</a></td>
<td class="nump">$ 2.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding, Number Outstanding</a></td>
<td class="nump">962,780<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Options Outstanding, Weighted- Average Remaining Contractual Life (in years)</a></td>
<td class="text">5 years 1 month 6 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Options Outstanding, Number Exercisable</a></td>
<td class="nump">962,780<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Options Outstanding, Weighted- Average Remaining Contractual Life (in years)</a></td>
<td class="text">5 years 1 month 6 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">$3.07</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Exercise Prices | $ / shares</a></td>
<td class="nump">$ 3.07<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding, Number Outstanding</a></td>
<td class="nump">800,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Options Outstanding, Weighted- Average Remaining Contractual Life (in years)</a></td>
<td class="text">8 years 8 months 12 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Options Outstanding, Number Exercisable</a></td>
<td class="nump">266,664<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Options Outstanding, Weighted- Average Remaining Contractual Life (in years)</a></td>
<td class="text">8 years 8 months 12 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">$25.00</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Exercise Prices | $ / shares</a></td>
<td class="nump">$ 25.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding, Number Outstanding</a></td>
<td class="nump">1,455,450<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Options Outstanding, Weighted- Average Remaining Contractual Life (in years)</a></td>
<td class="text">5 years 7 months 6 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Options Outstanding, Number Exercisable</a></td>
<td class="nump">1,455,450<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Options Outstanding, Weighted- Average Remaining Contractual Life (in years)</a></td>
<td class="text">5 years 7 months 6 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price as of the balance sheet date for those equity-based payment arrangements exercisable and outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=nk_ExercisePriceRangeOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=nk_ExercisePriceRangeOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=nk_ExercisePriceRangeTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=nk_ExercisePriceRangeTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=nk_ExercisePriceRangeThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=nk_ExercisePriceRangeThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=nk_ExercisePriceRangeFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=nk_ExercisePriceRangeFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=nk_ExercisePriceRangeFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=nk_ExercisePriceRangeFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>123
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6814490944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_ScheduleOfCommonStockReservedForIssuanceTableTextBlock', window );">Summary Of Common Stock Reserved For Issuance</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes the common shares reserved for issuance on exercise or vesting of various awards at December&#160;31, 2019:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:60%;">
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding stock options</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,506,950</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding RSUs</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,139,428</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:78.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding warrants</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.9%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.64%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:78.44%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total shares reserved for future issuance</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.9%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.64%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,646,378</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nk_ScheduleOfCommonStockReservedForIssuanceTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of common stock reserved for issuance .</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nk_ScheduleOfCommonStockReservedForIssuanceTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>124
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6814656688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Statement Details (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_FinancialStatementDetailsAbstract', window );"><strong>Financial Statement Details [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_PrepaidExpensesAndOtherCurrentAssetsTableTextBlock', window );">Prepaid Expenses and Other Current Assets</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2019 and 2018, prepaid expenses and other current assets were made up of (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid preclinical and clinical trial services - with</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; related party (Note 9)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,021</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Insurance premium financing asset</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">757</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">339</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid supplies - with related party (Note 9)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">467</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">532</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid services</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">440</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">230</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid rent</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">392</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">536</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid insurance</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">372</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">343</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid equipment maintenance</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">251</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">329</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest receivable - marketable debt securities</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">222</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">473</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid license fees</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">78</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">104</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Insurance claim receivables</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,882</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Due from related parties</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">90</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,105</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,900</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Property, Plant and Equipment, Net</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2019 and 2018, property, plant and equipment, net, was made up of (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Construction in progress</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,480</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33,406</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,087</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Buildings</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,690</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">59,356</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Equipment</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,434</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,878</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Software</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,195</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,264</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furniture &amp; fixtures</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">383</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">381</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">79,108</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">88,446</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulated depreciation</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(18,607</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(11,561</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">60,501</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">76,885</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_ScheduleOfImpactOfAdoptionOnPropertyPlantAndEquipmentTableTextBlock', window );">Impact of Adoption of ASC 842 on Property, Plant and Equipment</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The impact of adoption of ASC&#160;842 on property, plant, and equipment at December&#160;31, 2018 was as follows&#160;(in&#160;thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.24%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2018</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.24%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Adoption of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ASC 842</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Increase&#160;(Decrease)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.24%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">January 1, 2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,087</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32,014</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36,101</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Buildings</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">59,356</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(39,893</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,463</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property, plant and equipment, gross</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">88,446</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(7,879</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">80,567</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulated depreciation</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(11,561</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,293</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(10,268</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property, plant and equipment, net</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">76,885</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,586</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70,299</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Intangible Assets, Net</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2019 and 2018, intangible assets were made up of (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Technology license</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,042</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,042</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less accumulated amortization</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(9,042</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(8,477</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">565</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock', window );">Other Assets</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2019 and 2018, other assets were made up of (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid preclinical and clinical trial services - with</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; related party (Note 9)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,075</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted cash</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">179</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">179</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Security deposit</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">113</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">113</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid rent</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,205</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,386</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,527</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Accrued Expenses</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2019 and 2018, accrued expenses were made up of (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued bonus</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,002</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,079</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued compensation</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,064</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">943</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued professional and service fees</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">975</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">912</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued laboratory equipment and supplies</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">640</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">678</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued preclinical and clinical trial costs</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">281</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">704</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued franchise, sales/use and property taxes</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">200</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">250</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Litigation settlement accruals</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,000</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued construction costs</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,341</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">181</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">197</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,343</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,104</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCurrentLiabilitiesTableTextBlock', window );">Other Current Liabilities</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2019 and 2018, other current liabilities were made up of (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease liability - current portion (including</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">   amounts with related parties, Note 9)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,206</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financing obligation - current portion</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">757</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">965</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred rent - current portion</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">598</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">104</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,981</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,667</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeTextBlock', window );">Investment Income, Net</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net investment income is as follows for the years ended December&#160;31, 2019, 2018 and 2017 (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the Year Ended December&#160;31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest income</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,643</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,317</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,225</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Investment accretion income (amortization expense), net</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(463</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,597</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net realized (losses) gains on investments</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,642</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,857</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,665</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nk_FinancialStatementDetailsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Financial statement details.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nk_FinancialStatementDetailsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nk_PrepaidExpensesAndOtherCurrentAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Prepaid expenses and other current assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nk_PrepaidExpensesAndOtherCurrentAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nk_ScheduleOfImpactOfAdoptionOnPropertyPlantAndEquipmentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of impact of adoption on property, plant and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nk_ScheduleOfImpactOfAdoptionOnPropertyPlantAndEquipmentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment income, including, but not limited to, interest and dividend income and amortization of discount (premium) derived from debt and equity securities. Excludes realized and unrealized gain (loss) on investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(a),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCurrentLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCurrentLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of noncurrent assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>125
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6814509264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefits<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Compensation And Retirement Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">Employee Benefits</a></td>
<td class="text">
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">14. &#160;&#160;&#160;&#160;Employee Benefits</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Defined Contribution Benefit Plan &#8211; <font style="font-style:normal;">In December&#160;2015, the company adopted a 401(k) retirement and savings plan, or the 401(k) Plan, covering all employees. The 401(k)&#160;Plan allows employees to make pre- and post-tax contributions up to the maximum allowable amount set by the Internal Revenue Service. The company, at its discretion, may make certain contributions to the 401(k)&#160;Plan. We made contributions of $0.6&#160;million, $0.5&#160;million and $0.4&#160;million during the years ended December&#160;31, 2019, 2018 and 2017, respectively.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Compensated Absences &#8211; <font style="font-style:normal;">Under our vacation policy, salaried employees are provided unlimited vacation leave. Therefore, we do not record an accrual for paid leave related to these employees since we are unable to reasonably estimate the compensated absences that these employees will take.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for pension and other postretirement benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI http://asc.fasb.org/topic&amp;trid=2235017<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>126
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6895577056">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments Investments in Debt Securities - Accumulated Unrealized Losses on Debt Securities Classified as Available-for-Sale in Continuous Loss Position (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Available-for-Sale Investments, Less than 12 months, Estimated Fair Value</a></td>
<td class="nump">$ 11,021<span></span>
</td>
<td class="nump">$ 32,010<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Available-for-Sale Investments, Less than 12 months, Gross Unrealized Losses</a></td>
<td class="num">(3)<span></span>
</td>
<td class="num">(26)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">Available-for-Sale Investments, More than 12 months, Estimated Fair Value</a></td>
<td class="nump">4,245<span></span>
</td>
<td class="nump">29,373<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">Available-for-Sale Investments, More than 12 months, Gross Unrealized Losses</a></td>
<td class="num">(8)<span></span>
</td>
<td class="num">(232)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate Debt Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Available-for-Sale Investments, Less than 12 months, Estimated Fair Value</a></td>
<td class="nump">11,021<span></span>
</td>
<td class="nump">32,010<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Available-for-Sale Investments, Less than 12 months, Gross Unrealized Losses</a></td>
<td class="num">(3)<span></span>
</td>
<td class="num">(26)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">Available-for-Sale Investments, More than 12 months, Estimated Fair Value</a></td>
<td class="nump">1,497<span></span>
</td>
<td class="nump">26,663<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">Available-for-Sale Investments, More than 12 months, Gross Unrealized Losses</a></td>
<td class="num">(4)<span></span>
</td>
<td class="num">(186)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnderlyingAssetClassAxis=us-gaap_AgencySecuritiesMember', window );">Government Sponsored Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Available-for-Sale Investments, Less than 12 months, Estimated Fair Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Available-for-Sale Investments, Less than 12 months, Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">Available-for-Sale Investments, More than 12 months, Estimated Fair Value</a></td>
<td class="nump">2,748<span></span>
</td>
<td class="nump">2,710<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">Available-for-Sale Investments, More than 12 months, Gross Unrealized Losses</a></td>
<td class="num">$ (4)<span></span>
</td>
<td class="num">$ (46)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118955579&amp;loc=SL82922890-210455<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27337-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=118942371&amp;loc=SL82922954-210456<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27337-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118955579&amp;loc=SL82922890-210455<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27337-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118955579&amp;loc=SL82922890-210455<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=118942371&amp;loc=SL82922954-210456<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118955579&amp;loc=SL82922890-210455<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27337-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnderlyingAssetClassAxis=us-gaap_AgencySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnderlyingAssetClassAxis=us-gaap_AgencySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>127
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
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M/_QNPM9I<S#_V/@JV+7PZRZZ+U!+ P04    "  G@7E0F5R<(Q &  "<)P
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MA_.!X4&KTWCV$4T',,M_4$L#!!0    ( ">!>5#6Q15L#P0  #P3   8
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M/'0*I"+BFPJD4I8H4N-JC"<-\!0XGC0HGI0XK\,JGO.A*M61/;+&F-( 4_Q
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MZ/S+QOXWB Y\*LF-'Z'.?[#5D-"X<'SOSV8>L]EP."P_B*W?N/P#4$L#!!0
M   ( ">!>5#?[5$CM $  -(#   9    >&PO=V]R:W-H965T<R]S:&5E=#$P
M+GAM;'U388^<(!#]*X0?<*QHV^M&36ZO:=JD33;7M/W,ZJCD0"S@>OWW'="S
M]L[T"S##O#=OAB&?C'UT'8 G3UKUKJ"=]\.1,5=UH(6[,0/T>-,8JX5'T[;,
M#19$'4%:,7XXO&5:R)Z6>?2=;9F;T2O9P]D2-VHM[.\3*#,5-*'/C@?9=CXX
M6)D/HH5OX+\/9XL66UEJJ:%WTO3$0E/0N^1XRD)\#/@A87*;,PF57(QY#,;G
MNJ"'( @45#XP"-RN< ]*!2*4\6OAI&O* -R>G]D_QMJQEHMP<&_43UG[KJ"W
ME-30B%'Y!S-]@J6>-Y0LQ7^!*R@,#THP1V64BRNI1N>-7EA0BA9/\R[[N$_S
M3?I^@>T#^ +@*^ VYF%SHJC\@_"BS*V9B)U[/XCPQ,F18V^JX(RMB'<HWJ'W
M6O*$Y^P:B):8TQS#-S')&L&0?4W!]U*<^"LXWX>GNPK3"$__49CN$V2[!%DD
MR/Y;XEY,]B()V_14@VWC-#E2F;&/D[SQK@-[Q^.;_ V?I_VKL*WL';D8CR\;
M^]\8XP&E'&YPA#K\8*NAH/'A^ [/=AZSV?!F6'X06[]Q^0=02P,$%     @
M)X%Y4#VA5GRU 0  T@,  !D   !X;"]W;W)K<VAE971S+W-H965T,3$N>&UL
M?5-A;]P@#/TKB!]0+ERNK4Y)I%ZK:I,VZ=1IVV<N<1)4"!F02_?O9TB:95NT
M+X"-W_.S,=EH[*MK 3QYTZIS.6V][X^,N;(%+=R-Z:'#F]I8+3R:MF&NMR"J
M"-**\=WNEFDA.UIDT7>V168&KV0'9TO<H+6P/T^@S)C3A+X[7F33^N!@1=:+
M!KZ _]J?+5IL8:FDALY)TQ$+=4X?DN,I#?$QX)N$T:W.)%1R,>8U&!^KG.Z"
M(%!0^L @<+O"(R@5B%#&CYF3+BD#<'U^9W^.M6,M%^'@T:COLO)M3N\IJ: 6
M@_(O9OP <ST'2N;B/\$5%(8')9BC-,K%E92#\T;/+"A%B[=IEUW<Q^DF/<RP
M;0"? 7P!W,<\;$H4E3\)+XK,FI'8J?>]"$^<'#GVI@S.V(IXA^(=>J\%3PX9
MNP:B.>8TQ?!53+)$,&1?4O"M%"?^#YQOP_>;"O<1OO]#X>TV0;I)D$:"]+\E
M;L7<_96$K7JJP39QFAPIS=#%25YYEX%]X/%-?H=/T_Y9V$9VCER,QY>-_:^-
M\8!2=C<X0BU^L,504/MPO,.SG<9L,KSIYQ_$EF]<_ )02P,$%     @ )X%Y
M4!^>22"V 0  T@,  !D   !X;"]W;W)K<VAE971S+W-H965T,3(N>&UL?5/;
M;MP@$/T5Q <$FW72[<JVE$U5M5(KK5(U>6;ML8W"Q0&\3O^^@!W';:R\ #/,
M.7-F&/)1FR?; 3CT(H6R!>Z<ZP^$V*H#R>R5[D'YFT8;R9PW34ML;X#5$20%
MH4ER0R3C"I=Y])U,F>O!":[@9) =I&3FSQ&$'@N<XE?'/6\[%QRDS'O6PB]P
MO_N3\1996&HN05FN%3+0%/@V/1RS$!\#'CB,=G5&H9*SUD_!^%X7. F"0$#E
M @/SVP7N0(A Y&4\SYQX21F Z_,K^]=8NZ_ES"S<:?'(:]<5>(]1#0T;A+O7
MXS>8Z[G&:"[^!UQ ^/"@Q.>HM+!Q1=5@G98SBY<BV<NT<Q7W<;JYSF;8-H#.
M +H ]C$/F1)%Y5^88V5N](C,U/N>A2=.#]3WI@K.V(IXY\5;[[V4--WGY!*(
MYICC%$-7,>D203S[DH)NI3C2=W"Z#=]M*MQ%^.X?A9^W";)-@BP29!^6N!%#
MD_^2D%5/)9@V3I-%E1Y4G.25=QG86QK?Y"U\FO:?S+1<6736SK]L['^CM0,O
M);GR(]3Y#[88 AH7CI_\V4QC-AE.]_,/(LLW+O\"4$L#!!0    ( ">!>5#!
MNM><LP$  -(#   9    >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;'U386_<
M( S]*X@?4.Y(ME6G)%*OT[1*FW3JM/4SES@)*H04R*7[]S,D3=,NVQ? QN_Y
MV9AL-/;1M0">/&O5N9RVWO<'QES9@A;NRO30X4UMK!8>3=LPUUL0501IQ?AN
M]Y%I(3M:9-%WLD5F!J]D!R=+W*"UL+^/H,R8TSU]<=S+IO7!P8JL%PW\ /^S
M/UFTV,)220V=DZ8C%NJ<WNP/QS3$QX!?$D:W.I-0R=F8QV#<53G=!4&@H/2!
M0>!V@5M0*A"AC*>9DRXI W!]?F'_$FO'6L["P:U1#[+R;4ZO*:F@%H/R]V;\
M"G,]'RB9B_\&%U 8'I1@CM(H%U=2#LX;/;.@%"V>IUUV<1^GFR2=8=L /@/X
M KB.>=B4*"K_++PH,FM&8J?>]R(\\?[ L3=E<,96Q#L4[]![*3C?9^P2B.:8
MXQ3#5S&O$0S9EQ1\*\61_P7GV_!D4V$2X<D;A?\@2#<)TDB0_K?$K9CD71*V
MZJD&V\1I<J0T0Q<G>>5=!O:&QS=Y#9^F_;NPC>P<.1N/+QO[7QOC :7LKG"$
M6OQ@BZ&@]N'X"<]V&K/)\*:??Q!;OG'Q!U!+ P04    "  G@7E04R FQ;4!
M  #2 P  &0   'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q]4]MNW" 0_17$
M!P0OZW33E6TIFZAJI59:I6KZS-IC&P6,"WB=_GT'[+A6:^4%F.&<,Q>&;#3V
MQ;4 GKQJU;F<MM[W1\9<V8(6[L;TT.%-;:P6'DW;,-=;$%4D:<5XDGQ@6LB.
M%EGTG6V1F<$KV<'9$C=H+>SO$R@SYG1'WQQ/LFE]<+ BZT4#W\'_Z,\6+;:H
M5%)#YZ3IB(4ZI_>[XRD-^ AXEC"ZU9F$2B[&O 3C2Y73)"0$"DH?% 1N5W@
MI8(0IO%KUJ1+R$!<G]_4/\7:L9:+</!@U$]9^3:G=Y144(M!^2<S?H:YGEM*
MYN*_PA44PD,F&*,TRL65E(/S1L\JF(H6K],NN[B/T\WAXTS;)O"9P!?"78S#
MID Q\T?A19%9,Q([];X7X8EW1XZ]*8,SMB+>8?(.O=>"\S1CUR T8TX3AJ\P
MNP7!4'T)P;="G/A_=+Y-WV]FN(_T_9J>'+8%TDV!- JD[Y:XA;G])PA;]52#
M;>(T.5*:H8N3O/(N WO/XYO\A4_3_DW81G:.7(S'EXW]KXWQ@*DD-SA"+7ZP
MQ5!0^W \X-E.8S89WO3S#V++-R[^ %!+ P04    "  G@7E0 SS\3+<!  #2
M P  &0   'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6QM4V%OVR 0_2N('U 2
MDK999%MJ.DV;M$E1IVV?B7VV48'S ,?=OQ]@UW,[?P'NN/?NW7%D ]IGUP)X
M\J*5<3EMO>^.C+FR!2W<#79@PDV-5@L?3-LPUUD050)IQ?AF<\>TD(866?*=
M;9%A[Y4T<+;$]5H+^^<$"H><;NFKXTDVK8\.5F2=:. [^!_=V0:+S2R5U&"<
M1$,LU#E]V!Y/^QB? GY*&-SB3&(E%\3G:'RI<KJ)@D!!Z2.#"-L5'D&I2!1D
M_)XXZ9PR I?G5_9/J?90RT4X>$3U2U:^S>F!D@IJT2O_A,-GF.JYI60J_BM<
M087PJ"3D*%&YM)*R=Q[UQ!*D:/$R[M*D?1AO;OD$6P?P"<!GP"'E86.BI/RC
M\*+(+ [$CKWO1'SB[9&'WI31F5J1[H)X%[S7@O.[C%TCT11S&F/X(F8[1[#
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M>W\VTYA-AL-^_D%L^<;%3U!+ P04    "  G@7E0-K<><K0!  #2 P  &0
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MK\-WJPIW";[[0^%AG6"_2K!/!/O_EK@6<_PK"5OT5(-MTC0Y4F)OTB0OO//
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M]OGX2VZD-&!3B>YL+IWMXG7!H3%N>K!S-;_E>6'DL+0I6?\5Y0=02P,$%
M  @ )X%Y4+ ^;6D5 @  G 8  !D   !X;"]W;W)K<VAE971S+W-H965T,C4N
M>&UL=55A;YLP$/TKB!]08T@(B0A2TVK:I$V*.FW[[)!+0+4QLTWH_OUL0QFC
MER^Q[_SNO3M?..>]5*^Z C#!F^"-WH>5,>V.$%U6()A^D"TT]N0BE6#&FNI*
M=*N G7V0X"2.HI0(5C=AD7O?416Y[ RO&SBJ0'=",/7G %SV^Y"&[XZ7^EH9
MYR!%WK(K? ?SHSTJ:Y&)Y5P+:'0MFT#!91\^TMV!^@"/^%E#KV?[P)5RDO+5
M&5_.^S!R&0&'TC@*9I<;/ 'GCLGF\7LD#2=-%SC?O[-_\L7;8DY,PY/DO^JS
MJ?9A%@9GN+".FQ?9?X:QH'48C-5_A1MP"W>96(U2<NU_@[+31HJ1Q:8BV-NP
MUHU?^^$D3<8P/" > ^(I(/,Z9!#RF3\SPXI<R3Y0P^6WS/68[F)[-Z5S^JOP
M9S9Y;;VW(HFRG-P<T8@Y#)AXAJ$3@ECV22+&) [QA_ 8#T_0#!,?GLS#:8(3
MK%""E2=8_5?B=E$B@J$1+K)&1=8( 5V(8)@[5Y&B(BE"D"Q$,,P*%]F@(AN$
M8+T0P3 I+I*A(AE"L%F(8)@,%]FB(EN$8-EX!!/?:3R-\"\H0BB6K4=!=WI/
M[WRI%*%8=A\%+=M/9L-!@+KZL:B#4G:-G\DS[S1Z'V,_7/[!A[G]C:EKW>C@
M)(T=47Z07*0T8'.)'NS_O;)/Q61PN!BWW=B]&N;E8!C9CF\!F1ZDXB]02P,$
M%     @ )X%Y4*B2_K[/ 0  G 0  !D   !X;"]W;W)K<VAE971S+W-H965T
M,C8N>&UL=53KCIP@%'X5P@,LBC/N=J(F.]LT;=(FDVVZ_<WH\9(%L<",V[<O
MH&.M2_\(Y_!=SD$@&Z5ZU2V 06^"]SK'K3'#@1!=MB"8OI,#]':EEDHP8T/5
M$#TH8)4G"4YH%*5$L*['1>9S)U5D\F)XU\-)(7T1@JG?1^!RS'&,;XGGKFF-
M2Y B&U@#W\'\&$[*1F11J3H!O>YDCQ34.7Z,#\?4X3W@I8-1K^;(=7*6\M4%
M7ZH<1ZX@X% :I\#L<(4GX-P)V3)^S9IXL73$]?RF_LGW;GLY,PU/DO_L*M/F
M^ &C"FIVX>99CI]A[F>/T=S\5[@"MW!7B?4H)=?^B\J+-E+,*K84P=ZFL>O]
M.,[Z-UJ80&<"W1#(9.0K_\@,*S(E1Z2FO1^8^\7Q@=J]*5W2;X5?L\5KF[T6
M"=UGY.J$9LQQPM 5)EX0Q*HO%C1D<:3OZ#1,3X(5)IZ>K.GQA[# +BBP\P*[
M?UI,-RV&,/=ADWW09!\0>-B8A##_Z20-FJ3O!9)H8Q+";'\769T. :KQ]T*C
M4EYZ?R=7V>7J/5)_NO["IWO[C:FFZS4Z2V//J#])M90&;"G1G6VXM4_%$G"H
MC9O>V[F:+LP4&#G,;P%9'J3B#U!+ P04    "  G@7E0Z!J--;(!  #2 P
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M9'14458H?AO6NC%K/^K?:'9",!*"B> GGQ+"D1"^$Z)/"=%(B!8$-)1B>G/
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M"<.+*<1="@EB-0KWW-W"A]C*,8,XVL?M;L& ACHQ/K35=TWP(*2?*Z8J1]U
MY'&!J<KC"2=ES$"!&&AU/@_"/3989#='Y4^/%^M!2#]AS'<!]F'J<X'Y+MB$
M8<,T%H#&U.X& ,A[5A>>-QF P=2SO0O,8#&!P0(S6  &4_L@!4&^:C%]!=@
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M&M;?B^Z^KOM1Y2=S%QE<+D27_P-02P,$%     @ )X%Y4&0IXH1. @  L0@
M !D   !X;"]W;W)K<VAE971S+W-H965T,S4N>&ULE59A;YLP$/TKB!]0L(&0
M5 0IZ31MTB9%G;9]=L@EH!K,;"=T_WZV(2Q-#XE^"?;Q[MT]YXYSU@GYHDH
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MHQ :3"[A@RF2TMP?Q@V'H[;+U*QE/T3[C1;M<$$(QEM*_@]02P,$%     @
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M7MMA8L:R:9O-1(NZO1($W;UD]@]02P,$%     @ )X%Y4%J.UNZR @  4PH
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M3JZVIFD*VZZZ)U37,?K0/P^CZQMU\0]02P,$%     @ )X%Y4'(*</+^ 0
M[04  !D   !X;"]W;W)K<VAE971S+W-H965T-#$N>&ULC53;CILP$/T5Q'O7
MW&$C0&I25:W42M%6VSX[, 2T!E/;"=N_KVT((F U?<&>X<SQ.;Y,.E#VQFL
M8;VWI..970O1[Q#B10TMYD^TAT[^J2AKL9 A.R/>,\"E+FH)\APG0BUN.CM/
M=>[(\I1>!&DZ.#*+7]H6LS][('3(;->^)5Z:<RU4 N5IC\_P \1K?V0R0C-+
MV;30\89V%H,JLS^ZNT.B\!KPLX&!+^:6<G*B]$T%7\O,=I0@(% (Q8#E<(4#
M$**(I(S?$Z<]+ZD*E_,;^V?M77HY80X'2GXUI:@S.[&M$BI\(>*%#E]@\A/:
MUF3^&UR!2+A2(M<H*.'Z:Q47+F@[L4@I+7X?QZ;3XS#QW\K,!=Y4X,T%;O#/
M G\J\%<%:%2FK7[" N<IHX/%QL/JL;H3[LZ7FUFHI-X[_4^ZY3)[S8,X2=%5
M$4V8_8CQ%ACO'G'8(J)HAB I8%;A&55XNMZ_4_%L)O"-!+XF"!8$<;QR,4)B
M#>DTQ%FYV"+"*#2K"(PJ@HV*('',!*&1(/S_?8B,!)%!@;O:B!$3+FP^.\'Z
M1!^ [J3$1BFQ0<IJE7V\6>6#08L!E02+\[T3DQC%)(_O1_+P?FP1V_N!%@]/
M-<+OF)V;CELG*N0;UB^MHE2 Y'.>I*5:]MXY(% )-8WEG(T=: P$[:?FBN8.
MG_\%4$L#!!0    ( ">!>5!CJ@3J, (  /0&   9    >&PO=V]R:W-H965T
M<R]S:&5E=#0R+GAM;(V5[6Z;,!2&;P5Q 37?L(H@+433)FU2U&G;;R<Y":@&
M,]L)W=W/-A01VZWZ!W^]Y_5SS)%=CI0]\P9 >"\=Z?G&;X08'A'BQP8ZS!_H
M +U<.5/682&'[(+XP "?=%!'4!0$&>IPV_M5J>?VK"KI59"VASWS^+7K,/NW
M!4+'C1_ZKQ-/[:41:@)5Y8 O\!/$KV'/Y @M+J>V@YZWM/<8G#?^Y_!Q5RB]
M%OQN8>2KOJ<R.5#ZK ;?3AL_4$! X"B4 Y;-#6H@1!E)C+^SI[]LJ0+7_5?W
M+SIWF<L!<Z@I^=.>1+/Q"]\[P1E?B7BBXU>8\TE];T[^.]R 2+DBD7L<*>'Z
MZQVO7-!N=I$H'7Z9VK;7[3BMY,4<Y@Z(YH!H"0B3=P/B.2#^:$ R!R1& )I2
MT6>SPP)7):.CQZ:_.V!51.%C(D__J";U8>LU>3Q<SMZJI(A+=%-&LV8[::*5
M)KI7U+8BR^XE.UL2!NFB01)R(8V<I)$VB-<48>PVB)T&L39(UJDF!N5VTN1:
MTT^:($^-;&U1X.9(G!R)S5$D!L>D25=;A/DG ^,#FEUBH:XU=["I$S9UP!KG
ML4UMD-"HH?I]S1U(Y@3);) T,$ R:Q-#4=N*,'JK#',G1^[@R V.W-[%_'FV
M)'ZCB HG1N'X+V8Q%W8QQZ:HMD5A&N4&"EI=)^H]^('9I>VY=Z!"WDSZ_CA3
M*D :!@\RJ48^0<N P%FH;B[[;+J(IX&@P_S&H.6AJ_X#4$L#!!0    ( ">!
M>5!<[*G2<0(  +,(   9    >&PO=V]R:W-H965T<R]S:&5E=#0S+GAM;(66
MVX[;(!"&7\7R ZP!GU=.I"95U4JM%&W5]IHD)+;6-BZ09/OV!>Q87IBT-^'@
M?V:^GR"@NG'Q*FO&5/#6M;U<A;52PW,4R4/-.BJ?^,!Z_>7$14>5'HIS) ?!
MZ-$&=6U$$,JBCC9]N*[LW$ZL*WY1;=.SG0CDI>NH^+-A+;^M0AS>)UZ:<ZW,
M1+2N!GIFWYGZ,>R$'D5SEF/3L5XVO \$.ZW"#_AYBXD)L(J?#;O)13\P5O:<
MOYK!E^,J1(:(M>R@3 JJFRO;LK8UF33'[REI.-<T@<O^/?LG:UZ;V5/)MKS]
MU1Q5O0J+,#BR$[VTZH7?/K/)4!H&D_NO[,I:+3<DNL:!M]+^!H>+5+R;LFB4
MCKZ-;=/;]C;EOX?! 60*(', 3OX9$$\!L1,0C636ZD>JZ+H2_!:(\=\:J-D4
M^#G6BWDPDW;M[#?M5NK9ZSHI\BJZFD239C-JR$)#WBNVOB++9DFD 68* E(0
M&Q\O*^ 83A"#"6*;('EGHW!LC)K<:OJQ"$*N$TB4ES!* J(D $KIH(R:=%$%
MHRQQ4'Q1F3Q8E!0D27V2$CDDJ5\D3QT00(,)#)*!(!D @AV0S"N2)0[L%M#D
M!0R2@R Y .+L@$WN%2&% [OU-3E*8) "!"D D-@!*7P0Y*X(H$D1#%*"("4
MXFS$3>D5<3%\!=:L#T P@D\B!*"D[E&$_LL"2.(XP0]8'IR*V&=)O6,1^ZZ]
MG0*)ROP!#'PX8@(L3.;"$._@2N,D=FE\%<'8V[K1XO8PU_DW*LY-+X,]5_HB
MLM?%B7/%=$KTI*W5^@4Q#UIV4J:;Z[X8K]%QH/@P/1&B^9VR_@M02P,$%
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MZ$0B5 @RXI1H,%D,.I,(DR%#R6)UDLP83\Q9(MHUD)@"IXF,%TP6@Z 1JLB
M\T1IN('#:#$(+6&V;VAZ8!6[Q!A,( -2!,V-/2:0F8V'F,74L(@:(<0L/28
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MUKR?EOU&LF:X"=!X'67_ %!+ P04    "  G@7E0\X.TXZT"  #="@  &0
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M$@*3(B*<H,"DB! O*'R;YUWF<Y+K-0+F32+>"*LA,2DRP@5*3(H,<($;Z;M
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M:ET7+OW2-6WG\NUYHW O;?^SQZD>W\N.&VUUG-XY)^<7W^O_ 5!+ P04
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MISH/0,G"OLV7(KA5B%MBP5<$M^H,;C7!K0;<>N?"&MS+AKW'J 2[&F%)]9C
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M2*">$YKD1^26<T*37.ZKP"J6(KZ*"7)R@!RYBJ6(KV+"A[S+#BWO&']UU(V
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MZ6Z0L[UH;JF\K]I^LAT(?M*]<M U[//_4$L#!!0    ( ">!>5"L[FSN 0(
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M2\IZ!^PF4X8=<.B ]P[XC0.M'.L!$_:8<EB38*+/U@3Y$VUQ-_<Q-]D&,-L
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MNA&VVRA1]^-Y,/Q'6/T'4$L#!!0    ( ">!>5!*0J<A;@,  (4.   9
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M9?W2#_U+X+4^5E('0)%W^$A^$?G6;;DZ@4EE7S>D%35K/4X.2_\E7&R0QAO
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M^B;?4RJ(%.D_RI(>93<X3"JR%VJ8RC'K6J)N(FC;MWO>T',N_@-02P,$%
M  @ )X%Y4+[-E?D# P  40P  !D   !X;"]W;W)K<VAE971S+W-H965T-CDN
M>&ULA9?=CMHP$(5?)<H]&T^<Q/8*D I5U4JMM&K5]CH+!J)-8IH8V+Y]G9]%
MK&=";T@<SHR_&3L',[^8YJ4]:&V#UZJLVT5XL/;X&$7MYJ"KO'TP1UV[;W:F
MJ7+KALT^:H^-SK=]4%5&,6-95.5%'2[G_;.G9CDW)UL6M7YJ@O9457GS=Z5+
M<UF$$+X]^%[L#[9[$"WGQWRO?VC[\_C4N%%TS;(M*EVWA:F#1N\6X0=X7(/J
M GK%KT)?VIO[H"OEV9B7;O!ENPA91Z1+O;%=BMQ=SGJMR[++Y#C^C$G#ZYQ=
MX.W]6_9/??&NF.>\U6M3_BZV]K (91AL]2X_E?:[N7S68T%I&(S5?]5G73IY
M1^+FV)BR[3^#S:FUIAJS.)0J?QVN1=U?+V/^MS Z(!X#XFL )'<#^!C O8!H
M(.M+_9C;?#EOS"5HAM4ZYMVF@$?NFKGI'O:]Z[]SU;;NZ7DII9I'YR[1J%D-
MFOA&$[]7K+$BRZZ2R %<*6*2(N[C^2V%8G0"3B;@?8+D70+PRA@THM?4O49(
M+H17"E9EH""E81(2)B%@O(ZM!DUZ,XU,>>:Q8)%0L02:)2594L0"(O584C0-
MES+Q6+!H8H$RDB/#')G?DPQ-$;/$WVI8-,$A2 Y!K WW. 1>&R4]#$*33&P2
M28)(!)*@%T_B]?<7;TUHU 2((D$4T1%O\5<*39*D7M?66!,KIF@28+09,8+%
MWZVCB-X!HQUA"6=R F7"%X% R7P40/.H1&7^$A$R2#)VT\'W1+1' F628B(%
M[9) V:3TB^+_[R^6S"9<"6B+!.R1"6,^"?:_&8^YO_$(V80E .V10)@D,B>X
M9X C");,(!93[P!ME("=4BKTBXQ=D.P,(8-83G6'=DS EJGP4F$_5" X.B=@
M&22)$%-O FV=@+U3,?_7'K QSD@D0G>7B791P#:J&-I#"ATNT!ZZ)QE HINS
M77?8_I8W^Z)N@V=CW3&Q/\SMC+':I6,/KJZ#.]]?!Z7>V>Y6N/MF..0. VN.
MXP$^NOZ+6/X#4$L#!!0    ( ">!>5""#*+4H0(  %,*   9    >&PO=V]R
M:W-H965T<R]S:&5E=#<P+GAM;(V6W8Z;,!"%7P7Q  OF-UF12$E0U4JM%&W5
M]MI)G( 6,+6=9/OVM0W+DF$2[4W YIOCX\F )[MR\2H+QI3S5E>-7+B%4NVS
MY\E]P6HJGWC+&OWDR$5-E1Z*DR=;P>C!!M65%_A^XM6T;-QE9N>V8IGQLZK*
MAFV%(\]U3<6_-:OX=>$2]WWBI3P5RDQXRZRE)_:3J5_M5NB1-Z@<RIHULN2-
M(]AQX:[(<TX"$V")WR6[RM&]8[:RX_S5#+X=%JYO'+&*[961H/IR81M6549)
M^_C;B[K#FB9P?/^N_L5N7F]F1R7;\.I/>5#%PIVYSH$=Z;E2+_SZE?4;BEVG
MW_UW=F&5QHT3O<:>5]+^.ONS5+SN5;25FKYUU[*QUVOW)$WZ,#P@Z ."(8 \
M#@C[@/ C('H8$/4!$0CPNJW8W.14T64F^-41W=_;4E-%Y#G2V=^;29ML^TRG
M1^K9RW+NAYEW,4(]L^Z88,20@?"T^K!$@"VQ#B;AP>T"FRF1)+=(/D6('^,N
M0G2CH14(QRXB'Q>(4('("D0WF8I IC F!IO]!)-C3(*;C5&S,2*0 K,8,P-F
M,68.S"(,N9/9!#6;( ($F,486$88 VHYQY@(-YNB9E-$ /Q]ZRDSBV$9?(+)
ML;7NE,$,-3M#!& 98 PL XP!V<\Q9HZ;G:-FYU.!P =F,0:4R@9CH%F$&97*
MC5GBXQ].?R(1Q3"W"#3QLD$A6+<H=*=PR9U//4%>9OB>85  :Q>%X!<;A=([
MCM&38T4"1&(&'6/0'#I&H-"'CA]#G6-O=++63)QLUR*=/3\WRAQ0H]FA,UK9
MQ@C,KTW'9$_L#YFNW?I!Q:ELI+/C2I_[]G0^<JZ8]N@_Z:]MH3N\85"QHS*W
MJ;X779O3#11O^Q;.&_K(Y7]02P,$%     @ )X%Y4(D.\-4%!   K10  !D
M  !X;"]W;W)K<VAE971S+W-H965T-S$N>&ULE5C;CN(X$/V5*!\PB>W*K05(
M3:/5KK0KM68T,\]I,!=-$K.):6;_?G-K&NSC"/JA2<*I.E5%G;+CV5G5OYJ]
ME-K[7195,_?W6A^?@J!9[V69-U_445;M-UM5E[EN;^M=T!QKF6]ZH[((>!C&
M09D?*G\QZY^]UHN9.NGB4,G7VFM.99G7_RUEH<YSG_D?#[X>=GO=/0@6LV.^
MD]^D_GY\K=N[X.)E<RAEU1Q4Y=5R._>?V=,J"CN#'O'C(,_-U;77I?*FU*_N
MYJ_-W ^[B&0AU[ISD;<?[_)%%D7GJ8WCW]&I?^'L#*^O/[S_T2??)O.6-_)%
M%3\/&[V?^ZGO;>0V/Q7ZJSK_*<>$(M\;L_];OLNBA7>1M!QK533]?V]]:K0J
M1R]M*&7^>_@\5/WG>?3_888-^&C +P8LGC00HX'X-*!) QH-R# (AE3ZVJQR
MG2]FM3I[]?#S'O.NB]@3M=5?=P_[8O??M>5IVJ?OBTRP6?#>.1HQRP'#KS"?
MB*#U?J'@B&+)+7-^2_!B(^+X%K*R(2R,<!0")BIZ!^(F48X=$'1 O0.Z<2",
M2@',591#LG=@5@@3XV C&&P$@B4CV &3])AJ+&G_AXEB2!0#(C.;V"**6#+!
ME$"F!# 97;*T,<0%)DDA20I($H/$QI!P""*#)!D@20V2S*I9.E$Q%F)QAX I
M,]4]@*(KJHPE@E^3#9T[(F\ZABA)A#LNQ]!A=EP4FG$Q*ZY(3#4H@^/GF7%
M9HTX;I'Q*2H\8Y@ 5-RD$A85(S9%AN<1 T."',W.\)1@T?U#D6'],S  R)PT
M(^CFIYP:  Q/ &;+.TU=&6-]L_2!C+%ZF2W?-+/ZR=8OS]B4A#F6, <2)F/
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M]J)6* 67- (1(_<-3N$&![C! 6(P,"4,L(<)T4\*Z#$&,D9X +=P#/0#C_D
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M=8\)1I@; DCUP45@<[$.9O3@WL%FCDB2>\AV#O&]^!ZSFV-2&-@C#:W%"+5
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M8X.(]<9-J@K:_+;Q<U+=D5"[PC_2?S]FP*V1TNH/OBW3?9*M:;GR"BX3?*F
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M)+A0L+-N,3>(QDV)2D"L0,IW9OKBGBWX#%/*<=]H>4'V>*C@;*%,<*3'F7A
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M'4(<PGX.E']*LTEX["@B)<D$:BT<ZQ2]\?B:HBG9=RQ+JXN@_FD,ITORC\:
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MTIW)>+P8P_^'O?D25AI4RT4\F<QZ5QTI@GL7L("SP;SW%/X:QM/9L(>'938
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MJY58R^]V/\!>I"WB7&!.[U=92B&_KUY=T\OT2U\>R#@,Q "+*9%J)C0&6XY
M<TP LR9&DJVSA'44NVR*1;89VKO'QX',3%.4 9B%*)TZ:G".\IU[O)8)TM4Q
M\G@E<HY)@'$E.![-XF^10:]_E!R8?IW^#?@L;NU@^=UB,$2*_ ;6QG\U]CDP
M-7&=*]NA U'TND)UVG-;4PPQ:3M27$06P,:KZMHX=^*QQ.-#HB>>97)+TFJ(
M_M:^ F:5V#%5E$'- BGIQ.[KQ 'J,?D7YK^C*M&2:],72I"D#CI$ZUX\M>G1
M,2=C&3'Y^ZQ*S<:SQS*);BG',71)^;(P.L22DRUR?H*V;J '-SHJ<2'P(%]0
M(W8Y?#?P6BRQ%*C[7![W<1.0%OM@:U<A XZ"PM4NBIR3XZ":D97K2X;G*W>F
MS,"5@*7"K(>-O(T^^:.ZK[.J>TD9J>VSBU$F<RJH1X$TKN0:F6>T'#". "$I
M3V/C(F\E5>(5+]\VT@W*VEHT 7[/MPP^+^74.-TCD0_Y'-LGZLE **LZI%PP
M@$H8'> 3)79FG?)PI^GL@H2D0BHU"ML=)7^?'K&'V@0:? 4;D@@$(4-.Q\:%
M&U V)-B*9G(PI3HU!,#EYX3.I% UDX.)2)!5"2K!FSR5@J6MTP*7Y@C3L&*9
M([L_,J!:I-P>^ $9P7+$A/ QZ<J/:BD8-.C-QJ<V<7E1-QD"2RJ]05S4[T92
MDJ_@FKU%L/]Q@Q'PM.&^NA2_Y-BIRXI1II<FZ6>M&)1#CK4^0>A-*J U&0QT
MNK3!G!OSI3)T^?BRF5*30OO%3N?/Q6G:H'1-I[A1/WJ.FZ8U1^ 2K=A<2HF]
M+# K8P&1<]_('0&;D1VVJ;M+:@_Z,Z=,FE]CF%LGTP!*S2@WB18[W&0;JF^:
M9XAA2)S]4>X,%$4<WHU\(VN2Y-PJ$XF9FQ*EONCE*_D"1":@#_0<%WF&>!(L
MNH<Y"9#1\&[<? ,;(O3_U2;)UX60G18*$IJ$8\@$)^9JCRS54^)POB134J:G
MWSJ8\R"[)Z&Z(7"Z)B36*IB$^"P'\N$RA'(#MN&M112!-ALX:CTG(4PZCGYY
M]UDV=KQ<@@1["C=-8A>P#$S31%F"?K38:3*"O<Q;LJ"3/.)N7N:^$I#"_'.?
M/)A!DS:R@[M;,C*ML]N,CB;F,$+ 0NEV0](1.JNT]+(.N9&5IV!NWWDMIJT4
M! 9G(@(-S:I/AK9\'];S&TW-%YK"'LVD+<G(A=-YH(P?*UD>66)#J5$0:6)O
M3+SP@W5#85!X 6L"+P((4NE8_%+A.,HR;A[<G\(B"5,'HT+GB?[)50MLA3OB
M'LL!<(:'2JA&Y(_[$N_LW%6]"X"*P8UX8B9Z-Q,TBP,)G6'AIJ2;L& I%0-+
MRN/^X),M%[X+T,'OTEWA-[1:H3GX15'"'T>XPC3M-"9D*V\OW^_3A[2\_$MR
MY"HA/[S_"^NPS][]>/G]]GB0,H# ^( 5?Y^ GGKY*VB+,%_@![>7?P'Y Z9^
M^\/NYB_4P/?OG\7MY]OK@=,V=;6C5A$,B,8#[9X\[8$B:4I9Z34*[<@QQI9<
M]:I0*' UG3A8$_0=4MM1H#H@IT6=M[SY?H172BE9V59H>R^KVK;CL'5HQ^J<
MT44L4_N 8/;;R? >9QR21M?)EGLJ+L.&+X*/<Z4YSY<Q/K(M^;O:'DRB779Q
MW4L&N,M3_"9_A-]P62UTNCP9]H>-B&M7<=QD'E%$_7WR9:'1U1?%1@>&LXY[
M;PH"H%U&*;MG\A [XKU);PDP+K6$8??>@&+D@Q7N4\\)UJSU!+R@CI!MZ(.)
M%[E>%)_AV./]=4W$&%W3V6H_AJ/!8,($L>-)TA@'BT=L,QW'LZ-K8@7NM]C4
M0W<*:>U2MJ=!3F=X)/?\HR2INWXVG)&';X^2SDW*5J[7/\H97XX"M;_C[&15
M<X(MI\C/$>_=W^D<-.Y=(N(LN<U!H6FYAM>7A_N42V5W=2A%<'W2YWOG!)6:
M/DZ#)W?<L;H##9)D8'12_I2N23]XC'C:F/=PQ/$BGKO4Z.21SAKT820U1WFP
M&,12S3P"BT^']<EHH;72,(9<G&G(0A=P\[><G_-,:<ON.MMU*0A)%0\5A399
MNEW3V+7F@=>"I70P#4@2PX4C2EP!7RT>*J8=#"4933%"G!6B+]Y@N&=<04@F
M4%_02NS<M_ P2J5:=XGZ-&&5;JJJ 7(V=EP%G;PMRV7"YO84T?W4O>S+.G2H
ML*VI =TY:R6&[WS^05</1TPD+YY=L=2%@7VD QC#HJ9HJ!UB=T"ES4U6@H!#
M!X$%B)92K.YE]!>BW$$5JE? ;BA%B0FV^>!?$OR]EG\<CD0[HU,-9W(6^YN+
M!%^\+IM5NRB+"HT1P_,U:%DN5*X:BLJPWDM4CHR/(<F=QLS8-Q6%Y8Z+F:'J
MB(, *\K)OD]Q+V#/01W]5*PXBMH;(IV)\I)-E W.W(^>?9UVZI+F,WI'EL7E
M3\$ K#AZ,HEA(245#!VB,*%+7*\U]:6G2W5DWW,MTXN4D8VU;#!?TFL\[(B8
M(?WHRY*]O"ZL$,=Y&=+#UROY;XZ'RU=-O=[7$VV],UZD-Z4XJH:MCJKAW%X>
MW=5*U=5- C8::N6'CH@?%;_A.]=$$M:9-E)([&\5PB0;(3V0,PG.YB[Q,,A3
MY18N$LR"BJN>7I=-),1&- DWQ-; ;J2(B)UO*^',G(^5#/"A#('OW3UL*1H+
MEE+$R;OC+LF)C8M6P_&;_DVTES^N9%C-VRTJ2?.HY%#<*"G+FU0.EH^+;:D[
MJAG!9LS LJJU!JDO/^JJ&O[3:I#^_)O*CC+,2VY&8N_*+"@*M71A),UQ;PY4
M]<&X'1HE<+&=^OK4RP68&2O P><82*J@SJTIQRL;2?!-,C7=V43[31O0M[BS
MP^:ESY?+R]?/Q&#^7<=S4D[%UNN4=SON^N\"4OJ2AIHM$8L?M,DL_&:]R)\]
MS6T7>656$--"U^UV=#*\UM E/SYX$%Z@.;1VB5*+9VH4'$XJ M+ J9:%WGQE
MK* A,FGF>;KR%LV:J-TQ_]>MQ4JYN,213'"N/Q$DOS"1.]8Z/00@8,<&<MNW
M*[E8<'50&C+ZD;F_+[H^FY@8=,[9_"5(%5@5J"5LSCW+$7/!PP8/>P(.:YL0
M3'AW?PNJ4!,\'W89?NJH_Z;59<R30O,""56<M^+3!3/AJAMQ42X#?'6U:)T;
M0J*OC?Y 3F9-2TTC2'+&[SH/KBM,%\#K8V;DC5JSQA1$-QZ7*X)!HI1-"3J]
MM@6M'E)?2@^Y*9<[34SE(7*ANJHKX<C]7!U%%J6;%K5@BXLH4EPPN#BC*Y=<
M J5,1]J<;]IIP2X'L(+FR7>YS7:9D4EEF[AH#Z\W.QYY>[COF.4&$W]%5P76
M$39MFTO%6T.<D\/Z3&EDN(9T^?)%!TWO#XS5)KB;#@&U&B_V^@KP5%)8HK-;
MV^80=6N6B<.BAK&3PGB[\8IE/40=UC:QFOAFUZ!7KPX"96!UC]8IN<>[8">I
MT>V;6*&[;V-33>8VF[]HANE(N+Q,6">'(K*B1'.V@9Z+B9N!Z$CD@-F]/ZZ/
M>7(+XTNB3\!:08C]\3ZM#IJ9"+//;SM1(GZHDD")#*VCT$=#]$S]9IL-AR&
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M4-+?W\' ;FU>H[ @M(-PRE7!^2*-5^3#J77&LG,8B,VJM%-*W8PX5((IFE-
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MUMP;(@A<))@S9<358$;S(7X8]C G%R9-&8W@SQE_"Y_CZ62&?TXPH<)BW/N
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MT/GD%(W3>#F?DN'0]93Y$E5QW &#A)E6>J68Y#NE7:I,UP@C\R1S'[(:2LO
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MX<4'._B0I=MU;_!'?Y_H(NW2!,WE9!-9<Q4!G1E=!$OFR: &8G+-== @G>(
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MDDE<2-(RXO@1-QK._Y:=D]A^O\"(V6#'KE:.M"O)7.U 0M@V0Z\:YB7P@**
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MDYV>[RCEN#6$[WRX+ZYCAPYJ$'#9A!%K6EJ$V;Q>/!0[@6R:>-_D?/Y2?%M
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MQCG27?)T G-P%)KX;J+E,$YY*_T)I26E!_EGS$>>&NA4Q)]_,IUAL_K*_$!
M[X\<C+ZYB1)KUJZ%XRJ6",A#]3<<08>3MQM,IN>XH.RO/GGZJ;X+/Q/"^E)_
M(*U6FVO'S/C)2R9!LF!D;S,TR7$!8/RZ)0VHMT %Z=,3ZR/,GW[R:%>3CIOA
M2\N"8_2 AN"NZWK+;C5Q>/J,^Z!GW"OG*!2_U8'GHSS81SXOQ]2!I]^P]G5<
M4]+ILNN.JIJTZ2<^G@6)L_W@7:5;?+BT0\-Y= DU WQ2?V3XG]N9XR:D-D_]
MT0\&C<X.S\*Q!35WOZ&49Z[$X_DE3G@UZ%/D5Q,%[-#Q,CKR.2WO$/_%Y%2
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MRM=;@=[*UUN!WLK76X'>RM=;@=[*UUN!WLK7.P"] U_O /0.?+T#T#OP]0Y
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M96QS+RYR96QS4$L! A0#%     @ )X%Y4"?HAPZ"    L0   !
M     ( !Z0   &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    "  G@7E0+'I^
M=^X    K @  $0              @ &9 0  9&]C4')O<',O8V]R92YX;6Q0
M2P$"% ,4    "  G@7E0F5R<(Q &  "<)P  $P              @ &V @
M>&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( ">!>5"77'[<B@,  (P1
M   8              "  ?<(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q0
M2P$"% ,4    "  G@7E0UL45; \$   \$P  &               @ &W#
M>&PO=V]R:W-H965T<R]S:&5E=#(N>&UL4$L! A0#%     @ )X%Y4#[06]WZ
M 0  CP4  !@              ( !_!   'AL+W=O<FMS:&5E=',O<VAE970S
M+GAM;%!+ 0(4 Q0    ( ">!>5!7.SA<DP,  " /   8              "
M 2P3  !X;"]W;W)K<VAE971S+W-H965T-"YX;6Q02P$"% ,4    "  G@7E0
M'Q/2/FP"  #>!P  &               @ 'U%@  >&PO=V]R:W-H965T<R]S
M:&5E=#4N>&UL4$L! A0#%     @ )X%Y4&P9"%ZD!@  A2@  !@
M     ( !EQD  'AL+W=O<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4 Q0    (
M ">!>5!CYOYUCP8  -$D   8              "  7$@  !X;"]W;W)K<VAE
M971S+W-H965T-RYX;6Q02P$"% ,4    "  G@7E05BLY;+4!  #2 P  &
M            @ $V)P  >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L! A0#
M%     @ )X%Y4,^Z@H>T 0  T@,  !@              ( !(2D  'AL+W=O
M<FMS:&5E=',O<VAE970Y+GAM;%!+ 0(4 Q0    ( ">!>5#?[5$CM $  -(#
M   9              "  0LK  !X;"]W;W)K<VAE971S+W-H965T,3 N>&UL
M4$L! A0#%     @ )X%Y4#VA5GRU 0  T@,  !D              ( !]BP
M 'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q02P$"% ,4    "  G@7E0'YY)
M(+8!  #2 P  &0              @ 'B+@  >&PO=V]R:W-H965T<R]S:&5E
M=#$R+GAM;%!+ 0(4 Q0    ( ">!>5#!NM><LP$  -(#   9
M  "  <\P  !X;"]W;W)K<VAE971S+W-H965T,3,N>&UL4$L! A0#%     @
M)X%Y4%,@)L6U 0  T@,  !D              ( !N3(  'AL+W=O<FMS:&5E
M=',O<VAE970Q-"YX;6Q02P$"% ,4    "  G@7E0 SS\3+<!  #2 P  &0
M            @ &E-   >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4
M Q0    ( ">!>5 %$<T LP$  -(#   9              "  9,V  !X;"]W
M;W)K<VAE971S+W-H965T,38N>&UL4$L! A0#%     @ )X%Y4#:W'G*T 0
MT@,  !D              ( !?3@  'AL+W=O<FMS:&5E=',O<VAE970Q-RYX
M;6Q02P$"% ,4    "  G@7E0#'<@G+4!  #2 P  &0              @ %H
M.@  >&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    ( ">!>5"N
M<E>DM $  -(#   9              "  50\  !X;"]W;W)K<VAE971S+W-H
M965T,3DN>&UL4$L! A0#%     @ )X%Y4&*2M26T 0  T@,  !D
M     ( !/SX  'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( ">!>5"P/FUI%0(  )P&   9              "
M 49)  !X;"]W;W)K<VAE971S+W-H965T,C4N>&UL4$L! A0#%     @ )X%Y
M4*B2_K[/ 0  G 0  !D              ( !DDL  'AL+W=O<FMS:&5E=',O
M<VAE970R-BYX;6Q02P$"% ,4    "  G@7E0Z!J--;(!  #2 P  &0
M        @ &830  >&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4 Q0
M   ( ">!>5"^5)S$Q $  #<$   9              "  8%/  !X;"]W;W)K
M<VAE971S+W-H965T,C@N>&UL4$L! A0#%     @ )X%Y4-RA$#VX 0  TP,
M !D              ( !?%$  'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6Q0
M2P$"% ,4    "  G@7E0?<<@L_4!  #+!0  &0              @ %K4P
M>&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+ 0(4 Q0    ( ">!>5 #)M>-
M[0$  &8%   9              "  9=5  !X;"]W;W)K<VAE971S+W-H965T
M,S$N>&UL4$L! A0#%     @ )X%Y4&I-]C6X 0  T@,  !D
M ( !NU<  'AL+W=O<FMS:&5E=',O<VAE970S,BYX;6Q02P$"% ,4    "  G
M@7E0#J6)U!("  !T!0  &0              @ &J60  >&PO=V]R:W-H965T
M<R]S:&5E=#,S+GAM;%!+ 0(4 Q0    ( ">!>5!Q^U@L'P4  !P=   9
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M970S."YX;6Q02P$"% ,4    "  G@7E0EIVH=%D"  "?!P  &0
M    @ %Y;   >&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;%!+ 0(4 Q0    (
M ">!>5!63F)91@,  *\.   9              "  0EO  !X;"]W;W)K<VAE
M971S+W-H965T-# N>&UL4$L! A0#%     @ )X%Y4'(*</+^ 0  [04  !D
M             ( !AG(  'AL+W=O<FMS:&5E=',O<VAE970T,2YX;6Q02P$"
M% ,4    "  G@7E08ZH$ZC "  #T!@  &0              @ &[=   >&PO
M=V]R:W-H965T<R]S:&5E=#0R+GAM;%!+ 0(4 Q0    ( ">!>5!<[*G2<0(
M +,(   9              "  2)W  !X;"]W;W)K<VAE971S+W-H965T-#,N
M>&UL4$L! A0#%     @ )X%Y4,J>&* @ @  ; 8  !D              ( !
MRGD  'AL+W=O<FMS:&5E=',O<VAE970T-"YX;6Q02P$"% ,4    "  G@7E0
M@A5F9T$"  #E!@  &0              @ $A?   >&PO=V]R:W-H965T<R]S
M:&5E=#0U+GAM;%!+ 0(4 Q0    ( ">!>5#1G1>BP (  )L*   9
M      "  9E^  !X;"]W;W)K<VAE971S+W-H965T-#8N>&UL4$L! A0#%
M  @ )X%Y4$O].&ME!0  ]!X  !D              ( !D($  'AL+W=O<FMS
M:&5E=',O<VAE970T-RYX;6Q02P$"% ,4    "  G@7E0>Q$H*B,"  ":!@
M&0              @ $LAP  >&PO=V]R:W-H965T<R]S:&5E=#0X+GAM;%!+
M 0(4 Q0    ( ">!>5#S@[3CK0(  -T*   9              "  8:)  !X
M;"]W;W)K<VAE971S+W-H965T-#DN>&UL4$L! A0#%     @ )X%Y4%9%0<,@
M @  *08  !D              ( !:HP  'AL+W=O<FMS:&5E=',O<VAE970U
M,"YX;6Q02P$"% ,4    "  G@7E0>$KVS=4$   $'P  &0
M@ '!C@  >&PO=V]R:W-H965T<R]S:&5E=#4Q+GAM;%!+ 0(4 Q0    ( ">!
M>5 6&=MU'@0  '<5   9              "  <V3  !X;"]W;W)K<VAE971S
M+W-H965T-3(N>&UL4$L! A0#%     @ )X%Y4(GJN]ES!0  V1\  !D
M         ( !(I@  'AL+W=O<FMS:&5E=',O<VAE970U,RYX;6Q02P$"% ,4
M    "  G@7E09=>!%@ "  "G!0  &0              @ ',G0  >&PO=V]R
M:W-H965T<R]S:&5E=#4T+GAM;%!+ 0(4 Q0    ( ">!>5#WZM_[(0(  )0&
M   9              "  0.@  !X;"]W;W)K<VAE971S+W-H965T-34N>&UL
M4$L! A0#%     @ )X%Y4+8J5T^^ 0  U ,  !D              ( !6Z(
M 'AL+W=O<FMS:&5E=',O<VAE970U-BYX;6Q02P$"% ,4    "  G@7E0O4)]
M> 8)  #%.@  &0              @ %0I   >&PO=V]R:W-H965T<R]S:&5E
M=#4W+GAM;%!+ 0(4 Q0    ( ">!>5"99SP<_0(  +P+   9
M  "  8VM  !X;"]W;W)K<VAE971S+W-H965T-3@N>&UL4$L! A0#%     @
M)X%Y4*SN;.X! @  (08  !D              ( !P;   'AL+W=O<FMS:&5E
M=',O<VAE970U.2YX;6Q02P$"% ,4    "  G@7E062UX?UP$   #%@  &0
M            @ 'YL@  >&PO=V]R:W-H965T<R]S:&5E=#8P+GAM;%!+ 0(4
M Q0    ( ">!>5!D#.8)^@(  "\,   9              "  8RW  !X;"]W
M;W)K<VAE971S+W-H965T-C$N>&UL4$L! A0#%     @ )X%Y4$I"IR%N P
MA0X  !D              ( !O;H  'AL+W=O<FMS:&5E=',O<VAE970V,BYX
M;6Q02P$"% ,4    "  G@7E0.>?CZI<#  #N$0  &0              @ %B
MO@  >&PO=V]R:W-H965T<R]S:&5E=#8S+GAM;%!+ 0(4 Q0    ( ">!>5")
MFDC;*0(  -T&   9              "  3#"  !X;"]W;W)K<VAE971S+W-H
M965T-C0N>&UL4$L! A0#%     @ )X%Y4 )N0?(8 P  ; L  !D
M     ( !D,0  'AL+W=O<FMS:&5E=',O<VAE970V-2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( ">!>5""#*+4H0(  %,*   9              "
M ?G2  !X;"]W;W)K<VAE971S+W-H965T-S N>&UL4$L! A0#%     @ )X%Y
M4(D.\-4%!   K10  !D              ( !T=4  'AL+W=O<FMS:&5E=',O
M<VAE970W,2YX;6Q02P$"% ,4    "  G@7E0!06V+B\"  !&!@  &0
M        @ $-V@  >&PO=V]R:W-H965T<R]S:&5E=#<R+GAM;%!+ 0(4 Q0
M   ( ">!>5 ]>J=Z& 0  'P2   9              "  7/<  !X;"]W;W)K
M<VAE971S+W-H965T-S,N>&UL4$L! A0#%     @ )X%Y4*6UQ_3W 0  ' 4
M !D              ( !PN   'AL+W=O<FMS:&5E=',O<VAE970W-"YX;6Q0
M2P$"% ,4    "  G@7E0=EK!,40"   )!P  &0              @ 'PX@
M>&PO=V]R:W-H965T<R]S:&5E=#<U+GAM;%!+ 0(4 Q0    ( ">!>5#/.A8U
M.M<  !Q) P 4              "  6OE  !X;"]S:&%R9613=')I;F=S+GAM
M;%!+ 0(4 Q0    ( ">!>5!K*[J,30(  ( +   -              "  =>\
M 0!X;"]S='EL97,N>&UL4$L! A0#%     @ )X%Y4++K #6'!0   S(   \
M             ( !3[\! 'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( ">!
M>5!NQ0CI9@(  /8L   :              "  0/% 0!X;"]?<F5L<R]W;W)K
M8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    ( ">!>5#?"<DD% (  .DK   3
M          "  :'' 0!;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@    !4 %0
*_A8  .;) 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>128
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>371</ContextCount>
  <ElementCount>537</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>95</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>10</UnitCount>
  <MyReports>
    <Report instance="nk-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nantkwest.com/20191231/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="nk-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>100010 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nantkwest.com/20191231/taxonomy/role/StatementConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="nk-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>100020 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nantkwest.com/20191231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="nk-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>100030 - Statement - Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nantkwest.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfOperations</Role>
      <ShortName>Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="nk-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>100040 - Statement - Consolidated Statements of Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nantkwest.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveLoss</Role>
      <ShortName>Consolidated Statements of Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="nk-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>100050 - Statement - Consolidated Statements of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nantkwest.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="nk-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>100060 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nantkwest.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="nk-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>100070 - Disclosure - Description of Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nantkwest.com/20191231/taxonomy/role/DisclosureDescriptionOfBusiness</Role>
      <ShortName>Description of Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="nk-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>100080 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nantkwest.com/20191231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="nk-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>100090 - Disclosure - Financial Statement Details</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nantkwest.com/20191231/taxonomy/role/DisclosureFinancialStatementDetails</Role>
      <ShortName>Financial Statement Details</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="nk-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>100100 - Disclosure - Viracta Investment and Convertible Notes</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.nantkwest.com/20191231/taxonomy/role/DisclosureViractaInvestmentAndConvertibleNotes</Role>
      <ShortName>Viracta Investment and Convertible Notes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="nk-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>100110 - Disclosure - Financial Instruments Investments in Debt Securities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nantkwest.com/20191231/taxonomy/role/DisclosureFinancialInstrumentsInvestmentsInDebtSecurities</Role>
      <ShortName>Financial Instruments Investments in Debt Securities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="nk-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>100120 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nantkwest.com/20191231/taxonomy/role/DisclosureFairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="nk-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>100130 - Disclosure - Collaboration and License Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nantkwest.com/20191231/taxonomy/role/DisclosureCollaborationAndLicenseAgreements</Role>
      <ShortName>Collaboration and License Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="nk-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>100140 - Disclosure - Commitment and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nantkwest.com/20191231/taxonomy/role/DisclosureCommitmentAndContingencies</Role>
      <ShortName>Commitment and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="nk-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>100150 - Disclosure - Related Party Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nantkwest.com/20191231/taxonomy/role/DisclosureRelatedPartyAgreements</Role>
      <ShortName>Related Party Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="nk-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>100160 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nantkwest.com/20191231/taxonomy/role/DisclosureStockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="nk-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>100170 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nantkwest.com/20191231/taxonomy/role/DisclosureStockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="nk-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>100180 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nantkwest.com/20191231/taxonomy/role/DisclosureIncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="nk-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>100190 - Disclosure - Summarized Quarterly Data (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nantkwest.com/20191231/taxonomy/role/DisclosureSummarizedQuarterlyDataUnaudited</Role>
      <ShortName>Summarized Quarterly Data (Unaudited)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="nk-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>100200 - Disclosure - Employee Benefits</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nantkwest.com/20191231/taxonomy/role/DisclosureEmployeeBenefits</Role>
      <ShortName>Employee Benefits</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="nk-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>100210 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nantkwest.com/20191231/taxonomy/role/DisclosureSubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="nk-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>100220 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nantkwest.com/20191231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.nantkwest.com/20191231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="nk-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>100230 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nantkwest.com/20191231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.nantkwest.com/20191231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="nk-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>100240 - Disclosure - Financial Statement Details (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nantkwest.com/20191231/taxonomy/role/DisclosureFinancialStatementDetailsTables</Role>
      <ShortName>Financial Statement Details (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.nantkwest.com/20191231/taxonomy/role/DisclosureFinancialStatementDetails</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="nk-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>100250 - Disclosure - Financial Instruments Investments in Debt Securities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nantkwest.com/20191231/taxonomy/role/DisclosureFinancialInstrumentsInvestmentsInDebtSecuritiesTables</Role>
      <ShortName>Financial Instruments Investments in Debt Securities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.nantkwest.com/20191231/taxonomy/role/DisclosureFinancialInstrumentsInvestmentsInDebtSecurities</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="nk-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>100260 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nantkwest.com/20191231/taxonomy/role/DisclosureFairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.nantkwest.com/20191231/taxonomy/role/DisclosureFairValueMeasurements</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="nk-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>100270 - Disclosure - Commitment and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nantkwest.com/20191231/taxonomy/role/DisclosureCommitmentAndContingenciesTables</Role>
      <ShortName>Commitment and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.nantkwest.com/20191231/taxonomy/role/DisclosureCommitmentAndContingencies</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="nk-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>100280 - Disclosure - Stockholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nantkwest.com/20191231/taxonomy/role/DisclosureStockholdersEquityTables</Role>
      <ShortName>Stockholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.nantkwest.com/20191231/taxonomy/role/DisclosureStockholdersEquity</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="nk-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>100290 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nantkwest.com/20191231/taxonomy/role/DisclosureStockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.nantkwest.com/20191231/taxonomy/role/DisclosureStockBasedCompensation</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="nk-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>100300 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nantkwest.com/20191231/taxonomy/role/DisclosureIncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.nantkwest.com/20191231/taxonomy/role/DisclosureIncomeTaxes</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="nk-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>100310 - Disclosure - Summarized Quarterly Data (Unaudited) (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nantkwest.com/20191231/taxonomy/role/DisclosureSummarizedQuarterlyDataUnauditedTables</Role>
      <ShortName>Summarized Quarterly Data (Unaudited) (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.nantkwest.com/20191231/taxonomy/role/DisclosureSummarizedQuarterlyDataUnaudited</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="nk-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>100320 - Disclosure - Description of Business - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nantkwest.com/20191231/taxonomy/role/DisclosureDescriptionOfBusinessAdditionalInformationDetail</Role>
      <ShortName>Description of Business - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="nk-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>100330 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nantkwest.com/20191231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail</Role>
      <ShortName>Summary of Significant Accounting Policies - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="nk-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>100340 - Disclosure - Summary of Significant Accounting Policies - Schedule of Estimated Useful Lives of Property, Plant and Equipment (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nantkwest.com/20191231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentDetail</Role>
      <ShortName>Summary of Significant Accounting Policies - Schedule of Estimated Useful Lives of Property, Plant and Equipment (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="nk-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>100350 - Disclosure - Summary of Significant Accounting Policies - Securities Excluded from the Computation of Potentially Dilutive Securities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nantkwest.com/20191231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSecuritiesExcludedFromComputationOfPotentiallyDilutiveSecuritiesDetail</Role>
      <ShortName>Summary of Significant Accounting Policies - Securities Excluded from the Computation of Potentially Dilutive Securities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="nk-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>100360 - Disclosure - Financial Statement Details - Prepaid Expenses and Other Current Assets (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nantkwest.com/20191231/taxonomy/role/DisclosureFinancialStatementDetailsPrepaidExpensesAndOtherCurrentAssetsDetail</Role>
      <ShortName>Financial Statement Details - Prepaid Expenses and Other Current Assets (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="nk-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>100370 - Disclosure - Financial Statement Details - Property, Plant and Equipment, Net (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nantkwest.com/20191231/taxonomy/role/DisclosureFinancialStatementDetailsPropertyPlantAndEquipmentNetDetail</Role>
      <ShortName>Financial Statement Details - Property, Plant and Equipment, Net (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="nk-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>100380 - Disclosure - Financial Statement Details - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nantkwest.com/20191231/taxonomy/role/DisclosureFinancialStatementDetailsAdditionalInformationDetail</Role>
      <ShortName>Financial Statement Details - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="nk-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>100390 - Disclosure - Financial Statement Details - Impact of Adoption of ASC 842 on Property, Plant and Equipment (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nantkwest.com/20191231/taxonomy/role/DisclosureFinancialStatementDetailsImpactOfAdoptionOfASC842OnPropertyPlantAndEquipmentDetail</Role>
      <ShortName>Financial Statement Details - Impact of Adoption of ASC 842 on Property, Plant and Equipment (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="nk-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>100400 - Disclosure - Financial Statement Details - Intangible Assets, Net (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nantkwest.com/20191231/taxonomy/role/DisclosureFinancialStatementDetailsIntangibleAssetsNetDetail</Role>
      <ShortName>Financial Statement Details - Intangible Assets, Net (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="nk-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>100410 - Disclosure - Financial Statement Details - Other Assets (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nantkwest.com/20191231/taxonomy/role/DisclosureFinancialStatementDetailsOtherAssetsDetail</Role>
      <ShortName>Financial Statement Details - Other Assets (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="nk-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>100420 - Disclosure - Financial Statement Details - Accrued Expenses (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nantkwest.com/20191231/taxonomy/role/DisclosureFinancialStatementDetailsAccruedExpensesDetail</Role>
      <ShortName>Financial Statement Details - Accrued Expenses (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="nk-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>100430 - Disclosure - Financial Statement Details - Other Current Liabilities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nantkwest.com/20191231/taxonomy/role/DisclosureFinancialStatementDetailsOtherCurrentLiabilitiesDetail</Role>
      <ShortName>Financial Statement Details - Other Current Liabilities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="nk-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>100440 - Disclosure - Financial Statement Details - Investment Income, Net (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nantkwest.com/20191231/taxonomy/role/DisclosureFinancialStatementDetailsInvestmentIncomeNetDetail</Role>
      <ShortName>Financial Statement Details - Investment Income, Net (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="nk-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>100450 - Disclosure - Viracta Investment and Convertible Notes - Additional Information (Detail)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.nantkwest.com/20191231/taxonomy/role/DisclosureViractaInvestmentAndConvertibleNotesAdditionalInformationDetail</Role>
      <ShortName>Viracta Investment and Convertible Notes - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="nk-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>100460 - Disclosure - Financial Instruments Investments in Debt Securities - Schedule of Investments in Debt Securities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nantkwest.com/20191231/taxonomy/role/DisclosureFinancialInstrumentsInvestmentsInDebtSecuritiesScheduleOfInvestmentsInDebtSecuritiesDetail</Role>
      <ShortName>Financial Instruments Investments in Debt Securities - Schedule of Investments in Debt Securities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="nk-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>100470 - Disclosure - Financial Instruments Investments in Debt Securities - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nantkwest.com/20191231/taxonomy/role/DisclosureFinancialInstrumentsInvestmentsInDebtSecuritiesAdditionalInformationDetail</Role>
      <ShortName>Financial Instruments Investments in Debt Securities - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="nk-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>100480 - Disclosure - Financial Instruments Investments in Debt Securities - Accumulated Unrealized Losses on Debt Securities Classified as Available-for-Sale in Continuous Loss Position (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nantkwest.com/20191231/taxonomy/role/DisclosureFinancialInstrumentsInvestmentsInDebtSecuritiesAccumulatedUnrealizedLossesOnDebtSecuritiesClassifiedAsAvailableForSaleInContinuousLossPositionDetail</Role>
      <ShortName>Financial Instruments Investments in Debt Securities - Accumulated Unrealized Losses on Debt Securities Classified as Available-for-Sale in Continuous Loss Position (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="nk-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>100490 - Disclosure - Financial Instruments Investments in Debt Securities - Schedule of Realized Gains and Losses on Sales of Available-for-Sale Debt Securities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nantkwest.com/20191231/taxonomy/role/DisclosureFinancialInstrumentsInvestmentsInDebtSecuritiesScheduleOfRealizedGainsAndLossesOnSalesOfAvailableForSaleDebtSecuritiesDetail</Role>
      <ShortName>Financial Instruments Investments in Debt Securities - Schedule of Realized Gains and Losses on Sales of Available-for-Sale Debt Securities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="nk-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>100500 - Disclosure - Fair Value Measurements - Summary of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nantkwest.com/20191231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail</Role>
      <ShortName>Fair Value Measurements - Summary of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="nk-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>100510 - Disclosure - Collaboration and License Agreements - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nantkwest.com/20191231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail</Role>
      <ShortName>Collaboration and License Agreements - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="nk-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>100520 - Disclosure - Commitment and Contingencies - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nantkwest.com/20191231/taxonomy/role/DisclosureCommitmentAndContingenciesAdditionalInformationDetail</Role>
      <ShortName>Commitment and Contingencies - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="nk-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>100530 - Disclosure - Commitment and Contingencies - Schedule of Lease Balances (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nantkwest.com/20191231/taxonomy/role/DisclosureCommitmentAndContingenciesScheduleOfLeaseBalancesDetail</Role>
      <ShortName>Commitment and Contingencies - Schedule of Lease Balances (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="nk-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>100540 - Disclosure - Commitment and Contingencies - Summary of Future Minimum Lease Payments (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nantkwest.com/20191231/taxonomy/role/DisclosureCommitmentAndContingenciesSummaryOfFutureMinimumLeasePaymentsDetail</Role>
      <ShortName>Commitment and Contingencies - Summary of Future Minimum Lease Payments (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="nk-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>100550 - Disclosure - Commitment and Contingencies - Summary of Future Minimum Lease Payments (Parenthetical) (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nantkwest.com/20191231/taxonomy/role/DisclosureCommitmentAndContingenciesSummaryOfFutureMinimumLeasePaymentsParentheticalDetail</Role>
      <ShortName>Commitment and Contingencies - Summary of Future Minimum Lease Payments (Parenthetical) (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="nk-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>100560 - Disclosure - Related Party Agreements - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nantkwest.com/20191231/taxonomy/role/DisclosureRelatedPartyAgreementsAdditionalInformationDetail</Role>
      <ShortName>Related Party Agreements - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="nk-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>100570 - Disclosure - Stockholders' Equity - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nantkwest.com/20191231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail</Role>
      <ShortName>Stockholders' Equity - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="nk-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>100580 - Disclosure - Stockholders' Equity - Summary of Common Shares Reserved for Issuance (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nantkwest.com/20191231/taxonomy/role/DisclosureStockholdersEquitySummaryOfCommonSharesReservedForIssuanceDetail</Role>
      <ShortName>Stockholders' Equity - Summary of Common Shares Reserved for Issuance (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="nk-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>100590 - Disclosure - Stock-Based Compensation - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nantkwest.com/20191231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail</Role>
      <ShortName>Stock-Based Compensation - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="nk-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>100600 - Disclosure - Stock-Based Compensation - Stock Based Compensation Expenses Related to Statement of Operations (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nantkwest.com/20191231/taxonomy/role/DisclosureStockBasedCompensationStockBasedCompensationExpensesRelatedToStatementOfOperationsDetail</Role>
      <ShortName>Stock-Based Compensation - Stock Based Compensation Expenses Related to Statement of Operations (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="nk-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>100610 - Disclosure - Stock-Based Compensation - Stock Option Activity (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nantkwest.com/20191231/taxonomy/role/DisclosureStockBasedCompensationStockOptionActivityDetail</Role>
      <ShortName>Stock-Based Compensation - Stock Option Activity (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="nk-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>100620 - Disclosure - Stock-Based Compensation - Summary of Options Outstanding and Vested Pricing of Exercise Prices (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nantkwest.com/20191231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfOptionsOutstandingAndVestedPricingOfExercisePricesDetail</Role>
      <ShortName>Stock-Based Compensation - Summary of Options Outstanding and Vested Pricing of Exercise Prices (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="nk-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>100630 - Disclosure - Stock-Based Compensation - Black-Scholes Option-Pricing Model to Determine Fair Value of Assumptions Used for Employee Stock Options Granted (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nantkwest.com/20191231/taxonomy/role/DisclosureStockBasedCompensationBlackScholesOptionPricingModelToDetermineFairValueOfAssumptionsUsedForEmployeeStockOptionsGrantedDetail</Role>
      <ShortName>Stock-Based Compensation - Black-Scholes Option-Pricing Model to Determine Fair Value of Assumptions Used for Employee Stock Options Granted (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="nk-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>100640 - Disclosure - Stock-Based Compensation - Restricted Stock Units (RSUs) Activity (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nantkwest.com/20191231/taxonomy/role/DisclosureStockBasedCompensationRestrictedStockUnitsRsusActivityDetail</Role>
      <ShortName>Stock-Based Compensation - Restricted Stock Units (RSUs) Activity (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="nk-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>100650 - Disclosure - Stock-Based Compensation - Summary of Warrant Activity (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nantkwest.com/20191231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfWarrantActivityDetail</Role>
      <ShortName>Stock-Based Compensation - Summary of Warrant Activity (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="nk-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>100660 - Disclosure - Income Taxes - Summary of Loss Before Taxes (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nantkwest.com/20191231/taxonomy/role/DisclosureIncomeTaxesSummaryOfLossBeforeTaxesDetail</Role>
      <ShortName>Income Taxes - Summary of Loss Before Taxes (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="nk-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>100670 - Disclosure - Income Taxes - Summary of Income Tax Benefit (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nantkwest.com/20191231/taxonomy/role/DisclosureIncomeTaxesSummaryOfIncomeTaxBenefitDetail</Role>
      <ShortName>Income Taxes - Summary of Income Tax Benefit (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="nk-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>100680 - Disclosure - Income Taxes - Components of Net Deferred Tax Assets and Liabilities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nantkwest.com/20191231/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsAndLiabilitiesDetail</Role>
      <ShortName>Income Taxes - Components of Net Deferred Tax Assets and Liabilities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="nk-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>100690 - Disclosure - Income Taxes - Reconciliation of Federal Statutory Income Tax Rate (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nantkwest.com/20191231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateDetail</Role>
      <ShortName>Income Taxes - Reconciliation of Federal Statutory Income Tax Rate (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="nk-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>100700 - Disclosure - Income Taxes - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nantkwest.com/20191231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail</Role>
      <ShortName>Income Taxes - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="nk-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>100710 - Disclosure - Income Taxes - Summarizes of Changes in Unrecognized Tax Benefits (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nantkwest.com/20191231/taxonomy/role/DisclosureIncomeTaxesSummarizesOfChangesInUnrecognizedTaxBenefitsDetail</Role>
      <ShortName>Income Taxes - Summarizes of Changes in Unrecognized Tax Benefits (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="nk-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>100720 - Disclosure - Summary of Quarterly Data (Unaudited) (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nantkwest.com/20191231/taxonomy/role/DisclosureSummaryOfQuarterlyDataUnauditedDetail</Role>
      <ShortName>Summary of Quarterly Data (Unaudited) (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="nk-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>100730 - Disclosure - Employee Benefits - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nantkwest.com/20191231/taxonomy/role/DisclosureEmployeeBenefitsAdditionalInformationDetail</Role>
      <ShortName>Employee Benefits - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="nk-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>100740 - Disclosure - Subsequent Events - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nantkwest.com/20191231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail</Role>
      <ShortName>Subsequent Events - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>nk-20191231.xml</File>
    <File>nk-20191231.xsd</File>
    <File>nk-20191231_cal.xml</File>
    <File>nk-20191231_def.xml</File>
    <File>nk-20191231_lab.xml</File>
    <File>nk-20191231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/srt/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/stpr/2018-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>129
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6894028944">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Statement Details - Intangible Assets, Net (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 565<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=nk_TechnologyLicenseMember', window );">Technology License</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Total intangible assets</a></td>
<td class="nump">9,042<span></span>
</td>
<td class="nump">9,042<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Less accumulated amortization</a></td>
<td class="num">(9,042)<span></span>
</td>
<td class="num">(8,477)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 565<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=nk_TechnologyLicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=nk_TechnologyLicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>130
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6910081584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Statement Details - Investment Income, Net (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_FinancialStatementDetailsAbstract', window );"><strong>Financial Statement Details [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">$ 1,643<span></span>
</td>
<td class="nump">$ 2,317<span></span>
</td>
<td class="nump">$ 4,225<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium', window );">Investment accretion income (amortization expense), net</a></td>
<td class="nump">3<span></span>
</td>
<td class="num">(463)<span></span>
</td>
<td class="num">(1,597)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RealizedInvestmentGainsLosses', window );">Net realized (losses) gains on investments</a></td>
<td class="num">(4)<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">37<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeNet', window );">Investment income, net</a></td>
<td class="nump">$ 1,642<span></span>
</td>
<td class="nump">$ 1,857<span></span>
</td>
<td class="nump">$ 2,665<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nk_FinancialStatementDetailsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Financial statement details.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nk_FinancialStatementDetailsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(a),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accretion (amortization) of purchase discount (premium) on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RealizedInvestmentGainsLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net realized gains or losses on investments during the period, not including gains or losses on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.3(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RealizedInvestmentGainsLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>131
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6812911296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Warrant Activity (Detail) - Outstanding Warrants - shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_WarrantLineItems', window );"><strong>Warrant [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of shares Warrants, Beginning Balance</a></td>
<td class="nump">17,589,250<span></span>
</td>
<td class="nump">17,721,088<span></span>
</td>
<td class="nump">17,768,314<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_StockIssuedDuringPeriodSharesWarrantsExercised', window );">Number of shares Warrants exercised</a></td>
<td class="num">(17,589,250)<span></span>
</td>
<td class="num">(93,254)<span></span>
</td>
<td class="num">(47,226)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_StockIssuedDuringPeriodSharesWarrantsExpired', window );">Number of shares Warrants expired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(38,584)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of shares Warrants, Ending Balance</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">17,589,250<span></span>
</td>
<td class="nump">17,721,088<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_ClassOfWarrantOrVestedAndExercisable', window );">Number of shares Warrants, Vested and exercisable Ending Balance</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nk_ClassOfWarrantOrVestedAndExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Vested and exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nk_ClassOfWarrantOrVestedAndExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nk_StockIssuedDuringPeriodSharesWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares warrants exercised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nk_StockIssuedDuringPeriodSharesWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nk_StockIssuedDuringPeriodSharesWarrantsExpired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares warrants expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nk_StockIssuedDuringPeriodSharesWarrantsExpired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nk_WarrantLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrant.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nk_WarrantLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>132
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6896797936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Stock Option Activity (Detail) - Employee Stock Option - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Stock Options, Beginning Balance</a></td>
<td class="nump">6,493,250<span></span>
</td>
<td class="nump">5,693,250<span></span>
</td>
<td class="nump">6,307,386<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Stock Options, Options exercised</a></td>
<td class="num">(1,986,300)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(614,136)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Stock Options, Options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Stock Options, Ending Balance</a></td>
<td class="nump">4,506,950<span></span>
</td>
<td class="nump">6,493,250<span></span>
</td>
<td class="nump">5,693,250<span></span>
</td>
<td class="nump">6,307,386<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Stock Options, Vested and Exercisable</a></td>
<td class="nump">3,973,614<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Outstanding Beginning balance</a></td>
<td class="nump">$ 7.14<span></span>
</td>
<td class="nump">$ 7.71<span></span>
</td>
<td class="nump">$ 7.14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Options exercised</a></td>
<td class="nump">2.06<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.88<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.07<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Outstanding Ending balance</a></td>
<td class="nump">9.37<span></span>
</td>
<td class="nump">$ 7.14<span></span>
</td>
<td class="nump">$ 7.71<span></span>
</td>
<td class="nump">$ 7.14<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Vested and Exercisable</a></td>
<td class="nump">$ 10.22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract', window );"><strong>Aggregate Intrinsic Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Outstanding, Beginning balance</a></td>
<td class="nump">$ 563<span></span>
</td>
<td class="nump">$ 11,920<span></span>
</td>
<td class="nump">$ 19,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Outstanding, Ending balance</a></td>
<td class="nump">5,710<span></span>
</td>
<td class="nump">$ 563<span></span>
</td>
<td class="nump">$ 11,920<span></span>
</td>
<td class="nump">$ 19,100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue', window );">Aggregate Intrinsic Value, Vested and Exercisable</a></td>
<td class="nump">$ 5,326<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Weighted Average Remaining Contractual Life</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life, Outstanding</a></td>
<td class="text">5 years 9 months 18 days<span></span>
</td>
<td class="text">4 years 9 months 18 days<span></span>
</td>
<td class="text">5 years 3 months 18 days<span></span>
</td>
<td class="text">6 years 4 months 24 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Life, Vested and Exercisable</a></td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share-based payment award, options, aggregate intrinsic value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>133
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6814374112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_PropertyPlantAndEquipmentUsefulLifeTableTextBlock', window );">Schedule of Estimated Useful Lives of Property, Plant and Equipment</a></td>
<td class="text">Depreciation of property, plant and equipment is calculated using the straight-line method over the estimated useful lives of the assets, as follows:
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Buildings</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> 39 years</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Software</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> 3 years</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Laboratory equipment</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> 5 years</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furniture &amp; fixtures</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> 5 years</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">IT equipment</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> 3 years</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> The lesser of the lease term or the life of the asset</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Securities Excluded from the Computation of Potentially Dilutive Securities</a></td>
<td class="text">The following table details those securities that have been excluded from the computation of potentially dilutive securities:
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding options</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,506,950</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,493,250</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,693,250</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding RSUs</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,139,428</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">867,911</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">888,189</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding warrants</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,589,250</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,721,088</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,646,378</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,950,411</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,302,527</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amounts in the table above reflect the common stock equivalents of the noted instruments.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nk_PropertyPlantAndEquipmentUsefulLifeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Property plant and equipment useful life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nk_PropertyPlantAndEquipmentUsefulLifeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>134
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6814475184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summarized Quarterly Data (Unaudited)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract', window );"><strong>Quarterly Financial Information Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationTextBlock', window );">Summarized Quarterly Data (Unaudited)</a></td>
<td class="text">
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">13. &#160;&#160;&#160;&#160;Summarized Quarterly Data (Unaudited)</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following financial information reflects all normal recurring adjustments that are, in the opinion of management, necessary for a fair statement of the results of the interim periods.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The table below presents unaudited quarterly data for fiscal 2019 and 2018 (in thousands, except for share and per share amounts):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1st Quarter</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2nd Quarter</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">3rd Quarter</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">4th Quarter</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenue</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating expenses</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,340</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,313</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,077</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,120</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating loss</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(18,335</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(17,296</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(16,065</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(16,111</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(17,885</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(16,682</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(15,581</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(15,641</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per share - basic and diluted</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.22</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.17</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.16</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.16</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shares used in calculating net loss per share - basic and</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; diluted</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">81,261,302</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">98,594,355</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">98,331,695</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">98,419,166</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1st Quarter</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2nd Quarter</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">3rd Quarter</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">4th Quarter</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenue</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating expenses</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28,289</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28,282</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,139</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,726</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating loss</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(28,284</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(28,278</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(24,108</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(17,719</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">) </p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(27,519</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(27,732</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(23,635</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(17,340</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">) </p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per share - basic and diluted</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.35</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.35</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.30</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.22</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">) </p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shares used in calculating net loss per share - basic and</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; diluted</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">79,036,614</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">79,107,208</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">79,204,765</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">79,177,962</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for quarterly financial data. Includes, but is not limited to, tabular presentation of financial information for fiscal quarters, effect of year-end adjustments, and an explanation of matters or transactions that affect comparability of the information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -URI http://asc.fasb.org/topic&amp;trid=2126967<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>135
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6898420944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitment and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments And Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Lease Balances</a></td>
<td class="text">The following disclosures relate to our lease balances as of January&#160;1, 2019 and December&#160;31, 2019, under ASC&#160;842 (in thousands):
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.36%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">January 1, 2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.36%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease right-of-use assets, net</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.36%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,532</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.36%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,729</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other current liabilities</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.36%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,960</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.36%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,206</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease liability, less current portion</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.36%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,407</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.36%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,885</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock', window );">Summary of Future Minimum Lease Payments</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Future minimum lease payments at December&#160;31, 2019 are presented in the following table (in thousands). Common area maintenance costs and taxes are not included in these payments.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:81.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Years ending December 31:</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Operating</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Leases (a)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:81.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,271</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:81.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,753</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:81.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,671</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:81.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,546</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:81.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2024</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,083</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:81.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thereafter</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,729</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:81.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total future minimum lease payments</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,053</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:81.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: Interest</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,962</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:81.8%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Present value of operating lease liabilities</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,091</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;margin-right:75.93%;text-indent:0%;font-size:5pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:2pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:2pt;margin-bottom:0pt;font-size:10pt;">(a)</p></td>
<td valign="top">
<p style="margin-top:2pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease payments include $3.3&#160;million related to options to extend lease terms that are reasonably certain of being exercised.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>136
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6814474080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Agreements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Agreements</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">9. &#160;&#160;&#160;&#160;Related Party Agreements</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our Chairman and CEO founded and has a controlling interest in NantWorks, which is a collection of multiple companies in the healthcare and technology space. As described below, we have entered into arrangements with NantWorks, and certain affiliates of NantWorks, to facilitate the development of new genetically modified NK&#160;cells for our product pipeline.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Share Repurchase</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In November&#160;2018, we entered into a share repurchase agreement with an immediate family member of a director of the company, pursuant to which we repurchased 138,349&#160;of our common shares for a total of $0.2&#160;million under our existing share repurchase program.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">NantHealth Labs, Inc.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March&#160;2018, we entered into an agreement with NantHealth Labs, Inc., or NantHealth Labs, to obtain blood-based tumor profiling services. NantHealth Labs is a related party, as it is a wholly owned subsidiary of NantHealth, Inc., a majority owned subsidiary of NantWorks. We are obligated to pay NantHealth Labs fixed, per-patient fees. The agreement has an initial term of five&#160;years and renews automatically for successive one-year periods, unless terminated earlier. During the years ended December&#160;31, 2019 and 2018, $10,000 and $0.3&#160;million, respectively, has been recognized in research and development expense on the consolidated statements of operations. At December&#160;31, 2018, we owed NantHealth Labs $49,300, which is included in due to related parties on the consolidated balance sheets. At December&#160;31, 2019, no balances were due between the parties.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Immuno-Oncology Clinic, Inc.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Beginning in 2017, we entered into multiple agreements with Immuno-Oncology Clinic, Inc., or the Clinic, to conduct various clinical trials. The Clinic was formerly known as John Lee, M.D. and Leonard Sender, M.D., Inc., a professional medical corporation, dba&#160;Chan Soon-Shiong Institutes for Medicine, in El Segundo, California. The Clinic is a related party as it is owned by one officer of NantKwest and NantWorks manages the administrative operations of the Clinic. Prior to June&#160;30, 2019, one of the company&#8217;s officers was an investigator or sub-investigator for all of the company&#8217;s trials conducted at the Clinic.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In July&#160;2019, we entered into a new agreement with the Clinic which superseded our existing agreements with the Clinic, effective as of July&#160;1, 2019. The new agreement covers clinical trial and research related activities on a non-exclusive basis relating to our existing clinical trials, commenced prior to July&#160;1, 2019, and prospective clinical trials and research projects. The new agreement also specifies certain services and related costs that are excluded from the new agreement. Prior to commencing any work under the new agreement, the parties have agreed to execute written work orders setting forth the terms and conditions related to specific services to be performed, including financial terms. For existing clinical trials, commenced prior to July&#160;1, 2019, fees incurred for services performed after July&#160;1, 2019 are covered under the new agreement and applied towards the below-mentioned prepayments. The initial term of the new agreement is for one year, but the agreement allows for an automatic renewal and additional extensions beyond the initial term. In July&#160;2019, we executed a clinical trial work order under the new agreement with the Clinic for an open-label, phase&#160;I study of PD&#8209;L1.t&#8209;haNK for infusion in subjects with locally advanced or metastatic solid cancers.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In consideration of the services to be performed under the new agreement, we agreed to make payments of $7.5&#160;million to the Clinic, of which $3.75&#160;million and $1.875&#160;million were paid in July&#160;2019 and October&#160;2019, respectively. The prepayments constitute a prepayment by us for services to be performed by the Clinic. Under the term of the new agreement, the outstanding balance of our prepayment shall be increased on a quarterly basis by an interest credit computed in accordance with terms specified in the new agreement.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To the extent any portion of the prepayments remain unearned by the Clinic on the third anniversary of the new agreement, we may elect at our sole discretion either to&#160;(i)&#160;not extend the term of the new agreement and have the Clinic reimburse us for the total amount of any remaining unused portion of the prepayments, or (ii)&#160;extend the term of the new agreement for up to three additional one year periods, at which time the Clinic will reimburse us for the total amount of any remaining unused portion of the prepayments plus interest if reimbursement is not made within 60&#160;days of expiration. The Clinic may terminate this agreement upon each anniversary date upon sixty&#160;(60)&#160;days prior written notice and reimbursement in full to us of any outstanding unearned balance of the prepayments, provided that any such termination by the Clinic will not apply with respect to any work orders still in effect at the time of such termination.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the years ended December&#160;31, 2019, 2018 and 2017, expense of $1.1&#160;million, $2.7&#160;million and $0.8&#160;million, respectively, has been recognized in research and development expense on the consolidated statements of operations. At December&#160;31, 2019 and 2018, we owed the Clinic $0.1&#160;million and $0.6&#160;million, respectively, for services excluded from the new agreement, which are included in due to related parties on the consolidated balance sheets, and as of December&#160;31, 2019, we had a prepaid balance with the Clinic of $5.1&#160;million, which is included in prepaid expenses and other currents assets, and other assets, on the consolidated balance sheets. We anticipate that the remaining prepayment amount as of December&#160;31, 2019 will be utilized in future periods as the Clinic provides additional services pursuant to the new agreement.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Tensorcom, LLC</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In April&#160;2017, we entered into a sublease agreement with Tensorcom, LLC, or Tensorcom, for a portion of our San Diego, California, research and development laboratory and office space. The lease ran from May&#160;1, 2017 through April&#160;30, 2018. Tensorcom is a related party, as it is an affiliate of NantWorks. The sublease included a portion of the premises consisting of approximately 6,557&#160;rentable square feet of space. The monthly base rent was $25,000&#160;per month. For the years ended December&#160;31, 2018 and 2017, $0.1&#160;million and $0.2&#160;million, respectively, was recognized in other income on the consolidated statements of operations under the sublease agreement. At December&#160;31, 2019 and 2018, there were no balances due between the parties.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">605&#160;Doug&#160;St,&#160;LLC</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In September&#160;2016, we entered into a lease agreement with 605&#160;Doug&#160;St,&#160;LLC, an entity owned by our Chairman and CEO, for approximately 24,250&#160;square feet in El Segundo, California, which has been converted to a research and development laboratory and a cGMP laboratory manufacturing facility. The lease runs from July&#160;2016 through July&#160;2023. We have the option to extend the lease for an additional three-year term through July&#160;2026. The monthly rent is $0.1&#160;million with annual increases of 3% beginning in July&#160;2017. Lease expense for this facility is recorded in research and development expense on the consolidated statements of operations and was $0.9&#160;million, $0.2&#160;million and $0.2&#160;million, respectively, for the years ended December&#160;31, 2019, 2018 and 2017. At December&#160;31, 2019 and 2018, no balances were due between the parties.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">NantBio, Inc.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August&#160;2018, NantBio assigned an agreement to us for the use of a third-party research facility, which provides us with the exclusive right to use and access to a portion of the third party&#8217;s laboratory and vivarium premises. NantBio is a related party as it is an affiliate of NantWorks. In conjunction with the assignment, we reimbursed NantBio for upfront payments which it had made to the third party of $0.9&#160;million and paid $0.5&#160;million directly to the third party for an aggregate value of $1.4&#160;million. The assigned agreement is for a term of ten&#160;years and expires in June&#160;2027. The agreement may be terminated by us at any time, with or without cause. In case of termination of the agreement, the third party will reimburse us for a pro-rata amount based upon the passage of time.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In January&#160;2018, we entered into a laboratory services agreement with NantBio. The agreement, effective December&#160;2017, included a sublease of approximately 1,965&#160;square feet of laboratory and office space at our San Diego, California, research facility. This sublease was terminated effective December&#160;31, 2019, pursuant to the terms of the agreement. We recognized $0.1&#160;million, $0.1&#160;million and $10,000, respectively, in other income on the consolidated statements of operations for the years ended December&#160;31, 2019, 2018 and 2017. At December&#160;31, 2019 and 2018, NantBio owed us $8,400 and $49,000, respectively, which is included in prepaid expenses and other current assets on the consolidated balance sheets.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March&#160;2016, NantBio and the National Cancer Institute entered into a cooperative research and development agreement. The initial five-year agreement covers NantBio and its affiliates, including us. Under the agreement, the parties are collaborating on the preclinical and clinical development of proprietary recombinant natural killer cells and monoclonal antibodies in monotherapy and in combination immunotherapies. We benefited from the preclinical and clinical research conducted during the first four years under this agreement. In each of April&#160;2016, April&#160;2017, August&#160;2018, and May&#160;2019, we paid $0.6&#160;million to the National Cancer Institute as a prepayment for services under the agreement. We recognize research and development expense related to this agreement ratably over a 12-month period for each funding year and recorded $0.6&#160;million, of expense associated with the agreement in each of the years ended December&#160;31, 2019, 2018 and 2017. At December&#160;31, 2019 and 2018, we had balances of $0.1&#160;million and $0.1&#160;million, respectively, included in prepaid expenses and other current assets related to this agreement, on the consolidated balance sheets.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">NantWorks</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In May&#160;2018, we entered into an assignment agreement with NantWorks and a third-party construction firm. In connection with the agreement, we assigned our deposit of $0.4&#160;million with the third-party firm to NantWorks for which NantWorks reimbursed us. This assignment represented unutilized deposits that NantKwest had previously made with the construction company, for which NantWorks can now utilize in applying such funds to future planned construction projects.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the NantWorks shared services agreement executed in November&#160;2015, but effective August&#160;2015, NantWorks provides corporate, general and administrative, manufacturing strategy, research and development, regulatory and clinical trial strategy, and other support services. We are charged for the services at cost plus reasonable allocations for indirect costs that relate to the employees providing the services. For the years ended December&#160;31, 2019, 2018 and 2017, we recorded $2.1&#160;million, $2.8&#160;million and $3.6&#160;million, respectively, to selling, general and administrative expense, and $1.5&#160;million, $3.3&#160;million and $3.2&#160;million, respectively, in research and development expense under this arrangement on the consolidated statements of operations. These amounts exclude certain general and administrative expenses provided by third party vendors directly for our benefit, which have been reimbursed to NantWorks based on those vendors&#8217; invoiced amounts without markup by NantWorks.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June&#160;2016, we amended the existing shared services agreement with NantWorks whereby we can provide support services to NantWorks and/or any of its affiliates. For the years ended December&#160;31, 2019, 2018 and 2017, we recorded expense reimbursements of $1.2&#160;million, $0.6&#160;million and $0.4&#160;million, respectively, to selling, general and administrative expense and $2.3&#160;million, $2.6&#160;million and $1.0&#160;million, respectively, to research and development expense.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At December&#160;31, 2019 and 2018, we owed NantWorks a net amount of $0.4&#160;million and $1.1&#160;million, respectively, for all agreements between the two affiliates, which is included in due to related parties on the consolidated balance sheets.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In November&#160;2015, we entered into a facility license agreement with NantWorks, which became effective May&#160;2015, for approximately 9,500&#160;square feet in Culver City, California, which has been converted to a research and development laboratory and a cGMP manufacturing facility. Lease expense for this facility is recorded in research and development expense on the consolidated statements of operations and was $0.6&#160;million, $0.2&#160;million, and $0.2&#160;million for the years ended December&#160;31, 2019, 2018 and 2017.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">NantOmics, LLC</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June&#160;2015, we entered into an agreement, as amended in May&#160;2018, with NantOmics, LLC, or NantOmics, which is a related party, as it is an affiliate of NantWorks. Pursuant to this agreement we obtain genomic sequencing and proteomic analysis services, as well as related data management and bioinformatics services, exclusively from NantOmics. We will have rights to use the data and results generated from NantOmics&#8217; services in connection with the performance of the particular oncology trial with respect to which the services were performed, but NantOmics owns the data and results, as well as any other intellectual property it creates in performing these services on our behalf. We are obligated to pay NantOmics a fixed, per sample fee, determined based on the type of services being provided. The agreement has an initial term of five&#160;years and renews automatically for successive one-year periods, unless terminated earlier. For the years ended December&#160;31, 2019, 2018 and 2017, we recorded operating expense of $0.1&#160;million, $0.1&#160;million and $0.1&#160;million, respectively, to research and development under this arrangement on the consolidated statements of operations. At December&#160;31, 2018, we owed NantOmics $24,000, which is included in due to related parties on the consolidated balance sheets. At December&#160;31, 2019, no balances were due between the parties.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">ImmunityBio</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ImmunityBio, Inc., or ImmunityBio, is a related party, as it is an affiliate of NantWorks. ImmunityBio was formerly known as NantCell, Inc.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In January&#160;2020, we entered into a cost sharing agreement with ImmunityBio as further described in Note&#160;15&#160;&#8209;&#160;<font style="font-style:italic;">Subsequent Events</font>.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In November&#160;2018, we entered into an agreement with Etubics Corporation, or Etubics, a subsidiary of ImmunityBio. Pursuant to this agreement we sold used laboratory equipment to Etubics for $0.3&#160;million. In conjunction with this sale, we recognized a loss on disposal of related laboratory equipment of $0.1&#160;million, which was included in other income, net on the consolidated statements of operations.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February&#160;2017, we entered into a research grant agreement with VivaBioCell S.p.A., or VBC, a subsidiary of ImmunityBio. VBC conducted research and development activities related to our NK&#160;cell lines using VBC&#8217;s proprietary technology. For the years ended December&#160;31, 2018 and 2017, $0.1&#160;million and $0.6&#160;million, respectively, was recognized in research and development expense on the consolidated statements of operations. No expense was incurred for the year ended December&#160;31, 2019.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August&#160;2016, we entered into an exclusive Co-Development Agreement with Altor as described in Note&#160;7&#160;&#8211;&#160;<font style="font-style:italic;">Collaboration and License Agreements</font>. Altor is a related party as it is a wholly owned subsidiary of ImmunityBio. No charges for supplies by Altor were incurred in association with the trials during the years ended December&#160;31, 2019, 2018 and 2017.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June&#160;2015, we also entered into a supply agreement with ImmunityBio pursuant to which we have the right to purchase ImmunityBio&#8217;s proprietary bioreactors, made according to specifications mutually agreed to with ImmunityBio. We also have the right to purchase reagents and consumables associated with such equipment from ImmunityBio. When an upfront payment is made, it is included in prepaid expenses on the consolidated balance sheets until the product is received. The agreement has an initial term of five&#160;years and renews automatically for successive one-year periods unless terminated earlier.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At December&#160;31, 2019 and 2018, we had $1.8&#160;million and $1.1&#160;million, respectively, in capitalized equipment purchased from ImmunityBio, which is included in property, plant and equipment, net, on the consolidated balance sheets. During the years ended December&#160;31, 2019, 2018 and 2017, we recorded research and development expense associated with reagents and consumables purchased from ImmunityBio of $0.1&#160;million, $0.1&#160;million and $0.3&#160;million, respectively, on the consolidated statements of operations.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At December&#160;31, 2019 and 2018, we had $0.5&#160;million and $0.5&#160;million, respectively, included in prepaid expenses and other current assets on the consolidated balance sheets related to consumables purchased from ImmunityBio. At December&#160;31, 2019 and December&#160;31, 2018, no balances were due between the parties.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>137
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6898396352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments Investments in Debt Securities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_CashEquivalentsAndMarketableSecuritiesAbstract', window );"><strong>Cash Equivalents And Marketable Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock', window );">Financial Instruments Investments in Debt Securities</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">5. &#160;&#160;&#160;&#160;Financial Instruments &#8211; Investments in Debt Securities</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At December&#160;31, 2019, our investments in debt securities are detailed below (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="18" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contractual&#160;Life</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in years)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cost</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gains</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Losses</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current:</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Available-for-sale:</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt securities</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.2</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32,382</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32,389</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Foreign government bonds</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.3</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,007</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,007</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Government sponsored securities</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.5</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,752</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,748</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current portion</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.2</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36,141</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(7</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36,144</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Noncurrent:</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Available-for-sale:</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt securities</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.7</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,501</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,497</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Noncurrent portion</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.7</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,501</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,497</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.94%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.3</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37,642</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(11</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37,641</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At December&#160;31, 2018, our investments in debt securities are detailed below (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="14" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.42%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2018</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized&#160;Cost</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gains</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Losses</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair&#160;Value</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current:</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Available-for-sale:</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt securities</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">57,463</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(136</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">57,328</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total available-for-sale</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">57,463</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(136</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">57,328</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Held-to-maturity, notes receivable (Note 4)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">723</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">723</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current portion</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">58,186</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(136</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">58,051</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Noncurrent:</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Available-for-sale:</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt securities</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,067</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(76</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,991</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Government sponsored securities</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,756</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(46</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,710</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Noncurrent portion</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,823</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(122</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,701</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">64,009</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(258</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">63,752</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></div>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulated unrealized losses on debt securities classified as available-for-sale that have been in a continuous loss position for less than 12&#160;months and for more than 12&#160;months at December&#160;31, 2019 and 2018 were as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="14" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.42%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Less than 12 months</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">More than 12 months</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Estimated&#160;Fair</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross&#160;Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Losses</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Estimated&#160;Fair</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross&#160;Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Losses</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt securities</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,021</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,497</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Government sponsored securities</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,748</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,021</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,245</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(8</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="14" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.42%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2018</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Less than 12 months</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">More than 12 months</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Estimated&#160;Fair</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross&#160;Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Losses</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Estimated&#160;Fair</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross&#160;Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Losses</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt securities</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32,010</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(26</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26,663</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(186</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Government sponsored securities</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,710</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(46</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32,010</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(26</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29,373</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(232</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At December&#160;31, 2019, 14 of the securities were in an unrealized loss position. We evaluated our securities for other-than-temporary impairment and concluded that the decline in value was primarily caused by current economic and market conditions. We do not intend to sell the investments and it is not more likely than not that we will be required to sell the investments before recovery of their amortized cost bases. Therefore, we did not recognize any other-than-temporary impairment loss during the years ended December&#160;31, 2019, 2018 and 2017.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We recorded realized gains and losses on sales of available-for-sale debt securities as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;">
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.92%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Realized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gains</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.92%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Realized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Losses</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.92%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Net</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Realized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gains (Losses)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(8</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">52</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(15</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nk_CashEquivalentsAndMarketableSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash equivalents and marketable securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nk_CashEquivalentsAndMarketableSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>138
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6814680608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Statement Details - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_FinancialStatementDetailsLineItems', window );"><strong>Financial Statement Details [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense related to property, plant and equipment</a></td>
<td class="nump">$ 8,400,000<span></span>
</td>
<td class="nump">$ 7,300,000<span></span>
</td>
<td class="nump">$ 3,300,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense</a></td>
<td class="nump">600,000<span></span>
</td>
<td class="nump">2,300,000<span></span>
</td>
<td class="nump">2,300,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfInvestments', window );">Impairment loss on recognized investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member', window );">Accounting Standards Update 2016-02</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_FinancialStatementDetailsLineItems', window );"><strong>Financial Statement Details [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_LesseseOperatingLeaseReclassificationOfAssetsFromBuildingsToLeaseholdImprovements', window );">Reclassification of assets from buildings to leasehold improvements</a></td>
<td class="nump">32,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_DerecognizedBuildToSuitLeaseAssets', window );">Derecognized build-to-suit lease assets</a></td>
<td class="nump">$ 6,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nk_DerecognizedBuildToSuitLeaseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Derecognized build to suit lease assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nk_DerecognizedBuildToSuitLeaseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nk_FinancialStatementDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Financial statement details.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nk_FinancialStatementDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nk_LesseseOperatingLeaseReclassificationOfAssetsFromBuildingsToLeaseholdImprovements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessese, operating lease, reclassification of assets from buildings to leasehold improvements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nk_LesseseOperatingLeaseReclassificationOfAssetsFromBuildingsToLeaseholdImprovements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount by which the fair value of an investment is less than the amortized cost basis or carrying amount of that investment at the balance sheet date and the decline in fair value is deemed to be other than temporary, before considering whether or not such amount is recognized in earnings or other comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8A<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=SL6284422-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>139
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6661390080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">Summary of Loss Before Taxes</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The amount of loss before taxes is as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the Year Ended December&#160;31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. loss before taxes</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(65,286</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(94,423</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(94,734</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Foreign loss before taxes</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(600</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,306</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,182</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss before income taxes</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(65,886</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(96,729</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(96,916</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Summary of Income Tax Benefit</a></td>
<td class="text">
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Income tax benefit for the years ended December&#160;31, 2019, 2018 and 2017 consists of the following (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.84%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the Year Ended December&#160;31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.8%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.8%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current:</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.48%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Federal</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Foreign</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.48%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total Current</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.48%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred:</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.48%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Federal</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(79</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(21</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(8</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Foreign</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.48%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(498</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(497</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total Deferred</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(100</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(506</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(497</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.78%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Income tax benefit</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.48%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(97</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(503</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(493</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Components of Net Deferred Tax Assets and Liabilities</a></td>
<td class="text">
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The components that comprise the company&#8217;s net deferred tax assets at December&#160;31, 2019 and 2018 consist of the following (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.94%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax assets:</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net operating loss carryforwards</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">78,377</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61,915</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock compensation</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,536</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">79,281</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease liabilities</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,884</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation and amortization</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,042</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tax credits</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">898</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">845</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued compensation</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">775</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">795</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leases and other accrued liabilities</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">453</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,909</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued legal expenses</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">308</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred tax assets</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">94,965</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">146,053</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax liabilities:</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Foreign intangibles</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease right-of-use assets</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,233</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation and amortization</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,279</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred tax liabilities</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,233</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,280</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net deferred tax assets</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">91,732</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">144,773</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Valuation allowance</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(91,732</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(144,773</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.44%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net deferred tax liability</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.4%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Reconciliation of Federal Statutory Income Tax Rate</a></td>
<td class="text">
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A reconciliation of the federal statutory income tax rate to the company&#8217;s effective income tax rate is as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:55.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="12" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.08%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the Year Ended December&#160;31,</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:55.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.02%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.02%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tax computed at federal statutory rate</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.34%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.0</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.34%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.0</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.34%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34.0</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State income taxes, net of federal tax benefit</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.34%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(19.4</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.34%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.2</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.34%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.3</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tax rate adjustment</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.34%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.1</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.34%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.3</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.34%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.8</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tax Cuts and Jobs Act</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.34%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.34%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.34%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(53.4</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development credits</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.34%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.2</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.34%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.1</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.34%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.6</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.34%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(82.5</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.34%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.1</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.34%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.3</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.34%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.1</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.34%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.3</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.34%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.8</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:55.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Valuation allowance</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.34%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">80.5</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.34%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(26.7</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.34%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.7</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:55.54%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Effective income tax rate</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.34%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.2</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.02%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.34%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.5</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.02%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.34%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.5</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.02%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock', window );">Summarizes of Changes in Unrecognized Tax Benefits</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes the changes to the amount of unrecognized tax benefits (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:60%;">
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unrecognized tax benefits at December 31, 2017</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,577</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Increase for prior year tax positions</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">798</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Increase for current year tax positions</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,608</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unrecognized tax benefits at December 31, 2018</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,983</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Decrease for prior year tax positions</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(7</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Increase for current year tax positions</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,680</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unrecognized tax benefits at December 31, 2019</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,656</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 55<br> -Paragraph 217<br> -URI http://asc.fasb.org/extlink&amp;oid=117331294&amp;loc=d3e36027-109320<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>140
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6894110976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Schedule of Estimated Useful Lives of Property, Plant and Equipment (Detail)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember', window );">Buildings</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment estimated useful lives</a></td>
<td class="text">39 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember', window );">Software</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment estimated useful lives</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=nk_LaboratoryEquipmentMember', window );">Laboratory Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment estimated useful lives</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture And Fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment estimated useful lives</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=nk_ITEquipmentMember', window );">IT Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment estimated useful lives</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives', window );">Property and equipment estimated useful lives, term</a></td>
<td class="text">The lesser of the lease term or the life of the asset<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Describes the periods of time over which an entity anticipates to receive utility from its property, plant and equipment (that is, the periods of time over which an entity allocates the initial cost of its property, plant and equipment).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 35<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=68071081&amp;loc=d3e1205-110223<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=nk_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=nk_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=nk_ITEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=nk_ITEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>141
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6893884192">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitment and Contingencies - Schedule of Lease Balances (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Jan. 01, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAndLiabilitiesLesseeAbstract', window );"><strong>Assets And Liabilities Lessee [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets, net</a></td>
<td class="nump">$ 11,729<span></span>
</td>
<td class="nump">$ 13,532<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Other current liabilities</a></td>
<td class="nump">3,206<span></span>
</td>
<td class="nump">2,960<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability, less current portion</a></td>
<td class="nump">$ 10,885<span></span>
</td>
<td class="nump">$ 13,407<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsAndLiabilitiesLesseeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsAndLiabilitiesLesseeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>142
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6812845312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments Investments in Debt Securities - Schedule of Realized Gains and Losses on Sales of Available-for-Sale Debt Securities (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesRealizedGainLossAbstract', window );"><strong>Debt Securities Realized Gain Loss [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesGrossRealizedGains', window );">Available-for-sale Securities, Gross Realized Gains</a></td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">$ 52<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses', window );">Available-for-sale Securities, Gross Realized Losses</a></td>
<td class="num">(8)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(15)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossNet', window );">Available for Sale Securities, Net Realized Gains (Losses)</a></td>
<td class="num">$ (4)<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">$ 37<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the difference between the gross realized gains and losses realized on the sale of debt or equity securities categorized neither as held-to-maturity nor trading securities. Additionally, this item would include any losses recognized for other than temporary impairments (OTTI) of the subject investments in debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesGrossRealizedGains">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the gross profit realized on the sale of debt or equity securities categorized neither as held-to-maturity nor trading securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesGrossRealizedGains</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the gross loss realized on the sale of debt or equity securities categorized neither as held-to-maturity nor trading securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesRealizedGainLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesRealizedGainLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>143
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6909957968">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income (Loss)</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance at Dec. 31, 2016</a></td>
<td class="nump">$ 293,418<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
<td class="nump">$ 680,757<span></span>
</td>
<td class="num">$ (284)<span></span>
</td>
<td class="num">$ (387,063)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Beginning Balance, Shares at Dec. 31, 2016</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">81,983,937<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">36,997<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">36,997<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants', window );">Exercise of warrants</a></td>
<td class="nump">61<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">61<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_StockIssuedDuringPeriodSharesWarrantsExercised', window );">Exercise of warrants, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47,226<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">1,154<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">1,154<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">614,136<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Vesting of restricted stock units (RSUs)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Vesting of restricted stock units (RSUs), Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">244,209<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Net share settlement for restricted stock unit vesting and option/warrant exercises</a></td>
<td class="num">(1,039)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">(1,039)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation', window );">Net share settlement for restricted stock unit vesting and option/warrant exercises, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(234,020)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue', window );">Repurchase of common stock</a></td>
<td class="num">$ (15,227)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(15,227)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares', window );">Repurchase of common stock, Shares</a></td>
<td class="num">(3,633,610)<span></span>
</td>
<td class="num">(3,633,610)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="num">$ (97)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(97)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(96,423)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(96,423)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Dec. 31, 2017</a></td>
<td class="nump">218,844<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
<td class="nump">717,930<span></span>
</td>
<td class="num">(381)<span></span>
</td>
<td class="num">(498,713)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ending Balance, Shares at Dec. 31, 2017</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">79,021,878<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">23,382<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">23,382<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants', window );">Exercise of warrants</a></td>
<td class="nump">57<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">57<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_StockIssuedDuringPeriodSharesWarrantsExercised', window );">Exercise of warrants, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">93,254<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Vesting of restricted stock units (RSUs)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Vesting of restricted stock units (RSUs), Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">172,330<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Net share settlement for restricted stock unit vesting and option/warrant exercises</a></td>
<td class="num">(123)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">(123)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation', window );">Net share settlement for restricted stock unit vesting and option/warrant exercises, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(61,379)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue', window );">Repurchase of common stock</a></td>
<td class="num">$ (228)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(228)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares', window );">Repurchase of common stock, Shares</a></td>
<td class="num">(138,349)<span></span>
</td>
<td class="num">(138,349)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification', window );">Cumulative effect of the adoption of the new standard | Accounting Standards Update 2014-09</a></td>
<td class="nump">$ 186<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">186<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="nump">114<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">114<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(96,226)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(96,226)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Dec. 31, 2018</a></td>
<td class="nump">$ 146,006<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
<td class="nump">741,246<span></span>
</td>
<td class="num">(267)<span></span>
</td>
<td class="num">(594,981)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ending Balance, Shares at Dec. 31, 2018</a></td>
<td class="nump">79,087,734<span></span>
</td>
<td class="nump">79,087,734<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 2,627<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">2,627<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants', window );">Exercise of warrants</a></td>
<td class="nump">35,151<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">35,149<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_StockIssuedDuringPeriodSharesWarrantsExercised', window );">Exercise of warrants, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,589,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">4,070<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">4,070<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,986,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Vesting of restricted stock units (RSUs)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Vesting of restricted stock units (RSUs), Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">395,051<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Net share settlement for restricted stock unit vesting and option/warrant exercises</a></td>
<td class="num">(127)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">(127)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation', window );">Net share settlement for restricted stock unit vesting and option/warrant exercises, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(124,345)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue', window );">Repurchase of common stock</a></td>
<td class="num">$ (501)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(501)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares', window );">Repurchase of common stock, Shares</a></td>
<td class="num">(473,586)<span></span>
</td>
<td class="num">(473,586)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification', window );">Cumulative effect of the adoption of the new standard | Accounting Standards Update 2016-02</a></td>
<td class="num">$ (920)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(920)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="nump">162<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">162<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(65,789)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(65,789)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Dec. 31, 2019</a></td>
<td class="nump">$ 120,679<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="nump">$ 782,965<span></span>
</td>
<td class="num">$ (105)<span></span>
</td>
<td class="num">$ (662,191)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ending Balance, Shares at Dec. 31, 2019</a></td>
<td class="nump">98,460,404<span></span>
</td>
<td class="nump">98,460,404<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nk_StockIssuedDuringPeriodSharesWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares warrants exercised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nk_StockIssuedDuringPeriodSharesWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=118258462&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=118258462&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116855982&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the quantification of the effect of adopting the new accounting standard or change in accounting principle expected by the entity to have a significant effect on the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities. Excludes amounts related to other than temporary impairment (OTTI) loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of preferred stock and warrants for common stock issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate value of stock related to Restricted Stock Awards issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased and retired during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedAndRetiredDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased and retired during the period. The excess of the purchase price over par value can be charged against retained earnings (once the excess is fully allocated to additional paid in capital).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedAndRetiredDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201409Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201409Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>144
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6912306400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1">50 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Nov. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Nov. 30, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Total amount authorized for repurchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares', window );">Repurchase of common stock, shares</a></td>
<td class="nump">138,349<span></span>
</td>
<td class="nump">473,586<span></span>
</td>
<td class="nump">138,349<span></span>
</td>
<td class="nump">3,633,610<span></span>
</td>
<td class="nump">6,403,489<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_StockRepurchasedAndRetiredExcludingCommissionDuringPeriodValue', window );">Repurchase of common stock excluding commissions, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="nump">$ 15,200,000<span></span>
</td>
<td class="nump">$ 31,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesCommissionsAndFees', window );">Broker commissions on repurchases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1', window );">Remaining authorized repurchase amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98,460,404<span></span>
</td>
<td class="nump">79,087,734<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98,460,404<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98,460,404<span></span>
</td>
<td class="nump">79,087,734<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98,460,404<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nk_StockRepurchasedAndRetiredExcludingCommissionDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock repurchased and retired excluding commission during period value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nk_StockRepurchasedAndRetiredExcludingCommissionDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesCommissionsAndFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Primarily represents commissions incurred in the period based upon the sale by commissioned employees or third parties of the entity's goods or services, and fees for sales assistance or product enhancements performed by third parties (such as a distributor or value added reseller).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesCommissionsAndFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramAuthorizedAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount remaining of a stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased and retired during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedAndRetiredDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>145
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6908518896">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 15,508<span></span>
</td>
<td class="nump">$ 16,821<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets (including related parties)</a></td>
<td class="nump">4,105<span></span>
</td>
<td class="nump">13,900<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Marketable debt securities, available-for-sale</a></td>
<td class="nump">36,144<span></span>
</td>
<td class="nump">57,328<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesCurrent', window );">Notes receivable, held-to-maturity</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">723<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">55,757<span></span>
</td>
<td class="nump">88,772<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Marketable debt securities, noncurrent</a></td>
<td class="nump">1,497<span></span>
</td>
<td class="nump">5,701<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">60,501<span></span>
</td>
<td class="nump">76,885<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets, net (including related parties)</a></td>
<td class="nump">11,729<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount', window );">Equity investment</a></td>
<td class="nump">9,253<span></span>
</td>
<td class="nump">8,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">565<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets (including related parties)</a></td>
<td class="nump">4,386<span></span>
</td>
<td class="nump">1,527<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">143,123<span></span>
</td>
<td class="nump">181,950<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">1,749<span></span>
</td>
<td class="nump">2,793<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">5,343<span></span>
</td>
<td class="nump">21,104<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrent', window );">Due to related parties</a></td>
<td class="nump">486<span></span>
</td>
<td class="nump">1,696<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities (including related parties)</a></td>
<td class="nump">3,981<span></span>
</td>
<td class="nump">1,667<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">11,559<span></span>
</td>
<td class="nump">27,260<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability, less current portion (including related parties)</a></td>
<td class="nump">10,885<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nk_FinancingObligationNoncurrent', window );">Financing obligation, less current portion</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,945<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRentCreditNoncurrent', window );">Deferred rent</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,739<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">22,444<span></span>
</td>
<td class="nump">35,944<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 8)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value; 500,000,000 shares authorized; 98,460,404 and 79,087,734 issued and outstanding as of December 31, 2019 and December 31, 2018</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">782,965<span></span>
</td>
<td class="nump">741,246<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(105)<span></span>
</td>
<td class="num">(267)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(662,191)<span></span>
</td>
<td class="num">(594,981)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">120,679<span></span>
</td>
<td class="nump">146,006<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 143,123<span></span>
</td>
<td class="nump">$ 181,950<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nk_FinancingObligationNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Financing obligation noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nk_FinancingObligationNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e637-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669686-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6801-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942338&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942338&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRentCreditNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For a classified balance sheet, the cumulative difference between the rental income or payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense, by the lessor or lessee, respectively, more than one year after the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.26(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902458&amp;loc=d3e39927-112707<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRentCreditNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security without readily determinable fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116654751&amp;loc=SL75117539-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at amortized cost (held-to-maturity), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6904-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>146
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6894987728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Quarterly Data (Unaudited) (Detail) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialDataAbstract', window );"><strong>Quarterly Financial Data [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">$ 12<span></span>
</td>
<td class="nump">$ 17<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
<td class="nump">$ 31<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">$ 43<span></span>
</td>
<td class="nump">$ 47<span></span>
</td>
<td class="nump">$ 45<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Operating expenses</a></td>
<td class="nump">16,120<span></span>
</td>
<td class="nump">16,077<span></span>
</td>
<td class="nump">17,313<span></span>
</td>
<td class="nump">18,340<span></span>
</td>
<td class="nump">17,726<span></span>
</td>
<td class="nump">24,139<span></span>
</td>
<td class="nump">28,282<span></span>
</td>
<td class="nump">28,289<span></span>
</td>
<td class="nump">67,850<span></span>
</td>
<td class="nump">98,436<span></span>
</td>
<td class="nump">99,165<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="num">(16,111)<span></span>
</td>
<td class="num">(16,065)<span></span>
</td>
<td class="num">(17,296)<span></span>
</td>
<td class="num">(18,335)<span></span>
</td>
<td class="num">(17,719)<span></span>
</td>
<td class="num">(24,108)<span></span>
</td>
<td class="num">(28,278)<span></span>
</td>
<td class="num">(28,284)<span></span>
</td>
<td class="num">(67,807)<span></span>
</td>
<td class="num">(98,389)<span></span>
</td>
<td class="num">(99,120)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (15,641)<span></span>
</td>
<td class="num">$ (15,581)<span></span>
</td>
<td class="num">$ (16,682)<span></span>
</td>
<td class="num">$ (17,885)<span></span>
</td>
<td class="num">$ (17,340)<span></span>
</td>
<td class="num">$ (23,635)<span></span>
</td>
<td class="num">$ (27,732)<span></span>
</td>
<td class="num">$ (27,519)<span></span>
</td>
<td class="num">$ (65,789)<span></span>
</td>
<td class="num">$ (96,226)<span></span>
</td>
<td class="num">$ (96,423)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share - basic and diluted</a></td>
<td class="num">$ (0.16)<span></span>
</td>
<td class="num">$ (0.16)<span></span>
</td>
<td class="num">$ (0.17)<span></span>
</td>
<td class="num">$ (0.22)<span></span>
</td>
<td class="num">$ (0.22)<span></span>
</td>
<td class="num">$ (0.30)<span></span>
</td>
<td class="num">$ (0.35)<span></span>
</td>
<td class="num">$ (0.35)<span></span>
</td>
<td class="num">$ (0.70)<span></span>
</td>
<td class="num">$ (1.22)<span></span>
</td>
<td class="num">$ (1.20)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Shares used in calculating net loss per share - basic and diluted</a></td>
<td class="nump">98,419,166<span></span>
</td>
<td class="nump">98,331,695<span></span>
</td>
<td class="nump">98,594,355<span></span>
</td>
<td class="nump">81,261,302<span></span>
</td>
<td class="nump">79,177,962<span></span>
</td>
<td class="nump">79,204,765<span></span>
</td>
<td class="nump">79,107,208<span></span>
</td>
<td class="nump">79,036,614<span></span>
</td>
<td class="nump">94,210,087<span></span>
</td>
<td class="nump">79,132,220<span></span>
</td>
<td class="nump">80,583,910<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialDataAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialDataAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
